PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	DeVente, JE; Carey, JO; Bryant, WO; Pettit, GJ; Ways, DK				DeVente, JE; Carey, JO; Bryant, WO; Pettit, GJ; Ways, DK			Transcriptional regulation of insulin receptor substrate 1 by protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTERS; 3T3-L1 ADIPOCYTES; DOWN-REGULATION; BREAST-CANCER; CELLS; BRYOSTATIN-1; RESISTANCE; IRS-1; PHOSPHORYLATION; DIFFERENTIATION	Insulin receptor substrate-1 (IRS-1) is involved in insulin signal transduction distal to receptor occupation. Targeted disruption of IRS-1 leads to insulin resistance and hyperglycemia in mice, which suggests that altered IRS-1 expression could contribute to the insulin resistance seen in non-insulin dependent diabetes mellitus. In vitro studies using phorbol esters have implicated the protein kinase C (PKC) pathway as being involved in the pathogenesis of insulin resistance. Using the MCF-7 breast cancer cell, a role for PRC in regulating IRS-1 expression was examined. In an MCF-7 cell line (MCF-7-PKC-alpha) that exhibits multiple alterations in PI(C isoform expression, IRS-1 content was reduced to negligible levels relative to parental MCF-7 cells. This decrease in IRS-I content was associated with a 30-fold reduction in IRS-I transcription. In parental MCF-7 cells, PKC inhibitors (GF109203X (bisindolylmaleimide I) and staurosporine) reduced IRS-I content. Chronic exposure to 12-O-tetradecanoylphorbol-13-acetate TPA; > 8 h) reduced IRS-1 content and down-regulated the novel PKC-delta isoform. Bryostatin I inhibited TPA-induced depletion of both IRS-1 and PKC-delta expression in MCF-7 cells. Associated with TPA-induced reduction in IRS-1 content was a reduction in IRS-1 transcription. These data demonstrate that PKC can modulate IRS-1 content and suggest a potential role for PKC-delta in positively regulating IRS-1 expression.	E CAROLINA UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,GREENVILLE,NC 27858; ARIZONA STATE UNIV,CANC RES INST,TEMPE,AZ 85287	University of North Carolina; East Carolina University; Arizona State University; Arizona State University-Tempe	DeVente, JE (corresponding author), E CAROLINA UNIV,SCH MED,DEPT MED,GREENVILLE,NC 27858, USA.							ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; CARO JF, 1992, MOL CELL BIOCHEM, V109, P115; CONSIDINE RV, 1995, J CLIN INVEST, V95, P2938, DOI 10.1172/JCI118001; DANIELSEN AG, 1995, J BIOL CHEM, V270, P21600, DOI 10.1074/jbc.270.37.21600; DAVID P, 1992, J MED CHEM, V35, P944; DELLAQUILA ML, 1987, CANCER RES, V47, P6006; DeVente J, 1996, ONCOL REP, V3, P213; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; GOODYEAR LJ, 1995, J CLIN INVEST, V95, P2195, DOI 10.1172/JCI117909; MULLER HK, 1991, DIABETES, V40, P1440, DOI 10.2337/diabetes.40.11.1440; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PARKER PJ, 1989, MOL CELL ENDOCRINOL, V65, P1, DOI 10.1016/0303-7207(89)90159-7; PETTIT GR, 1982, J AM CHEM SOC, V104, P6846, DOI 10.1021/ja00388a092; RICE KM, 1993, BIOCHEM BIOPH RES CO, V190, P961, DOI 10.1006/bbrc.1993.1143; SAAD M, 1993, ENDOCRINOLOGY, V136, P1579; SAAD M, 1994, MOL ENDOCRINOL, V8, P454; SAAD MJA, 1992, J CLIN INVEST, V90, P1839, DOI 10.1172/JCI116060; SAKO T, 1987, CANCER RES, V47, P5445; SHMUELI E, 1993, J INTERN MED, V234, P397, DOI 10.1111/j.1365-2796.1993.tb00761.x; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SZALLASI Z, 1994, J BIOL CHEM, V269, P2118; SZALLASI Z, 1994, MOL PHARMACOL, V46, P840; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TURNBOW MA, 1994, J BIOL CHEM, V269, P2516; WAYS DK, 1992, CANCER RES, V52, P5604; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; WAYS DK, 1992, J BIOL CHEM, V267, P4799; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1994, J BIOL CHEM, V269, P1; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335	31	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32276	32280		10.1074/jbc.271.50.32276	http://dx.doi.org/10.1074/jbc.271.50.32276			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943287	hybrid			2022-12-25	WOS:A1996VY34000078
J	Huang, LE; Arany, Z; Livingston, DM; Bunn, HF				Huang, LE; Arany, Z; Livingston, DM; Bunn, HF			Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; NF-KAPPA-B; HUMAN ERYTHROPOIETIN GENE; SIGNAL-TRANSDUCTION PATHWAY; ARYL-HYDROCARBON RECEPTOR; LACTATE-DEHYDROGENASE-A; RESPONSE ELEMENTS; ACTIVITY INVITRO; CAROTID-BODY; FACTOR-I	Hypoxia-inducible factor 1 (HIF-1) is a heterodimeric transcription factor that is critical for hypoxic induction of a number of physiologically important genes, We present evidence that regulation of HIF-1 activity is primarily determined by the stability of the HLF-1 alpha protein, Both HIF-1 alpha and HIF-1 beta mRNAs were constitutively expressed in HeLa and Hep3B cells with no significant induction by hypoxia, However, the HIF-1 alpha protein was barely detectable in normoxic cells, even when HLF-1 alpha was overexpressed, but was highly induced in hypoxic cells, whereas HIF-1 beta protein levels remained constant, regardless of pO(2). Hypoxia-induced HIF-1 binding as well as the HIF-1 alpha protein were rapidly and drastically decreased in vivo following an abrupt increase to normal oxygen tension, Moreover, short pre-exposure of cells to hydrogen peroxide selectively prevented hypoxia-induced HIF-1 binding via blocking accumulation of HIF-1 alpha protein, whereas treatment of hypoxic cell extracts with H2O2 had no effect on HIF-1 binding. These observations suggest that an intact redox-dependent signaling pathway is required for destabilization of the RIF-la protein, In hypoxic cell extracts, HIF-1 DNA binding was reversibly abolished by sulfhydryl oxidation, Furthermore, the addition of reduced thioredoxin to cell extracts enhanced HIF-1 DNA binding, Consistent with these results, overexpression of thioredoxin and Ref-1 significantly potentiated hypoxia-induced expression of a reporter construct containing the wild-type HIF-1 binding site, These experiments indicate that activation of HIF-1 involves redox-dependent stabilization of HIF-1 alpha protein.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV HEMATOL ONCOL,LMRC 2,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School				Huang, Eric/0000-0002-6444-1708	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009365, R01DK041234] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK41234, DK09365-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ACKER H, 1995, NEWS PHYSIOL SCI, V10, P211; ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; ARANY Z, 1996, IN PRESS P NATL ACAD; BLANCHARD KL, 1992, MOL CELL BIOL, V12, P5373, DOI 10.1128/MCB.12.12.5373; BRAWN MK, 1995, FREE RADICAL RES, V22, P23, DOI 10.3109/10715769509147525; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; EBERT BL, 1995, J BIOL CHEM, V270, P29083, DOI 10.1074/jbc.270.49.29083; FANDREY J, 1994, BIOCHEM J, V303, P507, DOI 10.1042/bj3030507; FIRTH JD, 1995, J BIOL CHEM, V270, P21021, DOI 10.1074/jbc.270.36.21021; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; GALSON DL, 1995, MOL CELL BIOL, V15, P2135; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; GORLACH A, 1993, BIOCHEM J, V290, P771; Gradin K, 1996, MOL CELL BIOL, V16, P5221; Harrison Lynn, 1992, Human Molecular Genetics, V1, P677, DOI 10.1093/hmg/1.9.677; Ho VT, 1996, BIOCHEM BIOPH RES CO, V223, P175, DOI 10.1006/bbrc.1996.0865; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HUANG LE, 1995, BIOCHEM J, V307, P347, DOI 10.1042/bj3070347; HUANG LE, 1994, J BIOL CHEM, V269, P30718; KHAN AU, 1995, CHEM BIOL, V2, P437; KOSOWER NS, 1987, METHOD ENZYMOL, V143, P76; KOSOWER NS, 1987, METHOD ENZYMOL, V143, P264; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; LEVY AP, 1995, J BIOL CHEM, V270, P1333; MAXWELL PH, 1993, P NATL ACAD SCI USA, V90, P2423, DOI 10.1073/pnas.90.6.2423; MCBRIDE AA, 1992, P NATL ACAD SCI USA, V89, P7531, DOI 10.1073/pnas.89.16.7531; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; NORRIS ML, 1995, J BIOL CHEM, V270, P23774, DOI 10.1074/jbc.270.40.23774; PANTOPOULOS K, 1995, EMBO J, V14, P2917, DOI 10.1002/j.1460-2075.1995.tb07291.x; POGNONEC P, 1992, J BIOL CHEM, V267, P24563; REISZPORSZASZ S, 1994, MOL CELL BIOL, V14, P6075, DOI 10.1128/MCB.14.9.6075; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; SWANSON HI, 1993, ARCH BIOCHEM BIOPHYS, V302, P167, DOI 10.1006/abbi.1993.1195; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1995, BIOCHEM BIOPH RES CO, V212, P550, DOI 10.1006/bbrc.1995.2005; WANG GL, 1993, J BIOL CHEM, V268, P21513; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WOOD SM, 1996, J BIOL CHEM, V269, P15117; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x	51	971	1016	1	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32253	32259		10.1074/jbc.271.50.32253	http://dx.doi.org/10.1074/jbc.271.50.32253			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943284	hybrid			2022-12-25	WOS:A1996VY34000075
J	Roe, MW; Worley, JF; Mittal, AA; Kuznetsov, A; DasGupta, S; Mertz, RJ; Witherspoon, SM; Blair, N; Lancaster, ME; McIntyre, MS; Shehee, WR; Dukes, ID; Philipson, LH				Roe, MW; Worley, JF; Mittal, AA; Kuznetsov, A; DasGupta, S; Mertz, RJ; Witherspoon, SM; Blair, N; Lancaster, ME; McIntyre, MS; Shehee, WR; Dukes, ID; Philipson, LH			Expression and function of pancreatic beta-cell delayed rectifier K+ channels - Role in stimulus-secretion coupling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CELLS; EXTERNAL TETRAETHYLAMMONIUM; CYTOPLASMIC CALCIUM; POTASSIUM CURRENTS; INSULIN-SECRETION; RAT-BRAIN; GLUCOSE; ISLETS; CA2+; QUININE	Voltage-dependent delayed rectifier K+ channels regulate aspects of both stimulus-secretion and excitation-contraction coupling, but assigning specific roles to these channels has proved problematic, Using transgenically derived insulinoma cells (beta TC3-neo) and beta-cells purified from rodent pancreatic islets of Langerhans, we studied the expression and role of delayed rectifiers in glucose-stimulated insulin secretion, Using reverse-transcription polymerase chain reaction methods to amplify all known candidate delayed rectifier transcripts, the expression of the K+ channel gene Kv2.1 in beta TC3-neo insulinoma cells and purified rodent pancreatic beta-cells was detected and confirmed by immunoblotting in the insulinoma cells, beta TC3-neo cells were also found to express a related K+ channel, Kv3.2, Whole-cell patch clamp demonstrated the presence of delayed rectifier K+ currents inhibited by tetraethylammonium (TEA) and 4-aminopyridine, with similar K-d values to that of Kv2.1, correlating delayed rectifier gene expression with the K+ currents, The effect of these blockers on intracellular Ca2+ concentration ([Ca2+](i)) was studied with fura-2 microspectrofluorimetry and imaging techniques, In the absence of glucose, exposure to TEA (1-20 mM) had minimal effects on beta TC3-neo or rodent islet [Ca2+](i), but in the presence of glucose, TEA activated large amplitude [Ca2+](i) oscillations. In the insulinoma cells the TEA-induced [Ca2+](i) oscillations were driven by synchronous oscillations in membrane potential, resulting in a 4-fold potentiation of insulin secretion, Activation of specific delayed rectifier K+ channels can therefore suppress stimulus secretion coupling by damping oscillations in membrane potential and [Ca2+](i) and thereby regulate secretion, These studies implicate previously uncharacterized beta-cell delayed rectifier K+ channels in the regulation of membrane repolarization, [Ca2+](i), and insulin secretion.	UNIV CHICAGO,DEPT MED,MC 1027,CHICAGO,IL 60637; GLAXO WELLCOME RES INST,RES TRIANGLE PK,NC 27709	University of Chicago; GlaxoSmithKline					NIDDK NIH HHS [R01 DK 48494-01, P01 DK 144840] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048494] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; BETSHOLTZ C, 1990, FEBS LETT, V263, P121, DOI 10.1016/0014-5793(90)80719-Y; BOKVIST K, 1990, J PHYSIOL-LONDON, V423, P311, DOI 10.1113/jphysiol.1990.sp018024; BOKVIST K, 1990, J PHYSIOL-LONDON, V423, P327, DOI 10.1113/jphysiol.1990.sp018025; CHANDY KG, 1995, LIGAND VOLTAGE GATED, P1; COOK DL, 1984, NATURE, V312, P446; Dukes ID, 1996, DIABETES, V45, P845, DOI 10.2337/diabetes.45.7.845; DUKES ID, 1994, J BIOL CHEM, V269, P10979; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; GILON P, 1993, J BIOL CHEM, V268, P22265; GILON P, 1992, J BIOL CHEM, V267, P20713; GROMADA J, 1995, DIABETES, V44, P767, DOI 10.2337/diabetes.44.7.767; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HENQUIN JC, 1990, PFLUG ARCH EUR J PHY, V416, P568, DOI 10.1007/BF00382691; HENQUIN JC, 1984, EXPERIENTIA, V40, P1043, DOI 10.1007/BF01971450; Hille B., 1991, IONIC CHANNELS EXCIT; Kalman Katalin, 1995, Biophysical Journal, V68, pA268; KEAHEY HH, 1989, DIABETES, V38, P188, DOI 10.2337/diabetes.38.2.188; KELLY RP, 1991, J PHYSIOL-LONDON, V443, P175, DOI 10.1113/jphysiol.1991.sp018829; KINARD TA, 1995, DIABETES, V44, P1461, DOI 10.2337/diabetes.44.12.1461; KIRSCH GE, 1992, NEURON, V8, P473; MCCORMACK T, 1990, P NATL ACAD SCI USA, V87, P5227, DOI 10.1073/pnas.87.13.5227; PHILIPSON LH, 1994, J BIOL CHEM, V269, P27787; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P806, DOI 10.1210/endo-117-3-806; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; RETTIG J, 1992, EMBO J, V11, P2473, DOI 10.1002/j.1460-2075.1992.tb05312.x; ROE MW, 1993, J BIOL CHEM, V268, P9953; ROE MW, 1995, DIABETES, V44, pA207; RORSMAN P, 1992, EMBO J, V11, P2877, DOI 10.1002/j.1460-2075.1992.tb05356.x; RORSMAN P, 1986, J PHYSIOL-LONDON, V374, P531, DOI 10.1113/jphysiol.1986.sp016096; SANCHEZ DY, 1992, J GEN PHYSIOL, V100, P217, DOI 10.1085/jgp.100.2.217; SANDSTROM PE, 1987, EUR J PHARMACOL, V144, P389, DOI 10.1016/0014-2999(87)90394-3; SMITH PA, 1990, J GEN PHYSIOL, V95, P1041, DOI 10.1085/jgp.95.6.1041; STURIS J, 1994, AM J PHYSIOL, V267, pE250, DOI 10.1152/ajpendo.1994.267.2.E250; TRIMMER JS, 1991, P NATL ACAD SCI USA, V88, P10764, DOI 10.1073/pnas.88.23.10764; WORLEY JF, 1994, J BIOL CHEM, V269, P14359; WORLEY JF, 1994, J BIOL CHEM, V269, P32055	37	99	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32241	32246		10.1074/jbc.271.50.32241	http://dx.doi.org/10.1074/jbc.271.50.32241			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943282	hybrid			2022-12-25	WOS:A1996VY34000073
J	Aquilla, E; Whelchel, A; Knot, HJ; Nelson, M; Posada, J				Aquilla, E; Whelchel, A; Knot, HJ; Nelson, M; Posada, J			Activation of multiple mitogen-activated protein kinase signal transduction pathways by the endothelin B receptor requires the cytoplasmic tail	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; HUMAN BETA-2-ADRENERGIC RECEPTOR; TERNARY COMPLEX MODEL; MAP KINASE; LIGAND-BINDING; C-FOS; CELLS; EXPRESSION; MUTATION; CLONING	Endothelin is a 21-amino acid peptide with remarkably diverse biological properties, including potent vasoconstriction, induction of mitogenesis, and a role in the development of blood vessels, In the present study, stimulation of the endothelin B receptor was found to activate three distinct mitogen-activated protein kinase signal transduction pathways, the extracellular regulated kinase (ERR) 2, c-Jun N-terminal kinase 1 (JNK), and p38 kinase, These mitogen-activated protein kinase isozymes are thought to mediate very different biological outcomes, suggesting that the observed pattern of kinases activation may be important for the diverse biological properties of endothelin. The cytoplasmic tail of the endothelin B receptor was found to be required for activation of all three mitogen-activated protein kinases and stimulation of intracellular calcium levels. An endothelin B receptor truncated at the C-terminal tail was not able to stimulate the mitogen-activated protein kinases or increase cytosolic free calcium. Furthermore, ectopic expression of the cytoplasmic Bail attenuated signaling through the mild type receptor, The observed ERK activation appeared to be mediated by heterotrimeric G proteins, since ectopic expression of a transducin alpha-subunit inhibited endothelin-stimulated ERK activation. The data suggest that the cytosolic tail of the endothelin B receptor is involved in calcium mobilization and mitogen-activated protein kinase activation via a G protein-dependent mechanism.	UNIV VERMONT, COLL MED, DEPT PHYSIOL & MOL BIOPHYS, BURLINGTON, VT 05405 USA; UNIV VERMONT, COLL MED, DEPT PHARMACOL, BURLINGTON, VT 05405 USA	University of Vermont; University of Vermont				Nelson, Mark/0000-0002-6608-8784; Posada, James/0000-0003-3582-9612	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL055327, R01HL044455, R01HL051728] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44455, HL55327, HL51728] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADACHI M, 1993, J CARDIOVASC PHARM, V22, pS121, DOI 10.1097/00005344-199322008-00033; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; ARAMORI I, 1992, J BIOL CHEM, V267, P12468; Clapham DE, 1996, NATURE, V379, P297, DOI 10.1038/379297a0; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Coso OA, 1996, J BIOL CHEM, V271, P3963; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DELEAN A, 1980, J BIOL CHEM, V255, P7108; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FAURE M, 1994, J BIOL CHEM, V269, P7851; Greenstein-Baynash A., 1994, CELL, V79, P1277; HASHIDO K, 1993, CELL MOL BIOL RES, V39, P3; HAWES BE, 1994, J BIOL CHEM, V269, P15776; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HillEubanks D, 1996, J BIOL CHEM, V271, P3058, DOI 10.1074/jbc.271.6.3058; HOSODA K, 1994, CELL, V79, P1267, DOI 10.1016/0092-8674(94)90017-5; KENNEDY ME, 1993, J BIOL CHEM, V268, P8003; KOMURO I, 1988, FEBS LETT, V238, P249, DOI 10.1016/0014-5793(88)80489-7; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEE JA, 1994, BIOCHEMISTRY-US, V33, P14543, DOI 10.1021/bi00252a022; LEE JA, 1996, ENDOTHELIN MOL BIOL; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LIN HY, 1991, P NATL ACAD SCI USA, V88, P3185, DOI 10.1073/pnas.88.8.3185; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Mattingly RR, 1996, NATURE, V382, P268, DOI 10.1038/382268a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OVCHINNIKOV YA, 1988, FEBS LETT, V230, P1, DOI 10.1016/0014-5793(88)80628-8; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; PUFFENBERGER EG, 1994, CELL, V79, P1257, DOI 10.1016/0092-8674(94)90016-7; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; SAKAMOTO A, 1993, J BIOL CHEM, V268, P8547; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Shapiro PS, 1996, J BIOL CHEM, V271, P5750, DOI 10.1074/jbc.271.10.5750; SIMONSON MS, 1989, J CLIN INVEST, V83, P708, DOI 10.1172/JCI113935; Simonson MS, 1996, J BIOL CHEM, V271, P77, DOI 10.1074/jbc.271.1.77; SIMONSON MS, 1993, J BIOL CHEM, V268, P9347; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Spalding TA, 1995, J PHARMACOL EXP THER, V275, P1274; TAKAGI Y, 1995, J BIOL CHEM, V270, P10072, DOI 10.1074/jbc.270.17.10072; TOUHARA K, 1995, P NATL ACAD SCI USA, V92, P9284, DOI 10.1073/pnas.92.20.9284; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	54	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31572	31579		10.1074/jbc.271.49.31572	http://dx.doi.org/10.1074/jbc.271.49.31572			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940174	hybrid			2022-12-25	WOS:A1996VW68600085
J	Bao, M; Booth, JL; Elmendorf, BJ; Canfield, WM				Bao, M; Booth, JL; Elmendorf, BJ; Canfield, WM			Bovine UDP-N-acetylglucosamine:lysosomal-enzyme N-acetylglucosamine-1-phosphotransferase .1. Purification and subunit structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-CELL DISEASE; GLYCOPROTEIN N-ACETYLGLUCOSAMINE-1-PHOSPHOTRANSFERASE; RAT-LIVER; CDNA CLONING; PROTEINS; ACETYLGLUCOSAMINYLPHOSPHOTRANSFERASE; PHOSPHODIESTERASE; PHOSPHORYLATION; EXPRESSION; IDENTIFICATION	UDP-N-acetylglucosamine:lysosomal-enzyme N-acetylglucosamine-1-phosphotransferase (GlcNAc-phosphotransferase) catalyzes the initial step in the synthesis of the mannose 6-phosphate determinant required for efficient intracellular targeting of newly synthesized lysosomal hydrolases to the lysosome, The enzyme was partially purified similar to 30,000-fold by chromatography of solubilized membrane proteins from lactating bovine mammary glands on DEAE-Sepharose, reactive green 19-agarose, and Superose 6, The partially purified enzyme was used to generate a panel of murine monoclonal antibodies, The anti-GlcNAc-phosphotransferase monoclonal antibody PT18 was coupled to a solid support and used to immunopurify the enzyme similar to 480,000-fold to apparent homogeneity with an overall yield of 29%, The purified enzyme has a specific activity of 10-12 mu mol of GlcNAc phosphate transferred per h/mg using 100 mM alpha-methylmannoside as acceptor. The subunit structure of the enzyme was determined using a combination of analytical gel filtration chromatography, sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and amino-terminal sequencing. The data indicate that bovine GlcNAc-phosphotransferase is a 540,000-Da complex composed of disulfide-linked homodimers of 166,000- and 51,000-Da subunits and two identical, noncovalently associated 56,000-Da subunits.	UNIV OKLAHOMA,HLTH SCI CTR,WK WARREN MED RES INST,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT MED,OKLAHOMA CITY,OK 73104	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center								BARPELED M, 1991, J BIOL CHEM, V266, P20953; BENDIAK B, 1987, J BIOL CHEM, V262, P5775; BENYOSEPH Y, 1986, BIOCHEM J, V235, P883, DOI 10.1042/bj2350883; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BROWN EG, 1982, ANAL BIOCHEM, V123, P378, DOI 10.1016/0003-2697(82)90461-4; DAGOSTARO GAF, 1995, J BIOL CHEM, V270, P15211, DOI 10.1074/jbc.270.25.15211; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; Harlow E., 1988, ANTIBODIES LAB MANUA; HONEY NK, 1982, P NATL ACAD SCI-BIOL, V79, P7420, DOI 10.1073/pnas.79.23.7420; IHARA Y, 1993, J BIOCHEM-TOKYO, V113, P692, DOI 10.1093/oxfordjournals.jbchem.a124105; KETCHAM CM, 1992, J BIOL CHEM, V267, P11645; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KUMAR R, 1990, P NATL ACAD SCI USA, V87, P9948, DOI 10.1073/pnas.87.24.9948; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG L, 1986, J BIOL CHEM, V261, P6320; LANG L, 1984, J BIOL CHEM, V259, P4663; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; REITMAN ML, 1981, J CLIN INVEST, V67, P1574, DOI 10.1172/JCI110189; REITMAN ML, 1981, J BIOL CHEM, V256, P4275; REITMAN ML, 1981, J BIOL CHEM, V256, P1977; REITMAN ML, 1984, METHOD ENZYMOL, V107, P163; ROPP PA, 1990, ANAL BIOCHEM, V187, P104, DOI 10.1016/0003-2697(90)90424-8; SAITO H, 1994, BIOCHEM BIOPH RES CO, V198, P318, DOI 10.1006/bbrc.1994.1045; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHAILUBHAI K, 1988, J BIOL CHEM, V263, P15964; SHOWS TB, 1982, AM J MED GENET, V12, P343, DOI 10.1002/ajmg.1320120312; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITHIES O, 1971, BIOCHEMISTRY-US, V10, P4912, DOI 10.1021/bi00802a013; VARKI A, 1981, J BIOL CHEM, V256, P9937; VIJAY IK, 1977, J SUPRAMOL STR CELL, V7, P251, DOI 10.1002/jss.400070209; WAHEED A, 1982, J BIOL CHEM, V257, P2322; WAHEED A, 1981, J BIOL CHEM, V256, P5717; ZHAO KW, 1992, GLYCOBIOLOGY, V2, P119, DOI 10.1093/glycob/2.2.119	35	101	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31437	31445		10.1074/jbc.271.49.31437	http://dx.doi.org/10.1074/jbc.271.49.31437			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940155	hybrid			2022-12-25	WOS:A1996VW68600066
J	Jacobsen, L; Madsen, P; Moestrup, SK; Lund, AH; Tommerup, N; Nykjaer, A; SottrupJensen, L; Gliemann, J; Petersen, CM				Jacobsen, L; Madsen, P; Moestrup, SK; Lund, AH; Tommerup, N; Nykjaer, A; SottrupJensen, L; Gliemann, J; Petersen, CM			Molecular characterization of a novel human hybrid-type receptor that binds the alpha(2)-macroglobulin receptor-associated protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; ALPHA-2-MACROGLOBULIN RECEPTOR; PLASMINOGEN-ACTIVATOR; CYTOPLASMIC DOMAIN; LIGAND-BINDING; CELL-ADHESION; GENE; INTERNALIZATION; SEQUENCE; MEGALIN	The 39-40-kDa receptor-associated protein (RAP) binds to the members of the low density lipoprotein receptor gene family and functions as a specialized endoplasmic reticulum/Golgi chaperone, Using RAP affinity chromatography, we have purified a novel similar to 250-kDa brain protein and isolated the corresponding cDNA. The gene, designated SORL1, maps to chromosome 11q 23/24 and encodes a 2214-residue type 1 receptor containing a furin cleavage site immediately preceding the N terminus determined in the purified protein. The receptor, designated sorLA-1, has a short cytoplasmic tail containing a tyrosine-based internalization signal and a large external part containing (from the N-terminal): 1) a segment homologous to domains in the yeast vacuolar protein sorting 10 protein, Vps10p, that binds carboxypeptidase Y, 2) five tandemly arranged YWTD repeats and a cluster of 11 class A repeats characteristic of the low density lipoprotein receptor gene family receptors, and 3) six tandemly arranged fibronectin type III repeats also found in certain neural adhesion proteins. sorLA-1 may therefore be classified as a hybrid receptor, Northern blotting revealed specific mRNA transcripts in brain, spinal cord, and testis but not in several major organs, Both RAP and an antibody against a synthetic peptide derived from a sequence determined in the mature protein detected sorLA-1 in crude human brain extracts. The domain structure suggests that sorLA-1 is an endocytic receptor possibly implicated in the uptake of lipoproteins and of proteases.	AARHUS UNIV,DEPT BIOL MOL & STRUCT,DK-8000 AARHUS C,DENMARK; UNIV COPENHAGEN,PANUM INST,DEPT MED GENET,DK-2200 COPENHAGEN N,DENMARK	Aarhus University; University of Copenhagen	Jacobsen, L (corresponding author), AARHUS UNIV,DEPT BIOCHEM MED,OLE WORMS ALLE,BLDG 170,DK-8000 AARHUS C,DENMARK.		Moestrup, Søren Kragh/A-1403-2014; Moestrup, Søren Kragh/AAD-1735-2019; Lund, Anders H./F-4786-2014; Tommerup, Niels/T-8776-2017	Moestrup, Søren Kragh/0000-0003-3862-2107; Lund, Anders H./0000-0002-7407-3398; Tommerup, Niels/0000-0003-2304-0112; Madsen, Peder Sondergaard/0000-0002-8845-4802; Nykjaer, Anders/0000-0001-6422-6736				ATHERTON D, 1993, ANAL BIOCHEM, V212, P98, DOI 10.1006/abio.1993.1297; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; BURGOON MP, 1995, J CELL BIOL, V130, P733, DOI 10.1083/jcb.130.3.733; DALY NL, 1995, P NATL ACAD SCI USA, V92, P6334, DOI 10.1073/pnas.92.14.6334; FARQUHAR MG, 1995, J AM SOC NEPHROL, V6, P35; FERNANDEZ J, 1992, ANAL BIOCHEM, V210, P265; HONORE B, 1993, J BIOCHEM BIOPH METH, V27, P39, DOI 10.1016/0165-022X(93)90066-W; Jingami Hisato, 1995, Current Opinion in Lipidology, V6, P104, DOI 10.1097/00041433-199504000-00008; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; MARCUSSON EG, 1994, CELL, V77, P579, DOI 10.1016/0092-8674(94)90219-4; MOESTRUP SK, 1993, J BIOL CHEM, V268, P13691; NIELSEN MS, 1995, J BIOL CHEM, V270, P23713, DOI 10.1074/jbc.270.40.23713; Novak S, 1996, J BIOL CHEM, V271, P11732, DOI 10.1074/jbc.271.20.11732; Petersen CM, 1996, EMBO J, V15, P4165, DOI 10.1002/j.1460-2075.1996.tb00791.x; PRINCE JT, 1991, J NEUROSCI RES, V30, P567, DOI 10.1002/jnr.490300315; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; Schneider Wolfgang J., 1993, Current Opinion in Lipidology, V4, P205, DOI 10.1097/00041433-199306000-00005; SOTTRUPJENSEN L, 1995, ANAL BIOCHEM, V225, P187, DOI 10.1006/abio.1995.1137; STRITTMATTER WJ, 1995, P NATL ACAD SCI USA, V92, P4725, DOI 10.1073/pnas.92.11.4725; TENSEN CP, 1994, P NATL ACAD SCI USA, V91, P4816, DOI 10.1073/pnas.91.11.4816; TOMMERUP N, 1995, GENOMICS, V27, P259, DOI 10.1006/geno.1995.1040; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VOORHEES P, 1995, EMBO J, V14, P4961, DOI 10.1002/j.1460-2075.1995.tb00179.x; Willnow TE, 1996, EMBO J, V15, P2632, DOI 10.1002/j.1460-2075.1996.tb00623.x; WILLNOW TE, 1994, J BIOL CHEM, V269, P15827	31	201	210	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31379	31383		10.1074/jbc.271.49.31379	http://dx.doi.org/10.1074/jbc.271.49.31379			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940146	hybrid			2022-12-25	WOS:A1996VW68600057
J	Nielsen, AL; Norby, PL; Pedersen, FS; Jorgensen, P				Nielsen, AL; Norby, PL; Pedersen, FS; Jorgensen, P			E-box sequence and context-dependent TAL1/SCL modulation of basic helix-loop-helix protein-mediated transcriptional activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL LEUKEMIA; DNA-BINDING MOTIF; SCL GENE-PRODUCT; ERYTHROID-DIFFERENTIATION; MYELOID DIFFERENTIATION; ENHANCER-BINDING; E2A PROTEINS; ID PROTEINS; IN-VIVO; EXPRESSION	TAL1/SCL is a basic helix-loop-helix (bHLH) oncoprotein that is expressed in several cell lines including many hematolymphoid cells, but not in T- and B-lineage cells. The TALI gene was originally discovered as being transcriptionally activated by chromosomal rearrangements in T-cell acute lymphoblastic leukemia (T-ALL). Here we have shown that TAL1 and the ubiquitously expressed murine bHLH transcription factor ALF1 formed heterodimers that, compared with ALF1 homodimers, had a more restricted E-box specificity and bound preferentially to the glucocorticoid-responsive E-box (E(gre)) motif (AACGATGGT). Overexpression of the dominant inhibitory HLH protein Id1 in NIH3T3 cells reduced the transcriptional activity mediated by ALF1 homodimers, whereas the transcriptional activity mediated by TAL1/ALF1 heterodimers was resistant to Id overexpression. Our results show that ALF1 may serve as a dimerization partner for the bHLH oncoprotein TAL1 and form a complex with a distinctive DNA binding property. These findings support the hypothesis that the leukemic characteristics of the TAL1 oncoprotein could be mediated by activation of a set of target genes as heterodimeric complexes with ubiquitously expressed bHLH transcription factors such as ALF1 and that a principal role of TAL1 might be to neutralize an Id-mediated inactivation.	AARHUS UNIV,DEPT MOL BIOL,DK-8000 AARHUS C,DENMARK; AARHUS UNIV,DEPT MED MICROBIOL & IMMUNOL,DK-8000 AARHUS C,DENMARK	Aarhus University; Aarhus University			Nielsen, Anders Lade L/Q-9604-2016	Nielsen, Anders Lade L/0000-0003-4372-9961				APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; CORNELIUSSEN B, 1991, J VIROL, V65, P6084, DOI 10.1128/JVI.65.11.6084-6093.1991; DOYLE K, 1994, J BIOL CHEM, V269, P12099; FINKEL T, 1993, J BIOL CHEM, V268, P5; GOLDFARB AN, 1995, BLOOD, V85, P465; GOLEMIS EA, 1990, J VIROL, V64, P534, DOI 10.1128/JVI.64.2.534-542.1990; GREEN AR, 1991, EMBO J, V10, P4153, DOI 10.1002/j.1460-2075.1991.tb04993.x; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; Hoang T, 1996, BLOOD, V87, P102; HSU HL, 1994, P NATL ACAD SCI USA, V91, P3181, DOI 10.1073/pnas.91.8.3181; HSU HL, 1994, P NATL ACAD SCI USA, V91, P5947, DOI 10.1073/pnas.91.13.5947; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; HSU HL, 1994, MOL CELL BIOL, V14, P1256, DOI 10.1128/MCB.14.2.1256; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; HWANG LY, 1993, ONCOGENE, V8, P3043; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Nielsen AL, 1996, J VIROL, V70, P5893, DOI 10.1128/JVI.70.9.5893-5901.1996; NIELSEN AL, 1992, MOL CELL BIOL, V12, P3449, DOI 10.1128/MCB.12.8.3449; NIELSEN AL, 1994, J VIROL, V68, P5638, DOI 10.1128/JVI.68.9.5638-5647.1994; PALLISGAARD N, 1994, GENE, V138, P115, DOI 10.1016/0378-1119(94)90791-9; RIECHMANN V, 1994, NUCLEIC ACIDS RES, V22, P749, DOI 10.1093/nar/22.5.749; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; SAWADA S, 1993, MOL CELL BIOL, V13, P5620, DOI 10.1128/MCB.13.9.5620; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; SHOJI W, 1994, J BIOL CHEM, V269, P5078; SPECK NA, 1990, J VIROL, V64, P543, DOI 10.1128/JVI.64.2.543-550.1990; SPIRO C, 1988, VIROLOGY, V164, P350, DOI 10.1016/0042-6822(88)90548-X; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; TANIGAWA T, 1993, P NATL ACAD SCI USA, V90, P7864, DOI 10.1073/pnas.90.16.7864; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; VISVADER J, 1991, TRENDS BIOCHEM SCI, V16, P330, DOI 10.1016/0968-0004(91)90137-K; VORONOVA AF, 1994, P NATL ACAD SCI USA, V91, P5952, DOI 10.1073/pnas.91.13.5952; WADMAN IA, 1994, ONCOGENE, V9, P3713; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416; ZHANG Y, 1991, NUCLEIC ACIDS RES, V19, P4555, DOI 10.1093/nar/19.16.4555; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	47	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31463	31469		10.1074/jbc.271.49.31463	http://dx.doi.org/10.1074/jbc.271.49.31463			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940159	hybrid			2022-12-25	WOS:A1996VW68600070
J	OkudaAshitaka, E; Sakamoto, K; Ezashi, T; Miwa, K; Ito, S; Hayaishi, O				OkudaAshitaka, E; Sakamoto, K; Ezashi, T; Miwa, K; Ito, S; Hayaishi, O			Suppression of prostaglandin E receptor signaling by the variant form of EP(1) subtype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL TAIL; EXPRESSION CLONING; EP(3) RECEPTOR; MESSENGER-RNA; CDNA; PROTEIN; ISOFORMS; SEQUENCE; CELLS; INHIBITION	A cDNA clone of prostaglandin (PG) E receptor EP(1) subtype (rEP(1)) was isolated from a rat uterus cDNA library, It encodes 405 amino acid residues with seven transmembrane spanning domains and couples to Ca2+ mobilization, In addition, three cDNA clones encoding a variant form of rEP(1) were isolated, The open reading frame can code a 366-amino acid protein carrying a specific change of 49 amino acids from the middle of transmembrane segment VI to COOK terminus; it possesses a transmembrane segment VII-like structure lacking an intracellular COOK-terminal tail, Southern blot analysis of rat genomic DNA and genomic polymerase chain reaction demonstrated that these cDNAs were derived from a single copy gene, Northern blot analysis and ribonuclease protection assay revealed that both rEP(1) and rEP(1)-variant receptor mRNAs were highly expressed in the kidney, Immunoblot with an antibody directed toward the specific region of rEP(1)-variant receptor showed that rEP(1)-variant receptor protein was expressed in the membrane of the kidney and Chinese hamster ovary (CHO) cells transfected with rEP(1)-variant cDNA, Thus, the rEP(1)-variant receptor is translated from mRNA which is not spliced at nucleotide position 952 in the segment VI transmembrane region, rEP(1)-variant receptor retained the ligand binding activity with affinity and specificity similar to rEP(1) receptor, but lost the coupling of signal transduction systems by itself, However, when rEP(1)-variant receptor was stably co-expressed with rEP(1) receptor in CHO cells, the Ca2+ mobilization mediated by EP(1) receptor was significantly suppressed, Furthermore, when rEP(1)-variant receptor was expressed in CHO cells, cAMP formation by activation of endogenous EP(4) receptor was strongly blocked, These results suggest that the rEP(1)-variant receptor may affect the efficiency of signal coupling of PGE receptors and attenuate the action of PGE(2) on tissues.	OSAKA BIOSCI INST,DEPT CELL BIOL,SUITA,OSAKA 565,JAPAN; KANSAI MED UNIV,DEPT MED CHEM,MORIGUCHI,OSAKA 570,JAPAN	Kansai Medical University				ito, Seiji/0000-0002-0942-1624				ADAM M, 1994, FEBS LETT, V338, P170, DOI 10.1016/0014-5793(94)80358-7; BOIE Y, 1994, J BIOL CHEM, V269, P12173; BREYER RM, 1994, J BIOL CHEM, V269, P6163; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; COLEMAN RA, 1990, COMPREHENSIVE MED CH, V3, P643; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; FUNK CD, 1993, J BIOL CHEM, V268, P26767; FUNK CD, 1993, MOL PHARMACOL, V44, P934; HONDA A, 1993, J BIOL CHEM, V268, P7759; IRIE A, 1993, EUR J BIOCHEM, V217, P313, DOI 10.1111/j.1432-1033.1993.tb18248.x; KATOH H, 1995, BBA-GEN SUBJECTS, V1244, P41, DOI 10.1016/0304-4165(94)00182-W; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MARUYAMA K, 1994, 9 INT C PROST REL CO; MINAMI T, 1995, BRIT J PHARMACOL, V115, P73, DOI 10.1111/j.1476-5381.1995.tb16321.x; MIWA N, 1988, J NEUROCHEM, V50, P1418, DOI 10.1111/j.1471-4159.1988.tb03025.x; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAMBA T, 1994, J BIOL CHEM, V269, P9986; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; NEGISHI M, 1987, J BIOL CHEM, V262, P12077; NUSING RM, 1993, J BIOL CHEM, V268, P25253; OKUDAASHITAKA E, 1990, EICOSANOIDS, V3, P213; REGAN JW, 1994, MOL PHARMACOL, V46, P213; SAKAI H, 1995, J BIOL CHEM, V270, P18781, DOI 10.1074/jbc.270.32.18781; SAKAMOTO K, 1994, J BIOL CHEM, V269, P3881; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMID A, 1995, EUR J BIOCHEM, V228, P23, DOI 10.1111/j.1432-1033.1995.tb20223.x; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SOMPAYRAC LM, 1981, P NATL ACAD SCI-BIOL, V78, P7575, DOI 10.1073/pnas.78.12.7575; SUGIMOTO Y, 1992, J BIOL CHEM, V267, P6463; SUGIMOTO Y, 1993, J BIOL CHEM, V268, P2712; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; TSIEN RY, 1982, J CELL BIOL, V94, P325, DOI 10.1083/jcb.94.2.325; TYKOCINSKI ML, 1988, P NATL ACAD SCI USA, V85, P3555, DOI 10.1073/pnas.85.10.3555; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; WATABE A, 1993, J BIOL CHEM, V268, P20175; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; YAMASHITA M, 1991, P NATL ACAD SCI USA, V88, P11515, DOI 10.1073/pnas.88.24.11515	39	79	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31255	31261		10.1074/jbc.271.49.31255	http://dx.doi.org/10.1074/jbc.271.49.31255			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940129	hybrid			2022-12-25	WOS:A1996VW68600040
J	Shi, WX; Chammas, R; Varki, A				Shi, WX; Chammas, R; Varki, A			Regulation of sialic acid 9-O-acetylation during the growth and differentiation of murine erythroleukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-C-VIRUS; HUMAN-MELANOMA CELLS; HEPARAN-SULFATE PROTEOGLYCANS; O-ACETYL GROUPS; MONOCLONAL-ANTIBODY; 9-O-ACETYL-N-ACETYLNEURAMINIC ACID; LINKED OLIGOSACCHARIDES; HUMAN-LEUKOCYTES; SURFACE; GANGLIOSIDES	Sialic acids are typically found at the terminal position on vertebrate oligosaccharides. They are sometimes modified by an O-acetyl ester at the 9-position, potentially altering recognition of sialic acid by antibodies, lectins, and viruses, 9-O-Acetylation is known to be selectively expressed on gangliosides in melanoma cells and on N-linked chains in hepatocytes, Using a recently developed probe, we show here that in murine erythroleukemia cells, this modification is selectively expressed on another class of oligosaccharides, O-linked chains carried on cell surface sialomucins, These cells also express 9-O-acetylation on the ganglioside G(Da), but this modification appears to be undetectable on the cell surface, Increasing cell density in culture is associated with a decrease in cell surface 9-O-acetylation of sialomucins. This change correlates with the spontaneous differentiation toward a mature erythroid phenotype, This down-regulation upon differentiation and entry into the G(0)/G(1) stage of the cell cycle is confirmed by differentiation-inducing agents, In contrast, cells arrested in G(2)/M by the microtubule depolymerizing agent nocodazole show increased expression of cell surface 9-O-acetylated sialomucins (but not the 9-O-acetylated ganglioside), However, the microtubule stabilizer taxol does not induce this increase, showing that the nocodazole effect is independent of cell cycle stage, Indeed, direct analysis showed no correlation of 9-O-acetylation with cell cycle stage in rapidly growing cells, and shorter treatments with nocodazole also increased expression, Western blots of cell extracts confirmed that changes caused by differentiation and nocodazole are not due to redistribution of molecules from the cell surface, Indeed, follow ing selective removal of 9-O-acetyl groups from the cell surface by a specific esterase, the recovery of expression is mediated by new synthesis rather than by redistribution from an internal pool, Thus, 9-O-acetylation on these sialomucins appears to be primarily regulated by the rate of synthesis, and the increase with nocodazole treatment is likely due to the inhibition of turnover of cell surface molecules, These data show that 9-O-acetylation of sialic acids in murine erythroleukemia cells is a highly regulated modification, being selectively expressed in a cell type-specific manner on certain classes of oligosaccharides and differentially regulated with regard to subcellular localization and to the state of cellular differentiation.	UNIV CALIF SAN DIEGO,CTR CANC,GLYCOBIOL PROGRAM,DIV CELLULAR & MOL MED,LA JOLLA,CA 92093	University of California System; University of California San Diego			Chammas, Roger/A-8004-2011	Chammas, Roger/0000-0003-0342-8726	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032373] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA5869] Funding Source: Medline; NIGMS NIH HHS [R01-GM32373] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLUM AS, 1987, P NATL ACAD SCI USA, V84, P8716, DOI 10.1073/pnas.84.23.8716; BUTOR C, 1993, J BIOL CHEM, V268, P10197; CHERESH DA, 1984, SCIENCE, V225, P844, DOI 10.1126/science.6206564; CHERESH DA, 1984, J BIOL CHEM, V259, P7453; CONSTANTINEPATON M, 1986, NATURE, V324, P459, DOI 10.1038/324459a0; CORFIELD AP, 1986, BIOL CHEM H-S, V367, P433, DOI 10.1515/bchm3.1986.367.1.433; DIAZ S, 1985, ANAL BIOCHEM, V150, P32, DOI 10.1016/0003-2697(85)90438-5; DOLCI ED, 1989, J CELL SCI, V93, P191; DRAZBA J, 1991, DEV BIOL, V145, P154, DOI 10.1016/0012-1606(91)90221-N; ELKJAER ML, 1995, EUR J CELL BIOL, V67, P57; FRASER IP, 1994, EUR J CELL BIOL, V64, P217; GOLTZ JS, 1992, P NATL ACAD SCI USA, V89, P7026, DOI 10.1073/pnas.89.15.7026; Guimaraes MJ, 1996, J BIOL CHEM, V271, P13697, DOI 10.1074/jbc.271.23.13697; JIN M, 1983, J BIOL CHEM, V268, P18390; KAMERLING JP, 1982, BIOCHIM BIOPHYS ACTA, V714, P351, DOI 10.1016/0304-4165(82)90344-0; KAMERLING JP, 1987, EUR J BIOCHEM, V162, P601, DOI 10.1111/j.1432-1033.1987.tb10681.x; KELM S, 1994, GLYCOCONJUGATE J, V11, P576, DOI 10.1007/BF00731309; KLEIN A, 1994, P NATL ACAD SCI USA, V91, P7782, DOI 10.1073/pnas.91.16.7782; KNIEP B, 1992, BIOCHEM BIOPH RES CO, V187, P1343, DOI 10.1016/0006-291X(92)90450-Y; KNIEP B, 1993, BLOOD, V82, P1776; KNIEP B, 1995, J BIOL CHEM, V270, P30173; KREIS TE, 1990, CELL MOTIL CYTOSKEL, V15, P67, DOI 10.1002/cm.970150202; LEVINE JM, 1984, J NEUROSCI, V4, P820; LLOYD KO, 1992, CANCER RES, V52, P4948; MANZI AE, 1990, J BIOL CHEM, V265, P13091; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MELLORS A, 1995, METHOD ENZYMOL, V248, P728; MISAWA Y, 1992, ONCOGENE, V7, P919; Morrison SJ, 1995, ANNU REV CELL DEV BI, V11, P35, DOI 10.1146/annurev.cb.11.110195.000343; MUCHMORE EA, 1987, SCIENCE, V236, P1293, DOI 10.1126/science.3589663; NORGARD KE, 1993, J BIOL CHEM, V268, P12764; OKAYAMA M, 1991, J BIOL CHEM, V266, P3808; REUTER G, 1980, BIOCHEM BIOPH RES CO, V94, P567, DOI 10.1016/0006-291X(80)91269-3; ROGERS GN, 1986, J BIOL CHEM, V261, P5947; SARRIS AH, 1979, J BIOL CHEM, V254, P6724; SCHAUER R, 1991, Glycobiology, V1, P449, DOI 10.1093/glycob/1.5.449; Schauer R., 1982, CELL BIOL MONOGRAPHS, V10; SEN G, 1994, MOL CELL BIOCHEM, V136, P65, DOI 10.1007/BF00931606; Shi WX, 1996, J BIOL CHEM, V271, P31526, DOI 10.1074/jbc.271.49.31526; SJOBERG ER, 1994, J CELL BIOL, V126, P549, DOI 10.1083/jcb.126.2.549; SJOBERG ER, 1995, J BIOL CHEM, V270, P2921, DOI 10.1074/jbc.270.7.2921; TAKEUCHI Y, 1992, J BIOL CHEM, V267, P14685; THURIN J, 1985, J BIOL CHEM, V260, P4556; TOOZE J, 1991, J CELL BIOL, V115, P635, DOI 10.1083/jcb.115.3.635; ULMER JB, 1989, P NATL ACAD SCI USA, V86, P6992, DOI 10.1073/pnas.86.18.6992; VARKI A, 1984, ANAL BIOCHEM, V137, P236, DOI 10.1016/0003-2697(84)90377-4; VARKI A, 1980, J EXP MED, V152, P532, DOI 10.1084/jem.152.3.532; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; VLASAK R, 1987, VIROLOGY, V160, P419, DOI 10.1016/0042-6822(87)90013-4; WALLICK SC, 1988, J EXP MED, V168, P1099, DOI 10.1084/jem.168.3.1099; ZIMMER G, 1992, EUR J BIOCHEM, V204, P209, DOI 10.1111/j.1432-1033.1992.tb16626.x; ZIMMER G, 1994, GLYCOBIOLOGY, V4, P343, DOI 10.1093/glycob/4.3.343	52	32	32	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31517	31525		10.1074/jbc.271.49.31517	http://dx.doi.org/10.1074/jbc.271.49.31517			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940167	hybrid			2022-12-25	WOS:A1996VW68600078
J	Wright, DA; Futcher, B; Ghosh, P; Geha, RS				Wright, DA; Futcher, B; Ghosh, P; Geha, RS			Association of human Fas (CD95) with a ubiquitin-conjugating enzyme (UBC-FAP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; CELL-DEATH; LYMPHOPROLIFERATIVE SYNDROME; S-PHASE; APOPTOSIS; PROTEIN; ANTIGEN; GENE; ACTIVATION; RECEPTOR	A novel human ubiquitin conjugating enzyme (UBC) was found to associate with Fas (CD95). The mRNA for this UBC Fas-associated protein (FAP) was widely expressed in human tissues, and the protein was identified in several mammalian cell lines, UBC-FAP shows strong homology to two recently identified UBCs, Hus5 and Ubc9, which control yeast cell cycle progression, UBC-FAP, but not an active site mutant, complemented ubc9-1(ts) mutants, This suggests that UBC-FAP is a human homologue of Ubc9, possesses ubiquitin conjugating activity, and may play an important role in mammalian cell cycle regulation, A single amino acid substitution in the death domain of Fas that abolishes Fas-mediated apoptosis also abolished Fas association with UBC-FAP, suggesting that UBC-FAP may play a role in Fas signal transduction, The sequence of UBC-FAP is identical to that of HsUbc9, a UBC recently shown to interact with Rad51.	CHILDRENS HOSP,DIV IMMUNOL,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Cold Spring Harbor Laboratory					NIAMS NIH HHS [AR-43985] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043985] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALKHODAIRY F, 1995, J CELL SCI, V108, P475; BISSONNETTE RP, 1994, J EXP MED, V180, P2413, DOI 10.1084/jem.180.6.2413; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cenciarelli C, 1996, J BIOL CHEM, V271, P8709, DOI 10.1074/jbc.271.15.8709; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CHU KT, 1995, P NATL ACAD SCI USA, V92, P11894, DOI 10.1073/pnas.92.25.11894; CLEMENT MV, 1994, J EXP MED, V180, P557, DOI 10.1084/jem.180.2.557; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; FOTEDAR R, 1995, MOL CELL BIOL, V15, P932; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; HANDLEYGEARHART PM, 1994, J BIOL CHEM, V269, P33171; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kovalenko OV, 1996, P NATL ACAD SCI USA, V93, P2958, DOI 10.1073/pnas.93.7.2958; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PAOLINI R, 1993, EMBO J, V12, P779, DOI 10.1002/j.1460-2075.1993.tb05712.x; PLON SE, 1993, P NATL ACAD SCI USA, V90, P10484, DOI 10.1073/pnas.90.22.10484; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; VACCA A, 1992, J EXP MED, V175, P637, DOI 10.1084/jem.175.3.637; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	38	53	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31037	31043		10.1074/jbc.271.49.31037	http://dx.doi.org/10.1074/jbc.271.49.31037			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940097	hybrid			2022-12-25	WOS:A1996VW68600008
J	Pollenz, RS; Sullivan, HR; Holmes, J; Necela, B; Peterson, RE				Pollenz, RS; Sullivan, HR; Holmes, J; Necela, B; Peterson, RE			Isolation and expression of cDNAs from rainbow trout (Oncorhynchus mykiss) that encode two novel basic helix-loop-helix/PER-ARNT-SIM (bHLH/PAS) proteins with distinct functions in the presence of the aryl hydrocarbon receptor - Evidence for alternative mRNA splicing and dominant negative activity in the bhlh/pas family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; MOUSE HEPATOMA-CELLS; AH-RECEPTOR; NUCLEAR TRANSLOCATOR; DIOXIN RECEPTOR; DNA RECOGNITION; MESSENGER-RNAS; TRANSCRIPTION FACTOR; TERMINAL DOMAINS; BINDING-SITE	cDNAs encoding two distinct basic helix-loop-helix/ PER-ARNT-SIM (bHLH/PAS) proteins with similarity to the mammalian aryl hydrocarbon nuclear translocator (ARNT) protein were isolated from RTG-2 rainbow trout gonad cells, The deduced proteins, termed rtARNT(a) and rtARNT(b), are identical over the first 533 amino acids and contain a basic helix-loop-helix domain that is 100% identical to human ARNT. rtARNT(a) and rtARNT(b) differ in their COOH terminal domains due to the presence of an additional 373 base pairs of sequence that have the characteristics of an alternatively spliced exon, The presence of the 373-base pair region causes a shift in the reading frame, rtARNT(b) lacks the sequence and has a COOH-terminal domain of 104 residues rich in proline, serine, and threonine. rtARNT, contains the sequence and has a COOH-terminal domain of 190 residues rich in glutamine and asparagine. mRNAs for both rtARNT splice variants were detected in RTG-2 gonad cells, trout liver, and gonad tissue, rtARNT(a) and rtARN(b), protein were identified in cell lysates from RTG-2 cells, Transfection of rtARNT expression vectors into murine Hepa-1 cells that are defective in ARNT function (type II) result in rtARNT protein expression localized to the nucleus. Treatment of these cells with 2,3,7,8-tetrachlo rodibenzo-p-dioxin results in a 20-fold greater induction of endogenous P4501A1 protein in cells expressing rtARNT(a) when compared with rtARNT(b), even though both proteins effectively dimerize with the aryl hydrocarbon receptor, The decreased function of rtARNT(a), appears to be due to inefficient binding of rtARNT(a) AHR complexes to DNA, In addition, the presence of rtARNT(a) can reduce the aryl hydrocarbon receptor-dependent function of rtARNT(b) in vivo and in vitro.	UNIV WISCONSIN, CTR ENVIRONM TOXICOL, MADISON, WI 53706 USA; UNIV WISCONSIN, SCH PHARM, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Pollenz, RS (corresponding author), MED UNIV S CAROLINA, DEPT BIOCHEM & MOL BIOL, 171 ASHLEY AVE, CHARLESTON, SC 29425 USA.							ABBOTT BD, 1994, TOXICOL APPL PHARM, V126, P16, DOI 10.1006/taap.1994.1085; ANTONSSON C, 1995, J BIOL CHEM, V270, P13968, DOI 10.1074/jbc.270.23.13968; Bacsi SG, 1996, J BIOL CHEM, V271, P8843, DOI 10.1074/jbc.271.15.8843; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CARVER LA, 1994, NUCLEIC ACIDS RES, V22, P3038, DOI 10.1093/nar/22.15.3038; CHEVAILLIER P, 1993, INT J BIOCHEM, V25, P479, DOI 10.1016/0020-711X(93)90653-V; DENIS M, 1988, BIOCHEM BIOPH RES CO, V155, P801, DOI 10.1016/S0006-291X(88)80566-7; DENISON MS, 1988, J BIOL CHEM, V263, P17221; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; DOLWICK KM, 1993, MOL PHARMACOL, V44, P911; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; GIANNONE JV, 1995, CAN J PHYSIOL PHARM, V73, P7, DOI 10.1139/y95-002; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HEIN J, 1990, METHOD ENZYMOL, V183, P626; Hirose K, 1996, MOL CELL BIOL, V16, P1706; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HORD NG, 1994, MOL PHARMACOL, V46, P618; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; JAIN S, 1994, J BIOL CHEM, V269, P31518; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEGRAVEREND C, 1982, J BIOL CHEM, V257, P6402; LEWIN B, 1994, RNA CATALYST, P941; LI H, 1994, J BIOL CHEM, V269, P28098; LINDEBRO MC, 1995, EMBO J, V14, P3528, DOI 10.1002/j.1460-2075.1995.tb07359.x; Ma Q, 1996, MOL CELL BIOL, V16, P2144; MILLER AG, 1983, J BIOL CHEM, V258, P3523; NAGATA Y, 1995, BIOCHEM BIOPH RES CO, V207, P916, DOI 10.1006/bbrc.1995.1273; NEGISHI M, 1993, J BIOL CHEM, V268, P9517; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; PESCE S, 1993, MOL CELL BIOL, V13, P7874, DOI 10.1128/MCB.13.12.7874; PETERSON RE, 1993, CRIT REV TOXICOL, V23, P283, DOI 10.3109/10408449309105013; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLAND A, 1990, MOL PHARMACOL, V38, P306; POLAND A, 1994, MOL PHARMACOL, V46, P915; POLAND A, 1986, J BIOL CHEM, V261, P6352; POLLENZ RS, 1994, MOL PHARMACOL, V45, P428; Pollenz RS, 1996, MOL PHARMACOL, V49, P391; POLLENZ RS, 1996, ECL HIGHLIGHTS, V9, P2; PONGRATZ I, 1992, J BIOL CHEM, V267, P13728; REISZPORSZASZ S, 1994, MOL CELL BIOL, V14, P6075, DOI 10.1128/MCB.14.9.6075; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SHEN ES, 1992, J BIOL CHEM, V267, P6815; SOGAWA K, 1995, P NATL ACAD SCI USA, V92, P1936, DOI 10.1073/pnas.92.6.1936; SUGIMOTO Y, 1993, J BIOL CHEM, V268, P2712; SWANSON HI, 1991, TOXICOL LETT, V58, P85, DOI 10.1016/0378-4274(91)90194-B; WALKER MK, 1991, AQUAT TOXICOL, V21, P219, DOI 10.1016/0166-445X(91)90074-J; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WATSON AJ, 1992, MOL CELL BIOL, V12, P2115, DOI 10.1128/MCB.12.5.2115; WHITELAW M, 1993, MOL CELL BIOL, V13, P2504, DOI 10.1128/MCB.13.4.2504; WHITELAW ML, 1994, MOL CELL BIOL, V14, P8843; WHITLOCK JP, 1984, J BIOL CHEM, V259, P980; WHITLOCK JP, 1993, CHEM RES TOXICOL, V6, P754, DOI 10.1021/tx00036a003; ZABEL E, 1996, IN PRESS ENV TOXICOL, V125; ZACHARIAS DA, 1994, BIOTECHNIQUES, V17, P652	64	73	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30886	30896		10.1074/jbc.271.48.30886	http://dx.doi.org/10.1074/jbc.271.48.30886			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940073	hybrid			2022-12-25	WOS:A1996VV15800090
J	Qian, SW; Burmester, JK; Tsang, MLS; Weatherbee, JA; Hinck, AP; Ohlsen, DJ; Sporn, MB; Roberts, AB				Qian, SW; Burmester, JK; Tsang, MLS; Weatherbee, JA; Hinck, AP; Ohlsen, DJ; Sporn, MB; Roberts, AB			Binding affinity of transforming growth factor-beta for its type II receptor is determined by the C-terminal region of the molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMATOPOIETIC PROGENITOR CELLS; HUMAN ENDOTHELIAL-CELLS; EXPRESSION CLONING; CRYSTAL-STRUCTURE; 2 FORMS; ENDOGLIN; PROTEIN; SYSTEM; COMPLEX; LINES	Transforming growth factor-beta (TGF-beta) isoforms have differential binding affinities for the TGF-beta type II receptor (T beta RII). In most cells, TGF-beta 1 and TGF-beta 3 bind to T beta RII with much higher affinity than TGF-beta 2. Here, we report an analysis of the effect of TGF-beta structure on its binding to T beta RII by using TGF-beta mutants with domain deletions, amino acid replacements, and isoform chimeras, Examination of the binding of TGF-beta mutants to the recombinant extracellular domain of T beta RII by a solid-phase TGF-beta/T beta RII assay demonstrated that only those TGF-beta mutants containing the C terminus of TGF-beta 1 (TGF-beta 1-(Delta 69-73), TGF-beta 1-(Trp(71)), and TGF-beta 2/beta 1-(83-112)) bind with high affinity to T beta RII, similar to native TGF-beta 1. Moreover, replacement of only 6 amino acids in the C terminus of TGF-beta 1 with the corresponding sequence of TGF-beta 2 (TGF-beta 1/beta 2-(91-96)) completely eliminated the high affinity binding of TGF-beta 1. Proliferation of fetal bovine heart endothelial (FBHE) cells was inhibited to a similar degree by all of the TGF-beta mutants. However, recombinant soluble T beta RII blocked the inhibition of FBHE cell proliferation induced by TGF-beta mutants retaining the C terminus of TGF-beta 1, consistent with the high binding affinity between these TGF-beta molecules and T beta RII, It was further confirmed that the TGF-beta 2 mutant with its C terminus replaced by that of TGF-beta 1 (TGF-beta 2/beta 1-(83-112)) competed as effectively as TGF-beta 1 with I-125-TGF-beta 1 for binding to membrane T beta RI and T beta RII on FBHE cells. These observations clearly indicate that the domain in TGF-beta 1 responsible for its high affinity binding to T beta RII, both the soluble and membrane-bound forms, is located at C terminus of the molecule.	NCI,NIH,CHEMOPREVENT LAB,BETHESDA,MD 20892; MARSHFIELD MED RES FDN,MARSHFIELD,WI 54449; R&D SYST,MINNEAPOLIS,MN 55413; NIDR,NIH,STRUCT MOL BIOL UNIT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)				Hinck, Andrew/0000-0003-3320-8054				AMATAYAKULCHANTLER S, 1994, J BIOL CHEM, V269, P27687; ARCHER SJ, 1993, BIOCHEMISTRY-US, V32, P1164, DOI 10.1021/bi00055a022; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; BURMESTER JK, 1993, P NATL ACAD SCI USA, V90, P8628, DOI 10.1073/pnas.90.18.8628; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CHEIFETZ S, 1987, CELL, V48, P409, DOI 10.1016/0092-8674(87)90192-9; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; CHEN RH, 1994, J BIOL CHEM, V269, P22868; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; DANIELPOUR D, 1989, J CELL PHYSIOL, V138, P79, DOI 10.1002/jcp.1041380112; Danielpour D, 1989, GROWTH FACTORS, V2, P61, DOI 10.3109/08977198909069082; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; FLANDERS KC, 1991, DEVELOPMENT, V113, P183; FLANDERS KC, 1988, BIOCHEMISTRY-US, V27, P739, DOI 10.1021/bi00402a037; FROLIK CA, 1984, J BIOL CHEM, V259, P995; GEISER AG, 1992, J BIOL CHEM, V267, P2588; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; Griffith DL, 1996, P NATL ACAD SCI USA, V93, P878, DOI 10.1073/pnas.93.2.878; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; Hinck AP, 1996, BIOCHEMISTRY-US, V35, P8517, DOI 10.1021/bi9604946; JENNINGS JC, 1988, J CELL PHYSIOL, V137, P167, DOI 10.1002/jcp.1041370120; KENNEY WC, 1994, J BIOL CHEM, V269, P12351; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LIN HY, 1995, J BIOL CHEM, V270, P2747, DOI 10.1074/jbc.270.6.2747; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MASSAGUE J, 1992, MOL REPROD DEV, V32, P99, DOI 10.1002/mrd.1080320204; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MASSAGUE J, 1985, J BIOL CHEM, V260, P2636; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; MERWIN JR, 1991, AM J PATHOL, V138, P37; MOREN A, 1992, BIOCHEM BIOPH RES CO, V189, P356, DOI 10.1016/0006-291X(92)91566-9; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; OGAWA Y, 1992, J BIOL CHEM, V267, P2325; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; OTTMANN OG, 1988, J IMMUNOL, V140, P2661; POSTLETHWAITE AE, 1995, J CELL PHYSIOL, V164, P587, DOI 10.1002/jcp.1041640317; QIAN SW, 1992, P NATL ACAD SCI USA, V89, P6290, DOI 10.1073/pnas.89.14.6290; QIAN SW, 1994, BIOCHEMISTRY-US, V33, P12298, DOI 10.1021/bi00206a037; ROBERTS AB, 1992, GROWTH FACTORS, V8, P1; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; RODRIGUEZ C, 1995, J BIOL CHEM, V270, P15919, DOI 10.1074/jbc.270.27.15919; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; STJACQUES S, 1994, BIOL REPROD, V51, P405, DOI 10.1095/biolreprod51.3.405; SUARDET L, 1992, CANCER RES, V52, P3705; SUN LZ, 1994, J BIOL CHEM, V269, P26449; TSANG MLS, 1995, CYTOKINE, V7, P389, DOI 10.1006/cyto.1995.0054; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WEBB DJ, 1994, J BIOL CHEM, V269, P30402; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172	54	55	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30656	30662		10.1074/jbc.271.48.30656	http://dx.doi.org/10.1074/jbc.271.48.30656			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940041	hybrid			2022-12-25	WOS:A1996VV15800058
J	Yokote, K; Margolis, B; Heldin, CH; ClaessonWelsh, L				Yokote, K; Margolis, B; Heldin, CH; ClaessonWelsh, L			Grb7 is a downstream signaling component of platelet-derived growth factor alpha- and beta-receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2 DOMAIN PROTEINS; PHOSPHOLIPASE C-GAMMA-1; KINASE-ACTIVITY; PDGF RECEPTOR; BINDING; TRANSDUCTION; CLONING; FAMILY; IDENTIFICATION; ESTABLISHES	Ligand stimulation of the platelet-derived growth factor (PDGF) alpha- or beta-receptors leads to activation of their intrinsic tyrosine kinases and autophosphorylation of tyrosine residues. Grb7 is an SH2 and PH domain-con taining molecule that is known to be overexpressed in some breast cancer tissues and cell lines. Here we show that the SH2 domain of Grb7 can directly bind to the autophosphorylated PDGF beta-receptor in vitro, Grb7 association to the PDGF beta-receptor was dramatically reduced by replacement of tyrosine residues 716 or 775 with phenylalanine residues. Synthetic phosphorylated peptides containing Tyr-716 or Tyr 775 inhibited binding of the Grb7 SH2 domain to the autophosphorylated PDGF beta receptor in a manner similar to but distinct from the binding of the Grb2 SH2 domain. Grb7 associated with activated PDGF beta-receptors in vivo, and the association was dramatically reduced by substitution of Tyr-716 or Tyr-775 with a phenylalanine residue, Furthermore, complex formation between She and Grb7 was observed after ligand stimulation of PDGF alpha- or beta-receptors in cells transfected with Grb7 cDNA or in the breast cancer cell line BT-474. Thus, Grb7 is implicated in PDGF signaling pathways in certain cell types by binding to the receptor directly or indirectly via She.	LUDWIG INST CANC RES, CTR BIOMED, S-75124 UPPSALA, SWEDEN; UNIV MICHIGAN, SCH MED, DEPT INTERNAL MED & BIOCHEM, ANN ARBOR, MI 48109 USA	Ludwig Institute for Cancer Research; University of Michigan System; University of Michigan								ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; ERIKSSON A, 1995, J BIOL CHEM, V270, P7773, DOI 10.1074/jbc.270.13.7773; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; KARLSSON T, 1995, ONCOGENE, V10, P1475; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; LAROSE L, 1993, ONCOGENE, V8, P2493; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; MARGOLIS B, 1994, PROG BIOPHYS MOL BIO, V62, P223, DOI 10.1016/0079-6107(94)90013-2; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MORI S, 1994, J BIOL CHEM, V269, P4917; OOI J, 1995, ONCOGENE, V10, P1621; OSTMAN A, 1991, CELL REGUL, V2, P503, DOI 10.1091/mbc.2.7.503; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RAINES EW, 1990, HDB EXPT PHARM 1, V95, P173; RUPP E, 1994, EUR J BIOCHEM, V225, P29, DOI 10.1111/j.1432-1033.1994.00029.x; SALCINI AE, 1994, ONCOGENE, V9, P2827; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; STEIN J, 1991, ONCOGENE, V6, P601; TAVERNA D, 1991, CELL GROWTH DIFFER, V2, P145; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1995, MOL CELL BIOL, V15, P3058; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; Yokote K, 1996, J BIOL CHEM, V271, P5101; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; YU JC, 1991, MOL CELL BIOL, V11, P3780, DOI 10.1128/MCB.11.7.3780; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	33	64	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30942	30949		10.1074/jbc.271.48.30942	http://dx.doi.org/10.1074/jbc.271.48.30942			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940081	hybrid			2022-12-25	WOS:A1996VV15800098
J	Alam, KY; Frostholm, A; Hackshaw, KV; Evans, JE; Rotter, A; Chiu, IM				Alam, KY; Frostholm, A; Hackshaw, KV; Evans, JE; Rotter, A; Chiu, IM			Characterization of the 1B promoter of fibroblast growth factor 1 and its expression in the adult and developing mouse brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; FACTOR MESSENGER-RNA; FACTOR FAMILY; RAT-BRAIN; BACTERIOPHAGE-P1 SYSTEM; NUCLEOTIDE-SEQUENCE; FGF-RECEPTOR; ACIDIC FGF; FACTOR-I; CLONING	The present study elucidates the molecular structure of a murine fibroblast growth factor 1 (FGF-1) promoter and describes its distribution in the adult and developing mouse brain, A cDNA clone coding for FGF-1 was isolated from a mouse brain cDNA library. Nucleotide sequence analysis revealed that the clone contained, in addition to the protein coding region, an untranslated exon (FGF-1B) 34 base pairs upstream of the translation start codon ATG. The mouse cDNA clone corresponded to the sole FGF-1 transcript in the brain. An RNase protection assay was used to map the transcription start site of the 1B promoter. The sequences upstream from the major transcription initiation site lacked consensus TATA or CAAT boxes, In situ hybridization with cRNA probes specific for the 1B transcript showed the message to be restricted largely to sensory and motor nuclei in the brainstem, and to the ventral spinal cord and cerebellum, Although occasional brainstem nuclei were labeled at low levels by embryonic day 18, the majority of nuclei became detectable autoradiographically during postnatal weeks 1 and 2, and adult levels of grain density were reached during the 3rd and 4th postnatal weeks. FGF-1B mRNA was expressed in phylogenetically older brain regions, which are involved primarily in processing information from exteroceptive sensory mechanoreceptors and in motor control. The relatively late developmental expression suggests a role for FGF-1 in neuronal maturation, rather than in neurogenesis.	OHIO STATE UNIV, DEPT INTERNAL MED, COLL MED, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, DEPT PHARMACOL, COLL MED, COLUMBUS, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University			Chiu, Ing-Ming/B-1534-2008		NIAID NIH HHS [K11 AI01048] Funding Source: Medline; NINDS NIH HHS [R01 NS18089, R01 NS32276] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K11AI001048] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032276, R01NS018089] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTERIO J, 1988, FEBS LETT, V242, P41, DOI 10.1016/0014-5793(88)80981-5; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BESNARD F, 1989, INT J DEV NEUROSCI, V7, P401, DOI 10.1016/0736-5748(89)90061-0; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CADAY CG, 1990, DEV BRAIN RES, V52, P241, DOI 10.1016/0165-3806(90)90240-Y; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU IM, 1990, ONCOGENE, V5, P755; CHOTANI MA, 1995, NUCLEIC ACIDS RES, V23, P434, DOI 10.1093/nar/23.3.434; CORDEIRO PG, 1989, PLAST RECONSTR SURG, V83, P1013, DOI 10.1097/00006534-198906000-00014; DAVIS JB, 1990, J CELL BIOL, V110, P1353, DOI 10.1083/jcb.110.4.1353; ELDE R, 1991, NEURON, V7, P349, DOI 10.1016/0896-6273(91)90288-B; Fallon JH, 1992, GROWTH FACTORS, V6, P139; GOLDFARB M, 1990, CELL GROWTH DIFFER, V1, P439; GOODRICH SP, 1989, NUCLEIC ACIDS RES, V17, P2867, DOI 10.1093/nar/17.7.2867; GOSPODAROWICZ D, 1987, METHOD ENZYMOL, V147, P106; HALLEY C, 1988, NUCLEIC ACIDS RES, V16, P10913, DOI 10.1093/nar/16.22.10913; HEBERT JM, 1990, DEV BIOL, V138, P454, DOI 10.1016/0012-1606(90)90211-Z; HEUER JG, 1990, NEURON, V5, P283, DOI 10.1016/0896-6273(90)90165-C; KUZIS K, 1995, J COMP NEUROL, V358, P142, DOI 10.1002/cne.903580109; LIPTON SA, 1988, P NATL ACAD SCI USA, V85, P2388, DOI 10.1073/pnas.85.7.2388; LORET C, 1989, J BIOL CHEM, V264, P8319; LUNTZLEYBMAN V, 1993, MOL BRAIN RES, V19, P9, DOI 10.1016/0169-328X(93)90143-D; MATTSON MP, 1989, J NEUROSCI, V9, P3728; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MYERS RL, 1995, ONCOGENE, V11, P785; MYERS RL, 1995, J BIOL CHEM, V270, P8257, DOI 10.1074/jbc.270.14.8257; MYERS RL, 1993, ONCOGENE, V8, P341; NIETOSAMPEDRO M, 1988, NEUROSCI LETT, V86, P361, DOI 10.1016/0304-3940(88)90511-3; OELLIG C, 1995, EUR J NEUROSCI, V7, P863, DOI 10.1111/j.1460-9568.1995.tb01073.x; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PAYSON RA, 1993, NUCLEIC ACIDS RES, V21, P489, DOI 10.1093/nar/21.3.489; PIERCE JC, 1992, METHOD ENZYMOL, V216, P549; PIERCE JC, 1992, MAMM GENOME, V3, P550, DOI 10.1007/BF00350620; PIERCE JC, 1992, P NATL ACAD SCI USA, V89, P2056, DOI 10.1073/pnas.89.6.2056; POULIN ML, 1995, DEV DYNAM, V202, P378, DOI 10.1002/aja.1002020407; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; RYDEL RE, 1987, J NEUROSCI, V7, P3639; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STOCK A, 1992, J NEUROSCI, V12, P4688; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; UNSICKER K, 1987, P NATL ACAD SCI USA, V84, P5459, DOI 10.1073/pnas.84.15.5459; WALICKE PA, 1988, DEV BRAIN RES, V40, P71, DOI 10.1016/0165-3806(88)90009-0; WANAKA A, 1990, NEURON, V5, P267, DOI 10.1016/0896-6273(90)90164-B; WANG WP, 1989, MOL CELL BIOL, V9, P2387, DOI 10.1128/MCB.9.6.2387; WILCOX BJ, 1991, NEURON, V6, P397, DOI 10.1016/0896-6273(91)90248-X; WU DK, 1988, J CELL PHYSIOL, V136, P367, DOI 10.1002/jcp.1041360222	49	38	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30263	30271		10.1074/jbc.271.47.30263	http://dx.doi.org/10.1074/jbc.271.47.30263			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939980	hybrid			2022-12-25	WOS:A1996VU52500108
J	Jin, MJ; Saucan, L; Farquhar, MG; Palade, GE				Jin, MJ; Saucan, L; Farquhar, MG; Palade, GE			Rab1a and multiple other Rab proteins are associated transcytotic pathway in rat liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEINS; POLYMERIC IGA RECEPTOR; TRANS-GOLGI NETWORK; ZYMOGEN GRANULE MEMBRANES; ENDOPLASMIC-RETICULUM; EPITHELIAL-CELLS; PLASMA-MEMBRANE; MEDIATED ENDOCYTOSIS; VESICULAR TRANSPORT; IMMUNOELECTRON MICROSCOPY	To better understand the function of Rab1a, we have immunoisolated Rab1a-associated transport vesicles from rat liver using affinity-purified anti-Rab1a-coated magnetic beads. A fraction enriched in endoplasmic reticulum (ER) to Golgi transport vesicles (CV2, rho = 1.158) was subjected to immunoisolation, and proteins of the bound and non-bound subfractions were analyzed by Western blotting. To our surprise, we found that immunoisolated vesicles contained not only ER markers (105-kDa form of the polymeric IgA receptor (pIgAR)) but also transcytotic markers (dIgA and the 120-kDa form of pIgAR), suggesting that Rab1a is associated with transcytotic vesicles in rat liver. To investigate this possibility, we used an antibody to the cytoplasmic domain of pIgAR to immunoisolate transcytotic vesicles from a fraction (CV1, rho = 1.146) known to be enriched in these vesicles, Rab1a was detected in the immunoadsorbed subfractions. The composition of the vesicles immunoisolated from the CV1 fraction on anti-Rab1a was similar to that of transcytotic vesicles immunoisolated from the same fraction on pIgAR. Both were enriched in transcytotic markers and depleted in ER and Golgi markers. The main difference between the two was that those isolated on anti-Rab1a appeared to be enriched in post-endosomal transcytotic vesicles, whereas those isolated on pIgAR contained both pre- and postendosomal elements. Analysis of anti-Rab1a isolated vesicles using [alpha-P-32]GTP overlay demonstrated the presence of multiple GTP-binding proteins. Some of these were identified by immunoblotting as epithelia-specific Rab17 and ubiquitous Rabs1b, -2, and -6. Taken together, these results indicate that: 1) Rab1a is associated with both ER to Golgi and postendosomal transcytotic vesicles, and 2) multiple GTP-binding proteins are associated with each class of isolated vesicle.	UNIV CALIF SAN DIEGO, DIV CELL & MOL MED, SAN DIEGO, CA 92103 USA; UNIV CALIF SAN DIEGO, DEPT PATHOL, SAN DIEGO, CA 92103 USA; UNIV CALIF SAN DIEGO, DEPT MED, SAN DIEGO, CA 92103 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL CANCER INSTITUTE [P01CA058689] Funding Source: NIH RePORTER; NCI NIH HHS [CA58689] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APODACA G, 1994, J CELL BIOL, V125, P67, DOI 10.1083/jcb.125.1.67; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BARR VA, 1993, GASTROENTEROLOGY, V105, P554, DOI 10.1016/0016-5085(93)90734-T; BARR VA, 1995, J BIOL CHEM, V270, P27834, DOI 10.1074/jbc.270.46.27834; BARROSO M, 1994, J CELL BIOL, V124, P83, DOI 10.1083/jcb.124.1.83; BARTLES JR, 1988, TRENDS BIOCHEM SCI, V13, P181, DOI 10.1016/0968-0004(88)90147-8; Bollag D. M., 1991, PROTEIN METHODS, P161; BOMSEL M, 1989, J CELL BIOL, V109, P3243, DOI 10.1083/jcb.109.6.3243; BOMSEL M, 1990, CELL, V62, P719, DOI 10.1016/0092-8674(90)90117-W; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; BUCCI C, 1988, NUCLEIC ACIDS RES, V16, P9979, DOI 10.1093/nar/16.21.9979; BUCCI C, 1994, P NATL ACAD SCI USA, V91, P5061, DOI 10.1073/pnas.91.11.5061; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHAVRIER P, 1992, GENE, V112, P261, DOI 10.1016/0378-1119(92)90387-5; CORMONT M, 1993, J BIOL CHEM, V268, P19491; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; FARNSWORTH CC, 1994, P NATL ACAD SCI USA, V91, P11963, DOI 10.1073/pnas.91.25.11963; FENG Y, 1995, J CELL BIOL, V131, P1435, DOI 10.1083/jcb.131.6.1435; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; GEUZE HJ, 1984, CELL, V37, P195, DOI 10.1016/0092-8674(84)90315-5; GEUZE HJ, 1983, EUR J CELL BIOL, V32, P38; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; HOPPE CA, 1985, J CELL BIOL, V101, P2113, DOI 10.1083/jcb.101.6.2113; HOWELL KE, 1988, CELL FREE ANAL MEMBR, P77; HUBER LA, 1993, J CELL BIOL, V123, P47, DOI 10.1083/jcb.123.1.47; HUBER LA, 1994, P NATL ACAD SCI USA, V91, P7874, DOI 10.1073/pnas.91.17.7874; JENA BP, 1994, J CELL BIOL, V124, P43, DOI 10.1083/jcb.124.1.43; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; LAMBERT M, 1990, FEBS LETT, V271, P19, DOI 10.1016/0014-5793(90)80362-M; LARKIN JM, 1986, P NATL ACAD SCI USA, V83, P4759, DOI 10.1073/pnas.83.13.4759; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; LUTCKE A, 1993, J CELL BIOL, V121, P553, DOI 10.1083/jcb.121.3.553; LUTCKE A, 1994, J CELL SCI, V107, P3437; MCCAFFERY JM, 1995, METHOD ENZYMOL, V257, P259; MUELLER SC, 1986, J CELL BIOL, V102, P932, DOI 10.1083/jcb.102.3.932; NICKEL W, 1994, J CELL BIOL, V125, P721, DOI 10.1083/jcb.125.4.721; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; NUOFFER C, 1994, J CELL BIOL, V125, P225, DOI 10.1083/jcb.125.2.225; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; OLKKONEN VM, 1993, J CELL SCI, V106, P1249; PADFIELD PJ, 1991, BIOCHEM BIOPH RES CO, V174, P600, DOI 10.1016/0006-291X(91)91459-P; PARTON RG, 1989, J CELL BIOL, V109, P3259, DOI 10.1083/jcb.109.6.3259; PETER F, 1994, J CELL BIOL, V126, P1393, DOI 10.1083/jcb.126.6.1393; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; PIND SN, 1994, J CELL BIOL, V125, P239, DOI 10.1083/jcb.125.2.239; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; RIEDERER MA, 1994, J CELL BIOL, V125, P573, DOI 10.1083/jcb.125.3.573; SARASTE J, 1995, J CELL SCI, V108, P1541; SAUCAN L, 1994, J CELL BIOL, V125, P733, DOI 10.1083/jcb.125.4.733; SCHNEFEL S, 1992, Cellular Physiology and Biochemistry, V2, P77, DOI 10.1159/000154628; SMELAND TE, 1994, P NATL ACAD SCI USA, V91, P10712, DOI 10.1073/pnas.91.22.10712; SZTUL E, 1991, CELL, V64, P81, DOI 10.1016/0092-8674(91)90210-P; SZTUL ES, 1985, J CELL BIOL, V100, P1248, DOI 10.1083/jcb.100.4.1248; SZTUL ES, 1985, J CELL BIOL, V100, P1255, DOI 10.1083/jcb.100.4.1255; SZTUL ES, 1983, J CELL BIOL, V97, P1582, DOI 10.1083/jcb.97.5.1582; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; TOUCHOT N, 1989, FEBS LETT, V256, P79, DOI 10.1016/0014-5793(89)81722-3; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; WALL DA, 1985, J CELL BIOL, V101, P2104, DOI 10.1083/jcb.101.6.2104; WEBER E, 1994, J CELL BIOL, V125, P583, DOI 10.1083/jcb.125.3.583; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P1294; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	68	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30105	30113		10.1074/jbc.271.47.30105	http://dx.doi.org/10.1074/jbc.271.47.30105			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939959	hybrid			2022-12-25	WOS:A1996VU52500087
J	Kang, C; Kim, S; Fromm, HJ				Kang, C; Kim, S; Fromm, HJ			Subunit complementation of Escherichia coli adenylosuccinate synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ACTIVE-SITE; CHEMICAL MODIFICATION; THYMIDYLATE SYNTHASE; CONSENSUS SEQUENCE; BINDING-SITE; PROTEINS; IDENTIFICATION; SPECIFICITY; MUTANTS	Data are presented, based upon subunit complementation experiments, that suggest that Escherichia coli adenylosuccinate synthetase contains two shared active sites between its dimeric interface, This conclusion was alluded to by use of mutant forms of adenylosuccinate synthetase previously prepared by site-directed mutagenesis, The experiments indicate that, although the R143L and D13A mutants have low or no activity independently, when they are mixed, a significant amount of activity was obtained, These results indicate that the subunits exchange with each other to form heterodimers with a single viable wild-type active site, The k(cat) value for the active hybrid active site in the R143L-D13A heterodimer is virtually identical to that observed with the wild-type enzyme, and the other kinetic parameters are very similar to those found for the wild-type enzyme, An analysis of the restoration of the activity in the presence of substrates suggests that GTP and IMP stabilize the dimeric structure of the protein, A comparison of the restoration of the activity using different combinations of mutants provides evidence indicating that some of the GTP binding elements, including the P-loop, in the protein are important for subunit integrity, Also, for the first time, a comprehensive analysis of subunit complementation is performed for the two inactive mutants (R143L and D13A) where the dissociation constants for the R143L-D13A heterodimer and the D13A homodimer were determined to be 21 and 2.9 mu M, respectively, A concentration dependence of the specific activity of the wild-type protein in this study shows that the K-d for dimer dissociation is approximately 1 mu M.	IOWA STATE UNIV,DEPT BIOCHEM & BIOPHYS,AMES,IA 50011	Iowa State University					NINDS NIH HHS [NS 10546] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS010546, R56NS010546] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARNARA AS, 1974, EUR J BIOCHEM, V41, P421; BASS MB, 1987, ARCH BIOCHEM BIOPHYS, V256, P335, DOI 10.1016/0003-9861(87)90454-1; CASHEL M, 1975, ANNU REV MICROBIOL, V29, P301, DOI 10.1146/annurev.mi.29.100175.001505; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; DISTEFANO MD, 1990, BIOCHEMISTRY-US, V29, P2703, DOI 10.1021/bi00463a013; DONG Q, 1991, J BIOL CHEM, V266, P12228; DONG Q, 1990, J BIOL CHEM, V265, P6235; HARDY LW, 1987, SCIENCE, V235, P448, DOI 10.1126/science.3099389; KANG C, 1994, J BIOL CHEM, V269, P24046; KANG CH, 1994, ARCH BIOCHEM BIOPHYS, V310, P475, DOI 10.1006/abbi.1994.1195; KANG CH, 1995, J BIOL CHEM, V270, P15539, DOI 10.1074/jbc.270.26.15539; KAUZMANN W, 1959, ADV PROTEIN CHEM, V14, P1, DOI 10.1016/S0065-3233(08)60608-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARIMER FW, 1987, J BIOL CHEM, V262, P15327; LIU F, 1992, J BIOL CHEM, V267, P2388; MANFREDI JP, 1989, AM J PHYSIOL, V257, pC29, DOI 10.1152/ajpcell.1989.257.1.C29; MATSUDA Y, 1982, CANCER RES, V42, P112; Moe OA, 1996, BIOCHEMISTRY-US, V35, P9024, DOI 10.1021/bi960426j; MONACO HL, 1978, P NATL ACAD SCI USA, V75, P5276, DOI 10.1073/pnas.75.11.5276; POLAND BW, 1993, J BIOL CHEM, V268, P25334; POOKANJANATAVIP M, 1992, BIOCHEMISTRY-US, V31, P10303, DOI 10.1021/bi00157a018; RUDOLPH FB, 1971, THESIS IOWA STATE U; SCHULZ GE, 1978, NATURE, V273, P120, DOI 10.1038/273120a0; SILVA MM, 1995, J MOL BIOL, V254, P431, DOI 10.1006/jmbi.1995.0629; SPECTOR T, 1979, J BIOL CHEM, V254, P8422; STAYTON MM, 1983, CURR TOP CELL REGUL, V22, P103; WENTE SR, 1987, P NATL ACAD SCI USA, V84, P31, DOI 10.1073/pnas.84.1.31; WOLFE SA, 1988, J BIOL CHEM, V263, P19147; ZEIDLER R, 1993, J BIOL CHEM, V268, P20191	29	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29722	29728		10.1074/jbc.271.47.29722	http://dx.doi.org/10.1074/jbc.271.47.29722			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939906	hybrid			2022-12-25	WOS:A1996VU52500034
J	Kokame, K; Kato, H; Miyata, T				Kokame, K; Kato, H; Miyata, T			Homocysteine-respondent genes in vascular endothelial cells identified by differential display analysis - GRP78/BiP and novel genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC MESSENGER-RNA; PROTEIN-C ACTIVATION; RISK FACTOR; ATHEROGENIC STIMULUS; TRANSCRIPTION FACTOR; NUCLEOTIDE-SEQUENCE; THROMBOGENIC AGENT; NORMAL FIBROBLASTS; DISEASE; EXPRESSION	An elevated blood level of homocysteine is associated with arteriosclerosis and thrombosis. The mechanisms by which homocysteine may promote vascular diseases have not been elucidated yet, In the present study, we have applied a modified nonradioactive differential display analysis to evaluate changes in gene expression induced by homocysteine treatment of cultured human umbilical vein endothelial cells (HUVEC). We identified six up-regulated and one down-regulated genes. One up-regulated gene was GRP78/BiP, a stress protein, suggesting that misfolded proteins would accumulate in the endoplasmic reticulum because of redox potential changes caused by homocysteine. Another up-regulated gene encoded a bifunctional enzyme with activities of methylenetetrahydrofolate dehydrogenase and methenyltetrahydrofolate cyclohydrolase, which is involved in a homocysteine metabolism, A third up-regulated gene encoded activating transcription factor 4, and a fourth was a gene whose function is not identified yet. The remaining three were novel genes, We isolated a full-length cDNA of one of the up-regulated genes from a HUVEC library, It encoded a novel protein with 394 amino acids, which was termed reducing agents and tunicamycin-responsive protein (RTP). Northern blot analysis revealed that RTP gene expression was induced in HUVEC after 4 h incubation with homocysteine. RTP mRNA was also observed in unstimulated cells and induced by not only homocysteine but also S-mercaptoethanol and tunicamycin. The mRNA was ubiquitously expressed in human tissues, These observations indicate that homocysteine can alter the expressivity of multiple genes, including a stress protein and several novel genes. These responses may contribute to atherogenesis.			Kokame, K (corresponding author), NATL CARDIOVASC CTR,RES INST,FUJISHIRODAI 5-7-1,SUITA,OSAKA 565,JAPAN.			Kokame, Koichi/0000-0002-9654-6299				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; DEGROOT PG, 1983, EUR J CLIN INVEST, V13, P405, DOI 10.1111/j.1365-2362.1983.tb00121.x; ESTES SD, 1995, EXP CELL RES, V220, P47, DOI 10.1006/excr.1995.1290; EWADH MJA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P263, DOI 10.1016/0167-4889(90)90097-W; FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111; FRYER RH, 1993, ARTERIOSCLER THROMB, V13, P1327, DOI 10.1161/01.ATV.13.9.1327; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HAJJAR KA, 1993, J CLIN INVEST, V91, P2873, DOI 10.1172/JCI116532; HARPEL PC, 1992, P NATL ACAD SCI USA, V89, P10193, DOI 10.1073/pnas.89.21.10193; HAYASHI T, 1992, BLOOD, V79, P2930; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LENTZ SR, 1993, BLOOD, V81, P683; LENTZ SR, 1991, J CLIN INVEST, V88, P1906, DOI 10.1172/JCI115514; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; McCully KS, 1996, NAT MED, V2, P386, DOI 10.1038/nm0496-386; Mudd Sh, 1989, METABOLIC BASIS INHE, V1, P693; NISHINAGA M, 1993, J CLIN INVEST, V92, P1381, DOI 10.1172/JCI116712; Nomura N, 1994, DNA Res, V1, P27, DOI 10.1093/dnares/1.1.27; OLDEN K, 1979, P NATL ACAD SCI USA, V76, P791, DOI 10.1073/pnas.76.2.791; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERI KG, 1989, NUCLEIC ACIDS RES, V17, P8853, DOI 10.1093/nar/17.21.8853; POUYSSEGUR J, 1977, CELL, V11, P941, DOI 10.1016/0092-8674(77)90305-1; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; REES MM, 1993, THROMB RES, V71, P337, DOI 10.1016/0049-3848(93)90160-P; RESENDEZ E, 1985, MOL CELL BIOL, V5, P1212, DOI 10.1128/MCB.5.6.1212; RODGERS GM, 1986, J CLIN INVEST, V77, P1909, DOI 10.1172/JCI112519; RODGERS GM, 1990, BLOOD, V75, P895; ROLL DE, 1991, MOL CELL BIOCHEM, V103, P141; TING J, 1988, DNA-J MOLEC CELL BIO, V7, P275, DOI 10.1089/dna.1988.7.275; TSAI JC, 1994, P NATL ACAD SCI USA, V91, P6369, DOI 10.1073/pnas.91.14.6369; TSUJIMOTO A, 1991, J VIROL, V65, P1420, DOI 10.1128/JVI.65.3.1420-1426.1991; UELAND PM, 1989, J LAB CLIN MED, V114, P473; WANG J, 1992, ATHEROSCLEROSIS, V97, P97, DOI 10.1016/0021-9150(92)90055-L; WHELAN SA, 1985, J CELL PHYSIOL, V125, P251, DOI 10.1002/jcp.1041250212; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YANG XM, 1993, BIOCHEMISTRY-US, V32, P1118, DOI 10.1021/bi00092a022	39	289	315	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29659	29665		10.1074/jbc.271.47.29659	http://dx.doi.org/10.1074/jbc.271.47.29659			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939898	hybrid			2022-12-25	WOS:A1996VU52500026
J	Lenka, N; Basu, A; Mullick, J; Avadhani, NG				Lenka, N; Basu, A; Mullick, J; Avadhani, NG			The role of an E box binding basic helix loop helix protein in the cardiac muscle-specific expression of the rat cytochrome oxidase subunit VIII gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-ACTIN PROMOTER; C-OXIDASE; DNA-BINDING; IV GENE; STRUCTURAL ORGANIZATION; TRANSCRIPTION FACTORS; NUCLEOTIDE-SEQUENCE; BOVINE GENE; ACTIVATION; ELEMENTS	We have characterized the rat gene for muscle-specific cytochrome oxidase VIII (COX VIII(H)) and mapped the distal promoter region responsible for transcription activation in C2C12 skeletal myocytes and H9C2 cardiomyocytes. In both cell types, the promoter elements responding to the induced differentiation of myocytes map to two E boxes, designated as El and E2 boxes with a core sequence of CAGCTG. Gel mobility shift analysis showed that both El and E2 box motifs form complexes with nuclear extracts from H9C2 cardiomyocytes that were supershifted with monoclonal antibody to E2A but not with antibody to myo-D. Extracts from induced and uninduced H9C2 cardiomyocytes yielded different gel mobility patterns and also different E2A antibody supershifts suggesting a difference in the DNA-bound protein complexes cross-reacting with the E2A antibody. Transcriptional activity of the promoter construct containing intact E boxes was inhibited by coexpression with Id in differentiated H9C2 cardiomyocytes. Our results show the involvement of an E box binding basic helix loop helix protein in the cardiac muscle-specific regulation of the COX VIII(H) promoter.	UNIV PENN,SCH VET MED,DEPT ANIM BIOL,BIOCHEM LAB,PHILADELPHIA,PA 19104	University of Pennsylvania					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049683] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-49683] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMACHER SL, 1993, MOL CELL BIOL, V13, P2757; BASU A, 1993, J BIOL CHEM, V268, P4188; BASU A, 1991, J BIOL CHEM, V266, P15450; Basu A., UNPUB; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; CARTER RS, 1992, J BIOL CHEM, V267, P23418; CARTER RS, 1991, ARCH BIOCHEM BIOPHYS, V288, P97, DOI 10.1016/0003-9861(91)90169-J; CARTER RS, 1994, J BIOL CHEM, V269, P4381; CATALA F, 1995, MOL CELL BIOL, V15, P4585; CHAU CMA, 1992, J BIOL CHEM, V267, P6999; CROSS JC, 1995, DEVELOPMENT, V121, P2513; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; Emerson CP, 1990, CURR OPIN CELL BIOL, V2, P1065, DOI 10.1016/0955-0674(90)90157-A; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; FORSBURG SL, 1989, ANNU REV CELL BIOL, V5, P153, DOI 10.1146/annurev.cb.05.110189.001101; Genuario R. Robert, 1993, Gene Expression, V3, P279; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARAGUCHI Y, 1994, J BIOL CHEM, V269, P9330; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; IANNELLO RC, 1991, J BIOL CHEM, V266, P3309; IP HS, 1994, MOL CELL BIOL, V14, P7517, DOI 10.1128/MCB.14.11.7517; JAYNES JB, 1988, MOL CELL BIOL, V8, P62, DOI 10.1128/MCB.8.1.62; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LITVIN J, 1993, DEV BIOL, V156, P409, DOI 10.1006/dbio.1993.1088; LOMAX MI, 1995, MAMM GENOME, V6, P118, DOI 10.1007/BF00303255; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MOSS JB, 1994, J BIOL CHEM, V269, P12731; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; NAGLEY P, 1991, TRENDS GENET, V7, P1, DOI 10.1016/0168-9525(91)90002-8; NAVANKASATTUSAS S, 1992, MOL CELL BIOL, V12, P1469, DOI 10.1128/MCB.12.4.1469; OLSON EN, 1990, GENE DEV, V4, P2104; PFEIFER K, 1987, CELL, V49, P9, DOI 10.1016/0092-8674(87)90750-1; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; SADASIVAN E, 1994, J BIOL CHEM, V269, P4725; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARTORELLI V, 1992, P NATL ACAD SCI USA, V89, P4047, DOI 10.1073/pnas.89.9.4047; SAWADA J, 1994, EMBO J, V13, P1396, DOI 10.1002/j.1460-2075.1994.tb06393.x; SCHEJA K, 1992, BIOCHIM BIOPHYS ACTA, V1132, P91, DOI 10.1016/0167-4781(92)90059-9; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEELAN RS, 1992, BIOCHEMISTRY-US, V31, P4696, DOI 10.1021/bi00134a024; SHEN CP, 1995, MOL CELL BIOL, V15, P4518; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SMITH EO, 1993, BIOCHIM BIOPHYS ACTA, V1174, P63, DOI 10.1016/0167-4781(93)90092-R; SRIVASTAVA D, 1995, SCIENCE, V270, P1995, DOI 10.1126/science.270.5244.1995; Sucharov C, 1995, GENE EXPRESSION, V5, P93; SUSKE G, 1988, DNA-J MOLEC CELL BIO, V7, P163, DOI 10.1089/dna.1988.7.163; SUZUKI H, 1991, J BIOL CHEM, V266, P2333; TAANMAN JW, 1991, BIOCHIM BIOPHYS ACTA, V1089, P283, DOI 10.1016/0167-4781(91)90027-J; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; VINCENT CK, 1993, MOL CELL BIOL, V13, P1264, DOI 10.1128/MCB.13.2.1264; VIRBASIUS CMA, 1993, GENE DEV, V7, P2431, DOI 10.1101/gad.7.12a.2431; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WEINTRAUB H, 1994, GENE DEV, V8, P2203, DOI 10.1101/gad.8.18.2203; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WENTWORTH BM, 1991, P NATL ACAD SCI USA, V88, P1242, DOI 10.1073/pnas.88.4.1242; YAMADA M, 1990, J BIOL CHEM, V265, P7687	67	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30281	30289		10.1074/jbc.271.47.30281	http://dx.doi.org/10.1074/jbc.271.47.30281			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939982	hybrid			2022-12-25	WOS:A1996VU52500110
J	Melcher, ML; Thorner, J				Melcher, ML; Thorner, J			Identification and characterization of the CLK1 gene product, a novel CaM kinase-like protein kinase from the yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-EFFICIENCY TRANSFORMATION; ELONGATION FACTOR-II; SPINDLE POLE BODY; CELL-CYCLE; SCHIZOSACCHAROMYCES-POMBE; CONSERVED FEATURES; SHUTTLE VECTORS; CALMODULIN; SEQUENCE; DNA	The CLK1 gene of Saccharomyces cerevisiae encodes a 610-residue protein kinase that resembles known type II Ca2+/calmodulin-dependent protein kinases (CaM kinases), including the CMK1 and CMK2 gene products from the same yeast, The Clk1 kinase domain is preceded by a 162-residue N-terminal extension, followed by a 132-residue C-terminal extension (which contains a basic segment resembling known calmodulin-binding sites) and is as similar to mammalian CaM kinase (38% identity to rat CaM kinase cu) as it is to yeast CaM kinase (37% identity to Cmk2). However, Clk1 shares 52% identity with Rck1, another putative protein kinase encoded in the S. cerevisiae genome, Clk1 tagged with a c-myc epitope (expressed in yeast) and a GST-Clk1 fusion (expressed in bacteria) underwent autophosphorylation and phosphorylated an exogenous substrate (yeast protein synthesis elongation factor 2), primarily on Ser. Neither Clk1 activity was stimulated by purified yeast calmodulin (CMD1 gene product), with or without Ca2+; no association of Clk1 with Cmd1 was detectable by other methods, C-terminally truncated Clk1(Delta 487-610) was growth-inhibitory when overexpressed, whereas catalytically inactive Clk1(K201R Delta 487-610) was not, suggesting that the C terminus is a negative regulatory domain. Using immunofluorescence, Clk1 was localized to the cytosol and excluded from the nucleus, A clk1 Delta. mutant, a clk1 Delta rck1 Delta double mutant, a clk1 Delta cmk1 Delta cmk2 Delta triple mutant, and a clk1 Delta rck1 Delta cmk1 Delta cmk2 Delta quadruple mutant were all viable and manifested no other overt growth phenotype.	UNIV CALIF BERKELEY, DEPT CELL & MOL BIOL, DIV BIOCHEM & MOL BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley			THORNER, Jeremy/O-6132-2019; Melcher, Marc L./AAC-6130-2020	THORNER, Jeremy/0000-0002-2583-500X; Melcher, Marc L./0000-0002-7185-4383	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007232, R37GM021841, R01GM021841] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM21841, GM07232] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANRAKU Y, 1991, BIOCHIM BIOPHYS ACTA, V1093, P169, DOI 10.1016/0167-4889(91)90119-I; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BENTON BM, 1994, J CELL BIOL, V127, P623, DOI 10.1083/jcb.127.3.623; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; BROCKERHOFF SE, 1994, J CELL BIOL, V124, P315, DOI 10.1083/jcb.124.3.315; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; DAHLKVIST A, 1994, GENE, V139, P27, DOI 10.1016/0378-1119(94)90519-3; DAHLKVIST A, 1995, MOL GEN GENET, V246, P316, DOI 10.1007/BF00288604; DAVIS TN, 1986, CELL, V47, P423, DOI 10.1016/0092-8674(86)90599-4; DAVIS TN, 1986, YEAST CELL BIOL, V33, P477; DONOVAN MG, 1991, FEBS LETT, V291, P303, DOI 10.1016/0014-5793(91)81307-T; DUMONTMISCOPEIN A, 1994, FEBS LETT, V356, P283, DOI 10.1016/0014-5793(94)01272-5; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; GEISER JR, 1993, MOL CELL BIOL, V13, P7913, DOI 10.1128/MCB.13.12.7913; GERRING SL, 1991, METHOD ENZYMOL, V194, P57; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; HARRIS E, 1994, J CELL SCI, V107, P3235; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HOLMBERG L, 1994, BIOCHEMISTRY-US, V33, P15159, DOI 10.1021/bi00254a027; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; IIDA H, 1995, CURR GENET, V27, P190, DOI 10.1007/BF00313434; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; JOHNSTON GC, 1991, J CELL BIOL, V113, P539, DOI 10.1083/jcb.113.3.539; JONES EW, 1991, METHOD ENZYMOL, V194, P428; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; KUCHLER K, 1993, J CELL BIOL, V120, P1203, DOI 10.1083/jcb.120.5.1203; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINK AJ, 1991, GENETICS, V127, P681; MEANS AR, 1994, FEBS LETT, V347, P1, DOI 10.1016/0014-5793(94)00492-7; MELCHER ML, 1995, THESIS U CALIFORNIA; MITSUI K, 1993, J BIOL CHEM, V268, P13422; NAIRN AC, 1985, P NATL ACAD SCI USA, V82, P7939, DOI 10.1073/pnas.82.23.7939; NAIRN AC, 1994, SEMIN CANCER BIOL, V5, P295; NEMETH EF, 1990, CELL CALCIUM, V11, P319, DOI 10.1016/0143-4160(90)90032-P; OHYA Y, 1991, J BIOL CHEM, V266, P12784; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PAUSCH MH, 1991, EMBO J, V10, P1511, DOI 10.1002/j.1460-2075.1991.tb07671.x; PERENTESIS JP, 1992, J BIOL CHEM, V267, P1190; PLANASSILVA MD, 1992, EMBO J, V11, P507, DOI 10.1002/j.1460-2075.1992.tb05081.x; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; QIN SL, 1987, J BIOL CHEM, V262, P7802; QIN SL, 1990, J BIOL CHEM, V265, P1903; RASMUSSEN C, 1994, MOL BIOL CELL, V5, P785, DOI 10.1091/mbc.5.7.785; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHULMAN H, 1989, TRENDS BIOCHEM SCI, V14, P62, DOI 10.1016/0968-0004(89)90045-5; Schulman H, 1993, CURR OPIN CELL BIOL, V5, P247, DOI 10.1016/0955-0674(93)90111-3; Sherman F, 1986, LAB COURSE MANUAL ME; SIKORSKI RS, 1989, GENETICS, V122, P19; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STIRLING DA, 1994, EMBO J, V13, P4329, DOI 10.1002/j.1460-2075.1994.tb06753.x; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; TODA T, 1987, MOL CELL BIOL, V7, P1371, DOI 10.1128/MCB.7.4.1371; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEINSTEIN H, 1994, ANNU REV PHYSIOL, V56, P213, DOI 10.1146/annurev.ph.56.030194.001241; YON J, 1989, NUCLEIC ACIDS RES, V17, P4895, DOI 10.1093/nar/17.12.4895	68	34	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29958	29968		10.1074/jbc.271.47.29958	http://dx.doi.org/10.1074/jbc.271.47.29958			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939941	hybrid			2022-12-25	WOS:A1996VU52500069
J	Ruan, HJ; Shantz, LM; Pegg, AE; Morris, DR				Ruan, HJ; Shantz, LM; Pegg, AE; Morris, DR			The upstream open reading frame of the mRNA encoding S-adenosylmethionine decarboxylase is a polyamine-responsive translational control element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORNITHINE DECARBOXYLASE; MESSENGER-RNA; PROTEIN-SYNTHESIS; MAMMALIAN-CELLS; LEADER PEPTIDE; EXPRESSION; GROWTH; TRANSFORMATION; REPRESSION; METABOLISM	S-Adenosylmethionine decarboxylase (AdoMetDC) is a key enzyme in the pathway of polyamine biosynthesis. The cellular levels of the polyamines specifically regulate AdoMetDC translation through the 5'-leader of the mRNA, which contains a small upstream open reading frame (uORF) 14 nucleotides from the cap. Mutating the initiation codon of the uORF, which encodes a peptide product with the sequence MAGDIS, abolished regula tion, In addition, the uORF is sufficient, by itself, to provide polyamine regulation when inserted into the 5'-leader of the human growth hormone mRNA. Changing the amino acid sequence at the carboxyl terminus of the peptide product of the uORF abolished polyamine regulation. In contrast, altering the nucleotide sequence of the uORF at degenerate positions, without changing the amino acid sequence of the peptide, did not affect regulation. Extending the distance between cap and uORF, thereby changing the rate of initiation at the initiator AUG of the uORF, did not alter polyamine regulation. When the uORF was extended so as to overlap, out of frame, the downstream major cistron, polyamine regulation was abolished, We propose that polyamines do not modulate the rate of recognition of the uORF but rather regulate interaction of the peptide product of the uORF with its target.	UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; PENN STATE UNIV,MILTON S HERSHEY MED CTR,COLL MED,DEPT CELLULAR & MOL PHYSIOL,HERSHEY,PA 17033; PENN STATE UNIV,MILTON S HERSHEY MED CTR,COLL MED,DEPT PHARMACOL,HERSHEY,PA 17033	University of Washington; University of Washington Seattle; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health			Morris, David/G-4503-2011	Shantz, Lisa/0000-0001-8814-4022	NATIONAL CANCER INSTITUTE [R01CA018138, R01CA039053, R37CA018138] Funding Source: NIH RePORTER; NCI NIH HHS [CA39053, CA18138] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; BITONTI AJ, 1988, BIOCHEM J, V250, P295, DOI 10.1042/bj2500295; Cao JH, 1996, MOL CELL BIOL, V16, P603; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELBECQ P, 1994, MOL CELL BIOL, V14, P2378, DOI 10.1128/MCB.14.4.2378; FAJUNEN A, 1988, J BIOL CHEM, V263, P17040; GEBALLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159, DOI 10.1016/0968-0004(94)90277-1; GRILLO MA, 1994, BIOCHEM SOC T, V22, P894, DOI 10.1042/bst0220894; HEBY O, 1990, TRENDS BIOCHEM SCI, V15, P153, DOI 10.1016/0968-0004(90)90216-X; HILL JR, 1993, J BIOL CHEM, V268, P726; HILL JR, 1992, J BIOL CHEM, V267, P21886; JANNE J, 1991, ANN MED, V23, P241, DOI 10.3109/07853899109148056; KAMEJI T, 1987, J BIOL CHEM, V262, P2427; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LARGE PJ, 1992, FEMS MICROBIOL REV, V8, P249; LOWKVIST B, 1987, CELL TISSUE RES, V249, P151, DOI 10.1007/BF00215429; MACH M, 1986, J BIOL CHEM, V261, P1697; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; Marton LJ, 1987, INHIB POLYAM METABOL, P79; MEGOSH L, 1995, CANCER RES, V55, P4205; MIHM S, 1989, EXP CELL RES, V180, P383, DOI 10.1016/0014-4827(89)90065-7; MORRIS DR, 1991, J CELL BIOCHEM, V46, P102, DOI 10.1002/jcb.240460203; MOSHIER JA, 1993, CANCER RES, V53, P2618; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PEGG AE, 1989, BIOCHEMISTRY-US, V28, P8446, DOI 10.1021/bi00447a026; PEGG AE, 1988, CANCER RES, V48, P759; PEGG AE, 1982, AM J PHYSIOL, V243, pC212, DOI 10.1152/ajpcell.1982.243.5.C212; PERSSON L, 1989, BIOCHEM BIOPH RES CO, V160, P1196, DOI 10.1016/S0006-291X(89)80130-5; Poulin R, 1995, BIOCHEM J, V312, P749, DOI 10.1042/bj3120749; PULKKA A, 1993, GENOMICS, V16, P342, DOI 10.1006/geno.1993.1195; RUAN HJ, 1994, J BIOL CHEM, V269, P17905; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J., 1990, MOL CLONING LAB MANU, V2nd; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SHANTZ LM, 1994, CANCER RES, V54, P2313; SHANTZ LM, 1994, BIOCHEM J, V302, P765, DOI 10.1042/bj3020765; SHIRAHATA A, 1985, J BIOL CHEM, V260, P9583; SHIRAHATA A, 1986, J BIOL CHEM, V261, P3833; STJERNBORG L, 1993, EUR J BIOCHEM, V214, P671, DOI 10.1111/j.1432-1033.1993.tb17967.x; WARIS T, 1993, BIOCHEM BIOPH RES CO, V189, P424; WERNER M, 1987, CELL, V49, P805, DOI 10.1016/0092-8674(87)90618-0; WHITE MW, 1990, BIOCHEM J, V268, P657, DOI 10.1042/bj2680657; [No title captured]	44	86	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29576	29582		10.1074/jbc.271.47.29576	http://dx.doi.org/10.1074/jbc.271.47.29576			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939886	hybrid			2022-12-25	WOS:A1996VU52500014
J	Scherman, MS; KalbeBournonville, L; Bush, D; Deng, LY; McNeil, M				Scherman, MS; KalbeBournonville, L; Bush, D; Deng, LY; McNeil, M			Polyprenylphosphate-pentoses in mycobacteria are synthesized from 5-phosphoribose pyrophosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-WALLS; ARABINOGALACTAN; SMEGMATIS; BIOSYNTHESIS; ETHAMBUTOL; TUBERCULOSIS; DONOR	Polyprenylphosphate-arabinose (in which the polyprenyl unit is found both as decaprenyl and octahydroheptaprenyl) is a donor of mycobacterial cell wall arabinosyl residues. Because of this important role, its biosynthetic pathway, and that of the related lipid, polyprenylphosphate-D-ribose, was investigated. Surprisingly, phosphoribose pyrophosphate was shown to be a key intermediate on the pathway to both polyprenylphosphate-D-pentoses. Thus, incubation of 5-phospho-D-[C-14]ribose pyrophosphate with membranes prepared from Mycobacterium smegmatis resulted in the presence of organic-soluble radioactivity that was shown to be, in part, polyprenylphosphate-[C-14]arabinose and polyprenylphosphate-[C-14]ribose. Two additional intermediates, polyprenylphosphate-5-phospho[C-14]ribose and polyprenylphosphate-5-phospho[C-14]arabinose, were identified, Further experiments showed that the mature polyprenylphosphate-ribose is formed from phosphoribose pyrophosphate via a two-step pathway involving a transferase to form polyprenylphosphate-5-phosphoribose and then a phosphatase to form the final polyprenylphosphate-ribose. Polyprenylphosphate-arabinose is formed by a similar pathway with an additional step being the epimerization of the ribosyl residue, This epimerization at either the level of phosphoribose pyrophosphate or at the level of polyprenylphosphate-5-phosphoribose.	COLORADO STATE UNIV, DEPT MICROBIOL, FT COLLINS, CO 80523 USA	Colorado State University			McNeil, Michael/G-3325-2019	Deng, Lingyi Lynn/0000-0002-1906-8457	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033706] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-33706] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		DAFFE M, 1990, J BIOL CHEM, V265, P6734; KALBEBOURNONVIL.L, 1994, THESIS U CATHOLIQUE, P49; LEE RE, 1995, J AM CHEM SOC, V117, P11829, DOI 10.1021/ja00153a002; MCNEIL M, 1990, J BIOL CHEM, V265, P18200; MCNEIL M, 1991, J BIOL CHEM, V266, P13217; MORISAKI N, 1995, J ANTIBIOT, V48, P1299, DOI 10.7164/antibiotics.48.1299; SCHERMAN M, 1995, J BACTERIOL, V177, P7125, DOI 10.1128/jb.177.24.7125-7130.1995; SCHULTZ J, 1974, ARCH BIOCHEM BIOPHYS, V160, P311, DOI 10.1016/S0003-9861(74)80039-1; SHIBAEV VN, 1986, ADV CARBOHYD CHEM BI, V44, P277; SINGH S, 1994, MICROBIOS, V77, P217; TAKAYAMA K, 1970, J BIOL CHEM, V245, P6251; TAKAYAMA K, 1989, ANTIMICROB AGENTS CH, V33, P1493, DOI 10.1128/AAC.33.9.1493; WOLUCKA BA, 1994, J BIOL CHEM, V269, P23328; WOLUCKA BA, 1995, J BIOL CHEM, V270, P20151, DOI 10.1074/jbc.270.34.20151; WOLUCKA BA, 1995, J CELL BIOCHEM, V19, P71; YOKOYAMA K, 1989, J BIOL CHEM, V264, P21621	16	93	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29652	29658		10.1074/jbc.271.47.29652	http://dx.doi.org/10.1074/jbc.271.47.29652			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939897	hybrid			2022-12-25	WOS:A1996VU52500025
J	Vallejo, AN; Pease, LR				Vallejo, AN; Pease, LR			The locus-specific enhancer activity of the class I major histocompatibility complex interferon-responsive element is associated with a gamma-interferon (IFN)-inducible factor distinct from STAT1 alpha, p48, and IFN regulatory factor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HLA CLASS-I; TRANSCRIPTION FACTOR ISGF3; MHC ANTIGEN EXPRESSION; TUMOR-NECROSIS-FACTOR; GENE-EXPRESSION; BETA-2-MICROGLOBULIN-DEFICIENT MICE; PROMOTER ELEMENTS; STIMULATED GENES; SYNTHETASE GENE; DOWN-REGULATION	Recent analyses of the upstream regulatory regions of the class I major histocompatibility complex genes in higher primates provided a generalized structural basis for the differential expression of A- and B-locus gene products in response to specific physiological stimulus, Among the regulatory sequences that differ between the loci is the interferon-responsive element (IRE), While the B-IRE is conserved, the A-IREs have species-specific sequence variation, We previously demonstrated that the B-IRE was an interferon (IFN)-inducible enhancer, whereas none of the A-IREs were functional, In the present study, we examined the biochemical basis for the enhancer activity of the conserved B-IRE and found that this may be attributed to a novel gamma-IFN-inducible factor, This factor accumulated in nuclei of cells within minutes of exposure to gamma-IFN. Its appearance was independent of de novo protein synthesis, However, it was not detected in nuclei of cells treated with herbimycin A, suggesting that its appearance depends on a protein kinase activation pathway, Supershift assays indicated that it was distinct from STAT1 alpha, IFN regulatory factor-1, and p48, transcription factors known to bind IRE-like sequences found in regulatory regions of many nonmajor histocompatibility complex gamma-IFN-responsive genes, Competition assays show that this novel factor bound B-IRE with relatively high affinity, about 100-fold more than that for the A-IRE sequence, This factor was also present in STAT1 alpha and p48 somatic mutants that also exhibited B-IRE enhancer activity in reporter gene bioassays in a manner similar to those seen with wild type cells, These observations indicate the existence of a novel gamma-IFN-dependent transcriptional activation pathway that correlates with the differential enhancer activity of the HLA-B IRE.	MAYO CLIN & MAYO FDN,DEPT IMMUNOL,ROCHESTER,MN 55905	Mayo Clinic					NIAID NIH HHS [AI-22420] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022420] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTINTAS A, 1993, J IMMUNOL, V151, P2803; BENDER BS, 1992, J EXP MED, V175, P1143, DOI 10.1084/jem.175.4.1143; BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.bi.59.070190.001345; BRIKEN V, 1995, MOL CELL BIOL, V15, P975; BRUNN GJ, 1995, J BIOL CHEM, V270, P11628, DOI 10.1074/jbc.270.19.11628; CHANG CH, 1992, IMMUNOGENETICS, V35, P378; COCCIA EM, 1995, VIROLOGY, V211, P113, DOI 10.1006/viro.1995.1384; COHEN B, 1988, EMBO J, V7, P1411, DOI 10.1002/j.1460-2075.1988.tb02958.x; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID-WATINE B, 1990, IMMUNOL TODAY, V11, P286, DOI 10.1016/0167-5699(90)90114-O; EILERS A, 1994, MOL CELL BIOL, V14, P1364, DOI 10.1128/MCB.14.2.1364; FIETTE L, 1993, J VIROL, V67, P589, DOI 10.1128/JVI.67.1.589-592.1993; FRIEDMAN RL, 1985, NATURE, V314, P637, DOI 10.1038/314637a0; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; GAMBON F, 1988, EUR J IMMUNOL, V18, P153, DOI 10.1002/eji.1830180123; GARRIDO F, 1993, IMMUNOL TODAY, V14, P491, DOI 10.1016/0167-5699(93)90264-L; GE RW, 1994, VIROLOGY, V203, P389, DOI 10.1006/viro.1994.1499; GILMORE W, 1994, J EXP MED, V180, P1013, DOI 10.1084/jem.180.3.1013; GIRDLESTONE J, 1988, EUR J IMMUNOL, V18, P139, DOI 10.1002/eji.1830180121; GIRDLESTONE J, 1993, P NATL ACAD SCI USA, V90, P11568, DOI 10.1073/pnas.90.24.11568; HAKEM R, 1991, J IMMUNOL, V147, P2384; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HOWCROFT TK, 1993, EMBO J, V12, P3163, DOI 10.1002/j.1460-2075.1993.tb05985.x; IMREH MP, 1995, INT J CANCER, V62, P90, DOI 10.1002/ijc.2910620117; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JOHNSON DR, 1994, MOL CELL BIOL, V14, P1322, DOI 10.1128/MCB.14.2.1322; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6886; KRALLI A, 1992, J VIROL, V66, P6979, DOI 10.1128/JVI.66.12.6979-6988.1992; LAPIERRE LA, 1988, J EXP MED, V167, P794, DOI 10.1084/jem.167.3.794; LAWLOR DA, 1990, ANNU REV IMMUNOL, V8, P23, DOI 10.1146/annurev.iy.08.040190.000323; LEVY DE, 1990, EMBO J, V9, P1105, DOI 10.1002/j.1460-2075.1990.tb08216.x; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; MANSKY P, 1994, J IMMUNOL, V153, P5082; MARCHE PN, 1985, IMMUNOGENETICS, V21, P71, DOI 10.1007/BF00372243; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MAUDSLEY DJ, 1991, IMMUNOL TODAY, V12, P429, DOI 10.1016/0167-5699(91)90013-J; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MOLLER P, 1992, CANCER SURV, V13, P101; NIELSCH U, 1991, EMBO J, V10, P4169, DOI 10.1002/j.1460-2075.1991.tb04995.x; OPELZ G, 1987, TRANSPLANT P, V19, P641; PARRINGTON J, 1993, EUR J BIOCHEM, V214, P617, DOI 10.1111/j.1432-1033.1993.tb17961.x; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; PEASE LR, 1991, CRIT REV IMMUNOL, V11, P1; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; POGULIS RJ, 1993, J BIOL CHEM, V268, P2493; PROFFITT JL, 1994, NUCLEIC ACIDS RES, V22, P4779, DOI 10.1093/nar/22.22.4779; RAULET DH, 1994, ADV IMMUNOL, V55, P381; REID LE, 1989, P NATL ACAD SCI USA, V86, P840, DOI 10.1073/pnas.86.3.840; REIN T, 1994, NUCLEIC ACIDS RES, V22, P3033, DOI 10.1093/nar/22.15.3033; ROTH C, 1994, ADV IMMUNOL, V57, P281, DOI 10.1016/S0065-2776(08)60675-6; RUTHERFORD MN, 1988, EMBO J, V7, P751, DOI 10.1002/j.1460-2075.1988.tb02872.x; SHARROW SO, 1994, J IMMUNOL, V153, P110; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; SINGER DS, 1990, CRIT REV IMMUNOL, V10, P235; SOONG TW, 1992, J IMMUNOL, V149, P2008; STREHLOW I, 1993, J BIOL CHEM, V268, P16590; TARLETON RL, 1992, NATURE, V356, P338, DOI 10.1038/356338a0; THOROGOOD J, 1990, TRANSPLANTATION, V50, P146, DOI 10.1097/00007890-199007000-00027; VALLEJO AN, 1995, J IMMUNOL, V154, P3912; VALLEJO AN, 1995, IMMUNOL REV, V143, P249, DOI 10.1111/j.1600-065X.1995.tb00678.x; VALLEJO AN, 1995, INT IMMUNOL, V7, P853, DOI 10.1093/intimm/7.5.853; VALLEJO AN, 1994, PCR METH APPL, V4, pS123; van Meerwijk J P, 1994, Semin Immunol, V6, P231, DOI 10.1006/smim.1994.1030; VEALS SA, 1993, MOL CELL BIOL, V13, P196, DOI 10.1128/MCB.13.1.196; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VERSTEEG R, 1990, MOL CELL BIOL, V10, P5416, DOI 10.1128/MCB.10.10.5416; VERSTEEG R, 1989, J EXP MED, V170, P612; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WARING JF, 1995, J BIOL CHEM, V270, P12276, DOI 10.1074/jbc.270.20.12276; YAMITHEZI A, 1994, ONCOGENE, V9, P1065; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	74	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29813	29821		10.1074/jbc.271.47.29813	http://dx.doi.org/10.1074/jbc.271.47.29813			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939920	hybrid			2022-12-25	WOS:A1996VU52500048
J	Waxman, DJ; Zhao, SP; Choi, HK				Waxman, DJ; Zhao, SP; Choi, HK			Interaction of a novel sex-dependent, growth hormone-regulated liver nuclear factor with CYP2C12 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT HEPATIC CYTOCHROME-P-450; GENE-EXPRESSION; STEROID 16-ALPHA-HYDROXYLASE; TYROSINE PHOSPHORYLATION; TRANSCRIPTION FACTOR; DIFFERENTIAL REGULATION; INVITRO TRANSCRIPTION; PITUITARY REGULATION; BINDING PROTEIN; MESSENGER-RNAS	CYP2C12 is a steroid hydroxylase cytochrome P450 whose female specific expression in adult rat liver is transcriptionally activated by the continuous plasma growth hormone (GH) profile characteristic of adult fe male rats, DNase I footprinting and gel mobility shift analysis of the 5'-flank of the CYP2C12 gene were carried out to identify cis-acting elements and trans-acting factors that may contribute to the GH-regulated, sex-dependent transcription of this P450 gene, DNase I footprinting analysis revealed sex- and GH-regulated DNase I hypersensitivity sites at the boundaries of several protein binding sites detected along a 1560-nucleotide upstream segment of CYP2C12, Five distinct sites bound a novel continuous GH-regulated nuclear factor, GHNF, which is enriched in adult female and continuous GH-treated male liver nuclear extracts compared to untreated male liver nuclear extracts, Two other foot-printed sites correspond to binding sites for the liver transcription factors C/EBP and albumin D element-binding protein and a third to an HNF1 binding site. A specific binding site for GHNF was also found in the 5'-proximal promoter of CYP2C11, an adult male-specific liver P450 gene, suggesting that GHNF may contribute to the doum-regulation of that gene by continuous GH, GHNF was distinguished from the nuclear factors that bind to a GH response element upstream of the rat Spi 2.1 gene and is also distinct from the GH-activatable latent cytoplasmic transcription factors STAT 1, STAT 3, and STAT 5. These findings support the hypothesis that continuous GH-activated transcription of CYP2C12 in adult female rat liver (a) involves the activation of a novel GH-regulated nuclear factor which binds to multiple sites along the 5'-flank of this cytochrome P450 gene, and (b) proceeds via a signaling pathway distinct from the GH pulse-activated STAT5 pathway proposed to induce CYP2C11 and other male-expressed liver genes.			Waxman, DJ (corresponding author), BOSTON UNIV, DEPT BIOL, DIV CELL & MOL BIOL, 5 CUMMINGTON ST, BOSTON, MA 02215 USA.			Waxman, David/0000-0001-7982-9206				BERGAD PL, 1995, J BIOL CHEM, V270, P24903, DOI 10.1074/jbc.270.42.24903; BILLESTRUP N, 1995, P NATL ACAD SCI USA, V92, P2725, DOI 10.1073/pnas.92.7.2725; CAMPBELL GS, 1995, J BIOL CHEM, V270, P3974, DOI 10.1074/jbc.270.8.3974; CLARKSON RWE, 1995, MOL ENDOCRINOL, V9, P108, DOI 10.1210/me.9.1.108; GONZALEZ FJ, 1986, MOL CELL BIOL, V6, P2969, DOI 10.1128/MCB.6.8.2969; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRONOWSKI AM, 1995, MOL ENDOCRINOL, V9, P171, DOI 10.1210/me.9.2.171; GUZELIAN PS, 1988, P NATL ACAD SCI USA, V85, P9783, DOI 10.1073/pnas.85.24.9783; JANSSON JO, 1985, ENDOCR REV, V6, P128, DOI 10.1210/edrv-6-2-128; JEFFERY S, 1990, BIOCHEM J, V266, P69, DOI 10.1042/bj2660069; LECAM A, 1987, EMBO J, V6, P1225, DOI 10.1002/j.1460-2075.1987.tb02358.x; LEE YH, 1994, J BIOL CHEM, V269, P14681; LEE YH, 1994, MOL CELL BIOL, V14, P1383, DOI 10.1128/MCB.14.2.1383; LEGRAVEREND C, 1992, MOL ENDOCRINOL, V6, P259, DOI 10.1210/me.6.2.259; LIU SY, 1995, DNA CELL BIOL, V14, P285, DOI 10.1089/dna.1995.14.285; MACGEOCH C, 1985, ENDOCRINOLOGY, V117, P2085, DOI 10.1210/endo-117-5-2085; MENDEL DB, 1991, J BIOL CHEM, V266, P677; MORGAN ET, 1985, J BIOL CHEM, V260, P1895; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; NOSHIRO M, 1986, J BIOL CHEM, V261, P5923; Ram PA, 1996, J BIOL CHEM, V271, P5929, DOI 10.1074/jbc.271.10.5929; SHAYIQ RM, 1992, J BIOL CHEM, V267, P2421; SILVA CM, 1994, J BIOL CHEM, V269, P27532; SONDERFAN AJ, 1987, ARCH BIOCHEM BIOPHYS, V255, P27, DOI 10.1016/0003-9861(87)90291-8; SQUIRES EJ, 1988, J BIOL CHEM, V263, P4166; SRIVASTAVA PK, 1993, BIOCHEM J, V294, P159, DOI 10.1042/bj2940159; STROM A, 1995, J BIOL CHEM, V270, P11276, DOI 10.1074/jbc.270.19.11276; STROM A, 1994, DNA CELL BIOL, V13, P805, DOI 10.1089/dna.1994.13.805; SUBRAMANIAN A, 1995, MOL CELL BIOL, V15, P4672; SUNDSETH SS, 1992, J BIOL CHEM, V267, P3915; SUNDSETH SS, 1992, J BIOL CHEM, V267, P3907; TOLLET P, 1995, MOL ENDOCRINOL, V9, P1771, DOI 10.1210/me.9.12.1771; TOLLET P, 1990, MOL ENDOCRINOL, V4, P1934, DOI 10.1210/mend-4-12-1934; TOLLET P, 1995, J BIOL CHEM, V270, P12569, DOI 10.1074/jbc.270.21.12569; VENEPALLY P, 1992, J BIOL CHEM, V267, P17333; Waxman David J., 1995, P391; WAXMAN DJ, 1991, METHOD ENZYMOL, V206, P249; WAXMAN DJ, 1988, BIOCHEM PHARMACOL, V37, P71, DOI 10.1016/0006-2952(88)90756-3; WAXMAN DJ, 1985, BIOCHEMISTRY-US, V24, P4409, DOI 10.1021/bi00337a023; WAXMAN DJ, 1984, J BIOL CHEM, V259, P5481; WAXMAN DJ, 1990, MOL ENDOCRINOL, V4, P447, DOI 10.1210/mend-4-3-447; WAXMAN DJ, 1988, J BIOL CHEM, V263, P11396; WAXMAN DJ, 1992, J STEROID BIOCHEM, V43, P1055, DOI 10.1016/0960-0760(92)90333-E; WAXMAN DJ, 1995, J BIOL CHEM, V270, P13262, DOI 10.1074/jbc.270.22.13262; WAXMAN DJ, 1991, P NATL ACAD SCI USA, V88, P6868, DOI 10.1073/pnas.88.15.6868; WESTIN S, 1990, MOL PHARMACOL, V38, P192; WOOD TJJ, 1995, J BIOL CHEM, V270, P9448, DOI 10.1074/jbc.270.16.9448; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807; YAMAZOE Y, 1988, J BIOCHEM-TOKYO, V104, P785, DOI 10.1093/oxfordjournals.jbchem.a122550; YANO M, 1992, MOL CELL BIOL, V12, P2847, DOI 10.1128/MCB.12.6.2847; YOON JB, 1990, J BIOL CHEM, V265, P19947; YOSHIOKA H, 1990, J BIOL CHEM, V265, P14612; ZHAO SP, 1994, FASEB J, V8, pA1250	54	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29978	29987		10.1074/jbc.271.47.29978	http://dx.doi.org/10.1074/jbc.271.47.29978			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939943	hybrid			2022-12-25	WOS:A1996VU52500071
J	Blaukat, A; Alla, SA; Lohse, MJ; MullerEsterl, W				Blaukat, A; Alla, SA; Lohse, MJ; MullerEsterl, W			Ligand-induced phosphorylation dephosphorylation of the endogenous bradykinin B2 receptor from human fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; EPIDERMAL GROWTH-FACTOR; SWISS 3T3 FIBROBLASTS; PROTEIN-KINASE-C; BETA(2)-ADRENERGIC RECEPTOR; INDUCED DESENSITIZATION; CELLS; MEMBRANE; SEQUESTRATION; IDENTIFICATION	We have studied the ligand-induced phosphorylation/dephosphorylation of the bradykinin B2 receptor endogenously expressed in human HF-15 fibroblasts. An antiserum (AS346) to a synthetic peptide (CRS36), derived from the extreme carboxyl terminus of the human B2 receptor, precipitated the receptor from solubilized membranes of HF-15 cells that had been labeled with [P-32]orthophosphate. A low basal level of B2 receptor phosphorylation was found in the absence of a ligand, Stimulation of the cells with the B2 receptor agonists bradykinin, [Lys(0),Hyp(3)]bradykinin, kallidin, and T-kinin resulted in a rapid and efficient phosphorylation of the receptor, The B2 receptor antagonist HOE140 and the BI receptor agonist des-Arg(9)-bradykinin failed to induce significant phosphorylation of the B2 receptor, Phosphoamino acid analysis revealed that the B2 receptor is phosphorylated on serine and threonine, but not on tyrosine residues, The ligand-induced phosphorylation of the receptor was concentration-dependent, with an apparent EC(50) of 33 nM, and peaked at 1 min after challenge, The kinin-stimulated phosphorylation of the B2 receptor was rapid and transient and paralleled the kinetics of desensitization/resensitization of the receptor as followed by [Ca2+](i) release and radioligand binding assay, respectively, The ligand-induced phosphorylation of the B2 receptor was independent of the protein kinase C pathway, In vitro experiments suggest beta ARK1 (<(beta)under bar>-(a) under bar drenergic (r) under bar eceptor (k) under bar inase) as a candidate kinase that could mediate the homologous B2 receptor phosphorylation. Inhibitors of protein phosphatases 1 and 2A effectively blocked the dephosphorylation, but did not affect the internalization of the B2 receptor, whereas inhibitors of receptor internalization delayed its dephosphorylation, These finding point to a role of ligand-induced phosphorylation in the desensitization and redistribution of the bradykinin receptor in human fibroblasts.	UNIV MAINZ, INST PHYSIOL CHEM & PATHOBIOCHEM, D-55099 MAINZ, GERMANY; UNIV WURZBURG, INST PHARMACOL & TOXICOL, D-97078 WURZBURG, GERMANY	Johannes Gutenberg University of Mainz; University of Wurzburg			Lohse, Martin J/A-7160-2012	Lohse, Martin J/0000-0002-0599-3510				AbdAlla S, 1996, BIOCHEMISTRY-US, V35, P7514, DOI 10.1021/bi9601060; ABDALLA S, 1993, J BIOL CHEM, V268, P17277; Alla SA, 1996, J BIOL CHEM, V271, P1748, DOI 10.1074/jbc.271.3.1748; Baltensperger K, 1996, J BIOL CHEM, V271, P1061, DOI 10.1074/jbc.271.2.1061; BENOVIC JL, 1985, J BIOL CHEM, V260, P7094; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; BOYD RS, 1994, EUR J PHARM-MOLEC PH, V267, P161, DOI 10.1016/0922-4106(94)90167-8; BURCH RM, 1987, P NATL ACAD SCI USA, V84, P6374, DOI 10.1073/pnas.84.18.6374; CHUANG TT, 1995, J BIOL CHEM, V270, P18660, DOI 10.1074/jbc.270.31.18660; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; ERDOS EG, 1990, J CARDIOVASC PHARM, V15, pS20; FIGUEROA CD, 1995, J HISTOCHEM CYTOCHEM, V43, P137, DOI 10.1177/43.2.7822771; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; HARDIE DG, 1991, METHOD ENZYMOL, V201, P469; HENDERSON LM, 1994, BLOOD, V84, P474; Herwald H, 1996, J BIOL CHEM, V271, P13040, DOI 10.1074/jbc.271.22.13040; HESS JF, 1992, BIOCHEM BIOPH RES CO, V184, P260, DOI 10.1016/0006-291X(92)91187-U; HONDA Z, 1995, J BIOL CHEM, V270, P4840, DOI 10.1074/jbc.270.9.4840; HOSOI K, 1993, J CELL PHYSIOL, V157, P1, DOI 10.1002/jcp.1041570102; JONG YJI, 1993, P NATL ACAD SCI USA, V90, P10994, DOI 10.1073/pnas.90.23.10994; KAI H, 1994, HYPERTENSION, V24, P523, DOI 10.1161/01.HYP.24.4.523; KLUEPPELBERG UG, 1991, J BIOL CHEM, V266, P2403; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Liebmann C, 1996, BIOCHEM J, V313, P109, DOI 10.1042/bj3130109; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; MCEACHERN AE, 1991, P NATL ACAD SCI USA, V88, P7724, DOI 10.1073/pnas.88.17.7724; MUNOZ CM, 1993, ARCH BIOCHEM BIOPHYS, V301, P336, DOI 10.1006/abbi.1993.1153; OLSEN R, 1988, J BIOL CHEM, V263, P18030; Ozcelebi F, 1996, J BIOL CHEM, V271, P3750; PEI G, 1994, P NATL ACAD SCI USA, V91, P3633, DOI 10.1073/pnas.91.9.3633; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; PITCHER JA, 1995, P NATL ACAD SCI USA, V92, P8343, DOI 10.1073/pnas.92.18.8343; QUITTERER U, 1995, J BIOL CHEM, V270, P1992, DOI 10.1074/jbc.270.5.1992; REETZ G, 1994, J NEUROCHEM, V62, P890; REGOLI D, 1988, METHOD ENZYMOL, V163, P210; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; ROBERTS RA, 1989, J CELL SCI, V94, P527; ROBERTS RA, 1990, BIOCHEMISTRY-US, V29, P1975, DOI 10.1021/bi00460a002; ROSCHER AA, 1983, J CLIN INVEST, V72, P626, DOI 10.1172/JCI111012; ROSCHER AA, 1990, J CARDIOVASC PHARM, V15, pS39, DOI 10.1097/00005344-199015061-00008; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Stewart J.M., 1980, BRADYKININ KALLIDIN, P227; STRADER CD, 1987, CELL, V49, P855, DOI 10.1016/0092-8674(87)90623-4; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; TIPPMER S, 1994, EUR J BIOCHEM, V225, P297, DOI 10.1111/j.1432-1033.1994.00297.x; VALIQUETTE M, 1995, EMBO J, V14, P5542, DOI 10.1002/j.1460-2075.1995.tb00241.x; WALDO GL, 1983, J BIOL CHEM, V258, P3900; Winstel R, 1996, P NATL ACAD SCI USA, V93, P2105, DOI 10.1073/pnas.93.5.2105; WOLSING DH, 1991, J PHARMACOL EXP THER, V257, P621	52	109	110	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32366	32374		10.1074/jbc.271.50.32366	http://dx.doi.org/10.1074/jbc.271.50.32366			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943300	hybrid			2022-12-25	WOS:A1996VY34000091
J	Chen, MS; Silverstein, AM; Pratt, WB; Chinkers, M				Chen, MS; Silverstein, AM; Pratt, WB; Chinkers, M			The tetratricopeptide repeat domain of protein phosphatase 5 mediates binding to glucocorticoid receptor heterocomplexes and acts as a dominant negative mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-HORMONE RECEPTORS; SERINE/THREONINE PHOSPHATASE; MAMMALIAN-CELLS; EXPRESSION; COMPLEMENTATION; MITOSIS; COMPLEX; CLONING; MOTIFS; GENES	We previously identified a protein-serine phosphatase designated PP5, based on the binding of its tetratricopeptide repeat (TPR) domain to the atrial natriuretic peptide receptor (Chinkers, M. (1994) Proc. Natl. Acad. Sci. U.S.A. 91, 11075-11079). We have now identified another protein complex to which PP5 is targeted through its TPR domain, A 90-kDa protein, identified as heat shock protein 90 (hsp90) by immunoblotting, specifically co-immunoprecipitated from COS-7 cell lysates with the FLAG-tagged TPR domain of PP5, hsp90 also co-immunoprecipitated with full-length FLAG-tagged PP5 overexpressed in COS-7 cells and with endogenous PP5 from untransfected COS-7 cells or rat brain, During gel filtration, PP5 and hsp90 comigrated in a high molecular weight complex, Since glucocorticoid receptors (GR) exist as large heterocomplexes containing hsp90 bound to TPR proteins, we hypothesized that PP5 might be associated with these complexes, Consistent with this hypothesis, PP5 specifically co-immunoprecipitated with GR from mouse L cell lysates. To test the functional importance of this TPR-mediated association in living cells, we used a dominant negative PP5 mutant consisting only of its TPR domain, The mutant inhibited GR-mediated transactivation by approximately 70% in transfected CV-1 cells, This is the first evidence that the TPR proteins in steroid receptor heterocomplexes may be required for signaling in vivo.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT CELL & DEV BIOL,PORTLAND,OR 97201; UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,ANN ARBOR,MI 48109	Oregon Health & Science University; Oregon Health & Science University; University of Michigan System; University of Michigan					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047063] Funding Source: NIH RePORTER; NCI NIH HHS [CA 28101] Funding Source: Medline; NHLBI NIH HHS [HL 47063] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BECKER W, 1994, J BIOL CHEM, V269, P22586; BRAUTIGAN DL, 1994, RECENT PROG HORM RES, V49, P197; BROCARD C, 1994, BIOCHEM BIOPH RES CO, V204, P1016, DOI 10.1006/bbrc.1994.2564; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN MX, 1994, EMBO J, V13, P4278, DOI 10.1002/j.1460-2075.1994.tb06748.x; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; CHINKERS M, 1994, P NATL ACAD SCI USA, V91, P11075, DOI 10.1073/pnas.91.23.11075; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Dittmar KD, 1996, J BIOL CHEM, V271, P12833, DOI 10.1074/jbc.271.22.12833; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; GARBERS DL, 1994, J BIOL CHEM, V269, P30741; Haucke V, 1996, EMBO J, V15, P1231, DOI 10.1002/j.1460-2075.1996.tb00464.x; HIRANO T, 1990, CELL, V60, P319, DOI 10.1016/0092-8674(90)90746-2; LAMB JR, 1994, EMBO J, V13, P4321, DOI 10.1002/j.1460-2075.1994.tb06752.x; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; ORTI E, 1992, ENDOCR REV, V13, P105, DOI 10.1210/er.13.1.105; OwensGrillo JK, 1996, J BIOL CHEM, V271, P13468, DOI 10.1074/jbc.271.23.13468; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; PRATT WB, 1993, J BIOL CHEM, V268, P21455; PRATT WB, 1996, STRESS INDUCIBLE CEL, P79; RADANYI C, 1994, P NATL ACAD SCI USA, V91, P11197, DOI 10.1073/pnas.91.23.11197; Ratajczak T, 1996, J BIOL CHEM, V271, P2961, DOI 10.1074/jbc.271.6.2961; RUFF VA, 1992, J BIOL CHEM, V267, P21285; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7; TZAMARIAS D, 1995, GENE DEV, V9, P821, DOI 10.1101/gad.9.7.821; WILSON EM, 1995, BIOCHEMISTRY-US, V34, P4696, DOI 10.1021/bi00014a025; Xu XL, 1996, BIOCHEM BIOPH RES CO, V218, P514, DOI 10.1006/bbrc.1996.0092	35	193	198	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32315	32320		10.1074/jbc.271.50.32315	http://dx.doi.org/10.1074/jbc.271.50.32315			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943293	hybrid			2022-12-25	WOS:A1996VY34000084
J	Scott, DK; Mitchell, JA; Granner, DK				Scott, DK; Mitchell, JA; Granner, DK			The orphan receptor COUP-TF binds to a third glucocorticoid accessory factor element within the phosphoenolpyruvate carboxykinase gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTORS; RESPONSE ELEMENT; THYROID-HORMONE; PEPCK GENE; TRANSCRIPTION; INSULIN; COMPLEX; HETERODIMERS; EXPRESSION; PROTEIN	The phosphoenolpyruvate carboxykinase (PEPCK) gene promoter contains a glucocorticoid response unit (GRU) that includes, as a linear array, two accessory factor binding sites (AF1 and AF2) and two glucocorticoid receptor binding sites. All of these elements are required for a complete glucocorticoid response. AF1 and AF2 also partially account for the response of the PEPCK gene to retinoic acid and insulin, respectively. A second retinoic acid response element was recently located just downstream of the GRU, In this study we show that mutation of the 3' half-site of this element results in a 60% reduction of the glucocorticoid response of PEPCK promoter-chloramphenicol acetyltransferase (CAT) fusion constructs in transient transfection assays, thus the half-site is now termed AF3. A variety of assays were used to show that chicken ovalbumin upstream promoter transcription factor (COUP-TF) binds specifically to AF3 and that upstream stimulatory factor (USF) binds to an E-box motif located 2 base pairs downstream of AF3, Mutations of AF3 that diminish binding of COUP-TF reduce the glucocorticoid response, but mutation of the USF binding site has no effect. The functional roles of AF1, AF2, and AF3 in the glucocorticoid response were explored using constructs that contained combinations of mutations in all three elements. All three elements are required for a maximal glucocorticoid response, and mutation of any two abolish the response.	VANDERBILT UNIV, SCH MED, DEPT PHYSIOL & MOL BIOPHYS, NASHVILLE, TN 37232 USA	Vanderbilt University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593, R37DK035107, T32DK007061, P30DK020593, R01DK035107] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07061, DK20593, DK35107] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLAN GF, 1991, J BIOL CHEM, V266, P5905; BARIK S, 1993, PCR PROTOCOLS CURREN, P277; BRESNICK EH, 1993, J BIOL CHEM, V268, P18824; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRANNER DK, 1986, RECENT PROG HORM RES, V42, P111; GRANNER DK, 1996, THERAPEUTIC IMMUNOLO, P88; HALL RK, 1992, MOL CELL BIOL, V12, P5527, DOI 10.1128/MCB.12.12.5527; HALL RK, 1995, P NATL ACAD SCI USA, V92, P412, DOI 10.1073/pnas.92.2.412; HALL RK, 1993, I C S S, V3, P777; Hanson R W, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P203; IMAI E, 1993, J BIOL CHEM, V268, P5353; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIU JS, 1991, J BIOL CHEM, V266, P19095; LIU YH, 1993, MOL CELL BIOL, V13, P1836, DOI 10.1128/MCB.13.3.1836; LUCAS PC, 1992, ANNU REV BIOCHEM, V61, P1131; LUCAS PC, 1991, P NATL ACAD SCI USA, V88, P2184, DOI 10.1073/pnas.88.6.2184; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; MITCHELL J, 1994, MOL ENDOCRINOL, V8, P585, DOI 10.1210/me.8.5.585; MIYATA KS, 1993, J BIOL CHEM, V268, P19169; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; OBRIEN RM, 1994, J BIOL CHEM, V269, P30419; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; OBRIEN RM, 1991, P NATL ACAD SCI USA, V88, P6580, DOI 10.1073/pnas.88.15.6580; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; PARK EA, 1993, J BIOL CHEM, V268, P613; PETERSEN DD, 1988, MOL CELL BIOL, V8, P96, DOI 10.1128/MCB.8.1.96; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; QUINN PG, 1988, MOL CELL BIOL, V8, P3467, DOI 10.1128/MCB.8.8.3467; SAGAMI I, 1986, MOL CELL BIOL, V6, P4259, DOI 10.1128/MCB.6.12.4259; SASAKI K, 1984, J BIOL CHEM, V259, P5242; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SCOTT DK, 1995, BIOCHEM J, V310, P483, DOI 10.1042/bj3100483; Scott DK, 1996, J BIOL CHEM, V271, P6260, DOI 10.1074/jbc.271.11.6260; Sirito Mario, 1992, Gene Expression, V2, P231; TEBBEY PW, 1995, BIOCHEM BIOPH RES CO, V215, P1006, DOI 10.1006/bbrc.1995.2564; Wang JC, 1996, MOL ENDOCRINOL, V10, P794, DOI 10.1210/me.10.7.794	44	66	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					31909	31914		10.1074/jbc.271.50.31909	http://dx.doi.org/10.1074/jbc.271.50.31909			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943235	hybrid			2022-12-25	WOS:A1996VY34000026
J	Huston, E; Pooley, L; Julien, P; Scotland, G; McPhee, I; Sullivan, M; Bolger, G; Houslay, MD				Huston, E; Pooley, L; Julien, P; Scotland, G; McPhee, I; Sullivan, M; Bolger, G; Houslay, MD			The human cyclic AMP-specific phosphodiesterase PDE-46 (HSPDE4A4B) expressed in transfected COS7 cells occurs as both particulate and cytosolic species that exhibit distinct kinetics of inhibition by the antidepressant rolipram	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP-SPECIFIC PHOSPHODIESTERASE; LIVER PLASMA-MEMBRANES; N-TERMINAL DOMAIN; MOLECULAR-CLONING; NUCLEOTIDE PHOSPHODIESTERASES; SPLICE VARIANT; MONOPHOSPHATE PHOSPHODIESTERASE; DROSOPHILA-MELANOGASTER; IV INHIBITORS; BINDING-SITE	Transfection of COS7 cells with a plasmid encoding the human cyclic A-specific PDE4A phosphodiesterase PDE-46 (HSPDE4A4B) led to the expression of a rolipram-inhibited PDE4 activity, which contributed similar to-96% of the total COS cell PDE activity, A fusion protein was generated which encompassed residues (788-886) at the extreme C terminus of PDE-46 and was used to generate an antiserum that detected PDE-46 in transfected COS7 cells, Immunoblotting studies identified PDE-46 as a similar to 125-kDa species that was associated with both the soluble and particulate fractions. The relative V-max of particulate PDE-46 was similar to 56% that of cytosolic PDE-46. Particulate PDE-46 was not solubilized using Triton X-100 or high NaCl concentrations, Immunofluorescence analysis by laser scanning confocal micros copy showed that PDE-46 was located at discrete margins of the cen, indicative of association with membrane cortical regions. The human PDE4A species, h6.1 (HSPDE4A4C), which lacks the N-terminal extension of PDE-46, was found as an entirely soluble species when expressed in COS7 cells, h6.1 was shown to have an similar to 11-fold higher V-max relative to that of PDE-46. In dose-response studies rolipram inhibited particulate PDE-46 at much lower concentrations (IC50 = 0.195 mu M) than those needed to inhibit the cytosolic enzyme (IC50 = 1.6 mu M). The basis of this difference lag in the fact that rolipram served as a simple competitive inhibitor of the cytosol enzyme (K-i = 1.6 mu M) but as a partial competitive inhibitor of the particulate enzyme (K-i = 0.037 mu M; K-i' = 2.3 mu M) Particulate PDE-46 thus showed a similar to 60-fold higher affinity for rolipram than cytosolic PDE-46.	UNIV GLASGOW, DIV BIOCHEM & MOL BIOL, MOL PHARMACOL GRP, IBLS, GLASGOW G12 8QQ, LANARK, SCOTLAND; UNIV UTAH, VET ADM MED CTR, HUNTSMAN CTR INST, DEPT MED, SALT LAKE CITY, UT 84148 USA; UNIV UTAH, VET ADM MED CTR, HUNTSMAN CTR INST, DEPT ONCOL SCI, SALT LAKE CITY, UT 84148 USA	University of Glasgow; US Department of Veterans Affairs; Veterans Health Administration (VHA); Utah System of Higher Education; University of Utah; US Department of Veterans Affairs; Veterans Health Administration (VHA); Utah System of Higher Education; University of Utah			Houslay, Miles D/A-6825-2011; Houslay, Miles/AAM-5281-2020	Houslay, Miles/0000-0002-3826-8091	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALVAREZ R, 1995, MOL PHARMACOL, V48, P616; AMEGADZIE BY, 1995, CELL BIOL INT, V19, P477, DOI 10.1006/cbir.1995.1091; BAECKER PA, 1994, GENE, V138, P253, DOI 10.1016/0378-1119(94)90818-4; BEAVO JA, 1994, MOL PHARMACOL, V46, P399; BEAVO JA, 1990, TRENDS PHARMACOL SCI, V11, P150, DOI 10.1016/0165-6147(90)90066-H; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BOLGER G, 1993, MOL CELL BIOL, V13, P6558, DOI 10.1128/MCB.13.10.6558; BOLGER GB, 1994, CELL SIGNAL, V6, P851, DOI 10.1016/0898-6568(94)90018-3; Bolger GB, 1996, J BIOL CHEM, V271, P1065, DOI 10.1074/jbc.271.2.1065; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHENG JB, 1995, BIOORG MED CHEM LETT, V5, P1969, DOI 10.1016/0960-894X(95)00334-P; CHERRY JA, 1995, J NEUROBIOL, V28, P102, DOI 10.1002/neu.480280109; CONTI M, 1995, BIOCHEMISTRY-US, V34, P7979, DOI 10.1021/bi00025a003; CONTI M, 1995, ENDOCR REV, V16, P370, DOI 10.1210/er.16.3.370; CONTI M, 1992, ADV SEC MESS PHOSPH, V25, P87; DAVIS RL, 1988, METHOD ENZYMOL, V159, P786; DAVIS RL, 1989, P NATL ACAD SCI USA, V86, P3604, DOI 10.1073/pnas.86.10.3604; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; Dixon M., 1979, ENZYMES, Vthird; ENGELS P, 1995, FEBS LETT, V358, P305, DOI 10.1016/0014-5793(94)01460-I; HORTON YM, 1995, BIOCHEM J, V308, P683, DOI 10.1042/bj3080683; HOUSLAY MD, 1995, BIOCHEM SOC T, V23, P393, DOI 10.1042/bst0230393; HOUSLAY MD, 1974, BIOCHEM J, V139, P645, DOI 10.1042/bj1390645; HOUSLAY MD, 1992, BIOCHEM SOC T, V20, P140, DOI 10.1042/bst0200140; HOUSLAY MD, 1990, MOL PHARM CELL REGUL, V2, P185; JIN SLC, 1992, J BIOL CHEM, V267, P18929; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIVI GP, 1990, MOL CELL BIOL, V10, P2678, DOI 10.1128/MCB.10.6.2678; LOBBAN M, 1994, BIOCHEM J, V304, P399, DOI 10.1042/bj3040399; MANGANIELLO VC, 1995, ARCH BIOCHEM BIOPHYS, V322, P1, DOI 10.1006/abbi.1995.1429; MARCHMONT RJ, 1980, BIOCHEM J, V187, P381, DOI 10.1042/bj1870381; MARCHMONT RJ, 1981, BIOCHEM J, V195, P645, DOI 10.1042/bj1950645; MASAMUNE H, 1995, BIOORG MED CHEM LETT, V5, P1965, DOI 10.1016/0960-894X(95)00333-O; MCLAUGHLIN MM, 1993, J BIOL CHEM, V268, P6470; MCPHEE I, 1995, BIOCHEM J, V310, P965, DOI 10.1042/bj3100965; MERILAINEN J, 1993, J CELL SCI, V105, P647; MICHAELI T, 1993, J BIOL CHEM, V268, P12925; MILATOVICH A, 1994, SOMAT CELL MOLEC GEN, V20, P75, DOI 10.1007/BF02290677; PILLAI R, 1994, J BIOL CHEM, V269, P30676; REEVES ML, 1987, BIOCHEM J, V241, P535, DOI 10.1042/bj2410535; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; RUTTEN WJ, 1973, BIOCHIM BIOPHYS ACTA, V315, P378, DOI 10.1016/0005-2744(73)90267-2; SCHNEIDER HH, 1986, EUR J PHARMACOL, V127, P105, DOI 10.1016/0014-2999(86)90210-4; SCOTLAND G, 1995, BIOCHEM J, V308, P673, DOI 10.1042/bj3080673; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SHAKUR Y, 1993, BIOCHEM J, V292, P677, DOI 10.1042/bj2920677; SHAKUR Y, 1995, BIOCHEM J, V306, P801, DOI 10.1042/bj3060801; SULLIVAN M, 1994, CELL SIGNAL, V6, P793, DOI 10.1016/0898-6568(94)00039-5; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P5325, DOI 10.1073/pnas.86.14.5325; SZPIRER C, 1995, CYTOGENET CELL GENET, V69, P11, DOI 10.1159/000133927; THOMPSON WJ, 1991, PHARMACOL THERAPEUT, V51, P13, DOI 10.1016/0163-7258(91)90039-O; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311; THOMPSON WJ, 1979, BIOCHEMISTRY-US, V18, P5228, DOI 10.1021/bi00590a030; TOHDA M, 1994, NEUROSCI LETT, V175, P89, DOI 10.1016/0304-3940(94)91085-5; TORPHY TJ, 1992, J BIOL CHEM, V267, P1798; VERGHESE MW, 1995, MOL PHARMACOL, V47, P1164; WILSON M, 1994, BIOCHEM J, V304, P407, DOI 10.1042/bj3040407; WOODS A, 1989, J CELL SCI, V93, P491; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417	59	93	94	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31334	31344		10.1074/jbc.271.49.31334	http://dx.doi.org/10.1074/jbc.271.49.31334			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940140	hybrid			2022-12-25	WOS:A1996VW68600051
J	Kohn, AD; Summers, SA; Birnbaum, MJ; Roth, RA				Kohn, AD; Summers, SA; Birnbaum, MJ; Roth, RA			Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; GLUT4 TRANSLOCATION; S6 KINASE; PLASMA-MEMBRANE; INSULIN; ACTIVATION; CELLS; PHOSPHORYLATION; INHIBITION	Akt is a serine/threonine kinase that requires a functional phosphatidylinositol 3-kinase to be stimulated by insulin and other growth factors. When directed to membranes by the addition of a are myristoylation sequence, Akt becomes constitutively active. In the present studies, the constitutively active Akt and a nonmyristoylated control mutant were expressed in 3T3-L1 cells that can be induced to differentiate into adipocytes. The constitutively active Akt induced glucose uptake into adipocytes in the absence of insulin by stimulating translocation of the insulin-responsive glucose transporter 4 to the plasma membrane. The constitutively active Akt also increased the synthesis of the ubiquitously expressed glucose transporter 1. The increased glucose influx in the 3T3-L1 adipocytes directed Lipid but not glycogen synthesis. These results indicate that Akt can regulate glucose uptake and metabolism.	STANFORD UNIV,MED CTR,DEPT MOL PHARMACOL,STANFORD,CA 94305; UNIV PENN,SCH MED,HOWARD HUGHES MED INST,PHILADELPHIA,PA 19104	Stanford University; Howard Hughes Medical Institute; University of Pennsylvania			/AAE-5384-2020	Birnbaum, Morris/0000-0001-9972-8680	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034926, R01DK034926, R01DK039615] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007365] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 34926, DK39615] Funding Source: Medline; NIGMS NIH HHS [5T32 GM07365] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DEHERREROS AG, 1989, J BIOL CHEM, V264, P19994; FINGAR DC, 1993, J BIOL CHEM, V268, P3005; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FRY MJ, 1994, BBA-MOL BASIS DIS, V1226, P237, DOI 10.1016/0925-4439(94)90036-1; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; HARUTA T, 1995, J BIOL CHEM, V270, P27991; HASPEL HC, 1985, J BIOL CHEM, V260, P7219; HAUSDORFF SF, 1994, J BIOL CHEM, V269, P21391; KANAI F, 1993, J BIOL CHEM, V268, P14523; KAPLAN JM, 1990, MOL CELL BIOL, V10, P1000, DOI 10.1128/MCB.10.3.1000; Katagiri H, 1996, J BIOL CHEM, V271, P16987, DOI 10.1074/jbc.271.29.16987; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V209, P343, DOI 10.1006/bbrc.1995.1509; KOZKA IJ, 1991, J BIOL CHEM, V266, P11726; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; LEE JS, 1994, AM J PHYSIOL, V266, pC319, DOI 10.1152/ajpcell.1994.266.2.C319; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; OKADA T, 1994, J BIOL CHEM, V269, P3568; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; RAMIREZZACARIAS JL, 1992, HISTOCHEMISTRY, V97, P493, DOI 10.1007/BF00316069; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TORDJMAN KM, 1990, BIOCHEM J, V271, P201, DOI 10.1042/bj2710201; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; WHITE MF, 1994, J BIOL CHEM, V269, P1; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442; WINZ R, 1994, J BIOL CHEM, V269, P14438; YEH WC, 1995, P NATL ACAD SCI USA, V92, P11086, DOI 10.1073/pnas.92.24.11086; YEH WC, 1995, CURR OPIN CELL BIOL, V7, P885, DOI 10.1016/0955-0674(95)80074-3	36	1054	1080	0	55	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31372	31378		10.1074/jbc.271.49.31372	http://dx.doi.org/10.1074/jbc.271.49.31372			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940145	hybrid			2022-12-25	WOS:A1996VW68600056
J	Sekimoto, T; Nakajima, K; Tachibana, T; Hirano, T; Yoneda, Y				Sekimoto, T; Nakajima, K; Tachibana, T; Hirano, T; Yoneda, Y			Interferon-gamma-dependent nuclear import of Stat1 is mediated by the GTPase activity of Ran/TC4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORE-TARGETING COMPLEX; WHEAT-GERM AGGLUTININ; PROTEIN IMPORT; BINDING PROTEIN; LIVING CELLS; IDENTIFICATION; ACTIVATION; INHIBITION; TRANSPORT; RCC1	In response to interferon-gamma (IFN-gamma), Stat1 enters the nucleus, where it activates transcription. In order to better understand the mechanism of the extracellular signal-induced protein import into the nucleus, we have established an in vivo assay system that uses recombinant Stat1 protein as a model transport substrate. Using this system, we found that Stat1 is actively transported through the nuclear pores in an IFN-gamma dependent manner and tyrosine (Tyr(701)) phosphorylation of Stat1 is actually required for its nuclear import. When the antibody against Ran, which was identified as an essential factor for active nuclear protein transport, was injected, the IFN-gamma-dependent nuclear transport of Stat1 was completely inhibited, Furthermore, nuclear import of Stat1 was suppressed by microinjection of two mutant Ran proteins, one defective in GTP hydrolysis (G19V) and the other with little or no binding to GTP (T24N), both of which are known to act as dominant negative inhibitors of nuclear import. These results indicate that the conditional nuclear import of Stat1 requires GTP hydrolysis by Ran.	OSAKA UNIV, SCH MED, DEPT ANAT & CELL BIOL, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, SCH MED, DIV MOL ONCOL, BIOMED RES CTR, SUITA, OSAKA 565, JAPAN	Osaka University; Osaka University			Hirano, Toshio/C-8194-2009					BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; Carey KL, 1996, J CELL BIOL, V133, P985, DOI 10.1083/jcb.133.5.985; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; CORDES V, 1991, EUR J CELL BIOL, V55, P31; DABAUVALLE MC, 1988, EXP CELL RES, V174, P291, DOI 10.1016/0014-4827(88)90163-2; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Dickmanns A, 1996, J CELL SCI, V109, P1449; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Higuchi R., 1989, PCR TECHNOLOGY, P61; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; IMAMOTO N, 1995, FEBS LETT, V368, P415; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; LOEB JDJ, 1995, P NATL ACAD SCI USA, V92, P7647, DOI 10.1073/pnas.92.17.7647; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MELCHIOR F, 1995, METHOD ENZYMOL, V257, P279; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; Nakajima K, 1995, ANN NY ACAD SCI, V762, P55; Palacios I, 1996, J CELL BIOL, V133, P485, DOI 10.1083/jcb.133.3.485; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; STARR CM, 1990, J CELL BIOL, V110, P1861, DOI 10.1083/jcb.110.6.1861; TACHIBANA T, 1994, J BIOL CHEM, V269, P24542; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x; YONEDA Y, 1987, EXP CELL RES, V170, P439, DOI 10.1016/0014-4827(87)90319-3; YONEDA Y, 1987, EXP CELL RES, V173, P586, DOI 10.1016/0014-4827(87)90297-7	35	99	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31017	31020		10.1074/jbc.271.49.31017	http://dx.doi.org/10.1074/jbc.271.49.31017			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940092	hybrid			2022-12-25	WOS:A1996VW68600003
J	Singh, S; Darnay, BG; Aggarwal, BB				Singh, S; Darnay, BG; Aggarwal, BB			Site-specific tyrosine phosphorylation of I kappa B alpha negatively regulates its inducible phosphorylation and degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; SIGNAL-INDUCED PHOSPHORYLATION; UBIQUITIN-PROTEASOME PATHWAY; ACTIVATION; DISSOCIATION; PROTEOLYSIS; SUFFICIENT; INHIBITOR; STIMULATION; PHOSPHATASE	The transcription factor NF-kappa B is retained in the cytoplasm by its interaction with the inhibitory subunit known as I kappa B, Signal-induced serine phosphorylation and subsequent ubiquitination of I kappa B alpha target it for degradation by the 26 S proteasome, Recently, pervanadate, a protein-tyrosine phosphatase inhibitor, was shown to block the degradation of I kappa B alpha, thus inhibiting NF-kappa B activation, We investigated the mechanism by which pervanadate inhibits the degradation of I kappa B alpha, Western blot analysis of I kappa B alpha from tumor necrosis factor-treated cells revealed a slower migrating I kappa B alpha species that was subsequently degraded, However, pervanadate-treated cells also revealed a slower migrating species of I kappa B alpha that appeared in a time- and dose dependent manner and was not degraded by tumor necrosis factor, The slower migrating species of I kappa B alpha from pervanadate-treated cells was tyrosine-phosphorylated as revealed by cross-reactivity with anti-phosphotyrosine antibodies, by the ability of the specific tyrosine phosphatase PTP1B to dephosphorylate it, and by phosphoamino acid analysis of I kappa B alpha immunoprecipitated from P-32-labeled cells. By site-specific mutagenesis and deletion analysis, we identified Tyr-42 on I kappa B alpha as the phosphoacceptor site, Furthermore, in an in vitro reconstitution system, tyrosine-phosphorylated I kappa B alpha was protected from degradation, Our results demonstrate that inducible phosphorylation and degradation of I kappa B alpha are negatively regulated by phosphorylation at Tyr-42, thus preventing NF-kappa B activation.	UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT MOL ONCOL, CYTOKINE RES LAB, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center			Aggarwal, Bharat B/G-3388-2013					ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; Lin RT, 1996, MOL CELL BIOL, V16, P1401; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; MENON SD, 1995, J BIOL CHEM, V270, P18881; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; SINGH S, 1995, J BIOL CHEM, V270, P10631, DOI 10.1074/jbc.270.18.10631; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339	36	111	113	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31049	31054		10.1074/jbc.271.49.31049	http://dx.doi.org/10.1074/jbc.271.49.31049			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940099	hybrid			2022-12-25	WOS:A1996VW68600010
J	Giasson, BI; Mushynski, WE				Giasson, BI; Mushynski, WE			Aberrant stress-induced phosphorylation of perikaryal neurofilaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; NERVE GROWTH-FACTOR; MONOCLONAL-ANTIBODIES DISTINGUISH; ACTIVATED PROTEIN-KINASES; MOTOR-NEURON DISEASE; NF-H; AXONAL-TRANSPORT; C-JUN; MAMMALIAN NEUROFILAMENTS; INTERMEDIATE FILAMENTS	The aberrant phosphorylation of the neurofilament high molecular weight subunit (NFH) in the neuronal perikaryon is a common feature of several neurological diseases. We demonstrated a strong correlation between hyperphosphorylation of the NFH carboxyl-terminal domain and activation of stress-activated protein kinase (SAPK)-gamma in PC12 cells. Agents that activated SAPK gamma in PC12 cells also caused the hyperphosphorylation of perikaryal NFH in cultured dorsal root ganglion neurons. The NFH carboxyl-terminal domain was phosphorylated by SAPK gamma in vitro, and the use of peptide substrates indicated that this event occurred preferentially at KSPXE motifs. We propose that SAPK gamma, perhaps in concert with other SAPKs, is involved in the abnormal phosphorylation of perikaryal NFH. This finding could lead to new insights into the etiology of several neurological diseases.	MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA	McGill University								BERGERON C, 1995, J NEUROL SCI, V129, P81, DOI 10.1016/0022-510X(95)00071-9; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CARLETTI R, 1995, NEUROSCIENCE, V69, P1103, DOI 10.1016/0306-4522(95)00284-P; CHIN SSM, 1990, J NEUROSCI, V10, P3714; CHING GY, 1993, J CELL BIOL, V122, P1323, DOI 10.1083/jcb.122.6.1323; COLLARD JF, 1995, NATURE, V375, P61, DOI 10.1038/375061a0; COTE F, 1993, CELL, V73, P35, DOI 10.1016/0092-8674(93)90158-M; DELISLE MB, 1984, J NEUROL SCI, V63, P241, DOI 10.1016/0022-510X(84)90199-0; EISEN A, 1995, MUSCLE NERVE, V18, P741, DOI 10.1002/mus.880180711; ELHANANY E, 1994, J NEUROCHEM, V63, P2324; FIGLEWICZ DA, 1994, HUM MOL GENET, V3, P1757, DOI 10.1093/hmg/3.10.1757; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GEISLER N, 1983, EMBO J, V2, P1295, DOI 10.1002/j.1460-2075.1983.tb01584.x; GLICKSMAN MA, 1987, J NEUROBIOL, V18, P167, DOI 10.1002/neu.480180205; GOLDSTEIN ME, 1987, J NEUROSCI, V7, P1586; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Griffin JW, 1988, INTRINSIC DETERMINAN, P403; GUAN RJ, 1991, J BIOL CHEM, V266, P8262; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HARRIS J, 1991, J NEUROSCI RES, V30, P47, DOI 10.1002/jnr.490300107; Heasley LE, 1996, MOL CELL BIOL, V16, P648; HIROKAWA N, 1984, J CELL BIOL, V98, P1523, DOI 10.1083/jcb.98.4.1523; HISANAGA S, 1988, J MOL BIOL, V202, P297, DOI 10.1016/0022-2836(88)90459-7; HISANAGA S, 1990, J BIOL CHEM, V265, P21852; HOFFMAN PN, 1975, J CELL BIOL, V66, P351, DOI 10.1083/jcb.66.2.351; Jayaraman D, 1995, INT J DEV NEUROSCI, V13, P753, DOI 10.1016/0736-5748(95)00060-7; Julien JP, 1995, BIOCHEM CELL BIOL, V73, P593, DOI 10.1139/o95-064; JULIEN JP, 1982, J BIOL CHEM, V257, P467; JULIEN JP, 1983, J BIOL CHEM, V258, P4019; JULIEN JP, 1988, GENE, V68, P307, DOI 10.1016/0378-1119(88)90033-9; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MK, 1993, J CELL BIOL, V122, P1337, DOI 10.1083/jcb.122.6.1337; LEE MK, 1994, NEURON, V13, P975, DOI 10.1016/0896-6273(94)90263-1; LEE VMY, 1987, J NEUROSCI, V7, P3474; LEE VMY, 1988, P NATL ACAD SCI USA, V85, P1998, DOI 10.1073/pnas.85.6.1998; LEES JF, 1988, EMBO J, V7, P1947, DOI 10.1002/j.1460-2075.1988.tb03032.x; LEW J, 1992, J BIOL CHEM, V267, P25922; LEWIS SE, 1988, J CELL BIOL, V107, P2689, DOI 10.1083/jcb.107.6.2689; LINDENBAUM MH, 1988, J BIOL CHEM, V263, P5662; MACKLIS JD, 1985, IN VITRO CELL DEV B, V21, P189; MANETTO V, 1988, J NEUROPATH EXP NEUR, V47, P642, DOI 10.1097/00005072-198811000-00007; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; NIXON RA, 1989, MOL BRAIN RES, V5, P93, DOI 10.1016/0169-328X(89)90001-6; NIXON RA, 1993, BRAIN PATHOL, V3, P29, DOI 10.1111/j.1750-3639.1993.tb00723.x; OBLINGER MM, 1987, J NEUROSCI, V7, P453; OHARA O, 1993, J CELL BIOL, V121, P387, DOI 10.1083/jcb.121.2.387; POLLANEN MS, 1994, ACTA NEUROPATHOL, V88, P1, DOI 10.1007/BF00294352; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; RODER HM, 1991, J NEUROSCI, V11, P3325; RODER HM, 1945, J NEUROCHEM, V64, P2203; ROOTS BI, 1983, SCIENCE, V221, P971, DOI 10.1126/science.6192501; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SAITO KI, 1993, NEUROCHEM RES, V18, P231, DOI 10.1007/BF01474689; SAITO Y, 1989, J BIOCHEM, V106, P1035, DOI 10.1093/oxfordjournals.jbchem.a122960; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHLAEPFER WW, 1987, J NEUROPATH EXP NEUR, V46, P117, DOI 10.1097/00005072-198703000-00001; SHAW G, 1986, EUR J CELL BIOL, V42, P1; SHEA TB, 1993, J NEUROIMMUNOL, V44, P117, DOI 10.1016/0165-5728(93)90274-3; SHETTY KT, 1993, P NATL ACAD SCI USA, V90, P6844, DOI 10.1073/pnas.90.14.6844; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SOBUE G, 1990, ACTA NEUROPATHOL, V79, P402, DOI 10.1007/BF00308716; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; STERNBERGER NH, 1985, P NATL ACAD SCI USA, V82, P4274, DOI 10.1073/pnas.82.12.4274; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TSUBUKI S, 1993, BIOCHEM BIOPH RES CO, V196, P1195, DOI 10.1006/bbrc.1993.2378; VICKERS JC, 1994, J NEUROSCI, V14, P5603; WATSON DF, 1991, BRAIN RES, V539, P103, DOI 10.1016/0006-8993(91)90691-N; WUERKER RB, 1972, INT REV CYTOL, V33, P45, DOI 10.1016/S0074-7696(08)61448-5; XU ZS, 1993, CELL, V73, P23, DOI 10.1016/0092-8674(93)90157-L; YAN MH, 1994, NATURE, V372, P798	77	117	117	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30404	30409		10.1074/jbc.271.48.30404	http://dx.doi.org/10.1074/jbc.271.48.30404			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940004	hybrid			2022-12-25	WOS:A1996VV15800021
J	Hoober, KL; Joneja, B; White, HB; Thorpe, C				Hoober, KL; Joneja, B; White, HB; Thorpe, C			A sulfhydryl oxidase from chicken egg white	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOFLAVIN-BINDING PROTEIN; TRIMETHYLAMINE DEHYDROGENASE; DIFFERENTIAL REACTIVITY; LIPOAMIDE DEHYDROGENASE; GLUTATHIONE-REDUCTASE; ASPERGILLUS-NIGER; GLUCOSE-OXIDASE; PIG-KIDNEY; FLAVOPROTEIN; ENZYME	A dimeric glycoprotein containing one FAD per similar to 80,000 M(r) subunit has been isolated from chicken egg white and found to have sulfhydryl oxidase activity with a range of small molecular weight thiols, Dithiothreitol was the best substrate of those tested, with a turnover number of 1030/min, a K-m, of 150 mu M, and a pH optimum of about 7.5, Oxidation of thiol substrates generates hydrogen peroxide in aerobic solution, Anaerobically, the ferricenium ion is a facile alternative electron acceptor, Reduction of the oxidase with dithionite or dithiothreitol under anaerobic conditions yields a two electron intermediate (EH(2)) showing a charge transfer band (lambda(max) 560 nm; epsilon(obs) 2.5 mM(-1) cm(-1)). Complete bleaching of the flavin and discharge of the charge transfer complex require a total of four electrons, Borohydride and catalytic photoreduction give the same spectral changes, EH(2), but not the oxidized enzyme, is inactivated by iodoacetamide with alkylation of 2.7 cysteine residues/subunit. These data indicate that the oxidase contains a redox-active disulfide bridge generating a thiolate to oxidized flavin charge transfer complex at the EH(2) level, Sulfite treatment does not form the expected flavin adduct with the native enzyme but cleaves the active site disulfide, yielding an air-stable EH(2)-like species. The close functional resemblance of the oxidase to the pyridine nucleotide-dependent disulfide oxidoreductase family is discussed.	UNIV DELAWARE,DEPT CHEM & BIOCHEM,NEWARK,DE 19716	University of Delaware			White, Harold B/B-8024-2008		NIGMS NIH HHS [GM26643] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026643] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARSCOTT LD, 1981, BIOCHEMISTRY-US, V20, P1513, DOI 10.1021/bi00509a016; BANCROFT JD, 1990, THEORY PRACTICE HIST, V3, P187; CLARE DA, 1988, ARCH BIOCHEM BIOPHYS, V265, P351, DOI 10.1016/0003-9861(88)90138-5; DELAMOTTE RS, 1987, BIOCHEMISTRY-US, V26, P7363, DOI 10.1021/bi00397a025; DELAMOTTE RS, 1987, FED PROC, V46, P3529; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FAEDER EJ, 1973, ANAL BIOCHEM, V53, P332, DOI 10.1016/0003-2697(73)90442-9; FOX BS, 1983, BIOCHEMISTRY-US, V22, P4082, DOI 10.1021/bi00286a014; FREDERICK KR, 1990, J BIOL CHEM, V265, P3793; GILBERT HF, 1995, METHOD ENZYMOL, V251, P8, DOI 10.1016/0076-6879(95)51107-5; GOLDSMITH LA, 1987, METHOD ENZYMOL, V143, P510; GORELICK RJ, 1985, BIOCHEMISTRY-US, V24, P6830, DOI 10.1021/bi00345a015; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; JANOLINO VG, 1987, ARCH BIOCHEM BIOPHYS, V258, P265, DOI 10.1016/0003-9861(87)90344-4; JANOLINO VG, 1975, J BIOL CHEM, V250, P2532; JIANG ZY, 1983, BIOCHEMISTRY-US, V22, P3752, DOI 10.1021/bi00285a006; JOCELYN PC, 1972, BIOCH SH GROUP; KIERMEIER F., 1967, Zeitschrift fur Lebensmittel-Untersuchung und -Forschung, V132, P342, DOI 10.1007/BF01045314; KUSAKABE H, 1982, AGR BIOL CHEM TOKYO, V46, P2057, DOI 10.1080/00021369.1982.10865382; LASH LH, 1994, BIOCHIM BIOPHYS ACTA, V779, P191; LEHMAN TC, 1990, ANAL BIOCHEM, V186, P280, DOI 10.1016/0003-2697(90)90080-S; MACLACHLAN I, 1993, J BIOL CHEM, V268, P23222; MASSEY V, 1963, BIOCHEM Z, V338, P474; MASSEY V, 1978, BIOCHEMISTRY-US, V17, P9, DOI 10.1021/bi00594a002; MASSEY V, 1974, ANN NY ACAD SCI, V227, P446, DOI 10.1111/j.1749-6632.1974.tb14407.x; MASSEY V, 1969, J BIOL CHEM, V244, P3999; MASSEY V, 1966, BIOCHEMISTRY-US, V5, P3181, DOI 10.1021/bi00874a016; Massey V, 1980, BIOCHEM SOC T, V8, P246, DOI 10.1042/bst0080246; ODONNELL ME, 1985, BIOCHEMISTRY-US, V24, P7617, DOI 10.1021/bi00347a018; OSTROWSKI MC, 1980, BIOCHEMISTRY-US, V19, P2639, DOI 10.1021/bi00553a016; RHODES MB, 1959, J BIOL CHEM, V234, P2054; ROHLFS RJ, 1994, J BIOL CHEM, V269, P30869; ROHRER JS, 1993, ANAL BIOCHEM, V212, P7, DOI 10.1006/abio.1993.1283; ROHRER JS, 1995, TECHNIQUES PROTEIN C, V4, P65; SCHMELZER CH, 1982, BIOCHEM BIOPH RES CO, V107, P196, DOI 10.1016/0006-291X(82)91688-6; SLIWKOWSKI MX, 1984, BIOCHEM J, V220, P551; TEGOULIA V, 1993, BIOCHEM MOL BIOL INT, V31, P769; THORPE C, 1976, J BIOL CHEM, V251, P3553; THORPE C, 1979, BIOCHEMISTRY-US, V18, P331, DOI 10.1021/bi00569a016; TORCHINSKY YM, 1981, SULFUR PROTEINS, P75; WAITE JH, 1995, METHOD ENZYMOL, V258, P1; WHITE HB, 1988, ANNU REV NUTR, V8, P279, DOI 10.1146/annurev.nu.08.070188.001431; WHITE HB, 1992, ARCH BIOCHEM BIOPHYS, V295, P29, DOI 10.1016/0003-9861(92)90483-D; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121; WILSON EK, 1995, BIOCHEMISTRY-US, V34, P2584, DOI 10.1021/bi00008a024; WINTER WP, 1967, COMP BIOCHEM PHYSIOL, V22, P897, DOI 10.1016/0010-406X(67)90780-3; YAMADA H, 1989, J JPN DERMATOL SOC, V99, P861; ZIEGLER DM, 1977, TRENDS BIOCHEM SCI, V2, P79, DOI 10.1016/0968-0004(77)90042-1	48	88	94	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30510	30516		10.1074/jbc.271.48.30510	http://dx.doi.org/10.1074/jbc.271.48.30510			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940019	hybrid			2022-12-25	WOS:A1996VV15800036
J	Puddicombe, SM; Wood, L; Chamberlin, SG; Davies, DE				Puddicombe, SM; Wood, L; Chamberlin, SG; Davies, DE			The interaction of an epidermal growth factor transforming growth factor alpha tail chimera with the human epidermal growth factor receptor reveals unexpected complexities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR EGF RECEPTOR; TGF-ALPHA; SIDE-CHAIN; BINDING; CELLS; YEAST; SITE	It has been assumed that substitution of homologous regions of transforming growth factor alpha (TGF-alpha) into epidermal growth factor (EGF) can be used to probe ligand-receptor recognition without detrimental effects on ligand characteristics for the human EGF receptor (EGFR), We show that a chimera of murine (m) EGF in which the carboxyl-terminal tail is substituted for that of TGF-alpha (mEGF/TGF-alpha(44-50)) results in complex features that belie this initial simplistic assumption, Comparison of EGF and mEGF/TGF-alpha(44-50) in equilibrium binding assays showed that although the relative binding affinity of the chimera was reduced 80-200-fold, it was more potent than EGF in mitogenesis assays using NR6/HER cells, This superagonist activity could not be attributed to differences in ligand processing or to binding to other members of the c-erbB family. It appeared to be due, in part, to choice of an EGFR overexpressing target cell where high receptor number compensated for the low affinity of the ligand; it also appeared to be related to the ability of the chimera to activate the EGFR tyrosine kinase, Thus, when EGFR autophosphorylation was measured, mEGF/TGF-alpha(44-50) was more potent than EGF, despite its low affinity, When tested using chicken embryo fibroblasts, substitution of the TGF-alpha carboxyl-terminal tail into mEGF failed to enhance its binding affinity for chicken EGFRs; however, the chimera was intermediate in potency between TGF-alpha and mEGF in mitogenesis assays, Our results suggest a contextual requirement for EGFR recognition which is ligand-specific, Further, the unpredictable responses to chimeric ligands underline the complex nature of the processes of ligand recognition, receptor activation, and the ensuing cellular response.	SOUTHAMPTON GEN HOSP, CANC RES CAMPAIGN MED ONCOL UNIT, SOUTHAMPTON SO16 6YD, HANTS, ENGLAND	University of Southampton			Davies, Donna E/H-2993-2012	Davies, Donna/0000-0002-5117-2991	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; CARPENTER G, 1976, J CELL PHYSIOL, V88, P227, DOI 10.1002/jcp.1040880212; Chen XM, 1996, J BIOL CHEM, V271, P7620, DOI 10.1074/jbc.271.13.7620; CLARE JJ, 1991, GENE, V105, P205, DOI 10.1016/0378-1119(91)90152-2; COWLEY GP, 1986, BRIT J CANCER, V53, P223, DOI 10.1038/bjc.1986.39; DAVIES DE, 1996, FASEB J, V10, P1376; ENGLER DA, 1992, J BIOL CHEM, V267, P2274; ENGLER DA, 1991, MOL CELL BIOL, V11, P2425, DOI 10.1128/MCB.11.5.2425; GEORGENASCIMENTO C, 1988, BIOCHEMISTRY-US, V27, P797, DOI 10.1021/bi00402a046; GREGORY H, 1988, REGUL PEPTIDES, V22, P217, DOI 10.1016/0167-0115(88)90034-1; GRONEN LC, 1994, GROWTH FACTORS, V11, P235; HARTE MT, 1995, ARCH BIOCHEM BIOPHYS, V322, P378, DOI 10.1006/abbi.1995.1478; HOYT DW, 1994, BIOCHEMISTRY-US, V33, P15283, DOI 10.1021/bi00255a009; KLINE TP, 1990, BIOCHEMISTRY-US, V29, P7805, DOI 10.1021/bi00486a005; KOHDA D, 1992, BIOCHEMISTRY-US, V31, P11928, DOI 10.1021/bi00162a036; KRAMER RH, 1994, J BIOL CHEM, V269, P8708; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAX I, 1988, MOL CELL BIOL, V8, P1970, DOI 10.1128/MCB.8.5.1970; LAZAR E, 1989, MOL CELL BIOL, V9, P860, DOI 10.1128/MCB.9.2.860; MATSUNAMI RK, 1991, J CELL BIOCHEM, V46, P242, DOI 10.1002/jcb.240460307; PUDDICOMBE S, 1996, FASEB J, V10, P1376; Puddicombe SM, 1996, J BIOL CHEM, V271, P15367, DOI 10.1074/jbc.271.26.15367; Reddy CC, 1996, J CELL PHYSIOL, V166, P512, DOI 10.1002/(SICI)1097-4652(199603)166:3<512::AID-JCP6>3.0.CO;2-S; RICHTER A, 1995, J BIOL CHEM, V270, P1612, DOI 10.1074/jbc.270.4.1612; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; TADAKI DK, 1993, J BIOL CHEM, V268, P10114; TODARO GJ, 1980, P NATL ACAD SCI-BIOL, V77, P5258, DOI 10.1073/pnas.77.9.5258; WALKER F, 1990, BIOCHEMISTRY-US, V29, P10635, DOI 10.1021/bi00499a009; WINKLER ME, 1989, BIOCHEMISTRY-US, V28, P6373, DOI 10.1021/bi00441a033	29	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30392	30397		10.1074/jbc.271.48.30392	http://dx.doi.org/10.1074/jbc.271.48.30392			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940002	hybrid			2022-12-25	WOS:A1996VV15800019
J	Loh, E; Qi, WW; Vilaire, G; Bennett, JS				Loh, E; Qi, WW; Vilaire, G; Bennett, JS			Effect of cytoplasmic domain mutations on the agonist-stimulated ligand binding activity of the platelet integrin alpha IIb beta 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; FUNCTION-ASSOCIATED ANTIGEN-1; PHORBOL ESTER; GLANZMANN THROMBASTHENIA; ENDOPLASMIC-RETICULUM; FIBRINOGEN BINDING; FLOW-CYTOMETRY; CELL-ADHESION; BETA-SUBUNIT; MEMBRANE	Function of the platelet integrin alpha IIb beta 3 is regulated by agonist-generated signals interacting with its cytoplasmic tails, When alpha IIb beta 3 is expressed in Epstein-Barr virus-transformed B lymphocytes, stimulation of the cells with phorbol 12-myristate 13-acetate results in alpha IIb beta 3-mediated lymphocyte adherence to immobilized fibrinogen, as well as soluble fibrinogen binding to alpha IIb beta 3, indicating that agonists increase the affinity of alpha IIb beta 3 for fibrinogen in these cells, To address the contribution of the alpha IIb and beta 3 cytoplasmic tails to this process, we mutated each tail and expressed the mutants in B lymphocytes. Truncation of the alpha IIb tail did not impair unstimulated or stimulated lymphocyte adherence to fibrinogen, regardless whether the truncation was proximal or distal to the conserved GFFKR sequence. However, deleting GFFKR or replacing it with alanines markedly reduced alpha IIb beta 3 expression due to impaired intracellular assembly of alpha IIb beta 3 heterodimers, probably due to a mutation-induced change in the conformation of alpha IIb. Introducing beta 3 mutations known to impair alpha IIb beta 3 function in platelets into the cytoplasmic tail of beta 3 in lymphocytes also impaired alpha IIb beta 3 function in these cells, These studies demonstrate that the cytoplasmic tail of alpha IIb is not required for alpha IIb beta 3 function in lymphocytes, although the presence of GFFKR in the alpha IIb, tail is required for alpha IIb to interact with beta 3. Additionally, they indicate that signals interacting with the beta 3 cytoplasmic tail are responsible for the ability of agonists to stimulate alpha IIb beta 3 function.	UNIV PENN,SCH MED,DIV HEMATOL ONCOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT MED,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania					NHLBI NIH HHS [HL51258, HL40387] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387, R01HL051258] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAUER JS, 1993, J CELL BIOL, V122, P209, DOI 10.1083/jcb.122.1.209; BENNETT JS, 1993, J BIOL CHEM, V268, P3580; BENNETT JS, 1983, P NATL ACAD SCI-BIOL, V80, P2417, DOI 10.1073/pnas.80.9.2417; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BENNETT JS, 1996, TRENDS CARDIOVAS MED, V16, P31; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; BRAY PF, 1986, P NATL ACAD SCI USA, V83, P1480, DOI 10.1073/pnas.83.5.1480; CHEN YP, 1994, BLOOD, V84, P1857; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10169, DOI 10.1073/pnas.89.21.10169; DANILOV YN, 1989, J CELL BIOL, V108, P1925, DOI 10.1083/jcb.108.5.1925; DIAMOND MS, 1993, J CELL BIOL, V120, P545, DOI 10.1083/jcb.120.2.545; DU XP, 1993, J BIOL CHEM, V268, P23087; FARADAY N, 1994, J LAB CLIN MED, V123, P728; FILARDO EJ, 1994, J BIOL CHEM, V269, P4641; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; GROGER RK, 1989, GENE, V81, P285, DOI 10.1016/0378-1119(89)90189-3; HAVERSTICK DM, 1992, AM J PHYSIOL, V262, pC916, DOI 10.1152/ajpcell.1992.262.4.C916; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; HIBBS ML, 1991, SCIENCE, V251, P1611, DOI 10.1126/science.1672776; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; JOHNSTON GI, 1987, BLOOD, V69, P1401; KASSNER PD, 1993, J EXP MED, V178, P649, DOI 10.1084/jem.178.2.649; KASSNER PD, 1994, J BIOL CHEM, V269, P19859; KAWAGUCHI S, 1993, J BIOL CHEM, V268, P16279; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; KUROIWA T, 1991, J BIOL CHEM, V266, P9251; LAM SCT, 1992, J BIOL CHEM, V267, P5649; LOH E, 1995, J BIOL CHEM, V270, P18631, DOI 10.1074/jbc.270.31.18631; LOLLO BA, 1993, J BIOL CHEM, V268, P21693; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PALMER EL, 1993, J CELL BIOL, V123, P1289, DOI 10.1083/jcb.123.5.1289; PONCZ M, 1994, J CLIN INVEST, V93, P172, DOI 10.1172/JCI116942; RABB H, 1993, J IMMUNOL, V151, P990; ROTHLEIN R, 1986, J EXP MED, V163, P1132, DOI 10.1084/jem.163.5.1132; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SHATTIL SJ, 1995, J CELL BIOL, V131, P807, DOI 10.1083/jcb.131.3.807; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SHAW LM, 1993, J CELL BIOL, V123, P1017, DOI 10.1083/jcb.123.4.1017; SILVER SM, 1987, BLOOD, V69, P1031; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; WANG RG, 1994, BLOOD, V84, pA244; WEISEL JW, 1992, J BIOL CHEM, V267, P16637; Xia Z, 1996, BRIT J HAEMATOL, V93, P204, DOI 10.1046/j.1365-2141.1996.445980.x	45	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30233	30241		10.1074/jbc.271.47.30233	http://dx.doi.org/10.1074/jbc.271.47.30233			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939976	hybrid			2022-12-25	WOS:A1996VU52500104
J	Sato, M; Ribas, C; Hildebrandt, JD; Lanier, SM				Sato, M; Ribas, C; Hildebrandt, JD; Lanier, SM			Characterization of a G-protein activator in the neuroblastoma-glioma cell hybrid NG108-15	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY PROTEINS; GUANINE-NUCLEOTIDE-BINDING; SIGNAL-TRANSDUCTION; COUPLED RECEPTORS; BETA-GAMMA; ADENYLYL-CYCLASE; ALPHA-SUBUNITS; BRAIN; SPECIFICITY; PRECURSOR	Purified bovine brain G-protein was used in a solution phase assay to identify membrane-associated proteins that influenced the activation of heterotrimeric G-proteins, Detergent-solubilized membrane extracts from the neuroblastoma-glioma cell hybrid NG108-15, but not the parent C6B4 glioma cell line, increased [S-35]GTP gamma S binding to purified G-protein by similar to 460%. The G-protein activator was heat sensitive, and the magnitude of its action was related to the amount of extract protein. The biophysical and biochemical properties of the G-protein activator were determined using DEAE ion exchange chromatography, gel filtration, and a lectin affinity ma trix. In the presence of added GDP (1 mu M), the enriched G-protein activator increased the initial rate of [S-35]GTP gamma S binding to brain G-protein by up to 4-fold. In the absence of added GDP, the G-protein activator elicited an initial burst in [S-35]GTP gamma S binding to brain G-protein within the first 30 s, after which the rate of nucleotide binding to G-protein was similar in the absence or presence of the G-protein activator, The stimulation of nucleotide binding to brain G-protein by the activator was also observed after resolution of G alpha from G beta gamma. The G-protein activator was distinct from other proteins (neuromodulin, tubulin, and p-amyloid precursor protein) that influence nucleotide binding to G-protein, indicating the existence of a novel signal accelerator.	MED UNIV S CAROLINA,DEPT CELL & MOL PHARMACOL & EXPT THERAPEUT,CHARLESTON,SC 29425; MED UNIV S CAROLINA,DEPT PHARMACOL,CHARLESTON,SC 29425	Medical University of South Carolina; Medical University of South Carolina				Lanier, Stephen/0000-0002-2740-7607	NIDDK NIH HHS [DK37219] Funding Source: Medline; NINDS NIH HHS [R01-NS821] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037219] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; COUPRY I, 1992, J BIOL CHEM, V267, P9852; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; DINGUS J, 1994, METHOD ENZYMOL, V237, P457; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; DUZIC E, 1992, J BIOL CHEM, V267, P24045; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; HANLEY MR, 1993, NATURE, V362, P14, DOI 10.1038/362014a0; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HILDEBRANDT JD, 1990, J BIOL CHEM, V265, P9825; HUFF RM, 1985, J BIOL CHEM, V260, P864; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; MASURE HR, 1986, BIOCHEMISTRY-US, V25, P7553, DOI 10.1021/bi00371a044; MOUSLI M, 1990, FEBS LETT, V259, P260, DOI 10.1016/0014-5793(90)80023-C; NAOFF C, 1995, MOL PHARMACOL, V48, P806; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; OKAMOTO T, 1995, J BIOL CHEM, V270, P4205, DOI 10.1074/jbc.270.9.4205; POPOVA JS, 1994, J BIOL CHEM, V269, P21748; ROYCHOWDHURY S, 1993, BIOCHEMISTRY-US, V32, P4955, DOI 10.1021/bi00069a034; SATO M, 1995, J BIOL CHEM, V270, P15269, DOI 10.1074/jbc.270.25.15269; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SIM LJ, 1995, P NATL ACAD SCI USA, V92, P7242, DOI 10.1073/pnas.92.16.7242; STRITTMATTER SM, 1991, J BIOL CHEM, V266, P22465; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; STRITTMATTER SM, 1993, P NATL ACAD SCI USA, V90, P5327, DOI 10.1073/pnas.90.11.5327; WANG N, 1990, J BIOL CHEM, V265, P1239; WESSLINGRESNICK M, 1987, BIOCHEMISTRY-US, V26, P4316, DOI 10.1021/bi00388a020; WILCOX MD, 1995, J BIOL CHEM, V270, P4189, DOI 10.1074/jbc.270.9.4189	34	46	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30052	30060		10.1074/jbc.271.47.30052	http://dx.doi.org/10.1074/jbc.271.47.30052			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939952	hybrid			2022-12-25	WOS:A1996VU52500080
J	Artsimovitch, I; Murakami, K; Ishihama, A; Howe, MM				Artsimovitch, I; Murakami, K; Ishihama, A; Howe, MM			Transcription activation by the bacteriophage Mu Mor protein requires the C-terminal regions of both alpha and sigma(70) subunits of Escherichia coli RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMP RECEPTOR PROTEIN; POSITIVE REGULATOR; FUNCTIONAL MAP; FACTOR GATA-1; PROMOTER; DNA; RECOGNITION; EXPRESSION; SEQUENCE; CONTACT	Middle transcription of bacteriophage Mu requires Escherichia coli RNA polymerase and a Mu-encoded protein, Mor, Consistent with these requirements, the middle promoter, P-m, has a -10 hexamer but lacks a recognizable -35 hexamer, Interactions between Mor and RNA polymerase were studied using in vitro transcription, DNase I footprinting, and the yeast interaction trap system, We observed reduced promoter activity in vitro using reconstituted RNA polymerases with C-terminal deletions in alpha or sigma(70). As predicted if alpha were binding to P-m, we detected a polymerase-dependent footprint in the -60 region, Reconstituted RNA polymerases containing Ala substitutions in the alpha C-terminal domain were used to assay Mor-dependent transcription from P-m in vitro. The D258A substitution and alpha deletion gave large reductions in activation, whereas the L262A, R265A, and N268A substitutions caused smaller reductions, The interaction trap assay revealed weak interactions between Mor and both alpha and sigma(70); consistent with a key role of alpha-D258, the D258A substitution abolished interaction, whereas the R265A substitution did not, We propose that: (i) alpha-D258 is a Mor ''contact site''; and (ii) residues Leu-262, Arg-265, and Asn-268 indirectly affect Mor-polymerase interaction by stabilizing the ternary complex via alpha-DNA contact.	UNIV TENNESSEE,CTR HLTH SCI,DEPT MICROBIOL & IMMUNOL,MEMPHIS,TN 38163; NATL INST GENET,DEPT MOL GENET,MISHIMA,SHIZUOKA 411,JAPAN	University of Tennessee System; University of Tennessee Health Science Center; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan			Artsimovitch, Irina/L-3467-2019	Murakami, Katsuhiko/0000-0003-2244-0501				Artsimovitch I, 1996, P NATL ACAD SCI USA, V93, P9408, DOI 10.1073/pnas.93.18.9408; Artsimovitch I, 1996, NUCLEIC ACIDS RES, V24, P450, DOI 10.1093/nar/24.3.450; ATTEY A, 1994, NUCLEIC ACIDS RES, V22, P4375, DOI 10.1093/nar/22.21.4375; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BOKAL AJ, 1996, IN PRESS EMBO J; BUSBY S, 1994, CELL, V79, P743, DOI 10.1016/0092-8674(94)90063-9; CHATTERJEE S, 1995, NATURE, V374, P820, DOI 10.1038/374820a0; CHOY HE, 1995, EMBO J, V14, P4523, DOI 10.1002/j.1460-2075.1995.tb00131.x; COLLADOVIDES J, 1991, MICROBIOL REV, V55, P371, DOI 10.1128/MMBR.55.3.371-394.1991; CROSSLEY M, 1995, MOL CELL BIOL, V15, P2448; DEHASETH PL, 1995, MOL MICROBIOL, V16, P817, DOI 10.1111/j.1365-2958.1995.tb02309.x; ERICKSON JW, 1989, GENE DEV, V3, P1462, DOI 10.1101/gad.3.9.1462; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; Gaal T, 1996, GENE DEV, V10, P16, DOI 10.1101/gad.10.1.16; GARRETT KP, 1992, J BIOL CHEM, V267, P23942; GROSS CA, 1992, TRANSCRIPTIONAL REGU, P129; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HATTMAN S, 1985, GENE, V39, P71, DOI 10.1016/0378-1119(85)90109-X; IGARASHI K, 1991, P NATL ACAD SCI USA, V88, P8958, DOI 10.1073/pnas.88.20.8958; IGARASHI K, 1991, CELL, V65, P1015, DOI 10.1016/0092-8674(91)90553-B; ISHIHAMA A, 1993, J BACTERIOL, V175, P2483, DOI 10.1128/JB.175.9.2483-2489.1993; JAEHNING JA, 1991, SCIENCE, V253, P859, DOI 10.1126/science.1876846; JEON YH, 1995, SCIENCE, V270, P1495, DOI 10.1126/science.270.5241.1495; JIN RZ, 1995, J BIOL CHEM, V270, P19213, DOI 10.1074/jbc.270.33.19213; KahmeyerGabbe M, 1996, J BACTERIOL, V178, P1585, DOI 10.1128/jb.178.6.1585-1592.1996; KLEMM RD, 1995, P NATL ACAD SCI USA, V92, P5788, DOI 10.1073/pnas.92.13.5788; KULDELL N, 1994, J BACTERIOL, V176, P2991, DOI 10.1128/JB.176.10.2991-2998.1994; KUMAR A, 1994, J MOL BIOL, V235, P405, DOI 10.1006/jmbi.1994.1001; KUMAR A, 1993, J MOL BIOL, V232, P406, DOI 10.1006/jmbi.1993.1400; LANDINI P, 1995, EMBO J, V14, P4329, DOI 10.1002/j.1460-2075.1995.tb00107.x; LI M, 1994, SCIENCE, V263, P75, DOI 10.1126/science.8272867; LUSTIG B, 1995, NUCLEIC ACIDS RES, V23, P4707, DOI 10.1093/nar/23.22.4707; MARGOLIN W, 1986, NUCLEIC ACIDS RES, V14, P4881, DOI 10.1093/nar/14.12.4881; MATHEE K, 1993, J BACTERIOL, V175, P5314, DOI 10.1128/JB.175.17.5314-5323.1993; MATHEE K, 1990, J BACTERIOL, V172, P6641, DOI 10.1128/jb.172.12.6641-6650.1990; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; Murakami K, 1996, EMBO J, V15, P4358, DOI 10.1002/j.1460-2075.1996.tb00809.x; OZOLINE ON, 1995, NUCLEIC ACIDS RES, V23, P4533, DOI 10.1093/nar/23.22.4533; PINKNEY M, 1988, BIOCHEM J, V250, P897, DOI 10.1042/bj2500897; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; Sambrook J., 2002, MOL CLONING LAB MANU; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; SOLLNERWEBB B, 1979, CELL, V18, P485, DOI 10.1016/0092-8674(79)90066-7; STODDARD SF, 1990, J BACTERIOL, V172, P361, DOI 10.1128/JB.172.1.361-371.1990; Symonds N., 1987, PHAGE MU; TANG H, 1994, GENE DEV, V8, P3058, DOI 10.1101/gad.8.24.3058; TAO K, 1995, J BACTERIOL, V177, P6740, DOI 10.1128/jb.177.23.6740-6744.1995; TOUSSAINT A, 1974, MOL GEN GENET, V129, P185, DOI 10.1007/BF00268631	49	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32343	32348		10.1074/jbc.271.50.32343	http://dx.doi.org/10.1074/jbc.271.50.32343			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943297	hybrid			2022-12-25	WOS:A1996VY34000088
J	Brozek, KA; Carlson, RW; Raetz, CRH				Brozek, KA; Carlson, RW; Raetz, CRH			A special acyl carrier protein for transferring long hydroxylated fatty acids to lipid a in Rhizobium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESORPTION MASS-SPECTROMETRY; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; A BIOSYNTHESIS; 3-DEOXY-D-MANNOOCTULOSONATE-8-PHOSPHATE SYNTHETASE; 3-DEOXY-D-MANNO-OCTULOSONIC ACID; BACTERIAL-ENDOTOXINS; DEFICIENT MUTANT; LIPOPOLYSACCHARIDE; LEGUMINOSARUM	Lipid A, the hydrophobic anchor of lipopolysaccharides in the outer membranes of Gram-negative bacteria, varies in structure among different Rhizobiaceae. The Rhizobium meliloti lipid A backbone, like that of Escherichia coli, is a beta 1'-6-linked glucosamine disaccharide that is phosphorylated at positions 1 and 4'. Rhizobium leguminosarum lipid A lacks both phosphates, but contains aminogluconate in place of the proximal glucosamim I-phosphate, and galacturonic acid instead of the 4'-phosphate. A peculiar feature of the lipid As of all Rhizobiaceae is acylation with 27-hydroxyoctacosanoic acid, a long hydroxylated fatty acid not found in E. coli. We now describe an in vitro system, consisting of a membrane enzyme and a cytosolic acyl donor from R. leguminosarum, that transfers 27-hydroxyoctacosanoic acid to (Kdo)(2)-lipid IVA, a key lipid A precursor common to both E. coli and R. leguminosarum. The 27-hydroxyoctacosanoic acid moiety was detected in the lipid product by mass spectrometry. The membrane enzyme required the presence of Kdo residues in the acceptor substrate for activity. The cytosolic acyl donor was purified from wild-type R. leguminosarum using the acylation of (Kdo)(2)-[4'-P-32]-lipid IVA as the assay. Amino-terminal sequencing of the purified acyl donor revealed an exact 19-amino acid match with a partially sequenced gene (orf*) of R. leguminosarum. Orf* contains the consensus sequence, DSLD, for attachment of 4'-phosphopantetheine. When the entire orf* gene was sequenced, it was found to encode a protein of 92 amino acids. Orf* is a new kind of acyl carrier protein because it is only similar to 25% identical both to the constitutive acyl carrier protein (AcpP) and to the inducible acyl carrier protein (NodF) of R. leguminosarum. Mass spectrometry of purified active Orf* confirmed the presence of 4'-phosphopantetheine and 27-hydroxyoctacosanoic acid in the major species. Smaller mass peaks indicative of Orf* acylation with hydroxylated 20, 22, 24, and 26 carbon fatty acids were also observed. Given the specialized function of Orf* in lipid A acylation, we suggest the new designation AcpXL.	DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA; UNIV GEORGIA, COMPLEX CARBOHYDRATE RES CTR, ATHENS, GA 30602 USA	Duke University; University System of Georgia; University of Georgia					NIGMS NIH HHS [GM-39583, GM-51796] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051796, R01GM039583, R37GM051796] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKINSON EM, 1994, P NATL ACAD SCI USA, V91, P8418, DOI 10.1073/pnas.91.18.8418; BHAT UR, 1991, J BACTERIOL, V173, P2155, DOI 10.1128/JB.173.7.2155-2159.1991; BHAT UR, 1994, J BIOL CHEM, V269, P14402; BHAT UR, 1991, INT J SYST BACTERIOL, V41, P213; BROZEK K, 1995, FASEB J, V9, pA1376; Brozek KA, 1996, J BIOL CHEM, V271, P32112, DOI 10.1074/jbc.271.50.32119; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; BROZEK KA, 1990, J BIOL CHEM, V265, P15410; CAVA JR, 1989, J BACTERIOL, V171, P8, DOI 10.1128/jb.171.1.8-15.1989; CHAIT BT, 1992, SCIENCE, V257, P1885, DOI 10.1126/science.1411504; CHRIST WJ, 1995, SCIENCE, V268, P80, DOI 10.1126/science.7701344; CHRIST WJ, 1994, J AM CHEM SOC, V116, P3637, DOI 10.1021/ja00087a075; Clementz T, 1996, J BIOL CHEM, V271, P12095, DOI 10.1074/jbc.271.20.12095; CLEMENTZ T, 1995, FASEB J, V9, pA1311; COLEMAN J, 1988, J BACTERIOL, V170, P1268, DOI 10.1128/jb.170.3.1268-1274.1988; COLONNAROMANO S, 1990, MOL GEN GENET, V223, P138, DOI 10.1007/BF00315806; DEMONT N, 1994, EMBO J, V13, P2139, DOI 10.1002/j.1460-2075.1994.tb06490.x; Denarie J, 1996, ANNU REV BIOCHEM, V65, P503, DOI 10.1146/annurev.bi.65.070196.002443; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; GALLOWAY SM, 1990, J BIOL CHEM, V265, P6394; GEIGER O, 1991, J BACTERIOL, V173, P2872, DOI 10.1128/JB.173.9.2872-2878.1991; GOLDMAN R, 1987, NATURE, V329, P162, DOI 10.1038/329162a0; GOLENBOCK DT, 1991, J BIOL CHEM, V266, P19490; HAMMOND SM, 1987, NATURE, V327, P730, DOI 10.1038/327730a0; HAMPTON RY, 1992, METHOD ENZYMOL, V209, P466; IMOTO M, 1983, TETRAHEDRON LETT, V24, P4017, DOI 10.1016/S0040-4039(00)88251-9; JACKOWSKI S, 1987, J BACTERIOL, V169, P1469, DOI 10.1128/jb.169.4.1469-1473.1987; KARIBIAN D, 1993, J BACTERIOL, V175, P2988, DOI 10.1128/JB.175.10.2988-2993.1993; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN J, 1993, ENDOTOXIN RES SERIES, V2; LOPPNOW H, 1989, J IMMUNOL, V142, P3229; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; MOHAN S, 1994, J BIOL CHEM, V269, P32896; MORRISON DC, 1987, ANNU REV MED, V38, P417, DOI 10.1146/annurev.me.38.020187.002221; MYERS KR, 1992, BIOCONJUGATE CHEM, V3, P540, DOI 10.1021/bc00018a013; NISHIJIMA M, 1979, J BIOL CHEM, V254, P7837; PLATT MW, 1990, J BACTERIOL, V172, P5440, DOI 10.1128/jb.172.9.5440-5444.1990; POSTBEITTENMILLER D, 1991, J BIOL CHEM, V266, P1858; PRICE NPJ, 1995, P NATL ACAD SCI USA, V92, P7352, DOI 10.1073/pnas.92.16.7352; PRICE NPJ, 1994, J BACTERIOL, V176, P4646, DOI 10.1128/JB.176.15.4646-4655.1994; QURESHI N, 1988, J BIOL CHEM, V263, P11971; Raetz C. R. H., 1996, ESCHERICHIA COLI SAL, V1, P1035; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RAETZ CRH, 1985, J BIOL CHEM, V260, P6080; RICK PD, 1977, J BIOL CHEM, V252, P4904; RICK PD, 1977, J BIOL CHEM, V252, P4895; Rietschel E. T., 1983, ACS SYM SER, V231, P214; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; RIETSCHEL ET, 1992, SCI AM, V267, P54, DOI 10.1038/scientificamerican0892-54; ROSENFELD IS, 1975, ANAL BIOCHEM, V64, P221, DOI 10.1016/0003-2697(75)90422-4; SACKMANN U, 1991, EUR J BIOCHEM, V200, P463, DOI 10.1111/j.1432-1033.1991.tb16205.x; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STRAIN SM, 1985, J BIOL CHEM, V260, P6089; TAKAYAMA K, 1989, INFECT IMMUN, V57, P1336, DOI 10.1128/IAI.57.4.1336-1338.1989; TRUCHET G, 1985, J BACTERIOL, V164, P1200, DOI 10.1128/JB.164.3.1200-1210.1985; ULEVITCH RJ, 1994, CURR OPIN IMMUNOL, V6, P125, DOI 10.1016/0952-7915(94)90043-4; URBANIKSYPNIEWSKA T, 1989, ARCH MICROBIOL, V152, P527, DOI 10.1007/BF00425481; VANAMAN TC, 1968, J BIOL CHEM, V243, P6420; WOLLENWEBER HW, 1990, J MICROBIOL METH, V11, P195, DOI 10.1016/0167-7012(90)90056-C; Zahringer U, 1995, Prog Clin Biol Res, V392, P113; ZEVENHUIZEN LPTM, 1980, ARCH MICROBIOL, V125, P1, DOI 10.1007/BF00403191	62	66	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32126	32136		10.1074/jbc.271.50.32126	http://dx.doi.org/10.1074/jbc.271.50.32126			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943266	hybrid			2022-12-25	WOS:A1996VY34000057
J	Funderburgh, JL; Funderburgh, ML; Mann, MM; Prakash, S; Conrad, GW				Funderburgh, JL; Funderburgh, ML; Mann, MM; Prakash, S; Conrad, GW			Synthesis of corneal keratan sulfate proteoglycans by bovine keratocytes in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORE PROTEIN; LINKAGE-REGION; ORGAN-CULTURE; GLYCOSAMINOGLYCANS; BIOSYNTHESIS; FIBROBLASTS; LUMICAN; STROMA; GALACTOSIDASE; KERATOCONUS	Keratan sulfate proteoglycans (KSPGs) are the major proteoglycans of the cornea and are secreted by keratocytes in the corneal stroma. Previous studies have been able to show only transient secretion of KSPG in cell culture, In this study, cultures of bovine keratocytes were found to secrete the three previously characterized KSPG proteins into culture medium, Reactivity with monoclonal antibody 122 demonstrated substitution of these proteins with keratan sulfate chains. KSPG constituted 15% of the proteoglycan metabolically labeled with [S-35]sulfate in keratocyte culture medium. This labeled KSPG contained keratan sulfate chains of 4700 Da compared to 21,000 Da for bovine corneal keratan sulfate. Labeled keratan sulfate from cultures contained nonsulfated, monosulfated, and disulfated disaccharides that were released by digestion with endo-beta-galactosidase or keratanase II, Nonsulfated disaccharides were relatively more abundant in keratan sulfate from culture than in corneal keratan sulfate, These results show that cultured bovine keratocytes maintain the ability to express all three of the known KSPG proteins, modified with keratan sulfate chains and sulfated on both N-acetylglucosamine and galactose moieties. KSPG made in vitro differs from that found in vivo in the length and sulfation of its keratan sulfate chains, The availability of cell cultures secreting corneal keratan sulfate proteoglycans provides an opportunity to examine biosynthesis and control of this important class of molecules.			Funderburgh, JL (corresponding author), KANSAS STATE UNIV,DIV BIOL,ACKERT HALL,MANHATTAN,KS 66506, USA.				NATIONAL EYE INSTITUTE [R01EY000952, R01EY009368] Funding Source: NIH RePORTER; NEI NIH HHS [EY00952, EY09368] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AXELSSON I, 1975, BIOCHEM J, V145, P491, DOI 10.1042/bj1450491; BLECKMANN H, 1980, EXP EYE RES, V30, P469, DOI 10.1016/0014-4835(80)90031-7; BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P347; CINTRON C, 1977, DEV BIOL, V61, P346, DOI 10.1016/0012-1606(77)90304-9; CONRAD GW, 1982, J BIOL CHEM, V257, P464; CONRAD GW, 1974, EXP EYE RES, V18, P421, DOI 10.1016/0014-4835(74)90079-7; Corpuz LM, 1996, J BIOL CHEM, V271, P9759, DOI 10.1074/jbc.271.16.9759; COSTER L, 1983, EXP EYE RES, V36, P517, DOI 10.1016/0014-4835(83)90045-3; DAHL IMS, 1978, EXP EYE RES, V27, P175, DOI 10.1016/0014-4835(78)90087-8; DAHL IMS, 1982, EXP EYE RES, V34, P83, DOI 10.1016/0014-4835(82)90011-2; ERNST S, 1995, CRIT REV BIOCHEM MOL, V30, P387, DOI 10.3109/10409239509083490; FUKUDA MN, 1981, J BIOL CHEM, V256, P3900; FUNDERBURGH JL, 1989, INVEST OPHTH VIS SCI, V30, P2278; FUNDERBURGH JL, 1988, INVEST OPHTH VIS SCI, V29, P1116; FUNDERBURGH JL, 1989, INVEST OPHTH VIS SCI, V30, P435; FUNDERBURGH JL, 1983, CURR EYE RES, V2, P769; FUNDERBURGH JL, 1991, BIOCHEM SOC T, V19, P871, DOI 10.1042/bst0190871; FUNDERBURGH JL, 1983, INVEST OPHTH VIS SCI, V24, P208; FUNDERBURGH JL, 1990, INVEST OPHTH VIS SCI, V31, P419; FUNDERBURGH JL, 1986, DEV BIOL, V116, P267, DOI 10.1016/0012-1606(86)90130-2; FUNDERBURGH JL, 1991, J BIOL CHEM, V266, P24773; FUNDERBURGH JL, 1987, J BIOL CHEM, V262, P11634; FUNDERBURGH JL, 1991, J BIOL CHEM, V266, P14226; FUNDERBURGH JL, 1993, J BIOL CHEM, V268, P11874; FUNDERBURGH JL, 1990, J BIOL CHEM, V265, P8297; FUNDERBURGH JL, 1989, KERATAN SULPHATE CHE, P39; HART GW, 1976, J BIOL CHEM, V251, P6513; HART GW, 1978, DEV BIOL, V62, P78, DOI 10.1016/0012-1606(78)90094-5; HASCALL VC, 1991, LIMB DEV REGENERAT B, P3; HASSELL JR, 1992, INVEST OPHTH VIS SCI, V33, P547; HASSELL JR, 1983, ARCH BIOCHEM BIOPHYS, V222, P362, DOI 10.1016/0003-9861(83)90532-5; HOPWOOD JJ, 1973, BIOCHEM J, V135, P631, DOI 10.1042/bj1350631; KELLER R, 1983, H-S Z PHYSIOL CHEM, V364, P253; KELLER R, 1981, H-S Z PHYSIOL CHEM, V362, P327, DOI 10.1515/bchm2.1981.362.1.327; MELROSE J, 1988, ANAL BIOCHEM, V170, P293, DOI 10.1016/0003-2697(88)90634-3; Nakazawa K., 1989, KERATAN SULPHATE CHE, P99; NILSSON B, 1983, J BIOL CHEM, V258, P6056; OBEN M, 1987, BIOCHEM J, V248, P85; SAWAGUCHI S, 1991, INVEST OPHTH VIS SCI, V32, P1846; SCHRECENGOST PK, 1992, ARCH BIOCHEM BIOPHYS, V292, P54, DOI 10.1016/0003-9861(92)90050-7; YUE BYJ, 1976, J BIOCH, V158, P567	41	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31431	31436		10.1074/jbc.271.49.31431	http://dx.doi.org/10.1074/jbc.271.49.31431			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940154	hybrid			2022-12-25	WOS:A1996VW68600065
J	Maggio, R; Barbier, P; Fornai, F; Corsini, GU				Maggio, R; Barbier, P; Fornai, F; Corsini, GU			Functional role of the third cytoplasmic loop in muscarinic receptor dimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-RECEPTOR; ADRENERGIC-RECEPTORS; CHOLINERGIC RECEPTOR; SUBTYPES; CELLS; INTERNALIZATION; GENES; COEXPRESSION; DELINEATION; EXPRESSION	By means of the expression of two chimeric receptors, alpha(2)/m3 and m3/alpha(2), in which the carboxyl-terminal receptor portions, containing transmembrane (TM) domains VI and VII, were exchanged between the alpha(2C) adrenergic and the m3 muscarinic receptor, Maggio ct al, (Maggio, R., Vogel, Z., and Wess, J. (1993) Proc, Natl. Acad. Sci. U.S.A, 90, 3103-31073) demonstrated that G protein-linked receptors are able to interact functionally with each other at the molecular level to form (hetero)dimers. In the present study we tested the hypothesis that interaction between receptors might depend on the presence of a long third intracellular (i3) loop and that shortening this loop could impair the capability of receptors to form dimers, To address this question, we initially created short chimeric alpha(2) adrenergic/m3 muscarinic receptors in which 196 amino acids were deleted from the i3 loop (alpha(2)/m3-short and m3/alpha(2)-short). Although co-transfection of alpha(2)/m3 and m3/alpha(2) resulted in the appearance of specific binding, the co-expression of the two short constructs (alpha(2)/m3-short and m3/alpha(2)-short), either together or in combination, respectively, with m8/alpha(2) and alpha(2)/m3 did not result in any detectable binding activity, In another set of experiments, a mutant m3 receptor, m3/m2(16aa), containing 16 amino acids of the m2 receptor sequence at the amino terminus of the third cytoplasmic loop, which was capable of binding muscarinic ligands but was virtually unable to stimulate phosphatidylinositol hydrolysis, was also mutated in the i3 loop, resulting in the m3/m2(16aa)-short receptor, Although co-transfection of m3/m2(16aa) with a truncated form of the m3 receptor (m8-trunc, containing an in frame stop codon after amino acid codon 272 of the rat m3 sequence) resulted in a considerable carbachol-stimulated phosphatidylinositol breakdown, the co-transfection of m3/m2(16aa) short with the truncated form of the m3 receptor did not result in any recovery of the functional activity, Thus, these data suggest that intermolecular interaction between muscarinic receptors, involving the exchange of amino-terminal (containing TM domains I-V) and carboxyl-terminal (containing TRI domains VI and MI) receptor fragments depends on the presence of a long ia loop, One may speculate that when alternative forms of receptors with a different length of the i3 loop exist, they could have a different propensity to dimerize.	ASSOC ANNI VERDI,I-00152 ROME,ITALY		Maggio, R (corresponding author), UNIV PISA,SCH MED,INST PHARMACOL,VIA ROMA 55,I-56100 PISA,ITALY.		maggio, Roberto/Q-2032-2015; FORNAI, FRANCESCO/AAA-5312-2019	FORNAI, FRANCESCO/0000-0002-3883-5084; Maggio, Roberto/0000-0003-4436-2356				BARBIER P, 1995, EUR J PHARM-MOLEC PH, V290, P125, DOI 10.1016/0922-4106(95)90024-1; BERNHEIM L, 1992, P NATL ACAD SCI USA, V89, P9544, DOI 10.1073/pnas.89.20.9544; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CONKLIN BR, 1988, P NATL ACAD SCI USA, V85, P8698, DOI 10.1073/pnas.85.22.8698; GIROS B, 1989, NATURE, V342, P923, DOI 10.1038/342923a0; HU JG, 1993, J NEUROCHEM, V61, P578; HULME EC, 1990, ANNU REV PHARMACOL, V30, P633, DOI 10.1146/annurev.pa.30.040190.003221; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; LAMEH J, 1992, J BIOL CHEM, V267, P13406; MAEDA S, 1990, FEBS LETT, V269, P386, DOI 10.1016/0014-5793(90)81199-X; MAGGIO R, 1995, J NEUROCHEM, V65, P943; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; MAGGIO R, 1993, FEBS LETT, V319, P195, DOI 10.1016/0014-5793(93)80066-4; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; RICHARDSON RM, 1992, J BIOL CHEM, V267, P22249; SCHONEBERG T, 1995, J BIOL CHEM, V270, P18000; SHAPIRO RA, 1989, BIOCHEMISTRY-US, V28, P8946, DOI 10.1021/bi00448a039; VOIGT MM, 1991, FEBS LETT, V278, P45, DOI 10.1016/0014-5793(91)80080-M; WESS J, 1990, MOL PHARMACOL, V38, P517; WREGGETT KA, 1995, J BIOL CHEM, V270, P22488, DOI 10.1074/jbc.270.38.22488	23	91	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31055	31060		10.1074/jbc.271.49.31055	http://dx.doi.org/10.1074/jbc.271.49.31055			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940100	hybrid			2022-12-25	WOS:A1996VW68600011
J	Ullsperger, C; Cozzarelli, NR				Ullsperger, C; Cozzarelli, NR			Contrasting enzymatic activities of topoisomerase IV and DNA gyrase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERTWINED CATENATED DIMERS; NICKING-CLOSING ENZYME; REPLICATION IN-VITRO; CHROMOSOME SEGREGATION; RECOMBINATION SITE; TN3 RESOLVASE; PURIFICATION; MECHANISM; PROTEIN; DECATENATION	DNA gyrase and topoisomerase IV (Topo IV) have distinct roles as unlinking enzymes during DNA replication despite 40% sequence identity between them, DNA gyrase unlinks replicating DNA by introducing negative supercoils while Topo IV decatenates the two daughter molecules, For this study, we measured the rates of unlinking of various topoisomers of DNA by DNA gyrase and Topo TV, Each enzyme has marked preferences for certain strand-passage reactions. DNA gyrase is a relatively poor decatenase, catalyzing strand-passage events that result in supercoiling at rates several orders of magnitude faster than those causing decatenation, Topo IV, in contrast, decatenates linked circles 10-40 times more quickly than it removes the intramolecular crossings from supercoiled DNA. Supercoiled catenanes are unlinked at an even more increased rate by Topo IV. Thus, the supercoils augment decatenation rather than compete with catenane crossings for their removal. Knot crossings and the crossings of multiply interlinked catenanes are also preferentially removed by Topo TV, This ability of Topo IV to selectively unlink catenated molecules mirrors its key role in decatenation of replicating chromosomes in vivo.	UNIV CALIF BERKELEY,DEPT CELLULAR & MOL BIOL,DIV BIOCHEM & MOL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley								Bates AD, 1996, BIOCHEMISTRY-US, V35, P1408, DOI 10.1021/bi952433y; BENJAMIN HW, 1990, J BIOL CHEM, V265, P6441; BENJAMIN HW, 1985, CELL, V40, P147, DOI 10.1016/0092-8674(85)90318-6; BENJAMIN HW, 1986, P RA WELCH F C CHEM, V29, P107; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; BIRD RE, 1970, J MOL BIOL, V49, P343, DOI 10.1016/0022-2836(70)90249-4; BLISKA JB, 1988, THESIS U CALIFORNIA; BROWN PO, 1979, SCIENCE, V206, P1081, DOI 10.1126/science.227059; Champoux J J, 1994, Adv Pharmacol, V29A, P71; CHAMPOUX JJ, 1980, MECH STUDIES DNA REP, V19, P809; COZZARELLI NR, 1992, P S APPL MATH, V45, P1; CRISONA NJ, 1994, J MOL BIOL, V243, P437, DOI 10.1006/jmbi.1994.1671; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DYNAN WS, 1981, J BIOL CHEM, V256, P5860; Eckstein F., 1995, NUCLEIC ACIDS MOL BI, P115; HIASA H, 1994, J BIOL CHEM, V269, P2093; Hiasa H, 1996, J BIOL CHEM, V271, P21529, DOI 10.1074/jbc.271.35.21529; KATO J, 1990, CELL, V63, P393, DOI 10.1016/0092-8674(90)90172-B; KATO J, 1992, J BIOL CHEM, V267, P25676; KIRKEGAARD K, 1981, CELL, V23, P721, DOI 10.1016/0092-8674(81)90435-9; KREUZER KN, 1980, CELL, V20, P245, DOI 10.1016/0092-8674(80)90252-4; KREUZER KN, 1979, J BACTERIOL, V140, P425; LEVENE SD, 1995, BIOPHYS J, V69, P1036, DOI 10.1016/S0006-3495(95)79978-7; LINDSLEY JE, 1993, J BIOL CHEM, V268, P8096; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; LIU LF, 1978, CELL, V15, P979, DOI 10.1016/0092-8674(78)90281-7; MARIANS KJ, 1987, J BIOL CHEM, V262, P10362; MORRISON A, 1980, J BIOL CHEM, V255, P2211; MORRISON A, 1981, P NATL ACAD SCI-BIOL, V78, P1416, DOI 10.1073/pnas.78.3.1416; NASH HA, 1983, METHOD ENZYMOL, V100, P210; NASH HA, 1987, J BACTERIOL, V169, P4124, DOI 10.1128/jb.169.9.4124-4127.1987; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; PEEBLES CL, 1979, COLD SPRING HARB SYM, V43, P41, DOI 10.1101/SQB.1979.043.01.008; PENG H, 1993, P NATL ACAD SCI USA, V90, P8571, DOI 10.1073/pnas.90.18.8571; PENG H, 1995, J BIOL CHEM, V270, P25286, DOI 10.1074/jbc.270.42.25286; PENG H, 1993, J BIOL CHEM, V268, P24481; PETTIJOHN DE, 1982, CELL, V30, P667, DOI 10.1016/0092-8674(82)90269-0; REECE RJ, 1991, CRIT REV BIOCHEM MOL, V26, P335, DOI 10.3109/10409239109114072; REED RR, 1981, CELL, V25, P721, DOI 10.1016/0092-8674(81)90179-3; ROCA J, 1993, J BIOL CHEM, V268, P14250; ROCA J, 1994, CELL, V77, P609, DOI 10.1016/0092-8674(94)90222-4; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; ROCA J, 1995, TRENDS BIOCHEM SCI, V20, P156, DOI 10.1016/S0968-0004(00)88993-8; Roca J, 1996, GENES CELLS, V1, P17, DOI 10.1046/j.1365-2443.1996.01001.x; Sambrook J., 2002, MOL CLONING LAB MANU; STECK TR, 1984, CELL, V36, P1081, DOI 10.1016/0092-8674(84)90058-8; SUGINO A, 1978, P NATL ACAD SCI USA, V75, P4838, DOI 10.1073/pnas.75.10.4838; SUGINO A, 1977, P NATL ACAD SCI USA, V74, P4767, DOI 10.1073/pnas.74.11.4767; SUNDIN O, 1980, CELL, V21, P103, DOI 10.1016/0092-8674(80)90118-X; SUNDIN O, 1981, CELL, V25, P659, DOI 10.1016/0092-8674(81)90173-2; TSE YC, 1980, J BIOL CHEM, V255, P5560; Tse-Dinh Y C, 1994, Adv Pharmacol, V29A, P21; VARSHAVSKY A, 1983, MECHANISMS DNA REPLI, P463; Vologodskii A, 1996, BIOPHYS J, V70, P2548, DOI 10.1016/S0006-3495(96)79826-0; VOLOGODSKII AV, 1994, ANNU REV BIOPH BIOM, V23, P609, DOI 10.1146/annurev.bb.23.060194.003141; VOLOGODSKII AV, 1993, J MOL BIOL, V232, P1130, DOI 10.1006/jmbi.1993.1465; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WANG JC, 1981, MECHANISTIC STUDIES, P769; WASSERMAN SA, 1988, NATURE, V334, P448, DOI 10.1038/334448a0; WATSON JD, 1953, NATURE, V171, P123; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; WEAVER DT, 1985, CELL, V41, P565, DOI 10.1016/S0092-8674(85)80029-5; ZECHIEDRICH EL, 1995, GENE DEV, V9, P2859, DOI 10.1101/gad.9.22.2859	64	105	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31549	31555		10.1074/jbc.271.49.31549	http://dx.doi.org/10.1074/jbc.271.49.31549			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940171	hybrid			2022-12-25	WOS:A1996VW68600082
J	Decroly, E; Wouters, S; DiBello, C; Lazure, C; Ruysschaert, JM; Seidah, NG				Decroly, E; Wouters, S; DiBello, C; Lazure, C; Ruysschaert, JM; Seidah, NG			Identification of the paired basic convertases implicated in HIV gp160 processing based on in vitro assays and expression in CD4(+) cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ENVELOPE GLYCOPROTEIN; PROPROTEIN CONVERTASE; PROTEOLYTIC CLEAVAGE; PRO-PROTEIN; PROHORMONE CONVERTASES; MUTATIONAL ANALYSIS; HTLV-III/LAV; VIRAL FUSION; HUMAN FURIN	The human immunodeficiency virus HIV envelope glycoprotein gp160 is synthesized as an inactive precursor, which is processed into its fusiogenic form gp120/gp41 by host cell proteinases during its intracellular trafficking. Hexin/subtilisin-related endoproteases have been proposed to be enzyme candidates for this maturation process. In the present study, 1) we examined the ability of partially purified precursor convertases and their isoforms to cleave gp160 in vitro. The data demonstrate that all the convertases tested specifically cleave the HIV envelope glycoprotein into gp120 and gp41. 2) We demonstrated that a 19-amino acid model peptide spanning the gp120/gp41 junction is cleaved by all convertases at the same gp160 site as that recognized in HIV-infected cells. 3) In an effort to evaluate specific convertase inhibitors, we showed that the alpha(1)-antitrypsin variant, alpha(1)-PDX, inhibits equally well the ability of the tested convertases to cleave gp160 in vitro. 4) Three lymphocyte cell lines were screened by reverse transcription polymerase chain reaction in an effort to identify which are the convertases expressed in the most common HIV target, the CD4(+) lymphocytes. The data demonstrate that furin, PC5/6, and the newly cloned PC7 are the main transcribed convertases, suggesting that these proteinases are the major gp160-converting enzymes in T4 lymphocytes.	CLIN RES INST MONTREAL,BIOCHEM NEUROENDOCRINOL LAB,MONTREAL,PQ H2W 1R7,CANADA; CLIN RES INST MONTREAL,PEPTIDE METAB & STRUCT LAB,MONTREAL,PQ H2W 1R7,CANADA; FREE UNIV BRUSSELS,CHIM PHYS MACROMOL INTERFACES LAB,B-1050 BRUSSELS,BELGIUM; UNIV PADUA,INST IND CHEM,I-35131 PADUA,ITALY	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Padua			Seidah, Nabil/I-3596-2013	Seidah, Nabil/0000-0001-6503-9342; DECROLY, Etienne/0000-0002-6046-024X				ANDERSON ED, 1993, J BIOL CHEM, V268, P24887; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; Basak A, 1995, J Pept Sci, V1, P385, DOI 10.1002/psc.310010606; BENJANNET S, 1995, J NEUROCHEM, V64, P2303; BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BOSCH V, 1990, J VIROL, V64, P2337, DOI 10.1128/JVI.64.5.2337-2344.1990; BRAKCH N, 1995, BIOCHEM BIOPH RES CO, V213, P356, DOI 10.1006/bbrc.1995.2137; BRASSEUR R, 1990, BIOCHIM BIOPHYS ACTA, V1029, P267, DOI 10.1016/0005-2736(90)90163-I; Bruzzaniti A, 1996, BIOCHEM J, V314, P727, DOI 10.1042/bj3140727; CLEMENTS GJ, 1991, AIDS RES HUM RETROV, V7, P3, DOI 10.1089/aid.1991.7.3; DEBIE I, 1996, IN PRESS J CELL BIOL; DECROLY E, 1994, J BIOL CHEM, V269, P12240; DEWAR RL, 1989, J VIROL, V63, P2452, DOI 10.1128/JVI.63.6.2452-2456.1989; FENOUILLET E, 1992, VIROLOGY, V187, P825, DOI 10.1016/0042-6822(92)90487-A; FRANZUSOFF A, 1995, J BIOL CHEM, V270, P3154, DOI 10.1074/jbc.270.7.3154; FREED EO, 1989, J VIROL, V63, P4670, DOI 10.1128/JVI.63.11.4670-4675.1989; FTOUHI N, 1994, DNA CELL BIOL, V13, P395, DOI 10.1089/dna.1994.13.395; GU ML, 1995, FEBS LETT, V365, P95, DOI 10.1016/0014-5793(95)00447-H; GUO HG, 1990, VIROLOGY, V174, P217, DOI 10.1016/0042-6822(90)90070-8; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; HATSUZAWA K, 1992, J BIOCHEM-TOKYO, V111, P296, DOI 10.1093/oxfordjournals.jbchem.a123753; Hruby D E, 1986, Methods Enzymol, V124, P295; IVANOFF LA, 1992, VIROLOGY, V187, P423, DOI 10.1016/0042-6822(92)90444-T; JEAN F, 1993, BIOCHEM J, V292, P891, DOI 10.1042/bj2920891; KAMOSHITA K, 1995, J BIOCHEM, V117, P1244, DOI 10.1093/oxfordjournals.jbchem.a124851; KIDO H, 1993, J BIOL CHEM, V268, P13406; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; KOWALSKI M, 1987, SCIENCE, V237, P1351, DOI 10.1126/science.3629244; LEBEAU MC, 1991, NUCLEIC ACIDS RES, V19, P1337, DOI 10.1093/nar/19.6.1337; LEVY JA, 1993, MICROBIOL REV, V57, P183, DOI 10.1128/MMBR.57.1.183-289.1993; LUSSON J, 1993, P NATL ACAD SCI USA, V90, P6691, DOI 10.1073/pnas.90.14.6691; MALIDE D, 1995, J HISTOCHEM CYTOCHEM, V43, P11, DOI 10.1177/43.1.7822759; MCCUNE JM, 1988, CELL, V53, P55, DOI 10.1016/0092-8674(88)90487-4; MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934; Meerabux J, 1996, CANCER RES, V56, P448; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; Moore J P, 1991, AIDS, V5 Suppl 2, pS21, DOI 10.1097/00002030-199101001-00004; MORIKAWA Y, 1993, J VIROL, V67, P3601, DOI 10.1128/JVI.67.6.3601-3604.1993; MOULARD M, 1994, FEBS LETT, V338, P281, DOI 10.1016/0014-5793(94)80284-X; NAKAGAWA T, 1993, FEBS LETT, V327, P165, DOI 10.1016/0014-5793(93)80163-O; OHNISHI Y, 1994, J VIROL, V68, P4075, DOI 10.1128/JVI.68.6.4075-4079.1994; PAQUET L, 1994, J BIOL CHEM, V269, P19279; REHEMTULLA A, 1993, BIOCHEMISTRY-US, V32, P11586, DOI 10.1021/bi00094a015; SATTENTAU QJ, 1991, J EXP MED, V174, P407, DOI 10.1084/jem.174.2.407; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; SEIDAH NG, 1992, MOL ENDOCRINOL, V6, P1559, DOI 10.1210/me.6.10.1559; Seidah NG, 1996, BIOCHEM J, V314, P951, DOI 10.1042/bj3140951; Seidah NG, 1996, FEBS LETT, V379, P247, DOI 10.1016/0014-5793(95)01520-5; SEIDAH NG, 1994, METHOD ENZYMOL, V244, P175; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; Seidah NG, 1996, P NATL ACAD SCI USA, V93, P3388, DOI 10.1073/pnas.93.8.3388; SHENNAN KIJ, 1991, FEBS LETT, V284, P277, DOI 10.1016/0014-5793(91)80703-6; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; VERONESE FD, 1985, SCIENCE, V229, P1402, DOI 10.1126/science.2994223; VEY M, 1992, VIROLOGY, V188, P408, DOI 10.1016/0042-6822(92)90775-K; VIDRICAIRE G, 1993, BIOCHEM BIOPH RES CO, V195, P1011, DOI 10.1006/bbrc.1993.2145; Vollenweider F, 1996, BIOCHEM J, V314, P521, DOI 10.1042/bj3140521; WILLEY RL, 1988, P NATL ACAD SCI USA, V85, P9580, DOI 10.1073/pnas.85.24.9580	61	100	104	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30442	30450		10.1074/jbc.271.48.30442	http://dx.doi.org/10.1074/jbc.271.48.30442			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940009	hybrid			2022-12-25	WOS:A1996VV15800026
J	Guo, DP; Liu, J; Motlagh, A; Jewell, J; Miller, KW				Guo, DP; Liu, J; Motlagh, A; Jewell, J; Miller, KW			Efficient insertion of odd-numbered transmembrane segments of the tetracycline resistance protein requires even-numbered segments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNER MEMBRANE-PROTEINS; ESCHERICHIA-COLI; MALTOSE-BINDING; TOPOLOGY; DOMAIN; CARBOXYPEPTIDASE; MECHANISM; SEQUENCES; FRAGMENTS; PEPTIDES	Functional membrane insertion elements in the pBR322 tetracycline resistance protein were identified by comparing the ability of odd-numbered transmembrane segments and their attached periplasmic loops to insert into the membrane individually or when combined with the next even-numbered segment in the tetracycline resistance protein sequence, The efficiency with which individual odd-numbered segments and periplasmic loops inserted was probed by treating proteins truncated at the distal ends of periplasmic loops P2-P6 with carboxypeptidases and endoproteases in inside-out membrane vesicles, Insertion of odd-numbered segments and attached loops is inefficient when they occupy a C-terminal position in the protein, The C-terminal odd-numbered segment and loop sequences of 34-54% of the molecules of periplasmic loop truncation mutants could be removed by carboxypeptidase Y, In contrast, odd-numbered segments and loops insert efficiently if the next even-numbered segment in the sequence is present, In such cytoplasmic loop truncation mutants, only the cytoplasmic tail sequences of the proteins could be removed by carboxypeptidases. Remarkably, insertion of individual odd-numbered segments and loops is inefficient even though free energies for insertion of these sequences are highly favorable. The results indicate that pairs of adjacent segments, possibly ''helical hairpins,'' are necessary for efficient membrane insertion of the tetracycline resistance protein.	UNIV WYOMING,DEPT MOL BIOL,LARAMIE,WY 82071	University of Wyoming					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047269, R01GM047269] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47269] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLARD JD, 1992, J BIOL CHEM, V267, P17809; ANDERSSON H, 1993, EMBO J, V12, P683, DOI 10.1002/j.1460-2075.1993.tb05702.x; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; CAO GQ, 1994, J BIOL CHEM, V269, P26898; CURIALE MS, 1984, J BACTERIOL, V157, P211, DOI 10.1128/JB.157.1.211-217.1984; ECKERT B, 1989, J BIOL CHEM, V264, P11663; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P3211; FUTAI M, 1974, J MEMBRANE BIOL, V15, P15, DOI 10.1007/BF01870079; HAYASHI R, 1973, J BIOL CHEM, V248, P2296; HENGGE R, 1985, J BACTERIOL, V162, P972, DOI 10.1128/JB.162.3.972-978.1985; KUHN A, 1988, EUR J BIOCHEM, V177, P267, DOI 10.1111/j.1432-1033.1988.tb14372.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY SB, 1984, ANTIMICROBIAL DRUG R, P191; LEWIS WS, 1991, J BIOL CHEM, V266, P20818; LIAO MJ, 1984, J BIOL CHEM, V259, P4194; MILLER KW, 1993, ANAL BIOCHEM, V215, P118, DOI 10.1006/abio.1993.1563; MILLER KW, 1995, ARCH BIOCHEM BIOPHYS, V322, P445, DOI 10.1006/abbi.1995.1487; NGUYEN TT, 1983, GENE, V25, P83, DOI 10.1016/0378-1119(83)90170-1; NIKAIDO H, 1992, SCIENCE, V258, P936, DOI 10.1126/science.1279804; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHOLTZ JM, 1992, ANNU REV BIOPH BIOM, V21, P95, DOI 10.1146/annurev.bb.21.060192.000523; SHAINSKAYA A, 1994, J BIOL CHEM, V269, P10780; Soekarjo M, 1996, BIOCHEMISTRY-US, V35, P1232, DOI 10.1021/bi951087h; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; VONHEIJNE G, 1994, ANNU REV BIOPH BIOM, V23, P167; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; WEISS JB, 1990, J BACTERIOL, V172, P3023, DOI 10.1128/jb.172.6.3023-3029.1990; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZEN KH, 1994, BIOCHEMISTRY-US, V33, P8198, DOI 10.1021/bi00193a005	31	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30829	30834		10.1074/jbc.271.48.30829	http://dx.doi.org/10.1074/jbc.271.48.30829			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940065	hybrid			2022-12-25	WOS:A1996VV15800082
J	Hansen, S; Midgley, CA; Lane, DP; Freeman, BC; Morimoto, RI; Hupp, TR				Hansen, S; Midgley, CA; Lane, DP; Freeman, BC; Morimoto, RI; Hupp, TR			Modification of two distinct COOH-terminal domains is required for murine p53 activation by bacterial Hsp70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING FUNCTION; HEAT-SHOCK PROTEINS; MOLECULAR CHAPERONE BIP; ESCHERICHIA-COLI DNAK; PEPTIDE-BINDING; PHOSPHORYLATION SITE; COATED VESICLES; ATPASE ACTIVITY; GENE-PRODUCT; MUTANT P53	Activation of the latent DNA binding function of human p53 protein by the bacterial Hsp70, DnaK, represents a unique reaction in which a heat shock protein can interact with a native protein to affect its function, We have localized a likely DnaK interaction site on native human p53 tetramers to a motif flanking the COOH-terminal casein kinase II and protein kinase C phosphorylation sites, Murine p53 is less efficiently activated by DnaK, which has permitted a search for factors that might cooperate in p53 activation by DnaK. We show that optimal activation by DnaK may be dependent upon the phosphorylation state of murine p53, in particular, modification of p53 at the cdc2 phosphorylation site by point mutation decreases the extent of activation by DnaK. Additionally, the monoclonal antibody PAb241, binding in the vicinity of the cdc2 phosphorylation site, is able to activate the specific DNA binding function of p53. This has led us to propose a second regulatory motif flanking the tetramerization domain of p53 that cooperates with factors binding at the negative regulatory domain in the extreme COOH terminus.	UNIV DUNDEE, NINEWELLS HOSP & MED SCH, DEPT MOL & CELLULAR PATHOL, DUNDEE DD1 9SY, SCOTLAND; UNIV DUNDEE, CANC RES CAMPAIGN LABS, DEPT BIOCHEM, DUNDEE DD1 4HN, SCOTLAND; NORTHWESTERN UNIV, DEPT BIOCHEM MOL & CELL BIOL, EVANSTON, IL 60208 USA	University of Dundee; University of Dundee; Northwestern University			Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				ABARZUA P, 1995, CANCER RES, V55, P3490; BLONDELGUINDI S, 1993, J BIOL CHEM, V268, P12730; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; CLARKE CF, 1988, MOL CELL BIOL, V8, P1206, DOI 10.1128/MCB.8.3.1206; DELPHIN C, 1994, J BIOL CHEM, V269, P29579; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FISCELLA M, 1994, ONCOGENE, V9, P3249; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; FUCHS B, 1995, EUR J BIOCHEM, V228, P625, DOI 10.1111/j.1432-1033.1995.0625m.x; FUCHS B, 1995, ONCOGENE, V10, P789; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GEORGOPOULOS C, 1990, STRESS PROTEINS BIOL, P191; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; GRAGEROV A, 1994, J MOL BIOL, V241, P133, DOI 10.1006/jmbi.1994.1482; GRAGEROV A, 1994, J MOL BIOL, V235, P848, DOI 10.1006/jmbi.1994.1043; HAINAUT P, 1992, EMBO J, V11, P3513, DOI 10.1002/j.1460-2075.1992.tb05434.x; HALL AR, 1995, ONCOGENE, V10, P561; Hansen S, 1996, J BIOL CHEM, V271, P3917; Harlow E., 1988, ANTIBODIES LAB MANUA, V2nd, P479; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1993, J BIOL CHEM, V268, P13137; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Kernohan NM, 1996, J BIOL CHEM, V271, P4954; Lane DP, 1996, ONCOGENE, V12, P2461; LIBEREK K, 1988, P NATL ACAD SCI USA, V85, P6632, DOI 10.1073/pnas.85.18.6632; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NIHEI T, 1993, CANCER RES, V53, P1702; PICKSLEY SM, 1993, BIOESSAYS, V15, P689, DOI 10.1002/bies.950151008; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; RASSOW J, 1995, TRENDS CELL BIOL, V5, P207, DOI 10.1016/S0962-8924(00)89001-7; ROTHMAN JE, 1986, CELL, V46, P5, DOI 10.1016/0092-8674(86)90852-4; SAKAKIBARA Y, 1988, J BACTERIOL, V170, P972, DOI 10.1128/jb.170.2.972-979.1988; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; STURZBECHER HW, 1987, ONCOGENE, V1, P201; SUGITO K, 1995, FEBS LETT, V358, P161, DOI 10.1016/0014-5793(94)01417-Y; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; UNGEWICKELL E, 1995, NATURE, V378, P632, DOI 10.1038/378632a0; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19307, DOI 10.1074/jbc.270.33.19307; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19300, DOI 10.1074/jbc.270.33.19300; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; YEHIELY F, 1992, CELL GROWTH DIFFER, V3, P803	60	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30922	30928		10.1074/jbc.271.48.30922	http://dx.doi.org/10.1074/jbc.271.48.30922			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940078	hybrid			2022-12-25	WOS:A1996VV15800095
J	Haslam, SM; Coles, GC; Munn, EA; Smith, TS; Smith, HF; Morris, HR; Dell, A				Haslam, SM; Coles, GC; Munn, EA; Smith, TS; Smith, HF; Morris, HR; Dell, A			Haemonchus contortus glycoproteins contain N-linked oligosaccharides with novel highly fucosylated core structures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VENOM PHOSPHOLIPASE-A2; PROTECTIVE ANTIGEN; MASS-SPECTROMETRY; SURFACE; VACCINATION; PROTEINS; GLYCANS; LAMBS; ACETYLGLUCOSAMINE; PURIFICATION	Structural studies on the N-linked oligosaccharides of Haemonchus contortus, an economically important nematode that parasitizes domestic ruminants, have revealed core fucosylation of a type not previously observed in any eukaryotic glycoprotein. Mass spectrometric analyses were performed on detergent extracts of homogenized adult H. contortus and on purified H11, a glycoprotein isolated from intestinal brush borders which has been previously shown to be an effective vaccine antigen. The major N-linked glycans identified in the present study have up to three fucose residues attached to their chitobiose cores. The fucoses are found at the 3- and/or 6-positions of the proximal GlcNAc and at the 3-position of the distal GlcNAc. The latter substitution is unique in N-glycans. Most anti-H11 monoclonal antibodies are known to recognize carbohydrate epitopes, and it is possible that the newly discovered multifucosylated core structures are highly immunogenic in this glycoprotein.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,DEPT BIOCHEM,LONDON SW7 2AY,ENGLAND; UNIV BRISTOL,DEPT VET CLIN SCI,BRISTOL BS18 7DU,AVON,ENGLAND; BABRAHAM INST,DEPT IMMUNOL,CAMBRIDGE CB2 4AT,ENGLAND	Imperial College London; University of Bristol; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASHMAN K, 1995, MOL BIOCHEM PARASIT, V70, P175, DOI 10.1016/0166-6851(94)00210-E; COX GN, 1989, MOL BIOCHEM PARASIT, V36, P233, DOI 10.1016/0166-6851(89)90171-0; DELL A, 1994, METHOD ENZYMOL, V230, P108; DOUBET S, 1992, GLYCOBIOLOGY, V2, P505, DOI 10.1093/glycob/2.6.505; HANDMAN E, 1987, IMMUNOL TODAY, V8, P181, DOI 10.1016/0167-5699(87)90036-3; HIRAISHI K, 1993, GLYCOBIOLOGY, V3, P381, DOI 10.1093/glycob/3.4.381; JASMER DP, 1993, J IMMUNOL, V151, P5450; KHOO KH, 1995, J BIOL CHEM, V270, P17114, DOI 10.1074/jbc.270.29.17114; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUBELKA V, 1993, EUR J BIOCHEM, V213, P1193, DOI 10.1111/j.1432-1033.1993.tb17870.x; LEMOINE J, 1991, CARBOHYD RES, V221, P209, DOI 10.1016/0008-6215(91)80057-T; MAIZELS RM, 1987, J IMMUNOL, V139, P207; MUNN EA, 1993, INT J PARASITOL, V23, P261, DOI 10.1016/0020-7519(93)90149-S; MUNN EA, 1987, PARASITOLOGY, V94, P385, DOI 10.1017/S0031182000054032; NEWTON SE, 1995, INT J PARASITOL, V25, P511, DOI 10.1016/0020-7519(94)00143-C; PRENNER C, 1992, BIOCHEM J, V284, P377, DOI 10.1042/bj2840377; Raju TS, 1996, J BIOL CHEM, V271, P7484, DOI 10.1074/jbc.271.13.7484; Raju TS, 1995, J BIOL CHEM, V270, P30294, DOI 10.1074/jbc.270.51.30294; RAMIREZSOTO D, 1991, CARBOHYD RES, V213, P27, DOI 10.1016/S0008-6215(00)90595-0; RHOADS ML, 1990, MOL BIOCHEM PARASIT, V42, P155, DOI 10.1016/0166-6851(90)90158-I; RHOADS ML, 1994, J PARASITOL, V80, P756, DOI 10.2307/3283254; ROSEN SD, 1994, CURR OPIN CELL BIOL, V6, P663, DOI 10.1016/0955-0674(94)90092-2; SCHACHTER H, 1995, N COMP BIOC A, V29, P153; SMITH TS, 1993, INT J PARASITOL, V23, P271, DOI 10.1016/0020-7519(93)90150-W; SMITH WD, 1994, PARASITE IMMUNOL, V16, P231, DOI 10.1111/j.1365-3024.1994.tb00345.x; Sturm A., 1995, N COMP BIOC A, V29, P521; TAKAHASHI N, 1978, J BIOCHEM-TOKYO, V84, P1467, DOI 10.1093/oxfordjournals.jbchem.a132270; TAVERNOR AS, 1992, PARASITE IMMUNOL, V14, P645, DOI 10.1111/j.1365-3024.1992.tb00036.x; TRETTER V, 1991, EUR J BIOCHEM, V199, P647, DOI 10.1111/j.1432-1033.1991.tb16166.x; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; VELUPILLAI P, 1994, P NATL ACAD SCI USA, V91, P18, DOI 10.1073/pnas.91.1.18; WEBER A, 1987, ALLERGY, V42, P464, DOI 10.1111/j.1398-9995.1987.tb00364.x	32	130	133	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30561	30570		10.1074/jbc.271.48.30561	http://dx.doi.org/10.1074/jbc.271.48.30561			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940027	hybrid			2022-12-25	WOS:A1996VV15800044
J	Hwang, HY; Gilberts, T; Jardim, A; Shih, S; Ullman, B				Hwang, HY; Gilberts, T; Jardim, A; Shih, S; Ullman, B			Creation of homozygous mutants of Leishmania donovani with single targeting constructs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASE; HOMOLOGOUS RECOMBINATION; MITOTIC RECOMBINATION; TRYPANOSOMA-BRUCEI; GENE REPLACEMENT; ADENINE PHOSPHORIBOSYLTRANSFERASE; STABLE TRANSFECTION; PARASITIC PROTOZOA; MOLECULAR-CLONING; TUBULIN GENE	Homozygous null mutants of the hypoxanthine-guanine phosphoribosyltransferase (hgprt) and adenine phosphoribosyltransferase (aprt) loci were created in Leishmania donovani in which both alleles were elimi nated using only a single targeting construct, Functional heterozygotes mere first generated by homologous recombination after transfection with vectors containing 5'- and 3'-flanking regions of either the hgprt or the aprt gene circumscribing drug resistance markers. Homozygous null mutants were then isolated from the heterozygotes by negative selection in media containing subversive substrates of the encoded proteins, i.e. allopurinol for HGPRT and 4-aminopyrazolopyrimidine for APRT, The novel alleles created by homologous recombination were verified by Southern blotting, and the effects of gene replacement upon gene expression in intact parasites were evaluated by direct enzymatic assay and by immunoblotting, All mutant strains were viable under the selection conditions and exhibited appropriate drug resistance phenotypes. The ability to generate homozygous knockouts with single targeting constructs greatly facilitates the genetic dissection and subsequent biochemical investigations of the purine pathway in Leishmania and has important general implications for the genetic manipulation and analysis of the leishmanial genome.	OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOL BIOL,PORTLAND,OR 97201	Oregon Health & Science University				Hwang, Ho-Yon/0000-0003-0204-8932	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI023682, R01AI023682] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-23682] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allen T, 1995, MOL BIOCHEM PARASIT, V74, P99, DOI 10.1016/0166-6851(95)02475-1; ALLEN T, 1989, MOL BIOCHEM PARASIT, V33, P273, DOI 10.1016/0166-6851(89)90089-3; ALLEN TE, 1995, MOL BIOCHEM PARASIT, V73, P133, DOI 10.1016/0166-6851(94)00105-V; BERENS RL, 1995, BIOCH PARASITIC ORGA, pCH16; BEVERLEY SM, 1991, ANNU REV MICROBIOL, V45, P417, DOI 10.1146/annurev.mi.45.100191.002221; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL CE, 1981, MOL CELL BIOL, V1, P336, DOI 10.1128/MCB.1.4.336; CRUZ A, 1991, P NATL ACAD SCI USA, V88, P7170, DOI 10.1073/pnas.88.16.7170; CRUZ A, 1990, NATURE, V348, P171, DOI 10.1038/348171a0; DELAFAILLE MAC, 1992, J BIOL CHEM, V267, P23839; EID J, 1991, P NATL ACAD SCI USA, V88, P2118, DOI 10.1073/pnas.88.6.2118; FREEDMAN DJ, 1993, MOL BIOCHEM PARASIT, V62, P37, DOI 10.1016/0166-6851(93)90175-W; GueirosFilho FJ, 1996, MOL CELL BIOL, V16, P5655; HANSON S, 1992, J BIOL CHEM, V267, P2350; HASSAN HF, 1985, COMP BIOCHEM PHYS B, V81, P1037, DOI 10.1016/0305-0491(85)90110-5; IOVANNISCI DM, 1989, MOL BIOCHEM PARASIT, V34, P177, DOI 10.1016/0166-6851(89)90009-1; IOVANNISCI DM, 1984, J BIOL CHEM, V259, P4617; IOVANNISCI DM, 1984, MOL BIOCHEM PARASIT, V12, P139, DOI 10.1016/0166-6851(84)90131-2; IOVANNISCI DM, 1983, J PARASITOL, V69, P633, DOI 10.2307/3281131; JOSHI PB, 1995, GENE, V156, P145, DOI 10.1016/0378-1119(95)00042-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MGS, 1990, SCIENCE, V250, P1583, DOI 10.1126/science.2177225; LEON W, 1978, NUCLEIC ACIDS RES, V5, P491, DOI 10.1093/nar/5.2.491; MARR JJ, 1983, MOL BIOCHEM PARASIT, V7, P339, DOI 10.1016/0166-6851(83)90016-6; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; NELSON FK, 1989, MOL CELL BIOL, V9, P1284, DOI 10.1128/MCB.9.3.1284; NOZAKI T, 1994, MOL BIOCHEM PARASIT, V67, P91, DOI 10.1016/0166-6851(94)90099-X; PANTON LJ, 1991, J PROTOZOOL, V38, P224, DOI 10.1111/j.1550-7408.1991.tb04433.x; ROVAI L, 1992, MOL BIOCHEM PARASIT, V50, P115, DOI 10.1016/0166-6851(92)90249-J; Sambrook J., 2002, MOL CLONING LAB MANU; Sommer JM, 1996, MOL BIOCHEM PARASIT, V76, P83, DOI 10.1016/0166-6851(95)02543-X; SOUZA AE, 1994, MOL BIOCHEM PARASIT, V63, P213, DOI 10.1016/0166-6851(94)90057-4; TAIT A, 1983, PARASITOLOGY, V86, P29, DOI 10.1017/S0031182000050836; TENASBROEK ALMA, 1990, NATURE, V348, P174, DOI 10.1038/348174a0; TIBAYRENC M, 1990, P NATL ACAD SCI USA, V87, P2414, DOI 10.1073/pnas.87.7.2414; TOBIN JF, 1991, P NATL ACAD SCI USA, V88, P864, DOI 10.1073/pnas.88.3.864; TUTTLE JV, 1980, J BIOL CHEM, V255, P909; WASMUTH JJ, 1984, CELL, V36, P697, DOI 10.1016/0092-8674(84)90350-7; WEBB JR, 1994, MOL BIOCHEM PARASIT, V63, P231, DOI 10.1016/0166-6851(94)90059-0; WILSON K, 1991, J BIOL CHEM, V266, P1665; WILSON K, 1992, MOL BIOCHEM PARASIT, V55, P197, DOI 10.1016/0166-6851(92)90140-F	41	26	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30840	30846		10.1074/jbc.271.48.30840	http://dx.doi.org/10.1074/jbc.271.48.30840			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940067	hybrid			2022-12-25	WOS:A1996VV15800084
J	Kumar, S; Orsini, MJ; Lee, JC; McDonnell, PC; Debouck, C; Young, PR				Kumar, S; Orsini, MJ; Lee, JC; McDonnell, PC; Debouck, C; Young, PR			Activation of the HIV-1 long terminal repeat by cytokines and environmental stress requires an active CSBP/p38 MAP kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; HEAT-SHOCK PROTEIN; SIGNAL-TRANSDUCTION PATHWAYS; TRANSFECTED HUMAN-CELLS; TRANSCRIPTION FACTOR; GENE-EXPRESSION; MAMMALIAN-CELLS; ULTRAVIOLET-LIGHT	The human immunodeficiency virus, type 1 (HIV-1) promoter is known to be activated by proinflammatory cytokines and UV light, These stimuli also activate various members of the mitogen-activated protein kinase family, including JNK/SAPK and CSBP/p38. In HeLa cells containing an integrated HIV-1 long terminal repeat (LTR)-driven reporter, we now show that the specific p38 inhibitor, SB203580, inhibits activation of the HIV-1 LTR by interleukin-1, tumor necrosis factor, UV light, and osmotic stress, Inhibition was 70-90% in all but the case of tumor necrosis factor stimulation, where inhibition was 50%. Each of these stimuli activated p38, which was inhibited by SB203580 in vitro and in vivo with an IC50 (between 0.1 and 1 mu M) similar to that required to inhibit transcription. In contrast, SB203580 had no effect on JNK, which was also activated by these stimuli, The NF kappa B sites in the HIV-1 LTR were required for a response to cytokines but not to UV, and SB203580 remained capable of inhibiting UV activation in the absence of the NF kappa B sites, Studies in which SB203580 was added at different times relative to UV stimulation suggested that the critical p38-mediated phosphorylation event occurred between 2 and 4 h after UV treatment. These data indicate that p38 is required for HIV-1 LTR activation but that the action of p38 is delayed, presumably due to substrate unavailability or inaccessibility.	SMITHKLINE BEECHAM PHARMACEUT,DEPT MOL IMMUNOL,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT MOL GENET,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT CELLULAR BIOCHEM,KING OF PRUSSIA,PA 19406	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline								Adamczewski JP, 1996, EMBO J, V15, P1877, DOI 10.1002/j.1460-2075.1996.tb00538.x; AHLERS A, 1994, MOL PHARMACOL, V46, P1077; BARILLARI G, 1992, J IMMUNOL, V149, P3727; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; BIRD TA, 1994, FEBS LETT, V338, P31, DOI 10.1016/0014-5793(94)80111-8; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHESEBRO B, 1991, J INFECT DIS, V163, P64, DOI 10.1093/infdis/163.1.64; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974; ElKharroubi A, 1996, MOL CELL BIOL, V16, P2958; FRESHNEY NW, 1994, CELL, V78, P10399; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUESDON F, 1993, J BIOL CHEM, V268, P4236; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HUUOT J, 1995, EUR J BIOCHEM, V227, P416; JEANG KT, 1993, J BIOL CHEM, V268, P24940; KRAMER M, 1993, J BIOL CHEM, V268, P6734; KRETZREMY C, 1994, FEBS LETT, V351, P191, DOI 10.1016/S0014-5793(94)80103-7; LEE JC, 1993, ANN NY ACAD SCI, V696, P149; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEGRANDPOELS S, 1990, AIDS RES HUM RETROV, V6, P1389, DOI 10.1089/aid.1990.6.1389; LEGRANDPOELS S, 1995, J BIOL CHEM, V270, P6925, DOI 10.1074/jbc.270.12.6925; LEGRANDPOELS S, 1993, J PHOTOCH PHOTOBIO B, V17, P229, DOI 10.1016/1011-1344(93)80020-A; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; MULLER JM, 1993, IMMUNOBIOLOGY, V187, P233; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PIRET B, 1995, EUR J BIOCHEM, V228, P447, DOI 10.1111/j.1432-1033.1995.tb20283.x; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SACHSENMAIER C, 1994, BIOCHEM PHARMACOL, V47, P129, DOI 10.1016/0006-2952(94)90446-4; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SADAIE M R, 1990, New Biologist, V2, P479; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SMITH ML, 1995, ONCOGENE, V10, P1053; STEIN B, 1989, J VIROL, V63, P4540, DOI 10.1128/JVI.63.11.4540-4544.1989; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; TONGSTARKSEN SE, 1987, P NATL ACAD SCI USA, V84, P6845, DOI 10.1073/pnas.84.19.6845; VALERIE K, 1990, New Biologist, V2, P712; VALERIE K, 1995, BIOCHEMISTRY-US, V34, P15768, DOI 10.1021/bi00048a022; VALERIE K, 1995, BIOCHEMISTRY-US, V34, P15760, DOI 10.1021/bi00048a021; VALERIE K, 1988, NATURE, V333, P78, DOI 10.1038/333078a0; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WOLOSCHAK GE, 1995, CANCER RES, V55, P1696; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN MH, 1994, NATURE, V372, P798	58	94	98	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30864	30869		10.1074/jbc.271.48.30864	http://dx.doi.org/10.1074/jbc.271.48.30864			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940070	hybrid			2022-12-25	WOS:A1996VV15800087
J	Loris, R; Maes, D; Poortmans, F; Wyns, L; Bouckaert, J				Loris, R; Maes, D; Poortmans, F; Wyns, L; Bouckaert, J			A structure of the complex between concanavalin A and methyl-3,6-di-O-(alpha-D-mannopyranosyl)-alpha-D-mannopyranoside reveals two binding modes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED GLYCOPEPTIDES; HYBRID-TYPE GLYCOPEPTIDES; AMINO-ACID SEQUENCE; 3-DIMENSIONAL STRUCTURE; CARBOHYDRATE-BINDING; LEGUME LECTIN; HIGH MANNOSE; RESOLUTION; COVALENT; FRAGMENT	The structure of concanavalin A in complex with the trimannoside methyl-3,6-di-O-(alpha-D-mannopyranosyl)-alpha-D-mannopyranoside has been determined in a novel space group, In three of the four subunits of the concanavalin A tetramer, the interactions between the protein and the bound saccharide are essentially identical to those reported previously by other authors (Naismith, J, H., and Field, R, A. (1996) J, Biol, Chem, 271, 972-976), In the fourth subunit, however, the alpha 1-->3 linkage has a different conformation, resulting in a different part of the alpha 1-->3-linked mannose interacting with essentially the same surface of the protein, Furthermore, significant differences are observed in the quaternary associations of the subunits compared with the saccharide-free structures and other carbohydrate complexes, suggesting that the concanavalin A tetramer is a rather flexible entity.	FREE UNIV BRUSSELS VIB, LAB ULTRASTRUKTUUR, B-1640 RHODE ST GENESE, BELGIUM; VLAAMSE INSTELLING TECHNOL ONDERZOEK, B-2400 MOL, BELGIUM	Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel; VITO			Loris, Remy/GPG-0894-2022	Bouckaert, Julie/0000-0001-8112-1442; Loris, Remy/0000-0002-8862-3338				BECKER JW, 1975, J BIOL CHEM, V250, P1513; BHATTACHARYYA L, 1989, EUR J BIOCHEM, V178, P721, DOI 10.1111/j.1432-1033.1989.tb14503.x; BHATTACHARYYA L, 1987, J BIOL CHEM, V262, P1288; Bouckaert J, 1996, J BIOL CHEM, V271, P16144, DOI 10.1074/jbc.271.27.16144; Bouckaert J, 1996, ACTA CRYSTALLOGR D, V52, P879, DOI 10.1107/S0907444996001953; BOURNE Y, 1994, NAT STRUCT BIOL, V1, P863, DOI 10.1038/nsb1294-863; BOURNE Y, 1994, STRUCTURE, V2, P209, DOI 10.1016/S0969-2126(00)00022-8; BREWER F, 1985, BIOCHEM BIOPH RES CO, V127, P1066, DOI 10.1016/S0006-291X(85)80053-X; BRISSON JR, 1983, BIOCHEMISTRY-US, V22, P1362, DOI 10.1021/bi00275a007; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BUNGER AT, 1992, XPLOR SYSTEM XRAY CR; CASSET F, 1995, J BIOL CHEM, V270, P25619, DOI 10.1074/jbc.270.43.25619; CHERVENAK MC, 1995, BIOCHEMISTRY-US, V34, P5685, DOI 10.1021/bi00016a045; CUNNINGHAM BA, 1975, J BIOL CHEM, V250, P1503; DEBRAY H, 1981, EUR J BIOCHEM, V117, P41; DELBAERE LTJ, 1993, J MOL BIOL, V230, P950, DOI 10.1006/jmbi.1993.1212; DEREWENDA Z, 1989, EMBO J, V8, P2189, DOI 10.1002/j.1460-2075.1989.tb08341.x; GOLDSTEIN IJ, 1965, BIOCHEMISTRY-US, V4, P876, DOI 10.1021/bi00881a013; HARDMAN KD, 1972, BIOCHEMISTRY-US, V11, P4910, DOI 10.1021/bi00776a006; Harrop SJ, 1996, ACTA CRYSTALLOGR D, V52, P143, DOI 10.1107/S0907444995008742; IMBERTY A, 1990, GLYCOCONJUGATE J, V7, P27, DOI 10.1007/BF01050401; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KALB AJ, 1995, ACTA CRYSTALLOGR D, V51, P1077, DOI 10.1107/S0907444995002769; KIM MJ, 1992, BIOCHEM J, V287, P797, DOI 10.1042/bj2870797; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; KLEYWEGT GJ, 1996, IN PRESS METHODS ENZ; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MANDAL DK, 1992, BIOCHEMISTRY-US, V31, P12602, DOI 10.1021/bi00165a009; MANDAL DK, 1994, BIOCHEMISTRY-US, V33, P1157, DOI 10.1021/bi00171a015; MANDAL DK, 1994, BIOCHEMISTRY-US, V33, P1149, DOI 10.1021/bi00171a014; McDonald I, 1993, HBPLUS COMPUTER PROG; MIN W, 1992, EMBO J, V11, P1303, DOI 10.1002/j.1460-2075.1992.tb05174.x; NAISMITH JH, 1994, ACTA CRYSTALLOGR D, V50, P847, DOI 10.1107/S0907444994005287; Naismith JH, 1996, J BIOL CHEM, V271, P972, DOI 10.1074/jbc.271.2.972; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; QUIOCHO FA, 1989, NATURE, V340, P404, DOI 10.1038/340404a0; SHAANAN B, 1991, SCIENCE, V254, P862, DOI 10.1126/science.1948067; SUMNER JB, 1936, J BIOL CHEM, V115, P583; VYAS NK, 1991, J BIOL CHEM, V266, P5226; WANG JL, 1975, J BIOL CHEM, V250, P1490; WILLIAMS BA, 1992, J BIOL CHEM, V267, P22907	41	64	65	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30614	30618		10.1074/jbc.271.48.30614	http://dx.doi.org/10.1074/jbc.271.48.30614			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940035	hybrid			2022-12-25	WOS:A1996VV15800052
J	Oh, YM; Nagalla, SR; Yamanaka, Y; Kim, HS; Wilson, E; Rosenfeld, RG				Oh, YM; Nagalla, SR; Yamanaka, Y; Kim, HS; Wilson, E; Rosenfeld, RG			Synthesis and characterization of insulin-like growth factor-binding protein (IGFBP)-7 - Recombinant human mac25 protein specifically binds IGF-I and II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; EPITHELIAL-CELLS; IDENTIFICATION; INHIBITION; RECEPTORS	The mac25 cDNA was originally cloned from leptomeningial cells and subsequently reisolated through differential display as a sequence preferentially expressed in senescent human mammary epithelial cells. The deduced amino acid sequence of the human mac25 propeptide shares a 20-25% identity to human insulin-like growth factor-binding proteins (IGFBPs), suggesting that mac25 could be another member of the IGFBP family. In the present study, we have generated recombinant human mac25 (rh-mac25) in a baculovirus expression system and assessed its affinity for IGFs and have evaluated the pattern of expression of the mac25 gene in human tissues. Binding of I-125-IGF-I and I-125-IGF-II to rh-mac25 was demonstrated by Western ligand blotting after nondenaturing polyacrylamide gel electrophoresis and by affinity cross-linking with as little as 2 nM rh-mac25. Specificity of rh-mac25 binding to I-125-IGFs was demonstrated by competition for rh-mac25 binding with unlabeled IGFs, but not with [QAYLL]IGF-II analog, which has 100-fold less affinity for IGFBPs. In comparison with IGFBP-3, rh-mac25 has at least a 5-6-fold lower affinity for IGF-I and 20-25-fold lower affinity for IGF-II. mac25 mRNA was detectable in a wide range of normal human tissues, with decreased expression in breast, prostate, colon, and lung cancer cell lines, In conclusion, mac25 specifically binds IGFs and constitutes a new member of the IGFBP family, IGFBP-7. Its wider distribution in normal tissue and lower expression in several cancer cells indicate that IGFBP-7 may function as a growth-suppressing factor, as well as an IGF-binding protein.			Oh, YM (corresponding author), OREGON HLTH SCI UNIV,SCH MED NRC5,DEPT PEDIAT,PORTLAND,OR 97201, USA.				NATIONAL CANCER INSTITUTE [R01CA058110] Funding Source: NIH RePORTER; NCI NIH HHS [CA58110] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAXTER RC, 1989, P NATL ACAD SCI USA, V86, P6869; COHEN P, 1991, J CLIN ENDOCR METAB, V73, P401, DOI 10.1210/jcem-73-2-401; Conover CA, 1996, ENDOCRINOLOGY, V137, P2286, DOI 10.1210/en.137.6.2286; GARGOSKY SE, 1992, ENDOCRINOLOGY, V131, P3051, DOI 10.1210/en.131.6.3051; GIUDICE LC, 1990, J CLIN ENDOCR METAB, V71, P806, DOI 10.1210/jcem-71-4-806; Gucev ZS, 1996, CANCER RES, V56, P1545; GULER HP, 1989, ACTA ENDOCRINOL-COP, V121, P753, DOI 10.1530/acta.0.1210753; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; MCCUSKER RH, 1991, ENDOCRINOLOGY, V129, P939, DOI 10.1210/endo-129-2-939; MURPHY M, 1993, CELL GROWTH DIFFER, V4, P715; NAGALLA SR, 1995, P NATL ACAD SCI USA, V92, P6205, DOI 10.1073/pnas.92.13.6205; OH Y, 1993, J BIOL CHEM, V268, P26045; OH Y, 1995, J BIOL CHEM, V270, P13589, DOI 10.1074/jbc.270.23.13589; OH Y, 1994, ADV EXP MED BIOL, V343, P41; OH YM, 1993, J BIOL CHEM, V268, P14964; ROSENFELD RG, 1994, ACTA PAEDIAT S, V339, P154; Shi Q., 1990, GEL ELECTROPHORESIS; SHIMASAKI S, 1991, Progress in Growth Factor Research, V3, P243, DOI 10.1016/0955-2235(91)90003-M; SWISSHELM K, 1995, P NATL ACAD SCI USA, V92, P4472, DOI 10.1073/pnas.92.10.4472	19	314	345	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30322	30325		10.1074/jbc.271.48.30322	http://dx.doi.org/10.1074/jbc.271.48.30322			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8939990	hybrid			2022-12-25	WOS:A1996VV15800007
J	Harada, S; Smith, RM; Smith, JA; White, MF; Jarett, L				Harada, S; Smith, RM; Smith, JA; White, MF; Jarett, L			Insulin-induced egr-1 and c-fos expression in 32D cells requires insulin receptor, Shc, and mitogen-activated protein kinase, but not insulin receptor substrate-1 and phosphatidylinositol 3-kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; GENE-EXPRESSION; DNA-SYNTHESIS; MAP KINASE; S6 KINASE; STIMULATION; TRANSLOCATION; PATHWAY; IDENTIFICATION; ADIPOCYTES	Many studies suggest that insulin utilizes multiple signal transduction pathways. Insulin's effects are initiated by insulin binding to the insulin receptor, resulting in tyrosine phosphorylation of insulin receptor and in tracellular substrates, such as insulin receptor substrate-1 (IRS-1), IRS-2, or She. We recently demonstrated that immediate-early gene egr-1 transcription was fully induced without phosphorylation of IRS-1 in Chinese hamster ovary cells (Harada, S., Smith, R. M., Smith, J. A., Shah, N., Hu, D.-Q. & Jarett, L. (1995) J. Biol. Chem. 270, 26632-26638). In the present study, we examined the effects of insulin on immediate-early gene egr-1 and c-fos expression in 32D cells overexpressing the insulin receptor (32D/IR), IRS-1 (32D/IRS), or both (32D/IR+IRS) and compared these effects with insulin induced tyrosine phosphorylation. Insulin (17 nM) increased egr-1 and c-fos expression in 32D-IR and 32D/IR+IRS cells, but not in parental cells or 32D/IRS cells, as determined by Northern blot analysis. Insulin treatment (5 min at 37 degrees C) markedly increased tyrosine phosphorylation of several proteins, including the insulin receptor, IRS-1, and She, in 32D/IR+IRS cells as determined by immunoprecipitation and Western blot analysis with anti-phosphotyrosine antibody. In contrast, only two tyrosine-phosphorylated proteins, i.e. insulin receptor and She, were detected in 32D/IR cells. These data suggest that insulin receptor and She phosphorylation is necessary for insulin-induced egr-1 and c-fos expression, but IRS-I phosphorylation is not necessary or sufficient for the expression of these genes. Furthermore, the effect of specific inhibitors on insulin-induced egr-1 expression was examined. Wortmannin (25 nM), a phosphatidylinositol 3-kinase inhibitor, had no effect on insulin-induced egr-1 expression. In contrast, PD 98059 (30 mu M), a mitogen-activated protein kinase kinase inhibitor, totally blocked egr-1 expression induced by insulin. These data indicate that mitogen-activated protein kinase activation, but not phosphatidylinositol 3-kinase activation, is involved in insulin-induced egr-1 expression. Taken together, insulin receptor tyrosine phosphorylation, She tyrosine phosphorylation, and mitogen-activated protein kinase activation appear to be the signal transduction pathway responsible for insulin induced egr-1 expression in 32D cells. These data demonstrate that insulin has multiple signal transduction pathways that vary from cell to cell.	UNIV PENN,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104; JOSLIN DIABET CTR,BOSTON,MA 02215	University of Pennsylvania; Harvard University; Joslin Diabetes Center, Inc.					NIDDK NIH HHS [DK 43808, DK28143, DK28144] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028144, R01DK028143, R01DK043808] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Azpiazu I, 1996, J BIOL CHEM, V271, P5033; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; ELDREDGE ER, 1994, MOL CELL BIOL, V14, P7527, DOI 10.1128/MCB.14.11.7527; GOULD GW, 1994, CELL SIGNAL, V6, P313, DOI 10.1016/0898-6568(94)90036-1; HARADA S, 1995, J BIOL CHEM, V270, P26632, DOI 10.1074/jbc.270.44.26632; HARUTA T, 1995, J BIOL CHEM, V270, P27991; HE WM, 1995, J BIOL CHEM, V270, P23258, DOI 10.1074/jbc.270.40.23258; HUANG RP, 1994, J CELL BIOCHEM, V56, P469, DOI 10.1002/jcb.240560407; JHUN BH, 1994, J BIOL CHEM, V269, P5699; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MENDES P, 1996, MOL CELL BIOL, V16, P2857; MOHN KL, 1991, MOL CELL BIOL, V11, P381, DOI 10.1128/MCB.11.1.381; MUNDSCHAU LJ, 1994, J BIOL CHEM, V269, P16137; MYERS MG, 1994, J BIOL CHEM, V269, P28783; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; OBRIEN RM, 1991, BIOCHEM J, V278, P609, DOI 10.1042/bj2780609; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; TAUB R, 1987, J BIOL CHEM, V262, P10893; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; Yenush L, 1996, MOL CELL BIOL, V16, P2509	24	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30222	30226		10.1074/jbc.271.47.30222	http://dx.doi.org/10.1074/jbc.271.47.30222			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939974	hybrid			2022-12-25	WOS:A1996VU52500102
J	Langenfeld, J; Lonardo, F; Kiyokawa, H; Passalaris, T; Ahn, MJ; Rusch, V; Dmitrovsky, E				Langenfeld, J; Lonardo, F; Kiyokawa, H; Passalaris, T; Ahn, MJ; Rusch, V; Dmitrovsky, E			Inhibited transformation of immortalized human bronchial epithelial cells by retinoic acid is linked to cyclin E down-regulation	ONCOGENE			English	Article						retinoic acid; bronchial epithelial cells; transformation; cyclin E	ACUTE PROMYELOCYTIC LEUKEMIA; 13-CIS-RETINOIC ACID; NEOPLASTIC TRANSFORMATION; DIFFERENTIATION THERAPY; INTERFERON ALPHA-2A; PHASE-TRANSITION; LUNG-CANCER; VITAMIN-A; EXPRESSION; CARCINOMA	The retinoids are reported to reduce second primary aerodigestive tract tumors in patients with prior lung or head and neck carcinomas. Yet, the optimal retinoid useful for chemoprevention and those mechanisms linked to this chemoprevention are not identified. This study reports an in vitro model for carcinogen-induced transformation of immortalized human bronchial epithelial (BEAS-2B) cells that was adapted to study the anticarcinogenic effects of all-trans-retinoic acid (RA). Following exposure to carcinogens: cigarette smoke condensate (CSC) or N-nitrosamine-4-(methylnitrosamino)-1-(3 pyridyl)-1-butanone (NNK), BEAS-2B cells exhibited evidence of transformation. This included an increased anchorage independent growth or acquired ability to form tumors in athymic mice. This transformation was inhibited by RA as demonstrated by a lack of augmented anchorage independent growth or tumor formation in athymic mice for the cells treated with RA. The BEAS-2B cells transformed by NNK exhibited an increase in cyclin E expression which was associated with an increase in the cyclin E-Cdk2 kinase activity. Over-expression of human cyclin E by transfection shows cyclin E enhances the basal clonal growth of BEAS-2B cells. In both the parental and transformed BEAS-2B cells, RA down-regulated cyclin E protein levels which was associated with an inhibition of growth and an accumulation of cells in G1. The data reported here suggest the decline of cyclin E expression represents a potential mechanism for the RA-induced growth suppression which is linked to the anti-carcinogenic effects of RA. Thus, this study reports the adaption of an in vitro model of lung carcinogenesis suitable to test the activity of chemoprevention agents.	MEM SLOAN KETTERING CANC CTR,DEPT MED,MOL MED LAB,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,DEPT SURG,THORAC SERV,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,MEM HOSP,DEPT PATHOL,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,PROGRAM MOL BIOL,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,SLOAN KETTERING INST,MOL PHARMACOL & THERAPEUT PROGRAM,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center				Kiyokawa, Hiroaki/0000-0002-7942-6455	NCI NIH HHS [K12-CA01712, R01-CA5 4494-04, T32-CA09512] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054494, K12CA001712, T32CA009512] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn MJ, 1995, ONCOGENE, V11, P2357; BASELGA J, 1993, ONCOGENE, V8, P3257; BURGER C, 1994, J CELL SCI, V107, P2047; CASTAIGNE S, 1990, BLOOD, V76, P1704; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DMITROVSKY E, 1990, ONCOGENE RES, V5, P233; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; GERADTS J, 1993, CELL GROWTH DIFFER, V4, P799; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Gudas Lorraine J., 1994, P443; HONG WK, 1986, NEW ENGL J MED, V315, P1501, DOI 10.1056/NEJM198612113152401; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEYOMARSI K, 1994, CANCER RES, V54, P380; KLEINSZANTO AJP, 1992, P NATL ACAD SCI USA, V89, P6693, DOI 10.1073/pnas.89.15.6693; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LECHNER JF, 1982, IN VITRO CELL DEV B, V18, P633; LIPPMAN SM, 1992, J NATL CANCER I, V84, P235, DOI 10.1093/jnci/84.4.235; LIPPMAN SM, 1992, JNCI-J NATL CANCER I, V84, P241, DOI 10.1093/jnci/84.4.241; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; MAHAFFEY DT, 1995, FEBS LETT, V370, P109, DOI 10.1016/0014-5793(95)00799-F; MERRIMAN RL, 1979, CANCER RES, V39, P1661; MOASSER MM, 1995, ONCOGENE, V10, P1537; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PASTORINO U, 1993, J CLIN ONCOL, V11, P1216, DOI 10.1200/JCO.1993.11.7.1216; REDDEL RR, 1988, CANCER RES, V48, P1904; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Sgambato A, 1996, CANCER RES, V56, P1389; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; 1994, NEW ENGL J MED, V330, P1029	35	77	81	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 7	1996	13	9					1983	1990						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934545				2022-12-25	WOS:A1996VR79500018
J	Castano, EM; Prelli, F; Soto, C; Beavis, R; Matsubara, E; Shoji, M; Frangione, B				Castano, EM; Prelli, F; Soto, C; Beavis, R; Matsubara, E; Shoji, M; Frangione, B			The length of amyloid-beta in hereditary cerebral hemorrhage with amyloidosis, Dutch type - Implications for the role of amyloid-beta 1-42 in Alzheimer's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN A-BETA; MASS-SPECTROMETRY; FORMIC-ACID; PEPTIDE; GENE; PRECURSOR; DEPOSITION; FIBRILS; A-BETA-42(43); PATHOLOGY	In hereditary cerebral hemorrhage with amyloidosis, Dutch type (HCEFWA-D), a genetic variant (E22Q) of amyloid beta (A beta) accumulates predominantly in the small vessels of leptomeninges and cerebral cortex, leading to fatal strokes in the fifth or sixth decade of life, A beta deposition in the neuropil occurs mainly in the form of preamyloid, Congo red negative deposits, while mature neuritic plaques and neurofibrillary tangles, hallmark lesions in Alzheimer's disease (AD), are characteristically absent, A recent hypothesis regarding the patho genesis of AD states that A beta extending to residues 42-43 (as opposed to shorter species) can seed amyloid formation and trigger the development of neuritic plaques followed by neuronal damage in AD. We characterized biochemically and immunohistochemically A beta from three cases of HCHWA-D to determine its length in vascular and parenchymal deposits, Mass spectrometry of formic acid-soluble amyloid, purified by size-exclusion gel chromatography, showed that A beta 1-40 and its carboxyl-terminal truncated derivatives were the predominant forms in leptomeningeal and cortical vessels, A beta 1-42 was a minor component in these amyloid extracts, Immunohistochemistry with antibodies S40 and S42, specific for A beta ending at Val-40 or Ala-42, respectively, were consistent with the biochemical data from vascular amyloid. In addition, parenchymal preamyloid lesions were specifically stained with S42 and were not labeled by S40, in agreement with the pattern reported for AD, Down's syndrome, and aged dogs, Our results suggest that in HCHWA-D the carboxyl-terminal A beta heterogeneity is due to limited proteolysis in vivo, Moreover, they suggest that A beta species ending at Ala-42 may not be critical for the seeding of amyloid formation and the development of AD-like neuritic changes.	NYU,MED CTR,DEPT NEUROL,NEW YORK,NY 10016; NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016; GUNMA UNIV,SCH MED,DEPT NEUROL,GUNMA 371,JAPAN	New York University; New York University; Gunma University	Castano, EM (corresponding author), NYU,MED CTR,DEPT PATHOL,RM TH427,550 1ST AVE,NEW YORK,NY 10016, USA.				NIA NIH HHS [AG10953, AG05891] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R35AG010953, R37AG005891, R01AG005891] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Beavis RC, 1996, J AM SOC MASS SPECTR, V7, P107, DOI 10.1016/1044-0305(95)00592-7; CASTANO EM, 1988, LAB INVEST, V58, P122; CASTANO EM, 1986, BIOCHEM BIOPH RES CO, V141, P782, DOI 10.1016/S0006-291X(86)80241-8; CLEMENTS A, 1993, NEUROSCI LETT, V161, P17, DOI 10.1016/0304-3940(93)90129-9; Cohen SL, 1996, ANAL CHEM, V68, P31, DOI 10.1021/ac9507956; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Davis J, 1996, P NATL ACAD SCI USA, V93, P2996, DOI 10.1073/pnas.93.7.2996; FABIAN H, 1993, BIOCHEM BIOPH RES CO, V191, P232, DOI 10.1006/bbrc.1993.1207; FERNANDEZMADRID I, 1991, ANN NEUROL, V30, P730, DOI 10.1002/ana.410300516; Fukumoto H, 1996, AM J PATHOL, V148, P259; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; HARIGAYA Y, 1995, BIOCHEM BIOPH RES CO, V211, P1015, DOI 10.1006/bbrc.1995.1912; HENDRIKS L, 1992, NAT GENET, V1, P218, DOI 10.1038/ng0692-218; HILLENKAMP F, 1991, ANAL CHEM, V63, pA1193; IWATSUBO T, 1995, ANN NEUROL, V37, P294, DOI 10.1002/ana.410370305; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KLUNK WE, 1990, J NEUROCHEM, V54, P2050, DOI 10.1111/j.1471-4159.1990.tb04910.x; LALOWSKI M, 1996, IN PRESS J BIOL CHEM, V271; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; LUYENDIJK W, 1988, J NEUROL SCI, V85, P267, DOI 10.1016/0022-510X(88)90186-4; MAATSCHIEMAN MLC, 1994, ACTA NEUROPATHOL, V88, P371; Mann DMA, 1996, AM J PATHOL, V148, P1257; MILLER DL, 1993, ARCH BIOCHEM BIOPHYS, V301, P41, DOI 10.1006/abbi.1993.1112; MORI H, 1992, J BIOL CHEM, V267, P17082; NORDSTEDT C, 1994, J BIOL CHEM, V269, P30773; ORLANDO R, 1992, BIOCHEM BIOPH RES CO, V184, P686, DOI 10.1016/0006-291X(92)90644-Z; PRELLI F, 1988, BIOCHEM BIOPH RES CO, V151, P1150, DOI 10.1016/S0006-291X(88)80486-8; ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836; ROHER AE, 1993, J BIOL CHEM, V268, P3072; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SORIMACHI K, 1994, EUR J BIOCHEM, V219, P237, DOI 10.1111/j.1432-1033.1994.tb19935.x; SOTO C, 1995, J BIOL CHEM, V270, P3063, DOI 10.1074/jbc.270.7.3063; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TENNENT GA, 1995, P NATL ACAD SCI USA, V92, P4299, DOI 10.1073/pnas.92.10.4299; VANDUINEN SG, 1987, P NATL ACAD SCI USA, V84, P5991; VIGOPELFREY C, 1993, J NEUROCHEM, V61, P1965, DOI 10.1111/j.1471-4159.1993.tb09841.x; Wisniewski T, 1996, BIOCHEM J, V313, P575, DOI 10.1042/bj3130575; WISNIEWSKI T, 1994, NEUROBIOL AGING, V15, P143, DOI 10.1016/0197-4580(94)90105-8; WISNIEWSKI T, 1991, BIOCHEM BIOPH RES CO, V179, P1247, DOI 10.1016/0006-291X(91)91706-I; YAKAR S, 1994, SCAND J IMMUNOL, V40, P653, DOI 10.1111/j.1365-3083.1994.tb03519.x	47	84	84	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32185	32191		10.1074/jbc.271.50.32185	http://dx.doi.org/10.1074/jbc.271.50.32185			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943274	hybrid			2022-12-25	WOS:A1996VY34000065
J	Deves, R; Angelo, S				Deves, R; Angelo, S			Changes in membrane and surface potential explain the opposite effects of low ionic strength on the two lysine transporters of human erythrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEM-Y+; AMINO; CATION; DEPENDENCE	The sucrose-induced stimulation of lysine influx in human erythrocytes has been attributed to the removal of a competitive inhibition exerted by Na+ on system y(+) (Young, J. D., Fincham, D. A., and Harvey, C. M, (1991) Biochim Biophys. Acta 1070, 111-118). We have reexamined this phenomenon separating the contribution of the two cationic amino acid transporters present in these cells (system y(+) and system y(+)L). NaCl replacement with sucrose increased influx through system y(+)L, but decreased influx through system y(+). We conclude that 1) the inhibition of system y(+) is a response to the membrane depolarization that results from chloride removal, and 2) the stimulation of system y(+)L is due to the enhancement of the negative surface potential. Consistently, lysine influx through system y(+)L (in sucrose medium) was reduced by Na+, K+, Li+, and choline (K-0.5 = 25-34 mM), the effect reaching a maximum at 35-40% of the original flux. Divalent cations (Ca2+ and Mg2+) were also inhibitory, but lower concentrations were required (K-0.5 1.1-1.8 mM). The finding that sucrose stimulates uptake through changes in the surface potential explains similar effects observed in other cells with various cationic substrates.			Deves, R (corresponding author), UNIV CHILE,FAC MED,DEPAT FISIOL & BIOFIS,CASILLA 70005,SANTIAGO 7,CHILE.							ANGELO S, 1994, J MEMBRANE BIOL, V141, P183; BERNHARDT I, 1991, J PHYSIOL-LONDON, V434, P489, DOI 10.1113/jphysiol.1991.sp018482; Bernhardt I., 1994, CELL ELECTROPHORESIS, P163; CHRISTENSEN HN, 1969, P NATL ACAD SCI USA, V63, P948, DOI 10.1073/pnas.63.3.948; DEVES R, 1993, J PHYSIOL-LONDON, V468, P753, DOI 10.1113/jphysiol.1993.sp019799; DEVES R, 1992, J PHYSIOL-LONDON, V454, P491, DOI 10.1113/jphysiol.1992.sp019275; ELENO N, 1994, J PHYSIOL-LONDON, V479, P291, DOI 10.1113/jphysiol.1994.sp020296; FREEDMAN JC, 1979, J GEN PHYSIOL, V74, P187, DOI 10.1085/jgp.74.2.187; HEINRICH R, 1981, ACTA BIOL MED GER, V40, P765; HILLE B, 1992, IONIC CHANNELS EXCIT, P318; KAVANAUGH MP, 1993, BIOCHEMISTRY-US, V32, P5781, DOI 10.1021/bi00073a009; MCLAUGHLIN S, 1977, CURR TOP MEMBR TRANS, V9, P71; RINK TJ, 1982, RED CELL MEMBRANES M, P321; THEUVENET APR, 1976, J THEOR BIOL, V57, P313, DOI 10.1016/0022-5193(76)90004-7; THOMAS EL, 1971, J BIOL CHEM, V246, P1677; VANWINKLE LJ, 1993, BIOCHIM BIOPHYS ACTA, V1146, P38, DOI 10.1016/0005-2736(93)90335-W; VANWINKLE LJ, 1990, BIOCHIM BIOPHYS ACTA, V1025, P215, DOI 10.1016/0005-2736(90)90100-3; VANWINKLE LJ, 1993, BIOCHIM BIOPHYS ACTA, V1154, P157, DOI 10.1016/0304-4157(93)90009-D; YOUNG JD, 1991, BIOCHIM BIOPHYS ACTA, V1070, P111, DOI 10.1016/0005-2736(91)90152-X	19	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32034	32039		10.1074/jbc.271.50.32034	http://dx.doi.org/10.1074/jbc.271.50.32034			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943253	hybrid			2022-12-25	WOS:A1996VY34000044
J	Jung, D; Duclos, F; Apostol, B; Straub, V; Lee, JC; Allamand, V; Venzke, DP; Sunada, Y; Moomaw, CR; Leveille, CJ; Slaughter, CA; Crawford, TO; McPherson, JD; Campbell, KP				Jung, D; Duclos, F; Apostol, B; Straub, V; Lee, JC; Allamand, V; Venzke, DP; Sunada, Y; Moomaw, CR; Leveille, CJ; Slaughter, CA; Crawford, TO; McPherson, JD; Campbell, KP			Characterization of delta-sarcoglycan, a novel component of the oligomeric sarcoglycan complex involved in limb-girdle muscular dystrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-COMPLEX; SKELETAL-MUSCLE; EXTRACELLULAR-MATRIX; BETA-SARCOGLYCAN; BINDING DOMAIN; PROTEINS; MUTATIONS; GENE; LINKAGE; HETEROGENEITY	The sarcoglycan complex is known to be involved in limb-girdle muscular dystrophy (LGMD) and is composed of at least three proteins: alpha-, beta-, and gamma-sarcoglycan. delta-Sarcoglycan has now been identified as a second 35-kDa sarcolemmal transmembrane glycoprotein that shares high homology with gamma-sarcoglycan and is expressed mainly in skeletal and cardiac muscle. Biochemical analysis has demonstrated that gamma- and delta-sarcoglycan are separate entities within the sarcoglycan complex and that all four sarcoglycans exist in the complex on a stoichiometrically equal basis. Immunohistochemical analysis of skeletal muscle biopsies from patients with LGMD2C, LGMD2D, and LGMD2E demonstrated a reduction of the entire sarcoglycan complex in these muscular dystrophies. Furthermore, we have mapped the human delta-sarcoglycan gene to chromosome 5q33-q34 in a region overlapping the recently linked autosomal recessive LGMD2F locus.	UNIV CALIF IRVINE,DEPT BIOL CHEM,IRVINE,CA 92717; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,BIOPOLYMER FACIL,DALLAS,TX 75235; JOHNS HOPKINS UNIV,DEPT NEUROL,BALTIMORE,MD 21287; WASHINGTON UNIV,SCH MED,DEPT GENET,GENOME SEQUENCING CTR,ST LOUIS,MO 63108; UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	University of California System; University of California Irvine; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Johns Hopkins University; Washington University (WUSTL); Howard Hughes Medical Institute; University of Iowa			Allamand, Valerie/M-4333-2017; Allamand, Valérie/AAH-6272-2021; McPherson, John D/D-2633-2017; Crawford, Thomas/E-6307-2012	Allamand, Valérie/0000-0001-8997-9742; McPherson, John D/0000-0001-8049-9347; Venzke, David/0000-0001-8180-9562; Straub, Volker/0000-0001-9046-3540; Campbell, Kevin/0000-0003-2066-5889				ADAMS ME, 1993, NEURON, V11, P531, DOI 10.1016/0896-6273(93)90157-M; AHN AH, 1995, J CELL BIOL, V128, P363, DOI 10.1083/jcb.128.3.363; AZIBI K, 1993, HUM MOL GENET, V2, P1423; BASHIR R, 1994, HUM MOL GENET, V3, P455, DOI 10.1093/hmg/3.3.455; BECKMANN JS, 1991, CR ACAD SCI III-VIE, V312, P141; BENOTHMANE K, 1992, NAT GENET, V2, P315, DOI 10.1038/ng1292-315; BOEHNKE M, 1991, AM J HUM GENET, V49, P1174; BONNEMANN CG, 1995, NAT GENET, V11, P266, DOI 10.1038/ng1195-266; CAMPBELL KP, 1989, NATURE, V338, P259, DOI 10.1038/338259a0; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; GEE SH, 1993, J BIOL CHEM, V268, P14972; HELBLINGLECLERC A, 1995, NAT GENET, V11, P216, DOI 10.1038/ng1095-216; HEMMINGS L, 1992, J CELL BIOL, V116, P1369, DOI 10.1083/jcb.116.6.1369; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; Jung D, 1996, FEBS LETT, V381, P15, DOI 10.1016/0014-5793(96)00056-7; JUNG D, 1995, J BIOL CHEM, V270, P27305, DOI 10.1074/jbc.270.45.27305; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIM LE, 1995, NAT GENET, V11, P257, DOI 10.1038/ng1195-257; MATSUMURA K, 1992, NATURE, V359, P320, DOI 10.1038/359320a0; MCNALLY EM, 1994, P NATL ACAD SCI USA, V91, P9690, DOI 10.1073/pnas.91.21.9690; Nissinen M, 1996, AM J HUM GENET, V58, P1177; NOGUCHI S, 1995, SCIENCE, V270, P819, DOI 10.1126/science.270.5237.819; OHLENDIECK K, 1991, J CELL BIOL, V112, P135, DOI 10.1083/jcb.112.1.135; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; PassosBueno MR, 1996, HUM MOL GENET, V5, P815, DOI 10.1093/hmg/5.6.815; PASSOSBUENO MR, 1995, HUM MOL GENET, V4, P1163; PICCOLO F, 1995, NAT GENET, V10, P243, DOI 10.1038/ng0695-243; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; ROBERDS SL, 1994, CELL, V78, P625, DOI 10.1016/0092-8674(94)90527-4; ROBERDS SL, 1993, J BIOL CHEM, V268, P23739; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH DB, 1987, CURRENT PROTOCOLS MO; SOARES MB, 1994, P NATL ACAD SCI USA, V91, P9228, DOI 10.1073/pnas.91.20.9228; SPEER MC, 1992, AM J HUM GENET, V50, P1211; STEVENSON AC, 1953, ANN EUGENIC, V18, P50; SUZUKI A, 1995, J CELL BIOL, V128, P373, DOI 10.1083/jcb.128.3.373; SUZUKI A, 1994, EUR J BIOCHEM, V220, P283, DOI 10.1111/j.1432-1033.1994.tb18624.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALTON JN, 1954, BRAIN, V77, P169, DOI 10.1093/brain/77.2.169; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; YAMAMOTO H, 1993, J BIOCHEM-TOKYO, V114, P132, DOI 10.1093/oxfordjournals.jbchem.a124128; YAMAOKA LH, 1994, NEUROMUSCULAR DISORD, V4, P471, DOI 10.1016/0960-8966(94)90086-8; YANG B, 1994, J BIOL CHEM, V269, P6040; YANG B, 1995, J BIOL CHEM, V270, P4975, DOI 10.1074/jbc.270.10.4975; YOSHIDA M, 1994, EUR J BIOCHEM, V222, P1055, DOI 10.1111/j.1432-1033.1994.tb18958.x; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276	52	79	82	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32321	32329		10.1074/jbc.271.50.32321	http://dx.doi.org/10.1074/jbc.271.50.32321			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943294	hybrid			2022-12-25	WOS:A1996VY34000085
J	Kolaczkowski, M; vanderRest, M; CybularzKolaczkowska, A; Soumillion, JP; Konings, WN; Goffeau, A				Kolaczkowski, M; vanderRest, M; CybularzKolaczkowska, A; Soumillion, JP; Konings, WN; Goffeau, A			Drugs, ionophoric peptides, and steroids as substrates of the yeast multidrug transporter Pdr5p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-CASSETTE TRANSPORTER; ATP-DEPENDENT TRANSPORT; P-GLYCOPROTEIN; SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; GENE-PRODUCT; FUNCTIONAL CONSEQUENCES; RESISTANT CELLS; VESICLES; TRIPHOSPHATASE	Pdr5p is the yeast Saccharomyces cerevisiae ATP-binding cassette transporter conferring resistance to several unrelated drugs. Its high overproduction in Pdr1p transcription factor mutants allows us to study the molecular mechanism of multidrug transport and substrate specificity. We have developed new in vivo and in vitro assays of Pdr5p-mediated drug transport. We show that in spite of little sequence homology, and inverted topology in respect to that of mammalian P-glycoproteins, Pdr5p shares with them common substrate. Pdr5p extrudes rhodamines 6G and 123, from intact yeast cells in an energy dependent manner. Plasma membrane preparations from a Pdr5p-overproducing strain exhibit ATP hydrolysis-dependent, osmotically sensitive rhodamine 6G fluorescence quenching. The quenching is competitively inhibited by micromolar concentrations of many anticancer drugs, such as vinblastine, vincristine, taxol, and verapamil, and of ionophoric peptides as well as steroids. In contrast, other anticancer drugs, like colchicine and some multidrug resistance modifiers, such as quinidine, exert noncompetitive inhibition. Our experimental system opens new possibilities for the analysis of structure-function relationship of multidrug transporter substrates and inhibitors.	UNIV CATHOLIQUE LOUVAIN, UNITE BIOCHIM PHYSIOL, B-1348 LOUVAIN, BELGIUM; UNIV GRONINGEN, DEPT MICROBIOL, NL-9751 NN HAREN, NETHERLANDS; UNIV CATHOLIQUE LOUVAIN, DEPT CHIM, LAB CHIM ORGAN PHYS & PHOTOCHIM, B-1348 LOUVAIN, BELGIUM	Universite Catholique Louvain; University of Groningen; Universite Catholique Louvain			Konings, Wilhelmus N./C-7063-2013					ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; ARBELOA FL, 1988, J CHEM SOC FARAD T 2, V84, P1903, DOI 10.1039/f29888401903; BALZI E, 1987, J BIOL CHEM, V262, P16871; BALZI E, 1995, J BIOENERG BIOMEMBR, V27, P71, DOI 10.1007/BF02110333; BALZI E, 1994, J BIOL CHEM, V269, P3206; BEAUDET L, 1995, J BIOL CHEM, V270, P17159, DOI 10.1074/jbc.270.29.17159; BISSINGER PH, 1994, J BIOL CHEM, V269, P4180; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; Bolhuis H, 1996, EMBO J, V15, P4239, DOI 10.1002/j.1460-2075.1996.tb00798.x; DECOTTIGNIES A, 1995, J BIOL CHEM, V270, P18150, DOI 10.1074/jbc.270.30.18150; DECOTTIGNIES A, 1994, J BIOL CHEM, V269, P12797; DELAHODDE A, 1995, MOL CELL BIOL, V15, P4043; DEMAIS L, 1991, J BIOL CHEM, V266, P5736; DOIGE CA, 1993, ANNU REV MICROBIOL, V47, P291, DOI 10.1146/annurev.micro.47.1.291; DUFOUR JP, 1988, METHOD ENZYMOL, V157, P513; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; EIDELMAN O, 1989, BIOCHIM BIOPHYS ACTA, V988, P319, DOI 10.1016/0304-4157(89)90008-7; FERRY DR, 1992, BIOCHEM BIOPH RES CO, V188, P440, DOI 10.1016/0006-291X(92)92404-L; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; GOTTESMAN MM, 1994, CURR TOP MEMBR, V41, P3, DOI 10.1016/S0070-2161(08)60451-7; GUIRAL M, 1994, FEBS LETT, V346, P141, DOI 10.1016/0014-5793(94)00447-1; HIGGINS CF, 1994, CELL, V79, P393, DOI 10.1016/0092-8674(94)90248-8; HIRATA D, 1994, CURR GENET, V26, P285, DOI 10.1007/BF00310491; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; JOHNSON LV, 1980, P NATL ACAD SCI-BIOL, V77, P990, DOI 10.1073/pnas.77.2.990; KATZMANN DJ, 1994, MOL CELL BIOL, V14, P4653, DOI 10.1128/MCB.14.7.4653; Katzmann DJ, 1996, J BIOL CHEM, V271, P23049, DOI 10.1074/jbc.271.38.23049; KESSEL D, 1991, CANCER RES, V51, P4665; KRALLI A, 1995, P NATL ACAD SCI USA, V92, P4701, DOI 10.1073/pnas.92.10.4701; KUCHLER K, 1989, EMBO J, V8, P3973, DOI 10.1002/j.1460-2075.1989.tb08580.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leatherbarrow R. J., 1992, GRAFIT VERSION 3 0; LEE JS, 1994, MOL PHARMACOL, V46, P627; LEONARD PJ, 1994, ANTIMICROB AGENTS CH, V38, P2492, DOI 10.1128/AAC.38.10.2492; LEPPERT G, 1990, GENETICS, V125, P13; LOO TW, 1993, J BIOL CHEM, V268, P3143; LOO TW, 1994, J BIOL CHEM, V269, P7243; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALKHANDI J, 1994, EUR J PHARM-MOLEC PH, V288, P105, DOI 10.1016/0922-4106(94)90015-9; MEYERS S, 1992, CURR GENET, V21, P431, DOI 10.1007/BF00351651; Michaelis S, 1995, COLD SPRING HARB SYM, V60, P291, DOI 10.1101/SQB.1995.060.01.034; MICHELSON S, 1992, B MATH BIOL, V54, P1023; Pierce J. S., 1970, Journal of the Institute of Brewing, V76, P442; REUTZ S, 1994, CELL, V77, P1071; REUTZ S, 1994, J BIOL CHEM, V269, P12277; SERVOS J, 1993, MOL GEN GENET, V236, P214, DOI 10.1007/BF00277115; SHAPIRO AB, 1995, J BIOL CHEM, V270, P16167, DOI 10.1074/jbc.270.27.16167; SIKORSKI RS, 1989, GENETICS, V122, P19; TAMAI I, 1991, J BIOL CHEM, V266, P16796; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107	50	262	273	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31543	31548		10.1074/jbc.271.49.31543	http://dx.doi.org/10.1074/jbc.271.49.31543			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940170	hybrid			2022-12-25	WOS:A1996VW68600081
J	Larose, M; CassardDoulcier, AM; Fleury, C; Serra, F; Champigny, O; Bouillaud, F; Ricquier, D				Larose, M; CassardDoulcier, AM; Fleury, C; Serra, F; Champigny, O; Bouillaud, F; Ricquier, D			Essential cis-acting elements in rat uncoupling protein gene are in an enhancer containing a complex retinoic acid response domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN ADIPOSE-TISSUE; BETA-ADRENERGIC AGONIST; AP1 BINDING-SITE; MESSENGER-RNA; TRANSGENIC MICE; CELL-CULTURE; X-RECEPTOR; EXPRESSION; THERMOGENESIS; ADIPOCYTES	Transgenic mice were generated with a transgene containing the 211-base pair (bp) enhancer and 0.4 kilobase pairs of 5'-flanking DNA of the uncoupling protein (ucp) gene. Expression of this transgene was restricted to brown adipose tissue and was inducible by cold exposure or treatment of transgenic mice by norepinephrine, retinoic acid (RA), or CL-316,243 beta 3-adrenoreceptor agonist. A search for retinoic acid response elements in the ucp gene enhancer was undertaken using mutagenesis and transfection of cultured cells with chloramphenicol acetyltransferase constructs. Deletion or mutations of several putative retinoic acid response elements were ineffective. Mutations of a TGAATCA region dramatically decreased the transcriptional activity in the presence of RA, In vitro this region was able to bind a complex containing proteins recognized by antibodies against Jun or Fos. Mutations of an adjacent region related to an inverted repeat of type 2 also markedly decreased RA effect. This region was able to bind in vitro retinoid X receptor alpha and retinoic acid receptor beta. The two regions form an activating region between bp -2421 and -2402 (referred to as the ucp gene-activating region), which has an enhancer activity but cannot confer RA response to a promoter, This response was obtained with a larger DNA fragment (bp -2489 to -2398) constituting a complex RA response domain.	CNRS, CEREMOD, F-92190 MEUDON, FRANCE	Centre National de la Recherche Scientifique (CNRS)			Serra, Francisca/B-8641-2008; Bouillaud, Frédéric R/L-3238-2017; CASSARD, Anne-Marie/B-6095-2019	Serra, Francisca/0000-0002-8307-9732; Bouillaud, Frédéric R/0000-0002-7518-9237; CASSARD, Anne-Marie/0000-0002-1813-5128				ALVAREZ R, 1995, J BIOL CHEM, V270, P5666, DOI 10.1074/jbc.270.10.5666; ANTRASFERRY J, 1994, BIOCHEM J, V302, P943, DOI 10.1042/bj3020943; BIANCO AC, 1988, J BIOL CHEM, V263, P18168; BLOOM JD, 1992, J MED CHEM, V35, P3081, DOI 10.1021/jm00094a025; BOUILLAUD F, 1988, BIOCHEM BIOPH RES CO, V157, P783, DOI 10.1016/S0006-291X(88)80318-8; BOUILLAUD F, 1985, P NATL ACAD SCI USA, V82, P445, DOI 10.1073/pnas.82.2.445; BOUILLAUD F, 1984, J BIOL CHEM, V259, P1583; BOYER BB, 1991, MOL CELL BIOL, V11, P4147, DOI 10.1128/MCB.11.8.4147; CANNON B, 1985, ESSAYS BIOCHEM, V20, P110; CASSARDDOULCIER AM, 1993, MOL ENDOCRINOL, V7, P497, DOI 10.1210/me.7.4.497; CASSARDDOULCIER AM, 1994, J BIOL CHEM, V269, P24335; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHAMPIGNY O, 1992, MOL CELL ENDOCRINOL, V86, P73, DOI 10.1016/0303-7207(92)90177-8; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; COUSIN B, 1992, J CELL SCI, V103, P931; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; HIMMESHAGEN J, 1996, IN PRESS HDB OBESITY; HIMMSHAGEN J, 1994, AM J PHYSIOL, V266, pR1371, DOI 10.1152/ajpregu.1994.266.4.R1371; HOGAN B, 1986, MANIPULATING MOUSE E; JACOBSSON A, 1985, J BIOL CHEM, V260, P6250; KATO S, 1995, MOL CELL BIOL, V15, P5858; KLAUS S, 1994, J CELL SCI, V107, P313; KLAUS S, 1991, INT J BIOCHEM, V23, P791, DOI 10.1016/0020-711X(91)90062-R; KLAUS S, 1991, J CELL BIOL, V115, P1783, DOI 10.1083/jcb.115.6.1783; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KOPECKY J, 1990, J BIOL CHEM, V265, P22204; KOZAK UC, 1994, MOL CELL BIOL, V14, P59, DOI 10.1128/MCB.14.1.59; KOZAK UC, 1992, MOL ENDOCRINOL, V6, P763, DOI 10.1210/me.6.5.763; LEPAR GJ, 1992, MOL CELL ENDOCRINOL, V84, P65, DOI 10.1016/0303-7207(92)90072-E; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MEANS AL, 1995, ANNU REV BIOCHEM, V64, P201, DOI 10.1146/annurev.bi.64.070195.001221; MUKAI K, 1995, MOL CELL BIOL, V15, P6003; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; RABELO R, 1995, ENDOCRINOLOGY, V136, P1003, DOI 10.1210/en.136.3.1003; REHNMARK S, 1990, J BIOL CHEM, V265, P16464; RICQUIER D, 1986, J BIOL CHEM, V261, P13905; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; ROSS SR, 1992, P NATL ACAD SCI USA, V89, P7561, DOI 10.1073/pnas.89.16.7561; ROY DY, 1995, MOL CELL BIOL, V15, P6481; SAFONOVA I, 1994, BIOCHEM BIOPH RES CO, V204, P498, DOI 10.1006/bbrc.1994.2487; SAFONOVA I, 1994, MOL CELL ENDOCRINOL, V104, P201, DOI 10.1016/0303-7207(94)90123-6; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; Scott DK, 1996, J BIOL CHEM, V271, P6260, DOI 10.1074/jbc.271.11.6260; Sears IB, 1996, MOL CELL BIOL, V16, P3410; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SILVA JE, 1993, TRENDS ENDOCRIN MET, V4, P25, DOI 10.1016/1043-2760(93)90060-R; SISTA ND, 1995, NUCLEIC ACIDS RES, V23, P1729; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; THONBERG H, 1994, J BIOL CHEM, V269, P33179; WU FK, 1988, EMBO J, V7, P2117, DOI 10.1002/j.1460-2075.1988.tb03051.x; Xia CL, 1996, BIOCHEM J, V313, P155, DOI 10.1042/bj3130155; YANGYEN HF, 1991, NEW BIOL, V3, P1206	54	67	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31533	31542		10.1074/jbc.271.49.31533	http://dx.doi.org/10.1074/jbc.271.49.31533			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940169	hybrid			2022-12-25	WOS:A1996VW68600080
J	Nantel, A; Quatrano, RS				Nantel, A; Quatrano, RS			Characterization of three rice basic/leucine zipper factors, including two inhibitors of EmBP-1 DNA binding activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRANSCRIPTIONAL ACTIVATOR; ABSCISIC-ACID; BZIP PROTEINS; MOLECULAR CHARACTERIZATION; NEGATIVE REGULATOR; SEED DEVELOPMENT; HISTONE GENES; BASIC REGION; EXPRESSION	The promoter of the wheat Em gene contains elements with a CACGTG core sequence (G-boxes), which are recognized by EmBP-1, a wheat basic/leucine zipper (bZIP) protein, G-boxes are required for Em expression in response to the phytohormone abscisic acid and for transactivation by the Viviparous-1 protein (VP1) using transient expression systems, In order to identify other factors that are part of the transcriptional complex that associates with Gr-boxes, we have screened a rice (Oryza sativa) cDNA library with biotinylated EmBP-1. We have isolated osZIP-1a, a homolog of EmBP-1 and other plant G-box-binding factors. me show that EmBP-1 and osZIP-1a will preferentially heterodimerize in vitro, Over-expression of osZIP-1a in rice protoplasts can enhance expression from the Em promoter only in the presence of abscisic acid. Two Other clones have been identified by screening with EmBP-1: osZIP-2a and osZIP-2b. These osZIP-2 factors represent a novel class of bZIP proteins with an unusual DNA-binding domain that does not recognize G-boxes, The osZIP-2 factors can heterodimerize with EmBP-1 and prevent it from binding to the Em promoter. Interestingly, osZIP-1a does not heterodimerize with the osZIP-2 factors and its DNA binding activity is unaffected by their presence. Thus, osZIP-2 factors may be involved in sequestering a particular group of G-box binding factors into inactive heterodimers.	UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill					NIGMS NIH HHS [GM44288] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AESCHBACHER RA, 1991, PLANT J, V1, P303, DOI 10.1046/j.1365-313X.1991.t01-1-00999.x; AGUAN K, 1993, MOL GEN GENET, V240, P1, DOI 10.1007/BF00276876; ARMSTRONG GA, 1992, PLANT CELL, V4, P525, DOI 10.1105/tpc.4.5.525; AUKERMAN MJ, 1991, GENE DEV, V5, P310, DOI 10.1101/gad.5.2.310; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONAWAY RC, 1994, TRANSCRIPTION MECH R; DELISLE AJ, 1990, PLANT CELL, V2, P547, DOI 10.1105/tpc.2.6.547; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEVETTEN NC, 1994, INT J BIOCHEM, V26, P1055, DOI 10.1016/0020-711X(94)90128-7; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FELDBRUGGE M, 1994, PLANT CELL, V6, P1607, DOI 10.1105/tpc.6.11.1607; FOLEY RC, 1993, PLANT J, V3, P669, DOI 10.1111/j.1365-313X.1993.00669.x; FOSTER R, 1994, FASEB J, V8, P192, DOI 10.1096/fasebj.8.2.8119490; GIULIANO G, 1988, P NATL ACAD SCI USA, V85, P7089, DOI 10.1073/pnas.85.19.7089; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; GUILTINAN MJ, 1994, PLANT MOL BIOL, V26, P1041, DOI 10.1007/BF00040687; GUILTINAN MJ, 1990, SCIENCE, V250, P267, DOI 10.1126/science.2145628; GYURIS J, 1993, CELL, V74, P205; HARTER K, 1994, PLANT CELL, V6, P545, DOI 10.1105/tpc.6.4.545; HURST HC, 1994, PROTEIN PROFILE, V1, P123; IZAWA T, 1993, J MOL BIOL, V230, P1131, DOI 10.1006/jmbi.1993.1230; IZAWA T, 1994, PLANT CELL, V6, P1277, DOI 10.1105/tpc.6.9.1277; KATAGIRI F, 1989, NATURE, V340, P727, DOI 10.1038/340727a0; Litts J C, 1991, DNA Seq, V1, P263, DOI 10.3109/10425179109020781; LOHMER S, 1993, PLANT CELL, V5, P65, DOI 10.1105/tpc.5.1.65; LU GH, 1992, P NATL ACAD SCI USA, V89, P11490, DOI 10.1073/pnas.89.23.11490; LUTCKE HA, 1987, EMBO J, V6, P43, DOI 10.1002/j.1460-2075.1987.tb04716.x; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; MARCOTTE WR, 1988, NATURE, V335, P454, DOI 10.1038/335454a0; MARCOTTE WR, 1989, PLANT CELL, V1, P969, DOI 10.2307/3868997; MCCARTY DR, 1991, CELL, V66, P895, DOI 10.1016/0092-8674(91)90436-3; MCELROY D, 1990, PLANT CELL, V2, P163, DOI 10.1105/tpc.2.2.163; MEIER I, 1994, NUCLEIC ACIDS RES, V22, P470, DOI 10.1093/nar/22.3.470; MENKENS AE, 1994, P NATL ACAD SCI USA, V91, P2522, DOI 10.1073/pnas.91.7.2522; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MIKAMI K, 1994, J BIOL CHEM, V269, P9974; MONTECLARO FS, 1993, P NATL ACAD SCI USA, V90, P6726, DOI 10.1073/pnas.90.14.6726; NANTEL A, 1995, PLANT MOL BIOL REP, V13, P164, DOI 10.1007/BF02668788; NEUHAUS G, 1994, PLANT CELL, V6, P827, DOI 10.1105/tpc.6.6.827; OEDA K, 1991, EMBO J, V10, P1793, DOI 10.1002/j.1460-2075.1991.tb07704.x; PARCY F, 1994, PLANT CELL, V6, P1567, DOI 10.1105/tpc.6.11.1567; PIETRZAK M, 1986, NUCLEIC ACIDS RES, V14, P5857, DOI 10.1093/nar/14.14.5857; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PYSH LD, 1993, PLANT CELL, V5, P227, DOI 10.1105/tpc.5.2.227; Rogers S.O., 1988, PLANT MOL BIOL MANUA, pA6/1; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RUTH J, 1994, PLANT MOL BIOL, V25, P323, DOI 10.1007/BF00023248; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHINDLER U, 1992, EMBO J, V11, P1275, DOI 10.1002/j.1460-2075.1992.tb05171.x; SCHINDLER U, 1992, PLANT CELL, V4, P1309, DOI 10.1105/tpc.4.10.1309; SCHINDLER U, 1992, EMBO J, V11, P1261, DOI 10.1002/j.1460-2075.1992.tb05170.x; SCHMIDT RJ, 1990, P NATL ACAD SCI USA, V87, P46, DOI 10.1073/pnas.87.1.46; SINGH K, 1990, PLANT CELL, V2, P891, DOI 10.1105/tpc.2.9.891; SUCKOW M, 1994, NUCLEIC ACIDS RES, V22, P4395, DOI 10.1093/nar/22.21.4395; TABATA T, 1989, SCIENCE, V245, P965, DOI 10.1126/science.2772648; TABATA T, 1991, EMBO J, V10, P1459, DOI 10.1002/j.1460-2075.1991.tb07666.x; THOMAS D, 1992, MOL CELL BIOL, V12, P1719, DOI 10.1128/MCB.12.4.1719; TORRES JT, 1993, PLANT J, V4, P587, DOI 10.1046/j.1365-313X.1993.04030587.x; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; UNGER E, 1993, PLANT CELL, V5, P831, DOI 10.1105/tpc.5.8.831; VASIL V, 1995, PLANT CELL, V7, P1511, DOI 10.1105/tpc.7.9.1511; WILLIAMSON JD, 1988, PLANT PHYSIOL, V86, P208, DOI 10.1104/pp.86.1.208; YAMAZAKI K, 1990, P NATL ACAD SCI USA, V87, P7035, DOI 10.1073/pnas.87.18.7035	70	63	67	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31296	31305		10.1074/jbc.271.49.31296	http://dx.doi.org/10.1074/jbc.271.49.31296			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940135	Green Published, hybrid			2022-12-25	WOS:A1996VW68600046
J	Rangan, VS; Smith, S				Rangan, VS; Smith, S			Expression in Escherichia coli and refolding of the malonyl-/acetyltransferase domain of the multifunctional animal fatty acid synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIMITED TRYPSINIZATION; ACTIVE-SITE; AMINO-ACID; MUTAGENESIS; SYNTHETASE; COMPONENT; COMPLEX; GENE	A cDNA encoding residues 429-815 of the multifunctional rat fatty acid synthase has been expressed in Escherichia coli and the recombinant protein refolded in vitro as a catalytically active malonyl-/acetyltransferase. Kinetic properties of the refolded recombinant enzyme were indistinguishable from those of a transferase preparation derived from the natural fatty acid synthase by limited proteolysis, indicating that the transferase domain is capable of folding correctly as an independent protein, Replacement of the active site Ser-581 (full length fatty acid synthase numbering) with alanine completely eliminated catalytic activity, whereas replacement with cysteine resulted in retention of about 1% activity. The wild type transferase was extremely susceptible to inhibition by diethyl pyrocarbonate, and protection against inhibition was afforded by both malonyl- and acetyl-CoA. Replacement of the highly conserved residue His-683 with Ala reduced activity by 99.95%, and the residual activity was relatively unaffected by diethyl pyrocarbonate. The rate of acylation of the active site serine residue was also reduced by several orders of magnitude in the His-683 --> Ala mutant. These results indicate that His-683 plays an essential role in catalysis, likely by accepting a proton from the active site serine, thus increasing its nucleophilicity.	CHILDRENS HOSP,OAKLAND RES INST,OAKLAND,CA 94609	Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute					NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR006505] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016073, R01DK034400] Funding Source: NIH RePORTER; NCRR NIH HHS [RR06505] Funding Source: Medline; NIDDK NIH HHS [DK16073, DK34400] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMY CM, 1992, P NATL ACAD SCI USA, V89, P1105, DOI 10.1073/pnas.89.3.1105; AMY CM, 1989, P NATL ACAD SCI USA, V86, P3114, DOI 10.1073/pnas.86.9.3114; BEDORD CJ, 1978, ARCH BIOCHEM BIOPHYS, V186, P139, DOI 10.1016/0003-9861(78)90473-3; GIBNEY G, 1990, P NATL ACAD SCI USA, V87, P7546, DOI 10.1073/pnas.87.19.7546; HARDIE DG, 1986, MULTIDOMAIN PROTEINS, P229; HIGAKI JN, 1989, BIOCHEMISTRY-US, V28, P9256, DOI 10.1021/bi00450a004; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; JOSHI AK, 1993, J BIOL CHEM, V268, P22508; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MIKKELSEN J, 1985, BIOCHEM J, V227, P21, DOI 10.1042/bj2270021; NAGGERT J, 1991, BIOCHEM J, V273, P787, DOI 10.1042/bj2730787; NEET KE, 1966, P NATL ACAD SCI USA, V56, P1606, DOI 10.1073/pnas.56.5.1606; PAZIRANDEH M, 1991, J BIOL CHEM, V266, P20946; POLGAR L, 1966, J AM CHEM SOC, V88, P153; RANGAN VS, 1991, J BIOL CHEM, V266, P19180; SERRE L, 1995, J BIOL CHEM, V270, P12961, DOI 10.1074/jbc.270.22.12961; SMITH S, 1994, FASEB J, V8, P1248, DOI 10.1096/fasebj.8.15.8001737; SMITH S, 1976, P NATL ACAD SCI USA, V73, P1184, DOI 10.1073/pnas.73.4.1184; SMITH S, 1973, ARCH BIOCHEM BIOPHYS, V156, P751, DOI 10.1016/0003-9861(73)90328-7; TSUKAMOTO Y, 1983, J BIOL CHEM, V258, P5312; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; WITKOWSKI A, 1990, FASEB J, V4, pA2516	22	30	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31749	31755		10.1074/jbc.271.49.31749	http://dx.doi.org/10.1074/jbc.271.49.31749			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940200	hybrid			2022-12-25	WOS:A1996VW68600111
J	Urban, RJ; Bodenburg, Y				Urban, RJ; Bodenburg, Y			Transcriptional activation of the porcine P450 11A insulin-like growth factor response element in MCF-7 breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I; GENE-EXPRESSION; ELASTIN GENE; BINDING-PROTEINS; FACTOR RECEPTOR; SP1; STIMULATION; DISRUPTION; PROMOTER	Insulin-like growth factor-I (IGF-I) stimulates the growth of MCF-7 breast cancer cells. This study determined the transcriptional activity of an IGF-I-responsive region (IGFRE) of porcine P450 11A (P450scc) after transfection into MCF-7 cells. IGF-I induced transcriptional activity of a porcine P450scc core promoter luciferase construct containing the IGFRE transfected in MCF-7 cells. Electrophoretic mobility shift assay with nuclear protein extract from MCF-7 cells showed two transcription factors binding to the IGFRE. Supershift assay determined that one transcription factor was Sp1. Electrophoretic mobility shift assay and transfection experiments with selected mutations to the IGFRE found that binding of both transcription factors was necessary to confer an IGF-I response. The binding activity of both transcription factors was increased with IGF-I treatment. In conclusion, MCF-7 cells contain Sp1 and another unknown transcription factor, Pa, that bind to a known IGFRE (porcine P450scc) and induce reporter gene transcriptional activity with IGF-I treatment. Because Sp1 is a ubiquitous transcription factor, determining the identity of P2 may lead to cell-specific methods to impair breast cancer cell growth as mediated by IGF-I.			Urban, RJ (corresponding author), UNIV TEXAS,MED BRANCH,DIV ENDOCRINOL,DEPT INTERNAL MED,3142 MRB,GALVESTON,TX 77555, USA.				NICHD NIH HHS [HD28393] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028393] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALEMANY J, 1992, BIOCHEM BIOPH RES CO, V183, P659, DOI 10.1016/0006-291X(92)90533-Q; ALEMANY J, 1990, P NATL ACAD SCI USA, V87, P3353, DOI 10.1073/pnas.87.9.3353; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; BRASIER AR, 1991, METHODS NEUROSCI, V5, P108; CULLEN KJ, 1990, CANCER RES, V50, P48; HENTHORN P, 1988, P NATL ACAD SCI USA, V85, P6342, DOI 10.1073/pnas.85.17.6342; HERSHKOVITZ E, 1993, J CLIN ENDOCR METAB, V77, P963, DOI 10.1210/jc.77.4.963; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; JENSEN DE, 1995, J BIOL CHEM, V270, P6555, DOI 10.1074/jbc.270.12.6555; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; LAHTI EI, 1994, CANCER, V74, P618, DOI 10.1002/1097-0142(19940715)74:2<618::AID-CNCR2820740213>3.0.CO;2-J; LEROITH D, 1995, ANN INTERN MED, V122, P54, DOI 10.7326/0003-4819-122-1-199501010-00009; MACAULAY VM, 1992, BRIT J CANCER, V65, P311, DOI 10.1038/bjc.1992.65; NEUENSCHWANDER S, 1995, ENDOCRINOLOGY, V136, P4298, DOI 10.1210/en.136.10.4298; POLLAK MN, 1987, CANCER LETT, V38, P223, DOI 10.1016/0304-3835(87)90218-7; RICH CB, 1993, BIOCHEM BIOPH RES CO, V196, P1316, DOI 10.1006/bbrc.1993.2396; STEWART AJ, 1990, J BIOL CHEM, V265, P21172; TOROPAINEN E, 1995, EUR J CANCER, V31A, P1443, DOI 10.1016/0959-8049(94)00466-I; URBAN RJ, 1994, J BIOL CHEM, V269, P25761; WOLFE BL, 1993, J BIOL CHEM, V268, P12418	21	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31695	31698		10.1074/jbc.271.49.31695	http://dx.doi.org/10.1074/jbc.271.49.31695			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940191	hybrid			2022-12-25	WOS:A1996VW68600102
J	Wang, XP; Sheikh, S; Saigal, D; Robinson, L; Weiner, H				Wang, XP; Sheikh, S; Saigal, D; Robinson, L; Weiner, H			Heterotetramers of human liver mitochondrial (class 2) aldehyde dehydrogenase expressed in Escherichia coli - A model to study the heterotetramers expected to be found in oriental people	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETALDEHYDE METABOLISM; ALCOHOL SENSITIVITY; ALDH2 LOCUS; GENOTYPES; DEFICIENCY; ALLELE; POPULATION; ISOZYMES; JAPANESE; VARIANT	About 50% of the Oriental population have less liver mitochondrial aldehyde dehydrogenase (ALDH2) activity than do other people. It was found that they possessed an enzyme with a lysine at position 487 (E487K) instead of glutamate (GlU(487)). We previously found that the K-m, for NAD of recombinant human and rat E487K enzymes increased more than 150-fold (Farres, J., Wang X., Takahashi, IC, Cunningham, S. J., Wang, T.T., and Weiner, H (1994) J, Biol. Chem 269, 13854-13860). Many aldehyde dehydrogenase-deficient people were found to be heterozygous when genotyped for ALDH2, In this study liver tissue from heterozygous people was analyzed and found to possess mRNAs for both the glutamate and the lysine subunits, Western blot analysis showed that the glutamate subunit was present, The cDNAs for Glu(487) and E487K were coexpressed on one plasmid in Escherichia coli, and the enzyme forms were separated from each other by isoelectric focusing to show that heterotetramers were formed. Only one LC, value for NAD could be measured with the purified heterotetrameric enzyme that possessed just 16-18% activity of the glutamate homotetrameric enzyme, The E487K homotetramers had 8% specific activity of the GlU(487) enzyme, There was no pre-steady state burst of NADH formation with the heterotetramer, a property found with the glutamate enzyme, Similar results were found for the coexpressed rat liver enzyme, except that a higher specific activity, 48%, was obtained, Thus, we conclude that presence of the lysine subunit altered the activity of the glutamate subunit in the heterotetramer to make it function more like an E487K enzyme.	PURDUE UNIV, DEPT BIOCHEM, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NIAAA NIH HHS [AA05812] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA005812, R01AA005812] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		AINSLIE GR, 1982, ARCH BIOCHEM BIOPHYS, V216, P101, DOI 10.1016/0003-9861(82)90193-X; Chao You-Chen, 1993, Proceedings of the National Science Council Republic of China Part B Life Sciences, V17, P98; CRABB DW, 1989, J CLIN INVEST, V83, P314, DOI 10.1172/JCI113875; EISENSTEIN E, 1992, J BIOL CHEM, V267, P22148; ENOMOTO N, 1991, ALCOHOL CLIN EXP RES, V15, P141, DOI 10.1111/j.1530-0277.1991.tb00532.x; FARRES J, 1994, J BIOL CHEM, V269, P13854; FERENCZBIRO K, 1984, BIOCHEM BIOPH RES CO, V118, P97, DOI 10.1016/0006-291X(84)91072-6; GHENBOT G, 1992, PROTEIN EXPRES PURIF, V3, P470, DOI 10.1016/1046-5928(92)90064-4; GOEDDE HW, 1985, ALCOHOL, V2, P383, DOI 10.1016/0741-8329(85)90099-0; GOEDDE HW, 1989, HUM GENET, V81, P305, DOI 10.1007/BF00283679; GREENFIELD NJ, 1977, BIOCHIM BIOPHYS ACTA, V483, P35, DOI 10.1016/0005-2744(77)90005-5; HARADA S, 1981, LANCET, V2, P982; HEMPEL J, 1984, FEBS LETT, V173, P367, DOI 10.1016/0014-5793(84)80807-8; HEMPEL J, 1993, PROTEIN SCI, V2, P1890, DOI 10.1002/pro.5560021111; HSU LC, 1987, AM J HUM GENET, V41, P996; IKAWA M, 1983, J BIOL CHEM, V258, P6282; IMPRAIM C, 1982, AM J HUM GENET, V34, P837; MIZOI Y, 1979, PHARMACOL BIOCHEM BE, V10, P303, DOI 10.1016/0091-3057(79)90105-9; QING NC, 1988, ALCOHOL CLIN EXP RES, V12, P720, DOI 10.1111/j.1530-0277.1988.tb00271.x; SVANAS GW, 1985, ARCH BIOCHEM BIOPHYS, V236, P36, DOI 10.1016/0003-9861(85)90603-4; TAKAHASHI K, 1980, ARCH BIOCHEM BIOPHYS, V205, P571, DOI 10.1016/0003-9861(80)90140-X; TAKESHITA T, 1994, HUM GENET, V94, P217; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; TENG YS, 1981, BIOCHEM GENET, V19, P107, DOI 10.1007/BF00486141; TU GC, 1993, EUR J CLIN CHEM CLIN, V31, P591; WANG XP, 1995, BIOCHEMISTRY-US, V34, P237, DOI 10.1021/bi00001a028; WEINER H, 1976, J BIOL CHEM, V251, P3853; XIAO Q, 1995, J CLIN INVEST, V96, P2180, DOI 10.1172/JCI118272; Yamamoto Kenji, 1993, Japanese Journal of Alcohol Studies and Drug Dependence, V28, P13; YOSHIDA A, 1984, P NATL ACAD SCI-BIOL, V81, P258, DOI 10.1073/pnas.81.1.258; YOSHIDA A, 1983, AM J HUM GENET, V35, P1107; ZHENG CF, 1993, ALCOHOL CLIN EXP RES, V17, P828, DOI 10.1111/j.1530-0277.1993.tb00849.x	32	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31172	31178		10.1074/jbc.271.49.31172	http://dx.doi.org/10.1074/jbc.271.49.31172			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940116	hybrid			2022-12-25	WOS:A1996VW68600027
J	Weisel, JW; Nagaswami, C; Young, TA; Light, DR				Weisel, JW; Nagaswami, C; Young, TA; Light, DR			The shape of thrombomodulin and interactions with thrombin as determined by electron microscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN THROMBOMODULIN; HUMAN SOLUBLE THROMBOMODULIN; PROTEIN-C ACTIVATION; COFACTOR ACTIVITY; RABBIT THROMBOMODULIN; ANTICOAGULANT ACTIVITIES; FUNCTIONAL DOMAINS; SHUNT THROMBOSIS; MOLECULAR-WEIGHT; HOMOLOGY DOMAIN	Studies have been carried out to investigate aspects of the structure of thrombomodulin, an endothelial cell glycoprotein that binds thrombin and accelerates both the thrombin-dependent activation of protein C and the inhibition of antithrombin III. We have determined the shape of Solulin(TM), a soluble recombinant form of human thrombomodulin missing the transmembrane and cytoplasmic domains, by electron microscopy of preparations rotary-shadowed with tungsten. Solulin appears to be an elongated molecule about 20 nm long that has a large nodule at one end and a smaller nodule near the other end from which extends a thin strand. About half of the molecules form bipolar dimers apparently via interactions between these thin strands, Electron microscopy of complexes formed between Solulin and human alpha-thrombin revealed that a single thrombin molecule appears to bind to the smaller nodule of Solulin, suggesting that this region contains the epidermal growth factor-like domains 5 and 6. Epidermal growth factor-like domains 1-4 comprise the connector between the small and large nodule, which is the lectin-like domain; the thin strand at the other end of the molecule is the carbohydrate rich region. With chondroitin sulfate-containing soluble thrombomodulin produced from either human melanoma cells Bowes or Chinese hamster ovary cells, a higher percentage of molecules bound thrombin and, in some cases, two thrombin molecules were attached to one soluble thrombomodulin in approximately the same region, These structural studies provide insight into the structure of thrombomodulin and its interactions with thrombin as well as aspects of the mechanisms of its actions.	BERLEX BIOSCI, DEPT PROT CHEM, RICHMOND, CA 94804 USA		Weisel, JW (corresponding author), UNIV PENN, SCH MED, DEPT CELL & DEV BIOL, PHILADELPHIA, PA 19104 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030954] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30954] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AOKI Y, 1994, AM J HEMATOL, V47, P162, DOI 10.1002/ajh.2830470303; BODE W, 1993, SEMIN THROMB HEMOST, V19, P321, DOI 10.1055/s-2007-993283; BOURIN MC, 1988, J BIOL CHEM, V263, P8044; CLARKE JH, 1993, J BIOL CHEM, V268, P6309; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; DEBAULT LE, 1986, LAB INVEST, V54, P179; DITTMAN WA, 1990, BLOOD, V75, P329; ESMON CT, 1993, THROMB HAEMOSTASIS, V70, P29; ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; ESMON NL, 1989, PROG HEMOST THROMB, V9, P29; FENTON JW, 1991, BLOOD COAGUL FIBRIN, V2, P69, DOI 10.1097/00001721-199102000-00011; FOWLER WE, 1979, J MOL BIOL, V134, P241, DOI 10.1016/0022-2836(79)90034-2; FOWLER WE, 1983, J ULTRA MOL STRUCT R, V83, P319, DOI 10.1016/S0022-5320(83)90139-9; GAN ZR, 1993, ARCH BIOCHEM BIOPHYS, V301, P228, DOI 10.1006/abbi.1993.1138; GLASER CB, 1992, J CLIN INVEST, V90, P2565, DOI 10.1172/JCI116151; HEALY AM, 1995, P NATL ACAD SCI USA, V92, P850, DOI 10.1073/pnas.92.3.850; HORVAT R, 1993, EUR J CELL BIOL, V61, P299; JACKMAN RW, 1986, P NATL ACAD SCI USA, V83, P8834, DOI 10.1073/pnas.83.23.8834; KUROSAWA S, 1988, J BIOL CHEM, V263, P5993; KUROSAWA S, 1987, J BIOL CHEM, V262, P2206; LENTZ SR, 1993, J BIOL CHEM, V268, P15312; LIGHT DR, 1993, Patent No. 9315755; LIN JH, 1994, J BIOL CHEM, V269, P25021; LU RL, 1989, J BIOL CHEM, V264, P12956; MATHEWS II, 1994, BIOCHEMISTRY-US, V33, P13547, DOI 10.1021/bi00250a006; MCLEAN K, 1992, ZIMM C PROGR VASC BI; MEDVED LV, 1995, J BIOL CHEM, V270, P13652, DOI 10.1074/jbc.270.23.13652; MEININGER DP, 1995, PROTEIN SCI, V4, P1683, DOI 10.1002/pro.5560040904; MORGELIN M, 1992, J BIOL CHEM, V267, P14275; NAGASHIMA M, 1993, J BIOL CHEM, V268, P2888; NAWA K, 1990, BIOCHEM BIOPH RES CO, V171, P729, DOI 10.1016/0006-291X(90)91207-9; OHLIN AK, 1995, BLOOD, V85, P330; ONO M, 1994, THROMB HAEMOSTASIS, V72, P421; PARKINSON JF, 1990, J BIOL CHEM, V265, P12602; PARKINSON JF, 1992, ADV EXP MED BIOL, V313, P177; SADLER JE, 1993, HAEMOSTASIS, V23, P183; SASAKI T, 1995, J MOL BIOL, V245, P241, DOI 10.1006/jmbi.1994.0020; SOLIS MM, 1994, THROMB RES, V73, P385, DOI 10.1016/0049-3848(94)90040-X; SRINIVASAN J, 1994, BIOCHEMISTRY-US, V33, P13553, DOI 10.1021/bi00250a007; STEARNS DJ, 1989, J BIOL CHEM, V264, P3352; STENFLO J, 1991, BLOOD, V78, P1637; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; STUBBS MT, 1995, TRENDS BIOCHEM SCI, V20, P23, DOI 10.1016/S0968-0004(00)88945-8; SUZUKI K, 1989, J BIOL CHEM, V264, P4872; TIMPL R, 1993, EXPERIENTIA, V49, P417, DOI 10.1007/BF01923586; TSIANG M, 1992, J BIOL CHEM, V267, P6164; TULINSKY A, 1993, BLOOD COAGUL FIBRIN, V4, P305, DOI 10.1097/00001721-199304000-00012; VEKLICH YI, 1993, J BIOL CHEM, V268, P13577; WALKER FJ, 1992, FASEB J, V6, P2561, DOI 10.1096/fasebj.6.8.1317308; WEISEL JW, 1992, J BIOL CHEM, V267, P16637; WEISEL JW, 1994, J BIOL CHEM, V269, P10100; WEISEL JW, 1985, SCIENCE, V230, P1388, DOI 10.1126/science.4071058; WINNARD PT, 1989, ARCH BIOCHEM BIOPHYS, V269, P339, DOI 10.1016/0003-9861(89)90115-X; YE J, 1993, J BIOL CHEM, V268, P2373	54	41	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31485	31490		10.1074/jbc.271.49.31485	http://dx.doi.org/10.1074/jbc.271.49.31485			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940162	hybrid			2022-12-25	WOS:A1996VW68600073
J	Ho, LB; Fukuchi, K; Younkin, SG				Ho, LB; Fukuchi, K; Younkin, SG			The alternatively spliced Kunitz protease inhibitor domain alters amyloid beta protein precursor processing and amyloid beta protein production in cultured cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE-LIKE HISTOPATHOLOGY; EARLY ALZHEIMERS-DISEASE; MESSENGER-RNA; TRANSGENIC MICE; NEXIN-II; PEPTIDE; BRAIN; EXPRESSION; GENE; AGE	The insoluble amyloid deposited extracellularly in the brains of patients with Alzheimer's disease (AD) is composed of amyloid beta protein, a similar to 4-kDa secreted protein that is derived from a set of large proteins collectively referred to as the amyloid beta protein precursor (beta APP). During normal processing the beta APP is cleaved by beta secretase, producing a large NH2-terminal secreted derivative (sAPP beta) and a COOH-terminal fragment beginning at A beta 1, which is subsequently cleaved by gamma secretase releasing secreted A beta. Most secreted A beta is A beta 1-40, but similar to 10% of secreted A beta is A beta 1-42. Alternative beta APP cleavage by alpha secretase produces a slightly longer NH2-terminal secreted derivative (sAPP alpha) and a COOH-terminal fragment beginning at A beta 17, which is subsequently cleaved by gamma secretase releasing a similar to 3-kDa secreted form of A beta (P3), Several of the beta APP isoforms that are produced by alternative splicing contain a 56-amino acid Kunitz protease inhibitor (KPI) domain known to inhibit proteases such as trypsin and chymotrypsin, To determine whether the KPI domain influences the proteolytic cleavages that generate A beta, we compared A beta production in transfected cells expressing human KPI-containing beta APP751 or KPI-free beta APP695. We focused on A beta s ending at A beta 42 because these forms appear to be most relevant to AD. Using specific sandwich enzyme-linked immunosorbent assays, we analysed full-length A beta 1-42 and total A beta ending at A beta 42 (A beta 1-42 + P3(42)). In addition, we analysed the large secreted derivatives produced by alpha secretase (sAPP alpha) and beta secretase (sAPP beta). In mouse teratocarcinoma (P19) cells expressing beta APP695 or beta APP751, expression of the KPI-containing beta APP751 resulted in the secretion of a lower percentage of P3(42) and sAPP alpha and a correspondingly higher percentage of A beta 1-42 and sAPP beta. Similar results were obtained in human embryonic kidney (293) cells. These results indicate that expression of the KPI domain reduces alpha secretase cleavage so that less P3 and relatively more full-length A beta are produced. Thus, in human brain and in animal models of AD, the amount of KPI-containing beta APP produced may be an important factor influencing A beta deposition.	MAYO CLIN JACKSONVILLE,JACKSONVILLE,FL 32224; CASE WESTERN RESERVE UNIV,DEPT NEUROSCI,CLEVELAND,OH 44106; UNIV ALABAMA,DEPT COMPARAT MED,BIRMINGHAM,AL 35294	Mayo Clinic; Case Western Reserve University; University of Alabama System; University of Alabama Birmingham								BHASIN R, 1991, P NATL ACAD SCI USA, V88, P10307, DOI 10.1073/pnas.88.22.10307; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CHEUNG TT, 1994, AMYLOID, V1, P30, DOI 10.3109/13506129409148622; CITRON M, 1994, P NATL ACAD SCI USA, V91, P11993, DOI 10.1073/pnas.91.25.11993; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GOLDE TE, 1990, NEURON, V4, P253, DOI 10.1016/0896-6273(90)90100-T; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1994, J BIOL CHEM, V269, P17741; HIGGINS LS, 1993, ANN NY ACAD SCI, V695, P224, DOI 10.1111/j.1749-6632.1993.tb23056.x; HIGGINS LS, 1994, ANN NEUROL, V35, P598, DOI 10.1002/ana.410350514; HIGGINS LS, 1995, P NATL ACAD SCI USA, V92, P4402, DOI 10.1073/pnas.92.10.4402; JOHNSON SA, 1990, SCIENCE, V248, P854, DOI 10.1126/science.2111579; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KONIG G, 1992, J BIOL CHEM, V267, P10804; KOO EH, 1994, J BIOL CHEM, V269, P17386; LEMAIRE HG, 1989, NUCLEIC ACIDS RES, V17, P517, DOI 10.1093/nar/17.2.517; MORGAN PM, 1995, P NATL ACAD SCI USA, V92, P5341; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; QUON D, 1991, NATURE, V352, P239, DOI 10.1038/352239a0; ROBAKIS NK, 1987, LANCET, V1, P384; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SHIMOKAWA M, 1993, BIOCHIMIE, V75, P911, DOI 10.1016/0300-9084(93)90048-W; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TANAKA S, 1992, MOL BRAIN RES, V15, P303, DOI 10.1016/0169-328X(92)90122-R; TANAKA S, 1993, NEUROSCI LETT, V163, P19, DOI 10.1016/0304-3940(93)90219-B; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; VANNOSTRAND WE, 1990, J BIOL CHEM, V265, P9591; VANNOSTRAND WE, 1989, NATURE, V341, P546; WERTKIN AM, 1993, P NATL ACAD SCI USA, V90, P9513, DOI 10.1073/pnas.90.20.9513; YAMAGUCHI F, 1991, NEUROREPORT, V2, P781, DOI 10.1097/00001756-199112000-00013; YOSHIKAI S, 1990, GENE, V87, P257, DOI 10.1016/0378-1119(90)90310-N	42	56	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30929	30934		10.1074/jbc.271.48.30929	http://dx.doi.org/10.1074/jbc.271.48.30929			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940079	hybrid			2022-12-25	WOS:A1996VV15800096
J	Jubete, Y; Maurizi, MR; Gottesman, S				Jubete, Y; Maurizi, MR; Gottesman, S			Role of the heat shock protein DnaJ in the Lon-dependent degradation of naturally unstable proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; FUSION PROTEIN; ION GENE; LAMBDA-N; PROTEOLYSIS; CHAPERONE; MUTANTS; GRPE; SULA; PURIFICATION	We have investigated the role of DnaJ in protein degradation by examining the degradation of intrinsically unstable proteins by Lon protease in vivo. In Escherichia coli, Lon protease is responsible for the rate-limiting step in degradation of highly unstable proteins such as SulA, RcsA, and lambda N protein, as well as for about 50% of the rapid degradation of abnormal proteins such as canavanine-containing proteins. We found that Lon-dependent degradation of both SulA and AN protein was unaffected in cells lacking functional DnaJ, whereas Lon-dependent turnover of canavanine containing proteins was slower in dnaJ mutant cells. DnaJ also affected the slow SulA degradation seen in the absence of Lon. The rate of degradation of RcsA was reduced in dnaJ mutants, but both Lon-dependent and Lon-independent degradation was affected; abnormal, canavanine-containing proteins were similarly affected. Both the RcsA that accumulated in dnaJ mutant cells and the SulA that accumulated in ion dnaJ mutant cells was aggregated. The abnormal proteins that partitioned to the insoluble pellet became solubilized over time in dnaJ(+) cells but not in dnaJ(-) cells. Therefore, the co-chaperone DnaJ is not essential for Lon-dependent degradation and may act in protein turnover only as an accessory factor helping to maintain substrates in a soluble form. Such an accessory factor is apparently necessary for abnormal proteins and for RcsA. The relative rates of degradation and aggregation of specific protein targets may determine the importance of the chaperone systems in turnover of a given protein.	NCI, MOL BIOL LAB, BETHESDA, MD 20892 USA; NCI, CELL BIOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BARTON GJ, 1990, J MOL BIOL, V212, P389, DOI 10.1016/0022-2836(90)90133-7; BRILL JA, 1988, J BACTERIOL, V170, P2599, DOI 10.1128/jb.170.6.2599-2611.1988; CANCEILL D, 1990, J BACTERIOL, V172, P7297, DOI 10.1128/jb.172.12.7297-7300.1990; GOFF SA, 1984, P NATL ACAD SCI-BIOL, V81, P6647, DOI 10.1073/pnas.81.21.6647; GOLDBERG AL, 1972, P NATL ACAD SCI USA, V69, P422, DOI 10.1073/pnas.69.2.422; GOTTESMAN S, 1989, ANNU REV GENET, V23, P163, DOI 10.1146/annurev.ge.23.120189.001115; GOTTESMAN S, 1981, CELL, V24, P225, DOI 10.1016/0092-8674(81)90518-3; Gottesman S, 1995, COLD SPRING HARB SYM, V60, P533, DOI 10.1101/SQB.1995.060.01.057; Gottesman S, 1996, ANNU REV GENET, V30, P465, DOI 10.1146/annurev.genet.30.1.465; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; GRAGEROV A, 1992, P NATL ACAD SCI USA, V89, P10341, DOI 10.1073/pnas.89.21.10341; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; HUISMAN O, 1984, P NATL ACAD SCI-BIOL, V81, P4490, DOI 10.1073/pnas.81.14.4490; KELLER JA, 1988, MOL MICROBIOL, V2, P31, DOI 10.1111/j.1365-2958.1988.tb00004.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LAROSSA RA, 1991, MOL MICROBIOL, V5, P529, DOI 10.1111/j.1365-2958.1991.tb00724.x; MAGUIN E, 1986, J BACTERIOL, V166, P733, DOI 10.1128/jb.166.3.733-738.1986; MAURIZI MR, 1987, J BIOL CHEM, V262, P2696; MAURIZI MR, 1985, J BACTERIOL, V164, P1124, DOI 10.1128/JB.164.3.1124-1135.1985; MAURIZI MR, 1988, UBIQUITIN SYSTEM CUR, P147; MILLER JH, 1992, SHORT COURSE BACTERI, P287; MILLER S, 1987, J MOL BIOL, V196, P641, DOI 10.1016/0022-2836(87)90038-6; MIZUSAWA S, 1983, P NATL ACAD SCI-BIOL, V80, P358, DOI 10.1073/pnas.80.2.358; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; RICHARME G, 1993, J BIOL CHEM, V268, P24074; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SHERMAN MY, 1991, J BACTERIOL, V173, P7249, DOI 10.1128/jb.173.22.7249-7256.1991; SHERMAN MY, 1992, EMBO J, V11, P71; Silhavy T. J., 1984, EXPT GENE FUSIONS, P107; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; SONEZAKI S, 1995, APPL MICROBIOL BIOT, V43, P304; STOUT V, 1991, J BACTERIOL, V173, P1738, DOI 10.1128/jb.173.5.1738-1747.1991; STRAUS DB, 1988, GENE DEV, V2, P1851, DOI 10.1101/gad.2.12b.1851; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; TILLY K, 1990, New Biologist, V2, P812; TORRESCABASSA AS, 1987, J BACTERIOL, V169, P981, DOI 10.1128/jb.169.3.981-989.1987; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TREMPY JE, 1989, J BACTERIOL, V171, P3348, DOI 10.1128/jb.171.6.3348-3353.1989; VANDYK TK, 1989, NATURE, V342, P451, DOI 10.1038/342451a0; VANMELDEREN L, 1996, IN PRESS J BIOL CHEM, V271; WICKNER S, 1992, P NATL ACAD SCI USA, V89, P10345, DOI 10.1073/pnas.89.21.10345; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; [No title captured]	45	66	69	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30798	30803		10.1074/jbc.271.48.30798	http://dx.doi.org/10.1074/jbc.271.48.30798			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940060	hybrid			2022-12-25	WOS:A1996VV15800077
J	Kato, Y; Komatsu, S				Kato, Y; Komatsu, S			ASABF, a novel cysteine-rich antibacterial peptide isolated from the nematode Ascaris suum - Purification, primary structure, and molecular cloning of cDNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSECT IMMUNITY; ANTIMICROBIAL PEPTIDES; CAENORHABDITIS-ELEGANS; PARASITIC NEMATODE; SEQUENCE HOMOLOGY; INNATE IMMUNITY; DROSOPHILA; PROTEINS; DEFENSINS	Previously, we reported antibacterial activity in the body fluid of the nematode Ascaris suum (Kato, Y. (1995) Zool. Sci. 12, 225-230). The antibacterial activity is due to a heat-stable and trypsin-sensitive molecule that was designated as ASABF (A. suum antibacterial factor). In the present study, the purification, determination of primary structure, and cDNA cloning of ASABF were carried out. The mature peptide of ASABF is a basic peptide consisting of 71 residues and containing four intramolecular disulfide bridges. The amino acid sequence of a precursor for ASABF, deduced from a cDNA clone, indicates that Banking peptides both at the N terminus and at the C terminus are eliminated by processing. ASABF exhibits potent antibacterial activity particularly against Gram-positive bacteria. ASABF has several features that resemble those of insect/arthropod defensins, whereas the statistical significance of the similarity is not observed on comparison of amino acid sequences. A search of data bases revealed ASABF homologues in Caenorhabditis elegans.	NATL INST AGROBIOL RESOURCES, DEPT MOL BIOL, TSUKUBA, IBARAKI 305, JAPAN	National Institute of Agrobiological Sciences - Japan	Kato, Y (corresponding author), NATL INST SERICULTURAL & ENTOMOL SCI, DEPT INSECT PHYSIOL & BEHAV, METAB LAB, OOWASHI 1-2, TSUKUBA, IBARAKI 305, JAPAN.			Kato, Yusuke/0000-0003-2424-4571				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ALVAREZBRAVO J, 1994, BIOCHEM J, V302, P535, DOI 10.1042/bj3020535; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; BROEKAERT WF, 1995, PLANT PHYSIOL, V108, P1353, DOI [10.1104/pp.108.4.1353, 10.1016/j.chiabu.2021.105188]; BULET P, 1993, J BIOL CHEM, V268, P14893; Chernysh S, 1996, J INSECT PHYSIOL, V42, P81, DOI 10.1016/0022-1910(95)00085-2; COCIANCICH S, 1993, BIOCHEM BIOPH RES CO, V194, P17, DOI 10.1006/bbrc.1993.1778; DOOLITTLE RF, 1990, METHOD ENZYMOL, V183, P99; FEHLBAUM P, 1994, J BIOL CHEM, V269, P33159; HULTMARK D, 1993, TRENDS GENET, V9, P178, DOI 10.1016/0168-9525(93)90165-E; IP YT, 1993, CELL, V75, P753, DOI 10.1016/0092-8674(93)90495-C; KATO Y, 1995, ZOOL SCI, V12, P225, DOI 10.2108/zsj.12.225; KAZUHARA T, 1990, J BIOCHEM-TOKYO, V107, P514; KENNEDY MW, 1995, BIOCHEMISTRY-US, V34, P6700, DOI 10.1021/bi00020a015; KURAMOCHI T, 1994, MOL BIOCHEM PARASIT, V68, P177, DOI 10.1016/0166-6851(94)90163-5; LAMBERT J, 1989, P NATL ACAD SCI USA, V86, P262, DOI 10.1073/pnas.86.1.262; LEE JY, 1989, P NATL ACAD SCI USA, V86, P9159, DOI 10.1073/pnas.86.23.9159; MARONEY PA, 1995, RNA, V1, P714; MOON HJ, 1994, J BIOCHEM-TOKYO, V116, P53, DOI 10.1093/oxfordjournals.jbchem.a124502; NAGATA A, 1991, P NATL ACAD SCI USA, V88, P4020, DOI 10.1073/pnas.88.9.4020; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schwartz RM, 1978, ATLAS PROTEIN SEQ S3, P353; STEINER H, 1981, NATURE, V292, P246, DOI 10.1038/292246a0; VANFLETEREN JR, 1990, BIOCHEM J, V271, P613, DOI 10.1042/bj2710613; YAMADA K, 1993, BIOCHEM J, V291, P275, DOI 10.1042/bj2910275; ZEYA HI, 1963, SCIENCE, V142, P1085, DOI 10.1126/science.142.3595.1085	28	68	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30493	30498		10.1074/jbc.271.48.30493	http://dx.doi.org/10.1074/jbc.271.48.30493			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940016	hybrid			2022-12-25	WOS:A1996VV15800033
J	Silverman, SK; Lester, HA; Dougherty, DA				Silverman, SK; Lester, HA; Dougherty, DA			Subunit stoichiometry of a heteromultimeric G protein-coupled inward-rectifier K+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT POTASSIUM CHANNEL; COOPERATIVE INTERACTIONS; BINDING-SITE; SHAKER; TETRAETHYLAMMONIUM; EXPRESSION; CLONING; DROSOPHILA; CDNAS	We investigated the stoichiometry of the heteromultimeric G protein-coupled inward-recitfier K+ channel (GIRK) formed from GIRK1 and GIRK4 subunits. Multimeric GIRK constructs with several concatenated channel subunits were expressed in Xenopus oocytes. Coexpression of various trimeric constructs with different monomers clearly showed that the functional chan nel has stoichiometry (GIRK1)(2)(GIRK4)(2). Efforts to establish a preferred arrangement of subunits around the channel pore suggest that more than one arrangement may be viable.	CALTECH,DIV BIOL 15629,PASADENA,CA 91125; CALTECH,DIV CHEM,PASADENA,CA 91125; CALTECH,DIV CHEM ENGN,PASADENA,CA 91125	California Institute of Technology; California Institute of Technology; California Institute of Technology				Silverman, Scott/0000-0001-8166-3460	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH049176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS011756] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM29836] Funding Source: Medline; NIMH NIH HHS [MH49176] Funding Source: Medline; NINDS NIH HHS [NS11756] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASHFORD MLJ, 1994, NATURE, V370, P456, DOI 10.1038/370456a0; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; GLOWATZKI E, 1995, P ROY SOC B-BIOL SCI, V261, P251, DOI 10.1098/rspb.1995.0145; GORDON SE, 1995, P NATL ACAD SCI USA, V92, P10222, DOI 10.1073/pnas.92.22.10222; Hedin KE, 1996, NEURON, V16, P423, DOI 10.1016/S0896-6273(00)80060-4; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; HURST RS, 1992, J BIOL CHEM, V267, P23742; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; IVERSON LE, 1988, P NATL ACAD SCI USA, V85, P5723, DOI 10.1073/pnas.85.15.5723; KAVANAUGH MP, 1992, NEURON, V8, P493, DOI 10.1016/0896-6273(92)90277-K; KOFUJI P, 1995, P NATL ACAD SCI USA, V92, P6542, DOI 10.1073/pnas.92.14.6542; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; MACKINNON R, 1993, SCIENCE, V262, P757, DOI 10.1126/science.7694359; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; PASCUAL JM, 1995, BIOPHYS J, V69, P428, DOI 10.1016/S0006-3495(95)79915-5; PONGS O, 1988, EMBO J, V7, P1087, DOI 10.1002/j.1460-2075.1988.tb02917.x; QUICK MW, 1994, ION CHANNELS EXCITAB, P261; SLESINGER PA, 1995, NEURON, V15, P1145, DOI 10.1016/0896-6273(95)90102-7; TYTGAT J, 1992, NATURE, V359, P420, DOI 10.1038/359420a0; WEI A, 1994, NEURON, V13, P671, DOI 10.1016/0896-6273(94)90034-5; Yang J, 1995, NEURON, V15, P1441, DOI 10.1016/0896-6273(95)90021-7	24	71	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30524	30528		10.1074/jbc.271.48.30524	http://dx.doi.org/10.1074/jbc.271.48.30524			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940021	Green Accepted, hybrid			2022-12-25	WOS:A1996VV15800038
J	Uchiyama, A; Aoyama, T; Kamijo, K; Uchida, Y; Kondo, N; Orii, T; Hashimoto, T				Uchiyama, A; Aoyama, T; Kamijo, K; Uchida, Y; Kondo, N; Orii, T; Hashimoto, T			Molecular cloning of cDNA encoding rat very long-chain acyl-CoA synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED ADRENOLEUKODYSTROPHY; ACID BETA-OXIDATION; ALD GENE; CHILDHOOD ADRENOLEUKODYSTROPHY; FRAMESHIFT MUTATION; MISSENSE MUTATION; PROTEIN; IDENTIFICATION; LIVER; PEROXISOMES	The cDNA encoding rat very long-chain acyl-CoA synthetase (VLACS) was cloned, using degenerative primers synthesized according to the partial amino acid sequences of the peptide fragments of the purified rat liver enzyme. The longest cDNA insert was 2972 base pairs with a 1860-base pair open reading frame encoding 620 amino acids. The calculated molecular mass of 70,692 daltons was consistent with size of the purified enzyme. In Northern blot analysis, a single band was detected at the position of about 3 kilobases, corresponding to the size of the cloned cDNA. cDNA-directed expression in Escherichia coli resulted in accumulation of expressed protein, as an inclusion body. An antibody was raised using this expressed protein to characterize the cDNA and the enzyme. The subcellular localization of VLACS in peroxisomes and microsomes was demonstrated in Western blot analysis. The specific activity and the substrate specificity of the cDNA expressed enzyme in COS-1 cells were consistent with those of the purified rat enzyme. The predicted amino acid sequence of VLACS had a high sequence similarity to fatty acid transport protein (Schaffer, J. E., and Lodish, H. F. (1994) Cell 79, 427-436), and was considered to have domains for adenylation and thioester formation. The entire structure of VLACS was dissimilar to that of long-chain acyl-CoA synthetase (Suzuki, H., Kawarabayashi, Y., Kondo, Y., Abe, T., Nishikawa, K., Kimura, S., Hashimoto, T., and Yamamoto, T. (1990) J. Biol. Chen. 265, 8681-8685), except for the domains.	SHINSHU UNIV, SCH MED, DEPT BIOCHEM, MATSUMOTO, NAGANO 390, JAPAN	Shinshu University	Uchiyama, A (corresponding author), GIFU UNIV, SCH MED, DEPT PEDIAT, GIFU 500, JAPAN.							Aebi H., 1974, METHODS ENZYMATIC AN, P673, DOI [10.1016/B978-0-12-091302-2.50032-3, DOI 10.1016/B978-0-12-091302-2.50032-3]; AOYAMA T, 1989, J BIOL CHEM, V264, P10388; BARCELO A, 1995, HUM GENET, V95, P235; BARCELO A, 1994, HUM MOL GENET, V3, P1889, DOI 10.1093/hmg/3.10.1889; BERGER J, 1994, BIOCHEM BIOPH RES CO, V205, P1638, DOI 10.1006/bbrc.1994.2855; BRAUN A, 1995, AM J HUM GENET, V56, P854; CARTIER N, 1995, P NATL ACAD SCI USA, V92, P1674, DOI 10.1073/pnas.92.5.1674; CARTIER N, 1993, HUM MOL GENET, V2, P1949, DOI 10.1093/hmg/2.11.1949; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FANEN P, 1994, J CLIN INVEST, V94, P516, DOI 10.1172/JCI117363; FUCHS S, 1994, HUM MOL GENET, V3, P1903, DOI 10.1093/hmg/3.10.1903; FUJINO T, 1992, J BIOCHEM-TOKYO, V111, P197, DOI 10.1093/oxfordjournals.jbchem.a123737; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HASHMI M, 1986, FEBS LETT, V196, P247, DOI 10.1016/0014-5793(86)80256-3; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; JOHNSON DR, 1994, J BIOL CHEM, V269, P18037; KAMIJO K, 1990, J BIOL CHEM, V265, P4534; KEMP S, 1994, BIOCHEM BIOPH RES CO, V202, P647, DOI 10.1006/bbrc.1994.1979; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZO O, 1988, P NATL ACAD SCI USA, V85, P7647, DOI 10.1073/pnas.85.20.7647; LIGTENBERG MJL, 1995, AM J HUM GENET, V56, P44; MACCABE AP, 1991, J BIOL CHEM, V266, P12646; Masters B, 1967, METHOD ENZYMOL, V10, P565; MIURA S, 1992, J BIOL CHEM, V267, P14405; MIYAZAWA S, 1985, J BIOCHEM, V98, P723, DOI 10.1093/oxfordjournals.jbchem.a135330; MOSER HW, 1992, J INHERIT METAB DIS, V15, P645, DOI 10.1007/BF01799621; MOSER HW, 1989, METABOLIC BASIS INHE, P1511; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V181, P947, DOI 10.1016/0006-291X(91)92028-I; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SCHMIDT E, 1974, METHOD ENZYMAT AN, V2, P650; SINGH H, 1988, ARCH BIOCHEM BIOPHYS, V266, P486, DOI 10.1016/0003-9861(88)90281-0; SINGH H, 1987, ARCH BIOCHEM BIOPHYS, V259, P382, DOI 10.1016/0003-9861(87)90504-2; SINGH I, 1984, P NATL ACAD SCI-BIOL, V81, P4203, DOI 10.1073/pnas.81.13.4203; SONG XQ, 1995, HUM MOL GENET, V4, P1093, DOI 10.1093/hmg/4.6.1093; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; TANIGUCHI S, 1991, NUCLEIC ACIDS RES, V19, P6949, DOI 10.1093/nar/19.24.6949; TOH H, 1991, Protein Sequences and Data Analysis, V4, P111; Uchida Y, 1996, J BIOCHEM, V119, P565; UCHIYAMA A, 1994, BIOCHEM BIOPH RES CO, V198, P632, DOI 10.1006/bbrc.1994.1092; WANDERS RJA, 1988, J INHERIT METAB DIS, V11, P173, DOI 10.1007/BF01804228; WILCKE M, 1995, J BIOL CHEM, V270, P6949, DOI 10.1074/jbc.270.12.6949	46	118	125	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30360	30365		10.1074/jbc.271.48.30360	http://dx.doi.org/10.1074/jbc.271.48.30360			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8939997	hybrid			2022-12-25	WOS:A1996VV15800014
J	Kerry, DM; Dwivedi, PP; Hahn, CN; Morris, HA; Omdahl, JL; May, BK				Kerry, DM; Dwivedi, PP; Hahn, CN; Morris, HA; Omdahl, JL; May, BK			Transcriptional synergism between vitamin D-responsive elements in the rat 25-hydroxyvitamin D-3 24-hydroxylase (CYP24) promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X RECEPTORS; CELL-LINE HL-60; THYROID-HORMONE; GENE-EXPRESSION; CALCITROIC ACID; IN-VIVO; IDENTIFICATION; 1,25-DIHYDROXYVITAMIN-D3; KIDNEY; METABOLISM	Transcription of the CYP24 gene is induced by 1,25-(OH)(2)D-3 through a vitamin D receptor-dependent process. The functional activities of three possible vitamin D response elements (VDREs), located on the antisense strand of the rat CYP24 promoter, were investigated by transient expression of native and mutant promoter constructs in COS-1, JTC-12, and ROS 17/2.8 cells. A putative VDRE with a half-site spacing of 6 base pairs at -249/-232 (VDRE-3) did not contribute to 1,25-(OH)(2)D-3 induced expression in the native promoter, although activity has been reported when the element was fused to the heterologous thymidine kinase promoter, Two VDREs with half-site spacings of 3 base pairs at -150/-136 and -258/-244 (VDRE-1 and VDRE-2, respectively), showed transcriptional synergism in COS-1 cells when treated with 1,25-(OH)(2)D-3 (10(-7) to 10(-11) M). The contribution of both VDREs was hormone-concentration dependent from 10(-10) to 10(-12) M, with VDRE-1 demonstrating greatest sensitivity to 1,25-(OH)(2)D-3. Transactivation by VDRE-1 was always greater than VDRE-2, but the converse was observed for the binding of vitamin D receptor-retinoid X receptor complex by each VDRE in gel mobility shift assays, The synergy observed between VDRE-1 and VDRE-2 may have important implications in cellular responses to different circulating levels of 1,25-(OH)(2)D-3.	UNIV NEW MEXICO, DEPT BIOCHEM, ALBUQUERQUE, NM 87131 USA; UNIV ADELAIDE, DEPT BIOCHEM, ADELAIDE, SA 5005, AUSTRALIA	University of New Mexico; University of Adelaide			Morris, Howard A/G-4564-2010; Morris, Howard/L-6272-2019; Hahn, Christopher/C-1369-2009	Hahn, Christopher/0000-0001-5105-2554				ARMBRECHT HJ, 1991, FEBS LETT, V292, P17, DOI 10.1016/0014-5793(91)80823-L; BULUWELA L, 1989, NUCLEIC ACIDS RES, V17, P452, DOI 10.1093/nar/17.1.452; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; CARLBERG C, 1995, EUR J BIOCHEM, V231, P517, DOI 10.1111/j.1432-1033.1995.0517d.x; CHEN KS, 1995, BBA-GENE STRUCT EXPR, V1263, P1, DOI 10.1016/0167-4781(95)00060-T; CHI TH, 1995, NATURE, V377, P254, DOI 10.1038/377254a0; Darwish Hisham, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P89; DELUCA HF, 1983, ANNU REV BIOCHEM, V52, P411, DOI 10.1146/annurev.bi.52.070183.002211; EIL C, 1996, ADV EXP MED BIOL, V196, P407; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAHN CN, 1994, NUCLEIC ACIDS RES, V22, P2410, DOI 10.1093/nar/22.12.2410; HANNAH SS, 1994, NUTR REV, V52, P376, DOI 10.1111/j.1753-4887.1994.tb01368.x; KAHLEN JP, 1994, BIOCHEM BIOPH RES CO, V202, P1366, DOI 10.1006/bbrc.1994.2081; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; KURIBAYASHI T, 1983, ENDOCRINOLOGY, V113, P1992, DOI 10.1210/endo-113-6-1992; LEMAY J, 1995, J BONE MINER RES, V10, P1148; LIU M, 1994, MOL ENDOCRINOL, V8, P1593, DOI 10.1210/me.8.12.1593; MACDONALD PN, 1995, J BIOL CHEM, V270, P4748, DOI 10.1074/jbc.270.9.4748; MAKIN G, 1989, BIOCHEM J, V262, P173, DOI 10.1042/bj2620173; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANOLAGAS SC, 1990, KIDNEY INT, V38, pS9; MATKOVITS T, 1995, ENDOCRINOLOGY, V136, P3971, DOI 10.1210/en.136.9.3971; MATSUMOTO T, 1985, BIOCHIM BIOPHYS ACTA, V845, P358, DOI 10.1016/0167-4889(85)90199-5; MORGAN JW, 1994, J BIOL CHEM, V269, P13437; MORRISON NA, 1989, SCIENCE, V246, P1158, DOI 10.1126/science.2588000; NISHIMURA A, 1994, ENDOCRINOLOGY, V134, P1794, DOI 10.1210/en.134.4.1794; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; OHYAMA Y, 1994, J BIOL CHEM, V269, P10545; OMDAHL JL, 1978, J BIOL CHEM, V253, P8474; PIKE JW, 1991, ANNU REV NUTR, V11, P189, DOI 10.1146/annurev.nu.11.070191.001201; REDDY GS, 1989, BIOCHEMISTRY-US, V28, P1763, DOI 10.1021/bi00430a051; REICHEL H, 1986, ARCH BIOCHEM BIOPHYS, V251, P222, DOI 10.1016/0003-9861(86)90069-X; ROCHETTEEGLY C, 1994, BIOCHEM BIOPH RES CO, V204, P525, DOI 10.1006/bbrc.1994.2491; RUBIN LP, 1993, PEDIATR RES, V34, P98, DOI 10.1203/00006450-199307000-00023; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHRADER M, 1994, NATURE, V370, P382, DOI 10.1038/370382a0; SCHRADER M, 1994, J BIOL CHEM, V269, P5501; SCHRADER M, 1994, J MOL ENDOCRINOL, V12, P327, DOI 10.1677/jme.0.0120327; SHINKI T, 1992, J BIOL CHEM, V267, P13757; SMITH R, 1993, METABOLIC BONE STONE, P213; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; ZIEROLD C, 1994, P NATL ACAD SCI USA, V91, P900, DOI 10.1073/pnas.91.3.900; ZIEROLD C, 1995, J BIOL CHEM, V270, P1675, DOI 10.1074/jbc.270.4.1675	45	101	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29715	29721		10.1074/jbc.271.47.29715	http://dx.doi.org/10.1074/jbc.271.47.29715			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939905	hybrid			2022-12-25	WOS:A1996VU52500033
J	Sakamoto, K; Miyoshi, H; Takegami, K; Mogi, T; Anraku, Y; Iwamura, H				Sakamoto, K; Miyoshi, H; Takegami, K; Mogi, T; Anraku, Y; Iwamura, H			Probing substrate binding site of the Escherichia coli quinol oxidases using synthetic ubiquinol analogues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-D COMPLEX; TERMINAL OXIDASE; BO COMPLEX; PARACOCCUS-DENITRIFICANS; MONOCLONAL-ANTIBODIES; BIOLOGICAL PROPERTIES; C-OXIDASE; DERIVATIVES; PROTEIN; BD	Substrate binding sites of the Escherichia cell bo- and bd-type quinol oxidases were probed with systematically synthesized ubiquinol analogues, The apparent K-m values of ubiquinol-2 derivatives to the be-type enzyme were much lower than that of the corresponding 6-n-decyl derivatives, The isoprenoid structure is less hydrophobic than the saturated n-alkyl group with the same carbon number; therefore, the native isoprenoid side chain appears to play a specific role in quinol binding besides simply increasing hydrophobicity of the molecule, The V-max values of 2-methoxy-3-ethoxy analogues were greater than that of 2-ethoxy-3-methoxy analogues irrespective of the side chain structure, This result indicates not only that a methoxy group in the 2-position is recognized more strictly than the S-position by the binding site but also that the side chain structure does not affect binding of the quinol ring moiety, Systematic analysis of the electron-donating activities of the analogues with different substituents in the 5-position revealed that the B-methyl group is important for the activity, In the parallel studies with the bd-type enzyme, we obtained similar observations except that almost all quinol analogues, but not ubiquinol-1, elicited a remarkable substrate inhibition at higher concentrations, These results indicate that the two structurally unrelated terminal oxidases share common structural properties for the quinol-oxidation site.	KYOTO UNIV,DEPT AGR CHEM,SAKYO KU,KYOTO 606,JAPAN; UNIV TOKYO,GRAD SCH SCI,DEPT BIOL SCI,BUNKYO KU,TOKYO 113,JAPAN	Kyoto University; University of Tokyo			Sakamoto, Kimitoshi/G-4539-2014					ALLEN JP, 1987, P NATL ACAD SCI USA, V84, P5730, DOI 10.1073/pnas.84.16.5730; ANRAKU Y, 1987, TRENDS BIOCHEM SCI, V12, P262, DOI 10.1016/0968-0004(87)90131-9; CHEPURI V, 1990, J BIOL CHEM, V265, P11185; DASSA J, 1991, MOL GEN GENET, V229, P341, DOI 10.1007/BF00267454; DUEWEKE TJ, 1990, J BIOL CHEM, V265, P4273; DUEWEKE TJ, 1991, BIOCHEMISTRY-US, V30, P3401, DOI 10.1021/bi00228a007; ESTORNELL E, 1993, FEBS LETT, V332, P127, DOI 10.1016/0014-5793(93)80498-J; Fato R, 1996, BIOCHEMISTRY-US, V35, P2705, DOI 10.1021/bi9516034; GARCIAHORSMAN JA, 1994, J BACTERIOL, V176, P5587, DOI 10.1128/JB.176.18.5587-5600.1994; GREEN GN, 1988, J BIOL CHEM, V263, P13138; GREEN GN, 1984, GENE, V32, P99, DOI 10.1016/0378-1119(84)90037-4; HASTINGS SF, 1995, BIOCHEM SOC T, V24, P131; HE DY, 1994, J BIOL CHEM, V269, P27885; HE DY, 1994, BIOCHEMISTRY-US, V33, P880, DOI 10.1021/bi00170a005; INGLEDEW WJ, 1995, EUR J BIOCHEM, V227, P903, DOI 10.1111/j.1432-1033.1995.tb20217.x; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; JUNEMANN S, 1995, BIOCHEMISTRY-US, V34, P14861; KITA K, 1982, J BIOL CHEM, V257, P7933; KRANZ RG, 1984, J BIOL CHEM, V259, P7998; LORENCE RM, 1988, J BIOL CHEM, V263, P5271; MERZ A, 1993, SYNTHESIS-STUTTGART, P797; MEUNIER B, 1995, BIOCHEMISTRY-US, V34, P1076, DOI 10.1021/bi00003a044; MOGI T, 1994, J BIOCHEM-TOKYO, V116, P741; PUUSTINEN A, 1989, FEBS LETT, V249, P163, DOI 10.1016/0014-5793(89)80616-7; Rieske J. S., 1967, METHOD ENZYMOL, V10, P239; ROBINSON HH, 1990, J AM CHEM SOC, V112, P4728, DOI 10.1021/ja00168a017; SAITOH I, 1992, EUR J BIOCHEM, V209, P73, DOI 10.1111/j.1432-1033.1992.tb17262.x; Sakamoto K, 1996, EUR J BIOCHEM, V237, P128, DOI 10.1111/j.1432-1033.1996.0128n.x; SARASTE M, 1991, BIOCHEM SOC T, V19, P608, DOI 10.1042/bst0190608; SATOWATANABE M, 1995, FEBS LETT, V374, P265, DOI 10.1016/0014-5793(95)01125-X; SATOWATANABE M, 1994, J BIOL CHEM, V269, P28908; SATOWATANABE M, 1994, J BIOL CHEM, V269, P28899; SATOWATANABE M, 1995, BIOPHYS J, V68, P319; TSUBAKI M, 1995, J BIOL CHEM, V270, P28565, DOI 10.1074/jbc.270.48.28565; TSUBAKI M, 1993, BIOCHEMISTRY-US, V32, P6065, DOI 10.1021/bi00074a018; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; WARNCKE K, 1994, BIOCHEMISTRY-US, V33, P7830, DOI 10.1021/bi00191a010; WELTER R, 1994, J BIOL CHEM, V269, P28834; XIA D, 1996, BIOPHYS J, V70, P253; YANG FD, 1986, J BIOL CHEM, V261, P4987; YU CA, 1985, BIOCHEMISTRY-US, V24, P3897, DOI 10.1021/bi00336a013	41	47	49	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29897	29902		10.1074/jbc.271.47.29897	http://dx.doi.org/10.1074/jbc.271.47.29897			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939932	hybrid			2022-12-25	WOS:A1996VU52500060
J	Bider, MD; Wahlberg, JM; Kammerer, RA; Spiess, M				Bider, MD; Wahlberg, JM; Kammerer, RA; Spiess, M			The oligomerization domain of the asialoglycoprotein receptor preferentially forms 2:2 heterotetramers in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNAL SIGNAL SEQUENCE; COILED-COIL; 2 SUBUNITS; PROTEINS; GALACTOSYL; LECTINS	The human hepatic asialoglycoprotein receptor is a noncovalent hetero-oligomer composed of two homologous subunits, H1 and H2, with an as yet unknown stoichiometry, Ligand specificity and binding affinity depend on the arrangement of the subunits in the complex. An 80-amino acid segment connecting the transmembrane and the carbohydrate binding domains contains heptad repeats characteristic of alpha-helical coned coil structure, We expressed and purified corresponding peptides, H1S and H2S, and confirmed by circular dichroism spectroscopy that they can assume alpha-helical conformation. Oxidative cross-linking of amino-terminal cysteines generated specific covalent oligomers, indicating that separately H1S forms trimers and H2S tetramers, Upon mixing, covalent heterotetramers mere formed with a preferred stoichiometry of 2 H1S and 2 H2S peptides. These results suggest that the stalk segments of the receptor subunits oligomerize to constitute an alpha-helical coiled coil stalk on top of which the carbohydrate binding domains are exposed for ligand binding, We propose that the functional asialoglycoprotein receptor is a 2:2 heterotetramer.	UNIV BASEL, BIOZENTRUM, CH-4056 BASEL, SWITZERLAND	University of Basel				Spiess, Martin/0000-0001-7139-0550; Kammerer, Richard/0000-0003-4570-5197				BEAVIL AJ, 1992, P NATL ACAD SCI USA, V89, P753, DOI 10.1073/pnas.89.2.753; BISCHOFF J, 1988, J CELL BIOL, V106, P1067, DOI 10.1083/jcb.106.4.1067; BRANDENBERGER R, 1996, IN PRESS J CELL BIOL; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; Chew MWK, 1995, J STRUCT BIOL, V115, P233, DOI 10.1006/jsbi.1995.1048; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FUHRER C, 1994, J BIOL CHEM, V269, P3277; GEFFEN I, 1989, EMBO J, V8, P2855, DOI 10.1002/j.1460-2075.1989.tb08433.x; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HAUDENSCHILD DR, 1995, J BIOL CHEM, V270, P23150, DOI 10.1074/jbc.270.39.23150; HERZIG MCS, 1990, BIOCHEMISTRY-US, V29, P6437, DOI 10.1021/bi00479a015; HUNTER I, 1992, J BIOL CHEM, V267, P6006; ISHIBASHI S, 1994, J BIOL CHEM, V269, P27803; KNECHT R, 1986, ANAL CHEM, V58, P2375, DOI 10.1021/ac00125a006; LEUNG JO, 1985, J BIOL CHEM, V260, P2523; LODISH HF, 1991, TRENDS BIOCHEM SCI, V16, P374, DOI 10.1016/0968-0004(91)90154-N; LUPAS A, 1995, J MOL BIOL, V248, P180, DOI 10.1006/jmbi.1995.0210; MCPHAUL M, 1986, P NATL ACAD SCI USA, V83, P8863, DOI 10.1073/pnas.83.23.8863; NORTH ACT, 1994, PROTEINS, V20, P174, DOI 10.1002/prot.340200207; RICE KG, 1990, J BIOL CHEM, V265, P18429; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMID SR, 1988, J BIOL CHEM, V263, P16886; SHIA MA, 1989, P NATL ACAD SCI USA, V86, P1158, DOI 10.1073/pnas.86.4.1158; Simmerman HKB, 1996, J BIOL CHEM, V271, P5941, DOI 10.1074/jbc.271.10.5941; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; SPIESS M, 1985, J BIOL CHEM, V260, P1979; SPIESS M, 1986, CELL, V44, P177, DOI 10.1016/0092-8674(86)90496-4; WAHLBERG JM, 1995, J CELL BIOL, V130, P285, DOI 10.1083/jcb.130.2.285; WEIGEL PH, 1994, BIOESSAYS, V16, P519, DOI 10.1002/bies.950160713; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3	33	43	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					31996	32001		10.1074/jbc.271.50.31996	http://dx.doi.org/10.1074/jbc.271.50.31996			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943247	hybrid			2022-12-25	WOS:A1996VY34000038
J	Brunner, C; Lobentanz, EM; PethoSchramm, A; Ernst, A; Kang, C; Dieplinger, H; Muller, HJ; Utermann, G				Brunner, C; Lobentanz, EM; PethoSchramm, A; Ernst, A; Kang, C; Dieplinger, H; Muller, HJ; Utermann, G			The number of identical kringle IV repeats in apolipoprotein(a) affects its processing and secretion by HepG2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA LIPOPROTEIN(A) CONCENTRATIONS; LOW-DENSITY-LIPOPROTEIN; SIZE POLYMORPHISM; MAMMALIAN-CELLS; MOLECULAR-BASIS; GOLGI-COMPLEX; ETHNIC-GROUPS; ISOFORM SIZE; APO(A) GENE; LOCUS	A variable number of 5.6-kilobase kringle IV repeats in the human apolipoprotein(a) (apo(a)) gene results in a Size polymorphism of the protein and correlates inversely with the plasma levels of the atherogenic lipoprotein(a) (Lp(a)). In order to analyze whether this association reflects a direct effect: of kringle IV repeat number on Lp(a) plasma concentration, we have studied the expression of recombinant apo(a) (r-apo(a)) isoforms in the human hepatocarcinoma cell line HepG2, Following transient transfection of apo(a) cDNA expression plasmids that differed only in the number of kringle IV repeats, we observed a gradual decrease of Lp(a) in the medium of the cells with an increasing number of kringle IV repeats, mimicking the relationship present in humans in vivo. The analysis of apo(a) protein in the lysate and in the medium of cells that were transfected with a plasmid encoding an apo(a) isoform with 22 kringles revealed a predominant intracellular precursor with little secretion of the mature apo(a) protein. In contrast, transfection of a plasmid encoding an isoform with II kringles led to effective secretion of the mature peptide into the medium, indicating differential processing rates of apo(a) isoforms in the secretory path way, The intracellular accumulation of an apo(a) precursor in the endoplasmic reticulum was demonstrated by cell fractionation and [S-35]Met metabolic labeling/temperature block experiments using HepG2 cells stably transfected with recombinant apo(a), The direct and causal effect of kringle IV repeat number on the expression of recombinant apo(a) in HepG2 cells, and presumably liver cells, provides a novel mechanism for the genetic regulation of the concentration of a protein.	UNIV INNSBRUCK, INST MED BIOL & HUMAN GENET, A-6020 INNSBRUCK, AUSTRIA; BOEHRINGER MANNHEIM GMBH, DEPT MOL BIOL, D-68305 MANNHEIM, GERMANY; INSERM, U143, PARIS, FRANCE	University of Innsbruck; Institut National de la Sante et de la Recherche Medicale (Inserm)								ANIENTO F, 1993, J CELL BIOL, V123, P1373, DOI 10.1083/jcb.123.6.1373; BEAUFAY H, 1974, J CELL BIOL, V61, P213, DOI 10.1083/jcb.61.1.213; BOERWINKLE E, 1992, J CLIN INVEST, V90, P52, DOI 10.1172/JCI115855; BOPP S, 1995, J LIPID RES, V36, P1501; BRANDLI AW, 1988, J BIOL CHEM, V263, P16283; BRUNNER C, 1993, P NATL ACAD SCI USA, V90, P11643, DOI 10.1073/pnas.90.24.11643; CHIESA G, 1992, J BIOL CHEM, V267, P24369; DEMEESTER CA, 1995, AM J HUM GENET, V56, P287; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIEPLINGER H, 1995, J LIPID RES, V36, P813; ERNST A, 1995, J BIOL CHEM, V270, P6227, DOI 10.1074/jbc.270.11.6227; FRANK S, 1994, BIOCHEMISTRY-US, V33, P12329, DOI 10.1021/bi00206a041; GAW A, 1994, J CLIN INVEST, V93, P2526, DOI 10.1172/JCI117263; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; GRIFFITHS G, 1985, J CELL BIOL, V101, P949, DOI 10.1083/jcb.101.3.949; GUEVARA J, 1992, PROTEINS, V12, P188, DOI 10.1002/prot.340120212; KAMBOH MI, 1991, AM J HUM GENET, V49, P1063; KORGE BP, 1992, P NATL ACAD SCI USA, V89, P910, DOI 10.1073/pnas.89.3.910; KOSCHINSKY ML, 1991, BIOCHEMISTRY-US, V30, P5044, DOI 10.1021/bi00234a029; KOSCHINSKY ML, 1993, J BIOL CHEM, V268, P19819; Kraft HG, 1996, EUR J HUM GENET, V4, P74; KRAFT HG, 1995, HUM GENET, V95, P275; KRAFT HG, 1992, HUM GENET, V90, P220; KREMPLER F, 1980, J CLIN INVEST, V65, P1483, DOI 10.1172/JCI109813; KRONENBERG F, 1994, J LIPID RES, V35, P1318; LACKNER C, 1993, HUM MOL GENET, V2, P933, DOI 10.1093/hmg/2.7.933; LACKNER C, 1991, J CLIN INVEST, V87, P2153, DOI 10.1172/JCI115248; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUCERO MA, 1986, NUCLEIC ACIDS RES, V14, P8692; LYONS KM, 1988, GENETICS, V120, P267; MANCINI FP, 1995, HUM MOL GENET, V4, P535; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MOOSER V, 1995, HUM MOL GENET, V4, P173, DOI 10.1093/hmg/4.2.173; RADER DJ, 1994, J CLIN INVEST, V93, P2758, DOI 10.1172/JCI117292; Sambrook J., 2002, MOL CLONING LAB MANU; SANDHOLZER C, 1991, HUM GENET, V86, P607; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; SWALLOW DM, 1987, NATURE, V328, P82, DOI 10.1038/328082a0; TROMMSDORFF M, 1995, J CLIN INVEST, V96, P150, DOI 10.1172/JCI118015; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; UTERMANN G, 1987, J CLIN INVEST, V80, P458, DOI 10.1172/JCI113093; UTERMANN G, 1995, METABOLIC MOL BASES, P1887; VANDERHOEK YY, 1993, HUM MOL GENET, V2, P361, DOI 10.1093/hmg/2.4.361; WHITE AL, 1994, J BIOL CHEM, V269, P9060	45	67	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32403	32410		10.1074/jbc.271.50.32403	http://dx.doi.org/10.1074/jbc.271.50.32403			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943305	hybrid			2022-12-25	WOS:A1996VY34000096
J	Keesler, GA; Gabel, BR; Devlin, CM; Koschinsky, ML; Tabas, I				Keesler, GA; Gabel, BR; Devlin, CM; Koschinsky, ML; Tabas, I			The binding activity of the macrophage lipoprotein(a) apolipoprotein(a) receptor is induced by cholesterol via a post-translational mechanism and recognizes distinct kringle domains on apolipoprotein(a)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE PERITONEAL-MACROPHAGES; LOW-DENSITY LIPOPROTEIN; ACYL COENZYME-A; TRANSGENIC MICE; FOAM CELLS; INTERFERON-GAMMA; MAMMALIAN-CELLS; DNA; ATHEROSCLEROSIS; EXPRESSION	Elevated plasma levels of lipoprotein(a) (Lp(a)) can be a risk factor for atherosclerosis, and the interaction of Lp(a) with cholesterol-loaded macrophages (foam cells) in atheromata may be important in Lp(a)-induced atherogenesis, We have previously shown that when cultured macrophages are loaded with cholesterol, they acquire the ability to internalize and lysosomally degrade Lp(a) via interaction bet2een a novel cell-surface receptor activity and the apolipoprotein(a) (apo(a)) moiety of Lp(a). Herein we explore the cell-surface binding of recombinant apo(a) (r-apo(a)) by foam cells, Whereas the induction of degradation of r-apo(a) by cholesterol loading of macrophages depended on new protein synthesis, the induction of binding of r-apo(a) did not, Furthermore, J774 macrophages bound r-apo(a) in a cholesterol-regulatable and specific manner but degraded r-apo(a) poorly. Thus, the binding and internalization/degradation functions of the receptor activity are distinct, To explore which domains on r-apo(a) interact with the foam cell receptor, we conducted a series of competitive and direct binding and degradation experiments using 12 r-apo(a) constructs that differed in their content of specific kringle subtypes. These data, as well as complementary data with anti-apo(a) monoclonal antibodies, indicated that the region centered around kringle type IV, subtypes 6-7 (KIV6-7) is important in receptor binding, Remarkably, a cholesterol-induced receptor activity with similar structural specificity was also found on Chinese hamster ovary cells, In conclusion, the foam cell Lp(a)/apo(a) receptor consists of a cholesterol-regulatable binding activity and a short-lived component necessary for internalization or lysosomal degradation; the binding activity interacts with a distinct region of apo(a) that is different from that involved in competition for plasminogen binding.	COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT ANAT & CELL BIOL,NEW YORK,NY 10032; QUEENS UNIV,DEPT BIOCHEM,KINGSTON,ON K7L 3N6,CANADA	Columbia University; Columbia University; Queens University - Canada				Koschinsky, Marlys/0000-0002-2643-2288	NHLBI NIH HHS [HL-21006] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL021006] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAI H, 1989, BIOCHEM BIOPH RES CO, V159, P1375, DOI 10.1016/0006-291X(89)92262-6; ASHKENAS J, 1993, J LIPID RES, V34, P983; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BOTTALICO LA, 1993, J BIOL CHEM, V268, P8569; BRASITUS TA, 1988, J BIOL CHEM, V263, P8592; CALLOW MJ, 1994, P NATL ACAD SCI USA, V91, P2130, DOI 10.1073/pnas.91.6.2130; CHEN M, 1995, BBA-MOL BASIS DIS, V1272, P101, DOI 10.1016/0925-4439(95)00073-D; FAN K, 1992, J IMMUNOL, V149, P96; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; GABEL BR, 1996, IN PRESS ARTERIOSCLE; GANAL JM, 1996, J BIOL CHEM, V271, P10946; GERRITY RG, 1981, AM J PATHOL, V103, P181; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GONZALEZGRONOW M, 1989, BIOCHEMISTRY-US, V28, P2374, DOI 10.1021/bi00432a005; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRAINGER DJ, 1993, SCIENCE, V260, P1655, DOI 10.1126/science.8503012; HAJJAR KA, 1989, NATURE, V339, P303, DOI 10.1038/339303a0; Hannan LA, 1996, J CELL BIOL, V133, P1265, DOI 10.1083/jcb.133.6.1265; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; KASHFI K, 1991, BIOCHEM BIOPH RES CO, V177, P1121, DOI 10.1016/0006-291X(91)90655-Q; KEESLER GA, 1994, ARTERIOSCLER THROMB, V14, P1337, DOI 10.1161/01.ATV.14.8.1337; KHOO JC, 1989, BIOCHIM BIOPHYS ACTA, V1012, P215, DOI 10.1016/0167-4889(89)90099-2; KOSCHINSKY ML, 1991, BIOCHEMISTRY-US, V30, P5044, DOI 10.1021/bi00234a029; KOSCHINSKY ML, 1990, BIOCHEMISTRY-US, V29, P640, DOI 10.1021/bi00455a007; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LAWN RM, 1992, NATURE, V360, P670, DOI 10.1038/360670a0; LINTON MF, 1993, J CLIN INVEST, V92, P3029, DOI 10.1172/JCI116927; MANCINI FP, 1995, ARTERIOSCL THROM VAS, V15, P1911, DOI 10.1161/01.ATV.15.11.1911; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MILES LA, 1989, NATURE, V339, P301, DOI 10.1038/339301a0; MURAI M, 1995, J LEUKOCYTE BIOL, V57, P687, DOI 10.1002/jlb.57.4.687; NIENDORF A, 1990, VIRCHOWS ARCH A, V417, P105, DOI 10.1007/BF02190527; ORTEGA A, 1986, BIOCHEM BIOPH RES CO, V139, P868, DOI 10.1016/S0006-291X(86)80258-3; ROSS AC, 1984, J BIOL CHEM, V259, P815; SANGRAR W, 1994, PROTEIN ENG, V7, P723, DOI 10.1093/protein/7.5.723; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; SCANU AM, 1991, ANN INTERN MED, V115, P209, DOI 10.7326/0003-4819-115-3-209; SCHAFFNER T, 1980, AM J PATHOL, V100, P57; SHAMES R, 1994, INT J IMMUNOPHARMACO, V16, P335, DOI 10.1016/0192-0561(94)90009-4; SHIRATORI Y, 1995, J BIOL CHEM, V270, P29894; SKIBA P, 1993, CIRCULATION, V88, P272; SKIBA PJ, 1994, J BIOL CHEM, V269, P23059; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; TABAS I, 1990, J CELL BIOL, V111, P929, DOI 10.1083/jcb.111.3.929; TABAS I, 1987, J CLIN INVEST, V79, P418, DOI 10.1172/JCI112828; TABAS I, 1995, CURR OPIN LIPIDOL, V6, P260, DOI 10.1097/00041433-199510000-00004; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; WEIEL JE, 1983, BIOCHIM BIOPHYS ACTA, V759, P170, DOI 10.1016/0304-4165(83)90309-4; YEAGLE PL, 1983, BIOCHIM BIOPHYS ACTA, V727, P39, DOI 10.1016/0005-2736(83)90366-8; YEAGLE PL, 1989, FASEB J, V3, P1833, DOI 10.1096/fasebj.3.7.2469614; ZHA X, 1996, IN PRESS ARTERIOSCLE	56	26	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32096	32104		10.1074/jbc.271.50.32096	http://dx.doi.org/10.1074/jbc.271.50.32096			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943262	hybrid			2022-12-25	WOS:A1996VY34000053
J	Massari, S				Massari, S			Kinetic analysis of the mitochondrial permeability transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEART-MITOCHONDRIA; OXIDATIVE STRESS; CA-2+-DEPENDENT PORE; INORGANIC-PHOSPHATE; LIVER-MITOCHONDRIA; INNER MEMBRANE; CA-2+ RELEASE; CYCLOSPORINE; CALCIUM; BINDING	The permeability transition process in rat liver mitochondria was studied by following the swelling consequent to external solute equilibration through the membrane pore, The kinetics of the transition was analyzed according to a model based on the assumptions that the transition rate follows a first order process and that the solute diffusion rate strongly depends on the pore conformation. Three kinetic parameters, easily calculated from absorbance measurements during mitochondrial swelling, were used to determine whether changes of the swelling rate are due to changes of (i) the transition rate, (ii) the amount of permeabilized mitochondria, (iii) the mean pore dimension, or (iv) the number of pores per mitochondrion. The model was tested for transitions induced either by phenylarsine oxide (PhAsO) or by Ca2+ and P-i. Under both conditions, only a definite fraction of mitochondria was permeabilized, and the transition always followed a first-order reaction, indicating that mitochondria behaved as a homogeneous population, Hoc-ever, the equilibration of external solutes was rapid only in a fraction of permeabilized mitochondria and slow in the remaining fraction, due to restricted solute diffusion through narrower pores, With 0.2 mM PhAsO as the inducer, the fraction of permeabilized mitochondria was about 0.8. Sucrose diffusion was rapid only in 15% of this fraction (half-time less than 1 s) and restricted in the remaining 85% (half-time of about 60 s). Increasing PhAsO concentrations increased the number of pores per mitochondrion and the rate constant of the permeability transition, but not the mean pore diameter and the fraction of permeabilized mitochondria, With 0.28 mu M free [Ca2+] and 1 mM P-i as the inducers, the fraction of permeabilized mitochondria was about 0.43, Sucrose diffusion was rapid in 60% of this fraction and restricted in the remaining 40% (half-time of about 9 s), The permeabilization process started above a threshold- free [Ca2+] of 0.15 mu M, and the rate constant and the fraction of permeabilized mitochondria reached a maximum at about 0.2 mu M, while both parameters were inhibited at higher free [Ca2+].	UNIV PADUA, SCH MED, DEPT BIOMED SCI, LAB BIOPHYS & MEMBRANE BIOL, I-35121 PADUA, ITALY; CNR, UNIT STUDY BIOMEMBRANES, I-35121 PADUA, ITALY	University of Padua; Consiglio Nazionale delle Ricerche (CNR)								ALNASSER I, 1986, BIOCHEM J, V239, P19, DOI 10.1042/bj2390019; ALNASSER I, 1986, BIOCHEM J, V239, P31, DOI 10.1042/bj2390031; BEATRICE MC, 1982, J BIOL CHEM, V257, P7161; BEAVIS AD, 1985, J BIOL CHEM, V260, P3424; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; BERNARDI P, 1993, J BIOL CHEM, V268, P1005; BERNARDI P, 1992, J BIOL CHEM, V267, P8834; BERNARDI P, 1983, BIOCHIM BIOPHYS ACTA, V724, P212, DOI 10.1016/0005-2728(83)90140-8; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; CROMPTON M, 1987, BIOCHEM J, V245, P915, DOI 10.1042/bj2450915; CROMPTON M, 1988, EUR J BIOCHEM, V178, P489, DOI 10.1111/j.1432-1033.1988.tb14475.x; CROMPTON M, 1988, BIOCHEM J, V255, P357; CROMPTON M, 1987, BIOCHEM SOC T, V15, P408, DOI 10.1042/bst0150408; FABIATO A, 1979, J PHYSL, V256, pC160; FOURNIER N, 1987, J BIOENERG BIOMEMBR, V19, P297, DOI 10.1007/BF00762419; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313, DOI 10.1152/ajpcell.1994.267.2.C313; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P453, DOI 10.1016/0003-9861(79)90371-0; HUNTER DR, 1976, J BIOL CHEM, V251, P5069; IGBAVBOA U, 1988, J BIOL CHEM, V263, P1405; LEQUOC K, 1985, J BIOL CHEM, V260, P7422; MASSARI S, 1972, BIOCHIM BIOPHYS ACTA, V238, P23, DOI 10.1016/0005-2728(72)90094-1; PETRONILLI V, 1993, J BIOL CHEM, V268, P21939; PFEIFFER DR, 1995, J BIOL CHEM, V270, P4923, DOI 10.1074/jbc.270.9.4923; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; SZABO I, 1992, J BIOENERG BIOMEMBR, V24, P111, DOI 10.1007/BF00769537; TEDESCHI H, 1958, BIOCHIM BIOPHYS ACTA, V28, P392, DOI 10.1016/0006-3002(58)90487-6; TEDESCHI H, 1955, ARCH BIOCHEM BIOPHYS, V58, P52, DOI 10.1016/0003-9861(55)90092-8	29	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					31942	31948						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943240				2022-12-25	WOS:A1996VY34000031
J	McInnes, C; Hoyt, DW; Harkins, RN; Pagila, RN; Debanne, MT; OConnorMcCourt, M; Sykes, BD				McInnes, C; Hoyt, DW; Harkins, RN; Pagila, RN; Debanne, MT; OConnorMcCourt, M; Sykes, BD			NMR study of the transforming growth factor-alpha (TGF-alpha)-epidermal growth factor receptor complex - Visualization of human TGF-alpha binding determinants through nuclear overhauser enhancement analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOLOGICAL-ACTIVITY; SPECTROSCOPY; SITE; IDENTIFICATION; MITOGENS; REGIONS; H-1-NMR; MURINE; CHAIN; BETA	The study of human transforming growth factor-alpha (TGF-alpha) in complex with the epidermal growth factor (EGF) receptor extracellular domain has been undertaken in order to generate information on the interactions of these molecules. Analysis of H-1 NMR transferred nuclear Overhauser enhancement data for titration of the ligand with the receptor has yielded specific data on the residues of the growth factor involved in contact with the larger protein. Significant increases and decreases in nuclear Overhauser enhancement cross-peak intensity occur upon complexation, and interpretation of these changes indicates that residues of the A- and C-loops of TGF-alpha form the major binding interface, while the B-loop provides a structural scaffold for this site. These results corroborate the conclusions from NMR relaxation studies (Hoyt, D. W., Harkins, R. N., Debanne, M. T., O'Connor-McCourt, M., and Sykes, B. D. (1994) Biochemistry 33, 15283-15392), which suggest that the C-terminal residues of the polypeptide are immobilized upon receptor binding, while the N terminus of the molecule retains considerable flexibility, and are consistent with structure-function studies of the TGF-alpha/EGF system indicating a multidomain binding model. These results give a visualization, for the first time, of native TGF-alpha in complex with the EGF receptor and generate a picture of the ligand-binding site based upon the intact molecule. This will undoubtedly be of utility in the structure-based design of TGF-alpha/EGF agonists and/or antagonists.	UNIV ALBERTA,PROT ENGN NETWORK CTR EXCELLENCE,EDMONTON,AB T6G 2S2,CANADA; BERLEX BIOSCI,RICHMOND,CA 94804; NATL RES COUNCIL CANADA,BIOTECHNOL RES INST,MONTREAL,PQ H4P 2R2,CANADA	University of Alberta; National Research Council Canada			Hoyt, David/H-6295-2013; McInnes, Campbell/A-6721-2009	Hoyt, David/0000-0002-2857-719X; 				BENNETT NT, 1993, AM J SURG, V165, P728, DOI 10.1016/S0002-9610(05)80797-4; BENNETT NT, 1993, AM J SURG, V166, P74, DOI 10.1016/S0002-9610(05)80589-6; BODENHAUSEN G, 1984, J MAGN RESON, V58, P370, DOI 10.1016/0022-2364(84)90142-2; CAMPBELL A P, 1991, Journal of Biomolecular NMR, V1, P391, DOI 10.1007/BF02192862; CAMPBELL AP, 1993, ANNU REV BIOPH BIOM, V22, P99, DOI 10.1146/annurev.bb.22.060193.000531; Campbell I D, 1989, Prog Growth Factor Res, V1, P13, DOI 10.1016/0955-2235(89)90038-0; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHAMBERLIN SG, 1995, J BIOL CHEM, V270, P21062, DOI 10.1074/jbc.270.36.21062; DEFEOJONES D, 1988, MOL CELL BIOL, V8, P2999, DOI 10.1128/MCB.8.8.2999; DEFEOJONES D, 1989, MOL CELL BIOL, V9, P4083, DOI 10.1128/MCB.9.9.4083; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DERYNCK R, 1987, CANCER RES, V47, P707; ENGLER DA, 1990, FEBS LETT, V271, P47, DOI 10.1016/0014-5793(90)80368-S; ENGLER DA, 1991, MOL CELL BIOL, V11, P2425, DOI 10.1128/MCB.11.5.2425; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; GROENEN LC, 1994, GROWTH FACTORS, V11, P235, DOI 10.3109/08977199409010997; GULLICK WJ, 1994, EUR J CANCER, V30A, P2186, DOI 10.1016/0959-8049(94)00365-C; HARVEY TS, 1991, EUR J BIOCHEM, V198, P555, DOI 10.1111/j.1432-1033.1991.tb16050.x; HEATH WF, 1986, P NATL ACAD SCI USA, V83, P6367, DOI 10.1073/pnas.83.17.6367; HOEPRICH PD, 1989, J BIOL CHEM, V264, P19086; HOYT DW, 1994, BIOCHEMISTRY-US, V33, P15283, DOI 10.1021/bi00255a009; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KATSUURA M, 1989, J BIOCHEM-TOKYO, V106, P87, DOI 10.1093/oxfordjournals.jbchem.a122826; KLINE TP, 1990, BIOCHEMISTRY-US, V29, P7805, DOI 10.1021/bi00486a005; KOHDA D, 1989, BIOCHEMISTRY-US, V28, P953, DOI 10.1021/bi00429a005; KORC M, 1989, J BIOL CHEM, V264, P14990; KRAMER RH, 1994, J BIOL CHEM, V269, P8708; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; LAX I, 1991, CELL REGUL, V2, P337, DOI 10.1091/mbc.2.5.337; LAZAR E, 1989, MOL CELL BIOL, V9, P860, DOI 10.1128/MCB.9.2.860; LAZAR E, 1988, MOL CELL BIOL, V8, P1247, DOI 10.1128/MCB.8.3.1247; LONDON RE, 1992, J MAGN RESON, V97, P79, DOI 10.1016/0022-2364(92)90238-3; MOY FJ, 1993, BIOCHEMISTRY-US, V32, P7334, DOI 10.1021/bi00080a003; RICHTER A, 1992, BIOCHEMISTRY-US, V31, P9546, DOI 10.1021/bi00155a006; RICHTER A, 1995, J BIOL CHEM, V270, P1612, DOI 10.1074/jbc.270.4.1612; SIMPSON RJ, 1985, EUR J BIOCHEM, V153, P629, DOI 10.1111/j.1432-1033.1985.tb09346.x; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; TAM JP, 1991, INT J PEPT PROT RES, V38, P204; TENDIJKE P, 1989, BIO-TECHNOL, V7, P793, DOI 10.1038/nbt0889-793	39	21	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32204	32211		10.1074/jbc.271.50.32204	http://dx.doi.org/10.1074/jbc.271.50.32204			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943277	hybrid			2022-12-25	WOS:A1996VY34000068
J	Persechini, A; Stemmer, PM; Ohashi, I				Persechini, A; Stemmer, PM; Ohashi, I			Localization of unique functional determinants in the calmodulin lobes to individual EF hands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; CENTRAL HELIX; ENZYME ACTIVATION; CALCIUM-BINDING; PEPTIDE COMPLEX; TARGET ENZYMES; BASIC RESIDUES; MYOSIN; DOMAIN; SKELETAL	We have investigated the functional interchangeability of EF hands I and III or II and IV, which occupy structurally analogous positions in the native I-II and III-IV EF hand pairs of calmodulin. Our approach was to functionally characterize four engineered proteins, made by replacing in turn each EF hand in one pair by a duplicate of its structural analog in the other. In this way functional determinants we define as unique were localized to the component EF hands in each pair, Replacement of EF hand I by III reduces calmodulin-dependent activation of cerebellar nitric oxide synthase activity by 50%, Replacement of EF hand IV by II reduces by 60% activation of skeletal muscle myosin light chain kinase activity, There appear to be no major unique determinants for activation of these enzyme activities in the other EF hands. Replacement of EF hand III by I or IV by II reduces by 50-80% activation of smooth muscle myosin light chain kinase activity, and replacement of EF hand I by III or II by IV reduces by 90% activation of this enzyme activity. Thus, calmodulin-dependent activation of each of the enzyme activities examined, even the closely related kinases, is dependent upon a distinct pattern of unique determinants in the four EF hands of calmodulin, All the engineered proteins examined bind four Ca2+ ions with high affinity, Comparison of the Ca2+-binding properties of native and engineered CaMs indicates that the Ca2+-binding affinity of an engineered I-IV EF hand pair and a native I-II pair are similar, but an engineered III-II EF hand pair is intermediate in affinity to the native III-IV and I-II pairs, minimally suggesting that EF hands I and III contain unique determinants for the formation and function of EF hand pairs, The residues directly coordinating Ca2+ ion appear to play little or no role in establishing the different Ca2+-binding properties of the EF hand pairs in calmodulin.	UNIV NEBRASKA,MED CTR,DEPT PEDIAT,OMAHA,NE 68198; UNIV NEBRASKA,MED CTR,DEPT ANESTHESIOL,OMAHA,NE 68198	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Persechini, A (corresponding author), UNIV ROCHESTER,MED CTR,DEPT PHYSIOL & PHARMACOL,601 ELMWOOD AVE,BOX 642,ROCHESTER,NY 14642, USA.			Stemmer, Paul/0000-0003-3315-9846	NIDDK NIH HHS [DK44322] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK044322] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; CROUCH TH, 1980, BIOCHEMISTRY-US, V19, P3692, DOI 10.1021/bi00557a009; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FINDLAY WA, 1995, PROTEIN SCI, V4, P2375, DOI 10.1002/pro.5560041116; FITZSIMONS DP, 1992, J BIOL CHEM, V267, P23903; FORSEN S, 1986, CALCIUM CELL FUNCTIO, V6, P113; GEORGE SE, 1990, J BIOL CHEM, V265, P9228; GEORGE SE, 1993, J BIOL CHEM, V268, P25213; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; GUERRIERO V, 1986, BIOCHEMISTRY-US, V25, P8372, DOI 10.1021/bi00374a007; HERRING BP, 1991, J BIOL CHEM, V266, P11838; HERRING BP, 1990, J BIOL CHEM, V265, P1724; HUANG CC, 1991, J MOL GRAPHICS, V9, P230, DOI 10.1016/0263-7855(91)80016-S; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; KNIGHTON DR, 1992, SCIENCE, V258, P130, DOI 10.1126/science.1439761; LEACHMAN SA, 1992, J BIOL CHEM, V267, P4930; LINSE S, 1991, BIOCHEMISTRY-US, V30, P154, DOI 10.1021/bi00215a023; LINSE S, 1991, J BIOL CHEM, V266, P8050; MACKALL J, 1991, BIOCHEMISTRY-US, V30, P7242, DOI 10.1021/bi00243a028; MAUNE JF, 1992, J BIOL CHEM, V267, P5286; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; Nakashima K, 1996, BIOCHEMISTRY-US, V35, P5602, DOI 10.1021/bi952586l; NEWTON DL, 1984, J BIOL CHEM, V259, P4419; NI WC, 1985, J BIOL CHEM, V260, P6974; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PERSECHINI A, 1989, J BIOL CHEM, V264, P8052; PERSECHINI A, 1994, J BIOL CHEM, V269, P16148; Persechini A, 1996, J BIOL CHEM, V271, P19279, DOI 10.1074/jbc.271.32.19279; PERSECHINI A, 1988, J BIOL CHEM, V263, P12175; Persechini A, 1996, BIOCHEMISTRY-US, V35, P224, DOI 10.1021/bi952383x; PERSECHINI A, 1989, TRENDS NEUROSCI, V12, P462, DOI 10.1016/0166-2236(89)90097-0; PERSECHINI A, 1988, J CARDIOVASC PHARM, V12, pS1; PUTKEY JA, 1988, J BIOL CHEM, V263, P11242; SHOEMAKER MO, 1990, J CELL BIOL, V111, P1107, DOI 10.1083/jcb.111.3.1107; SIIVARI K, 1995, FEBS LETT, V366, P104, DOI 10.1016/0014-5793(95)00504-3; STEMMER PM, 1994, BIOCHEMISTRY-US, V33, P6859, DOI 10.1021/bi00188a015; SU ZZ, 1995, J BIOL CHEM, V270, P29117, DOI 10.1074/jbc.270.49.29117; VANBERKUM MFA, 1990, J BIOL CHEM, V265, P3750; VANBERKUM MFA, 1991, J BIOL CHEM, V266, P21488	43	26	26	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32217	32225		10.1074/jbc.271.50.32217	http://dx.doi.org/10.1074/jbc.271.50.32217			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943279	hybrid			2022-12-25	WOS:A1996VY34000070
J	Sundstrom, M; Hallen, D; Svensson, A; Schad, E; Dohlsten, M; Abrahmsen, L				Sundstrom, M; Hallen, D; Svensson, A; Schad, E; Dohlsten, M; Abrahmsen, L			The co-crystal structure of staphylococcal enterotoxin type A with Zn2+ at 2.7 angstrom resolution - Implications for major histocompatibility complex class II binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK SYNDROME TOXIN-1; SUPERANTIGEN; SITE; SYSTEM	Superantigens form complexes with major histocompatibility complex (MHC) class II molecules and T-cell receptors resulting in extremely strong immunostimulatory properties. Staphylococcus aureus enterotoxin A (SEA) belongs to a subgroup of the staphylococcal superantigens that utilizes Zn2+ in the high affinity interaction with MHC class II molecules. A high affinity metal binding site was described previously in SEA cocrystallized with Cd2+ in which the metal ion was octahedrally co-ordinated, involving the N-terminal serine. We have now co-crystallized SEA with its native cofactor Zn2+ and determined its crystal structure at 2.1 Angstrom resolution. As expected for a Zn2+ ion, the co ordination was found to be tetrahedral. Three of the ligands are located on the SEA surface on a C-terminal domain beta-sheet, while the fourth varies with the conditions. Further analysis of the zinc binding event was performed using titration microcalorimetry, which showed that SEA binds Zn2+ with an affinity of K-D = 0.3 mu M in an entropy driven process. The differential Zn2+ co-ordination observed here has implications for the mechanism of the SEA-MHC class II interaction.	LUND UNIV, CTR CHEM, DEPT MOL BIOPHYS, LUND, SWEDEN; PHARMACIA & UPJOHN INC, DEPT IMMUNOBIOL, LUND, SWEDEN; PHARMACIA & UPJOHN INC, DEPT MOL BIOL, STOCKHOLM, SWEDEN	Lund University; Pfizer; Pharmacia Corporation; Pfizer; Pharmacia Corporation	Sundstrom, M (corresponding author), PHARMACIA & UPJOHN INC, DEPT STRUCT BIOCHEM, S-11287 STOCKHOLM, SWEDEN.			Schad, Elinor/0000-0001-7482-5329				ABRAHMSEN L, 1995, EMBO J, V14, P2978, DOI 10.1002/j.1460-2075.1995.tb07300.x; ACHARYA KR, 1994, NATURE, V367, P94, DOI 10.1038/367094a0; BACKMAN P, 1994, J BIOCHEM BIOPH METH, V28, P85, DOI 10.1016/0165-022X(94)90023-X; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BALDWIN RL, 1986, P NATL ACAD SCI USA, V83, P8069, DOI 10.1073/pnas.83.21.8069; BRUNGER AT, 1989, ACTA CRYSTALLOGR A, V45, P50, DOI 10.1107/S0108767388009195; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, XPLOR MANUAL; CHAUDHRY M, 1994, J CHEM SOC FARADAY T, V90, P2235, DOI 10.1039/ft9949002235; FRASER JD, 1992, P NATL ACAD SCI USA, V89, P5507, DOI 10.1073/pnas.89.12.5507; FRASER JD, 1993, SUPERANTIGENS PATHOG, P7; HERMAN A, 1991, P NATL ACAD SCI USA, V88, P9954, DOI 10.1073/pnas.88.22.9954; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KIM JS, 1994, SCIENCE, V266, P1870, DOI 10.1126/science.7997880; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MURPHY KP, 1990, SCIENCE, V247, P559, DOI 10.1126/science.2300815; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NORDMARK MG, 1984, J BIOCHEM BIOPH METH, V10, P187, DOI 10.1016/0165-022X(84)90039-3; PAPAGEORGIOU AC, 1995, STRUCTURE, V3, P769, DOI 10.1016/S0969-2126(01)00212-X; PRASAD GS, 1993, BIOCHEMISTRY-US, V32, P13762, DOI 10.1021/bi00213a001; SCHAD EM, 1995, EMBO J, V14, P3292, DOI 10.1002/j.1460-2075.1995.tb07336.x; SCHERER MT, 1993, ANNU REV CELL BIOL, V9, P101, DOI 10.1146/annurev.cb.09.110193.000533; SUURKUUSK J, 1982, CHEM SCRIPTA, V20, P155; SWAMINATHAN S, 1992, NATURE, V359, P801, DOI 10.1038/359801a0; VALLEE BL, 1990, P NATL ACAD SCI USA, V87, P220, DOI 10.1073/pnas.87.1.220; XIE D, 1994, PROTEINS, V19, P291, DOI 10.1002/prot.340190404	31	47	50	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32212	32216		10.1074/jbc.271.50.32212	http://dx.doi.org/10.1074/jbc.271.50.32212			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943278	hybrid			2022-12-25	WOS:A1996VY34000069
J	Blystone, SD; Lindberg, FP; Williams, MP; McHugh, KP; Brown, EJ				Blystone, SD; Lindberg, FP; Williams, MP; McHugh, KP; Brown, EJ			Inducible tyrosine phosphorylation of the beta(3) integrin requires the alpha(v) integrin cytoplasmic tail	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NPXY MOTIF; ENDOTHELIAL-CELLS; RESPIRATORY BURST; PROTEIN CD47; IN-VIVO; DOMAIN; VITRONECTIN; ALPHA-V-BETA-3; FIBRONECTIN; ADHESION	We have found that the integrin pa chain can be phosphorylated on tyrosine residues in K562 cells transfected with alpha(v) beta(3). Tyrosine phosphorylation of the beta(3) cytoplasmic tail is induced by adhesion to alpha(v) beta(3)-specific ligand or antibody or by incubation in manganese-containing buffer, Under the same conditions, beta(5) does not become tyrosine-phosphorylated in K562 transfected with alpha(v) beta(5). Phosphorylation of the beta(3) subunit requires the simultaneous presence of the alpha(v) subunit cytoplasmic tail, because neither the alpha(IIb) subunit nor a truncated alpha(v) subunit is sufficient to permit phosphorylation of beta(3), when coexpressed as a heterodimer with beta(3). Finally, tyrosine phosphorylation of the beta(3) cytoplasmic tail occurs on both human and murine beta(3) and is inducible in the ovarian carcinoma OV10 as well, independent of expression of integrin-associated protein (CD47), Tyrosine phosphorylation of the beta(3) integrin subunit facilitates association of Grb-2, an adaptor protein leading to activation of the Ras signaling pathway, and may contribute to the unique functional and signaling capabilities of alpha(v) beta(3).	WASHINGTON UNIV,SCH MED,DEPT MED,DIV INFECT DIS,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)					NIAID NIH HHS [AI24674, AI08990-02] Funding Source: Medline; NIAMS NIH HHS [F32 AR008335] Funding Source: Medline; NIGMS NIH HHS [GM38330] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024674, R37AI024674] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [F32AR008335] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038330] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANESKIEVICH BJ, 1991, ONCOGENE, V6, P1381; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BLYSTONE SD, 1995, J CELL BIOL, V130, P745, DOI 10.1083/jcb.130.3.745; BLYSTONE SD, 1994, J CELL BIOL, V127, P1129, DOI 10.1083/jcb.127.4.1129; BROWN EJ, 1991, RECEPTORS EXTRACELLU, P39; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; CHEN YP, 1995, BLOOD, V86, P2606, DOI 10.1182/blood.V86.7.2606.bloodjournal8672606; COOPER D, 1995, P NATL ACAD SCI USA, V92, P3978, DOI 10.1073/pnas.92.9.3978; DELANNET M, 1994, DEVELOPMENT, V120, P2687; FELDINGHABERMANN B, 1992, J CLIN INVEST, V89, P2018, DOI 10.1172/JCI115811; FILARDO EJ, 1995, J CELL BIOL, V130, P441, DOI 10.1083/jcb.130.2.441; Gao AG, 1996, J BIOL CHEM, V271, P21, DOI 10.1074/jbc.271.1.21; HIRST R, 1986, P NATL ACAD SCI USA, V83, P6470, DOI 10.1073/pnas.83.17.6470; JOHANSSON MW, 1994, J CELL BIOL, V126, P1299, DOI 10.1083/jcb.126.5.1299; LAFRENIE RM, 1992, CANCER RES, V52, P2202; Law DA, 1996, J BIOL CHEM, V271, P10811, DOI 10.1074/jbc.271.18.10811; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; NIP J, 1992, J CLIN INVEST, V90, P1406, DOI 10.1172/JCI116007; OTOOLE TE, 1995, J BIOL CHEM, V270, P8553, DOI 10.1074/jbc.270.15.8553; PIALI L, 1995, J CELL BIOL, V130, P451, DOI 10.1083/jcb.130.2.451; PRIGENT SA, 1995, J BIOL CHEM, V270, P22097, DOI 10.1074/jbc.270.38.22097; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; REINHOLD MI, 1995, J CELL SCI, V108, P3419; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARTZ MA, 1993, J CELL BIOL, V120, P1003, DOI 10.1083/jcb.120.4.1003; SCHWARTZ MA, 1993, J BIOL CHEM, V268, P19931; SEFTOR REB, 1992, P NATL ACAD SCI USA, V89, P1557, DOI 10.1073/pnas.89.5.1557; SHATTIL SJ, 1995, J CELL BIOL, V131, P807, DOI 10.1083/jcb.131.3.807; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; WHITE MF, 1994, J BIOL CHEM, V269, P1; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; YLANNE J, 1995, J BIOL CHEM, V270, P9550; ZHOU MJ, 1995, J BIOL CHEM, V270, P13553, DOI 10.1074/jbc.270.22.13553; ZHOU MJ, 1993, J EXP MED, V178, P1165, DOI 10.1084/jem.178.4.1165	37	60	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31458	31462		10.1074/jbc.271.49.31458	http://dx.doi.org/10.1074/jbc.271.49.31458			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940158				2022-12-25	WOS:A1996VW68600069
J	DavisSmyth, T; Duncan, RC; Zheng, T; Michelotti, G; Levens, D				DavisSmyth, T; Duncan, RC; Zheng, T; Michelotti, G; Levens, D			The far upstream element-binding proteins comprise an ancient family of single-strand DNA-binding transactivators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RICH ACTIVATION MOTIF; TRANSCRIPTION FACTOR; RNA-BINDING; C-MYC; FOS PROTEINS; NUCLEIC-ACID; KH DOMAIN; REPLICATION; EXPRESSION; PROMOTER	The cloning and expression of two new human cDNAs encoding proteins highly related to the far upstream element-binding protein (FBP) are described, FBP, FBP2, and FBP3 comprise a family of single-strand DNA-binding proteins that possess all of the general features of more conventional transcription factors. The FBPs each bind sequence specifically to only one strand of the far upstream element (FUSE; originally identified upstream of c-myc), and each possesses potent activation domains when fused to the GAL4 DNA-binding domain and assayed by transient transfection. Typical of transcription factors, the proteins are most highly related in their central, DNA-binding domains, but extensive homology is also shared within the tyrosine-rich, carboxyl-terminal activation domains. Comparison with Gen Bank sequences revealed a fourth FBP family member encoded by Caenorhabditis elegans chromosome III, illustrating the high degree of homology in this evolutionarily ancient and conserved family.	NCI, PATHOL LAB, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Duncan, Robert/I-8168-2015; Levens, David/C-9216-2009	Duncan, Robert/0000-0001-8409-2501; Levens, David/0000-0002-7616-922X; , Gregory/0000-0002-3936-4675				ALTIOK S, 1993, MOL CELL BIOL, V13, P7303, DOI 10.1128/MCB.13.12.7303; ASHLEY CT, 1993, SCIENCE, V262, P563, DOI 10.1126/science.7692601; ATTARDI LD, 1993, GENE DEV, V7, P1341, DOI 10.1101/gad.7.7b.1341; AVIGAN MI, 1990, J BIOL CHEM, V265, P18538; BAZAR L, 1995, ONCOGENE, V10, P2229; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P1257, DOI 10.1128/MCB.12.3.1257; CHEN LL, 1993, CELL GROWTH DIFFER, V4, P975; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Duncan R, 1996, MOL CELL BIOL, V16, P2274; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FARINA AR, 1993, J BIOL CHEM, V268, P26466; GARTE SJ, 1993, CRIT REV ONCOGENESIS, V4, P435; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; GIBSON TJ, 1993, FEBS LETT, V324, P361, DOI 10.1016/0014-5793(93)80152-K; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HOLLOWAY JM, 1995, GENE DEV, V9, P1992, DOI 10.1101/gad.9.16.1992; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MEIJER D, 1992, NUCLEIC ACIDS RES, V20, P2241, DOI 10.1093/nar/20.9.2241; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; Michelotti GA, 1996, MOL CELL BIOL, V16, P2656, DOI 10.1128/mcb.16.6.2656; NAKAI A, 1993, MOL CELL BIOL, V13, P1983, DOI 10.1128/MCB.13.4.1983; PRINS J, 1993, ANTICANCER RES, V13, P1373; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; ROBERTS RJ, 1995, CELL, V82, P9, DOI 10.1016/0092-8674(95)90046-2; RUDDLE FH, 1994, ANNU REV GENET, V28, P423, DOI 10.1146/annurev.ge.28.120194.002231; RYSECK RP, 1991, ONCOGENE, V6, P533; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIOMI H, 1994, CELL, V77, P33, DOI 10.1016/0092-8674(94)90232-1; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TOMONAGA T, 1995, J BIOL CHEM, V270, P4875, DOI 10.1074/jbc.270.9.4875; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; WADA KN, 1992, NUCLEIC ACIDS RES, V20, P2111, DOI 10.1093/nar/20.suppl.2111; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L	41	128	132	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31679	31687		10.1074/jbc.271.49.31679	http://dx.doi.org/10.1074/jbc.271.49.31679			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940189	hybrid			2022-12-25	WOS:A1996VW68600100
J	Li, HH; Quinn, J; Culler, D; GirardBascou, J; Merchant, S				Li, HH; Quinn, J; Culler, D; GirardBascou, J; Merchant, S			Molecular genetic analysis of plastocyanin biosynthesis in Chlamydomonas reinhardtii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC TOBACCO PLANTS; MESSENGER-RNA STABILITY; PROTEIN-TRANSPORT; TRANSCRIPTIONAL REGULATION; THYLAKOID MEMBRANE; NONSENSE MUTATIONS; PEA PLASTOCYANIN; OXYGEN EVOLUTION; EXPRESSION; COPPER	Five plastocyanin-deficient mutants were identified from a population of W-mutagenized Chlamydomonas reinhardtii cells, Genetic complementation experiments indicated that four mutants represented alleles at the PCY1 locus (pcy1-2, pcy1-3, pcy1-4, and pcy1-5), Sequence analysis confirmed that two strains, pcy1-2 and pcy1-3, carry a frameshift (-1) and a nonsense mutation, respectively, while strains pcy1-4 and pcy1-5 synthesize an extended protein as a result of read-through mutations at the stop codon, The C-terminal extension does not affect synthesis or processing of the pre-proteins, but the polypeptides are rapidly degraded after the second (lumenal) processing event, The frameshift mutation in pcy1-2 results in loss of Pcy1 mRNA, as noted previously for strain ac208 (pcy1-1), but the abundance of Pcy1 mRNA in strain pcy1-3, which carries a nonsense mutation at codon 26, is unaffected relative to wild-type cells, The decreased abundance of frameshifted Pcy1 mRNA is attributed to increased degradation rather than decreased synthesis, since the mRNAs can be stabilized by treatment of cells with cycloheximide or anisomycin, The fifth strain has a wild-type plastocyanin-encoding gene, but the strain accumulates apoplastocyanin at the expense of holoplastocyanin. We suggest that the mutation identifies a new locus (PCY2) whose function is required for normal holoplastocyanin accumulation, Like ac208 (pcy1-1), several of the new mutants were suppressed spontaneously owing to accumulation of cytochrome c(6) (a functional substitute for plastocyanin), The suppressor mutation(s) displayed Mendelian inheritance and segregated independently from the PCY1 locus, which confirms that regulation of Cyc6 expression is not tightly linked to plastocyanin function.	UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90095; INST BIOL PHYSICOCHIM,SERV PHOTOSYNTH,F-75005 PARIS,FRANCE	University of California System; University of California Los Angeles					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [K04GM000594] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 00594] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER EJ, 1993, NUCLEIC ACIDS RES, V21, P2237, DOI 10.1093/nar/21.9.2237; BARKAN A, 1995, PHYSIOL PLANTARUM, V93, P163, DOI 10.1034/j.1399-3054.1995.930123.x; BARKAN A, 1993, PLANT CELL, V5, P389, DOI 10.1105/tpc.5.4.389; BARTSEVICH VV, 1995, EMBO J, V14, P1845, DOI 10.1002/j.1460-2075.1995.tb07176.x; BEELMAN CA, 1994, J BIOL CHEM, V269, P9687; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; Bennoun P, 1982, METHODS CHLOROPLAST, P25; BOVY A, 1992, MOL MICROBIOL, V6, P1507, DOI 10.1111/j.1365-2958.1992.tb00871.x; CHEN LY, 1992, J BIOL CHEM, V267, P20100; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; Cline K, 1996, ANNU REV CELL DEV BI, V12, P1, DOI 10.1146/annurev.cellbio.12.1.1; ERICKSON JM, 1996, OXYGENIC PHOTOSYNTHE, P589; FISSCHER U, 1994, PLANT MOL BIOL, V26, P873, DOI 10.1007/BF00028855; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; GOLDSCHMIDTCLERMONT M, 1986, J MOL BIOL, V191, P421, DOI 10.1016/0022-2836(86)90137-3; GOLDSCHMIDTCLERMONT M, 1990, MOL GEN GENET, V223, P417, DOI 10.1007/BF00264448; GORMAN DS, 1965, P NATL ACAD SCI USA, V54, P1665, DOI 10.1073/pnas.54.6.1665; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; HILL KL, 1991, J BIOL CHEM, V266, P15060; HOWE G, 1995, MOL GEN GENET, V246, P156, DOI 10.1007/BF00294678; HOWE G, 1993, P NATL ACAD SCI USA, V90, P1862, DOI 10.1073/pnas.90.5.1862; HOWE G, 1992, EMBO J, V11, P2789, DOI 10.1002/j.1460-2075.1992.tb05346.x; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; KINDLE KL, 1989, J CELL BIOL, V109, P2589, DOI 10.1083/jcb.109.6.2589; KIRWIN PM, 1988, J BIOL CHEM, V263, P18128; KOIDE S, 1993, BIOCHEMISTRY-US, V32, P12299, DOI 10.1021/bi00097a005; LAST DI, 1990, PLANT MOL BIOL, V14, P229, DOI 10.1007/BF00018563; LEE MH, 1992, J BACTERIOL, V174, P4324, DOI 10.1128/JB.174.13.4324-4330.1992; LI HH, 1995, J BIOL CHEM, V270, P23504, DOI 10.1074/jbc.270.40.23504; LI HH, 1992, J BIOL CHEM, V267, P9368; LI HM, 1990, P NATL ACAD SCI USA, V87, P6748, DOI 10.1073/pnas.87.17.6748; Li JM, 1996, PLANT MOL BIOL, V30, P15, DOI 10.1007/BF00017800; LOSSON R, 1979, P NATL ACAD SCI USA, V76, P5134, DOI 10.1073/pnas.76.10.5134; MAQUAT LE, 1981, CELL, V27, P543, DOI 10.1016/0092-8674(81)90396-2; MAYFIELD SP, 1987, EMBO J, V6, P313, DOI 10.1002/j.1460-2075.1987.tb04756.x; MERCHANT S, 1987, EMBO J, V6, P2531, DOI 10.1002/j.1460-2075.1987.tb02540.x; MERCHANT S, 1986, MOL CELL BIOL, V6, P462, DOI 10.1128/MCB.6.2.462; MERCHANT S, 1991, EMBO J, V10, P1383, DOI 10.1002/j.1460-2075.1991.tb07658.x; MERCHANT S, 1990, J BIOL CHEM, V265, P12372; MERCHANT S, 1986, J BIOL CHEM, V261, P5850; MERCHANT S, 1997, IN PRESS METAL IONS; NIELSEN PS, 1993, EUR J BIOCHEM, V217, P97, DOI 10.1111/j.1432-1033.1993.tb18223.x; NILSSON G, 1987, P NATL ACAD SCI USA, V84, P4890, DOI 10.1073/pnas.84.14.4890; PWEE KH, 1993, PLANT J, V3, P437, DOI 10.1046/j.1365-313X.1993.t01-22-00999.x; QUINN J, 1993, J BIOL CHEM, V268, P7832; REDINBO MR, 1994, J BIOENERG BIOMEMBR, V26, P49, DOI 10.1007/BF00763219; ROBINSON C, 1994, PLANT MOL BIOL, V26, P15, DOI 10.1007/BF00039516; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SCHMIDT GW, 1977, P NATL ACAD SCI USA, V74, P610, DOI 10.1073/pnas.74.2.610; SIMPSON SB, 1994, MOL CELL BIOL, V14, P1835, DOI 10.1128/MCB.14.3.1835; SMEEKENS S, 1990, TRENDS BIOCHEM SCI, V15, P73, DOI 10.1016/0968-0004(90)90180-J; TAUTZ D, 1983, ANAL BIOCHEM, V132, P14, DOI 10.1016/0003-2697(83)90419-0; THOMPSON WF, 1991, ANNU REV PLANT PHYS, V42, P423, DOI 10.1146/annurev.pp.42.060191.002231; URLAUB G, 1989, MOL CELL BIOL, V9, P2868, DOI 10.1128/MCB.9.7.2868; VOELKER R, 1995, EMBO J, V14, P3905, DOI 10.1002/j.1460-2075.1995.tb00062.x; VORST O, 1993, PLANT J, V4, P933, DOI 10.1046/j.1365-313X.1993.04060933.x; WYNN RM, 1988, BIOCHEMISTRY-US, V27, P5863, DOI 10.1021/bi00416a007; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632; YUAN JG, 1994, SCIENCE, V266, P796, DOI 10.1126/science.7973633	60	27	27	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31283	31289		10.1074/jbc.271.49.31283	http://dx.doi.org/10.1074/jbc.271.49.31283			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940133	hybrid			2022-12-25	WOS:A1996VW68600044
J	Macalma, T; Otte, J; Hensler, ME; Bockholt, SM; Louis, HA; KalffSuske, M; Grzeschik, KH; vonderAhe, D; Beckerle, MC				Macalma, T; Otte, J; Hensler, ME; Bockholt, SM; Louis, HA; KalffSuske, M; Grzeschik, KH; vonderAhe, D; Beckerle, MC			Molecular characterization of human zyxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROFILAMENT PROTEIN VASP; GLYCOPROTEIN-IIB-IIIA; ACTIN-BASED MOTILITY; RICH FOCAL ADHESION; TYROSINE PHOSPHORYLATION; LISTERIA-MONOCYTOGENES; REGIONAL LOCALIZATION; SIGNAL-TRANSDUCTION; LIM DOMAIN; SEQUENCE	Zyxin is a component of adhesion plaques that has been suggested to perform regulatory functions at these specialized regions of the plasma membrane, Here we describe the isolation and characterization of cDNAs encoding human and mouse zyxin. Both the human and mouse zyxin proteins display a collection of proline-rich sequences as well as three copies of the LIM domain, a zinc finger domain found in many signaling molecules. The human zyxin protein is closely related in sequence to proteins implicated in benign tumorigenesis and steroid receptor binding. Antibodies raised against human zyxin recognize an 84-kDa protein by Western immunoblot analysis. The protein is localized at focal contacts in adherent erythroleukemia cells. By Northern analysis, we show that zyxin is widely expressed in human tissues. The zyxin gene maps to human chromosome 7q32-q36.	UNIV UTAH, DEPT BIOL, SALT LAKE CITY, UT 84112 USA; MAX PLANCK INST, KERCKHOFF KLIN, HEMOSTASIS RES UNIT, D-61231 BAD NAUHEIM, GERMANY; UNIV MARBURG, MED CTR HUMAN GENET, D-35037 MARBURG, GERMANY	Utah System of Higher Education; University of Utah; Kerckhoff Clinic; Max Planck Society; Philipps University Marburg					NCI NIH HHS [CA42014] Funding Source: Medline; NHLBI NIH HHS [HL41553] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041553] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADZHUBEI AA, 1993, J MOL BIOL, V229, P472, DOI 10.1006/jmbi.1993.1047; ARBER S, 1994, CELL, V79, P221, DOI 10.1016/0092-8674(94)90192-9; ASHAR HR, 1995, CELL, V82, P57; BECKERLE MC, 1986, J CELL BIOL, V103, P1679, DOI 10.1083/jcb.103.5.1679; BECKERLE MC, 1984, J CELL BIOL, V98, P2126, DOI 10.1083/jcb.98.6.2126; BOYLE JM, 1992, GENOMICS, V12, P693, DOI 10.1016/0888-7543(92)90296-5; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CRAWFORD AW, 1991, J BIOL CHEM, V266, P5847; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; CROCE CM, 1974, J EXP MED, V140, P1221, DOI 10.1084/jem.140.5.1221; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOMANN E, 1992, EMBO J, V11, P1981, DOI 10.1002/j.1460-2075.1992.tb05252.x; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; FEUERSTEIN R, 1994, P NATL ACAD SCI USA, V91, P10655, DOI 10.1073/pnas.91.22.10655; *GEN COMP GROUP, 1994, PROGR MAN GCG SEQ AN; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; HAFFNER C, 1995, EMBO J, V14, P19, DOI 10.1002/j.1460-2075.1995.tb06971.x; HALBRUGGE M, 1989, EUR J BIOCHEM, V185, P41, DOI 10.1111/j.1432-1033.1989.tb15079.x; Hobert O, 1996, ONCOGENE, V12, P1577; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KOCKS C, 1992, CELL, V68, P521, DOI 10.1016/0092-8674(92)90188-I; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASA I, 1995, MOL MICROBIOL, V18, P425, DOI 10.1111/j.1365-2958.1995.mmi_18030425.x; Lasa I, 1996, TRENDS CELL BIOL, V6, P109, DOI 10.1016/0962-8924(96)81001-4; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LUERSSEN H, 1990, GENOMICS, V8, P324, DOI 10.1016/0888-7543(90)90289-7; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; PEREZALVARADO GC, 1994, NAT STRUCT BIOL, V1, P388, DOI 10.1038/nsb0694-388; PETIT MMR, 1996, IN PRESS GENOMICS; PISTOR S, 1994, EMBO J, V13, P758, DOI 10.1002/j.1460-2075.1994.tb06318.x; PISTOR S, 1995, CURR BIOL, V5, P517, DOI 10.1016/S0960-9822(95)00104-7; REINHARD M, 1995, P NATL ACAD SCI USA, V92, P7956, DOI 10.1073/pnas.92.17.7956; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROMMENS JM, 1988, AM J HUM GENET, V43, P645; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; SCHNURCH H, 1993, DEVELOPMENT, V119, P957; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; SCHUURMAN R, 1991, BIOTECHNIQUES, V10, P185; Shattil SJ, 1991, CURR OPIN CELL BIOL, V3, P869, DOI 10.1016/0955-0674(91)90062-4; SHATTIL SJ, 1994, CURR OPIN CELL BIOL, V6, P695, DOI 10.1016/0955-0674(94)90096-5; SOUTHWICK FS, 1994, P NATL ACAD SCI USA, V91, P5168, DOI 10.1073/pnas.91.11.5168; SPANAKIS E, 1993, NUCLEIC ACIDS RES, V21, P3809, DOI 10.1093/nar/21.16.3809; STRYER L, 1967, P NATL ACAD SCI USA, V58, P719, DOI 10.1073/pnas.58.2.719; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; Tilney Lewis G., 1993, Trends in Microbiology, V1, P25, DOI 10.1016/0966-842X(93)90021-I; VORTKAMP A, 1991, GENOMICS, V11, P737, DOI 10.1016/0888-7543(91)90082-P; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; WOLFFE AP, 1994, SCIENCE, V264, P1100, DOI 10.1126/science.8178167; WU RY, 1994, J BIOL CHEM, V269, P25085; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0	58	97	108	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31470	31478		10.1074/jbc.271.49.31470	http://dx.doi.org/10.1074/jbc.271.49.31470			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940160	hybrid			2022-12-25	WOS:A1996VW68600071
J	Chin, D; Means, AR				Chin, D; Means, AR			Methionine to glutamine substitutions in the C-terminal domain of calmodulin impair the activation of three protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; SEQUENCE-INDEPENDENT RECOGNITION; TARGET ENZYMES; CENTRAL HELIX; ALPHA-HELICES; CALCIUM; BINDING; FRAGMENTS; PEPTIDE; PARAMETERS	The 9 methionine residues of vertebrate calmodulin (CaM) were individually changed to glutamine residues in order to investigate their roles in enzyme binding and activation. The mutant proteins showed three classes of effect on the activation of smooth muscle myosin light chain kinase, CaM-dependent protein kinase II alpha, and CaM-dependent protein kinase IV. First, some mutations had no appreciable effect on the ability of CaM to activate the three protein kinases. Included in this category were glutamine substitutions at residues 36 and 51 in the N-terminal domain, at residue 76 in the domain linker sequence, and at residues 144 and 145 in the C-terminal domain. Second, glutamine substitutions in the N-terminal domain of CaM, particularly those at positions 71 and 72, lowered the maximal activity of smooth muscle myosin light chain kinase while having no effect on the other two enzymes. Finally the affinity of CaM for all three enzymes was lowered by glutamine mutations at the neighboring methionines 109 and 124, located on a solvent-accessible surface of the C-terminal domain of Ca2+/CaM. This last result provides the first demonstration of the involvement of the same hydrophobic groups in the high affinity binding of CaM to three different enzymes.	DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710	Duke University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033976] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-33976] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005; BLUMENTHAL DK, 1982, BIOCHEMISTRY-US, V21, P2386, DOI 10.1021/bi00539a017; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAKRABARTTY A, 1995, ADV PROTEIN CHEM, V46, P141, DOI 10.1016/S0065-3233(08)60334-4; CHATTOPADHYAYA R, 1992, J MOL BIOL, V228, P1177, DOI 10.1016/0022-2836(92)90324-D; COX JA, 1988, BIOCHEM J, V249, P621, DOI 10.1042/bj2490621; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; CRUZALEGUI FH, 1992, P NATL ACAD SCI USA, V89, P12127, DOI 10.1073/pnas.89.24.12127; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; FAUCHERE JL, 1983, EUR J MED CHEM, V18, P369; GELLMAN SH, 1991, BIOCHEMISTRY-US, V30, P6633, DOI 10.1021/bi00241a001; GEORGE SE, 1990, J BIOL CHEM, V265, P9228; GEORGE SE, 1993, J BIOL CHEM, V268, P25213; GEORGE SE, 1996, BIOCHEMISTRY-US, V35, P3807; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; GUERINI D, 1987, EUR J BIOCHEM, V170, P35, DOI 10.1111/j.1432-1033.1987.tb13664.x; GUERINI D, 1984, J BIOL CHEM, V259, P5172; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; Johnson JD, 1996, J BIOL CHEM, V271, P761, DOI 10.1074/jbc.271.2.761; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; KINCAID RL, 1986, P NATL ACAD SCI USA, V83, P1193, DOI 10.1073/pnas.83.5.1193; KLEVIT RE, 1983, METHOD ENZYMOL, V102, P82; LAPORTE DC, 1980, BIOCHEMISTRY-US, V19, P3814, DOI 10.1021/bi00557a025; MAMARBACHI A, 1987, CELL CALCIUM, V8, P473, DOI 10.1016/0143-4160(87)90030-3; MATSUSHIMA S, 1994, BIOCHEM BIOPH RES CO, V202, P1329, DOI 10.1006/bbrc.1994.2076; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1995, NAT STRUCT BIOL, V2, P943, DOI 10.1038/nsb1195-943; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MILOS M, 1987, J BIOL CHEM, V262, P2746; MINOWA O, 1988, J BIOCHEM-TOKYO, V103, P531, DOI 10.1093/oxfordjournals.jbchem.a122303; Nakashima K, 1996, BIOCHEMISTRY-US, V35, P5602, DOI 10.1021/bi952586l; NEWTON DL, 1987, METHOD ENZYMOL, V139, P405; NEWTON DL, 1984, J BIOL CHEM, V259, P4419; OHYA Y, 1994, GENETICS, V138, P1041; OLSON NJ, 1990, P NATL ACAD SCI USA, V87, P2284, DOI 10.1073/pnas.87.6.2284; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PERSECHINI A, 1989, J BIOL CHEM, V264, P8052; TANAKA M, 1995, EMBO J, V14, P2839, DOI 10.1002/j.1460-2075.1995.tb07283.x; URBAUER JL, 1995, BIOCHEMISTRY-US, V34, P8099, DOI 10.1021/bi00025a016; VANBERKUM MFA, 1990, J BIOL CHEM, V265, P3750; VANBERKUM MFA, 1991, J BIOL CHEM, V266, P21488; VORHERR T, 1990, BIOCHEMISTRY-US, V29, P355, DOI 10.1021/bi00454a008; WALSH M, 1978, BIOCHEMISTRY-US, V17, P3924, DOI 10.1021/bi00612a006; WEBER PC, 1989, PROTEINS, V6, P70, DOI 10.1002/prot.340060107; WOJCIK J, 1990, BIOPOLYMERS, V30, P121, DOI 10.1002/bip.360300113; ZHANG M, 1995, NAT STRUCT BIOL, V2, P758, DOI 10.1038/nsb0995-758; ZHANG MJ, 1994, J BIOL CHEM, V269, P15546	49	66	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30465	30471		10.1074/jbc.271.48.30465	http://dx.doi.org/10.1074/jbc.271.48.30465			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940012	hybrid			2022-12-25	WOS:A1996VV15800029
J	Cohen, BD; Kiener, PA; Green, JM; Foy, L; Fell, HP; Zhang, K				Cohen, BD; Kiener, PA; Green, JM; Foy, L; Fell, HP; Zhang, K			The relationship between human epidermal growth-like factor receptor expression and cellular transformation in NIH3T3 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C-GAMMA; TYROSINE KINASE-ACTIVITY; EGF RECEPTOR; PROTO-ONCOGENE; INTERMOLECULAR ASSOCIATION; SIGNAL TRANSDUCTION; POINT MUTATION; TUMOR-CELLS; HEREGULIN; FAMILY	A collection of cell lines expressing each human epidermal growth factor receptor (HER) family member alone or in all pairwise combinations in a clone of NIH3T3 cells (3T3-7d) devoid of detectable epidermal growth factor receptor family members has been generated. Transformation, as measured by growth in soft agar, occurred only in the presence of appropriate ligand and only in cells expressing two different HER family members, Transfection of oncogenic neu (Tneu), conferred ligand-independent transformation only in cells which co-expressed HER1, HER3, or HER4, but not when expressed alone or with HERS, Cell lines were also tested for their ability to form tumors in animals, None of the cell lines expressing single HER family members was able to form tumors in animals with the exception of HER1, which was weakly tumorigenic. Although unable to form tumors when expressed alone, HERS was tumorigenic when expressed with HER1 or HER3, but not HER4. Of all complexes analyzed, cells expressing HER1 + HERS were the most aggressive, The relationship between HER1 activation, intracellular calcium fluxes, and phospholipase C gamma 1 activation is web established, We found that activation of HER1 was required for the induction of a calcium flux and the phosphorylation of phospholipase C gamma 1. These activities were independent of, and unaffected by, the co-expression of any other family member. Further, heregulin stimulation of all cell lines including those containing HER1 did not demonstrate any effect on intracellular calcium levels or phospholipase C gamma 1 phosphorylation, This demonstrates that heregulin induced cellular transformation by activating HER3- and HER4-containing complexes does not require the activation of either phospholipase C gamma 1 or the mobilization of intracellular calcium.	AMGEN INC, THOUSAND OAKS, CA 91320 USA	Amgen	Cohen, BD (corresponding author), BRISTOL MYERS SQUIBB CO, PHARMACEUT RES INST, DEPT MOL IMMUNOL, SEATTLE, WA 98121 USA.							BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BASELGA J, 1994, PHARMACOL THERAPEUT, V64, P127, DOI 10.1016/0163-7258(94)90036-1; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CARPENTER G, 1993, ADV SEC MESS PHOSPH, V28, P179; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; Chen XM, 1996, J BIOL CHEM, V271, P7620, DOI 10.1074/jbc.271.13.7620; Cohen BM, 1996, J BIOL CHEM, V271, P4813; CULOUSCOU JM, 1995, J BIOL CHEM, V270, P12857, DOI 10.1074/jbc.270.21.12857; Decker SJ, 1995, J BIOL CHEM, V270, P30841, DOI 10.1074/jbc.270.52.30841; DIEGEL ML, 1994, J BIOL CHEM, V269, P11409; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1990, MOL CELL BIOL, V10, P2749, DOI 10.1128/MCB.10.6.2749; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; GULLICK WJ, 1990, INT J CANCER, P55; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; JALLAL B, 1992, J BIOL CHEM, V267, P4357; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; QIAN XL, 1995, ONCOGENE, V10, P211; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1996, ONCOGENE, V12, P345; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SASADA R, 1993, BIOCHEM BIOPH RES CO, V190, P1173, DOI 10.1006/bbrc.1993.1173; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SIEGALL CB, 1995, J BIOL CHEM, V270, P7625, DOI 10.1074/jbc.270.13.7625; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VEIGL ML, 1983, BIOCHIM BIOPHYS ACTA, V738, P21, DOI 10.1016/0304-419X(84)90018-0; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; Zhang K, 1996, J BIOL CHEM, V271, P3884	56	100	104	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30897	30903		10.1074/jbc.271.48.30897	http://dx.doi.org/10.1074/jbc.271.48.30897			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940074	hybrid			2022-12-25	WOS:A1996VV15800091
J	Koshkin, V; Lotan, O; Pick, E				Koshkin, V; Lotan, O; Pick, E			The cytosolic component p47(phox) is not a sine qua non participant in the activation of NADPH oxidase but is required for optimal superoxide production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; RESPIRATORY BURST OXIDASE; ADENINE-DINUCLEOTIDE PHOSPHATE; CHRONIC GRANULOMATOUS-DISEASE; SODIUM DODECYL-SULFATE; SRC HOMOLOGY-3 DOMAINS; HUMAN-NEUTROPHILS; PLASMA-MEMBRANE; FLAVOCYTOCHROME B(558); ELECTRON FLOW	The superoxide (O-2(radical anion))-generating NADPH oxidase of phagocytes is a multicomponent complex consisting of a membrane-associated flavocytochrome (cytochrome b(559)), bearing the NADPH binding site and two redox centers (FAD and heme) and three cytosolic activating components: p47(phox), p67(phox), and the small GTPase Rac (1 or 2). The canonical view is that the induction of OX generation involves the stimulus-dependent assembly of all three cytosolic components with cytochrome b(559), a process mimicked in vitro by a cell-free system activated by anionic amphiphiles. We studied the requirement for individual cytosolic components in the activation of NADPH oxidase in a cell-free system consisting of purified and relipidated cytochrome b(559), recombinant p47(phox), p67(phox), and Rac1, and the amphiphile, lithium dodecyl sulfate. We found that pronounced activation of NADPH oxidase can be achieved by exposing cytochrome b(559) to p67(phox) and Rac1, in the total absence of p47(phox) (turnover = 60 mol O-2((radical anion))/mol cytochrome b(559)). However, maximal activation (turnover = 153 mol O-2((radical anion))/s/mol cytochrome b(559)) could only be obtained in the presence of p47(phox). O-2((radical anion)) production, in the absence of p47(phox), was dependent on: high molar ratios of p67(phox) and Rac1 to cytochrome b(559), Rac1 being in the GTP-bound form, cytochrome b(559) being saturated with FAD, and an optimal concentration of amphiphile. Single cytosolic components or combinations of two cytosolic components, other than p67(phox) and Rac1, were incapable of activation. We conclude that p67(phox) and Rac1 are the only cytosolic components directly involved in the induction of electron transport in cytochrome b(559). p47(phox) appears to facilitate or stabilize the interaction of p67(phox) and, possibly, Rac1 with cytochrome b(559), and is required for optimal generation of O-2((radical anion)) under physiological conditions.			Koshkin, V (corresponding author), TEL AVIV UNIV,SACKLER SCH MED,DEPT HUMAN MICROBIOL,IL-69978 TEL AVIV,ISRAEL.		Pick, Edgar/B-1795-2008	Pick, Edgar/0000-0003-4625-3233				ABO A, 1992, J BIOL CHEM, V267, P16767; ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BELLAVITE P, 1988, J BIOL CHEM, V263, P8210; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; CROSS AR, 1995, J BIOL CHEM, V270, P6543, DOI 10.1074/jbc.270.12.6543; CROSS AR, 1994, J BIOL CHEM, V269, P21448; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; DELEO FR, 1995, J BIOL CHEM, V270, P26246, DOI 10.1074/jbc.270.44.26246; DeLeo FR, 1996, J BIOL CHEM, V271, P17013, DOI 10.1074/jbc.271.29.17013; DELEO FR, 1995, P NATL ACAD SCI USA, V92, P7110, DOI 10.1073/pnas.92.15.7110; DEMENDEZ I, 1994, J BIOL CHEM, V269, P16326; deMendez I, 1996, EMBO J, V15, P1211, DOI 10.1002/j.1460-2075.1996.tb00462.x; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; DUSI S, 1995, BIOCHEM J, V308, P991, DOI 10.1042/bj3080991; FINAN P, 1994, J BIOL CHEM, V269, P13752; Freeman JL, 1996, J BIOL CHEM, V271, P22578, DOI 10.1074/jbc.271.37.22578; HEYNEMAN RA, 1984, J LEUKOCYTE BIOL, V36, P751, DOI 10.1002/jlb.36.6.751; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; HEYWORTH PG, 1994, J BIOL CHEM, V269, P30749; IYER SS, 1994, J BIOL CHEM, V269, P22405; JOUAN A, 1993, ANAL BIOCHEM, V214, P252, DOI 10.1006/abio.1993.1485; KNOLLER S, 1991, J BIOL CHEM, V266, P2795; KOSHKIN V, 1993, FEBS LETT, V327, P57, DOI 10.1016/0014-5793(93)81039-3; KOSHKIN V, 1994, FEBS LETT, V338, P285, DOI 10.1016/0014-5793(94)80285-8; KOSHKIN V, 1995, BBA-BIOENERGETICS, V1229, P329, DOI 10.1016/0005-2728(95)00009-8; KWONG CH, 1993, BIOCHEMISTRY-US, V32, P5711, DOI 10.1021/bi00072a029; LECABEC V, 1994, BIOCHEM BIOPH RES CO, V198, P1216, DOI 10.1006/bbrc.1994.1172; LETO TL, 1991, J BIOL CHEM, V266, P19812; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; LEUSEN JHW, 1995, J BIOL CHEM, V270, P11216, DOI 10.1074/jbc.270.19.11216; MCPHAIL LC, 1985, J CLIN INVEST, V75, P1735, DOI 10.1172/JCI111884; MCPHAIL LC, 1994, J EXP MED, V180, P2011, DOI 10.1084/jem.180.6.2011; NAUSEEF WM, 1993, J BIOL CHEM, V268, P23646; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; OKAMURA N, 1988, J BIOL CHEM, V263, P6777; PARK JW, 1992, J BIOL CHEM, V267, P17327; PRIGMORE E, 1995, J BIOL CHEM, V270, P10717, DOI 10.1074/jbc.270.18.10717; QUINN MT, 1993, J BIOL CHEM, V268, P20983; ROBINSON JM, 1995, HISTOCHEM CELL BIOL, V103, P163, DOI 10.1007/BF01454021; ROTROSEN D, 1993, J BIOL CHEM, V268, P14256; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; ROTROSEN D, 1990, J BIOL CHEM, V265, P8745; ROTROSEN D, 1992, INFLAMMATION BASIC P, P589; SHPUNGIN S, 1989, J BIOL CHEM, V264, P9195; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; THRASHER AJ, 1994, BBA-MOL BASIS DIS, V1227, P1, DOI 10.1016/0925-4439(94)90100-7; UHLINGER DJ, 1994, J BIOL CHEM, V269, P22095; WIENTJES FB, 1993, BIOCHEM J, V296, P557, DOI 10.1042/bj2960557; WOODMAN RC, 1991, J CLIN INVEST, V87, P1345, DOI 10.1172/JCI115138	51	133	134	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30326	30329		10.1074/jbc.271.48.30326	http://dx.doi.org/10.1074/jbc.271.48.30326			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8939991	hybrid			2022-12-25	WOS:A1996VV15800008
J	Kume, T; Watanabe, T; Sanokawo, R; Chida, D; Nakamura, T; Oishi, M				Kume, T; Watanabe, T; Sanokawo, R; Chida, D; Nakamura, T; Oishi, M			Expression of the protein tyrosine phosphatase beta 2 gene in mouse erythroleukemia cells induces terminal erythroid differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INVITRO DIFFERENTIATION; MOLECULAR-CLONING; MEL CELLS; INDUCTION; TRANSCRIPTION; KINASES; INHIBITORS; COMMITMENT; GENISTEIN	We have cloned cDNA for protein tyrosine phosphatase beta 2, which had been implicated in erythroid differentiation of mouse erythroleukemia cells. Expression of cDNA constructs, in which beta 2 cDNA is placed under the control of mouse metallothionein-I promoter, by ZnCl2, converted a significant portion (20 to 38%) of the cells to erythroid-like cells, which is 25-50% of the erythroid differentiation efficiency observed by conventional erythroid-inducing agents, Furthermore, introduction and expression of altered protein tyrosine phosphatase beta 2 cDNA constructs designed to produce the enzyme lacking the phosphatase activity inhibited erythroid differentiation by 100-20%, depending upon the concentration of erythroid-inducing agents employed. These results strongly suggest that protein tyrosine phosphatase beta 2 is involved in triggering erythroid differentiation in mouse erythroleukemia cells.	UNIV TOKYO,INST MOL & CELLULAR BIOSCI,BUNKYO KU,TOKYO 113,JAPAN; TOHOKU UNIV,INST DEV AGING & CANC,SENDAI,MIYAGI 980,JAPAN; SUMITOMO ELECT IND LTD,BIOMED RES & DEV DEPT,SAKAE KU,YOKOHAMA,KANAGAWA 244,JAPAN; NATL INST BIOSCI & HUMAN TECHNOL,TSUKUBA,IBARAKI 305,JAPAN	University of Tokyo; Tohoku University; Sumitomo Electric Industries; National Institute of Advanced Industrial Science & Technology (AIST)								APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; BOER PH, 1990, BIOCHEM GENET, V28, P299, DOI 10.1007/BF02401419; CHIDA D, 1995, FEBS LETT, V358, P233, DOI 10.1016/0014-5793(94)01432-Z; FIBACH E, 1977, CANCER RES, V37, P440; GUSELLA J, 1976, CELL, V9, P221, DOI 10.1016/0092-8674(76)90113-6; HONDA H, 1994, BLOOD, V84, P4186, DOI 10.1182/blood.V84.12.4186.bloodjournal84124186; IGARASHI K, 1995, P NATL ACAD SCI USA, V92, P7445, DOI 10.1073/pnas.92.16.7445; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KONDO K, 1989, J CELL BIOL, V109, P285, DOI 10.1083/jcb.109.1.285; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KUME T, 1994, J BIOL CHEM, V269, P4709; Kuramochi S, 1996, FEBS LETT, V378, P7, DOI 10.1016/0014-5793(95)01415-2; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MUNAKATA H, 1993, J BIOCHEM, V114, P103, DOI 10.1093/oxfordjournals.jbchem.a124123; OISHI M, 1990, MECHANISM DIFFERENTI, V2, P129; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; ORKIN SH, 1975, P NATL ACAD SCI USA, V72, P98, DOI 10.1073/pnas.72.1.98; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; THOMAS ML, 1993, PROG IMMUNOL, V8, P213; THOMAS PE, 1994, J BIOL CHEM, V269, P19953; WATANABE T, 1991, CANCER RES, V51, P764; WATANABE T, 1992, EXP CELL RES, V199, P269, DOI 10.1016/0014-4827(92)90434-A; WATANABE T, 1995, GENOMICS, V29, P793, DOI 10.1006/geno.1995.9932; WATANABE T, 1989, EXP CELL RES, V183, P335, DOI 10.1016/0014-4827(89)90394-7; WATANABE T, 1992, CELL GROWTH DIFFER, V3, P865; WATANABE T, 1992, J BIOL CHEM, V67, P17116; YANG XH, 1991, CELL, V67, P661, DOI 10.1016/0092-8674(91)90062-4	29	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30916	30921		10.1074/jbc.271.48.30916	http://dx.doi.org/10.1074/jbc.271.48.30916			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940077	hybrid			2022-12-25	WOS:A1996VV15800094
J	Mellet, P; Michels, B; Bieth, JG				Mellet, P; Michels, B; Bieth, JG			Heat-induced conversion of ovalbumin into a proteinase inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-1-PROTEINASE INHIBITOR; MOLECULAR CHARACTERIZATION; CRYSTAL-STRUCTURE; ANTITHROMBIN-III; S-OVALBUMIN; SERPINS; ELASTASE; KINETICS; MODEL; ALPHA-1-ANTICHYMOTRYPSIN	Ovalbumin is a member of the serine proteinase inhibitor (serpin) family but is unable to inhibit proteinases. Here we show that heating transforms it into inhibitory ovalbumin (I-ovalbumin), a potent reversible competitive inhibitor of human neutrophil elastase (K-i = 5 nM) and cathepsin G (K-i = 60 nM) and bovine chymotrypsin (K-i = 30 nM). I-ovalbumin also inhibits bovine trypsin, porcine elastase and alpha-lytic proteinase with K-i values in the micromolar range, Thus, I-ovalbumin differs from active serpins by its inability to form irreversible complexes with proteinases. I-ovalbumin is unusually thermostable: it does not undergo any structural transition between 45 degrees C and 120 degrees C as tested by differential scanning calorimetry, and it retains full inhibitory capacity after heating at 120 degrees C. It has 8% less alpha-helices and 9% more beta-sheet structures than native ovalbumin, as shown by circular dichroism, Our results show that the primary sequence of ovalbumin contains the information required for enabling the first step of the serpin-proteinase interaction to occur, i.e. the formation of the Michaelis-like reversible complex, but does not contain the information needed for stabilizing this initial complex.	UNIV STRASBOURG 1,ENZYMOL LAB,INSERM U392,F-67400 ILLKIRCH GRAFFENS,FRANCE; UNIV STRASBOURG 1,LAB ULTRASONS & DYNAM FLUIDES COMPLEXES,CNRS URA 851,F-67070 STRASBOURG,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg				Mellet, Philippe/0000-0001-5499-9735				BEATTY K, 1980, J BIOL CHEM, V255, P3931; BELITZ HD, 1987, FOOD CHEM, P403; BIETH JG, 1995, METHOD ENZYMOL, V248, P59; BRUCH M, 1989, BIOCHEM J, V259, P929, DOI 10.1042/bj2590929; COUGHLIN P, 1993, P NATL ACAD SCI USA, V90, P9417, DOI 10.1073/pnas.90.20.9417; DONOVAN JW, 1976, J SCI FOOD AGR, V27, P197, DOI 10.1002/jsfa.2740270220; GOUX WJ, 1986, BIOCHEMISTRY-US, V25, P84, DOI 10.1021/bi00349a013; HUNKAPILLER MW, 1973, BIOCHEMISTRY-US, V12, P4733; HUNT LT, 1980, BIOCHEM BIOPH RES CO, V95, P864, DOI 10.1016/0006-291X(80)90867-0; HUNTINGTON JA, 1995, PROTEIN SCI, V4, P613; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; KINT S, 1979, BIOPOLYMERS, V18, P1073, DOI 10.1002/bip.1979.360180505; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; MARTODAM RR, 1979, PREP BIOCHEM, V9, P15, DOI 10.1080/00327487908061669; MAST AE, 1991, BIOCHEMISTRY-US, V30, P1723, DOI 10.1021/bi00220a039; NAKAMURA R, 1981, AGR BIOL CHEM TOKYO, V45, P1653, DOI 10.1080/00021369.1981.10864762; PATSTON PA, 1991, BIOCHEMISTRY-US, V30, P8876, DOI 10.1021/bi00100a022; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; PRIVALOV PL, 1980, PURE APPL CHEM, V52, P479, DOI 10.1351/pac198052020479; Rasmussen SK, 1996, PLANT MOL BIOL, V30, P673, DOI 10.1007/BF00049343; REMOLDODONNELL E, 1992, P NATL ACAD SCI USA, V89, P5635, DOI 10.1073/pnas.89.12.5635; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; SHIEH BH, 1989, J BIOL CHEM, V264, P13420; Shotton D. M., 1970, METHOD ENZYMOL, V19, P113, DOI 10.1016/0076-6879(70)19009-4; SMITH MB, 1965, AUST J BIOL SCI, V18, P365, DOI 10.1071/BI9650365; Song HK, 1995, FEBS LETT, V377, P150; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; WEI AZ, 1994, NAT STRUCT BIOL, V1, P251, DOI 10.1038/nsb0494-251; WRIGHT HT, 1995, PROTEINS, V22, P210, DOI 10.1002/prot.340220303; WRIGHT HT, 1990, J MOL BIOL, V213, P513; WRIGHT HT, 1984, J BIOL CHEM, V259, P4335	31	20	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30311	30314		10.1074/jbc.271.48.30311	http://dx.doi.org/10.1074/jbc.271.48.30311			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8939987	hybrid			2022-12-25	WOS:A1996VV15800004
J	Nakagawa, T; Higashiyama, S; Mitamura, T; Mekada, E; Taniguchi, N				Nakagawa, T; Higashiyama, S; Mitamura, T; Mekada, E; Taniguchi, N			Amino-terminal processing of cell surface heparin-binding epidermal growth factor-like growth factor up-regulates its juxtacrine but not its paracrine growth factor activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHTHERIA-TOXIN RECEPTOR; SMOOTH-MUSCLE CELLS; EGF-RECEPTOR; KIT-LIGAND; SIGNAL TRANSDUCTION; MITOGENIC ACTIVITY; PHORBOL ESTER; EXPRESSION; PROTEIN; TRANSMEMBRANE	Human heparin-binding epidermal growth factor (EGF)-like growth factor (HB-EGF) expressed on Chinese hamster ovary (CHO) cells is synthesized as a 19-kDa major, and 22- and 27-kDa minor, membrane-anchored precursors (proHB-EGF). In contrast, the 27-kDa species is major and the 19- and 22-kDa ones are minor in mouse proHB-EGF. The juxtacrine growth factor activities of human and mouse proHB-EGFs on CHO cells toward EP170.7 cells in co-culture are significantly different. To investigate the relationship between the juxtacrine growth factor activities and the molecular species, we prepared human-mouse chimeras. Chimeras that have the human amino-terminal sequence with a mouse EGF-like domain showed approximately 8 fold up-regulation of the juxtacrine growth factor activity and the predominance of a 19-22-kDa major species. In contrast, chimeras that have the mouse amino-terminal sequence with a human EGF-like domain showed approximately B-fold down-regulation of the juxtacrine activity and the predominance of the 27-kDa major species. A Gly(32)HB-EGF (117-amino acid form), which is amino-terminally extended, induced the same mitogenic activity as that of Arg(73)-HB-EGF (75-amino acid form), which is amino-terminally truncated. These results strongly suggested that amino-terminal processing of human proHB-EGF would be required for up-regulation of its juxtacrine growth factor activity, but not for its paracrine activity.	OSAKA UNIV,SCH MED,DEPT BIOCHEM,SUITA,OSAKA 565,JAPAN; KURUME UNIV,INST LIFE SCI,DIV CELL BIOL,KURUME,FUKUOKA 830,JAPAN; OSAKA UNIV,MICROBIAL DIS RES INST,DEPT MOL PROTOZOOL,SUITA,OSAKA 565,JAPAN	Osaka University; Kurume University; Osaka University			Taniguchi, Naoyuki/I-4182-2014; Taniguchi, Naoyuki/A-7086-2016	Taniguchi, Naoyuki/0000-0001-5889-5968; Mekada, Eisuke/0000-0001-8858-4781				ANKLESARIA P, 1990, P NATL ACAD SCI USA, V87, P3289, DOI 10.1073/pnas.87.9.3289; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BESNER G, 1990, CELL REGUL, V1, P811, DOI 10.1091/mbc.1.11.811; BLASBAND AJ, 1990, ONCOGENE, V5, P1213; BLOTNICK S, 1994, P NATL ACAD SCI USA, V91, P2890, DOI 10.1073/pnas.91.8.2890; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BRANNAN CI, 1991, P NATL ACAD SCI USA, V88, P4671, DOI 10.1073/pnas.88.11.4671; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAS SK, 1994, DEVELOPMENT, V120, P1071; DLUZ SM, 1993, J BIOL CHEM, V268, P18330; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; GOISHI K, 1995, MOL BIOL CELL, V6, P967, DOI 10.1091/mbc.6.8.967; HASHIMOTO K, 1994, J BIOL CHEM, V269, P20060; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1993, J CELL BIOL, V122, P933, DOI 10.1083/jcb.122.4.933; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; HIGASHIYAMA S, 1995, J CELL BIOL, V128, P929, DOI 10.1083/jcb.128.5.929; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; ITO N, 1994, BIOCHEM BIOPH RES CO, V198, P25, DOI 10.1006/bbrc.1994.1004; IWAMOTO R, 1994, EMBO J, V13, P2322, DOI 10.1002/j.1460-2075.1994.tb06516.x; KOMADA M, 1993, FEBS LETT, V328, P25, DOI 10.1016/0014-5793(93)80958-W; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MITAMURA T, 1995, J BIOL CHEM, V270, P1015, DOI 10.1074/jbc.270.3.1015; MITAMURA T, 1992, J CELL BIOL, V118, P1389, DOI 10.1083/jcb.118.6.1389; MIYAGAWA J, 1995, J CLIN INVEST, V95, P404, DOI 10.1172/JCI117669; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; NAKAMURA K, 1995, J CELL BIOL, V129, P1691, DOI 10.1083/jcb.129.6.1691; ONO M, 1994, J BIOL CHEM, V269, P31315; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; RAAB G, 1994, BIOCHEM BIOPH RES CO, V204, P592, DOI 10.1006/bbrc.1994.2500; Raab G, 1996, DEVELOPMENT, V122, P637; Sambrook J., 2002, MOL CLONING LAB MANU; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SHISHIDO Y, 1995, J BIOL CHEM, V270, P29578, DOI 10.1074/jbc.270.49.29578; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; STROOBANT P, 1985, CELL, V42, P383, DOI 10.1016/S0092-8674(85)80133-1; THOMPSON SA, 1994, J BIOL CHEM, V269, P2541; TOYODA H, 1995, J BIOL CHEM, V270, P7495, DOI 10.1074/jbc.270.13.7495; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3	42	31	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30858	30863		10.1074/jbc.271.48.30858	http://dx.doi.org/10.1074/jbc.271.48.30858			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940069	hybrid			2022-12-25	WOS:A1996VV15800086
J	Neddermann, P; Graziani, R; Ciliberto, G; Paonessa, G				Neddermann, P; Graziani, R; Ciliberto, G; Paonessa, G			Functional expression of soluble human interleukin-11 (IL-11) receptor alpha and stoichiometry of in vitro IL-11 receptor complexes with gp130	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CILIARY NEUROTROPHIC FACTOR; SIGNAL TRANSDUCER GP130; PHASE RESPONSE FACTOR; MOLECULAR-CLONING; TYROSINE PHOSPHORYLATION; HEMATOPOIETIC CYTOKINE; HEXAMERIC COMPLEX; FACTOR-BINDING; GROWTH-FACTORS; CNTF RECEPTOR	The interleukin-6 (IL-6) family of cytokines activates signaling through the formation of either gp130 homodimers, as for IL-6, or gp130-leukemia inhibitory factor receptor (LLFR) heterodimers as for ciliary neurotrophic factor (CNTF), leukemia inhibitory factor, oncostatin(M), and cardiotrophin-1. Recent in vitro studies with IL-6 and CNTF have demonstrated that higher order hexameric receptor complexes are assembled in which signaling chain dimerization is accompanied by the dimerization of both the cytokine molecule and its specific receptor alpha subunits (IL-6R alpha or CNTFR alpha, respectively), IL-11 is a member of the IL-6 family and known to require gp130 but not LIFR for signaling, In this study we investigate the functional and biochemical composition of the IL-11 receptor complex. The human IL-11 receptor alpha-chain was cloned from a human bone marrow cDNA library. IL-11R alpha was shown to confer IL-11 responsiveness to human hepatoma cells either by cDNA transfection or by adding a soluble form of the receptor (sHL11R alpha) expressed in the baculovirus system to the culture medium. Iii vitro immunoprecipitation experiments showed that sIL11R alpha specifically binds IL-11 and that binding is enhanced by gp130, Similarly to IL-6 and CNTF, gp130 is able to induce dimerization of the IL-11 . IL-11R alpha subcomplex, the result of which is the formation of a pentameric receptor complex, However, in contrast to the other two cytokines, IL-ll was unable to induce either gp130 homodimerization or gp130/LIFR heterodimerization. These results strongly suggest that an as yet unidentified receptor beta-chain is involved in IL-11 signaling.			Neddermann, P (corresponding author), IST RIC BIOL MOL P ANGELETTI,DEPT GENET,VIA PONTINA KM 30600,I-00040 POMEZIA,ROMA,ITALY.		Ciliberto, Gennaro/J-4131-2017	Ciliberto, Gennaro/0000-0003-2851-8605				AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ARCONE R, 1991, EUR J BIOCHEM, V198, P541, DOI 10.1111/j.1432-1033.1991.tb16048.x; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; CHEREL M, 1995, BLOOD, V86, P2534; CZUPRYN MJ, 1995, J BIOL CHEM, V270, P978, DOI 10.1074/jbc.270.2.978; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DESERIO A, 1995, J MOL BIOL, V254, P795, DOI 10.1006/jmbi.1995.0655; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; Heaney ML, 1996, BLOOD, V87, P847, DOI 10.1182/blood.V87.3.847.bloodjournal873847; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; HOCKE GM, 1992, MOL CELL BIOL, V12, P2282, DOI 10.1128/MCB.12.5.2282; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; LIU JW, 1992, J BIOL CHEM, V267, P16763; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MULLER G, 1988, EMBO J, V7, P2723, DOI 10.1002/j.1460-2075.1988.tb03126.x; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; Nandurkar HH, 1996, ONCOGENE, V12, P585; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; NEUHAUS H, 1994, DEV BIOL, V166, P531, DOI 10.1006/dbio.1994.1335; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; PAUL SR, 1990, P NATL ACAD SCI USA, V87, P7512, DOI 10.1073/pnas.87.19.7512; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; STAHL N, 1993, J BIOL CHEM, V268, P7628; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WARD LD, 1994, J BIOL CHEM, V269, P23286; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YANG YC, 1993, STEM CELLS, V11, P474, DOI 10.1002/stem.5530110617; YIN TG, 1993, J IMMUNOL, V151, P2555; YIN TG, 1993, CELL GROWTH DIFFER, V4, P603; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	48	41	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30986	30991		10.1074/jbc.271.48.30986	http://dx.doi.org/10.1074/jbc.271.48.30986			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940087	hybrid			2022-12-25	WOS:A1996VV15800104
J	Ohyama, Y; Ozono, K; Uchida, M; Yoshimura, M; Shinki, T; Suda, T; Yamamoto, O				Ohyama, Y; Ozono, K; Uchida, M; Yoshimura, M; Shinki, T; Suda, T; Yamamoto, O			Functional assessment of two vitamin D-responsive elements in the rat 25-hydroxyvitamin D-3 24-hydroxylase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-RECEPTOR; OSTEOCALCIN GENE; 1,25-DIHYDROXYVITAMIN-D3 RECEPTOR; IDENTIFICATION; EXPRESSION; PROMOTER; DNA; HORMONE; BINDING; KIDNEY	Two vitamin D-responsive elements (VDRE-1 and VDRE-2) were recently identified in the 5'-upstream region of the rat 25-hydroxyvitamin D-3 24-hydroxylase gene at -151/-137 and -259/-245, respectively. We studied the transcriptional regulation of this gene by vitamin D by means of mutational analysis. Introducing mutations into VDRE-1 and VDRE-2 in the native promoter -291/+9 reduced vitamin D-dependent chloramphenicol acetyltransferase activity by 86 and 41%, respectively. Mutation of the direct repeat -169/-155 located at 3 base pairs upstream of VDRE-1 also caused 50% decrease of chloramphenicol acetyltransferase activity. Connection of the element -169/-155 to VDRE-1 enhanced the vitamin D responsiveness of VDRE-1 5-fold through the heterologous beta-globin promoter. The fragment -291/-102 containing the two VDREs showed two shifted bands in the presence of the vitamin D receptor and retinoid X receptor in gel retardation analysis, and the appearance of the slower migrating band indicates that two sets of receptor complexes bind to this fragment simultaneously. These results demonstrate that VDRE-1 is a stronger mediator of vitamin D function than VDRE-2 due to the presence of the accessory element -169/-155 located adjacent to VDRE-1, although VDRE-2 exhibits a smaller dissociation constant for the vitamin D receptor-retinoid X receptor complex than VDRE-1.	OSAKA MED CTR MATERNAL & CHILD HLTH, IZUMI, OSAKA 59002, JAPAN; KUREHA CHEM IND CO LTD, BIOMED RES LABS, SHINJYUKU KU, TOKYO 169, JAPAN; SHOWA UNIV, SCH DENT, DEPT BIOCHEM, SHINAGAWA KU, TOKYO 142, JAPAN	Showa University	Ohyama, Y (corresponding author), HIROSHIMA UNIV, FAC SCI, GRAD DEPT GENE SCI, 1-3-1 KAGAMIYAMA, HIGASHIHIROSHIMA 739, JAPAN.							BROMMAGE R, 1985, ENDOCR REV, V6, P491, DOI 10.1210/edrv-6-4-491; CHEN KS, 1995, BBA-GENE STRUCT EXPR, V1263, P1, DOI 10.1016/0167-4781(95)00060-T; DELUCA HF, 1988, FASEB J, V2, P224, DOI 10.1096/fasebj.2.3.3280376; DEMAY MB, 1990, P NATL ACAD SCI USA, V87, P369, DOI 10.1073/pnas.87.1.369; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GILL RK, 1993, P NATL ACAD SCI USA, V90, P2984, DOI 10.1073/pnas.90.7.2984; HAHN CN, 1994, NUCLEIC ACIDS RES, V22, P2410, DOI 10.1093/nar/22.12.2410; HAUSSLER MR, 1988, RECENT PROG HORM RES, V44, P263; HERSCHLAG D, 1993, GENE DEV, V7, P173, DOI 10.1101/gad.7.2.173; IIDA K, 1995, P NATL ACAD SCI USA, V92, P6112, DOI 10.1073/pnas.92.13.6112; KAHLEN JP, 1994, BIOCHEM BIOPH RES CO, V202, P1366, DOI 10.1006/bbrc.1994.2081; KATO S, 1992, CELL, V68, P731, DOI 10.1016/0092-8674(92)90148-6; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LIU M, 1994, MOL ENDOCRINOL, V8, P1593, DOI 10.1210/me.8.12.1593; MACDONALD PN, 1995, J BIOL CHEM, V270, P4748, DOI 10.1074/jbc.270.9.4748; MACDONALD PN, 1991, J BIOL CHEM, V266, P18808; MARKOSE ER, 1990, P NATL ACAD SCI USA, V87, P1701, DOI 10.1073/pnas.87.5.1701; MINGHETTI PP, 1988, FASEB J, V2, P3043, DOI 10.1096/fasebj.2.15.2847948; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NISHIMURA A, 1994, ENDOCRINOLOGY, V134, P1794, DOI 10.1210/en.134.4.1794; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; OHYAMA Y, 1993, BIOCHEMISTRY-US, V32, P76, DOI 10.1021/bi00052a011; OHYAMA Y, 1994, J BIOL CHEM, V269, P10545; OHYAMA Y, 1991, FEBS LETT, V278, P195, DOI 10.1016/0014-5793(91)80115-J; OHYAMA Y, 1991, J BIOL CHEM, V266, P8690; OZONO K, 1990, J BIOL CHEM, V265, P21881; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PIKE JW, 1991, ANNU REV NUTR, V11, P189, DOI 10.1146/annurev.nu.11.070191.001201; REINHARDT TA, 1989, J BIOL CHEM, V264, P15917; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCARLETT CO, 1995, MOL ENDOCRINOL, V9, P413, DOI 10.1210/me.9.4.413; SHINKI T, 1992, J BIOL CHEM, V267, P13757; SONE T, 1991, J BIOL CHEM, V266, P23296; SUDA T, 1990, ANNU REV NUTR, V10, P195, DOI 10.1146/annurev.nu.10.070190.001211; TANAKA Y, 1974, SCIENCE, V183, P1198, DOI 10.1126/science.183.4130.1198; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZIEROLD C, 1994, P NATL ACAD SCI USA, V91, P900, DOI 10.1073/pnas.91.3.900; ZIEROLD C, 1995, J BIOL CHEM, V270, P1675, DOI 10.1074/jbc.270.4.1675	39	78	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30381	30385		10.1074/jbc.271.48.30381	http://dx.doi.org/10.1074/jbc.271.48.30381			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940000	hybrid			2022-12-25	WOS:A1996VV15800017
J	Pathan, NI; Ashendel, CL; Geahlen, RL; Harrison, ML				Pathan, NI; Ashendel, CL; Geahlen, RL; Harrison, ML			Activation of T cell Raf-1 at mitosis requires the protein-tyrosine kinase Lck	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-DEPENDENT PATHWAY; ANTIGEN RECEPTOR; SIGNAL TRANSDUCTION; PHOSPHORYLATION; ASSOCIATION; STIMULATION; COMPLEX; LSTRA	The serine/threonine protein kinase Raf-1 is activated in response to a variety of growth factors in fibroblasts and hematopoietic cells. In T cells, Raf-1 is activated in response to stimulation through the T cell antigen receptor, the interleukin-2 receptor, and by stimulation of protein kinase C. We demonstrate here that in T cells, Raf-1 is also activated during mitosis. The mitotic activation of Raf-1 was not observed in the Lck-deficient cell line, J.CaM.1. During mitosis, Raf-1 was found to interact selectively with a mitotic form of Lck that migrated with a reduced electrophoretic mobility on SDS-polyacrylamide gels. We conclude that Raf-1 is activated during mitosis in T cells and that this mitotic activation of Raf-1 is dependent on the presence of Lck.	PURDUE UNIV,DEPT MED CHEM & MOL PHARMACOL,W LAFAYETTE,IN 47907; PURDUE UNIV,DEPT BIOL,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus				Geahlen, Robert/0000-0001-8400-2924	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048099] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48099] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHAN AC, 1995, CURR OPIN IMMUNOL, V8, P394; GUPTA S, 1994, J BIOL CHEM, V269, P17349; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; IZQUIERDO M, 1994, J EXP MED, V180, P401, DOI 10.1084/jem.180.1.401; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; LAIRD AD, 1995, J BIOL CHEM, V270, P26742, DOI 10.1074/jbc.270.45.26742; LOH C, 1994, J BIOL CHEM, V269, P8817; Lovric J, 1996, ONCOGENE, V12, P1109; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; OWAKI H, 1993, EMBO J, V12, P4367, DOI 10.1002/j.1460-2075.1993.tb06121.x; PAIGE LA, 1993, J BIOL CHEM, V268, P8669; PASTOR MI, 1995, CANCER SURV, V22, P75; Pathan NI, 1996, J BIOL CHEM, V271, P27517, DOI 10.1074/jbc.271.44.27517; RAPP UR, 1991, ONCOGENE, V6, P495; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; SIEGEL JN, 1993, J IMMUNOL, V151, P4116; SOZERI O, 1992, ONCOGENE, V7, P2259; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; THOMPSON PA, 1991, CELL GROWTH DIFFER, V2, P609; TURNER BC, 1993, P NATL ACAD SCI USA, V90, P5544, DOI 10.1073/pnas.90.12.5544; VORONOVA AF, 1984, MOL CELL BIOL, V4, P2705, DOI 10.1128/MCB.4.12.2705; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; Whitehurst CE, 1996, J IMMUNOL, V156, P1020; WLODZIMIERZ M, 1992, J BIOL CHEM, V267, P15281; ZHENG CF, 1993, J BIOL CHEM, V268, P23933; ZMUIDZINAS A, 1991, MOL CELL BIOL, V11, P2794, DOI 10.1128/MCB.11.5.2794	27	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30315	30317		10.1074/jbc.271.48.30315	http://dx.doi.org/10.1074/jbc.271.48.30315			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8939988	hybrid			2022-12-25	WOS:A1996VV15800005
J	Roberson, ED; Sweatt, JD				Roberson, ED; Sweatt, JD			Transient activation of cyclic AMP-dependent protein kinase during hippocampal long-term potentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE; PYRAMIDAL CELLS; CA1 REGION; AREA CA1; CAMP; INHIBITOR; NEURONS; APLYSIA; LTP; PHOSPHORYLATION	Long-term potentiation (LTP) in the hippocampus is a possible mechanism for mammalian learning and memory in which protein kinases play critical roles. We have investigated the involvement of cyclic AMP dependent protein kinase (PKA) in LTP by directly studying its activation. We developed an in vitro assay which is useful for selective and accurate measurement of stimulus-induced changes in PKA activity in hippocampal slices. PKA was transiently activated 2 and 10 min after delivery of LTP-inducing stimuli in area CA1 of the hip pocampus. This activation did not persist during early or late phases of LTP, suggesting that the role of PKA is in the induction of LTP, not in its expression. LTP was not associated with any change in the total activity of PKA, consistent with activation by cyclic AMP, as opposed to an increase in the amount or efficacy of the enzyme. The LTP-associated activation of PKA required stimulation of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor, and bath application of NMDA was sufficient to activate PKA. Together, these results indicate that at the initiation of LTP, NMDA receptor stimulation leads to transient activation of PKA, and support a role for PKA in the induction of LTP.	BAYLOR COLL MED,DIV NEUROSCI,HOUSTON,TX 77030	Baylor College of Medicine			Roberson, Erik/A-5718-2009	Roberson, Erik/0000-0002-1810-9763; Sweatt, J. David/0000-0003-3567-485X	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH048186] Funding Source: NIH RePORTER; NIMH NIH HHS [MH48186] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABRAMS TW, 1991, J NEUROSCI, V11, P2655; BEAVO JA, 1974, P NATL ACAD SCI USA, V71, P3580, DOI 10.1073/pnas.71.9.3580; BERGOLD PJ, 1990, P NATL ACAD SCI USA, V87, P3788, DOI 10.1073/pnas.87.10.3788; Blitzer RD, 1995, NEURON, V15, P1403, DOI 10.1016/0896-6273(95)90018-7; CHENG HC, 1986, J BIOL CHEM, V261, P989; CHETKOVICH DM, 1991, P NATL ACAD SCI USA, V88, P6467, DOI 10.1073/pnas.88.15.6467; CHETKOVICH DM, 1993, J NEUROCHEM, V61, P1933, DOI 10.1111/j.1471-4159.1993.tb09836.x; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; CORBIN JD, 1975, J BIOL CHEM, V250, P218; CORBIN JD, 1973, J BIOL CHEM, V248, P1813; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; FREY U, 1988, BRAIN RES, V452, P57, DOI 10.1016/0006-8993(88)90008-X; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; GLASS DB, 1986, J BIOL CHEM, V261, P2166; GREENBERG SM, 1987, NATURE, V329, P62, DOI 10.1038/329062a0; GREENGARD P, 1991, SCIENCE, V253, P1135, DOI 10.1126/science.1716001; HELL JW, 1995, EMBO J, V14, P3036, DOI 10.1002/j.1460-2075.1995.tb07306.x; Huang Y Y, 1994, Learn Mem, V1, P74; Impey S, 1996, NEURON, V16, P973, DOI 10.1016/S0896-6273(00)80120-8; KEMP BE, 1977, J BIOL CHEM, V252, P4888; Klann E., 1995, Society for Neuroscience Abstracts, V21, P1809; MALINOW R, 1988, NATURE, V335, P820, DOI 10.1038/335820a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MATTHIES H, 1993, NEUROREPORT, V4, P712, DOI 10.1097/00001756-199306000-00028; MIYAKAWA H, 1992, NEURON, V9, P1163, DOI 10.1016/0896-6273(92)90074-N; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; Osten P, 1996, J NEUROSCI, V16, P2444; PALMER WK, 1980, J BIOL CHEM, V255, P2663; REGEHR WG, 1992, J NEUROSCI, V12, P4202; Roberson ED, 1996, LEARN MEMORY, V3, P1, DOI 10.1101/lm.3.1.1; Sah P, 1996, J NEUROSCI, V16, P4537; SCOTT JD, 1991, PHARMACOL THERAPEUT, V50, P123, DOI 10.1016/0163-7258(91)90075-W; SMITH MK, 1990, J BIOL CHEM, V265, P1837; SWEATT JD, 1989, NATURE, V339, P51, DOI 10.1038/339051a0; WALSH DA, 1971, J BIOL CHEM, V246, P1977; WANG LY, 1993, SCIENCE, V259, P1173, DOI 10.1126/science.8382377; WISE BC, 1982, J BIOL CHEM, V257, P8499; XIA ZG, 1991, NEURON, V6, P431, DOI 10.1016/0896-6273(91)90251-T	38	130	133	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30436	30441		10.1074/jbc.271.48.30436	http://dx.doi.org/10.1074/jbc.271.48.30436			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940008	hybrid			2022-12-25	WOS:A1996VV15800025
J	Tinhofer, I; Maly, K; Dietl, P; Hochholdinger, F; Mayr, S; Obermeier, A; Grunicke, HH				Tinhofer, I; Maly, K; Dietl, P; Hochholdinger, F; Mayr, S; Obermeier, A; Grunicke, HH			Differential Ca2+ signaling induced by activation of the epidermal growth factor and nerve growth factor receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; PHOSPHOLIPASE C-GAMMA-1; CELL-PROLIFERATION; RAS ONCOGENE; BINDING-SITE; EGF-RECEPTOR; HA-RAS; PROTEIN; SPECIFICITY; INHIBITION	Stimulation by epidermal growth factor (EGF) of NIH3T3 cells overexpressing the EGF receptor (EGFR) results in a release of Ca2+ from internal stores, Ca2+ release is followed by an influx of extracellular calcium which can be recorded by the influx of the calcium surrogate Mn2+, Both Ca2+ release and Mn2+/Ca2+ influx are inhibited by expression of the dominant negative Asn(17)-Ras mutant and abrogated by microinjected neutralizing anti-aas antibody Y13-259, whereas microinjection of the anti-Ras antibody Y13-238 which does not interact with the effector binding domain of pas is without any effect on the EGF-induced Ca2+ transient, Neither Asn(17)-Ha-Ras nor the Y13-259 antibody interferes with the thapsigargin-induced Mn2+/Ca2+ influx. The nerve growth factor receptor (Trk)-mediated Ca2+ transient was found to be unaffected by the dominant negative Ras mutant or microinjected neutralizing anti-Ras antibodies, Substitution of the phospholipase C gamma 1 (PLC gamma 1) binding site of the EGFR by the PLC gamma binding domain of Trk renders the EGFR-induced Ca2+ influx insensitive to the expression of Asn(17)-Ha-Ras, whereas the Ca2+ signal induced by Trk carrying the PLC binding site of EGFR is Ras-dependent and abrogated by the dominant negative Ras mutant. It is concluded that the Ca2+ transient induced by the activated EGFR, not, however, the Ca2+ transient elicited by the activated NGFR/Trk, is a Ras-mediated phenomenon and that the role of Ras in regulating EGFR-induced Ca2+ influx depends on the structure of the PLC gamma binding domain.	UNIV INNSBRUCK, DEPT MED CHEM & BIOCHEM, A-6020 INNSBRUCK, AUSTRIA; MAX PLANCK INST BIOCHEM, DEPT BIOL MOL, D-82152 MARTINSRIED, GERMANY; UNIV INNSBRUCK, DEPT PHYSIOL, A-6020 INNSBRUCK, AUSTRIA	University of Innsbruck; Max Planck Society; University of Innsbruck				Mayr, Stefan/0000-0002-3319-4396; Tinhofer, Ingeborg/0000-0002-0512-549X				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CARDO CC, 1991, CELL, V66, P173; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHEN CF, 1988, SCIENCE, V239, P1024, DOI 10.1126/science.2449730; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COLLIN C, 1990, SCIENCE, V250, P1743, DOI 10.1126/science.2176747; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GRUNICKE HH, 1993, CRIT REV ONCOGENESIS, V4, P389; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; HUANG Y, 1993, J PHYSIOL-LONDON, V461, P601, DOI 10.1113/jphysiol.1993.sp019531; KASS GEN, 1990, J BIOL CHEM, V265, P17486; LANG F, 1991, J BIOL CHEM, V266, P4938; LANG F, 1992, PFLUG ARCH EUR J PHY, V421, P416, DOI 10.1007/BF00370251; MALY K, 1995, CELL CALCIUM, V18, P120, DOI 10.1016/0143-4160(95)90003-9; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MILARSKI KL, 1993, J BIOL CHEM, V268, P23634; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MOOLENAAR WH, 1988, EMBO J, V7, P707, DOI 10.1002/j.1460-2075.1988.tb02866.x; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; Obermeier A, 1996, EMBO J, V15, P73, DOI 10.1002/j.1460-2075.1996.tb00335.x; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; PANDIELLA A, 1988, BIOCHEM J, V254, P223, DOI 10.1042/bj2540223; Peppelenbosch MP, 1996, J BIOL CHEM, V271, P7883, DOI 10.1074/jbc.271.14.7883; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; QIU MS, 1991, NEURON, V7, P937, DOI 10.1016/0896-6273(91)90339-2; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SERTH J, 1992, BIOCHEMISTRY-US, V31, P6361, DOI 10.1021/bi00143a001; SMITH MR, 1990, SCIENCE, V247, P1074, DOI 10.1126/science.2408147; SOLER C, 1994, J BIOL CHEM, V269, P12320; VALIUS M, 1995, MOL CELL BIOL, V15, P3058; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251	43	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30505	30509		10.1074/jbc.271.48.30505	http://dx.doi.org/10.1074/jbc.271.48.30505			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940018	hybrid			2022-12-25	WOS:A1996VV15800035
J	Gleizes, PE; Beavis, RC; Mazzieri, R; Shen, B; Rifkin, DB				Gleizes, PE; Beavis, RC; Mazzieri, R; Shen, B; Rifkin, DB			Identification and characterization of an eight-cysteine repeat of the latent transforming growth factor-beta binding protein-1 that mediates bonding to the latent transforming growth factor-beta 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; EXTRACELLULAR-MATRIX; MARFAN-SYNDROME; EXPRESSION; CELLS; TGF-BETA-1; ACTIVATION; COMPONENT	Most cultured cell types secrete small latent transforming growth factor-beta (TGF-beta) as a disulfide-bonded complex with a member of the latent TGF-beta binding protein (LTBP) family. Using the baculovirus expression system, we have mapped the domain of LTBP-1 mediating covalent association with small latent TGF-beta 1. Coexpression in Sf9 cells of small latent TGF-beta 1 with deletion mutants of LTBP-1 showed that the third eight-cysteine repeat of LTBP-1 is necessary and sufficient for covalent interaction with small latent TGF-beta 1. Analysis by mass spectrometry of this eight-cysteine repeat, produced as a recombinant peptide in Sf9 cells, confirmed that it was N-glycosylated, as expected from the primary sequence, No other post-translational modifications of this domain were detected. Alkylation of the recombinant peptide with vinyl pyridine failed to reveal any free cysteines, indicating that, in the absence of small latent TGF-beta, the eight cysteines of this domain are engaged in intramolecular bonds. These data demonstrate that the third LTBP-1 eight-cysteine repeat recognizes and associates covalently with small latent TGF-beta 1 through a mechanism that does not require any specific post-translational modification of this domain. They also suggest that this domain adopts different conformations depending on whether it is free or bound to small latent TGF-beta.	NYU,MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016; NYU,MED CTR,RAYMOND & BEVERLY SACKLER FDN LAB,NEW YORK,NY 10016; NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016; NYU,MED CTR,SKIRBALL INST BIOMED RES,NEW YORK,NY 10016; NYU,DEPT CHEM,NEW YORK,NY 10003	New York University; New York University; New York University; New York University; New York University	Gleizes, PE (corresponding author), NYU,MED CTR,DEPT CELL BIOL,550 1ST AVE,NEW YORK,NY 10016, USA.		Gleizes, Pierre-Emmanuel/H-3821-2014; Gleizes, Pierre-Emmanuel/ABB-9653-2021; Mazzieri, Roberta/C-9773-2015	Gleizes, Pierre-Emmanuel/0000-0003-0830-7341; Gleizes, Pierre-Emmanuel/0000-0003-0830-7341; Mazzieri, Roberta/0000-0002-5172-0927	NATIONAL CANCER INSTITUTE [T32CA009161] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA 09161, CA 23753] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; ARRICK BA, 1992, J CELL BIOL, V118, P715, DOI 10.1083/jcb.118.3.715; BRUNNER AM, 1989, J BIOL CHEM, V264, P13660; DALLAS SL, 1995, J CELL BIOL, V131, P539, DOI 10.1083/jcb.131.2.539; DAVIDSON DJ, 1990, BIOCHEMISTRY-US, V29, P5584, DOI 10.1021/bi00475a024; DAVIDSON DJ, 1991, BIOCHEMISTRY-US, V30, P6689, DOI 10.1021/bi00241a008; FLAUMENHAFT R, 1993, J CELL BIOL, V120, P995, DOI 10.1083/jcb.120.4.995; GENTRY LE, 1988, MOL CELL BIOL, V8, P4162, DOI 10.1128/MCB.8.10.4162; GIBSON MA, 1995, MOL CELL BIOL, V15, P6932; HILLENKAMP F, 1991, ANAL CHEM, V63, pA1193; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MIYAZONO K, 1991, EMBO J, V10, P1091, DOI 10.1002/j.1460-2075.1991.tb08049.x; MOREN A, 1994, J BIOL CHEM, V269, P32469; NUNES I, 1995, J IMMUNOL, V155, P1450; Olofsson A, 1995, J BIOL CHEM, V270, P31294, DOI 10.1074/jbc.270.52.31294; Saharinen J, 1996, EMBO J, V15, P245, DOI 10.1002/j.1460-2075.1996.tb00355.x; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; STAUDACHER E, 1992, EUR J BIOCHEM, V207, P987, DOI 10.1111/j.1432-1033.1992.tb17134.x; TAIPALE J, 1995, J BIOL CHEM, V270, P4689, DOI 10.1074/jbc.270.9.4689; TAIPALE J, 1994, J CELL BIOL, V124, P171, DOI 10.1083/jcb.124.1.171; TSUJI T, 1990, P NATL ACAD SCI USA, V87, P8835, DOI 10.1073/pnas.87.22.8835; WAHL SM, 1992, J CLIN IMMUNOL, V12, P1; YIN WS, 1995, J BIOL CHEM, V270, P10147, DOI 10.1074/jbc.270.17.10147; ZHANG H, 1994, J CELL BIOL, V124, P855, DOI 10.1083/jcb.124.5.855	27	109	112	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29891	29896		10.1074/jbc.271.47.29891	http://dx.doi.org/10.1074/jbc.271.47.29891			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939931	hybrid			2022-12-25	WOS:A1996VU52500059
J	Klein, M; Weissenbock, G; Dufaud, A; Gaillard, C; Kreuz, K; Martinoia, E				Klein, M; Weissenbock, G; Dufaud, A; Gaillard, C; Kreuz, K; Martinoia, E			Different energization mechanisms drive the vacuolar uptake of a flavonoid glucoside and a herbicide glucoside	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONJUGATE EXPORT PUMP; BILE-ACID TRANSPORT; MEMBRANE-VESICLES; PLANT VACUOLES; ACCUMULATION; PROTOPLASTS; ATPASES; SYSTEM	Glycosylation of endogenous secondary plant products and abiotic substances such as herbicides increases their water solubility and enables vacuolar deposition of these potentially toxic substances. We characterized and compared the transport mechanisms of two glucosides, isovitexin, a native barley flavonoid C-glucoside and hydroxyprimisulfuron-glucoside, a herbicide glucoside, into barley vacuoles, Uptake of isovitexin is saturable (K-m=82 mu M) and stimulated by MgATP 1.3-1.5-fold. ATP-dependent uptake was inhibited by bafilomycin Al, a specific inhibitor of vacuolar H+-ATPase, but not by vanadate, Transport of isovitexin is strongly inhibited after dissipation of the Delta pH or the Delta psi across the vacuolar membrane. Uptake experiments with the heterologue flavonoid orientin and competition experiments with other phenolic compounds suggest that transport of flavonoid glucosides into barley vacuoles is specific for apigenin derivatives. In contrast, transport of hydroxyprimisulfuron-glucoside is strongly stimulated by MgATP (2.5-3 fold), not sensitive toward bafilomycin, and much less sensitive to dissipation of the Delta pH, but strongly inhibited by vanadate, Uptake of hydroxyprimisulfuron-glucoside is also stimulated by MgGTP or MgUTP by about 2-fold. Transport of both substrates is not stimulated by ATP or Mg2+ alone, ADP, or the nonhydrolyzable ATP analogue 5'-adenylyl-beta,gamma-imido-diphosphate. Our results suggest that different uptake mechanisms exist in the vacuolar membrane, a Delta pH-dependent uptake mechanism for specific endogenous flavonoid-glucosides, and a directly energized mechanism for abiotic glucosides, which appears to be the main transport system for these substrates. The herbicide glucoside may therefore be transported by an additional member of the ABC transporters.	UNIV POITIERS,FAC SCI,PHYSIOL & BIOCHIM VEGETALES LAB,F-86022 POITIERS,FRANCE; UNIV COLOGNE,INST BOT,D-50931 COLOGNE,GERMANY; CIBA GEIGY AG,CROP PROTECT WEED CONTROL PLANT BIOCHEM,CH-4002 BASEL,SWITZERLAND	Universite de Poitiers; University of Cologne; Novartis								[Anonymous], 1990, FLAVONOID METABOLISM; BALZI E, 1994, BBA-BIOENERGETICS, V1187, P152, DOI 10.1016/0005-2728(94)90102-3; BLUME DE, 1979, PLANTA, V146, P199, DOI 10.1007/BF00388232; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; DEUSNEUMANN B, 1986, PLANTA, V167, P44, DOI 10.1007/BF00446367; DEUSNEUMANN B, 1984, PLANTA, V162, P250, DOI 10.1007/BF00397447; GAILLARD C, 1994, FEBS LETT, V352, P219, DOI 10.1016/0014-5793(94)00961-9; GETZ HP, 1995, PLANT PHYSIOL, V107, P459, DOI 10.1104/pp.107.2.459; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HOPP W, 1987, PLANTA, V170, P74, DOI 10.1007/BF00392383; HORTENSTEINER S, 1993, J BIOL CHEM, V268, P18446; ISHIKAWA T, 1992, TRENDS BIOCHEM SCI, V17, P463, DOI 10.1016/0968-0004(92)90489-V; Kreuz K, 1996, PLANT PHYSIOL, V111, P349, DOI 10.1104/pp.111.2.349; LI ZS, 1995, PLANT PHYSIOL, V107, P1257, DOI 10.1104/pp.107.4.1257; MARGNA U, 1978, BIOCHEM PHYSIOL PFL, V173, P2; MARRS KA, 1995, NATURE, V375, P397, DOI 10.1038/375397a0; MARTINOIA E, 1993, NATURE, V364, P247, DOI 10.1038/364247a0; MARTINOIA E, 1992, BOT ACTA, V105, P232, DOI 10.1111/j.1438-8677.1992.tb00293.x; MATERN U, 1986, PLANTA, V167, P183, DOI 10.1007/BF00391413; NISHIDA T, 1991, P NATL ACAD SCI USA, V88, P6590, DOI 10.1073/pnas.88.15.6590; RATABOUL P, 1985, BIOCHIM BIOPHYS ACTA, V816, P25, DOI 10.1016/0005-2736(85)90389-X; RENTSCH D, 1991, PLANTA, V184, P532, DOI 10.1007/BF00197903; REUBER S, 1993, Z NATURFORSCH C, V48, P749; Reuber S, 1996, PLANT CELL ENVIRON, V19, P593, DOI 10.1111/j.1365-3040.1996.tb00393.x; SANDERMANN H, 1992, TRENDS BIOCHEM SCI, V17, P82, DOI 10.1016/0968-0004(92)90507-6; SEIKEL MK, 1957, ARCH BIOCHEM BIOPHYS, V71, P17, DOI 10.1016/0003-9861(57)90004-8; SZE H, 1992, J BIOENERG BIOMEMBR, V24, P371, DOI 10.1007/BF00762530; WERNER C, 1985, J PLANT PHYSIOL, V118, P237, DOI 10.1016/S0176-1617(85)80225-X	28	100	117	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29666	29671		10.1074/jbc.271.47.29666	http://dx.doi.org/10.1074/jbc.271.47.29666			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939899	hybrid			2022-12-25	WOS:A1996VU52500027
J	Lang, IM; Chuang, TL; Barbas, CF; Schleef, RR				Lang, IM; Chuang, TL; Barbas, CF; Schleef, RR			Purification of storage granule protein-23 - A novel protein identified by phage display technology and interaction with type 1 plasminogen activator inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATED SECRETORY PATHWAY; ENDOTHELIAL-CELLS; GROWTH-FACTOR; EPITOPE LIBRARIES; HUMAN-PLATELETS; MESSENGER-RNA; ATT-20 CELLS; CDNA CLONING; P-SELECTIN; SIS GENE	Type 1 plasminogen activator inhibitor (PAI-1) is a key regulator of the fibrinolytic cascade that is stored in a rapidly releasable form within platelet alpha-granules. To identify proteins that may participate in the targeting or storage of this potent inhibitor, this report investigates the applicability of utilizing filamentous bacteriophages to display proteins expressed by cells containing a regulated secretory pathway and their enrichment based upon an interaction with PAI-1, For this purpose, RNA was extracted from AtT-20 cells (i.e. a classical model cell system for intracellular protein sorting), reverse transcribed, amplified using polymerase chain reaction primers containing internal restriction sites, and cloned into the phagemid pCOMB3H for expression as fusion constructs with the bacteriophage gene III protein, Escherichia coli was transformed with the phagemids and infected with VCSM13 helper phage, and the resulting AtT-20 cDNA-bacteriophage library was enriched by panning against solid- and solution-phase PAI-1, The enriched cDNA library was subcloned into a prokaryotic expression vector system that replaces the gene III protein with a decapeptide tag for immunologic quantitation, One novel cDNA clone (i.e. A-61), which preferentially recognized solution-phase PAI-1 and reacted positively with antibodies derived from a rabbit immunized with alpha-granules, was subcloned into the prokaryotic expression vector pTrcHis to create a construct containing an N-terminal six-histidine purification tag, This construct was expressed in E. coli, purified by nickel-chelate chromatography followed by preparative SDS-polyacrylamide gel electrophoresis, and utilized for the generation of polyclonal antibodies, Immunoblotting analysis employing antibodies against the purified A-61 construct revealed a 23-kDa protein present in the regulated secretory pathway of AtT-20 cells, The 23-kDa molecule was purified from media conditioned by AtT-20 cells by ion exchange chromatography on DEAE-Sephacel, molecular sieve chromatography on Sephacryl S-100, chromatofocusing on Polybuffer exchanger 94, and affinity chromatography on PAI-1-Sepharose, N-terminal amino acid sequencing of a 16-kDa Lys-C proteolytic fragment of the 23-kDa storage granule protein was employed to confirm its identity with the cDNA sequence of clone A-61, These data indicate that phage display of cDNA libraries fused to the C-terminal region of the gene III protein and their enrichment via an interaction with a target molecule can be utilized to define other proteins present within a particular cellular pathway.	Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT MOL BIOL & CHEM, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute				Lang, Irene/0000-0003-0485-2692	NHLBI NIH HHS [HL45954, HL49563] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045954, R01HL049563] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALESSI MC, 1994, THROMB HAEMOSTASIS, V72, P931; BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; BARRETT TB, 1984, P NATL ACAD SCI-BIOL, V81, P6772, DOI 10.1073/pnas.81.21.6772; BITHELL TC, 1993, WINTROBES CLIN HEMAT, P511; BOOTH NA, 1985, J CLIN PATHOL, V38, P825, DOI 10.1136/jcp.38.7.825; BOOTH NA, 1988, BRIT J HAEMATOL, V70, P327, DOI 10.1111/j.1365-2141.1988.tb02490.x; BOOTH NA, 1990, FIBRINOLYSIS, V4, P138, DOI 10.1016/0268-9499(90)90391-V; BURGESS TL, 1985, J CELL BIOL, V101, P639, DOI 10.1083/jcb.101.2.639; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; BURGESS TL, 1987, J CELL BIOL, V105, P659, DOI 10.1083/jcb.105.2.659; BURTON DR, 1994, ADV IMMUNOL, V57, P191, DOI 10.1016/S0065-2776(08)60674-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS T, 1985, NATURE, V316, P748, DOI 10.1038/316748a0; CRAMERI R, 1994, EUR J BIOCHEM, V226, P53, DOI 10.1111/j.1432-1033.1994.tb20025.x; CRAMERI R, 1993, GENE, V137, P69, DOI 10.1016/0378-1119(93)90253-Y; DECLERCK PJ, 1988, BLOOD, V71, P220; DIEVAL J, 1991, BLOOD, V77, P528; DISDIER M, 1992, MOL BIOL CELL, V3, P309, DOI 10.1091/mbc.3.3.309; ERICKSON LA, 1984, J CLIN INVEST, V74, P1465, DOI 10.1172/JCI111559; FAY WP, 1992, NEW ENGL J MED, V327, P1729, DOI 10.1056/NEJM199212103272406; FINK LM, 1994, VIRCHOWS ARCH, V424, P1; GOMBAU L, 1994, J BIOL CHEM, V269, P3875; GRAMATIKOFF K, 1994, NUCLEIC ACIDS RES, V22, P5761, DOI 10.1093/nar/22.25.5761; GREENBERG SM, 1988, BLOOD, V72, P1968; GUMBINER B, 1982, CELL, V28, P51, DOI 10.1016/0092-8674(82)90374-9; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HOESS RH, 1994, J IMMUNOL, V153, P724; HOTTIGER M, 1995, NUCLEIC ACIDS RES, V23, P736; HUSE WD, 1989, SCIENCE, V246, P1275, DOI 10.1126/science.2531466; JOHNSSON A, 1984, EMBO J, V3, P921, DOI 10.1002/j.1460-2075.1984.tb01908.x; KELLY R B, 1991, Current Opinion in Cell Biology, V3, P654, DOI 10.1016/0955-0674(91)90037-Y; KOEDAM JA, 1992, J CELL BIOL, V116, P617, DOI 10.1083/jcb.116.3.617; KONKLE BA, 1993, ARTERIOSCLER THROMB, V13, P669, DOI 10.1161/01.ATV.13.5.669; KRUITHOF EKO, 1987, BLOOD, V70, P1645; KRUITHOF EKO, 1986, THROMB HAEMOSTASIS, V55, P201; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1993, CURR OPIN IMMUNOL, V5, P268, DOI 10.1016/0952-7915(93)90016-L; Lang IM, 1996, GENE, V172, P295, DOI 10.1016/0378-1119(96)00021-2; LANG IM, 1992, BLOOD, V80, P2269; Lang IM, 1996, J BIOL CHEM, V271, P2754, DOI 10.1074/jbc.271.5.2754; LEE MH, 1993, BLOOD, V81, P2357; LERNER RA, 1992, SCIENCE, V258, P1313, DOI 10.1126/science.1455226; MANIATIS T, 1992, MOL CLONING; MILGRAM SL, 1992, J CELL BIOL, V117, P717, DOI 10.1083/jcb.117.4.717; MIMURO J, 1987, BLOOD, V70, P721; MOORE HPH, 1986, NATURE, V321, P443, DOI 10.1038/321443a0; MOORE HPH, 1983, CELL, V35, P531, DOI 10.1016/0092-8674(83)90187-3; PANNEKOEK H, 1993, GENE, V128, P135, DOI 10.1016/0378-1119(93)90164-X; PAULSSON Y, 1987, NATURE, V328, P715, DOI 10.1038/328715a0; PREISSNER KT, 1991, THROMB HAEMOSTASIS, V66, P123; REILLY TM, 1994, BLOOD COAGUL FIBRIN, V5, P73, DOI 10.1097/00001721-199402000-00011; RINDLER M J, 1992, Current Opinion in Cell Biology, V4, P616, DOI 10.1016/0955-0674(92)90080-V; ROBBINS KC, 1983, NATURE, V305, P605, DOI 10.1038/305605a0; RUSSELL R, 1986, CELL, V46, P155; Salonen EM, 1996, FEBS LETT, V393, P216, DOI 10.1016/0014-5793(96)00865-4; SCHLEEF RR, 1991, J CELL BIOL, V113, P1413, DOI 10.1083/jcb.113.6.1413; SCHLEEF RR, 1988, J BIOL CHEM, V263, P5797; SCHLEEF RR, 1989, J CLIN INVEST, V83, P1747, DOI 10.1172/JCI114076; SCOTT JK, 1992, TRENDS BIOCHEM SCI, V17, P241, DOI 10.1016/0968-0004(92)90401-T; SIMPSON AJ, 1991, J CLIN PATHOL, V44, P139, DOI 10.1136/jcp.44.2.139; SIMPSON AJ, 1990, BRIT J HAEMATOL, V75, P543, DOI 10.1111/j.1365-2141.1990.tb07796.x; SPRENGERS ED, 1986, THROMB HAEMOSTASIS, V55, P325; VANMEIJER M, 1995, FIBRINOLYSIS, V9, P263, DOI 10.1016/S0268-9499(95)80015-8; WAGNER DD, 1991, CELL, V64, P403, DOI 10.1016/0092-8674(91)90648-I; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245	65	11	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30126	30135		10.1074/jbc.271.47.30126	http://dx.doi.org/10.1074/jbc.271.47.30126			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939962	hybrid, Green Submitted			2022-12-25	WOS:A1996VU52500090
J	Mazzoni, MR; Hamm, HE				Mazzoni, MR; Hamm, HE			Interaction of transducin with light-activated rhodopsin protects it from proteolytic digestion by trypsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; BOVINE PHOTORECEPTOR-MEMBRANES; GTP-BINDING PROTEIN; ALPHA-SUBUNIT; MONOCLONAL-ANTIBODY; AMINO TERMINUS; BETA-GAMMA; LIPID MODIFICATIONS; CRYSTAL-STRUCTURE; GDP	The tryptic cleavage pattern of transducin (G(t)) in solution was compared with that in the presence of phospholipid vesicles, rod outer segment (ROS) membranes kept in the dark, or ROS membranes containing light-activated rhodopsin, metarhodopsin II (Rh*). When G(t) was in the high affinity complex with Rh*, the alpha(t) subunit was almost completely protected from proteolysis. The protection of at at Arg(310) was complete, while Arg(204) was substantially protected. The cleavage of alpha(t) at Lys's was protected in the presence of phospholipid vesicles, ROS membranes kept in the dark, or ROS membranes containing Rh*. The cleavage of beta(t) was slower in the presence of ROS membranes or phospholipid vesicles. When the Rh*. G(t) complex was incubated with guanyl-5'-yl thiophosphate, a guanine nucleotide analog known to release the high affinity interaction between G(t) and Rh*, the protection at Arg(310) and Arg(304) was diminished. From our results, we propose that Rh* either physically blocks access of trypsin to Arg(204) and Arg(310) or maintains the heterotrimer in such a conformation that these cleavage sites are not available. Since Arg(204) is involved in the switch interface with beta gamma(t) (Lambright, D. G., Sondek, J., Bohm, A., Skiba, N. P., Hamm, H. E., and Sigler, P. B. (1996) Nature 379, 311-319), it may be that beta gamma(t) is implicated in protecting this cleavage site in the receptor-bound, stabilized heterotrimer. Arg(310) is not near the beta gamma(t) subunit, thus we believe that the high affinity binding of G(t) to Rh* physically or sterically blocks access of trypsin to this site. Thus, Arg(310), only a few angstroms away from the carboxyl terminus of a,, which is known to directly bind to Rh*, is likely to also be a part of the Rh* binding site. This is in agreement with other studies and has implications for the mechanism by which receptors catalyze GDP release from G proteins. The protection of Lys(18) in the presence of phospholipid vesicles suggests that the amino-terminal region is in contact with the membrane, consistent with the crystal structure of the heterotrimer (Lambright, D. G., Sondek, J., Bohm, A., Skiba, N. P., Hamm, H. E., and Sigler, P. B.(1996) Nature 379, 311-319).	UNIV ILLINOIS, DEPT PHYSIOL & BIOPHYS, CHICAGO, IL 60612 USA; UNIV PISA, IST POLICATTEDRA DISCIPLINE BIOL, I-56126 PISA, ITALY	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Pisa			Hamm, Heidi E/G-2374-2014; Mazzoni, Maria Rosa/AAA-2366-2022	Mazzoni, Maria Rosa/0000-0003-2612-432X	NATIONAL EYE INSTITUTE [R01EY006062] Funding Source: NIH RePORTER; NEI NIH HHS [EY 06062] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BIGAY J, 1994, BIOCHEMISTRY-US, V33, P14081, DOI 10.1021/bi00251a017; BOURNAUCIN F, 1989, EUR J BIOCHEM, V184, P687; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; COLEMAN DE, 1994, J MOL BIOL, V238, P630, DOI 10.1006/jmbi.1994.1320; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; DENKER BM, 1992, J BIOL CHEM, V267, P9998; DENKER BM, 1992, J BIOL CHEM, V267, P6272; EMEIS D, 1982, FEBS LETT, V143, P29, DOI 10.1016/0014-5793(82)80266-4; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GARCIA PD, 1995, EMBO J, V14, P4460, DOI 10.1002/j.1460-2075.1995.tb00125.x; GRAF R, 1992, J BIOL CHEM, V267, P24307; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HAMM HE, 1990, ADV SEC MESS PHOSPH, V24, P76; HAMM HE, 1984, J GEN PHYSIOL, V84, P265, DOI 10.1085/jgp.84.2.265; HARGRAVE PA, 1993, BIOESSAYS, V15, P43, DOI 10.1002/bies.950150107; HEIN L, 1995, NEUROPHARMACOLOGY, V34, P357, DOI 10.1016/0028-3908(95)00018-2; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; IYENGAR R, 1980, J BIOL CHEM, V255, P312; KAHLERT M, 1990, J BIOL CHEM, V265, P18928; KIM JY, 1994, BIOPHYS J, V67, P227, DOI 10.1016/S0006-3495(94)80473-4; KOKAME K, 1992, NATURE, V359, P749, DOI 10.1038/359749a0; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEE CH, 1995, MOL PHARMACOL, V47, P218; MALINSKI JA, 1992, BIOCHEMISTRY-US, V31, P9502, DOI 10.1021/bi00154a024; MAZZONI MR, 1993, J PROTEIN CHEM, V12, P215, DOI 10.1007/BF01026043; MAZZONI MR, 1991, J BIOL CHEM, V266, P14072; MAZZONI MR, 1989, BIOCHEMISTRY-US, V28, P9873, DOI 10.1021/bi00451a047; NAVON SE, 1987, J BIOL CHEM, V262, P15746; NEER EJ, 1988, J BIOL CHEM, V263, P8996; NEUBERT TA, 1992, J BIOL CHEM, V267, P18274; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PANICO J, 1990, J BIOL CHEM, V265, P18922; PFISTER C, 1983, EUR J BIOCHEM, V136, P489, DOI 10.1111/j.1432-1033.1983.tb07767.x; RENSDOMIANO S, 1995, FASEB J, V9, P1059, DOI 10.1096/fasebj.9.11.7649405; ROJAS FJ, 1985, J BIOL CHEM, V260, P7829; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; STRYER L, 1983, METHOD ENZYMOL, V96, P617; THOMAS TC, 1993, P NATL ACAD SCI USA, V90, P10295, DOI 10.1073/pnas.90.21.10295; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WITT PL, 1984, J GEN PHYSIOL, V84, P251, DOI 10.1085/jgp.84.2.251; YAMANAKA G, 1985, BIOCHEMISTRY-US, V24, P8094, DOI 10.1021/bi00348a039; YAMANE HK, 1993, ANN REV PHARM TOXICO, V32, P201	51	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30034	30040		10.1074/jbc.271.47.30034	http://dx.doi.org/10.1074/jbc.271.47.30034			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939950	hybrid			2022-12-25	WOS:A1996VU52500078
J	Perregaux, DG; Laliberte, RE; Gabel, CA				Perregaux, DG; Laliberte, RE; Gabel, CA			Human monocyte interleukin-1 beta posttranslational processing - Evidence of a volume-regulated response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; DEATH GENE CED-3; K-CL COTRANSPORT; EXTRACELLULAR ATP; IL-1-BETA PRODUCTION; MOUSE MACROPHAGES; MESSENGER-RNA; IL-1-BETA-CONVERTING ENZYME; MONONUCLEAR PHAGOCYTES; BUMETANIDE BINDING	Interleukin (IL)-1 beta produced by monocytes and macrophages is not released via the normal secretory apparatus, and prior to its release, this cytokine must be proteolytically processed to generate a mature biologically active species, Biochemical mechanisms that regulate these posttranslational steps are not well understood, Lipopolysaccharide (LPS) is a poor activator of IL-1 posttranslational processing despite serving as a potent inducer of IL-1 synthesis, For example, freshly isolated human monocytes treated with LPS released <30% of their newly synthesized IL-1 beta as the mature 17-kDa cytokine species, and monocytes that were aged overnight in culture prior to LPS treatment released no 17-kDa cytokine. In contrast, addition of extracellular ATP promoted IL-1 beta posttranslational processing from both monocyte populations, Previous studies indicated that ATP, acting via surface P-2Z-type receptors, promoted major intracellular ionic changes, To explore whether these ionic changes were required for cytokine posttranslational processing, LPS-stimulated human monocytes were maintained in ionically altered media, Hypotonic conditions promoted an efficient and selective release of mature 17-kDa IL-1 beta from LPS-activated monocytes in the absence of ATP, In contrast, hypertonic conditions blocked the ATP-induced posttranslational processing reactions, Both hypotonic stress- and ATP-induced processing were blocked when NaI was substituted for NaCl within the medium; substitution with NaSCN or NaNO3 also blocked the ATP response, but these salts were less inhibitory against the hypotonic stimulus, Sodium glucuronate substitution did not inhibit cytokine processing induced by either stimulus, Removal of divalent cations from the medium did not affect the ATP response, but pretreatment of monocytes with the phosphatase inhibitor okadaic acid dose-dependently suppressed ATP-induced IL-1 beta posttranslational processing. A volume-induced change to the intracellular ionic environment, therefore, may represent a key element of the mechanism by which IL-1 beta posttranslational processing is initiated, The strong dependence of this cytokine release mechanism on chloride anions suggests that selective anion transporters function as important components of this response.	PFIZER INC,CENT RES,DEPT CANC IMMUNOL & INFECT DIS,GROTON,CT 06340	Pfizer								ALONSOTORRE SR, 1993, J BIOL CHEM, V268, P18640; AREND WP, 1989, J IMMUNOL, V143, P118; AYALA JM, 1994, J IMMUNOL, V153, P2592; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BLACK RA, 1989, FEBS LETT, V247, P386, DOI 10.1016/0014-5793(89)81376-6; BLANCHARD DK, 1991, J LEUKOCYTE BIOL, V50, P28, DOI 10.1002/jlb.50.1.28; BLANCHARD DK, 1991, J IMMUNOL, V147, P2579; BURCHETT SK, 1988, J IMMUNOL, V140, P3473; CABANTCHIK ZI, 1992, AM J PHYSIOL, V262, pC803, DOI 10.1152/ajpcell.1992.262.4.C803; CHIN J, 1993, J IMMUNOL, V151, P5574; DAYER JM, 1986, J CLIN INVEST, V77, P645, DOI 10.1172/JCI112350; DINARELLO CA, 1991, BLOOD, V77, P1627; DINARELLO CA, 1986, J EXP MED, V163, P1433, DOI 10.1084/jem.163.6.1433; DODGE GR, 1989, J CLIN INVEST, V83, P647, DOI 10.1172/JCI113929; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; ELMOATASSIM C, 1992, BIOCHIM BIOPHYS ACTA, V1134, P31, DOI 10.1016/0167-4889(92)90025-7; FALZONI S, 1995, J CLIN INVEST, V95, P1207, DOI 10.1172/JCI117770; Ferrari D, 1996, J IMMUNOL, V156, P1531; FONG P, 1995, J MEMBRANE BIOL, V144, P189; GALLIN EK, 1994, J CELL PHYSIOL, V159, P573, DOI 10.1002/jcp.1041590321; GAMBA G, 1994, J BIOL CHEM, V269, P17713; Gillen CM, 1996, J BIOL CHEM, V271, P16237, DOI 10.1074/jbc.271.27.16237; GREENBERG S, 1988, J BIOL CHEM, V263, P10337; GRINSTEIN S, 1984, AM J PHYSIOL, V246, pC204, DOI 10.1152/ajpcell.1984.246.3.C204; HARA N, 1990, FEBS LETT, V267, P281, DOI 10.1016/0014-5793(90)80945-F; HASS M, 1994, AM J PHYSIOL, V267, pC869; HEGDE RS, 1992, J MEMBRANE BIOL, V126, P27; HERZYK DJ, 1992, J IMMUNOL, V149, P3052; HICKMAN SE, 1994, BLOOD, V84, P2452; HOFFMANN EK, 1989, PHYSIOL REV, V69, P315, DOI 10.1152/physrev.1989.69.2.315; HOGQUIST KA, 1991, J IMMUNOL, V147, P2181; HOGQUIST KA, 1991, P NATL ACAD SCI USA, V88, P8485, DOI 10.1073/pnas.88.19.8485; JENNINGS ML, 1991, J GEN PHYSIOL, V97, P799, DOI 10.1085/jgp.97.4.799; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALIBERTE R, 1994, J IMMUNOL, V153, P2168; LANDIS RC, 1991, J IMMUNOL, V146, P128; LAUF PK, 1988, AM J PHYSIOL, V255, pC331, DOI 10.1152/ajpcell.1988.255.3.C331; LAUF PK, 1992, AM J PHYSIOL, V263, pC917, DOI 10.1152/ajpcell.1992.263.5.C917; LEWIS CE, 1990, IMMUNOLOGY, V69, P402; LI M, 1990, AM J PHYSIOL, V259, pC295, DOI 10.1152/ajpcell.1990.259.2.C295; MATSUURA H, 1992, CIRC RES, V70, P851, DOI 10.1161/01.RES.70.4.851; MCKINNEY LC, 1990, J MEMBRANE BIOL, V116, P47, DOI 10.1007/BF01871671; MILLER BE, 1995, J IMMUNOL, V154, P1331; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NELSON DJ, 1992, J MEMBRANE BIOL, V125, P207; NELSON DJ, 1990, J MEMBRANE BIOL, V117, P29, DOI 10.1007/BF01871563; OGRADY SM, 1987, AM J PHYSIOL, V253, pC177, DOI 10.1152/ajpcell.1987.253.2.C177; ONEILL WC, 1987, AM J PHYSIOL, V253, pC883, DOI 10.1152/ajpcell.1987.253.6.C883; PALFREY HC, 1993, AM J PHYSIOL, V264, pC1270, DOI 10.1152/ajpcell.1993.264.5.C1270; PERREGAUX D, 1992, J IMMUNOL, V149, P1294; PERREGAUX D, 1994, J BIOL CHEM, V269, P15195; PRESSMAN BC, 1976, ANNU REV BIOCHEM, V45, P501, DOI 10.1146/annurev.bi.45.070176.002441; SARKADI B, 1991, BIOCHIM BIOPHYS ACTA, V1071, P407, DOI 10.1016/0304-4157(91)90005-H; SCHINDLER R, 1990, BLOOD, V76, P1631; SIDERS WM, 1993, J BIOL CHEM, V268, P22170; SOLER A, 1993, J PHYSIOL-LONDON, V465, P387, DOI 10.1113/jphysiol.1993.sp019682; STEINBERG TH, 1987, J BIOL CHEM, V262, P8884; STEPHENSON ML, 1987, BIOCHEM BIOPH RES CO, V144, P583, DOI 10.1016/S0006-291X(87)80006-2; STUTTS MJ, 1992, P NATL ACAD SCI USA, V89, P1621, DOI 10.1073/pnas.89.5.1621; SUNG SSJ, 1985, J BIOL CHEM, V260, P3442; TSAI V, 1992, CELL IMMUNOL, V144, P203, DOI 10.1016/0008-8749(92)90237-J; WALEV I, 1995, EMBO J, V14, P1607, DOI 10.1002/j.1460-2075.1995.tb07149.x; WANG SY, 1992, IMMUNOLOGY, V77, P298; WEWERS MD, 1989, J IMMUNOL, V143, P1635; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	65	87	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29830	29838		10.1074/jbc.271.47.29830	http://dx.doi.org/10.1074/jbc.271.47.29830			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939922	hybrid			2022-12-25	WOS:A1996VU52500050
J	Rehberg, EF; SamsonBouma, ME; Kienzle, B; Blinderman, L; Jamil, H; Wetterau, JR; Aggerbeck, LP; Gordon, DA				Rehberg, EF; SamsonBouma, ME; Kienzle, B; Blinderman, L; Jamil, H; Wetterau, JR; Aggerbeck, LP; Gordon, DA			A novel abetalipoproteinemia genotype - Identification of a missense mutation in the 97-kDa subunit of the microsomal triglyceride transfer protein that prevents complex formation with protein disulfide isomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CONTAINING LIPOPROTEINS; GENE; CELLS; EXPRESSION; SECRETION; DEFECTS; CLONING	The microsomal triglyceride transfer protein (MTP) is a heterodimer composed of the ubiquitous multifunctional protein, protein disulfide isomerase, and a unique 97-kDa subunit, Mutations that lead to the absence of a functional 97-kDa subunit cause abetalipoproteinemia, an autosomal recessive disease characterized by a defect in the assembly and secretion of apolipoprotein B (apoB) containing lipoproteins, Previous studies of abetalipoproteinemic patient, C.L., showed that the 97-kDa subunit was undetectable, In this report, [S-35]methionine labeling showed that this tissue was capable of synthesizing the 97-kDa MTP subunit, Electrophoretic analysis showed two bands, one with a molecular mass of the wild type 97-kDa subunit and the other with a slightly lower molecular weight, Sequence analysis of cDNAs from additional intestinal biopsies showed this patient to be a compound heterozygote. One allele contained a perfect in-frame deletion of exon 10, explaining the lower molecular weight band, cDNAs of the second allele were found to contain 3 missense mutations: His(297) --> Gln, Asp(384) --> Ala, and Arg(540) --> His. Transient expression of each mutant showed that only the Arg(540) His mutant was non-functional based upon its inability to reconstitute apoB secretion in a cell culture system, The other amino acid changes are silent polymorphisms, High level coexpression in a baculovirus system of the wild type 97-kDa subunit or the Arg(540) --> His mutant along with human protein disulfide isomerase showed that the wild type was capable of forming an active MTP complex while the mutant was not, Biochemical analysis of lysates from these cells showed that the Arg to His conversion interrupted the interaction between the 97-kDa subunit and protein disulfide isomerase, Replacement of Arg(540) With a lysine residue maintained the ability of the 97-kDa subunit to complex with protein disulfide isomerase and form the active MTP holoprotein, These results indicate that a positively charged amino acid at position 540 in the 97-kDa subunit is critical for the productive association with protein disulfide isomerase, Of the 13 mutant MTP 97-kDa subunit alleles described to date, this is the first encoding a missense mutation.	BRISTOL MYERS SQUIBB,DEPT METAB DIS,PRINCETON,NJ 08543; UNIV PARIS 07,U327 INSERM,F-75870 PARIS 18,FRANCE; CNRS,CTR GENET MOL,F-91198 GIF SUR YVETTE,FRANCE	Bristol-Myers Squibb; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay								BOUMA ME, 1990, J LIPID RES, V31, P1; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; GORDON DA, 1995, TRENDS CELL BIOL, V5, P317, DOI 10.1016/S0962-8924(00)89054-6; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; Kawasaki ES, 1990, PCR PROTOCOLS GUIDE; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; LIN MCM, 1994, J BIOL CHEM, V269, P29138; LIN MCM, 1995, J LIPID RES, V36, P1073; MAROTTI KR, 1989, GENE ANAL TECH, V6, P67, DOI 10.1016/0735-0651(89)90017-4; NAIM HY, 1988, J BIOL CHEM, V263, P19709; NARCISI TME, 1995, AM J HUM GENET, V57, P1298; RICCI B, 1995, J BIOL CHEM, V270, P14281, DOI 10.1074/jbc.270.24.14281; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; SHARP D, 1994, BIOCHEMISTRY-US, V33, P9057, DOI 10.1021/bi00197a005; SHOULDERS CC, 1993, HUM MOL GENET, V2, P2109, DOI 10.1093/hmg/2.12.2109; SHOULDERS CC, 1994, NAT STRUCT BIOL, V1, P285, DOI 10.1038/nsb0594-285; WETTERAU JR, 1992, SCIENCE, V258, P999; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P9728, DOI 10.1021/bi00104a023; WETTERAU JR, 1986, BIOCHIM BIOPHYS ACTA, V875, P610, DOI 10.1016/0005-2760(86)90084-6	21	68	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29945	29952		10.1074/jbc.271.47.29945	http://dx.doi.org/10.1074/jbc.271.47.29945			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939939	hybrid			2022-12-25	WOS:A1996VU52500067
J	Robinson, MJ; Cheng, M; Khokhlatchev, A; Ebert, D; Ahn, N; Guan, KL; Stein, B; Goldsmith, E; Cobb, MH				Robinson, MJ; Cheng, M; Khokhlatchev, A; Ebert, D; Ahn, N; Guan, KL; Stein, B; Goldsmith, E; Cobb, MH			Contributions of the mitogen-activated protein (MAP) kinase backbone and phosphorylation loop to MEK specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; GROWTH-FACTOR; MAMMALIAN-CELLS; PURIFICATION; CASCADE; COMPONENTS; INVITRO; STRESS	To examine the specificity of MEKs for MAP kinase family members, we determined the abilities of several MEK isoforms to phosphorylate mutants of the MAP kinase ERK2 and the related kinase ERK3 which are modified in the phosphorylation loop, The ERK2 mutants included mutations of the two phosphorylation sites, mutations of the acidic residue between these two sites, and mutations that shorten the length of this loop. All mutants were tested for phosphorylation by six mammalian MEKs and compared with several wild type MAP kinases. MEK1 and MEK2 phosphorylate a major ity of the ERK2 mutants. MEK2 but not MEK1 will phosphorylate ERK3. Alteration of the residue between the two phosphorylation sites neither dramatically affected the activity of MEK1 and MEK2 toward ERK2 nor conferred recognition by other MEKs. Likewise, reduction of the length of the phosphorylation loop only partially reduces recognition by MEK1 and MEK2 but does not promote recognition by other MEKs. Thus other yet to be identified factors must contribute to the specificity of MEK recognition of MAP kinases.	UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV COLORADO,HOWARD HUGHES MED INST,BOULDER,CO 80309; UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109; SIGNAL PHARMACEUT INC,SAN DIEGO,CA 92121	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; University of Michigan System; University of Michigan				Cobb, Melanie/0000-0003-0833-5473	NIDDK NIH HHS [DK34128] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034128, R01DK034128] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHN NG, 1991, J BIOL CHEM, V266, P4220; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; Butch ER, 1996, J BIOL CHEM, V271, P4230; Cheng M, 1996, J BIOL CHEM, V271, P8951, DOI 10.1074/jbc.271.15.8951; Cheng M, 1996, J BIOL CHEM, V271, P12057, DOI 10.1074/jbc.271.20.12057; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Mansour SJ, 1996, CELL GROWTH DIFFER, V7, P243; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROBBINS DJ, 1992, MOL BIOL CELL, V3, P299, DOI 10.1091/mbc.3.3.299; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Robinson MJ, 1996, BIOCHEMISTRY-US, V35, P5641, DOI 10.1021/bi952723e; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SCOTT A, 1995, J BIOL CHEM, V270, P24540, DOI 10.1074/jbc.270.41.24540; SEGER R, 1992, J BIOL CHEM, V267, P14373; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; Wu XY, 1996, J BIOL CHEM, V271, P3265, DOI 10.1074/jbc.271.6.3265; XU SC, 1995, P NATL ACAD SCI USA, V92, P6808, DOI 10.1073/pnas.92.15.6808; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHANG JD, 1995, STRUCTURE, V3, P299, DOI 10.1016/S0969-2126(01)00160-5; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	35	65	69	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29734	29739		10.1074/jbc.271.47.29734	http://dx.doi.org/10.1074/jbc.271.47.29734			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939908	hybrid			2022-12-25	WOS:A1996VU52500036
J	Coe, IR; Yao, LN; Diamond, I; Gordon, AS				Coe, IR; Yao, LN; Diamond, I; Gordon, AS			The role of protein kinase C in cellular tolerance to ethanol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; ANCHORING PROTEINS; ADENOSINE UPTAKE; XENOPUS-OOCYTES; RECEPTORS; CELLS; INCREASES; PHOSPHORYLATION; LOCALIZATION; ACTIVATION	We have shown that ethanol inhibits uptake of adenosine by a specific nucleoside transporter in NG108-15 neuroblastoma x glioma cells and that cAMP-dependent protein kinase (PKA) activity is required for this inhibition. After chronic exposure to ethanol, adenosine uptake is no longer inhibited on rechallenge with ethanol, i.e. transport has become tolerant to ethanol. Here we show that protein kinase C (PKC) contributes to ethanol-induced tolerance of adenosine transport. Activation of PKC by phorbol esters in control cells results in an ethanol-tolerant phenotype, similar to that produced by chronic ethanol exposure. In addition, chronic exposure to ethanol increases the amounts of alpha, delta, and epsilon PKC. However, reducing PKC activity by inhibition with chelerythrine during chronic exposure to ethanol or down-regulation by phorbol esters prevents the development of ethanol-induced tolerance of adenosine transport. By contrast, the inhibition of PKA activity produces tolerance to ethanol inhibition of adenosine uptake. When protein phosphatase inhibitors are present, inhibiting PKA activity has no effect on ethanol sensitivity of adenosine uptake, suggesting a role for protein phosphatases in the regulation of ethanol sensitivity of uptake. Taken together, our results suggest that PKA and PKC have opposing effects on the ethanol sensitivity of adenosine transport; PKA activity is required for ethanol sensitivity, and PKC activation produces tolerance. Based on these data, we propose that chronic ethanol exposure increases PKC activity, leading to the activation of a protein phosphatase (1 or 2A). This phosphatase then dephosphorylates a PKA-phosphorylated site, which is required for ethanol to inhibit adenosine uptake. Therefore, the sensitivity of adenosine transport to ethanol appears to be maintained by a balance of PKA and protein phosphatase activities, and PKC may regulate phosphatase activity.	UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,ERNEST GALLO CLIN & RES CTR,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,DEPT NEUROL,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,DEPT MOL & CELLULAR PHARMACOL,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,PROGRAM NEUROSCI,SAN FRANCISCO,CA 94110	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco								BECKMANN R, 1994, EUR J BIOCHEM, V222, P335, DOI 10.1111/j.1432-1033.1994.tb18872.x; BLACKSHEAR PJ, 1988, AM J MED SCI, V296, P231, DOI 10.1016/S0002-9629(15)40866-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN Y, 1994, J BIOL CHEM, V269, P7839; Coe IR, 1996, J PHARMACOL EXP THER, V276, P365; DEPETRILLO PB, 1993, ALCOHOL CLIN EXP RES, V17, P351, DOI 10.1111/j.1530-0277.1993.tb00774.x; DILDYMAYFIELD JE, 1995, J NEUROSCI, V15, P3162; DISATNIK MH, 1994, EXP CELL RES, V210, P287, DOI 10.1006/excr.1994.1041; GERWINS P, 1995, N-S ARCH PHARMACOL, V351, P186; GORDON AS, 1986, P NATL ACAD SCI USA, V83, P2105, DOI 10.1073/pnas.83.7.2105; HARRIS RA, 1995, P NATL ACAD SCI USA, V92, P3658, DOI 10.1073/pnas.92.9.3658; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HOEK JB, 1993, ALCOHOL, CELL MEMBRANES, AND SIGNAL TRANSDUCTION IN BRAIN, P219; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; INAGAKI N, 1994, TRENDS BIOCHEM SCI, V19, P448, DOI 10.1016/0968-0004(94)90128-7; KHARBANDA S, 1993, BIOCHEM PHARMACOL, V45, P675, DOI 10.1016/0006-2952(93)90142-J; KRAUSS SW, 1993, MOL PHARMACOL, V44, P1021; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MESSING RO, 1991, J BIOL CHEM, V266, P23428; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; NAGY LE, 1991, MOL PHARMACOL, V40, P812; NAGY LE, 1990, J BIOL CHEM, V265, P1946; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; SANNA E, 1994, MOL PHARMACOL, V45, P1004; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SKWISH S, 1990, LIFE SCI, V47, P1037, DOI 10.1016/0024-3205(90)90476-8; SNELL LD, 1994, J NEUROCHEM, V62, P1783; SRINIVASAN M, 1994, J BIOL CHEM, V269, P16662; TIPPMER S, 1994, EUR J BIOCHEM, V225, P297, DOI 10.1111/j.1432-1033.1994.00297.x; TRACYS, 1995, J BIOL CHEM, V270, P10587; VAELLO ML, 1994, J BIOL CHEM, V269, P2002; WAFFORD KA, 1992, FEBS LETT, V313, P113, DOI 10.1016/0014-5793(92)81424-K; WEINER JL, 1994, J PHARMACOL EXP THER, V268, P1388; WOLSING DH, 1991, J PHARMACOL EXP THER, V257, P621	34	67	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29468	29472		10.1074/jbc.271.46.29468	http://dx.doi.org/10.1074/jbc.271.46.29468			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910614	hybrid			2022-12-25	WOS:A1996VT05200106
J	Leshkowitz, D; Rozenblatt, O; Nakamura, T; Yano, T; Dautry, F; Croce, CM; Canaani, E				Leshkowitz, D; Rozenblatt, O; Nakamura, T; Yano, T; Dautry, F; Croce, CM; Canaani, E			ALL-1 interacts with unr, a protein containing multiple cold shock domains	ONCOGENE			English	Article						yeast two hybrid screening; nucleic acid-binding proteins	NUCLEIC-ACID-BINDING; Y-BOX; N-RAS; DROSOPHILA-TRITHORAX; BACILLUS-SUBTILIS; DNA-BINDING; TRANSCRIPTION FACTOR; ACUTE LEUKEMIAS; GENE; MOTIF	The ALL-1 gene is involved in human acute leukemia through chromosome translocations and fusion to partner genes, or through partial tandem duplications, ALL-1 is the human homologue of Drosophila trithorax which transregulates the homeotic genes of the Antennapedia and bithorax complexes controlling body segment identity, ALL-1 encodes a very large protein of 3968 amino acids which presumably interacts with many proteins, Here we applied yeast two hybrid screening to identify proteins interacting with the N-terminal segment of ALL-1, One protein obtained in this way was the product of the unr gene, This protein consists of multiple repeats homologous to the cold shock domain (CSD), a motif common to some bacterial and eukaryotic nucleic acids-binding proteins, The minimal region on unr required for the interaction with ALL-1 included two CSD and two intervening polypeptides. The interaction was confirmed by in vitro binding studies, and by coimmunoprecipitation from COS cells overexpressing the relevant segments of the two proteins, These results suggest that unr is involved in an interaction of ALL-1 with DNA or RNA.	WEIZMANN INST SCI,DEPT MOL CELL BIOL,IL-76100 REHOVOT,ISRAEL; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,JEFFERSON CANC INST,PHILADELPHIA,PA 19107; INST RECH CANC,CNRS,F-94801 VILLEJUIF,FRANCE	Weizmann Institute of Science; Jefferson University; Centre National de la Recherche Scientifique (CNRS)			Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647				AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; ALLAIN KS, 1990, GENE CHROMOSOME CANC, V2, P53; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BERNARD OA, 1995, GENE CHROMOSOME CANC, V13, P75, DOI 10.1002/gcc.2870130202; CANAANI E, 1995, ADV CANCER RES, V66, P213, DOI 10.1016/S0065-230X(08)60255-9; CORTES P, 1994, P NATL ACAD SCI USA, V91, P7633, DOI 10.1073/pnas.91.16.7633; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; DONIGER J, 1988, NUCLEIC ACIDS RES, V16, P969, DOI 10.1093/nar/16.3.969; DONIGER J, 1992, NEW BIOL, V4, P389; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Fidanza V, 1996, CANCER RES, V56, P1179; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GAI XX, 1992, NUCLEIC ACIDS RES, V20, P601, DOI 10.1093/nar/20.3.601; GOLDSTEIN J, 1990, P NATL ACAD SCI USA, V87, P283, DOI 10.1073/pnas.87.1.283; GRANT CE, 1993, MOL CELL BIOL, V13, P4186, DOI 10.1128/MCB.13.7.4186; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; JACQUEMINSABLON H, 1994, NUCLEIC ACIDS RES, V22, P2643, DOI 10.1093/nar/22.13.2643; JEFFERS M, 1990, NUCLEIC ACIDS RES, V18, P4891; KUZIN B, 1994, GENE DEV, V8, P2478, DOI 10.1101/gad.8.20.2478; MURRAY MT, 1994, BIOCHEMISTRY-US, V33, P13910, DOI 10.1021/bi00250a046; NICOLAIEW N, 1991, ONCOGENE, V6, P721; OZER J, 1990, J BIOL CHEM, V265, P22143; Prasad R, 1995, P NATL ACAD SCI USA, V92, P12160, DOI 10.1073/pnas.92.26.12160; RAIMONDI SC, 1993, BLOOD, V81, P2237; SAHA V, 1995, P NATL ACAD SCI USA, V92, P9737, DOI 10.1073/pnas.92.21.9737; SCHICHMAN SA, 1995, JAMA-J AM MED ASSOC, V273, P571, DOI 10.1001/jama.273.7.571; SCHINDELIN H, 1993, NATURE, V364, P164, DOI 10.1038/364164a0; SCHNUCHEL A, 1993, NATURE, V364, P169, DOI 10.1038/364169a0; Sommerville J, 1996, FASEB J, V10, P435, DOI 10.1096/fasebj.10.4.8647342; TAFURI SR, 1990, P NATL ACAD SCI USA, V87, P9028, DOI 10.1073/pnas.87.22.9028; TILLIB S, 1995, MECH DEVELOP, V52, P1; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; WILLIMSKY G, 1992, J BACTERIOL, V174, P6326, DOI 10.1128/JB.174.20.6326-6335.1992; WISTOW G, 1990, NATURE, V344, P823, DOI 10.1038/344823c0; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0	36	11	12	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 7	1996	13	9					2027	2031						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934551				2022-12-25	WOS:A1996VR79500024
J	Sincoff, R; Tanguy, J; Hamilton, B; Carter, D; Brunner, EA; Yeh, JZ				Sincoff, R; Tanguy, J; Hamilton, B; Carter, D; Brunner, EA; Yeh, JZ			Halothane acts as a partial agonist of the alpha 6 beta 2 gamma 2S GABA(A) receptor	FASEB JOURNAL			English	Article						volatile anesthetics; HEK 293 cells	GAMMA-AMINOBUTYRIC-ACID; RAT HIPPOCAMPAL-NEURONS; SUBUNIT MESSENGER-RNAS; ROOT GANGLION NEURONS; VOLATILE ANESTHETICS; PYRAMIDAL NEURONS; CHANNEL COMPLEX; A RECEPTORS; PROPOFOL; ENHANCEMENT	Whole-cell patch clamp recording was performed on human embryonic kidney 293 cells stably transfected with rat cDNAs for the alpha 6, beta 2, and gamma 2S subunits of the GABA(A) receptor, The volatile anesthetic halothane directly activated a current in the absence of the ligand gamma-aminobutyric acid (GABA), Both the current amplitude and the rate of desensitization increased in a dose-dependent manner with an EC(50) of 1.0+/-0.2 mM and a Hill coefficient (n(h)) of 1.5+/-0.1, The EC(50) and n(h) for GABA to activate the receptor were 1.0+/-0.3 mu M and 1.4+/-0.2, respectively, The peak amplitude of the halothane-activated current was about 4% of the maximal GABA response, which was not changed when the concentration of Ca2+ in the external solution was decreased from 2 mM to 0.2 mM. The reversal potential of both halothane- and GABA-activated currents changed with the external Cl- concentration as predicted by the Nernst equation for chloride ions, The halothane- and GABA-activated currents were blocked by both the noncompetitive GABA(A) receptor antagonist picrotoxin and the competitive GABA(A) receptor antagonist bicuculline. Schild plots revealed that the K(i)s for bicuculline to competitively antagonize the currents activated by halothane and GABA are similar (0.69 and 0.72 mu M, respectively), These results indicate that halothane activates the alpha 6 beta 2 gamma 2S GABA(A) receptor to induce a current similar to the GABA-induced current.	NORTHWESTERN UNIV,SCH MED,DEPT BIOL CHEM & MOL PHARMACOL,CHICAGO,IL 60611; NORTHWESTERN UNIV,SCH MED,DEPT ANESTHESIOL,CHICAGO,IL 60611; UPJOHN CO,CNS DIS RES,KALAMAZOO,MI 49001	Northwestern University; Northwestern University; Pfizer								ADODRA S, 1995, BRIT J PHARMACOL, V115, P953, DOI 10.1111/j.1476-5381.1995.tb15903.x; BORMANN J, 1987, J PHYSIOL-LONDON, V385, P243, DOI 10.1113/jphysiol.1987.sp016493; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; HALES TG, 1991, BRIT J PHARMACOL, V104, P619, DOI 10.1111/j.1476-5381.1991.tb12479.x; HALL AC, 1994, BRIT J PHARMACOL, V112, P906, DOI 10.1111/j.1476-5381.1994.tb13166.x; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAMILTON BJ, 1993, NEUROSCI LETT, V153, P206, DOI 10.1016/0304-3940(93)90323-D; HARA M, 1994, ANESTHESIOLOGY, V81, P988, DOI 10.1097/00000542-199410000-00026; HARA M, 1993, ANESTHESIOLOGY, V79, P781, DOI 10.1097/00000542-199310000-00021; IM WB, 1991, MOL PHARMACOL, V39, P394; JONES MV, 1995, J PHARMACOL EXP THER, V274, P962; JONES MV, 1992, J PHYSIOL-LONDON, V449, P279, DOI 10.1113/jphysiol.1992.sp019086; LAURIE DJ, 1992, J NEUROSCI, V12, P1063; LONGONI B, 1993, J PHARMACOL EXP THER, V266, P153; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; MALHERBE P, 1990, FEBS LETT, V260, P261, DOI 10.1016/0014-5793(90)80118-3; MOODY EJ, 1988, J NEUROCHEM, V51, P1386, DOI 10.1111/j.1471-4159.1988.tb01102.x; NAKAHIRO M, 1989, FASEB J, V3, P1850, DOI 10.1096/fasebj.3.7.2541038; NICOLL RA, 1980, BRAIN RES, V191, P225, DOI 10.1016/0006-8993(80)90325-X; ORSER BA, 1994, J NEUROSCI, V14, P7747; PERSOHN E, 1991, NEUROSCIENCE, V42, P497, DOI 10.1016/0306-4522(91)90392-2; ROBERTSON B, 1989, BRIT J PHARMACOL, V98, P167, DOI 10.1111/j.1476-5381.1989.tb16878.x; SANNA E, 1995, J PHARMACOL EXP THER, V274, P353; SANNA E, 1995, MOL PHARMACOL, V47, P213; SCHULZ DW, 1981, BRAIN RES, V209, P177, DOI 10.1016/0006-8993(81)91179-3; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SETO T, 1992, J PHARMACEUT BIOMED, V10, P1, DOI 10.1016/0731-7085(92)80003-6; SIVILOTTI L, 1991, PROG NEUROBIOL, V36, P35, DOI 10.1016/0301-0082(91)90036-Z; TANGUY J, 1995, PROG ANESTH MECH, V3, P82; VALEYEV AY, 1993, NEUROSCI LETT, V155, P199, DOI 10.1016/0304-3940(93)90707-R; WAKAMORI M, 1991, J NEUROPHYSIOL, V66, P2014, DOI 10.1152/jn.1991.66.6.2014; Winters W D, 1982, Prog Drug Res, V26, P225; WISDEN W, 1992, J NEUROSCI, V12, P1040; YANG J, 1992, FASEB J, V6, P914, DOI 10.1096/fasebj.6.3.1740240; YEH JZ, 1994, ANESTHESIOLOGY, V81, pA800	36	16	16	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1996	10	13					1539	1545		10.1096/fasebj.10.13.8940300	http://dx.doi.org/10.1096/fasebj.10.13.8940300			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VU982	8940300				2022-12-25	WOS:A1996VU98200011
J	Balsinde, J; Dennis, EA				Balsinde, J; Dennis, EA			Bromoenol lactone inhibits magnesium-dependent phosphatidate phosphohydrolase and blocks triacylglycerol biosynthesis in mouse P388D(1) macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDEPENDENT PHOSPHOLIPASE A(2); ARACHIDONIC-ACID RELEASE; PROTEIN-KINASE-C; PERITONEAL-MACROPHAGES; MEDIATED PHAGOCYTOSIS; PANCREATIC-ISLETS; INSULIN-SECRETION; HUMAN NEUTROPHILS; PLASMA-MEMBRANE; RAT-LIVER	Bromoenol lactone (BEL) has previously been identified as a potent, irreversible, mechanism-based phospholipase A(2) (PLA(2)) inhibitor that possesses greater than 1000-fold selectivity for inhibition of Ca2+-independent PLA(2) (iPLA(2)) versus the Ca2+-dependent ones. Thus, this compound has been used as a selective tool for studies aimed at elucidating the role of iPLA(2) in certain cellular functions, Herein we report that BEL also inhibits cellular phosphatidic acid phosphohydrolase (PAP) activity in intact P388D(1) macrophages with an IC50 of about 8 mu M, which is very similar to that previously found for inhibition of iPLA(2), under the same experimental conditions, This results in the blockage of the incorporation of exogenous arachidonate and palmitate into diacylglycerol and triacylglycerol, Thus, inhibition of PAP by BEL blocks triacylglycerol biosynthesis in P388D(1) cells due to decreased diacylglycerol availability, Because two forms of PAP activity exist in mammalian cells, differential assays were performed to identify which of these forms was inhibited by BEL. The results of these experiments revealed that BEL selectively inhibits the cytosolic, Mg2+-dependent enzyme. No apparent effect of EEL on the membrane-bound Mg2+-independent PAP form could be detected, Collectively, the results reported herein establish that BEL inhibits two cellular phospholipases, namely iPLA(2) and Mg2+-dependent PAP, with similar potency, Therefore, the inhibitory effect of BEL on Mg2+-dependent PAP might explain several cellular functions previously attributed to iPLA(2).	UNIV CALIF SAN DIEGO,REVELL COLL,DEPT CHEM & BIOCHEM,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego			Balsinde, Jesús/C-7833-2018; Dennis, Edward A./M-5554-2019	Balsinde, Jesús/0000-0002-4157-6714; Dennis, Edward A./0000-0003-3738-3140	NICHD NIH HHS [HD 26,171] Funding Source: Medline; NIGMS NIH HHS [GM 20,501] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026171] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ACKERMANN EJ, 1995, BBA-LIPID LIPID MET, V1259, P125, DOI 10.1016/0005-2760(95)00143-Z; ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; BALBOA MA, 1995, J BIOL CHEM, V270, P11738, DOI 10.1074/jbc.270.20.11738; Balsinde J, 1996, EUR J BIOCHEM, V235, P480, DOI 10.1111/j.1432-1033.1996.00480.x; BALSINDE J, 1991, J BIOL CHEM, V266, P15638; BALSINDE J, 1992, BIOCHIM BIOPHYS ACTA, V1136, P75, DOI 10.1016/0167-4889(92)90087-R; BALSINDE J, 1994, P NATL ACAD SCI USA, V91, P11060, DOI 10.1073/pnas.91.23.11060; BALSINDE J, 1994, EUR J BIOCHEM, V221, P1013, DOI 10.1111/j.1432-1033.1994.tb18818.x; BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8527, DOI 10.1073/pnas.92.18.8527; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BALSINDE J, 1996, IN PRESS EICOSANOIDS; BLANK ML, 1992, BIOCHIM BIOPHYS ACTA, V1124, P262, DOI 10.1016/0005-2760(92)90138-L; BLANK ML, 1993, BIOCHIM BIOPHYS ACTA, V1170, P275, DOI 10.1016/0005-2760(93)90010-7; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brindley DN, 1996, CHEM PHYS LIPIDS, V80, P45, DOI 10.1016/0009-3084(96)02545-5; Chilton FH, 1996, BBA-LIPID LIPID MET, V1299, P1, DOI 10.1016/0005-2760(95)00169-7; DANIELS SB, 1983, J BIOL CHEM, V258, P5046; DAY CP, 1992, BIOCHIM BIOPHYS ACTA, V1127, P87, DOI 10.1016/0005-2760(92)90205-A; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DENNIS EA, 1992, METHOD ENZYMOL, V209, P1; GROSS RW, 1995, J BIOL CHEM, V270, P14855, DOI 10.1074/jbc.270.25.14855; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; JAMAL Z, 1991, J BIOL CHEM, V266, P2988; KARIMI K, 1995, J IMMUNOL, V155, P5786; KESTER M, 1993, J CELL PHYSIOL, V156, P317, DOI 10.1002/jcp.1041560214; KONRAD RJ, 1994, BIOCHEMISTRY-US, V33, P13284, DOI 10.1021/bi00249a015; Lands W., 1976, ENZYMES BIOL MEMBRAN, V2, P3; LEHMAN JJ, 1993, J BIOL CHEM, V268, P20713; LEHNER R, 1995, J BIOL CHEM, V270, P13630, DOI 10.1074/jbc.270.23.13630; LENNARTZ MR, 1993, J LEUKOCYTE BIOL, V54, P389, DOI 10.1002/jlb.54.5.389; Ma ZM, 1996, J BIOL CHEM, V271, P1029, DOI 10.1074/jbc.271.2.1029; MARTIN A, 1994, SIGNAL ACTIVATED PHO, P139; MORLOCK KR, 1991, J BIOL CHEM, V266, P3586; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P337, DOI 10.1021/bi00052a042; ROSSI F, 1991, J BIOL CHEM, V266, P8034; TOU JS, 1995, BIOCHEM J, V30, P373; TRIGGIANI M, 1995, J EXP MED, V182, P1181, DOI 10.1084/jem.182.5.1181; TRIGGIANI M, 1994, J IMMUNOL, V152, P1394	39	183	185	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					31937	31941		10.1074/jbc.271.50.31937	http://dx.doi.org/10.1074/jbc.271.50.31937			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943239	hybrid, Green Published			2022-12-25	WOS:A1996VY34000030
J	Cohen, NA; Sha, Q; Makhina, EN; Lopatin, AN; Linder, ME; Snyder, SH; Nichols, CG				Cohen, NA; Sha, Q; Makhina, EN; Lopatin, AN; Linder, ME; Snyder, SH; Nichols, CG			Inhibition of an inward rectifier potassium channel (Kim2.3) by G-protein beta gamma subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFYING K+ CURRENT; FUNCTIONAL EXPRESSION; PERTUSSIS TOXIN; ANGIOTENSIN-II; CELLS; BRAIN; ACTIVATION; CLONING; IDENTIFICATION; MODULATION	The molecular basis of G-protein inhibition of inward rectifier K+ currents was examined by co-expression of G-proteins and cloned Kir2 channel subunits in Xenopus oocytes, Channels encoded by Kir2.3 (HRK1/HIR/BIRK2/BIR11) were completely suppressed by co-expression with G-protein beta gamma subunits, whereas channels encoded by Kir2.1 (IRK1), which shares 60% amino acid identity with Kir2.3, were unaffected, Co-expression of G alpha(il) and G alpha(q) subunits also partially suppressed Kir2.3 currents, but G alpha(t), G alpha(s), and a constitutively active mutant of G alpha(il) (Q204L) were ineffective. G beta gamma and Kir2.3 subunits were co-immunoprecipitated using an anti-Kir2.3 antibody. Direct binding of G-protein beta gamma subunits to fusion proteins containing Kir2.3 N terminus, but not to fusion proteins containing Kir2.1 N terminus, was also demonstrated, The results are consistent with suppression of Kir2.3 currents resulting from a direct protein-protein interaction between the channel and G-protein beta gamma subunits, When Kir2.1 and Kir2.3 subunits were coexpressed, the G-protein inhibitory phenotype of Kir2.3 was dominant, suggesting that co-expression of Kir2.3 with other Kir subunits might give rise to novel G-protein-inhibitable inward rectifier currents.	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT,BALTIMORE,MD 21205	Washington University (WUSTL); Johns Hopkins University; Johns Hopkins University; Johns Hopkins University			Nichols, Colin/D-6336-2012; Linder, Maurine/AAU-9999-2021	Linder, Maurine/0000-0003-2202-9712; Cohen, Noam/0000-0002-9462-3932	NHLBI NIH HHS [HL54171, HL45742] Funding Source: Medline; NIGMS NIH HHS [GM50556] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054171, R01HL045742] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAUER CK, 1990, J PHYSIOL-LONDON, V429, P169, DOI 10.1113/jphysiol.1990.sp018250; BLACKSTONE CD, 1992, ANN NEUROL, V31, P680, DOI 10.1002/ana.410310620; BREDT DS, 1995, P NATL ACAD SCI USA, V92, P6753, DOI 10.1073/pnas.92.15.6753; CARBONAROHALL D, 1993, ONCOGENE, V8, P1649; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; Chuang H., 1996, Biophysical Journal, V70, pA73; COVARRUBIAS M, 1991, NEURON, V7, P763, DOI 10.1016/0896-6273(91)90279-9; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; FARGON F, 1990, PFLUG ARCH EUR J PHY, V417, P240, DOI 10.1007/BF00370706; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GLOWATZKI E, 1995, P ROY SOC B-BIOL SCI, V261, P251, DOI 10.1098/rspb.1995.0145; Henry P, 1996, J PHYSIOL-LONDON, V495, P681, DOI 10.1113/jphysiol.1996.sp021625; HERMOUET S, 1992, FEBS LETT, V312, P223, DOI 10.1016/0014-5793(92)80940-I; Horio Y, 1996, FEBS LETT, V379, P239, DOI 10.1016/0014-5793(95)01519-1; HOYER J, 1991, J MEMBRANE BIOL, V123, P55, DOI 10.1007/BF01993963; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; ILSCHNER S, 1995, NEUROSCIENCE, V66, P983, DOI 10.1016/0306-4522(95)00030-M; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P29059, DOI 10.1074/jbc.270.49.29059; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; KUNKEL MT, 1995, CELL, V83, P443, DOI 10.1016/0092-8674(95)90122-1; KURTZ A, 1989, P NATL ACAD SCI USA, V86, P3423, DOI 10.1073/pnas.86.9.3423; LINDER ME, 1991, J BIOL CHEM, V266, P4654; MAKHINA EN, 1994, J BIOL CHEM, V269, P20468; MCCLOSKEY MA, 1990, J GEN PHYSIOL, V95, P205, DOI 10.1085/jgp.95.2.205; NAKAJIMA Y, 1988, P NATL ACAD SCI USA, V85, P3643, DOI 10.1073/pnas.85.10.3643; NICHOLS CG, 1997, IN PRESS ANN REV PHY; PERIER F, 1994, P NATL ACAD SCI USA, V91, P6240, DOI 10.1073/pnas.91.13.6240; PFAFFINGER P, 1988, J NEUROSCI, V8, P3343; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; Roche KW, 1996, NEURON, V16, P1179, DOI 10.1016/S0896-6273(00)80144-0; SABATINI DM, 1995, J BIOL CHEM, V270, P20875, DOI 10.1074/jbc.270.36.20875; SLESINGER PA, 1995, NEURON, V15, P1145, DOI 10.1016/0896-6273(95)90102-7; Wang HS, 1996, J PHYSIOL-LONDON, V492, P467, DOI 10.1113/jphysiol.1996.sp021322; WICKMAN K, 1995, PHYSIOL REV, V75, P865, DOI 10.1152/physrev.1995.75.4.865; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; WIELAND SJ, 1995, AM J PHYSIOL-CELL PH, V268, pC490, DOI 10.1152/ajpcell.1995.268.2.C490; WU WH, 1994, P NATL ACAD SCI USA, V91, P6310, DOI 10.1073/pnas.91.14.6310; Yang J, 1995, NEURON, V15, P1441, DOI 10.1016/0896-6273(95)90021-7	40	49	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32301	32305		10.1074/jbc.271.50.32301	http://dx.doi.org/10.1074/jbc.271.50.32301			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943291	hybrid			2022-12-25	WOS:A1996VY34000082
J	Fan, F; Macnab, RM				Fan, F; Macnab, RM			Enzymatic characterization of FliI - An ATPase involved in flagellar assembly in Salmonella typhimurium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI F1-ATPASE; SITE-DIRECTED MUTAGENESIS; GRAM-NEGATIVE BACTERIA; BETA-SUBUNIT; ANGSTROM RESOLUTION; SECA-PROTEIN; F0F1 ATPASE; BINDING; MUTANTS; MITOCHONDRIA	FliI is a protein needed for flagellar assembly in Salmonella typhimurium. It shows sequence similarity to the catalytic beta subunit of the F0F1-ATPase and is even more closely related to putative ATPases in Type III bacterial secretory pathways. A His-tagged version of FliI, which was fully functional in complementation tests, was purified to homogeneity. It had an ATPase activity of 0.16 s(-1) at 25 degrees C and pH 7, and a K-m for ATP of 0.3 mM; Mg2+ was required. The activity was not affected by inhibitors of the F-, V- or P-type ATPases, or inhibitors of the Type I or Type II bacterial secretory pathways. Mutations K188I and Y363S decreased the ATPase activity about 100 fold, increased the K-m about 10-fold, blocked flagellar assembly, and were dominant. Other FliI mutations that disrupted flagellar protein export were found near the N terminus; they permitted essentially wild-type ATPase activity, were not dominant, and showed a dosage-dependent phenotype. We propose that FliI has a C-terminal ATPase domain and an N-terminal domain that interacts with other components in the flagellum-specific export apparatus.	YALE UNIV,DEPT MOL BIOPHYS & BIOCHEM,NEW HAVEN,CT 06520	Yale University					NIAID NIH HHS [AI12202] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Aizawa SI, 1996, MOL MICROBIOL, V19, P1, DOI 10.1046/j.1365-2958.1996.344874.x; ALBERTINI AM, 1991, J BACTERIOL, V173, P3573, DOI 10.1128/jb.173.11.3573-3579.1991; AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; Ballado T, 1996, GENE, V170, P69, DOI 10.1016/0378-1119(95)00855-1; BOWMAN BJ, 1986, J MEMBRANE BIOL, V94, P83, DOI 10.1007/BF01871190; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; Cleland W W, 1979, Methods Enzymol, V63, P103; CROSS RL, 1987, P NATL ACAD SCI USA, V84, P5715, DOI 10.1073/pnas.84.16.5715; DELEPELAIRE P, 1994, J BIOL CHEM, V269, P27952; DREYFUS G, 1993, J BACTERIOL, V175, P3131, DOI 10.1128/JB.175.10.3131-3138.1993; DUBENDORFF JW, 1991, J MOL BIOL, V219, P45, DOI 10.1016/0022-2836(91)90856-2; EICHELBERG K, 1994, J BACTERIOL, V176, P4501, DOI 10.1128/JB.176.15.4501-4510.1994; EMERSON SU, 1970, SCIENCE, V169, P190, DOI 10.1126/science.169.3941.190; FATH MJ, 1993, MICROBIOL REV, V57, P995, DOI 10.1128/MMBR.57.4.995-1017.1993; Galan JE, 1996, MOL MICROBIOL, V20, P263, DOI 10.1111/j.1365-2958.1996.tb02615.x; GAO BC, 1994, BIOCHEMISTRY-US, V33, P2048, DOI 10.1021/bi00174a010; Ge YG, 1996, GENE, V168, P73, DOI 10.1016/0378-1119(95)00743-1; GOODFELLOW IG, 1996, FEMS MICROBIOL LETT, V1142, P111; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; IINO T, 1969, J GEN MICROBIOL, V56, P227, DOI 10.1099/00221287-56-2-227; JONES CJ, 1990, J BACTERIOL, V172, P1327, DOI 10.1128/jb.172.3.1327-1339.1990; JONES CJ, 1989, J BACTERIOL, V171, P3890, DOI 10.1128/jb.171.7.3890-3900.1989; KORONAKIS E, 1995, MOL MICROBIOL, V16, P87, DOI 10.1111/j.1365-2958.1995.tb02394.x; KORONAKIS V, 1993, MOL MICROBIOL, V8, P1163, DOI 10.1111/j.1365-2958.1993.tb01661.x; KUBORI T, 1992, J MOL BIOL, V226, P433, DOI 10.1016/0022-2836(92)90958-M; KUSUKAWA N, 1990, BIOTECHNIQUES, V9, P66; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LEE RSF, 1989, FEBS LETT, V253, P269, DOI 10.1016/0014-5793(89)80973-1; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; MACARA IG, 1980, TRENDS BIOCHEM SCI, V5, P92, DOI 10.1016/0968-0004(80)90256-X; Macnab R., 1996, ESCHERICHIA COLI SAL, V2nd ed, P119; MACNAB RM, 1976, J CLIN MICROBIOL, V4, P258; MIMORI Y, 1995, J MOL BIOL, V249, P69, DOI 10.1006/jmbi.1995.0281; MORBACH S, 1993, J BIOL CHEM, V268, P18617; MORGAN DG, 1995, J MOL BIOL, V249, P88, DOI 10.1006/jmbi.1995.0282; NEUHARD J, 1987, ESCHERICHIA COLI SAL, V1, P445; NOUMI T, 1987, FEBS LETT, V213, P381, DOI 10.1016/0014-5793(87)81526-0; OBrien MC, 1996, J BIOL CHEM, V271, P15874, DOI 10.1074/jbc.271.27.15874; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; PALLEROS DR, 1994, J BIOL CHEM, V269, P13107; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; PARSONAGE D, 1987, J BIOL CHEM, V262, P8022; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PERCZEL A, 1992, ANAL BIOCHEM, V203, P83, DOI 10.1016/0003-2697(92)90046-A; POSSOT O, 1994, MOL MICROBIOL, V12, P287, DOI 10.1111/j.1365-2958.1994.tb01017.x; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; SALMOND GPC, 1993, TRENDS BIOCHEM SCI, V18, P7, DOI 10.1016/0968-0004(93)90080-7; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATRE M, 1979, BIOCHEMISTRY-US, V18, P3134, DOI 10.1021/bi00581a034; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; Schoenhals GJ, 1996, J BACTERIOL, V178, P4200, DOI 10.1128/jb.178.14.4200-4207.1996; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SLONCZEWSKI JL, 1981, P NATL ACAD SCI-BIOL, V78, P6271, DOI 10.1073/pnas.78.10.6271; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAKEDA K, 1985, J BIOCHEM-TOKYO, V97, P1401, DOI 10.1093/oxfordjournals.jbchem.a135194; VOGEL G, 1976, BIOCHEMISTRY-US, V15, P208, DOI 10.1021/bi00646a032; VOGLER AP, 1991, J BACTERIOL, V173, P3564, DOI 10.1128/jb.173.11.3564-3572.1991; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; WEBER J, 1992, BIOCHEMISTRY-US, V31, P5112, DOI 10.1021/bi00137a004; WILLIAMS AW, 1995, THESIS YALE U NEW HA; WISE JG, 1984, BIOCHEMISTRY-US, V23, P1426, DOI 10.1021/bi00302a014; WISE JG, 1990, J BIOL CHEM, V265, P10403; WISE JG, 1983, BIOCHEM J, V215, P343, DOI 10.1042/bj2150343; WOO THS, 1992, BIOTECHNIQUES, V13, P696; YAMAGUCHI S, 1984, J GEN MICROBIOL, V130, P3339	70	128	128	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					31981	31988		10.1074/jbc.271.50.31981	http://dx.doi.org/10.1074/jbc.271.50.31981			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943245	hybrid			2022-12-25	WOS:A1996VY34000036
J	Weber, IT; Harrison, RW; Iozzo, RV				Weber, IT; Harrison, RW; Iozzo, RV			Model structure of decorin and implications for collagen fibrillogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH REPEATS; PROTEIN; BINDING; CDNA; CLONING	The three-dimensional structure of human decorin, a secreted proteoglycan involved in the regulation of collagen fibrillogenesis and cellular growth, has been modeled based on the crystal structure of the porcine ribonuclease inhibitor. Both proteins contain leucine-rich repeats and share 18% identical residues. This model structure of decorin has an arch shape with the single glycosaminoglycan chain and the three N-linked oligosaccharides located on the same side of the molecule. Decorin was modeled as binding to a polar sequence of collagen type I found in the d band. The inner concave surface is the appropriate size and shape to accommodate only one collagen triple helix of similar to 3 nm in length. The binding of one collagen triple helix to decorin is proposed to play a major role in the formation of the staggered arrangement of collagen molecules within the microfibrils by preventing lateral fusion of collagen molecules.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT PATHOL ANAT & CELL BIOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT BIOCHEM & MOL PHARMACOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,KIMMEL CANC CTR,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University; Jefferson University			Iozzo, Renato/AAS-1980-2020	Harrison, Robert/0000-0003-2449-1214; Iozzo, Renato/0000-0002-5908-5112				BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; DAY AA, 1987, BIOCHEM J, V248, P801, DOI 10.1042/bj2480801; GREER J, 1990, PROTEINS, V7, P317, DOI 10.1002/prot.340070404; HARRISON RW, 1993, J COMPUT CHEM, V14, P1112, DOI 10.1002/jcc.540140912; Harrison RW, 1995, PROTEINS, V23, P463, DOI 10.1002/prot.340230402; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; KAJAVA AV, 1995, STRUCTURE, V3, P867, DOI 10.1016/S0969-2126(01)00222-2; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LI W, 1992, ARCH BIOCHEM BIOPHYS, V296, P190, DOI 10.1016/0003-9861(92)90562-B; NEMETHY G, 1992, J PHYS CHEM-US, V96, P6472, DOI 10.1021/j100194a068; PIEZ KA, 1984, EXTRACELLULAR MATRIX, P1; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; RING CS, 1993, FASEB J, V7, P783, DOI 10.1096/fasebj.7.9.8330685; SCHOLZEN T, 1994, J BIOL CHEM, V269, P28270; SCHONHERR E, 1995, J BIOL CHEM, V270, P8877, DOI 10.1074/jbc.270.15.8877; SCOTT JE, 1988, BIOCHEM J, V252, P313, DOI 10.1042/bj2520313; SCOTT JE, 1981, BIOCHEM J, V197, P213, DOI 10.1042/bj1970213; Scott JE, 1996, BIOCHEMISTRY-US, V35, P8795, DOI 10.1021/bi960773t; SCOTT Y, 1993, DERMATAN SULPHATE PR, V21, P123; Spiro R.C., 1994, MOL BIOL CELL, V55, P303; SVENSSON L, 1995, J BIOL CHEM, V270, P20712, DOI 10.1074/jbc.270.35.20712; THIESZEN SL, 1994, MATRIX BIOL, V14, P573; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; WEBER IT, 1990, PROTEINS, V7, P172, DOI 10.1002/prot.340070206; Weber IT, 1996, PROTEIN ENG, V9, P679, DOI 10.1093/protein/9.8.679; WINDISCH JM, 1995, J BIOL CHEM, V270, P28133	28	284	289	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					31767	31770		10.1074/jbc.271.50.31767	http://dx.doi.org/10.1074/jbc.271.50.31767			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943211	hybrid			2022-12-25	WOS:A1996VY34000002
J	Kuroda, S; Tokunaga, C; Kiyohara, Y; Higuchi, O; Konishi, H; Mizuno, K; Gill, GN; Kikkawa, U				Kuroda, S; Tokunaga, C; Kiyohara, Y; Higuchi, O; Konishi, H; Mizuno, K; Gill, GN; Kikkawa, U			Protein-protein interaction of zinc finger LIM domains with protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOTIF; HETEROGENEITY; PURIFICATION; SPECIFICITY; EXPRESSION; INHIBITOR	The LIM domain comprising two zinc-finger motifs is found in a variety of proteins and has been proposed to direct protein-protein interactions. During the identification of protein kinase C (PKC)-interacting proteins by a yeast two-hybrid assay, a novel protein containing three LIM domains, designated ENH, was shown to associate with PKC in an isoform-specific manner. Deletion analysis demonstrated that any single LIM domain of ENH associates with the NH2-terminal region of PKC, ENH associated with PKC in COS-7 cells and was phosphorylated by PKC in vitro. Upon treatment of the cells with phorbol ester, ENH in the membrane fraction was translocated to the cytosol fraction in vivo. Other LIM domain-containing proteins, such as Enigma and LIM-kinase 1, also interacted with PKC through their LIM domains. These results suggest that the LIM domain is one of the targets of PHC and that the LIM-PKC interaction may shed light on undefined roles of LIM domain-containing proteins.	KYUSHU UNIV,FAC MED,DEPT BIOL,FUKUOKA 81281,JAPAN; RES DEV CORP JAPAN,PRESTO,INHERITANCE & VARIAT GRP,KYOTO 61902,JAPAN; UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093	Kyushu University; Japan Science & Technology Agency (JST); University of California System; University of California San Diego	Kuroda, S (corresponding author), KOBE UNIV,BIOL RES CTR,NADA KU,1-1 ROKKODAI CHO,KOBE 657,JAPAN.		Mizuno, Kensaku/G-8631-2015					CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; DAWID IB, 1995, CR ACAD SCI III-VIE, V318, P295; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; FEUERSTEIN R, 1994, P NATL ACAD SCI USA, V91, P10655, DOI 10.1073/pnas.91.22.10655; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; IWASA Y, 1980, BIOCHEM BIOPH RES CO, V96, P180, DOI 10.1016/0006-291X(80)91198-5; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; KIKKAWA U, 1986, BIOCHEM BIOPH RES CO, V135, P636, DOI 10.1016/0006-291X(86)90040-9; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; KOBAYASHI E, 1989, J ANTIBIOT, V42, P153, DOI 10.7164/antibiotics.42.153; KOSA JL, 1994, BIOCHEMISTRY-US, V33, P468, DOI 10.1021/bi00168a011; MICHELSEN JW, 1994, J BIOL CHEM, V269, P11108; MIZUNO K, 1994, ONCOGENE, V9, P1605; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Okano I, 1995, J BIOL CHEM, V270, P31321, DOI 10.1074/jbc.270.52.31321; ONO Y, 1987, SCIENCE, V236, P1116, DOI 10.1126/science.3576226; ONO Y, 1988, NUCLEIC ACIDS RES, V16, P5199, DOI 10.1093/nar/16.11.5199; ONO Y, 1986, FEBS LETT, V206, P347, DOI 10.1016/0014-5793(86)81010-9; ONO Y, 1988, J BIOL CHEM, V263, P6927; PEREZALVARADO GC, 1994, STRUCT BIOL, V1, P388; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; WU RY, 1994, J BIOL CHEM, V269, P25085	32	210	221	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31029	31032		10.1074/jbc.271.49.31029	http://dx.doi.org/10.1074/jbc.271.49.31029			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940095	hybrid			2022-12-25	WOS:A1996VW68600006
J	Condon, TP; Bennett, CF				Condon, TP; Bennett, CF			Altered mRNA splicing and inhibition of human E-selectin expression by an antisense oligonucleotide in human umbilical vein endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESION MOLECULE EXPRESSION; MESSENGER-RNA; GENE-EXPRESSION; RIBONUCLEASE; RECOGNITION	We have characterized the mechanism of action of an antisense oligodeoxynucleotide (ASO) targeting human endothelial leukocyte adhesion molecule, E-selectin. LSIS 4730, a 20-base ASO designed to be complementary to a region in the 3'-untranslated region (3'-UTR) of human E-selectin, is a potent and specific inhibitor of both mRNA and protein expression in human umbilical vein endothelial cells, Following treatment with ISIS 4730, a lower molecular weight mRNA (3300 bases) species was detected by Northern blot analysis with a corresponding decrease in the mature E-selectin transcript (3875 bases). The ASO-induced low molecular weight mRNA is stable and remains in the nucleus. We demonstrate that ISIS 4730 targets E-selectin pre-mRNA in the nucleus and promotes cleavage of the pre-mRNA at the hybridization site, resulting in prevention of splicing of the last intron, The change in molecular weight of the E-selectin transcript is the result of loss of the 3'-UTR due to ASO-mediated RNA cleavage and retention of the last intron, Cleavage of the E-selectin pre-mRNA appears to be due to endogenous RNase H or a related enzyme activity.			Condon, TP (corresponding author), ISIS PHARMACEUT,DEPT MOL PHARMACOL,2292 FARADAY AVE,CARLSBAD,CA 92008, USA.							ALTAVILLA D, 1994, EUR J PHARM-ENVIRON, V270, P45, DOI 10.1016/0926-6917(94)90079-5; BEDNARCZUK TA, 1991, BIOTECHNIQUES, V10, P478; Bennett C F, 1994, Adv Pharmacol, V28, P1, DOI 10.1016/S1054-3589(08)60492-5; BENNETT CF, 1992, MOL PHARMACOL, V41, P1023; BENNETT CF, 1994, J IMMUNOL, V152, P3530; BERGAN R, 1993, NUCLEIC ACIDS RES, V21, P3567, DOI 10.1093/nar/21.15.3567; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CAMPBELL JM, 1990, J BIOCHEM BIOPH METH, V20, P259, DOI 10.1016/0165-022X(90)90084-P; CHANG DD, 1989, CELL, V59, P789, DOI 10.1016/0092-8674(89)90602-8; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHU W, 1994, J IMMUNOL, V153, P4179; COLLINS T, 1991, J BIOL CHEM, V266, P2466; COWSERT LM, 1993, ANTIMICROB AGENTS CH, V37, P171, DOI 10.1128/AAC.37.2.171; Crooke ST., 1995, THERAPEUTIC APPL OLI; DAHLE CE, 1993, BIOTECHNIQUES, V15, P1; DOMINSKI Z, 1993, P NATL ACAD SCI USA, V90, P8673, DOI 10.1073/pnas.90.18.8673; FISHER TL, 1993, NUCLEIC ACIDS RES, V21, P3857, DOI 10.1093/nar/21.16.3857; GILES RV, 1992, ANTI-CANCER DRUG DES, V7, P37; GILES RV, 1995, ANTISENSE RES DEV, V5, P23, DOI 10.1089/ard.1995.5.23; GREENBERG ME, 1994, CURRENT PROTOCOLS MO; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; HODGE D, 1995, MOL PHARMACOL, V48, P905; HOGREFE HH, 1990, J BIOL CHEM, V265, P5561; Lebleu B., 1993, ANTISENSE RES APPL; LEGRAIN P, 1989, CELL, V57, P573, DOI 10.1016/0092-8674(89)90127-X; MIRABELLI CK, 1991, ANTI-CANCER DRUG DES, V6, P647; MONIA BP, 1993, J BIOL CHEM, V268, P14514; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515	33	52	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30398	30403		10.1074/jbc.271.48.30398	http://dx.doi.org/10.1074/jbc.271.48.30398			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940003	hybrid			2022-12-25	WOS:A1996VV15800020
J	Karecla, PI; Green, SJ; Bowden, SJ; Coadwell, J; Kilshaw, PJ				Karecla, PI; Green, SJ; Bowden, SJ; Coadwell, J; Kilshaw, PJ			Identification of a binding site for integrin alpha E beta(7) in the N-terminal domain of E-cadherin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; INTRAEPITHELIAL LYMPHOCYTES; INTESTINAL LYMPHOCYTES; CYTOPLASMIC DOMAIN; SURFACE-ANTIGEN; BINDING; UVOMORULIN; VCAM-1; ALPHA-4-BETA-1; SUPERFAMILY	The integrin alpha E beta 7, which is predominantly expressed on mucosal T lymphocytes, has recently been shown to recognize the cell adhesion molecule, E-cadherin, on epithelial cells. We have carried out mutations on E-cadherin, involving domain deletions as web as substitutions of specific amino acids, in order to identify the sites recognized by the integrin. Binding of alpha E beta 7 required the presence of the first two N-terminal domains of E-cadherin, Deletion of extracellular domains 3 and 4 or truncation of the cytoplasmic domain of E-cadherin had no consequence on integrin binding, Substitution of a glutamic acid in the BC loop of the Ig structure of the fist, N-terminal, domain of E-cadherin abrogated binding of alpha E beta 7. This mutation did not appear to affect the conformation of the domain nor the pattern of expression of E-cadherin on the cell surface, Synthetic peptides encompassing the first domain of E-cadherin had very little inhibitory effect on the interaction with alpha E beta 7. Our results highlight structural dissimilarities between recognition of E-cadherin by alpha E beta 7 and recognition of other members of the IgSF by integrins and show that the heterophilic (integrin binding) and homophilic sites in the N-terminal domain of E-cadherin are distinct.	BABRAHAM INST, DEPT IMMUNOL, CAMBRIDGE CB2 4AT, ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute				Bowden, Simon/0000-0003-4609-8114				AUSTRUP F, 1995, EUR J IMMUNOL, V25, P1487, DOI 10.1002/eji.1830250602; BOLLER K, 1985, J CELL BIOL, V100, P3327; Briskin MJ, 1996, J IMMUNOL, V156, P719; CEPEK KL, 1994, NATURE, V372, P1190; CERFBENSUSSAN N, 1987, EUR J IMMUNOL, V17, P1279, DOI 10.1002/eji.1830170910; CERFBENSUSSAN N, 1992, EUR J IMMUNOL, V22, P273, DOI 10.1002/eji.1830220140; CLEMENTS JM, 1994, J CELL SCI, V107, P2127; COWIN P, 1994, P NATL ACAD SCI USA, V91, P10759, DOI 10.1073/pnas.91.23.10759; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; GEIGER B, 1992, ANNU REV CELL BIOL, V8, P307, DOI 10.1146/annurev.cb.08.110192.001515; Grunwald GB, 1993, CURR OPIN CELL BIOL, V5, P797, DOI 10.1016/0955-0674(93)90028-O; HAMANN A, 1994, J IMMUNOL, V152, P3282; HAURY M, 1993, EUR J IMMUNOL, V23, P313, DOI 10.1002/eji.1830230202; HINCK L, 1994, TRENDS BIOCHEM SCI, V19, P538, DOI 10.1016/0968-0004(94)90057-4; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLNESS CL, 1995, J BIOL CHEM, V270, P877, DOI 10.1074/jbc.270.2.877; HOLNESS CL, 1994, J CELL SCI, V107, P2065; KARECLA PI, 1995, EUR J IMMUNOL, V25, P852, DOI 10.1002/eji.1830250333; KILSHAW PJ, 1990, EUR J IMMUNOL, V20, P2201, DOI 10.1002/eji.1830201008; KILSHAW PJ, 1988, IMMUNOL LETT, V18, P149, DOI 10.1016/0165-2478(88)90056-9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LI R, 1993, J BIOL CHEM, V268, P17513; MCNEILL H, 1990, CELL, V62, P309, DOI 10.1016/0092-8674(90)90368-O; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; NOSE A, 1990, CELL, V61, P147, DOI 10.1016/0092-8674(90)90222-Z; NOSE A, 1987, EMBO J, V6, P3655, DOI 10.1002/j.1460-2075.1987.tb02698.x; OSBORN L, 1994, J CELL BIOL, V124, P601, DOI 10.1083/jcb.124.4.601; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; OZAWA M, 1991, MECH DEVELOP, V33, P49; POKUTTA S, 1994, EUR J BIOCHEM, V223, P1019, DOI 10.1111/j.1432-1033.1994.tb19080.x; RENZ ME, 1994, J CELL BIOL, V125, P1395, DOI 10.1083/jcb.125.6.1395; RINGWALD M, 1987, EMBO J, V6, P3647, DOI 10.1002/j.1460-2075.1987.tb02697.x; ROBERTS K, 1993, EUR J IMMUNOL, V23, P1630, DOI 10.1002/eji.1830230735; SARNACKI S, 1991, IMMUNOL RES, V10, P302, DOI 10.1007/BF02919711; SHAPIROO L, 1994, NATURE, V374, P327; SHIRAYOSHI Y, 1986, CELL STRUCT FUNCT, V11, P245, DOI 10.1247/csf.11.245; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Viney JL, 1996, J IMMUNOL, V157, P2488; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; VONDERHEIDE RH, 1994, J CELL BIOL, V125, P215, DOI 10.1083/jcb.125.1.215; WANG JH, 1995, P NATL ACAD SCI USA, V92, P5714, DOI 10.1073/pnas.92.12.5714	48	75	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30909	30915		10.1074/jbc.271.48.30909	http://dx.doi.org/10.1074/jbc.271.48.30909			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940076	hybrid			2022-12-25	WOS:A1996VV15800093
J	Niimura, Y; Massey, V				Niimura, Y; Massey, V			Reaction mechanism of Amphibacillus xylanus NADH oxidase alkyl hydroperoxide reductase flavoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA GLUTATHIONE-PEROXIDASE; SALMONELLA-TYPHIMURIUM; ESCHERICHIA-COLI; THIOREDOXIN REDUCTASE; LACKING CYTOCHROME; PURIFICATION; CATALASE; QUINONE; DISTINCT; ENZYME	NADH oxidase from Amphibacillus xylanus is a potent alkyl hydroperoxide reductase in the presence of the small disulfide-containing protein (AhpC) of Salmonella typhimurium, In the presence of saturating AhpC, k(cat) values for reduction of hydroperoxides are approximately 180 s(-1), and the double mutant flavoprotein enzyme C337S/C340S cannot support hydroperoxide reduction (Niimura, Y., Poole, L. B., and Massey, V. (1995) J. Biol. Chem. 270, 25645-25650). Kinetics of reduction of wild-type and mutant enzymes are reported here with wild-type enzyme; reduction by NADH was triphasic, with consumption of 2.6 equivalents of NADH, consistent with the known composition of one FAD and two disulfides per subunit, Rate constants for the first two phases (each approximately 200 s(-1)) where FAD and one disulfide are reduced are slightly greater than k(cat) values for AhpC-linked hydroperoxide reduction, The rate constant for the third phase (reduction to the 6-electron level) is too small for catalysis, Only the first phase of the wild-type enzyme occurs with the mutant enzyme. These results and the stoichiometry of NADH consumption indicate Cys(337) and Cys(340) as the active site disulfide of the flavoprotein and that electrons from FADH(2) must pass through this disulfide to reduce the disulfide of AhpC.	TOKYO UNIV AGR, DEPT FOOD SCI & TECHNOL, ABASHIRI, HOKKAIDO 09924, JAPAN	Tokyo University of Agriculture	Niimura, Y (corresponding author), UNIV MICHIGAN, SCH MED, DEPT BIOL CHEM, 1301 CATHERINE RD, ANN ARBOR, MI 48109 USA.				NIGMS NIH HHS [GM-11106] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM011106, R37GM011106] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEATY NB, 1981, J BIOL CHEM, V256, P4611; Bevington P. R., 1969, DATA REDUCTION ERROR, P235; BJORNSTEDT M, 1994, J BIOL CHEM, V269, P29382; BRISSETTE P, 1989, ANAL BIOCHEM, V181, P234, DOI 10.1016/0003-2697(89)90235-2; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; CHAUDIERE J, 1983, ARCH BIOCHEM BIOPHYS, V226, P448, DOI 10.1016/0003-9861(83)90314-4; COCCO D, 1988, EUR J BIOCHEM, V174, P267, DOI 10.1111/j.1432-1033.1988.tb14093.x; FLOHE L, 1972, H-S Z PHYSIOL CHEM, V353, P987, DOI 10.1515/bchm2.1972.353.1.987; HIGUCHI M, 1993, J GEN MICROBIOL, V139, P2343, DOI 10.1099/00221287-139-10-2343; JACOBSON FS, 1989, J BIOL CHEM, V264, P1488; KOIKE K, 1985, J BIOCHEM, V97, P1279, DOI 10.1093/oxfordjournals.jbchem.a135179; KOYAMA N, 1988, FEMS MICROBIOL LETT, V49, P128; LITTLE C, 1972, BIOCHIM BIOPHYS ACTA, V284, P375, DOI 10.1016/0005-2744(72)90133-7; NIIMURA Y, 1993, J BACTERIOL, V175, P7945, DOI 10.1128/JB.175.24.7945-7950.1993; NIIMURA Y, 1995, J BIOL CHEM, V270, P25645, DOI 10.1074/jbc.270.43.25645; NIIMURA Y, 1987, AGR BIOL CHEM TOKYO, V51, P2271; NIIMURA Y, 1990, INT J SYST BACTERIOL, V40, P297, DOI 10.1099/00207713-40-3-297; NIIMURA Y, 1989, FEMS MICROBIOL LETT, V61, P79, DOI 10.1016/S0378-1097(98)00072-X; OGURA Y, 1955, ARCH BIOCHEM BIOPHYS, V57, P288, DOI 10.1016/0003-9861(55)90291-5; OHNISHI K, 1995, J BIOL CHEM, V270, P5812, DOI 10.1074/jbc.270.11.5812; OHNISHI K, 1994, J BIOL CHEM, V269, P31418; PARK HJ, 1992, EUR J BIOCHEM, V205, P881, DOI 10.1111/j.1432-1033.1992.tb16853.x; PARSONAGE D, 1993, J BIOL CHEM, V268, P3161; PRONGAY AJ, 1989, J BIOL CHEM, V264, P2656; REINARDS R, 1981, EUR J BIOCHEM, V120, P329, DOI 10.1111/j.1432-1033.1981.tb05708.x; SAEKI Y, 1985, J BIOCHEM-TOKYO, V98, P1433, DOI 10.1093/oxfordjournals.jbchem.a135411; SCHMIDT HL, 1986, EUR J BIOCHEM, V156, P149, DOI 10.1111/j.1432-1033.1986.tb09560.x; TAKAHASHI K, 1987, ARCH BIOCHEM BIOPHYS, V256, P677, DOI 10.1016/0003-9861(87)90624-2; TARTAGLIA LA, 1990, J BIOL CHEM, V265, P10535; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121	31	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30459	30464		10.1074/jbc.271.48.30459	http://dx.doi.org/10.1074/jbc.271.48.30459			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940011	hybrid			2022-12-25	WOS:A1996VV15800028
J	Wakiya, K; Begue, A; Stehelin, D; Shibuya, M				Wakiya, K; Begue, A; Stehelin, D; Shibuya, M			A cAMP response element and an Ets motif are involved in the transcriptional regulation of flt-1 tyrosine kinase (vascular endothelial growth factor receptor 1) gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; PERMEABILITY FACTOR; TUMOR ANGIOGENESIS; BINDING PROTEINS; CELLS SECRETE; C-FOS; EXPRESSION; FAMILY; PROMOTER; IDENTIFICATION	The fit-1 gene encodes a transmembrane tyrosine kinase, Fit-1, a receptor for vascular endothelial growth factor. The expression of fit-1 gene is restricted to endothelial cells in vivo, To understand the molecular mechanism underlying endothelial-specific expression of this gene, we studied the functional significance of transcriptional motifs in the 200-base pair region of the human fit-1 gene promoter, which has been identified to confer cell type specificity. By point mutation analysis using chloramphenicol acetyltransferase plasmids in 293E1 cells, which express significant levels of fit-1 mRNA, me found that an Ets motif, E4, at -54 to -51 and a cAMP response element (GRE) at -83 to -76 are involved in the transcriptional regulation of this gene, Disruption of either this GRE or E4 within the promoter sequence of 90 base pairs resulted in a decrease in chloramphenicol acetyltransferase activity of 90%, indicating that co-existence of both of CRE and Ets motif E4 is necessary for transcription of the fit-1 gene. Go-transfection of an expression vector containing c-ets-l, c-ets-2, or c-erg cDNA with this 90-base pair sequence yielded a 5-8-fold elevation of chloramphenicol acetyltransferase activity, further supporting the idea that Ets family protein(s) participates in the regulation of the fit-1 gene. Gel shift assays using nuclear extracts of 293E1 and endothelial cells demonstrated the existence of protein factor(s) that specifically binds to CRE and Ets motif E4, respectively. Taken together, our results strongly suggest cooperation of a GRE and an Ets motif for the function of the fit-1 gene promoter.	UNIV TOKYO,INST MED SCI,DEPT GENET,MINATO KU,TOKYO 108,JAPAN; INST PASTEUR,CNRS URA 1160,UNITE ONCOL MOL,F-59019 LILLE,FRANCE	University of Tokyo; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille								AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BREIER G, 1992, DEVELOPMENT, V114, P521; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRISCUOLO GR, 1993, YALE J BIOL MED, V66, P277; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUTERQUECOQUILLAUD M, 1993, ONCOGENE, V8, P1865; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GALLAND F, 1993, ONCOGENE, V8, P1233; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IKEDA T, 1996, IN PRESS GROWTH FACT; JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568; KAIPAINEN A, 1993, J EXP MED, V178, P2077, DOI 10.1084/jem.178.6.2077; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MCCLURE N, 1994, LANCET, V344, P235, DOI 10.1016/S0140-6736(94)93001-5; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MORISHITA K, 1995, J BIOL CHEM, V270, P27948, DOI 10.1074/jbc.270.46.27948; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PAJUSOLA K, 1992, CANCER RES, V52, P5738; PATTERSON C, 1995, J BIOL CHEM, V270, P23111, DOI 10.1074/jbc.270.39.23111; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLATE KH, 1993, CANCER RES, V53, P5822; Sambrook J., 2002, MOL CLONING LAB MANU; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHIBUYA M, 1990, ONCOGENE, V5, P519; Shibuya M, 1995, ADV CANCER RES, V67, P281, DOI 10.1016/S0065-230X(08)60716-2; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SHWEIKI D, 1993, J CLIN INVEST, V91, P2235, DOI 10.1172/JCI116450; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TERMAN BI, 1991, ONCOGENE, V6, P1677; VANDENBUNDER B, 1989, DEVELOPMENT, V106, P265; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WERNERT N, 1994, CANCER RES, V54, P5683; WERNERT N, 1992, AM J PATHOL, V140, P119; YAMANE A, 1994, ONCOGENE, V9, P2683	50	128	129	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30823	30828		10.1074/jbc.271.48.30823	http://dx.doi.org/10.1074/jbc.271.48.30823			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940064	hybrid			2022-12-25	WOS:A1996VV15800081
J	Yanagi, S; Sugawara, H; Kurosaki, M; Sabe, H; Yamamura, H; Kurosaki, T				Yanagi, S; Sugawara, H; Kurosaki, M; Sabe, H; Yamamura, H; Kurosaki, T			CD45 modulates phosphorylation of both autophosphorylation and negative regulatory tyrosines of Lyn in B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN RECEPTOR COMPLEX; NATURAL-KILLER CELLS; FC-GAMMA-RECEPTOR; SIGNAL-TRANSDUCTION; AUTOIMMUNE-DISEASE; DEFICIENT MICE; PROTEIN-KINASE; PHOSPHATASE; ACTIVATION; SRC	CD45 is a tyrosine phosphatase that is required for normal B cell receptor (BCR)-mediated signaling. It has been shown that Src-family tyrosine kinases such as Lyn could be a potential substrate for CD45. In vitro studies indicate that activities of Src family tyrosine kinases are regulated by tyrosine phosphorylation; C-terminal phosphorylation is inhibitory, and autophosphorylation is stimulatory. We report here that both autophosphorylation and C-terminal negative regulatory tyrosines of Lyn were hyperphosphorylated in CD45-deficient DT40 B cells, In this mutant cell, BCR-induced protein-tyrosine phosphorylation and calcium mobilization were severely compromised, as seen in Lyn-deficient cells. Consistent with this observation, Lyn activation upon receptor ligation was profoundly decreased in CD45-deficient cells. Taken together, our results suggest that dephosphorylation of tyrosine residues at both autophosphorylation and negative regulatory sites is mediated by CD45 in vivo, and that dephosphorylation of C-terminal tyrosine is a prerequisite for participation of Lyn in BCR signaling.	KANSAI MED UNIV, INST HEPAT RES, DEPT MOL GENET, MORIGUCHI, OSAKA 570, JAPAN; YALE UNIV, SCH MED, IMMUNOBIOL SECT, NEW HAVEN, CT 06510 USA; KOBE UNIV, SCH MED, DEPT BIOCHEM, KOBE 650, JAPAN; JAPAN SCI & TECHNOL CORP, PRECURSOR RES & EMBRYON SCI & TECHNOL, KYOTO 606, JAPAN; KYOTO UNIV, INST VIRUS RES, SAKYO KU, KYOTO 606, JAPAN	Kansai Medical University; Yale University; Kobe University; Japan Science & Technology Agency (JST); Kyoto University			Sugawara, Hitoshi/Y-5081-2019; Sabe, Hisataka/A-4066-2012; Sabe, Hisataka/GPF-4385-2022; Kurosaki, Tomohiro/D-1306-2009	Sugawara, Hitoshi/0000-0002-5060-9020; Kurosaki, Tomohiro/0000-0002-6352-304X				BOLEN JB, 1995, CURR OPIN IMMUNOL, V7, P306, DOI 10.1016/0952-7915(95)80103-0; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BROWN VK, 1994, J BIOL CHEM, V269, P17238; BURNS CM, 1994, J BIOL CHEM, V269, P13594; CLARK MR, 1994, EMBO J, V13, P1911, DOI 10.1002/j.1460-2075.1994.tb06460.x; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DEFRANCO AL, 1995, CURR OPIN CELL BIOL, V7, P163, DOI 10.1016/0955-0674(95)80024-7; FANG KS, 1994, J BIOL CHEM, V269, P14056; FLEIT HB, 1982, P NATL ACAD SCI-BIOL, V79, P3275, DOI 10.1073/pnas.79.10.3275; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HATA A, 1994, MOL CELL BIOL, V14, P7306, DOI 10.1128/MCB.14.11.7306; HIBBS ML, 1995, CELL, V83, P301, DOI 10.1016/0092-8674(95)90171-X; HOVIS RR, 1993, SCIENCE, V260, P544, DOI 10.1126/science.8475387; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; JUSTEMENT LB, 1994, IMMUNOL TODAY, V15, P399, DOI 10.1016/0167-5699(94)90268-2; KATAGIRI T, 1995, J BIOL CHEM, V270, P27987; KAWAUCHI K, 1994, J IMMUNOL, V152, P3306; KIM TJ, 1995, J BIOL CHEM, V270, P27504, DOI 10.1074/jbc.270.46.27504; KUROSAKI T, 1995, J EXP MED, V182, P1815, DOI 10.1084/jem.182.6.1815; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; NISHIZUMI H, 1995, IMMUNITY, V3, P549, DOI 10.1016/1074-7613(95)90126-4; OGIMOTO M, 1995, EUR J IMMUNOL, V25, P2265, DOI 10.1002/eji.1830250823; OGIMOTO M, 1994, INT IMMUNOL, V6, P647, DOI 10.1093/intimm/6.4.647; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PELTZ GA, 1989, P NATL ACAD SCI USA, V86, P1013, DOI 10.1073/pnas.86.3.1013; PLEIMAN CM, 1994, IMMUNOL TODAY, V15, P393, DOI 10.1016/0167-5699(94)90267-4; RAVETCH JV, 1989, J EXP MED, V170, P481, DOI 10.1084/jem.170.2.481; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SAGA Y, 1986, P NATL ACAD SCI USA, V83, P6940, DOI 10.1073/pnas.83.18.6940; SCALLON BJ, 1989, P NATL ACAD SCI USA, V86, P5079, DOI 10.1073/pnas.86.13.5079; SIMMONS D, 1988, NATURE, V333, P568, DOI 10.1038/333568a0; SUN H, 1994, TRENDS BIOCHEM SCI, V19, P480, DOI 10.1016/0968-0004(94)90134-1; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; Tezuka T, 1996, J EXP MED, V183, P675, DOI 10.1084/jem.183.2.675; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; VOLAREVIC S, 1993, SCIENCE, V260, P541, DOI 10.1126/science.8475386	39	94	97	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30487	30492		10.1074/jbc.271.48.30487	http://dx.doi.org/10.1074/jbc.271.48.30487			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940015	hybrid			2022-12-25	WOS:A1996VV15800032
J	Zhang, JZ; Redman, C				Zhang, JZ; Redman, C			Fibrinogen assembly and secretion - Role of intrachain disulfide loops	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CHAIN; ELECTRON-MICROSCOPY; ALPHA-CHAINS; SEQUENCES; BONDS; CELLS; IDENTIFICATION; MOLECULES; HOMOLOGY; DOMAINS	Human fibrinogen is a homodimer composed of three different (A alpha, B beta, gamma) polypeptide chains, The chains are linked by 29 inter- and intrachain disulfide bonds. Each half-molecule has 6 intrachain disulfide bonds, which form loops in the carboxyl-terminal region of each of the chains, A alpha chain has one disufide loop (Cys(442)-Cys(472)), B beta has three (Cys(201)-Cys(286), Cys(211)-Cys(240), and Cys(394)-Cys(407)), and gamma has two loops (Cys(153)-Cys(182) and Cys(826)-Cys(339)). The intrachain loops are conserved in fibrinogens of different species, We changed, by site-directed mutagenesis, the cysteines, which form the intrachain loops, to serine or alanine, Fibrinogen chain assembly and secretion was determined in transiently transfected COS cells expressing two normal and a mutant fibrinogen chain. In the B beta and gamma chains, disruption of the disulfide loops closest to the ''coiled-coil'' region (Cys(B beta 211)-Cys(240), Cys(B beta 201)-Cys(286), and Cys(gamma 153)-Cys(182)) abolished chain assembly and secretion, indicating that the disulfide loops closest to the coiled-coil region are essential for chain assembly, By contrast, preventing formation of the disulfide loops, which are toward the carboxyl termini of each of the chains, had different effects, Disruption of the single A alpha disulfide loop had no effect, as did disruption of B beta Cys(394)-Cys(407). However, disruption of Cys(gamma 326)-Cys(339), which is similar in size and location to Cys(B beta 394)-Cys(407), allowed chain assembly to occur, but the assembled chains were not secreted.	NEW YORK BLOOD CTR, LINDSLEY F KIMBALL RES INST, NEW YORK, NY 10021 USA	New York Blood Center					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037457] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL37457] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAKER NE, 1990, SCIENCE, V250, P1370, DOI 10.1126/science.2175046; BLOMBACK B, 1968, NATURE, V218, P130, DOI 10.1038/218130a0; Blomback B, 1996, THROMB RES, V83, P1, DOI 10.1016/0049-3848(96)00111-9; BLOMBACK B, 1976, THROMB RES, V8, P639, DOI 10.1016/0049-3848(76)90245-0; BOUMA H, 1978, THROMB RES, V13, P557, DOI 10.1016/0049-3848(78)90142-1; DANISHEFSKY K, 1990, BIOCHIM BIOPHYS ACTA, V1048, P202, DOI 10.1016/0167-4781(90)90057-9; DOOLITTLE RF, 1978, J MOL BIOL, V120, P311, DOI 10.1016/0022-2836(78)90070-0; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; DOOLITTLE RF, 1981, SCI AM, V245, P126, DOI 10.1038/scientificamerican1281-126; FU YP, 1992, BIOCHEMISTRY-US, V31, P11968, DOI 10.1021/bi00163a002; FU YP, 1994, P NATL ACAD SCI USA, V91, P2625, DOI 10.1073/pnas.91.7.2625; HALL CE, 1959, J BIOPHYS BIOCHEM CY, V5, P11, DOI 10.1083/jcb.5.1.11; HENSCHEN A, 1983, ANN NY ACAD SCI, V408, P28, DOI 10.1111/j.1749-6632.1983.tb23232.x; HOEPRICH PD, 1983, BIOCHEMISTRY-US, V22, P2049, DOI 10.1021/bi00278a003; HUANG SM, 1993, J BIOL CHEM, V268, P8919; HUANG SM, 1993, BIOCHEM BIOPH RES CO, V190, P488, DOI 10.1006/bbrc.1993.1074; IWANAGA S, 1967, BIOCHIM BIOPHYS ACTA, V147, P606, DOI 10.1016/0005-2795(67)90025-6; JONES FS, 1988, P NATL ACAD SCI USA, V85, P2186, DOI 10.1073/pnas.85.7.2186; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; KOYAMA T, 1987, P NATL ACAD SCI USA, V84, P1609, DOI 10.1073/pnas.84.6.1609; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MOSESSON MW, 1981, J MOL BIOL, V153, P695, DOI 10.1016/0022-2836(81)90414-9; MURAKAWA M, 1993, THROMB HAEMOSTASIS, V69, P351; PAN Y, 1992, P NATL ACAD SCI USA, V89, P2066, DOI 10.1073/pnas.89.6.2066; RAO SPS, 1991, J MOL BIOL, V222, P89, DOI 10.1016/0022-2836(91)90739-S; ROY SN, 1991, J BIOL CHEM, V266, P4758; ROY SN, 1990, J BIOL CHEM, V265, P6389; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; WEISEL JW, 1981, NATURE, V289, P263, DOI 10.1038/289263a0; YU S, 1984, J BIOL CHEM, V259, P574; YU S, 1983, J BIOL CHEM, V258, P3407; ZHANG JZ, 1992, J BIOL CHEM, V267, P21727; ZHANG JZ, 1994, J BIOL CHEM, V269, P652; ZHANG JZ, 1993, J BIOL CHEM, V268, P11278; Zhang JZ, 1996, J BIOL CHEM, V271, P12674, DOI 10.1074/jbc.271.21.12674	35	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30083	30088		10.1074/jbc.271.47.30083	http://dx.doi.org/10.1074/jbc.271.47.30083			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939956	hybrid			2022-12-25	WOS:A1996VU52500084
J	Zhao, Y; Bjorbaek, C; Moller, DE				Zhao, Y; Bjorbaek, C; Moller, DE			Regulation and interaction of pp90(rsk) isoforms with mitogen-activated protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL S6 KINASE; NERVE GROWTH-FACTOR; NIH 3T3 CELLS; MAP KINASE; SIGNAL-TRANSDUCTION; NUCLEAR TRANSLOCATION; XENOPUS OOCYTES; SKELETAL-MUSCLE; PHORBOL ESTER; PC12 CELLS	Each of the three known mammalian 90-kDa S6 kinase (pp90(rsk)) isoforms (RSK1, RSK2, and RSK3) was expressed in transfected cells and further characterized, The kinase activity (immunocomplex toward S6 peptide) of each isoform was activated by in vivo growth factor (epidermal growth factor (EGF)) stimulation; RSK1 was more responsive (10-15-fold) versus RSK2 and RSK3 (2-4-fold). Pretreatment with PD98059 (MEK1 inhibitor) partially (80%) blocked EGF-mediated ERK1 activation and had similar effects on EGF stimulation of each ribosomal S6 kinase (RSK). Cotransfection with dominant-negative MEK1 inhibited activation of each RSK; furthermore, the kinase activity of RSK1, RSK2, and RSK3 was markedly increased by cotransfection with constitutively active MEK1. A specific association between mitogen-activated protein kinases (MAPKs) (ERK1 and ERK2) and RSK isoforms was tested by MAPK immunoblotting after immunoprecipitation of RSKs. ERK1 and ERK2 were present in RSK3 (and to a lesser extent, RSK2) immunoprecipitates, but were absent in RSK1 immunoprecipitates. Both dephosphorylated (from quiescent cells) and phosphorylated (from stimulated cells) MAPKs were associated with RSK2 and RSK3. Deletion mutants of RSK3 were characterized: the C terminus (33 residues) was shown to be required for association with MAPKs. The kinase activity of RSK1 or RSK2 was enhanced by in vitro incubation with ERK1. In contrast, RSK3 activity was not affected by exposure to ERK1. Furthermore, MAPKs in RSK3 immunoprecipitates were phosphorylated by purified MEK1; however, RSK3 kinase activity was unaffected. We conclude that 1) the MEK1-MAPK signaling pathway is both necessary and sufficient for in vivo growth factor-mediated activation of all three RSK isoforms; 2) RSK isoforms differ with respect to growth factor responsiveness and their physical association with MAPK; and 3) formation of the MAPK RSK complex is mediated by the RSK C terminus.	MERCK & CO INC,MERCK SHARP & DOHME RES LABS,DEPT MOL ENDOCRINOL,RAHWAY,NJ 07065; BETH ISRAEL HOSP,DEPT MED,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02215	Merck & Company; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School			Bjorbaek, Christian/S-4727-2019		PHS HHS [R01 45874-02] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AHN NG, 1991, J BIOL CHEM, V266, P4220; ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ANDERSON NG, 1993, BIOCHEM BIOPH RES CO, V193, P284, DOI 10.1006/bbrc.1993.1621; BJORBAEK C, 1995, J BIOL CHEM, V270, P18848, DOI 10.1074/jbc.270.32.18848; BJORBAEK C, 1995, DIABETES, V44, P90, DOI 10.2337/diabetes.44.1.90; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P336; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHEN RH, 1993, BIOCHEM SOC T, V21, P895, DOI 10.1042/bst0210895; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ERIKSON E, 1987, MOL CELL BIOL, V7, P3147, DOI 10.1128/MCB.7.9.3147; GREGORY JS, 1989, J BIOL CHEM, V264, P18397; GROVE JR, 1993, BIOCHEMISTRY-US, V32, P7727, DOI 10.1021/bi00081a018; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; JURIVICH DA, 1991, J CELL PHYSIOL, V148, P252, DOI 10.1002/jcp.1041480210; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KHARBANDA S, 1994, P NATL ACAD SCI USA, V91, P5416, DOI 10.1073/pnas.91.12.5416; KYRIAKIS JM, 1993, PROTEIN KINASES FRON; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVOINNE A, 1991, EUR J BIOCHEM, V199, P723, DOI 10.1111/j.1432-1033.1991.tb16176.x; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MOLLER DE, 1994, AM J PHYSIOL, V266, pC351, DOI 10.1152/ajpcell.1994.266.2.C351; MOLLER DE, 1990, J BIOL CHEM, V265, P14979; MYERS MP, 1994, MOL CELL BIOL, V14, P6954, DOI 10.1128/MCB.14.10.6954; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCIMECA JC, 1992, J BIOL CHEM, V267, P17369; SEGER R, 1994, J BIOL CHEM, V269, P25699; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUTHERLAND C, 1993, EUR J BIOCHEM, V212, P581, DOI 10.1111/j.1432-1033.1993.tb17696.x; THOMAS G, 1993, BIOCHEM SOC T, V21, P901, DOI 10.1042/bst0210901; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WU J, 1993, MOL CELL BIOL, V13, P4539, DOI 10.1128/MCB.13.8.4539; ZHAO Y, 1995, MOL CELL BIOL, V15, P4353; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	51	141	149	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29773	29779		10.1074/jbc.271.47.29773	http://dx.doi.org/10.1074/jbc.271.47.29773			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939914	hybrid			2022-12-25	WOS:A1996VU52500042
J	Warren, RS; Yuan, H; Matli, MR; Ferrara, N; Donner, DB				Warren, RS; Yuan, H; Matli, MR; Ferrara, N; Donner, DB			Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; MESSENGER-RNA EXPRESSION; PERMEABILITY FACTOR; RAT GLIOBLASTOMA; TUMOR-GROWTH; DEVELOPMENTAL EXPRESSION; FACTOR FAMILY; FACTOR VEGF; ANGIOGENESIS; CELLS	Vascular endothelial growth factor (VEGF) is an angiogenic hormone that is produced by and supports the growth of many types of malignancies. The present study shows that insulin-like growth factor 1 (IGF-I), a mitogen that promotes the propagation of cancers through autocrine and paracrine mechanisms, in creases the expression of mRNA for VEGF and production of VEGF protein by COLO 205 colon carcinoma cells. IGF-I also induces expression of VEGF mRNA in SW620, LSLiM6, and HCT15 colon carcinoma cells showing that this is a common response to IGF-I. Whereas IGF-I induced VEGF mRNA in each cell line examined (2.3-12-fold), it induced proliferation only in COLO 205 and LSLiM6 cells. Thus, the proliferative response induced by IGF-I and its ability to induce VEGF occur through distinguishable mechanisms. IGF-I increases the cellular content of VEGF mRNA by increasing the rate of transcription (5-fold after 4 h) and also by increasing the half-life of VEGF mRNA (0.6 +/- 0.07 h in control cells to 2.0 +/- 0.37 h in IGF-I-treated cells). Monoclonal antibody (alpha IR3) directed against the type 1 IGF receptor significantly attenuated the ability of IGF-I to promote expression of VEGF mRNA. interestingly, by itself alpha IR3 acted as a weak agonist and induced a modest increase in the cellular content of VEGF mRNA. alpha IR3 also promoted tyrosine phosphorylation of the beta subunit of the IGF-I receptor, and the magnitude of this response was comparable with that induced by IGF-I. These observations point to a nonlinear relationship between activation of the IGF-I receptor and induction of VEGF mRNA. Thus, in addition to its direct, growth stimulatory effect on transformed cells, IGF-I induces the expression of VEGF which can promote the progression of cancer by regulating the development of new blood vessels.	GENENTECH INC, DEPT CARDIOVASC RES, San Francisco, CA 94080 USA; INDIANA UNIV, SCH MED, DEPT PHYSIOL & BIOPHYS, INDIANAPOLIS, IN 46202 USA	Roche Holding; Genentech; Indiana University System; Indiana University-Purdue University Indianapolis	Warren, RS (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT SURG, SCH MED, 533 PARNASSUS AVE, ROOM U-372, SAN FRANCISCO, CA 94143 USA.				NCI NIH HHS [CA52863, CA67891] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA067891, R29CA052863, R01CA067891] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010; ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671; AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; BASERGA R, 1995, CANCER RES, V55, P249; BERGMANN U, 1995, CANCER RES, V55, P2007; BREIER G, 1992, DEVELOPMENT, V114, P521; BROWN LF, 1992, J EXP MED, V176, P1375, DOI 10.1084/jem.176.5.1375; BROWN LF, 1993, CANCER RES, V53, P4727; COHICK WS, 1993, ANNU REV PHYSIOL, V55, P131, DOI 10.1146/annurev.ph.55.030193.001023; COLVILLENASH PR, 1992, ANN RHEUM DIS, V51, P919, DOI 10.1136/ard.51.7.919; CULLEN KJ, 1991, CANCER RES, V51, P4978; DAUGHADAY WH, 1990, ENDOCRINOLOGY, V127, P1; DETMAR M, 1994, J EXP MED, V180, P1141, DOI 10.1084/jem.180.3.1141; DILLS DG, 1991, DIABETES, V40, P1725, DOI 10.2337/diabetes.40.12.1725; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; GARTNER MH, 1992, J SURG RES, V52, P389, DOI 10.1016/0022-4804(92)90121-F; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HOWARD LA, 1989, BIOTECHNIQUES, V7, P940; JAKEMAN LB, 1993, ENDOCRINOLOGY, V133, P848, DOI 10.1210/en.133.2.848; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; KOHN EC, 1990, INT J CANCER, V46, P287, DOI 10.1002/ijc.2910460225; KONDO S, 1994, BBA-MOL CELL RES, V1221, P211, DOI 10.1016/0167-4889(94)90016-7; KONDO S, 1993, BIOCHEM BIOPH RES CO, V194, P1234, DOI 10.1006/bbrc.1993.1955; LONG L, 1994, CANCER RES, V54, P3732; LONG L, 1995, CANCER RES, V55, P1006; MACAULAY VM, 1992, BRIT J CANCER, V65, P311, DOI 10.1038/bjc.1992.65; MEYERSCHWICKERATH R, 1993, J CLIN INVEST, V92, P2620, DOI 10.1172/JCI116877; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MIURA M, 1995, J BIOL CHEM, V270, P22639, DOI 10.1074/jbc.270.38.22639; OLSON TA, 1994, CANCER RES, V54, P276; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; RESNICOFF M, 1994, CANCER RES, V54, P2218; ROWEIN P, 1986, P NATL ACAD SCI USA, V83, P77; SATO K, 1995, J CLIN INVEST, V96, P1295, DOI 10.1172/JCI118164; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SENGER DR, 1990, CANCER RES, V50, P1774; SHWEIKI D, 1993, J CLIN INVEST, V91, P2235, DOI 10.1172/JCI116450; SLADOWSKI D, 1993, J IMMUNOL METHODS, V157, P203, DOI 10.1016/0022-1759(93)90088-O; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; STRACKE ML, 1989, J BIOL CHEM, V264, P21544; Thomas KA, 1996, J BIOL CHEM, V271, P603, DOI 10.1074/jbc.271.2.603; TROJAN J, 1993, SCIENCE, V259, P94, DOI 10.1126/science.8418502; TROJAN J, 1992, P NATL ACAD SCI USA, V89, P4874, DOI 10.1073/pnas.89.11.4874; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; WARREN RS, 1995, J CLIN INVEST, V95, P1789, DOI 10.1172/JCI117857	57	211	225	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29483	29488		10.1074/jbc.271.46.29483	http://dx.doi.org/10.1074/jbc.271.46.29483			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910616	hybrid			2022-12-25	WOS:A1996VT05200108
J	Aroca, P; Mahadevan, D; Santos, E				Aroca, P; Mahadevan, D; Santos, E			Functional interactions between isolated SH2 domains and insulin/Ras signaling pathways of Xenopus oocytes: Opposite effects of the carboxy- and amino-terminal SH2 domains of p85 PI 3-kinase	ONCOGENE			English	Article						SH2; Ras; insulin signaling; p85 alpha PI 3-kinase; Xenopus	RECEPTOR TYROSINE KINASES; PHOSPHOLIPASE-C-GAMMA; PHOSPHATIDYLINOSITOL 3-KINASE; MEIOTIC MATURATION; ONCOGENE PRODUCT; BETA-RECEPTOR; HIGH-AFFINITY; RAS PROTEINS; SPECIFICITY; ACTIVATION	Purified amino-terminal Src homology 2 (SH2) domains of GAP, PLC gamma 1 and the p85 alpha subunit of PI 3-kinase, as well as the carboxy-terminal SH2 domain of the latter protein and the unique SH2 domain of Grb2, were injected into full grown, stage VI Xenopus laevis oocytes, None of the injected domains showed any effect when injected alone, nor did they affect the rate of GVBD induced by progesterone, an adenylate cyclase-dependent process, On the other hand, the unique Grb2 SH2 domain and all N-terminal SH2 domains injected inhibited to various degrees the rate of insulin-induced GVBD, a tyrosine kinase dependent pathway, Interestingly, and in contrast to the behavior shown by the N-terminal domain of the same molecule, the C-terminal SH2 domain of p85 did not inhibit, but slightly accelerated the rate of GVBD induced by insulin, Furthermore, whereas the Grb SH2 domain and all N-terminal SH2 domains tested failed to co-operate with normal Ras protein to induce GVBD, the C-terminal SH2 domain of p85 alpha exhibited significant synergy when coinjected with normal Pas protein, indicating that the C- and N-terminal SH2 domains of p85 alpha exert opposite (positive and negative, respectively) regulatory roles in the control of oocyte insulin/Ras signaling pathways, Our results demonstrate that the purified, isolated SH2 domains retain structural and functional specificity and that Xenopus oocytes constitute an useful biological system to analyse their functional role in tyrosine kinase signaling pathways.	NCI, DBS, CELLULAR & MOL BIOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Aroca, Pilar/P-2141-2017	Aroca, Pilar/0000-0002-7557-6931				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; AROCA P, 1995, J BIOL CHEM, V270, P14229, DOI 10.1074/jbc.270.23.14229; BACKER JM, 1992, J BIOL CHEM, V267, P1367; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CHUANG LM, 1993, MOL CELL BIOL, V13, P6653, DOI 10.1128/MCB.13.11.6653; DAAR IO, 1991, MOL CELL BIOL, V11, P5985, DOI 10.1128/MCB.11.12.5985; deMora JF, 1996, J BIOL CHEM, V271, P18272, DOI 10.1074/jbc.271.30.18272; DESHPANDE AK, 1987, MOL CELL BIOL, V7, P1285, DOI 10.1128/MCB.7.3.1285; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; Gotoh N, 1995, ONCOGENE, V11, P2525; GRAZIANI G, 1992, ONCOGENE, V7, P229; GRIGORESCU F, 1994, HORM RES, V42, P55, DOI 10.1159/000184146; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; KATZAV S, 1995, ONCOGENE, V11, P1079; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2675, DOI 10.1128/MCB.14.4.2675; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; LIU XJ, 1995, MOL CELL BIOL, V15, P3563; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MAHADEVAN D, 1994, BIOCHEMISTRY-US, V33, P746, DOI 10.1021/bi00169a016; Maller James L., 1994, Seminars in Developmental Biology, V5, P183, DOI 10.1006/sedb.1994.1024; MALLER JL, 1990, BIOCHEMISTRY-US, V29, P3157, DOI 10.1021/bi00465a001; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P6661, DOI 10.1128/MCB.13.11.6661; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; NEBREDA AR, 1993, ONCOGENE, V8, P467; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; Northrop JP, 1996, MOL CELL BIOL, V16, P2255; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PINES J, 1990, New Biologist, V2, P389; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; VANHORN DJ, 1994, J BIOL CHEM, V269, P29; YOAKIM M, 1994, MOL CELL BIOL, V14, P5929, DOI 10.1128/MCB.14.9.5929; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	52	14	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	1996	13	9					1839	1846						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934529				2022-12-25	WOS:A1996VR79500002
J	Phinney, DG; Tseng, SW; Hall, B; Ryder, K				Phinney, DG; Tseng, SW; Hall, B; Ryder, K			Chromosomal integration dependent induction of junB by growth factors requires multiple flanking evolutionarily conserved sequences	ONCOGENE			English	Article						chromatin; regulation; evolutionary conservation	SERUM RESPONSE ELEMENT; C-FOS PROMOTER; TRANSCRIPTION FACTORS; SIGNAL-TRANSDUCTION; GENE; BINDING; COMPLEX; PROTEINS; DIFFERENTIATION; IDENTIFICATION	The junB locus contains nine flanking evolutionarily conserved sequences (FECS) that share 72% to 91% sequence identity between human and mouse, These FECS encompass the same regions of flanking DNA necessary for maximal mitogenic induction of junB, Most of the cis elements reported to date that affect junB regulation also reside within FECS, These observations suggest that the persistence of FECS through evolution reflects a necessary role in junB transcriptional regulation, In this report, we identify specific regulatory cis elements within junB FECS II and III and provide a quantitative analysis of the contribution made by these sequences to junB induction, These cis elements include a Serum Response Element (SRE), two Ets sites previously unrecognized as contributing to junB expression, and two novel Ets-linked motifs (ELMs), In general, mutating any single element significantly impairs junB induction, Moreover, the same mutations alter the structure of junB 5' flanking DNA within chromatin, Collectively, these results suggest that multiple proteins bound within FECS confederate to form a functional promoter complex, the activity of which is dependent upon a specific chromatin architecture.	FOX CHASE CANC CTR,PHILADELPHIA,PA 19007	Fox Chase Cancer Center			Phinney, Donald G/D-2155-2014	Phinney, Donald/0000-0002-8688-2619	NATIONAL CANCER INSTITUTE [R01CA052752, P30CA006927] Funding Source: NIH RePORTER; NCI NIH HHS [CA-06927-31, CA-52752] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOSSYWETZEL E, 1992, GENE DEV, V6, P2340, DOI 10.1101/gad.6.12a.2340; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COFFER P, 1994, ONCOGENE, V9, P911; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P775, DOI 10.1093/nar/19.4.775; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; GARRITY PA, 1994, MOL CELL BIOL, V14, P2159, DOI 10.1128/MCB.14.3.2159; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LIU JK, 1991, MOL CELL BIOL, V11, P773, DOI 10.1128/MCB.11.2.773; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; NORDHEIM A, 1994, FOS JUN FAMILIES TRA, P97; PEREZALBUERNE ED, 1993, P NATL ACAD SCI USA, V90, P11960, DOI 10.1073/pnas.90.24.11960; PHINNEY DG, 1994, ONCOGENE, V9, P2353; PHINNEY DG, 1995, GENOMICS, V28, P228, DOI 10.1006/geno.1995.1135; RAO VN, 1994, ONCOGENE, V9, P1855; RIVERA FM, 1990, GENE DEV, V4, P225; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; RYAN WA, 1989, EMBO J, V8, P1785, DOI 10.1002/j.1460-2075.1989.tb03572.x; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; WOLFFE AP, 1994, SCIENCE, V264, P1100, DOI 10.1126/science.8178167	34	3	3	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 7	1996	13	9					1875	1883						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934533				2022-12-25	WOS:A1996VR79500006
J	Andley, UP; Mathur, S; Griest, TA; Petrash, JM				Andley, UP; Mathur, S; Griest, TA; Petrash, JM			Cloning expression, and chaperone-like activity of human alpha A-crystallin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; BOVINE LENS CRYSTALLINS; MOLECULAR CHAPERONE; ALDOSE REDUCTASE; SINGLET OXYGEN; B-CRYSTALLIN; PHOTODYNAMIC SYSTEM; CIRCULAR-DICHROISM; GAMMA-CRYSTALLINS; GENE FAMILY	One of the major protein components of the ocular lens, alpha-crystallin, is composed of alpha A and alpha B chain subunits that have structural homology to the family of mammalian small heat shock proteins, Like other small heat shock proteins, alpha-crystallin subunits associate to form large oligomeric aggregates that express chaperone-like activity, as defined by the ability to suppress nonspecific aggregation of proteins destabilized by treatment with a variety of denaturants including heat, UV irradiation, and chemical modification, It has been proposed that age-related loss of sequences at the C terminus of the alpha A chain subunit may be a factor in the pathogenesis of cataract due to diminished capacity of the truncated crystallin to protect against nonspecific aggregation of lens proteins, To evaluate the functional consequences of alpha-crystallin modification, two mutant forms of alpha A subunits were prepared by site-directed mutagenesis, Like wild type (WT), aggregates of similar to 540 kDa were formed from a tryptophan-free alpha A mutant (W9F), When added in stoichiometric amounts, both WT and W9F subunits completely suppressed the heat-induced aggregation of aldose reductase, In contrast, subunits encoded by a truncation mutant in which the C-terminal 17 residues were deleted (R157STOP), despite having spectroscopic properties similar to WT, formed much larger aggregates with a marked reduction in chaperone-like activity, Similar results were observed when the chaperone-like activity was assessed through inhibition of gamma-crystallin aggregation induced by singlet oxygen, These results demonstrate that the structurally conservative substitution of Phe for Trp-9 has a negligible effect on the functional interaction of alpha A subunits, and that deletion of C-terminal sequences from the alpha A subunit results in substantial loss of chaperone-like activity, despite overall preservation of secondary structure.	WASHINGTON UNIV,SCH MED,DEPT OPHTHALMOL & VISUAL SCI,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOL BIOPHYS,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)				Andley, Usha/0000-0001-7049-7591	NEI NIH HHS [EY05681, EY05856, P30 EY02687] Funding Source: Medline; NATIONAL EYE INSTITUTE [P30EY002687, R01EY005856, R55EY005856, R01EY005681, R23EY005856] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDLEY U, 1994, PRINCIPLES PRACTICE, P575; ANDLEY UP, 1986, PHOTOCHEM PHOTOBIOL, V44, P67, DOI 10.1111/j.1751-1097.1986.tb03565.x; ANDLEY UP, 1988, BIOCHEMISTRY-US, V27, P810, DOI 10.1021/bi00402a048; ANDLEY UP, 1989, INVEST OPHTH VIS SCI, V30, P706; ARRIGO AP, 1987, J BIOL CHEM, V262, P15359; ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; BALASUBRAMANIAN D, 1990, PHOTOCHEM PHOTOBIOL, V52, P761, DOI 10.1111/j.1751-1097.1990.tb08679.x; Bettelheim F. A., 1985, OCULAR LENS STRUCTUR, P265; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; BHAT SP, 1991, EUR J BIOCHEM, V102, P775; Bloemendal H, 1981, MOL CELLULAR BIOL EY, P1; Borkman RF, 1995, PHOTOCHEM PHOTOBIOL, V62, P1046; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAKENHOFF RH, 1990, J MOL BIOL, V216, P519, DOI 10.1016/0022-2836(90)90380-5; CARVER JA, 1992, FEBS LETT, V311, P143, DOI 10.1016/0014-5793(92)81386-Z; DAS KP, 1995, BIOCHEM J, V311, P367, DOI 10.1042/bj3110367; Das KP, 1996, J BIOL CHEM, V271, P10449, DOI 10.1074/jbc.271.18.10449; DEJONG WW, 1993, MOL BIOL EVOL, V10, P103; DELAYE M, 1983, NATURE, V302, P415, DOI 10.1038/302415a0; DENDUNNEN JT, 1985, GENE, V38, P197, DOI 10.1016/0378-1119(85)90218-5; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P509, DOI 10.1021/bi00002a015; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOOSEY JD, 1980, SCIENCE, V208, P1278, DOI 10.1126/science.7375939; GROENEN PJTA, 1994, EUR J BIOCHEM, V225, P1, DOI 10.1111/j.1432-1033.1994.00001.x; HAY RE, 1994, EXP EYE RES, V58, P573, DOI 10.1006/exer.1994.1052; HAY RE, 1987, BIOCHEM BIOPH RES CO, V146, P332, DOI 10.1016/0006-291X(87)90729-7; HORWITZ J, 1992, CURR EYE RES, V11, P817, DOI 10.3109/02713689209000754; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; JAKOB U, 1993, J BIOL CHEM, V268, P1517; JAWORSKI CJ, 1989, NATURE, V337, P752, DOI 10.1038/337752a0; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1080, P173, DOI 10.1016/0167-4838(91)90146-Q; KINOSHITA JH, 1988, DIABETES METAB REV, V4, P323, DOI 10.1002/dmr.5610040403; KRAJLIC I, 1978, PHOTOCHEM PHOTOBIOL, V28, P577; LAMBERTS JJM, 1985, TETRAHEDRON, V41, P2183, DOI 10.1016/S0040-4020(01)96591-3; LIANG JN, 1982, BIOCHEMISTRY-US, V21, P1847, DOI 10.1021/bi00537a022; LIANG JN, 1985, BIOCHIM BIOPHYS ACTA, V832, P197, DOI 10.1016/0167-4838(85)90332-2; MARINI I, 1995, BIOCHEM BIOPH RES CO, V212, P413, DOI 10.1006/bbrc.1995.1985; MEAKIN SO, 1987, MOL CELL BIOL, V7, P2671, DOI 10.1128/MCB.7.8.2671; MERCK KB, 1992, BIOCHIM BIOPHYS ACTA, V1130, P267, DOI 10.1016/0167-4781(92)90439-7; NGO JT, 1989, GENOMICS, V5, P665, DOI 10.1016/0888-7543(89)90106-7; PETRASH JM, 1992, J BIOL CHEM, V267, P24833; PETRASH JM, 1991, ELECTROPHORESIS, V12, P84, DOI 10.1002/elps.1150120116; QUAXJEUKEN Y, 1985, CYTOGENET CELL GENET, V40, P727; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sax C M, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P155; SIEZEN RJ, 1982, EXP EYE RES, V34, P969, DOI 10.1016/0014-4835(82)90077-X; SIEZEN RJ, 1980, EUR J BIOCHEM, V111, P435, DOI 10.1111/j.1432-1033.1980.tb04958.x; SIEZEN RJ, 1983, BIOCHIM BIOPHYS ACTA, V749, P227, DOI 10.1016/0167-4838(83)90229-7; SMULDERS RHPH, 1995, EUR J BIOCHEM, V232, P834, DOI 10.1111/j.1432-1033.1995.834zz.x; TAKEMOTO L, 1993, BIOCHEM J, V294, P435, DOI 10.1042/bj2940435; TAKEMOTO L, 1994, EXP EYE RES, V59, P239, DOI 10.1006/exer.1994.1103; THOMSON JA, 1984, J BIOL CHEM, V259, P4339; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403	54	159	163	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					31973	31980		10.1074/jbc.271.50.31973	http://dx.doi.org/10.1074/jbc.271.50.31973			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943244	hybrid			2022-12-25	WOS:A1996VY34000035
J	Bieberich, CJ; Fujita, K; He, WW; Jay, G				Bieberich, CJ; Fujita, K; He, WW; Jay, G			Prostate-specific and androgen-dependent expression of a novel homeobox gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMEODOMAIN-DNA COMPLEX; MORPHOGENESIS; PROTEINS; GROWTH	A new member of the mouse NK family of homeobox genes that is related to Drosophila NK-3 has been identified, Expression of this gene, termed Nkx-3.1, is largely restricted to the prostate gland in adult animals, The level of Nkx-3.1 mRNA decreases markedly in response to castration, suggesting that its expression is androgen-dependent. In situ hybridization analyses demonstrated that expression of Nkx-3.1 in the prostate is confined to epithelial cells, In newborns, Nkx-3.1 mRNA is detected in the urethral epithelium that is being induced by the surrounding mesenchyme to invaginate to form prostatic buds. Together, these observations suggest that the Nkx-3.1 protein, which likely functions as a transcription factor, plays a prominent role both in the initiation of prostate development and in the maintenance of the differentiated state of prostatic epithelial cells.	GEORGE WASHINGTON UNIV,MED CTR,DEPT BIOCHEM & MOL BIOL,WASHINGTON,DC 20037; HUMAN GENOME SCI INC,ROCKVILLE,MD 20850	George Washington University; GlaxoSmithKline; Human Genome Sciences Inc	Bieberich, CJ (corresponding author), AMER RED CROSS,JEROME H HOLLAND LAB,VIROL LAB,ROCKVILLE,MD 20855, USA.		Jay, Gregory/C-6346-2013					BOGARAD LD, 1989, DEV BIOL, V133, P537, DOI 10.1016/0012-1606(89)90056-0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CUNHA GR, 1983, RECENT PROG HORM RES, V39, P559; DAVIES P, 1991, J ENDOCRINOL, V131, P5, DOI 10.1677/joe.0.1310005; DIAMANDIS EP, 1994, BREAST CANCER RES TR, V32, P301, DOI 10.1007/BF00666007; Donjacour A A, 1987, Prog Clin Biol Res, V239, P583; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; HAYWARD SW, 1996, ACTA ANAT, V155, P84; KIM YS, 1989, P NATL ACAD SCI USA, V86, P7716, DOI 10.1073/pnas.86.20.7716; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LAUGHON A, 1984, NATURE, V310, P25, DOI 10.1038/310025a0; LINTS TJ, 1993, DEVELOPMENT, V119, P419; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MILLS JS, 1987, EMBO J, V6, P3711, DOI 10.1002/j.1460-2075.1987.tb02705.x; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; PRICE M, 1992, NEURON, V8, P241, DOI 10.1016/0896-6273(92)90291-K; PRINS GS, 1991, ENDOCRINOLOGY, V129, P3187, DOI 10.1210/endo-129-6-3187; Sambrook J., 2002, MOL CLONING LAB MANU; SHEPHERD JCW, 1984, NATURE, V310, P70, DOI 10.1038/310070a0; Stein S, 1996, MECH DEVELOP, V55, P91, DOI 10.1016/0925-4773(95)00494-7; SUGIMURA Y, 1986, BIOL REPROD, V34, P961, DOI 10.1095/biolreprod34.5.961; WAYNFORTH HB, 1980, EXPT SURGICAL TECHNI	24	185	203	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					31779	31782		10.1074/jbc.271.50.31779	http://dx.doi.org/10.1074/jbc.271.50.31779			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943214	hybrid			2022-12-25	WOS:A1996VY34000005
J	Kroon, AR; Hoff, WD; Fenneman, HPM; Gijzen, J; Koomen, GJ; Verhoeven, JW; Crielaard, W; Hellingwerf, KJ				Kroon, AR; Hoff, WD; Fenneman, HPM; Gijzen, J; Koomen, GJ; Verhoeven, JW; Crielaard, W; Hellingwerf, KJ			Spectral tuning, fluorescence, and photoactivity in hybrids of photoactive yellow protein, reconstituted with native or modified chromophores	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURPLE PHOTOTROPHIC BACTERIUM; P-COUMARIC ACID; ECTOTHIORHODOSPIRA-HALOPHILA; SOLUBLE CYTOCHROMES; QUANTUM YIELD; BACTERIORHODOPSIN; PHOTORECEPTOR; TEMPERATURE; ABSORBENCY; PHOTOCYCLE	Photoactive yellow proteins (PYPs) constitute a new class of eubacterial photoreceptors, containing a deprotonated thiol ester-linked 4-hydroxycinnamic acid chromophore. Interactions with the protein dramatically change the (photo)chemical properties of this cofactor. Here we describe the reconstitution of apoPYP with anhydrides of various chromophore analogues. The resulting hybrid PYPs, their acid-denatured states, and corresponding model compounds were characterized with respect to their absorption spectrum, pK for chromophore deprotonation, fluorescence quantum yield, and Stokes shift. Three factors contributing to the tuning of the absorption of the hybrid PYPs were quantified: (i) thiol ester bond formation, (ii) chromophore deprotonation, and (iii) specific chromophore-protein interactions. Analogues lacking the 4-hydroxy substituent lack both contributions (chromophore deprotonation and specific chromophore-protein interactions), confirming the importance of this substituent in optical tuning of PYP. Hydroxy and methoxy substituents in the 3- and/or 5-position do not disrupt strong interactions with the protein but increase their pK for protonation and the fluorescence quantum yield, Both deprotonation and binding to apoPYP strongly decrease the Stokes shift of chromophore fluorescence, Therefore, coupling of the chromophore to the apoprotein not only reduces the energy gap between its ground and excited state but also the extent of reorganization between these two states. Two of the PYP hybrids show photoactivity comparable with native PYP, although with retarded recovery of the initial state.	UNIV AMSTERDAM,EC SLATER INST BIOCHEM RES,MICROBIOL LAB,BIOCENTRUM,NL-1018 WS AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,DEPT ORGAN CHEM,NL-1018 WS AMSTERDAM,NETHERLANDS	University of Amsterdam; University of Amsterdam				Kroon, Arthur/0000-0003-1695-4645				AULINERDTMAN G, 1968, ACTA CHEM SCAND, V22, P1187, DOI 10.3891/acta.chem.scand.22-1187; BACA M, 1994, BIOCHEMISTRY-US, V33, P14369, DOI 10.1021/bi00252a001; BORGSTAHL GEO, 1995, BIOCHEMISTRY-US, V34, P6278, DOI 10.1021/bi00019a004; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; DELANEY JK, 1995, P NATL ACAD SCI USA, V92, P2101, DOI 10.1073/pnas.92.6.2101; Hellingwerf KJ, 1996, MOL MICROBIOL, V21, P683, DOI 10.1046/j.1365-2958.1996.411402.x; HOFF WD, 1992, PHOTOCHEM PHOTOBIOL, V56, P529, DOI 10.1111/j.1751-1097.1992.tb02197.x; HOFF WD, 1994, J BACTERIOL, V176, P3920, DOI 10.1128/JB.176.13.3920-3927.1994; Hoff WD, 1996, BIOCHEMISTRY-US, V35, P1274, DOI 10.1021/bi951755z; HOFF WD, 1994, BIOCHEMISTRY-US, V33, P13959, DOI 10.1021/bi00251a001; HOFF WD, 1994, BIOPHYS J, V67, P1691, DOI 10.1016/S0006-3495(94)80643-5; HOFF WD, 1995, THESIS U AMSTERDAM A; HONIG B, 1971, P NATL ACAD SCI USA, V68, P1289, DOI 10.1073/pnas.68.6.1289; IMAMOTO Y, 1995, FEBS LETT, V374, P157, DOI 10.1016/0014-5793(95)01096-W; KIM M, 1995, BIOCHEMISTRY-US, V34, P12669, DOI 10.1021/bi00039a024; Koh M, 1996, BIOCHEMISTRY-US, V35, P2526, DOI 10.1021/bi951494t; Kort R, 1996, FEBS LETT, V382, P73, DOI 10.1016/0014-5793(96)00149-4; Kort R, 1996, EMBO J, V15, P3209, DOI 10.1002/j.1460-2075.1996.tb00685.x; MATHIES RA, 1991, ANNU REV BIOPHYS BIO, V20, P491, DOI 10.1146/annurev.bb.20.060191.002423; MELHUISH WH, 1961, J PHYS CHEM-US, V65, P229, DOI 10.1021/j100820a009; MEYER TE, 1990, BIOCHIM BIOPHYS ACTA, V1016, P364, DOI 10.1016/0005-2728(90)90170-9; MEYER TE, 1991, BIOPHYS J, V59, P988, DOI 10.1016/S0006-3495(91)82313-X; MEYER TE, 1989, BIOPHYS J, V56, P559, DOI 10.1016/S0006-3495(89)82703-1; MEYER TE, 1987, BIOCHEMISTRY-US, V26, P418, DOI 10.1021/bi00376a012; MEYER TE, 1985, BIOCHIM BIOPHYS ACTA, V806, P175, DOI 10.1016/0005-2728(85)90094-5; NAKANISHI K, 1980, J AM CHEM SOC, V102, P7945, DOI 10.1021/ja00547a028; Neises B., 1978, ANGEW CHEM, V90, P556, DOI [10.1002/ange.19780900718, DOI 10.1002/ANGE.19780900718]; NG K, 1995, BIOCHEMISTRY-US, V34, P879, DOI 10.1021/bi00003a022; *QIAG INC, 1992, QIA EXPR; SPRENGER WW, 1993, J BACTERIOL, V175, P3096, DOI 10.1128/JB.175.10.3096-3104.1993; VANBREDERODE ME, 1995, BIOPHYS J, V68, P1101, DOI 10.1016/S0006-3495(95)80284-5; VANBREDERODE ME, 1996, IN PRES BIOPHYS J; WARD WW, 1982, PHOTOCHEM PHOTOBIOL, V35, P803, DOI 10.1111/j.1751-1097.1982.tb02651.x; YAN B, 1995, J BIOL CHEM, V270, P29668	34	94	96	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					31949	31956		10.1074/jbc.271.50.31949	http://dx.doi.org/10.1074/jbc.271.50.31949			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943241	Green Published, hybrid			2022-12-25	WOS:A1996VY34000032
J	Qiu, XB; Forman, HJ; Schonthal, AH; Cadenas, E				Qiu, XB; Forman, HJ; Schonthal, AH; Cadenas, E			Induction of p21 mediated by reactive oxygen species formed during the metabolism of aziridinylbenzoquinones by HCT116 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; DNA STRAND BREAKS; DT-DIAPHORASE; P53-INDEPENDENT PATHWAY; IONIZING-RADIATION; TUMOR SUPPRESSION; HYDROGEN-PEROXIDE; GENE-EXPRESSION; THIOL OXIDATION; REDUCTION	Aziridinylbenzoquinones are a group of antitumor agents that elicit cytotoxicity by generating either alkylating intermediates or reactive oxygen species, The mechanism of toxicity may not always, however, involve profound damage of cellular constituents, but may involve a cytostatic effect through interference with the cell cycle, In this context, we have examined the induction of the cell cycle inhibitor p21 (WAF1, CIP1, or sdi1), whose overexpression suppresses the growth of various tumor cells, in human tumor cells metabolizing 3,6-diaziridinyl-1,4-benzoquinone (DZQ) and its C-2,C-5-substituted derivatives: 2,5-bis-(carboethoxyamino) (AZQ) and 2,5-bis-2(-hydroxyethylamino) (BZQ). Both DZQ and AZQ were effectively activated by HCT116 human colonic carcinoma cells; the activation of the former involved largely a dicoumarol-sensitive activity, whereas that of the latter appeared to be accomplished primarily by one-electron transfer reductases, BZQ was not a substrate for the dicoumarol-sensitive enzyme in HCT116 cells, Cellular activation of the first two quinones was associated with formation of oxygen-centered radicals as detected by EPR in conjunction with the spin trap 5,5'-dimethyl-1-pyrroline-N-oxide. The redox transitions of DZQ involved hydroxyl radical formation and were strongly inhibited by catalase, whereas those of AZQ showed a strong superoxide anion component sensitive to superoxide dismutase, These signals were suppressed by N-acetylcysteine with concomitant production of a thiyl radical adduct, This suggests an effective electron transfer between the thiol and free radicals formed during the activation of these quinones. DZQ and AZQ induced significantly the expression of p21 in HCT116 cells, but a 10-fold higher concentration of AZQ was required to achieve the level of induction elicited by DZQ, BZQ had little effect on p21 expression, p21 induction at both mRNA and protein levels correlated with the inhibition of either cyclin-dependent kinase activity or cell proliferation, p21 induction elicited by the above quinones was inhibited by N-acetylcysteine, whereas the non-sulfur analog, N-acetylalanine, was without effect, Catalase and superoxide dismutase did not effect p21 induction by aziridinylbenzoquinones in HCT116 cells, thus suggesting that extracellular sources of oxygen radicals generated by plasma membrane reductases have no influence in the expression of this gene, Hydrogen peroxide, a product of quinone redox cycling, elicited an increase of p21 mRNA levels in HCT116 and K562 human chronic myelogenous leukemia cells, The latter lacks p53, one of the activators of p21 transcription, thus suggesting that p21 expression can be accomplished in a p53-independent manner in these cells. This study suggests that p21 induction is mediated by an increase in the cellular steady-state concentration of oxygen radicals and that the greater effectiveness in p21 induction by DZQ may be related to its efficient metabolism by NAD(P)H:quinone oxidoreductase activity in HCT116 cells.	UNIV SO CALIF,SCH PHARM,DEPT MOL PHARMACOL & TOXICOL,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT MICROBIOL,LOS ANGELES,CA 90033	University of Southern California; University of Southern California			Schonthal, Axel/ABH-3846-2020	Qiu, Xiao-Bo/0000-0003-2608-9376; Forman, Henry Jay/0000-0001-5838-2791; Schonthal, Axel/0000-0003-0662-5653	NIEHS NIH HHS [1RO1 ES05423] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005423] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BERARDINI MD, 1993, BIOCHEMISTRY-US, V32, P3306, DOI 10.1021/bi00064a013; BHATIA K, 1995, CANCER RES, V55, P1431; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BUETTNER GR, 1990, METHOD ENZYMOL, V186, P127; BUTLER J, 1987, BIOCHIM BIOPHYS ACTA, V925, P144, DOI 10.1016/0304-4165(87)90103-6; CADENAS E, 1995, METHOD ENZYMOL, V251, P106, DOI 10.1016/0076-6879(95)51114-8; CADENAS E, 1995, BIOCHEM PHARMACOL, V49, P127, DOI 10.1016/S0006-2952(94)00333-5; CHEN YQ, 1995, CANCER RES, V55, P4536; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; DATTA R, 1992, BIOCHEMISTRY-US, V31, P8300, DOI 10.1021/bi00150a025; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FISHER GR, 1991, FREE RADICAL BIO MED, V10, P358; GIBSON NW, 1992, MOL PHARMACOL, V42, P531; Harlow E., 1988, ANTIBODIES LAB MANUA; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; IMLAY JA, 1988, SCIENCE, V240, P640, DOI 10.1126/science.2834821; JOHNSON M, 1994, MOL CARCINOGEN, V11, P59, DOI 10.1002/mc.2940110202; JONES DP, 1995, IMMUNOL LETT, V45, P205, DOI 10.1016/0165-2478(95)00004-O; KATAYOSE D, 1995, CELL GROWTH DIFFER, V6, P1204; KING CL, 1984, CANCER RES, V44, P5634; LEE CS, 1992, BIOCHEMISTRY-US, V31, P3019, DOI 10.1021/bi00126a025; LI YJ, 1995, ONCOGENE, V10, P599; LIND C, 1990, METHOD ENZYMOL, V186, P287; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MANS DRA, 1992, BIOCHEM PHARMACOL, V43, P1761, DOI 10.1016/0006-2952(92)90708-Q; MICHIELI P, 1994, CANCER RES, V54, P3391; NAKANISHI M, 1995, P NATL ACAD SCI USA, V92, P4352, DOI 10.1073/pnas.92.10.4352; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; ODOM AL, 1992, BIOCHEM PHARMACOL, V43, P831, DOI 10.1016/0006-2952(92)90250-M; ORDONEZ ID, 1992, BIOCHEM J, V286, P481, DOI 10.1042/bj2860481; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; RILEY RJ, 1992, BIOCHEM PHARMACOL, V43, P1657, DOI 10.1016/0006-2952(92)90694-E; RUSSO T, 1995, J BIOL CHEM, V270, P29386, DOI 10.1074/jbc.270.49.29386; SHEIKH MS, 1994, ONCOGENE, V9, P3407; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; SHIOHARA M, 1994, BLOOD, V84, P613; SILVA JM, 1992, INT J RADIAT ONCOL, V22, P639, DOI 10.1016/0360-3016(92)90494-3; SILVA JM, 1989, CANCER RES, V49, P5550; SIMON AR, 1995, J CELL BIOCH A S, V21, P256; SKOTZKI M, 1995, CANCER RES, V55, P493; TRAVER RD, 1992, CANCER RES, V52, P797; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wardman P, 1988, GLUTATHIONE CONJUGAT, P43; WATANABE H, 1995, BBA-GENE STRUCT EXPR, V1263, P275, DOI 10.1016/0167-4781(95)00110-3; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	52	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					31915	31921		10.1074/jbc.271.50.31915	http://dx.doi.org/10.1074/jbc.271.50.31915			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943236	hybrid			2022-12-25	WOS:A1996VY34000027
J	Hiraiwa, N; Dohi, T; KawakamiKimura, N; Yumen, M; Ohmori, K; Maeda, M; Kannagi, R				Hiraiwa, N; Dohi, T; KawakamiKimura, N; Yumen, M; Ohmori, K; Maeda, M; Kannagi, R			Suppression of sialyl Lewis X expression and E-selectin-mediated cell adhesion in cultured human lymphoid cells by transfection of antisense cDNA of an alpha 1->3 fucosyltransferase (Fuc-T VII)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; HUMAN CANCER-CELLS; VASCULAR ENDOTHELIUM; MOLECULAR-CLONING; DETERMINES EXPRESSION; CARBOHYDRATE ANTIGEN; LEUKEMIA; LIGAND; RNA; SEQUENCES	The antisense cDNA approach was used to identify the endogenous fucosyltransferase species responsible for synthesis of the sialyl Lewis Ii (NeuAc alpha 2-->3 Gal beta 1-->4[FUC alpha 1-->31]GlcNAc beta 1-->R) determinant in human lymphoid cells, The cultured human adult T-cell leukemia cell line, ED40515-N, expressed the message of alpha 1-->3 fucosyltransferase (Fuc-T) IV and VII, with a low level of the Fuc-T III and VI message, and manifested the sialyl Lewis X as well as Lewis X (Gal beta 1-->4 [Fuc alpha 1-->3]GlcNAc beta 1->-R) determinant at the cell surface, Transfection of this cell Line with the pRc/CMV vector containing an antisense human Fuc-T VII construct (pRc/CMV/5'FT7AS) resulted in a significant decrease of endogenous Fuc-T VII message and a marked reduction in the cell surface expression of sialyl Lewis Ii determinant as well as a reduction in the enzymatic activity of alpha 1-->3 fucosyltransferase against sialylated type 2 chain substrate, This was accompanied by diminution of cell adhesive activity toward E-selectin on interleukin-lp-treated endothelial cells, These results indicated that the synthesis of the sialyl Lewis Ii determinants that were functionally active as E-selectin ligands was mainly mediated by Fuc-T VII in these lymphoid cells. On the other hand, the message of Fuc-T IV showed no significant change in the transfectant clones, and the surface expression of the Lewis Ii antigen as well as the enzymatic activity of alpha 1-->3 fucosyltransferase against non-sialylated type 2 chain substrate was well preserved, The clear contrast between the diminished expression of sialyl Lewis Ii and the conserved manifestation of Lewis Ii in the transfectant clones suggested that the synthesis of sialyl Lewis Ii and that of Lewis Ii are independently regulated by different fucosyltransferases in human lymphoid cells. Fuc-T VII must be involved in the synthesis of sialyl Lewis Ii, while the synthesis of Lewis X is mediated by an enzyme other than Fuc-T VII, most probably Fuc-T IV.	AICHI CANC CTR,RES INST,PROGRAM EXPT PATHOL,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; INT MED CTR JAPAN,RES INST,DIV BIOCHEM & NUTR,TOKYO 162,JAPAN; KYOTO UNIV,SCH MED,DEPT LAB MED,KYOTO 606,JAPAN; KYOTO UNIV,SCH MED,CHEST DIS INST,KYOTO 606,JAPAN	Aichi Cancer Center; National Center for Global Health & Medicine - Japan; Kyoto University; Kyoto University			Kannagi, Reiji/Q-6459-2018	Kannagi, Reiji/0000-0003-4202-2921; Ohmori, Katsuyuki/0000-0002-3794-6970				Chen TZ, 1996, J BIOCHEM-TOKYO, V119, P252; CHNG JLC, 1989, P NATL ACAD SCI USA, V86, P10006, DOI 10.1073/pnas.86.24.10006; Clarke JL, 1996, J BIOL CHEM, V271, P10317, DOI 10.1074/jbc.271.17.10317; DOHI T, 1994, CANCER, V73, P1552, DOI 10.1002/1097-0142(19940315)73:6<1552::AID-CNCR2820730605>3.0.CO;2-6; FURUKAWA Y, 1994, CANCER RES, V54, P6533; GOELZ S, 1994, J BIOL CHEM, V269, P1033; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; HAKOMORI SI, 1992, HISTOCHEM J, V24, P771, DOI 10.1007/BF01046348; ISHIKAWA T, 1993, BLOOD, V82, P1590; KANNAGI R, 1995, LEUKOCYTE TYPING, V5, P1529; KOSZDIN KL, 1992, BIOCHEM BIOPH RES CO, V187, P152, DOI 10.1016/S0006-291X(05)81472-X; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; Lowe J B, 1991, Semin Cell Biol, V2, P289; LOWE JB, 1991, J BIOL CHEM, V266, P17467; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MAEDA M, 1987, BLOOD, V70, P1407; MAEDA M, 1985, J EXP MED, V162, P2169, DOI 10.1084/jem.162.6.2169; MANIATIS T, 1989, MOL CLONING LAB MANU, P187; MUNROE SH, 1991, J BIOL CHEM, V266, P22083; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; NELLEN W, 1993, TRENDS BIOCHEM SCI, V18, P419, DOI 10.1016/0968-0004(93)90137-C; OHMORI K, 1989, BLOOD, V74, P255; OHMORI K, 1993, BLOOD, V82, P2797; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; Prins J, 1993, Clin Oncol (R Coll Radiol), V5, P245, DOI 10.1016/S0936-6555(05)80238-9; SAIJO Y, 1993, CANCER LETT, V68, P95, DOI 10.1016/0304-3835(93)90134-U; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SHIIZU Y, 1989, NATURE, V349, P799; Smith PL, 1996, J BIOL CHEM, V271, P8250, DOI 10.1074/jbc.271.14.8250; STOOLMAN LM, 1989, CELL, V56, P907, DOI 10.1016/0092-8674(89)90620-X; TAKADA A, 1993, CANCER RES, V53, P354; TAKADA A, 1991, BIOCHEM BIOPH RES CO, V179, P713, DOI 10.1016/0006-291X(91)91875-D; WAKASUGI N, 1990, P NATL ACAD SCI USA, V87, P8282, DOI 10.1073/pnas.87.21.8282; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; Warren HS, 1996, J IMMUNOL, V156, P2866; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; YAGO K, 1993, CANCER RES, V53, P5559; YODOI J, 1985, J IMMUNOL, V134, P1623; YOKOYAMA K, 1987, P NATL ACAD SCI USA, V84, P7363, DOI 10.1073/pnas.84.21.7363; ZENG GC, 1995, P NATL ACAD SCI USA, V92, P8670, DOI 10.1073/pnas.92.19.8670	43	46	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31556	31561		10.1074/jbc.271.49.31556	http://dx.doi.org/10.1074/jbc.271.49.31556			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940172	hybrid			2022-12-25	WOS:A1996VW68600083
J	Nissim, I; Yudkoff, M; Brosnan, JT				Nissim, I; Yudkoff, M; Brosnan, JT			Regulation of [N-15]urea synthesis from [5-N-15]glutamine - Role of pH, hormones, and pyruvate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBAMOYL-PHOSPHATE SYNTHETASE; N-ACETYLGLUTAMATE CONTENT; RAT-LIVER GLUTAMINASE; UREA SYNTHESIS; GLUTAMATE-DEHYDROGENASE; NITROGEN-METABOLISM; GLUCAGON ACTIONS; TERM REGULATION; UREAGENESIS; HEPATOCYTES	We have utilized both [5-N-15]glutamine and [3-C-13] pyruvate as metabolic tracers in order to: (i) examine the effect of pH, glucagon (GLU), or insulin on the precursor-product relationship between (NH3)-N-15, [N-15]citrulline, and, thereby, [N-15]urea synthesis and (ii) elucidate the mechanism(s) by which pyruvate stimulates [N-15] urea synthesis. Hepatocytes isolated from rat were incubated at pH 6.8, 7.4, or 7.6 with 1 mM [5-N-15]glutamine and 0.1 mM (NH4Cl)-N-14 in the presence or the absence of [3-C-13] pyruvate (2 mM). A separate series of experiments was performed at pH 7.4 in the presence of insulin or GLU. (NH3)-N-15 enrichment exceeded or was equal to that of [N-15]citrulline under all conditions except for pH 7.6, when the N-15 enrichment in citrulline exceeded that in ammonia. The formation of [N-15]citrulline (atom % excess) was increased with higher pH. Flux through phosphate-dependent glutaminase (PDG) and [N-15]urea synthesis were stimulated (p < 0.05) at pH 7.6 or with GLU and decreased (p < 0.05) at pH 6.8. Insulin had no significant effect on flux through PDG or on [N-15]urea synthesis, Decreased [N-15]urea production at pH 6.8 was associated with depleted aspartate and glutamate levels, Pyruvate attenuated this decrease in the aspartate and glutamate pools and stimulated [N-15]urea synthesis. Production of Asp from pyruvate was increased with increasing medium pH. Approximately 80% of Asp was derived from [3-C-13]pyruvate regardless of incubation pH or addition of hormone. Furthermore, approxiately 20, 40, and 50% of the mitochondrial N-acetylglutamate (NAG) pool was derived from [3-C-13]pyruvate at pH 6.8, 7.4, and 7.6, respectively. Both the concentration and formation of [C-13]NAG from [3-C-13]pyruvate were increased (p < 0.05) with glucagon and decreased (p < 0.05) with insulin or at pH 6.8. The data suggest a correlation between changes in [N-15]urea synthesis and alterations in the level and synthesis of [C-13]NAG from pyruvate, The current observations suggest that the stimulation of [N-15]urea synthesis in acute alkalosis is mediated via increased flux through PDG and subsequent increased utilization of [5-N-15] Of glutamine for [N-15]citrulline synthesis and/or increased synthesis of NAG from glutamate and pyruvate. The opposite may have occurred in acute acidosis. Glucagon, but not insulin, stimulated [N-15]urea synthesis via increased flux through PDG and synthesis of NAG. Pyruvate stimulated urea synthesis via increased availability of aspartate and/or increased synthesis of NAG, The formation of NAG and aspartate from pyruvate are both pH-sensitive processes.	UNIV PENN, SCH MED,CHILDRENS HOSP PHILADELPHIA,DEPT PEDIAT, DIV BIOCHEM DEV & MOL DIS, PHILADELPHIA, PA USA; UNIV PENN, SCH MED,CHILDRENS HOSP PHILADELPHIA,DEPT PEDIAT, DIV CHILD DEV, PHILADELPHIA, PA USA; MEM UNIV NEWFOUNDLAND, DEPT BIOCHEM, St John, NF A1B 3X9, CANADA	University of Pennsylvania; Childrens Hospital of Philadelphia; University of Pennsylvania; Childrens Hospital of Philadelphia; Memorial University Newfoundland					NIDDK NIH HHS [DK-39348] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039348] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALMDAL TP, 1994, METABOLISM, V43, P328, DOI 10.1016/0026-0495(94)90101-5; BEAN ES, 1984, J BIOL CHEM, V259, P1552; BLACKMORE PF, 1979, J BIOL CHEM, V254, P2828; BOON L, 1994, AM J PHYSIOL-RENAL, V267, pF1015, DOI 10.1152/ajprenal.1994.267.6.F1015; BROSNAN JT, 1974, BIOCHEM J, V138, P453, DOI 10.1042/bj1380453; Brosnan JT, 1996, J BIOL CHEM, V271, P16199, DOI 10.1074/jbc.271.27.16199; BROSNAN JT, 1982, FED PROC, V41, P91; BROSNAN JT, 1995, ADV ENZYME REGUL, V35, P131, DOI 10.1016/0065-2571(94)00003-L; COHEN NS, 1985, BIOCHEM J, V229, P205, DOI 10.1042/bj2290205; COHEN NS, 1984, ARCH BIOCHEM BIOPHYS, V234, P31, DOI 10.1016/0003-9861(84)90321-7; COHEN NS, 1980, J BIOL CHEM, V255, P248; COOPER AJL, 1990, ANN NY ACAD SCI, V585, P118, DOI 10.1111/j.1749-6632.1990.tb28048.x; COOPER AJL, 1988, J BIOL CHEM, V263, P12268; CORVERA S, 1983, BIOCHEM J, V210, P957, DOI 10.1042/bj2100957; CYR DM, 1991, BIOCHEM PHARMACOL, V42, P645, DOI 10.1016/0006-2952(91)90328-3; DODGSON SJ, 1987, AM J PHYSIOL, V63, pF2134; EXTON JH, 1980, AM J PHYSIOL, V238, pE3, DOI 10.1152/ajpendo.1980.238.1.E3; FAHIEN LA, 1964, J BIOL CHEM, V239, P1935; GARCIASAINZ JA, 1989, BIOCHEM INT, V18, P243; HALL LM, 1958, J BIOL CHEM, V230, P1013; HALPERIN ML, 1986, AM J PHYSIOL, V250, pF605, DOI 10.1152/ajprenal.1986.250.4.F605; HAMBERG O, 1994, J HEPATOL, V21, P381, DOI 10.1016/S0168-8278(05)80317-4; HAUSSINGER D, 1990, BIOCHEM J, V267, P281; HENSGENS HESJ, 1980, EUR J BIOCHEM, V107, P197, DOI 10.1111/j.1432-1033.1980.tb04640.x; KAMEMOTO ES, 1985, ARCH BIOCHEM BIOPHYS, V243, P100, DOI 10.1016/0003-9861(85)90777-5; KASHIWAGURA T, 1985, J BIOL CHEM, V260, P407; KUN E, 1974, METHOD ENZYMAT AN, V4, P1704; LUND P, 1984, BIOCHEM J, V218, P991, DOI 10.1042/bj2180991; LUND P, 1986, BIOCHEM J, V239, P773, DOI 10.1042/bj2390773; MARIUSZ K, 1994, AM J PHYSIOL, V267, pG754; MARTINREQUERO A, 1992, AM J PHYSIOL, V263, pE493, DOI 10.1152/ajpendo.1992.263.3.E493; MCGIVAN JD, 1983, BIOCHIM BIOPHYS ACTA, V759, P296, DOI 10.1016/0304-4165(83)90327-6; MCGIVAN JD, 1975, FEBS LETT, V52, P1, DOI 10.1016/0014-5793(75)80624-7; MCGIVAN JD, 1991, BIOCHEM J, V274, P103, DOI 10.1042/bj2740103; MEIJER AJ, 1978, J BIOL CHEM, V253, P2308; MEIJER AJ, 1990, PHYSIOL REV, V70, P701, DOI 10.1152/physrev.1990.70.3.701; MEIJER AJ, 1985, FEBS LETT, V191, P249, DOI 10.1016/0014-5793(85)80018-1; NISSIM I, 1991, BIOCHEM J, V277, P33, DOI 10.1042/bj2770033; NISSIM I, 1995, KIDNEY INT, V47, P96, DOI 10.1038/ki.1995.11; NISSIM I, 1993, J AM SOC NEPHROL, V3, P1416; NISSIM I, 1985, J BIOL CHEM, V260, P3955; NISSIM I, 1992, ARCH BIOCHEM BIOPHYS, V292, P393, DOI 10.1016/0003-9861(92)90008-K; STEWART PM, 1980, J BIOL CHEM, V255, P5270; SZWEDA LI, 1989, J BIOL CHEM, V264, P15357; TUCHMAN M, 1990, PEDIATR RES, V27, P408, DOI 10.1203/00006450-199004000-00020; TUCHMAN M, 1990, BIOCHEM J, V271, P325, DOI 10.1042/bj2710325; VERHOEVEN AJ, 1983, EUR J BIOCHEM, V133, P241, DOI 10.1111/j.1432-1033.1983.tb07454.x; VINAY P, 1980, KIDNEY INT, V17, P312, DOI 10.1038/ki.1980.37; WILLIAMSON JR, 1980, FEBS LETT, V117, pK73, DOI 10.1016/0014-5793(80)80572-2; WOLFE RR, 1992, RADIOACTIVE STABLE I, P49	50	41	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31234	31242		10.1074/jbc.271.49.31234	http://dx.doi.org/10.1074/jbc.271.49.31234			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940126	hybrid			2022-12-25	WOS:A1996VW68600037
J	Postina, R; Kojro, E; Fahrenholz, F				Postina, R; Kojro, E; Fahrenholz, F			Separate agonist and peptide antagonist binding sites of the oxytocin receptor defined by their transfer into the V-2 vasopressin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; IDENTIFICATION; LOCALIZATION; SELECTIVITY; AFFINITY; RESIDUE; DOMAIN	The neurohypophyseal nonapeptide oxytocin (OT) is the main hormone responsible for the initiation of labor; uterus contraction can be enhanced by application of oxytocin or suppressed by oxytocin antagonists, By transfer of domains from the G protein-coupled OT receptor into the related V-2 vasopressin receptor, chimeric ''gain in function'' V-2/OT receptors were produced that were able to bind either OT receptor agonists or a competitive peptide antagonist with high affinity, The binding site for the OT antagonist d(CH2)(5)[Tyr(Me)(2), Thr(4),Orn(8),Tyr(9)]vasotocin was found to be formed by transmembrane helices 1, 2, and 7 with a major contribution to binding affinity by the upper part of helix 7. These transmembrane receptor regions could be excluded from participating in OT binding, For agonist binding and selectivity the first three extracellular receptor domains were most important. The interaction of the N-terminal domain and of the first extracellular loop of the OT receptor with the linear C-terminal tripeptidic part of oxytocin was demonstrated, Furthermore, the second extracellular loop of the OT receptor could be identified to interact with the cyclic hormone part. These three domains contribute to OT binding by synergistic interaction with oxytocin but not with the competitive antagonist. Our results provide evidence for the existence of separate domains and different conformations of a peptide hormone receptor involved in binding and selectivity for agonists and peptide antagonists.	MAX PLANCK INST BIOPHYS, D-60596 FRANKFURT, GERMANY	Max Planck Society								Akerlund M, 1995, ADV EXP MED BIOL, V395, P595; Bathgate R, 1995, DNA CELL BIOL, V14, P1037, DOI 10.1089/dna.1995.14.1037; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAO YJ, 1995, BIOCHEM BIOPH RES CO, V212, P673, DOI 10.1006/bbrc.1995.2021; CARTER CS, 1992, ANN NY ACAD SCI, V652, P204, DOI 10.1111/j.1749-6632.1992.tb34356.x; CARTER CS, 1992, NEUROSCI BIOBEHAV R, V16, P131, DOI 10.1016/S0149-7634(05)80176-9; CHINI B, 1995, EMBO J, V14, P2176, DOI 10.1002/j.1460-2075.1995.tb07211.x; ELANDS J, 1988, EUR J PHARMACOL, V147, P197, DOI 10.1016/0014-2999(88)90778-9; FITZPATRICK VD, 1994, J BIOL CHEM, V269, P24621; FUCHS AR, 1984, AM J OBSTET GYNECOL, V150, P734, DOI 10.1016/0002-9378(84)90677-X; FUCHS AR, 1990, AM J OBSTET GYNECOL, V163, P1961, DOI 10.1016/0002-9378(90)90781-2; GORBULEV V, 1993, EUR J BIOCHEM, V215, P1, DOI 10.1111/j.1432-1033.1993.tb18000.x; Hausmann H, 1996, P NATL ACAD SCI USA, V93, P6907, DOI 10.1073/pnas.93.14.6907; HENDERSON R, 1975, NATURE, V257, P28, DOI 10.1038/257028a0; HOWL J, 1995, BIOCHEM SOC T, V23, P103, DOI 10.1042/bst0230103; JANS DA, 1993, FEBS LETT, V315, P134, DOI 10.1016/0014-5793(93)81149-T; KIMURA T, 1994, EUR J ENDOCRINOL, V131, P385, DOI 10.1530/eje.0.1310385; KIMURA T, 1992, NATURE, V356, P526, DOI 10.1038/356526a0; KLEIN U, 1995, PEPTIDES, V16, P851, DOI 10.1016/0196-9781(95)00039-M; KOJRO E, 1991, J BIOL CHEM, V266, P21416; KOJRO E, 1993, BIOCHEMISTRY-US, V32, P13537, DOI 10.1021/bi00212a020; KOJRO E, 1995, J BIOL CHEM, V270, P6476, DOI 10.1074/jbc.270.12.6476; KU CY, 1995, ENDOCRINOLOGY, V136, P1509, DOI 10.1210/en.136.4.1509; Liu J, 1996, J BIOL CHEM, V271, P8772, DOI 10.1074/jbc.271.15.8772; Manning M, 1995, ADV EXP MED BIOL, V395, P559; METCALF MA, 1992, BIOCHEM PHARMACOL, V44, P1917, DOI 10.1016/0006-2952(92)90092-W; METZGER TG, 1995, FEBS LETT, V375, P1, DOI 10.1016/0014-5793(95)01185-H; Mizobe T, 1996, J BIOL CHEM, V271, P2387, DOI 10.1074/jbc.271.5.2387; MOUILLAC B, 1995, J BIOL CHEM, V270, P25771, DOI 10.1074/jbc.270.43.25771; Postina R, 1995, ANAL BIOCHEM, V232, P254, DOI 10.1006/abio.1995.0017; RILEY PR, 1995, J MOL ENDOCRINOL, V15, P195, DOI 10.1677/jme.0.0150195; ROSENKILDE MM, 1994, J BIOL CHEM, V269, P28160; ROZEN F, 1995, P NATL ACAD SCI USA, V92, P200, DOI 10.1073/pnas.92.1.200; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SCHMIDT JM, 1991, EUR J BIOCHEM, V201, P355, DOI 10.1111/j.1432-1033.1991.tb16293.x; SURYANARAYANA S, 1991, J BIOL CHEM, V266, P15488; UFER E, 1995, FEBS LETT, V362, P19, DOI 10.1016/0014-5793(95)00150-8; WOOD SP, 1986, SCIENCE, V232, P633, DOI 10.1126/science.3008332	38	107	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31593	31601		10.1074/jbc.271.49.31593	http://dx.doi.org/10.1074/jbc.271.49.31593			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940177	hybrid			2022-12-25	WOS:A1996VW68600088
J	Freire, R; Serrano, M; Salas, M; Hermoso, JM				Freire, R; Serrano, M; Salas, M; Hermoso, JM			Activation of replication origins in phi 29-related phages requires the recognition of initiation proteins to specific nucleoprotein complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHI-29 DNA-REPLICATION; TERMINAL PROTEIN; BACTERIOPHAGE PHI-29; INVITRO; TRANSCRIPTION; SIGNALS; BINDING; GENES; P6; M2	Protein p6 of Bacillus subtilis phage phi 29 activates the initiation of viral DNA replication by forming a multimeric nucleoprotein complex at the origins of replication, located at both ends of the linear genome, This activation requires a precise positioning of the protein p6 array with respect to the initiation site, To investigate this activation mechanism, we have purified the phi 29 protein p6 counterparts from the related phages Nf and GA-1 and analyzed the formation of complexes with DNA. In the homologous protein p6-DNA complexes the phi 29 and Nf protein arrays showed an identical positioning, different than that of the GA-1 protein array, In contrast, in the heterologous complexes the protein showed a different arrangement except in the case of the Nf protein-phi 29 DNA complex. We have also purified the proteins involved in the initiation of replication (terminal protein and DNA polymerase) from phages Nf and GA-1 and measured the ability of the different p6 proteins to activate homologous and heterologous replication origins. The results obtained indicate that the activation requires not only the formation of a specific nucleoprotein complex but also its specific recognition by the proteins involved in the initiation of DNA and the initiation sites, in which the protein p6 moiety was replication.	UNIV AUTONOMA MADRID,CSIC,CTR BIOL MOL,E-28049 MADRID,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)			Salas, Margarita/J-9873-2014; Freire, Raimundo/Q-7660-2019; Serrano, Manuel/H-2634-2015	Salas, Margarita/0000-0001-5939-3441; Freire, Raimundo/0000-0003-4473-8894; Serrano, Manuel/0000-0001-7177-9312	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027242] Funding Source: NIH RePORTER; NIGMS NIH HHS [5R01 GM27242-16] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARWERT F, 1974, J VIROL, V13, P584, DOI 10.1128/JVI.13.3.584-589.1974; BLANCO L, 1986, NUCLEIC ACIDS RES, V14, P4923, DOI 10.1093/nar/14.12.4923; BOROWIEC JA, 1988, EMBO J, V7, P3149, DOI 10.1002/j.1460-2075.1988.tb03182.x; BRAMHILL D, 1988, CELL, V52, P747; BRAVO A, 1994, GENE, V148, P107, DOI 10.1016/0378-1119(94)90242-9; CARRASCOSA JL, 1976, EUR J BIOCHEM, V66, P229, DOI 10.1111/j.1432-1033.1976.tb10512.x; CHEN M, 1990, J BIOL CHEM, V265, P18634; DIXON WJ, 1991, METHOD ENZYMOL, V208, P380; DODSON M, 1986, P NATL ACAD SCI USA, V83, P7638, DOI 10.1073/pnas.83.20.7638; DURKHOFF AM, 1987, CELL, V48, P935; FREIRE R, 1994, EMBO J, V13, P4353, DOI 10.1002/j.1460-2075.1994.tb06755.x; GALAS D, 1978, NUCLEIC ACIDS RES, V9, P3157; GUTIERREZ C, 1994, EMBO J, V13, P269, DOI 10.1002/j.1460-2075.1994.tb06257.x; GUTIERREZ J, 1986, VIROLOGY, V155, P474, DOI 10.1016/0042-6822(86)90209-6; HIROKAWA H, 1972, P NATL ACAD SCI USA, V69, P1555, DOI 10.1073/pnas.69.6.1555; HIROKAWA H, 1977, MODERN TRENDS BACTER, P3; INIS MA, 1988, P NATL ACAD SCI USA, V85, P9436; KISHI T, 1993, JPN J GENET, V68, P243, DOI 10.1266/jjg.68.243; MATSUMOTO K, 1983, MOL GEN GENET, V191, P26, DOI 10.1007/BF00330885; MELLADO RP, 1980, VIROLOGY, V104, P84, DOI 10.1016/0042-6822(80)90367-0; MUL YM, 1990, J VIROL, V64, P5510, DOI 10.1128/JVI.64.11.5510-5518.1990; MURRAY CL, 1982, J BIOL CHEM, V257, P1053; PASTRANA R, 1985, NUCLEIC ACIDS RES, V85, P314; PENALVA MA, 1982, P NATL ACAD SCI-BIOL, V79, P5522, DOI 10.1073/pnas.79.18.5522; PRIETO I, 1988, P NATL ACAD SCI USA, V85, P314, DOI 10.1073/pnas.85.2.314; ROJO F, 1990, J MOL BIOL, V211, P713, DOI 10.1016/0022-2836(90)90072-T; SALAS M, 1991, ANNU REV BIOCHEM, V60, P39, DOI 10.1146/annurev.bi.60.070191.000351; Salas Margarita, 1993, P843; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SERRANO M, 1993, J MOL BIOL, V230, P248, DOI 10.1006/jmbi.1993.1140; SERRANO M, 1990, SCIENCE, V248, P1012, DOI 10.1126/science.2111580; SERRANO M, 1989, EMBO J, V8, P1879, DOI 10.1002/j.1460-2075.1989.tb03584.x; SERRANO M, 1991, THESIS U AUTONOMA MA; YOSHIKAWA H, 1986, J GEN APPL MICROBIOL, V33, P39	34	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					31000	31007		10.1074/jbc.271.48.31000	http://dx.doi.org/10.1074/jbc.271.48.31000			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940089	hybrid			2022-12-25	WOS:A1996VV15800106
J	Gramatikova, SI; Christen, P				Gramatikova, SI; Christen, P			Pyridoxal 5'-phosphate-dependent catalytic antibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Cofactors might efficiently extend the catalytic potential of antibodies. Monoclonal antibodies against N-alpha-phosphopyridoxyl-L-lysine were screened for: 1) binding of 5'-phosphopyridoxyl amino acids, 2) binding of Schiff base of pyridoxal 5'-phosphate (PLP) and amino acids, the first intermediate of all PLP-dependent reactions, and 3) catalysis of PLP-dependent alpha,beta-elimination with beta-chloro-D/L-alanine. All three criteria were met by antibody 15A9. Further analysis for PLP-dependent reactions showed that this antibody catalyzes the cofactor-dependent transamination of hydrophobic D-amino acids and oxo acids (k(cat) = 0.42 min(-1) with D-alanine). No other reactions with either D- or L-amino acids were taking place. PLP markedly contributes to catalytic efficacy, being a 10(4) times more efficient acceptor of the amino group than pyruvate. The antibody further accelerates the reaction (k'(cat(antibody))/k'(cat(PLP)) = 5 x 10(3) with D-alanine as substrate) and ensures reaction specificity, stereospecificity, as well as limited substrate specificity.	UNIV ZURICH,INST BIOCHEM,CH-8057 ZURICH,SWITZERLAND	University of Zurich								Christen P, 1985, TRANSAMINASES; COCHRAN AG, 1991, J AM CHEM SOC, V113, P6670, DOI 10.1021/ja00017a046; Coligan JKA, 1991, CURRENT PROTOCOLS IM; FREEDMAN MH, 1968, BIOCHEMISTRY-US, V7, P1941, DOI 10.1021/bi00845a044; Harlow E, 1988, ANTIBODIES LAB MANUA, P211; HELLER JS, 1975, BIOCHIM BIOPHYS ACTA, V403, P197, DOI 10.1016/0005-2744(75)90022-4; JENCKS WP, 1969, CATALYSIS CHEM ENZYM, P133; KHOMUTOV RM, 1971, BIOCHEM J, V124, P99, DOI 10.1042/bj1240099; KIRSCH JF, 1984, J MOL BIOL, V174, P497, DOI 10.1016/0022-2836(84)90333-4; KOCHHAR S, 1989, ANAL BIOCHEM, V178, P17, DOI 10.1016/0003-2697(89)90348-5; MORINO Y, 1974, J BIOL CHEM, V249, P6684; RASO V, 1975, BIOCHEMISTRY-US, V14, P591, DOI 10.1021/bi00674a020	12	23	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30583	30586		10.1074/jbc.271.48.30583	http://dx.doi.org/10.1074/jbc.271.48.30583			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940030	hybrid			2022-12-25	WOS:A1996VV15800047
J	Gresham, HD; Graham, IL; Griffin, GL; Hsieh, JC; Dong, LJ; Chung, AE; Senior, RM				Gresham, HD; Graham, IL; Griffin, GL; Hsieh, JC; Dong, LJ; Chung, AE; Senior, RM			Domain-specific interactions between entactin and neutrophil integrins - G2 domain ligation of integrin alpha(3)beta(1) and E domain ligation of the leukocyte response integrin signal for different responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE GLYCOPROTEIN ENTACTIN; MATRIX METALLOPROTEINASES; TYROSINE PHOSPHORYLATION; PHAGOCYTIC FUNCTION; RESPIRATORY BURST; RGD SEQUENCE; RECEPTOR; LAMININ; BINDING; FIBRONECTIN	Extracellular matrix proteins activate neutrophils to up-regulate many physiologic functions that are necessary at sites of tissue injury. To elucidate the ligand-receptor interactions that mediate these functions, we examined neutrophil activation by the basement membrane protein, entactin. Entactin is structurally and functionally organized into distinct domains; therefore, we utilized glutathione S-transferase -fusion proteins encompassing its four major domains, G1, G2, E, and G3, to assess interactions between entactin and neutrophil integrin receptors. We show that the E domain, which contains the single RGD sequence of entactin, is sufficient for ligation of the beta(3)-like integrin, leukocyte response integrin, and signaling for chemotaxis. Moreover, the G2 domain signals for stimulation of Fc receptor-mediated phagocytosis via ligation of alpha(3) beta(1). This receptor-ligand interaction was revealed only after stimulation of neutrophil by immune complexes or phorbol esters. Interestingly, the E domain does not enhance phagocytosis, and the G2 domain is not chemotactic. Furthermore, cleavage of entactin with the matrix metalloproteinase, matrilysin, liberates peptides that retain E domain-mediated chemotaxis and G2 domain-mediated enhancement of phagocytosis. These studies indicate that multiple domains of entactin have the ability to ligate individual integrins expressed by neutrophils and to activate distinct functions.	UNIV MISSOURI,RES SERV,TRAUMA VET ADM MED CTR,COLUMBIA,MO 65201; UNIV MISSOURI,DEPT PHARMACOL,COLUMBIA,MO 65201; UNIV MISSOURI,DEPT MOL MICROBIOL & IMMUNOL,COLUMBIA,MO 65201; WASHINGTON UNIV,SCH MED,BARNES JEWISH HOSP,DEPT MED,RESP & CRIT CARE DIV,ST LOUIS,MO 63110; UNIV PITTSBURGH,DEPT BIOL SCI,PITTSBURGH,PA 15260	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; Barnes-Jewish Hospital; Washington University (WUSTL); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NCI NIH HHS [CA-21246] Funding Source: Medline; NHLBI NIH HHS [HL-29594] Funding Source: Medline; NIAID NIH HHS [AI-36309] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA021246] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F30AI136309, R29AI036309] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; ARROYO AG, 1992, J CELL BIOL, V117, P659, DOI 10.1083/jcb.117.3.659; BATTAGLIA C, 1992, EUR J BIOCHEM, V208, P359, DOI 10.1111/j.1432-1033.1992.tb17195.x; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BOHNSACK JF, 1990, J EXP MED, V171, P1221, DOI 10.1084/jem.171.4.1221; BOHNSACK JF, 1992, J IMMUNOL, V149, P1340; BOHNSACK JF, 1992, BLOOD, V79, P1545; CARRENO MP, 1993, CLIN IMMUNOL IMMUNOP, V69, P43, DOI 10.1006/clin.1993.1148; CHUNG AE, 1990, AM J RESP CELL MOL, V3, P275, DOI 10.1165/ajrcmb/3.4.275; COLOGNATOPYKE H, 1995, J BIOL CHEM, V270, P9398, DOI 10.1074/jbc.270.16.9398; DEDHAR S, 1992, J BIOL CHEM, V267, P18908; DELWEL GO, 1994, MOL BIOL CELL, V5, P203, DOI 10.1091/mbc.5.2.203; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DONG LJ, 1995, J BIOL CHEM, V270, P15838, DOI 10.1074/jbc.270.26.15838; DURKIN ME, 1988, J CELL BIOL, V107, P2749, DOI 10.1083/jcb.107.6.2749; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; FOX JW, 1991, EMBO J, V10, P3137, DOI 10.1002/j.1460-2075.1991.tb04875.x; FUORTES M, 1994, J CELL BIOL, V127, P1477, DOI 10.1083/jcb.127.5.1477; GRAHAM IL, 1994, J CELL BIOL, V127, P1139, DOI 10.1083/jcb.127.4.1139; GRESHAM HD, 1987, J IMMUNOL, V139, P4159; GRESHAM HD, 1992, J BIOL CHEM, V267, P13895; GRESHAM HD, 1991, J CLIN INVEST, V88, P588, DOI 10.1172/JCI115343; GRESHAM HD, 1989, J CELL BIOL, V108, P1935, DOI 10.1083/jcb.108.5.1935; HENDEY B, 1992, SCIENCE, V258, P296, DOI 10.1126/science.1384129; HSIEH JC, 1994, BIOCHEM BIOPH RES CO, V199, P1509, DOI 10.1006/bbrc.1994.1402; ISHIBASHI Y, 1994, J EXP MED, V180, P1225, DOI 10.1084/jem.180.4.1225; MURPHY G, 1992, AM J RESP CELL MOL, V7, P120, DOI 10.1165/ajrcmb/7.2.120; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; SENIOR RM, 1989, AM J RESP CELL MOL, V1, P479, DOI 10.1165/ajrcmb/1.6.479; SENIOR RM, 1992, J CLIN INVEST, V90, P2251, DOI 10.1172/JCI116111; SHARMA CP, 1995, J IMMUNOL, V154, P3461; SIRES UI, 1993, J BIOL CHEM, V268, P2069; SUCHARD SJ, 1991, J IMMUNOL, V147, P651; TSAO T, 1990, J BIOL CHEM, V265, P5188; VANSTRIJP JAG, 1993, J IMMUNOL, V151, P3324; VUORI K, 1993, J BIOL CHEM, V268, P21459; WAYNER EA, 1993, J CELL BIOL, V121, P1141, DOI 10.1083/jcb.121.5.1141; WU CY, 1995, J CELL SCI, V108, P2511; ZHOU MJ, 1993, J EXP MED, V178, P1165, DOI 10.1084/jem.178.4.1165	41	34	34	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30587	30594		10.1074/jbc.271.48.30587	http://dx.doi.org/10.1074/jbc.271.48.30587			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940031	hybrid			2022-12-25	WOS:A1996VV15800048
J	Tikhonenko, AT; Black, DJ; Linial, ML				Tikhonenko, AT; Black, DJ; Linial, ML			Viral Myc oncoproteins in infected fibroblasts down-modulate thrombospondin-1, a possible tumor suppressor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTHYMOSIN-ALPHA GENE; 3' UNTRANSLATED REGION; C-MYC; ENDOTHELIAL-CELLS; GROWTH-FACTOR; V-MYC; TRANSCRIPTIONAL REGULATION; NUCLEOTIDE-SEQUENCE; CYCLIN D1; EXPRESSION	We are interested in identifying the transcriptional targets of the Myc oncoproteins, To this end, we have fused Myc of the MC29 retrovirus with the rat glucocorticoid receptor, This chimeric protein requires dexamethasone to undergo nuclear translocation and achieve an active conformation, We employed a differential hybridization approach to identify mRNAs that are induced or repressed in infected avian fibroblasts in response to dexamethasone. This screen yielded one mRNA underrepresented in the dexamethasone-treated cells. In Myc-transformed cell clones, its level decreases B-fold as early as 4 h and more than 30-fold after 32 h of exposure to the hormone, This mRNA was also downregulated by recombinant Myc retroviruses in rodent fibroblasts, including those refractory to transformation, Sequence analysis revealed that it is homologous to the 3' untranslated regions of the mammalian thrombospondin-l genes, Using an anti-thrombospondin antibody, we confirmed that rodent cells overexpressing Myc produce very small amounts of this protein. Also, they do not support efficient expression of a reporter gene driven by the thrombospondin-l promoter. Thus, thrombospondin-l is a bona fide target of Myc. Moreover, its silencing might pertain to the transforming activity of Myc, since in several systems thrombospondin-l exhibits tumor suppressor properties, presumably due to its negative effect on neovascularization.			Tikhonenko, AT (corresponding author), FRED HUTCHINSON CANC RES CTR, DIV BASIC SCI, 1124 COLUMBIA ST, SEATTLE, WA 98104 USA.		Thomas-Tikhonenko, Andrei/E-5329-2011	Thomas-Tikhonenko, Andrei/0000-0002-2739-2206	NATIONAL CANCER INSTITUTE [R01CA058809, P30CA015704] Funding Source: NIH RePORTER; NCI NIH HHS [CA58809, P30 CA15704] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P100, DOI 10.1073/pnas.80.1.100; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; Baulieu EE., 1991, ANN NY ACAD SCI, V626, P545, DOI 10.1111/j.1749-6632.1991.tb37946.x; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERNARDS R, 1995, CURR BIOL, V5, P859, DOI 10.1016/S0960-9822(95)00173-4; BLACKWOOD EM, 1994, MOL BIOL CELL, V5, P597, DOI 10.1091/mbc.5.5.597; BORNSTEIN P, 1994, METHOD ENZYMOL, V245, P62; CASTLE VP, 1993, J BIOL CHEM, V268, P2899; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; DONOVIEL DB, 1988, J BIOL CHEM, V263, P18590; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; ENRIETTO PJ, 1987, CANCER SURV, V6, P85; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HENNESSY SW, 1989, J CELL BIOL, V108, P729, DOI 10.1083/jcb.108.2.729; HUANG LQ, 1995, BLOOD COAGUL FIBRIN, V6, P438, DOI 10.1097/00001721-199507000-00011; IRUELAARISPE ML, 1991, P NATL ACAD SCI USA, V88, P5026, DOI 10.1073/pnas.88.11.5026; JAIN VK, 1991, ANAL BIOCHEM, V199, P119, DOI 10.1016/0003-2697(91)90278-2; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; JOHNSTON JM, 1992, LEUKEMIA LYMPHOMA, V8, P431, DOI 10.3109/10428199209051025; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LABELL TL, 1993, GENOMICS, V17, P225, DOI 10.1006/geno.1993.1308; LAHAV J, 1993, BIOCHIM BIOPHYS ACTA, V1182, P1, DOI 10.1016/0925-4439(93)90146-R; LAHERTY CD, 1989, J BIOL CHEM, V264, P11222; LAWLER J, 1991, J BIOL CHEM, V266, P8039; LAWLER J, 1991, GENOMICS, V11, P587, DOI 10.1016/0888-7543(91)90066-N; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LOVEC H, 1994, ONCOGENE, V9, P323; MAJACK RA, 1987, J BIOL CHEM, V262, P8821; MATTIONI T, 1994, METHOD CELL BIOL, V43, P335; METTOUCHI A, 1994, EMBO J, V13, P5668, DOI 10.1002/j.1460-2075.1994.tb06905.x; MOL PC, 1995, MOL CELL BIOL, V15, P6999; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; SALNIKOW K, 1994, MOL CELL BIOL, V14, P851, DOI 10.1128/MCB.14.1.851; SCHULTZCHERRY S, 1995, J BIOL CHEM, V270, P7304, DOI 10.1074/jbc.270.13.7304; SHEIBANI N, 1995, P NATL ACAD SCI USA, V92, P6788, DOI 10.1073/pnas.92.15.6788; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; Shrivastava A, 1995, Curr Top Microbiol Immunol, V194, P273; SLACK JL, 1994, CELL GROWTH DIFFER, V5, P1373; SMALL MB, 1987, MOL CELL BIOL, V7, P1638, DOI 10.1128/MCB.7.5.1638; SMITH JB, 1995, J BIOL CHEM, V270, P16756, DOI 10.1074/jbc.270.28.16756; SPAETE RR, 1985, J VIROL, V56, P135, DOI 10.1128/JVI.56.1.135-143.1985; TIKHONENKO AT, 1992, J VIROL, V66, P946, DOI 10.1128/JVI.66.2.946-955.1992; TIKHONENKO AT, 1995, ONCOGENE, V11, P1499; TIKHONENKO AT, 1993, MOL CELL BIOL, V13, P3623, DOI 10.1128/MCB.13.6.3623; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; TRIEZENBERG SJ, 1988, GENE DEV, V2, P730, DOI 10.1101/gad.2.6.730; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; TUCKER RP, 1995, DEV DYNAM, V203, P477, DOI 10.1002/aja.1002030410; Tuszynski GP, 1996, BIOESSAYS, V18, P71, DOI 10.1002/bies.950180113; VANDEVIJVER MJ, 1993, ADV CANCER RES, V61, P25; VOLPERT OV, 1995, BIOCHEM BIOPH RES CO, V217, P326, DOI 10.1006/bbrc.1995.2780; WATSON DK, 1983, P NATL ACAD SCI-BIOL, V80, P2146, DOI 10.1073/pnas.80.8.2146; WEINSTATSASLOW DL, 1994, CANCER RES, V54, P6504; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; ZABRENETZKY V, 1994, INT J CANCER, V59, P191, DOI 10.1002/ijc.2910590209	70	81	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30741	30747		10.1074/jbc.271.48.30741	http://dx.doi.org/10.1074/jbc.271.48.30741			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940053	hybrid			2022-12-25	WOS:A1996VV15800070
J	Vance, BA; Zacharchuk, CM; Segal, DM				Vance, BA; Zacharchuk, CM; Segal, DM			Recombinant mouse Bcl-2((1-203)) - Two domains connected by a long protease-sensitive linker	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; BCL-2 GENE; CONSERVED DOMAINS; INDUCED APOPTOSIS; BAX; HETERODIMERIZATION; BCL-2-ALPHA; PROTEINS; FAMILY; BH1	Bcl-2 is a cytoplasmic integral membrane protein with potent anti-apoptotic activity but whose mechanism of action is poorly understood. The purpose of this paper was to obtain large amounts of soluble Bcl-2 protein for structural and functional studies. Mouse Bcl-2((1-203)) (missing the COOH-terminal hydrophobic tail) was produced in bacterial inclusion bodies, solubilized in guanidine, and refolded by dialysis. The resulting protein was monomeric in nondenaturing solution and was active in protecting mouse T hybridoma cells from glucocorticoid-induced apoptosis. Refolded Bcl-2((1-203)) showed no tendency to homodimerize by gel filtration or analytical ultracentrifugation. Limited proteolysis experiments identified a region between the BH3 and BH4 homology domains of Bcl-2((1-203)) which was extremely susceptible to digestion by several common proteases, but not by a cell extract known to contain CPP-32-like (interleukin-1 beta-converting enzyme family) protease activity. The protease-sensitive sites were located within a 50-residue stretch that contained most of the nonconserved and proline residues of Bcl-2((1-203)). Trypsin-cleaved Bcl-2((1-203)) eluted in the same position as the undigested protein on gel filtration in nondenaturing solution, indicating that the two portions of the molecule connected by the protease-sensitive region associate stably and noncovalently. The solution properties of Bcl-2((1-203)) suggest that it consists of two noncovalently associated domains connected by a long protease-sensitive linker and that its structure is similar to that of Bcl-x(L), which has been determined by x-ray and NMR analysis.	NCI,NIH,EXPT IMMUNOL BRANCH,BETHESDA,MD 20892; NCI,NIH,LAB IMMUNE CELL BIOL,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Vance, Barbara/GYA-0940-2022					Boise L H, 1995, Curr Top Microbiol Immunol, V200, P107; BORNER C, 1994, BIOCHEM CELL BIOL, V72, P463, DOI 10.1139/o94-062; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; Chen CY, 1996, J BIOL CHEM, V271, P2376, DOI 10.1074/jbc.271.5.2376; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Haldar S, 1996, CANCER RES, V56, P1253; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; HOCKENBERY DM, 1995, BIOESSAYS, V17, P631, DOI 10.1002/bies.950170709; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; KURUCZ I, 1993, P NATL ACAD SCI USA, V90, P3830, DOI 10.1073/pnas.90.9.3830; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; MEMON SA, 1995, J IMMUNOL, V155, P4644; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SCHLEGEL J, 1995, FEBS LETT, V364, P139, DOI 10.1016/0014-5793(95)00374-I; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; YIN XM, 1994, COLD SPRING HARB SYM, V59, P387, DOI 10.1101/SQB.1994.059.01.043; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	25	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30811	30815		10.1074/jbc.271.48.30811	http://dx.doi.org/10.1074/jbc.271.48.30811			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940062	hybrid			2022-12-25	WOS:A1996VV15800079
J	Han, M; Lin, SW; Minkova, M; Smith, SO; Sakmar, TP				Han, M; Lin, SW; Minkova, M; Smith, SO; Sakmar, TP			Functional interaction of transmembrane helices 3 and 6 in rhodopsin - Replacement of phenylalanine 261 by alanine causes reversion of phenotype of a glycine 121 replacement mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIFF-BASE COUNTERION; PROTEIN-COUPLED RECEPTORS; BINDING-SITE CREVICE; BOVINE RHODOPSIN; RETINAL CHROMOPHORE; PROJECTION STRUCTURE; VISUAL PIGMENTS; AMINO-ACIDS; TRANSDUCIN; LOCATION	Replacement of a highly conserved glycine residue on transmembrane (TM) helix 3 of bovine rhodopsin (Gly(121)) by amino acid residues with larger side chains causes a progressive blue-shift in the lambda(max) value of the pigment, a decrease in thermal stability, and an increase in reactivity with hydroxylamine. In addition, mutation of Gly(121) causes a relative reversal in the selectivity of opsin for 11-cis-retinal, over all-trans-retinal, It was suggested that Gly(121) plays an important role in defining the 11-cis-retinal binding pocket of rhodopsin (Han, M., Lin, S. W., Smith, S. O., and Sakmar, T. P. (1996) J. Biol. Chem. 271, 32330-32336), Here, we combined the mutant opsin G121L with second site replacements of four different amino acid residues on TM helix 6: Met(257), Val(258), Phe(261), or Trp(265), We show that the loss of function phenotypes of the G121L mutant described above can be partially reverted specifically by the mutation of Phe(261) a residue highly conserved in all G protein-coupled receptors, For example, the double-replacement mutant G121L/F261A has spectral, chromophore-binding, and transducin-activating properties intermediate between those of G121L and rhodopsin, This rescue of the G121L defects did not occur with the other second site mutations tested, We conclude that specific portions of TM helices 3 and 6, which include Gly(121) and Phe(261), respectively, define the chromophore-binding pocket in rhodopsin, Finally, the results are placed in the context of a molecular graphics model of the TM domain of rhodopsin, which includes the retinal-binding pocket.	YALE UNIV,DEPT MOL BIOPHYS & BIOCHEM,NEW HAVEN,CT 06520; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,BIOCHEM & MOL BIOL LAB,NEW YORK,NY 10021	Yale University; Howard Hughes Medical Institute; Rockefeller University			Sakmar, Thomas P/D-1833-2015	Sakmar, Thomas P/0000-0002-2836-8953	NIGMS NIH HHS [GM 41412] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041412] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALKORTA I, 1994, PROTEIN ENG, V7, P1231, DOI 10.1093/protein/7.10.1231; Almaula N, 1996, J BIOL CHEM, V271, P14672, DOI 10.1074/jbc.271.25.14672; ASENJO AB, 1994, NEURON, V12, P1131, DOI 10.1016/0896-6273(94)90320-4; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BIRGE RR, 1985, P NATL ACAD SCI USA, V82, P4117, DOI 10.1073/pnas.82.12.4117; CHAN T, 1992, J BIOL CHEM, V267, P9478; COHEN GB, 1992, BIOCHEMISTRY-US, V31, P12592, DOI 10.1021/bi00165a008; DONNELLY D, 1994, RECEPTOR CHANNEL, V2, P61; ERNST OP, 1995, J BIOL CHEM, V270, P10580, DOI 10.1074/jbc.270.18.10580; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P8812, DOI 10.1021/bi00027a033; FARENS DL, 1996, SCIENCE, V274, P768; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; GARCIA PD, 1995, EMBO J, V14, P4460, DOI 10.1002/j.1460-2075.1995.tb00125.x; HAN M, 1993, BIOPHYS J, V65, P899, DOI 10.1016/S0006-3495(93)81117-2; Han M, 1996, J BIOL CHEM, V271, P32330, DOI 10.1074/jbc.271.50.32330; HAN M, 1995, BIOCHEMISTRY-US, V34, P1425, DOI 10.1021/bi00004a037; JAVITCH JA, 1995, NEURON, V14, P825, DOI 10.1016/0896-6273(95)90226-0; JAVITCH JA, 1994, P NATL ACAD SCI USA, V91, P10355, DOI 10.1073/pnas.91.22.10355; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; Lin SW, 1996, BIOCHEMISTRY-US, V35, P11149, DOI 10.1021/bi960858u; LIN SW, 1994, BIOCHEMISTRY-US, V33, P2151, DOI 10.1021/bi00174a023; NAKAYAMA TA, 1990, J BIOL CHEM, V265, P15762; NAKAYAMA TA, 1991, J BIOL CHEM, V266, P4269; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; SAKMAR TP, 1991, P NATL ACAD SCI USA, V88, P3079, DOI 10.1073/pnas.88.8.3079; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SCHERTLER GFX, 1995, P NATL ACAD SCI USA, V92, P11578, DOI 10.1073/pnas.92.25.11578; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; ZHANG HZ, 1994, J AM CHEM SOC, V116, P10165, DOI 10.1021/ja00101a040; ZHUKOVSKY EA, 1989, SCIENCE, V246, P928, DOI 10.1126/science.2573154; ZHUKOVSKY EA, 1992, BIOCHEMISTRY-US, V31, P10400, DOI 10.1021/bi00157a030; ZVYAGA TA, 1994, BIOCHEMISTRY-US, V33, P9753, DOI 10.1021/bi00198a046; ZVYAGA TA, 1994, J BIOL CHEM, V269, P13056; ZVYAGA TA, 1993, J BIOL CHEM, V268, P4661	37	85	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32337	32342		10.1074/jbc.271.50.32337	http://dx.doi.org/10.1074/jbc.271.50.32337			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943296	hybrid			2022-12-25	WOS:A1996VY34000087
J	Scholtz, B; KingsleyKallesen, M; Rizzino, A				Scholtz, B; KingsleyKallesen, M; Rizzino, A			Transcription of the transforming growth factor-beta 2 gene is dependent on an E-box located between an essential cAMP response element/activating transcription factor motif and the TATA box of the gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX-LOOP-HELIX; EMBRYONAL CARCINOMA-CELLS; FACTOR USF; DNA-BINDING; GROWTH-FACTOR-BETA-2 GENE; FACTOR-BETA; DIFFERENTIATED CELLS; ZIPPER PROTEIN; MYC PROTEINS; PROMOTER	Transforming growth factor-beta 2 (TGF-beta 2) is an important regulator of cell proliferation and differentiation; however, its transcriptional regulation is not well understood, Here we report characterization of an essential E-box motif, positioned at -50/-45 between a previously described functional cAMP response element/activating transcription factor site and the TATA box of the human TGF-beta 2 promoter, By site directed mutagenesis, we demonstrate that this E-box motif is necessary for the promoter activity, not only in differentiated cells derived from embryonal carcinoma cells, but also in choriocarcinoma cells and in MCF-7 breast carcinoma cells, We also demonstrate that the transcription factors USF1 and USF2 bind to this E-box motif in vitro when nuclear extracts from each of these cell lines are examined by gel retardation assays, Moreover, using a dominant-negative USF2 protein, we show that USF proteins are critical for TGF-beta 2 promoter activity in vivo. The importance of the E-box motif described in this study is supported by the presence of an E-box motif in the same position in the chicken TGF-beta 2 gene promoter.	UNIV NEBRASKA, MED CTR, EPPLEY INST RES CANC & ALLIED DIS, OMAHA, NE 68198 USA; UNIV NEBRASKA, MED CTR, DEPT PATHOL & MICROBIOL, OMAHA, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center				Scholtz, Beata/0000-0002-2737-5027	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD019837] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA036727] Funding Source: NIH RePORTER; NCI NIH HHS [CA 36727] Funding Source: Medline; NICHD NIH HHS [HD 19837] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENDALL AJ, 1994, NUCLEIC ACIDS RES, V22, P2801, DOI 10.1093/nar/22.14.2801; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, COLD SPRING HARB SYM, V56, P109; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BURT DW, 1991, DNA CELL BIOL, V10, P723, DOI 10.1089/dna.1991.10.723; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CLARK DA, 1991, ANN NY ACAD SCI, V626, P524; DAS SK, 1992, ENDOCRINOLOGY, V130, P3459, DOI 10.1210/en.130.6.3459; DAVIS LG, 1986, BASIC METHODS MOL BI, P286; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; KELLY D, 1992, DEV BIOL, V153, P172, DOI 10.1016/0012-1606(92)90102-M; KELLY D, 1995, MOL REPROD DEV, V40, P135, DOI 10.1002/mrd.1080400202; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KINGSLEYKALLESE.M, 1996, IN PRESS IN VITRO CE; KIRSCHBAUM BJ, 1992, MOL CELL BIOL, V12, P5094, DOI 10.1128/MCB.12.11.5094; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MA A, 1993, ONCOGENE, V8, P1093; MEIER JL, 1994, MOL CELL BIOL, V14, P6896, DOI 10.1128/MCB.14.10.6896; Noma T, 1991, GROWTH FACTORS, V4, P247, DOI 10.3109/08977199109043910; OREILLY MA, 1992, J BIOL CHEM, V267, P19938; OUTRAM SV, 1994, J BIOL CHEM, V269, P26525; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; POGNONEC P, 1992, J BIOL CHEM, V267, P24563; RIZZINO A, 1988, DEV BIOL, V130, P411, DOI 10.1016/0012-1606(88)90337-5; RIZZINO A, 1983, EXP CELL RES, V143, P143, DOI 10.1016/0014-4827(83)90116-7; RIZZINO A, 1989, GROWTH FACTORS MAMMA, P113; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHOLTZ B, 1995, MOL REPROD DEV, V41, P140, DOI 10.1002/mrd.1080410204; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Sirito Mario, 1992, Gene Expression, V2, P231; SUN LZ, 1994, J BIOL CHEM, V269, P26449; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZHAO GQ, 1993, MOL CELL BIOL, V13, P4505, DOI 10.1128/MCB.13.8.4505; ZHOU QJ, 1995, J VIROL, V69, P4323, DOI 10.1128/JVI.69.7.4323-4330.1995	43	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32375	32380		10.1074/jbc.271.50.32375	http://dx.doi.org/10.1074/jbc.271.50.32375			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943301	hybrid			2022-12-25	WOS:A1996VY34000092
J	Christoffels, VM; vandenHoff, MJB; Lamers, MC; vanRoon, MA; deBoer, PAJ; Moorman, AFM; Lamers, WH				Christoffels, VM; vandenHoff, MJB; Lamers, MC; vanRoon, MA; deBoer, PAJ; Moorman, AFM; Lamers, WH			The upstream regulatory region of the carbamoyl-phosphate synthetase I gene controls its tissue-specific, developmental, and hormonal regulation in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOENOLPYRUVATE CARBOXYKINASE; TYROSINE AMINOTRANSFERASE GENE; LIVER-SPECIFIC GENES; RAT-LIVER; MESSENGER-RNA; TRANSCRIPTION FACTORS; GLUTAMINE-SYNTHETASE; TRANSGENIC MICE; ORNITHINE AMINOTRANSFERASE; HEPATOCYTE HETEROGENEITY	The carbamoyl-phosphate synthetase I gene is expressed in the periportal region of the liver, where it is activated by glucocorticosteroids and glucagon (via cyclic AMP), and in the crypts of the intestinal mucosa. The enhancer of the gene is located 6.3 kilobase pairs upstream of the transcription start site and has been shown to direct the hormone-dependent hepatocyte-specific expression in vitro, To analyze the function of the upstream region in vivo, three groups of transgenic mice were generated, In the first group the promoter drives expression of the reporter gene, whereas the prometer and upstream region including the far upstream enhancer drive expression of the reporter gene in the second group. In the third group the far upstream enhancer was directly coupled to a minimized promoter fragment. Reporter-gene expression was virtually undetectable in the first group. In the second group spatial, temporal, and hormonal regulation of expression of the reporter gene and the endogenous carbamoyl-phosphate synthetase gene were identical, The third group showed liver-specific periportal reporter gene expres sion, but failed to activate expression in the intestine. These results show that the upstream region of the carbamoyl phosphate synthetase gene controls four characteristics of its expression: tissue specificity, spatial pattern of expression within the liver and intestine, hormone sensitivity, and developmental regulation, Within the upstream region, the far upstream enhancer at -6.3 kilobase pairs is the determinant of the characteristic hepatocyte-specific periportal expression pattern of carbamoyl-phosphate synthetase.	UNIV AMSTERDAM, DEPT ANAT & EMBRYOL, NL-1105 AZ AMSTERDAM, NETHERLANDS; MAX PLANCK INST IMMUNBIOL, D-79108 FREIBURG, GERMANY; ACAD MED CTR, GENETICALLY MODIFIED MICE FACIL, NL-1105 AZ AMSTERDAM, NETHERLANDS	University of Amsterdam; Max Planck Society; University of Amsterdam; Academic Medical Center Amsterdam			Lamers, Wouter H./D-2965-2012					ADCOCK MW, 1984, J BIOL CHEM, V259, P3471; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BEALE EG, 1992, FASEB J, V6, P3330, DOI 10.1096/fasebj.6.15.1281456; BERTHOUD VM, 1992, AM J PHYSIOL, V263, pG650, DOI 10.1152/ajpgi.1992.263.5.G650; CHRISTOFFELS VM, 1995, J BIOL CHEM, V270, P24932, DOI 10.1074/jbc.270.42.24932; DEGROOT CJ, 1986, BIOCHIM BIOPHYS ACTA, V866, P61, DOI 10.1016/0167-4781(86)90101-6; DESIMONE V, 1992, BIOCHIM BIOPHYS ACTA, V1132, P119, DOI 10.1016/0167-4781(92)90001-G; Dingemanse MA, 1996, HEPATOLOGY, V24, P407; DINGEMANSE MA, 1994, DIFFERENTIATION, V56, P153, DOI 10.1046/j.1432-0436.1994.5630153.x; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; GEBHARDT R, 1992, PHARMACOL THERAPEUT, V53, P275, DOI 10.1016/0163-7258(92)90055-5; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOPING IS, 1994, J BIOL CHEM, V269, P3891; GOPING IS, 1995, NUCLEIC ACIDS RES, V23, P1717, DOI 10.1093/nar/23.10.1717; GOPING IS, 1992, GENE, V118, P283, DOI 10.1016/0378-1119(92)90201-Y; GRANGE T, 1991, NUCLEIC ACIDS RES, V19, P131, DOI 10.1093/nar/19.1.131; HAUSSINGER D, 1992, ENZYME, V46, P72; HOGAN B, 1986, MANIPULATING MOUSE E; JANZEN JWG, 1988, J HISTOCHEM CYTOCHEM, V36, P1223, DOI 10.1177/36.10.2458406; JANZEN JWG, 1985, J HISTOCHEM CYTOCHEM, V339, P1205; JOHNSON PF, 1990, CELL GROWTH DIFFER, V1, P47; JUNGERMANN K, 1995, HISTOCHEM CELL BIOL, V103, P81, DOI 10.1007/BF01454004; KUO CF, 1988, MOL CELL BIOL, V8, P4966, DOI 10.1128/MCB.8.11.4966; KUO CF, 1989, J MOL BIOL, V208, P45, DOI 10.1016/0022-2836(89)90086-7; KUO FC, 1991, P NATL ACAD SCI USA, V88, P9468, DOI 10.1073/pnas.88.21.9468; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAGACE M, 1987, J BIOL CHEM, V262, P10415; LAGACE M, 1992, GENE, V118, P231, DOI 10.1016/0378-1119(92)90193-S; LAI E, 1991, TRENDS BIOCHEM SCI, V16, P427, DOI 10.1016/0968-0004(91)90169-V; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LAMERS WH, 1981, MECH AGEING DEV, V15, P93, DOI 10.1016/0047-6374(81)90010-5; LAMERS WH, 1987, DIFFERENTIATION, V35, P228, DOI 10.1111/j.1432-0436.1987.tb00173.x; LAMERS WH, 1984, DEV BIOL, V105, P500, DOI 10.1016/0012-1606(84)90307-5; LAMERS WH, 1990, ANAT REC, V228, P297, DOI 10.1002/ar.1092280309; LIEVENEMA H, 1995, J BIOL CHEM, V270, P28251; MEEHAN R, 1992, J CELL SCI, P9; MEIJER AJ, 1990, PHYSIOL REV, V70, P701, DOI 10.1152/physrev.1990.70.3.701; MIZUTANI A, 1968, J HISTOCHEM CYTOCHEM, V16, P172, DOI 10.1177/16.3.172; MOORMAN AFM, 1990, HISTOCHEM J, V22, P457, DOI 10.1007/BF01007229; MOORMAN AFM, 1993, HISTOCHEM J, V25, P251, DOI 10.1007/BF00159117; MOORMAN AFM, 1991, FEBS LETT, V288, P133, DOI 10.1016/0014-5793(91)81019-5; MOORMAN AFM, 1990, FEBS LETT, V276, P9, DOI 10.1016/0014-5793(90)80494-4; MOORMAN AFM, 1994, FEBS LETT, V356, P76, DOI 10.1016/0014-5793(94)01230-X; MORRIS SM, 1992, ANNU REV NUTR, V12, P81, DOI 10.1146/annurev.nu.12.070192.000501; MORRIS SM, 1987, ARCH BIOCHEM BIOPHYS, V256, P343, DOI 10.1016/0003-9861(87)90455-3; MUECKLER MM, 1983, J BIOL CHEM, V258, P6109; NAGY P, 1994, J CELL BIOL, V126, P223, DOI 10.1083/jcb.126.1.223; NISHIYORI A, 1994, J BIOL CHEM, V269, P1323; NITSCH D, 1993, P NATL ACAD SCI USA, V90, P5479, DOI 10.1073/pnas.90.12.5479; NOTENBOOM RGE, 1996, IN PRESS MICROSC RES; NYUNOYA H, 1985, J BIOL CHEM, V260, P9346; OSSIPOW V, 1995, CELL, V83, P137, DOI 10.1016/0092-8674(95)90242-2; PATEL YM, 1994, J BIOL CHEM, V269, P5619; RIGAUD G, 1991, CELL, V67, P977, DOI 10.1016/0092-8674(91)90370-E; ROUX J, 1995, DNA CELL BIOL, V14, P385, DOI 10.1089/dna.1995.14.385; RYALL JC, 1986, EUR J BIOCHEM, V156, P453, DOI 10.1111/j.1432-1033.1986.tb09603.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHORT MK, 1992, MOL CELL BIOL, V12, P1007, DOI 10.1128/MCB.12.3.1007; Takiguchi M, 1995, BIOCHEM J, V312, P649, DOI 10.1042/bj3120649; THOMPSON JF, 1991, GENE, V103, P171, DOI 10.1016/0378-1119(91)90270-L; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; VANDENHOFF MJB, 1993, NUCLEIC ACIDS RES, V21, P4987, DOI 10.1093/nar/21.21.4987; VANDENHOFF MJB, 1995, EUR J BIOCHEM, V228, P351; VANROON MA, 1989, DIFFERENTIATION, V41, P139, DOI 10.1111/j.1432-0436.1989.tb00741.x; WORKMAN JL, 1993, TRENDS BIOCHEM SCI, V18, P90, DOI 10.1016/0968-0004(93)90160-O; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YOOWARREN H, 1983, P NATL ACAD SCI-BIOL, V80, P3656, DOI 10.1073/pnas.80.12.3656	68	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31243	31250		10.1074/jbc.271.49.31243	http://dx.doi.org/10.1074/jbc.271.49.31243			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940127	hybrid			2022-12-25	WOS:A1996VW68600038
J	Jung, YS; Vassiliev, IR; Qiao, FY; Yang, F; Bryant, DA; Golbeck, JH				Jung, YS; Vassiliev, IR; Qiao, FY; Yang, F; Bryant, DA; Golbeck, JH			Modified ligands to F-A and F-B in Photosystem I - Proposed chemical rescue of a [4Fe-4S] cluster with an external thiolate in alanine, glycine, and serine mutants of PsaC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; IRON-SULFUR CLUSTERS; COLI FUMARATE REDUCTASE; ESCHERICHIA-COLI; ELECTRON-TRANSFER; PROTEIN; CONVERSION; CYSTEINE; COMPLEX; BINDING	The F-B and F-A electron accepters in Photosystem I (PS I) are [4Fe-4S] clusters ligated by cysteines provided by PsaC. In a previous study (Mehari, T., Qiao, F., Scott, M. P., Nellis, D., Zhao, J., Bryant, D., and Golbeck, J. H. (1995) J. Biol. Chem. 270, 28108-28117), we showed that when cysteines 14 and 51 were replaced with serine or alanine, the free proteins contained a S = 1/2, [4Fe-4S] cluster at the unmodified site and a mixed population of S = 1/2, [3Fe-4S] and S = 3/2, [4Fe-4S] clusters at the modified site. We show here that these mutant PsaC proteins can be rebound to P700-F-X cores, resulting in fully functional PS I complexes. The low temperature EPR spectra of the C14X(PsaC). PS I complexes (where X = S, A, or G) show the photoreduction of a wild-type F-A cluster and a modified F-B cluster, the latter with g values of 2.115, 1.899, and 1.852 and linewidths of 110, 70, and 85 MHz. Since neither alanine nor glycine contains a suitable side group, an external thiolate provided by beta-mercaptoethanol has likely been recruited to supply the requisite ligand to the [4Fe-4S] cluster. The EPR spectrum of the C51S(PsaC). PS I complex differs from that of the C51A(PsaC). PS I or C51G(PSaC). PS I complexes by the presence of an additional set of resonances, which may be derived from the serine oxygen-ligated cluster. In all other mutant PS I complexes, a wild-type spin-coupled interaction spectrum appears when FA and F, are simultaneously reduced. Single turnover flash studies indicate similar to 50% efficient electron transfer to F-A/F-B in the C14SP(Sac). PS I, C51S(PsaC). PS I, C14G(PSaC). PS I, and CB14S(PsaC). PS I mutants and less than 40% in the C14A(PsaC). PS I and C51A(PsaC). PS I mutants, compared with similar to 76% in the PS I core reconstructed with wild-type PsaC. These data are consistent with the measurements of the rates of cytochrome c(6)-NADP(+) reductase activity, indicating lower rates in the alanine mutants. It is proposed that the chemical rescue of a [4Fe-4S] cluster with a recruited external thiolate at the modified site allows the mutant PsaC proteins to rebind to PS I and to function in forward electron transfer.	PENN STATE UNIV,DEPT BIOCHEM & MOL BIOL,UNIVERSITY PK,PA 16802; PENN STATE UNIV,CTR BIOMOL STRUCT & FUNCT,UNIVERSITY PK,PA 16802; UNIV NEBRASKA,DEPT BIOCHEM,GEORGE W BEADLE CTR,LINCOLN,NE 68588; UNIV NEBRASKA,CTR BIOL CHEM,GEORGE W BEADLE CTR,LINCOLN,NE 68588	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln								ALTMAN TE, 1981, THESIS U ILLINOIS UR; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BASSILIEV I, 1996, IN PRESS BIOPHYS J; BEINERT H, 1989, EUR J BIOCHEM, V186, P5, DOI 10.1111/j.1432-1033.1989.tb15170.x; BEINERT H, 1983, ARCH BIOCHEM BIOPHYS, V222, P333, DOI 10.1016/0003-9861(83)90531-3; Belford R L., 1979, EPR S 21 ROCK MOUNT; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brettel K, 1995, PHOTOSYNTH RES, V45, P183, DOI 10.1007/BF00015559; BRITT RD, 1991, BIOCHEMISTRY-US, V30, P1892, DOI 10.1021/bi00221a023; CONOVER RC, 1990, J BIOL CHEM, V265, P8533; DAVIDSON E, 1992, BIOCHEMISTRY-US, V31, P3342, DOI 10.1021/bi00128a006; DUNN PPJ, 1988, FEBS LETT, V228, P157, DOI 10.1016/0014-5793(88)80607-0; Golbeck J. H., 1995, CRC HDB ORGANIC PHOT, P1407; GOLBECK JH, 1993, CURR OPIN STRUC BIOL, V3, P508, DOI 10.1016/0959-440X(93)90076-W; Jung YS, 1995, PHOTOSYNTH RES, V46, P249, DOI 10.1007/BF00020437; JUNG YS, 1995, PHOTOSYNTHESIS LIGHT, V2, P127; KOJIMA Y, 1987, PROGR PHOTOSYNTHESIS, V2, P57; KOWAL AT, 1995, BIOCHEMISTRY-US, V34, P12284, DOI 10.1021/bi00038a024; KRAUSS N, 1993, NATURE, V361, P326, DOI 10.1038/361326a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LI N, 1991, BIOCHEMISTRY-US, V30, P7863, DOI 10.1021/bi00245a028; Mannan RM, 1996, EMBO J, V15, P1826, DOI 10.1002/j.1460-2075.1996.tb00532.x; MANODORI A, 1992, BIOCHEMISTRY-US, V31, P2703, DOI 10.1021/bi00125a010; MATHIS P, 1988, PHOTOSYNTH RES, V16, P203, DOI 10.1007/BF00028839; MEHARI T, 1995, J BIOL CHEM, V270, P28108; MEYER TE, 1994, METHOD ENZYMOL, V243, P435; MOUESCA JM, 1994, INORG CHEM, V33, P4819, DOI 10.1021/ic00100a004; MOURA JJG, 1994, METHOD ENZYMOL, V243, P165; Muhlenhoff U, 1996, EUR J BIOCHEM, V235, P324, DOI 10.1111/j.1432-1033.1996.00324.x; Nilges M. J., 1979, THESIS U ILLINOIS UR; OHOKA H, 1989, PLANT CELL PHYSIOL, V30, P869, DOI 10.1093/oxfordjournals.pcp.a077818; ROTHERY RA, 1991, BIOCHEMISTRY-US, V30, P8296, DOI 10.1021/bi00098a003; SAKURAI H, 1991, PHOTOSYNTH RES, V27, P65, DOI 10.1007/BF00029977; SHERGILL JK, 1994, BBA-BIOENERGETICS, V1185, P35, DOI 10.1016/0005-2728(94)90190-2; THOMSON AJ, 1992, J INORG BIOCHEM, V47, P197, DOI 10.1016/0162-0134(92)84065-U; THOMSON AJ, 1991, BIOCHEM SOC T, V19, P594, DOI 10.1042/bst0190594; VASSILIEV IR, 1995, BIOPHYS J, V69, P1544, DOI 10.1016/S0006-3495(95)80026-3; WARREN PV, 1993, BIOCHEMISTRY-US, V32, P4411, DOI 10.1021/bi00067a034; WERTH MT, 1990, P NATL ACAD SCI USA, V87, P8965, DOI 10.1073/pnas.87.22.8965; YU J, 1995, PLANT MOL BIOL, V29, P311; YU L, 1995, BIOCHEMISTRY-US, V34, P7861, DOI 10.1021/bi00024a010; YU LA, 1995, J BIOL CHEM, V270, P28118; ZHAO JD, 1992, BIOCHEMISTRY-US, V31, P5093, DOI 10.1021/bi00137a001; ZHAO JD, 1990, FEBS LETT, V276, P175, DOI 10.1016/0014-5793(90)80536-R	44	27	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31135	31144		10.1074/jbc.271.49.31135	http://dx.doi.org/10.1074/jbc.271.49.31135			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940111	hybrid			2022-12-25	WOS:A1996VW68600022
J	Chu, BY; Soncin, F; Price, BD; Stevenson, MA; Calderwood, SK				Chu, BY; Soncin, F; Price, BD; Stevenson, MA; Calderwood, SK			Sequential phosphorylation by mitogen-activated protein kinase and glycogen synthase kinase 3 represses transcriptional activation by heat shock factor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; MAP KINASE; CELLS; STRESS; EXPRESSION; YEAST; GENE; MECHANISMS; TRANSITION; PATHWAYS	Mammalian heat shock genes are regulated at the transcriptional level by heat shock factor-1 (HSF-1), a sequence-specific transcription factor. We have examined the role of serine phosphorylation of HSF-1 in the regulation of heat shock gene transcription, Our experiments show that mitogen-activated protein kinases (MAPKs) of the ERK-1 family phosphorylate HSF-1 on serine residues and repress the transcriptional activation of the heat shock protein 70B (HSP70B) promoter by HSP-1 in vivo, These effects of MAPK are transmitted through a specific serine residue (Ser-303) located in a proline-rich sequence within the transcriptional regulatory domain of human HSF-1, However, despite the importance of Ser-303 in transmitting the signal from the MAPK cascade to HSP70 transcription, there was no evidence that Ser-303 could be phosphorylated by MAPK in vitro, although an adjacent residue (Ser-307) was avidly phosphorylated by MAPK. Further studies revealed that Ser-303 is phosphorylated by glycogen synthase kinase 3 (GSK3) through a mechanism dependent on primary phosphorylation of Ser-307 by MAPK, Secondary phosphorylation of Ser-303 by GSK3 may thus repress the activity of HSF-1, and its requirement for priming by MAPK phosphorylation of Ser-307 provides a potential link between the MAPK cascade and HSF-1, Our experiments thus indicate that MAPK is a potent inhibitor of HSF-1 function and may be involved in repressing the heat shock response during normal growth and development and deactivating the heat shock response during recovery from stress.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, JOINT CTR RADIAT THERAPY, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School			SONCIN, Fabrice/A-1475-2009	SONCIN, Fabrice/0000-0001-6312-0673	NATIONAL CANCER INSTITUTE [R01CA050642, P01CA031303, R01CA047407] Funding Source: NIH RePORTER; NCI NIH HHS [CA50642, CA31303, CA47407] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRUCE JL, 1993, CANCER RES, V53, P12; Cahill CM, 1996, J BIOL CHEM, V271, P24874; Cotto JJ, 1996, J BIOL CHEM, V271, P3355; ENGELBERG D, 1994, MOL CELL BIOL, V14, P4929, DOI 10.1128/MCB.14.7.4929; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GREEN M, 1995, MOL CELL BIOL, V15, P3354; HENSOLD JO, 1990, MOL CELL BIOL, V10, P1600, DOI 10.1128/MCB.10.4.1600; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOJ A, 1994, EMBO J, V13, P2617; JAKOBSEN BK, 1991, EMBO J, V10, P369, DOI 10.1002/j.1460-2075.1991.tb07958.x; KEMP BE, 1991, METHOD ENZYMOL, V200, P121; LANDRY J, 1992, J BIOL CHEM, V267, P794; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MIVECHI NF, 1995, CANCER RES, V55, P5512; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; Newton EM, 1996, MOL CELL BIOL, V16, P839; PRICE BD, 1991, MOL CELL BIOL, V11, P3365, DOI 10.1128/MCB.11.6.3365; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SCHILLER P, 1988, J MOL BIOL, V203, P97, DOI 10.1016/0022-2836(88)90094-0; SHI YH, 1995, MOL CELL BIOL, V15, P4309; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; STEVENSON MA, 1994, CANCER RES, V54, P12; STEVENSON MA, 1996, IN PRESS BIOCH BIOPH; VENETIANER A, 1995, EUR J BIOCHEM, V233, P83, DOI 10.1111/j.1432-1033.1995.083_1.x; Voellmy Richard, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P357; WESTWOOD JT, 1993, MOL CELL BIOL, V13, P3481, DOI 10.1128/MCB.13.6.3481; Woodgett JR, 1991, METHOD ENZYMOL, V200, P564; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; ZUO JR, 1994, MOL CELL BIOL, V14, P7557, DOI 10.1128/MCB.14.11.7557; ZUO JR, 1995, MOL CELL BIOL, V15, P4319	40	309	329	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30847	30857		10.1074/jbc.271.48.30847	http://dx.doi.org/10.1074/jbc.271.48.30847			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940068	hybrid			2022-12-25	WOS:A1996VV15800085
J	Kamalati, T; Jolin, HE; Mitchell, PJ; Barker, KT; Jackson, LE; Dean, CJ; Page, MJ; Gusterson, BA; Crompton, MR				Kamalati, T; Jolin, HE; Mitchell, PJ; Barker, KT; Jackson, LE; Dean, CJ; Page, MJ; Gusterson, BA; Crompton, MR			Brk, a breast tumor-derived non-receptor protein-tyrosine kinase, sensitizes mammary epithelial cells to epidermal growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC-FAMILY KINASES; C-SRC; SIGNAL-TRANSDUCTION; FACTOR-ALPHA; MITOGENIC RESPONSIVENESS; NEU PROTOONCOGENE; PDGF RECEPTOR; SH2 DOMAIN; HUMAN-MILK; CANCER	brk (breast tumor kinase) shows homology to the src family of non-receptor protein-tyrosine kinases and is expressed in breast carcinomas. in order to investigate the role of brk in breast tumor development, we have examined the growth and transformation properties of human mammary epithelial cells engineered to overexpress Brk, interestingly, like c-Src, overexpression of Brk leads to sensitization to EGF, and also results in a partially transformed phenotype. Further investigation of the latter activity was attempted by mutational analysis, targeting key residues known to affect tyrosine kinase activity in Src-like kinases. Mutation of amino acid residue Lys-219 to Met, by analogy to Src, abolished both kinase activity and transformation capacity. Mutation of amino acid residue Tyr-447 to Phe, however, resulted in a decrease in transforming potential without affecting kinase activity, These results suggest that while Src and Brk share some functional properties, they act differently during transformation. These differences are discussed in the context of the mechanisms underlying breast cancer development.	INST CANC RES,IMMUNOL SECT,SUTTON SM2 5NG,SURREY,ENGLAND; GLAXO WELLCOME RES & DEV LTD,RES LABS,STEVENAGE SG1 2NY,HERTS,ENGLAND	University of London; Institute of Cancer Research - UK; GlaxoSmithKline	Kamalati, T (corresponding author), INST CANC RES,SECT CELL BIOL & EXPT PATHOL,15 COTSWOLD RD,SUTTON SM2 5NG,SURREY,ENGLAND.		Mitchell, Philip J/F-6393-2013; gusterson, barry a/D-3752-2009		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; BERNS EMJJ, 1992, CANCER RES, V52, P1107; BOLEN JB, 1993, ONCOGENE, V8, P2025; BOLLA M, 1993, BREAST CANCER RES TR, V26, P283, DOI 10.1007/BF00665806; BORG A, 1991, BRIT J CANCER, V63, P136, DOI 10.1038/bjc.1991.28; BORG A, 1992, CANCER RES, V52, P2991; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; COLEMAN S, 1988, DEV BIOL, V127, P304, DOI 10.1016/0012-1606(88)90317-X; COLLINS MKL, 1983, J BIOL CHEM, V258, P1689; CONNOLLY JM, 1988, LIFE SCI, V42, P1751, DOI 10.1016/0024-3205(88)90041-0; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; COURTNEIDGE SA, 1993, DEVELOPMENT, P57; DANIEL CW, 1990, REGULATORY MECH BREA, P79; DAVIDSON D, 1994, J BIOL CHEM, V269, P10956; DEAN CJ, 1986, METHOD ENZYMOL, V121, P52; DERYNCK R, 1988, CELL, V54, P593, DOI 10.1016/S0092-8674(88)80001-1; EELES RA, 1993, CANCER SURV, V18, P57; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GREEN MR, 1983, DEV BIOL, V100, P506, DOI 10.1016/0012-1606(83)90243-9; GULLICK WJ, 1991, BRIT J CANCER, V63, P434, DOI 10.1038/bjc.1991.100; GUSTERSON BA, 1982, CANCER RES, V42, P4763; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HAYMAN MJ, 1991, CANCER CELL-MON REV, V3, P302; HENNIPMAN A, 1989, CANCER RES, V49, P516; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HU WL, 1992, MOL CELL BIOL, V12, P5824; JACOBS C, 1983, CANCER RES, V43, P1696; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; JOHNSON GD, 1982, J IMMUNOL METHODS, V55, P231, DOI 10.1016/0022-1759(82)90035-7; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; KAMALATI T, 1996, MAMMARY TUMOUR CELL, P227; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAWAKAMI T, 1988, P NATL ACAD SCI USA, V85, P3870, DOI 10.1073/pnas.85.11.3870; KELSEY JL, 1988, CANCER RES, V48, P5615; KLIJN JGM, 1994, BREAST CANCER RES TR, V29, P73, DOI 10.1007/BF00666183; KLIJN JGM, 1995, DRUG HORMONAL RESIST, P134; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; LIN PH, 1995, ONCOGENE, V10, P401; LISCIA DS, 1990, DEV BIOL, V140, P123, DOI 10.1016/0012-1606(90)90059-R; Liu QY, 1996, CANCER RES, V56, P1155; LIU XQ, 1994, RECENT PROG HORM RES, V49, P149; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LOWER EE, 1993, BREAST CANCER RES TR, V26, P217, DOI 10.1007/BF00665799; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MITCHELL PJ, 1994, ONCOGENE, V9, P2383; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P1801; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; NIRANJAN B, 1995, DEVELOPMENT, V121, P2897; NORMANNO N, 1994, BREAST CANCER RES TR, V29, P11, DOI 10.1007/BF00666178; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; OUDE WPA, 1994, FEBS LETT, V352, P296; OUDE WPA, 1995, J BIOL CHEM, V270, P2264; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RAJKUMAR T, 1994, BREAST CANCER RES TR, V29, P3, DOI 10.1007/BF00666177; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; ROSEN N, 1986, J BIOL CHEM, V261, P3754; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; SALOMON DS, 1990, REGULATORY MECH BREA, P107; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SIERKE SL, 1993, BIOCHEM BIOPH RES CO, V191, P45, DOI 10.1006/bbrc.1993.1182; SOULE HD, 1990, CANCER RES, V50, P6075; STAMPS AC, 1994, INT J CANCER, V57, P865, DOI 10.1002/ijc.2910570616; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRIPATHY D, 1995, DRUG HORMONAL RESIST, P3; TWAMLEY GM, 1992, ONCOGENE, V7, P1893; VANDERHAAR BK, 1987, J CELL PHYSL, V132, P581; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; YEE D, 1990, REGULATORY MECH BREA, P79; ZIEGLER SF, 1989, MOL CELL BIOL, V9, P2724, DOI 10.1128/MCB.9.6.2724; ZWIEBEL JA, 1986, CANCER RES, V46, P933	89	105	110	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30956	30963		10.1074/jbc.271.48.30956	http://dx.doi.org/10.1074/jbc.271.48.30956			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940083	hybrid			2022-12-25	WOS:A1996VV15800100
J	Mandal, M; Maggirwar, SB; Sharma, N; Kaufmann, SH; Sun, SC; Kumar, R				Mandal, M; Maggirwar, SB; Sharma, N; Kaufmann, SH; Sun, SC; Kumar, R			Bcl-2 prevents CD95 (Fas/APO-1)-induced degradation of lamin B and poly(ADP-ribose) polymerase and restores the NF-kappa B signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAS-MEDIATED APOPTOSIS; PROGRAMMED CELL-DEATH; TNF RECEPTOR; ACTIVATION; GENE; ALPHA; EXPRESSION; INDUCTION; PHOSPHORYLATION; REQUIREMENT	In the study presented here, we investigated the possible interactions between CD95 (Fas/APO-1) and Bcl-2 by studying the effects of Bcl-2 on the modulation of cellular pathways activated by CD95 using HeLa cells as a model system, We report that stable expression of Bcl-2 in HeLa cells is associated with multiple phenotypic changes. Treatment of HeLa cells with anti-CD95 monoclonal antibody (mAb) resulted in preferential degradation of lamin B compared with lamins A and C. Significant lamin B degradation was detected as early as 1 h after anti-CD95 mAb treatment. In contrast, lamins A and C as well as actin remained unchanged until 4 h after treatment with anti-CD95 mAb, a time point that correlated with the period of DNA fragmentation, These results indicate that selective degradation of lamin B is an early cellular event in response to activation of the CD95 pathway and that it precedes DNA fragmentation, Overexpression of Bcl-2 resulted in prevention of lamin B degradation and DNA fragmentation into oligonucleosome fragments in response to the apoptotic signal by anti-CD95 mAb. In addition, in Bcl-2-overexpressing cells that were protected against apoptosis, anti-CD95 mAb-induced cleavage of poly(ADP-ribose) polymerase was completely blocked. Overexpression of Bcl-2 also resulted in restoration of the CD95-mediated signaling pathway involving activation of the transcription factor NF-kappa B (p50/RelA). These findings suggest that Bcl-2 prevents apoptosis in part by preventing the degradation of major nuclear polypeptides such as lamin B and poly(ADP-ribose) polymerase, In addition, our results demonstrate that CD95-mediated signaling involves activation of NF-kappa B (p50/RelA).	PENN STATE UNIV,COLL MED,DEPT MED,HERSHEY,PA 17033; PENN STATE UNIV,COLL MED,DEPT CELLULAR & MOL PHYSIOL,HERSHEY,PA 17033; PENN STATE UNIV,COLL MED,DEPT MICROBIOL & IMMUNOL,HERSHEY,PA 17033; MAYO CLIN & MAYO GRAD SCH MED,DIV ONCOL RES,ROCHESTER,MN 55905	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Mayo Clinic			Mandal, Mahitosh/GMW-6195-2022	Mandal, Mahitosh/0000-0003-3861-3323; Kaufmann, Scott/0000-0002-4900-7145	NCI NIH HHS [CA 56564, R01 CA069008] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069008, R01CA056564] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBRECHT H, 1994, FEBS LETT, V351, P45, DOI 10.1016/0014-5793(94)00817-5; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Boulakia CA, 1996, ONCOGENE, V12, P529; CARSON DA, 1993, LANCET, V341, P1251, DOI 10.1016/0140-6736(93)91154-E; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; HUG H, 1994, FEBS LETT, V351, P311, DOI 10.1016/0014-5793(94)00852-3; ITOH N, 1993, J BIOL CHEM, V268, P10932; JAATTELA M, 1995, ONCOGENE, V10, P2297; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KAUFMANN SH, 1989, J BIOL CHEM, V264, P13946; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; KUMAR R, 1995, EXP CELL RES, V216, P143, DOI 10.1006/excr.1995.1018; KUMAR R, 1992, P NATL ACAD SCI USA, V89, P6599, DOI 10.1073/pnas.89.14.6599; Kumar R, 1996, CLIN CANCER RES, V2, P1215; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; LAMARRE D, 1988, BIOCHIM BIOPHYS ACTA, V950, P147, DOI 10.1016/0167-4781(88)90007-3; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LIN KI, 1995, J CELL BIOL, V131, P1149, DOI 10.1083/jcb.131.5.1149; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; Mandal M, 1996, CELL GROWTH DIFFER, V7, P311; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NEAMATI N, 1995, J IMMUNOL, V154, P3788; NICOLSON DW, 1995, NATURE, V376, P37; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Ponton A, 1996, J BIOL CHEM, V271, P8991, DOI 10.1074/jbc.271.15.8991; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUN SC, 1995, J BIOL CHEM, V270, P18347, DOI 10.1074/jbc.270.31.18347; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TIWARI M, 1995, CELL, V81, P801; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	41	106	110	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30354	30359		10.1074/jbc.271.48.30354	http://dx.doi.org/10.1074/jbc.271.48.30354			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8939996	hybrid			2022-12-25	WOS:A1996VV15800013
J	Deryckere, F; Burgert, HG				Deryckere, F; Burgert, HG			Tumor necrosis factor alpha induces the adenovirus early 3 promoter by activation of NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE EXPRESSION; CLASS-I ANTIGENS; NUCLEOTIDE-SEQUENCE; ENDOPLASMIC-RETICULUM; STIMULATES EXPRESSION; INFECTED-CELLS; E3/19K PROTEIN; EIII PROMOTER; DNA-SEQUENCE; BINDING	The early transcription unit 3 (E3) of human adenoviruses encodes proteins which appear to subvert host defense mechanisms. For example, the E3/19K protein inhibits the transport of major histocompatibility complex (MHC) class I molecules to the cell surface and thereby prevents cell lysis by cytotoxic T cells. Tumor necrosis factor alpha (TNF) stimulates expression of MHC molecules on the cell surface of normal cells but not of E3(+) cells, rather, a further reduction of MHC expression is evident. This was attributed to the increased expression of E3/19K upon TNF treatment, an effect also observed for other E3 proteins. We investigated the mechanism of the TNF-mediated up-regulation of E3 products. We show that TNF stimulates expression of a luciferase reporter gene driven by the E3 promoter. Mutation of individual transcription factor binding sites within the E3 promoter reveals the importance of the NF-kappa B binding site kappa 2 for TNF inducibility. Electrophoretic mobility shift assays using antibodies directed against various members of the NF-kappa B family demonstrate that stimulation by TNF is mediated by the p50-p65 NF-kappa B complex. TNF inducibility does not depend on coexpression of E1A and can be observed during infection. Interestingly, the E3 promoter seems to be the only early promoter responsive to TNF and the only adenovirus promoter containing an NF-kappa B site. The implications of this regulatory mechanism for the adenovirus life cycle and its pathogenesis are discussed.	MAX PLANCK INST IMMUNBIOL, HANS SPEMANN LAB, D-79108 FREIBURG, GERMANY	Max Planck Society			Burgert, Hans-Gerhard/AAE-6668-2020	Burgert, Hans-Gerhard/0000-0002-1650-9878				Akusjarvi G, 1993, Trends Microbiol, V1, P163, DOI 10.1016/0966-842X(93)90085-6; ANDERSSON M, 1987, J IMMUNOL, V138, P3960; ANDERSSON M, 1985, CELL, V43, P215, DOI 10.1016/0092-8674(85)90026-1; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; Basler CF, 1996, GENE, V170, P249, DOI 10.1016/0378-1119(95)00898-5; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BEUTLER BE, 1992, TUMOR NECROSIS FACTO; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; BUCKBINDER L, 1989, EMBO J, V8, P4239, DOI 10.1002/j.1460-2075.1989.tb08609.x; BURGERT HG, 1985, CELL, V41, P987, DOI 10.1016/S0092-8674(85)80079-9; Burgert HG, 1996, TRENDS MICROBIOL, V4, P107, DOI 10.1016/0966-842X(96)81527-7; BURGERT HG, 1987, P NATL ACAD SCI USA, V84, P1356, DOI 10.1073/pnas.84.5.1356; CLADARAS C, 1985, VIROLOGY, V140, P28, DOI 10.1016/0042-6822(85)90443-X; COX JH, 1990, SCIENCE, V247, P715, DOI 10.1126/science.2137259; COX JH, 1991, J EXP MED, V174, P1629, DOI 10.1084/jem.174.6.1629; DAVISON AJ, 1993, J MOL BIOL, V234, P1308, DOI 10.1006/jmbi.1993.1687; DERY CV, 1987, ONCOGENE, V2, P15; DERYCKERE F, 1995, IMMUNOBIOLOGY, V193, P186, DOI 10.1016/S0171-2985(11)80542-5; Deryckere F, 1996, J VIROL, V70, P2832, DOI 10.1128/JVI.70.5.2832-2841.1996; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EFRAT S, 1995, P NATL ACAD SCI USA, V92, P6947, DOI 10.1073/pnas.92.15.6947; FEJER G, 1994, J VIROL, V68, P5871, DOI 10.1128/JVI.68.9.5871-5881.1994; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; FOX JP, 1977, AM J EPIDEMIOL, V105, P362, DOI 10.1093/oxfordjournals.aje.a112394; GARCIA J, 1987, NUCLEIC ACIDS RES, V15, P8367, DOI 10.1093/nar/15.20.8367; GINSBERG HS, 1989, P NATL ACAD SCI USA, V86, P3823, DOI 10.1073/pnas.86.10.3823; GINSBERG HS, 1991, P NATL ACAD SCI USA, V88, P1651, DOI 10.1073/pnas.88.5.1651; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HAGMEYER BM, 1995, BIOESSAYS, V17, P621, DOI 10.1002/bies.950170708; HERISSE J, 1980, NUCLEIC ACIDS RES, V8, P2173, DOI 10.1093/nar/8.10.2173; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Horwitz M.S., 1996, VIROLOGY, P2149; HURST HC, 1987, GENE DEV, V1, P1132, DOI 10.1101/gad.1.10.1132; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; JAIN VK, 1991, ANAL BIOCHEM, V199, P119, DOI 10.1016/0003-2697(91)90278-2; KORNER H, 1992, P NATL ACAD SCI USA, V89, P11857, DOI 10.1073/pnas.89.24.11857; KORNUC M, 1990, J VIROL, V64, P2004, DOI 10.1128/JVI.64.5.2004-2013.1990; LEFF T, 1985, NUCLEIC ACIDS RES, V13, P1209, DOI 10.1093/nar/13.4.1209; LEFF T, 1984, P NATL ACAD SCI-BIOL, V81, P4381, DOI 10.1073/pnas.81.14.4381; MESTAN J, 1986, NATURE, V323, P816, DOI 10.1038/323816a0; MISTCHENKO AS, 1994, J PEDIATR-US, V124, P714, DOI 10.1016/S0022-3476(05)81360-5; Pahl HL, 1996, J CELL BIOL, V132, P511, DOI 10.1083/jcb.132.4.511; PIENIAZEK N, 1989, NUCLEIC ACIDS RES, V17, P5398, DOI 10.1093/nar/17.13.5398; RAWLE FC, 1991, J IMMUNOL, V146, P3977; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SESTER M, 1994, J VIROL, V68, P5423, DOI 10.1128/JVI.68.9.5423-5432.1994; SHENK T, 1984, CURR TOP MICROBIOL, V111, P1; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SPRENGEL J, 1994, J VIROL, V68, P379, DOI 10.1128/JVI.68.1.379-389.1994; Strauss SE, 1984, ADENOVIRUSES, P451; VILCEK J, 1991, J BIOL CHEM, V266, P7313; WEEKS DL, 1985, NUCLEIC ACIDS RES, V13, P5389, DOI 10.1093/nar/13.14.5389; WILLIAMS JL, 1990, EMBO J, V9, P4435, DOI 10.1002/j.1460-2075.1990.tb07894.x; WOLD WSM, 1993, J CELL BIOCHEM, V53, P329, DOI 10.1002/jcb.240530410; WOLD WSM, 1991, VIROLOGY, V184, P1, DOI 10.1016/0042-6822(91)90815-S; WONG GHW, 1986, NATURE, V323, P819, DOI 10.1038/323819a0	58	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30249	30255		10.1074/jbc.271.47.30249	http://dx.doi.org/10.1074/jbc.271.47.30249			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939978	hybrid			2022-12-25	WOS:A1996VU52500106
J	DiazGuerra, MJM; Velasco, M; MartinSanz, P; Bosca, L				DiazGuerra, MJM; Velasco, M; MartinSanz, P; Bosca, L			Evidence for common mechanisms in the transcriptional control of type II nitric oxide synthase in isolated hepatocytes - Requirement of NF-kappa B activation after stimulation with bacterial cell wall products and phorbol esters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; MURINE PERITONEAL-MACROPHAGES; NECROSIS-FACTOR-ALPHA; INTERFERON-GAMMA; MAMMALIAN-CELLS; AP-1 ACTIVITY; INDUCTION; LIPOPOLYSACCHARIDE; GENE; EXPRESSION	Incubation of primary cultures of rat hepatocytes with lipopolysaccharide (LPS), S-[2,3-bis(palmitoyloxy)(2-R,S)-propyl] -N-palmitoyl-(R)-Cys-Ser-Lys(4) (TPP), a synthetic lipopeptide present in bacterial cell wall lipoproteins, or with phorbol 12,13-dibutyrate (PDBu) induced an increase in nitric oxide synthesis through the expression of type II nitric oxide synthase (iNOS), Transfection of hepatocytes with a HindII fragment corresponding to the promoter region of the murine iNOS gene (from nucleotide -1588 to +165) resulted in the expression of the reporter gene when cells were stimulated with these factors, The transcription factors activated by these stimuli involved an increase in the nuclear content of proteins that bind to kappa B, AP-1, GAS, and SIE sequences, Inhibition of NF-kappa B activation with pyrrolidine dithiocarbamate eliminated the expression of iNOS in hepatocytes stimulated with LPS, TPP, or PDBu. In addition to this, transfection of hepatocytes with promoter mutants in which a sequential 2-base pair change within the kappa B sites was introduced (position -971 to -961 and -85 to -75, respectively), resulted in approximately 17 and 35%, respectively, of the activity of the naive promoter, Simultaneous mutation of both kappa B sites abolished the promoter activity. Analysis of the proteins involved in kappa B binding showed the presence of p50/p65 dimers in the nuclei of activated cells at the time that an important decrease of I kappa B-alpha was observed soon after cell stimulation with LPS, TPP, or PDBu. However, only LPS was able to decrease the amount of I kappa B-beta. These results suggest that LPS, TPP, and PDBu, although activating different signal transduction pathways, use a common mechanism mediating iNOS expression in cultured hepatocytes.	UNIV COMPLUTENSE,FAC FARM,INST BIOQUIM,CSIC,UCM,E-28040 MADRID,SPAIN	Complutense University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)			Bosca, Lisardo/A-2059-2008; Díaz-Guerra, María José M/M-2855-2014; Martín-Sanz, Paloma/K-1303-2014	Bosca, Lisardo/0000-0002-0253-5469; Díaz-Guerra, María José M/0000-0003-3843-3912; 				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; BESSLER WG, 1992, RES IMMUNOL, V143, P548, DOI 10.1016/0923-2494(92)80067-U; BOMZON A, 1994, HEPATOLOGY, V20, P1343, DOI 10.1002/hep.1840200535; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU SC, 1995, J BIOL CHEM, V270, P10625, DOI 10.1074/jbc.270.18.10625; DELUDE RL, 1994, J BIOL CHEM, V269, P22253; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; FAUSTO N, 1990, HEPATOLOGY TXB LIVER, P49; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P522, DOI 10.1073/pnas.90.2.522; GHOSH P, 1993, P NATL ACAD SCI USA, V90, P1696, DOI 10.1073/pnas.90.5.1696; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HABER BA, 1993, J CLIN INVEST, V91, P1319, DOI 10.1172/JCI116332; HABRECHT BG, 1994, AM J PHYSIOL, V266, pG1004; HORTELANO S, 1993, FEBS LETT, V320, P135, DOI 10.1016/0014-5793(93)80078-9; HORTELANO S, 1992, J BIOL CHEM, V267, P24937; HORTELANO S, 1995, HEPATOLOGY, V21, P776; JUN CD, 1995, J IMMUNOL, V154, P6541; JUN CD, 1994, J IMMUNOL, V153, P3684; KONIG H, 1992, EMBO J, V11, P2241, DOI 10.1002/j.1460-2075.1992.tb05283.x; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NUSSLER AK, 1995, HEPATOLOGY, V21, P1552, DOI 10.1016/0270-9139(95)90459-X; PENG HB, 1995, J BIOL CHEM, V270, P14214, DOI 10.1074/jbc.270.23.14214; PIMENTELMUINOS FX, 1994, J BIOL CHEM, V269, P24424; PIMENTELMUINOS FX, 1994, J IMMUNOL, V152, P5714; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SIMMONS ML, 1994, GLIA, V11, P227, DOI 10.1002/glia.440110303; SPINK J, 1995, J BIOL CHEM, V270, P29541, DOI 10.1074/jbc.270.49.29541; TERENZI F, 1995, J BIOL CHEM, V270, P6017, DOI 10.1074/jbc.270.11.6017; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; WEISZ A, 1994, J BIOL CHEM, V269, P8324; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; XIE QW, 1994, J BIOL CHEM, V269, P4705; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	51	92	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30114	30120		10.1074/jbc.271.47.30114	http://dx.doi.org/10.1074/jbc.271.47.30114			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939960	hybrid			2022-12-25	WOS:A1996VU52500088
J	EhretSabatier, L; Loew, D; Goyffon, M; Fehlbaum, P; Hoffmann, JA; vanDorsselaer, A; Bulet, P				EhretSabatier, L; Loew, D; Goyffon, M; Fehlbaum, P; Hoffmann, JA; vanDorsselaer, A; Bulet, P			Characterization of novel cysteine-rich antimicrobial peptides from scorpion blood	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANDROCTONUS-MAURETANICUS-MAURETANICUS; INDUCIBLE ANTIBACTERIAL PEPTIDE; CRAB TACHYPLEUS-TRIDENTATUS; K+ CHANNELS; INSECT DEFENSINS; ALPHA-CONOTOXIN; HEBRAEUS VENOM; PURIFICATION; CHARYBDOTOXIN; INHIBITOR	We have isolated, from the hemolymph of unchallenged scorpions of the species Androctonus australis, three distinct antimicrobial peptides, which we have fully characterized by Edman degradation, electrospray ionization mass spectrometry, and matrix-assisted laser desorption/ionization mass spectrometry. Two are novel molecules: (i) androctonin, a 25-residue peptide with two disulfide bridges, active against both bacteria (Gram-positive and Gram-negative) and fungi and showing marked sequence homology to tachyplesins and polyphemusins from horseshoe crabs; and (ii) buthinin, a 34-residue antibacterial (Gram-positive and Gram-negative) peptide with three disulfide bridges. The third peptide contains 37 residues and three disulfide bridges and clearly belongs to the family of anti-Gram-positive insect defensins, We have synthesized androctonin and explored its activity spectrum and mode of action.	INST BIOL MOL & CELLULAIRE,UPR 9022 CNRS,F-67084 STRASBOURG,FRANCE; UNIV STRASBOURG 1,FAC CHIM,LAB SPECTROMETRIE MASSE BIOORGAN,URA 31 CNRS,F-67008 STRASBOURG,FRANCE; MUSEUM NATL HIST NAT,F-75005 PARIS,FRANCE; DIV BIOL GEN & ECOL,LAB ETUD & RECH ARTHROPODES IRRADIES,F-75005 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Museum National d'Histoire Naturelle (MNHN)			BULET, Philippe/C-8557-2014	BULET, Philippe/0000-0001-9016-265X; Damarys, Loew/0000-0002-9111-8842				AUGUSTE P, 1990, J BIOL CHEM, V265, P4753; BONTEMS F, 1991, SCIENCE, V254, P1521, DOI 10.1126/science.1720574; BULET P, 1991, J BIOL CHEM, V266, P24520; BULET P, 1992, EUR J BIOCHEM, V209, P977, DOI 10.1111/j.1432-1033.1992.tb17371.x; BULET P, 1993, J BIOL CHEM, V268, P14893; CHICCHI GG, 1988, J BIOL CHEM, V263, P10192; COCIANCICH S, 1993, BIOCHEM BIOPH RES CO, V194, P17, DOI 10.1006/bbrc.1993.1778; CORNET B, 1995, STRUCTURE, V3, P435, DOI 10.1016/S0969-2126(01)00177-0; COURAUD F, 1982, TOXICON, V20, P9, DOI 10.1016/0041-0101(82)90138-6; CREST M, 1992, J BIOL CHEM, V267, P1640; Fehlbaum P, 1996, P NATL ACAD SCI USA, V93, P1221, DOI 10.1073/pnas.93.3.1221; FEHLBAUM P, 1994, J BIOL CHEM, V269, P33159; GALVEZ A, 1990, J BIOL CHEM, V265, P11083; GARCIA ML, 1994, BIOCHEMISTRY-US, V33, P6834, DOI 10.1021/bi00188a012; GIMENEZGALLEGO G, 1988, P NATL ACAD SCI USA, V85, P3329, DOI 10.1073/pnas.85.10.3329; HOFFMANN JA, 1992, IMMUNOL TODAY, V13, P411, DOI 10.1016/0167-5699(92)90092-L; HOFFMANN JA, 1995, CURR OPIN IMMUNOL, V7, P4, DOI 10.1016/0952-7915(95)80022-0; IWANAGA S, 1994, ANTIMICROBIAL PEPTID, P160; KATSU T, 1993, BIOL PHARM BULL, V16, P178; KAWANO K, 1990, J BIOL CHEM, V265, P15365; KING DS, 1990, INT J PEPT PROT RES, V36, P255; LARABADJEBARI F, 1994, J BIOL CHEM, V269, P32835; MCINTOSH JM, 1994, J BIOL CHEM, V269, P16733; MILLER C, 1995, NEURON, V15, P5, DOI 10.1016/0896-6273(95)90057-8; MILLER C, 1985, NATURE, V313, P316, DOI 10.1038/313316a0; MIYATA T, 1989, J BIOCHEM, V106, P663, DOI 10.1093/oxfordjournals.jbchem.a122913; NAKAMURA T, 1988, J BIOL CHEM, V263, P16709; NEIMARK J, 1993, PEPTIDE RES, V6, P219; PARK CS, 1992, NEURON, V9, P307, DOI 10.1016/0896-6273(92)90169-E; RAMILO CA, 1992, BIOCHEMISTRY-US, V31, P9919, DOI 10.1021/bi00156a009; ZERROUK H, 1993, FEBS LETT, V320, P189, DOI 10.1016/0014-5793(93)80583-G	31	167	181	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29537	29544		10.1074/jbc.271.47.29537	http://dx.doi.org/10.1074/jbc.271.47.29537			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939880	hybrid			2022-12-25	WOS:A1996VU52500008
J	Herzig, MCS; Nash, NR; Connolly, M; Kyle, DJ; LeebLundberg, LMF				Herzig, MCS; Nash, NR; Connolly, M; Kyle, DJ; LeebLundberg, LMF			The N terminus of bradykinin when bound to the human bradykinin B2 receptor is adjacent to extracellular Cys(20) and Cys(277) in the receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; LIGAND-BINDING; PHARMACOLOGICAL CHARACTERIZATION; FUNCTIONAL EXPRESSION; ENDOTHELIN RECEPTOR; AGONIST BINDING; CLONING; PROTEIN; RESIDUES; BACTERIORHODOPSIN	Chemical cross-linking combined with site-directed mutagenesis was used to evaluate the role of extracellular cysteines and their positions relative to the binding site for the agonist bradykinin (BK) in the human BK B2 receptor. All extracellular cysteines, Cys(20), Cys(103) Cys(184), and Cys(277), in the receptor were mutated to serines, and single and double mutants were transfected into COS-7 cells. The Ser(20) and Ser(277) single mutants and the Ser(20)/Ser(277) double mutant bound [H-3]BK and the antagonist [H-3]NPC17731 with pharmacological profiles identical to the wild-type B2 receptor, in contrast, the Ser(103) and Ser(184) single mutants were unable to bind either of the two radioligands. However, these mutants were still expressed as determined by immunoblotting with anti-B2 receptor antibodies. Previous studies on the bovine B2 receptor showed that bifunctional reagents, which are reactive to amines at one end and to free sulfhydryls in the opposite end, cross-link the N terminus of receptor-bound BK to a sulfhydryl in the receptor (Herzig, M. C. S., and Leeb-Lundberg, L. M. F. (1995) J. Biol, Chem. 270, 20591-20598), Here, we show that m-maleimidobenzoyl-N-hydroxysuccinimide ester and 1,5-difluoro-2,4-dinitrobenzene cross-linked BK to the wild-type human B2 receptor and the Ser(20) and Ser(277) Single mutant receptors, whereas these reagents were unable to cross-link BK to the Ser(20)/Ser(277) double mutant, These results show that Cys(103) and Cys(184) are both required for expression of high affinity agonist and antagonist binding sites in the human B2 receptor, while Cys(20) and Cys(277) are not required. Furthermore, the results provide direct biochemical evidence that the N terminus of BK, when bound to the B2 receptor, is adjacent to Cys(277) in extracellular domain 4 and Cys(20) in extracellular domain 1 of the receptor.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284; EMORY UNIV,DEPT NEUROL,ATLANTA,GA 30322; GUILFORD PHARMACEUT,BALTIMORE,MD 21224; SCIOS INC,DEPT STRUCT BIOL & MED CHEM,SUNNYVALE,CA 94086	University of Texas System; University of Texas Health San Antonio; Emory University; Scios					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM041659, R01GM041659] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41659] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abd Alla S., 1996, J BIOL CHEM, V271, P1748; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; Bachvarov DR, 1995, J PHARMACOL EXP THER, V275, P1623; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; COUGHLIN SR, 1994, CURR OPIN CELL BIOL, V6, P191, DOI 10.1016/0955-0674(94)90135-X; DIXON RAF, 1987, EMBO J, V6, P3269, DOI 10.1002/j.1460-2075.1987.tb02645.x; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DOHLMAN HG, 1990, BIOCHEMISTRY-US, V29, P2335, DOI 10.1021/bi00461a018; EGGERICKX D, 1992, BIOCHEM BIOPH RES CO, V187, P1306, DOI 10.1016/0006-291X(92)90445-Q; ENGELMAN DM, 1980, P NATL ACAD SCI-BIOL, V77, P2023, DOI 10.1073/pnas.77.4.2023; FRASER CM, 1989, J BIOL CHEM, V264, P9266; FREDRICK MJ, 1984, BIOCHEM PHARMACOL, V33, P2887, DOI 10.1016/0006-2952(84)90212-0; FREEDMAN R, 1992, RECENT PROGR KININS, P487; HERZIG MCS, 1995, J BIOL CHEM, V270, P20591, DOI 10.1074/jbc.270.35.20591; HESS JF, 1994, MOL PHARMACOL, V45, P1; HESS JF, 1992, BIOCHEM BIOPH RES CO, V184, P260, DOI 10.1016/0006-291X(92)91187-U; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KHORANA HG, 1988, J BIOL CHEM, V263, P7439; Kyle D. J., 1995, CURR PHARM DESIGN, V1, P233; LARHAMMAR D, 1992, J BIOL CHEM, V267, P10935; LEEBLUNDBERG LMF, 1994, J BIOL CHEM, V269, P25970; LEEBLUNDBERG LMF, 1990, J BIOL CHEM, V265, P9621; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACNEIL T, 1995, BBA-GENE STRUCT EXPR, V1264, P223, DOI 10.1016/0167-4781(95)00152-7; MCEACHERN AE, 1991, P NATL ACAD SCI USA, V88, P7724, DOI 10.1073/pnas.88.17.7724; MENKE JG, 1994, J BIOL CHEM, V269, P21583; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NARDONE J, 1994, P NATL ACAD SCI USA, V91, P4417, DOI 10.1073/pnas.91.10.4417; NOVOTNY EA, 1994, BIOCHEM BIOPH RES CO, V201, P523, DOI 10.1006/bbrc.1994.1733; REGOLI D, 1980, PHARMACOL REV, V32, P1; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SANDBERG K, 1994, TRENDS ENDOCRIN MET, V5, P28, DOI 10.1016/1043-2760(94)90118-X; SCHERTLER GF, 1993, NATURE, V362, P7700; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; YAMANO Y, 1992, BIOCHEM BIOPH RES CO, V187, P1426, DOI 10.1016/0006-291X(92)90461-S	37	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29746	29751		10.1074/jbc.271.47.29746	http://dx.doi.org/10.1074/jbc.271.47.29746			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939910	hybrid			2022-12-25	WOS:A1996VU52500038
J	Peterson, SN; Trabalzini, L; Brtva, TR; Fischer, T; Altschuler, DL; Martelli, P; Lapetina, EG; Der, CJ; White, GC				Peterson, SN; Trabalzini, L; Brtva, TR; Fischer, T; Altschuler, DL; Martelli, P; Lapetina, EG; Der, CJ; White, GC			Identification of a novel RalGDS-related protein as a candidate effector for Ras and Rap1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPPRESSOR ACTIVITY; POINT MUTATIONS; RAS-P21 GTPASE; R-RAS; TRANSFORMATION; ACTIVATION; GENE; BINDING; DOMAIN; INHIBITION	Although Ras and Rap1 share interaction with common candidate effector proteins, Rap1 lacks the transforming activity exhibited by Ras proteins, It has been speculated that Rap antagonizes Ras transformation through the formation of nonproductive complexes with critical Ras effector targets. To understand further the distinct biological functions of these two closely related proteins, we searched for Rap1b-binding proteins by yeast two-hybrid screening, We identified multiple clones that encode the COOH-terminal sequences of a protein that shares sequence identity with Ra1GDS and RGL, which we have designated RGL2. A 158-amino acid COOH-terminal fragment of RGL2 (RGL2 C-158) bound to Ras superfamily proteins which shared identical effector domain sequences with Rap1 (Ha-Ras, R-Ras, and TC21), RGL2 C-158 binding was impaired by effector domain mutations in Rap1b and Ha-Ras. Furthermore, RGL2 C-158 bound exclusively to the GTP-, but not the GDP-bound form of Ha-Ras. Finally, coexpression of RGL2 C-158 impaired oncogenic Ras activation of transcription from a Ras-responsive promoter element and focus-forming activity in NIH 3T3 cells, We conclude that RGL2 may be an effector for Ras and/or Rap proteins.	GLAXO WELLCOME INC,DIV CELL BIOL,RES TRIANGLE PK,NC 27709; UNIV N CAROLINA,DEPT MED,CHAPEL HILL,NC 27599; UNIV N CAROLINA,CURRICULUM GEN & MOL BIOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PHARMACOL,CHAPEL HILL,NC 27599; UNIV SIENA,DEPT MOL BIOL,I-53100 SIENA,ITALY	GlaxoSmithKline; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Siena				Der, Channing/0000-0002-7751-2747; Trabalzini, Lorenza/0000-0002-0850-7186	NATIONAL CANCER INSTITUTE [R01CA042978, R01CA055008] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL026309] Funding Source: NIH RePORTER; NCI NIH HHS [CA42978, CA55008] Funding Source: Medline; NHLBI NIH HHS [HL26309] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOTWELL D, 1992, P NATL ACAD SCI USA, V89, P6511; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CAMPA MJ, 1991, BIOCHEM BIOPH RES CO, V174, P1, DOI 10.1016/0006-291X(91)90475-M; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; COX AD, 1994, METHOD ENZYMOL, V238, P277; COX AD, 1994, ONCOGENE, V9, P3281; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GALANG CK, 1994, ONCOGENE, V9, P2913; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; HAN LM, 1995, MOL CELL BIOL, V15, P1318; HARIHARAN IK, 1991, CELL, V67, P717, DOI 10.1016/0092-8674(91)90066-8; HATA Y, 1990, J BIOL CHEM, V265, P7104; HAUSER CA, 1995, METHOD ENZYMOL, V255, P412; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; JELINEK MA, 1992, ONCOGENE, V7, P1687; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KHOSRAVIFAR R, 1996, IN PRESS MOL CELL BI; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; LopezBarahona M, 1996, ONCOGENE, V12, P463; MCCABE PC, 1992, MOL CELL BIOL, V12, P4084, DOI 10.1128/MCB.12.9.4084; PIZON V, 1988, ONCOGENE, V3, P201; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P1719; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SAEZ R, 1994, ONCOGENE, V9, P2977; SAKODA T, 1992, ONCOGENE, V7, P1705; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; YATANI A, 1991, J BIOL CHEM, V266, P22222; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	50	56	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29903	29908		10.1074/jbc.271.47.29903	http://dx.doi.org/10.1074/jbc.271.47.29903			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939933	Green Published, hybrid			2022-12-25	WOS:A1996VU52500061
J	BenYosef, T; Yanuka, O; Benvenisty, N				BenYosef, T; Yanuka, O; Benvenisty, N			ECA39 is regulated by c-Myc in human and by a Jun/Fos homolog, Gcn4, in yeast	ONCOGENE			English	Article						Gcn4; c-Jun; c-Myc; oncogenesis; targets; transcription	HELIX-LOOP-HELIX; DNA-BINDING; CELL-LINE; N-MYC; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; EMBRYONIC LETHALITY; CONTINUOUS CULTURE; GENERAL CONTROL; PROTEIN-KINASE	myc oncogenes are transcription factors regulating the level of expression of other genes, Using a subtraction/coexpression strategy, a murine genetic target for Myc regulation was isolated, To further characterize this target gene, named ECA39, we have recently isolated the human, nematode and budding yeast homologs of the mouse gene, The recognition site for Myc binding, located 3' to the start site of transcription in the mouse gene, is conserved in the human homolog, Transfection experiments demonstrated that the Myc binding site of the human gene, mediates activation of a reporter gene in response to over-expression of c-myc, The activation was better executed when the c-Myc binding element was positioned downstream to the promoter, which is the usual position of the c-Myc DNA binding element in its genetic targets, The tissue specific expression of human ECA39 during embryogenesis is similar to that of the mouse homolog, Moreover, ECA39 is expressed in c-myc induced human tumors, It is expressed in Burkitt's lymphoma (where c-myc is translocated and activated) but not in non Burkitt's B-cell lymphoma or in T-cell lymphoma, Thus, it seems that ECA39 is a target for c-myc oncogenesis in humans, In yeast, where c-myc is absent, the ECA39 sequences lack the c-Myc binding element, However, the promoter region of the yeast ECA39 harbors several Gcn4 binding elements, Moreover, ECA39 is markedly down regulated in cells deleted for gcn4, and deletion of Gcn4 binding elements down regulated the transcription from ECA39 promoter, We thus suggest that ECA39 is a target for c-Myc regulation in mammals, while in yeast the regulator is not c-Myc but the c-Jun/c-Fos homolog - Gcn4.	HEBREW UNIV JERUSALEM,INST LIFE SCI,DEPT GENET,IL-91904 JERUSALEM,ISRAEL	Hebrew University of Jerusalem								AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; ARNDT K, 1986, P NATL ACAD SCI USA, V83, P8516, DOI 10.1073/pnas.83.22.8516; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; Bello-Fernandez C, 1992, Curr Top Microbiol Immunol, V182, P445; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENBASSAT H, 1977, INT J CANCER, V19, P27, DOI 10.1002/ijc.2910190105; BENBASSAT H, 1980, INT J CANCER, V25, P583, DOI 10.1002/ijc.2910250506; BENBASSAT H, 1992, LEUKEMIA LYMPHOMA, V6, P513, DOI 10.3109/10428199209053591; BENVENISTY N, 1995, GROWTH FACTORS, V12, P49, DOI 10.3109/08977199509003213; BENVENISTY N, 1992, ONCOGENE, V7, P2399; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHARRON J, 1992, GENE DEV, V6, P2248, DOI 10.1101/gad.6.12a.2248; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; DAVIS LJ, 1993, ONCOGENE, V8, P125; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUERIN M, 1988, ONCOGENE RES, V3, P21; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; Hinnebusch A. G., 1992, MOL CELLULAR BIOL YE, P319, DOI DOI 10.1016/J.ACA.2008.01.060; HINNEBUSCH AG, 1988, MICROBIOL REV, V52, P248, DOI 10.1128/MMBR.52.2.248-273.1988; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LANDSCHULTZ WH, 1987, SCIENCE, V240, P1759; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MIFFLIN D, 1988, BIOSCIENCE REP, V8, P415, DOI 10.1007/BF01121638; Miller JH., 1972, EXPT MOL GENETICS; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; PERSSON H, 1984, SCIENCE, V225, P718, DOI 10.1126/science.6463648; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PRENDERGAST GC, 1989, NATURE, V341, P362; PULVERTA.RJ, 1965, J CLIN PATHOL, V18, P261, DOI 10.1136/jcp.18.3.261; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAMSAY G, 1984, P NATL ACAD SCI-BIOL, V81, P7742, DOI 10.1073/pnas.81.24.7742; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; ROLFES RJ, 1993, MOL CELL BIOL, V13, P5099, DOI 10.1128/MCB.13.8.5099; RONEN D, 1991, P NATL ACAD SCI USA, V88, P4128, DOI 10.1073/pnas.88.10.4128; ROSE M, 1983, METHOD ENZYMOL, V101, P167; Rose MD., 1990, METHODS YEAST GENETI; SARID J, 1988, NUCLEIC ACIDS RES, V16, P4725, DOI 10.1093/nar/16.10.4725; SCHREIBERAGUS N, 1993, MOL CELL BIOL, V13, P2456, DOI 10.1128/MCB.13.4.2456; SCHREIBERAGUS N, 1993, MOL CELL BIOL, V13, P2765, DOI 10.1128/MCB.13.5.2765; Schuldiner O, 1996, P NATL ACAD SCI USA, V93, P7143, DOI 10.1073/pnas.93.14.7143; SHILO BZ, 1982, P NATL ACAD SCI USA, V78, P6789; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STANTON BR, 1992, GENE DEV, V6, P2235, DOI 10.1101/gad.6.12a.2235; STEINITZ M, 1975, P NATL ACAD SCI USA, V72, P8515; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TODA T, 1987, MOL CELL BIOL, V7, P1371, DOI 10.1128/MCB.7.4.1371; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; WALKER CW, 1992, ONCOGENE, V7, P2007	64	18	19	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 7	1996	13	9					1859	1866						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934531				2022-12-25	WOS:A1996VR79500004
J	Eichacker, LA; Helfrich, M; Rudiger, W; Muller, B				Eichacker, LA; Helfrich, M; Rudiger, W; Muller, B			Stabilization of chlorophyll a-binding apoproteins P700, CP47, CP43, D2, and D1 by chlorophyll a or Zn-pheophytin a	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-DEPENDENT ACCUMULATION; BARLEY HORDEUM-VULGARE; II REACTION CENTER; PHOTOSYSTEM-II; REGULATES ACCUMULATION; CORE COMPLEX; PROTEIN; SYNTHETASE; CHLOROPLASTS; TRANSLATION	Stabilization of chlorophyll a-binding apoproteins P700, CP47, CP43, D2, and D1 against proteolytic degradation has been investigated through in vitro synthesis of chlorophyll a or Zn-pheophytin a in intact etioplasts from barley. Stabilization of the apoproteins was dependent on the concentration of chlorophyll a or Zn-pheophytin a. Zn-pheophytin a was superior to chlorophyll a with respect to the concentration of pigment required for an equal yield of the stabilized chlorophyll a protein CP47, CP43, and P700 and for the total yield of chlorophyll a proteins. Zn-pheophytin a was most efficient for stabilizing CP47 and, at an increased concentration, efficient for stabilizing CP43, P700, and D1. Stabilization of apoproteins was highest after de novo synthesis of 90-300 pmol of Zn-pheophytin a or of about 400-600 pmol of chlorophyll a/4.2 x 10(7) etioplasts. The yield of stabilized chlorophyll proteins decreased at higher concentrations of Zn-pheophytin a, but was unaffected by higher concentrations of chlorophyll a.			Eichacker, LA (corresponding author), UNIV MUNICH,INST BOT,MENZINGER STR 67,D-80638 MUNICH,GERMANY.							AKABORI K, 1988, BIOCHIM BIOPHYS ACTA, V932, P345, DOI 10.1016/0005-2728(88)90170-3; APEL K, 1980, EUR J BIOCHEM, V111, P251, DOI 10.1111/j.1432-1033.1980.tb06100.x; APEL K, 1979, EUR J BIOCHEM, V97, P183, DOI 10.1111/j.1432-1033.1979.tb13101.x; BAUMGARTNER BJ, 1989, PLANT PHYSIOL, V89, P1011, DOI 10.1104/pp.89.3.1011; BENNETT J, 1984, J CELL BIOCHEM, V25, P1, DOI 10.1002/jcb.240250102; BENZ J, 1981, PLANTA, V152, P54, DOI 10.1007/BF00384985; BUCHLER JW, 1964, PORPHYRINS METALLOPO, V2; CHEN LX, 1995, CHEM PHYS LETT, V234, P437, DOI 10.1016/0009-2614(95)00038-6; COTTON TM, 1974, BIOCHIM BIOPHYS ACTA, V368, P181, DOI 10.1016/0005-2728(74)90148-0; EICHACKER LA, 1990, J BIOL CHEM, V265, P13566; ERMLER U, 1994, STRUCTURE, V2, P925, DOI 10.1016/S0969-2126(94)00094-8; EVANS TA, 1975, BIOCHIM BIOPHYS ACTA, V396, P414, DOI 10.1016/0005-2728(75)90147-4; FOESSLER TP, 1981, PLANT PHYSL BETHESDA, V67, pS246; FRIEMANN A, 1988, PLANTA, V175, P50, DOI 10.1007/BF00402881; GAVEL Y, 1991, FEBS LETT, V282, P41, DOI 10.1016/0014-5793(91)80440-E; HANSON LK, 1990, CHLOROPHYLLS, P993; HARTWICH G, 1996, IN PRESS J AM CHEM S; HELFRICH M, 1992, Z NATURFORSCH C, V47, P231; HELFRICH M, 1994, EUR J BIOCHEM, V219, P267, DOI 10.1111/j.1432-1033.1994.tb19938.x; HENNINGSEN KW, 1982, ENCY PLANT PHYSL B, V14, P597; Herrmann R.G., 1985, MOL FORM FUNCTION PL, P233; HOOBER JK, 1992, PLANT PHYSIOL, V99, P932, DOI 10.1104/pp.99.3.932; JONES ID, 1977, J AGR FOOD CHEM, V25, P146, DOI 10.1021/jf60209a025; KIM J, 1994, PLANT PHYSIOL, V104, P907, DOI 10.1104/pp.104.3.907; KLEIN RR, 1988, J CELL BIOL, V106, P289, DOI 10.1083/jcb.106.2.289; KLEIN RR, 1988, PLANT PHYSIOL, V88, P1246, DOI 10.1104/pp.88.4.1246; KLEIN RR, 1986, J BIOL CHEM, V261, P1138; KRAUSS N, 1993, NATURE, V361, P326, DOI 10.1038/361326a0; KREUZ K, 1986, EUR J BIOCHEM, V159, P459, DOI 10.1111/j.1432-1033.1986.tb09908.x; LINDSTEN A, 1990, PHYSIOL PLANTARUM, V80, P277, DOI 10.1111/j.1399-3054.1990.tb04408.x; MULLET JE, 1990, P NATL ACAD SCI USA, V87, P4038, DOI 10.1073/pnas.87.11.4038; MULLET JE, 1986, EUR J BIOCHEM, V155, P331, DOI 10.1111/j.1432-1033.1986.tb09495.x; NANBA O, 1987, P NATL ACAD SCI USA, V84, P109, DOI 10.1073/pnas.84.1.109; OHYAMA K, 1986, NATURE, V322, P572, DOI 10.1038/322572a0; PAULSEN H, 1993, EUR J BIOCHEM, V215, P809, DOI 10.1111/j.1432-1033.1993.tb18096.x; Porra RJ., 1991, CHLOROPHYLLS, P31; ROBERTSON D, 1974, PLANT PHYSIOL, V54, P148, DOI 10.1104/pp.54.2.148; RUDIGER W, 1980, EUR J BIOCHEM, V109, P193, DOI 10.1111/j.1432-1033.1980.tb04784.x; SCHOCH S, 1977, Z PFLANZENPHYSIOL, V83, P427, DOI 10.1016/S0044-328X(77)80049-4; SOLL J, 1983, PLANT PHYSIOL, V71, P849, DOI 10.1104/pp.71.4.849; VANWIJK KJ, 1995, J BIOL CHEM, V270, P25685, DOI 10.1074/jbc.270.43.25685; Watanabe T., 1991, CHLOROPHYLLS, P287; YAMAGUCHI N, 1988, PLANT CELL PHYSIOL, V29, P123	43	53	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32174	32179		10.1074/jbc.271.50.32174	http://dx.doi.org/10.1074/jbc.271.50.32174			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943272	hybrid			2022-12-25	WOS:A1996VY34000063
J	Frolov, A; Cho, TH; Billheimer, JT; Schroeder, F				Frolov, A; Cho, TH; Billheimer, JT; Schroeder, F			Sterol carrier protein-2, a new fatty acyl coenzyme A-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-TRANSFER PROTEIN; TIME-RESOLVED FLUORESCENCE; ESCHERICHIA-COLI; RAT-LIVER; SECONDARY STRUCTURE; ENERGY-TRANSFER; LIGAND-BINDING; BETA-OXIDATION; HEART-MUSCLE; ACID	The ability of sterol carrier protein-2 (SCP-2) to interact with long chain fatty acyl-CoAs was examined. SCP-2 bound fluorescent fatty acyl-CoAs at a single site with high affinity, K-d values for cis- and trans-parinaroyl-CoA were 4.5 and 2.8 nM, respectively. Saturated 10-18-carbon and unsaturated 14-20-carbon fatty acyl-CoAs displaced SCP-2-bound fluorescent ligand. Oleoyl-CoA and oleic acid (but not coenzyme A) significantly altered SCP-2 Trp(50) emission and anisotropy decay, thereby increasing SCP-2 rotational correlation time, SCP-2 hydrodynamic radius, and SCP-2 Trp(50) remaining anisotropy up to 1.7-, 1.2-, and 1.3-fold, respectively. These changes were not accompanied by significant alterations in protein secondary structure as determined by circular dichroism, Finally, SCP-2 differentially altered the fluorescence emission and anisotropy decays of bound cis- and trans-parinaroyl-CoA. Both fluorescent fatty acyl-CoAs were located within a very ordered (limited cone angle of rotation) environment within SCP-2, as shown by a remaining anisotropy of 0.365 and 0.361 and a wobbling cone angle of 12 and 13 degrees, respectively. These anisotropy values were very close to those of such ligands in a propylene glass. However, the rotational relaxation times exhibited by SCP-2-bound cis- and trans-parinaroyl-CoA, 8.4-8.8 ns, were longer than those for the corresponding free fatty acid, 7.5-6.6 ns. These data show for the first time that SCP-2 is a fatty acyl-CoA-binding protein.	TEXAS A&M UNIV,TEXAS VET MED CTR,DEPT PHYSIOL & PHARMACOL,COLLEGE STN,TX 77843; DUPONT MERCK PHARMACEUT CO,EXPT STN,CARDIOVASC DEPT,WILMINGTON,DE 19898	Texas A&M University System; Texas A&M University College Station; DuPont					NIDDK NIH HHS [DK41402] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041402] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURSTEIN EA, 1973, PHOTOCHEM PHOTOBIOL, V18, P263, DOI 10.1111/j.1751-1097.1973.tb06422.x; Cantor C.R., 1980, BIOPHYS CHEM; DEDUKHOVA VI, 1991, FEBS LETT, V295, P51, DOI 10.1016/0014-5793(91)81382-I; DIRUSSO CC, 1992, J BIOL CHEM, V267, P8685; ELOFSSON A, 1991, BIOCHEMISTRY-US, V30, P9648, DOI 10.1021/bi00104a012; Frolov A, 1996, J LIPID RES, V37, P1862; Frolov A, 1996, J BIOL CHEM, V271, P16075, DOI 10.1074/jbc.271.27.16075; GADELLA TWJ, 1991, BIOCHIM BIOPHYS ACTA, V1070, P237, DOI 10.1016/0005-2736(91)90170-D; GADELLA TWJ, 1991, BIOCHEMISTRY-US, V30, P5555, DOI 10.1021/bi00236a031; Gossett RE, 1996, LIPIDS, V31, P895, DOI 10.1007/BF02522684; GUTFREUND H, 1972, ENZYMES PHYSICAL PRI, P68; HILL RB, 1995, PROTEIN EXPRES PURIF, V6, P394, DOI 10.1006/prep.1995.1052; HUBBELL T, 1994, BIOCHEMISTRY-US, V33, P3327, DOI 10.1021/bi00177a025; KELLER GA, 1989, J CELL BIOL, V108, P1353, DOI 10.1083/jcb.108.4.1353; KNUDSEN J, 1990, MOL CELL BIOCHEM, V98, P217; KNUDSEN J, 1989, BIOCHEM J, V262, P513, DOI 10.1042/bj2620513; Kurian E, 1996, BIOCHEMISTRY-US, V35, P3865, DOI 10.1021/bi952589y; MATSUURA JE, 1993, BIOCHEMISTRY-US, V32, P567, DOI 10.1021/bi00053a023; MEIJER EA, 1993, MOL CELL BIOCHEM, V123, P159, DOI 10.1007/BF01076488; MILLER KR, 1993, MOL CELL BIOCHEM, V123, P29, DOI 10.1007/BF01076472; Moncecchi DM, 1991, PHYSL BIOCH STEROLS, P1; MURPHY EJ, 1996, IN PRESS BIOCH BIOPH; MyersPayne SC, 1996, J NEUROCHEM, V66, P313; NEMECZ G, 1991, J BIOL CHEM, V266, P17112; NEMECZ G, 1991, ARCH BIOCHEM BIOPHYS, V286, P300, DOI 10.1016/0003-9861(91)90044-J; NIKAWA J, 1979, FEBS LETT, V102, P223, DOI 10.1016/0014-5793(79)80005-8; ORAM JF, 1975, J BIOL CHEM, V250, P73; PARASASSI T, 1984, BIOCHEMISTRY-US, V23, P5660, DOI 10.1021/bi00318a042; PEETERS RA, 1989, INT J BIOCHEM, V21, P407, DOI 10.1016/0020-711X(89)90365-0; PUGLIELLI L, 1995, J BIOL CHEM, V270, P18723, DOI 10.1074/jbc.270.32.18723; RAMAN N, 1995, J BIOL CHEM, V270, P1092, DOI 10.1074/jbc.270.3.1092; RASMUSSEN JT, 1994, BIOCHEM J, V299, P165, DOI 10.1042/bj2990165; RASMUSSEN JT, 1990, BIOCHEM J, V265, P849, DOI 10.1042/bj2650849; REINHART MP, 1993, BIOCHEM J, V295, P787, DOI 10.1042/bj2950787; Rolf B, 1995, BBA-LIPID LIPID MET, V1259, P245, DOI 10.1016/0005-2760(95)00170-0; ROSENDAL J, 1993, BIOCHEM J, V290, P321, DOI 10.1042/bj2900321; SCHROEDER F, 1993, MOL CELL BIOCHEM, V123, P73, DOI 10.1007/BF01076477; SCHROEDER F, 1995, BIOCHEMISTRY-US, V34, P11919, DOI 10.1021/bi00037a033; SCHROEDER F, 1991, P SOC EXP BIOL MED, V196, P235; SCHROEDER F, 1996, P SOC EXP BIOL MED, V213, P149; SEEDORF U, 1994, J BIOL CHEM, V269, P21277; SPENCER RD, 1970, J CHEM PHYS, V52, P1654, DOI 10.1063/1.1673201; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; SUMPER M, 1973, FEBS LETT, V30, P29, DOI 10.1016/0014-5793(73)80612-X; SZYPERSKI T, 1993, FEBS LETT, V335, P18, DOI 10.1016/0014-5793(93)80431-S; TAN H, 1990, EUR J BIOCHEM, V190, P107, DOI 10.1111/j.1432-1033.1990.tb15552.x; THUMSER AEA, 1994, BIOCHEM J, V300, P827, DOI 10.1042/bj3000827; VAHOUNY GV, 1987, ADV LIPID RES, V22, P83; VANDERKRIFT TP, 1985, BIOCHIM BIOPHYS ACTA, V812, P387, DOI 10.1016/0005-2736(85)90313-X; WOLBER PK, 1981, BIOCHEMISTRY-US, V20, P2800, DOI 10.1021/bi00513a015; YAMAMOTO R, 1991, P NATL ACAD SCI USA, V88, P463, DOI 10.1073/pnas.88.2.463	53	119	123	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					31878	31884		10.1074/jbc.271.50.31878	http://dx.doi.org/10.1074/jbc.271.50.31878			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943231	hybrid			2022-12-25	WOS:A1996VY34000022
J	Quick, MW; Lester, HA; Davidson, N; Simon, MI; Aragay, AM				Quick, MW; Lester, HA; Davidson, N; Simon, MI; Aragay, AM			Desensitization of inositol 1,4,5-trisphosphate Ca2+-induced Cl- currents by prolonged activation of G proteins in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; PHOSPHOLIPASE-C; ALPHA-SUBUNITS; POTASSIUM CHANNEL; CA2+ RELEASE; RECEPTORS; EXPRESSION; ISOZYMES; CALCIUM; PATHWAY	Expression of G protein a subunits of the G(q) family with various G protein-coupled receptors induces activation of an inositol 1,4,5-trisphosphate (IP3)/Ca2+-mediated Cl- conductance in Xenopus oocytes, Our present data show that two members of this family, the human G alpha(16) subunit and the murine homologue G alpha(15) can induce both activation and inhibition of these agonist-induced currents, Although extremely low amounts (10-50 pg) of injected G alpha(16) subunit cRNA cause modest (similar to 2-fold) enhancement of ligand-induced Cl- currents in oocytes co-injected with thyrotropin-releasing hormone (TRH) receptor cRNA 48 h postinjection, larger G alpha(16) and G alpha(15) cRNA injections cause > 10-fold inhibition of TRH or 5HT2c receptor responses, The inhibition is analyzed in this study, The inhibited currents are recovered if various G beta gamma subunit combinations are also expressed with the G alpha subunits. The constitutively active mutant, G alpha(16)Q212L, also causes a strong attenuation of the ligand-induced Cl- currents, but this inhibition is not recovered by co-expression of G beta gamma subunits, These results indicate that the free G alpha subunit is responsible for the inhibitory signal, Although expression of TRH receptor alone produces maximum responses approximately 48 h after injection, co-expression of TRH receptor with G alpha(16) results in enhanced responses 6-12 h postinjection, followed by complete attenuation at 36 h, Furthermore, injection of G alpha(16) cRNA alone at comparable levels gives rise to spontaneous Cl- currents within 6-12 h postinjection, suggesting that the early spontaneous activation underlies the later suppression, Expression of other G protein a subunits of the G(q) family, at cRNA levels considerably higher than effective for G alpha(16) produces both analogous spontaneous Cl- currents and, later, inhibition of ligand-induced Cl- currents, Experiments with direct injection of IP3 and of Ca2+ suggest that this inhibition is consistent with the down-regulation of IP3 receptors, These data indicate that both enhancement and inhibition of signaling through G protein-coupled receptors can be mediated by the expression level and/or activity of an individual G protein.	UNIV ALABAMA,NEUROBIOL RES CTR,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,BIRMINGHAM,AL 35294; CALTECH,DEPT BIOL,PASADENA,CA 91125	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; California Institute of Technology			Aragay, Anna M/K-3813-2014	Aragay, Anna M/0000-0002-8240-4126	NATIONAL CANCER INSTITUTE [P30CA013148] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH049176] Funding Source: NIH RePORTER; NCI NIH HHS [CA13148] Funding Source: Medline; NIMH NIH HHS [MH-49176] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; AMATRUDA TT, 1993, J BIOL CHEM, V268, P10139; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLITZER RD, 1993, J BIOL CHEM, V268, P7532; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P6596, DOI 10.1073/pnas.90.14.6596; Exton JH, 1996, ANNU REV PHARMACOL, V36, P481, DOI 10.1146/annurev.pa.36.040196.002405; Gallo CJ, 1996, DEV BIOL, V177, P300, DOI 10.1006/dbio.1996.0164; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; GUTTRIDGE KL, 1995, P NATL ACAD SCI USA, V92, P1297, DOI 10.1073/pnas.92.5.1297; HONDA Z, 1995, J BIOL CHEM, V270, P4840, DOI 10.1074/jbc.270.9.4840; ILYIN V, 1994, J PHYSIOL-LONDON, V477, P503, DOI 10.1113/jphysiol.1994.sp020211; JAFFE LF, 1983, DEV BIOL, V99, P265, DOI 10.1016/0012-1606(83)90276-2; Joseph SK, 1996, CELL SIGNAL, V8, P1, DOI 10.1016/0898-6568(95)02012-8; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KOFUJI P, 1995, P NATL ACAD SCI USA, V92, P6542, DOI 10.1073/pnas.92.14.6542; Kuang YN, 1996, P NATL ACAD SCI USA, V93, P2964, DOI 10.1073/pnas.93.7.2964; KUME S, 1993, CELL, V73, P555, DOI 10.1016/0092-8674(93)90142-D; LEE CH, 1992, J BIOL CHEM, V267, P16044; LIM NF, 1995, J GEN PHYSIOL, V105, P421, DOI 10.1085/jgp.105.3.421; LIPINSKY D, 1992, FEBS LETT, V307, P237, DOI 10.1016/0014-5793(92)80775-C; Liu MY, 1996, NATURE, V382, P83, DOI 10.1038/382083a0; MORIARTY TM, 1988, MOL BRAIN RES, V4, P75, DOI 10.1016/0169-328X(88)90021-6; MORIARTY TM, 1989, J BIOL CHEM, V264, P13524; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; PARK DG, 1993, J BIOL CHEM, V268, P4573; PARKER I, 1994, CELL CALCIUM, V15, P276, DOI 10.1016/0143-4160(94)90067-1; Quick Michael W., 1994, V19, P261; QUICK MW, 1992, BIOTECHNIQUES, V13, P357; QUICK MW, 1994, J BIOL CHEM, V269, P30164; RHEE SG, 1992, J BIOL CHEM, V267, P12393; RYU SH, 1990, J BIOL CHEM, V265, P17941; SAKUTA H, 1991, EUR J PHARM-MOLEC PH, V208, P31, DOI 10.1016/0922-4106(91)90048-M; SHAPIRA H, 1994, FEBS LETT, V348, P89, DOI 10.1016/0014-5793(94)00570-2; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; STEHNOBITTEL L, 1995, J BIOL CHEM, V270, P30068; SUGIYAMA H, 1987, NATURE, V325, P531, DOI 10.1038/325531a0; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; WOJCIKIEWICZ RJH, 1994, J BIOL CHEM, V269, P7963; WOJCIKIEWICZ RJH, 1992, J NEUROCHEM, V59, P393; WU DQ, 1993, P NATL ACAD SCI USA, V90, P5297, DOI 10.1073/pnas.90.11.5297; WU DQ, 1992, J BIOL CHEM, V267, P25798; Zhu X, 1996, P NATL ACAD SCI USA, V93, P2827, DOI 10.1073/pnas.93.7.2827	45	16	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32021	32027		10.1074/jbc.271.50.32021	http://dx.doi.org/10.1074/jbc.271.50.32021			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943251	hybrid, Green Accepted			2022-12-25	WOS:A1996VY34000042
J	Schock, HB; Garsky, VM; Kuo, LC				Schock, HB; Garsky, VM; Kuo, LC			Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials - Compensatory modulations of binding and activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1 PROTEASE; DECREASED SENSITIVITY; REDUCED SENSITIVITY; CLEAVAGE SITES; IN-VIVO; PROTEINASE; MUTANT; SELECTION; POTENT	Site-specific substitutions of as few as four amino acids (M46I/L63P/V82T/I84V) of the human immunodeficiency virus type 1 (HIV-1) protease engenders cross-resistance to a panel of protease inhibitors that are either in clinical trials or have recently been approved for HN therapy (Condra, J. H., Schleif, W. A., Blahy, O. M., Gadryelski, L. J., Graham, D. J., Quintero, J. C., Rhodes, A, Robbins, H. L., Roth, E., Shivaprakash, M., Titus, D., Yang, T., Teppler, H., Squires, K. E., Deutsch, P. J., and Emini, E, A. (1995) Nature 374, 569-571). These four substitutions are among the prominent mutations found in primary HIV isolates obtained from patients undergoing therapy with several protease inhibitors. Two of these mutations (V82T/I84V) are located in, while the other two (M46I/L63P) are away from, the binding cleft of the enzyme. The functional role of these mutations has now been delineated in terms of their influence on the binding affinity and catalytic efficiency of the protease. We have found that the double substitutions of M46I and L63P do not affect binding but instead endow the enzyme with a catalytic efficiency significantly exceeding (110-360%) that of the wild-type enzyme. In contrast, the double substitutions of V82T and I84V are detrimental to the ability of the protease to bind and, thereby, to catalyze. When combined, the four amino acid replacements institute in the protease resistance against inhibitors and a significantly higher catalytic activity than one containing only mutations in its active site. The results suggest that in raising drug resistance, these four site-specific mutations of the protease are compensatory in function; those in the active site diminish equilibrium binding (by increasing K-i), and those away from the active site enhance catalysis (by increasing k(cat)/K-M. This conclusion is further supported by energy estimates in that the Gibbs free energies of binding and catalysis for the quadruple mutant are quantitatively dictated by those of the double mutants.			Schock, HB (corresponding author), MERCK RES LABS,DEPT ANTIVIRAL RES,W POINT,PA 19486, USA.							BALDWIN ET, 1995, NAT STRUCT BIOL, V2, P244, DOI 10.1038/nsb0395-244; CHEN ZG, 1995, J BIOL CHEM, V270, P21433, DOI 10.1074/jbc.270.37.21942; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; CRAIG JC, 1991, ANTIVIR RES, V16, P295, DOI 10.1016/0166-3542(91)90045-S; DARKE PL, 1994, BIOCHEMISTRY-US, V33, P98, DOI 10.1021/bi00167a013; DORSEY BD, 1994, J MED CHEM, V37, P3443, DOI 10.1021/jm00047a001; DUNN BM, 1994, METHOD ENZYMOL, V241, P254; EBERLE J, 1995, AIDS RES HUM RETROV, V11, P671, DOI 10.1089/aid.1995.11.671; ELFARRASH MA, 1994, J VIROL, V68, P233, DOI 10.1128/JVI.68.1.233-239.1994; ERICKSON JW, 1995, NAT STRUCT BIOL, V2, P523, DOI 10.1038/nsb0795-523; ESTELL DA, 1986, SCIENCE, V233, P659, DOI 10.1126/science.233.4764.659; FERSHT A, 1985, ENZYME STRUCTURE MEC, P311; FERSHT AR, 1988, BIOCHEMISTRY-US, V27, P1581, DOI 10.1021/bi00405a028; GOLDSMITH JO, 1993, J BIOL CHEM, V268, P18481; GRIFFITHS JT, 1992, BIOCHEMISTRY-US, V31, P5193, DOI 10.1021/bi00137a015; GULNIK SV, 1995, BIOCHEMISTRY-US, V34, P9282, DOI 10.1021/bi00029a002; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1994, J VIROL, V68, P2016, DOI 10.1128/JVI.68.3.2016-2020.1994; HUSSON RN, 1993, J PEDIATR-US, V123, P9, DOI 10.1016/S0022-3476(05)81530-6; IDO E, 1991, J BIOL CHEM, V266, P24359; JACOBSEN H, 1995, VIROLOGY, V206, P527, DOI 10.1016/S0042-6822(95)80069-7; KAPLAN AH, 1994, P NATL ACAD SCI USA, V91, P5597, DOI 10.1073/pnas.91.12.5597; KEMPF DJ, 1995, P NATL ACAD SCI USA, V92, P2484, DOI 10.1073/pnas.92.7.2484; KIM EE, 1995, J AM CHEM SOC, V117, P1181, DOI 10.1021/ja00108a056; LIN YZ, 1995, BIOCHEMISTRY-US, V34, P1143, DOI 10.1021/bi00004a007; MARKOWITZ M, 1995, J VIROL, V69, P701, DOI 10.1128/JVI.69.2.701-706.1995; MERRIFIELD RB, 1964, BIOCHEMISTRY-US, V3, P1385, DOI 10.1021/bi00897a032; OTTO MJ, 1993, P NATL ACAD SCI USA, V90, P7543, DOI 10.1073/pnas.90.16.7543; PARTALEDIS JA, 1995, J VIROL, V69, P5228, DOI 10.1128/JVI.69.9.5228-5235.1995; Pazhanisamy S, 1996, J BIOL CHEM, V271, P17979, DOI 10.1074/jbc.271.30.17979; PETIT SC, 1991, J BIOL CHEM, V266, P14539; PETTIT SC, 1994, J VIROL, V68, P8017, DOI 10.1128/JVI.68.12.8017-8027.1994; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; RICHMAN DD, 1994, TXB AIDS MED, P795; Ridky TW, 1996, J BIOL CHEM, V271, P4709, DOI 10.1074/jbc.271.9.4709; ROSE JR, 1995, J VIROL, V69, P2751; SARDANA VV, 1994, BIOCHEMISTRY-US, V33, P2004, DOI 10.1021/bi00174a005; TADDEO B, 1994, J VIROL, V68, P8401, DOI 10.1128/JVI.68.12.8401-8405.1994; TISDALE M, 1995, ANTIMICROB AGENTS CH, V39, P1704, DOI 10.1128/AAC.39.8.1704; TOMASSELLI AG, 1994, METHOD ENZYMOL, V241, P279; TOZSER J, 1991, FEBS LETT, V281, P77, DOI 10.1016/0014-5793(91)80362-7; TOZSER J, 1992, BIOCHEMISTRY-US, V31, P4793, DOI 10.1021/bi00135a008; TOZSER J, 1991, FEBS LETT, V279, P356, DOI 10.1016/0014-5793(91)80186-7; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WINSLOW DL, 1995, AIDS RES HUM RETROV, V11, P107, DOI 10.1089/aid.1995.11.107; YAMAGUCHI K, 1995, BBA-PROTEIN STRUCT M, V1253, P136, DOI 10.1016/0167-4838(95)00167-1	47	124	134	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					31957	31963		10.1074/jbc.271.50.31957	http://dx.doi.org/10.1074/jbc.271.50.31957			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943242	hybrid			2022-12-25	WOS:A1996VY34000033
J	Ducancel, F; Merienne, K; FromenRomano, C; Tremeau, O; Pillet, L; Drevet, P; ZinnJustin, S; Boulain, JC; Menez, A				Ducancel, F; Merienne, K; FromenRomano, C; Tremeau, O; Pillet, L; Drevet, P; ZinnJustin, S; Boulain, JC; Menez, A			Mimicry between receptors and antibodies - Identification of snake toxin determinants recognized by the acetylcholine receptor and an acetylcholine receptor-mimicking monoclonal antibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; GATED ION CHANNELS; STAPHYLOCOCCAL PROTEIN-A; BINDING-SITE; CURAREMIMETIC TOXINS; ALPHA-BUNGAROTOXIN; CRYSTAL-STRUCTURE; ANTIGEN INTERACTIONS; CATALYTIC ANTIBODY; FUNCTIONAL EPITOPE	In several instances, a monoclonal antibody raised against a receptor ligand has been claimed to mimic the ligand receptor, Thus, a specific monoclonal antibody (M alpha 2-3) raised against a short chain toxin from snake was proposed to mimic the nicotinic acetylcholine receptor (AChR) (1), Further confirming this mimicry, we show that (i) like AChR, M alpha 2-3 elicits anti-AChR antibodies, which in turn elicit anti-toxin antibodies; and (ii) the region 106-122 of the alpha-chain of AChR shares 66% primary structure identity with complementarity-determining regions of M alpha 2-3. Also, a mutational analysis of erabutoxin a reveals that the epitope recognized by M alpha 2-3 consists of 10 residues, distributed within the three toxin loops, Eight of these residues also belong to the 10-residue epitope recognized by AChR, a result that offers an explanation as to the functional similarities between the receptor and the antibody, Strikingly, however, most of the residues common to the two epitopes contribute differentially to the energetic formation of the antibody-toxin and the receptor-toxin complexes, Together, the data suggest that the mimicry between AChR and M alpha 2-3 is partial only.	CEA SACLAY, DSV, DEPT INGN & ETUD PROT, F-91191 GIF SUR YVETTE, FRANCE	CEA; UDICE-French Research Universities; Universite Paris Saclay				Merienne, Karine/0000-0003-2549-2315				AMATI V, 1995, PROTEIN ENG, V8, P403, DOI 10.1093/protein/8.4.403; ARNOUX B, 1994, FEBS LETT, V342, P12, DOI 10.1016/0014-5793(94)80574-1; BASUS VJ, 1993, BIOCHEMISTRY-US, V32, P12290, DOI 10.1021/bi00097a004; Benkovic SJ., 1990, CHEMTRACTS ORG CHEM, V3, P1; BOULAIN JC, 1982, SCIENCE, V217, P732, DOI 10.1126/science.7100919; BOULAIN JC, 1982, BIOCHEMISTRY-US, V21, P2910, DOI 10.1021/bi00541a016; BOULTER J, 1985, J NEUROSCI, V5, P2545; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; BOYOT P, 1990, FEBS LETT, V266, P87, DOI 10.1016/0014-5793(90)81513-N; BRADEN BC, 1995, FASEB J, V9, P9, DOI 10.1096/fasebj.9.1.7821765; BRUCK C, 1986, P NATL ACAD SCI USA, V83, P6578, DOI 10.1073/pnas.83.17.6578; Chang C.C., 1979, SNAKE VENOMS, P309; CHANGEUX JP, 1990, TRENDS PHARMACOL SCI, V11, P485, DOI 10.1016/0165-6147(90)90049-E; Charpentier I, 1990, J Mol Recognit, V3, P74, DOI 10.1002/jmr.300030204; CHINCHETRU MA, 1989, BIOCHEMISTRY-US, V28, P4222, DOI 10.1021/bi00436a015; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DAVIS SJ, 1992, NATURE, V358, P76, DOI 10.1038/358076a0; DEVILLERSTHIERY A, 1993, J MEMBRANE BIOL, V136, P97, DOI 10.1007/BF02505755; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DORING E, 1994, MOL IMMUNOL, V31, P1059, DOI 10.1016/0161-5890(94)90101-5; DUCANCEL F, 1989, PROTEIN ENG, V3, P139, DOI 10.1093/protein/3.2.139; Endo T., 1991, P165; FAMBROUGH DM, 1973, SCIENCE, V182, P293, DOI 10.1126/science.182.4109.293; FAURE G, 1983, BIOCHEMISTRY-US, V22, P2068, DOI 10.1021/bi00278a006; FIELDS BA, 1995, NATURE, V374, P739, DOI 10.1038/374739a0; FULACHIER MH, 1994, FEBS LETT, V338, P331, DOI 10.1016/0014-5793(94)80294-7; GALZI JL, 1994, CURR OPIN STRUC BIOL, V4, P554, DOI 10.1016/S0959-440X(94)90218-6; GAUCHER JF, 1996, THESIS U PARIS 11 PA; GIBBS RA, 1991, P NATL ACAD SCI USA, V88, P4001, DOI 10.1073/pnas.88.9.4001; HERVE M, 1992, EUR J BIOCHEM, V208, P125, DOI 10.1111/j.1432-1033.1992.tb17165.x; HILL BL, 1988, ENDOCRINOLOGY, V122, P2840, DOI 10.1210/endo-122-6-2840; ISHIKAWA Y, 1977, TOXICON, V15, P477, DOI 10.1016/0041-0101(77)90098-8; JANIN J, 1990, J BIOL CHEM, V265, P16027; JARRIN A, 1994, FEBS LETT, V354, P169, DOI 10.1016/0014-5793(94)01113-3; JIN L, 1992, J MOL BIOL, V226, P851, DOI 10.1016/0022-2836(92)90636-X; Kabat EA, 1991, SEQUENCES PROTEINS I; KAMMORGAN LNW, 1993, P NATL ACAD SCI USA, V90, P3958, DOI 10.1073/pnas.90.9.3958; KELLEY RF, 1993, BIOCHEMISTRY-US, V32, P6828, DOI 10.1021/bi00078a005; LENTZ TL, 1995, BIOCHEMISTRY-US, V34, P1316, DOI 10.1021/bi00004a026; LEU JG, 1994, P NATL ACAD SCI USA, V91, P10690, DOI 10.1073/pnas.91.22.10690; LINDSTROM J, 1988, ADV IMMUNOL, V42, P233, DOI 10.1016/S0065-2776(08)60847-0; LOW BW, 1976, P NATL ACAD SCI USA, V73, P2991, DOI 10.1073/pnas.73.9.2991; LOWENADLER B, 1987, GENE, V58, P87, DOI 10.1016/0378-1119(87)90032-1; MENEZ A, 1971, FEBS LETT, V17, P333, DOI 10.1016/0014-5793(71)80180-1; MENEZ A, 1984, J PHYSIOLOGY PARIS, V79, P196; NILSSON B, 1985, EMBO J, V4, P1075, DOI 10.1002/j.1460-2075.1985.tb03741.x; NILSSON B, 1987, PROTEIN ENG, V1, P107, DOI 10.1093/protein/1.2.107; NODA M, 1982, NATURE, V299, P793, DOI 10.1038/299793a0; NOVOTNY J, 1989, BIOCHEMISTRY-US, V28, P4735, DOI 10.1021/bi00437a034; NOVOTNY J, 1991, MOL IMMUNOL, V28, P201, DOI 10.1016/0161-5890(91)90062-O; PATRICK J, 1973, SCIENCE, V180, P871, DOI 10.1126/science.180.4088.871; PEARCE SF, 1990, BIOCHEMISTRY-US, V29, P10649, DOI 10.1021/bi00499a011; PILLET L, 1993, J BIOL CHEM, V268, P909; PILLET L, 1992, BIOCHIM BIOPHYS ACTA, V1138, P282, DOI 10.1016/0925-4439(92)90005-8; POLJAK RJ, 1994, P NATL ACAD SCI USA, V91, P1599, DOI 10.1073/pnas.91.5.1599; PRASAD L, 1993, J BIOL CHEM, V268, P10705; PRIDE MW, 1992, P NATL ACAD SCI USA, V89, P11900, DOI 10.1073/pnas.89.24.11900; RUAN KH, 1991, BIOCHEM J, V274, P849, DOI 10.1042/bj2740849; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARAGOVI HU, 1991, SCIENCE, V253, P792, DOI 10.1126/science.1876837; SATO S, 1971, BIOCHEM J, V122, P453, DOI 10.1042/bj1220453; SMITH AM, 1991, J IMMUNOL, V146, P1259; SMITHGILL SJ, 1984, J IMMUNOL, V133, P384; SUGIYAMA H, 1973, FEBS LETT, V35, P124, DOI 10.1016/0014-5793(73)80592-7; TAMIYA T, 1985, BIOCHIMIE, V67, P185, DOI 10.1016/S0300-9084(85)80046-8; TAUB R, 1989, J BIOL CHEM, V264, P259; Tenette C, 1996, PROTEINS, V26, P9, DOI 10.1002/(SICI)1097-0134(199609)26:1<9::AID-PROT2>3.0.CO;2-E; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; TREMEAU O, 1986, FEBS LETT, V208, P236, DOI 10.1016/0014-5793(86)81024-9; TREMEAU O, 1995, J BIOL CHEM, V270, P9362, DOI 10.1074/jbc.270.16.9362; VINCENT A, 1983, TRENDS NEUROCHEM SCI, P249; WANG MW, 1989, P NATL ACAD SCI USA, V86, P7098, DOI 10.1073/pnas.86.18.7098; WEBSTER DM, 1994, CURR OPIN STRUC BIOL, V4, P123, DOI 10.1016/S0959-440X(94)90070-1; WILLIAMS WV, 1991, J BIOL CHEM, V266, P5182; WILLIAMS WV, 1989, P NATL ACAD SCI USA, V86, P5537, DOI 10.1073/pnas.86.14.5537; WILLIAMS WV, 1989, VIROL IMMUNOL, V22, P321; WILSON IA, 1993, CURR OPIN STRUC BIOL, V3, P113, DOI 10.1016/0959-440X(93)90210-C; ZHOU GW, 1994, SCIENCE, V265, P1059, DOI 10.1126/science.8066444; [No title captured]	82	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31345	31353		10.1074/jbc.271.49.31345	http://dx.doi.org/10.1074/jbc.271.49.31345			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940141	hybrid			2022-12-25	WOS:A1996VW68600052
J	Groblewski, GE; Wishart, MJ; Yoshida, M; Williams, JA				Groblewski, GE; Wishart, MJ; Yoshida, M; Williams, JA			Purification and identification of a 28-kDa calcium-regulated heat-stable protein - A novel secretagogue-regulated phosphoprotein in exocrine pancreas	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE ACTIVITY; ACINAR-CELLS; PHOSPHORYLATION; CARBACHOL; SEQUENCE	This study reports the purification and identification of a novel 28 kDa phosphoprotein from rat pancreatic acini, previously described as being highly regulated by calcium mobilizing secretagogues, which we have designated calcium-regulated heat-stable protein 28 (CRHSP-28). Internal amino acid sequences of purified CRHSP-28 were obtained following trypsin digestion and found to match with >95% identity the predicted amino acid sequence of a novel cDNA recently identified as being highly expressed in human breast carcinomas, Verification that this cDNA codes for human CRHSP-28 was demonstrated by the ability of antiserum raised against purified rat CRHSP-28 to recognize the recombinant human protein when expressed in bacteria. Furthermore, this antibody was found to specifically react with CRHSP-28 in rat acini following one- and tno dimensional electrophoresis and underwent a marked acidic shift in mobility after cholecystokinin stimulation, a phenomenon indicative of an increase in its phosphorylation. CRHSP-28 is predicted to be extremely hydrophilic, is phosphorylated entirely on serine residues, and bears little homology to any known proteins, Finally, the distribution of the CRHSP-28 protein in various rat tissues revealed that although it was present at low levels in almost all tissues, it was most highly expressed in pancreas, followed by the gastric, intestinal, and colonic mucosa. In view of its relative abundance throughout the digestive system and its apparent regulation by calcium-mobilizing agents, this protein may provide valuable insight into the mechanism(s) of calcium signaling in these tissues.	UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	Groblewski, GE (corresponding author), UNIV MICHIGAN,SCH MED,DEPT PHYSIOL,7737 MED SCI I,ANN ARBOR,MI 48109, USA.			Williams, John/0000-0002-6063-7615	NIDDK NIH HHS [DK-08819, DK-41122] Funding Source: Medline; PHS HHS [P30 KD34922] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK041122, R01DK041122, F32DK008819] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BROWN MR, 1989, AM J PHYSIOL, V257, pG99, DOI 10.1152/ajpgi.1989.257.1.G99; BURNHAM DB, 1984, AM J PHYSIOL, V246, pG500, DOI 10.1152/ajpgi.1984.246.5.G500; BURNHAM DB, 1988, AM J PHYSIOL, V254, pG130, DOI 10.1152/ajpgi.1988.254.1.G130; BURNHAM DB, 1982, J BIOL CHEM, V257, P523; BURNHAM DB, 1986, BIOCHEM J, V235, P125, DOI 10.1042/bj2350125; BYRNE JA, 1995, CANCER RES, V55, P2896; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHN JA, 1989, BIOCHEM BIOPH RES CO, V165, P819; DUAN RD, 1994, BIOCHEM BIOPH RES CO, V199, P368, DOI 10.1006/bbrc.1994.1238; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; GORELICK FS, 1983, J CELL BIOL, V97, P1294, DOI 10.1083/jcb.97.4.1294; GROBLEWSKI GE, 1994, J BIOL CHEM, V269, P15111; GROBLEWSKI GE, IN PRESS 2 MESSENGER; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; JELINEK T, 1993, BIOTECHNIQUES, V15, P628; MATOZAKI T, 1991, AM J PHYSIOL, V260, pG858, DOI 10.1152/ajpgi.1991.260.6.G858; NAIRN AC, 1985, P NATL ACAD SCI USA, V82, P7939, DOI 10.1073/pnas.82.23.7939; NAIRN AC, 1994, SEMIN CANCER BIOL, V5, P295; Parente JA, 1996, J BIOL CHEM, V271, P20096, DOI 10.1074/jbc.271.33.20096; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; Williams John A., 1993, P167; WISHART MJ, 1994, AM J PHYSIOL-GASTR L, V267, pG676, DOI 10.1152/ajpgi.1994.267.4.G676	24	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31502	31507		10.1074/jbc.271.49.31502	http://dx.doi.org/10.1074/jbc.271.49.31502			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940165	hybrid			2022-12-25	WOS:A1996VW68600076
J	Zhang, X; Bennett, V				Zhang, X; Bennett, V			Identification of O-linked N-acetylglucosamine modification of ankyrin(G) isoforms targeted to nodes of Ranvier	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ERYTHROCYTE ANKYRIN; AXONAL-TRANSPORT; SCHWANN-CELLS; GENE FAMILY; C-MYC; GLYCOSYLATION; NUCLEAR; DOMAIN; PHOSPHORYLATION; GLCNAC	Ankyrin(G)s of 270 and 480 kDa are localized at nodes of Ranvier and are candidates to couple the voltage-dependent sodium channel and neurofascin to the spectrin/actin network. This study presents evidence that these ankyrins contain O-linked GlcNAc residues and identifies as the site of glycosylation a serine-rich domain that distinguishes them from other ankyrin isoforms. The 480-kDa ankyrin(G), extracted from brain membranes associated with wheat germ agglutinin-affinity columns, was [H-3]galactose-labeled with UDP-[H-3] galactose and galactosyltransferase, and cross-reacted with an antibody against O-GlcNAc monosaccharides. Ankyrin(G)-associated sugars are O-linked monosaccharides based on resistance to peptide-N-glycosidase F and analysis of saccharides released by beta-elimination. The serine-rich domain is the site of glycosylation based on wheat germ agglutinin binding activity of polypeptides produced by in vitro translation in reticulocyte lysates. Immunofluorescence revealed co-localization of ankyrin, and O-GlcNAc immunoreactivity at nodes of Ranvier. These observations suggest that ankyrin at the node of Ranvier is O-GlcNAc glycosylated and are the first demonstration of a post translational modification that is concentrated at the node of Ranvier and not in adjacent areas of myelinated axons.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710	Duke University; Duke University; Howard Hughes Medical Institute	Zhang, X (corresponding author), DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710, USA.							BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Brady Scott T., 1993, P7; CHAN W, 1993, J CELL BIOL, V123, P1463, DOI 10.1083/jcb.123.6.1463; CHOU CF, 1992, J BIOL CHEM, V267, P3901; CHOU TY, 1995, P NATL ACAD SCI USA, V92, P4417, DOI 10.1073/pnas.92.10.4417; CHOU TY, 1995, J BIOL CHEM, V270, P18961, DOI 10.1074/jbc.270.32.18961; Davis J., 1995, Molecular Biology of the Cell, V6, p177A; DAVIS J, 1983, J BIOL CHEM, V258, P7757; DAVIS JQ, 1984, J BIOL CHEM, V259, P3550; DAVIS LI, 1987, P NATL ACAD SCI USA, V84, P7552, DOI 10.1073/pnas.84.21.7552; DEWAEGH SM, 1992, CELL, V68, P451, DOI 10.1016/0092-8674(92)90183-D; DEWAEGH SM, 1991, J NEUROSCI RES, V30, P201, DOI 10.1002/jnr.490300121; DONG DLY, 1993, J BIOL CHEM, V268, P16679; ELLIOT SP, 1993, J NEUROSCI, V13, P2424, DOI 10.1523/JNEUROSCI.13-06-02424.1993; GRIFFITH LS, 1995, J NEUROSCI RES, V41, P270, DOI 10.1002/jnr.490410214; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; HART GW, 1995, ADV EXP MED BIOL, V376, P115; HOLT GD, 1987, J BIOL CHEM, V262, P14847; HSIEH ST, 1994, J NEUROSCI, V14, P6392; KELLY WG, 1993, J BIOL CHEM, V268, P10416; KORDELI E, 1990, J CELL BIOL, V110, P1341, DOI 10.1083/jcb.110.4.1341; KORDELI E, 1991, J CELL BIOL, V114, P1243, DOI 10.1083/jcb.114.6.1243; KORDELI E, 1995, J BIOL CHEM, V270, P2352, DOI 10.1074/jbc.270.5.2352; Kunimoto M, 1995, J CELL BIOL, V131, P1821, DOI 10.1083/jcb.131.6.1821; LAMBERT S, 1990, P NATL ACAD SCI USA, V87, P1730, DOI 10.1073/pnas.87.5.1730; LAMBERT S, 1993, EUR J BIOCHEM, V211, P1, DOI 10.1111/j.1432-1033.1993.tb19863.x; Lambert S., 1995, Molecular Biology of the Cell, V6, p98A; LUTHI T, 1991, J NEUROCHEM, V56, P1493; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MATA M, 1992, J NEUROCYTOL, V21, P199, DOI 10.1007/BF01194978; MURPHY JE, 1995, J BIOL CHEM, V269, P21346; OTTO E, 1991, J CELL BIOL, V114, P241, DOI 10.1083/jcb.114.2.241; PETERS LL, 1995, J CELL BIOL, V130, P313, DOI 10.1083/jcb.130.2.313; ROQUEMORE EP, 1994, METHOD ENZYMOL, V230, P443; Sambrook J., 2002, MOL CLONING LAB MANU; SRINIVASAN Y, 1992, J BIOL CHEM, V267, P7483; STARR CM, 1990, J BIOL CHEM, V265, P6868; TRAVELYAN WE, 1950, NATURE, V166, P444; TURNER JR, 1990, P NATL ACAD SCI USA, V87, P5608, DOI 10.1073/pnas.87.15.5608	40	56	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31391	31398		10.1074/jbc.271.49.31391	http://dx.doi.org/10.1074/jbc.271.49.31391			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940148	hybrid			2022-12-25	WOS:A1996VW68600059
J	Bloom, LB; Turner, J; Kelman, Z; Beechem, JM; ODonnell, M; Goodman, MF				Bloom, LB; Turner, J; Kelman, Z; Beechem, JM; ODonnell, M; Goodman, MF			Dynamics of loading the beta sliding clamp of DNA polymerase III onto DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL REPLICATION MACHINE; ONE HOLOENZYME PARTICLE; ESCHERICHIA-COLI; ACCESSORY PROTEINS; SUBUNIT; LOADER; COMPLEX; PURIFICATION; EXONUCLEASE; MECHANISM	A ''minimal'' DNA primer-template system, consisting of an 80-mer template and 30-mer primer, supports processive DNA synthesis by DNA polymerase III core in the presence of the beta sliding clamp, gamma complex clamp loader, and single-stranded binding protein from Escherichia coli, This primer-template system was used to measure the loading of the beta sliding clamp by the gamma complex in an ATP-dependent reaction, Bound protein-DNA complexes were detected by monitoring fluorescence depolarization of DNA. Steady state and time-resolved anisotropies were measured, and stopped-flow pre-steady state fluorescence measurements allowed visualization of the loading reactions in real time. The rate of loading beta onto DNA was 12 s(-1), demonstrating that clamp assembly is rapid on the time scale required for lagging strand Okazaki fragment synthesis. The association rate appears to be limited by an intramolecular step occurring prior to the clamp-loading reaction, possibly the opening of the toroidal beta dimer.	UNIV SO CALIF,HEDCO MOL BIOL LABS,DEPT BIOL SCI,LOS ANGELES,CA 90089; HEARST RES FDN,DEPT MICROBIOL,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,HOWARD HUGHES MED INST,NEW YORK,NY 10021; VANDERBILT UNIV,DEPT MOL PHYSIOL & BIOPHYS,NASHVILLE,TN 37232	University of Southern California; Cornell University; Howard Hughes Medical Institute; Vanderbilt University			Bloom, Linda B/F-3684-2014		NIGMS NIH HHS [GM21422, GM38839, GM42554] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038839, R01GM042554, R37GM038839, R01GM021422, R37GM021422] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BONNER CA, 1992, J BIOL CHEM, V267, P11431; DIFRANCESCO R, 1984, J BIOL CHEM, V259, P5567; DONG ZM, 1993, J BIOL CHEM, V268, P11758; FAY PJ, 1981, J BIOL CHEM, V256, P976; GUPTA A, 1982, J BIOL CHEM, V257, P7689; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; KELMAN Z, 1994, CURR OPIN GENET DEV, V4, P185, DOI 10.1016/S0959-437X(05)80044-9; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KORNBERG A, 1992, DNA REPLICATION, P169; Lakowicz J.R., 1983, PRINCIPLES FLUORESCE, P145; LETILLY V, 1993, BIOCHEMISTRY-US, V32, P7753, DOI 10.1021/bi00081a021; MAKI H, 1985, J BIOL CHEM, V260, P2987; MAKI S, 1988, J BIOL CHEM, V263, P6555; MCHENRY CS, 1991, J BIOL CHEM, V266, P19127; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; ONRUST R, 1991, J BIOL CHEM, V266, P21681; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; OTTO MR, 1994, BIOPHYS J, V67, P2511, DOI 10.1016/S0006-3495(94)80741-6; PEREZHOWARD GM, 1995, BIOCHEMISTRY-US, V34, P8005, DOI 10.1021/bi00025a006; SCHEUERMANN RH, 1984, P NATL ACAD SCI-BIOL, V81, P7747, DOI 10.1073/pnas.81.24.7747; SINHA NK, 1980, J BIOL CHEM, V263, P6561; STUDWELL PS, 1990, J BIOL CHEM, V265, P1171; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUDWELLVAUGHAN PS, 1993, J BIOL CHEM, V268, P11785; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; STUKENBERG PT, 1995, J BIOL CHEM, V270, P13384, DOI 10.1074/jbc.270.22.13384; XIAO H, 1993, J BIOL CHEM, V268, P11773	30	55	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30699	30708		10.1074/jbc.271.48.30699	http://dx.doi.org/10.1074/jbc.271.48.30699			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940047	hybrid			2022-12-25	WOS:A1996VV15800064
J	Dan, N; Middleton, RB; Lehrman, MA				Dan, N; Middleton, RB; Lehrman, MA			Hamster UDP-N-acetylglucosamine:dolichol-P N-acetylglucosamine-1-P transferase has multiple transmembrane spans and a critical cytosolic loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-D-GLUCOSAMINE; ENDOPLASMIC-RETICULUM; SACCHAROMYCES-CEREVISIAE; LINKED OLIGOSACCHARIDES; MICROSOMAL VESICLES; MOLECULAR-CLONING; MEMBRANE TOPOLOGY; OVARY CELLS; PHOSPHATE; GLCNAC	UDP-GlcNAc:dolichol-P GlcNAc-1-P transferase (GPT) is an endoplasmic reticulum (ER) enzyme responsible for synthesis of GlcNAc-P-P-dolichol, the committed step of dolichol-P-P-oligosaccharide synthesis. The sequence of hamster GPT predicted multiple transmembrane segments (Zhu, X, and Lehrman, M. A. (1990) J. Biol. Chem. 265, 14250-14255). GPT has also been predicted to act on the cytosolic face of the ER membrane, based on topological studies of its substrates and products. In this report we test these predictions by: (i) immunofluorescence microscopy with antibodies specific for native GPT sequences or epitope tags inserted into GPT, after selective permeabilization of the plasma membrane with digitonin; (ii) insertion of Factor Xa cleavage sites; (iii) in vitro translation of GPT; and (iv) site-directed mutagenesis, The loops between the Ist and 2nd and between the 9th and 10th predicted transmembrane spans of GPT were found to be cytosolic. In contrast, the loop between the 6th and 7th transmembrane spans, as well as the carboxyl terminus, were lumenal. Thus, hamster GPT must cross the ER membrane at least three times, consistent with previous computer-assisted predictions. There was no apparent N-glycosylation or signal sequence cleavage detected by in vitro translation. The cytosolic loop between the 9th and 10th transmembrane spans is the largest hydrophilic segment in GPT and, as judged by site-directed mutagenesis, has a number of conserved residues essential for activity. Hence, these results directly support the hypothesis that dolichol-PP-oligosaccharide assembly is initiated in the cytosol and that a downstream intermediate must translocate to the lumenal face of the ER membrane.	UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIGMS NIH HHS [GM38545] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038545, R56GM038545] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEIJON C, 1990, J BIOL CHEM, V265, P14691; BORJIGIN J, 1994, J BIOL CHEM, V269, P14715; DATTA AK, 1993, J BIOL CHEM, V268, P12663; HANOVER JA, 1979, J BIOL CHEM, V254, P9237; HARTOG KO, 1987, NUCLEIC ACIDS RES, V15, P3627, DOI 10.1093/nar/15.8.3627; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; JACKSON BJ, 1989, ARCH BIOCHEM BIOPHYS, V272, P203, DOI 10.1016/0003-9861(89)90211-7; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; KAST C, 1995, BIOCHEMISTRY-US, V34, P4402, DOI 10.1021/bi00013a032; KEAN EL, 1991, J BIOL CHEM, V266, P942; KEAN EL, 1994, BIOCHEMISTRY-US, V33, P10508, DOI 10.1021/bi00200a036; KEAN EL, 1993, BIOCHIM BIOPHYS ACTA, V1168, P321, DOI 10.1016/0005-2760(93)90189-G; LEHRMAN M A, 1991, Glycobiology, V1, P553, DOI 10.1093/glycob/1.6.553; LEHRMAN MA, 1994, GLYCOBIOLOGY, V4, P768, DOI 10.1093/glycob/4.6.768; LEHRMAN MA, 1988, J BIOL CHEM, V263, P19796; LENNARZ WJ, 1987, BIOCHEMISTRY-US, V26, P7205, DOI 10.1021/bi00397a001; LIU X, 1992, MOL CELL BIOL, V12, P4112, DOI 10.1128/MCB.12.9.4112; MIDDLETON RB, 1993, BIOCHEM J, V296, P511, DOI 10.1042/bj2960511; ORLEAN P, 1988, J BIOL CHEM, V263, P17499; PATTERSON SI, 1994, J CELL BIOL, V124, P521, DOI 10.1083/jcb.124.4.521; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; RAJPUT B, 1992, BIOCHEM J, V285, P985, DOI 10.1042/bj2850985; RINE J, 1983, P NATL ACAD SCI-BIOL, V80, P6750, DOI 10.1073/pnas.80.22.6750; ROITELMAN J, 1992, J CELL BIOL, V117, P959, DOI 10.1083/jcb.117.5.959; SCOCCA JR, 1990, J BIOL CHEM, V265, P20621; SHAILUBHAI K, 1988, J BIOL CHEM, V263, P15964; SINGH P, 1993, MOL CELL BIOL, V13, P6435, DOI 10.1128/MCB.13.10.6435; SLONINA AE, 1993, J BIOL CHEM, V268, P6729; SNIDER MD, 1980, CELL, V21, P385, DOI 10.1016/0092-8674(80)90475-4; Spiro RG, 1996, J BIOL CHEM, V271, P11588, DOI 10.1074/jbc.271.19.11588; TAKEDA J, 1995, TRENDS BIOCHEM SCI, V20, P367, DOI 10.1016/S0968-0004(00)89078-7; TEHEESEN S, 1994, EUR J BIOCHEM, V224, P71, DOI 10.1111/j.1432-1033.1994.tb19996.x; THIGPEN AE, 1993, J BIOL CHEM, V268, P17404; VALTERSSON C, 1985, J BIOL CHEM, V260, P2742; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; YOON KL, 1994, J BIOL CHEM, V269, P28249; ZARA J, 1994, J BIOL CHEM, V269, P19108; ZHU XY, 1990, J BIOL CHEM, V265, P14250; ZHU XY, 1992, J BIOL CHEM, V267, P8895; ZOU J, 1995, ARCH BIOCHEM BIOPHYS, V317, P487, DOI 10.1006/abbi.1995.1192	42	32	38	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30717	30724		10.1074/jbc.271.48.30717	http://dx.doi.org/10.1074/jbc.271.48.30717			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940049	hybrid			2022-12-25	WOS:A1996VV15800066
J	Greene, J; Wang, MS; Liu, YLE; Raymond, LA; Rosen, C; Shi, YNE				Greene, J; Wang, MS; Liu, YLE; Raymond, LA; Rosen, C; Shi, YNE			Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-SITU HYBRIDIZATION; C-TERMINAL DOMAIN; TIMP GENE FAMILY; GELATINASE-A; MATRIX METALLOPROTEINASES; MESSENGER-RNAS; CELL-LINES; HORMONAL-REGULATION; BREAST CARCINOMAS; IV COLLAGENASE	The tissue inhibitors of metalloproteinases (TIMPs) constitute a family of proteins, of which three members have so far been described. Using the expressed sequence tag sequencing approach, we have identified a novel TIMP-related cDNA fragment and subsequently cloned a fourth human TIMP (TIMP-4) from a human heart cDNA library. The open reading frame encodes a 224-amino acid precursor including a 29-residue secretion signal. The predicted structure of the new protein shares 37% sequence identity with TIMP-1 and 51% identity with TIMP-2 and -3. The protein has a predicted isoelectric point of 7.34. The open reading frame-directed expression of TIMP-4 protein in MDA-MB-435 human breast cancer cells showed metalloproteinase inhibitory activity on reverse zymography. By Northern analysis, only the adult heart showed abundant TIMP-4 transcripts with a 1.4-kilobase predominant transcript band; very low levels of the transcripts were detected in the kidney, placenta, colon, and testes, and no transcripts were detected in the liver, brain, lung, thymus, and spleen. This unique expression pattern suggests that TIMP-4 may function in a tissue-specific fashion in extracellular matrix homeostasis.	HUMAN GENOME SCI INC,ROCKVILLE,MD 20850; ALBERT EINSTEIN COLL MED,LONG ISL JEWISH MED CTR,DEPT PEDIAT,NEW HYDE PK,NY 11042	GlaxoSmithKline; Human Genome Sciences Inc; Northwell Health; Yeshiva University					NATIONAL CANCER INSTITUTE [R29CA068064] Funding Source: NIH RePORTER; NCI NIH HHS [CA68064-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ALVAREZ OA, 1990, J NATL CANCER I, V82, P589, DOI 10.1093/jnci/82.7.589; APODACA G, 1990, CANCER RES, V50, P2322; APTE SS, 1995, J BIOL CHEM, V270, P14313, DOI 10.1074/jbc.270.24.14313; AZZAM HS, 1993, J NATL CANCER I, V85, P1758, DOI 10.1093/jnci/85.21.1758; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BASSET P, 1994, CANCER-AM CANCER SOC, V74, P1045, DOI 10.1002/1097-0142(19940801)74:3+<1045::AID-CNCR2820741511>3.0.CO;2-7; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; CARMICHAEL DF, 1986, P NATL ACAD SCI USA, V83, P2407, DOI 10.1073/pnas.83.8.2407; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DECLERCK YA, 1993, BIOCHEM J, V289, P65, DOI 10.1042/bj2890065; DECLERCK YA, 1992, CANCER RES, V52, P701; Denhardt D T, 1992, Matrix Suppl, V1, P281; DENHARDT DT, 1993, PHARMACOL THERAPEUT, V59, P329, DOI 10.1016/0163-7258(93)90074-N; DOCHERTY AJP, 1992, TRENDS BIOTECHNOL, V10, P200, DOI 10.1016/0167-7799(92)90214-G; EDWARDS DR, 1992, BIOCHIM BIOPHYS ACTA, V1171, P41, DOI 10.1016/0167-4781(92)90138-P; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; HOYHTYA M, 1994, INT J CANCER, V56, P500, DOI 10.1002/ijc.2910560408; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KHOKHA R, 1994, J NATL CANCER I, V86, P299, DOI 10.1093/jnci/86.4.299; KLEINER DE, 1992, BIOCHEMISTRY-US, V31, P1665, DOI 10.1021/bi00121a013; KOSSAKOWSKA AE, 1991, BLOOD, V77, P2475; LECO KJ, 1994, J BIOL CHEM, V269, P9352; LENNARZ WJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P149, DOI 10.1016/0304-4157(91)90022-O; Liotta L A, 1990, Semin Cancer Biol, V1, P99; LOTZ M, 1991, J BIOL CHEM, V266, P2017; MANN JS, 1991, ENDOCRINOLOGY, V128, P1825, DOI 10.1210/endo-128-4-1825; MCLESKEY SW, 1993, CANCER RES, V53, P2168; MIYAZAKI K, 1993, J BIOL CHEM, V268, P14387; MOHANAM S, 1995, CLIN EXP METASTAS, V13, P57, DOI 10.1007/BF00144019; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; NAYLOR MS, 1994, INT J CANCER, V58, P50, DOI 10.1002/ijc.2910580110; POLETTE M, 1993, INVAS METAST, V13, P31; POLETTE M, 1994, VIRCHOWS ARCH, V424, P641, DOI 10.1007/BF01069745; POLETTE M, 1993, PATHOL RES PRACT, V189, P1052; POULSOM R, 1993, J CLIN PATHOL, V46, P429, DOI 10.1136/jcp.46.5.429; PYKE C, 1993, AM J PATHOL, V142, P359; SATO T, 1991, BIOCHEM J, V275, P645, DOI 10.1042/bj2750645; STASKUS PW, 1991, J BIOL CHEM, V266, P449; STETLERSTEVENSON WG, 1990, J BIOL CHEM, V265, P13933; TESTA JE, 1992, CANCER RES, V52, P5597; TSUCHIYA Y, 1993, CANCER RES, V53, P1397; URIA JA, 1994, CANCER RES, V54, P2091; VISSCHER DW, 1994, INT J CANCER, V59, P339, DOI 10.1002/ijc.2910590308; WICK M, 1994, J BIOL CHEM, V269, P18953; WILDE CG, 1994, DNA CELL BIOL, V13, P711, DOI 10.1089/dna.1994.13.711; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; WILLIAMSON RA, 1990, BIOCHEM J, V268, P267, DOI 10.1042/bj2680267; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WOLF C, 1993, P NATL ACAD SCI USA, V90, P1843, DOI 10.1073/pnas.90.5.1843	52	363	396	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30375	30380		10.1074/jbc.271.48.30375	http://dx.doi.org/10.1074/jbc.271.48.30375			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8939999	hybrid			2022-12-25	WOS:A1996VV15800016
J	Igarashi, T; Kono, Y; Tanaka, K				Igarashi, T; Kono, Y; Tanaka, K			Molecular cloning of manganese catalase from Lactobacillus plantarum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; THERMUS-THERMOPHILUS; BEEF-LIVER; T-CATALASE; PROTEINS; RESOLUTION; PSEUDOCATALASE; STATE	A genomic clone encoding manganese-containing catalase has been isolated from lactic acid bacterium Lactobacillus plantarum, sequenced, and expressed in Escherichia coli cells with an inducible expression system. The primary structure of the enzyme deduced from the nucleotide sequence, that comprises 266 amino acid residues, showed no significant homology with that of any other proteins registered on the available data bases. No peptide motifs conserved among active sites of proteins including manganese-containing enzymes were found. The E. coli cells carrying an expression construct, in which the 5'-noncoding region of the manganese catalase gene was replaced with the lac promoter, highly induced a protein reacting with the antiserum to manganese catalase. The prediction of secondary structure from the deduced primary structure suggested that the L. plantarum manganese catalase, that is classified as a novel protein on the basis of its primary structure, has a main structural motif formed by four near parallel helices between which is the catalytic site manganese.	SHIMANE UNIV, FAC LIFE & ENVIRONM SCI, DEPT LIFE SCI & BIOTECHNOL, MATSUE, SHIMANE 690, JAPAN; TOTTORI UNIV, FAC AGR, DEPT BIOCHEM & BIOTECHNOL, LAB PLANT BIOTECHNOL, TOTTORI 680, JAPAN	Shimane University; Tottori University	Igarashi, T (corresponding author), NATL INST ENVIRONM STUDIES, DIV ENVIRONM BIOL, TSUKUBA, IBARAKI 305, JAPAN.							ALLGOOD GS, 1986, J BACTERIOL, V168, P563, DOI 10.1128/jb.168.2.563-567.1986; BALDWIN ET, 1990, THESIS U N CAROLINA; BARYNIN VV, 1986, DOKL AKAD NAUK SSSR+, V288, P877; BARYNIN VV, 1986, DOKL AKAD NAUK SSSR+, V286, P461; BERNS KI, 1965, J MOL BIOL, V11, P476, DOI 10.1016/S0022-2836(65)80004-3; BEYER WF, 1985, BIOCHEMISTRY-US, V24, P6460, DOI 10.1021/bi00344a023; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; FRONKO RM, 1988, J AM CHEM SOC, V110, P7554, DOI 10.1021/ja00230a055; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GREGORY EM, 1974, ANAL BIOCHEM, V58, P57, DOI 10.1016/0003-2697(74)90440-0; IVANCICH A, 1995, BIOCHEMISTRY-US, V34, P6628, DOI 10.1021/bi00020a008; KHANGULOV SV, 1990, BIOCHIM BIOPHYS ACTA, V1020, P25, DOI 10.1016/0005-2728(90)90089-M; KONO Y, 1983, J BIOL CHEM, V258, P6015; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T, 1989, MOL CLONING; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; MELIKADAMYAN WR, 1986, J MOL BIOL, V188, P63, DOI 10.1016/0022-2836(86)90480-8; MURSHUDOV GN, 1992, FEBS LETT, V312, P127, DOI 10.1016/0014-5793(92)80919-8; MURTHY MRN, 1981, J MOL BIOL, V152, P465, DOI 10.1016/0022-2836(81)90254-0; Penner-Hahn J.E., 1992, MANGANESE REDOX ENZY, P29; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; SHANK M, 1994, BIOCHEMISTRY-US, V33, P15433, DOI 10.1021/bi00255a025; SHERIFF S, 1987, J MOL BIOL, V197, P273, DOI 10.1016/0022-2836(87)90124-0; TAKEDA Y, 1986, NUCLEIC ACIDS RES, V14, P4577, DOI 10.1093/nar/14.11.4577; VAINSHTEIN BK, 1985, J BIOSCIENCE, V8, P471, DOI 10.1007/BF02703998; VILLAFRANCA JJ, 1974, J BIOL CHEM, V249, P3532; WALDO GS, 1995, BIOCHEMISTRY-US, V34, P1507, DOI 10.1021/bi00005a006; WALDO GS, 1991, BIOCHEMISTRY-US, V30, P10486, DOI 10.1021/bi00107a017; WEBER PC, 1980, NATURE, V287, P82, DOI 10.1038/287082a0; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	30	58	62	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29521	29524		10.1074/jbc.271.47.29521	http://dx.doi.org/10.1074/jbc.271.47.29521			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939876	hybrid			2022-12-25	WOS:A1996VU52500004
J	Panda, D; Jordan, MA; Chu, KC; Wilson, L				Panda, D; Jordan, MA; Chu, KC; Wilson, L			Differential effects of vinblastine on polymerization and dynamics at opposite microtubule ends	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDIVIDUAL MICROTUBULES; MITOTIC SPINDLE; GTP HYDROLYSIS; ANTIMICROTUBULE AGENTS; TRANSITION FREQUENCIES; KINETIC STABILIZATION; CELL-PROLIFERATION; INTERPHASE CELLS; VINCA ALKALOIDS; PLUS-END	We have characterized the effects of vinblastine on the growing and shortening dynamics at opposite ends of individual bovine brain microtubules at steady state in vitro by video microscopy. Vinblastine exerted strikingly different effects on the dynamics and polymer mass at the plus and minus ends of microtubules. At concentrations between 0.1 and 0.4 mu M, the drug strongly depolymerized microtubules at minus ends, whereas it did not significantly depolymerize microtubules at plus ends, Vinblastine stabilized plus ends by suppressing the rate and extent of growth and shortening, decreasing the catastrophe frequency, and increasing the rescue frequency, In contrast, vinblastine destabilized minus ends by increasing the catastrophe frequency and decreasing the rescue frequency, whereas it had no effect on the rate or extent of growth or shortening, Thus, vinblastine moderately increased the overall dynamicity at minus ends while strongly suppressing dynamicity at plus ends. Both the kinetic destabilization of microtubules at minus ends and the stabilization at plus ends may contribute to the altered function of mitotic spindle Microtubules of cells blocked in mitosis by low concentrations of vinblastine.			Panda, D (corresponding author), UNIV CALIF SANTA BARBARA, DEPT MOL CELLULAR & DEV BIOL, SANTA BARBARA, CA 93106 USA.							BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burns Roy G., 1994, V13, P3; CARLIER MF, 1989, INT REV CYTOL, V115, P139; CASSIMERIS L, 1988, CELL MOTIL CYTOSKEL, V10, P185, DOI 10.1002/cm.970100123; CUTTS JH, 1960, CANCER RES, V20, P1023; DAVIDPFEUTY T, 1979, J BIOL CHEM, V254, P1696; DHAMODHARAN R, 1995, MOL BIOL CELL, V6, P1215, DOI 10.1091/mbc.6.9.1215; GLIKSMAN NR, 1993, MOL BIOL CELL, V4, P1035, DOI 10.1091/mbc.4.10.1035; HAYDEN JH, 1990, J CELL BIOL, V111, P1039, DOI 10.1083/jcb.111.3.1039; HIMES RH, 1976, CANCER RES, V36, P3798; HORIO T, 1986, NATURE, V321, P605, DOI 10.1038/321605a0; HYMAN AA, 1995, J CELL BIOL, V128, P117, DOI 10.1083/jcb.128.1.117; JORDAN MA, 1990, BIOCHEMISTRY-US, V29, P2730, DOI 10.1021/bi00463a016; JORDAN MA, 1991, CANCER RES, V51, P2212; JORDAN MA, 1992, J CELL SCI, V102, P401; JORDAN MA, 1986, J MOL BIOL, V187, P61, DOI 10.1016/0022-2836(86)90406-7; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; KOWALSKI RJ, 1993, CELL MOTIL CYTOSKEL, V26, P282, DOI 10.1002/cm.970260403; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; LUDUENA RF, 1991, PHARMACOL THERAPEUT, V49, P133, DOI 10.1016/0163-7258(91)90027-J; MARGOLIS RL, 1981, NATURE, V293, P705, DOI 10.1038/293705a0; MICKEY B, 1995, J CELL BIOL, V130, P909, DOI 10.1083/jcb.130.4.909; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MITCHISON TJ, 1993, SCIENCE, V261, P1044, DOI 10.1126/science.8102497; MITCHISON TJ, 1989, J CELL BIOL, V109, P637, DOI 10.1083/jcb.109.2.637; NA GC, 1980, BIOCHEMISTRY-US, V19, P1347, DOI 10.1021/bi00548a013; NA GC, 1982, J MOL BIOL, V160, P499; OBRIEN ET, 1987, BIOCHEMISTRY-US, V26, P4148, DOI 10.1021/bi00387a061; PANDA D, 1995, BIOCHEMISTRY-US, V34, P9921, DOI 10.1021/bi00031a014; PIERSON GB, 1978, J CELL BIOL, V76, P223, DOI 10.1083/jcb.76.1.223; RIEDER CL, 1990, ELECTRON MICROSC REV, V3, P269, DOI 10.1016/0892-0354(90)90005-D; ROWINSKY EK, 1991, PHARMACOL THERAPEUT, V52, P35, DOI 10.1016/0163-7258(91)90086-2; SAXTON WM, 1984, J CELL BIOL, V99, P2175, DOI 10.1083/jcb.99.6.2175; SCHULZE E, 1986, J CELL BIOL, V102, P1020, DOI 10.1083/jcb.102.3.1020; SINGER WD, 1989, MOL PHARMACOL, V36, P366; SONG YH, 1995, J CELL BIOL, V128, P81, DOI 10.1083/jcb.128.1.81; Spittle CS, 1996, CELL MOTIL CYTOSKEL, V34, P324; STEWART RJ, 1990, BIOCHEMISTRY-US, V29, P6489, DOI 10.1021/bi00479a022; TOSO RJ, 1993, BIOCHEMISTRY-US, V32, P1285, DOI 10.1021/bi00056a013; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; WENDELL KL, 1993, J CELL SCI, V104, P261; WILSON L, 1982, J MOL BIOL, V159, P125, DOI 10.1016/0022-2836(82)90035-3; Wilson Leslie, 1994, V13, P59	44	93	120	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29807	29812		10.1074/jbc.271.47.29807	http://dx.doi.org/10.1074/jbc.271.47.29807			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939919	hybrid			2022-12-25	WOS:A1996VU52500047
J	Sakakibara, H; Shimizu, H; Hase, T; Yamazaki, Y; Takao, T; Shimonishi, Y; Sugiyama, T				Sakakibara, H; Shimizu, H; Hase, T; Yamazaki, Y; Takao, T; Shimonishi, Y; Sugiyama, T			Molecular identification and characterization of cytosolic isoforms of glutamine synthetase in maize roots	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHASEOLUS-VULGARIS L; AMINO-ACID SEQUENCE; DIFFERENTIAL EXPRESSION; ESCHERICHIA-COLI; GENE FAMILY; LEAVES; SYNTHASE; PROTEINS; NODULES; CLONING	In maize, a small multigene family encodes the cytosolic isoforms of glutamine synthetase (GS), and five cDNAs, designated pGS1a, pGS1b, pGS1c, pGS1d, and pGS1e, have been cloned (Sakakibara, H., Kawabata, S., Takahashi, H., Hase, T., and Sugiyama, T. (1992) Plant Cell Physiol. 33, 49-58; Li, M., Villemur, R., Hussey, P. J., Silflow, C. D., Gantt, J. S., and Snustad, D. P. (1993) Plant Mel. Biol. 23, 401-407). This report describes the identification and enzymatic characterization of the cytosolic isoforms of GS in maize roots, namely GS1 and GSr. The purified isoforms, as well as recombinant enzymes that had been overexpressed in Escherichia coli, were analyzed by capillary liquid chromatography/electrospray ionization-mass spectrometry, and GSI and GSr were identified as the products of the GS1a/GS1b and GS1c/GS1d genes, respectively. Upon the addition of ammonia to the culture medium, significant amounts of GSr accumulated and a preferential increase in GS synthetase activity, as compared to G:S transferase activity, was found in the root extract. Assays with the purified recombinant enzymes confirmed that the specific biosynthetic and synthetase activities of GSr were 1.6-fold higher than those of GS1. Marked differences in stability were also found between the two isoforms: GSr was more sensitive to heat than GS1 and octameric aggregates of the subunits of GSr were easily dissociated to monomers than those of GS1 at low concentrations of Mn2+ and Mg2+ ions. These characteristics of the ammonia-induced isoform of GS seem to be physiologically important for the primary assimilation of external ammonia by roots.	OSAKA UNIV, INST PROT RES, SUITA, OSAKA 565, JAPAN	Osaka University	Sakakibara, H (corresponding author), NAGOYA UNIV, SCH AGR SCI, DEPT APPL BIOL SCI, NAGOYA, AICHI 46401, JAPAN.		Sakakibara, Hitoshi/A-6040-2010; Hase, Toshiharu/H-9271-2013	Sakakibara, Hitoshi/0000-0001-5449-6492; 				Arnon DI, 1940, SOIL SCI, V50, P463; BENNETT MJ, 1989, PLANTA, V179, P433, DOI 10.1007/BF00397582; BENNETT MJ, 1989, PLANT MOL BIOL, V12, P553, DOI 10.1007/BF00036969; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COCK JM, 1990, PLANT MOL BIOL, V14, P549, DOI 10.1007/BF00027500; COLOMBO G, 1986, J BIOL CHEM, V261, P587; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P622; CULLIMORE JV, 1980, PLANTA, V150, P392, DOI 10.1007/BF00390175; CULLIMORE JV, 1992, SOC EXP BIOL SEMIN S, V49, P79, DOI 10.1017/CBO9780511600395.005; DELAMARTER JF, 1985, EMBO J, V4, P2575, DOI 10.1002/j.1460-2075.1985.tb03973.x; GEBHARDT C, 1986, EMBO J, V5, P1429, DOI 10.1002/j.1460-2075.1986.tb04379.x; HASE T, 1991, PLANT PHYSIOL, V97, P1395, DOI 10.1104/pp.97.4.1395; HEINRIKSON RL, 1971, J BIOL CHEM, V246, P1099; HIREL B, 1987, EMBO J, V6, P1167, DOI 10.1002/j.1460-2075.1987.tb02350.x; HIREL B, 1980, PLANT PHYSIOL, V66, P619, DOI 10.1104/pp.66.4.619; KNIGHT TJ, 1988, J BIOL CHEM, V263, P11084; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lea P.J., 1990, METHODS PLANT BIOCH, V3, P257, DOI [10.1016/B978-0-12-461013-2.50022-8, DOI 10.1016/B978-0-12-461013-2.50022-8]; Lea PJ, 1990, INTERMEDIARY NITROGE, V16, P121, DOI [10.1016/B978-0-08-092616-2.50010-3, DOI 10.1016/B978-0-08-092616-2.50010-3]; LI MG, 1993, PLANT MOL BIOL, V23, P401, DOI 10.1007/BF00029015; MANCO G, 1992, J GEN MICROBIOL, V138, P1453, DOI 10.1099/00221287-138-7-1453; MANN AF, 1979, BIOCHEM BIOPH RES CO, V88, P515, DOI 10.1016/0006-291X(79)92078-3; Miflin B. J., 1980, The biochemistry of plants. A comprehensive treatise. Volume 5. Amino acids and derivatives., P169; MITCHELL AP, 1984, J BIOL CHEM, V259, P2054; MURATA H, 1994, RAPID COMMUN MASS SP, V8, P205, DOI 10.1002/rcm.1290080216; MURATA H, 1993, ANAL BIOCHEM, V210, P206, DOI 10.1006/abio.1993.1174; PALACIOS R, 1976, J BIOL CHEM, V251, P4787; PETERMAN TK, 1991, MOL GEN GENET, V230, P145, DOI 10.1007/BF00290662; RHEE SG, 1989, ADV ENZYMOL RAMB, V62, P37; SAKAKIBARA H, 1992, PLANT CELL PHYSIOL, V33, P1193; SAKAKIBARA H, 1991, J BIOL CHEM, V266, P2028; SAKAKIBARA H, 1992, PLANT CELL PHYSIOL, V33, P49; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHAPIRO BM, 1967, J BIOL CHEM, V242, P5069; SHAPIRO BM, 1968, BIOCHEMISTRY-US, V7, P2153, DOI 10.1021/bi00846a018; STANFORD AC, 1993, PLANT PHYSIOL, V103, P73, DOI 10.1104/pp.103.1.73; TINGEY SV, 1987, EMBO J, V6, P1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VEZINA LP, 1989, PLANT PHYSIOL, V90, P1129, DOI 10.1104/pp.90.3.1129; WADSWORTH GJ, 1988, ANAL BIOCHEM, V172, P279, DOI 10.1016/0003-2697(88)90443-5; WOOLFOLK CA, 1967, ARCH BIOCHEM BIOPHYS, V122, P174, DOI 10.1016/0003-9861(67)90137-3	41	64	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29561	29568		10.1074/jbc.271.47.29561	http://dx.doi.org/10.1074/jbc.271.47.29561			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939884	hybrid			2022-12-25	WOS:A1996VU52500012
J	Swarts, HGP; Klaassen, CHW; deBoer, M; Fransen, JAM; DePont, JJHHM				Swarts, HGP; Klaassen, CHW; deBoer, M; Fransen, JAM; DePont, JJHHM			Role of negatively charged residues in the fifth and sixth transmembrane domains of the catalytic subunit of gastric H+,K+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; RAT-KIDNEY NA+,K+-ATPASE; INHIBITORY MONOCLONAL-ANTIBODY; IN-VITRO TRANSLATION; SARCOPLASMIC-RETICULUM; ALPHA-SUBUNIT; CATION-BINDING; H+/K+-ATPASE; FUNCTIONAL CONSEQUENCES; MEMBRANE TOPOLOGY	The role of six negatively charged residues located in or around the fifth and sixth transmembrane domain of the catalytic subunit of gastric H+,K+-ATPase, which are conserved in P-type ATPases, was investigated by site-directed mutagenesis of each of these residues. The acid residues were converted into their corresponding acid amides, Sf9 cells were used as the expression system using a baculovirus with coding sequences for the alpha- and beta-subunits of H+,K+-ATPase behind two different promoters, Both subunits of all mutants were expressed like the wild type enzyme in intracellular membranes of Sf9 cells as indicated by Western blotting experiments, an enzyme-linked immunosorbent assay, and confocal laser scan microscopy studies, The mutants D824N, E834Q, E837Q, and D839N showed no 3-(cyanomethyl)-2-methyl-8(phenylmethoxy)-imidazo[1,2a]pyridine (SCH 28080)-sensitive ATP dependent phosphorylation capacity, Mutants E795Q and E820Q formed a phosphorylated intermediate, which, like the wild type enzyme, was hydroxylamine-sensitive, indicating that an acylphosphate was formed, Formation of the phosphorylated intermediate from the E795Q mutant was similarly inhibited by K+ (I-50 = 0.4 mM) and SCH 28080 (I-50 = 10 nM) as the wild type enzyme, when the membranes were preincubated with these ligands before phosphorylation, The dephosphorylation reaction was K+-sensitive, whereas ADP had hardly any effect, Formation of the phosphorylated intermediate of mutant E820Q was much less sensitive toward K+ (I-50 = 4.5 mM) and SCH 28080 (I-50 = 1.7 mu M) than the wild type enzyme, The dephosphorylation reaction of this intermediate was not stimulated by either K+ or ADP, In contrast to the wild type enzyme and mutant E795Q, mutant E820Q did not show any K+-stimulated ATPase activity, These findings indicate that residue Glu(820) might be involved in K+ binding and transition to the E(2) form of gastric H+,K+-ATPase.	UNIV NIJMEGEN,DEPT BIOCHEM,NL-6500 HB NIJMEGEN,NETHERLANDS; UNIV NIJMEGEN,INST CELLULAR SIGNALLING,DEPT CELL BIOL & HISTOL,NL-6500 HB NIJMEGEN,NETHERLANDS	Radboud University Nijmegen; Radboud University Nijmegen			Fransen, Jack/E-8924-2010	Fransen, Jack/0000-0002-0571-7639				ADEBAYO AO, 1995, J BIOL CHEM, V270, P27812, DOI 10.1074/jbc.270.46.27812; ANDERSEN JP, 1994, J BIOL CHEM, V269, P15931; ANDERSEN JP, 1994, FEBS LETT, V354, P93, DOI 10.1016/0014-5793(94)01100-1; ANDERSEN JP, 1992, J BIOL CHEM, V267, P19383; Andersen JP, 1995, BIOSCIENCE REP, V15, P243, DOI 10.1007/BF01788358; ANDERSEN JP, 1995, FEBS LETT, V359, P101, DOI 10.1016/0014-5793(95)00019-6; ARGUELLO JM, 1991, J BIOL CHEM, V266, P14627; ARGUELLO JM, 1994, J BIOL CHEM, V269, P6892; Asano S, 1996, J BIOL CHEM, V271, P2740, DOI 10.1074/jbc.271.5.2740; BAMBERG K, 1994, J BIOL CHEM, V269, P16909; BAYLE D, 1995, J BIOL CHEM, V270, P25678, DOI 10.1074/jbc.270.43.25678; BESANCON M, 1993, BIOCHEMISTRY-US, V32, P2345, DOI 10.1021/bi00060a028; BLANCO G, 1994, J BIOL CHEM, V269, P23420; BLOSTEIN R, 1993, J BIOL CHEM, V268, P10654; BRENNA E, 1994, GUT, V35, P1547, DOI 10.1136/gut.35.11.1547; CHOW DC, 1993, AM J PHYSIOL, V265, pC1562, DOI 10.1152/ajpcell.1993.265.6.C1562; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; DETOMASO AW, 1993, J BIOL CHEM, V268, P1470; FENG JN, 1995, CELL MOL BIOL RES, V41, P29; GOLDSHLEGER R, 1995, BIOCHEMISTRY-US, V34, P8668, DOI 10.1021/bi00027a016; GOLDSHLEGER R, 1992, P NATL ACAD SCI USA, V89, P6911, DOI 10.1073/pnas.89.15.6911; HELMICHDEJONG ML, 1985, BIOCHIM BIOPHYS ACTA, V821, P377, DOI 10.1016/0005-2736(85)90041-0; HERSEY SJ, 1995, PHYSIOL REV, V75, P155, DOI 10.1152/physrev.1995.75.1.155; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13523, DOI 10.1021/bi00212a018; KEELING DJ, 1989, J BIOL CHEM, V264, P5545; KLAASSEN CHW, 1994, CELL PHYSIOL BIOCHEM, V4, P115, DOI 10.1159/000154716; KLAASSEN CHW, 1995, BIOCHEM BIOPH RES CO, V210, P907, DOI 10.1006/bbrc.1995.1743; KLAASSEN CHW, 1993, FEBS LETT, V329, P277, DOI 10.1016/0014-5793(93)80237-O; Koster JC, 1996, J BIOL CHEM, V271, P2413, DOI 10.1074/jbc.271.5.2413; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUTSENKO S, 1995, P NATL ACAD SCI USA, V92, P7936, DOI 10.1073/pnas.92.17.7936; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MATTHEWS PM, 1995, AM J PHYSIOL, V37, pC1207; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; RAY TK, 1976, BIOCHIM BIOPHYS ACTA, V443, P451, DOI 10.1016/0005-2736(76)90465-X; Sambrook J., 2002, MOL CLONING LAB MANU; SHIN JM, 1993, BIOCHIM BIOPHYS ACTA, V1148, P223, DOI 10.1016/0005-2736(93)90133-K; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1985, NATURE, V316, P391; SKERJANC IS, 1993, J BIOL CHEM, V268, P15944; SMOLKA A, 1991, BIOCHEM BIOPH RES CO, V180, P1356, DOI 10.1016/S0006-291X(05)81345-2; SWARTS HGP, 1995, J BIOL CHEM, V270, P7890, DOI 10.1074/jbc.270.14.7890; SWARTS HGP, 1991, BIOCHIM BIOPHYS ACTA, V1070, P283, DOI 10.1016/0005-2736(91)90068-J; SWEADNER KJ, 1992, ANN NY ACAD SCI, V671, P217, DOI 10.1111/j.1749-6632.1992.tb43798.x; VANDERHIJDEN HTWM, 1991, BIOCHIM BIOPHYS ACTA, V1061, P141, DOI 10.1016/0005-2736(91)90278-G; VANDEYAR MA, 1988, GENE, V65, P129, DOI 10.1016/0378-1119(88)90425-8; VANHUYSSE JW, 1993, BIOCHEMISTRY-US, V32, P819, DOI 10.1021/bi00054a012; VANHUYSSE JW, 1993, CELL MOL BIOL RES, V39, P497; VANUEM TJF, 1991, BIOCHEM J, V280, P243, DOI 10.1042/bj2800243; VANUEM TJF, 1990, BIOCHIM BIOPHYS ACTA, V1023, P56, DOI 10.1016/0005-2736(90)90009-D; VANUEM TJF, 1992, MOL ASPECTS TRANSPOR, P27; VERMA AK, 1988, J BIOL CHEM, V263, P14152; VILSEN B, 1992, J BIOL CHEM, V267, P25739; VILSEN B, 1993, BIOCHEMISTRY-US, V32, P13340, DOI 10.1021/bi00211a048; VILSEN B, 1995, BIOCHEMISTRY-US, V34, P1455, DOI 10.1021/bi00004a041; VILSEN B, 1993, FEBS LETT, V333, P44, DOI 10.1016/0014-5793(93)80372-2; VLAK JM, 1990, VIROLOGY, V179, P312, DOI 10.1016/0042-6822(90)90299-7	60	74	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29764	29772		10.1074/jbc.271.47.29764	http://dx.doi.org/10.1074/jbc.271.47.29764			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939913	Green Published, hybrid			2022-12-25	WOS:A1996VU52500041
J	Zanke, BW; Rubie, EA; Winnett, E; Chan, J; Randall, S; Parsons, M; Boudreau, K; McInnis, M; Yan, MH; Templeton, DJ; Woodgett, JR				Zanke, BW; Rubie, EA; Winnett, E; Chan, J; Randall, S; Parsons, M; Boudreau, K; McInnis, M; Yan, MH; Templeton, DJ; Woodgett, JR			Mammalian mitogen-activated protein kinase pathways are regulated through formation of specific kinase-activator complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; HEAT-SHOCK PROTEINS; C-JUN; MAPKAP KINASE-2; PHOSPHORYLATION; STRESS; CASCADE; YEAST; CELLS; DOMAIN	Mammalian cells contain at least three signaling systems which are structurally related to the mitogen-activated protein kinase (MAPK) pathway, Growth factors acting through Ras primarily stimulate the Raf/MEK/MAPK cascade of protein kinases, In contrast, many stress-related signals such as heat shock, inflammatory cytokines, and hyperosmolarity induce the MEKK/SEK(MKK4)/SAPK(JNK) and/or the MKK3 or MKK6/p38(hog) pathways. Physiological agonists of these pathway types are either qualitatively or quantitatively distinct, suggesting few common proximal signaling elements, although past studies performed in vitro, or in cells using transient over-expression, reveal interaction between the components of all three pathways, These studies suggest a high degree of cross-talk apparently not seen in vivo. We have examined the possible molecular basis of the differing agonist profiles of these three MAPK pathways, We report preferential association between MAP kinases and their activators in eukaryotic cells. Furthermore, using the yeast 8-hybrid system, we show that association between these components can occur independent of additional eukaryotic proteins, We show that SAPK(JNK) or p38(hog) activation is specifically impaired by co-expression of cognate dominant negative MAP kinase kinase mutants, demonstrating functional specificity at this level. Further divergence and insulation of the stress pathways occurs proximal to the MAPK kinases since activation of the MAPK kinase kinase MEKK results in SAPK(JNK) activation but does not cause p38(hog) phosphorylation, Therefore, in intact cells, the three MAPK pathways may be independently regulated and their components show specificity in their interaction with cognate cascade members, The degree of intermolecular specificity suggests that mammalian MAPK signaling pathways may remain distinct without the need for specific scaffolding proteins to sequester components of individual pathways.	PRINCESS MARGARET HOSP,ONTARIO CANC INST,TORONTO,ON M5G 2M9,CANADA; CASE WESTERN RESERVE UNIV,INST PATHOL,CLEVELAND,OH 44106	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Case Western Reserve University	Zanke, BW (corresponding author), PRINCESS MARGARET HOSP,DEPT MED,610 UNIV AVE,TORONTO,ON M5G 2M9,CANADA.		McInnes, Matthew/D-4532-2013; Templeton, Dennis J/F-7695-2011; Woodgett, Jim/F-1087-2010	McInnes, Matthew/0000-0001-8404-4075; Woodgett, Jim/0000-0003-3731-5797				BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CHOI KY, 1994, CELL, V78, P499; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; HAHN GM, 1988, CANCER RES, V48, P1803; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LASZLO A, 1993, INT J RADIAT BIOL, V63, P569, DOI 10.1080/09553009314450751; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; LIN A, 1993, ADV SEC MESS PHOSPH, V28, P255; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; POMBO CM, 1994, J BIOL CHEM, V269, P26546; PRINTEN JA, 1994, GENETICS, V138, P609; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; XIA A, 1996, SCIENCE, V270, P1326; YAN MH, 1994, NATURE, V372, P798; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	36	102	104	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29876	29881		10.1074/jbc.271.47.29876	http://dx.doi.org/10.1074/jbc.271.47.29876			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939929	hybrid			2022-12-25	WOS:A1996VU52500057
J	Rizzo, C; Califano, D; ColucciDAmato, GL; DeVita, G; DAlessio, A; Dathan, NA; Fusco, A; Monaco, C; Santelli, G; Vecchio, G; Santoro, M; deFranciscis, V				Rizzo, C; Califano, D; ColucciDAmato, GL; DeVita, G; DAlessio, A; Dathan, NA; Fusco, A; Monaco, C; Santelli, G; Vecchio, G; Santoro, M; deFranciscis, V			Ligand stimulation of a Ret chimeric receptor carrying the activating mutation responsible for the multiple endocrine neoplasia type 2B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; TYROSINE KINASE; PC12 CELLS; PROTOONCOGENE; GENE; SPECIFICITY; SEQUENCE; CLONING; LINE; 2A	Inherited activating mutations of Ret, a receptor tyrosine kinase, predispose to multiple endocrine neoplasia (MEN) types 2A and 2B and familial medullary thyroid carcinoma. To investigate the effects induced by acute stimulation of Ret, we transfected both PC12 and NIH 3T3 cells with a molecular construct in which the ligand-binding domain of the epidermal growth factor receptor was fused to the catalytic domain of Ret. Acute stimulation of the chimeric receptor induced PC12 cells to express a neuronal-like phenotype. Moreover, we introduced the dominant mutation, responsible for the multiple endocrine neoplasia type 2B, in the catalytic domain of the Ret chimera. Expression of the mutant chimera, in the absence of ligand stimulation, induces the PC12 cells to acquire a flat morphology with short neuritic processes and transforms the NIH 3T3 cells. Stimulation of the mutant chimera with epidermal growth factor causes a drastic overgrowth of long neuritic processes, with the induction of the suc1-associated protein tyrosine phosphorylation in PC12 cells and higher transforming efficiency in NIH 3T3 cells. These data indicate that the gain-of-function MEN2B mutation does not abrogate ligand responsiveness of Ret and suggest that the presence of Ret ligand could play a role in the pathogenesis of the MEN2B syndrome.	UNIV NAPLES FEDERICO II,CNR,CTR ENDOCRINOL & ONCOL SPERIMENTALE,FAC MED & CHIRURG,I-80131 NAPLES,ITALY; UNIV REGGIO CALABRIA,DIPARTIMENTO MED SPERIMENTALE & CLIN,I-88100 CATANZARO,ITALY; FDN G PASCALE,IST NAZL TUMORI,I-80131 NAPLES,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Universita Mediterranea di Reggio Calabria; IRCCS Fondazione Pascale			Califano, Daniela/Y-6313-2018; De Vita, Gabriella/H-4422-2011	Califano, Daniela/0000-0001-6945-3209; De Vita, Gabriella/0000-0002-7302-1174; Fusco, Alfredo/0000-0003-3332-5197				ASAI N, 1995, MOL CELL BIOL, V15, P1613; Borrello MG, 1995, ONCOGENE, V11, P2419; CALIFANO D, 1995, ONCOGENE, V11, P107; Califano D, 1996, P NATL ACAD SCI USA, V93, P7933, DOI 10.1073/pnas.93.15.7933; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; GOODFELLOW PJ, 1994, CURR OPIN GENET DEV, V4, P446, DOI 10.1016/0959-437X(94)90034-5; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; LEVI A, 1991, ANNU REV PHARMACOL, V31, P205; LEVI A, 1985, SCIENCE, V229, P393, DOI 10.1126/science.3839317; Mak YF, 1996, CURR OPIN GENET DEV, V6, P82, DOI 10.1016/S0959-437X(96)90015-5; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; PENG X, 1995, NEURON, V15, P395, DOI 10.1016/0896-6273(95)90043-8; POSSENTI R, 1992, P NATL ACAD SCI USA, V89, P3815, DOI 10.1073/pnas.89.9.3815; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; vanWeering DHJ, 1995, ONCOGENE, V11, P2207	29	14	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29497	29501		10.1074/jbc.271.46.29497	http://dx.doi.org/10.1074/jbc.271.46.29497			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910618	hybrid			2022-12-25	WOS:A1996VT05200110
J	Hauser, N; Paulsson, M; Heinegard, D; Morgelin, M				Hauser, N; Paulsson, M; Heinegard, D; Morgelin, M			Interaction of cartilage matrix protein with aggrecan - Increased covalent cross-linking with tissue maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-MICROSCOPY; BOVINE CARTILAGE; EXTRACELLULAR-MATRIX; VONWILLEBRAND-FACTOR; STRUCTURAL FEATURES; KERATAN SULFATE; PROTEOGLYCANS; EXPRESSION; DOMAINS; CDNA	Cartilage matrix protein (CMP) is a trimeric protein present in many types of cartilage extracellular matrix, It has recently been purified under native conditions that allowed the proposal of a structural model (Hauser, N., and Paulsson, M. (1994) J. Biol. Chem, 269, 25747-25753). To examine the functional properties of CMP we studied its interaction with aggrecan within cartilage extracellular matrix. Aggrecan-enriched fractions were purified from bovine tracheal cartilage of different ages under nondenaturing and denaturing conditions, respectively, and characterized by a combination of biochemical methods and electron microscopy. The fractions contained a pool of GRIP noncovalently associated with aggrecan as well as a pool of CMP that appears covalently cross-linked to the aggrecan core protein. Only about two thirds of the CMP subunits could be released even upon reduction under denaturing conditions, It appears that CMP is attached by a nonreducible covalent interaction of one of its subunits with the protein core. The amount of CMP strongly bound to aggrecan increases with age. Electron microscopy revealed interaction sites for CMP in the extended chondroitin-sulfate attachment domain E2. In old tissue five distinct binding sites for CMP were found while in young cartilage only three of these were occupied. The extent of decoration of E2 with CMP increases with age.	UNIV COLOGNE,FAC MED,INST BIOCHEM,D-50931 COLOGNE,GERMANY; LUND UNIV,DEPT CELL & MOL BIOL,SECT CONNECT TISSUE BIOL,S-22100 LUND,SWEDEN	University of Cologne; Lund University								AESCHLIMANN D, 1993, J CELL BIOL, V120, P1461, DOI 10.1083/jcb.120.6.1461; ANTONSSON P, 1989, J BIOL CHEM, V264, P16170; ARGRAVES WS, 1987, P NATL ACAD SCI USA, V84, P464, DOI 10.1073/pnas.84.2.464; Aszodi A, 1996, EUR J BIOCHEM, V236, P970, DOI 10.1111/j.1432-1033.1996.00970.x; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; CHEN Q, 1995, MOL BIOL CELL, V6, P1743, DOI 10.1091/mbc.6.12.1743; COLOMBATTI A, 1991, BLOOD, V77, P2305; DOEGE K, 1987, J BIOL CHEM, V262, P17757; ENGEL J, 1987, METHOD ENZYMOL, V145, P1; FOSANG AJ, 1989, BIOCHEM J, V261, P801, DOI 10.1042/bj2610801; FOWLER WE, 1979, J MOL BIOL, V134, P241, DOI 10.1016/0022-2836(79)90034-2; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; HAUDENSCHILD DR, 1995, J BIOL CHEM, V270, P23150, DOI 10.1074/jbc.270.39.23150; HAUSER N, 1994, J BIOL CHEM, V269, P25747; Hauser N, 1995, ACTA ORTHOP SCAND, V66, P19, DOI 10.3109/17453679509157641; HEINEGARD D, 1973, CHEM SCRIPTA, V4, P199; HEINEGARD D, 1989, FASEB J, V3, P2042, DOI 10.1096/fasebj.3.9.2663581; HEINEGARD D, 1977, J BIOL CHEM, V252, P1980; HEINEGARD D, 1977, J BIOL CHEM, V252, P1971; HEINEGARD D, 1974, J BIOL CHEM, V249, P4250; JENKINS RN, 1990, J BIOL CHEM, V265, P19624; KISS I, 1989, J BIOL CHEM, V264, P8126; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORGELIN M, 1994, BIOPHYS CHEM, V50, P113, DOI 10.1016/0301-4622(94)85024-0; MORGELIN M, 1988, BIOCHEM J, V253, P175; MORGELIN M, 1989, J BIOL CHEM, V264, P12080; OLDBERG A, 1987, BIOCHEM J, V243, P255, DOI 10.1042/bj2430255; PAULSSON M, 1979, BIOCHEM J, V183, P539, DOI 10.1042/bj1830539; PAULSSON M, 1987, BIOCHEM J, V245, P763, DOI 10.1042/bj2450763; PAULSSON M, 1982, BIOCHEM J, V207, P207, DOI 10.1042/bj2070207; PAULSSON M, 1984, BIOCHEM J, V221, P623, DOI 10.1042/bj2210623; PAULSSON M, 1981, BIOCHEM J, V197, P367, DOI 10.1042/bj1970367; PAULSSON M, 1984, COLLAGEN REL RES, V4, P219; SALEQUE S, 1993, GLYCOBIOLOGY, V3, P185, DOI 10.1093/glycob/3.2.185; SHOTTON DM, 1979, J MOL BIOL, V131, P303, DOI 10.1016/0022-2836(79)90078-0; TYLER JM, 1980, J ULTRA MOL STRUCT R, V71, P95, DOI 10.1016/S0022-5320(80)90098-2; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; WINTERBOTTOM N, 1992, DEV DYNAM, V193, P266, DOI 10.1002/aja.1001930307	38	76	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32247	32252		10.1074/jbc.271.50.32247	http://dx.doi.org/10.1074/jbc.271.50.32247			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943283	hybrid			2022-12-25	WOS:A1996VY34000074
J	Nolten, LA; Steenbergh, PH; Sussenbach, JS				Nolten, LA; Steenbergh, PH; Sussenbach, JS			The hepatocyte nuclear factor 3 beta stimulates the transcription of the human insulin-like growth factor I gene in a direct and indirect manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE AMINOTRANSFERASE GENE; LIVER-SPECIFIC FACTOR; MESSENGER-RNA; DNA-BINDING; NUCLEOTIDE-SEQUENCE; ALBUMIN GENE; FORK-HEAD; EXPRESSION; PROMOTER; PROTEIN	Promoter 1 (P1) of the human insulin-like growth factor I (IGF-I) gene is most active in adult liver. In this study we show that HNF-3 beta, a member of the winged helix protein family of Liver-enriched transcription factors, has a strong stimulatory effect on the activity of P1. Transient transfection experiments in combination with bandshift and DNase I footprinting analysis revealed the presence of two HNF-3 binding sites in the proximal promoter region of P1. Both binding sites, which are well conserved in evolution, are required for maximal transactivation. Studies employing HNF-3 mutant constructs indicated that IGF-I expression is also regulated indirectly by HNF-3 beta as a consequence of enhanced expression of HNF-1 alpha. This liver-enriched transcription factor bets previously been shown to transactivate P1. Thus, HNF-3 beta regulates the expression of the human IGF-I gene via two distinct mechanisms.	UNIV UTRECHT,GRAD SCH DEV BIOL,PHYSIOL CHEM LAB,NL-3584 CG UTRECHT,NETHERLANDS	Utrecht University								ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; AUGEGOUILLOU C, 1993, FEBS LETT, V323, P4, DOI 10.1016/0014-5793(93)81436-4; BRENNAN RG, 1993, CELL, V74, P773, DOI 10.1016/0092-8674(93)90456-Z; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; DAUGHADAY WH, 1972, NATURE, V235, P107, DOI 10.1038/235107a0; DEPAGTERHOLTHUIZEN P, 1986, FEBS LETT, V195, P179, DOI 10.1016/0014-5793(86)80156-9; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DESIMONE V, 1992, BIOCHIM BIOPHYS ACTA, V1132, P119, DOI 10.1016/0167-4781(92)90001-G; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FROESCH ER, 1985, ANNU REV PHYSIOL, V47, P443; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREGORI C, 1993, NUCLEIC ACIDS RES, V21, P897, DOI 10.1093/nar/21.4.897; HERBST RS, 1991, NEW BIOL, V3, P289; IP YT, 1990, MOL CELL BIOL, V10, P3770, DOI 10.1128/MCB.10.7.3770; JANSEN E, 1991, MOL CELL ENDOCRINOL, V78, P115, DOI 10.1016/0303-7207(91)90192-U; JANSEN E, 1992, BIOCHEM BIOPH RES CO, V187, P1219, DOI 10.1016/0006-291X(92)90433-L; JOHNSON PF, 1990, CELL GROWTH DIFFER, V1, P47; KAESTNER KH, 1994, GENOMICS, V20, P377, DOI 10.1006/geno.1994.1191; KAJIMOTO Y, 1991, J BIOL CHEM, V266, P9724; KAVSAN VM, 1993, DNA CELL BIOL, V12, P729, DOI 10.1089/dna.1993.12.729; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KUO CJ, 1990, P NATL ACAD SCI USA, V87, P9838, DOI 10.1073/pnas.87.24.9838; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; LAI E, 1991, TRENDS BIOCHEM SCI, V16, P427, DOI 10.1016/0968-0004(91)90169-V; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LEGRAVEREND C, 1994, BIOCHEMISTRY-US, V33, P9889, DOI 10.1021/bi00199a010; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; MATHEWS LS, 1986, P NATL ACAD SCI USA, V83, P9343, DOI 10.1073/pnas.83.24.9343; Maxam A M, 1980, Methods Enzymol, V65, P499; MILLONIG JH, 1995, MOL CELL BIOL, V15, P3848; MULLER M, 1990, NUCLEIC ACIDS RES, V18, P364, DOI 10.1093/nar/18.2.364; NITSCH D, 1993, P NATL ACAD SCI USA, V90, P5479, DOI 10.1073/pnas.90.12.5479; NODA C, 1993, CELL STRUCT FUNCT, V18, P189, DOI 10.1247/csf.18.189; NOLTEN LA, 1995, MOL ENDOCRINOL, V9, P1488, DOI 10.1210/me.9.11.1488; NOLTEN LA, 1994, MOL ENDOCRINOL, V8, P1636, DOI 10.1210/me.8.12.1636; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; PANI L, 1992, MOL CELL BIOL, V12, P3723, DOI 10.1128/MCB.12.9.3723; PANI L, 1992, MOL CELL BIOL, V12, P552, DOI 10.1128/MCB.12.2.552; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; PRUIJN GJM, 1987, EMBO J, V6, P3771, DOI 10.1002/j.1460-2075.1987.tb02712.x; RIGAUD G, 1991, CELL, V67, P977, DOI 10.1016/0092-8674(91)90370-E; ROBERTS CT, 1987, BIOCHEM BIOPH RES CO, V146, P1154, DOI 10.1016/0006-291X(87)90768-6; ROTWEIN P, 1986, J BIOL CHEM, V261, P4828; ROUX J, 1995, DNA CELL BIOL, V14, P385, DOI 10.1089/dna.1995.14.385; Sambrook J., 2002, MOL CLONING LAB MANU; SAWAYA PL, 1994, J BIOL CHEM, V269, P22211; STEENBERGH PH, 1991, BIOCHEM BIOPH RES CO, V175, P507, DOI 10.1016/0006-291X(91)91593-2; URANO Y, 1986, J BIOL CHEM, V261, P3244; VALLET V, 1995, MOL CELL BIOL, V15, P5453; WONG EA, 1989, DNA-J MOLEC CELL BIO, V8, P649, DOI 10.1089/dna.1.1989.8.649; XANTHOPOULOS KG, 1993, EUR J BIOCHEM, V216, P353, DOI 10.1111/j.1432-1033.1993.tb18152.x	54	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					31846	31854		10.1074/jbc.271.50.31846	http://dx.doi.org/10.1074/jbc.271.50.31846			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943227	hybrid			2022-12-25	WOS:A1996VY34000018
J	Rabon, EC; Hoggatt, M; Smillie, K				Rabon, EC; Hoggatt, M; Smillie, K			Transmembrane carboxyl residues are essential for cation-dependent function in the gastric H,K-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; SARCOPLASMIC-RETICULUM; H+/K+-ATPASE; BINDING DOMAIN; ALPHA-SUBUNIT; CHEMICAL MODIFICATION; MEMBRANE TOPOLOGY; CROSS-LINKING; CDNA CLONING; BETA-SUBUNIT	The K+-dependent ATPase activity of the H,K-ATPase was irreversibly inhibited by the carboxyl activating reagent, dicyclohexylcarbodiimide (DCCD), The inhibition was first order and displayed a concentration dependence with the K-0.5 (DCCD) = 0.65 +/- 0.04 mM. KCl protected 70% of the ATPase activity from DCCD-dependent inhibition in a concentration dependent manner with a K-0.5 (K+) = 0.58 +/- 0.1 mM KCl. DCCD modification selectively inhibited the K+-dependent rather than ATP-dependent partial reactions including eosin fluorescence responses and ligand-stabilized initial tryptic cleavage patterns of the membrane-associated enzyme, DCCD modification also inhibited the binding of Rb-86(+) and the fluorescent responses of the K+-competitive, fluorescent inhibitor 1-(2-methylphenyl)-4-methylamino-6-methyl-2, 3-dihydropyrrolo[3,2-c] quinoline. [C-14]DCCD was incorporated into the H,K-ATPase in a time course identical to that describing the inactivation of the K+-dependent ATPase activity of the H,K-ATPase. A component of the [C-14]DCCD incorporated into the H,K-ATPase was K+-sensitive where K+ reduced the [C-14]DCCD incorporated into the enzyme by 1.6 nmol of [C-14]DCCD/mg of protein, Membrane-associated tryptic peptides resolved from the [C-14]DCCD modified H,K-ATPase exhibited various K+ sensitivities with peptides at 23, 9.6, 8.2, 7.1, and 6.1 kDa containing 10-78%, 23-52%, 24-36%, 2%, and 3-4% K+-sensitivity, respectively. The N-terminal sequence of the K+-sensitive, similar to 23- and 9.6-kDa peptides was LVNE(857), a C-terminal fragment of the ATPase alpha-subunit, The mass of the smaller peptide limited the residue assignment to the transmembrane M7/M8 domains and an intervening extracytoplasmic loop, An N-terminal sequence, SD(840)IM, was obtained from a 3,3-kDa, [C-14]DCCD-labeled peptide resolved from a V8 digest of the partially purified alpha-subunit. This mass was sufficient to include LVNE but would exclude M8 and the intervening loop between M7 and M8. Glu(857) is a unique residue present in each of the proteolytic preparations of the H,K-ATPase modified by [C-14]DCCD. These data provide functional evidence of the selective inactivation of the K+-dependent partial reactions of the H,K-ATPase and show that Glu(857) located at the M7 boundary in the C terminus of the pump molecule is a significant site of DCCD modification, These data are interpreted to indicate that this carboxyl residue is important for cation binding function.	VET ADM CTR, NEW ORLEANS, LA 70112 USA		Rabon, EC (corresponding author), TULANE UNIV, MED CTR, NEW ORLEANS, LA 70112 USA.				NIDDK NIH HHS [DK34286] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034286] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGUELLO JM, 1991, J BIOL CHEM, V266, P14627; BAMBERG K, 1992, BIOCHIM BIOPHYS ACTA, V1131, P69, DOI 10.1016/0167-4781(92)90100-E; BAYLE D, 1992, J BIOL CHEM, V267, P19060; BESANCON M, 1993, BIOCHEMISTRY-US, V32, P2345, DOI 10.1021/bi00060a028; CHADWICK CC, 1984, BIOCHIM BIOPHYS ACTA, V769, P291, DOI 10.1016/0005-2736(84)90309-2; CHADWICK CC, 1983, BIOCHIM BIOPHYS ACTA, V730, P201, DOI 10.1016/0005-2736(83)90334-6; CHANG H, 1977, BIOCHIM BIOPHYS ACTA, V464, P313, DOI 10.1016/0005-2736(77)90006-2; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; DEANCOS JG, 1988, BIOCHEMISTRY-US, V27, P1793; ELLISDAVIES GCR, 1993, J BIOL CHEM, V268, P11622; FALLER LD, 1991, BIOCHEMISTRY-US, V30, P3503, DOI 10.1021/bi00228a022; FARLEY RA, 1985, J BIOL CHEM, V260, P3899; GANSER AL, 1973, BIOCHIM BIOPHYS ACTA, V307, P169, DOI 10.1016/0005-2736(73)90035-7; GOLDSHLEGER R, 1992, P NATL ACAD SCI USA, V89, P6911, DOI 10.1073/pnas.89.15.6911; GORGA FR, 1985, BIOCHEMISTRY-US, V24, P6783, DOI 10.1021/bi00345a009; HALL K, 1991, BIOCHIM BIOPHYS ACTA, V1077, P173, DOI 10.1016/0167-4838(91)90055-5; HELMICHDEJONG ML, 1987, BIOCHIM BIOPHYS ACTA, V905, P358, DOI 10.1016/0005-2736(87)90464-0; HELMICHDEJONG ML, 1986, BIOCHIM BIOPHYS ACTA, V858, P254, DOI 10.1016/0005-2736(86)90330-5; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13523, DOI 10.1021/bi00212a018; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P4566, DOI 10.1073/pnas.87.12.4566; KARLISH SJD, 1992, ACTA PHYSIOL SCAND, V146, P69; LEVY HM, 1963, J BIOL CHEM, V238, P3654; LINGREL JB, 1994, KIDNEY INT, V45, pS32; MAEDA M, 1988, BIOCHEM BIOPH RES CO, V157, P203, DOI 10.1016/S0006-291X(88)80033-0; MERCIER F, 1993, BIOCHIM BIOPHYS ACTA, V1149, P151, DOI 10.1016/0005-2736(93)90036-Y; MUNSON KB, 1991, J BIOL CHEM, V266, P18976; OHTSUBO M, 1990, BIOCHIM BIOPHYS ACTA, V1021, P157, DOI 10.1016/0005-2736(90)90028-M; OKAMOTO CT, 1990, BIOCHIM BIOPHYS ACTA, V1037, P360, DOI 10.1016/0167-4838(90)90038-H; PEDEMONTE CH, 1986, J BIOL CHEM, V261, P3632; PEDEMONTE CH, 1990, AM J PHYSIOL, V258, pC1, DOI 10.1152/ajpcell.1990.258.1.C1; PICK U, 1979, BIOCHEMISTRY-US, V18, P108, DOI 10.1021/bi00568a017; RABON E, 1991, J BIOL CHEM, V266, P12395; RABON EC, 1993, J BIOL CHEM, V268, P8012; RABON EC, 1990, ANNU REV PHYSIOL, V52, P321; RABON EC, 1990, J BIOL CHEM, V265, P19594; RABON EC, 1990, BIOCHIM BIOPHYS ACTA, V1039, P277, DOI 10.1016/0167-4838(90)90260-M; RABON EC, 1992, ACTA PHYSIOL SCAND, V146, P269; SACCOMANI G, 1981, J BIOL CHEM, V256, P2405; SACHS G, 1976, J BIOL CHEM, V251, P7690; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHANI M, 1987, BIOCHIM BIOPHYS ACTA, V904, P13, DOI 10.1016/0005-2736(87)90081-2; SHIN JM, 1993, BIOCHIM BIOPHYS ACTA, V1148, P223, DOI 10.1016/0005-2736(93)90133-K; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SMOLKA A, 1992, BIOCHIM BIOPHYS ACTA, V1108, P75, DOI 10.1016/0005-2736(92)90116-4; STENGELIN M, 1993, J MEMBRANE BIOL, V132, P211; TAMURA S, 1989, J BIOL CHEM, V264, P8580; TOYOFUKU T, 1992, J BIOL CHEM, V267, P14490; TREUHEIT MJ, 1993, PREP BIOCHEM, V23, P375, DOI 10.1080/10826069308544563; WILSEN B, 1993, BIOCHEMISTRY-US, V32, P13440	51	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32137	32146		10.1074/jbc.271.50.32137	http://dx.doi.org/10.1074/jbc.271.50.32137			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943267	hybrid			2022-12-25	WOS:A1996VY34000058
J	Dillon, DA; Wu, WI; Riedel, B; Wissing, JB; Dowhan, W; Carman, GM				Dillon, DA; Wu, WI; Riedel, B; Wissing, JB; Dowhan, W; Carman, GM			The Escherichia coli pgpB gene encodes for a diacylglycerol pyrophosphate phosphatase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID-MIXED MICELLES; MEMBRANE-BOUND PHOSPHATASES; RAT-LIVER; PHOSPHATIDYLINOSITOL SYNTHASE; SUBCELLULAR-LOCALIZATION; SACCHAROMYCES-CEREVISIAE; ACID; PURIFICATION; YEAST; PHOSPHOHYDROLASE	We provided genetic and biochemical evidence that supported the conclusion that the product of pgpB gene of Escherichia coli exhibited diacylglycerol pyrophosphate (DGPP) phosphatase activity. DGPP phosphatase activity was absent in pgpB mutant cells and was expressed at high levels in cells carrying the wild-type pgpB gene on a runaway replication plasmid. The pgpB mutant has been primarily characterized by a defect in phosphatidate (PA) phosphatase activity and also exhibits defects in lyse-PA phosphatase and phosphatidylglycerophosphate phosphatase activities. The defective PA phosphatase in the pgpB mutant was shown to be a Mg2+-independent PA phosphatase activity of the DGPP phosphatase enzyme. We characterized DG:PP phosphatase activity in membranes from cells overproducing the pgpB gene product. DGPP phosphatase catalyzed the dephosphorylation of the beta phosphate of DGPP to form PA followed by the dephosphorylation of PA to form diacylglycerol. The specificity constant (V-max/K-m) for DG:PP was 9.3-fold greater than that for PA. The pH optimum for the DGPP phosphatase reaction was 6.5. Activity was independent of a divalent cation requirement, was potently inhibited by Mn2+ ions, and was insensitive to inhibition by N-ethylmaleimide. Pure DGPP phosphatase from Saccharomyces cerevisiae was shown to be similar to the E. coli DGPP phosphatase in its ability to utilize lyso-PA and phosphatidylglycerophosphate as substrates in vitro.	RUTGERS STATE UNIV, COOK COLL, NEW JERSEY AGR EXPT STN, DEPT FOOD SCI, NEW BRUNSWICK, NJ 08903 USA; GESELL BIOTECHNOL FORSCH MBH, ENZYMOL, D-38124 BRAUNSCHWEIG, GERMANY; UNIV TEXAS, SCH MED, DEPT BIOCHEM & MOL BIOL, HOUSTON, TX 77225 USA	Rutgers State University New Brunswick; Gesellschaft fur Biotechnologische Forschung mbH; University of Texas System					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028140, R37GM028140] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-20487, GM-28140] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAELEE M, 1990, J BIOL CHEM, V265, P7221; BHAT BG, 1994, J BIOL CHEM, V269, P13172; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARMAN GM, 1991, METHOD ENZYMOL, V197, P548; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; Carman GM, 1996, J BIOL CHEM, V271, P13293, DOI 10.1074/jbc.271.23.13293; CARMAN GM, 1992, METHOD ENZYMOL, V209, P305; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; EXTON JH, 1990, J BIOL CHEM, V265, P1; FLEMING IN, 1995, BIOCHEM J, V308, P983, DOI 10.1042/bj3080983; FUNK CR, 1992, J BACTERIOL, V174, P205, DOI 10.1128/jb.174.1.205-213.1992; GARMAN GM, 1995, J BIOL CHEM, V270, P18711; GOMEZMUNOZ A, 1994, J BIOL CHEM, V269, P8937; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; ICHO T, 1983, J BACTERIOL, V153, P722, DOI 10.1128/JB.153.2.722-730.1983; ICHO T, 1988, J BACTERIOL, V170, P5117, DOI 10.1128/jb.170.11.5117-5124.1988; JAMAL Z, 1991, J BIOL CHEM, V266, P2988; JONES GA, 1993, J BIOL CHEM, V268, P20845; KANOH H, 1992, J BIOL CHEM, V267, P25309; Kennedy E. P., 1986, LIPIDS MEMBRANES PRE, P171; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; LIN YP, 1989, J BIOL CHEM, V264, P8641; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; MORITZ A, 1992, J BIOL CHEM, V267, P7207; MORLOCK KR, 1991, J BIOL CHEM, V266, P3586; Munnik T, 1995, PLANT CELL, V7, P2197, DOI 10.1105/tpc.7.12.2197; Munnik T, 1996, J BIOL CHEM, V271, P15708, DOI 10.1074/jbc.271.26.15708; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; QUARMBY LM, 1992, J CELL BIOL, V116, P737, DOI 10.1083/jcb.116.3.737; SPIEGEL S, 1995, J MEMBRANE BIOL, V146, P225; VANDENBOSCH H, 1970, BIOCHIM BIOPHYS ACTA, V218, P233, DOI 10.1016/0005-2760(70)90142-6; Waggoner DW, 1996, J BIOL CHEM, V271, P16506, DOI 10.1074/jbc.271.28.16506; WAGGONER DW, 1995, J BIOL CHEM, V270, P19422, DOI 10.1074/jbc.270.33.19422; WALSH JP, 1986, J BIOL CHEM, V261, P6239; WISSING JB, 1993, PLANT PHYSIOL, V102, P1243, DOI 10.1104/pp.102.4.1243; WISSING JB, 1993, FEBS LETT, V315, P95, DOI 10.1016/0014-5793(93)81141-L; Wu WI, 1996, J BIOL CHEM, V271, P1868, DOI 10.1074/jbc.271.4.1868; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4	39	81	84	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30548	30553		10.1074/jbc.271.48.30548	http://dx.doi.org/10.1074/jbc.271.48.30548			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940025	hybrid			2022-12-25	WOS:A1996VV15800042
J	Goetz, J; Chatton, B; Mattei, MG; Kedinger, C				Goetz, J; Chatton, B; Mattei, MG; Kedinger, C			Structure and expression of the ATFa gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GENE; AMP RESPONSE ELEMENT; NUCLEAR TARGETING SEQUENCE; HUMAN ESTROGEN-RECEPTOR; IN-SITU HYBRIDIZATION; BINDING PROTEIN; LEUCINE ZIPPER; SIGNAL-TRANSDUCTION; MYXOID LIPOSARCOMA; REGULATOR BINDING	The human ATFa proteins belong to the ATF/CREB family of transcription factors, We have previously shown that they mediate the transcriptional activation by the largest Ela protein and can heterodimerize with members of the Jun/Fos family, ATFa proteins have also been found tightly associated with JNK2, a stress-activated kinase. We now report on the structure of the ATFa gene, which mapped to chromosome 12 (band 12q13). Sequence analysis revealed that ATFa isoforms are generated by alternative splice donor site usage, A minimal promoter region of similar to 200 base pairs was identified that retained nearly full transcriptional activity, Binding sites for potential transcription factors were delineated within a GC-rich segment by DNase I foot printing. Expression studies revealed that ATFa accumulates in the nuclei of transfected cells, and the nuclear localization signal was defined next to the leucine zipper domain. As revealed by hybridization with mouse ATFa sequences, low levels of ATFa mRNAs were ubiquitously distributed in fetal or adult mice, with enhanced expression in particular tissues, like squamous epithelia and specific brain cell layers. The possible significance of coexpression of ATFa, ATF-2, and Jun at similar sites in the brain is discussed.	UNIV STRASBOURG 1,IGBMC,CNRS,INSERM,F-67404 ILLKIRCH GRAFFENS,FRANCE; FAC MED MARSEILLE,INSERM U406,F-13385 MARSEILLE,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite			CHATTON, Bruno/R-3813-2019	CHATTON, Bruno/0000-0003-4515-7119				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; AMAN P, 1992, GENE CHROMOSOME CANC, V5, P278, DOI 10.1002/gcc.2870050403; AUSUBUEL FM, 1987, CURRENT PROTOCOLS MO; BANERJI J, 1981, CELL, V27, P299, DOI 10.1016/0092-8674(81)90413-X; BENBROOK DM, 1990, ONCOGENE, V5, P295; Bocco JL, 1996, ONCOGENE, V12, P1971; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; BOULIKAS T, 1994, J CELL BIOCHEM, V55, P32, DOI 10.1002/jcb.240550106; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; BUREAU JF, 1995, GENOMICS, V28, P109, DOI 10.1006/geno.1995.1114; CANNIZZARO LA, 1987, AM J HUM GENET, V41, P1; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; CHATTON B, 1994, ONCOGENE, V9, P375; CHATTON B, 1995, BIOTECHNIQUES, V18, P142; CHIDA K, 1992, P NATL ACAD SCI USA, V89, P4290, DOI 10.1073/pnas.89.10.4290; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DAI TN, 1995, ONCOGENE, V10, P849; DECIMO D, 1995, GENE PROBES PRACTICA, V2, P183; DEMETRICK DJ, 1994, CYTOGENET CELL GENET, V66, P72, DOI 10.1159/000133669; DESMAZE C, 1994, HUM GENET, V93, P207; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; GAIRE M, 1990, NUCLEIC ACIDS RES, V18, P3467, DOI 10.1093/nar/18.12.3467; GAUB MP, 1992, EXP CELL RES, V201, P335, DOI 10.1016/0014-4827(92)90282-D; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HABER N, 1994, HUM GENET, V94, P69, DOI 10.1007/BF02272844; HAGMEYER BM, 1995, BIOESSAYS, V17, P621, DOI 10.1002/bies.950170708; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KAZMIERCZAK B, 1995, CANCER RES, V55, P2497; KOUZARIDES T, 1989, CANCER CELL-MON REV, V1, P71; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Liang GS, 1996, J BIOL CHEM, V271, P1695, DOI 10.1074/jbc.271.3.1695; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MAEKAWA T, 1991, ONCOGENE, V6, P627; MASQUILIER D, 1992, J BIOL CHEM, V267, P22460; MATERA AG, 1993, GENOMICS, V17, P793, DOI 10.1006/geno.1993.1413; MATTEI MG, 1985, HUM GENET, V69, P327, DOI 10.1007/BF00291650; MATTEI MG, 1991, GENOMICS, V10, P1061, DOI 10.1016/0888-7543(91)90199-O; MELLSTROM B, 1991, ONCOGENE, V6, P1959; MENDELSOHN C, 1994, DEV BIOL, V166, P246, DOI 10.1006/dbio.1994.1311; MIKAELIAN I, 1993, J VIROL, V67, P734; NAGASE T, 1990, J BIOL CHEM, V265, P17300; PANAGOPOULOS I, 1995, ONCOGENE, V11, P1133; PARK JS, 1992, GENE, V116, P259, DOI 10.1016/0378-1119(92)90523-R; PESCINI R, 1994, J BIOL CHEM, V269, P1159; Reimold AM, 1996, NATURE, V379, P262, DOI 10.1038/379262a0; REYNOLDS GA, 1984, CELL, V38, P275, DOI 10.1016/0092-8674(84)90549-X; ROUSSEAUMERCK MF, 1990, CYTOGENET CELL GENET, V53, P2, DOI 10.1159/000132883; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SassoneCorsi P, 1995, ANNU REV CELL DEV BI, V11, P355, DOI 10.1146/annurev.cellbio.11.1.355; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SZPIRER J, 1991, GENOMICS, V11, P168, DOI 10.1016/0888-7543(91)90114-T; TAKEDA J, 1991, ONCOGENE, V6, P1009; TRATNER I, 1991, ONCOGENE, V6, P2049; VANDAM H, 1995, EMBO J, V14, P1785; WEBSTER NJG, 1989, EMBO J, V8, P1441, DOI 10.1002/j.1460-2075.1989.tb03526.x; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x; ZU YL, 1991, J BIOL CHEM, V266, P24134; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341	68	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29589	29598		10.1074/jbc.271.47.29589	http://dx.doi.org/10.1074/jbc.271.47.29589			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939888	hybrid			2022-12-25	WOS:A1996VU52500016
J	Katoh, H; Negishi, M; Ichikawa, A				Katoh, H; Negishi, M; Ichikawa, A			Prostaglandin E receptor EP3 subtype induces neurite retraction via small GTPase Rho	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN-RHO; EP(3) SUBTYPE; ADP-RIBOSYLTRANSFERASE; NORADRENALINE RELEASE; PROSTANOID RECEPTORS; NERVOUS-SYSTEM; MESSENGER-RNA; RAT-BRAIN; EXPRESSION; CLONING	Prostaglandin E receptor EP3 subtype is widely distributed in the nervous system and is specifically localized to neurons, suggesting that the EP3 receptor plays important roles in the nervous system. We established a PC12 cell line that stably expresses the EP3B receptor isoform isolated from bovine adrenal chromaffin cells and examined the effect of agonist stimulation on the neuronal morphology of the PC12 cells, In the differentiated cells, M&B28767, an EP3 agonist, caused neurite retraction in a pertussis toxin-insensitive manner, 12-O-Tetradecanoylphorbol-13-acetate (TPA) also induced neurite retraction. However, when protein kinase C was down-regulated by long term exposure to TPA, TPA failed to induce neurite retraction, while the EP3B receptor-mediated retraction occurred normally, Clostridium botulinum C3 exoenzyme completely inhibited both EP3 agonist- and TPA-induced neurite retraction when microinjected into the cells, indicating that the morphological effect of the EP3B receptor is dependent on Rho activity, Thus, the activation of the EP3B receptor induced neurite retraction through a protein kinase C-independent Rho-activation pathway.	KYOTO UNIV, FAC PHARMACEUT SCI, DEPT PHYSIOL CHEM, SAKYO KU, KYOTO 606, JAPAN	Kyoto University								AKTORIES K, 1987, FEBS LETT, V212, P109, DOI 10.1016/0014-5793(87)81566-1; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; COLEMAN RA, 1994, PROSTAGLANDINS, V47, P151, DOI 10.1016/0090-6980(94)90084-1; Coleman RA, 1990, COMPREHENSIVE MED CH, P643; DeWitt DS, 1988, J NEUROTRAUM, V5, P303, DOI 10.1089/neu.1988.5.303; DYER D, 1992, MOL BRAIN RES, V14, P293, DOI 10.1016/0169-328X(92)90096-T; ELLIS E F, 1989, Journal of Neurotrauma, V6, P31, DOI 10.1089/neu.1989.6.31; EXNER HJ, 1995, N-S ARCH PHARMACOL, V351, P46; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FERREIRA SH, 1972, NATURE-NEW BIOL, V240, P200, DOI 10.1038/newbio240200a0; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HERTTING G, 1989, ANN NY ACAD SCI, V559, P84; Holscher C, 1995, EUR J PHARMACOL, V294, P253, DOI 10.1016/0014-2999(95)00541-2; HONDA A, 1993, J BIOL CHEM, V268, P7759; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; KATSUYAMA M, 1995, FEBS LETT, V372, P151, DOI 10.1016/0014-5793(95)00966-D; KEYNES R, 1995, CELL, V83, P161, DOI 10.1016/0092-8674(95)90157-4; KUMAZAWA T, 1993, BRAIN RES, V632, P321, DOI 10.1016/0006-8993(93)91169-S; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; MATTHIES HJG, 1987, J NEUROSCI, V7, P1198; MENT LR, 1987, J NEUROSURG, V67, P278, DOI 10.3171/jns.1987.67.2.0278; MILTON AS, 1970, J PHYSIOL-LONDON, V207, pP76; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; NEGISHI M, 1995, BBA-LIPID LIPID MET, V1259, P109, DOI 10.1016/0005-2760(95)00146-4; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; OIDA H, 1995, BRIT J PHARMACOL, V116, P2828, DOI 10.1111/j.1476-5381.1995.tb15933.x; OJEDA SR, 1982, ENDOCRINOLOGY, V111, P1031, DOI 10.1210/endo-111-4-1031; REIMANN W, 1981, EUR J PHARMACOL, V69, P421, DOI 10.1016/0014-2999(81)90445-3; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROBERTS PJ, 1976, BRAIN RES, V112, P425, DOI 10.1016/0006-8993(76)90299-7; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; STITT JT, 1986, YALE J BIOL MED, V59, P137; SUGIMOTO Y, 1992, J BIOL CHEM, V267, P6463; SUGIMOTO Y, 1994, NEUROSCIENCE, V62, P919, DOI 10.1016/0306-4522(94)90483-9; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1995, ONCOGENE, V11, P39; Tigyi G, 1996, J NEUROCHEM, V66, P549; Tigyi G, 1996, J NEUROCHEM, V66, P537; WATABE A, 1993, J BIOL CHEM, V268, P20175; WOLFE LS, 1982, J NEUROCHEM, V38, P1, DOI 10.1111/j.1471-4159.1982.tb10847.x; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T	43	63	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29780	29784		10.1074/jbc.271.47.29780	http://dx.doi.org/10.1074/jbc.271.47.29780			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939915	hybrid			2022-12-25	WOS:A1996VU52500043
J	Lustigman, S; McKerrow, JH; Shah, K; Lui, J; Huima, T; Hough, M; Brotman, B				Lustigman, S; McKerrow, JH; Shah, K; Lui, J; Huima, T; Hough, M; Brotman, B			Cloning of a cysteine protease required for the molting of Onchocerca volvulus third stage larvae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							4TH-STAGE LARVAE; CATHEPSIN-B; CAENORHABDITIS-ELEGANS; DIROFILARIA-IMMITIS; PROTOZOAN PARASITES; SPLICED LEADER; SEQUENCE; 3RD-STAGE; ECDYSIS; IDENTIFICATION	We have investigated the involvement of a cysteine protease in the development of Onchocerca volvulus fourth stage larvae (L4) by testing the effect of cysteine protease inhibitors on the survival of third stage larvae (L3), and the molting of L3 to L4 in vitro. When larvae were cultured in the presence of specific inhibitors, the peptidyl monofluoromethylketones, viability of either L3 or L4 was not affected, However, the inhibitors reduced the number of L3 that molted to L4 in vitro in a time- and dose-dependent manner, Molting was completely inhibited in the presence of 50-250 mu M inhibitor, Ultrastructural examination of L3 that did not molt in the presence of inhibitors indicated that new L4 cuticle was synthesized, but there was no separation between the L3 and the L4 cuticles, The endogenous cysteine protease was detected in molting larvae after binding to labeled inhibitors, and by antibodies directed against a recombinant O. volvulus L3 cysteine protease that was cloned and expressed. The enzyme was detected in cuticle regions where the separation between the cuticles occurs in molting larvae, These studies suggest that molting and successful development of L4 depends on the expression and release of a cysteine protease.	UNIV CALIF SAN FRANCISCO, DEPT PATHOL, SAN FRANCISCO, CA 94121 USA; DEPT VET AFFAIRS MED CTR, SAN FRANCISCO, CA 94121 USA; LIBERIAN INST BIOMED RES, VILAB 2, ROBERTSFIELD, LIBERIA	University of California System; University of California San Francisco	Lustigman, S (corresponding author), NEW YORK BLOOD CTR, LINDSLEY F KIMBALL RES INST, LAB VIROL & PARASITOL, 310 E 67TH ST, NEW YORK, NY 10021 USA.							BARKER GC, 1990, PARASITOL TODAY, V6, P384, DOI 10.1016/0169-4758(90)90147-V; BARRETT AJ, 1986, RES MONOG CELL TISSU, V12, P515; BEKTESH SL, 1988, NUCLEIC ACIDS RES, V16, P5692, DOI 10.1093/nar/16.12.5692; BIRD AL, 1991, STRUCTURE NEMATODES, P81; CHUNG YB, 1995, J PARASITOL, V81, P137, DOI 10.2307/3283911; COMLEY JCW, 1989, TROP MED PARASITOL, V40, P311; COX GN, 1981, DEV BIOL, V86, P456, DOI 10.1016/0012-1606(81)90204-9; CULLEN BM, 1992, BIOCHEM J, V283, P461, DOI 10.1042/bj2830461; DAVEY KG, 1968, CAN J ZOOLOG, V46, P893, DOI 10.1139/z68-125; DUFOUR E, 1988, BIOCHIMIE, V70, P1335, DOI 10.1016/0300-9084(88)90004-1; EAKIN AE, 1990, MOL BIOCHEM PARASIT, V39, P1, DOI 10.1016/0166-6851(90)90002-4; EAKIN AE, 1992, J BIOL CHEM, V267, P7411; FRANK GR, 1991, J PARASITOL, V77, P950, DOI 10.2307/3282748; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GAMBLE HR, 1989, J PARASITOL, V75, P303, DOI 10.2307/3282779; GAMBLE HR, 1989, MOL BIOCHEM PARASIT, V33, P49, DOI 10.1016/0166-6851(89)90041-8; HONG XQ, 1993, EXP PARASITOL, V76, P127, DOI 10.1006/expr.1993.1015; HOTEZ P, 1990, INFECT IMMUN, V58, P3883, DOI 10.1128/IAI.58.12.3883-3892.1990; IRVINE M, 1994, MOL BIOCHEM PARASIT, V65, P35; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAPAGE G., 1935, Parasitology, V27, P186, DOI 10.1017/S0031182000015079; LUSTIGMAN S, 1990, EXP PARASITOL, V71, P489, DOI 10.1016/0014-4894(90)90075-N; LUSTIGMAN S, 1995, ANTIMICROB AGENTS CH, V39, P1913, DOI 10.1128/AAC.39.9.1913; LUSTIGMAN S, 1993, PARASITOL TODAY, V9, P294, DOI 10.1016/0169-4758(93)90128-3; LUSTIGMAN S, 1992, J BIOL CHEM, V267, P17339; MASON RW, 1989, BIOCHEM J, V257, P125, DOI 10.1042/bj2570125; McKerrow J. H., 1994, PERSPECT DRUG DISCOV, V2, P437; MILLER KM, 1990, TROP MED PARASITOL, V41, P221; RASNICK D, 1985, ANAL BIOCHEM, V149, P461, DOI 10.1016/0003-2697(85)90598-6; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P461; RICHER JK, 1992, EXP PARASITOL, V75, P213, DOI 10.1016/0014-4894(92)90181-9; SAKANARI JA, 1989, P NATL ACAD SCI USA, V86, P4863, DOI 10.1073/pnas.86.13.4863; Sambrook J., 2002, MOL CLONING LAB MANU; SAMUALS RI, 1995, COMP BIOCH PHYSL B, V110, P66661; SMITH SM, 1989, J BIOL CHEM, V264, P20487; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; WHO Expert Committee on Onchocerciasis, 1987, WHO TECH REP SER, V752, P1; ZENG WL, 1990, MOL CELL BIOL, V10, P2765, DOI 10.1128/MCB.10.6.2765	38	92	97	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30181	30189		10.1074/jbc.271.47.30181	http://dx.doi.org/10.1074/jbc.271.47.30181			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939969	hybrid			2022-12-25	WOS:A1996VU52500097
J	Waterman, MR				Waterman, MR			Introduction: Transcription and regulation of activities of cytochromes P450 metabolizing endogenous substrates	FASEB JOURNAL			English	Editorial Material											Waterman, MR (corresponding author), VANDERBILT UNIV,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232, USA.							ESTABROOK RW, 1963, BIOCHEM Z, V338, P741; HOLTON TA, 1993, NATURE, V366, P276, DOI 10.1038/366276a0; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; SCHLINGER BA, 1991, P NATL ACAD SCI USA, V88, P4191, DOI 10.1073/pnas.88.10.4191; Simpson E.R., 1995, ENDOCRINOLOGY, P1630; Stromstedt M, 1996, ARCH BIOCHEM BIOPHYS, V329, P73, DOI 10.1006/abbi.1996.0193; YOSHIKUNI M, 1994, DEV BIOL, V166, P615, DOI 10.1006/dbio.1994.1341	7	3	3	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1996	10	13					1455	1455		10.1096/fasebj.10.13.8940290	http://dx.doi.org/10.1096/fasebj.10.13.8940290			1	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VU982	8940290				2022-12-25	WOS:A1996VU98200001
J	Chen, SH; Lin, F; Iismaa, S; Lee, KN; Birckbichler, PJ; Graham, RM				Chen, SH; Lin, F; Iismaa, S; Lee, KN; Birckbichler, PJ; Graham, RM			alpha(1)-adrenergic receptor signaling via G(h) is subtype specific and independent of its transglutaminase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; TISSUE TRANSGLUTAMINASE; PHOSPHOLIPASE-C; EXPRESSION; CELL; RECONSTITUTION; IDENTIFICATION; PURIFICATION; PROGRESSION; FAMILY	Tissue transglutaminase (TGase II) is a Ca2+- and thioldependent enzyme that catalyzes the post-translational modification of proteins via the formation of epsilon(gamma-glutamyl) lysine bonds. We have shown previously that the GTP-binding protein, G(h), is a TGase II that mediates intracellular signaling by the alpha(1B)-adrenergic receptor (AR) (Nakaoka, H., Perez, D. M., Baek, K. J., Das, T., Husain, A., Mison, K., Im, M.-J., and Graham, R. M. (1994) Science 264, 1593-1596). Here, we evaluated the ability of G(h) as compared with G(q) to mediate receptor-stimulated inositol phosphate turnover by the three alpha(1)-subtypes (alpha(1A), alpha(1B) and alpha(1D)). In addition, we questioned if the transglutaminase function of G(h) is involved in its receptor signaling activity. A mutant form of a human TGase II cDNA in which the codon for the active site cysteine (Cys(277)) was replaced by serine was cloned into the mammalian expression vector pMT2'. Compared with wild-type TGase II, no transglutaminase activity was observed with transient transfection of this Cys-->Ser mutant in COS-1 cells. However, like wild-type TGase, the Cys-->Ser mutant mediated receptor-stimulated inositol phosphate turnover when cotransfected with an alpha(1B)-AR CDNA. G(alpha q) supported alpha(1)-AR-mediated inositol phosphate turnover by all three receptor subtypes. By contrast, although both the wild-type and Cys-->Ser construct mediated receptor signaling by the alpha(1B) AR and alpha(1D) AR, the alpha(1A)-AR was unable to interact with G(h). However, a G(h)-dependent signaling phenotype could be rescued by a chimeric alpha(1A) construct in which the third intracellular loop of the alpha(1A)-AR was replaced by that of the alpha(1B)-AR. Thus, the signaling function of G(h) is independent of its transglutaminase activity and is alpha(1)-AR subtype specific. This subtype specificity of the interaction between alpha(1) ARs and G(h) involves important determinants in their third intracellular loops.	ST VINCENTS HOSP, VICTOR CHANG CARDIAC RES INST, DARLINGHURST, NSW 2010, AUSTRALIA; SAMUEL ROBERTS NOBLE FDN INC, ARDMORE, OK 73401 USA	St Vincents Hospital Sydney; Victor Chang Cardiac Research Institute; Noble Research Institute			Iismaa, Siiri/C-9300-2013	Iismaa, Siiri/0000-0003-2409-7356; chen, songhai/0000-0001-7316-7125; Lin, Fang/0000-0003-2179-7031				ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; BERGER SL, 1993, ANAL BIOCHEM, V214, P571, DOI 10.1006/abio.1993.1540; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BIRCKBICHLER PJ, 1985, HYBRIDOMA, V4, P179, DOI 10.1089/hyb.1985.4.179; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUNGAY PJ, 1986, BIOCHEM J, V235, P269, DOI 10.1042/bj2350269; CHABRE O, 1994, J BIOL CHEM, V269, P5730; DAS T, 1993, J BIOL CHEM, V268, P27398; DAVIES PJA, 1980, NATURE, V283, P162, DOI 10.1038/283162a0; FESUS L, 1989, FEBS LETT, V245, P150, DOI 10.1016/0014-5793(89)80210-8; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; Graham RM, 1996, CIRC RES, V78, P737, DOI 10.1161/01.RES.78.5.737; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; Hwa J, 1996, J BIOL CHEM, V271, P7956, DOI 10.1074/jbc.271.14.7956; HWA J, 1995, J BIOL CHEM, V270, P23189, DOI 10.1074/jbc.270.39.23189; IM MJ, 1990, J BIOL CHEM, V265, P18952; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; KNIGHT CRL, 1991, BIOCHIM BIOPHYS ACTA, V1096, P312, DOI 10.1016/0925-4439(91)90067-J; LEE KN, 1993, BIOCHIM BIOPHYS ACTA, V1202, P1, DOI 10.1016/0167-4838(93)90055-V; MARTINEZ J, 1994, BIOCHEMISTRY-US, V33, P2538, DOI 10.1021/bi00175a024; MIAN S, 1995, FEBS LETT, V370, P27, DOI 10.1016/0014-5793(95)00782-5; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; PEREZ DM, 1994, MOL PHARMACOL, V46, P823; PEREZ DM, 1991, MOL PHARMACOL, V40, P876; PEREZ DM, 1993, MOL PHARMACOL, V44, P784; QIAN NX, 1993, P NATL ACAD SCI USA, V90, P4077, DOI 10.1073/pnas.90.9.4077; Smethurst PA, 1996, BIOCHEM J, V313, P803, DOI 10.1042/bj3130803; VINCAN E, 1995, J MOL CELL CARDIOL, V27, P2393, DOI 10.1016/S0022-2828(95)92127-3; VINCAN E, 1995, 9 INT C 2 MESS PHOSP, P161; WONG SKF, 1994, J BIOL CHEM, V269, P18968; WU DQ, 1992, J BIOL CHEM, V267, P25798	32	94	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32385	32391		10.1074/jbc.271.50.32385	http://dx.doi.org/10.1074/jbc.271.50.32385			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943303	hybrid			2022-12-25	WOS:A1996VY34000094
J	Delhase, M; Castrillo, JL; delaHoya, M; Rajas, F; HooghePeters, EL				Delhase, M; Castrillo, JL; delaHoya, M; Rajas, F; HooghePeters, EL			AP-1 and Oct-1 transcription factors down-regulate the expression of the human PIT1/GHF1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-ACTING FACTOR; CELL-SPECIFIC EXPRESSION; GROWTH-HORMONE PROMOTER; POU-SPECIFIC DOMAIN; ENHANCER ELEMENTS; AUTO-REGULATION; PROLACTIN GENE; DNA-BINDING; PIT-1 GENE; SYNERGISTIC INTERACTIONS	The pituitary-specific transcription factor Pit-1/GHF-1 is a member of the POU domain family of regulatory proteins, It is involved in the commitment and expansion of the somatotropic cell lineage and activates the transcription of a set of anterior pituitary genes. We have cloned the human PIT1/GHF1 gene and characterized the regulatory mechanisms controlling its promoter activation and regulation. A minimal promoter region (-102 to +15) contains the cis-acting elements that confer to the human PIT1/GHF1 gene a high basal transcriptional activity, the tissue-specific expression, and the autoregulation by Pit-1/GHF-1 protein. The upstream promoter region contains a multiplicity of Pit-1/GHF-1 binding sites that do not show any synergistic interaction with the minimal promoter, The transcriptional activity is negatively regulated by Oct-1 and mediated by an octamer-binding site (OTF). In addition, we have also identified a 12-O-tetradecanoylphorbol-13-acetate-responsive element, which overlaps with a Pit-1/GHF-1 binding site. A mutually exclusive binding of the activator protein-1 (AP-1) and Pit-1/GHF-1 has been observed on this composite site, and AP-1 was shown to down-regulate PIT1/GHF1 transcription.	FREE UNIV BRUSSELS,SCH MED,DEPT PHARMACOL,LAARBEEKLAAN 103,B-1090 BRUSSELS,BELGIUM; UNIV AUTONOMA MADRID,CSIC,CTR BIOL MOL SEVERO OCHOA,E-28049 CANTO BLANCO,MADRID,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)			Delhase, Mireille/ABE-5256-2021; de la Hoya, MIguel/Z-2911-2019; RAJAS, Fabienne/P-4091-2016	Delhase, Mireille/0000-0003-2312-1051; RAJAS, Fabienne/0000-0002-9233-7633				ANDERSEN B, 1994, J BIOL CHEM, V269, P29335; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BACH I, 1995, P NATL ACAD SCI USA, V92, P2720, DOI 10.1073/pnas.92.7.2720; BAUMRUKER T, 1988, GENE DEV, V2, P1400, DOI 10.1101/gad.2.11.1400; BENDALL AJ, 1993, EUR J BIOCHEM, V217, P799, DOI 10.1111/j.1432-1033.1993.tb18308.x; BERGER I, 1994, DNA CELL BIOL, V13, P249, DOI 10.1089/dna.1994.13.249; BODNER M, 1987, CELL, V50, P267, DOI 10.1016/0092-8674(87)90222-4; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CAELLES C, 1995, MOL CELL BIOL, V15, P6694; CASTRILLO JL, 1991, SCIENCE, V253, P197, DOI 10.1126/science.1677216; CHEN RP, 1990, NATURE, V346, P583, DOI 10.1038/346583a0; CRENSHAW EB, 1989, GENE DEV, V3, P959, DOI 10.1101/gad.3.7.959; DAY RN, 1990, MOL ENDOCRINOL, V4, P1964, DOI 10.1210/mend-4-12-1964; DELHASE M, 1995, GENE, V155, P273, DOI 10.1016/0378-1119(94)00757-J; DELHASE M, 1993, J MOL ENDOCRINOL, V11, P129, DOI 10.1677/jme.0.0110129; DOLLE P, 1990, CELL, V60, P809, DOI 10.1016/0092-8674(90)90095-V; Habener JF, 1995, VITAM HORM, V51, P1, DOI 10.1016/S0083-6729(08)61037-7; HAUGEN BR, 1993, J BIOL CHEM, V268, P20818; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; HOLLOWAY JM, 1995, GENE DEV, V9, P1992, DOI 10.1101/gad.9.16.1992; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; JONG MTC, 1994, MOL ENDOCRINOL, V8, P1320, DOI 10.1210/me.8.10.1320; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; KEMLER I, 1991, NUCLEIC ACIDS RES, V19, P237, DOI 10.1093/nar/19.2.237; KIM MK, 1993, J BIOL CHEM, V268, P23366; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEFEVRE C, 1987, EMBO J, V6, P971, DOI 10.1002/j.1460-2075.1987.tb04847.x; LEW D, 1993, GENE DEV, V7, P683, DOI 10.1101/gad.7.4.683; LI P, 1993, GENE DEV, V7, P2483, DOI 10.1101/gad.7.12b.2483; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LIN CJ, 1992, NATURE, V360, P765, DOI 10.1038/360765a0; LIN SC, 1994, DEVELOPMENT, V120, P515; MANLEY JL, 1984, TRANSCRIPTION TRANSL, P71; MCCORMICK A, 1990, NATURE, V345, P829, DOI 10.1038/345829a0; MCCORMICK A, 1991, GENE DEV, V5, P1490, DOI 10.1101/gad.5.8.1490; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; PARKS JS, 1993, TRENDS ENDOCRIN MET, V4, P81, DOI 10.1016/1043-2760(93)90083-Q; PEERS B, 1990, MOL CELL BIOL, V10, P4690, DOI 10.1128/MCB.10.9.4690; POGNONEC P, 1991, NUCLEIC ACIDS RES, V19, P6650, DOI 10.1093/nar/19.23.6650; RHODES SJ, 1993, GENE DEV, V7, P913, DOI 10.1101/gad.7.6.913; Sambrook J., 2002, MOL CLONING LAB MANU; SANCHEZPACHECO A, 1995, MOL CELL BIOL, V15, P6322; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHAUFELE F, 1992, MOL ENDOCRINOL, V6, P656, DOI 10.1210/me.6.4.656; SHARP ZD, 1995, BIOCHEM BIOPH RES CO, V206, P40, DOI 10.1006/bbrc.1995.1006; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; STEINFELDER HJ, 1991, P NATL ACAD SCI USA, V88, P3130, DOI 10.1073/pnas.88.8.3130; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; THEILL LE, 1989, NATURE, V342, P945, DOI 10.1038/342945a0; THEILL LE, 1993, ENDOCR REV, V14, P670, DOI 10.1210/er.14.6.670; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; VERRIJZER CP, 1991, EMBO J, V10, P3007, DOI 10.1002/j.1460-2075.1991.tb07851.x	58	63	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32349	32358		10.1074/jbc.271.50.32349	http://dx.doi.org/10.1074/jbc.271.50.32349			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943298	hybrid			2022-12-25	WOS:A1996VY34000089
J	Espinas, ML; JimenezGarcia, E; MartinezBalbas, A; Azorin, F				Espinas, ML; JimenezGarcia, E; MartinezBalbas, A; Azorin, F			Formation of triple-stranded DNA at d(GA center dot TC)(n) sequences prevents nucleosome assembly and is hindered by nucleosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAGA TRANSCRIPTION FACTOR; DROSOPHILA-MELANOGASTER; HSP26 PROMOTER; CORE PARTICLES; HISTONES; HETEROCHROMATIN; CHROMATIN; REGIONS; GENE	Simple repeating d(GA . TC)(n) DNA sequences are frequently found at eukaryotic promoters, and in some cases they have been shown to be nucleosome free in vivo. These sequences show a high degree of structural polymorphism and are capable of adopting several types of non-B-DNA conformations, Here we show that the structural versatility of these sequences affects their ability to be packed into nucleosomes. Nucleosome assembly onto short double-stranded DNA fragments carrying d(GA . TC)(n) sequences of different length (n = 10 and n = 22) is very efficient, However, when the simple repeating sequence is forming a [CT(GA . TC)] tripler, nucleosome assembly is either prevented, as in the case of the d(GA . TC)(22) sequence, or results in the destabilization of the triple-stranded conformation, as in the case of the d(GA . TC)(10) sequence, Similarly, formation of triple-stranded DNA is hindered when the sequence is organized as nucleosomes. Efficient formation of tripler DNA occurs only at relatively high ionic strength (0.6 M NaCl), when the nucleosome is partially destabilized, and results in the disruption of the nucleosomal particle, These results indicate that nucleosome assembly and tripler formation are competing processes.	CSIC,CID,DEPT MOL & CELLULAR BIOL,BARCELONA 08034,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion y Desarrollo Pascual Vila (CID-CSIC)			Azorin, Fernando/N-4388-2014	Azorin, Fernando/0000-0002-8426-7858; Martinez-Balbas, Marian/0000-0003-0173-0964; Espinas, M Lluisa/0000-0003-3914-2228				AUSIO J, 1984, J MOL BIOL, V176, P77, DOI 10.1016/0022-2836(84)90383-8; Bernues J., 1995, NUCL ACIDS MOL BIOL, V9, P1; BIGGIN MD, 1988, CELL, V53, P699, DOI 10.1016/0092-8674(88)90088-8; BIRNBOIM HC, 1979, EUR J BIOCHEM, V98, P301, DOI 10.1111/j.1432-1033.1979.tb13189.x; EISENBERG H, 1981, J MOL BIOL, V150, P537, DOI 10.1016/0022-2836(81)90379-X; FRNAKKAMENETSKI.M, 1995, ANN REV BIOCH, V64, P65; GILMOUR DS, 1989, SCIENCE, V245, P1487, DOI 10.1126/science.2781290; KUNKEL GR, 1981, NUCLEIC ACIDS RES, V9, P6869, DOI 10.1093/nar/9.24.6869; LEE HS, 1992, GENE DEV, V6, P284, DOI 10.1101/gad.6.2.284; LINXWEILER W, 1985, CELL, V42, P281; LIXWEILER W, 1984, NUCLEIC ACIDS RES, V12, P9395; LOHE AR, 1993, GENETICS, V134, P1149; LU Q, 1995, EMBO J, V14, P4738, DOI 10.1002/j.1460-2075.1995.tb00155.x; MANOR H, 1988, J MOL EVOL, V27, P96, DOI 10.1007/BF02138367; MIRKIN MS, 1994, ANNU REV BIOPH BIOM, V23, P541; OHLENBUSCH HH, 1967, J MOL BIOL, V25, P299, DOI 10.1016/0022-2836(67)90143-X; PALECEK E, 1991, CRIT REV BIOCHEM MOL, V26, P151, DOI 10.3109/10409239109081126; PRUNELL A, 1982, EMBO J, V2, P173; RAFF JW, 1994, EMBO J, V13, P5977, DOI 10.1002/j.1460-2075.1994.tb06943.x; RHODES D, 1979, NUCLEIC ACIDS RES, V6, P1805, DOI 10.1093/nar/6.5.1805; SATCHWELL SC, 1986, J MOL BIOL, V191, P659, DOI 10.1016/0022-2836(86)90452-3; SIMPSON RT, 1979, NUCLEIC ACIDS RES, V6, P1387, DOI 10.1093/nar/6.4.1387; SOELLER WC, 1988, GENE DEV, V2, P68, DOI 10.1101/gad.2.1.68; SOELLER WC, 1993, MOL CELL BIOL, V13, P7961, DOI 10.1128/MCB.13.12.7961; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; WALL G, 1995, EMBO J, V14, P1727, DOI 10.1002/j.1460-2075.1995.tb07162.x; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; WESTIN L, 1995, NUCLEIC ACIDS RES, V23, P2184, DOI 10.1093/nar/23.12.2184	29	45	45	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					31807	31812		10.1074/jbc.271.50.31807	http://dx.doi.org/10.1074/jbc.271.50.31807			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943221	hybrid			2022-12-25	WOS:A1996VY34000012
J	McCullough, AK; Scharer, O; Verdine, GL; Lloyd, RS				McCullough, AK; Scharer, O; Verdine, GL; Lloyd, RS			Structural determinants for specific recognition by T4 endonuclease V	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCISION-REPAIR ENZYME; PYRIMIDINE DIMER; CATALYTIC ACTIVITIES; DNA; MECHANISM; T4-ENDONUCLEASE-V; BINDING	DNA glycosylases catalyze the scission of the N-glycosyl bond linking either a damaged or mismatched base to the DNA sugar phosphate backbone. T4 endonuclease V is a glycosylase/apurinic (AP) lyase that is specific for UV light-induced cis-syn pyrimidine dimers. As a proposed transition state analog/inhibitor for glycosylases, a phosphoramidite derivative containing a pyrrolidine residue has been synthesized. The binding of endonuclease V to this duplex was analyzed by gel mobility shift assays and resulted in a single stable complex of reduced mobility and an apparent K-d of 17 nM. To assess the importance of the positive charge for specific binding, studies using other non-cleavable substrate analogs were performed. Wild type T4 endonuclease V shows an g-fold decreased affinity for a tetrahydrofuran as compared with the pyrrolidine residue, demonstrating the significance of the positive charge for recognition. A S-fold increase in binding affinity for a reduced AP site was observed. Similar assays using catalytically compromised mutants (E23Q and E28D) of endonuclease V demonstrate altered affinities for the pyrrolidine as well as tetrahydrofuran and reduced AP sites. This approach has provided insight into the structural mechanism by which specific lesions are targeted by the protein as well as the structural determinants of the DNA required for specific recognition by T4 endonuclease V.	UNIV TEXAS,MED BRANCH,SEALY CTR MOL SCI,GALVESTON,TX 77555; UNIV TEXAS,MED BRANCH,DEPT HUMAN BIOL CHEM & GENET,GALVESTON,TX 77555; HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Harvard University			Schärer, Orlando D./AAF-8613-2021; Scharer, Orlando/B-8908-2008	Scharer, Orlando/0000-0003-2425-2715; Lloyd, R. Stephen/0000-0001-7273-372X	NIEHS NIH HHS [P30 ES06676, R01 ES04091] Funding Source: Medline; NIGMS NIH HHS [R55 GM51330-01] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676, R01ES004091] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM051330] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DODSON ML, 1993, BIOCHEMISTRY-US, V32, P8284, DOI 10.1021/bi00083a032; DODSON ML, 1994, J BIOL CHEM, V269, P32709; DOI T, 1992, P NATL ACAD SCI USA, V89, P9420, DOI 10.1073/pnas.89.20.9420; DOWD DR, 1989, J MOL BIOL, V208, P701, DOI 10.1016/0022-2836(89)90160-5; GRUSKIN EA, 1986, J BIOL CHEM, V261, P9607; LLOYD RS, 1980, NUCLEIC ACIDS RES, V8, P5113, DOI 10.1093/nar/8.21.5113; LLOYD RS, 1993, NUCLEASES, V2, P263; MANUEL RC, 1995, J BIOL CHEM, V270, P2652, DOI 10.1074/jbc.270.6.2652; MORIKAWA K, 1992, SCIENCE, V256, P523, DOI 10.1126/science.1575827; MORIKAWA K, 1995, J MOL BIOL, V249, P360, DOI 10.1006/jmbi.1995.0302; PRINCE MA, 1991, J BIOL CHEM, V266, P10686; SCHARER OD, 1995, J AM CHEM SOC, V117, P6623, DOI 10.1021/ja00129a039; SCHARER OD, 1996, THESIS HARVARD U CAM; SCHROCK RD, 1991, J BIOL CHEM, V266, P17631; SMITH CA, 1993, J BIOL CHEM, V268, P11143; TERRY BJ, 1983, J BIOL CHEM, V258, P9820; VASSYLYEV DG, 1995, CELL, V83, P773, DOI 10.1016/0092-8674(95)90190-6	17	30	30	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32147	32152		10.1074/jbc.271.50.32147	http://dx.doi.org/10.1074/jbc.271.50.32147			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943268	Green Published, hybrid			2022-12-25	WOS:A1996VY34000059
J	Sturrock, A; Franklin, KF; Hoidal, JR				Sturrock, A; Franklin, KF; Hoidal, JR			Human proteinase-3 expression is regulated by PU.1 in conjunction with a cytidine-rich element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR PU.1; COLONY-STIMULATING FACTOR; NEUTROPHIL SERINE PROTEINASE; LEUKEMIA CELL-LINE; FC-GAMMA RECEPTOR; CD11B PROMOTER; POLYMORPHONUCLEAR LEUKOCYTE; MURINE MYELOPEROXIDASE; RESTRICTED EXPRESSION; PUTATIVE ONCOGENE	Human proteinase-3 is one of three serine proteinases present in the azurophil granules of polymorphonuclear leukocytes along with elastase and cathepsin G. Proteinase-3 gene expression is confined to the promyelocytic stage of polymorphonuclear leukocyte maturation. The present investigation identifies elements responsible for this highly controlled tissue- and developmental-specific expression of proteinase-3. Within the first 200 base pairs of the proteinase-3 promoter, two elements were identified as important for expression, these elements at -101 and -190 confer the majority of the activity, The element at -101 has a PU.1 consensus, It binds a myeloid nuclear protein of approximately 45 kDa that ''super-shifts'' with PU,I antibody and is competed by the CD11b PU.1 element. The element at -190 has a core sequence of CCCCGCCC (CG element). The cytidines but not the guanidine are essential for promoter activity, The CG element binds a second nuclear protein with a molecular mass of approximately 40 kDa that is found in cells of myeloid Lineage as well as non-myeloid HeLa cells. However, the proteinase-3 promoter is not active in HeLa cells which suggests that the CG element alone is not sufficient for proteinase-3 gene expression. Maturation of promyelocytic cells results in an inhibition of proteinase-3 gene expression and a reduction in nuclear protein binding to the PU.1 and CG elements, Similar elements occur in the elastase and cathepsin G promoters, Using the elastase and cathepsin G PU.1 and CG-Like elements as probes results in identical band shift patterns to that obtained with proteinase-3 PU.1 and CG elements. These data suggest that there is cooperative interaction between a PU.1 and a CG element with a consensus of CCCCXCCC and that they are important control elements for tissue- and developmental-specific expression of azurophil serine proteinases of polymorphonuclear leukocytes.	UNIV UTAH, HLTH SCI CTR, DEPT INTERNAL MED, DIV RESP CRIT CARE & OCCUPAT MED, SALT LAKE CITY, UT 84132 USA	Utah System of Higher Education; University of Utah					NHLBI NIH HHS [5P50HL50153, 5R01HL37615] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL050153, R01HL037615] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHNE B, 1994, J BIOL CHEM, V269, P17794; ANDERSON GM, 1991, MOL CELL BIOL, V11, P1935, DOI 10.1128/MCB.11.4.1935; BAGGIOLINI M, 1978, AGENTS ACTIONS, V8, P3, DOI 10.1007/BF01972395; BARKER KA, 1988, MOL CELL BIOL, V8, P2804, DOI 10.1128/MCB.8.7.2804; BAUM C, 1994, BIOTECHNIQUES, V17, P1058; BORIES D, 1989, CELL, V59, P959, DOI 10.1016/0092-8674(89)90752-6; Carey JO, 1996, BLOOD, V87, P4316, DOI 10.1182/blood.V87.10.4316.bloodjournal87104316; CHEN HM, 1995, BLOOD, V85, P2918, DOI 10.1182/blood.V85.10.2918.bloodjournal85102918; CHEN HM, 1993, J BIOL CHEM, V268, P8230; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EICHBAUM QG, 1994, J EXP MED, V179, P1985, DOI 10.1084/jem.179.6.1985; FEINMAN R, 1994, EMBO J, V13, P3852, DOI 10.1002/j.1460-2075.1994.tb06696.x; FRANZOSO G, 1994, J EXP MED, V180, P1445, DOI 10.1084/jem.180.4.1445; GABAY JE, 1993, CURR OPIN IMMUNOL, V5, P97, DOI 10.1016/0952-7915(93)90087-9; GHOSH D, 1992, NUCLEIC ACIDS RES, V20, P2091, DOI 10.1093/nar/20.suppl.2091; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GREER P, 1990, MOL CELL BIOL, V10, P2521, DOI 10.1128/MCB.10.6.2521; HANSON RD, 1990, J BIOL CHEM, V265, P1524; HENSON PM, 1987, J CLIN INVEST, V79, P669, DOI 10.1172/JCI112869; HEUSEL JW, 1991, J BIOL CHEM, V266, P6152; HOHAUS S, 1995, MOL CELL BIOL, V15, P5830; HOHN PA, 1989, J BIOL CHEM, V264, P13412; HROMAS R, 1993, BLOOD, V82, P2998; JANOFF A, 1985, ANNU REV MED, V36, P207; JENNE DE, 1990, NATURE, V346, P520, DOI 10.1038/346520a0; JENNETTE JC, 1991, INT REV EXP PATHOL, V32, P193; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KALLENBERG CGM, 1991, IMMUNOL TODAY, V12, P61, DOI 10.1016/0167-5699(91)90159-Q; KAO RC, 1988, J CLIN INVEST, V82, P1963, DOI 10.1172/JCI113816; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOMINATO Y, 1995, MOL CELL BIOL, V15, P58; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LUDEMANN J, 1990, J EXP MED, V171, P357, DOI 10.1084/jem.171.1.357; MAURY W, 1994, J VIROL, V68, P6270, DOI 10.1128/JVI.68.10.6270-6279.1994; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MORISHITA K, 1987, J BIOL CHEM, V262, P15208; MORRIS JF, 1995, BLOOD, V86, P3640; NILES JL, 1989, BLOOD, V74, P1888; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; PAHL HL, 1992, BLOOD, V79, P865; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PARRY GCN, 1994, J BIOL CHEM, V269, P20823; PAUL R, 1991, J VIROL, V65, P464, DOI 10.1128/JVI.65.1.464-467.1991; PEREZ C, 1993, MOL CELL BIOL, V13, P2182, DOI 10.1128/MCB.13.4.2182; PEREZ C, 1994, MOL CELL BIOL, V14, P5023, DOI 10.1128/MCB.14.8.5023; PERLINO E, 1987, EMBO J, V6, P2767, DOI 10.1002/j.1460-2075.1987.tb02571.x; PETTERSSON M, 1987, GENE DEV, V1, P962, DOI 10.1101/gad.1.9.962; RAO NV, 1991, J BIOL CHEM, V266, P9540; RAO NV, 1993, AM J RESP CELL MOL, V8, P612, DOI 10.1165/ajrcmb/8.6.612; ROSMARIN AG, 1995, P NATL ACAD SCI USA, V92, P801, DOI 10.1073/pnas.92.3.801; ROSMARIN AG, 1992, BLOOD, V79, P2598; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHAPIRO LH, 1991, J BIOL CHEM, V266, P11999; SHELLEY CS, 1993, P NATL ACAD SCI USA, V90, P5364, DOI 10.1073/pnas.90.11.5364; SMITH LT, 1994, BLOOD, V84, pA372; SPANOPOULOU E, 1991, MOL CELL BIOL, V11, P2216, DOI 10.1128/MCB.11.4.2216; SPECTOR NL, 1995, J BIOL CHEM, V270, P1003, DOI 10.1074/jbc.270.3.1003; SRIKANTH S, 1994, J BIOL CHEM, V269, P32626; STURROCK AB, 1992, J BIOL CHEM, V267, P21193; SUN ZJ, 1995, J BIOL CHEM, V270, P1462, DOI 10.1074/jbc.270.3.1462; SUZOW J, 1993, MOL CELL BIOL, V13, P2141, DOI 10.1128/MCB.13.4.2141; TAKAHASHI H, 1988, J BIOL CHEM, V263, P14739; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; VOSO MT, 1994, P NATL ACAD SCI USA, V91, P7932, DOI 10.1073/pnas.91.17.7932; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WU C, 1987, SCIENCE, V238, P1247, DOI 10.1126/science.3685975; Zhang DE, 1996, CURR TOP MICROBIOL, V211, P137; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085; ZIMMER M, 1992, P NATL ACAD SCI USA, V89, P8215, DOI 10.1073/pnas.89.17.8215	75	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32392	32402		10.1074/jbc.271.50.32392	http://dx.doi.org/10.1074/jbc.271.50.32392			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943304	hybrid			2022-12-25	WOS:A1996VY34000095
J	Bao, M; Elmendorf, BJ; Booth, JL; Drake, RR; Canfield, WM				Bao, M; Elmendorf, BJ; Booth, JL; Drake, RR; Canfield, WM			Bovine UDP-N-acetylglucosamine:lysosomal-enzyme N-acetylglucosamine-1-phosphotransferase .2. Enzymatic characterization and identification of the catalytic subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN RECOGNITION DETERMINANTS; GLYCOPROTEIN N-ACETYLGLUCOSAMINE-1-PHOSPHOTRANSFERASE; ACANTHAMOEBA-CASTELLANII; CARBOHYDRATE STRUCTURE; PROCATHEPSIN-D; CATHEPSIN-D; PHOSPHORYLATION; UTEROFERRIN; OLIGOSACCHARIDES; PURIFICATION	The kinetic properties of UDP-N-acetylglucosamine: lysosomal-enzyme N-acetylglucosamine-1-phosphotransferase (GlcNAc-phosphotransferase) purified to homogeneity from lactating bovine mammary gland have been investigated. GlcNAc-phosphotransferase transferred GlcNAc 1-phosphate from UDP-GlcNAc to the synthetic acceptor alpha-methylmannoside, generating GlcNAc-1-phospho-6-mannose alpha-methyl, the structure of which was confirmed by mass spectroscopy, GlcNAc-phosphotransferase was active between pH 5.7 and 9.3, with optimal activity between pH 6.6 and 7.5, Activity was strictly dependent on Mg2+ or Mn2+. The K-m for Mn2+ was 185 mu M. The K-m for UDP-GlcNAc was 30 mu M, and that for alpha-methylmannoside was 63 mM. The enzyme was competitively inhibited by UDP-Glc, with a K-i of 733 mu M. The 166-kDa subunit was identified as the catalytic subunit by photoaffinity labeling with azido-[beta-P-32]UDP-Glc. Purified GlcNAc-phosphotransferase utilizes the lysosomal enzyme uteroferrin similar to 163-fold more effectively than the non-lysosomal glycoprotein ribonuclease B. Antibodies to GlcNAc-phosphotransferase blocked the transfer to cathepsin D, but not to alpha-methylmannoside, suggesting that protein-protein interactions are required for the efficient utilization of glycoprotein accepters, These results indicate that the purified bovine GlcNAc-phosphotransferase retains the specificity for lysosomal enzymes as accepters previously observed with crude preparations.	UNIV OKLAHOMA,HLTH SCI CTR,WK WARREN MED RES INST,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT MED,OKLAHOMA CITY,OK 73104; UNIV ARKANSAS MED SCI HOSP,DEPT BIOCHEM & MOL BIOL,LITTLE ROCK,AR 72205	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Arkansas System; University of Arkansas Medical Sciences								Bao M, 1996, J BIOL CHEM, V271, P31437, DOI 10.1074/jbc.271.49.31437; BARANSKI TJ, 1992, J BIOL CHEM, V267, P23342; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; BUHI WC, 1982, BIOCHIM BIOPHYS ACTA, V701, P32, DOI 10.1016/0167-4838(82)90308-9; CANTOR AB, 1992, J BIOL CHEM, V267, P23349; COUSO R, 1986, J BIOL CHEM, V261, P6326; DRAKE RR, 1989, J BIOL CHEM, V264, P11928; HUANG JS, 1979, J BIOL CHEM, V254, P1405; KETCHAM CM, 1992, J BIOL CHEM, V267, P11645; KETCHAM CM, 1992, J BIOL CHEM, V267, P11654; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG L, 1986, J BIOL CHEM, V261, P6320; LANG L, 1984, J BIOL CHEM, V259, P4663; MULLIS KG, 1992, ANAL BIOCHEM, V205, P200, DOI 10.1016/0003-2697(92)90424-6; RADOMINSKA A, 1994, METHOD ENZYMOL, V230, P330; REITMAN ML, 1984, METHOD ENZYMOL, V107, P163; SAUNDERS PTK, 1985, J BIOL CHEM, V260, P3658; SHERWOOD LM, 1965, J BIOL CHEM, V240, P3799; TAKAHASHI T, 1983, J BIOL CHEM, V258, P2819	19	51	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31446	31451		10.1074/jbc.271.49.31446	http://dx.doi.org/10.1074/jbc.271.49.31446			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940156	hybrid			2022-12-25	WOS:A1996VW68600067
J	Braun, RP; Wyatt, GR				Braun, RP; Wyatt, GR			Sequence of the hexameric juvenile hormone-binding protein from the hemolymph of Locusta migratoria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-MOLECULAR-WEIGHT; PHENOL OXIDASE; MANDUCA-SEXTA; FAT-BODY; ARTHROPOD HEMOCYANINS; NUCLEOTIDE-SEQUENCE; INSECT HEMOLYMPH; MESSENGER-RNA; JH-III; CLONING	The cDNA for the hexameric hemolymph juvenile hormone-binding protein (JRBP) from the migratory locust has been cloned and sequenced, Antiserum raised against purified JHBP was used to identify clones in an expression library. The 4.3-kilobase JHBP mRNA codes for 668 amino acids (74.4 kDa) and contains 2 kilobases of 3'-untranslated region, The derived amino acid sequence reveals that locust JHBP represents a new group within the hexamerin family of arthropod proteins. JHBP appears to be more closely related to arthropod hemocyanins, the believed ancestors of the family, than to the other known insect hexamerins. The mRNA shows a high (89%) bias to codons ending in G or C and the codons ending in A or T are clustered and concentrated toward the 5' end, suggesting a mosaic gene structure. The recombinant bacterially expressed protein bound [H-3]JH III with the same affinity as the protein from hemolymph. A truncated version of JHBP lacking 53 amino acids from the N terminus did not bind JH III. Hybridization analysis of fat body JHBP mRNA in locusts that had been treated with precocene and a JH analog did not give clear evidence for regulation by JH.	QUEENS UNIV,DEPT BIOL,KINGSTON,ON K7L 3N6,CANADA	Queens University - Canada								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ancsin JB, 1996, INSECT BIOCHEM MOLEC, V26, P501, DOI 10.1016/0965-1748(96)00005-7; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BEINTEMA JJ, 1994, MOL BIOL EVOL, V11, P493; BRADFIELD JY, 1985, DNA-J MOLEC CELL BIO, V4, P357, DOI 10.1089/dna.1985.4.357; BRAUN RP, 1995, ARCH INSECT BIOCHEM, V28, P291, DOI 10.1002/arch.940280309; CHINZEI Y, 1982, CAN J BIOCHEM CELL B, V60, P243, DOI 10.1139/o82-029; CHINZEI Y, 1985, J INSECT PHYSIOL, V31, P441, DOI 10.1016/0022-1910(85)90090-3; COUILLAUD F, 1987, EXPERIENTIA, V43, P312, DOI 10.1007/BF01945564; DEBRUIJN SM, 1986, PHYSIOL ENTOMOL, V11, P7, DOI 10.1111/j.1365-3032.1986.tb00385.x; DEKORT CAD, 1986, EXPERIENTIA, V42, P834, DOI 10.1007/BF01941544; EDWARDS GC, 1993, J INSECT PHYSIOL, V39, P609, DOI 10.1016/0022-1910(93)90043-Q; FAJARDO MA, 1994, DEV BIOL, V166, P643, DOI 10.1006/dbio.1994.1344; FUJIMOTO K, 1995, P NATL ACAD SCI USA, V92, P7769, DOI 10.1073/pnas.92.17.7769; GAYKEMA WPJ, 1984, NATURE, V309, P23, DOI 10.1038/309023a0; GELLISSEN G, 1981, CAN J BIOCHEM CELL B, V59, P648, DOI 10.1139/o81-090; GLINKA AV, 1995, INSECT BIOCHEM MOLEC, V25, P775, DOI 10.1016/0965-1748(94)00098-3; Glinka AV, 1996, INSECT BIOCHEM MOLEC, V26, P13, DOI 10.1016/0965-1748(95)00045-3; HALL M, 1995, P NATL ACAD SCI USA, V92, P7764, DOI 10.1073/pnas.92.17.7764; HANZLIK TN, 1989, J BIOL CHEM, V264, P12419; ISMAIL SM, 1995, ARCH INSECT BIOCHEM, V29, P415, DOI 10.1002/arch.940290408; Jamroz RC, 1996, J INSECT PHYSIOL, V42, P115, DOI 10.1016/0022-1910(95)00093-3; JONES G, 1990, J BIOL CHEM, V265, P8596; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; Kanost M.R., 1990, Advances in Insect Physiology, V22, P299, DOI 10.1016/S0065-2806(08)60008-9; KANOST MR, 1988, J BIOL CHEM, V263, P10568; KANOST MR, 1988, ARCH INSECT BIOCHEM, V8, P203, DOI 10.1002/arch.940080402; KAWABATA T, 1995, P NATL ACAD SCI USA, V92, P7774, DOI 10.1073/pnas.92.17.7774; KOOPMANSCHAP AB, 1988, ARCH INSECT BIOCHEM, V7, P105, DOI 10.1002/arch.940070204; KRIEGER J, 1990, INSECT BIOCHEM, V20, P173, DOI 10.1016/0020-1790(90)90010-R; LERRO KA, 1990, J BIOL CHEM, V265, P19800; MATTMAN RG, 1994, EUR J BIOCHEM, V221, P801; MEMMEL NA, 1994, INSECT BIOCHEM MOLEC, V24, P133, DOI 10.1016/0965-1748(94)90079-5; MIURA K, 1994, ZOOL SCI, V11, P537; RAMING K, 1993, CELL SIGNAL, V5, P69, DOI 10.1016/0898-6568(93)90009-B; RETNAKARAN A, 1985, COMPREHENSIVE INSECT, V8, P529; RIDDIFORD LM, 1994, ADV INSECT PHYSIOL, V24, P213, DOI 10.1016/S0065-2806(08)60084-3; SACCHETTINI JC, 1989, P NATL ACAD SCI USA, V86, P7736, DOI 10.1073/pnas.86.20.7736; SHARE MR, 1988, ANAL BIOCHEM, V169, P81, DOI 10.1016/0003-2697(88)90257-6; TELFER WH, 1991, ANNU REV ENTOMOL, V36, P205, DOI 10.1146/annurev.en.36.010191.001225; TOBE SS, 1985, INSECT BIOCHEM, V15, P175, DOI 10.1016/0020-1790(85)90005-8; TOUHARA K, 1993, BIOCHEMISTRY-US, V32, P2068, DOI 10.1021/bi00059a026; TROWELL SC, 1992, COMP BIOCHEM PHYS B, V103, P795, DOI 10.1016/0305-0491(92)90196-X; WILLOTT E, 1989, J BIOL CHEM, V264, P19052; Wyatt GR, 1996, ADV INSECT PHYSIOL, V26, P1, DOI 10.1016/S0065-2806(08)60030-2; ZHANG JZ, 1993, J BIOL CHEM, V268, P3282	46	68	76	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31756	31762		10.1074/jbc.271.49.31756	http://dx.doi.org/10.1074/jbc.271.49.31756			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940201	hybrid			2022-12-25	WOS:A1996VW68600112
J	Lai, TS; Slaughter, TF; Koropchak, CM; Haroon, ZA; Greenberg, CS				Lai, TS; Slaughter, TF; Koropchak, CM; Haroon, ZA; Greenberg, CS			C-terminal deletion of human tissue transglutaminase enhances magnesium-dependent GTP/ATPase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG LIVER TRANSGLUTAMINASE; GTP-BINDING PROTEIN; CROSS-LINKING ENZYMES; PROGRAMMED CELL-DEATH; FACTOR-XIII; SITE; IDENTIFICATION; HYDROLYSIS; G(H)	Tissue transglutaminase (tTG) exhibits a magnesium-dependent GTP/ATPase activity that is involved in the regulation of the cell cycle and cell receptor signaling, The portion of the molecule involved in GTP/ATP hydrolysis is unknown, We expressed and purified a series of C-terminal truncation mutants of human tTG as glutathione S-transferase fusion proteins (Delta S538, Delta E447, Delta P345, Delta C290, Delta V228, and Delta F185) to determine the effect on GTP/ATPase activity, The truncation of the C terminus did not change significantly the apparent k(m) value for either GTP or ATP, In contrast, the K-cat value for GTP was increased by 4.6- and S-fold for the Delta 5538 and Delta E447 mutants, respectively, The Delta P845 mutant had the highest hydrolysis activity with a 34-fold increase, The hydrolysis activity then declined to 8.1, 8.7-, and 1.9-fold for the Delta C240, Delta V228, and Delta F185 mutants, respectively, The K-cat for ATP changed in parallel with the GTPase results, Thin layer chromatography analysis of the hydrolysis reaction products revealed that ATP was rapidly converted to ADP followed by a much slower conversion of ADP to AMP when incubated with wild type tTG or the Delta P345 mutant, There was a substantial decrease in the calcium-dependent TGase activity when the last 149 amino acid residues were deleted from the C terminus, Less than 5% of the TGase activity was detected for the Delta S538 and Delta E447 mutants, In conclusion, we have located the ATP and GTP hydrolytic domain to amino acid residues 1-185, The C terminus functions to inhibit the expression of endogenous GTP/ATPase activity of tTG, and the potential role of the C terminus in modulating this activity is discussed.	DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT ANESTHESIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710	Duke University; Duke University; Duke University				, Thung-Shen/0000-0002-8791-9698	NHLBI NIH HHS [HL28391, HL 38245] Funding Source: Medline; NIAMS NIH HHS [AR 39162] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038245, P60HL028391] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR039162] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ACHYUTHAN KE, 1987, J BIOL CHEM, V262, P1901; AESCHLIMANN D, 1993, J CELL BIOL, V120, P1461, DOI 10.1083/jcb.120.6.1461; AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; Azim AC, 1996, BIOCHEMISTRY-US, V35, P3001, DOI 10.1021/bi951745y; BERGAMINI CM, 1988, FEBS LETT, V239, P255, DOI 10.1016/0014-5793(88)80928-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN ZP, 1995, J NEUROENDOCRINOL, V7, P83, DOI 10.1111/j.1365-2826.1995.tb00671.x; FESUS L, 1991, EUR J CELL BIOL, V56, P170; FESUS L, 1987, FEBS LETT, V224, P104, DOI 10.1016/0014-5793(87)80430-1; FRAIJ BM, 1992, J BIOL CHEM, V267, P22616; Fraij BM, 1996, BIOCHEM BIOPH RES CO, V218, P45, DOI 10.1006/bbrc.1996.0009; Fraij BM, 1996, BBA-GENE STRUCT EXPR, V1306, P63, DOI 10.1016/0167-4781(95)00219-7; GENTILE V, 1991, J BIOL CHEM, V266, P478; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HWANG KC, 1995, J BIOL CHEM, V270, P27058, DOI 10.1074/jbc.270.45.27058; IKURA K, 1995, ARCH BIOCHEM BIOPHYS, V318, P307, DOI 10.1006/abbi.1995.1234; JEONG JM, 1995, J BIOL CHEM, V270, P5654, DOI 10.1074/jbc.270.10.5654; JOHNSON TS, 1994, ONCOGENE, V9, P2935; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; KORNER G, 1989, BIOCHEM J, V262, P633, DOI 10.1042/bj2620633; LAI TS, 1994, J BIOL CHEM, V269, P24596; LEE KN, 1993, BIOCHIM BIOPHYS ACTA, V1202, P1, DOI 10.1016/0167-4838(93)90055-V; LEE KN, 1989, BIOCHEM BIOPH RES CO, V162, P1370, DOI 10.1016/0006-291X(89)90825-5; MIAN S, 1995, FEBS LETT, V370, P27, DOI 10.1016/0014-5793(95)00782-5; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; RINAS U, 1990, BIOL CHEM H-S, V371, P49, DOI 10.1515/bchm3.1990.371.1.49; SINGH US, 1995, BIOCHEMISTRY-US, V34, P15863, DOI 10.1021/bi00048a032; SLAUGHTER TF, 1992, ANAL BIOCHEM, V205, P166, DOI 10.1016/0003-2697(92)90594-W; TAKEUCHI Y, 1992, FEBS LETT, V307, P177, DOI 10.1016/0014-5793(92)80762-6; TAKEUCHI Y, 1994, Z NATURFORSCH C, V49, P453; UPCHURCH HF, 1991, J CELL PHYSIOL, V149, P375, DOI 10.1002/jcp.1041490304; YEE VC, 1994, P NATL ACAD SCI USA, V91, P7296, DOI 10.1073/pnas.91.15.7296	32	72	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31191	31195		10.1074/jbc.271.49.31191	http://dx.doi.org/10.1074/jbc.271.49.31191			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940119	hybrid			2022-12-25	WOS:A1996VW68600030
J	Metz, AM; Browning, KS				Metz, AM; Browning, KS			Mutational analysis of the functional domains of the large subunit of the isozyme form of wheat initiation factor eIF4F	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS INITIATION; MESSENGER-RNA; TRANSLATION INITIATION; ELONGATION-FACTORS; GERM; PHOSPHORYLATION; BINDING; COMPLEX; INSULIN; SEQUENCE	The isozyme form of plant eukaryotic initiation factor 4F (eIF(iso)4F) contains two subunits: p28, a cap-binding protein, and p86. To identify the functional domains of p86, truncations of the p86 cDNA were made, and the protein was expressed in Escherichia coli and purified, The deletion mutants were tested for the ability to bind the p28 subunit by two methods, In addition, these deletion mutants were evaluated in vitro by the ability to catalyze eIF4A and RNA-dependent ATP hydrolysis and to support polypeptide synthesis. The loss of the ability to bind p28 occurs within the first 90 amino acids of the N terminus and abrogates the ability of pad to participate in translation initiation and bind to eIF4A, but does not affect ATP hydrolysis, Up to 299 amino acid residues from the C terminus of p86 must be deleted before an effect is observed on the ATP hydrolysis activity. Thus, the p28 binding and ATP hydrolysis activities appear to lie on two separate domains and are functionally uncoupled. In addition, at least a portion of the eIF4A binding domain appears to be in close proximity to the p28 binding domain and is also uncoupled from the ATP hydrolysis activity.	UNIV TEXAS, DEPT CHEM & BIOCHEM, AUSTIN, TX 78712 USA	University of Texas System; University of Texas Austin								ABRAMSON RD, 1988, J BIOL CHEM, V263, P5462; ALLEN ML, 1992, J BIOL CHEM, V267, P23232; BOKROS CL, 1995, P NATL ACAD SCI USA, V92, P7120, DOI 10.1073/pnas.92.15.7120; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNING KS, 1987, J BIOL CHEM, V262, P11228; BROWNING KS, 1992, J BIOL CHEM, V267, P10096; BROWNING KS, 1990, J BIOL CHEM, V265, P17967; BROWNING KS, 1996, IN PRESS PLANT MOL B; BU X, 1993, J BIOL CHEM, V268, P4975; ETCHISON D, 1987, MOL CELL BIOCHEM, V76, P15; GOYER C, 1993, MOL CELL BIOL, V13, P4860, DOI 10.1128/MCB.13.8.4860; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; LAX S, 1985, P NATL ACAD SCI USA, V82, P330, DOI 10.1073/pnas.82.2.330; LAX SR, 1986, METHOD ENZYMOL, V118, P109; LAX SR, 1986, J BIOL CHEM, V261, P5632; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MADER S, 1995, MOL CELL BIOL, V15, P4990; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MERRICK WC, 1994, BIOCHIMIE, V76, P822, DOI 10.1016/0300-9084(94)90183-X; MORLEY SJ, 1995, J CELL SCI, V108, P1751; MORLEY SJ, 1990, J BIOL CHEM, V265, P10611; Ohlmann T, 1996, EMBO J, V15, P1371, DOI 10.1002/j.1460-2075.1996.tb00479.x; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; RHOADS RE, 1994, BIOCHIMIE, V76, P831, DOI 10.1016/0300-9084(94)90184-8; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SHA M, 1995, J BIOL CHEM, V270, P29904; SONENBERG N, 1994, BIOCHIMIE, V76, P839, DOI 10.1016/0300-9084(94)90185-6; SONENBERG N, 1990, New Biologist, V2, P402; TIMMER RT, 1993, J BIOL CHEM, V268, P9504; TIMMER RT, 1993, J BIOL CHEM, V268, P24863; VANHEERDEN A, 1994, J BIOL CHEM, V269, P17454; WEBSTER C, 1991, J BIOL CHEM, V266, P23341; YAN RQ, 1992, J BIOL CHEM, V267, P23226	36	27	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31033	31036		10.1074/jbc.271.49.31033	http://dx.doi.org/10.1074/jbc.271.49.31033			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940096	hybrid			2022-12-25	WOS:A1996VW68600007
J	Sah, VP; Hoshijima, M; Chien, KR; Brown, JH				Sah, VP; Hoshijima, M; Chien, KR; Brown, JH			Rho is required for G alpha(q) and alpha(1)-adrenergic receptor signaling in cardiomyocytes - Dissociation of Ras and Rho pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; MYOSIN LIGHT CHAIN-2; ATRIAL-NATRIURETIC-FACTOR; MUSCLE CELL HYPERTROPHY; ACTIN STRESS FIBERS; SWISS 3T3 CELLS; GENE-EXPRESSION; TYROSINE PHOSPHORYLATION; VENTRICULAR MYOCYTES; MYOCARDIAL-CELLS	G protein coupled receptor agonists initiate a cascade of signaling events in neonatal rat ventricular myocytes that culminates in changes in gene expression and cell growth characteristic of hypertrophy, These responses have been previously shown to be dependent on G(q) and Ras, Rho, a member of the Ras superfamily of GTPases, regulates cytoskeletal rearrangement and transcrip tional activation of the c-fos serum response element, Immunofluorescence staining of cardiomyocytes shows that Rho is present and predominantly cytosolic, We used two inhibitors of Rho function, dominant negative N19RhoA and Clostridium botulinum C3 transferase, to examine the possible requirement for Rho in alpha(1)-adrenergic receptor mediated hypertrophy, Both inhibitors markedly attenuated atrial natriuretic factor (ANF) reporter gene expression induced by alpha(1)-adrenergic receptor stimulation with phenylephrine, and virtually abolished the increase in ANF reporter gene expression induced by GTPase-deficient G alpha(q). These effects were reproduced with the myosin light chain-g reporter gene, Notably, N19RhoA did not block the ability of activated Ras to induce ANF and myosin light chain-a reporter gene expression, Furthermore, activation of the extracellular signal-regulated kinase by phenylephrine was not blocked by N19RhoA, nor was it stimulated by an activated mutant of RhoA, Since activated RhoA and Ras produce a large synergistic effect on ANF-luciferase gene expression, we conclude that Rho functions in a pathway separate from but complementary to Ras, Our results provide direct evidence that Rho is an effector of G alpha(q) signaling and suggest for the first time that a low molecular weight GTPase other than Ras is involved in regulating myocardial cell growth and gene expression in response to heterotrimeric G protein-linked receptor activation.	UNIV CALIF SAN DIEGO, DEPT PHARMACOL, SAN DIEGO, CA 92093 USA; UNIV CALIF SAN DIEGO, GRAD PROGRAM BIOMED SCI, SAN DIEGO, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT MED, CTR MOL GENET, SAN DIEGO, CA 92093 USA; UNIV CALIF SAN DIEGO, AMER HEART ASSOC, BUGHER FDN CTR MOL BIOL, SAN DIEGO, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028143, R37HL028143, P01HL046345] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL28143, HL46345] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; ARAGAY AM, 1995, J BIOL CHEM, V270, P20073, DOI 10.1074/jbc.270.34.20073; BISHOPRIC NH, 1987, J CLIN INVEST, V80, P1194, DOI 10.1172/JCI113179; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P26303, DOI 10.1074/jbc.270.44.26303; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BRYANT SS, 1995, J BIOL CHEM, V270, P17947, DOI 10.1074/jbc.270.30.17947; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; FRITZ G, 1994, BBA-MOL CELL RES, V1222, P331, DOI 10.1016/0167-4889(94)90038-8; GILLESPIEBROWN J, 1995, J BIOL CHEM, V270, P28092; Glennon PE, 1996, CIRC RES, V78, P954, DOI 10.1161/01.RES.78.6.954; HENDERSON SA, 1989, J BIOL CHEM, V264, P18142; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; IWAKI K, 1990, J BIOL CHEM, V265, P13809; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; JUST I, 1992, J BIOL CHEM, V267, P10274; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; KNOWLTON KU, 1993, J BIOL CHEM, V268, P15374; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; LAMORTE VJ, 1994, J BIOL CHEM, V269, P13490; LEE HR, 1988, J BIOL CHEM, V263, P7352; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MOHR C, 1992, FEBS LETT, V297, P95, DOI 10.1016/0014-5793(92)80335-E; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Post GR, 1996, J BIOL CHEM, V271, P8452, DOI 10.1074/jbc.271.14.8452; Post GR, 1996, MOL BIOL CELL, V7, P1679, DOI 10.1091/mbc.7.11.1679; RAMIREZ MT, 1995, J BIOL CHEM, V270, P8446, DOI 10.1074/jbc.270.15.8446; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SCHLAEPFER DD, 1994, NATURE, V372, P786; SECKL MJ, 1995, J BIOL CHEM, V270, P6984, DOI 10.1074/jbc.270.12.6984; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SHUBEITA HE, 1992, P NATL ACAD SCI USA, V89, P1305, DOI 10.1073/pnas.89.4.1305; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023; SIMPSON P, 1985, CIRC RES, V56, P884, DOI 10.1161/01.RES.56.6.884; THORBURN A, 1994, BIOCHEM BIOPH RES CO, V205, P1417, DOI 10.1006/bbrc.1994.2823; THORBURN A, 1993, J BIOL CHEM, V268, P2244; THORBURN J, 1994, J BIOL CHEM, V269, P30580; THORBURN J, 1994, J CELL BIOL, V126, P1565, DOI 10.1083/jcb.126.6.1565; Tigyi G, 1996, J NEUROCHEM, V66, P537; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; WASPE LE, 1990, J CLIN INVEST, V85, P1206, DOI 10.1172/JCI114554; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	62	193	204	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31185	31190		10.1074/jbc.271.49.31185	http://dx.doi.org/10.1074/jbc.271.49.31185			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940118	hybrid			2022-12-25	WOS:A1996VW68600029
J	Tabuchi, A; Oh, E; Taoka, A; Sakurai, H; Tsuchiya, T; Tsuda, M				Tabuchi, A; Oh, E; Taoka, A; Sakurai, H; Tsuchiya, T; Tsuda, M			Rapid attenuation of AP-1 transcriptional factors associated with nitric oxide (NO)-mediated neuronal cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; CEREBELLAR GRANULE CELLS; METHYL-D-ASPARTATE; C-FOS; MESSENGER-RNA; ACTIVATION; PROTEIN; JUN; APOPTOSIS; CULTURES	Stimulation of glutamate receptors causes several intracellular reactions including activation of activator protein-1 (AP-1) production and nitric oxide (NO) generation, Exposing mouse cerebellar granule cells to N-methyl-D-aspartate or kainate (KA) in culture induced an increase of AP 1 DNA binding activity that was blocked by further addition of sodium nitroprusside (SNP), a typical NO donor. Immunoblotting using antic-Fos antiserum revealed the specific attenuation of AP-1, although total protein synthesis was not affected, Since the level of c-fos mRNA expression stimulated by KA remained constant even after exposure to SNP, the AP-1 attenuation can be post-transcriptionally induced. SNP did not affect the Ca2+ influx into the cells stimulated by KA. The involvement of NO in the AP-1 attenuation was supported by the fact that potassium ferrocyanide (K4Fe(CN)(6)), an analogue of SNP but devoid of NO, failed to inhibit the AP-1 DNA binding activity stimulated by Kk SNP alone induced neuronal cell death, which was blocked by the simultaneous addition of antioxidants, superoxide dismutase and catalase, and an NO scavenger, suggesting a direct role of peroxynitrite in the cell death. In good agreement with Obese effects, the AP-I attenuation by SNP was also blocked by anti oxidants. These results indicated that post-transcriptional attenuation of AP-1 is involved in the early processes of NO-mediated neuronal cell death.	OKAYAMA UNIV,FAC PHARMACEUT SCI,DEPT MICROBIOL,OKAYAMA 700,JAPAN	Okayama University			Sakurai, Hiroaki/AAE-4294-2019	Sakurai, Hiroaki/0000-0003-0657-9570				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; AKAIKE T, 1993, BIOCHEMISTRY-US, V32, P827, DOI 10.1021/bi00054a013; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; BATES JN, 1991, BIOCHEM PHARMACOL, V42, pS157, DOI 10.1016/0006-2952(91)90406-U; BECKMAN JS, 1991, J DEV PHYSIOL, V15, P53; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BUISSON A, 1993, J NEUROCHEM, V61, P690; CURRAN RD, 1991, FASEB J, V5, P2085, DOI 10.1096/fasebj.5.7.1707021; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; DRAGUNOW M, 1995, BRAIN RES REV, V21, P1, DOI 10.1016/0165-0173(95)00003-L; DRAPIER JC, 1993, EMBO J, V12, P3643, DOI 10.1002/j.1460-2075.1993.tb06038.x; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; HEALES SJR, 1994, BRAIN RES, V668, P243, DOI 10.1016/0006-8993(94)90530-4; KIEDROWSKI L, 1992, MOL PHARMACOL, V41, P779; KIESSLING M, 1993, J CEREBR BLOOD F MET, V13, P914, DOI 10.1038/jcbfm.1993.114; KUMAR S, 1995, FEBS LETT, V375, P169, DOI 10.1016/0014-5793(95)01186-I; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MAKI A, 1992, FASEB J, V6, P919, DOI 10.1096/fasebj.6.3.1740241; MCDONALD LJ, 1993, P NATL ACAD SCI USA, V90, P6238, DOI 10.1073/pnas.90.13.6238; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MURPHY TH, 1988, BRAIN RES, V460, P155, DOI 10.1016/0006-8993(88)91216-4; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OHTANI K, 1995, J NEUROCHEM, V65, P605; PELLEGRINIGIAMPIETRO DE, 1990, J NEUROSCI, V10, P1035, DOI 10.1523/jneurosci.10-03-01035.1990; SAKURAI H, 1992, J NEUROCHEM, V59, P2067; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; SHIBUKI K, 1991, NATURE, V349, P326, DOI 10.1038/349326a0; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; SZEKELY AM, 1989, MOL PHARMACOL, V35, P401; SZEKELY AM, 1990, MOL PHARMACOL, V38, P624; TABUCHI A, 1994, FEBS LETT, V351, P123, DOI 10.1016/0014-5793(94)00839-6; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; WANG XD, 1995, J BIOL CHEM, V270, P18044, DOI 10.1074/jbc.270.30.18044; WILKINSON M, 1988, NUCLEIC ACIDS RES, V16, P10933, DOI 10.1093/nar/16.22.10933; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500	42	53	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31061	31067		10.1074/jbc.271.49.31061	http://dx.doi.org/10.1074/jbc.271.49.31061			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940101	hybrid			2022-12-25	WOS:A1996VW68600012
J	Zhang, JM; Carrell, CJ; Huang, DR; Sled, V; Ohnishi, T; Smith, JL; Cramer, WA				Zhang, JM; Carrell, CJ; Huang, DR; Sled, V; Ohnishi, T; Smith, JL; Cramer, WA			Characterization and crystallization of the lumen side domain of the chloroplast Rieske iron-sulfur protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME B(6)F COMPLEX; 2FE-2S CLUSTER; RHODOBACTER-SPHAEROIDES; SPINACH-CHLOROPLASTS; CHLAMYDOMONAS-REINHARDTII; RESONANCE SPECTROSCOPY; MEMBRANE ASSOCIATION; MUTATIONAL ANALYSIS; 2 HISTIDINES; BC1 COMPLEX	A soluble, 139-residue COOH-terminal polypeptide fragment of the Rieske iron-sulfur protein of the cytochrome b(6)f complex from spinach chloroplasts was obtained by Limited proteolysis of the complex and a two-step chromatography purification protocol, The purified Rieske iron-sulfur protein fragment was characterized by: (i) a single NH2-terminal sequence, NH2-Phe-Val-Pro-Pro-Gly-Gly, starting with residue 41 of the intact Rieske protein; (ii) a single molecular weight species determined by mass spectrometry with a molecular weight of 14,620 +/- 2 without the [2Fe-2S] cluster; (iii) an optical absorbance spectrum with redox- and pH-dependent maxima and minima; and (iv) a reduced-oxidized optical difference spectrum characterized by Delta epsilon(mM) = 3.8 mM(-1) cm(-1) for Delta A at 394 versus 409 nm, which was used to determine the midpoint oxidation-reduction potential, which is +359 +/- 7 mV at 25 degrees C from pH 5.5-6.5, and +319 +/- 2 mV at pH 7, with an apparent pK(ox) = 6.5 +/- 0.2 for the oxidized protein The EPR spectrum measured at 17 K was characterized by the g values, g(z) = 2.03 and g(y) = 1.90, and a broad band centered at g(x) approximate to 1.74, very similar or identical to those of the Rieske cluster in the b(6)f complex, implying that the environment of the [2Fe-2S] cluster is similar to that in the complex, Midpoint potential determination by low temperature EPR yielded a redox midpoint potential (E(m)) of +365-375 mV of the soluble Rieske fragment at pH 6 and 7 and an E(m) of +295-300 mV of the Rieske cluster in the cytochrome b(6)f complex at pH 6 and 7, The E(m) difference implies that the environment of the cluster in the soluble Rieske fragment is slightly more polar than that of the cluster in the intact complex, Single crystals of the Rieske poly-peptide were obtained that are capable of x-ray diffraction to atomic resolution (<2.5 Angstrom), contain one molecule per assymetric unit, a solvent content of approximately 30%, and belong to the triclinic space group P1 with cell dimensions, a = 29.1 Angstrom b = 31.9 Angstrom, c = 35.8 Angstrom, alpha = 95.6 degrees, beta = 107.1 degrees, gamma = 117.3 degrees.	PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907; UNIV PENN,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104	Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of Pennsylvania					NIGMS NIH HHS [GM-18457] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018457] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARR R, 1967, PLANT PHYSIOL, V42, P1246, DOI 10.1104/pp.42.9.1246; BATES R, 1968, HDB BIOCH, P7; BLACK MT, 1987, ARCH BIOCHEM BIOPHYS, V252, P655, DOI 10.1016/0003-9861(87)90071-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREYTON C, 1994, J BIOL CHEM, V269, P7597; BRITT RD, 1991, BIOCHEMISTRY-US, V30, P1892, DOI 10.1021/bi00221a023; Brumby P.E., 1967, METHOD ENZYMOL, V10, P463, DOI DOI 10.1016/0076-6879(67)10078-5; CRAMER WA, 1994, CURR OPIN STRUC BIOL, V4, P536, DOI 10.1016/S0959-440X(94)90216-X; DAVIDSON E, 1992, BIOCHEMISTRY-US, V31, P3342, DOI 10.1021/bi00128a006; DING HG, 1992, BIOCHEMISTRY-US, V31, P3144, DOI 10.1021/bi00127a015; Dutton P L, 1978, Methods Enzymol, V54, P411; FEE JA, 1984, J BIOL CHEM, V259, P124; Furbacher P. N., 1996, P221; GATTI DL, 1989, J MOL BIOL, V205, P421, DOI 10.1016/0022-2836(89)90352-5; GENNIS RB, 1993, J BIOENERG BIOMEMBR, V25, P195, DOI 10.1007/BF00762582; GRAHAM LA, 1993, J BIOENERG BIOMEMBR, V25, P245, DOI 10.1007/BF00762586; Gurbiel RJ, 1996, BIOCHEMISTRY-US, V35, P7834, DOI 10.1021/bi960380u; GURBIEL RJ, 1989, BIOCHEMISTRY-US, V28, P4861, DOI 10.1021/bi00437a051; GURBIEL RJ, 1991, BIOCHEMISTRY-US, V30, P11579, DOI 10.1021/bi00113a013; HAUSKA G, 1986, METHOD ENZYMOL, V126, P271; HAUSKA G, 1983, BIOCHIM BIOPHYS ACTA, V726, P97, DOI 10.1016/0304-4173(83)90002-2; HUANG D, 1994, BIOCHEMISTRY-US, V33, P4401, DOI 10.1021/bi00180a038; HURT E, 1981, EUR J BIOCHEM, V117, P591; Iwata S, 1996, STRUCTURE, V4, P567, DOI 10.1016/S0969-2126(96)00062-7; JAENICKE L, 1974, ANAL BIOCHEM, V61, P623, DOI 10.1016/0003-2697(74)90429-1; KUILA D, 1986, J BIOL CHEM, V261, P2768; Link TA, 1996, EUR J BIOCHEM, V237, P71, DOI 10.1111/j.1432-1033.1996.0071n.x; LINK TA, 1992, EUR J BIOCHEM, V208, P685, DOI 10.1111/j.1432-1033.1992.tb17235.x; MALKIN R, 1982, BIOCHEMISTRY-US, V21, P2945, DOI 10.1021/bi00541a022; Martinez SE, 1996, PROTEIN SCI, V5, P1081; MARTINEZ SE, 1994, STRUCTURE, V2, P95, DOI 10.1016/S0969-2126(00)00012-5; NITSCHKE W, 1992, BIOCHIM BIOPHYS ACTA, V1102, P266, DOI 10.1016/0167-4838(92)90519-J; PIERRE Y, 1995, J BIOL CHEM, V270, P29342, DOI 10.1074/jbc.270.49.29342; POWERS L, 1989, BIOCHIM BIOPHYS ACTA, V975, P293, DOI 10.1016/S0005-2728(89)80261-0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHERGILL JK, 1994, BBA-BIOENERGETICS, V1185, P35, DOI 10.1016/0005-2728(94)90190-2; STEPPUHN J, 1987, MOL GEN GENET, V210, P171, DOI 10.1007/BF00337775; SZCZEPANIAK A, 1995, Z NATURFORSCH C, V50, P535; TELSER J, 1987, FEBS LETT, V214, P117, DOI 10.1016/0014-5793(87)80024-8; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VANDOREN SR, 1993, BIOCHEMISTRY-US, V32, P8083, DOI 10.1021/bi00083a005; VANDOREN SR, 1993, BIOCHEMISTRY-US, V32, P628, DOI 10.1021/bi00053a031; WHITMARSH J, 1979, P NATL ACAD SCI USA, V76, P4417, DOI 10.1073/pnas.76.9.4417; WILLIAMSSMITH DL, 1977, BIOCHEM J, V167, P593, DOI 10.1042/bj1670593	44	66	67	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31360	31366		10.1074/jbc.271.49.31360	http://dx.doi.org/10.1074/jbc.271.49.31360			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940143				2022-12-25	WOS:A1996VW68600054
J	Barth, A; vonGermar, F; Kreutz, W; Mantele, W				Barth, A; vonGermar, F; Kreutz, W; Mantele, W			Time-resolved infrared spectroscopy of the Ca2+-ATPase - The enzyme at work	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; QUANTITATIVE IR SPECTROPHOTOMETRY; CALCIUM ADENOSINE-TRIPHOSPHATASE; CA2+-DEPENDENT ATP HYDROLYSIS; PROTEIN SECONDARY STRUCTURE; WATER H2O SOLUTIONS; ALKALI-METAL SALTS; REACTION-MECHANISM; SKELETAL-MUSCLE; PEPTIDE COMPOUNDS	Changes in the vibrational spectrum of the sarcoplasmic reticulum Ca2+-ATPase in the course of its catalytic cycle were followed in real time using rapid scan Fourier transform infrared spectroscopy, In the presence of Ca2+, the cycle was induced by the photochemical release of ATP from a biologically inactive precursor (caged ATP, P-3-1-(2-nitro)phenylethyladenosine 5'-triphosphate), Absorbance changes arising from ATP binding to the ATPase were observed within the first 65 ms after initiation of ATP release, After ATP binding, up to two subsequent partial reactions of the ATPase reaction cycle were observed depending on the buffer composition (10 nM CaCl2 + 330 mM KCl or 1 mM CaCl2 + 20% Me(2)SO): (i) formation of the ADP-sensitive phosphoenzyme (k(app) = 0.79 s(-1) +/- 15% at 1 degrees C, pH 7.0, 10 mM CaCl2, 330 mM KCl) and (ii) phosphoenzyme conversion to the ADP-insensitive phosphoenzyme concomitant with Ca2+ release (k(app) = 0.092 s(-1) +/- 7% at 1 degrees C, pH 7.0, 1 mM CaCl2, 20% Me(2)SO). Each reaction step could well be described by a single time constant for all associated changes in the vibrational spectrum, and no intermediates other than those mentioned above were found. In particular, there is no evidence for a delay between the transition from ADP-sensitive to ADP-insensitive phosphoenzyme and Ca2+ release, In (H2O)-H-2 a kinetic isotope effect was observed: both the phosphorylation reaction and phosphoenzyme conversion were slowed down by factors of 1.5 and 3.0, respectively, The small amplitudes of the observed changes in the infrared spectrum indicate that the net change of secondary structure is very small and of the same order of magnitude for ATP binding, phosphorylation, and phosphoenzyme conversion, Therefore, our results do not support a distinction between minor and major secondary structure changes in the catalytic cycle of the ATPase, which might be expected according to the classical E(1)-E(2) model.	UNIV FREIBURG, INST BIOPHYS & STRAHLENBIOL, D-79104 FREIBURG, GERMANY	University of Freiburg			Barth, Andreas/N-8872-2013	Barth, Andreas/0000-0001-5784-7673				ANDERSEN JP, 1989, BIOCHIM BIOPHYS ACTA, V988, P47, DOI 10.1016/0304-4157(89)90003-8; ANDERSEN JP, 1985, J BIOL CHEM, V260, P371; ARRONDO JLR, 1993, PROG BIOPHYS MOL BIO, V59, P23, DOI 10.1016/0079-6107(93)90006-6; BAKER KJ, 1994, BBA-BIOMEMBRANES, V1192, P53, DOI 10.1016/0005-2736(94)90142-2; BARTH A, 1994, BBA-BIOMEMBRANES, V1194, P75, DOI 10.1016/0005-2736(94)90205-4; BARTH A, 1991, BIOCHIM BIOPHYS ACTA, V1057, P115, DOI 10.1016/S0005-2728(05)80091-X; BARTH A, 1995, J AM CHEM SOC, V117, P10311, DOI 10.1021/ja00146a015; BIGELOW DJ, 1992, BIOCHIM BIOPHYS ACTA, V1113, P323, DOI 10.1016/0304-4157(92)90005-U; BLASIE JK, 1985, BIOPHYS J, V48, P9, DOI 10.1016/S0006-3495(85)83756-5; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BUCHET R, 1991, BIOCHIM BIOPHYS ACTA, V1069, P209, DOI 10.1016/0005-2736(91)90126-S; CHAMPEIL P, 1986, BIOCHEMISTRY-US, V25, P7623, DOI 10.1021/bi00371a053; CHAMPEIL P, 1988, J BIOL CHEM, V263, P12288; CHIRGADZE YN, 1973, BIOPOLYMERS, V12, P1337, DOI 10.1002/bip.1973.360120610; CHIRGADZE YN, 1975, BIOPOLYMERS, V14, P679, DOI 10.1002/bip.1975.360140402; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; DORGAN LJ, 1981, J BIOL CHEM, V256, P3910; FERNANDEZBELDA F, 1984, J BIOL CHEM, V259, P9687; Ferreira ST, 1996, BIOSCIENCE REP, V16, P87, DOI 10.1007/BF01206199; GEORG H, 1994, BBA-BIOENERGETICS, V1188, P139, DOI 10.1016/0005-2728(94)90032-9; GIRARDET JL, 1992, FEBS LETT, V296, P103, DOI 10.1016/0014-5793(92)80413-B; Haris P I, 1994, Methods Mol Biol, V22, P183; INESI G, 1987, J BIOL CHEM, V262, P16338; INESI G, 1984, TOPICS MOL STRUCTURA, V4, P355; INESI G, 1985, ENZYMES BIOL MEMBR, V3, P157; ISAACS NS, 1987, PHYSICAL ORGANIC CHE, P255; JACKSON M, 1995, CRIT REV BIOCHEM MOL, V30, P95, DOI 10.3109/10409239509085140; JAWORSKY M, 1986, SPECTROCHIM ACTA A, V42, P191, DOI 10.1016/0584-8539(86)80179-9; JENCKS WP, 1993, BIOCHEMISTRY-US, V32, P7030, DOI 10.1021/bi00078a031; KALNIN NN, 1990, BIOPOLYMERS, V30, P1273, DOI 10.1002/bip.360301311; Kanazawa T, 1995, BIOSCIENCE REP, V15, P317, DOI 10.1007/BF01788364; KHANANSHVILI D, 1988, BIOCHEMISTRY-US, V27, P2943, DOI 10.1021/bi00408a041; LACAPERE JJ, 1990, J BIOL CHEM, V265, P8583; Lin SH, 1996, BIOCHEMISTRY-US, V35, P8419, DOI 10.1021/bi960407+; LINSE S, 1995, P NATL ACAD SCI USA, V92, P4748, DOI 10.1073/pnas.92.11.4748; MAHANEY JE, 1995, BIOCHEMISTRY-US, V34, P4864, DOI 10.1021/bi00014a044; MAKINOSE M, 1969, EUR J BIOCHEM, V10, P74; MARTINEZ G, 1995, J STRUCT BIOL, V114, P23, DOI 10.1006/jsbi.1995.1002; MEIS LD, 1971, J BIOL CHEM, V246, P4759; MYUNG J, 1995, BIOCHEMISTRY-US, V34, P3077, DOI 10.1021/bi00009a039; NAKAMURA Y, 1982, J BIOCHEM-TOKYO, V91, P449, DOI 10.1093/oxfordjournals.jbchem.a133717; PETITHORY JR, 1986, BIOCHEMISTRY-US, V25, P4493, DOI 10.1021/bi00364a006; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P5553, DOI 10.1021/bi00415a025; PICKART CM, 1984, J BIOL CHEM, V259, P1629; PRIBIC R, 1993, ANAL BIOCHEM, V214, P366, DOI 10.1006/abio.1993.1511; SARVER RW, 1991, ANAL BIOCHEM, V194, P89, DOI 10.1016/0003-2697(91)90155-M; SCHOWEN KB, 1982, METHOD ENZYMOL, V87, P551; SHIGEKAWA M, 1983, J BIOL CHEM, V258, P8698; SHIGEKAWA M, 1978, J BIOL CHEM, V253, P1458; SHIGEKAWA M, 1983, J BIOL CHEM, V258, P4157; SHIGEKAWA M, 1978, J BIOL CHEM, V253, P1442; SHIGEKAWA M, 1978, J BIOL CHEM, V253, P1451; STAHL N, 1987, BIOCHEMISTRY-US, V26, P7654, DOI 10.1021/bi00398a019; STEFANOVA HI, 1993, BIOCHEMISTRY-US, V32, P356, DOI 10.1021/bi00052a044; STEFANOVA HI, 1993, BIOCHEMISTRY-US, V32, P6095, DOI 10.1021/bi00074a022; SUZUKI H, 1994, BIOCHEMISTRY-US, V33, P8240, DOI 10.1021/bi00193a010; URBAUER JL, 1984, ARCH BIOCHEM BIOPHYS, V231, P498, DOI 10.1016/0003-9861(84)90413-2; VENYAMINOV SY, 1990, BIOPOLYMERS, V30, P1259, DOI 10.1002/bip.360301310; VENYAMINOV SY, 1990, BIOPOLYMERS, V30, P1243, DOI 10.1002/bip.360301309; VONGERMAR F, 1994, INVESTIGATION NUCL B; WAKABAYASHI S, 1986, J BIOL CHEM, V261, P9762; WALKER JW, 1988, J AM CHEM SOC, V110, P7170, DOI 10.1021/ja00229a036; YAMADA S, 1980, J BIOL CHEM, V255, P3108	63	73	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30637	30646		10.1074/jbc.271.48.30637	http://dx.doi.org/10.1074/jbc.271.48.30637			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940039	hybrid			2022-12-25	WOS:A1996VV15800056
J	Moxham, CM; Tabrizchi, A; Davis, RJ; Malbon, CC				Moxham, CM; Tabrizchi, A; Davis, RJ; Malbon, CC			jun N-terminal kinase mediates activation of skeletal muscle glycogen synthase by insulin in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED PROTEIN-KINASE; P70 S6 KINASE; C-JUN; IN-VIVO; SIGNAL-TRANSDUCTION; MAMMALIAN-TISSUES; AP-1 ACTIVITY; HA-RAS; PHOSPHORYLATION; JNK	Mitogen-activated protein kinases (MAPKs) represent a conserved family of Ser/Thr protein kinases with central roles in intracellular signaling. Activation of three prominent members of the MAPK family, i.e. extracellular response kinases (ERR), jun N-terminal kinase (JNK), and p38, was defined in vivo in order to establish their role, if any, in the cardinal response of skeletal muscle to insulin, the activation of glycogen synthesis. Insulin was found to activate ERK, JNK, and p38 in skeletal muscle. The time courses for activation of the three MAPKs by insulin, however, are distinctly different. Activation of JNK occurs most rapidly, within seconds. Activation of p38 by insulin follows that of JNK, within minutes. Activation of ERK occurs last, 4 min after administration of insulin. The temporal relationship between the activation of ERR, JNK, p38 and the downstream elements p90(rsk) and PP-1 in vivo suggest that JNK, but neither ERR nor p38 MAPKs, mediates insulin activation of glycogen synthase in vivo. Activation of JNK by anisomycin in vivo mimics activation of glycogen synthase by insulin. Challenge by anisomycin and insulin, in combination, are not additive, suggesting a common mode of glycogen synthase activation. The p90(rsk) isoform rapidly activated by insulin is identified as RSK3. In addition, RSK3 can be activated by JNK in vitro. Based upon these data a signal linkage map for activation of glycogen synthase in vivo in skeletal muscle can be constructed in which JNK mediates activation of glycogen synthase via RSK3.	SUNY STONY BROOK,HLTH SCI CTR,DEPT MOL PHARMACOL,DMDRP,MED CTR,STONY BROOK,NY 11794; UNIV MASSACHUSETTS,MED CTR,PROGRAM MOL MED,WORCESTER,MA 01605; UNIV MASSACHUSETTS,MED CTR,HOWARD HUGHES MED INST,WORCESTER,MA 01605	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester			malbon, craig/ABF-3604-2020		NIDDK NIH HHS [T32 DK07521] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007521] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; BARON AD, 1988, AM J PHYSIOL, V255, pE769, DOI 10.1152/ajpendo.1988.255.6.E769; BJORBAEK C, 1995, J BIOL CHEM, V270, P18848, DOI 10.1074/jbc.270.32.18848; BJORBAEK C, 1995, DIABETES, V44, P90, DOI 10.2337/diabetes.44.1.90; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CHANG PY, 1995, J BIOL CHEM, V270, P29928; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; COHEN P, 1993, BIOCHEM SOC T, V21, P555, DOI 10.1042/bst0210555; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; CZECH MP, 1988, J BIOL CHEM, V263, P11017; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DENTON RM, 1995, EUR J BIOCHEM, V227, P597, DOI 10.1111/j.1432-1033.1995.tb20179.x; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; ERIKSON E, 1987, MOL CELL BIOL, V7, P3147, DOI 10.1128/MCB.7.9.3147; GALCHEVAGARGOVN.Z, 1994, SCIENCE, V265, P308; GARDNER AM, 1994, METHOD ENZYMOL, V238, P258; GROVE JR, 1993, BIOCHEMISTRY-US, V32, P7727, DOI 10.1021/bi00081a018; GUINOVART JJ, 1979, FEBS LETT, V106, P284, DOI 10.1016/0014-5793(79)80515-3; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HAYES N, 1993, BIOCHEM BIOPH RES CO, V190, P881, DOI 10.1006/bbrc.1993.1131; HEI YJ, 1993, J BIOL CHEM, V268, P13203; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; HUBBARD MJ, 1989, EUR J BIOCHEM, V186, P711, DOI 10.1111/j.1432-1033.1989.tb15264.x; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P297, DOI 10.1111/j.1432-1033.1983.tb07362.x; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KIM SJ, 1994, J BIOL CHEM, V269, P11887; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; LAVOINNE A, 1991, EUR J BIOCHEM, V199, P723, DOI 10.1111/j.1432-1033.1991.tb16176.x; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lin Tai-An, 1994, Journal of Biological Chemistry, V269, P21255; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHADEVAN LC, 1991, NATURE, V349, P747, DOI 10.1038/349747c0; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MOLLER DE, 1994, AM J PHYSIOL, V266, pC351, DOI 10.1152/ajpcell.1994.266.2.C351; Moxham CM, 1996, NATURE, V379, P840, DOI 10.1038/379840a0; MOXHAM CM, 1993, DEV GENET, V14, P266, DOI 10.1002/dvg.1020140404; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; PARKER PJ, 1983, EUR J BIOCHEM, V130, P227; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCIMECA JC, 1992, J BIOL CHEM, V267, P17369; SHULMAN RG, 1995, P NATL ACAD SCI USA, V92, P8535, DOI 10.1073/pnas.92.19.8535; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014-5793(94)80112-6; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITMARSH AJ, 1996, IN PRESS J MOL MED; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; ZHAO Y, 1995, MOL CELL BIOL, V15, P4353	67	92	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30765	30773		10.1074/jbc.271.48.30765	http://dx.doi.org/10.1074/jbc.271.48.30765			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940056	hybrid			2022-12-25	WOS:A1996VV15800073
J	Olashaw, NE				Olashaw, NE			Inducible activation of RelB in fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRANSCRIPTION FACTOR; GROWTH-FACTOR; CYCLIC-AMP; SIGNAL-TRANSDUCTION; MOUSE FIBROBLASTS; BALB/C-3T3 CELLS; GENE-EXPRESSION; B/REL FAMILY; INDUCTION	RelB, a member of NF-kappa B/Rel family of transcriptional regulators, is an immediate-early gene product that mediates constitutive lymphoid-specific kappa B-directed gene expression. Data presented here show that RelB also functions as a mitogen-inducible DNA binding activity in fibroblasts. Activation of RelB was observed in three mouse fibroblast lines, and agents activating RelB in quiescent and cycling cells included platelet-derived growth factor, phorbol ester, and serum. Additional data implicate cyclic AMP in the regulation of RelB activity. These findings suggest that RelB may play different roles in different cell types.	UNIV S FLORIDA,DEPT ANAT,TAMPA,FL 33612; UNIV S FLORIDA,H LEE MOFFITT CANC CTR,TAMPA,FL 33612	State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida					NIGMS NIH HHS [GM8476-04] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BERTRAND F, 1995, J BIOL CHEM, V270, P24435, DOI 10.1074/jbc.270.41.24435; BOMSZTYK K, 1990, J BIOL CHEM, V265, P9413; BOYNTON AL, 1983, ADV CYCLIC NUCL PROT, V15, P193; CARRASCO D, 1993, DEVELOPMENT, V118, P1221; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CRESSMAN DE, 1994, J BIOL CHEM, V269, P30429; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOBRZANSKI P, 1994, EMBO J, V13, P4608, DOI 10.1002/j.1460-2075.1994.tb06782.x; DUCKETT CS, 1995, J BIOL CHEM, V270, P18836, DOI 10.1074/jbc.270.32.18836; FINCO TS, 1993, J BIOL CHEM, V268, P17676; FRANTZ CN, 1979, J CELL PHYSIOL, V100, P413, DOI 10.1002/jcp.1041000305; GRILLI M, 1993, INT REV CYTOL, V143, P1; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LEOF EB, 1982, J CELL BIOCHEM, V19, P93, DOI 10.1002/jcb.240190108; LERNBECHER T, 1994, EMBO J, V13, P4060, DOI 10.1002/j.1460-2075.1994.tb06723.x; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; MIYAMOTO S, 1994, MOL CELL BIOL, V14, P3276, DOI 10.1128/MCB.14.5.3276; OLASHAW NE, 1988, J BIOL CHEM, V263, P1111; OLASHAW NE, 1992, MOL BIOL CELL, V3, P1131, DOI 10.1091/mbc.3.10.1131; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHER CD, 1979, NATURE, V281, P390, DOI 10.1038/281390a0; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; URBAN MB, 1990, GENE DEV, V4, P1975, DOI 10.1101/gad.4.11.1975; WEIH F, 1994, ONCOGENE, V9, P3289; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; WHARTON W, 1982, J CELL PHYSIOL, V111, P201, DOI 10.1002/jcp.1041110212; WU J, 1993, SCIENCE, V262, P1965; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P	40	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30307	30310						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8939986				2022-12-25	WOS:A1996VV15800003
J	Patel, N; Herrman, JM; Timans, JC; Kastelein, RA				Patel, N; Herrman, JM; Timans, JC; Kastelein, RA			Functional replacement of cytokine receptor extracellular domains by leucine zippers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; INTERFERON-GAMMA RECEPTOR; HIGH-AFFINITY RECEPTOR; HUMAN GROWTH-HORMONE; GM-CSF RECEPTOR; BETA-SUBUNIT; NEU ONCOGENE; TRANSMEMBRANE DOMAIN; SIGNAL-TRANSDUCTION; EXPRESSION CLONING	Granulocyte-macrophage colony-stimulating factor receptor signals by a complex which includes the ligand and two different receptor subunits: a low affinity alpha receptor binding chain (granulocyte-macrophage colony-stimulating factor receptor or subunit (GM-R alpha)) and a signal-transducing beta chain (GM-R beta). To investigate two unresolved issues in the initiation of signaling, the role of receptor extracellular domains and receptor stoichiometry, we replaced the mouse GM-R alpha and GM-R beta extracellular domains with the leucine zipper domain of either the Fos or Jun molecule. We co transfected combinations of chimeric receptors into Ba/F3 cells and found that both simple heterodimers of the GM-R alpha and GM-R beta intracellular domains and homodimers of the GM-R beta intracellular domain signaled for proliferation. Surprisingly, homodimers of the GM-R alpha intracellular domain also signaled for prevention of apoptosis in transfected cells. We similarly engineered dimers of the intracellular domain of the human interferon gamma receptor beta subunit and found that homodimers of the intracellular lar domain signaled for proliferation. When Fos peptide was added to Ba/F3 cells expressing the human interferon gamma receptor beta subunit construct, thereby preventing homodimer formation, the cells no longer proliferated in the absence of mouse interleukin 3.	DNAX RES INST MOL & CELLULAR BIOL INC,DEPT MOL BIOL,PALO ALTO,CA 94304	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.								AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BRANDTRAUF PW, 1989, J PROTEIN CHEM, V8, P749, DOI 10.1007/BF01024899; Cochran AG, 1996, SCIENCE, V271, P1113, DOI 10.1126/science.271.5252.1113; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; EDER M, 1994, J BIOL CHEM, V269, P30173; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GOODALL GJ, 1993, GROWTH FACTORS, V8, P87, DOI 10.3109/08977199309046929; GORMAN DM, 1990, P NATL ACAD SCI USA, V87, P5459, DOI 10.1073/pnas.87.14.5459; HANNEMANN J, 1995, MOL CELL BIOL, V15, P2402; IGARASHI K, 1994, J BIOL CHEM, V269, P14333; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; JENKINS BJ, 1995, EMBO J, V14, P4276, DOI 10.1002/j.1460-2075.1995.tb00102.x; KASTELEIN RA, 1993, ONCOGENE, V8, P231; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; KOSTELNY SA, 1992, J IMMUNOL, V148, P1547; KOTENKO SV, 1995, J BIOL CHEM, V270, P20915, DOI 10.1074/jbc.270.36.20915; LIU Y, 1994, J IMMUNOL, V152, P1821; MARSTERS SA, 1995, P NATL ACAD SCI USA, V92, P5401, DOI 10.1073/pnas.92.12.5401; MUTO A, 1995, BIOCHEM BIOPH RES CO, V208, P368, DOI 10.1006/bbrc.1995.1347; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PARK LS, 1992, P NATL ACAD SCI USA, V89, P4295, DOI 10.1073/pnas.89.10.4295; POLOTSKAYA A, 1994, J BIOL CHEM, V269, P14607; ROZWARSKI DA, 1994, STRUCTURE, V2, P159, DOI 10.1016/S0969-2126(00)00018-6; SAKATSUME M, 1995, J BIOL CHEM, V270, P17528, DOI 10.1074/jbc.270.29.17528; SHANAFELT AB, 1991, EMBO J, V10, P4105, DOI 10.1002/j.1460-2075.1991.tb04987.x; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; STERNBERG MJE, 1989, NATURE, V339, P587, DOI 10.1038/339587a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WALTER MR, 1995, NATURE, V376, P230, DOI 10.1038/376230a0; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WEISS M, 1993, BLOOD, V82, P3298; WELLS JA, 1993, ANNU REV BIOPH BIOM, V22, P329, DOI 10.1146/annurev.bb.22.060193.001553	37	20	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30386	30391		10.1074/jbc.271.48.30386	http://dx.doi.org/10.1074/jbc.271.48.30386			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940001	hybrid			2022-12-25	WOS:A1996VV15800018
J	Tarcsa, E; Marekov, LN; Mei, G; Melino, G; Lee, SC; Steinert, PM				Tarcsa, E; Marekov, LN; Mei, G; Melino, G; Lee, SC; Steinert, PM			Protein unfolding by peptidylarginine deiminase - Substrate specificity and structural relationships of the natural substrates trichohyalin and filaggrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; CORNIFIED CELL-ENVELOPE; INTERMEDIATE FILAMENTS; GEL-ELECTROPHORESIS; HAIR FOLLICLE; MOLECULAR-CLONING; ARGININE RESIDUE; SKELETAL-MUSCLE; MOUSE; PURIFICATION	Peptidylarginine deiminases, which are commonly found in mammalian cells, catalyze the deimination of protein-bound arginine residues to citrullines. However, very little is known about their substrate requirements and the significance or consequences of this postsynthetic modification. We have explored this reaction in vitro with two known substrates filaggrin and trichohyalin. First, the degree and rate of modification of arginines to citrullines directly correlates with the structural order of the substrate. In filaggrin, which has little structural order, the reaction proceeded rapidly to >95% completion. However, in the highly a-helical protein trichohyalin, the reaction proceeded slowly to about 25% and could be forced to a maximum of about 65%. Second, the rate and degree of modification depends on the sequence location of the target arginines. Third, we show by gel electrophoresis, circular dichroism, and fluorescence spectroscopy that the reaction interferes with organized protein structure: the net formation of greater than or equal to 10% citrulline results in protein denaturation. Cyanate modification of the lysines in model alpha-helix-rich proteins to homocitrullines also results in loss of organized structure. These data suggest that the ureido group on the citrulline formed by the peptidylarginine deiminase enzyme modification functions to unfold proteins due to decrease in net charge, loss of potential ionic bonds, and interference with H bonds.	NIAMSD, SKIN BIOL LAB, NIH, BETHESDA, MD 20892 USA; UNIV ROMA TOR VERGATA, IST DERMOPAT IMMACOLATA, BIOCHEM LABS, DEPT EXPT MED & BIOCHEM SCI, I-00133 ROME, ITALY; UNIV AQUILA, DEPT BIOL, I-67100 LAQUILA, ITALY	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Rome Tor Vergata; University of L'Aquila								AUBER L., 1952, TRANS ROY SOC EDINBURGH, V62, P191; BIRBECK MSC, 1957, J BIOPHYS BIOCHEM CY, V3, P223, DOI 10.1083/jcb.3.2.223; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRESLOW E, 1965, J BIOL CHEM, V240, P304; CANDI E, 1995, J BIOL CHEM, V270, P26382, DOI 10.1074/jbc.270.44.26382; COHEN LH, 1971, J BIOL CHEM, V246, P1841; FARNSWORTH V, 1993, ANAL BIOCHEM, V215, P190, DOI 10.1006/abio.1993.1575; FIETZ MJ, 1993, J CELL BIOL, V121, P855, DOI 10.1083/jcb.121.4.855; FUJISAKI M, 1981, J BIOCHEM, V89, P257, DOI 10.1093/oxfordjournals.jbchem.a133189; GOTO Y, 1990, P NATL ACAD SCI USA, V87, P573, DOI 10.1073/pnas.87.2.573; HAMILTON EH, 1992, J INVEST DERMATOL, V98, P881, DOI 10.1111/1523-1747.ep12459412; HARDING CR, 1983, J MOL BIOL, V170, P651, DOI 10.1016/S0022-2836(83)80126-0; HARDING HWJ, 1976, BIOCHIM BIOPHYS ACTA, V427, P315, DOI 10.1016/0005-2795(76)90307-X; HARDING HWJ, 1971, BIOCHEMISTRY-US, V10, P624, DOI 10.1021/bi00780a013; HUGHSON FM, 1990, SCIENCE, V249, P1544, DOI 10.1126/science.2218495; INAGAKI M, 1989, J BIOL CHEM, V264, P18119; KIM SY, 1994, J BIOL CHEM, V269, P27979; KUBILUS J, 1983, BIOCHIM BIOPHYS ACTA, V745, P285, DOI 10.1016/0167-4838(83)90060-2; KUBILUS J, 1980, BIOCHIM BIOPHYS ACTA, V615, P246, DOI 10.1016/0005-2744(80)90027-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SC, 1993, J BIOL CHEM, V268, P12164; MACK JW, 1993, J MOL BIOL, V232, P50, DOI 10.1006/jmbi.1993.1369; MANABE M, 1994, DIFFERENTIATION, V58, P65, DOI 10.1046/j.1432-0436.1994.5810065.x; MARQUSEE S, 1987, P NATL ACAD SCI USA, V84, P8898, DOI 10.1073/pnas.84.24.8898; MEI G, 1992, BIOCHEMISTRY-US, V31, P7224, DOI 10.1021/bi00147a003; NISHIIYO T, 1995, J INVEST DERMATOL, V104, P577; NOEL D, 1979, BIOCHEMISTRY-US, V18, P4159, DOI 10.1021/bi00586a017; NOMURA K, 1992, ARCH BIOCHEM BIOPHYS, V293, P362, DOI 10.1016/0003-9861(92)90407-N; OGUIN WM, 1992, J INVEST DERMATOL, V98, P24, DOI 10.1111/1523-1747.ep12494172; OKEEFE EJ, 1993, J INVEST DERMATOL, V101, pS65, DOI 10.1111/1523-1747.ep12362866; PANYIM S, 1971, J BIOL CHEM, V246, P7557; REYNOLDS JA, 1970, J BIOL CHEM, V245, P5161; RICKWOOD D, 1981, GEL ELECT PROTEINS P; Rogers G E, 1977, Adv Exp Med Biol, V86A, P283; ROGERS GE, 1977, BIOCHIM BIOPHYS ACTA, V495, P159, DOI 10.1016/0005-2795(77)90250-1; ROGERS GE, 1963, J HISTOCHEM CYTOCHEM, V11, P700, DOI 10.1177/11.6.700; ROGERS GE, 1964, EPIDERMIS, V179; ROTHNAGEL JA, 1990, J BIOL CHEM, V265, P1862; ROTHNAGEL JA, 1986, J CELL BIOL, V102, P1419, DOI 10.1083/jcb.102.4.1419; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANTUCCI R, 1987, BIOCHIM BIOPHYS ACTA, V914, P185, DOI 10.1016/0167-4838(87)90062-8; SENSHU T, 1995, J INVEST DERMATOL, V105, P163, DOI 10.1111/1523-1747.ep12317070; Stark GR., 1967, METHOD ENZYMOL, V25, P590; STEINERT PM, 1981, P NATL ACAD SCI-BIOL, V78, P4097, DOI 10.1073/pnas.78.7.4097; STEINERT PM, 1978, BIOCHEMISTRY-US, V17, P5045, DOI 10.1021/bi00616a029; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; STEINERT PM, 1979, BIOCHEMISTRY-US, V18, P5664, DOI 10.1021/bi00592a022; STEINERT PM, 1969, BIOCHIM BIOPHYS ACTA, V175, P1, DOI 10.1016/0005-2795(69)90138-X; TAKAGI T, 1975, J BIOCHEM, V77, P939, DOI 10.1093/oxfordjournals.jbchem.a130818; TAKAHARA H, 1983, J BIOCHEM, V94, P1945, DOI 10.1093/oxfordjournals.jbchem.a134548; TAKAHARA H, 1989, J BIOL CHEM, V264, P13361; TAKAHARA H, 1987, AGR BIOL CHEM TOKYO, V51, P1657, DOI 10.1080/00021369.1987.10868246; TAKAHARA H, 1985, J BIOL CHEM, V260, P8378; TERAKAWA H, 1991, J BIOCHEM, V110, P661, DOI 10.1093/oxfordjournals.jbchem.a123636; TSUCHIDA M, 1991, AGR BIOL CHEM TOKYO, V55, P295, DOI 10.1080/00021369.1991.10870549; TSUCHIDA M, 1993, EUR J BIOCHEM, V215, P677, DOI 10.1111/j.1432-1033.1993.tb18079.x; TUNG JS, 1971, BIOCHEM BIOPH RES CO, V42, P1117, DOI 10.1016/0006-291X(71)90020-9; WATANABE K, 1988, BIOCHIM BIOPHYS ACTA, V966, P375, DOI 10.1016/0304-4165(88)90088-8; WATANABE K, 1989, J BIOL CHEM, V264, P15255	59	274	288	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30709	30716		10.1074/jbc.271.48.30709	http://dx.doi.org/10.1074/jbc.271.48.30709			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940048	hybrid			2022-12-25	WOS:A1996VV15800065
J	Wolf, MJ; Gross, RW				Wolf, MJ; Gross, RW			Expression, purification, and kinetic characterization of a recombinant 80-kDa intracellular calcium-independent phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE-A2; INHIBITION; MECHANISM; CELLS; ATP; TRANSLOCATION	A CHO cell-derived 80-kDa recombinant polypeptide (GenBank number I15470) putatively encoding a calcium-independent phospholipase A, was expressed in S. frugiperda cells resulting in over a 15-fold increase in a calcium-independent phospholipase A(1)/A(2) activity which was entirely inhibitable by (E)-6-(bromomethylene)-3-(1-naphthalenyl)-2H-tetrahydropyran-2-one. The recombinant polypeptide was purified from cytosol by sequential tandem affinity chromatographies employing ATP-agarose and calmodulin-Sepharose stationary phases. This strategy resulted in the rapid purification (36 h) of recombinant phospholipase A, activity in 56% overall yield to a single intense 80-kDa protein band on SDS-polyacrylamide gel electrophoresis after silver staining. The purified protein possessed phospholipase A,, phospholipase A,, and lysophospholipase activities, Microbore anion exchange chromatography demonstrated that the 80-kDa protein band was comprised of multiple distinct isoforms including an anionic isoform which possessed over a B-fold higher specific activity (5 mu mo/mg . min) than earlier eluting isoforms. Collectively, these results unambiguously demonstrate that: 1) the 80-kDa polypeptide catalyzes phospholipase A(1)/A(2) and lysophospholipase activities with distinct kinetic parameters; 2) calmodulin and ATP both interact with the catalytic polypeptide independent of regulatory proteins; and 3) distinct isoforms of this polypeptide exist which possess markedly different specific activities.	WASHINGTON UNIV,SCH MED,DIV BIOORGAN CHEM & MOL PHARMACOL,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DIV BIOORGAN CHEM & MOL PHARMACOL,DEPT CHEM,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DIV BIOORGAN CHEM & MOL PHARMACOL,DEPT PHARMACOL & MOL BIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)			WOLF, MATTHEW/AHC-5201-2022; wolf, matthew/C-2315-2008	Wolf, Matthew/0000-0001-8004-4852	NHLBI NIH HHS [1 PO1 HL57278-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057278] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; GONES SS, 1996, FASEB J, V10, pL15; HAZEN SL, 1990, J BIOL CHEM, V265, P10622; HAZEN SL, 1991, J BIOL CHEM, V266, P14526; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; HAZEN SL, 1991, BIOCHEM J, V280, P581, DOI 10.1042/bj2800581; JAKOBY WB, 1979, METHOD ENZYMOL, V58, P132; LUCKOW VA, 1993, J VIROL, V67, P4566, DOI 10.1128/JVI.67.8.4566-4579.1993; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; RAMANADHAM S, 1994, BIOCHEMISTRY-US, V33, P7442, DOI 10.1021/bi00189a052; Sambrook J., 2002, MOL CLONING LAB MANU; SHARP JD, 1991, J BIOL CHEM, V266, P14850; STAFFORD RE, 1989, BIOCHEMISTRY-US, V28, P5113, DOI 10.1021/bi00438a031; STURDIER FW, 1991, J MOL BIOL, V2119, P37; STURDIER FW, 1986, J MOL BIOL, V189, P113; Wolf MJ, 1996, J BIOL CHEM, V271, P20989, DOI 10.1074/jbc.271.35.20989; ZUPAN LA, 1991, J MED CHEM, V336, P95	25	81	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30879	30885		10.1074/jbc.271.48.30879	http://dx.doi.org/10.1074/jbc.271.48.30879			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940072	hybrid			2022-12-25	WOS:A1996VV15800089
J	Ernst, M; Oates, A; Dunn, AR				Ernst, M; Oates, A; Dunn, AR			gp130-mediated signal transduction in embryonic stem cells involves activation of Jak and Ras/mitogen-activated protein kinase pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; PHEOCHROMOCYTOMA PC12 CELLS; TYROSINE KINASE; FACTOR-RECEPTOR; HEMATOPOIETIN RECEPTORS; INTERLEUKIN-6 FAMILY; CYTOPLASMIC DOMAIN; MOUSE EMBRYOS; GROWTH-FACTOR; MAP KINASE	The leukemia inhibitory factor/interleukin 6 (LIF/IL6) family of cytokines promotes cell type-specific pleiotropic effects by engaging multimeric receptor complexes that share the common affinity converter/signal transducing subunit gp130, While the maintenance of embryonic stem (ES) cell self-renewal is an activity unique to this family of cytokines, the intracellular signaling events mediated by gp130 remain largely unknown, Here we show a rapid and transient increase in the specific activity of the Src-related kinase Hck as well as of the Janus kinases Jak1, Jak2, and Tyk2 following treatment of ES cells with LIF or a combination of IL6 plus a soluble form of the IL6 receptor, Within 2 min of stimulation, we also observed increased tyrosine phosphorylation of SHC, activation of the guanidine nucleotide exchange activity on p21(ras), and an electrophoretic mobility shift of MBP kinase. Functional involvement of Hck and p21(ras) activation in gp130-mediated signaling is supported by the finding that the introduction of constitutively activated Hck or v-Ha-ras partially alleviates the requirement of ES cells for LIF to remain undifferentiated. In contrast, suppression of Jak1 in ES cells by antisense technology increased the amount of LIF required to retain their pluripotentiality. These results are consistent with the notion that gp130-mediated suppression of ES cell differentiation depends on signaling through at least two cascades, namely a p21(ras)-dependent pathway that possibly involves Hck, as well as a Jak kinase-dependent pathway.	ROYAL MELBOURNE HOSP,LUDWIG INST CANC RES,MELBOURNE TUMOUR BIOL BRANCH,PARKVILLE,VIC 3050,AUSTRALIA	Ludwig Institute for Cancer Research; Royal Melbourne Hospital			Ernst, Matthias/D-5111-2012	Ernst, Matthias/0000-0002-6399-1177				BAUMANN H, 1994, MOL CELL BIOL, V14, P138, DOI 10.1128/MCB.14.1.138; BAUMANN H, 1994, J BIOL CHEM, V269, P16297; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; BRIGGS SD, 1995, J BIOL CHEM, V270, P14718, DOI 10.1074/jbc.270.24.14718; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CONOVER JC, 1993, DEVELOPMENT, V119, P559; CONQUET F, 1990, MOL CELL BIOL, V10, P3801, DOI 10.1128/MCB.10.7.3801; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DURDEN DL, 1995, J IMMUNOL, V154, P4039; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; ERNST M, 1994, EMBO J, V13, P1574, DOI 10.1002/j.1460-2075.1994.tb06420.x; FUKUNAGA R, 1993, CELL, V74, P1079, DOI 10.1016/0092-8674(93)90729-A; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GEARING DP, 1993, CURR OPIN HEMATOL, V3, P138; GULBINS E, 1994, MOL CELL BIOL, V14, P906, DOI 10.1128/MCB.14.2.906; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; HASHIMOTO Y, 1994, ONCOGENE, V9, P869; HE TC, 1995, J BIOL CHEM, V270, P11055, DOI 10.1074/jbc.270.19.11055; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; JOHN J, 1988, J BIOL CHEM, V263, P11792; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KUMAR G, 1994, J IMMUNOL, V153, P4436; LAI CF, 1995, J BIOL CHEM, V270, P23254, DOI 10.1074/jbc.270.40.23254; LAI CF, 1995, J BIOL CHEM, V270, P14847, DOI 10.1074/jbc.270.25.14847; Laminet AA, 1996, J BIOL CHEM, V271, P264, DOI 10.1074/jbc.271.1.264; Li BQ, 1996, P NATL ACAD SCI USA, V93, P1001, DOI 10.1073/pnas.93.3.1001; LOCK P, 1991, MOL CELL BIOL, V11, P4363, DOI 10.1128/MCB.11.9.4363; MARUTA H, 1991, J BIOL CHEM, V266, P11661; MATSUDA T, 1995, J BIOL CHEM, V270, P11037, DOI 10.1074/jbc.270.19.11037; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; MATSUI Y, 1991, NATURE, V353, P750, DOI 10.1038/353750a0; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MURRAY R, 1990, MOL CELL BIOL, V10, P4953, DOI 10.1128/MCB.10.9.4953; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; NICHOLS J, 1994, EXP CELL RES, V215, P237, DOI 10.1006/excr.1994.1338; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460-2075.1994.tb06368.x; ROSE TM, 1994, CYTOKINE, V6, P48, DOI 10.1016/1043-4666(94)90007-8; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WANG YP, 1995, BLOOD, V86, P1671, DOI 10.1182/blood.V86.5.1671.bloodjournal8651671; WARE CB, 1995, DEVELOPMENT, V121, P1283; WHYATT LM, 1993, MOL CELL BIOL, V13, P7971, DOI 10.1128/MCB.13.12.7971; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; YASUKAWA K, 1990, J BIOCHEM-TOKYO, V108, P673, DOI 10.1093/oxfordjournals.jbchem.a123261; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; ZHANG JG, 1992, EUR J BIOCHEM, V207, P903, DOI 10.1111/j.1432-1033.1992.tb17123.x	56	112	117	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30136	30143		10.1074/jbc.271.47.30136	http://dx.doi.org/10.1074/jbc.271.47.30136			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939963	hybrid			2022-12-25	WOS:A1996VU52500091
J	Jez, JM; Schlegel, BP; Penning, TM				Jez, JM; Schlegel, BP; Penning, TM			Characterization of the substrate binding site in rat liver 3 alpha-hydroxysteroid dihydrodiol dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDOSE REDUCTASE INHIBITORS; MOLECULAR-CLONING; TRIOSEPHOSPHATE ISOMERASE; CONFORMATIONAL CHANGE; KINETIC MECHANISM; CDNA; SUPERFAMILY; MUTAGENESIS; ZOPOLRESTAT; CYSTEINES	Rat liver 3 alpha-hydroxysteroid dehydrogenase (3 alpha-HSD), a member of the aldoketoreductase superfamily, inactivates circulating steroid hormones using NAD(P)H as cofactor, Despite determination of the 3 alpha-HSD . NADP(+) binary complex structure, the functional elements that dictate the binding of steroids remain unclear (Bennett, M.J., Schlegel, B.P., Jez, J.M., Penning, T.M., and Lewis, M. (1996) Biochemistry 35, 10702-10711), Two tryptophans (Trp(86) and Trp(227)) near the active site may have roles in substrate binding, and their fluorescence may be quenched upon binding of NADPH, Trp(86) is located within an apolar cleft, while Trp(227) is found on an opposing loop near the active site, A third tryptophan, Trp(148), is on the periphery of the structure, To investigate the roles of these tryptophans in protein fluorescence and ligand binding, we generated three mutant enzymes (W86Y, W148Y, and W227Y) by site-directed mutagenesis, Spectroscopic measurements on these proteins showed that Trp(148) contributed the most to the enzyme fluorescence spectra, with Trp(227) adding the least, Trp(86) was identified as the tryptophan quenched by bound NADPH through an energy transfer mechanism, The W86Y mutant altered binding of cofactor (a 3-fold increase in K-d for NADPH) and steroid (a 7-fold increase in K-d for testosterone). This mutation also dramatically decreased the catalytic efficiency observed with one-, two-, and three-ring substrates and decreased the binding affinity for nonsteroidal anti-inflammatory drugs but had little effect on the binding of aldose reductase inhibitors, Interestingly, mutation of Trp(227) significantly impaired steroid binding (a 22-fold increase in k(d) for testosterone), but did not alter binding of cofactor, smaller substrates, or inhibitors, Kinetically, the W148Y mutant was similar to wild-type enzyme, Our results demonstrate that Trp(86) and the apolar cleft is part of the substrate binding pocket, In addition, we propose a role for Trp(227) and its associated loop in binding steroids, but not small substrates or inhibitors, most likely through interaction with the C- and D-rings of the steroid. This work provides the first evidence that tryptophans on opposite sides of the apolar cleft are part of the steroid binding pocket and suggests how the enzymemay discriminate between nonsteroidal anti-inflammatory drugs and aldose reductase Inhibitors like zopolrestat, A model of how androstanedione binds in the apolar cleft is developed, These data provide further evidence that loop structures in members of the aldoketoreductase superfamily are critical determinants of ligand binding.	UNIV PENN, SCH MED, DEPT PHARMACOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT BIOCHEM & BIOPHYS, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; University of Pennsylvania				Penning, Trevor/0000-0002-3937-1066	NIDDK NIH HHS [DK47015] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047015] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASKONAS LJ, 1991, BIOCHEM J, V278, P835, DOI 10.1042/bj2780835; Bennett MJ, 1996, BIOCHEMISTRY-US, V35, P10702, DOI 10.1021/bi9604688; BOHREN KM, 1989, J BIOL CHEM, V264, P9547; BORHANI DW, 1992, J BIOL CHEM, V267, P24841; BRUCE NC, 1994, BIOCHEM J, V299, P805, DOI 10.1042/bj2990805; CHOU TC, 1981, EUR J BIOCHEM, V115, P207, DOI 10.1111/j.1432-1033.1981.tb06218.x; COIRO VM, 1973, ACTA CRYSTALLOGR B, VB 29, P1404, DOI 10.1107/S0567740873004644; DEYASHIKI Y, 1995, J BIOL CHEM, V270, P10461, DOI 10.1074/jbc.270.18.10461; DEYASHIKI Y, 1994, BIOCHEM J, V299, P545, DOI 10.1042/bj2990545; EHRIG T, 1994, BIOCHEMISTRY-US, V33, P7157, DOI 10.1021/bi00189a019; EVANS SY, 1990, J MOL GRAPHICS, V12, P134; FORSTER T, 1948, ANN PHYS-LEIPZIG, V2, P3110; HOFF HG, 1973, H-S Z PHYSIOL CHEM, V354, P507, DOI 10.1515/bchm2.1973.354.1.507; HOOG SS, 1994, P NATL ACAD SCI USA, V91, P2517, DOI 10.1073/pnas.91.7.2517; JOSEPH D, 1990, SCIENCE, V249, P1425, DOI 10.1126/science.2402636; KADOR PF, 1983, MOL PHARMACOL, V24, P521; KHANNA M, 1995, J BIOL CHEM, V270, P20162, DOI 10.1074/jbc.270.34.20162; KUBISESKI TJ, 1992, J BIOL CHEM, V267, P6510; LACY WR, 1993, MOL ENDOCRINOL, V7, P58, DOI 10.1210/me.7.1.58; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leatherbarrow R.J, 1987, ENZFITTER NONLINEAR; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MIURA R, 1994, BIOCHEM J, V299, P561, DOI 10.1042/bj2990561; MYLARI BL, 1991, J MED CHEM, V34, P108, DOI 10.1021/jm00105a018; PAWLOWSKI JE, 1994, J BIOL CHEM, V269, P13502; PAWLOWSKI JE, 1991, J BIOL CHEM, V266, P8820; Penning TM, 1996, CHEM RES TOXICOL, V9, P84, DOI 10.1021/tx950055s; PENNING TM, 1993, CHEM-BIOL INTERACT, V89, P1, DOI 10.1016/0009-2797(93)03203-7; PENNING TM, 1983, P NATL ACAD SCI-BIOL, V80, P4504, DOI 10.1073/pnas.80.14.4504; PENNING TM, 1991, J BIOL CHEM, V266, P8826; Permyakov E. A., 1993, LUMINESCENT SPECTROS, P57; PETRASH JM, 1994, DIABETES, V43, P955, DOI 10.2337/diabetes.43.8.955; POMPLIANO DL, 1990, BIOCHEMISTRY-US, V29, P3186, DOI 10.1021/bi00465a005; RICIGLIANO JW, 1990, BIOCHEM J, V269, P749, DOI 10.1042/bj2690749; SCHLEGEL BP, 1994, BIOCHEMISTRY-US, V33, P10367, DOI 10.1021/bi00200a017; SHEN TY, 1965, NONSTEROIDAL ANTIINF, P13; SMITHGALL TE, 1988, BIOCHEM J, V254, P715, DOI 10.1042/bj2540715; SMITHGALL TE, 1986, J BIOL CHEM, V261, P6184; TETEFAVIER F, 1995, EUR J MED CHEM, V30, pS589; TOMLINSON DR, 1994, TRENDS PHARMACOL SCI, V15, P293, DOI 10.1016/0165-6147(94)90010-8; WERMUTH B, 1983, EUR J BIOCHEM, V131, P423, DOI 10.1111/j.1432-1033.1983.tb07280.x; WIERENGA RK, 1992, J MOL BIOL, V224, P1115, DOI 10.1016/0022-2836(92)90473-W; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324; WILSON DK, 1993, P NATL ACAD SCI USA, V90, P9847, DOI 10.1073/pnas.90.21.9847	44	62	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30190	30198		10.1074/jbc.271.47.30190	http://dx.doi.org/10.1074/jbc.271.47.30190			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939970	hybrid			2022-12-25	WOS:A1996VU52500098
J	Liu, QL; Levy, EJ; Chirico, WJ				Liu, QL; Levy, EJ; Chirico, WJ			N-ethylmaleimide inactivates a nucleotide-free Hsp70 molecular chaperone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI DNAJ; HEAT-SHOCK PROTEINS; ATPASE ACTIVITY; BINDING-SPECIFICITY; MITOCHONDRIAL HSP70; IMPORT COMPETENCE; SUBSTRATE-BINDING; CYTOSOLIC FACTORS; POTASSIUM AFFECTS; STRESS PROTEINS	Hsp70 molecular chaperones are ATPases that bind to hydrophobic regions of proteins and guide their folding, assembly, and translocation across membranes. The ability of purified Hsp70s to uncoat clathrin-coated vesicles or to stimulate the post-translational translocation of precursor proteins into the endoplasmic reticulum, mitochondria, and the nucleus was previously shown not to be sensitive to the sulfhydryl-modifying reagent N-ethylmaleimide (NEM). During purification of factors required for protein folding in the cytosol, we found that the ATP-agarose binding activity of the yeast Hsp70 Ssa1p in postribosomal supernatants was inhibited by NEM. We also found that completely removing nucleo tides from purified Ssa1p rendered its ATP-agarose binding activity, ATPase activity, and post-translational translocation-stimulating activity sensitive to NEM, We modified nucleotide-free Ssa1p with [C-14]NEM and then digested it with proteases. Purification and sequencing of the radiolabeled proteolytic fragments revealed that each of Ssa1p's three cysteine residues (Cys-15, Cys-264, and Cys-303) was modified with [C-14]NEM. ADP protected each of the cysteine residues from modification and protected Ssa1p from inactivation. The cysteine residues are the reactive centers of three NEM-reactive sites (NRS1-3). A comparison of Ssa1p's NRSs to sequences of other Hsp70s and actin revealed that Cys-15 of NRS1 is highly conserved and that sensitivity to NEM may be a property of many Hsp70s. Based on the three-dimensional structure of Hsc70, the predicted locations of Ssa1p's cysteine residues suggest that NEM may disrupt the conformation of Ssa1p or interfere with its ability to bind nucleotides, Together the results demonstrate that Ssa1p is an NEM-sensitive factor in cytosolic extracts from yeast that stimulates post-translational translocation of proteins into organelles.	SUNY HLTH SCI CTR,DEPT ANAT & CELL BIOL,BROOKLYN,NY 11203	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center								BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BOLLIGER L, 1994, EMBO J, V13, P1998, DOI 10.1002/j.1460-2075.1994.tb06469.x; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRODSKY JL, 1996, TRENDS BIOCHEM SCI, V21, P51; BROT N, 1994, P NATL ACAD SCI USA, V91, P12120, DOI 10.1073/pnas.91.25.12120; BUCHBERGER A, 1995, J BIOL CHEM, V270, P16903, DOI 10.1074/jbc.270.28.16903; CAPLAN AJ, 1993, MOL BIOL CELL, V4, P555, DOI 10.1091/mbc.4.6.555; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DUPONT D, 1988, USER B APPL BIOSYSTE, V2; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; FRESE R, 1972, EXPERIENTIA, V28, P1013, DOI 10.1007/BF01918643; Fung KL, 1996, J BIOL CHEM, V271, P21559, DOI 10.1074/jbc.271.35.21559; GAO BC, 1994, BIOCHEMISTRY-US, V33, P2048, DOI 10.1021/bi00174a010; HACHIYA N, 1993, EMBO J, V12, P1579, DOI 10.1002/j.1460-2075.1993.tb05802.x; HUTCHISON KA, 1994, J BIOL CHEM, V269, P5043; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; LAIN B, 1994, J BIOL CHEM, V269, P15588; LALORAYA S, 1994, P NATL ACAD SCI USA, V91, P6481, DOI 10.1073/pnas.91.14.6481; LAMBETH DO, 1993, ANAL BIOCHEM, V209, P192, DOI 10.1006/abio.1993.1102; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LEVY EJ, 1995, FEBS LETT, V368, P435, DOI 10.1016/0014-5793(95)00704-D; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; NAKAI M, 1994, BIOCHEM BIOPH RES CO, V200, P435, DOI 10.1006/bbrc.1994.1468; NICOLET CM, 1991, YEAST, V726, P699; OBRIEN MC, 1995, J BIOL CHEM, V270, P2247, DOI 10.1074/jbc.270.5.2247; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; Penefsky H S, 1979, Methods Enzymol, V56, P527; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SHEFFIELD WP, 1990, J BIOL CHEM, V265, P11069; SHETERLINE P, 1994, PROTEIN PROFILE, V1, P1; SHI YG, 1992, MOL CELL BIOL, V12, P2186, DOI 10.1128/MCB.12.5.2186; STONE KL, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P31; WAEGEMANN K, 1990, FEBS LETT, V261, P89, DOI 10.1016/0014-5793(90)80643-W; WATERS MG, 1986, J CELL BIOL, V102, P1543, DOI 10.1083/jcb.102.5.1543; WATERS MG, 1986, J CELL BIOL, V103, P2629, DOI 10.1083/jcb.103.6.2629; WEI JY, 1995, J BIOL CHEM, V270, P26677, DOI 10.1074/jbc.270.44.26677; WERNERWASHBURNE M, 1987, MOL CELL BIOL, V7, P2568, DOI 10.1128/MCB.7.7.2568; WILBANKS SM, 1995, J BIOL CHEM, V270, P2251, DOI 10.1074/jbc.270.5.2251; [No title captured]	49	28	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29937	29944		10.1074/jbc.271.47.29937	http://dx.doi.org/10.1074/jbc.271.47.29937			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939938	hybrid			2022-12-25	WOS:A1996VU52500066
J	Passafaro, M; Rosa, P; Sala, C; Clementi, F; Sher, E				Passafaro, M; Rosa, P; Sala, C; Clementi, F; Sher, E			N-type Ca2+ channels are present in secretory granules and are transiently translocated to the plasma membrane during regulated exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHEOCHROMOCYTOMA CELL-LINES; OPERATED CALCIUM CHANNELS; NEUROBLASTOMA IMR32 CELLS; GLUCOSE-TRANSPORTER GLUT4; SENSITIVE CA-2+ CHANNELS; HUMAN NEURO-BLASTOMA; NERVE GROWTH-FACTOR; OMEGA-CONOTOXIN; RAT PHEOCHROMOCYTOMA	An intracellular pool of N-type voltage-operated calcium channels has recently been described in different neuronal cell lines, We have now further characterized the intracellular pool of N-type calcium channels in both IMR32 human neuroblastoma and PC12 rat pheochromocytoma cells, Intracellular N-type calcium channels were found to be accumulated in subcellular fractions where the chromogranin B-containing secretory granules were also enriched, I-125-omega-Conotoxin GVIA binding assays on fixed and permeabilized cells revealed that intracellular N-type calcium channels translocate to the plasma membrane in cells exposed to secretagogues (KCl, ionomycin, and phorbol esters). The kinetics, Ca2+ and protein kinase C dependence, and brefeldin A insensitivity of N-type calcium channels translocation were similar to the regulated release of chromogranin B, while no correlation was found with the constitutive secretion of a heparan sulfate proteoglycan. A PC12 subclone deficient in the regulated but not in the constitutive pathway of secretion had a small intracellular pool of N-type calcium channels, and no secretagogue-induced translocation occurred in these cells, Calcium channel translocation was accompanied by a stronger response of Fura-2-loaded cells to depolarizing stimuli, suggesting that the newly inserted channels are functional.	UNIV MILAN,CNR,CELLULAR & MOL PHARMACOL CTR,DEPT MED PHARMACOL,I-20129 MILAN,ITALY; CNR,INST BIOTECHNOL APPL PHARMACOL,I-88021 ROCCELLETTA BORGI,CZ,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Milan; Consiglio Nazionale delle Ricerche (CNR)			Sala, Carlo/A-2493-2009	Sala, Carlo/0000-0003-0662-9523; Rosa, Patrizia/0000-0002-2590-6955	Multiple Sclerosis Society [858] Funding Source: Medline; Fondazione Telethon Funding Source: Custom	Multiple Sclerosis Society(National Multiple Sclerosis Society); Fondazione Telethon(Fondazione Telethon)		AHLIJANIAN MK, 1991, J BIOL CHEM, V266, P20192; BASSETTI M, 1995, ENDOCRINOLOGY, V136, P1168, DOI 10.1210/en.136.3.1168; BEAN BP, 1989, ANNU REV PHYSIOL, V51, P367, DOI 10.1146/annurev.physiol.51.1.367; BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BEZPROZVANNY I, 1995, NATURE, V378, P623, DOI 10.1038/378623a0; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CARBONE E, 1990, PFLUG ARCH EUR J PHY, V416, P170, DOI 10.1007/BF00370239; CARBONE E, 1989, PROG BIOPHYS MOL BIO, V54, P31, DOI 10.1016/0079-6107(89)90008-4; CAVALIE A, 1994, J PHYSIOL-LONDON, V479, P11, DOI 10.1113/jphysiol.1994.sp020274; CLEMENTI E, 1992, EUR J NEUROSCI, V4, P944, DOI 10.1111/j.1460-9568.1992.tb00121.x; DOHERTY P, 1993, J CELL BIOL, V122, P181, DOI 10.1083/jcb.122.1.181; FRANKLIN JL, 1992, J NEUROSCI, V12, P1726; GARCIA DE, 1994, J NEUROSCI, V14, P545; HAYDON PG, 1994, NEURON, V13, P1275, DOI 10.1016/0896-6273(94)90414-6; HERMAN GA, 1994, P NATL ACAD SCI USA, V91, P12750, DOI 10.1073/pnas.91.26.12750; HUDSON AW, 1993, J CELL BIOL, V122, P579, DOI 10.1083/jcb.122.3.579; JONES OT, 1989, SCIENCE, V244, P1189, DOI 10.1126/science.2543080; KNOX RJ, 1992, NEURON, V8, P883, DOI 10.1016/0896-6273(92)90202-O; KOIKE T, 1987, J NEUROCHEM, V49, P1784, DOI 10.1111/j.1471-4159.1987.tb02436.x; KOMURO H, 1992, SCIENCE, V257, P806, DOI 10.1126/science.1323145; KUO CC, 1993, NATURE, V365, P258, DOI 10.1038/365258a0; LUEBKE JI, 1994, PFLUG ARCH EUR J PHY, V428, P499, DOI 10.1007/BF00374571; MILLER RJ, 1992, J BIOL CHEM, V267, P1403; MILLER SG, 1992, J CELL BIOL, V118, P267, DOI 10.1083/jcb.118.2.267; OCONNOR VM, 1993, FEBS LETT, V326, P255, DOI 10.1016/0014-5793(93)81802-7; OLIVERA BM, 1994, ANNU REV BIOCHEM, V63, P823, DOI 10.1146/annurev.bi.63.070194.004135; PASSAFARO M, 1994, NEURON, V12, P317, DOI 10.1016/0896-6273(94)90274-7; PASSAFARO M, 1992, J NEUROSCI, V12, P3372; PASSAFARO M, 1993, CLIN CHEM ENZYME COM, V6, P15; PIETRINI G, 1992, P NATL ACAD SCI USA, V89, P8414, DOI 10.1073/pnas.89.18.8414; POLLO A, 1992, PFLUG ARCH EUR J PHY, V422, P75; PUGH PC, 1994, J NEUROSCI, V14, P889; REEVE HL, 1995, PFLUG ARCH EUR J PHY, V429, P729, DOI 10.1007/BF00373996; REGNIERVIGOUROUX A, 1991, EMBO J, V10, P3589, DOI 10.1002/j.1460-2075.1991.tb04925.x; ROSA P, 1989, J CELL BIOL, V109, P17, DOI 10.1083/jcb.109.1.17; ROSA P, 1985, J CELL BIOL, V101, P1999, DOI 10.1083/jcb.101.5.1999; ROSA P, 1992, EUR J CELL BIOL, V59, P265; SCHULTZ G, 1990, ANNU REV PHYSIOL, V52, P275, DOI 10.1146/annurev.ph.52.030190.001423; SCHWEITZER ES, 1993, J CELL SCI, V106, P731; SHENG ZH, 1994, NEURON, V13, P1303, DOI 10.1016/0896-6273(94)90417-0; SHER E, 1989, LANCET, V2, P640; SHER E, 1989, J CELL BIOL, V108, P2291, DOI 10.1083/jcb.108.6.2291; SHER E, 1988, FEBS LETT, V235, P178, DOI 10.1016/0014-5793(88)81258-4; SHER E, 1991, NEUROSCIENCE, V42, P301, DOI 10.1016/0306-4522(91)90376-Y; STINCHCOMBE JC, 1994, CELL BIOL LAB HDB, P557; STRONG JA, 1987, NATURE, V325, P714, DOI 10.1038/325714a0; TAGAYA M, 1995, J BIOL CHEM, V270, P15930, DOI 10.1074/jbc.270.27.15930; TARELLI FT, 1991, BRAIN RES, V547, P331, DOI 10.1016/0006-8993(91)90981-Z; TOOZE SA, 1990, CELL, V60, P837, DOI 10.1016/0092-8674(90)90097-X; USOWICZ MM, 1990, J PHYSIOL-LONDON, V426, P95, DOI 10.1113/jphysiol.1990.sp018128; WOLLHEIM CB, 1988, EMBO J, V7, P2443, DOI 10.1002/j.1460-2075.1988.tb03090.x; WOOD MR, 1992, J NEUROSCI, V12, P2948, DOI 10.1523/JNEUROSCI.12-08-02948.1992	53	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30096	30104		10.1074/jbc.271.47.30096	http://dx.doi.org/10.1074/jbc.271.47.30096			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939958	hybrid			2022-12-25	WOS:A1996VU52500086
J	Wen, PH; Blumenthal, KM				Wen, PH; Blumenthal, KM			Role of electrostatic interactions in defining the potency of neurotoxin B-IV from Cerebratulus lacteus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETERONEMERTINE POLYPEPTIDE TOXINS; HYDROPHOBIC PROTEIN CRAMBIN; SENSITIVE SODIUM-CHANNELS; AXON MEMBRANE-VESICLES; CIRCULAR-DICHROISM; SECONDARY STRUCTURE; SCORPION; SITE; BINDING; VENOM	Chemical modification implicates arginine residues of the Cerebratulus lacteus neurotoxin B-IV in biological activity, In the present study, we used site-directed mutagenesis to assess the functional contributions of each of these residues.]Panels of mutants at each site have been constructed by polymerase chain reaction and recombinant proteins expressed and purified to homogeneity using an Escherichia coli expression system developed in this laboratory, All substitutions for Arg-17 (Gin, Ala, or Lys) yield proteins having undetectable levels of activity, while charge neutralizing replacement of Arg-25 (R25Q) causes a 400-fold reduction in specific toxicity, However, the R25K mutein is almost as active as natural toxin. Circular dichroism spectroscopy indicates that there are no major conformational changes in any of these muteins. These results therefore demonstrate the requirement for a guanidinium group at position 17, and a positive charge at position 25. NMR analyses (Hansen, P. E., Mem, W. R., Bieber, A. L., and Norton, R. S. (1992) fur. J. Biochem. 210, 231-240) reveal neurotoxin B-TV to contain two antiparallel alpha-helices, which together include 57% of the sequence. Both Arg-17 and Arg-25 lie on the same face of the N-terminal helix (residues 13-26), as do the carboxyl groups of Glu-13 and Asp-al, However, charge neutralizing mutations of the latter two sites have no effects on biological activity, Arg-34, situated near the N terminus of helix 2 (residues 33-49) is also important for activity, as its replacement by Gin or Ala diminishes activity by 20- and 80-fold, respectively, However, unlike Arg-17 and Arg-25, thermal denaturation experiments suggest that R34Q may be structurally destabilized relative to wild-type B-TV.	UNIV CINCINNATI,COLL MED,DEPT MOL GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267	University of Cincinnati					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048676] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48676] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLUMENTHAL KM, 1980, ARCH BIOCHEM BIOPHYS, V203, P822, DOI 10.1016/0003-9861(80)90244-1; BLUMENTHAL KM, 1980, ARCH BIOCHEM BIOPHYS, V203, P816, DOI 10.1016/0003-9861(80)90243-X; BLUMENTHAL KM, 1986, TOXICON, V24, P63, DOI 10.1016/0041-0101(86)90166-2; CATTERALL WA, 1980, ANNU REV PHARMACOL, V20, P15, DOI 10.1146/annurev.pa.20.040180.000311; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; CATTERALL WA, 1978, J BIOL CHEM, V253, P7393; CATTERALL WA, 1986, ANNU REV BIOCHEM, V55, P953, DOI 10.1146/annurev.biochem.55.1.953; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COURAUD F, 1978, BIOCHEM BIOPH RES CO, V83, P1525, DOI 10.1016/0006-291X(78)91394-3; FAINZILBER M, 1992, TOXICON, V30, P465, DOI 10.1016/0041-0101(92)90543-E; FAINZILBER M, 1991, EUR J BIOCHEM, V202, P589, DOI 10.1111/j.1432-1033.1991.tb16412.x; GALLAGHER MJ, 1994, J BIOL CHEM, V269, P254; Gordon D, 1996, J BIOL CHEM, V271, P8034, DOI 10.1074/jbc.271.14.8034; HANSEN PE, 1992, EUR J BIOCHEM, V210, P231, DOI 10.1111/j.1432-1033.1992.tb17413.x; HENDRICKSON WA, 1981, NATURE, V290, P107, DOI 10.1038/290107a0; HILLE B, 1975, BIOPHYS J, V15, P615, DOI 10.1016/S0006-3495(75)85842-5; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOWELL ML, 1991, J BIOL CHEM, V266, P12884; HOWELL ML, 1989, J BIOL CHEM, V264, P15268; KEM WR, 1990, J PROTEIN CHEM, V9, P433, DOI 10.1007/BF01024619; KEM WR, 1976, J BIOL CHEM, V251, P4184; KEM WR, 1978, FED PROC, V37, P559; KHARRAT R, 1989, EUR J BIOCHEM, V181, P381, DOI 10.1111/j.1432-1033.1989.tb14735.x; LEBRETON F, 1994, BIOCHEMISTRY-US, V33, P11135, DOI 10.1021/bi00203a010; LIEBERMAN DL, 1986, BIOCHIM BIOPHYS ACTA, V855, P41, DOI 10.1016/0005-2736(86)90186-0; LORET EP, 1990, BIOCHEMISTRY-US, V29, P1492, DOI 10.1021/bi00458a021; NORTON RS, 1991, TOXICON, V29, P1051, DOI 10.1016/0041-0101(91)90205-6; PERCZEL A, 1991, PROTEIN ENG, V4, P669, DOI 10.1093/protein/4.6.669; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUKUMAR M, 1995, PROTEIN SCI, V4, P1718, DOI 10.1002/pro.5560040907; TEETER MM, 1993, J MOL BIOL, V230, P292, DOI 10.1006/jmbi.1993.1143; TEETER MM, 1981, BIOCHEMISTRY-US, V20, P5437, DOI 10.1021/bi00522a013; TOTH GP, 1983, BIOCHIM BIOPHYS ACTA, V732, P160, DOI 10.1016/0005-2736(83)90199-2; ZLOTKIN E, 1985, ARCH BIOCHEM BIOPHYS, V240, P877, DOI 10.1016/0003-9861(85)90098-0; ZLOTKIN E, 1991, BIOCHEMISTRY-US, V30, P4814, DOI 10.1021/bi00233a025; ZLOTKIN E, 1972, TOXICON, V10, P207, DOI 10.1016/0041-0101(72)90004-9	36	6	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29752	29758		10.1074/jbc.271.47.29752	http://dx.doi.org/10.1074/jbc.271.47.29752			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939911	hybrid			2022-12-25	WOS:A1996VU52500039
J	Barrett, MT; Sanchez, CA; Galipeau, PC; Neshat, K; Emond, M; Reid, BJ				Barrett, MT; Sanchez, CA; Galipeau, PC; Neshat, K; Emond, M; Reid, BJ			Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus	ONCOGENE			English	Article						9p21; CDKN2/p16; Barrett's esophagus	SQUAMOUS-CELL CARCINOMA; TUMOR-SUPPRESSOR GENE; FREQUENT LOSS; HOMOZYGOUS DELETIONS; LUNG-CANCER; P16 GENE; ADENOCARCINOMA; MELANOMA; CHROMOSOME-9; P16/CDKN2	High frequency allelic loss of chromosome 9p21 has been reported in a number of human cancers, including those of the esophagus, The CDKN2 gene on chromosome 9p21 that encodes the p16 inhibitor of cyclinD/Cdk4 complexes is a target of allelic loss and inactivation in a variety of human cancers and cell lines, However, the roles of 9p21 allelic losses and CDKN2 mutations in human neoplastic progression in vivo remain controversial, We determined the prevalence of allelic loss at 9p21 and mutations in CDKN2 in esophageal adenocarcinomas and investigated the order in which they occurred relative to the development of aneuploidy and cancer during neoplastic progression, Aneuploid cell populations from 32 patients with Barrett's esophagus who had premalignant epithelium, cancer, or both, were purified by DNA content flow cytometric cell sorting and evaluated by polymerase chain reaction, Twenty-four of 32 informative patients (75%) had allelic loss at 9p21 in aneuploid cell populations, Premalignant epithelium was available for seven of the patients who had 9p21 allelic losses in cancer; allelic loss of 9p21 was detected before cancer in all seven (100%), Allelic loss of 9p21 preceded the development of aneuploidy in 13 of 15 patients (87%) who had aneuploid cell populations detected in premalignant epithelium, and the two events were detected simultaneously in the remaining two patients, Five of 22 aneuploid populations (23%) with 9p21 loss had somatic mutations in the remaining CDKN2 allele, The same mutations and 9p21 allelic losses were also found in the corresponding diploid cells from premalignant epithelium in all three cases that were evaluable, However, there was no evidence for mutation or homozygous deletion of p16 in the other 17 patients with 9p21 allelic loss, Our results indicate that 9p21 allelic losses and CDKN2 mutations develop as early lesions in diploid cells before aneuploidy and cancer during neoplastic progression in Barrett's esophagus.	FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104; UNIV WASHINGTON,DEPT MED,DIV GASTROENTEROL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOSTAT,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT GENET,SEATTLE,WA 98195	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle			Reid, Brian John/AFT-8587-2022	Reid, Brian John/0000-0002-9613-979X; Galipeau, Patricia/0000-0001-7961-7430	NCI NIH HHS [R01CA61202] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061202] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barrett MT, 1996, ONCOGENE, V12, P1873; BARRETT MT, 1995, NUC ACIDS RES, V23, P3368; BLOT WJ, 1991, JAMA-J AM MED ASSOC, V265, P1287, DOI 10.1001/jama.265.10.1287; BLOUNT PL, 1993, P NATL ACAD SCI USA, V90, P3221, DOI 10.1073/pnas.90.8.3221; BLOUNT PL, 1994, CANCER RES, V54, P2292; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CAIRNS P, 1994, CANCER RES, V54, P1422; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; DREYLING MH, 1995, CANCER RES, V55, P984; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; Galipeau PC, 1996, P NATL ACAD SCI USA, V93, P7081, DOI 10.1073/pnas.93.14.7081; GLENDENING JM, 1995, CANCER RES, V55, P5531; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; HAMILTON SR, 1988, HUM PATHOL, V19, P942, DOI 10.1016/S0046-8177(88)80010-8; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HEREFORD LM, 1974, J MOL BIOL, V84, P445, DOI 10.1016/0022-2836(74)90451-3; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; LI YJ, 1995, ONCOGENE, V11, P597; LIU Q, 1995, ONCOGENE, V10, P1061; MERLO A, 1994, CANCER RES, V54, P640; NAKAGAWA K, 1995, ONCOGENE, V11, P1843; NESHAT K, 1994, COLD SPRING HARB SYM, V59, P577, DOI 10.1101/SQB.1994.059.01.065; NISHIKAWA R, 1995, CANCER RES, V55, P1941; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1995, CANCER RES, V55, P1448; PHILLIPS RW, 1991, GASTROENTEROL CLIN N, V20, P791; REID BI, 1992, GASTROENTEROLOGY, V102, P1211; RODABAUGH KJ, 1995, ONCOGENE, V11, P1249; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; SUZUKI H, 1995, HUM MOL GENET, V4, P1883, DOI 10.1093/hmg/4.10.1883; TARMIN L, 1994, CANCER RES, V54, P6094; VANDERRIET P, 1994, CANCER RES, V54, P1156; WALKER GJ, 1995, HUM MOL GENET, V4, P1845, DOI 10.1093/hmg/4.10.1845; WICK ST, 1995, XU L, V11, P2013; XU L, 1994, CANCER RES, V54, P5262; Zariwala M, 1996, ONCOGENE, V12, P451; ZHANG L, 1992, P NATL ACAD SCI USA, V89, P5847, DOI 10.1073/pnas.89.13.5847; ZHANG SY, 1994, CANCER RES, V54, P5050; Zhou P, 1996, CANCER RES, V56, P36	42	150	155	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 7	1996	13	9					1867	1873						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934532				2022-12-25	WOS:A1996VR79500005
J	Simonides, WS; Brent, GA; Thelen, MHM; vanderLinden, CG; Larsen, PR; vanHardeveld, C				Simonides, WS; Brent, GA; Thelen, MHM; vanderLinden, CG; Larsen, PR; vanHardeveld, C			Characterization of the promoter of the rat sarcoplasmic endoplasmic reticulum Ca2+-ATPase 1 gene and analysis of thyroid hormone responsiveness	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; SKELETAL-MUSCLE FIBERS; MESSENGER-RNA LEVELS; GROWTH-FACTOR-I; RESPONSE ELEMENTS; TRANSCRIPTION FACTOR; HIGH-AFFINITY; FAST-TWITCH; CA-ATPASE; HISTOCHEMICAL PROPERTIES	Relaxation of skeletal muscle requires the re-uptake of Ca2+, which is mediated by the sarcoplasmic reticulum Ca2+-ATPase (SERCA). Thyroid hormone (T-3) stimulates the expression of the SERCA1 isoform, which is essential for fast skeletal muscle fiber phenotype. We have cloned and studied the first 962 base pairs of the 5'-flanking region of the rat SERCA1 gene. This sequence was tested for T-3-regulated expression in transient transfection experiments using COS7 cells and for binding of thyroid hormone receptor (TR) alpha in mobility shift assays. A construct of the 5'-flanking region and a reporter gene was unresponsive to T-3 in the absence of co-transfected thyroid hormone receptor. In the presence of TR alpha T-3 induction ratio of almost 4.0 was found, and this induction ratio was doubled with co-transfection of an RXR expression plasmid. Analysis of progressive 5'-deletion fragments of the sequence indicated multiple regions involved in T-3 responsiveness. Three regions, R1, R2, and R3, were identified that bound TR complexes in mobility shift assays and conferred T-3 responsiveness to a heterologous promoter. The most potent of these thyroid hormone response elements, R3, increased the 2-fold background T-3 stimulation of the thymidine kinase promoter to nearly 6-fold. Detailed analysis of this element showed that four TR-binding half-sites, comprising two independent thyroid hormone response elements, interact cooperatively to give the maximal T-3 response. T-3 regulation of SERCA1 expression is mediated by a complex thyroid hormone response element that may serve to provide a greater range of response in interaction with nuclear receptor partners or cell-specific transcription factors.	HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,THYROID DIV, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Simonides, WS (corresponding author), FREE UNIV AMSTERDAM, PHYSIOL LAB, INST CARDIOVASC RES, VANDERBOECHORSTSTR 7, NL-1081 BT AMSTERDAM, NETHERLANDS.				NIDDK NIH HHS [DK 44128] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044128] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BERRODIN TJ, 1992, MOL ENDOCRINOL, V6, P1468, DOI 10.1210/me.6.9.1468; BODENNER DL, 1991, J BIOL CHEM, V266, P21666; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; BRENT G A, 1989, New Biologist, V1, P329; BRENT GA, 1991, MOL ENDOCRINOL, V5, P542, DOI 10.1210/mend-5-4-542; BRENT GA, 1992, MOL ENDOCRINOL, V6, P502, DOI 10.1210/me.6.4.502; BRENT GA, 1989, J BIOL CHEM, V264, P178; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; BRIGGS FN, 1990, FEBS LETT, V259, P269, DOI 10.1016/0014-5793(90)80025-E; BURK SE, 1989, J BIOL CHEM, V264, P18561; BUTLERBROWNE GS, 1984, FEBS LETT, V166, P71, DOI 10.1016/0014-5793(84)80047-2; CARLBERG C, 1993, BIOCHEM BIOPH RES CO, V195, P1345, DOI 10.1006/bbrc.1993.2191; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DALBIS A, 1990, EUR J BIOCHEM, V193, P155, DOI 10.1111/j.1432-1033.1990.tb19317.x; DESVERGNE B, 1994, MOL CELL ENDOCRINOL, V100, P125, DOI 10.1016/0303-7207(94)90291-7; DULHUNTY AF, 1990, PFLUG ARCH EUR J PHY, V415, P433, DOI 10.1007/BF00373620; DULHUNTY AF, 1987, J MEMBRANE BIOL, V99, P79, DOI 10.1007/BF01871228; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; EVERTS ME, 1990, CELL CALCIUM, V11, P343, DOI 10.1016/0143-4160(90)90037-U; EVERTS ME, 1989, BIOCHEM J, V260, P443, DOI 10.1042/bj2600443; FARSETTI A, 1992, J BIOL CHEM, V267, P15784; FITTS RH, 1980, AM J PHYSIOL, V238, pC15; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; GAMBKE B, 1983, FEBS LETT, V156, P335, DOI 10.1016/0014-5793(83)80524-9; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GLASS CK, 1990, BIOCHIM BIOPHYS ACTA, V1032, P157, DOI 10.1016/0304-419X(90)90002-I; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; HARTONG R, 1994, J BIOL CHEM, V269, P13021; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HSU JH, 1995, ENDOCRINOLOGY, V136, P421, DOI 10.1210/en.136.2.421; ING NH, 1992, J BIOL CHEM, V267, P17617; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; JORGENSEN AO, 1988, CELL MOTIL CYTOSKEL, V9, P164, DOI 10.1002/cm.970090208; KATZ RW, 1995, J BIOL CHEM, V270, P5238, DOI 10.1074/jbc.270.10.5238; KATZ RW, 1993, J BIOL CHEM, V268, P19392; KIM DH, 1982, AM J PHYSIOL, V243, pC151, DOI 10.1152/ajpcell.1982.243.3.C151; KIM HS, 1992, MOL ENDOCRINOL, V6, P1489, DOI 10.1210/me.6.9.1489; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KORCZAK B, 1988, J BIOL CHEM, V263, P4813; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; LEBERER E, 1986, EUR J BIOCHEM, V156, P489, DOI 10.1111/j.1432-1033.1986.tb09607.x; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LOMPRE AM, 1989, FEBS LETT, V249, P35, DOI 10.1016/0014-5793(89)80010-9; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MAHDAVI V, 1987, CIRC RES, V60, P804, DOI 10.1161/01.RES.60.6.804; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MIYAMOTO T, 1993, MOL ENDOCRINOL, V7, P224, DOI 10.1210/me.7.2.224; MIYAMOTO T, 1994, MOL CELL ENDOCRINOL, V102, P111, DOI 10.1016/0303-7207(94)90104-X; MULLER A, 1992, BIOCHEM J, V283, P713, DOI 10.1042/bj2830713; MULLER A, 1994, BIOCHEM BIOPH RES CO, V203, P1035, DOI 10.1006/bbrc.1994.2286; MULLER A, 1991, BIOCHEM J, V275, P35, DOI 10.1042/bj2750035; MUNTENER M, 1987, EXP NEUROL, V98, P529, DOI 10.1016/0014-4886(87)90262-7; NICOL CJM, 1981, PFLUG ARCH EUR J PHY, V390, P73, DOI 10.1007/BF00582715; NWOYE L, 1982, AM J PHYSIOL, V242, pR401, DOI 10.1152/ajpregu.1982.242.3.R401; OLSON EN, 1993, MOL ENDOCRINOL, V7, P1369, DOI 10.1210/me.7.11.1369; PROST E, 1986, GENE, V45, P107, DOI 10.1016/0378-1119(86)90138-1; ROHRER DK, 1991, J BIOL CHEM, V266, P8638; SCHRADER M, 1994, J BIOL CHEM, V269, P6444; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SIMONIDES WS, 1990, FEBS LETT, V274, P73, DOI 10.1016/0014-5793(90)81332-I; SIMONIDES WS, 1990, ANAL BIOCHEM, V191, P321, DOI 10.1016/0003-2697(90)90226-Y; SIMONIDES WS, 1989, ENDOCRINOLOGY, V124, P1145, DOI 10.1210/endo-124-3-1145; SIMONIDES WS, 1985, BIOCHIM BIOPHYS ACTA, V844, P129, DOI 10.1016/0167-4889(85)90083-7; SIMONIDES WS, 1986, CELL CALCIUM, V7, P147, DOI 10.1016/0143-4160(86)90018-7; SUZUKI S, 1994, MOL ENDOCRINOL, V8, P305, DOI 10.1210/me.8.3.305; THELEN MHM, 1994, BIOCHEM J, V303, P467, DOI 10.1042/bj3030467; TOYODA N, 1995, MOL CELL BIOL, V15, P5100; VANDERLINDEN GC, 1992, MOL CELL ENDOCRINOL, V90, P125, DOI 10.1016/0303-7207(92)90110-R; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; VOZ ML, 1992, MOL CELL BIOL, V12, P3991, DOI 10.1128/MCB.12.9.3991; WAHLSTROM GM, 1992, MOL ENDOCRINOL, V6, P1013, DOI 10.1210/me.6.7.1013; Williams G. R., 1994, MOL ENDOCRINOLOGY BA, P217; WILLIAMS GR, 1991, J BIOL CHEM, V266, P19636; WILLIAMS GR, 1992, MOL ENDOCRINOL, V6, P1527, DOI 10.1210/me.6.10.1527; WILLIAMS GR, 1994, ENDOCRINOLOGY, V134, P1888, DOI 10.1210/en.134.4.1888; WU KD, 1993, AM J PHYSIOL, V264, pC333, DOI 10.1152/ajpcell.1993.264.2.C333; YEN PM, 1994, TRENDS ENDOCRIN MET, V5, P65, DOI 10.1016/1043-2760(94)90004-3; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	84	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32048	32056		10.1074/jbc.271.50.32048	http://dx.doi.org/10.1074/jbc.271.50.32048			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943255	hybrid			2022-12-25	WOS:A1996VY34000046
J	Badminton, MN; Campbell, AK; Rembold, CM				Badminton, MN; Campbell, AK; Rembold, CM			Differential regulation of nuclear and cytosolic Ca2+ in HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; TARGETED RECOMBINANT AEQUORIN; RAT-LIVER NUCLEI; INOSITOL TRISPHOSPHATE; ENDOPLASMIC-RETICULUM; ION CHANNELS; INTACT-CELLS; CALCIUM; ENVELOPE; BINDING	The results reported in this study address the controversial issue that nuclear free Ca2+ ([Ca2+](n)) may be regulated independently of cytosolic free Ca2+ ([Ca2+](c)), We have measured [Ca2+](n) and [Ca2+](c) with recombinant aequorin targeted to the nucleus and cytosol in HeLa cells. We found that histamine, ATP, and ionomycin increased [Ca2+](c) quantitatively more than [Ca2+](n), although the time course of these changes was similar. The difference between [Ca2+](c) and [Ca2+](n) depended on the stimulus, and the relative difference between [Ca2+](n) and [Ca2+]c was less with ionomycin than with histamine or ATP. After depletion of the internal Ca2+ store, restoration of extracellular Ca2+ resulted in only increased [Ca2+](c) without a significant increase in [Ca2+](n). Treatment with cyclopiazonic acid resulted in a delayed increases in [Ca2+](n) compared to [Ca2+](c). These differences in both timing and magnitude of nuclear Ca2+ signals confirm that the cell can Limit or delay increases in nuclear free Ca2+. Taken with the fact that an inositol phosphate signaling system resides in the nucleus and its envelope, our data support the hypothesis that [Ca2+](n) may be independently regulated.	UNIV VIRGINIA,HLTH SCI CTR,DIV CARDIOVASC,CHARLOTTESVILLE,VA 22908	University of Virginia	Badminton, MN (corresponding author), UNIV WALES COLL MED,DEPT MED BIOCHEM,HEATH PK,CARDIFF CF4 4XN,S GLAM,WALES.		Campbell, Anthony K/N-5855-2014; Rembold, Christopher/K-8359-2013	Campbell, Anthony K/0000-0002-2506-5500; Rembold, Christopher/0000-0003-0819-7488	NHLBI NIH HHS [HL38918] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R55HL038918, R01HL038918] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBRITTON NL, 1994, P NATL ACAD SCI USA, V91, P12458; ALMOHANNA FA, 1994, NATURE, V367, P745, DOI 10.1038/367745a0; BACHS O, 1992, BIOCHIM BIOPHYS ACTA, V1113, P259, DOI 10.1016/0304-4157(92)90041-8; BADMINTON MN, 1995, EXP CELL RES, V216, P236, DOI 10.1006/excr.1995.1030; BADMINTON MN, 1996, BIOCHEM BIOPH RES CO, V217, P950; BELLOMO G, 1992, CANCER RES, V52, P1342; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; BRINI M, 1993, EMBO J, V12, P4813, DOI 10.1002/j.1460-2075.1993.tb06170.x; BRINI M, 1994, CELL CALCIUM, V16, P259, DOI 10.1016/0143-4160(94)90089-2; BUSTAMANTE JO, 1994, MOL MEMBR BIOL, V11, P141, DOI 10.3109/09687689409162232; Campbell A. K., 1988, CHEMILUMINESCENCE PR, P374; Campbell AK, 1996, CELL CALCIUM, V19, P211, DOI 10.1016/S0143-4160(96)90022-6; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COBBOLD PH, 1992, CELLULAR CALCIUM PRA, P55; CONNOR JA, 1993, CELL CALCIUM, V14, P185, DOI 10.1016/0143-4160(93)90066-F; GERASIMENKO OV, 1995, CELL, V80, P439, DOI 10.1016/0092-8674(95)90494-8; GILCHRIST JSC, 1994, MOL CELL BIOCHEM, V135, P79, DOI 10.1007/BF00925963; GREBER UF, 1995, J CELL BIOL, V128, P4; HENNAGER DJ, 1995, J BIOL CHEM, V270, P4959, DOI 10.1074/jbc.270.10.4959; HERNANDEZCRUZ A, 1990, SCIENCE, V247, P858, DOI 10.1126/science.2154851; HIMPENS B, 1992, AM J PHYSIOL, V263, pC978, DOI 10.1152/ajpcell.1992.263.5.C978; HIMPENS B, 1992, AM J PHYSIOL, V263, pC95, DOI 10.1152/ajpcell.1992.263.1.C95; Humbert JP, 1996, J BIOL CHEM, V271, P478, DOI 10.1074/jbc.271.1.478; Kendall JM, 1996, CELL CALCIUM, V19, P133, DOI 10.1016/S0143-4160(96)90082-2; KENDALL JM, 1994, ANAL BIOCHEM, V221, P173, DOI 10.1006/abio.1994.1394; Kong SK, 1996, BIOCHEM BIOPH RES CO, V218, P595, DOI 10.1006/bbrc.1996.0105; KOPPLER P, 1993, J BIOL CHEM, V268, P26248; MALVIYA AN, 1990, P NATL ACAD SCI USA, V87, P9270, DOI 10.1073/pnas.87.23.9270; MARTELLI AM, 1992, NATURE, V358, P242, DOI 10.1038/358242a0; MAZZANTI M, 1990, NATURE, V343, P764, DOI 10.1038/343764a0; MAZZANTI M, 1994, FASEB J, V8, P231, DOI 10.1096/fasebj.8.2.7509760; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; OMALLEY DM, 1994, J NEUROSCI, V14, P5741; PETERS R, 1986, BIOCHIM BIOPHYS ACTA, V864, P305, DOI 10.1016/0304-4157(86)90003-1; REMBOLD CM, 1995, J PHYSIOL-LONDON, V488, P549, DOI 10.1113/jphysiol.1995.sp020989; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; SANTELLA L, 1994, BIOCHEM BIOPH RES CO, V203, P950; SHANKAR G, 1993, J CELL SCI, V105, P61; STEHNOBITTEL L, 1995, SCIENCE, V270, P1835, DOI 10.1126/science.270.5243.1835; WILLIAMS DA, 1985, NATURE, V318, P558, DOI 10.1038/318558a0	41	87	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31210	31214		10.1074/jbc.271.49.31210	http://dx.doi.org/10.1074/jbc.271.49.31210			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940122	hybrid			2022-12-25	WOS:A1996VW68600033
J	Liu, M; Iavarone, A; Freedman, LP				Liu, M; Iavarone, A; Freedman, LP			Transcriptional activation of the human p21(WAF1/CIP1) gene by retinoic acid receptor - Correlation with retinoid induction of U937 cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; CYCLIN-DEPENDENT KINASES; RAR-ALPHA; TGF-BETA; EXPRESSION; P21; INHIBITOR; ARREST; TRANSLOCATION; HETERODIMERS	We reported previously that the induced differentiation of the myelomonocytic cell line U937 by vitamin D-3 is facilitated by the transcriptional induction of the p21(WAF1/CIP1) gene by the vitamin D-3 receptor (Liu, M., Lee, M.-H., Cohen, M., and Freedman, L. P. (1996) Genes Dev. 10, 143-158), Retinoic acid (RA), a physiological metabolite of vitamin A, is also a potent inducer of differentiation of several cell types, including myeloid leukemic cells, Like vitamin D-3, RA acts through a subfamily of nuclear hormone receptors, RARs and RXRs (retinoid X receptors), which regulate the expression of target genes by binding to specific DNA elements and modulating transcription initiation. In this report we demonstrate that the gene encoding p21 is also a RA-responsive target gene, and we describe a functional RA response element in this gene's promoter which is required to confer RA induction through RAR . RXR heterodimers. These results correlate the RA induction of monocytic differentiation of U937 cells with the transcriptional activation of the p21 gene and suggest a role for this cyclin/cyclin-dependent kinase complex inhibitor in facilitating this differentiation pathway.	CORNELL UNIV,CELL BIOL PROGRAM,MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021; CORNELL UNIV,DEPT PHARMACOL,NEW YORK,NY 10021; CORNELL UNIV,GRAD SCH MED SCI,NEW YORK,NY 10021	Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Cornell University					NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045460, R37DK045460] Funding Source: NIH RePORTER; NCI NIH HHS [CA08748] Funding Source: Medline; NIDDK NIH HHS [DK45460] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BREARD J, 1980, J IMMUNOL, V124, P1943; CHESKIS B, 1994, MOL CELL BIOL, V14, P3329, DOI 10.1128/MCB.14.5.3329; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; COLLINS SJ, 1987, BLOOD, V70, P1233; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; ELDIERY WS, 1993, CELL, V75, P817; ELDIERY WS, 1995, CANCER RES, V55, P2910; FREEDMAN LP, 1993, J CELL BIOCHEM, V51, P140, DOI 10.1002/jcb.240510205; GOYERT SM, 1988, SCIENCE, V239, P497, DOI 10.1126/science.2448876; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; JIANG HP, 1994, ONCOGENE, V9, P3397; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEMON BD, 1995, MOL CELL BIOL, V16, P1006; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MEANS AL, 1995, ANNU REV BIOCHEM, V64, P201, DOI 10.1146/annurev.bi.64.070195.001221; NAGY L, 1995, MOL CELL BIOL, V15, P3540; OBERG F, 1993, J IMMUNOL, V150, P3487; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TOWERS TL, 1993, P NATL ACAD SCI USA, V90, P6310, DOI 10.1073/pnas.90.13.6310; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002	34	286	293	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31723	31728		10.1074/jbc.271.49.31723	http://dx.doi.org/10.1074/jbc.271.49.31723			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940196	hybrid			2022-12-25	WOS:A1996VW68600107
J	Xie, WL; Herschman, HR				Xie, WL; Herschman, HR			Transcriptional regulation of prostaglandin synthase 2 gene expression by platelet-derived growth factor and serum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; ACTIVATED PROTEIN-KINASES; RAT MESANGIAL CELLS; C-JUN ACTIVITY; MESSENGER-RNA; RESPONSE ELEMENT; PHORBOL ESTER; TERMINAL PHOSPHORYLATION; ENDOPEROXIDE SYNTHASE; G/H SYNTHASE	Prostaglandin synthase 2 (PGS2) is an immediate-early gene induced in a variety of cellular contexts. me investigate here the transcriptional activation of the murine PGS2 gene in NIH 3T3 cells, in response to the mitogens platelet-derived growth factor (PDGF) or serum. Site-directed mutagenesis experiments demonstrate that a consensus cyclic AMP response element (CRE) in the murine PGS2 promoter is essential for optimal PGS2 gene expression in response to PDGF or to serum, Overexpression of c-Jun potentiates PDGF- or serum-induced luciferase expression from a reporter construct containing the first 371 nucleotides of the PGS2 promoter, In contrast, overexpression of other transcription factors binding to the CRE element of the PGS2 gene inhibits induction by PDGF or serum. Moreover, positioning the c-Jun activation domain nest to the minimal PGS2 promoter via a GAL4 DNA binding site rather than the CRE is sufficient to permit serum or PDGF stimulation of luciferase expression from this modified reporter construct, PDGF or serum treatment both activate c-Jun N-terminal kinase (JNK), the mitogen-activated protein kinase responsible for phosphorylation and activation of c-Jun, Cotransfection of plasmids expressing dominant-negative Ras, Rad, MEKK-1, or JNK along with the [PGS2][luciferase] reporter prevents induction by PDGF or serum, demonstrating that serum and PDGF induction of the PGS2 gene in NIH 3T3 cells requires activation of a Ras/Rac1/MEKE-1/JNK kinase/JNK signal transduction leading to phosphorylation of c-Jun. Additional cotransfection experiments with plasmids expressing dominant-negative Raf1 and ERR demonstrate that induction of PGS2 gene expression by PDGF and serum also requires activation of a Ras/Raf1/mitogen-activated protein kinase kinase (MAPKK)/ERK signal transduction pathway.	UNIV CALIF LOS ANGELES,INST MOL BIOL,SCH MED,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,DEPT MOL & MED PHARMACOL,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NIGMS NIH HHS [GM24797] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024797] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BRUNNER C, 1993, P NATL ACAD SCI USA, V90, P11643, DOI 10.1073/pnas.90.24.11643; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Hayakawa M, 1996, BIOCHEM BIOPH RES CO, V220, P681, DOI 10.1006/bbrc.1996.0464; HERSCHMAN HR, 1995, BIOESSAYS, V17, P1031, DOI 10.1002/bies.950171207; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HERSCHMAN HR, 1994, PROG NUCL ACID RES M, V47, P115; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; INOUE H, 1994, FEBS LETT, V350, P51, DOI 10.1016/0014-5793(94)00731-4; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KESTER M, 1994, J BIOL CHEM, V269, P22574; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; Morris JK, 1996, J BIOL CHEM, V271, P16633, DOI 10.1074/jbc.271.28.16633; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; OBANION MK, 1991, J BIOL CHEM, V266, P23261; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; REDDY ST, 1994, J BIOL CHEM, V269, P15473; SIROIS J, 1993, J BIOL CHEM, V268, P21931; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; STROEBEL M, 1994, J BIOL CHEM, V269, P22952; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; WARNOCK LJ, 1995, J CELL PHYSIOL, V163, P172, DOI 10.1002/jcp.1041630120; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; XIE WL, 1994, MOL CELL BIOL, V14, P6531, DOI 10.1128/MCB.14.10.6531; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315	45	215	219	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31742	31748		10.1074/jbc.271.49.31742	http://dx.doi.org/10.1074/jbc.271.49.31742			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940199	hybrid			2022-12-25	WOS:A1996VW68600110
J	Sung, YJ; Hwang, MCC; Hwang, YW				Sung, YJ; Hwang, MCC; Hwang, YW			The dominant negative effects of H-Ras harboring a Gly to Ala mutation at position 60	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; XENOPUS-LAEVIS OOCYTES; NUCLEOTIDE DISSOCIATION STIMULATOR; SIGNAL-REGULATED KINASE; BINDING DOMAIN; PLASMA-MEMBRANE; MEK ACTIVATION; MAP KINASE; IN-VITRO; RAF-1	v-H-Ras harboring the Gly-60 to Ala mutation (G60A) lacks the ability to induce germinal vesicle breakdown in Xenopus oocytes. Moreover, this mutant is capable of inhibiting the activity of v-H-Ras to induce oocyte germinal vesicle breakdown when co-injected. The duration and the extent of inhibition depends on the molar ratio of v-H-Ras(G60A) to v-H-Ras. The inhibition is not due to a general toxicity of v-H-Ras(G60A) to oocytes because oocytes injected with v-H-Ras(G60A) can be readily induced to mature by other mitogenic agents, such as insulin, insulin-like growth factor 1, insulin-like growth factor 2, and phosphatidylcholine-specific phospholipase C. The dominant negative effect of v-H-Ras(G60A) requires proper membrane attachment of v-H-Ras(G60A). By using a competition assay, it was concluded that the dominant negative phenotype of v-H-Ras(G60A) resulted from sequestering H-Ras downstream effector(s). Raf-1 was identified as one of the sequestered targets.	NEW YORK STATE INST BASIC RES DEV DISABIL, DEPT BIOL MOL, STATEN ISL, NY 10314 USA; CUNY COLL STATEN ISL, INST BASIC RES, CTR DEV NEUROSCI, NEW YORK, NY 10036 USA; CUNY COLL STATEN ISL, GRAD PROGRAM BIOL, NEW YORK, NY 10036 USA	Institute for Basic Research in Developmental Disabilities; City University of New York (CUNY) System; College of Staten Island (CUNY); City University of New York (CUNY) System; College of Staten Island (CUNY)					NATIONAL CANCER INSTITUTE [R29CA053782] Funding Source: NIH RePORTER; NCI NIH HHS [CA53782] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DEHERREROS AG, 1991, J BIOL CHEM, V266, P6825; DESHPANDE AK, 1987, MOL CELL BIOL, V7, P1285, DOI 10.1128/MCB.7.3.1285; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; ELETR M, 1979, SCIENCE, V205, P1397, DOI 10.1126/science.472755; EPPIG JJ, 1976, IN VITRO CELL DEV B, V12, P418; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GURDON JB, 1985, CELL, V41, P913, DOI 10.1016/S0092-8674(85)80072-6; HAN LM, 1995, MOL CELL BIOL, V15, P1318; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; Hwang MCC, 1996, J BIOL CHEM, V271, P8196, DOI 10.1074/jbc.271.14.8196; HWANG YW, 1989, NATO ADV SCI I A-LIF, V165, P77; HWANG YW, 1993, J BIOL CHEM, V268, P24692; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KJAERSGARD IVH, 1995, EUR J BIOCHEM, V228, P184; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; KURODA S, 1995, J BIOL CHEM, V270, P2460, DOI 10.1074/jbc.270.6.2460; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE E, 1992, J BIOL CHEM, V267, P1212; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MAGUIRE J, 1994, SCIENCE, V265, P241, DOI 10.1126/science.7912851; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MASUDA T, 1995, J BIOL CHEM, V270, P1979, DOI 10.1074/jbc.270.5.1979; MICHAELI T, 1989, EMBO J, V8, P3039, DOI 10.1002/j.1460-2075.1989.tb08454.x; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; MOODIE SA, 1993, SCIENCE, V260, P1588; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; OGISO Y, 1990, CELL GROWTH DIFFER, V1, P217; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PUMIGLIA K, 1995, MOL CELL BIOL, V15, P398, DOI 10.1128/MCB.15.1.398; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; REYNET C, 1993, SCIENCE, V262, P1441, DOI 10.1126/science.8248782; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SADLER SE, 1987, J BIOL CHEM, V262, P10644; SCHEFFLER JE, 1994, J BIOL CHEM, V269, P22340; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; SHIROUZU M, 1994, ONCOGENE, V9, P2153; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; STOUTEN PFW, 1993, FEBS LETT, V320, P1, DOI 10.1016/0014-5793(93)81644-F; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUNG YJ, 1995, BIOCHEMISTRY-US, V34, P3470, DOI 10.1021/bi00010a040; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHENG CF, 1994, BIOCHEMISTRY-US, V33, P5595, DOI 10.1021/bi00184a031	67	16	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30537	30543		10.1074/jbc.271.48.30537	http://dx.doi.org/10.1074/jbc.271.48.30537			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940023	hybrid			2022-12-25	WOS:A1996VV15800040
J	Dong, G; Schulick, AH; DeYoung, MB; Dichek, DA				Dong, G; Schulick, AH; DeYoung, MB; Dichek, DA			Identification of a cis-acting sequence in the human plasminogen activator inhibitor type-1 gene that mediates transforming growth factor-beta 1 responsiveness in endothelium in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE-1; NECROSIS-FACTOR-ALPHA; MESSENGER-RNA LEVELS; HEP G2 CELLS; FACTOR-BETA; EXPRESSION; TISSUE; INDUCTION; PAI-1; LIPOPOLYSACCHARIDE	The mechanism of regulation of the plasminogen activator inhibitor type-1 (PAI-1) gene by transforming growth factor-beta 1 (TGF-beta 1) was studied in vitro and in vivo in endothelial cells. We constructed adenovirus vectors containing PAI-1 5'-flanking sequences driving expression of a beta p-galactosidase (beta-gal) reporter gene, Cultured bovine endothelial cells were transduced with the vectors and treated with TGF-beta 1. beta-Gal expression was up-regulated 10-20-fold by TGF-beta 1 when vectors contained 799-base pair (bp) of 5'-flanking sequence, but only minimally (2-3 fold) from a vector containing only 82-bp of 5' PAI-1 flanking sequence. TGF-beta 1 up-regulated p-gal expression at the mRNA level, congruently with TGF-beta P1 up-regulation of expression of the endogenous PAI-1 gene. The constructs were transduced into intact rat carotid endothelium, and TGF-P1 was injected systemically. In vivo, TGF-beta 1 up-regulated endothelium-specific expression of beta-gal 3-fold (p < 0.03) from a vector containing the 799-bp sequence, but did not alter expression from a vector containing the 82-bp sequence. The sequence between -799 and -82 mediates up-regulation of reporter gene expression by TGF-beta 1 in endothelial cells in vitro and in vivo. This general method permits the elucidation of mechanisms of gene regulation by physiologic stimuli delivered to the endothelium of intact animals.	UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,SAN FRANCISCO,CA 94141; NHLBI,MOL HEMATOL BRANCH,NIH,BETHESDA,MD 20892	University of California System; University of California San Francisco; The J David Gladstone Institutes; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)				Dichek, David/0000-0002-5224-2736				AIRD WC, 1995, P NATL ACAD SCI USA, V92, P4567, DOI 10.1073/pnas.92.10.4567; ALESSI MC, 1995, FIBRINOLYSIS, V9, P237, DOI 10.1016/S0268-9499(08)80065-3; ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; BRAND T, 1993, J BIOL CHEM, V268, P11500; CHANG E, 1995, J BIOL CHEM, V270, P4473, DOI 10.1074/jbc.270.9.4473; COLUCCI M, 1985, J CLIN INVEST, V75, P818, DOI 10.1172/JCI111777; DAVIDSON BL, 1994, EXP NEUROL, V125, P258, DOI 10.1006/exnr.1994.1028; DESCHEEMAEKER KA, 1992, J BIOL CHEM, V267, P15086; DEWEY CF, 1979, DYNAMICS ARTERIAL FL, P55; DICHEK D, 1989, BLOOD, V74, P222; DICHEK D, 1989, IN VITRO CELL DEV B, V25, P289; EMEIS JJ, 1986, J EXP MED, V163, P1260, DOI 10.1084/jem.163.5.1260; FUJII S, 1992, CIRCULATION, V86, P2000, DOI 10.1161/01.CIR.86.6.2000; GALILEO DS, 1990, P NATL ACAD SCI USA, V87, P458, DOI 10.1073/pnas.87.1.458; GINSBERG HS, 1989, P NATL ACAD SCI USA, V86, P3823, DOI 10.1073/pnas.86.10.3823; Ginsberg HS, 1984, ADENOVIRUSES; HASENSTAB D, 1994, FASEB J, V8, pA319; IADEMARCO MF, 1993, P NATL ACAD SCI USA, V90, P3943, DOI 10.1073/pnas.90.9.3943; JUHANVAGUE I, 1993, THROMB HAEMOSTASIS, V70, P138; KEETON M, 1993, AM J PATHOL, V142, P59; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KOZARSKY KF, 1994, J BIOL CHEM, V269, P13695; LEE SW, 1993, CIRC RES, V73, P797, DOI 10.1161/01.RES.73.5.797; MIMURO J, 1987, THROMB HAEMOSTASIS, V58, P447; Newman KD, 1995, J CLIN INVEST, V96, P2955, DOI 10.1172/JCI118367; PRALONG G, 1989, THROMB HAEMOSTASIS, V61, P459; RADE JJ, 1993, CIRCULATION, V88, P1; RESNICK N, 1993, P NATL ACAD SCI USA, V90, P4591, DOI 10.1073/pnas.90.10.4591; RICCIO A, 1992, MOL CELL BIOL, V12, P1846, DOI 10.1128/MCB.12.4.1846; SAKSELA O, 1987, J CELL BIOL, V105, P957, DOI 10.1083/jcb.105.2.957; SAMUEL SK, 1992, EMBO J, V11, P1599, DOI 10.1002/j.1460-2075.1992.tb05205.x; SANDLER MA, 1994, J BIOL CHEM, V269, P21500; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SAWDEY M, 1989, J BIOL CHEM, V264, P10396; SAWDEY MS, 1991, J CLIN INVEST, V88, P1346, DOI 10.1172/JCI115440; SCHLEEF RR, 1988, J BIOL CHEM, V263, P5797; SCHNEIDERMAN J, 1992, P NATL ACAD SCI USA, V89, P6998, DOI 10.1073/pnas.89.15.6998; SCHULICK AH, 1995, CIRC RES, V77, P475, DOI 10.1161/01.RES.77.3.475; SHU HB, 1993, MOL CELL BIOL, V13, P6283, DOI 10.1128/MCB.13.10.6283; SIMPSON AJ, 1991, J CLIN PATHOL, V44, P139, DOI 10.1136/jcp.44.2.139; SLIVKA SR, 1991, BLOOD, V77, P1013; SPRENGERS ED, 1987, BLOOD, V69, P381; VANLEEUWEN RTJ, 1994, CIRCULATION, V90, P362, DOI 10.1161/01.CIR.90.1.362; VANMEIJER M, 1995, FIBRINOLYSIS, V9, P263, DOI 10.1016/S0268-9499(95)80015-8; VANMOURIK JA, 1984, J BIOL CHEM, V259, P14914; VANZONNEVELD AJ, 1988, P NATL ACAD SCI USA, V85, P5525; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; WATSON CA, 1995, SCIENCE, V268, P447, DOI 10.1126/science.7716553; WESTERHAUSEN DR, 1991, J BIOL CHEM, V266, P1092; ZEHEB R, 1988, GENE, V73, P459, DOI 10.1016/0378-1119(88)90510-0	50	40	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29969	29977		10.1074/jbc.271.47.29969	http://dx.doi.org/10.1074/jbc.271.47.29969			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939942	hybrid			2022-12-25	WOS:A1996VU52500070
J	Jiang, YW; Lu, ZM; Zang, Q; Foster, DA				Jiang, YW; Lu, ZM; Zang, Q; Foster, DA			Regulation of phosphatidic acid phosphohydrolase by epidermal growth factor - Reduced association with the EGF receptor followed by increased association with protein kinase C epsilon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; PHOSPHOLIPASE-D ACTIVITY; ADP-RIBOSYLATION FACTOR; SIGNAL-TRANSDUCTION; SERUM STIMULATION; V-SRC; RAS; CELLS; PHOSPHORYLATION; MECHANISM	An important component of receptor-mediated intracellular signal transduction is the generation of lipid second messengers. Lipid second messenger production is a complex process involving a variety of regulatory enzymes that control the intracellular response to the extracellular signal. Phosphatidic acid (PA) is generated in response to phospholipase D and can be con verted to other lipid second messengers including diacylglycerol (DG) and lysophosphatidic acid. PA is converted to DG by PA phosphohydrolase (PAP). We report here that PAP activity can be detected in epidermal growth factor (EGF) receptor immunoprecipitates. Following treatment with EGF, there is a substantial reduction in the PAP activity that co-precipitates with the EGF receptor, The loss of EGF receptor-associated PAP activity occurs with a concomitant increase in PAP activity associated with the epsilon isoform of protein kinase C (PKC). The PAP activity associated with PKC epsilon was dependent upon the PKC co-factors phosphatidylserine and DG but was independent of the kinase activity of PKC epsilon. These data suggest a novel signaling mechanism for the regulation of lipid second messenger production and implicate PAP as an important regulatory component for lipid second messenger production in receptor-mediated intracellular signaling.	CUNY HUNTER COLL,DEPT BIOL SCI,NEW YORK,NY 10021	City University of New York (CUNY) System; Hunter College (CUNY)				Zang, Qun (Sophia)/0000-0002-6397-8896	NATIONAL CANCER INSTITUTE [R01CA046677, R29CA046677] Funding Source: NIH RePORTER; NCI NIH HHS [CA46677] Funding Source: Medline; NCRR NIH HHS [RR-03037] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARNERO A, 1994, ONCOGENE, V9, P1387; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FOSTER DA, 1993, CELL SIGNAL, V5, P389, DOI 10.1016/0898-6568(93)90078-Z; JADMAR SC, 1994, BIOCHEM J, V301, P793; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; JAMAL Z, 1991, J BIOL CHEM, V266, P2988; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; JIANG H, 1995, J BIOL CHEM, V270, P6006, DOI 10.1074/jbc.270.11.6006; JIANG YW, 1994, BIOCHEM BIOPH RES CO, V203, P1195, DOI 10.1006/bbrc.1994.2309; JONES GA, 1993, J BIOL CHEM, V268, P20845; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARTIN A, 1993, J BIOL CHEM, V268, P23924; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; MORITZ A, 1992, J BIOL CHEM, V267, P7207; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; Singer WD, 1996, J BIOL CHEM, V271, P4504; SONG JG, 1994, CELL GROWTH DIFFER, V5, P79; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; TSAI MH, 1990, SCIENCE, V250, P982, DOI 10.1126/science.2237442; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Vance DE., 1985, BIOCH LIPIDS MEMBRAN; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; YU CL, 1990, MOL CELL BIOL, V10, P6683, DOI 10.1128/MCB.10.12.6683	29	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29529	29532		10.1074/jbc.271.47.29529	http://dx.doi.org/10.1074/jbc.271.47.29529			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939878	hybrid			2022-12-25	WOS:A1996VU52500006
J	Rosenfeld, SS; Correia, JJ; Xing, J; Rener, B; Cheung, HC				Rosenfeld, SS; Correia, JJ; Xing, J; Rener, B; Cheung, HC			Structural studies of kinesin-nucleotide intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; MYOSIN SUBFRAGMENT-1; BOUNDARY ANALYSIS; SEDIMENTATION; ATPASE; DOMAIN; MOTOR; MICROTUBULES; COMPLEXES; KINETICS	We have investigated the structural changes that occur in the molecular motor kinesin during its ATPase cycle, utilizing two bacterially expressed constructs, The structure of both constructs has been examined as a function of the nature of the nucleotide intermediate occupying the active site by means of sedimentation velocity, sedimentation equilibrium, fluorescence solute quenching, fluorescence anisotropy decay, and limited proteolysis, While the molecular weight of monomeric and dimeric human kinesin constructs, as measured by sedimentation velocity and sedimentation equilibrium, and the tryptic cleavage pattern are unaffected by the nucleotide intermediate occupying the active site, significant changes in the rotational correlation time of fluorescently labeled kinesin-nucleotide intermediates can be detected, These results suggest that kinesin contains an internal ''hinge'' whose flexibility varies through the course of the ATPase cycle, In prehydrolytic, ''strong'' binding states, this hinge is relatively rigid, while in posthydrolytic, ''weak'' binding states, it is more flexible. Our results, in conjunction with anisotropy decay studies of myosin, suggest that these two molecular motors may share a common structural feature; viz. weak binding states are characterized by segmental flexibility, which is lost upon assumption of a strong binding conformation.	UNIV ALABAMA,DEPT CELL BIOL,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT BIOCHEM & MOL GENET,BIRMINGHAM,AL 35294; UNIV MISSISSIPPI,MED CTR,DEPT BIOCHEM,JACKSON,MS 39216	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Mississippi; University of Mississippi Medical Center	Rosenfeld, SS (corresponding author), UNIV ALABAMA,DEPT NEUROL,UAB STN,BIRMINGHAM,AL 35294, USA.				NINDS NIH HHS [NS 01500, NS 31096] Funding Source: Medline; PHS HHS [BIR-9216150] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P20NS031096] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CORREIA JJ, 1995, BIOCHEMISTRY-US, V34, P4898, DOI 10.1021/bi00014a047; CREMO CR, 1990, BIOCHEMISTRY-US, V29, P3309, DOI 10.1021/bi00465a023; ENDOW SA, 1992, ANNU REV CELL BIOL, V8, P29; GILBERT GA, 1959, PROC R SOC LON SER-A, V250, P377, DOI 10.1098/rspa.1959.0070; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; GILBERT SP, 1994, BIOCHEMISTRY-US, V33, P1951, DOI 10.1021/bi00173a044; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HACKNEY DD, 1988, P NATL ACAD SCI USA, V85, P6314, DOI 10.1073/pnas.85.17.6314; HACKNEY DD, 1994, P NATL ACAD SCI USA, V76, P2620; HIROSE K, 1995, NATURE, V376, P277, DOI 10.1038/376277a0; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Kashina AS, 1996, NATURE, V379, P270, DOI 10.1038/379270a0; KOENIG SH, 1975, BIOPOLYMERS, V14, P2421, DOI 10.1002/bip.1975.360141115; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; Lansing WD, 1935, J AM CHEM SOC, V57, P1369, DOI 10.1021/ja01310a058; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LEHRER SS, 1978, METHOD ENZYMOL, V49, P220; Ma Y. Z., 1995, Biophysical Journal, V68, pA28; NA GC, 1985, METHOD ENZYMOL, V117, P459; NAVONE F, 1992, J CELL BIOL, V117, P1263, DOI 10.1083/jcb.117.6.1263; Phan BC, 1996, BIOPHYS CHEM, V59, P341, DOI 10.1016/0301-4622(95)00127-1; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; ROMBERG L, 1993, NATURE, V361, P168, DOI 10.1038/361168a0; Rosenfeld SS, 1996, J BIOL CHEM, V271, P9473, DOI 10.1074/jbc.271.16.9473; ROSENFELD SS, 1994, J BIOL CHEM, V269, P30187; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; SADHU A, 1992, J BIOL CHEM, V267, P11352; SHRIVER JW, 1981, BIOCHEMISTRY-US, V20, P2004, DOI 10.1021/bi00510a041; SHRIVER JW, 1981, BIOCHEMISTRY-US, V20, P6357, DOI 10.1021/bi00525a011; Stafford Walter F., 1996, Biophysical Journal, V70, pA231; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; STAFFORD WF, 1994, METHOD ENZYMOL, V240, P478; STAFFORD WF, 1992, ANAL ULTRACENTRIFUGA, P353; Stern O, 1919, PHYS Z, V20, P183; WALKER RA, 1993, ANNU REV BIOCHEM, V62, P429; WANG CK, 1992, BIOCHIM BIOPHYS ACTA, V1121, P16, DOI 10.1016/0167-4838(92)90331-7; Waxman E, 1994, MODERN ANAL ULTRACEN, P189; YPHANTIS DA, 1956, J PHYS CHEM-US, V60, P623; [No title captured]	40	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30212	30221		10.1074/jbc.271.47.30212	http://dx.doi.org/10.1074/jbc.271.47.30212			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939973	hybrid			2022-12-25	WOS:A1996VU52500101
J	Gambarotta, G; Boccaccio, C; Giordano, S; Ando, M; Stella, MC; Comoglio, PM				Gambarotta, G; Boccaccio, C; Giordano, S; Ando, M; Stella, MC; Comoglio, PM			Ets up-regulates MET transcription	ONCOGENE			English	Article						proto-oncogenes; ETS; transcription factors; HGF receptor	HEPATOCYTE GROWTH-FACTOR; DNA-BINDING MOTIF; SCATTER FACTOR; RECEPTOR EXPRESSION; MET/HGF RECEPTOR; EPITHELIAL-CELLS; PROTEIN; OVEREXPRESSION; GENE; PROTOONCOGENE	MET, a potentially harmful oncogene controlling invasive growth, is overexpressed in a significant percentage of human cancers, Since amplification of the MET gene occurs only in a fraction of these cases, we investigated the transcriptional mechanisms responsible for up-regulation of the promoter activity, The transcription driven by the 3.1 kbp DNA fragment containing the minimal promoter was studied by 5' progressive deletion analysis, The patterns of MET promoter activity suggest the presence of weak negative and positive elements in the region between 300 and 840 bp upstream to the transcription start site, The region encompassing the first 300 bp strongly upregulates the promoter, This region contains four putative binding sites for members of the Ets transcription factor family, known to be involved in invasive growth, Transient co-expression of Ets1 resulted in a strong enhancement of the MET promoter activity, Increased expression of the Met protein was observed in cells stably transfected with ETS1, Double stranded oligonucleotides with Ets consensus sequence were used as a 'decoy' to inhibit binding to DNA native sites, They dramatically reduced the amount of Met protein in a human carcinoma cell line overexpressing the oncogene, Interestingly, Met activation induces transcription of ETS1 mRNA, showing that Ets proteins act both upstream and downstream to MET, These data indicate that members of the Ets family promote MET transcription and suggest their contribution to the invasive phenotype through overexpression of MET.	UNIV TURIN,SCH MED,INST CANC RES,IRCC,I-10060 CANDIOLO,TORINO,ITALY	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin			Boccaccio, Carla/AHE-7875-2022; Giordano, Silvia/J-9858-2018; Gambarotta, Giovanna/I-8473-2012	Boccaccio, Carla/0000-0003-2620-9083; Giordano, Silvia/0000-0003-1854-1086; Gambarotta, Giovanna/0000-0002-8380-5925; Comoglio, Paolo/0000-0002-7056-5328				BIELINSKA A, 1990, SCIENCE, V250, P997, DOI 10.1126/science.2237444; BOCCACCIO C, 1994, J BIOL CHEM, V269, P12846; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Comoglio PM, 1996, GENES CELLS, V1, P347, DOI 10.1046/j.1365-2443.1996.37037.x; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; DIRENZO MF, 1992, ONCOGENE, V7, P2549; Epstein JA, 1996, P NATL ACAD SCI USA, V93, P4213, DOI 10.1073/pnas.93.9.4213; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FERRACINI R, 1995, ONCOGENE, V10, P739; Ferracini R, 1996, ONCOGENE, V12, P1697; FOLKMAN J, 1992, ADV EXP MED BIOL, V313, P355; GALANG CK, 1994, ONCOGENE, V9, P2913; GAMBAROTTA G, 1994, J BIOL CHEM, V269, P12852; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; HIGASHINO F, 1995, ONCOGENE, V10, P1461; HOLLYWOOD DP, 1993, EMBO J, V12, P2369, DOI 10.1002/j.1460-2075.1993.tb05891.x; Jeffers M, 1996, MOL CELL BIOL, V16, P115; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; Kaya M, 1996, ONCOGENE, V12, P221; KRAMER B, 1995, J BIOL CHEM, V270, P65787; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIU C, 1992, ONCOGENE, V7, P181; Mao C, 1996, ONCOGENE, V12, P863; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NALDINI L, 1995, J BIOL CHEM, V270, P603, DOI 10.1074/jbc.270.2.603; NERLOV C, 1991, ONCOGENE, V6, P1583; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; PANKOV R, 1994, P NATL ACAD SCI USA, V91, P873, DOI 10.1073/pnas.91.3.873; PEPPER MS, 1992, J BIOL CHEM, V267, P20493; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; RABAULT B, 1994, J BIOL CHEM, V269, P28143; RAPTIS L, 1990, DNA CELL BIOL, V9, P615, DOI 10.1089/dna.1990.9.615; RAPTIS LH, 1995, BIOTECHNOLOGY, V4, P129; RONG S, 1993, CANCER RES, V53, P5355; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; SACCHI N, 1991, ONCOGENE, V6, P2149; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCOTT GK, 1994, J BIOL CHEM, V269, P19848; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WASYLYK B, 1993, EUR J BIOCHEM, V211, P8; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WASYLYK C, 1994, ONCOGENE, V9, P3665; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; WERNERT N, 1994, CANCER RES, V54, P5683; WERNERT N, 1992, AM J PATHOL, V140, P119; ZHEN Z, 1994, ONCOGENE, V9, P1691	64	119	127	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 7	1996	13	9					1911	1917						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934537				2022-12-25	WOS:A1996VR79500010
J	Muller, S; Sideras, P; Smith, CE; Xanthopoulos, KG				Muller, S; Sideras, P; Smith, CE; Xanthopoulos, KG			Cell specific expression of human Bruton's agammaglobulinemia tyrosine kinase gene (Btk) is regulated by Sp1- and Spi-1/PU.1-family members	ONCOGENE			English	Article						Bruton's tyrosine kinase; transcription factors; cell restricted expression	X-LINKED AGAMMAGLOBULINEMIA; BOX-BINDING-PROTEINS; GENOMIC ORGANIZATION; TRANSCRIPTIONAL ACTIVATION; FAMILY; SITE; MUTATIONS; EVOLUTION; ONCOGENE; LINEAGE	Bruton's agammaglobulinemia tyrosine kinase (Btk) is a cytoplasmic tyrosine kinase involved in the human disease X-linked agammaglobulinemia (XLA), The gene is expressed in all hematopoietic cells with the exception of T-cells and plasma cells, For this expression pattern the first 280 bp upstream of the major transcriptional start site seems to be sufficient, In vitro footprinting analysis within this part of the promoter revealed two Spl binding sites as web as a PU-box, The transcription factor Spi-1/PU.1 as well as the closely related factor Spi-B bound to the PU-box in B-cells, In the erythroleukemia cell line K562, due to the absence of Spi-B, only PU.1 bound to the Btk promoter, Mutation of either site reduced the expression in transient transfection experiments, However, mutation of the PU box had no effect in the T-cell line Jurkat, where none of the Spi-1 family members is expressed, In addition Spi-B as well as PU.1 were able to transactivate Btk expression, Tn fetal liver of PU.1(-)/(-) mice, which lack lymphoid and myeloid cells, expression of Btk was reduced two- to threefold but not abolished, Collectively this study shows that expression of the Btk gene is regulated by the combined action of Sp1- and PU.1-family members.	KAROLINSKA INST, NOVUM, DEPT BIOSCI, CTR BIOTECHNOL, S-14157 HUDDINGE, SWEDEN; UMEA UNIV, DEPT MOL & CELL BIOL, S-90187 UMEA, SWEDEN; HUDDINGE UNIV HOSP, DEPT IMMUNOL MICROBIOL PATHOL & INFECT DIS, DIV CLIN IMMUNOL, S-14186 HUDDINGE, SWEDEN	Karolinska Institutet; Umea University; Karolinska Institutet				SMITH, C. I. Edvard/0000-0003-1907-3392				BRUTON OC, 1952, PEDIATRICS, V9, P722; CHEN HM, 1995, ONCOGENE, V11, P1549; DEWEERS M, 1993, EUR J IMMUNOL, V23, P3109, DOI 10.1002/eji.1830231210; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FLODBY P, 1993, EXP CELL RES, V208, P248, DOI 10.1006/excr.1993.1244; GACHELIN FM, 1993, BIOCHIM BIOPHYS ACTA, V1198, P149; GENEVIER HC, 1994, EUR J IMMUNOL, V24, P3100, DOI 10.1002/eji.1830241228; HAGEMANN TL, 1994, HUM MOL GENET, V3, P1743, DOI 10.1093/hmg/3.10.1743; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Himmelmann A, 1996, BLOOD, V87, P1036, DOI 10.1182/blood.V87.3.1036.bloodjournal8731036; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HROMAS R, 1993, BLOOD, V82, P2998; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KUDO S, 1994, EUR J BIOCHEM, V223, P319, DOI 10.1111/j.1432-1033.1994.tb18997.x; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; LAUX G, 1995, EMBO J, V13, P6524; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LETOVSKY J, 1989, NUCLEIC ACIDS RES, V17, P2639, DOI 10.1093/nar/17.7.2639; Maniatis T, 1989, MOL CLONING; Mao C, 1996, ONCOGENE, V12, P863; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; NILSSON L, 1995, INT IMMUNOL, V7, P1191, DOI 10.1093/intimm/7.8.1191; NILSSON L, 1993, INT IMMUNOL, V5, P271; OHTA Y, 1994, P NATL ACAD SCI USA, V91, P9062, DOI 10.1073/pnas.91.19.9062; Olson MC, 1995, IMMUNITY, V3, P703, DOI 10.1016/1074-7613(95)90060-8; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; RAYGALLET D, 1995, ONCOGENE, V11, P303; ROHRER J, 1994, IMMUNOGENETICS, V40, P319, DOI 10.1007/BF01246672; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SIDERAS P, 1992, J IMMUNOL, V149, P244; SIDERAS P, 1995, ADV IMMUNOL, V59, P135, DOI 10.1016/S0065-2776(08)60631-8; SIDERAS P, 1994, J IMMUNOL, V153, P5607; SMITH CIE, 1994, J IMMUNOL, V152, P557; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; Vihinen M, 1996, NUCLEIC ACIDS RES, V24, P160, DOI 10.1093/nar/24.1.160	41	56	56	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	1996	13	9					1955	1964						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934542				2022-12-25	WOS:A1996VR79500015
J	Bagley, CJ; Phillips, J; Cambareri, B; Vadas, MA; Lopez, AF				Bagley, CJ; Phillips, J; Cambareri, B; Vadas, MA; Lopez, AF			A discontinuous eight amino acid epitope in human interleukin-3 binds the alpha-chain of its receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; HIGH-AFFINITY BINDING; GM-CSF; BIOLOGICAL-ACTIVITY; BETA-CHAIN; SECONDARY STRUCTURE; IL-5 RECEPTORS; RESIDUES; IDENTIFICATION; RECONSTITUTION	We have previously reported that, within the first helix of human interleukin (IL)-3, residues Asp(21) and Glu(22) are important for interaction with the alpha- and beta-chains of the IL-3 receptor, respectively, In order to define more precisely the sites of interaction with the receptor, we have performed molecular modeling of the helical core of IL-3 and single amino acid substitution mutagenesis of residues predicted to lie on the surfaces of the A, C, and D helices. The resulting analogues were characterized for their abilities to stimulate proliferation of TF-l cells and for binding to the high affinity (alpha- and beta-chain; IL-3R alpha/R beta) or low affinity (alpha-chain alone; IL-3R alpha) IL-3 receptor. We found that in addition to Asp(21), residues Ser(17), Asn(18), and Thr(25) within the A helix and Arg(108), Phe(113), Lys(116), and Glu(119) within the D helix of IL-3 were important for biological activity, Analysis of their binding characteristics revealed that these analogues were deficient in binding to both the IL-3R alpha/R beta and the IL-3R alpha forms of the receptor, consistent with a selective impairment of interaction with IL-3R alpha. Molecular modeling suggests that these eight amino acid residues are adjacent in the tertiary structure, consistent with a discontinuous epitope interacting selectively with IL-3R alpha. On the other hand, Glu(22) of IL-3 was found to interact preferentially with the beta-chain with bulky and positively charged substitutions causing greater than 10,000-fold reduction in biological activity. These results show fundamental differences between IL-3 and granulocyte-macrophage colony-stimulating factor in the structural basis for recognition of their receptors that has implications for the construction of novel analogues and our understanding of receptor activation.	INST MED & VET SCI,HANSON CTR CANC RES,DEPT HUMAN IMMUNOL,ADELAIDE,SA 5001,AUSTRALIA	Institute Medical & Veterinary Science Australia			Vadas, Mathew/R-1378-2019; Lopez, Angel F/E-2260-2011	Lopez, Angel F/0000-0001-7430-0135				BARRY SC, 1994, J BIOL CHEM, V269, P8488; BRUMBY AM, 1994, THESIS U ADELAIDE; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; CLARKLEWIS I, 1988, P NATL ACAD SCI USA, V85, P7897, DOI 10.1073/pnas.85.21.7897; CLAYBERGER C, 1992, J EXP MED, V175, P371, DOI 10.1084/jem.175.2.371; CONTRERAS MA, 1983, METHOD ENZYMOL, V92, P277; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DIEDERICHS K, 1991, SCIENCE, V254, P1779, DOI 10.1126/science.1837174; DORSSERS LCJ, 1991, J BIOL CHEM, V266, P21310; DURONIO V, 1992, J BIOL CHEM, V267, P21856; ELLIOTT MJ, 1990, J IMMUNOL, V145, P167; FENG YQ, 1995, BIOCHEMISTRY-US, V34, P6540, DOI 10.1021/bi00019a036; Garnier J., 1989, PREDICTION PROTEIN S, P417; GESNER TG, 1988, J CELL PHYSIOL, V136, P493, DOI 10.1002/jcp.1041360314; GOODALL GJ, 1993, GROWTH FACTORS, V8, P87, DOI 10.3109/08977199309046929; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HERCUS TR, 1994, P NATL ACAD SCI USA, V91, P5838, DOI 10.1073/pnas.91.13.5838; HERCUS TR, 1994, BLOOD, V83, P3500; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAUSHANSKY K, 1992, J CLIN INVEST, V90, P1879, DOI 10.1172/JCI116065; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1992, BLOOD, V80, P84; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KORPELAINEN EI, 1993, P NATL ACAD SCI USA, V90, P11137, DOI 10.1073/pnas.90.23.11137; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LOKKER NA, 1991, EMBO J, V10, P2125, DOI 10.1002/j.1460-2075.1991.tb07746.x; LOKKER NA, 1991, J BIOL CHEM, V266, P10624; LOPEZ AF, 1992, EMBO J, V11, P909, DOI 10.1002/j.1460-2075.1992.tb05129.x; LOPEZ AF, 1988, BLOOD, V72, P1797; LOPEZ AF, 1992, P NATL ACAD SCI USA, V89, P11842, DOI 10.1073/pnas.89.24.11842; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; OLINS PO, 1995, J BIOL CHEM, V270, P23754, DOI 10.1074/jbc.270.40.23754; Pace C.N., 1990, PROTEIN STRUCTURE PR, P311; Parry D A, 1991, J Mol Recognit, V4, P63, DOI 10.1002/jmr.300040205; PHILLIPS JA, 1990, GENE AMST, V84, P501; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; SHANAFELT AB, 1991, EMBO J, V10, P4105, DOI 10.1002/j.1460-2075.1991.tb04987.x; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; Stomski FC, 1996, MOL CELL BIOL, V16, P3035; Sun QY, 1996, BLOOD, V87, P83; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; WOODCOCK JM, 1994, EMBO J, V13, P5176, DOI 10.1002/j.1460-2075.1994.tb06848.x	43	17	18	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					31922	31928		10.1074/jbc.271.50.31922	http://dx.doi.org/10.1074/jbc.271.50.31922			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943237	hybrid			2022-12-25	WOS:A1996VY34000028
J	Eggertsen, G; Olin, M; Andersson, U; Ishida, H; Kubota, S; Hellman, U; KyuIchiro, O; Bjorkhem, I				Eggertsen, G; Olin, M; Andersson, U; Ishida, H; Kubota, S; Hellman, U; KyuIchiro, O; Bjorkhem, I			Molecular cloning and expression of rabbit sterol 12 alpha-hydroxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTEROL 7-ALPHA-HYDROXYLASE; PROSTACYCLIN SYNTHASE; BILE-ACIDS; CYTOCHROME-P-450; GENE; SEQUENCE; LIVER; 7-ALPHA-HYDROXY-4-CHOLESTEN-3-ONE; BIOSYNTHESIS; PROTEINS	Sterol 12 alpha-hydroxylase is an important enzyme in bile acid biosynthesis, responsible for the balance between formation of cholic acid and chenodeoxycholic acid, The enzyme has been purified to apparent homogeneity from rabbit liver (Ishida, H., Noshiro, M., Okuda, R., and Goon, M. J. (1992) J. Biol. Chem. 267, 21519-21323), and we here describe the cloning and sequencing of a cDNA coding for this enzyme, After tryptic digestion of purified protein in a polyacrylamide gel, eight different peptides were isolated and sequenced, Using oligonucleotides deduced from the amino acid sequences, clones were isolated from a rabbit liver cDNA library, In addition to several overlapping clones, one full-length clone was obtained that coded for a polypeptide of 500 amino acids, corresponding to a molecular mass of 57 kDa. All of the eight peptides and the reported NH2-terminal amino acid sequence were matched against the sequence. The peptide sequence showed a 39% similarity with human prostacyclin synthase (CYP8) and 31% similarity with the rate-limiting enzyme in over-all synthesis of bile acids, the cholesterol 7 alpha-hydroxylase (CYP7) of the rabbit, The similarity with most other sterol cytochrome P-450 hydroxylases was less, Thus, this species of cytochrome P-450 should belong to a group of its own, here denoted CYP12, Transfection of COS cells with the coding part of the cDNA resulted in a significant expression of sterol 12 alpha-hydroxylase activity toward 7 alpha-hydroxy-4-cholesten-3-one. Northern blotting showed that the enzyme was exclusively expressed in the liver, The major mRNA fraction in rabbit liver had a size of approximately 2.9 kilobases, and those found in rat and human liver were about 2.5 and 4.5 kilobases, respectively, Fasting of rats and mice led to a severalfold increase in both enzyme activity and mRNA levels, In contrast, starvation of rabbits had little or nostimulatory effect on enzyme activity and mRNA levels.	HUDDINGE UNIV HOSP,KAROLINSKA INST,DIV CLIN CHEM,DEPT MED & LAB SCI & TECHNOL,HUDDINGE 14186,SWEDEN; UNIV TOKYO,FAC MED,DEPT PHYSIOL CHEM & NUTR,TOKYO 113,JAPAN; UPPSALA UNIV,LUDWIG INST,UPPSALA,SWEDEN; MIYAZAKI MED COLL,DEPT SURG,MIYAZAKI 88916,JAPAN	Karolinska Institutet; University of Tokyo; Ludwig Institute for Cancer Research; Uppsala University; University of Miyazaki				Bjorkhem, Ingemar/0000-0002-0575-9425; Bjorkhem, Ingemar/0000-0001-6087-9190				BEAUNE PH, 1986, P NATL ACAD SCI USA, V83, P8064, DOI 10.1073/pnas.83.21.8064; BERNHARDSSON C, 1973, BIOCHEM BIOPH RES CO, V54, P1030, DOI 10.1016/0006-291X(73)90797-3; BJORKHEM I, 1987, HEPATOLOGY, V7, P266, DOI 10.1002/hep.1840070210; BJORKHEM I, 1973, FEBS LETT, V31, P20, DOI 10.1016/0014-5793(73)80064-X; BJORKHEM I, 1993, J LIPID RES, V34, P1497; BJORKHEM I, 1975, EUR J BIOCHEM, V51, P137, DOI 10.1111/j.1432-1033.1975.tb03914.x; BJORKHEM I, 1985, COMPREHENSIVE BIOCH, P231; CALI JJ, 1991, J BIOL CHEM, V266, P7774; CORBIN CJ, 1988, P NATL ACAD SCI USA, V85, P8948, DOI 10.1073/pnas.85.23.8948; EINARSSO.K, 1968, EUR J BIOCHEM, V5, P101, DOI 10.1111/j.1432-1033.1968.tb00342.x; EINARSSON K, 1992, J LIPID RES, V33, P1591; HANSSON R, 1982, EUR J BIOCHEM, V125, P423, DOI 10.1111/j.1432-1033.1982.tb06700.x; HARA S, 1994, J BIOL CHEM, V269, P19897; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; HIGASHI Y, 1986, P NATL ACAD SCI USA, V83, P2841, DOI 10.1073/pnas.83.9.2841; IMAI Y, 1989, BIOCHEM BIOPH RES CO, V158, P717, DOI 10.1016/0006-291X(89)92780-0; ISHIDA H, 1992, J BIOL CHEM, V267, P21319; JOHANSSO.G, 1970, EUR J BIOCHEM, V17, P292, DOI 10.1111/j.1432-1033.1970.tb01167.x; KAI MH, 1995, J LIPID RES, V36, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIYATA A, 1994, BIOCHEM BIOPH RES CO, V200, P1728, DOI 10.1006/bbrc.1994.1652; MORNET E, 1989, J BIOL CHEM, V264, P20961; MOROHASHI K, 1987, J BIOCHEM-TOKYO, V101, P879, DOI 10.1093/oxfordjournals.jbchem.a121955; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; NELSON DR, 1988, J BIOL CHEM, V263, P6038; NIWA H, 1991, GENE AMST, V108, P1193; PICADOLEONARD J, 1987, DNA-J MOLEC CELL BIO, V6, P439, DOI 10.1089/dna.1987.6.439; Sambrook J., 2002, MOL CLONING LAB MANU; SHAW R, 1979, J BIOL CHEM, V254, P7177; STAPLETON G, 1995, J BIOL CHEM, V270, P29739, DOI 10.1074/jbc.270.50.29739; SUZUKI M, 1968, BIOCHEM BIOPH RES CO, V30, P516, DOI 10.1016/0006-291X(68)90082-X; WADA K, 1991, NUCLEIC ACIDS RES, V19, P1981, DOI 10.1093/nar/19.suppl.1981; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	33	59	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32269	32275		10.1074/jbc.271.50.32269	http://dx.doi.org/10.1074/jbc.271.50.32269			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943286	hybrid			2022-12-25	WOS:A1996VY34000077
J	Simonian, PL; Grillot, DAM; Andrews, DW; Leber, B; Nunez, G				Simonian, PL; Grillot, DAM; Andrews, DW; Leber, B; Nunez, G			Bax homodimerization is not required for Bax to accelerate chemotherapy-induced cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 FAMILY; APOPTOSIS; SURVIVAL; PROTEINS; DISTINCT; BCL-X(L); CANCER; BH1	Bax, a member of the Bcl-2 family of proteins, has been shown to accelerate apoptosis induced by growth factor withdrawal, gamma-irradiation, and the chemotherapeutic agent, etoposide, The mechanism by which Bax promotes apoptosis is poorly understood, Bax forms homodimers which have been suggested to act as accelerators or inducers of cell death, However, the requirement for homodimerization of Bax to promote cell death remains unclear. We performed site-directed mutagenesis of the BH1, BH2, and BH3 in Bax to determine the regions of Bax required for homodimerization and to define the role of fax homodimers in cell death induced by chemotherapy drugs, Bax proteins expressing alanine substitutions of the highly conserved amino acids glycine 108 (G108) in BH1, tryptophan 158 (W158) in BH2, and glycine 67 and aspartic acid 68 (GD67-68) in BH3 as well as deletion of the most conserved amino acids in BH1 (Delta 102-112) and BH2 (Delta 151-159) and deletion of BH3 (Delta 63-71) maintained their ability to accelerate chemotherapy-induced cell death, Immunoprecipitation studies revealed that Bax with deletions in BH1 and BH2 still associated with wild-type Bax while deletion of BH3 disrupted Bax homodimerization. These results demonstrate that Bax does not require the conserved regions of homology, BH1, BH2, or BH3, to accelerate chemotherapy-induced cell death, Furthermore, our results established BH3 as a region required for Bax homodimerization in mammalian cells and demonstrate that monomeric forms of Bax are active in accelerating cell death induced by chemotherapy agents.	UNIV MICHIGAN, SCH MED, DEPT PATHOL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, CTR COMPREHENS CANC, ANN ARBOR, MI 48109 USA; MCMASTER UNIV, DEPT BIOCHEM, HAMILTON, ON L8N 3Z5, CANADA; MCMASTER UNIV, DEPT MED & BIOCHEM, HAMILTON, ON L8N 3Z5, CANADA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; McMaster University; McMaster University			Nuñez, Gabriel/A-7160-2014	Andrews, David/0000-0002-9266-7157; Leber, Brian/0000-0001-5502-1480	NATIONAL CANCER INSTITUTE [K04CA064421, R01CA064556] Funding Source: NIH RePORTER; NCI NIH HHS [CA-64421, CA-64556] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; BOYD JM, 1995, ONCOGENE, V11, P1921; Brady HJM, 1996, EMBO J, V15, P1221, DOI 10.1002/j.1460-2075.1996.tb00463.x; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Hunter JJ, 1996, J BIOL CHEM, V271, P8521, DOI 10.1074/jbc.271.15.8521; INNIS MA, 1990, PCR PROTOCOLS GUIDE, P177; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; MARTIN SJ, 1995, CRIT REV ONCOL HEMAT, V18, P137, DOI 10.1016/1040-8428(94)00124-C; MERINO R, 1995, J IMMUNOL, V155, P3830; Middleton G, 1996, DEVELOPMENT, V122, P695; Minn AJ, 1996, J BIOL CHEM, V271, P6306, DOI 10.1074/jbc.271.11.6306; MIYASHITA T, 1993, BLOOD, V81, P151; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NUNEZ G, 1990, J IMMUNOL, V144, P3602; Nunez Gabriel, 1994, Trends in Cell Biology, V4, P399, DOI 10.1016/0962-8924(94)90053-1; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Simonian PL, 1996, J BIOL CHEM, V271, P22764, DOI 10.1074/jbc.271.37.22764; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	30	39	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32073	32077		10.1074/jbc.271.50.32073	http://dx.doi.org/10.1074/jbc.271.50.32073			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943258	hybrid			2022-12-25	WOS:A1996VY34000049
J	Singleton, JR; Dixit, VM; Feldman, EL				Singleton, JR; Dixit, VM; Feldman, EL			Type I insulin-like growth factor receptor activation regulates apoptotic proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; HUMAN NEUROBLASTOMA-CELLS; CHEMOTHERAPY-INDUCED APOPTOSIS; SYMPATHETIC NEURONS; POLY(ADP-RIBOSE) POLYMERASE; SIGNAL-TRANSDUCTION; NERVOUS-SYSTEM; BCL-2 PROTEIN; C-MYC; EXPRESSION	Activation of the type I insulin-like growth factor receptor (IGF-IR) blocks osmotic mediated programmed cell death (PCD) in neurons. We speculated that IGF-IR activation could afford neuroprotection either by effecting the negative regulators of the death pathway, Bcl-2 and Bcl-x(L), or by altering activity of the ced-3/ICE-like proteases. Here we report that osmotic stress decreases total neuronal Bcl-2 by 4-fold and that hyperosmotic PCD correlates with proteolytic processing of neuronal ced-3/ICE-like proteases. IGF-IR activation maintains normal Bcl-2 levels, and signaling via the IGF-IR:phosphatidylinositol S-kinase pathway prevents ICE/LAP-3 and Yama/CPP32 processing. Finally, increased neuronal IGF-IR expression enhances the negative death regulator Bcl-x(L). We suggest that IGF-IR signaling exerts its short-term inhibitory effects upon PCD ''upstream'' of both Eel proteins and ced-3/ICE-like proteases, while chronic increased IGF-IR expression may modulate susceptibility to death signals by mediating the negative death regulator, Bcl-x(L).	UNIV MICHIGAN, DEPT NEUROL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT PATHOL, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			dixit, vishva m/A-4496-2012; Roszak, Joanna/F-4003-2010	dixit, vishva m/0000-0001-6983-0326; Feldman, Eva/0000-0002-9162-2694	NIEHS NIH HHS [ES 08111] Funding Source: Medline; NINDS NIH HHS [R29 NS32843, T32 NS07222] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS032843, T32NS007222] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BAUR AM, 1995, ACTA OTO-LARYNGOL, V115, P517, DOI 10.3109/00016489509139359; BIEDLER JL, 1978, CANCER RES, V38, P3751; BIEDLER JL, 1988, ADV NEUROBLASTOMA RE, V2, P265; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; CORCORAN GB, 1994, TOXICOL APPL PHARM, V128, P169, DOI 10.1006/taap.1994.1195; CORKINS MR, 1995, BIOCHEM BIOPH RES CO, V211, P707, DOI 10.1006/bbrc.1995.1870; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; DECKWERTH TL, 1993, J CELL BIOL, V123, P1207, DOI 10.1083/jcb.123.5.1207; DEMEYTS P, 1994, HORM RES, V42, P152, DOI 10.1159/000184188; DOLE M, 1994, CANCER RES, V54, P3253; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FRANKOWSKI H, 1995, NEUROREPORT, V6, P1917, DOI 10.1097/00001756-199510020-00023; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; Gazzaniga P, 1996, INT J CANCER, V69, P100, DOI 10.1002/(SICI)1097-0215(19960422)69:2<100::AID-IJC5>3.0.CO;2-4; GILLARDON F, 1994, EUR J NEUROSCI, V6, P1641, DOI 10.1111/j.1460-9568.1994.tb00555.x; Gillardon F, 1996, J NEUROSCI RES, V43, P726, DOI 10.1002/(SICI)1097-4547(19960315)43:6<726::AID-JNR9>3.0.CO;2-G; GREENLUND LJS, 1995, NEURON, V15, P649, DOI 10.1016/0896-6273(95)90153-1; HANADA M, 1993, CANCER RES, V53, P4978; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; JACOBSON MD, 1994, CURR BIOL, V4, P337, DOI 10.1016/S0960-9822(00)00073-7; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; LEVENTHAL PS, 1995, EXP CELL RES, V221, P179, DOI 10.1006/excr.1995.1365; Leventhal PS, 1996, J BIOL CHEM, V271, P5957, DOI 10.1074/jbc.271.11.5957; MAH SP, 1993, J NEUROCHEM, V60, P1183, DOI 10.1111/j.1471-4159.1993.tb03275.x; MARTIN DM, 1993, J CELL PHYSIOL, V155, P290, DOI 10.1002/jcp.1041550210; MARTIN DM, 1993, J NEUROSCI RES, V34, P489, DOI 10.1002/jnr.490340502; MARTIN DM, 1992, MOL BRAIN RES, V15, P241, DOI 10.1016/0169-328X(92)90114-Q; MARTIN DM, 1993, REGUL PEPTIDES, V48, P225, DOI 10.1016/0167-0115(93)90351-8; MARTIN DM, 1993, ANN NY ACAD SCI, V692, P259; MARTIN DP, 1992, J NEUROBIOL, V23, P1205, DOI 10.1002/neu.480230911; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; Mathews CC, 1996, J CELL PHYSIOL, V166, P323; MATTHEWS C, 1996, IN PRESS NEUROSCIENC; MERRY DE, 1994, DEVELOPMENT, V120, P301; Mills E. M., 1995, Society for Neuroscience Abstracts, V21, P751; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; MONAGHAN P, 1992, HISTOCHEM J, V24, P476; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Roth KA, 1996, J NEUROSCI, V16, P1753; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Singleton JR, 1996, CANCER RES, V56, P4522; STELLER H, 1994, NEURON, V13, P1269, DOI 10.1016/0896-6273(94)90413-8; SUMANTRAN VN, 1993, ENDOCRINOLOGY, V132, P2017, DOI 10.1210/en.132.5.2017; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; WYLLIE AH, 1995, CURR OPIN GENET DEV, V5, P97, DOI 10.1016/S0959-437X(95)90060-8; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	63	159	163	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					31791	31794		10.1074/jbc.271.50.31791	http://dx.doi.org/10.1074/jbc.271.50.31791			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943217	hybrid			2022-12-25	WOS:A1996VY34000008
J	Wang, R; Sweeney, D; Gandy, SE; Sisodia, SS				Wang, R; Sweeney, D; Gandy, SE; Sisodia, SS			The profile of soluble amyloid beta protein in cultured cell media - Detection and quantification of amyloid beta protein and variants by immunoprecipitation mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE BRAIN; CEREBROSPINAL-FLUID; CORE PROTEIN; A-BETA; PEPTIDE; PRECURSOR; MUTATION; MATRIX; ANTIBODIES; DEPOSITS	To study the metabolism of amyloid beta protein (A beta) in Alzheimer's disease, we have developed a new approach for analyzing the profile of soluble A beta and its variants, In the present method, A beta and its variants are immunoisolated with A beta-specific monoclonal antibodies. The identities of the Ap variants are determined by measuring their molecular masses using matrix-assisted laser desorption ionization time-of-flight mass spectrometry. The levels of A beta variants are determined by their relative peak intensities in mass spectrometric measurements by comparison with internal standards of known identities and concentrations. We used this method to examine the A beta species in conditioned media of mouse neuroblastoma cells transfected with cDNAs encoding wild type or mutant human amyloid precursor protein. In addition to human A beta-(1-40) and A beta-(1-42), more than 40 different human A beta variants were identified. Endogenous murine A beta and its variants were also identified by this approach. The present approach is a new and sensitive method to characterize the profile of soluble A beta in conditioned media and biological fluids. Furthermore, it allows direct measurement of each individual peptide in a peptide mixture and provides comprehensive information on the identity and concentration of A beta and A beta variants.	CORNELL UNIV,COLL MED,DEPT NEUROL & NEUROSCI,NEW YORK,NY 10021; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,NEUROPATHOL LAB,BALTIMORE,MD 21205	Cornell University; Johns Hopkins University	Wang, R (corresponding author), ROCKEFELLER UNIV,LAB MASS SPECT,1230 YORK AVE,NEW YORK,NY 10021, USA.		Wang, Rong/A-8721-2009		NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG005146, R01AG011508, R55AG011508] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00862] Funding Source: Medline; NIA NIH HHS [AG05146, AG11508] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BEAVIS RC, 1990, ANAL CHEM, V62, P1836, DOI 10.1021/ac00216a020; BEAVIS RC, 1992, ORG MASS SPECTROM, V27, P156, DOI 10.1002/oms.1210270217; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CITRON M, 1994, P NATL ACAD SCI USA, V91, P11993, DOI 10.1073/pnas.91.25.11993; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; GOWING E, 1994, J BIOL CHEM, V269, P10987; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HILLENKAMP F, 1991, ANAL CHEM, V63, pA1193; HUTCHENS TW, 1993, RAPID COMMUN MASS SP, V7, P576, DOI 10.1002/rcm.1290070703; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; JOACHIM CL, 1988, BRAIN RES, V474, P100, DOI 10.1016/0006-8993(88)90673-7; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Katzman Robert, 1994, P105; Kim K., 1988, NEUROSCI RES COMMUN, V2, P121; KIM KS, 1990, NEUROSCI RES COMMUN, V7, P113; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MILLER DL, 1993, ARCH BIOCHEM BIOPHYS, V301, P41, DOI 10.1006/abbi.1993.1112; MORI H, 1992, J BIOL CHEM, V267, P17082; NAIDU A, 1995, J BIOL CHEM, V270, P1369, DOI 10.1074/jbc.270.3.1369; NASLUND J, 1994, P NATL ACAD SCI USA, V91, P8378, DOI 10.1073/pnas.91.18.8378; NELSON RW, 1995, ANAL CHEM, V67, P1153, DOI 10.1021/ac00103a003; PERRY G, 1992, AM J PATHOL, V140, P283; PRELLI F, 1988, J NEUROCHEM, V51, P648, DOI 10.1111/j.1471-4159.1988.tb01087.x; PRICE DL, 1986, ANNU REV NEUROSCI, V9, P489; Qiu WQ, 1996, J BIOL CHEM, V271, P8443, DOI 10.1074/jbc.271.14.8443; ROHER AE, 1993, J BIOL CHEM, V268, P3072; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHIVERS BD, 1988, EMBO J, V7, P1365, DOI 10.1002/j.1460-2075.1988.tb02952.x; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; Southwick PC, 1996, J NEUROCHEM, V66, P259; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TABATON M, 1994, BIOCHEM BIOPH RES CO, V200, P1598, DOI 10.1006/bbrc.1994.1634; TAMAOKA A, 1994, J BIOL CHEM, V269, P32721; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TERRY RD, 1983, AGING-US, V22, P47; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; VANGOOL WA, 1995, ANN NEUROL, V37, P277, DOI 10.1002/ana.410370221; VIGOPELFREY C, 1993, J NEUROCHEM, V61, P1965, DOI 10.1111/j.1471-4159.1993.tb09841.x; WANG R, 1996, 44 ASMS C MASS SPECT; ZHAO YM, 1994, ANAL CHEM, V66, P3723, DOI 10.1021/ac00093a029	44	268	288	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					31894	31902		10.1074/jbc.271.50.31894	http://dx.doi.org/10.1074/jbc.271.50.31894			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943233	hybrid			2022-12-25	WOS:A1996VY34000024
J	Cryns, VL; Bergeron, L; Zhu, H; Li, HL; Yuan, JY				Cryns, VL; Bergeron, L; Zhu, H; Li, HL; Yuan, JY			Specific cleavage of alpha-fodrin during Fas- and tumor necrosis factor-induced apoptosis is mediated by an interleukin-1 beta-converting enzyme Ced-3 protease distinct from the poly(ADP-ribose) polymerase protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEATH GENE CED-3; SMALL NUCLEAR RIBONUCLEOPROTEIN; PROGRAMMED CELL-DEATH; CONVERTING-ENZYME; CYSTEINE PROTEASE; IN-VITRO; IL-1-BETA-CONVERTING ENZYME; ICE/CED-3 PROTEASE; MULTIPLE PROTEASES; MAMMALIAN HOMOLOG	Interleukin 1 beta-converting enzyme (ICE)/Ced-3 proteases play a critical role in apoptosis. One well characterized substrate of these proteases is the DNA repair enzyme poly(ADP-ribose) polymerase. We report here that alpha-fodrin, an abundant membrane-associated cytoskeletal protein, is cleaved rapidly and specifically during Fas- and tumor necrosis factor-induced apopto sis; this cleavage is mediated by an ICE/Ced-3 protease distinct from the poly(ADP-ribose) polymerase protease. Studies in cells treated with these apoptotic stimuli reveal that both fodrin and poly(ADP-ribose) polymerase proteolysis are inhibited by acetyl-Tyr-Val-Ala-Asp chloromethyl ketone and CrmA, specific inhibitors of ICE/Ced-3 proteases. However, fodrin proteolysis can be distinguished from poly(ADP-ribose) polymerase prote olysis by its relative insensitivity to acetyl-Asp-Glu-Val-Asp aldehyde (DEVD-CHO), a selective inhibitor of a subset of ICE/Ced-3 proteases that includes CPP32. DEVD-CHO protects cells from Fas induced apoptosis but does not prevent fodrin proteolysis, indicating that cleavage of this protein can be uncoupled from apoptotic cell, death. Moreover, purified fodrin is cleaved in vitro by CPP32 (but not by ICE) into fragments of the same size observed in vivo during apoptosis. These findings suggest that fodrin proteolysis in vivo may reflect the activity of multiple ICE/Ced-3 proteases whose partial sensitivity to DEVD-CHO reflects a limited contribution from CPP32, or an ICE/Ced-3 protease less sensitive than CPP32 to DEVD-CHO inhibition.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP EAST,CARDIOVASC RES CTR,CHARLESTOWN,MA 02129	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital				Zhu, Hong/0000-0002-2575-4031	NATIONAL CANCER INSTITUTE [K08CA001752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012859, R37AG012859] Funding Source: NIH RePORTER; NCI NIH HHS [K08-CA01752-03] Funding Source: Medline; NIA NIH HHS [AG12859-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		An B, 1996, CANCER RES, V56, P438; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; CHOW SC, 1995, FEBS LETT, V364, P134, DOI 10.1016/0014-5793(95)00370-O; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; EASTMAN A, 1995, METHOD CELL BIOL, V46, P41; EMORI Y, 1987, P NATL ACAD SCI USA, V84, P3590, DOI 10.1073/pnas.84.11.3590; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FENTEANY G, 1994, P NATL ACAD SCI USA, V91, P3358, DOI 10.1073/pnas.91.8.3358; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GU Y, 1995, J BIOL CHEM, V270, P18715, DOI 10.1074/jbc.270.32.18715; HARRIS AS, 1988, J BIOL CHEM, V263, P15754; HARRIS AS, 1988, J NEUROSCI, V8, P2640; IIZUKA K, 1993, J MOL CELL CARDIOL, V25, P1101, DOI 10.1006/jmcc.1993.1122; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LEE KS, 1991, P NATL ACAD SCI USA, V88, P7233, DOI 10.1073/pnas.88.16.7233; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P153; MILLIGAN CE, 1995, NEURON, V15, P385, DOI 10.1016/0896-6273(95)90042-X; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIURA M, 1995, P NATL ACAD SCI USA, V92, P8318, DOI 10.1073/pnas.92.18.8318; MOON RT, 1990, J BIOL CHEM, V265, P4427; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P18738, DOI 10.1074/jbc.270.32.18738; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; WANG XD, 1995, J BIOL CHEM, V270, P18044, DOI 10.1074/jbc.270.30.18044; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZHIVOTOVSKY B, 1995, EXP CELL RES, V221, P404, DOI 10.1006/excr.1995.1391	58	184	186	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31277	31282		10.1074/jbc.271.49.31277	http://dx.doi.org/10.1074/jbc.271.49.31277			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940132	Green Published, hybrid			2022-12-25	WOS:A1996VW68600043
J	Huang, CS; Ma, WY; Bowden, GT; Dong, ZG				Huang, CS; Ma, WY; Bowden, GT; Dong, ZG			Ultraviolet B-induced activated protein-1 activation does not require epidermal growth factor receptor but is blocked by a dominant negative PKC lambda/i	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C-ZETA; XENOPUS-LAEVIS OOCYTES; SIGNAL-TRANSDUCTION; SUBSPECIES BLOCKS; PHORBOL ESTER; EGF RECEPTOR; FOS GENE; UV; ISOFORM; CELLS	The exposure of mammalian cells to UV irradiation leads to the activation of transcription factors such as activated protein-1 (AP-1) and NF kappa B. It is postulated that epidermal growth factor (EGF) receptor, but not protein kinase C (PKC), is the major membrane mediator in UV-induced signal transduction. Since UVB is responsible for most of the carcinogenic effects of sun exposure, we investigated the role of EGF receptors and PKC in UVB-induced AP-1 activation. Our results indicated that while the down-regulation of novel PKC (nPKC) and conventional PKC (cPKC) by pretreatment of cells with 12-O-tetradecanoyl phorbol-13-actetate cannot block UVB-induced AP-1 activity, it can block 12-O-tetradecanoyl phorbol-13-acetate-induced AP-I activity, Further, the dominant negative mutant PKC lambda/iota blocked UVB-induced AP-1 activity in all doses and time courses studied. In contrast, UVB-induced AP-1 activity from cells devoid of EGF receptor (B82) was not significantly different from that of the stable transfectants with a kinase-deficient EGF receptor (B82M721) or those with a wild-type EGF receptor (B82L) at all UVB irradiation doses and time courses studied, All of this evidence indicated that aPKC, but not EGF receptor, is involved in UVE-induced AP-1 activation.	UNIV MINNESOTA,HORMEL INST,AUSTIN,MN 55912; UNIV ARIZONA,ARIZONA HLTH SCI CTR,DEPT RADIAT ONCOL,TUCSON,AZ 85724	University of Minnesota System; University of Arizona; University of Arizona Health Sciences				Huang, Chuanshu/0000-0003-4133-5096				AKIMOTO K, 1994, J BIOL CHEM, V269, P12677; ANGEL P, 1995, INDUCED GENE EXPRESS, P63; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; BIRT DF, 1994, CARCINOGENESIS, V15, P2727, DOI 10.1093/carcin/15.12.2727; BIRT DF, 1994, CARCINOGENESIS, V15, P2341, DOI 10.1093/carcin/15.10.2341; BJORKOY G, 1995, J BIOL CHEM, V270, P21299; BROWN PH, 1993, ONCOGENE, V8, P877; BUSCHER M, 1988, ONCOGENE, V3, P301; Chapline C, 1996, J BIOL CHEM, V271, P6417, DOI 10.1074/jbc.271.11.6417; CHEN HX, 1993, J MED CHEM, V36, P4094, DOI 10.1021/jm00077a014; CRESPO P, 1995, BIOCHEM BIOPH RES CO, V213, P266, DOI 10.1006/bbrc.1995.2125; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DiazMeco MT, 1996, MOL CELL BIOL, V16, P105; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; DOMINGUEZ I, 1993, MOL CELL BIOL, V13, P1290, DOI 10.1128/MCB.13.2.1290; DOMINGUEZ I, 1992, MOL CELL BIOL, V12, P3776, DOI 10.1128/MCB.12.9.3776; DONG LQ, 1995, J BIOL CHEM, V270, P25534, DOI 10.1074/jbc.270.43.25534; DONG ZG, 1995, CARCINOGENESIS, V16, P749, DOI 10.1093/carcin/16.4.749; ELDREDGE ER, 1994, MOL CELL BIOL, V14, P7527, DOI 10.1128/MCB.14.11.7527; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; LIN CR, 1986, CELL, V44, P839, DOI 10.1016/0092-8674(86)90006-1; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHNO Y, 1989, P NATL ACAD SCI USA, V86, P3099; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; PARRISH JA, 1993, BIOCH PHYSL SKIN, V2, P713; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; RONAI ZA, 1988, J VIROL, V62, P1057, DOI 10.1128/JVI.62.3.1057-1060.1988; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; SETLOW RB, 1974, P NATL ACAD SCI USA, V71, P3363, DOI 10.1073/pnas.71.9.3363; SHAH G, 1993, CANCER RES, V53, P38; SHEA CR, 1991, PHYSL BIOCH MOL BIOL, P910; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; STABERG B, 1983, J INVEST DERMATOL, V81, P517, DOI 10.1111/1523-1747.ep12522855; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; STRICKLAND PT, 1986, J INVEST DERMATOL, V87, P272, DOI 10.1111/1523-1747.ep12696669; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0	48	102	105	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31262	31268		10.1074/jbc.271.49.31262	http://dx.doi.org/10.1074/jbc.271.49.31262			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940130	hybrid			2022-12-25	WOS:A1996VW68600041
J	Omkumar, RV; Kiely, MJ; Rosenstein, AJ; Min, KT; Kennedy, MB				Omkumar, RV; Kiely, MJ; Rosenstein, AJ; Min, KT; Kennedy, MB			Identification of a phosphorylation site for calcium/calmodulin-dependent protein kinase II in the NR2B subunit of the N-methyl-D-aspartate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTSYNAPTIC DENSITY PROTEIN; LONG-TERM POTENTIATION; GLUTATHIONE-S-TRANSFERASE; SPINAL-CORD NEURONS; NMDA RECEPTORS; GLUTAMATE RECEPTORS; HIPPOCAMPAL-NEURONS; CALCIUM; BRAIN; PURIFICATION	The N-methyl-D-aspartate (NMDA) subtype of excitatory glutamate receptors plays critical roles in embryonic and adult synaptic plasticity in the central nervous system. The receptor is a heteromultimer of core subunits, NR1, and one or more regulatory subunits, NR2A-D. Protein phosphorylation can regulate NMDA receptor function (Lieberman, D. N., and Mody, I. (1994) Nature 369, 235-239; Wang, Y. T., and Salter, M. W. (1994) Nature 369, 233-235; Wang, L.-Y., Orser, B. A. Brautigan, D. L., and MacDonald, J. F. (1994) Nature 369, 230-232). Here we identify a major phosphorylation site on subunit NR2B that is phosphorylated by Ca2+/calmodulin-dependent protein kinase II (CaM kinase II), an abundant protein kinase located at postsynaptic sites in glutamatergic synapses. For the initial identification of the site, we constructed a recombinant fusion protein containing 334 amino acids of the C terminus of the NR2B subunit and phosphorylated it with CaM kinase II in vitro. By peptide mapping, automated sequencing, and mass spectrometry, we identified the major site of phosphorylation on the fusion protein as Ser-383, corresponding to Ser-1303 of full-length NR2B. The K-m for phosphorylation of this site in the fusion protein was similar to 50 nM, much lower than that of other known substrates for CaM kinase II, suggesting that the receptor is a high affinity substrate. We show that serine 1303 in the full-length NR2B and/or the cognate site in NR2A is a major site of phosphorylation of the receptor both in the postsynaptic density fraction and in living hippocampal neurons.	CALTECH, DIV BIOL, PASADENA, CA 91125 USA	California Institute of Technology				min, kyung-tai/0000-0003-0983-4258; Kennedy, Mary/0000-0003-1369-0525	NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH049176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028710, R01NS017660] Funding Source: NIH RePORTER; NIMH NIH HHS [MH49176] Funding Source: Medline; NINDS NIH HHS [NS28710, NS17660] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CARLIN RK, 1980, J CELL BIOL, V86, P831, DOI 10.1083/jcb.86.3.831; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; DUDEK SM, 1993, J NEUROSCI, V13, P2910; GOLDENRING JR, 1984, J NEUROCHEM, V42, P1077, DOI 10.1111/j.1471-4159.1984.tb12713.x; GRIECO F, 1992, BIOTECHNIQUES, V13, P856; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; ISHII T, 1993, J BIOL CHEM, V268, P2836; KELLY PT, 1984, P NATL ACAD SCI-BIOL, V81, P945, DOI 10.1073/pnas.81.3.945; KENNEDY MB, 1983, J NEUROSCI, V3, P818; KENNEDY MB, 1990, COLD SH Q B, V55, P101; KENNEDY MB, 1983, P NATL ACAD SCI-BIOL, V80, P7357, DOI 10.1073/pnas.80.23.7357; Kindler S, 1996, J NEUROSCI METH, V68, P61, DOI 10.1016/0165-0270(96)00074-X; KOHLER G, 1976, EUR J IMMUNOL, V6, P511, DOI 10.1002/eji.1830060713; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBERMAN DN, 1994, NATURE, V369, P235, DOI 10.1038/369235a0; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; MAYER ML, 1987, J NEUROSCI, V7, P3230; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; MCGLADEMCCULLOH E, 1993, NATURE, V362, P640, DOI 10.1038/362640a0; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; MILLER SG, 1985, J BIOL CHEM, V260, P9039; MOLLOY SS, 1991, P NATL ACAD SCI USA, V88, P4756, DOI 10.1073/pnas.88.11.4756; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MOON IS, 1994, P NATL ACAD SCI USA, V91, P3954, DOI 10.1073/pnas.91.9.3954; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; PARTEN B, 1994, TECHNIQUES PROTEIN C, V5, P159; PATTON BL, 1993, MOL BIOL CELL, V4, P159, DOI 10.1091/mbc.4.2.159; PEARSON RB, 1985, J BIOL CHEM, V260, P4471; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; PETTIT DL, 1994, SCIENCE, V266, P1881, DOI 10.1126/science.7997883; PODELL DN, 1978, BIOCHEM BIOPH RES CO, V81, P176, DOI 10.1016/0006-291X(78)91646-7; Raman IM, 1996, NEURON, V16, P415, DOI 10.1016/S0896-6273(00)80059-8; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; STEVENS CF, 1994, CURR BIOL, V4, P687, DOI 10.1016/S0960-9822(00)00153-6; TALBO G, 1994, TECHNIQUES PROTEIN C, V5, P105; TINGLEY WG, 1993, NATURE, V364, P70, DOI 10.1038/364070a0; WANG LY, 1994, NATURE, V369, P230, DOI 10.1038/369230a0; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; WATTERSON DM, 1976, J BIOL CHEM, V251, P4501	49	246	254	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31670	31678		10.1074/jbc.271.49.31670	http://dx.doi.org/10.1074/jbc.271.49.31670			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940188	Green Accepted, hybrid			2022-12-25	WOS:A1996VW68600099
J	Hobba, GD; Forbes, BE; Parkinson, EJ; Francis, GL; Wallace, JC				Hobba, GD; Forbes, BE; Parkinson, EJ; Francis, GL; Wallace, JC			The insulin-like growth factor (IGF) binding site of bovine insulin-like growth factor binding protein-2 (bIGFBP-2) probed by iodination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I; CHEMICAL MODIFICATION; DIRECTED MUTAGENESIS; TYROSINE RESIDUES; PROTEOLYSIS; RECEPTORS; H-1-NMR; MUTANTS; SERUM	The insulin-like growth factor (IGF) binding site of bovine insulin-like growth factor binding protein 2 (bIGFBP-2) has been probed by chemical iodination. Tyrosyl residues of bIGFBP-2 were reacted by chloramine T-mediated iodination. The modification patterns of free bIGFBP-2 and bIGFBP-2 associated with insulin-like growth factor II (IGF-II) were compared by tryptic mapping using electrospray mass spectrometry and N-terminal sequencing. The presence of bound IGF-II resulted in protection of tyrosine at position 60 from iodination measured by the relative loss of tyrosine specific fluorescence and the incorporation of the radioisotope I-125. In addition, the pattern of iodine incorporation of bIGFBP-2 was not different whether IGF-I or IGF-II was the protective ligand. bIGFBP-2, when iodinated alone sustained a 8-fold loss of binding affinity for IGF-I and a 4-fold loss in binding affinity for IGF-II. In contrast, bIGFBP-2 iodinated while complexed with either IGF-I or IGF-II retained the same binding affinity for IGF-I or IGF-II as non-iodinated bIGFBP-2. We conclude that tyrosine 60 Lies either in a region of bIGFBP-2 which directly interacts with both IGF-I and IGF-II or lies in a region of bIGFBP-2 which undergoes a conformational change that is important for IGF binding. Furthermore, iodination of tyrosine residues at positions 71, 98, 213, 226, and 269 has no detectable impact on binding of bIGFBP-2 to the IGFs.	COOPERAT RES CTR TISSUE GROWTH & REPAIR, ADELAIDE, SA 5005, AUSTRALIA; CSIRO, DIV HUMAN NUTR, ADELAIDE, SA 5000, AUSTRALIA	Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Hobba, GD (corresponding author), UNIV ADELAIDE, DEPT BIOCHEM, NORTH TERRACE, ADELAIDE, SA 5005, AUSTRALIA.		Parkinson-Lawrence, Emma/F-4085-2013; Forbes, Briony/R-1838-2019; , John/AAP-5150-2020	Forbes, Briony/0000-0003-4360-9927; Parkinson-Lawrence, Emma/0000-0002-3845-4847				BACH LA, 1993, J BIOL CHEM, V268, P9246; BAGLEY CJ, 1989, BIOCHEM J, V259, P665, DOI 10.1042/bj2590665; BAKER MS, 1990, BIOCHEM BIOPH RES CO, V166, P993, DOI 10.1016/0006-291X(90)90909-7; BAXTER RC, 1993, BIOCHEM J, V294, P847, DOI 10.1042/bj2940847; BAXTER RC, 1994, HORM RES, V42, P140, DOI 10.1159/000184186; BRINKMAN A, 1991, MOL ENDOCRINOL, V5, P987, DOI 10.1210/mend-5-7-987; BRINKMAN A, 1991, FEBS LETT, V291, P264, DOI 10.1016/0014-5793(91)81298-M; BUCK MA, 1989, ANAL BIOCHEM, V182, P295, DOI 10.1016/0003-2697(89)90597-6; CLEMMONS DR, 1992, ENDOCRINOLOGY, V131, P890, DOI 10.1210/en.131.2.890; CONOVER CA, 1994, J BIOL CHEM, V269, P7076; CONOVER CA, 1995, J BIOL CHEM, V270, P4395, DOI 10.1074/jbc.270.9.4395; COOKE RM, 1991, BIOCHEMISTRY-US, V30, P5484, DOI 10.1021/bi00236a022; COWGILL RW, 1965, BIOCHIM BIOPHYS ACTA, V94, P74, DOI 10.1016/0926-6585(65)90009-9; FORBES B, 1988, BIOCHEM BIOPH RES CO, V157, P196, DOI 10.1016/S0006-291X(88)80032-9; FRANCIS GL, 1993, BIOCHEM J, V293, P713, DOI 10.1042/bj2930713; GASCIERI MA, 1994, HORM RES, V41, P80; HUHTALA ML, 1986, BIOCHEM BIOPH RES CO, V141, P263, DOI 10.1016/S0006-291X(86)80363-1; JONES JI, 1993, P NATL ACAD SCI USA, V90, P10553, DOI 10.1073/pnas.90.22.10553; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; JONES JI, 1993, GROWTH REGULAT, V3, P37; LEE CY, 1995, ENDOCRINOLOGY, V136, P668, DOI 10.1210/en.136.2.668; LEE PDK, 1993, P SOC EXP BIOL MED, V204, P4; MALY P, 1988, J BIOL CHEM, V263, P7068; MEANS GE, 1971, CHEM MODIFICATION PR, P181; MISTRY R, 1991, BIOCHEM J, V273, P685, DOI 10.1042/bj2730685; MOSS JA, 1991, J BIOL CHEM, V266, P909; RECHLER MM, 1993, VITAM HORM, V47, P1, DOI 10.1016/S0083-6729(08)60444-6; SATO A, 1992, J BIOCHEM-TOKYO, V111, P529, DOI 10.1093/oxfordjournals.jbchem.a123791; SATO A, 1993, INT J PEPT PROT RES, V41, P433; SCHAFFER L, 1993, BIOCHIM BIOPHYS ACTA, V1203, P205, DOI 10.1016/0167-4838(93)90084-5; SOMMER A, 1991, MODERN CONCEPTS INSU, P715; SZABO L, 1988, BIOCHEM BIOPH RES CO, V151, P207, DOI 10.1016/0006-291X(88)90580-3; TERASAWA H, 1994, EMBO J, V13, P5590, DOI 10.1002/j.1460-2075.1994.tb06896.x; TORRES AM, 1995, J MOL BIOL, V248, P385, DOI 10.1006/jmbi.1995.0229; TSOMIDES TJ, 1993, ANAL BIOCHEM, V210, P129, DOI 10.1006/abio.1993.1162; UPTON Z, 1990, J MOL ENDOCRINOL, V5, P77, DOI 10.1677/jme.0.0050077; WANG JF, 1988, BIOCHEM BIOPH RES CO, V157, P718, DOI 10.1016/S0006-291X(88)80309-7	37	31	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30529	30536		10.1074/jbc.271.48.30529	http://dx.doi.org/10.1074/jbc.271.48.30529			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940022	hybrid			2022-12-25	WOS:A1996VV15800039
J	Mitterdorfer, J; Wang, ZY; Sinnegger, MJ; Hering, S; Striessnig, J; Grabner, M; Glossmann, H				Mitterdorfer, J; Wang, ZY; Sinnegger, MJ; Hering, S; Striessnig, J; Grabner, M; Glossmann, H			Two amino acid residues in the IIIS5 segment of L-type calcium channels differentially contribute to 1,4-dihydropyridine sensitivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR DETERMINANTS; FUNCTIONAL EXPRESSION; SKELETAL-MUSCLE; MESSENGER-RNAS; CA2+ CHANNELS; MODULATION; ACTIVATOR; SUBUNIT; CELLS; BLOCK	The transmembrane segment IIIS5 of the L-type calcium channel alpha(1) subunit participates in the formation of the 1,4 dihydropyridine (DHP) interaction domain (Grabner, M,, Wang, Z., Hering, S., Striessnig, J., and Glossmann, H. (1996) Neuron 16, 207-218), We applied mutational analysis to identify amino acid residues within this segment that contribute to DHP sensitivity. DHP agonist and antagonist modulation of Ba2+ inward currents was assessed after coexpression of chimeric and mutant calcium channel alpha(1) subunits with alpha(2) delta and beta(1a) subunits in Xenopus oocytes. Whereas DHP antagonists required Thr-1066, DHP agonist modulation crucially depended on the additional presence of Gln-1070 (numbering according to alpha(1C-a)), which also further increased the sensitivity to DHP antagonists, Asp-955, which is found at the corresponding position in the calcium channel alpha(1S) subunit from carp skeletal muscle, displayed functional similarity to Gln-1070 with respect to DHP interaction, We conclude that these residues (Thr-1066 plus Gln-1070 or Asp-955), which are located in close vicinity on the same side of the putative a-helix of transmembrane segment IIIS5, form a crucial DHP binding motif.	INST BIOCHEM PHARMAKOL,A-6020 INNSBRUCK,AUSTRIA				Striessnig, Joerg/S-9334-2017; Glossmann, Hartmut/AAL-9790-2020; Tuluc, Petronel/C-2527-2011	Striessnig, Joerg/0000-0002-9406-7120; Brauns, Martina/0000-0002-0547-2731; glossmann, hartmut h./0000-0002-7392-3266				BIRNBAUMER L, 1994, NEURON, V13, P505, DOI 10.1016/0896-6273(94)90021-3; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; Doring F, 1996, J BIOL CHEM, V271, P11745, DOI 10.1074/jbc.271.20.11745; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; GINAP T, 1993, NEUROSCI LETT, V156, P35, DOI 10.1016/0304-3940(93)90433-L; Grabner M, 1996, NEURON, V16, P207, DOI 10.1016/S0896-6273(00)80037-9; GRABNER M, 1991, P NATL ACAD SCI USA, V88, P727, DOI 10.1073/pnas.88.3.727; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; HERING S, 1993, J GEN PHYSIOL, V101, P393, DOI 10.1085/jgp.101.3.393; HOCKERMAN GH, 1995, J BIOL CHEM, V270, P22119, DOI 10.1074/jbc.270.38.22119; HOFMANN F, 1994, ANNU REV NEUROSCI, V17, P399, DOI 10.1146/annurev.neuro.17.1.399; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; KASS RS, 1987, CIRC RES, V61, P1; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KUNZE DL, 1992, MOL PHARMACOL, V42, P666; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; Peterson BZ, 1996, J BIOL CHEM, V271, P5293, DOI 10.1074/jbc.271.10.5293; RAGSDALE DS, 1994, SCIENCE, V265, P1724, DOI 10.1126/science.8085162; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schuster A, 1996, EMBO J, V15, P2365, DOI 10.1002/j.1460-2075.1996.tb00592.x; STRIESSNIG J, 1991, P NATL ACAD SCI USA, V88, P10769, DOI 10.1073/pnas.88.23.10769; STRIESSNIG J, 1993, CELL PHYSIOL BIOCHEM, V3, P295, DOI 10.1159/000154695; Sudhakar Pamidighantam V., 1996, Biophysical Journal, V70, pA306; TANG SQ, 1993, NEURON, V11, P1013, DOI 10.1016/0896-6273(93)90215-D; TRIGGLE DJ, 1992, CLEV CLIN J MED, V59, P617	28	59	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30330	30335		10.1074/jbc.271.48.30330	http://dx.doi.org/10.1074/jbc.271.48.30330			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8939992	hybrid			2022-12-25	WOS:A1996VV15800009
J	Murphy, C; Nikodem, D; Howcroft, K; Weissman, JD; Singer, DS				Murphy, C; Nikodem, D; Howcroft, K; Weissman, JD; Singer, DS			Active repression of major histocompatibility complex class I genes in a human neuroblastoma cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; NF-KAPPA-B; EXPRESSION; BETA-2-MICROGLOBULIN; ANTIGENS; INTERFERON; SEQUENCES; ENHANCER; PROMOTER; DNA	Human neuronal cells express neither major histocompatibility complex (MHC) class I RNA nor cell surface molecules but can be induced to do so by various cytokines, In the present studies, we report that expression of MHC class I in a neuroblastoma cell line, CHP-126, is actively repressed. This repression is mediated by the combined effects of a series of upstream silencer elements. Removal of the silencers reveals not only an active promoter element but also the presence of an active enhancer, Four silencers have been identified and shown to have distinct sequences, binding factors, and patterns of function, One element is located between -724 and -697 base pairs (bp) and corresponds to a silencer involved in tissue-specific regulation of class I gene expression. Three additional elements occur between -503 and -402 bp, One of these corresponds to a c-jun, responsive element. Neither of the remaining elements corresponds to DNA sequences known to regulate expression of other genes, These data demonstrate that MHC class I expression normally is actively repressed in neuronal cells and suggest a model of rapid and specific triggering of class I in neuronal cells in response to infection.	NCI,EXPT IMMUNOL BRANCH,DBS,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								DREW P, 1995, J IMMUNOL, V155, P2096; DREW PD, 1993, J IMMUNOL, V150, P3300; Drew PD, 1995, J NEUROIMMUNOL, V63, P157, DOI 10.1016/0165-5728(95)00140-9; EHRLICH R, 1988, MOL CELL BIOL, V8, P695, DOI 10.1128/MCB.8.2.695; EHRLICH R, 1989, IMMUNOGENETICS, V30, P18, DOI 10.1007/BF02421465; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FRELS W I, 1990, New Biologist, V2, P1024; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HOWCROFT TK, 1993, EMBO J, V12, P3163, DOI 10.1002/j.1460-2075.1993.tb05985.x; HOWCROFT TK, 1993, SCIENCE, V260, P1320, DOI 10.1126/science.8493575; KIMURA A, 1986, CELL, V44, P261, DOI 10.1016/0092-8674(86)90760-9; LAMPSON LA, 1984, P NATL ACAD SCI-BIOL, V81, P6476, DOI 10.1073/pnas.81.20.6476; LAMPSON LA, 1990, J IMMUNOL, V144, P512; LAVI E, 1988, J NEUROIMMUNOL, V18, P245, DOI 10.1016/0165-5728(88)90102-6; MIYAZAKI J, 1986, P NATL ACAD SCI USA, V83, P9537, DOI 10.1073/pnas.83.24.9537; MOZES E, 1993, SCIENCE, V261, P91, DOI 10.1126/science.8316860; NEUMANN H, 1995, SCIENCE, V269, P549, DOI 10.1126/science.7624779; SINGER DS, 1990, CRIT REV IMMUNOL, V10, P235; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TING JPY, 1987, J NEUROIMMUNOL, V14, P87, DOI 10.1016/0165-5728(87)90103-2; VANTVEER LJ, 1993, EMBO J, V12, P195, DOI 10.1002/j.1460-2075.1993.tb05645.x; WEISSMAN JD, 1991, MOL CELL BIOL, V11, P4217, DOI 10.1128/MCB.11.8.4217; Zinkernagel R M, 1979, Adv Immunol, V27, P51, DOI 10.1016/S0065-2776(08)60262-X	23	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30992	30999		10.1074/jbc.271.48.30992	http://dx.doi.org/10.1074/jbc.271.48.30992			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940088	hybrid			2022-12-25	WOS:A1996VV15800105
J	Ohnuma, S; Narita, K; Nakazawa, T; Ishida, C; Takeuchi, Y; Ohto, C; Nishino, T				Ohnuma, S; Narita, K; Nakazawa, T; Ishida, C; Takeuchi, Y; Ohto, C; Nishino, T			A role of the amino acid residue located on the fifth position before the first aspartate-rich motif of farnesyl diphosphate synthase on determination of the final product	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CONSERVED ASPARTATE; MOLECULAR-CLONING; DOMAIN-II; GENE; PRENYLTRANSFERASE; PURIFICATION; SEQUENCES; PROTEINS	Farnesyl diphosphate (FPP) synthase catalyzes consecutive condensations of isopentenyl diphosphate with allylic substrates to give FPP, C-15 compound, as a final product and does not catalyze a condensation beyond FPP. Recently, it was observed that, in Bacillus stearothermophilus FPP synthase, a replacement of tyrosine with histidine at position 81, which is located on the fifth amino acid before the first aspartate-rich motif, caused the mutated FPP synthase to catalyze geranylgeranyl diphosphate (C-20) synthesis (Ohnuma, S.-i., Nakazawa, T., Hemmi, H., Hallberg, A.-M., Koyama, T., Ogura, K., and Nishino, T. (1996) J. Biol. Chem. 271, 10087-10095). Thus, we constructed 20 FPP synthases, each of which has a different amino acid at position 81, and analyzed them. All enzymes except for Y81P can catalyze the condensations of isopentenyl diphosphate. The final products and the product distributions are different from each other. Y81A, Y81G, and Y81S can produce hexaprenyl diphosphate (C-30) as their final product. The final product of Y81C, Y81H, Y81I, Y81L, Y81N, Y81T, and Y81V are geranylfarnesyl diphosphate (C-25), and Y81D, Y81E, Y81F, Y81K, Y81M, Y81Q, and Y81R cannot produce polyprenyl diphosphates more than geranylgeranyl diphosphate. Substitution of tryptophan does not affect the product specificity of FPP synthase. The average chain length of products is inversely proportional to the accessible surface area of substituted amino acid. However, no significant relation between the final chain length and the kinetic constants K-m and V-max are observed. These observations strongly indicate that the amino acid does not come into contact with the substrates but directly contacts the omega-terminal of an elongating allylic product. This interaction must prevent further condensation of isopentenyl diphosphate.	TOYOTA MOTOR CO LTD,BIO RES LAB,TOYOTA 47171,JAPAN	Toyota Motor Corporation	Ohnuma, S (corresponding author), TOHOKU UNIV,DEPT BIOCHEM & ENGN,AOBA KU,SENDAI,MIYAGI 98077,JAPAN.		Narita, Keishi/E-3539-2010; Ohto, Chikara/GQB-4702-2022	Narita, Keishi/0000-0002-7602-8523; Ohnuma, Shin-ichi/0000-0002-3305-5126				ASAI K, 1994, BIOCHEM BIOPH RES CO, V202, P340, DOI 10.1006/bbrc.1994.1933; ASHBY MN, 1990, J BIOL CHEM, V265, P13157; CHEN AJ, 1994, PROTEIN SCI, V3, P600; CHOTHIA C, 1976, J MOL BIOL, V105, P1, DOI 10.1016/0022-2836(76)90191-1; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; FUJII H, 1982, BIOCHIM BIOPHYS ACTA, V712, P716; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; JOLY A, 1993, J BIOL CHEM, V268, P26983; KOIKETAKESHITA A, 1995, J BIOL CHEM, V270, P18396, DOI 10.1074/jbc.270.31.18396; KOYAMA T, 1993, J BIOCHEM-TOKYO, V113, P355, DOI 10.1093/oxfordjournals.jbchem.a124051; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; MARRERO PF, 1992, J BIOL CHEM, V267, P21873; OHNUMA S, 1991, J BIOL CHEM, V266, P23706; Ohnuma S, 1996, J BIOL CHEM, V271, P18831, DOI 10.1074/jbc.271.31.18831; OHNUMA S, 1994, J BIOL CHEM, V269, P14792; Ohnuma SI, 1996, J BIOL CHEM, V271, P10087, DOI 10.1074/jbc.271.17.10087; POULTER CD, 1982, BIOSYNTHESIS ISOPREN, P161; Sambrook J., 2002, MOL CLONING LAB MANU; SONG LS, 1994, P NATL ACAD SCI USA, V91, P3044, DOI 10.1073/pnas.91.8.3044; TARSHIS LC, 1994, BIOCHEMISTRY-US, V33, P10871, DOI 10.1021/bi00202a004	21	116	133	3	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30748	30754		10.1074/jbc.271.48.30748	http://dx.doi.org/10.1074/jbc.271.48.30748			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940054	hybrid			2022-12-25	WOS:A1996VV15800071
J	Alevizopoulos, A; Mermod, N				Alevizopoulos, A; Mermod, N			Antagonistic regulation of a proline-rich transcription factor by transforming growth factor beta and tumor necrosis factor alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN GENE-EXPRESSION; NUCLEAR FACTOR-I; ACTIVATED PROTEIN-KINASES; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; DNA-REPLICATION; CTF/NF-I; HA-RAS; RECEPTOR; JUN	Transforming growth factor beta (TGF-beta) and tumor necrosis factor alpha (TNF-alpha) often exhibit antagonistic actions on the regulation of various activities such as immune responses, cell growth, and gene expression. However, the molecular mechanisms involved in the mutually opposing effects of TGF-beta and TNF-alpha are unknown. Here, we report that binding sites for the transcription factor CTF/NF-I mediate antagonistic TGF-beta and TNF-alpha transcriptional regulation in NIH3T3 fibroblasts. TGF-beta induces the proline rich transactivation domain of specific CTF/NF-I family members, such as CTF-1, whereas TNF-alpha represses both the uninduced as well as the TGF-beta-induced CTF-1 transcriptional activity. CTF-1 is thus the first transcription factor reported to be repressed by TNF-alpha. The previously identified TGF-beta-responsive domain in the proline-rich transcriptional activation sequence of CTF-1 mediates both transcriptional induction and repression by the two growth factors, Analysis of potential signal transduction intermediates does not support a role for known mediators of TNF-alpha action, such as arachidonic acid, in CTF-1 regulation. However, overexpression of oncogenic forms of the small GTPase Ras or of the Raf-1 kinase represses CTF-1 transcriptional activity, as does TNF-alpha. Furthermore, TNF-alpha is unable to repress CTF-1 activity in NIH3T3 cells overexpressing ras or raf, suggesting that TNF-alpha regulates CTF-1 by a Ras-Raf kinase-dependent pathway, Mutagenesis studies demonstrated that the CTF-1 TGF-beta-responsive domain is not the primary target of regulatory phosphorylations. Interestingly, however, the domain mediating TGF-beta and TNF-alpha antagonistic regulation overlapped precisely the previously identified histone H3 interaction domain of CTF-1. These results identify CTF-1 as a molecular target of mutually antagonistic TGF-beta and TNF-alpha regulation, and they further suggest a molecular mechanism for the opposing effects of these growth factors on gene expression.	UNIV LAUSANNE,INST BIOL ANIM,CH-1015 LAUSANNE,SWITZERLAND	University of Lausanne								Alevizopoulos A, 1995, GENE DEV, V9, P3051, DOI 10.1101/gad.9.24.3051; ARMENDARIZBORUNDA J, 1992, J BIOL CHEM, V267, P14316; ARMENTERO MT, 1994, P NATL ACAD SCI USA, V91, P11537, DOI 10.1073/pnas.91.24.11537; BELKA C, 1995, EMBO J, V14, P1156, DOI 10.1002/j.1460-2075.1995.tb07099.x; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; DIAZ A, 1993, J BIOL CHEM, V268, P10364; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; ESPEVIK T, 1988, J IMMUNOL, V140, P2312; GAILIT J, 1994, CURR OPIN CELL BIOL, V6, P717, DOI 10.1016/0955-0674(94)90099-X; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; HELLER RA, 1992, CELL, V70, P47; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; INAGAKI Y, 1995, J BIOL CHEM, V270, P3353, DOI 10.1074/jbc.270.7.3353; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; JONES KA, 1988, GENE DEV, V2, P1101, DOI 10.1101/gad.2.9.1101; KAHARI VM, 1990, J CLIN INVEST, V86, P1489, DOI 10.1172/JCI114866; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; MARTINEZ E, 1991, MOL CELL BIOL, V11, P2937, DOI 10.1128/MCB.11.6.2937; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; NEHLS MC, 1991, MOL CELL BIOL, V11, P4065, DOI 10.1128/MCB.11.8.4065; NIEDERREITHER K, 1992, J CELL BIOL, V119, P1361, DOI 10.1083/jcb.119.5.1361; ODONNELL VB, 1995, BIOCHEM J, V310, P133, DOI 10.1042/bj3100133; QURESHI SA, 1992, J BIOL CHEM, V267, P17635; ROBERTS AB, 1992, MOL ENDOCRINOL, V6, P1921, DOI 10.1210/me.6.11.1921; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sambrook J., 2002, MOL CLONING LAB MANU; SANTAMBROGIO L, 1993, J IMMUNOL, V151, P1116; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SLACK JL, 1992, MOL CELL BIOL, V12, P4714, DOI 10.1128/MCB.12.10.4714; THORBECKE GJ, 1992, P NATL ACAD SCI USA, V89, P7375, DOI 10.1073/pnas.89.16.7375; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; VERDIN E, 1993, EMBO J, V12, P3249, DOI 10.1002/j.1460-2075.1993.tb05994.x; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YANG BS, 1993, MOL CELL BIOL, V13, P3093, DOI 10.1128/MCB.13.5.3093	54	28	28	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29672	29681		10.1074/jbc.271.47.29672	http://dx.doi.org/10.1074/jbc.271.47.29672			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939900	hybrid			2022-12-25	WOS:A1996VU52500028
J	Barila, D; Plateroti, M; Nobili, F; Muda, AO; Xie, YH; Morimoto, T; Perozzi, G				Barila, D; Plateroti, M; Nobili, F; Muda, AO; Xie, YH; Morimoto, T; Perozzi, G			The Dri 42 gene, whose expression is up-regulated during epithelial differentiation, encodes a novel endoplasmic reticulum resident transmembrane protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO; CELLS; INTESTINE; ANTIBODIES; BIOGENESIS; CHANNELS; BIOLOGY; MODEL; MOTIF; ACID	A search for novel genes that are up-regulated during development and differentiation of the epithelial cells of the intestinal mucosa led us to the isolation of the Dri 42 cDNA clone (Dri, differentially expressed in rat intestine), The nucleotide sequence of the full-length cDNA has shown that it encodes a 35.5-kDa protein with one consensus sequence for N-linked glycosylation and alternating hydrophilic and hydrophobic domains, To determine the intracellular localization of Dri 42 we have raised polyclonal antibodies in hens against a bacterially produced Dri 42-glutathione S-transferase fusion protein, Immunofluorescence detection with these anbibodies has shown specific staining of the endoplasmic reticulum (ER) in the relatively undifferentiated fetal rat intestinal cell line FRIC B and in sections of rat small intestine, ER membrane localization of Dri 42 was confirmed by laser confocal microscopy of polarized Madin-Darby canine kidney cells overexpressing a Dri 42-chloramphenicol acetyltransferase (CAT) fusion protein by transfection, Pulse labeling experiments on transiently transfected cells demonstrated that the protein does not acquire Golgi modifications up to 4 h after synthesis, thus indicating that Dri 42 is an ER resident protein, The transmembrane disposition of Dri 42 was studied using in vitro insertion of Dri 42-CAT fusion proteins into microsomal membranes, The fusion proteins consisted of several different lengths of truncated Dri 42 and a reporter protein, CAT, that was linked in-frame after each hydrophobic segment, We found that hydrophobic segments H1, H3, and H5 had a signal/anchor function, and that membrane insertion of Dri 42 was achieved co-translationally by the action of a series of alternating insertion signals and halt transfer signals, resulting in the exposure of both termini of the protein to the cytosolic side, The functional implications of the structure and localization of Dri 42, whose primary sequence does not share significant homology to any previously described protein, are discussed.	IST NAZL NUTR,I-00178 ROME,ITALY; UNIV ROMA LA SAPIENZA,DIPARTIMENTO MED SPERIMENTALE & PATOL,I-00185 ROME,ITALY; NYU,MED CTR,DEPT CELL BIOL,NEW YORK,NY 10016	Consiglio per la Ricerca in Agricoltura e L'analisi Dell'economia Agraria (CREA); Sapienza University Rome; New York University			Perozzi, Giuditta/AFV-2497-2022; Muda, Andrea Onetti/AAA-5105-2020; Plateroti, Michelina/F-2928-2017; Onetti Muda, Andrea/G-5384-2012; Barilà, Daniela/K-8506-2016; Perozzi, Giuditta/A-7460-2016	Onetti Muda, Andrea/0000-0002-0274-6178; Barilà, Daniela/0000-0002-6192-1562; Perozzi, Giuditta/0000-0003-1755-6104				ALAWQATI Q, 1995, CURR OPIN CELL BIOL, V7, P504, DOI 10.1016/0955-0674(95)80006-9; ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; BAILA D, 1995, BIOCHIM BIOPHYS ACTA, V1263, P133; BAMBERG K, 1994, J BIOL CHEM, V269, P16909; BARILA D, 1994, EUR J BIOCHEM, V223, P701, DOI 10.1111/j.1432-1033.1994.tb19043.x; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BOYLE WJ, 1995, CURR OPIN GASTROEN, V11, P121, DOI 10.1097/00001574-199503000-00006; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CRABTREE GR, 1992, TRANSCRIPTIONAL REGU, P1063; DUPREY P, 1988, GENE DEV, V2, P1647, DOI 10.1101/gad.2.12a.1647; EGAWA K, 1995, FEBS LETT, V372, P74, DOI 10.1016/0014-5793(95)00957-B; FISCHER B, 1993, BIOTECHNOL BIOENG, V41, P3, DOI 10.1002/bit.260410103; GASSMANN M, 1990, FASEB J, V4, P2528, DOI 10.1096/fasebj.4.8.1970792; GORDON JI, 1989, J CELL BIOL, V108, P1187, DOI 10.1083/jcb.108.4.1187; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; McRoberts J. A., 1981, FUNCTIONALLY DIFFERE, P117; PLATEROTI M, 1993, EXP CELL RES, V208, P137, DOI 10.1006/excr.1993.1231; POLSON A, 1980, IMMUNOL COMMUN, V9, P475, DOI 10.3109/08820138009066010; PONGS O, 1992, PHYSIOL REV, V72, pS69, DOI 10.1152/physrev.1992.72.suppl_4.S69; RAJASEKARAN AK, 1994, MOL BIOL CELL, V5, P1093, DOI 10.1091/mbc.5.10.1093; RANALDI G, 1992, ANTIMICROB AGENTS CH, V36, P1374, DOI 10.1128/AAC.36.7.1374; Sambrook J., 2002, MOL CLONING LAB MANU; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; SKACH WR, 1994, J CELL BIOL, V125, P803, DOI 10.1083/jcb.125.4.803; SKACH WR, 1993, J BIOL CHEM, V268, P6903; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; VANOS CH, 1994, BBA-REV BIOMEMBRANES, V1197, P291; VONHEIJNE G, 1994, ANNU REV BIOPH BIOM, V23, P167; WU R, 1987, METHOD ENZYMOL, V152, P343; Xie YH, 1996, J BIOL CHEM, V271, P2563, DOI 10.1074/jbc.271.5.2563; XIE YH, 1995, J BIOL CHEM, V270, P11985, DOI 10.1074/jbc.270.20.11985	35	68	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29928	29936		10.1074/jbc.271.47.29928	http://dx.doi.org/10.1074/jbc.271.47.29928			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939937	hybrid			2022-12-25	WOS:A1996VU52500065
J	Brandstetter, H; Kuhne, A; Bode, W; Huber, R; vonderSaal, W; Wirthensohn, K; Engh, RA				Brandstetter, H; Kuhne, A; Bode, W; Huber, R; vonderSaal, W; Wirthensohn, K; Engh, RA			X-ray structure of active site-inhibited clotting factor Xa - Implications for drug design and substrate recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC TRYPSIN-INHIBITOR; PROTHROMBINASE COMPLEX; CRYSTALLOGRAPHIC REFINEMENT; MOLECULAR RECOGNITION; HIPPOCAMPAL-NEURONS; BOVINE TRYPSINOGEN; CRYSTAL-STRUCTURES; FACTOR-IXA; THROMBIN; RESOLUTION	The 3.0-Angstrom resolution x-ray structure of human des-Gla-coagulation factor Xa (fXa) has been determined in complex with the synthetic inhibitor DX-9065a. The binding geometry is characterized primarily by two interaction sites: the naphthamidine group is fixed in the S1 pocket by a typical salt bridge to Asp-189, while the pyrrolidine ring binds in the unique aryl-binding site (S4) of fXa. Unlike the large majority of inhibitor complexes with serine proteinases, Gly-216 (S3) does not contribute to hydrogen bond formation. In contrast to typical thrombin binding modes, the S2 site of fXa cannot be used by DX-9065a since it is blocked by Tyr-99, and the aryl-binding site (S4) of fXa is lined by carbonyl oxygen atoms that can accommodate positive charges. This has implications for natural substrate recognition as well as for drug design.	MAX PLANCK INST BIOCHEM, D-82125 MARTINSRIED, GERMANY; BOEHRINGER MANNHEIM GMBH, D-68305 MANNHEIM, GERMANY; BOEHRINGER MANNHEIM GMBH, D-82372 PENZBERG, GERMANY	Max Planck Society			Brandstetter, Hans/E-6754-2011	Brandstetter, Hans/0000-0002-6089-3045; Engh, Richard/0000-0002-6207-0560				BODE W, 1976, FEBS LETT, V68, P231, DOI 10.1016/0014-5793(76)80443-7; BODE W, 1975, J MOL BIOL, V98, P693, DOI 10.1016/S0022-2836(75)80005-2; BODE W, 1978, J MOL BIOL, V118, P99, DOI 10.1016/0022-2836(78)90246-2; BRANDSTETTER H, 1995, P NATL ACAD SCI USA, V92, P9796, DOI 10.1073/pnas.92.21.9796; BRANDSTETTER H, 1992, J MOL BIOL, V226, P1085, DOI 10.1016/0022-2836(92)91054-S; BRANDSTETTER H, 1994, THESIS TU MUNCHEN; BREWER GJ, 1995, BRAIN RES, V683, P258, DOI 10.1016/0006-8993(95)00332-K; Brunger A. T., 1993, XPLOR SYSTEM XRAY CR; CHATTOPADHYAY A, 1992, J BIOL CHEM, V267, P12323; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; ENGH R, 1996, IN PRESS STRUCTURE; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; GABRIEL B, 1996, THESIS U REGENSBURG; Grand RJA, 1996, BIOCHEM J, V313, P353, DOI 10.1042/bj3130353; HARA T, 1994, THROMB HAEMOSTASIS, V71, P314; HOPPE W, 1957, ACTA CRYSTALLOGR, V10, P750; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; HUBER R, 1965, ACTA CRYSTALLOGR, V19, P353, DOI 10.1107/S0365110X65003444; HUBER R, 1974, J MOL BIOL, V89, P73, DOI 10.1016/0022-2836(74)90163-6; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; KATAKURA S, 1993, BIOCHEM BIOPH RES CO, V197, P965, DOI 10.1006/bbrc.1993.2573; KATAKURA S, 1995, EUR J MED CHEM, V30, P387, DOI 10.1016/0223-5234(96)88248-1; KOMIYAMA Y, 1990, BIOCHEMISTRY-US, V29, P9418, DOI 10.1021/bi00492a016; LEE KR, 1995, J NEUROSURG, V83, P1045, DOI 10.3171/jns.1995.83.6.1045; LIN ZL, 1995, FEBS LETT, V370, P1, DOI 10.1016/0014-5793(95)00811-M; LIU Y, 1994, P NATL ACAD SCI USA, V91, P10300, DOI 10.1073/pnas.91.22.10300; LOLLAR P, 1985, BIOCHEMISTRY-US, V24, P8056, DOI 10.1021/bi00348a033; MUTUCUMARANA VP, 1992, J BIOL CHEM, V267, P17012; NIERODZIK ML, 1995, THROMB HAEMOSTASIS, V74, P282; NISHINO A, 1994, ACTA NEUROCHIR, P86; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; SINGH J, 1987, FEBS LETT, V224, P161, DOI 10.1016/0014-5793(87)80441-6; SMITHSWINTOSKY VL, 1995, J NEUROCHEM, V65, P1415; STUBBS MT, 1995, FEBS LETT, V375, P103, DOI 10.1016/0014-5793(95)01190-P; STUBBS MT, 1992, EUR J BIOCHEM, V206, P187, DOI 10.1111/j.1432-1033.1992.tb16916.x; TEO M, 1995, J BIOL CHEM, V270, P26690, DOI 10.1074/jbc.270.44.26690; TURK D, 1992, THESIS TU MUNCHEN; WALKER RK, 1994, J BIOL CHEM, V269, P27441	39	276	288	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29988	29992		10.1074/jbc.271.47.29988	http://dx.doi.org/10.1074/jbc.271.47.29988			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939944	hybrid			2022-12-25	WOS:A1996VU52500072
J	Chestukhin, A; Muradov, K; Litovchick, L; Shaltiel, S				Chestukhin, A; Muradov, K; Litovchick, L; Shaltiel, S			The cleavage of protein kinase A by the kinase-splitting membranal proteinase is reproduced by meprin beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NON-PANCREATIC HYDROLYSIS; BRUSH-BORDER MEMBRANES; RAT-KIDNEY CORTEX; ACID PABA-PEPTIDE; MOUSE KIDNEY; CATALYTIC SUBUNIT; MICROVILLAR MEMBRANES; METALLO-ENDOPEPTIDASE; INSULIN-RECEPTOR; SMALL-INTESTINE	The Kinase-Splitting Membranal Proteinase (KSMP) is a metallo-endoproteinase that clips off the carboxyl terminus tail of the catalytic (C) subunit of protein kinase A to yield a truncated, catalytically inactive protein (C'), Here we report (a) a new procedure for the purification of KSMP, yielding a major protein band in SDS-polyacrylamide gel electrophoresis that correlates with the characteristic KSMP activity; (b) the sequence of tryptic peptides obtained from this band, suggesting an identity between this protein and meprin beta; (c) the immune-detection by specific anti-peptide antibodies of both the alpha and the beta subunits of meprin in KSMP preparations; (d) the stable expression of meprin beta in a mammalian cell line (293) to establish a clone that constitutively expresses the full-length precursor of meprin beta; and (e) the optimalization of the proteolytic activation of this precursor to obtain an enzyme exhibiting the specific KSMP cleavage, suggesting that KSMP is either derived from, or identical with, the meprin beta gene product, It is hoped that these results will shed light on the possible physiological role of KSMP and the way it may affect protein kinase A-mediated processes.	WEIZMANN INST SCI, DEPT REGULAT BIOL, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science				Litovchick, Larisa/0000-0002-9540-597X				ALHANATY E, 1979, BIOCHEM BIOPH RES CO, V89, P323, DOI 10.1016/0006-291X(79)90633-8; ALHANATY E, 1981, P NATL ACAD SCI-BIOL, V78, P3492, DOI 10.1073/pnas.78.6.3492; ALHANATY E, 1985, CURR TOP CELL REGUL, V27, P267; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BEYNON RJ, 1981, BIOCHEM J, V199, P591, DOI 10.1042/bj1990591; BODE W, 1992, NATURE, V358, P164, DOI 10.1038/358164a0; BOND JS, 1986, CURR TOP CELL REGUL, V28, P263; BOND JS, 1983, BIOCHEM J, V209, P251, DOI 10.1042/bj2090251; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; BOND JS, 1995, ZINC METALLOPROTEASE, P23; BUTLER PE, 1988, J BIOL CHEM, V263, P13419; Chestukhin A, 1996, J BIOL CHEM, V271, P10175, DOI 10.1074/jbc.271.17.10175; Chestukhin A, 1996, FEBS LETT, V382, P265, DOI 10.1016/0014-5793(96)00178-0; CHESTUKHIN A, 1995, ASBMB DBC ACS JOINT; CHOUDRY Y, 1991, BIOCHEM J, V280, P57, DOI 10.1042/bj2800057; CORBEIL D, 1992, FEBS LETT, V309, P203, DOI 10.1016/0014-5793(92)81095-4; DEJONGE H, 1987, EUR J BIOCHEM, V169, P503; EVERS C, 1978, MEMBRANE BIOCHEM, V1, P203, DOI 10.3109/09687687809063848; GOMISRUTH FX, 1993, J MOL BIOL, V229, P945, DOI 10.1006/jmbi.1993.1098; GORBEA CM, 1993, J BIOL CHEM, V268, P21035; GORBEA CM, 1991, ARCH BIOCHEM BIOPHYS, V290, P549, DOI 10.1016/0003-9861(91)90580-C; GORBEA KCM, 1994, MAMMALIAN BRUSH BORD, P89; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Harlow E., 1988, ANTIBODIES LAB MANUA; JIANG WP, 1992, J BIOL CHEM, V267, P9185; JOHNSON GD, 1994, J BIOL CHEM, V269, P7682; JOHNSON GD, 1992, J BIOL CHEM, V267, P13505; JOHNSON GD, 1993, J BIOL CHEM, V268, P17647; KAUSHAL GP, 1994, J CELL BIOL, V126, P1319, DOI 10.1083/jcb.126.5.1319; KENNY AJ, 1981, ACTA BIOL MED GER, V40, P1465; KENNY AJ, 1987, BIOCHEM J, V245, P515, DOI 10.1042/bj2450515; KENNY AJ, 1977, PROTEINASES MAMMALIA, P393; KORCGRODZICKI B, 1988, P NATL ACAD SCI USA, V85, P7541, DOI 10.1073/pnas.85.20.7541; KOUNNAS MZ, 1991, J BIOL CHEM, V266, P17350; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACADAM GC, 1990, INT J BIOCHEM, V22, P989, DOI 10.1016/0020-711X(90)90205-H; MARCHAND P, 1994, J BIOL CHEM, V269, P15388; MCDONALD JK, 1977, PROTEINASES MAMMALIA, V2, P311; MILHIET PE, 1994, BIOCHEM J, V300, P37, DOI 10.1042/bj3000037; ORTIZ ML, 1992, FEBS LETT, V296, P300, DOI 10.1016/0014-5793(92)80309-5; PORATH J, 1983, BIOCHEMISTRY-US, V22, P1621, DOI 10.1021/bi00276a015; REIMANN EM, 1983, METHOD ENZYMOL, V99, P51; SEGER R, 1989, EMBO J, V8, P435, DOI 10.1002/j.1460-2075.1989.tb03395.x; SEGER R, 1988, J BIOL CHEM, V263, P3496; SEGER R, 1993, INNOVATION PROTEASES, P231; SHALTIEL S, 1993, MOL CELL BIOCHEM, V128, P283, DOI 10.1007/BF01076778; SHALTIEL S, 1989, MECH REGULATION INTR, P188; STEPHENSON SL, 1988, BIOCHEM J, V255, P45, DOI 10.1042/bj2550045; STERCHI EE, 1983, J PEDIATR GASTR NUTR, V2, P539, DOI 10.1097/00005176-198302030-00024; STERCHI EE, 1982, CLIN SCI, V62, P557, DOI 10.1042/cs0620557; TAYLOR SS, 1995, FASEB J, V9, P1255, DOI 10.1096/fasebj.9.13.7557015; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; TITANI K, 1987, BIOCHEMISTRY-US, V26, P222, DOI 10.1021/bi00375a029; WALSH DA, 1994, FASEB J, V8, P1227, DOI 10.1096/fasebj.8.15.8001734; YAMAGUCHI T, 1994, LIFE SCI, V54, P381, DOI 10.1016/0024-3205(94)00795-0	55	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30272	30280		10.1074/jbc.271.47.30272	http://dx.doi.org/10.1074/jbc.271.47.30272			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939981	hybrid			2022-12-25	WOS:A1996VU52500109
J	White, JA; Guo, YD; Baetz, K; BeckettJones, B; Bonasoro, J; Hsu, KE; Dilworth, FJ; Jones, G; Petkovich, M				White, JA; Guo, YD; Baetz, K; BeckettJones, B; Bonasoro, J; Hsu, KE; Dilworth, FJ; Jones, G; Petkovich, M			Identification of the retinoic acid-inducible all-trans-retinoic acid 4-hydroxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							24-HYDROXYLASE GENE; INVIVO METABOLISM; ESCHERICHIA-COLI; INVITRO; EXPRESSION; ZEBRAFISH; FIN; TRANSCRIPTION; INHIBITION; LIAROZOLE	Retinoic acid (RA) metabolites of vitamin A are key regulators of gene expression involved in embryonic development and maintenance of epithelial tissues, The cellular effects of RA are dependent upon the complement of nuclear receptors expressed (RARs and RXRs), which transduce retinoid signals into transcriptional regulation, the presence of cellular retinoid-binding proteins (CRABP and CRBP), which may be involved in RA metabolism, and the activity of RA metabolizing enzymes, We have been using the zebrafish as a model to study these processes, To identify genes regulated by RA during exogenous RA exposure, we utilized mRNA differential display, We describe the isolation and characterization of a cDNA, P450RAI, encoding a novel member of the cytochrome P450 family, mRNA transcripts for P450RAI are expressed normally during gastrulation, and in a defined pattern in epithelial cells of the regenerating caudal fin in response to exogenous RA. In COS-1 cells transfected with the P450RAI cDNA, all-trans-RA is rapidly metabolized to more polar metabolites. We have identified 4-oxo-RA and 4-OH-RA as major metabolic products of this enzyme. P450RAI represents the first enzymatic component of RA metabolism to be isolated and characterized at the molecular level and provides key insight into regulation of retinoid homeostasis.	QUEENS UNIV,CANC RES LABS,KINGSTON,ON K7L 3N6,CANADA; QUEENS UNIV,DEPT PATHOL,KINGSTON,ON K7L 3N6,CANADA; QUEENS UNIV,DEPT BIOCHEM,KINGSTON,ON K7L 3N6,CANADA; QUEENS UNIV,DEPT MED,KINGSTON,ON K7L 3N6,CANADA	Queens University - Canada; Queens University - Canada; Queens University - Canada; Queens University - Canada			Baetz, Kristin/E-6859-2013	Dilworth, F. Jeffrey/0000-0002-6265-8102				AKIMENKO MA, 1995, DEV BIOL, V170, P243, DOI 10.1006/dbio.1995.1211; AKIMENKO MA, 1995, DEVELOPMENT, V121, P347; AKIYOSHISHIBATA M, 1994, EUR J BIOCHEM, V224, P335, DOI 10.1111/j.1432-1033.1994.00335.x; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Blumberg B, 1996, P NATL ACAD SCI USA, V93, P4873, DOI 10.1073/pnas.93.10.4873; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; CHAMBON P, 1995, RECENT PROG HORM RES, V50, P317; CHEN KS, 1995, BBA-GENE STRUCT EXPR, V1263, P1, DOI 10.1016/0167-4781(95)00060-T; DAWSON MI, 1990, METHOD ENZYMOL, V189, P1; DUELL EA, 1992, J CLIN INVEST, V90, P1269, DOI 10.1172/JCI115990; FIORELLA PD, 1993, J BIOL CHEM, V268, P21545; FROLIK CA, 1979, BIOCHEMISTRY-US, V18, P2092, DOI 10.1021/bi00577a039; Gotoh O., 1989, FRONTIERS BIOTRANSFO, V1, P195; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; JONES BB, 1995, MOL CELL BIOL, V15, P5226; KRAFT JC, 1994, BIOCHEM J, V301, P111, DOI 10.1042/bj3010111; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MADEN M, 1992, BIOESSAYS, V14, P431, DOI 10.1002/bies.950140702; MAKIN G, 1989, BIOCHEM J, V262, P173, DOI 10.1042/bj2620173; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MUINDI JRF, 1992, CANCER RES, V52, P2138; NAPOLI JL, 1987, ARCH BIOCHEM BIOPHYS, V255, P95, DOI 10.1016/0003-9861(87)90298-0; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; OHYAMA Y, 1994, J BIOL CHEM, V269, P10545; PIJNAPPEL WWM, 1993, NATURE, V366, P340, DOI 10.1038/366340a0; REDDY AP, 1992, BIOCHEM J, V287, P833, DOI 10.1042/bj2870833; ROBERTS AB, 1979, J BIOL CHEM, V254, P6296; Takatsuka J, 1996, CANCER RES, V56, P675; THALLER C, 1990, NATURE, V345, P815, DOI 10.1038/345815a0; VANWAUWE J, 1992, J PHARMACOL EXP THER, V261, P773; VANWAUWE JP, 1990, J PHARMACOL EXP THER, V252, P365; VANWAUWE JP, 1988, J PHARMACOL EXP THER, V245, P718; WHITE J, 1996, IN PRESS MEHTODS MOL; WHITE JA, 1994, DEVELOPMENT, V120, P1861; WILLIAMS JB, 1987, BIOCHEM PHARMACOL, V36, P1386, DOI 10.1016/0006-2952(87)90102-X; WOUTERS W, 1992, CANCER RES, V52, P2841; ZIEROLD C, 1995, J BIOL CHEM, V270, P1675, DOI 10.1074/jbc.270.4.1675	37	316	335	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29922	29927		10.1074/jbc.271.47.29922	http://dx.doi.org/10.1074/jbc.271.47.29922			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939936	hybrid			2022-12-25	WOS:A1996VU52500064
J	FernandezRachubinski, FA; Weiner, JH; Blajchman, MA				FernandezRachubinski, FA; Weiner, JH; Blajchman, MA			Regions flanking exon 1 regulate constitutive expression of the human antithrombin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR HORMONE RECEPTORS; BINDING-PROTEIN; PROMOTER; TRANSCRIPTION; LIVER; CELLS; ELEMENT; RECOGNITION; SEQUENCES; INTERACTS	We have identified cis-acting elements and trans-acting factors that regulate constitutive expression of the human antithrombin gene. The activity of the sequences flanking the first exon of the gene was investigated using a luciferase-based reporter assay in transiently transfected HepG2, COS1, BSC40, and HeLa cells. Deletion analysis allowed the mapping of two elements able to promote antithrombin gene transcription in HepG2 and COS1 cells. The first element is located upstream of the first exon (-150/+68 nucleotides). The second element is in the first intervening sequence (+300/+700 nucleotides) and functions in an orientation opposite to that of the first. Footprint analysis showed three protected areas in the 5' upstream element at -92/-68 (element A), -14/+37 (element B), and -126/-100 nucleotides (element C). These elements acted as enhancers in luciferase reporter assays. Gel retardation analysis demonstrated that two liver-enriched transcription factors, hepatocyte nuclear factor 4 (HNF4) and CCAAT enhancer-binding protein (C/EBPa), bound to the 5' upstream element. HNF4 bound to elements A and C, whereas C/EBPa bound to element B. Element A also interacted with the ubiquitous nuclear hormone receptors chicken ovalbumin upstream promoter transcription factor 1 (COUP-TF1), thyroid hormone receptor alpha (TR alpha), peroxisome proliferator-activated receptor alpha(PPAR alpha), and retinoid X receptor alpha (RXR alpha). In HepG2 and BSC40 cells, HNF4, C/EBP alpha, and RXR alpha activated luciferase expression from a reporter construct containing the 5'-upstream minimal antithrombin gene promoter, while COUP-TF1, TR alpha, and HNF3 (alpha or beta) repressed such expression. Our results show that constitutive expression of the human antithrombin gene depends in part upon the interplay of these transcription factors and suggest that signaling pathways regulated by these factors can modulate antithrombin gene transcription.	MCMASTER UNIV,MED CTR,HSC 2N34,DEPT PATHOL,HAMILTON,ON L8N 3Z5,CANADA; UNIV ALBERTA,DEPT MED,EDMONTON,AB T6G 2H7,CANADA; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON,AB T6G 2H7,CANADA	McMaster University; University of Alberta; University of Alberta								BLAJCHMAN MA, 1992, BLOOD, V80, P2159; BOSSU JP, 1994, BIOCHEM BIOPH RES CO, V202, P822, DOI 10.1006/bbrc.1994.2004; BRUNEL F, 1991, NUCLEIC ACIDS RES, V19, P5237, DOI 10.1093/nar/19.19.5237; CARLSSON P, 1989, GENE, V77, P113, DOI 10.1016/0378-1119(89)90365-X; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Ciliberto Gennaro, 1993, P162; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; GILLMAN MZ, 1986, MOL CELL BIOL, V6, P4305; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; HOWELL BW, 1989, MOL CELL BIOL, V9, P2928, DOI 10.1128/MCB.9.7.2928; HUANG MN, 1992, J BIOL CHEM, V267, P15440; JANSENDURR P, 1992, NUCLEIC ACIDS RES, V20, P1243, DOI 10.1093/nar/20.6.1243; KENNEDY GC, 1992, P NATL ACAD SCI USA, V89, P11498, DOI 10.1073/pnas.89.23.11498; LECAM A, 1994, J BIOL CHEM, V269, P21532; Mangelsdorf David J., 1994, P319; MARCUS SL, 1993, P NATL ACAD SCI USA, V90, P5723, DOI 10.1073/pnas.90.12.5723; METZGER S, 1993, J BIOL CHEM, V268, P16831; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; MIYATA KS, 1993, J BIOL CHEM, V268, P19169; OCHOA A, 1989, NUCLEIC ACIDS RES, V17, P119, DOI 10.1093/nar/17.1.119; PROCHOWNIK EV, 1985, NATURE, V316, P845, DOI 10.1038/316845a0; PROCHOWNIK EV, 1984, J BIOL CHEM, V259, P5386; ROBERTS HR, 1993, THROMB HAEMOSTASIS, V70, P1; SALIER JP, 1990, J BIOL CHEM, V265, P7062; SCHAEFFER E, 1993, J BIOL CHEM, V268, P23399; Sheffield WP, 1995, MOL BASIS THROMBOSIS, P355; SLADEK FM, 1994, TRANSCRIPTIONAL REGU, P1; TREMP GL, 1995, GENE AMST, V156, P192; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; ZHANG BW, 1992, P NATL ACAD SCI USA, V89, P7541, DOI 10.1073/pnas.89.16.7541	34	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29502	29512		10.1074/jbc.271.46.29502	http://dx.doi.org/10.1074/jbc.271.46.29502			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910619	hybrid			2022-12-25	WOS:A1996VT05200111
J	Berx, G; CletonJansen, AM; Strumane, K; deLeeuw, WJF; Nollet, F; vanRoy, F; Cornelisse, C				Berx, G; CletonJansen, AM; Strumane, K; deLeeuw, WJF; Nollet, F; vanRoy, F; Cornelisse, C			E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain	ONCOGENE			English	Article						lobular breast cancer; E-cadherin; mutations; LOH; tumour suppressor gene	CELL-ADHESION MOLECULE; EPITHELIAL TUMOR-CELLS; SUPPRESSOR GENE; ALPHA-CATENIN; BETA-CATENIN; GASTRIC CARCINOMAS; CPG METHYLATION; EXPRESSION; ASSOCIATION; DNA	We have analysed a series of 49 human breast cancers for mutations in the entire coding region plus flanking intron sequences of the E-cadherin gene, The tumours included 41 infiltrating lobular carcinomas, two infiltrating ducto-lobular carcinomas and six infiltrative ductal carcinomas, In the lobular carcinomas 23 different somatic mutations were detected, of which seven were insertions, 11 deletions, two nonsense mutations and three splice site mutations, The other tumours showed no detectable E-cadherin mutations, All the frameshift and nonsense mutations are expected to generate a secreted E-cadherin fragment instead of a transmembrane protein with cell adhesion activity, The majority of the mutations (21 of 23) were found in combination with loss of heterozygosity of the wild type E-cadherin locus (16q22.1), a hallmark of classical tumour suppressor genes, The mutations were scattered over the whole coding region and no hot spots could be identified, All mutations described here were previously unreported, In conclusion, we have identified up to now E-cadherin mutations in 27 of 48 (56%) infiltrating lobular breast carcinomas and in 0 of 50 breast cancers of other histopathological subtypes, These data provide strong evidence that frequent E-cadherin mutations are involved in the particular etiology of sporadic lobular breast cancers.	STATE UNIV GHENT,MOL CELL BIOL LAB,DEPT BIOL MOL,B-9000 GHENT,BELGIUM; VIB,B-9000 GHENT,BELGIUM; ACAD HOSP LEIDEN,DEPT PATHOL,NL-2300 RC LEIDEN,NETHERLANDS	Ghent University; Flanders Institute for Biotechnology (VIB); Leiden University; Leiden University Medical Center (LUMC)			van Roy, Frans M/C-6123-2009	van Roy, Frans M/0000-0003-4358-1039; Berx, Geert/0000-0001-5770-2458				ABERLE H, 1994, J CELL SCI, V107, P3655; BEAUDET AL, 1993, HUM MUTAT, V2, P245, DOI 10.1002/humu.1380020402; BECKER KF, 1993, HUM MOL GENET, V2, P803, DOI 10.1093/hmg/2.6.803; BECKER KF, 1994, CANCER RES, V54, P3845; BERX G, 1995, GENOMICS, V26, P281, DOI 10.1016/0888-7543(95)80212-5; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; BUSSEMAKERS MJG, 1993, MOL BIOL REP, V17, P123, DOI 10.1007/BF00996219; Candidus S, 1996, CANCER RES, V56, P49; CLETONJANSEN AM, 1994, GENE CHROMOSOME CANC, V9, P101, DOI 10.1002/gcc.2870090205; CORNELIS RS, 1994, CANCER RES, V54, P4200; COWIN P, 1994, P NATL ACAD SCI USA, V91, P10759, DOI 10.1073/pnas.91.23.10759; DEVILEE P, 1994, BBA-REV CANCER, V1198, P113, DOI 10.1016/0304-419X(94)90009-4; DSOUZA B, 1994, P NATL ACAD SCI USA, V91, P7202, DOI 10.1073/pnas.91.15.7202; EWING CM, 1995, CANCER RES, V55, P4813; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; FUJIOKA S, 1995, JPN J CANCER RES, V86, P368, DOI 10.1111/j.1349-7006.1995.tb03066.x; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GAMALLO C, 1993, AM J PATHOL, V142, P987; GRAFF JR, 1995, CANCER RES, V55, P5195; Hayashi K, 1991, PCR Methods Appl, V1, P34; HENNIG G, 1995, ONCOGENE, V11, P475; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; KANAI Y, 1994, JPN J CANCER RES, V85, P1035, DOI 10.1111/j.1349-7006.1994.tb02902.x; KATAYAMA M, 1994, BRIT J CANCER, V69, P580, DOI 10.1038/bjc.1994.106; KATAYAMA M, 1994, INT J ONCOL, V5, P1049; KNUDSON AG, 1985, CANCER RES, V45, P1437; Marcus JN, 1996, CANCER-AM CANCER SOC, V77, P697, DOI 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MOLL R, 1993, AM J PATHOL, V143, P1731; NAVARRO P, 1991, J CELL BIOL, V115, P517, DOI 10.1083/jcb.115.2.517; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; PIERCEALL WE, 1995, ONCOGENE, V11, P1319; RASBRIDGE SA, 1993, J PATHOL, V169, P245, DOI 10.1002/path.1711690211; RIMM DL, 1995, LAB INVEST, V72, P506; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; ROSEN PP, 1993, ATLAS TUMOUR PATHOLO; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TAKAYAMA T, 1994, INT J ONCOL, V5, P775; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; VLEMINCKX KL, 1994, CANCER RES, V54, P873; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; WHEELOCK MJ, 1987, J CELL BIOCHEM, V34, P187, DOI 10.1002/jcb.240340305; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416	51	376	385	0	14	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 7	1996	13	9					1919	1925						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934538				2022-12-25	WOS:A1996VR79500011
J	Kumar, A; Toscani, A; Rane, S; Reddy, EP				Kumar, A; Toscani, A; Rane, S; Reddy, EP			Structural organization and chromosomal mapping of JAK3 locus	ONCOGENE			English	Article						JAK3 genomic sequence; chromosome 19; intron exon organization	PROTEIN-TYROSINE KINASE; GAMMA SIGNAL-TRANSDUCTION; MICE LACKING JAK3; INSITU HYBRIDIZATION; TRANSCRIPTION FACTOR; LYMPHOID DEVELOPMENT; RECEPTOR; ACTIVATION; CELLS; PHOSPHORYLATION	In this study, we have isolated the genomic DNA clone encoding the murine JAK3 gene and determined its sequence. Partial genomic clones of the JAK1 and JAK2 genes encoding the tyrosine kinase domain were also isolated and compared with JAK3. The genomic structure of JAK3 consists of 23 exons. The exon/intron boundaries and the distribution of coding sequences within the exons of each of the three JAK genes were found to follow a similar pattern suggesting that various members of the JAK family have originated from a single primordial gene by duplication and the structure has been closely maintained through evolution. Using in situ hybridization and FISH analysis, we have mapped the JAK3 gene to human chromosome 19p13.1-p13.2.	TEMPLE UNIV, SCH MED, FELS INST CANC RES & MOL BIOL, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV, SCH MED, DEPT BIOCHEM, PHILADELPHIA, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University					NCI NIH HHS [CA68239] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068239] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; HARPUR AG, 1992, ONCOGENE, V7, P1347; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HENG HHQ, 1994, HUM MOL GENET, V3, P61, DOI 10.1093/hmg/3.1.61; HUNTER T, 1993, NATURE, V366, P114, DOI 10.1038/366114a0; INOUE M, 1991, P NATL ACAD SCI USA, V88, P2278, DOI 10.1073/pnas.88.6.2278; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Kono DH, 1996, MAMM GENOME, V7, P476, DOI 10.1007/s003359900145; LAI KS, 1995, J BIOL CHEM, V270, P25028, DOI 10.1074/jbc.270.42.25028; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MUSSO T, 1995, J EXP MED, V181, P1425, DOI 10.1084/jem.181.4.1425; NICHOLSON SE, 1994, P NATL ACAD SCI USA, V91, P2985, DOI 10.1073/pnas.91.8.2985; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; RANE SG, 1994, ONCOGENE, V9, P2415; RUI H, 1994, J BIOL CHEM, V269, P5364; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLINDER C, 1995, ANNU REV BIOCHEM, V64, P621; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	32	16	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	1996	13	9					2009	2014						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934548				2022-12-25	WOS:A1996VR79500021
J	Lin, JC; Scherer, SW; Tougas, L; Traverso, G; Tsui, LC; Andrulis, IL; Jothy, S; Park, M				Lin, JC; Scherer, SW; Tougas, L; Traverso, G; Tsui, LC; Andrulis, IL; Jothy, S; Park, M			Detailed deletion mapping with a refined physical map of 7q31 localizes a putative tumor suppressor gene for breast cancer in the region of MET	ONCOGENE			English	Article						breast cancer; tumor suppressor gene; chromosome 7q31; MET receptor tyrosine kinase; loss of heterozygosity	HEPATOCYTE GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; CYSTIC-FIBROSIS LOCUS; EPITHELIAL-CELLS; SCATTER FACTOR; C-MET; MAMMARY-GLAND; FREQUENT LOSS; ALLELIC LOSS; RET PROTOONCOGENE	In breast cancer, loss of heterozygosity (LOH) has been described on the long arm of chromosome 7 at band q31, suggesting the presence of a tumor suppressor gene in this region. To define the deleted region, we analysed 73 cases of breast cancer and matched normal DNAs with 17 polymorphic markers. A minimal area of LOH was identified as the chromosomal interval flanked by markers D7S687 and metH, spanning a segment of 2 Mb on chromosome 7q31, Of the 73 breast cancer patients studied, all were informative for at least one marker in this region and nine patients showed LOH at one or more loci (12.3%). To define the physical size of the deletion and to ensure the correct interpretation of the LOH deletion studies, we redefined the physical map of markers within this region of 7q31, We present a new physical order for markers at 7q31. More significantly, we have mapped the minimum deletion of 7q31 in the breast cancers studied to date to a physical distance of 1000 kb, contained on a single YAC clone, which includes the MET receptor tyrosine kinase but no other known genes.	MCGILL UNIV,DEPT MED,MONTREAL,PQ,CANADA; MCGILL UNIV,DEPT ONCOL,MONTREAL,PQ,CANADA; MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ,CANADA; MCGILL UNIV,DEPT PATHOL,MONTREAL,PQ,CANADA; UNIV TORONTO,DEPT MOL & MED GENET,TORONTO,ON,CANADA; UNIV TORONTO,DEPT PATHOL,TORONTO,ON,CANADA	McGill University; McGill University; McGill University; McGill University; University of Toronto; University of Toronto			Scherer, Stephen W./B-3785-2013; Andrulis, Irene L./E-7267-2013; Tsui, Lap-chee/A-1081-2010	Scherer, Stephen W./0000-0002-8326-1999; 				BERDICHEVSKY F, 1994, J CELL SCI, V107, P3557; BIECHE I, 1992, LANCET, V339, P139, DOI 10.1016/0140-6736(92)90208-K; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; CALLAHAN R, 1993, CLIN CHIM ACTA, V217, P63, DOI 10.1016/0009-8981(93)90238-Y; CALLAHAN R, 1992, CANCER, V69, P1582, DOI 10.1002/1097-0142(19920315)69:6+<1582::AID-CNCR2820691313>3.0.CO;2-Y; CHAMPEME MH, 1995, GENE CHROMOSOME CANC, V12, P304, DOI 10.1002/gcc.2870120411; CHEN LC, 1992, J NATL CANCER I, V84, P506, DOI 10.1093/jnci/84.7.506; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; DENG G, 1994, CANCER RES, V54, P499; DEVILEE P, 1991, ONCOGENE, V6, P1705; DEVILEE P, 1994, CRIT REV ONCOGENESIS, V5, P247, DOI 10.1615/CritRevOncog.v5.i2-3.70; DIRENZO MF, 1991, ONCOGENE, V6, P1997; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HAMPTON GM, 1994, CANCER RES, V54, P4586; HORN GT, 1990, CLIN CHEM, V36, P1614; ISOBE M, 1986, NATURE, V320, P84, DOI 10.1038/320084a0; KERANGUEVEN F, 1995, ONCOL REP, V2, P89; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KUNIYASU H, 1994, INT J CANCER, V59, P597, DOI 10.1002/ijc.2910590504; Latil A, 1995, CLIN CANCER RES, V1, P1385; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LITT M, 1993, BIOTECHNIQUES, V15, P280; MANIATIS T, 1992, MOL CLONING; MCBRIDE OW, 1986, P NATL ACAD SCI USA, V83, P130, DOI 10.1073/pnas.83.1.130; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MILLER C, 1986, NATURE, V319, P783, DOI 10.1038/319783a0; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; MULLER D, 1995, ONCOL REP, V2, P847; NAGY J, 1995, J SURG ONCOL, V60, P95, DOI 10.1002/jso.2930600206; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; NIRANJAN B, 1995, DEVELOPMENT, V121, P2897; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PEPPER MS, 1995, EXP CELL RES, V219, P204, DOI 10.1006/excr.1995.1220; Poustka A, 1988, GENOMICS, V2, P337, DOI 10.1016/0888-7543(88)90023-7; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; RAHIMI N, 1994, DNA CELL BIOL, V13, P1189, DOI 10.1089/dna.1994.13.1189; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; ROMMENS JM, 1989, AM J HUM GENET, V45, P932; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SATO T, 1990, CANCER RES, V50, P7184; SCHERER S, 1991, P33; SCHERER SW, 1992, MAMM GENOME, V3, P179, DOI 10.1007/BF00352464; SORIANO JV, 1995, J CELL SCI, V108, P413; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TAKAHASHI S, 1995, CANCER RES, V55, P4114; TSARFATY I, 1992, SCIENCE, V257, P1258, DOI 10.1126/science.1387731; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; YANG XM, 1995, LAB INVEST, V73, P483; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347	60	50	50	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 7	1996	13	9					2001	2008						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934547				2022-12-25	WOS:A1996VR79500020
J	Ou, XL; Campau, S; Slusher, R; Jasti, RK; Mabry, M; Kalemkerian, GP				Ou, XL; Campau, S; Slusher, R; Jasti, RK; Mabry, M; Kalemkerian, GP			Mechanism of all-trans-retinoic acid-mediated L-myc gene regulation in small cell lung cancer	ONCOGENE			English	Article						retinoic acid; myc; lung cancer; transcription	N-MYC; CARCINOMA-CELLS; HIGH-FREQUENCY; RECEPTOR-BETA; C-MYC; EXPRESSION; FAMILY; LINES; ONCOGENES; DIFFERENTIATION	The L-myc oncogene is commonly expressed in small cell lung cancer (SCLC) cells and is associated with SCLC cells with a high level of neuroendocrine differentiation and a relatively low proliferative index, We have previously reported that all-trans-retinoic acid (RA) inhibits the growth of NCI-H82 SCLC cells in association with increased neuroendocrine differentiation, increased L-myc gene expression and decreased c-myc gene expression, In the present report, the mechanism of RA-mediated L-myc up-regulation in NCI-H82 SCLC cells was determined by analysing transcriptional and post-transcriptional control of L-myc gene expression, Increases in steady-state levels of L-myc mRNA occurred in a dose-dependent manner after exposure to RA at a time-point prior to discernible changes in cellular morphology or growth, By nuclear run-on analysis, there was a clear increase in L-myc transcript initiation in NCI-H82 cells treated with 1 mu M RA, but no alteration was noted in the baseline degree of transcript attenuation when compared to control cells, L-myc transcript half-life remained unchanged after exposure to 1 mu M RA, indicating that post-transcriptional regulation is not a major factor in the control of L-myc gene expression, A marked dose-dependent increase in RAR beta expression was also demonstrated in RA-treated NCI-H82 cells, We conclude that RA-mediated up-regulation of L-myc gene expression occurs through stimulation of transcript initiation and that the biological effects of RA in SCLC cells may be mediated through RAR beta-dependent pathways.	WAYNE STATE UNIV, DIV HEMATOL & ONCOL, DETROIT, MI 48201 USA; KARMANOS CANC INST, DETROIT, MI 48201 USA; JOHNS HOPKINS ONCOL CTR, DEPT RADIAT ONCOL, BALTIMORE, MD 21287 USA	Wayne State University; Barbara Ann Karmanos Cancer Institute; Johns Hopkins University; Johns Hopkins Medicine					NATIONAL CANCER INSTITUTE [R01CA048081, R01CA058974] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007076] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA58974-03, R01CA48081-06] Funding Source: Medline; NIEHS NIH HHS [R01ES07076-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERNARD O, 1992, NEURON, V9, P1217, DOI 10.1016/0896-6273(92)90079-S; BIRRER MJ, 1988, MOL CELL BIOL, V8, P2668, DOI 10.1128/MCB.8.6.2668; BRENNAN J, 1991, CANCER RES, V51, P1708; BROOKS BJ, 1987, ADV VIRAL ONCOL, V7, P155; CELANO P, 1989, BIOTECHNIQUES, V7, P942; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; DOYLE LA, 1989, CANCER RES, V49, P6745; GAZZERI S, 1991, CANCER RES, V51, P2566; GEBERT JF, 1991, ONCOGENE, V6, P1859; GERADTS J, 1993, CELL GROWTH DIFFER, V4, P799; Gudas Lorraine J., 1994, P443; HONG WK, 1993, RETINOIDS ONCOLOGY; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; INGVARSSON S, 1988, ONCOGENE, V3, P679; Jetten A M, 1992, J Natl Cancer Inst Monogr, P93; JOHNSON BE, 1996, LUNG CANC PRINCIPLES, P83; KALEMKERIAN G, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P370; KALEMKERIAN GP, 1994, CELL GROWTH DIFFER, V5, P55; KAYE F, 1988, MOL CELL BIOL, V8, P186, DOI 10.1128/MCB.8.1.186; KIM YH, 1995, CANCER RES, V55, P5603; KRUMM A, 1993, BIOESSAYS, V15, P659, DOI 10.1002/bies.950151005; KRUPITZA G, 1995, INT J CANCER, V61, P649, DOI 10.1002/ijc.2910610511; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LIN X, 1991, MOL CELL BIOL, V11, P6007, DOI 10.1128/MCB.11.12.6007; LIPPMAN SM, 1987, CANCER TREAT REP, V71, P493; MILLER WH, 1990, ONCOGENE, V5, P511; MOROY T, 1991, ONCOGENE, V6, P1941; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; PRINS J, 1993, ANTICANCER RES, V13, P1373; RYGAARD K, 1993, INT J CANCER, V54, P144, DOI 10.1002/ijc.2910540123; SAKSELA K, 1990, J CELL BIOCHEM, V42, P153, DOI 10.1002/jcb.240420306; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; Sporn M B, 1984, J Natl Cancer Inst, V73, P1381; TAKAHASHI T, 1989, CANCER RES, V49, P2683; THIELE CJ, 1988, ONCOGENE, V3, P281; WADA RK, 1992, ONCOGENE, V7, P711; Weber E., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P503; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490	41	9	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	1996	13	9					1893	1899						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934535				2022-12-25	WOS:A1996VR79500008
J	Gibbons, DL; Hixson, JD; Hay, N; Lund, P; Gorovits, BM; Ybarra, J; Horowitz, PM				Gibbons, DL; Hixson, JD; Hay, N; Lund, P; Gorovits, BM; Ybarra, J; Horowitz, PM			Intrinsic fluorescence studies of the chaperonin GroEL containing single Tyr -> Trp replacements reveal ligand-induced conformational changes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; ESCHERICHIA-COLI; MITOCHONDRIAL RHODANESE; PROTEIN; MONOMERS; BINDING; CYCLE; ATP; INTERMEDIATE; PURIFICATION	Two mutants of GroEL containing the single tyrosine to tryptophan replacement of either residue 203 or 360 in the apical domain have been purified, characterized, and used for fluorescence studies, Both mutants can facilitate the in vitro refolding of rhodanese in an ATP- and GroES-dependent manner, producing yields of recoverable activity comparable to the wild-type chaperonin. Y203W shows some increased hydrophobic exposure and easier urea-induced disassembly compared with wild-type or Y360W, although the unfolding of all the species was similar at high concentrations of urea. Intrinsic fluorescence studies of the two mutants reveal that nucleotide binding (ADP or AMP-PNP (adenosine 5'-(beta,gamma-imino)triphosphate)) induces conformational changes in the tetradecamer that are independent presence of the co chaperonin, GroES. The K-1/2 for this transition is approximately 5 mu M for both mutants, Energy transfer experiments show that the tryptophan fluorescence of the Y360W mutant is partially quenched (similar to 50%) upon binding of the fluorescent, hydrophobic probe 4,4'-bis(1-anilino-8-naphthalenesulfonic acid), while the fluorescence of the Y203W mutant is significantly quenched (similar to 75%). These results are discussed in relation to the molecular mechanism for GroEL function.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284; UNIV BIRMINGHAM,SCH BIOL SCI,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Texas System; University of Texas Health San Antonio; University of Birmingham			lund, peter a/N-9785-2018	Lund, Peter/0000-0002-6381-8526	NIEHS NIH HHS [ES05729] Funding Source: Medline; NIGMS NIH HHS [GM25177] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIRD BA, 1990, BIOCHIM BIOPHYS ACTA, V1038, P10, DOI 10.1016/0167-4838(90)90003-X; AZEM A, 1994, BIOCHEMISTRY-US, V33, P6671, DOI 10.1021/bi00187a037; BOCHKAREVA ES, 1994, J BIOL CHEM, V269, P23869; Boisvert DC, 1996, NAT STRUCT BIOL, V3, P170, DOI 10.1038/nsb0296-170; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BURSTON SG, 1995, J MOL BIOL, V249, P138, DOI 10.1006/jmbi.1995.0285; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; ELLIS RJ, 1990, BIOCH SOC S, V55, P145; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; FISHER MT, 1992, BIOCHEMISTRY-US, V31, P3955, DOI 10.1021/bi00131a010; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Gibbons DL, 1996, J BIOL CHEM, V271, P238, DOI 10.1074/jbc.271.1.238; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GOROVITS BM, 1995, J BIOL CHEM, V270, P28551, DOI 10.1074/jbc.270.48.28551; GRAY TE, 1993, J MOL BIOL, V232, P1197, DOI 10.1006/jmbi.1993.1471; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOROWITZ PM, 1995, J BIOL CHEM, V270, P1535, DOI 10.1074/jbc.270.4.1535; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; JENTOFT N, 1979, J BIOL CHEM, V254, P4359; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P270; LIN ZL, 1995, J BIOL CHEM, V270, P1011, DOI 10.1074/jbc.270.3.1011; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENDOZA JA, 1992, J BIOL CHEM, V267, P24648; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MENDOZA JA, 1994, J BIOL CHEM, V269, P25963; MIZOBATA T, 1994, BBA-PROTEIN STRUCT M, V1209, P83, DOI 10.1016/0167-4838(94)90140-6; SAIBIL HR, 1993, CURR BIOL, V3, P285; SEALE JW, 1995, BIOCHEMISTRY-US, V34, P7443, DOI 10.1021/bi00022a018; STANIFORTH RA, 1994, BIOCHEM J, V300, P651, DOI 10.1042/bj3000651; STANIFORTH RA, 1994, FEBS LETT, V344, P129, DOI 10.1016/0014-5793(94)00348-3; STANSSENS P, 1989, NUCLEIC ACIDS RES, V17, P4441, DOI 10.1093/nar/17.12.4441; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; YBARRA J, 1995, J BIOL CHEM, V270, P22962, DOI 10.1074/jbc.270.39.22962; YBARRA J, 1995, J BIOL CHEM, V270, P22113, DOI 10.1074/jbc.270.38.22113; Yifrach O, 1996, J MOL BIOL, V255, P356, DOI 10.1006/jmbi.1996.0028	41	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					31989	31995		10.1074/jbc.271.50.31989	http://dx.doi.org/10.1074/jbc.271.50.31989			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943246	hybrid			2022-12-25	WOS:A1996VY34000037
J	Rossi, A; Elia, G; Santoro, MG				Rossi, A; Elia, G; Santoro, MG			2-cyclopenten-1-one, a new inducer of heat shock protein 70 with antiviral activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN A(1); VIRUS-REPLICATION; STRESS PROTEIN; HUMAN-CELLS; HSP70; EXPRESSION; INDUCTION; DIFFERENTIATION; INHIBITION; PROTECTION	The cytoprotective role of heat shock proteins (HSP) described in variety of human diseases, including ischemia, inflammation, and infection, suggests new therapeutic strategies relying upon the development of drugs that selectively turn on heat shock genes. Cyclopentenone prostaglandins, which contain an alpha,beta-unsaturated carbonyl group in the cyclopentane ring and possess antiviral activity against several RNA and DNA viruses, were shown to function as signal for HSP synthesis in a nonstressful situation in a variety of mammalian cells. me now report that 2-cyclopenten-1-one selectively induces the expression of the 70-kDa HSP (HSP70) in human cells, through cycloheximide-sensitive activation of heat shock transcription factor 1 (HSF1). The alpha,beta-unsaturated carbonyl group is the key structure triggering HSF1 activation, Induction is associated with antiviral activity during infection with vesicular stomatitis virus, These results identify the molecular structure of natural prostaglandins responsible for HSF1 activation and open new perspectives in the search for novel antiviral and cytoprotective drugs.	CNR, INST EXPT MED, I-00137 ROME, ITALY; UNIV AQUILA, DEPT EXPT MED, I-67100 LAQUILA, ITALY	Consiglio Nazionale delle Ricerche (CNR); University of L'Aquila			Elia, Giuliano/H-3438-2011; Elia, Giuliano/P-4725-2019	Elia, Giuliano/0000-0001-8216-9560; Elia, Giuliano/0000-0002-7941-223X; ROSSI, ANTONIO/0000-0003-0383-3828; Santoro, Maria Gabriella/0000-0003-1432-4949				AMICI C, 1994, J VIROL, V68, P6890, DOI 10.1128/JVI.68.11.6890-6899.1994; AMICI C, 1992, P NATL ACAD SCI USA, V89, P6227, DOI 10.1073/pnas.89.14.6227; BALER R, 1992, J CELL BIOL, V117, P1151, DOI 10.1083/jcb.117.6.1151; BANERJI SS, 1984, MOL CELL BIOL, V4, P2437, DOI 10.1128/MCB.4.11.2437; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FUKUSHIMA M, 1990, EICOSANOIDS, V3, P189; IAATTELA M, 1992, EMBO J, V11, P3507; KHAN SH, 1990, P NATL ACAD SCI USA, V87, P9401, DOI 10.1073/pnas.87.23.9401; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MARBER MS, 1994, J CLIN INVEST, V93, P1087, DOI 10.1172/JCI117059; MESTRIL R, 1994, J CLIN INVEST, V93, P759, DOI 10.1172/JCI117030; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; MORIMOTO RI, 1990, BIOL HEAT SHOCK PROT; Morris SD, 1996, J CLIN INVEST, V97, P706, DOI 10.1172/JCI118468; MOSSER DD, 1988, MOL CELL BIOL, V8, P4736, DOI 10.1128/MCB.8.11.4736; NOWAK TS, 1990, J NEUROCHEM, V54, P451, DOI 10.1111/j.1471-4159.1990.tb01893.x; PICA F, 1993, ANTIVIR RES, V20, P193, DOI 10.1016/0166-3542(93)90020-J; Pica F, 1996, ANTIVIR RES, V29, P187, DOI 10.1016/0166-3542(95)00834-9; POLLA BS, 1991, CURR TOP MICROBIOL, V167, P93; RODRIGUEZBOULAN E, 1983, METHOD ENZYMOL, V98, P486; ROSSI A, 1995, BIOCHEM J, V308, P455, DOI 10.1042/bj3080455; ROSSI A, 1996, IN PRESS P NATL ACAD; Rozera C, 1996, J CLIN INVEST, V97, P1795, DOI 10.1172/JCI118609; SANTORO M G, 1990, P27; SANTORO MG, 1991, ADV PROSTAG THROMB L, V21, P867; SANTORO MG, 1994, EXPERIENTIA, V50, P1039, DOI 10.1007/BF01923459; SANTORO MG, 1988, ARCH VIROL, V99, P89, DOI 10.1007/BF01311026; SANTORO MG, 1980, SCIENCE, V209, P1032, DOI 10.1126/science.6157190; SANTORO MG, 1989, P NATL ACAD SCI USA, V86, P8407, DOI 10.1073/pnas.86.21.8407; SANTORO MG, 1996, STRESS INDUCIBLE CEL, P335; SISTONEN L, 1992, MOL CELL BIOL, V12, P4104, DOI 10.1128/MCB.12.9.4104; UNEY JB, 1988, FEBS LETT, V235, P215, DOI 10.1016/0014-5793(88)81265-1; WILLIAMS RS, 1993, J CLIN INVEST, V92, P503, DOI 10.1172/JCI116594; WU B, 1985, MOL CELL BIOL, V5, P330, DOI 10.1128/MCB.5.2.330	35	91	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32192	32196		10.1074/jbc.271.50.32192	http://dx.doi.org/10.1074/jbc.271.50.32192			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943275	hybrid			2022-12-25	WOS:A1996VY34000066
J	Zhang, B; Berger, J; Zhou, GC; Elbrecht, A; Biswas, S; WhiteCarrington, S; Szalkowski, D; Moller, DE				Zhang, B; Berger, J; Zhou, GC; Elbrecht, A; Biswas, S; WhiteCarrington, S; Szalkowski, D; Moller, DE			Insulin- and mitogen-activated protein kinase-mediated phosphorylation and activation of peroxisome proliferator-activated receptor gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-I; ESTROGEN-RECEPTOR; MAP KINASE; ADIPOCYTE DIFFERENTIATION; GENE-EXPRESSION; STIMULATION; FIBROBLASTS; TRANSCRIPTION; ADIPOGENESIS; REGULATOR	Peroxisome proliferator-activated receptor (PPAR) gamma plays an important role in adipocyte differentiation and the regulation of adipocyte gene expression. Insulin also serves to promote adipogenesis. We report that insulin and a PPAR gamma ligand (thiazolidinedione (TZD)) stimulate in a synergistic manner the expression of an adipocyte-specific gene (aP2) in rat adipocytes and 3T3-L1 cells. Potential cross-talk between insulin signaling and PPAR gamma was studied in Chinese hamster ovary cells expressing insulin receptors (CHO.T), PPAR gamma, and reporter genes. Both TZD and insulin independently stimulated PPAR gamma-mediated transactivation of aP2 promoter-luciferase reporter genes; both agents combined resulted in a synergistic effect. Co-transfection of CHO.T cells with dominant-negative mitogen-activated protein (MAP) kinase-kinase (MKK1) abrogated both insulin- and TZD-mediated activation of PPAR gamma; transactivation was markedly increased in cells co-transfected with constitutively active MKK1. Both insulin and constitutively active MKK1 also stimulated P-32 incorporation into PPAR gamma in vivo. The conclusions are: 1) insulin synergizes with a PPAR gamma ligand and can activate the receptor in a ligand-independent fashion. 2) PPAR gamma is phosphorylated in vivo by insulin stimulation or activation of the MAP kinase pathway. 3) MAP kinase is an important mediator of cross-talk between insulin signal transduction pathways and PPAR gamma function.			Zhang, B (corresponding author), MERCK & CO INC,MERCK SHARP & DOHME RES LABS,DEPT MOL ENDOCRINOL,R80W250,POB 2000,RAHWAY,NJ 07065, USA.							ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743; BOULOUMIE A, 1994, J BIOL CHEM, V269, P30254; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; CAMPBELL GS, 1992, J BIOL CHEM, V267, P6074; CHANG AY, 1983, DIABETES, V32, P830, DOI 10.2337/diabetes.32.9.830; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Elbrecht A, 1996, BIOCHEM BIOPH RES CO, V224, P431, DOI 10.1006/bbrc.1996.1044; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GRAVES RA, 1992, MOL CELL BIOL, V12, P1202, DOI 10.1128/MCB.12.3.1202; GULLER S, 1988, ENDOCRINOLOGY, V122, P2084, DOI 10.1210/endo-122-5-2084; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; IKEDA H, 1990, ARZNEIMITTEL-FORSCH, V40, P152; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KRUETTER DK, 1990, DIABETES, V39, P1414; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; RODBELL M, 1964, J BIOL CHEM, V239, P375; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; *SAMBROOK J, 1989, MOL CLONING LAB MANU; SMITH PJ, 1988, J BIOL CHEM, V263, P9402; SPIEGELMAN BM, 1993, J BIOL CHEM, V268, P6823; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; VidalPuig A, 1996, J CLIN INVEST, V97, P2553, DOI 10.1172/JCI118703; WHITE MF, 1994, J BIOL CHEM, V269, P1; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921	30	252	259	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					31771	31774		10.1074/jbc.271.50.31771	http://dx.doi.org/10.1074/jbc.271.50.31771			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943212	hybrid			2022-12-25	WOS:A1996VY34000003
J	Kole, HK; Liotta, AS; Kole, S; Roth, J; MontroseRafizadeh, C; Bernier, M				Kole, HK; Liotta, AS; Kole, S; Roth, J; MontroseRafizadeh, C; Bernier, M			A synthetic peptide derived from a COOH-terminal domain of the insulin receptor specifically enhances insulin receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; SRC HOMOLOGY-2 DOMAINS; GROWTH-FACTOR RECEPTOR; HAMSTER OVARY CELLS; BETA-SUBUNIT DOMAIN; FACTOR-I RECEPTORS; PHOSPHATIDYLINOSITOL 3'-KINASE; C-TERMINUS; SUBSTRATE PHOSPHORYLATION; AUTOPHOSPHORYLATION SITES	The role of the insulin receptor COOH-terminal domain in the regulation of insulin signal transduction was explored with a variety of synthetic peptides, One of the peptides, termed peptide HC, whose structure corresponds to residues 1293-1307 of the insulin proreceptor sequence, enhanced insulin-stimulated autophosphorylation of the insulin receptor in cell-free systems and in semipermeabilized Chinese hamster ovary (CHO) cells that had been transfected with an expression plasmid encoding the human insulin receptor (CHO/HIRc) at concentrations where there was no detectable effect on basal autophosphorylation levels or on receptor de phosphorylation, A lipophilic analogue of peptide HC, stearyl peptide HC, added to intact CHO/HIRc cells enhanced significantly insulin-stimulated insulin receptor autophosphorylation while having no effect on ligand-stimulated receptor phosphorylation in CHO cells overexpressing either the IGF-1 receptor or epidermal growth factor receptor, Addition of stearyl peptide HC to CHO/HIRc cells resulted in a 2.4 +/- 0.3-fold increase in the amount of insulin stimulated phosphatidylinositol 3-kinase detected in anti-IRS-1 immunoprecipitates and a 2.1 +/- 0.6-fold increase in the levels of tyrosine phosphorylation of mitogen-activated protein kinase in response to insulin, Finally, a derivative of peptide HC coupled to a biotin moiety was prepared and showed to bind with the beta-subunit of the wild-type insulin receptor and a truncated receptor that lacks 43 amino acids from its carboxyl terminus, However, there was little binding, if any, of the peptide with the IGF-1 receptors or the epidermal growth factor receptors, Taken together, our data demonstrate that a pentadecapeptide related to the carboxyl terminus of the insulin receptor binds to the insulin receptor beta-subunit and that this interaction may contribute to the increased receptor's intrinsic activity and signal transduction.	NIA,GERONTOL RES CTR,DIABET SECT,LAB CLIN PHYSIOL,NIH,BALTIMORE,MD 21224; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV GERIATR MED & GERONTOL,BALTIMORE,MD 21224	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Johns Hopkins University			Bernier, Michel/Y-7139-2019; Bernier, Michel/AAO-3983-2021	Bernier, Michel/0000-0002-5948-368X				ADAMO M, 1992, BIOFACTORS, V3, P151; ANDO A, 1992, J BIOL CHEM, V267, P12788; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BERNIER M, 1994, BIOCHEMISTRY-US, V33, P4343, DOI 10.1021/bi00180a031; BERNIER M, 1995, BIOCHEMISTRY-US, V34, P8357, DOI 10.1021/bi00026a017; BURKE TR, 1994, BIOCHEM BIOPH RES CO, V204, P129, DOI 10.1006/bbrc.1994.2435; CHIN JE, 1993, J BIOL CHEM, V268, P6338; CHOU CK, 1987, J BIOL CHEM, V262, P1842; CLARK S, 1994, BIOCHEM BIOPH RES CO, V200, P330, DOI 10.1006/bbrc.1994.1452; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FARIA TN, 1994, J BIOL CHEM, V269, P13922; FEENER EP, 1994, BIOCHEM J, V303, P43, DOI 10.1042/bj3030043; FLORESRIVEROS JR, 1989, J BIOL CHEM, V264, P21557; GOLDSTEIN BJ, 1990, MOL ENDOCRINOL, V4, P235, DOI 10.1210/mend-4-2-235; GUAN KL, 1994, CELL SIGNAL, V6, P581, DOI 10.1016/0898-6568(94)90041-8; HAFT CR, 1994, BIOCHEMISTRY-US, V33, P9143, DOI 10.1021/bi00197a017; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; KALIMAN P, 1993, BIOCHEMISTRY-US, V32, P9539, DOI 10.1021/bi00088a004; KASUYA J, 1994, BIOCHEM BIOPH RES CO, V200, P777, DOI 10.1006/bbrc.1994.1518; KATO H, 1993, J CELL PHYSIOL, V156, P145, DOI 10.1002/jcp.1041560120; KOHANSKI RA, 1986, BIOCHEM BIOPH RES CO, V134, P1312, DOI 10.1016/0006-291X(86)90393-1; Kole HK, 1996, J BIOL CHEM, V271, P14302, DOI 10.1074/jbc.271.24.14302; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMMERS R, 1989, EMBO J, V8, P1369, DOI 10.1002/j.1460-2075.1989.tb03517.x; LEBRUN C, 1993, J BIOL CHEM, V268, P11272; LEE JS, 1994, AM J PHYSIOL, V266, pC319, DOI 10.1152/ajpcell.1994.266.2.C319; LEVYTOLEDANO R, 1994, J BIOL CHEM, V269, P31178; LEVYTOLEDANO R, 1993, BIOCHIM BIOPHYS ACTA, V1220, P1, DOI 10.1016/0167-4889(93)90090-C; LEWIS RE, 1990, J BIOL CHEM, V265, P947; LEWIS RE, 1994, J BIOL CHEM, V269, P26259; LIOTTA AS, 1994, J BIOL CHEM, V269, P22996; MAEGAWA H, 1993, BIOCHEM BIOPH RES CO, V194, P208, DOI 10.1006/bbrc.1993.1805; MYERS MG, 1991, J BIOL CHEM, V266, P10616; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SHOELSON SE, 1989, J BIOL CHEM, V264, P7831; STAUBS PA, 1994, J BIOL CHEM, V269, P27186; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TAKATA Y, 1992, J BIOL CHEM, V267, P9065; TARTARE S, 1994, J BIOL CHEM, V269, P11449; TAVARE JM, 1992, BIOCHEM BIOPH RES CO, V188, P86, DOI 10.1016/0006-291X(92)92353-Y; UGI S, 1994, FEBS LETT, V340, P216, DOI 10.1016/0014-5793(94)80141-X; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANHORN DJ, 1994, J BIOL CHEM, V269, P29; WHITE MF, 1994, J BIOL CHEM, V269, P1; YAMAMOTO K, 1992, J BIOL CHEM, V267, P11337; YAMAMOTOHONDA R, 1993, J BIOL CHEM, V268, P16859; YAN PF, 1993, J BIOL CHEM, V268, P22444; YONEZAWA K, 1992, J BIOL CHEM, V267, P440	52	15	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31619	31626		10.1074/jbc.271.49.31619	http://dx.doi.org/10.1074/jbc.271.49.31619			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940181	hybrid			2022-12-25	WOS:A1996VW68600092
J	Mozzherin, DJ; McConnell, M; Jasko, MV; Krayevsky, AA; Tan, CK; Downey, KM; Fisher, PA				Mozzherin, DJ; McConnell, M; Jasko, MV; Krayevsky, AA; Tan, CK; Downey, KM; Fisher, PA			Proliferating cell nuclear antigen promotes misincorporation catalyzed by calf thymus DNA polymerase delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TEMPLATE-PRIMERS; ESCHERICHIA-COLI; III HOLOENZYME; BETA-SUBUNIT; ALPHA HOLOENZYME; REPLICATION; INVITRO; RECOGNITION; MECHANISM; FIDELITY	A proliferating cell nuclear antigen (PCNA)-dependent complex, detectable after nondenaturing polyacrylamide gel electrophoresis, is formed between calf thymus DNA polymerase delta (pol delta) and synthetic oligonucleotide template-primers containing a mispaired nucleotide at the 3'-terminal position of the primer, This complex is indistinguishable in composition from that formed with a fully base paired template-primer. Extension of a mispaired primer terminus is a component of DNA polymerase fidelity, The fidelity of pol delta on synthetic oligonucleotide template-primers was compared with and without its specific processivity factor, PCNA In the absence of PCNA, pol delta misincorporates less than one nucleotide for every 100,000 nucleotides incorporated correctly. Addition of PCNA to reactions reduces fidelity by at least 27-fold, PCNA also confers upon pol delta, the ability to incorporate (and/or not excise) the dTTP analog, 2'-deoxythymidine-5'-O-(alpha-phosphonomethyl)- beta,gamma-diphosphate. A model is proposed whereby the increased stability (decreased off-rate) of the pol delta . template-primer complex in the presence of PCNA facilitates unfavorable events catalyzed by pol delta, This model suggests an explicit mechanistic requirement for the intrinsic 3'-5'-exonuclease of pol delta.	SUNY STONY BROOK,MED CTR,DEPT PHARMACOL SCI,STONY BROOK,NY 11794; RUSSIAN ACAD SCI,ENGELHARDT INST MOL BIOL,MOSCOW 1179984,RUSSIA; UNIV MIAMI,SCH MED,DEPT MED,MIAMI,FL 33101; UNIV MIAMI,SCH MED,DEPT BIOCHEM,MIAMI,FL 33101	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; University of Miami; University of Miami			Jasko, Maxim/GVR-7803-2022	Jasko, Maxim/0000-0003-0462-8930	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026206] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES004068] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-26206] Funding Source: Medline; NIEHS NIH HHS [ES-04068] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		CREIGHTON S, 1995, J BIOL CHEM, V270, P4759, DOI 10.1074/jbc.270.9.4759; FERGUSON KA, 1964, METABOLISM, V13, P985, DOI 10.1016/S0026-0495(64)80018-4; FISHER PA, 1981, BIOCHEMISTRY-US, V20, P4560, DOI 10.1021/bi00519a008; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; JASKO MV, 1995, FEBS LETT, V357, P23, DOI 10.1016/0014-5793(94)01319-V; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; Kukhanova M K, 1994, Mol Biol (Mosk), V28, P530; KUNKEL TA, 1994, P NATL ACAD SCI USA, V91, P6830, DOI 10.1073/pnas.91.15.6830; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; McConnell M, 1996, BIOCHEMISTRY-US, V35, P8268, DOI 10.1021/bi9530649; Mozzherin DJ, 1996, BIOCHEMISTRY-US, V35, P3572, DOI 10.1021/bi952142p; NG L, 1989, J BIOL CHEM, V264, P13018; NG L, 1991, J BIOL CHEM, V266, P11699; NG L, 1993, J BIOL CHEM, V268, P13571; ODAY CL, 1992, NUCLEIC ACIDS RES, V20, P5403, DOI 10.1093/nar/20.20.5403; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; RANDALL SK, 1987, J BIOL CHEM, V262, P6864; SHAVITT O, 1989, J BIOL CHEM, V264, P11275; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; SWARTZ J, 1963, METHOD ENZYMOL, V6, P739; TADMOR Y, 1992, J BACTERIOL, V174, P2517, DOI 10.1128/jb.174.8.2517-2524.1992; TAN CK, 1986, J BIOL CHEM, V261, P2310; VICTOROVA LS, 1992, NUCLEIC ACIDS RES, V20, P783, DOI 10.1093/nar/20.4.783; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WANG TSF, 1974, J BIOL CHEM, V249, P841; WEISS SJ, 1992, J BIOL CHEM, V267, P18520	27	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31711	31717		10.1074/jbc.271.49.31711	http://dx.doi.org/10.1074/jbc.271.49.31711			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940194	hybrid			2022-12-25	WOS:A1996VW68600105
J	Roghani, M; Mohammadi, M; Schlessinger, J; Moscatelli, D				Roghani, M; Mohammadi, M; Schlessinger, J; Moscatelli, D			Induction of urokinase-type plasminogen activator by fibroblast growth factor (FGF)-2 is dependent on expression of FGF receptors and does not require activation of phospholipase C gamma 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPILLARY ENDOTHELIAL-CELLS; ELIMINATES PHOSPHATIDYLINOSITOL HYDROLYSIS; HEPARAN-SULFATE; POINT MUTATION; SIGNAL-TRANSDUCTION; TYROSINE KINASE; DNA-SYNTHESIS; C-GAMMA; BINDING; INTERNALIZATION	The roles of heparan sulfate proteoglgcans and tyrosine kinase fibroblast growth factor (FGF) receptors in mediating the induction of plasminogen activator (PA) by FGF-2 were investigated using L6 myoblast cells that normally do not express detectable FGF receptors. PA was induced by FGF-2 in a dose-dependent manner in L6 cells expressing transfected FGF receptor-1 but not in nontransfected cells or cells transfected with the vector alone. The PA produced in these cells was characterized as urokinase-type PA (uPA), Thus, expression of a tyrosine kinase FGF receptor was required for induction of uPA, Internalization of FGF through heparan sulfates does not seem to be involved in this response as soluble heparin and suramin at concentrations which inhibited FGF-2 binding to heparan sulfates but not receptors did not affect the induction of uPA by FGF-2, Mutant receptors in which the tyrosine kinase was inactivated were not able to respond to FGF-2, In contrast, mutation of the site of phospholipase C gamma 1 (PLC gamma) binding in the receptor, which causes loss of PLC gamma activation, had no effect on uPA induction by FGF-2. These results suggest that PLC gamma activation is not required for induction of uPA by FGF-2.	NYU,MED CTR,DEPT CELL BIOL,NEW YORK,NY 10016; NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016; NYU,MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016	New York University; New York University; New York University			Mohammadi, Moosa/ABA-6745-2020; kasaei, fahime/T-7197-2018	Mohammadi, Moosa/0000-0003-2434-9437; Moscatelli, David/0000-0002-4627-4213	NCI NIH HHS [CA34289, CA42229] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042229] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BESSER D, 1995, CELL GROWTH DIFFER, V6, P1009; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; BURRUS LW, 1992, MOL CELL BIOL, V12, P5600, DOI 10.1128/MCB.12.12.5600; CLYMAN RI, 1994, CELL ADHES COMMUN, V1, P333, DOI 10.3109/15419069409097264; COFFEY RJ, 1987, J CELL PHYSIOL, V132, P143, DOI 10.1002/jcp.1041320120; COUGHLIN SR, 1988, J BIOL CHEM, V263, P988; Fannon M, 1996, J BIOL CHEM, V271, P17949, DOI 10.1074/jbc.271.30.17949; GANNOUNZAKI L, 1991, EXP CELL RES, V197, P272, DOI 10.1016/0014-4827(91)90433-U; GROSS JL, 1982, J CELL BIOL, V95, P947; HUANG JT, 1995, J BIOL CHEM, V270, P5065, DOI 10.1074/jbc.270.10.5065; ISACCHI A, 1991, P NATL ACAD SCI USA, V88, P2628, DOI 10.1073/pnas.88.7.2628; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; KELLER KM, 1989, BIOCHEMISTRY-US, V28, P8100, DOI 10.1021/bi00446a021; MIGNATTI P, 1991, J CELL BIOL, V113, P1193, DOI 10.1083/jcb.113.5.1193; MIGNATTI P, 1989, J CELL BIOL, V108, P671, DOI 10.1083/jcb.108.2.671; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; MOSCATELLI D, 1989, J CELL BIOL, V109, P2519, DOI 10.1083/jcb.109.5.2519; MOSCATELLI D, 1988, J CELL BIOL, V107, P753, DOI 10.1083/jcb.107.2.753; MOSCATELLI D, 1988, BIOCHIM BIOPHYS ACTA, V948, P67, DOI 10.1016/0304-419X(88)90005-4; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; MOSCATELLI D, 1986, P NATL ACAD SCI USA, V83, P2091, DOI 10.1073/pnas.83.7.2091; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PRESTA M, 1986, MOL CELL BIOL, V6, P4060, DOI 10.1128/MCB.6.11.4060; PRESTA M, 1989, J CELL BIOL, V109, P1877, DOI 10.1083/jcb.109.4.1877; PRESTA M, 1989, J CELL PHYSIOL, V141, P517, DOI 10.1002/jcp.1041410310; QUARTO N, 1994, J CELL SCI, V107, P3201; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; REILAND J, 1993, J CELL SCI, V105, P1085; ROGHANI M, 1992, J BIOL CHEM, V267, P22156; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; RUSNATI M, 1993, J CELL PHYSIOL, V154, P152, DOI 10.1002/jcp.1041540119; Rusnati M, 1996, MOL BIOL CELL, V7, P369, DOI 10.1091/mbc.7.3.369; SAKSELA O, 1987, J CELL BIOL, V105, P957, DOI 10.1083/jcb.105.2.957; SOROKIN A, 1994, J BIOL CHEM, V269, P17056; SPIVAKKROIZMAN T, 1994, J BIOL CHEM, V269, P14419; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6	41	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31154	31159		10.1074/jbc.271.49.31154	http://dx.doi.org/10.1074/jbc.271.49.31154			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940113	hybrid			2022-12-25	WOS:A1996VW68600024
J	Shi, WX; Chammas, R; Varki, NM; Powell, L; Varki, A				Shi, WX; Chammas, R; Varki, NM; Powell, L; Varki, A			Sialic acid 9-O-acetylation on murine erythroleukemia cells affects complement activation, binding to I-type lectins, and tissue homing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-H; STRUCTURAL CHARACTERIZATION; ALTERNATIVE PATHWAY; MONOCLONAL-ANTIBODY; HUMAN-LEUKOCYTES; SIALOADHESIN; ADHESION; LYMPHOCYTES; RECEPTOR; FAMILY	O-Acetylation of the 9-hydroxyl group of sialic acids has been suggested to modify various recognition phenomena involving these molecules, but direct proof has been lacking in most situations. In the accompanying paper (Shi, W.-X., Chammas, R., and Varki, A. (1996) J. Biol. Chem. 261, 31517-31525), we report that the extent of 9-O-acetylation of cell surface sialic acids on murine erythroleukemia (MEL) cells can be modified by various manipulations, including differentiation, nocodazole treatment, and 9-O-acetyl esterase treatment. We have used this system to explore the putative roles of 9-O-acetylation in modulating alternative pathway complement activation, I-type lectin binding, and tissue homing, MEL cells are shown to be sensitive to lysis in vitro by the alternative pathway of human complement. Induced differentiation of the MEL cells causes resistance to lysis, and this correlates directly with extent of decrease in 9-O-acetylation. A similar resistance to alternative pathway lysis can be obtained by selective enzymatic removal of 9-O-acetyl groups from sialic acids. Conversely the increase in cell, surface 9-O-acetylation caused by nocodazole treatment correlates with increased sensitivity to alternative pathway lysis. Thus, a 9-O-acetyl group added to the side chain of cell. surface sialic acids may abrogate its normal function in restricting alternative pathway activation. Indeed, the binding of human complement factor H, a negative regulator of the alternative pathway, is shown to be blocked by O-acetylation of the sialic acids on MEL cells. MEL cells are also shown to have cell surface ligands for the I-type lectins sialoadhesin and CD22. Sialoadhesin (but not CD22) binding is selectively enhanced by differentiation-induced loss of cell surface 9-O-acetylation and by direct enzymatic removal of the ester groups, Thus, some sialoadhesin ligands are masked by 9-O-acetylation, presumably because the side chain is required for recognition, Since sialoadhesin is expressed on some macrophages in vice, we reasoned that tissue homing of MEL cells might be affected by O-acetylation. Indeed, enzymatic removal of cell surface 9-O-acetyl groups alters the tissue distribution of intravenously injected cells. In particular, de-O-acetylation caused significant increase in homing to the liver and spleen. These data demonstrate that cell surface 9-O-acetylation can affect a variety of biological recognition phenomena and provide a system for further exploration of the specific molecular mechanisms involved.	UNIV CALIF SAN DIEGO,CTR CANC,GLYCOBIOL PROGRAM,DIV CELLULAR & MOL MED,LA JOLLA,CA 92093	University of California System; University of California San Diego			Chammas, Roger/A-8004-2011	Chammas, Roger/0000-0003-0342-8726	NCI NIH HHS [P01-CA5869] Funding Source: Medline; NIGMS NIH HHS [R01-GM32373] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032373] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVERY VM, 1993, J IMMUNOL, V151, P5545; BLUM AS, 1987, P NATL ACAD SCI USA, V84, P8716, DOI 10.1073/pnas.84.23.8716; CONSTANTINEPATON M, 1986, NATURE, V324, P459, DOI 10.1038/324459a0; CROCKER PR, 1995, J CLIN INVEST, V95, P635, DOI 10.1172/JCI117708; CROCKER PR, 1994, EMBO J, V13, P4490, DOI 10.1002/j.1460-2075.1994.tb06771.x; DOLCI ED, 1989, J CELL SCI, V93, P191; DRAZBA J, 1991, DEV BIOL, V145, P154, DOI 10.1016/0012-1606(91)90221-N; FRASER IP, 1994, EUR J CELL BIOL, V64, P217; FREEMAN SD, 1995, BLOOD, V85, P2005, DOI 10.1182/blood.V85.8.2005.bloodjournal8582005; HANASAKI K, 1995, J BIOL CHEM, V270, P7533, DOI 10.1074/jbc.270.13.7533; HIGA HH, 1985, VIROLOGY, V144, P279, DOI 10.1016/0042-6822(85)90325-3; KAMERLING JP, 1982, BIOCHIM BIOPHYS ACTA, V714, P351, DOI 10.1016/0304-4165(82)90344-0; KAZATCHKINE MD, 1979, J IMMUNOL, V122, P75; KELM S, 1994, GLYCOCONJUGATE J, V11, P576, DOI 10.1007/BF00731309; KELM S, 1994, CURR BIOL, V4, P965, DOI 10.1016/S0960-9822(00)00220-7; KLEIN A, 1994, P NATL ACAD SCI USA, V91, P7782, DOI 10.1073/pnas.91.16.7782; KLOTZ FW, 1992, MOL BIOCHEM PARASIT, V51, P49, DOI 10.1016/0166-6851(92)90199-T; KNIEP B, 1992, BIOCHEM BIOPH RES CO, V187, P1343, DOI 10.1016/0006-291X(92)90450-Y; KNIEP B, 1993, BLOOD, V82, P1776; KNIEP B, 1995, J BIOL CHEM, V270, P30173; Law S.K.A., 1995, COMPLEMENT; LEVINE JM, 1984, J NEUROSCI, V4, P820; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MERI S, 1990, P NATL ACAD SCI USA, V87, P3982, DOI 10.1073/pnas.87.10.3982; MICHALEK MT, 1988, J IMMUNOL, V140, P1588; NATH D, 1995, J BIOL CHEM, V270, P26184, DOI 10.1074/jbc.270.44.26184; NYDEGGER UE, 1978, P NATL ACAD SCI USA, V75, P6078, DOI 10.1073/pnas.75.12.6078; OLLERT MW, 1995, J IMMUNOL, V155, P4955; POWELL LD, 1995, J BIOL CHEM, V270, P14243, DOI 10.1074/jbc.270.24.14243; SCHAUER R, 1991, Glycobiology, V1, P449, DOI 10.1093/glycob/1.5.449; Schauer R., 1982, CELL BIOL MONOGRAPHS, V10; SCHWARTING GA, 1983, J BIOL CHEM, V258, P5893; SHI WS, 1978, UNPUB J BIOL CHEM, V271, P31517; SJOBERG ER, 1994, J CELL BIOL, V126, P549, DOI 10.1083/jcb.126.2.549; STICKL H, 1991, KLIN WOCHENSCHR, V69, P5, DOI 10.1007/BF01649046; ULMER JB, 1989, P NATL ACAD SCI USA, V86, P6992, DOI 10.1073/pnas.86.18.6992; VARKI A, 1980, J EXP MED, V152, P532, DOI 10.1084/jem.152.3.532; VARKI A, 1991, CELL, V65, P65, DOI 10.1016/0092-8674(91)90408-Q; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; ZIMMER G, 1994, GLYCOBIOLOGY, V4, P343, DOI 10.1093/glycob/4.3.343; ZIPFEL PF, 1994, IMMUNOL TODAY, V15, P121, DOI 10.1016/0167-5699(94)90155-4	41	88	91	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31526	31532		10.1074/jbc.271.49.31526	http://dx.doi.org/10.1074/jbc.271.49.31526			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940168	hybrid			2022-12-25	WOS:A1996VW68600079
J	Wu, CB; Narayan, P; Puett, D				Wu, CB; Narayan, P; Puett, D			Protein engineering of a novel constitutively active hormone-receptor complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; LUTROPIN-CHORIOGONADOTROPIN RECEPTOR; GLYCOPROTEIN HORMONES; EXTRACELLULAR DOMAIN; ALPHA-SUBUNIT; HIGH-AFFINITY; BETA-SUBUNIT; BINDING; REGION; CELLS	Human chorionic gonadotropin (hCG) is a heterodimeric glycoprotein hormone consisting of an alpha and a beta subunit that stimulates intracellular levels of cAMP via a G protein-coupled receptor, Herein we report the engineering and characterization of a novel molecule in which the receptor and its heterodimeric ligand were covalently Linked in a single polypeptide chain, The hormone-receptor complex was expressed in cells transfected with this construct, but the cells were unable to bind significant amounts of exogenous hCG. However, cleavage of the hormone with a site-specific protease rendered the receptor accessible to exogenously added hormone. Cells transfected with the hCG-receptor construct contained elevated basal levels of cAMP; moreover, addition of hormone had no significant effect. These results are consistent with a strong and stable interaction between the single-chain hormone and its covalently linked receptor that results in a constitutively active complex.	UNIV GEORGIA,DEPT BIOCHEM & MOL BIOL,ATHENS,GA 30602	University System of Georgia; University of Georgia					NIDDK NIH HHS [DK-33973] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033973] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bhowmick N, 1996, MOL ENDOCRINOL, V10, P1147, DOI 10.1210/me.10.9.1147; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; CHEN F, 1991, J BIOL CHEM, V266, P19357; CHEN F, 1992, MOL ENDOCRINOL, V6, P914, DOI 10.1210/me.6.6.914; Couture L, 1996, J MOL ENDOCRINOL, V16, P15, DOI 10.1677/jme.0.0160015; ELDEIRY S, 1989, MOL ENDOCRINOL, V3, P1523, DOI 10.1210/mend-3-10-1523; Fernandez LM, 1996, BIOCHEMISTRY-US, V35, P3986, DOI 10.1021/bi952421c; Fernandez LM, 1996, J BIOL CHEM, V271, P925, DOI 10.1074/jbc.271.2.925; HUANG JN, 1995, J BIOL CHEM, V270, P30023; JI IH, 1991, ENDOCRINOLOGY, V128, P2648, DOI 10.1210/endo-128-5-2648; Jiang XL, 1995, STRUCTURE, V3, P1341, DOI 10.1016/S0969-2126(01)00272-6; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; MAGNUSSON S, 1975, PROTEASES BIOL CONTR, P123; MATZUK MM, 1990, ENDOCRINOLOGY, V126, P376, DOI 10.1210/endo-126-1-376; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MOYLE WR, 1991, J BIOL CHEM, V266, P10807; MOYLE WR, 1995, J BIOL CHEM, V270, P20020, DOI 10.1074/jbc.270.34.20020; NARAYAN P, 1995, MOL ENDOCRINOL, V9, P1720, DOI 10.1210/me.9.12.1720; Narayan P, 1996, MOL CELL ENDOCRINOL, V117, P95, DOI 10.1016/0303-7207(95)03735-7; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; RYAN RJ, 1988, FASEB J, V2, P2661, DOI 10.1096/fasebj.2.11.2456242; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; Sugahara T, 1996, J BIOL CHEM, V271, P10445, DOI 10.1074/jbc.271.18.10445; SUGAHARA T, 1995, P NATL ACAD SCI USA, V92, P2041, DOI 10.1073/pnas.92.6.2041; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; XIA HY, 1994, ENDOCRINOLOGY, V134, P1768, DOI 10.1210/en.134.4.1768; XIE YB, 1990, J BIOL CHEM, V265, P21411	28	29	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31638	31642		10.1074/jbc.271.49.31638	http://dx.doi.org/10.1074/jbc.271.49.31638			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940183	hybrid			2022-12-25	WOS:A1996VW68600094
J	Datta, K; Bellacosa, A; Chan, TO; Tsichlis, PN				Datta, K; Bellacosa, A; Chan, TO; Tsichlis, PN			Akt is a direct target of the phosphatidylinositol 3-kinase - Activation by growth factors, v-src and v-Ha-ras, in Sf9 and mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; SIGNAL-TRANSDUCTION; DOMAIN; PP60C-SRC; HOMOLOGY; RAF-1; SITES	The Akt protooncogene encodes a serine-threonine protein kinase which is activated by growth factor-generated signals that are transduced via the phosphatidylinositol 3'-kinase (PI3-K). Earlier studies suggested that the activation of Akt by PB-K may be mediated by the binding of D-3-phosphorylated phosphoinositides to the Akt pleckstrin homology (PH) domain. On the basis of these studies, it was hypothesized that Abt is a direct PB-K target. To test this hypothesis, we reconstituted the pathway of Akt activation in baculovirus-infected Sf9 cells. The results showed that Akt, which is normally catalytically inactive in these cells, was activated when coexpressed with the activated PI3-K. Moreover, they showed that activated forms of c-Ha-ras (v-Ha-ras) and c-src (v-src or srcY527F), two molecules that transduce growth factor-generated signals, also activate Akt in a PI3-K-dependent manner in Sf9 as well as NIH 3T3 cells, The activation of Akt by both growth factors and v-ras and v-src (or srcY527F) depends on the integrity of the Akt PH domain and carboxyl-terminal tail. These results show that Akt activation via the PB-B: can be faithfully reproduced in baculovirus-infected Sf9 cells, The same results support the hypothesis that Akt is a direct target of the PI3-K and identify cytoplasmic signaling molecules that may contribute to the transduction of PI3-K/Akt activation signals.	FOX CHASE CANC CTR,PHILADELPHIA,PA 19111	Fox Chase Cancer Center				Chan, Tung/0000-0001-6574-9555	NCI NIH HHS [CA57436, CA06927] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057436, P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; DATTA K, 1995, MOL CELL BIOL, V15, P2304; FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; PATRIOTIS C, 1993, P NATL ACAD SCI USA, V90, P2251, DOI 10.1073/pnas.90.6.2251; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0	19	253	257	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30835	30839		10.1074/jbc.271.48.30835	http://dx.doi.org/10.1074/jbc.271.48.30835			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940066	hybrid			2022-12-25	WOS:A1996VV15800083
J	Kumar, R; Chen, SM; Scheurer, D; Wang, QL; Duh, E; Sung, CH; Rehemtulla, A; Swaroop, A; Adler, R; Zack, DJ				Kumar, R; Chen, SM; Scheurer, D; Wang, QL; Duh, E; Sung, CH; Rehemtulla, A; Swaroop, A; Adler, R; Zack, DJ			The bZIP transcription factor Nrl stimulates rhodopsin promoter activity in primary retinal cell cultures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PROTEIN BINDING; SMALL MAF PROTEINS; RAT OPSIN GENE; RETINITIS-PIGMENTOSA; SEGMENTATION MUTANT; BOVINE RHODOPSIN; UPSTREAM REGION; BASIC DOMAIN; FACTOR NF-E2; EXPRESSION	In vitro DNA binding assays and transient transfection analysis with monkey kidney cells have implicated Nrl, a member of the Maf-Nrl subfamily of bZIP transcription factors, and the Nrl response element (NRE) in the regulation of rhodopsin expression, We have now further explored the role of the NRE and surrounding promoter elements. Using the yeast one-hybrid screen with integrated NRE and flanking DNA as bait, the predominant clone obtained was bovine Nrl. Recovery of truncated clones in the screen demonstrated that the carboxyl-terminal half of Nrl, which contains the basic and leucine zipper domains, is sufficient for DNA binding. To functionally dissect the rhodopsin promoter, transient expression studies with primary chick retinal cell cultures were performed. Deletion and mutation analyses identified two positive regulatory sequences: one between -40 and -84 base pairs (bp) and another between -84 and -130 bp. Activity of the -40 to -84 region was shown to be largely due to the NRE, On co-transfection with an NRL expression vector, there were 3-5-fold increases in the activity of rhodopsin promoter constructs containing an intact NRE but little or no effect with rhodopsin promoters containing a mutated or deleted NRE. Nrl was more effective than the related bZIP proteins, c-Fos and c-Jun, in stimulating rhodopsin promoter activity. The -84- to -130-bp region acted synergistically with the NRE to enhance both the level of basal expression and the degree of Nrl-mediated trans-activation. These studies support Nrl as a regulator of rhodopsin expression in vivo, identify an additional regulatory region just upstream of the NRE, and demonstrate the utility of primary retinal cell cultures for characterizing both the cis-acting response elements and trans-acting factors that regulate photoreceptor gene expression.	JOHNS HOPKINS UNIV,SCH MED,DEPT OPHTHALMOL,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH MED,DEPT MOL BIOL & GENET,BALTIMORE,MD 21287; CORNELL UNIV,SCH MED,DEPT OPHTHALMOL,NEW YORK,NY 10021; CORNELL UNIV,SCH MED,DEPT CELL BIOL,NEW YORK,NY 10021; CORNELL UNIV,SCH MED,DEPT ANAT,NEW YORK,NY 10021; UNIV MICHIGAN,DEPT RADIAT ONCOL,ANN ARBOR,MI 48105; UNIV MICHIGAN,DEPT OPHTHALMOL & HUMAN GENET,ANN ARBOR,MI 48105	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Cornell University; Cornell University; Cornell University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan				Swaroop, Anand/0000-0002-1975-1141; Zack, Don/0000-0002-7966-1973	NATIONAL EYE INSTITUTE [R01EY009769, R01EY011307, F32EY006614, R01EY004859, F32EY006434] Funding Source: NIH RePORTER; NEI NIH HHS [EY09769, EY04859, EY06434, F32 EY006614, R01 EY011307] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADLER R, 1984, J CELL BIOL, V99, P1173, DOI 10.1083/jcb.99.3.1173; Adler R, 1990, Adv Exp Med Biol, V265, P147; ADLER R, 1993, INVEST OPHTH VIS SCI, V34, P1677; Ahmad I, 1995, DEV BRAIN RES, V90, P184, DOI 10.1016/0165-3806(96)83500-0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; BOGENMANN E, 1988, SCIENCE, V240, P76, DOI 10.1126/science.2451289; Chen SM, 1996, J BIOL CHEM, V271, P28549, DOI 10.1074/jbc.271.45.28549; CORDES SP, 1994, CELL, V79, P1025, DOI 10.1016/0092-8674(94)90033-7; DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0; EARNEST DJ, 1990, EXP NEUROL, V109, P353, DOI 10.1016/S0014-4886(05)80027-5; FARJO Q, 1993, GENOMICS, V18, P216, DOI 10.1006/geno.1993.1458; FROHMAN MA, 1993, DEVELOPMENT, V117, P925; GALE JM, 1992, J MOL BIOL, V224, P343, DOI 10.1016/0022-2836(92)90999-Z; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; KERPPOLA TK, 1994, ONCOGENE, V9, P3149; KERPPOLA TK, 1994, ONCOGENE, V9, P675; KIKUCHI T, 1993, MOL CELL BIOL, V13, P4400, DOI 10.1128/MCB.13.7.4400; KUMAR R, 1995, MOL GENETICS OCULAR, P139; KURSCHNER C, 1995, MOL CELL BIOL, V15, P246, DOI 10.1128/MCB.15.1.246; LEM J, 1991, NEURON, V6, P201, DOI 10.1016/0896-6273(91)90356-5; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; Liu Q, 1996, ONCOGENE, V12, P207; MCKAY IJ, 1994, DEVELOPMENT, V120, P2199; MORABITO MA, 1991, J BIOL CHEM, V266, P9667; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NATHANS J, 1984, P NATL ACAD SCI-BIOL, V81, P4851, DOI 10.1073/pnas.81.15.4851; NATHANS J, 1983, CELL, V34, P807, DOI 10.1016/0092-8674(83)90537-8; NATHANS J, 1987, ANNU REV NEUROSCI, V10, P163; Nie ZQ, 1996, J BIOL CHEM, V271, P2667, DOI 10.1074/jbc.271.5.2667; PIERANI A, 1995, MOL CELL BIOL, V15, P642; POLITI LE, 1988, INVEST OPHTH VIS SCI, V29, P534; Rehemtulla A, 1996, P NATL ACAD SCI USA, V93, P191, DOI 10.1073/pnas.93.1.191; Saga T, 1996, INVEST OPHTH VIS SCI, V37, P561; SAGAR SM, 1990, MOL BRAIN RES, V7, P17, DOI 10.1016/0169-328X(90)90068-O; Sambrook J., 2002, MOL CLONING LAB MANU; SHESHBERADARAN H, 1994, MOL CELL NEUROSCI, V5, P309, DOI 10.1006/mcne.1994.1037; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P6481, DOI 10.1073/pnas.88.15.6481; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; TIMMERS AM, 1993, EXP EYE RES, V56, P257, DOI 10.1006/exer.1993.1034; TREISMAN JE, 1988, MOL CELL BIOL, V8, P1570, DOI 10.1128/MCB.8.4.1570; WANG MM, 1993, MOL CELL BIOL, V13, P5805, DOI 10.1128/MCB.13.9.5805; WANG YS, 1992, NEURON, V9, P429, DOI 10.1016/0896-6273(92)90181-C; WERNER M, 1990, J NEUROSCI RES, V25, P50, DOI 10.1002/jnr.490250107; YU X, 1993, BIOCHEM BIOPH RES CO, V191, P76, DOI 10.1006/bbrc.1993.1186; ZACK DJ, 1991, NEURON, V6, P187, DOI 10.1016/0896-6273(91)90355-4; ZACK DJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P1477, DOI 10.1001/archopht.1993.01090110043019	51	130	131	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29612	29618		10.1074/jbc.271.47.29612	http://dx.doi.org/10.1074/jbc.271.47.29612			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939891	hybrid			2022-12-25	WOS:A1996VU52500019
J	Kuntzweiler, TA; Arguello, JM; Lingrel, JB				Kuntzweiler, TA; Arguello, JM; Lingrel, JB			Asp(804) and Asp(808) in the transmembrane domain of the Na,K-ATPase alpha subunit are cation coordinating residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; RAT-KIDNEY NA+,K+-ATPASE; MEMBRANE H+-ATPASE; SARCOPLASMIC-RETICULUM; CARDIAC-GLYCOSIDES; OUABAIN BINDING; VOLTAGE-DEPENDENCE; ACTIVE-TRANSPORT; POTASSIUM-IONS; SODIUM	The functional roles of Asp(804) and Asp(808), located in the sixth transmembrane segment of the Na,R-ATPase alpha subunit, were examined. Nonconservative replacement of these residues yielded enzymes unable to support cell viability. Only the conservative substitution, Ala(808) --> Glu, was able to maintain the essential cation gradients (Van Huysse, J. W., Kuntzweiler, T. A., and Lingrel, J. B (1996) FEES Left. 389, 179-185). Asp(804) and Asp(808) were replaced by Ala, Asn, and Glu in the sheep alpha 1 subunit and expressed in a mouse cell line where [H-3]ouabain binding was utilized to probe the exogenous proteins. All of the heterologous proteins were targeted into the plasma membrane, bound ouabain and nucleotides, and adopted E(1)Na, E(1)ATP, and E(2)P conformations. K+ competition of ouabain binding to sheep alpha 1 and Asp(808) --> Glu enzymes displayed IC50 values of 4.11 mM (n(Hill) = 1.4) and 23.8 mM (n(Hill) = 1.6), respectively. All other substituted proteins lacked this K+-ouabain antagonism, e.g. 150 min KCl did not inhibit ouabain binding. Na+ antagonized ouabain binding to all the expressed isoforms, however, the proteins carrying nonconservative substitutions displayed reduced Hill coefficients (n(Hill) less than or equal to 2.0) compared to the control (n(Hill) less than or equal to 2.8), Therefore, Asp(804) and Asp(808) of the Na,K-ATPase are required for normal Na+ and K+ transport, possibly coordinating these cations during transport.	UNIV CINCINNATI, COLL MED, DEPT MOL GENET BIOCHEM & MICROBIOL, CINCINNATI, OH 45267 USA	University of Cincinnati			Arguello, Jose/D-1997-2012	Arguello, Jose/0000-0003-3940-6297	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028573, K14HL003373, F32HL008612] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL28573, HL08612, HL03373] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSEN JP, 1994, J BIOL CHEM, V269, P15931; ARGUELLO JM, 1991, J BIOL CHEM, V266, P14627; ARGUELLO JM, 1994, J BIOL CHEM, V269, P6892; ARGUELLO JM, 1995, J BIOL CHEM, V270, P22764, DOI 10.1074/jbc.270.39.22764; Arguello JM, 1996, BIOPHYS J, V70, pTU370; ASKARI A, 1988, J BIOL CHEM, V263, P235; BAMBERG E, 1994, SODIUM PUMP STRUCTUR; BLOSTEIN R, 1983, J BIOL CHEM, V258, P7948; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CORNELIUS F, 1991, BIOCHIM BIOPHYS ACTA, V1071, P19, DOI 10.1016/0304-4157(91)90011-K; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DEWEER P, 1988, ANNU REV PHYSIOL, V50, P225, DOI 10.1146/annurev.physiol.50.1.225; DUNHAM ET, 1961, J PHYSIOL-LONDON, V156, P274, DOI 10.1113/jphysiol.1961.sp006675; ERDMANN E, 1973, BIOCHIM BIOPHYS ACTA, V330, P302, DOI 10.1016/0005-2736(73)90235-6; FENG JN, 1994, BIOCHEMISTRY-US, V33, P4218, DOI 10.1021/bi00180a015; FENG JN, 1995, CELL MOL BIOL RES, V41, P29; FORBUSH B, 1987, J BIOL CHEM, V262, P11116; Glynn I. M., 1985, ENZYMES BIOL MEMBR, P35; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; GOLDSHLEGGER R, 1987, J PHYSIOL-LONDON, V387, P331, DOI 10.1113/jphysiol.1987.sp016576; GREEN NM, 1989, BIOCHEM SOC T, V17, P972, DOI 10.1042/bst0170972; HANSEN O, 1973, BIOCHIM BIOPHYS ACTA, V311, P51, DOI 10.1016/0005-2736(73)90254-X; HANSEN O, 1984, PHARMACOL REV, V36, P143; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13523, DOI 10.1021/bi00212a018; JOHNSON CL, 1995, BIOCHEM J, V309, P187, DOI 10.1042/bj3090187; JOHNSON CL, 1995, ARCH BIOCHEM BIOPHYS, V317, P133, DOI 10.1006/abbi.1995.1145; JORGENSEN PL, 1992, MOL ASPECTS TRANSPOR, P1; KARLISH SJD, 1980, J BIOENERG BIOMEMBR, V12, P111, DOI 10.1007/BF00744678; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P4566, DOI 10.1073/pnas.87.12.4566; Koster JC, 1996, J BIOL CHEM, V271, P2413, DOI 10.1074/jbc.271.5.2413; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUNTZWEILER TA, 1995, J BIOL CHEM, V270, P2993, DOI 10.1074/jbc.270.7.2993; KUNTZWEILER TA, 1995, J BIOL CHEM, V270, P16206, DOI 10.1074/jbc.270.27.16206; LANE LK, 1979, NA K ATPASE STRUCTUR; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; LUTSENKO S, 1995, P NATL ACAD SCI USA, V92, P7936, DOI 10.1073/pnas.92.17.7936; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; OBRIEN WJ, 1993, J BIOL CHEM, V268, P7707; Palasis M, 1996, J BIOL CHEM, V271, P14176, DOI 10.1074/jbc.271.24.14176; PEDEMONTE CH, 1988, J THEOR BIOL, V134, P165, DOI 10.1016/S0022-5193(88)80200-5; PEDEMONTE CH, 1990, AM J PHYSIOL, V258, pC1, DOI 10.1152/ajpcell.1990.258.1.C1; PEDEMONTE CH, 1988, BIOCHEMISTRY-US, V27, P7966, DOI 10.1021/bi00420a056; Pedersen PA, 1996, J BIOL CHEM, V271, P2514, DOI 10.1074/jbc.271.5.2514; Peluffo R. D., 1996, Biophysical Journal, V70, pA18; POST RL, 1972, J BIOL CHEM, V247, P6530; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; RAO R, 1993, J BIOL CHEM, V268, P6708; RAO R, 1992, BIOPHYS J, V62, P228, DOI 10.1016/S0006-3495(92)81808-8; SAGAR A, 1994, J GEN PHYSIOL, V103, P869, DOI 10.1085/jgp.103.5.869; SAMPOGNA RV, 1994, BIOPHYS J, V66, P1341, DOI 10.1016/S0006-3495(94)80925-7; SCHATZMANN HJ, 1965, BIOCHIM BIOPHYS ACTA, V94, P89, DOI 10.1016/0926-6585(65)90011-7; SCHULTHEIS PJ, 1993, J BIOL CHEM, V268, P22686; SHANISEKLER M, 1988, J BIOL CHEM, V263, P19331; VANHUYSSE JW, 1993, BIOCHEMISTRY-US, V32, P819, DOI 10.1021/bi00054a012; VanHuysse JW, 1996, FEBS LETT, V389, P179, DOI 10.1016/0014-5793(96)00578-9; VILSEN B, 1993, BIOCHEMISTRY-US, V32, P13340, DOI 10.1021/bi00211a048; VILSEN B, 1995, BIOCHEMISTRY-US, V34, P1455, DOI 10.1021/bi00004a041; WALLICK ET, 1988, METHOD ENZYMOL, V156, P201; YODA A, 1982, MOL PHARMACOL, V22, P700	62	93	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29682	29687		10.1074/jbc.271.47.29682	http://dx.doi.org/10.1074/jbc.271.47.29682			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939901	hybrid			2022-12-25	WOS:A1996VU52500029
J	Tchou, WW; Rom, WN; TchouWong, KM				Tchou, WW; Rom, WN; TchouWong, KM			Novel form of p21(WAF1)/(CIP1)/(SDI1) protein in phorbol ester-induced G(2)/M arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C; CELL-CYCLE; P53-INDEPENDENT INDUCTION; TUMOR SUPPRESSION; GROWTH-INHIBITION; DOWN-REGULATION; LEUKEMIA-CELLS; P21; EXPRESSION; WAF1/CIP1	Cell cycle progression requires activation of different cyclin-dependent kinases (CDKs) which are positively regulated by cyclins and negatively regulated by CDK inhibitors. Growth inhibition of the Calu-1 lung carcinoma cells induced with the phorbol ester 12-O-tetra-decanoylphorbol-13-acetate (TPA), a potent activator of protein kinase C, is associated with G(2)/M arrest and induction of expression of a novel, faster-migrating form of p21(WAF1/CIP1/SDI1) (p21) protein, an inhibitor of cyclin-dependent kinases. This faster-migrating p21 protein was also expressed in TPA-treated A549 lung carcinoma cells which also exhibited G(2)/M arrest but not in TPA-treated U937 leukemia cells, which only expressed a slower-migrating form of p21 protein. However, reverse transcriptase-polymerase chain reaction and Southern analysis demonstrated no evidence of novel splice in TPA-treated Calu-1 cells. On the other hand, immuno-blotting analysis demonstrated that the faster-migrating p21 protein could be detected only by peptide antibody directed against the N terminus but not the C terminus, suggestive of truncation of the latter or protein modification that results in the loss of the C-terminal epitope. Correlation of G(2)/M arrest with expression of the faster-migrating p21 protein suggests that this novel form of p21 protein may be a mediator of G(2)/M arrest and growth inhibition.	NYU,MED CTR,DEPT MED,NEW YORK,NY 10016; NYU,MED CTR,DEPT ENVIRONM MED,NEW YORK,NY 10016; NYU,MED CTR,DEPT MICROBIOL,NEW YORK,NY 10016; NYU,MED CTR,DIV HEMATOL & ONCOL,NEW YORK,NY 10016; NYU,MED CTR,DIV PULM & CRIT CARE MED,NEW YORK,NY 10016	New York University; New York University; New York University; New York University; New York University				Rom, William/0000-0002-8793-7028	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051494] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035233] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL51494] Funding Source: Medline; NIAID NIH HHS [AI35233] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BJORNBERG F, 1994, LYMPHOKINE CYTOK RES, V13, P203; CHEDID M, 1994, ONCOGENE, V9, P3021; CHOI PM, 1990, MOL CELL BIOL, V10, P4650, DOI 10.1128/MCB.10.9.4650; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GRAFIA X, 1995, ONCOGENE, V11, P211; Guadagno TM, 1996, CELL, V84, P73, DOI 10.1016/S0092-8674(00)80994-0; HARANO T, 1994, J BIOL CHEM, V269, P20305; HARPER JW, 1993, CELL, V75, P805; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG HP, 1994, ONCOGENE, V9, P3397; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; LI Y, 1994, ONCOGENE, V9, P2261; MICHIELI P, 1994, CANCER RES, V54, P3391; NAKANISHI M, 1995, P NATL ACAD SCI USA, V92, P4352, DOI 10.1073/pnas.92.10.4352; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OKAMOTO A, 1995, CANCER RES, V55, P1448; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; QUELLE DE, 1995, CELL, V83, P993; REMOLDODONNELL E, 1994, J IMMUNOL, V152, P3595; SCHWALLER J, 1995, J CLIN INVEST, V95, P973, DOI 10.1172/JCI117806; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TCHOUWONG KM, 1992, MOL CELL BIOL, V12, P394, DOI 10.1128/MCB.12.1.394; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YEE NS, 1994, J BIOL CHEM, V269, P31991; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHANG W, 1995, CANCER RES, V55, P668	35	55	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29556	29560		10.1074/jbc.271.47.29556	http://dx.doi.org/10.1074/jbc.271.47.29556			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939883	hybrid			2022-12-25	WOS:A1996VU52500011
J	Casey, G; Lopez, ME; Ramos, JC; Plummer, SJ; Arboleda, MJ; Shaughnessy, M; Karlan, B; Slamon, DJ				Casey, G; Lopez, ME; Ramos, JC; Plummer, SJ; Arboleda, MJ; Shaughnessy, M; Karlan, B; Slamon, DJ			DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies	ONCOGENE			English	Article						p53 tumor suppressor gene; breast cancer; ovarian cancer; lung cancer; mutations; immunohistochemical staining	HUMAN BREAST-CANCER; TUMOR-SUPPRESSOR GENE; CELL LUNG-CANCER; STRAND CONFORMATION POLYMORPHISM; DENATURANT GEL-ELECTROPHORESIS; LI-FRAUMENI-SYNDROME; PROTEIN EXPRESSION; OVARIAN-CANCER; MUTANT P53; PROGNOSTIC-SIGNIFICANCE	p53 mutations are the most common genetic alterations found in human malignancies, However current estimates of p53 alterations in cancers may be inaccurate because there is evidence that current approaches do not detect all p53 alterations, In this study we determine the status of the p53 gene by complete DNA sequencing of exons 2 through 11 as well as immunohistochemical staining in cohorts of primary human breast, ovarian and non small cell lung cancer, Overall, 24 of 93 (26%) breast cancers, 62 of 108 (57%) ovarian cancers and 88 of 154 (57%) non small cell lung cancers contained DNA sequence mutations, whereas positive immunohistochemical staining was detected in 15 of 64 (23%) breast, 35 of 94 (37%) ovarian, and 63 of 137 (46%) lung cancers, Of those tumors that contained mutations, the mutation occurred outside the 'hot-spot' region in 19% of breast, 18% of ovarian and 17% of lung tumors, indicating that a substantial number of mutations remain undetected in studies that are restricted to exons 5 through 9, We observed a high concordance between the presence of p53 missense mutations and positive immunohistochemical staining, but a poor concordance between other types of mutations and staining in all three types of malignancies. We conclude that a combination of DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known alterations in the p53 gene in human malignancies.	UNIV CALIF LOS ANGELES, DEPT MED, DIV HEMATOL & ONCOL, LOS ANGELES, CA 90024 USA; CEDARS SINAI MED CTR, DEPT OBSTET & GYNECOL, LOS ANGELES, CA 90048 USA; UNIV CALIF LOS ANGELES, SCH MED, LOS ANGELES, CA 90048 USA	University of California System; University of California Los Angeles; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Casey, G (corresponding author), CLEVELAND CLIN FDN, RES INST, DEPT CANC BIOL, 9500 EUCLID AVE, CLEVELAND, OH 44195 USA.							ALLRED DC, 1993, J NATL CANCER I, V85, P200, DOI 10.1093/jnci/85.3.200; ANDERSEN TI, 1993, BRIT J CANCER, V68, P540, DOI 10.1038/bjc.1993.383; BARTEK J, 1991, ONCOGENE, V6, P1699; BARTEK J, 1990, INT J CANCER, V46, P839, DOI 10.1002/ijc.2910460515; BERGH J, 1995, NAT MED, V1, P1029, DOI 10.1038/nm1095-1029; BHATIA K, 1993, FASEB J, V7, P951, DOI 10.1096/fasebj.7.10.8344493; BIGGS PJ, 1993, MUTAGENESIS, V8, P275, DOI 10.1093/mutage/8.4.275; BLASZYK H, 1994, LANCET, V343, P1195, DOI 10.1016/S0140-6736(94)92403-1; BODNER SM, 1992, ONCOGENE, V7, P743; BORRESEN AL, 1991, P NATL ACAD SCI USA, V88, P8405, DOI 10.1073/pnas.88.19.8405; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; CASEY G, 1993, HUM MOL GENET, V2, P1921, DOI 10.1093/hmg/2.11.1921; CASEY G, 1993, CANCER LETT, V69, P151, DOI 10.1016/0304-3835(93)90168-9; CASEY G, 1991, ONCOGENE, V6, P1791; CASTRESANA JS, 1993, INT J CANCER, V55, P562, DOI 10.1002/ijc.2910550407; CHIBA I, 1990, ONCOGENE, V5, P1603; CHO KR, 1992, J CELL BIOCHEM, P137; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COLES C, 1992, CANCER RES, V52, P5291; CONDIE A, 1993, HUM MUTAT, V2, P58, DOI 10.1002/humu.1380020111; DAVIDOFF AM, 1991, SURGERY, V110, P259; DAVIDOFF AM, 1991, P NATL ACAD SCI USA, V88, P5006, DOI 10.1073/pnas.88.11.5006; DAVIDOFF AM, 1991, CANCER RES, V51, P2605; DENG G, 1994, CANCER RES, V54, P499; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EELES RA, 1993, CANCER SURV, V18, P57; EELES RA, 1993, ONCOGENE, V8, P1269; ELLEDGE RM, 1994, CANCER RES, V54, P3752; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HALL PA, 1993, ONCOGENE, V8, P203; HARTMANN A, 1995, ONCOGENE, V10, P681; HARTMANN A, 1995, J CLIN INVEST, V95, P686, DOI 10.1172/JCI117714; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORAK E, 1991, ONCOGENE, V6, P2277; HORIO Y, 1993, CANCER RES, V53, P1; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; ISOLA J, 1992, J NATL CANCER I, V84, P1109, DOI 10.1093/jnci/84.14.1109; KOVACH JS, 1991, JNCI-J NATL CANCER I, V83, P1004, DOI 10.1093/jnci/83.14.1004; KUPRYJANCZYK J, 1993, P NATL ACAD SCI USA, V90, P4961, DOI 10.1073/pnas.90.11.4961; LANE DP, 1994, MOL BIOL REP, V19, P23, DOI 10.1007/BF00987319; LEHMAN TA, 1991, CANCER RES, V51, P4090; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1990, BIOESSAYS, V12, P60, DOI 10.1002/bies.950120203; LIPPONEN P, 1993, INT J CANCER, V55, P51, DOI 10.1002/ijc.2910550110; LOHMANN D, 1993, DIAGN MOL PATHOL, V2, P36, DOI 10.1097/00019606-199300020-00006; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARKS JR, 1991, CANCER RES, V51, P2979; MAZARS R, 1992, CANCER RES, V52, P3918; MAZARS R, 1991, ONCOGENE, V6, P1685; MAZUR M, 1988, SOMAT CELL MOLEC GEN, V14, P393, DOI 10.1007/BF01534647; MILNER BJ, 1993, CANCER RES, V53, P2128; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MOLES JP, 1993, ONCOGENE, V8, P583; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOYRET C, 1994, ONCOGENE, V9, P1739; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OSBORNE RJ, 1991, CANCER RES, V51, P6194; OSTROWSKI JL, 1991, J PATHOL, V164, P75, DOI 10.1002/path.1711640113; PENG HQ, 1993, CANCER RES, V53, P3574; PLUMMER SJ, 1994, ONCOGENE, V9, P3273; POLLER DN, 1993, HUM PATHOL, V24, P463, DOI 10.1016/0046-8177(93)90157-C; PROSSER J, 1990, ONCOGENE, V5, P1573; PURDIE CA, 1994, ONCOGENE, V9, P603; REIHSAUS E, 1990, ONCOGENE, V5, P137; REISSMANN PT, 1993, ONCOGENE, V8, P1913; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; SAITOH S, 1994, ONCOGENE, V9, P2869; SAMESHIMA Y, 1992, ONCOGENE, V7, P451; SHEFFIELD VC, 1993, GENOMICS, V16, P325, DOI 10.1006/geno.1993.1193; SILVERSTEIN MJ, 1995, LANCET, V345, P1154; SOMERS KD, 1992, CANCER RES, V52, P5997; SOMMER SS, 1992, J NATL CANCER I, V84, P246, DOI 10.1093/jnci/84.4.246; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STACK M, 1995, HUM MOL GENET, V4, P2047, DOI 10.1093/hmg/4.11.2047; SUZUKI H, 1992, CANCER RES, V52, P734; TAKAHASHI K, 1993, MOL CARCINOGEN, V8, P58, DOI 10.1002/mc.2940080112; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKAHASHI T, 1991, ONCOGENE, V6, P1775; THOMPSON AM, 1992, INT J CANCER, V50, P528, DOI 10.1002/ijc.2910500405; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; THORLACIUS S, 1993, CANCER RES, V53, P1637; VARLEY JM, 1991, ONCOGENE, V6, P413; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOJTESEK B, 1993, J CELL SCI, V105, P607; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; WALKER RA, 1991, J PATHOL, V165, P203, DOI 10.1002/path.1711650303; WARNEFORD SG, 1992, CELL GROWTH DIFFER, V3, P839	93	205	207	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	1996	13	9					1971	1981						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934544				2022-12-25	WOS:A1996VR79500017
J	Zariwala, M; Xiong, Y				Zariwala, M; Xiong, Y			Lack of mutation in the cyclin-dependent kinase inhibitor, p19(INK4d), in tumor-derived cell lines and primary tumors	ONCOGENE			English	Article						p15(INK4b); p16(INK4a); p18(INK4c); p19(INK4d); CDK inhibitors	SUPPRESSOR GENE; MOLECULAR ANALYSIS; HUMAN MALIGNANCIES; FAMILIAL MELANOMA; P15(INK4B) GENE; CDK6 INHIBITOR; P27(KIP1) GENE; HUMAN CANCERS; P18 GENES; EXPRESSION	Inhibitors of cyclin-dependent kinases provide a major mechanism of negative regulation on cell cycle progression, Defects in the function of the CDK inhibitors may lead to uncontrolled cell proliferation and potentially facilitate tumorigenesis. The p16(INK4) family of CDK inhibitors specifically prevent the phosphorylation of the retinoblastoma susceptibility gene product, pRb, by inhibiting the kinase activity of CDK4 and CDK6, thereby keeping pRb in its active form as a growth suppressor, The loss of p16(INK4) inhibitory activity would, therefore, have the same consequence as the loss of pRb growth suppressing activity, The p16(INK4) family currently includes four members, p15(INK4b), p16INK(4a)) p18INK(4c) and p19(INK4d). Two members, p15(INK4b) and p16(INK4a) have been found to be deleted and mutated in a variety of human tumor-derived cell lines and primary tumors, In the present study we have examined the genomic status of the newly isolated p19(INK4d) gene in 75 tumor-derived cell lines; 13 immortalized, transformed or normal cell lines; 19 ovarian tumors and 18 acute myelogenous leukemias, No deletions or point mutations were observed in the p19(INK4d) gene, A genetic polymorphism at codon 30 (CGC-->CGG) in exon 1 of the p19(INK4d) gene was observed in 10% of the samples under investigation, In the same set of samples, p16(INK4a) was found to be homozygously deleted in 32% of the tumor derived cell lines, These results together with our previous data that showed a 22% deletion frequency in p(15INK4b) and rare alterations in the p18(INK4c) gene, indicating that the p16(INK4a) and p15(INK4b), but not the p18(INK4c) and p19(INK4d) genes, are frequently mutated in human tumors, Hence, members of the p16(INK4) CDK inhibitor family, while evolutionary related and biochemically indistinguishable, carry out distinct biological functions.	UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill					NATIONAL CANCER INSTITUTE [R01CA065572] Funding Source: NIH RePORTER; NCI NIH HHS [CA 65572] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BHATIA K, 1995, CANCER RES, V55, P1431; BULLRICH F, 1995, CANCER RES, V55, P1199; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GAO X, 1995, ONCOGENE, V11, P1395; GLENDENING JM, 1995, CANCER RES, V55, P5531; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GRUIS NA, 1995, NAT GENET, V10, P351, DOI 10.1038/ng0795-351; Guan KL, 1996, MOL BIOL CELL, V7, P57, DOI 10.1091/mbc.7.1.57; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HAIDAR MA, 1995, BLOOD, V86, P311, DOI 10.1182/blood.V86.1.311.bloodjournal861311; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hara E, 1996, MOL CELL BIOL, V16, P859; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HATADA I, 1995, NAT GENET, V11, P204, DOI 10.1038/ng1095-204; HE J, 1994, CANCER RES, V54, P5804; Herman JG, 1996, CANCER RES, V56, P722; HERMAN JG, 1995, CANCER RES, V55, P4525; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HURET JL, 1993, LEUKEMIA, V7, P152; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAWAMATA N, 1995, CANCER RES, V55, P2266; KIECHLESCHWARZ M, 1994, GYNECOL ONCOL, V55, P198, DOI 10.1006/gyno.1994.1277; KODORU PRK, 1995, BLOOD, V86, P2900; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LI Y, 1994, CANCER RES, V54, P6078; LOIS AF, 1995, CANCER RES, V55, P4010; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Matsuoka S, 1996, P NATL ACAD SCI USA, V93, P3026, DOI 10.1073/pnas.93.7.3026; MOROSETTI R, 1995, BLOOD, V86, P1924, DOI 10.1182/blood.V86.5.1924.bloodjournal8651924; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OKAMOTO A, 1995, CANCER RES, V55, P1448; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; Orlow I, 1996, CANCER RES, V56, P1219; OTSUKI T, 1995, CANCER RES, V55, P1436; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PIETENPOL JA, 1995, CANCER RES, V55, P1206; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; QUELLE DE, 1995, CELL, V83, P993; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHERRANO M, 1996, CELL, V85, P27; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; Spirin KS, 1996, CANCER RES, V56, P2400; Stegmaier K, 1996, CANCER RES, V56, P1413; TAKEUCHI S, 1995, BLOOD, V86, P755, DOI 10.1182/blood.V86.2.755.bloodjournal862755; TAM SW, 1994, CANCER RES, V54, P5816; WALKER GJ, 1995, HUM MOL GENET, V4, P1845, DOI 10.1093/hmg/4.10.1845; WATANABE H, 1995, BBA-GENE STRUCT EXPR, V1263, P275, DOI 10.1016/0167-4781(95)00110-3; Wong H, 1996, EXP GERONTOL, V31, P311, DOI 10.1016/0531-5565(95)00025-9; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; XIONG Y, 1996, IN PRESS BIOCH BIOPH; XU L, 1994, CANCER RES, V54, P5262; Zariwala M, 1996, ONCOGENE, V12, P451; ZHANG SY, 1994, CANCER RES, V54, P5050	65	26	26	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 7	1996	13	9					2033	2038						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934552				2022-12-25	WOS:A1996VR79500025
J	Cayrol, C; Flemington, E				Cayrol, C; Flemington, E			G(0)/G(1), growth arrest mediated by a region encompassing the basic leucine zipper (bZIP) domain of the Epstein-Barr virus transactivator Zta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; DNA-BINDING; DIMERIZATION DOMAIN; ACTIVATION DOMAIN; BZLF1 PROTEIN; PROMOTER DNA; DIFFERENTIATION; CELLS; EXPRESSION; INHIBITOR	The Epstein-Barr virus (EBV) immediate early transactivator Zta is a basic leucine zipper (bZIP) transcription factor that causes G(0)/G(1) cell cycle arrest through induction of the tumor suppressor protein, p53, and the cyclin-dependent kinase inhibitors, p21 and p27 (Cayrol, C., and Flemington, E. K. (1996) EMBO J. 15, 2748-2759). Here, we report a genetic analysis of Zta-mediated G(0)/G(1) growth arrest and p21 induction. The majority of the Zta transactivation domain can be deleted (Z Delta 1-128) without significantly affecting the ability of Zta to elicit growth arrest. A larger amino-terminal deletion (Z Delta 1-167) abrogates the ability of Zta to inhibit proliferation, mapping the growth-inhibitory domain to a carboxyl-terminal region encompassing the bZIP domain (amino acids 128-245), The integrity of the bZIP domain is required for growth suppression since a two-amino acid mutant which is defective for homodimerization, fails to induce cell cycle arrest. Western blot analysis of p21 expression in cells expressing Zta mutants reveals that the ability of Zta mutants to cause G(0)/G(1) growth arrest is intimately related to their capacity to induce p21 expression. Together, these data demonstrate that a carboxyl-terminal region of Zta that includes the bZIP domain is sufficient to mediate G(0)/G(1) growth arrest and p21 induction.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR VIROL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV NEOPLAST DIS MECHANISMS,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School			CAYROL, Corinne/C-2106-2011	CAYROL, Corinne/0000-0002-7813-4397	NATIONAL CANCER INSTITUTE [R35CA047554] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048045] Funding Source: NIH RePORTER; NCI NIH HHS [CA47554] Funding Source: Medline; NIGMS NIH HHS [R29 GM48045] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cayrol C, 1996, EMBO J, V15, P2748, DOI 10.1002/j.1460-2075.1996.tb00635.x; CAYROL C, 1995, J VIROL, V69, P4206, DOI 10.1128/JVI.69.7.4206-4212.1995; CHANG YN, 1990, J VIROL, V64, P3358, DOI 10.1128/JVI.64.7.3358-3369.1990; CHI TH, 1993, MOL CELL BIOL, V13, P7045, DOI 10.1128/MCB.13.11.7045; DEGROOT RP, 1991, CELL GROWTH DIFFER, V2, P631; DEGROOT RP, 1990, EMBO J, V9, P1831, DOI 10.1002/j.1460-2075.1990.tb08308.x; ELDIERY WS, 1993, CELL, V75, P817; FARRELL PJ, 1989, EMBO J, V8, P127, DOI 10.1002/j.1460-2075.1989.tb03356.x; FIXMAN ED, 1992, J VIROL, V66, P5030, DOI 10.1128/JVI.66.8.5030-5039.1992; FLEMINGTON E, 1990, P NATL ACAD SCI USA, V87, P9459, DOI 10.1073/pnas.87.23.9459; FLEMINGTON EK, 1992, J VIROL, V66, P922, DOI 10.1128/JVI.66.2.922-929.1992; FLEMINGTON EK, 1994, MOL CELL BIOL, V14, P3041, DOI 10.1128/MCB.14.5.3041; FRANGIONI JV, 1994, J CELL SCI, V107, P827; GANDARILLAS A, 1995, MAMM GENOME, V6, P680, DOI 10.1007/BF00352383; GANDARILLAS A, 1995, ONCOGENE, V11, P1403; GIOT JF, 1991, NUCLEIC ACIDS RES, V19, P1251, DOI 10.1093/nar/19.6.1251; GROGAN E, 1987, P NATL ACAD SCI USA, V84, P1332, DOI 10.1073/pnas.84.5.1332; HARPER JW, 1993, CELL, V75, P805; KIEFF E, 1990, VIROLOGY, P1889; KOUZARIDES T, 1991, ONCOGENE, V6, P195; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; Metzstein MM, 1996, NATURE, V382, P545, DOI 10.1038/382545a0; MILLER G, 1990, VIROLOGY, P1921; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; SCHEPERS A, 1993, EMBO J, V12, P3921, DOI 10.1002/j.1460-2075.1993.tb06070.x; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SZABO E, 1994, CELL GROWTH DIFFER, V5, P439; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; ZHANG Q, 1994, MOL CELL BIOL, V14, P1929, DOI 10.1128/MCB.14.3.1929	32	56	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					31799	31802		10.1074/jbc.271.50.31799	http://dx.doi.org/10.1074/jbc.271.50.31799			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943219	hybrid			2022-12-25	WOS:A1996VY34000010
J	Elsevier, JP; FridovichKeil, JL				Elsevier, JP; FridovichKeil, JL			The Q188R mutation in human galactose-1-phosphate uridylyltransferase acts as a partial dominant negative	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRESENILE CATARACT FORMATION; URIDYL TRANSFERASE; ESCHERICHIA-COLI; GALACTOSEMIA; ENZYME; URIDYLTRANSFERASE; PURIFICATION; PROTEIN; CELLS	A longstanding goal in the fields of molecular genetics and biochemistry has been to explain how naturally occurring mutations associated with human metabolic disease impair activity of the enzymes involved. This goal is particularly complex for enzymes composed of multiple subunits, because single mutations may exert both intra- and intersubunit effects on holoenzyme structure and function. We have previously applied a yeast coexpression system for human galactose-1-phosphate uridylyltransferase, a dimeric enzyme associated with galactosemia, to investigate the impact of naturally occurring mutations on subunit association and holoenzyme function (1). Here we describe the purification and characterization of two heterodimers, R333W/wild type (WT) and Q188R/WT, revealing that although the first exhibits similar to 50% wild-type activity, the second exhibits only similar to 15% wild-type activity. Neither heterodimer varied significantly hom the wild type with regard to apparent K-m for either substrate, although Q188R/WT but not R333W/WT heterodimers demonstrated significantly increased thermal sensitivity relative to the wild-type enzyme. These results demonstrate for the first time a partial dominant negative effect caused by a naturally occurring mutation in human galactose-1-phosphate uridylyltransferase.	EMORY UNIV,DEPT MOL & MED GENET,ATLANTA,GA 30322; EMORY UNIV,GRAD PROGRAM BIOCHEM & MOL BIOL,ATLANTA,GA 30322	Emory University; Emory University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046403, R29DK046403] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46403] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANROQUES J, 1981, BIOCHIM BIOPHYS ACTA, V657, P374, DOI 10.1016/0005-2744(81)90323-5; BANROQUES J, 1983, BIOCHIMIE, V65, P7, DOI 10.1016/S0300-9084(83)80023-6; BRIVET M, 1989, J INHERIT METAB DIS, V12, P343, DOI 10.1007/BF03335417; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CRAMER DW, 1994, J CLIN ENDOCR METAB, V79, P1105, DOI 10.1210/jc.79.4.1105; ELSAS LJ, 1995, AM J HUM GENET, V56, P630; Elsas LJ, 1993, INT PEDIATR, V8, P101; Elsevier JP, 1996, P NATL ACAD SCI USA, V93, P7166, DOI 10.1073/pnas.93.14.7166; FREY PA, 1982, METHOD ENZYMOL, V87, P20; FRIDOVICHKEIL JL, 1995, AM J HUM GENET, V56, P640; FRIDOVICHKEIL JL, 1993, P NATL ACAD SCI USA, V90, P398, DOI 10.1073/pnas.90.2.398; FridovichKeil JL, 1995, BIOCHEM MOL MED, V56, P121, DOI 10.1006/bmme.1995.1067; GENTZ R, 1989, P NATL ACAD SCI USA, V86, P821, DOI 10.1073/pnas.86.3.821; HELMER GR, 1981, ARCH BIOCHEM BIOPHYS, V210, P573, DOI 10.1016/0003-9861(81)90223-X; HESTER LS, 1987, J BIOL CHEM, V262, P12092; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; KIM JM, 1990, BIOCHEMISTRY-US, V29, P10590, DOI 10.1021/bi00499a003; LIN LJ, 1994, BBA-PROTEIN STRUCT M, V1206, P97; MARKUS HB, 1977, J BIOL CHEM, V252, P5363; NADLER HL, 1970, P NATL ACAD SCI USA, V67, P976, DOI 10.1073/pnas.67.2.976; NG WG, 1994, HUM GENET, V94, P359; QUIMBY BB, 1996, J BIOL CHEM, V270, P26835; REICHARDT JKV, 1991, AM J HUM GENET, V49, P860; ROBYT JF, 1990, BIOCH TECHNIQUES THE, P297; RUZICKA FJ, 1995, BIOCHEMISTRY-US, V34, P5610, DOI 10.1021/bi00016a036; SAITO S, 1967, J BIOL CHEM, V242, P2362; Sambrook J., 2002, MOL CLONING LAB MANU; SCRIVER CR, 1995, METABOLIC MOL BASES, P3417; Segal S, 1995, METABOLIC MOL BASIS, P967; SEGAWA T, 1979, J BIOL CHEM, V254, P707; SKALKA HW, 1980, ARCH OPHTHALMOL-CHIC, V98, P269; STEVENS RE, 1989, BRIT J OPHTHALMOL, V73, P48, DOI 10.1136/bjo.73.1.48; WEDEKIND JE, 1995, BIOCHEMISTRY-US, V34, P11049, DOI 10.1021/bi00035a010; WILLIAMS VP, 1978, ARCH BIOCHEM BIOPHYS, V191, P182, DOI 10.1016/0003-9861(78)90080-2; WONG LJ, 1974, J BIOL CHEM, V249, P2322; WU JW, 1974, J BIOL CHEM, V249, P7038	36	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32002	32007		10.1074/jbc.271.50.32002	http://dx.doi.org/10.1074/jbc.271.50.32002			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943248	hybrid			2022-12-25	WOS:A1996VY34000039
J	Roshak, AK; Jackson, JR; McGough, K; ChabotFletcher, M; Mochan, E; Marshall, LA				Roshak, AK; Jackson, JR; McGough, K; ChabotFletcher, M; Mochan, E; Marshall, LA			Manipulation of distinct NF kappa B proteins alters interleukin-1 beta-induced human rheumatoid synovial fibroblast prostaglandin E(2) formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); ENDOPEROXIDE SYNTHASE-2 GENE; NUCLEAR FACTOR; ENDOTHELIAL-CELLS; RESPONSE ELEMENT; EXPRESSION; ACTIVATION; SUBUNIT; SITE; LIPOPOLYSACCHARIDE	Interleukin 1 beta (IL-1 beta) up-regulates human rheumatoid synovial fibroblast (RSF) 85-kDa phospholipase A(2) (PLA(2)) and mitogen-inducible cyclooxygenase (COX) II. Promoter regions for these genes contain a motif that closely resembles the ''classic'' NF kappa B consensus site, Immunoblot analysis identified NF kappa B1 (p50), RelA (p65), and c-Rel in RSF, Upon IL-1 beta-stimulation, p65 and c-Rel but not p50 protein levels were reduced suggesting nuclear translocation, IL-1 beta-induced RSF nuclear extracts contained a p65-containing complex, which bound to the classical NF kappa B consensus motif, An NF kappa B classical oligonucleotide decoy produced a concentration-dependent decrease in IL-1-stimulated PGE(2) production (IC50 = similar to 2 mu M), indicating a role of NF kappa B. Utilization of antisense technology showed that p65 but not p50 or c-Rel mediated IL-1 beta-stimulated PGE(2) formation, Treated RSF could not transcribe COX II or 85-kDa PLA(2) mRNA, which reduced their respective proteins, Interestingly, stimulated IL-8 production was not inhibited by the classical NF kappa B decoy but was reduced by treatment with antisense to both p65 and c-Rel supporting preferential binding of c-Rel-p65 to the ''alternative'' IL-8 kappa B motif, Taken together, these data provide the first direct evidence for a role of p65 in COX II and 85-kDa PLA(2) gene induction and support the IL-1 activation and participation of distinct NF kappa B protein dimers in RSF prostanoid and IL-8 formation.	SMITHKLINE BEECHAM PHARMACEUT, IMMUNOPHARMACOL, KING OF PRUSSIA, PA 19406 USA; PHILADELPHIA COLL OSTEOPATH MED, PHILADELPHIA, PA 19131 USA									ANGEL J, 1994, EUR J BIOCHEM, V226, P125, DOI 10.1111/j.1432-1033.1994.tb20033.x; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; CARRASCO D, 1993, DEVELOPMENT, V118, P1221; DAYER JM, 1986, J CLIN INVEST, V77, P645, DOI 10.1172/JCI112350; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GILMAN SC, 1988, ARTHRITIS RHEUM, V31, P127, DOI 10.1002/art.1780310118; GODDARD DH, 1992, CYTOKINE, V4, P377, DOI 10.1016/1043-4666(92)90081-2; GOLFIELD AE, 1993, J EXP BIOL, V178, P1365; Handel ML, 1995, ARTHRITIS RHEUM, V38, P1762, DOI 10.1002/art.1780381209; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231; HULKOWER KI, 1994, ARTHRITIS RHEUM-US, V37, P653, DOI 10.1002/art.1780370508; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; INOUE H, 1994, FEBS LETT, V350, P51, DOI 10.1016/0014-5793(94)00731-4; KOSAKA T, 1994, EUR J BIOCHEM, V221, P889, DOI 10.1111/j.1432-1033.1994.tb18804.x; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; MIYASHITA A, 1995, NUCLEIC ACIDS RES, V23, P293, DOI 10.1093/nar/23.2.293; MORII H, 1994, BIOCHEM BIOPH RES CO, V205, P6, DOI 10.1006/bbrc.1994.2621; MULLER JM, 1993, IMMUNOBIOLOGY, V187, P233; NARAYANAN R, 1993, MOL CELL BIOL, V13, P3802, DOI 10.1128/MCB.13.6.3802; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PARRY GCN, 1994, J BIOL CHEM, V269, P20823; ROSHAK A, 1994, J BIOL CHEM, V269, P25999; Roshak A, 1996, J RHEUMATOL, V23, P420; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Schuster RL, 1993, P ANN S JAP LANDSL S, P1; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIPE JD, 1994, MEDIAT INFLAMM, V3, P243, DOI 10.1155/S0962935194000359; SOKOLOSKI JA, 1993, BLOOD, V82, P625; TANAKA H, 1994, NUCLEIC ACIDS RES, V22, P3069, DOI 10.1093/nar/22.15.3069; TAY A, 1994, BIOCHEM J, V304, P417, DOI 10.1042/bj3040417; TAY A, 1995, GENOMICS, V26, P138, DOI 10.1016/0888-7543(95)80093-2; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; VELLANOWETH RL, 1994, LAB INVEST, V70, P784; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; ZIEGLERHEITBROCK HWL, 1993, J IMMUNOL, V151, P6986	39	165	176	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31496	31501		10.1074/jbc.271.49.31496	http://dx.doi.org/10.1074/jbc.271.49.31496			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940164	hybrid			2022-12-25	WOS:A1996VW68600075
J	Swift, LL				Swift, LL			Role of the golgi apparatus in the phosphorylation of apolipoprotein B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; RAT MAMMARY-GLAND; HEP G2 CELLS; CASEIN KINASE-ACTIVITY; ENDOPLASMIC-RETICULUM; INTRACELLULAR DEGRADATION; BREFELDIN-A; OLEIC-ACID; APO-B; SECRETION	Rat hepatic Golgi apparatus-rich fractions were utilized in an in vitro phosphorylation system containing [gamma-P-32]ATP to investigate the phosphorylation of apolipoproteins (ape) B48 and B100, Our results demonstrate that the Golgi apparatus contains a kinase(s) that phosphorylates both apoB48 and apoB100 as well as 290- and 460-kDa proteins recognized by antibody to apoB, We refer to the latter proteins as apoB57 and apoB90, respectively. Phosphorylations in the presence of Triton X-100, which increases the permeability of the membranes, or alamethicin, an ionophore that facilitates transmembrane diffusion of ATP, indicate that the active site of the kinase is on the luminal side of the membranes, However, studies with EDTA and EGTA, which are inhibitory to the kinase, suggest binding sites for Mg2+ and perhaps Ca2+ on the cytosolic membrane face. Phosphorylation of apoB was not stimulated by cAMP nor inhibited by protein kinase inhibitor peptide (5-24), indicating that cAMP dependent protein kinase was not involved in the phosphorylation process, Sodium carbonate treatment of the phosphorylated fraction, which permits separation of membrane and luminal contents, revealed that phosphorylated apoB90 and apoB57 are associated primarily with the membrane, whereas phosphorylated apoB48 is found in luminal contents as well as with the membranes, Phosphorylated apoB100 was found primarily with the membrane fraction, No evidence was found for phosphorylation of apoB in rough endoplasmic reticulum fractions. These studies demonstrate the importance of the Golgi apparatus as a subcellular site for the phosphorylation of apoB and suggest that apoB phosphorylation may be important in the assembly and secretion of apoB-containing lipoproteins.			Swift, LL (corresponding author), VANDERBILT UNIV,MED CTR N,SCH MED,DEPT PATHOL,C-3321,NASHVILLE,TN 37232, USA.							ADELI K, 1994, J BIOL CHEM, V269, P9166; Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; BEG ZH, 1994, J PROTEIN CHEM, V13, P509; BESCH HR, 1977, J BIOL CHEM, V252, P7905; BINGHAM EW, 1972, J BIOL CHEM, V247, P8193; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOSTROM K, 1986, J BIOL CHEM, V261, P3800; CAPASSO JM, 1989, J BIOL CHEM, V264, P5233; CAPASSO JM, 1985, J BIOL CHEM, V260, P4879; CAREY DJ, 1981, J BIOL CHEM, V256, P989; CARTWRIGHT IJ, 1992, BIOCHEM J, V285, P153, DOI 10.1042/bj2850153; DASHTI N, 1989, J LIPID RES, V30, P1365; DAVIS RA, 1984, J BIOL CHEM, V259, P3383; DIXON JL, 1993, J LIPID RES, V34, P167; FARQUHAR MG, 1974, J CELL BIOL, V60, P8, DOI 10.1083/jcb.60.1.8; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; FURUKAWA S, 1992, J BIOL CHEM, V267, P22630; GOLDFISC.S, 1971, J HISTOCHEM CYTOCHEM, V19, P349, DOI 10.1177/19.6.349; HIGGINS JA, 1988, FEBS LETT, V232, P405, DOI 10.1016/0014-5793(88)80780-4; HOEG JM, 1988, J LIPID RES, V29, P1215; HUANG G, 1988, BIOCHEMISTRY-US, V27, P1395, DOI 10.1021/bi00405a001; JACKSON TK, 1990, J CLIN INVEST, V86, P1746, DOI 10.1172/JCI114900; LEIGHTON JK, 1990, J LIPID RES, V31, P1663; MOBERLY JB, 1990, BIOCHIM BIOPHYS ACTA, V1042, P70, DOI 10.1016/0005-2760(90)90058-6; MORRE DJ, 1969, BIOCHEM BIOPH RES CO, V37, P813; PULLINGER CR, 1989, J LIPID RES, V30, P1065; REUBEN MA, 1988, J LIPID RES, V29, P1337; RINDRESS D, 1993, J BIOL CHEM, V268, P5139; ROSA P, 1992, J BIOL CHEM, V267, P12227; SATO R, 1990, J BIOL CHEM, V265, P11880; SIUTAMANGANO P, 1982, J BIOL CHEM, V257, P1463; SPARKS JD, 1988, J BIOL CHEM, V263, P5001; SWIFT LL, 1995, J LIPID RES, V36, P395; SWIFT LL, 1984, J LIPID RES, V25, P1; VARRO A, 1993, BIOCHEM J, V295, P813, DOI 10.1042/bj2950813; VEGH M, 1994, BBA-PROTEIN STRUCT M, V1205, P49, DOI 10.1016/0167-4838(94)90090-6; WANG CN, 1995, J BIOL CHEM, V270, P24924, DOI 10.1074/jbc.270.42.24924; WANG SY, 1982, J BIOL CHEM, V257, P3837; WEST DW, 1984, BIOCHEM J, V219, P181, DOI 10.1042/bj2190181; WEST DW, 1983, EUR J BIOCHEM, V137, P215, DOI 10.1111/j.1432-1033.1983.tb07817.x; WINDMUELLER HG, 1985, J LIPID RES, V26, P70; YAO ZM, 1994, BBA-LIPID LIPID MET, V1212, P152, DOI 10.1016/0005-2760(94)90249-6	43	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31491	31495						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940163				2022-12-25	WOS:A1996VW68600074
J	Urban, RJ; Nagamani, M; Bodenburg, Y				Urban, RJ; Nagamani, M; Bodenburg, Y			Tumor necrosis factor alpha inhibits transcriptional activity of the porcine P-45011A insulin-like growth factor response element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IGF-I RECEPTOR; GRANULOSA-CELLS; RIBONUCLEIC-ACID; CORPUS-LUTEUM; EXPRESSION; GENE; PROGESTERONE; DOMAIN	We investigated the effects of tumor necrosis factor alpha (TNF alpha) on the transcriptional activity of the porcine P-45011A (P450scc) insulin-like growth factor response element (IGFRE), TNF alpha inhibited insulin-like growth factor-I (IGF-I)-stimulated P450scc mRNA concentrations in cultures of porcine granulosa cells. Transient transfection experiments in granulosa cells with deletion P450scc/luciferase constructs showed that TNF alpha inhibited the transcriptional activity of the IGFRE. IGF-I binding and IGF-I receptor mRNA concentrations in porcine granulosa cells were not inhibited by TNF alpha. Electrophoretic mobility shift assay with nuclear extract protein from porcine granulosa cells treated with IGF-I and TNF alpha showed that Sp1 and a second transcription factor, P2, bound to the IGFRE, While IGF-I treatment increased the binding activity of both factors, TNF alpha specifically inhibited the IGF-I stimulated binding activity of P2. Transient transfection studies done in mouse fibroblasts overexpressing the IGF-I receptor (NWTb3) with the porcine IGFRE (three repeats) in an SV40/luciferase construct also showed TNF alpha inhibited IGF-I-stimulated reporter gene expression. We conclude that TNF alpha inhibits the transcriptional activity of the porcine P450scc IGFRE by preventing IGF-I-stimulated binding of P2.	UNIV TEXAS,MED BRANCH,DEPT OBSTET & GYNECOL,DIV REPROD ENDOCRINOL,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston	Urban, RJ (corresponding author), UNIV TEXAS,MED BRANCH,DIV ENDOCRINOL,DEPT INTERNAL MED,3142 MRB,GALVESTON,TX 77555, USA.				NCI NIH HHS [CA45181] Funding Source: Medline; NICHD NIH HHS [HD28393] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028393] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA045181] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADASHI EY, 1990, AM J OBSTET GYNECOL, V162, P889, DOI 10.1016/0002-9378(90)91289-O; ADASHI EY, 1990, ENDOCR REV, V11, P454, DOI 10.1210/edrv-11-3-454; BLAKESLEY VA, 1995, J BIOL CHEM, V270, P2764, DOI 10.1074/jbc.270.6.2764; BRASIER AR, 1991, METHODS NEUROSCI, V5, P108; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Gadsby JE, 1996, BIOL REPROD, V54, P339, DOI 10.1095/biolreprod54.2.339; HEHNKEVAGNONI KE, 1995, BIOL REPROD, V53, P1339, DOI 10.1095/biolreprod53.6.1339; HENTHORN P, 1988, P NATL ACAD SCI USA, V85, P6342, DOI 10.1073/pnas.85.17.6342; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; KATO H, 1994, MOL ENDOCRINOL, V8, P40, DOI 10.1210/me.8.1.40; KATO H, 1993, J BIOL CHEM, V268, P2655; KNOLL BJ, 1983, NUCLEIC ACIDS RES, V11, P6733, DOI 10.1093/nar/11.19.6733; Kroder G, 1996, J CLIN INVEST, V97, P1471, DOI 10.1172/JCI118569; LABARCA C, 1980, ANAL BIOCHEM, V102, P340; LAZARUS DD, 1993, LYMPHOKINE CYTOK RES, V12, P219; MULHERON GW, 1989, NUCLEIC ACIDS RES, V17, P1773, DOI 10.1093/nar/17.4.1773; NAGAMANI M, 1979, AM J OBSTET GYNECOL, V134, P674, DOI 10.1016/0002-9378(79)90649-5; RICHARDS RG, 1994, BIOL REPROD, V51, P1285, DOI 10.1095/biolreprod51.6.1285; SHAW DW, 1995, BIOL REPROD, V53, P847, DOI 10.1095/biolreprod53.4.847; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; Urban RJ, 1996, J BIOL CHEM, V271, P31695, DOI 10.1074/jbc.271.49.31695; URBAN RJ, 1990, ENDOCRINOLOGY, V127, P2481, DOI 10.1210/endo-127-5-2481; URBAN RJ, 1994, J BIOL CHEM, V269, P25761; URBAN RJ, 1994, AM J PHYSIOL, V267, pE115, DOI 10.1152/ajpendo.1994.267.1.E115; VanDessel HJHMT, 1996, J CLIN ENDOCR METAB, V81, P1224; VELDHUIS JD, 1991, ENDOCRINOLOGY, V129, P641, DOI 10.1210/endo-129-2-641	27	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31699	31703		10.1074/jbc.271.49.31699	http://dx.doi.org/10.1074/jbc.271.49.31699			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940192	hybrid			2022-12-25	WOS:A1996VW68600103
J	Wang, XHS; Diener, K; Jannuzzi, D; Trollinger, D; Tan, TH; Lichenstein, H; Zukowski, M; Yao, ZB				Wang, XHS; Diener, K; Jannuzzi, D; Trollinger, D; Tan, TH; Lichenstein, H; Zukowski, M; Yao, ZB			Molecular cloning and characterization of a novel protein kinase with a catalytic domain homologous to mitogen-activated protein kinase kinase kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; MAP KINASE; MAMMALIAN-CELLS; PHOSPHORYLATION; RAF-1; SPECIFICITY; PROGRESS; CASCADE; FAMILY; STRESS	Mitogen-activated protein kinase (MAPK) signaling cascades include MAPK or extracellular signal-regulated kinase (ERK), MAPK kinase (MKK or MEK), and MAPK kinase kinase (MAPKKK or MEKK). MAPKK kinase/MEKK phosphorylates and activates its downstream protein kinase, MAPK kinase/MEK, which in turn activates MAPK. We report herein the isolation of a cDNA encoding a novel protein kinase designated MAP-KKK5 from a human macrophage library. The nucleotide sequence predicts that MAP-KKK5 encodes an open reading frame of 1374 amino acids with all 11 kinase subdomains. The putative catalytic domain of MAP-KKK5 shows significant sequence homology to the kinase domains of the MAPKKK/MEKK level protein kinases from mouse MEKK2 and -3, Drosophila melanogaster PK92B, Saccharomyces cerevisiae STE11, and Schizosaccharomyces pombe BYR2. Northern blot analysis showed that MAPKKK5 transcript is abundantly expressed in human heart and pancreas. When transiently expressed in COS and 293 cells, MAPKKK5 markedly activated c-Jun N-terminal kinase or stress-activated protein kinase, but not MAPK/ERK. Furthermore, MAPKKK5 that was immunoprecipitated from transfected 293 cells was able to phosphorylate and activate MKK4 in vitro, suggesting that MAPKKK5 may be an upstream activator of MKK4 in the c-Jun N terminal kinase pathway.	AMGEN INC,BOULDER,CO 80301; BAYLOR COLL MED,DEPT MICROBIOL & IMMUNOL,HOUSTON,TX 77030	Amgen; Baylor College of Medicine			Tan, Tse-Hua/ABD-7080-2021; Tan, Tse-Hua/E-3983-2010	Tan, Tse-Hua/0000-0003-4969-3170; Tan, Tse-Hua/0000-0003-4969-3170				AHMAD MF, 1994, NATURE, V369, P156; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Cobb MH, 1991, CURR OPIN CELL BIOL, V3, P1025, DOI 10.1016/0955-0674(91)90124-H; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COBH MH, 1995, J BIOL CHEM, V270, P14843; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; NEBREDA AR, 1993, FEBS LETT, V333, P183, DOI 10.1016/0014-5793(93)80401-F; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PHAM CD, 1995, ONCOGENE, V10, P1683; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; WASSARMAN DA, 1969, GENE AMST, V169, P283; XU SC, 1995, P NATL ACAD SCI USA, V92, P6808, DOI 10.1073/pnas.92.15.6808; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	37	132	147	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31607	31611						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940179				2022-12-25	WOS:A1996VW68600090
J	Eble, JA; Ries, A; Lichy, A; Mann, K; Stanton, H; Gavrilovic, J; Murphy, G; Kuhn, K				Eble, JA; Ries, A; Lichy, A; Mann, K; Stanton, H; Gavrilovic, J; Murphy, G; Kuhn, K			The recognition sites of the integrins alpha(1)beta(1) and alpha(2)beta(1) within collagen IV are protected against gelatinase A attack in the native protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE COLLAGEN; POLYMORPHONUCLEAR LEUKOCYTES; PARTIAL-PURIFICATION; ENZYMATIC-PROPERTIES; TUMOR; DOMAIN; MATRIX; PROCOLLAGEN; ACTIVATION; CELLS	The susceptibility of three different solubilized forms of type IV collagen to gelatinase A cleavage and the concomitant effects on cell and integrin binding have been assessed, Dithiothreitol-solubilized Engelbreth-Holm Swarm (EHS) type TV collagen with disrupted intramolecular disulfide bonds in the CE3[N] region was cleaved N-terminally to the CB3[IV] region into the two characteristic 100-300-nm fragments at 30 degrees C and was totally degraded at 37 degrees C. This was reflected in the partial or total loss of the alpha(1) beta(1) and alpha(2) beta(1) integrin binding sites within this region, The ability of gelatinase A to cleave EHS type TV collagen preparations with intact interchain disulfide bonds in CB3[IV] only occurred at higher temperatures. Furthermore, no effect on binding of cells or isolated integrins to the gelatinase-treated collagen could be detected after treatment at 37 degrees C, Dimeric collagen TV of human placenta with intact disulfide bonds in the CB3[IV] region was not degraded at all by gelatinase A at 37 degrees C.	MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY; STRANGEWAYS RES LAB,DEPT CELL & MOL BIOL,CAMBRIDGE CB1 4RN,ENGLAND	Max Planck Society			Mann, Karlheinz/C-4254-2008	Gavrilovic, Jelena/0000-0002-5312-1784; STANTON, HEATHER/0000-0002-3427-5614				BOND MD, 1984, BIOCHEMISTRY-US, V23, P3077, DOI 10.1021/bi00308a035; BRAZEL D, 1988, EUR J BIOCHEM, V172, P35, DOI 10.1111/j.1432-1033.1988.tb13852.x; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; EBLE JA, 1993, EMBO J, V12, P4795, DOI 10.1002/j.1460-2075.1993.tb06168.x; FESSLER LI, 1984, J BIOL CHEM, V259, P9783; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KERN A, 1993, EUR J BIOCHEM, V215, P151, DOI 10.1111/j.1432-1033.1993.tb18017.x; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; Kuhn K, 1994, Trends Cell Biol, V4, P256, DOI 10.1016/0962-8924(94)90124-4; KUHN K, 1981, FEBS LETT, V125, P123, DOI 10.1016/0014-5793(81)81012-5; KUHN K, 1994, MATRIX BIOL, V14, P439; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIOTTA LA, 1979, P NATL ACAD SCI USA, V76, P2268, DOI 10.1073/pnas.76.5.2268; LIOTTA LA, 1981, BIOCHEMISTRY-US, V20, P100, DOI 10.1021/bi00504a017; MACKAY AR, 1990, J BIOL CHEM, V265, P21929; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MURPHY G, 1989, BIOCHEM J, V258, P463, DOI 10.1042/bj2580463; MURPHY G, 1982, BIOCHEM J, V203, P209, DOI 10.1042/bj2030209; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; MURPHY G, 1983, COLLAGEN REL RES, V3, P158; OBERBAUMER I, 1982, EMBO J, V1, P805, DOI 10.1002/j.1460-2075.1982.tb01251.x; OKADA Y, 1992, J BIOL CHEM, V267, P21712; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; RIES A, 1995, J BIOL CHEM, V270, P23790, DOI 10.1074/jbc.270.40.23790; SALO T, 1983, J BIOL CHEM, V258, P3058; SIEBOLD B, 1988, EUR J BIOCHEM, V176, P617, DOI 10.1111/j.1432-1033.1988.tb14321.x; SIEBOLD B, 1987, EUR J BIOCHEM, V168, P569, DOI 10.1111/j.1432-1033.1987.tb13455.x; STARK M, 1968, EUR J BIOCHEM, V6, P534, DOI 10.1111/j.1432-1033.1968.tb00477.x; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; TIMPL R, 1981, EUR J BIOCHEM, V120, P203, DOI 10.1111/j.1432-1033.1981.tb05690.x; VANDENBERG P, 1991, J CELL BIOL, V113, P1475, DOI 10.1083/jcb.113.6.1475; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; YURCHENCO PD, 1987, J CELL BIOL, V105, P2559, DOI 10.1083/jcb.105.6.2559	34	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30964	30970		10.1074/jbc.271.48.30964	http://dx.doi.org/10.1074/jbc.271.48.30964			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940084	hybrid			2022-12-25	WOS:A1996VV15800101
J	Graceffa, P; Adam, LP; Morgan, KG				Graceffa, P; Adam, LP; Morgan, KG			Strong interaction between caldesmon and calponin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; LIGHT-CHAIN PHOSPHORYLATION; ACTIVATED PROTEIN-KINASE; KILODALTON ACTIN-BINDING; DISULFIDE CROSS-LINKING; THIN-FILAMENTS; SEQUENCE-ANALYSIS; CHICKEN GIZZARD; H-CALDESMON; C-TERMINUS	Caldesmon was labeled at either Cys-153 in the NH2-terminal domain or Cys-580 in the COOH terminal domain with a 6-acryloyl-2-dimethylaminonaphthalene (acrylodan) fluorescence probe. The addition of smooth muscle calponin to Cys-580-labeled caldesmon resulted in an 18% drop in fluorescence intensity, which titrated with a stoichiometry of 0.9 and a binding constant of 9.5 x 10(7) M(-1). For Cys-153-labeled caldesmon, there was no change in fluorescence upon adding calponin. These findings indicate strong binding between calponin and the COOH-domain of caldesmon. The association was sensitive to ionic strength, suggesting that ionic interactions between calponin, a basic protein, and caldesmon, an acidic protein, contribute to the stabilization of the protein complex. That non-muscle acidic calponin interacts with caldesmon with a much reduced association constant of 3.5 x 10(6) M(-1) supports such a model. The binding between acidic calponin and caldesmon is strengthened to 1.8 x 10(7) M(-1) in the presence of Ca2+, which might bind to acidic residues of the calponin and partially neutralize its negative charge. The strong, specific binding between calponin and caldesmon suggests that this interaction occurs within smooth muscle cells and possibly plays a role in the regulation of contraction.			Graceffa, P (corresponding author), BOSTON BIOMED RES INST,20 STANIFORD ST,BOSTON,MA 02114, USA.			Morgan, Kathleen/0000-0003-3300-3630	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056035] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR041637, R01AR030917] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56035] Funding Source: Medline; NIAMS NIH HHS [AR-30917, AR-41637] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAM LP, 1992, FEBS LETT, V302, P223, DOI 10.1016/0014-5793(92)80446-N; ADAM LP, 1993, FEBS LETT, V322, P56, DOI 10.1016/0014-5793(93)81110-L; ADAM LP, 1996, BIOCH SMOOTH MUSCLE, P167; APPLEGATE D, 1994, J BIOL CHEM, V269, P10683; BRYAN J, 1989, J BIOL CHEM, V264, P13873; FURST DO, 1986, EMBO J, V5, P251, DOI 10.1002/j.1460-2075.1986.tb04206.x; GERTHOFFER WT, 1991, AM J PHYSIOL, V261, pL15, DOI 10.1152/ajplung.1991.261.2.L15; GERTHOFFER WT, 1994, CAN J PHYSIOL PHARM, V72, P1410, DOI 10.1139/y94-203; GIMONA M, 1996, BIOCH SMOOTH MUSCLE, P91; GONG BJ, 1993, J BIOCHEM-TOKYO, V114, P453, DOI 10.1093/oxfordjournals.jbchem.a124197; GRABAREK Z, 1995, BIOCHEMISTRY-US, V34, P11872, DOI 10.1021/bi00037a027; GRACEFFA P, 1993, ARCH BIOCHEM BIOPHYS, V307, P21, DOI 10.1006/abbi.1993.1554; GRACEFFA P, 1988, J BIOL CHEM, V263, P14196; GRACEFFA P, 1991, J BIOL CHEM, V266, P20305; GRACEFFA P, 1995, J BIOL CHEM, V270, P30187; GRACEFFA P, 1992, ARCH BIOCHEM BIOPHYS, V297, P46, DOI 10.1016/0003-9861(92)90639-E; GRACEFFA P, 1993, BIOCHEM J, V294, P63, DOI 10.1042/bj2940063; HAEBERLE JR, 1994, CAN J PHYSIOL PHARM, V72, P1400, DOI 10.1139/y94-202; HAEBERLE JR, 1994, J BIOL CHEM, V269, P12424; Horowitz A, 1996, AM J PHYSIOL-HEART C, V270, pH1858, DOI 10.1152/ajpheart.1996.270.5.H1858; ITOH T, 1995, J BIOL CHEM, V270, P20400, DOI 10.1074/jbc.270.35.20400; JAWOROWSKI A, 1995, FEBS LETT, V365, P167, DOI 10.1016/0014-5793(95)00451-E; KAMM KE, 1989, ANNU REV PHYSIOL, V51, P299; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; KATSUYAMA H, 1992, J BIOL CHEM, V267, P14555; KHALIL RA, 1995, CIRC RES, V76, P1101, DOI 10.1161/01.RES.76.6.1101; LEHMAN W, 1991, J MUSCLE RES CELL M, V12, P221, DOI 10.1007/BF01745110; LEHMAN W, 1987, BIOCHIM BIOPHYS ACTA, V914, P35, DOI 10.1016/0167-4838(87)90158-0; LESZYK J, 1989, BIOCHEM BIOPH RES CO, V160, P1371, DOI 10.1016/S0006-291X(89)80155-X; Mabuchi K, 1996, J MUSCLE RES CELL M, V17, P243, DOI 10.1007/BF00124246; MAKUCH R, 1991, BIOCHEM J, V280, P33, DOI 10.1042/bj2800033; MANI RS, 1996, BIOCH SMOOTH MUSCLE, P105; MARSTON SB, 1991, BIOCHEM J, V279, P1; MORNET D, 1988, BIOCHEM BIOPH RES CO, V154, P564, DOI 10.1016/0006-291X(88)90177-5; MORRIS EP, 1984, BIOCHEMISTRY-US, V23, P2214, DOI 10.1021/bi00305a018; NORTH AJ, 1994, J CELL SCI, V107, P437; OBARA K, 1996, AM J PHYSIOL, V270, pC461; PARKER CA, 1994, AM J PHYSIOL-CELL PH, V267, pC1262, DOI 10.1152/ajpcell.1994.267.5.C1262; PFITZER G, 1993, P NATL ACAD SCI USA, V90, P5904, DOI 10.1073/pnas.90.13.5904; PRENDERGAST FG, 1983, J BIOL CHEM, V258, P7541; SMALL JV, 1995, BIOESSAYS, V17, P785, DOI 10.1002/bies.950170908; SMALL JV, 1992, EUR J BIOCHEM, V208, P559, DOI 10.1111/j.1432-1033.1992.tb17220.x; SMITH CWJ, 1987, J BIOL CHEM, V262, P116; SOBUE K, 1991, J BIOL CHEM, V266, P12115; SOBUE K, 1981, P NATL ACAD SCI-BIOL, V78, P5652, DOI 10.1073/pnas.78.9.5652; SZAPACENKO A, 1985, FEBS LETT, V192, P9; TAKAHASHI K, 1991, J BIOL CHEM, V266, P13284; VANCOMPERNOLLE K, 1990, FEBS LETT, V274, P146, DOI 10.1016/0014-5793(90)81350-W; VELAZ L, 1989, J BIOL CHEM, V264, P9602; WALSH MP, 1994, CAN J PHYSIOL PHARM, V72, P919, DOI 10.1139/y94-130; WINDER SJ, 1991, ADV EXP MED BIOL, V304, P37; ZHANG YW, 1994, CAN J PHYSIOL PHARM, V72, P1386, DOI 10.1139/y94-200	52	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30336	30339		10.1074/jbc.271.48.30336	http://dx.doi.org/10.1074/jbc.271.48.30336			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8939993	hybrid			2022-12-25	WOS:A1996VV15800010
J	Meric, F; Searfoss, AM; Wormington, M; Wolffe, AP				Meric, F; Searfoss, AM; Wormington, M; Wolffe, AP			Masking and unmasking maternal mRNA - The role of polyadenylation, transcription, splicing, and nuclear history	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS OOCYTE MATURATION; MESSENGER-RIBONUCLEOPROTEIN PARTICLES; ACID BINDING-PROTEINS; CYTOPLASMIC POLYADENYLATION; TRANSLATIONAL REGULATION; POLY(A) POLYMERASE; RNA TRANSLATION; SOMATIC-CELLS; FROG OOCYTES; 3' UTR	We establish that masked mRNAs synthesized from exogenous plasmid templates microinjected into the nuclei of Xenopus oocytes are translationally activated (unmasked) on oocyte maturation concomitant with polyadenylation. Synthetic mRNA injected into the cytoplasm of the oocyte is translated over an order of magnitude more efficiently than is the cognate mRNA synthesized in vivo. Both mRNA synthesized in vivo and mRNA microinjected into the oocyte cytoplasm require a cytoplasmic polyadenylation element in the 3'-untranslated region to activate translation on maturation. Although polyadenylation upon oocyte maturation can relieve the translational repression of mRNA synthesized in vivo, the excision of an intron within the nucleus does not relieve repression. We suggest that the translational repression coupled to the transcription process will more effectively repress inappropriate gene expression in the oocyte and offer the potential to achieve a wider range of gene regulation.	NICHHD,MOL EMBRYOL LAB,NIH,BETHESDA,MD 20892; UNIV VIRGINIA,DEPT BIOL,CHARLOTTESVILLE,VA 22903	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Virginia					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017691] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD 17691] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALMOUZNI G, 1993, GENE DEV, V7, P2033, DOI 10.1101/gad.7.10.2033; BACHVAROVA RF, 1992, CELL, V69, P895, DOI 10.1016/0092-8674(92)90606-D; BALLANTYNE S, 1995, RNA, V1, P64; BOUVET P, 1994, CELL, V77, P931, DOI 10.1016/0092-8674(94)90141-4; BOUVET P, 1995, J BIOL CHEM, V270, P28297; BRADDOCK M, 1990, CELL, V62, P1123, DOI 10.1016/0092-8674(90)90389-V; BRADDOCK M, 1994, NUCLEIC ACIDS RES, V22, P5255, DOI 10.1093/nar/22.24.5255; BRADDOCK M, 1989, CELL, V58, P269, DOI 10.1016/0092-8674(89)90841-6; BRADDOCK M, 1991, NATURE, V350, P439, DOI 10.1038/350439a0; CONAWAY L, 1985, P NATL ACAD SCI USA, V82, P3949; Davidson E. H., 1986, GENE ACTIVITY EARLY; EVDOKIMOVA VM, 1995, J BIOL CHEM, V270, P3186, DOI 10.1074/jbc.270.7.3186; FOX CA, 1992, EMBO J, V11, P5021, DOI 10.1002/j.1460-2075.1992.tb05609.x; FOX CA, 1990, GENE DEV, V4, P2287, DOI 10.1101/gad.4.12b.2287; GEBAUER F, 1995, MOL CELL BIOL, V15, P1422; GUNKEL N, 1995, NUCLEIC ACIDS RES, V23, P405, DOI 10.1093/nar/23.3.405; Gurdon J.B., 1977, Methods Cell Biol, V16, P125; HAKE LE, 1994, CELL, V79, P617, DOI 10.1016/0092-8674(94)90547-9; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HEASMAN J, 1991, METHOD CELL BIOL, V34, P214; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; KICK D, 1987, NUCLEIC ACIDS RES, V15, P4099, DOI 10.1093/nar/15.10.4099; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; MCGREW LL, 1989, GENE DEV, V3, P803, DOI 10.1101/gad.3.6.803; MURRAY MT, 1991, J CELL BIOL, V112, P1, DOI 10.1083/jcb.112.1.1; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; RANJAN M, 1993, GENE DEV, V7, P1725, DOI 10.1101/gad.7.9.1725; RICHTER JD, 1984, NATURE, V309, P378, DOI 10.1038/309378a0; RICHTER JD, 1991, BIOESSAYS, V13, P179, DOI 10.1002/bies.950130406; SALLES FJ, 1992, GENE DEV, V6, P1202, DOI 10.1101/gad.6.7.1202; SHEETS MD, 1995, NATURE, V374, P511, DOI 10.1038/374511a0; SHI YB, 1994, DEV BIOL, V161, P48, DOI 10.1006/dbio.1994.1006; STANDART N, 1994, CURR BIOL, V4, P939, DOI 10.1016/S0960-9822(00)00212-8; Standart Nancy, 1992, Seminars in Developmental Biology, V3, P367; TAFURI SR, 1993, J BIOL CHEM, V268, P24255; TOYODA T, 1992, DEV BIOL, V153, P150, DOI 10.1016/0012-1606(92)90099-3; VARNUM SM, 1990, GENE DEV, V4, P2278, DOI 10.1101/gad.4.12b.2278; WICKENS M, 1992, SEM DEV BIOL, V3, P399; WICKENS MP, 1983, J MOL BIOL, V163, P1, DOI 10.1016/0022-2836(83)90027-X; Wolffe A., 1995, CHROMATIN STRUCTURE; Wolffe AP, 1996, INT J BIOCHEM CELL B, V28, P247, DOI 10.1016/1357-2725(95)00141-7; WOLFFE AP, 1992, NEW BIOL, V4, P290; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; WOODLAND HR, 1979, CELL, V18, P165, DOI 10.1016/0092-8674(79)90365-9; WORMINGTON M, 1994, BIOESSAYS, V16, P533, DOI 10.1002/bies.950160804; WORMINGTON M, 1991, METHOD CELL BIOL, V36, P167; Wormington M, 1996, EMBO J, V15, P900, DOI 10.1002/j.1460-2075.1996.tb00424.x; Wormington M, 1993, CURR OPIN CELL BIOL, V5, P950, DOI 10.1016/0955-0674(93)90075-2	48	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30804	30810		10.1074/jbc.271.48.30804	http://dx.doi.org/10.1074/jbc.271.48.30804			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940061	hybrid			2022-12-25	WOS:A1996VV15800078
J	Mikhailov, VS; Bogenhagen, DF				Mikhailov, VS; Bogenhagen, DF			Termination within oligo(dT) tracts in template DNA by DNA polymerase gamma occurs with formation of a DNA triplex structure and is relieved by mitochondrial single-stranded DNA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS; SACCHAROMYCES-CEREVISIAE; SUBSTRATE-SPECIFICITY; 3'->5' EXONUCLEASE; CATALYTIC SUBUNIT; ESCHERICHIA-COLI; KLENOW FRAGMENT; POLYMERIZATION; REPLICATION; IDENTIFICATION	Xenopus laevis DNA polymerase gamma (pol gamma) exhibits low activity on a poly(dT)-oligo(dA) primer-template. We prepared a single-stranded phagemid template containing a dT(41) sequence to test the ability of pol gamma to extend a primer through a defined oligo(dT) tract. pol gamma terminates in the center of this dT,, sequence. This replication arrest is abrogated by addition of single stranded DNA-binding protein or by substitution of 7-deaza-dATP for dATP. These features are consistent with the formation of a T . A*T DNA tripler involving the primer stem. Replication arrest occurs under conditions that permit highly processive DNA synthesis by pol gamma. A similar replication arrest occurs for T7 DNA polymerase, which is also a highly processive DNA polymerase. These results suggest the possibility that DNA tripler formation can occur prior to dissociation of DNA polymerase. Primers with S'-oligo(dA) termini annealed to a template with a longer oligo(dT) tract are not efficiently extended by pol gamma unless single-stranded DNA-binding protein is added. Thus, one of the functions of single-stranded DNA-binding protein in mtDNA maintenance may be to enable pol gamma to successfully replicate through dT-rich sequences.	SUNY STONY BROOK,DEPT PHARMACOL SCI,STONY BROOK,NY 11794; RUSSIAN ACAD SCI,INST DEV BIOL,MOSCOW 117808,RUSSIA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Russian Academy of Sciences; Koltzov Institute of Developmental Biology of the Russian Academy of Sciences			Mikhailov, Victor S/O-2063-2016		NIGMS NIH HHS [GM29681] Funding Source: Medline; PHS HHS [04068] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029681] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARAN N, 1991, P NATL ACAD SCI USA, V88, P507, DOI 10.1073/pnas.88.2.507; BEESE LS, 1993, BIOCHEMISTRY-US, V32, P14095, DOI 10.1021/bi00214a004; BOGENHAGEN D, 1979, COLD SPRING HARB SYM, V43, P253, DOI 10.1101/SQB.1979.043.01.031; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6; CURTH U, 1994, EUR J BIOCHEM, V221, P435, DOI 10.1111/j.1432-1033.1994.tb18756.x; DAYN A, 1992, P NATL ACAD SCI USA, V89, P11406, DOI 10.1073/pnas.89.23.11406; FOURY F, 1989, J BIOL CHEM, V264, P20552; FRANKKAMENETSKII MD, 1995, ANNU REV BIOCHEM, V64, P65, DOI 10.1146/annurev.bi.64.070195.000433; GHRIR R, 1991, ARCH BIOCHEM BIOPHYS, V291, P395, DOI 10.1016/0003-9861(91)90152-9; GRAY H, 1992, J BIOL CHEM, V267, P5835; HACIA JG, 1994, BIOCHEMISTRY-US, V33, P6192, DOI 10.1021/bi00186a019; HOKE GD, 1990, ARCH BIOCHEM BIOPHYS, V282, P116, DOI 10.1016/0003-9861(90)90094-F; INSDORF NF, 1989, J BIOL CHEM, V264, P21498; INSDORF NF, 1989, J BIOL CHEM, V264, P21491; Kornberg A., 1992, DNA REPLICATION; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; KUNKEL TA, 1988, J BIOL CHEM, V263, P4450; LAPIDOT A, 1989, NUCLEIC ACIDS RES, V17, P883, DOI 10.1093/nar/17.3.883; LONGLEY MJ, 1991, J BIOL CHEM, V266, P24702; MIGNOTTE B, 1988, EUR J BIOCHEM, V174, P479, DOI 10.1111/j.1432-1033.1988.tb14123.x; Mikhailov VS, 1996, J BIOL CHEM, V271, P18939, DOI 10.1074/jbc.271.31.18939; OLSON MW, 1992, J BIOL CHEM, V267, P23136; ROPP PA, 1995, GENE, V165, P103, DOI 10.1016/0378-1119(95)00412-Y; SAMADASHWILY GM, 1993, EMBO J, V12, P4975, DOI 10.1002/j.1460-2075.1993.tb06191.x; SAMADASHWILY GM, 1994, GENE, V149, P127, DOI 10.1016/0378-1119(94)90421-9; Sambrook J., 2002, MOL CLONING LAB MANU; THOMMES P, 1995, J BIOL CHEM, V270, P21137, DOI 10.1074/jbc.270.36.21137; TIRANTI V, 1991, NUCLEIC ACIDS RES, V19, P4291, DOI 10.1093/nar/19.15.4291; TIRANTI V, 1993, GENE, V126, P219, DOI 10.1016/0378-1119(93)90370-I; VANDYCK E, 1992, EMBO J, V11, P3421, DOI 10.1002/j.1460-2075.1992.tb05421.x; WILLIAMS AJ, 1995, J BIOL CHEM, V270, P860, DOI 10.1074/jbc.270.2.860; Ye F, 1996, NUCLEIC ACIDS RES, V24, P1481, DOI 10.1093/nar/24.8.1481	33	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30774	30780		10.1074/jbc.271.48.30774	http://dx.doi.org/10.1074/jbc.271.48.30774			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940057	hybrid			2022-12-25	WOS:A1996VV15800074
J	Malik, RK; Parsons, JT				Malik, RK; Parsons, JT			Integrin-dependent activation of the p70 ribosomal S6 kinase signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; FOCAL ADHESION KINASE; EXTRACELLULAR-MATRIX; CELL-ADHESION; PHOSPHATIDYLINOSITOL 3-KINASE; MESSENGER-RNA; MAMMALIAN PROTEIN; RAPAMYCIN; TRANSDUCTION; PP125(FAK)	Interaction of the cell surface integrin receptors with extracellular matrix proteins results in the activation of intracellular signaling pathways, including activation of the p42/p44 mitogen-activated protein kinases. The protein tyrosine kinase focal adhesion kinase, or FAK, is linked to integrin signaling and interacts with several molecules involved in signal transduction, Here we report that exposure of fibroblast cells to extracellular matrix proteins activates the p70/p85 ribosomal S6 kinase (S6K) pathway in a ligand dependent manner. Treatment of cells with inhibitors of phosphatidylinositol 3-kinase, or FRAP (FKBP 12/rapamycin-associated protein) blocks integrin-mediated activation of S6K. In contrast to the integrin-directed activation of the mitogen-activated protein kinases, cytochalasin D treatment does not inhibit S6K activation, Treatment with the protein tyrosine kinase inhibitors herbimycin A and genistein completely blocks S6K activation, indicating a requirement for tyrosine kinase activity. Overexpression of the COOH-terminal noncatalytic domain of FAK, FRNK (FAK-related non-kinase) in chick embryo cells results in a significant reduction in the integrin-mediated activation of S6K and a concomitant reduction in FAK tyrosine phosphorylation, These results indicate at least a partial requirement for FAK in the S6K activation pathway.	UNIV VIRGINIA,HLTH SCI CTR,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,DEPT PEDIAT,CHARLOTTESVILLE,VA 22908	University of Virginia; University of Virginia					NCI NIH HHS [CA29243, CA40042] Funding Source: Medline; NICHD NIH HHS [HD-28810] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD028810] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R37CA029243, R01CA029243] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JC, 1993, DEVELOPMENT, V117, P1183; ALBELDA SM, 1993, LAB INVEST, V68, P4; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BLAU HM, 1991, J CELL BIOL, V112, P781, DOI 10.1083/jcb.112.5.781; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; BRYANT DL, 1984, MOL CELL BIOL, V4, P862, DOI 10.1128/MCB.4.5.862; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; DESIMONE DW, 1994, CURR OPIN CELL BIOL, V6, P747, DOI 10.1016/0955-0674(94)90103-1; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LANE HA, 1992, EMBO J, V11, P1743, DOI 10.1002/j.1460-2075.1992.tb05226.x; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LATHAM VM, 1994, J CELL BIOL, V126, P1211, DOI 10.1083/jcb.126.5.1211; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; NIELSEN FC, 1995, NATURE, V377, P358, DOI 10.1038/377358a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLAEPFER DD, 1994, NATURE, V372, P786; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; Turner CE, 1991, CURR OPIN CELL BIOL, V3, P849, DOI 10.1016/0955-0674(91)90059-8; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	51	52	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29785	29791		10.1074/jbc.271.47.29785	http://dx.doi.org/10.1074/jbc.271.47.29785			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939916	hybrid			2022-12-25	WOS:A1996VU52500044
J	Nagata, K; Ohashi, K; Nakano, T; Arita, H; Zong, C; Hanafusa, H; Mizuno, K				Nagata, K; Ohashi, K; Nakano, T; Arita, H; Zong, C; Hanafusa, H; Mizuno, K			Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; IGG FUSION PROTEINS; EXPRESSION ANALYSIS; V-RYK; C-MER; CLONING; BRAIN; FAMILY; GAS6; PROTOONCOGENE	Axl, Sky, and Mer, members of an Axl/Sky receptor tyrosine kinase subfamily, are typified by the cell adhesion molecule-related extracellular domain. The product of growth arrest-specific gene 6 (Gas6), structurally homologous to the anticoagulant protein S, was recently identified as the ligand for Axl and Sky, but the ligand for Mer remained unknown. We have now obtained evidence that Gas6 can also function as a ligand for Mer, Go-precipitation analysis, using soluble receptors of Axl, Sky, and Mer (Axl-Fc, Sky-Fc, and Mer-Fc) composed of the extracellular domain of receptors fused to the Fc domain of immunoglobulin G1, clearly showed that Case, but not protein S, specifically bound to Axl-Fc, Sky-Fc, and Mer-Fc fusion proteins, Quantitative kinetic analyses using a BIAcore biosensor instrument revealed dissociation constants (K-d) of the binding of rat Gas6 to Axl-Fc, Sky-Fc, and Mer-Fc are 0.4, 2.7, and 29 nM, respectively. We also found that Gas6 stimulated tyrosine phosphorylation of Axl, Sky, and Mer receptors ectopically expressed in Chinese hamster ovary cells. Taken together, these findings suggest that Gas6 is a common ligand for Axl, Sky, and Mer, all known members of an Axl/Sky receptor subfamily.	KYUSHU UNIV,FAC SCI,DEPT BIOL,FUKUOKA 81281,JAPAN; SHIONOGI & CO LTD,SHIONOGI RES LABS,OSAKA 553,JAPAN; ROCKEFELLER UNIV,MOL ONCOL LAB,NEW YORK,NY 10021	Kyushu University; Shionogi & Company Limited; Rockefeller University			Ohashi, Kazumasa/U-7028-2019; Mizuno, Kensaku/G-8631-2015	Ohashi, Kazumasa/0000-0001-7617-403X; 	NATIONAL CANCER INSTITUTE [R35CA044356] Funding Source: NIH RePORTER; NCI NIH HHS [CA44356] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barbacid M, 1995, ANN NY ACAD SCI, V766, P442, DOI 10.1111/j.1749-6632.1995.tb26693.x; BENNETT BD, 1991, J BIOL CHEM, V266, P23060; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DAHLBACK B, 1991, THROMB HAEMOSTASIS, V66, P49; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; Friedman GC, 1996, CURR OPIN NEUROBIOL, V6, P127, DOI 10.1016/S0959-4388(96)80018-3; FUJIMOTO J, 1994, ONCOGENE, V9, P693; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; GODOWSKI PJ, 1995, CELL, V82, P355, DOI 10.1016/0092-8674(95)90424-7; Goruppi S, 1996, ONCOGENE, V12, P471; GRAHAM DK, 1994, CELL GROWTH DIFFER, V5, P647; GRAHAM DK, 1995, ONCOGENE, V10, P2349; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; JIA R, 1992, J VIROL, V66, P5975, DOI 10.1128/JVI.66.10.5975-5987.1992; JIA R, 1994, J BIOL CHEM, V269, P1839; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; LAI C, 1994, ONCOGENE, V9, P2567; LING L, 1995, MOL CELL BIOL, V15, P6582; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; MARK MR, 1992, J BIOL CHEM, V267, P26166; MARK MR, 1994, J BIOL CHEM, V269, P10720; NAKANO T, 1995, J BIOL CHEM, V270, P5702, DOI 10.1074/jbc.270.11.5702; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OHASHI K, 1995, J BIOCHEM, V117, P1267, DOI 10.1093/oxfordjournals.jbchem.a124854; OHASHI K, 1994, ONCOGENE, V9, P699; OHASHI K, 1995, J BIOL CHEM, V270, P22681, DOI 10.1074/jbc.270.39.22681; Okano I, 1995, J BIOL CHEM, V270, P31321, DOI 10.1074/jbc.270.52.31321; RESCIGNO J, 1991, ONCOGENE, V6, P1909; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; SUZUKI K, 1983, J BIOCHEM-TOKYO, V94, P699, DOI 10.1093/oxfordjournals.jbchem.a134409; TAYLOR ICA, 1995, J BIOL CHEM, V270, P6872, DOI 10.1074/jbc.270.12.6872; Toshima J, 1995, J BIOL CHEM, V270, P31331, DOI 10.1074/jbc.270.52.31331; TOSHIMA J, 1995, BIOCHEM BIOPH RES CO, V209, P656, DOI 10.1006/bbrc.1995.1549; TSUKAMOTO T, 1995, NAT GENET, V11, P395, DOI 10.1038/ng1295-395; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0	37	399	424	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30022	30027		10.1074/jbc.271.47.30022	http://dx.doi.org/10.1074/jbc.271.47.30022			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939948	hybrid			2022-12-25	WOS:A1996VU52500076
J	Pastorino, JG; Simbula, G; Yamamoto, K; Glascott, PA; Rothman, RJ; Farber, JL				Pastorino, JG; Simbula, G; Yamamoto, K; Glascott, PA; Rothman, RJ; Farber, JL			The cytotoxicity of tumor necrosis factor depends on induction of the mitochondrial permeability transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED-HEPATOCYTES; PHOSPHOLIPASE-C; CYCLOSPORINE-A; BENZODIAZEPINE RECEPTOR; DUAL ROLE; INHIBITION; MEMBRANE; TRANSPORT; CELLS; PORE	Complete prevention of the killing of L929 fibroblasts by tumor necrosis factor alpha (TNF) in the presence of 0.5 mu g/ml actinomycin D (ActD) was obtained with cyclosporin A (CyA), an inhibitor of the mitochondrial permeability transition (MPT), and aristolochic acid (ArA), a phospholipase A(2) inhibitor, Peripheral benzodiazepine receptor (PBzR) agonists (PK11195, FGIN 1-27, or chlorodiazepam), agents known to potentiate induction of the MPT, potentiated the cytotoxicity of TNF in the absence of ActD, an effect prevented by CyA plus ArA, The MPT was demonstrated independently of its effect on viability as the CyA-sensitive loss of rhodamine 123 fluorescence from cells preloaded with the dye, Treatment with TNF and ActD resulted in the loss of 80% of rhodamine fluorescence within 6 h, a time prior to any loss of viability, CyA plus ArA completely prevented this effect of TNF, Potentiation of the cytotoxicity of TNF by PBzR agonists was associated with induction of the MPT, as assessed by the loss of rhodamine fluorescence, CyA plus ArA completely prevented the loss of rhodamine 123, Ceramide replaced TNF in killing L929 fibroblasts, an effect also prevented by CyA plus Ark Ceramide in the presence of ActD resulted in the loss of rhodamine fluorescence, an effect that was again prevented by CyA plus ArA. In addition, CyA plus ArA prevented the ability of PBzR agonists to potentiate the cytotoxicity of ceramide, In the presence of each PBzR agonist, ceramide caused the loss of rhodamine fluorescence, an effect completely prevented by CyA plus ArA. D609, an inhibitor of phosphatidylcholine-specific phospholipase C, completely prevented the killing by TNF, but not by ceramide, in the presence of ActD, D609 prevented induction of the MPT occurring with TNF, but not with ceramide. Inhibitors of endocytosis, as well as lysosomotropic amines, prevented the cytotoxicity of TNF, but not that of ceramide, It is concluded that the MPT is causally linked to the genesis of irreversible cell injury with TNF, In the face of an inhibition of protein synthesis, the MPT occurs as a consequence of the formation of ceramide.	THOMAS JEFFERSON UNIV,DEPT PATHOL,PHILADELPHIA,PA 19107	Jefferson University			Simbula, Gabriella/AAN-4390-2020	Simbula, Gabriella/0000-0003-4946-532X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038305] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-38305] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANHOLT RRH, 1986, J BIOL CHEM, V261, P576; ARRIGONI E, 1987, BIOCHEM PHARMACOL, V36, P3697, DOI 10.1016/0006-2952(87)90022-0; BANGA HS, 1986, P NATL ACAD SCI USA, V83, P9197, DOI 10.1073/pnas.83.23.9197; BASILE AS, 1986, J NEUROCHEM, V46, P305, DOI 10.1111/j.1471-4159.1986.tb12965.x; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; BERNARDI P, 1992, J BIOL CHEM, V267, P8834; BEYAERT R, 1994, FEBS LETT, V340, P91; BIGDA J, 1994, J EXP MED, V180, P445, DOI 10.1084/jem.180.2.445; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; BROEKEMEIER KM, 1989, BIOCHEM BIOPH RES CO, V163, P561, DOI 10.1016/0006-291X(89)92174-8; CROMPTON M, 1988, BIOCHEM J, V255, P357; DAS SK, 1987, BIOCHEM PHARMACOL, V36, P2221, DOI 10.1016/0006-2952(87)90154-7; GLASCOTT PA, 1992, MOL PHARMACOL, V41, P1155; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Goossens V, 1996, J BIOL CHEM, V271, P192, DOI 10.1074/jbc.271.1.192; GROOTEN J, 1993, CYTOKINE, V5, P546, DOI 10.1016/S1043-4666(05)80003-1; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313, DOI 10.1152/ajpcell.1994.267.2.C313; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; KOHLER T, 1991, AGENTS ACTIONS, V32, P70; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; LANCASTER JR, 1989, FEBS LETT, V248, P169, DOI 10.1016/0014-5793(89)80454-5; MATTHEWS N, 1983, BRIT J CANCER, V48, P405, DOI 10.1038/bjc.1983.205; MATTHEWS N, 1987, IMMUNOLOGY, V62, P153; MCENERY MW, 1992, J BIOENERG BIOMEMBR, V24, P63, DOI 10.1007/BF00769532; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MIZUMOTO K, 1994, MOL PHARMACOL, V46, P890; MULLERDECKER K, 1989, BIOCHEM BIOPH RES CO, V162, P198, DOI 10.1016/0006-291X(89)91981-5; OBEIRNE GB, 1990, EUR J BIOCHEM, V188, P131, DOI 10.1111/j.1432-1033.1990.tb15380.x; PASTORINO JG, 1994, J BIOL CHEM, V269, P31041; PASTORINO JG, 1993, J BIOL CHEM, V268, P13791; PASTORINO JG, 1995, AM J PHYSIOL-CELL PH, V268, pC676, DOI 10.1152/ajpcell.1995.268.3.C676; ROMEO E, 1992, J PHARMACOL EXP THER, V262, P971; RUFF MR, 1981, INFECT IMMUN, V31, P380, DOI 10.1128/IAI.31.1.380-385.1981; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SCHUTZE S, 1991, J EXP MED, V174, P975, DOI 10.1084/jem.174.5.975; SNYDER JW, 1992, BIOCHEM PHARMACOL, V44, P833, DOI 10.1016/0006-2952(92)90425-I; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; VERMA A, 1988, MOL PHARMACOL, V34, P800; VISHWANATH BS, 1988, INFLAMMATION, V12, P549, DOI 10.1007/BF00914317; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WONG GHW, 1989, CELL, V58, P924; YAMAUCHI N, 1989, CANCER RES, V49, P1671; ZIMMERMAN RJ, 1989, CANCER RES, V49, P1644; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	48	242	247	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29792	29798		10.1074/jbc.271.47.29792	http://dx.doi.org/10.1074/jbc.271.47.29792			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939917	hybrid			2022-12-25	WOS:A1996VU52500045
J	Putkey, JA; Waxham, MN				Putkey, JA; Waxham, MN			A peptide model for calmodulin trapping by calcium/calmodulin-dependent protein kinase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTSYNAPTIC DENSITY PROTEIN; CA-2+ CALMODULIN; AUTOPHOSPHORYLATION SITES; BINDING; EXPRESSION; PHOSPHORYLATION; INHIBITION; SUBUNIT; MUTAGENESIS; MECHANISM	Autophosphorylation of Ca2+/calmodulin-dependent protein kinase II (CaM-kinase) induces a more than 1000-fold increase in calmodulin (CaM)-binding affinity by dramatically decreasing the off-rate for CaM. In this report, we investigate the molecular mechanism for this phenomenon by comparing the rate of dissociation of a novel fluorescently labeled CaM from two synthetic peptides and from the phosphorylated and nonphosphorylated forms of a recombinant preparation of CaM-kinase, Dissociation of a complex of CaM and CKII(296-312), a peptide representing close to the minimum CaM-binding domain of the alpha subunit of CaM-kinase, exhibited a fast off-rate of 5.0 s(-1). This was similar to the off-rate of 1.1 s(-1) for the dissociation of CaM from the nonphosphorylated form of CaM kinase. In contrast, dissociation of CaM from either autophosphorylated CaM-kinase or peptide CKII(290-314) was extremely slow with apparent off-rates of about 3-9x10(-5) s(-1). Along with information from the crystal structure of Ca2+/CaM bound to CKII(290-314) (Meador, W. E., Means, A. R., and Quiocho, F. A. (1993) Science 262, 1718-1721), our results suggest a model in which CaM-dependent autophosphorylation of CaM-kinase induces a conformational change in the region of the CaM-binding domain which allows the formation of additional stabilizing interactions with CaM, We predict that this involves amino acids 293-298 in CaM-kinase. The possible consequences of these observations on the reversibility of CaM trapping in native CaM-kinase are discussed.	UNIV TEXAS, SCH MED, DEPT BIOCHEM & MOL BIOL, HOUSTON, TX 77225 USA	University of Texas System	Putkey, JA (corresponding author), UNIV TEXAS, SCH MED, DEPT NEUROBIOL & ANAT, POB 20708, HOUSTON, TX 77225 USA.			Waxham, M. Neal/0000-0003-4801-1190	NHLBI NIH HHS [HL-45724] Funding Source: Medline; NINDS NIH HHS [NS-01509, NS-26086] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045724] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026086, K04NS001509, R56NS026086] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BRICKEY DA, 1990, BIOCHEM BIOPH RES CO, V173, P578, DOI 10.1016/S0006-291X(05)80074-9; COLBRAN RJ, 1988, J BIOL CHEM, V263, P18145; COLBRAN RJ, 1989, J BIOL CHEM, V264, P4800; COLBRAN RJ, 1993, J BIOL CHEM, V268, P7163; COLBRAN RJ, 1990, J BIOL CHEM, V265, P11213; FONG YL, 1989, J BIOL CHEM, V264, P16759; HANLEY RM, 1987, SCIENCE, V237, P293, DOI 10.1126/science.3037704; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; HANSON PI, 1992, J BIOL CHEM, V267, P17216; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Hudmon A, 1996, J BIOL CHEM, V271, P8800, DOI 10.1074/jbc.271.15.8800; KELLY PT, 1984, P NATL ACAD SCI-BIOL, V81, P945, DOI 10.1073/pnas.81.3.945; KELLY PT, 1988, P NATL ACAD SCI USA, V85, P4991, DOI 10.1073/pnas.85.14.4991; KENNEDY MB, 1983, P NATL ACAD SCI-BIOL, V80, P7357, DOI 10.1073/pnas.80.23.7357; KWIATKOWSKI AP, 1989, BIOCHEMISTRY-US, V28, P5380, DOI 10.1021/bi00439a010; LOU LL, 1989, J NEUROSCI, V9, P2020; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MUKHERJI S, 1994, J BIOL CHEM, V269, P13744; PATTON BL, 1990, J BIOL CHEM, V265, P11204; PAYNE ME, 1988, J BIOL CHEM, V263, P7190; PUTKEY JA, 1987, METHOD ENZYMOL, V139, P303; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; SAITOH T, 1985, J CELL BIOL, V100, P835, DOI 10.1083/jcb.100.3.835; SHATZMAN AR, 1986, ANN NY ACAD SCI, V478, P233, DOI 10.1111/j.1749-6632.1986.tb15534.x; WAXHAM MN, 1990, P NATL ACAD SCI USA, V87, P1273, DOI 10.1073/pnas.87.4.1273; YAMAGATA Y, 1991, J BIOL CHEM, V266, P15391	31	75	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29619	29623		10.1074/jbc.271.47.29619	http://dx.doi.org/10.1074/jbc.271.47.29619			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939892	hybrid			2022-12-25	WOS:A1996VU52500020
J	Tirumalai, RS; Pargellis, CA; Landy, A				Tirumalai, RS; Pargellis, CA; Landy, A			Identification and characterization of the N-ethylmaleimide-sensitive site in lambda-integrase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INT GENE-PRODUCT; BACTERIOPHAGE-LAMBDA; POLYACRYLAMIDE-GEL; PROTEIN; RECOMBINATION; SEQUENCE; DNA; BINDING; ELECTROPHORESIS; REGIONS	Integrase (Int) of bacteriophage lambda is a heterobivalent DNA binding protein and a type I topoisomerase. Upon modification with N-ethylmaleimide (NEM), a sulfhydryl-directed reagent, Int loses its capacity to bind ''arm-type'' DNA sequences and, consequently, to carry out recombination; however, its ability to bind ''core-type'' sequences and its topoisomerase activity are unaffected, In this report, the NEM-sensitive site was identified by modifying Int with [C-14]NEM. Following cleavage by formic acid, which cleaves Asp-Pro bonds, and fractionation on a Fractogel HW-50 (F) sizing column, the fragment containing the primary site of [C-14]NEM incorporation was subjected to amino acid sequencing. The results indicate that the primary site of [C-14]NEM incorporation is in the peptide-spanning amino acid residues 1-28, which contains a cysteine at position 25. To confirm that Cys-25 is the target of NEM reactivity, site-directed mutagenesis was used to change this cysteine to alanine or serine. The mutant protein is not chemically modified by NEM and shows no loss of activity after NEM treatment. The fact that C25A and C25S both retain full recombination activity indicates that the SH group of Cys-25 does not provide any critical contacts, either with arm-type DNA or with other parts of the Int protein to form the arm-type recognition pocket. The loss of arm-type DNA binding and the con-comitant loss of recombination function as a result of NEM modification must be due to the presence of the maleimide moiety and not due to loss of a critical cysteine contact.	BROWN UNIV,DIV BIOL & MED,PROVIDENCE,RI 02912; BOEHRINGER INGELHEIM PHARMACEUT INC,RIDGEFIELD,CT 06877	Brown University; Boehringer Ingelheim					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI013544, R01AI013544] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033928] Funding Source: NIH RePORTER; NIAID NIH HHS [AI13544] Funding Source: Medline; NIGMS NIH HHS [GM33928] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES GFL, 1974, J BIOL CHEM, V249, P634; BETTER M, 1982, P NATL ACAD SCI-BIOL, V79, P5837, DOI 10.1073/pnas.79.19.5837; BONNER WM, 1984, METHOD ENZYMOL, V104, P460; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREWER CF, 1967, ANAL BIOCHEM, V18, P248, DOI 10.1016/0003-2697(67)90007-3; CRAIG NL, 1988, ANNU REV GENET, V22, P77; DEVARGAS LM, 1988, CELL, V54, P923, DOI 10.1016/0092-8674(88)90107-9; GORIN G, 1966, ARCH BIOCHEM BIOPHYS, V115, P593, DOI 10.1016/0003-9861(66)90079-8; GREGORY JD, 1955, J AM CHEM SOC, V77, P3922, DOI 10.1021/ja01619a073; HAN YPW, 1994, J MOL BIOL, V235, P908, DOI 10.1006/jmbi.1994.1048; HOESS RH, 1980, P NATL ACAD SCI-BIOL, V77, P2482, DOI 10.1073/pnas.77.5.2482; KIKUCHI Y, 1979, P NATL ACAD SCI USA, V76, P3760, DOI 10.1073/pnas.76.8.3760; KIKUCHI Y, 1978, J BIOL CHEM, V253, P7149; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; Mizuuchi K, 1981, Cold Spring Harb Symp Quant Biol, V45 Pt 1, P429; NASH HA, 1987, J BACTERIOL, V169, P4124, DOI 10.1128/jb.169.9.4124-4127.1987; PISZKIEW.D, 1970, BIOCHEM BIOPH RES CO, V40, P1173, DOI 10.1016/0006-291X(70)90918-6; ROSS W, 1983, CELL, V33, P261, DOI 10.1016/0092-8674(83)90355-0; ROSS W, 1982, P NATL ACAD SCI-BIOL, V79, P7724, DOI 10.1073/pnas.79.24.7724; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNETGER J, 1966, THESIS U FRANKFURT G; Smyth DG, 1960, J AM CHEM SOC, V82, P4600, DOI 10.1021/ja01502a039; SMYTH DG, 1964, BIOCHEM J, V91, P589, DOI 10.1042/bj0910589; SWANK RT, 1971, ANAL BIOCHEM, V39, P462, DOI 10.1016/0003-2697(71)90436-2; THOMPSON JF, 1987, J MOL BIOL, V195, P481, DOI 10.1016/0022-2836(87)90177-X	25	12	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29599	29604		10.1074/jbc.271.47.29599	http://dx.doi.org/10.1074/jbc.271.47.29599			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939889	hybrid			2022-12-25	WOS:A1996VU52500017
J	Zhuang, SB; Mabuchi, K; Wang, CLA				Zhuang, SB; Mabuchi, K; Wang, CLA			Heat treatment could affect the biochemical properties of caldesmon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CALDESMON; LIGHT CHAIN KINASE; THIN-FILAMENTS; ACTIN-TROPOMYOSIN; CHICKEN GIZZARD; MYOSIN INTERACTION; MOLECULAR-WEIGHT; CA-2+ REGULATION; BINDING PROTEIN; F-ACTIN	Smooth muscle caldesmon (CaD) exhibits apparent heat stability, A widely used purification procedure of CaD involves extensive heat treatment (Bretscher, A. (1984) J. Biol. Chem. 259, 12873-12880). CaD thus purified co-sediments with actin, inhibits actomyosin ATPase activity, and interacts with Ca2+/calmodulin, similarly to the unheated protein, On the other hand, heat-treated CaD binds to actin filaments in a tether-like fashion, whereas lengthwise binding dominates in vivo (Mabuchi, K., Lin, J. J.-C., and Wang, C.-L. A. (1993) J. Muscle Res. Cell Motil. 14, 54-64), suggesting that differences do exist between heat purified CaD and the native protein, We have isolated, without heat treatment, full-length recombinant chicken gizzard CaD overexpressed in insect cells (High-Five(TM)) using a baculovirus expression system, We found that such unheated CaD interacts with calmodulin 10 times stronger than does the heated CaD; its inhibitory action on actomyosin ATPase is reversed by a much lesser amount of calmodulin. Moreover, electron microscopic examination indicated that actin binding at the N-terminal region is more frequent in the unheated CaD, resulting in more lengthwise binding. These findings point to the fact that CaD is not entirely heat-stable; the C-terminal CaM-binding regions and the N-terminal actin binding region are possibly affected by heat treatment.	BOSTON BIOMED RES INST, MUSCLE RES GRP, BOSTON, MA 02114 USA	Boston Biomedical Research Institute					NIAMS NIH HHS [P01-AR41637] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR041637] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BLUMENTHAL DK, 1985, P NATL ACAD SCI USA, V82, P3187, DOI 10.1073/pnas.82.10.3187; BRETSCHER A, 1984, J BIOL CHEM, V259, P2873; DEDMAN JR, 1983, METHOD ENZYMOL, V102, P1; Fiske CH, 1925, J BIOL CHEM, V66, P375; GRACEFFA P, 1993, ARCH BIOCHEM BIOPHYS, V307, P21, DOI 10.1006/abbi.1993.1554; GRACEFFA P, 1988, J BIOL CHEM, V263, P14196; GRACEFFA P, 1987, FEBS LETT, V218, P139, DOI 10.1016/0014-5793(87)81034-7; IKEBE M, 1978, J BIOCHEM, V83, P1643, DOI 10.1093/oxfordjournals.jbchem.a132077; KASTURI R, 1993, J BIOL CHEM, V268, P7958; KATAYAMA E, 1995, BIOPHYS J, V68, P2419, DOI 10.1016/S0006-3495(95)80424-8; KATSUYAMA H, 1992, J BIOL CHEM, V267, P14555; LEHMAN W, 1989, J MUSCLE RES CELL M, V10, P101, DOI 10.1007/BF01739966; LIN JJC, 1991, CELL MOTIL CYTOSKEL, V20, P95, DOI 10.1002/cm.970200203; LYNCH W, 1986, METHOD ENZYMOL, V134, P37; MABUCHI K, 1991, J STRUCT BIOL, V107, P22, DOI 10.1016/1047-8477(91)90027-T; MABUCHI K, 1993, J MUSCLE RES CELL M, V14, P54, DOI 10.1007/BF00132180; MALENCIK DA, 1989, BIOCHEMISTRY-US, V28, P8227, DOI 10.1021/bi00446a039; MARSTON SB, 1994, J BIOL CHEM, V269, P32104; MARSTON SB, 1991, BIOCHEM J, V279, P1; Matsumura F, 1993, CURR OPIN CELL BIOL, V5, P70, DOI 10.1016/S0955-0674(05)80010-9; MOODY C, 1990, J MUSCLE RES CELL M, V11, P176, DOI 10.1007/BF01766496; MORRIS EP, 1984, BIOCHEMISTRY-US, V23, P2214, DOI 10.1021/bi00305a018; NGAI PK, 1984, J BIOL CHEM, V259, P3656; NOMURA M, 1987, BIOCHEM BIOPH RES CO, V144, P936, DOI 10.1016/S0006-291X(87)80054-2; PHILLIPS JE, 1994, J BIOL CHEM, V269, P16696; PRITCHARD K, 1989, BIOCHEM J, V257, P839, DOI 10.1042/bj2570839; PRITCHARD K, 1988, SARCOMERIC NONSARCOM, P649; SHIRINSKY VP, 1988, BIOCHEM J, V255, P203; SMITH CWJ, 1987, J BIOL CHEM, V262, P116; SMITH CWJ, 1985, FEBS LETT, V184, P115, DOI 10.1016/0014-5793(85)80665-7; SOBUE K, 1982, BIOMED RES-TOKYO, V3, P188, DOI 10.2220/biomedres.3.188; SOBUE K, 1981, P NATL ACAD SCI-BIOL, V78, P5652, DOI 10.1073/pnas.78.9.5652; SOBUE K, 1985, BIOCHEM BIOPH RES CO, V132, P645, DOI 10.1016/0006-291X(85)91181-7; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; WALSH MP, 1983, METHOD ENZYMOL, V99, P279; WANG CLA, 1991, J BIOL CHEM, V266, P13958; WANG CLA, 1988, BIOCHEM BIOPH RES CO, V156, P1033, DOI 10.1016/S0006-291X(88)80948-3; WANG Z, 1994, J MUSCLE RES CELL M, V15, P646, DOI 10.1007/BF00121072; ZHAN Q, 1991, J BIOL CHEM, V266, P21810; ZHUANG SB, 1995, J BIOL CHEM, V270, P19964, DOI 10.1074/jbc.270.34.19964	40	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30242	30248		10.1074/jbc.271.47.30242	http://dx.doi.org/10.1074/jbc.271.47.30242			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939977	hybrid			2022-12-25	WOS:A1996VU52500105
J	Tate, BF; Allenby, G; Perez, JR; Levin, AA; Grippo, JF				Tate, BF; Allenby, G; Perez, JR; Levin, AA; Grippo, JF			Systematic analysis of the AF-2 domain of human retinoic acid receptor alpha reveals amino acids critical for transcriptional activation and conformational integrity	FASEB JOURNAL			English	Article						RARE; retinoic acids; plasmid mutants; transactivation; gel mobility shift assay	THYROID-HORMONE RECEPTOR; LIGAND-BINDING DOMAIN; 9-CIS-RETINOIC ACID; RESPONSIVE ELEMENT; NUCLEAR RECEPTORS; CRYSTAL-STRUCTURE; VITAMIN-D; V-ERBA; C-ERBA; IDENTIFICATION	We previously identified a carboxy-terminal transactivation function termed AF-2 within the last 15 amino acids of the ligand binding domain of the human retinoic acid receptor alpha (hRAR alpha). Truncation of this region abolished transcriptional activity, Here we provide a systematic analysis using alanine scanning mutagenesis of amino acids from Ser(405) to Gly(419) on a truncated hRAR alpha (Delta 419) to identify residues within this region that are responsible for transcriptional activity, Whereas mutations in positions 405, 408, 411, and 415-419 have little or no effect on the ability of modified receptors to activate a DR5 response element, mutations in positions 406, 407, 409, 410, and 412-413 modify either the potency or efficacy of all-trans retinoic acid (tRA) -induced gene transcription, Therefore, receptors with mutations in positions 409, 410, 413, and 414 have low transcriptional activity over a wide range of tRA concentrations, Receptors with mutations in positions 406, 407, and 412 exhibit a maximum transcriptional activity similar to wild-type hRAR alpha, but require higher concentrations of tRA, Replacing residues 405-419 on Delta 419 with the conserved AF-2 domain from the vitamin DQ receptor or the estrogen receptor results in a receptor with wild-type or low transcriptional activity, respectively, A full-length hRAR alpha mutant with an alanine substitution at position 406 (hRAR alpha M406A) binds tRA, but unlike the truncated M406A, which lacks the ''F'' region, it is not transcriptionally active, Protease mapping experiments detect a consistent difference in the conformation of hRAR alpha M406A compared to wild-type hRAR alpha, These data define amino acids from Ser(405) to Gly(419) on Delta 419 that are critical for transcriptional activity and point to the importance of the conformational integrity of receptor domains in maintaining ligand-induced transcriptional activation.	HOFFMANN LA ROCHE INC,DEPT METAB DIS,NUTLEY,NJ 07110; HOFFMANN LA ROCHE INC,DEPT ONCOL,NUTLEY,NJ 07110; UNIV LONDON ST BARTHOLOMEWS HOSP MED COLL,DEPT TOXICOL,LONDON EC1 7ED,ENGLAND; ISIS PHARMACEUT,DEPT PHARMACOKINET & TOXICOL,CARLSBAD RES CTR,CARLSBAD,CA 92008	Roche Holding; Roche Holding; University of London; Queen Mary University London; Isis Pharmaceuticals Inc								ALLAN GF, 1992, J BIOL CHEM, V267, P19513; ALLENBY G, 1994, J BIOL CHEM, V269, P16689; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; COSTAGIOMI MP, 1992, NUCLEIC ACIDS RES, V20, P3223, DOI 10.1093/nar/20.12.3223; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; Kastner P., 1994, Vitamin A in health and disease., P189; KEIDEL S, 1994, MOL CELL BIOL, V14, P287, DOI 10.1128/MCB.14.1.287; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LENG XH, 1995, MOL CELL BIOL, V15, P255, DOI 10.1128/MCB.15.1.255; LENG XH, 1993, J STEROID BIOCHEM, V46, P643, DOI 10.1016/0960-0760(93)90306-H; Mangelsdorf David J., 1994, P319; MORRISSKAY G, 1992, RETINOIDS NORMAL DEV; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NERVI C, 1989, P NATL ACAD SCI USA, V86, P5854, DOI 10.1073/pnas.86.15.5854; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; ROSEN ED, 1993, J BIOL CHEM, V268, P11534; SAATCIOGLU F, 1993, MOL CELL BIOL, V13, P3675, DOI 10.1128/MCB.13.6.3675; Sporn M.B., 1994, RETINOIDS BIOL CHEM; TATE BF, 1994, TRENDS ENDOCRIN MET, V5, P189, DOI 10.1016/1043-2760(94)90076-0; TATE BF, 1995, J BIOL CHEM, V270, P20258, DOI 10.1074/jbc.270.35.20258; TATE BF, 1994, MOL CELL BIOL, V14, P2323, DOI 10.1128/MCB.14.4.2323; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P	33	10	11	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1996	10	13					1524	1531		10.1096/fasebj.10.13.8940298	http://dx.doi.org/10.1096/fasebj.10.13.8940298			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VU982	8940298				2022-12-25	WOS:A1996VU98200009
J	ElvirMairena, JR; Jovanovic, A; Gomez, LA; Alekseev, AE; Terzic, A				ElvirMairena, JR; Jovanovic, A; Gomez, LA; Alekseev, AE; Terzic, A			Reversal of the ATP-liganded state of ATP-sensitive K+ channels by adenylate kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT VENTRICULAR MYOCYTES; POTASSIUM CHANNELS; ESCHERICHIA-COLI; INSULIN RELEASE; CARDIAC-MUSCLE; BETA-CELLS; GUINEA-PIG; ADP; GLYCOLYSIS; INHIBITOR	The mechanism that promotes transition from the ATP- to the ADP-liganded state of ATP-sensitive K+ (K-ATP) channels and consequent channel opening in a cytosolic environment of high ATP concentration has yet to be understood. A mechanism examined here that could reverse the ATP-inhibited state is based on the action of adenylate kinase to catalyze phosphoryl transfer between ATP and AMP, resulting in transformation of ATP into ADP. In membrane patches excised from guinea pig cardiomyocytes, AMP alone did not affect channel behavior but increased the open probability of ATP-inhibited K-ATP channels. This required MgCl2 and a hydrolyzable form of ATP and was prevented by P1,P5-di-adenosine-5'-pentaphosphate, an inhibitor of adenylate kinase, The single channel amplitude and kinetics of channel openings induced by the ADP-generating substrates of adenylate kinase, AMP and MgATP, were indistinguishable from the biophysical properties of the channel exhibited after addition of MgADP. In whole cell voltage-clamped cardiomyocytes, introduction of exogenous adenylate kinase along with millimolar MgATP and AMP induced a K+ current that was suppressed by a sulfonylurea blocker of K-ATP channels. Enriched sarcolemmal membrane preparations were found to possess ATP . AMP phosphotransferase activity with properties attributable to an extramitochondrial isoform of adenylate kinase, These results indicate that adenylate kinase is a naturally occurring component of sarcolemmal membranes that could provide dynamic governance of K-ATP channel opening through its phosphoryl transfer catalytic action in the microenvironment of the channel.	MAYO CLIN & MAYO FDN,DEPT MED,DIV CARDIOVASC DIS,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT PHARMACOL,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic			Grosso, Luis Alberto Gomez/Q-3185-2019; Jovanovic, Aleksandar/A-4482-2008; Alekseev, Alexey/I-5346-2013	Grosso, Luis Alberto Gomez/0000-0001-6998-9556; Jovanovic, Aleksandar/0000-0002-1214-9318; 				AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; Boyer P.D, 1973, ENZYMES, P279; BRDICZKA D, 1968, EUR J BIOCHEM, V5, P294, DOI 10.1111/j.1432-1033.1968.tb00370.x; DECKING UKM, 1995, AM J PHYSIOL-HEART C, V269, pH734, DOI 10.1152/ajpheart.1995.269.2.H734; DETIMARY P, 1995, J CLIN INVEST, V96, P1738, DOI 10.1172/JCI118219; Dzeja PP, 1996, J BIOL CHEM, V271, P12847, DOI 10.1074/jbc.271.22.12847; ESGUERRA M, 1994, NATURE, V369, P563, DOI 10.1038/369563a0; FINDLAY I, 1988, PFLUG ARCH EUR J PHY, V412, P37, DOI 10.1007/BF00583729; FINDLAY I, 1994, J CARDIOVASC PHARM, V24, pS6, DOI 10.1097/00005344-199424014-00002; FINDLAY I, 1988, J MEMBRANE BIOL, V101, P83, DOI 10.1007/BF01872823; FORBUSH B, 1982, J BIOL CHEM, V257, P2678; GHOSH A, 1991, J BIOL CHEM, V266, P22887; GUITERREZ JA, 1995, J BACTERIOL, V177, P390; HELLER M, 1972, BIOCHIM BIOPHYS ACTA, V255, P239, DOI 10.1016/0005-2736(72)90026-0; HUSS RJ, 1983, J BIOL CHEM, V258, P3370; IMAGAKI N, 1995, SCIENCE, V270, P1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Jovanovic A, 1996, N-S ARCH PHARMACOL, V353, P241; KHOO JC, 1972, BIOCHIM BIOPHYS ACTA, V268, P98, DOI 10.1016/0005-2744(72)90202-1; King T.E., 1967, METHOD ENZYMOL, V10, P322, DOI DOI 10.1016/0076-6879(67)10061-X; KUBO S, 1974, EUR J BIOCHEM, V48, P325, DOI 10.1111/j.1432-1033.1974.tb03772.x; LARSSON O, 1993, J PHYSIOL-LONDON, V463, P349, DOI 10.1113/jphysiol.1993.sp019598; LAZDUNSKI M, 1994, J CARDIOVASC PHARM, V24, pS1; LEDERER WJ, 1989, J PHYSIOL-LONDON, V419, P193, DOI 10.1113/jphysiol.1989.sp017869; LIENHARD GE, 1973, J BIOL CHEM, V248, P1121; MULLER CW, 1992, J MOL BIOL, V224, P159, DOI 10.1016/0022-2836(92)90582-5; NAGY AK, 1989, J NEUROCHEM, V53, P1166, DOI 10.1111/j.1471-4159.1989.tb07410.x; NICHOLS CG, 1991, AM J PHYSIOL, V261, pH1675, DOI 10.1152/ajpheart.1991.261.6.H1675; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; Olson LK, 1996, J BIOL CHEM, V271, P16544, DOI 10.1074/jbc.271.28.16544; PITTS BJR, 1979, J BIOL CHEM, V254, P6232; Priebe L, 1996, J PHYSIOL-LONDON, V492, P405, DOI 10.1113/jphysiol.1996.sp021317; PROVERBIO F, 1986, BIOCHIM BIOPHYS ACTA, V858, P202, DOI 10.1016/0005-2736(86)90307-X; QUITON PM, 1992, NATURE, V360, P79; Ribalet B, 1996, J GEN PHYSIOL, V107, P231, DOI 10.1085/jgp.107.2.231; SAVABI F, 1994, MOL CELL BIOCHEM, V133, P145, DOI 10.1007/BF01267953; SUMINAMI Y, 1988, J BIOCHEM-TOKYO, V103, P611, DOI 10.1093/oxfordjournals.jbchem.a122315; TERZIC A, 1994, NEURON, V12, P1049, DOI 10.1016/0896-6273(94)90313-1; TERZIC A, 1994, NEURON, V12, P885, DOI 10.1016/0896-6273(94)90340-9; TERZIC A, 1994, CARDIOVASC RES, V28, P746, DOI 10.1093/cvr/28.6.746; Terzic A, 1996, J PHYSIOL-LONDON, V492, P395, DOI 10.1113/jphysiol.1996.sp021316; TERZIC A, 1995, AM J PHYSIOL, V38, pC525; TUNG RT, 1991, J PHYSIOL-LONDON, V437, P239, DOI 10.1113/jphysiol.1991.sp018593; WALKER EJ, 1982, BIOCHEM J, V203, P361, DOI 10.1042/bj2030361; WEISS JN, 1993, CARDIOVASC DRUG THER, V7, P499, DOI 10.1007/BF00877614; WEISS JN, 1987, SCIENCE, V238, P67, DOI 10.1126/science.2443972; WONG PCL, 1989, BIOCHEM INT, V19, P881; ZELEZNIKAR RJ, 1990, J BIOL CHEM, V265, P300; ZELEZNIKAR RJ, 1995, J BIOL CHEM, V270, P7311, DOI 10.1074/jbc.270.13.7311	51	55	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					31903	31908		10.1074/jbc.271.50.31903	http://dx.doi.org/10.1074/jbc.271.50.31903			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943234	hybrid			2022-12-25	WOS:A1996VY34000025
J	Lim, F; Spingola, M; Peabody, DS				Lim, F; Spingola, M; Peabody, DS			The RNA-binding site of bacteriophage Q beta coat protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLATIONAL REPRESSION; CRYSTAL-STRUCTURE; PLASMID; MS2	The coat proteins of the RNA bacteriophages Q beta and MS2 are specific RNA binding proteins, Although they possess common tertiary structures, they bind different RNA stem loops and thus provide useful models of specific protein-RNA recognition, Although the RNA-binding site of MS2 coat protein has been extensively characterized previously, little is known about Q beta, Here we describe the isolation of mutants that define the RNA-binding site of Q beta coat protein, showing that, as with MS2, it resides on the surface of a large beta-sheet, Mutations are also described that convert Q beta coat protein to the RNA binding specificity of MS2, The results of these and other studies indicate that, although they bind different RNAs, the binding sites of the two coat proteins are sufficiently similar that each is easily converted by mutation to the RNA binding specificity of the other.	UNIV NEW MEXICO, SCH MED, DEPT CELL BIOL, ALBUQUERQUE, NM 87131 USA; CANC RES & TREATMENT CTR, ALBUQUERQUE, NM 87131 USA	University of New Mexico								Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; CAREY J, 1983, BIOCHEMISTRY-US, V22, P4723, DOI 10.1021/bi00289a017; DRAPER DE, 1988, METHOD ENZYMOL, V164, P221; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LIM F, 1994, NUCLEIC ACIDS RES, V22, P3748, DOI 10.1093/nar/22.18.3748; LIM F, 1994, J BIOL CHEM, V269, P9006; NI CZ, 1995, STRUCTURE, V3, P255, DOI 10.1016/S0969-2126(01)00156-3; PEABODY DS, 1990, J BIOL CHEM, V265, P5684; PEABODY DS, 1993, EMBO J, V12, P595, DOI 10.1002/j.1460-2075.1993.tb05691.x; PEABODY DS, 1992, NUCLEIC ACIDS RES, V20, P1649, DOI 10.1093/nar/20.7.1649; ROMANIUK PJ, 1987, BIOCHEMISTRY-US, V26, P1563, DOI 10.1021/bi00380a011; SHAKLEE PN, 1988, VIROLOGY, V163, P209, DOI 10.1016/0042-6822(88)90250-4; VALEGARD K, 1990, NATURE, V345, P36, DOI 10.1038/345036a0; VALEGARD K, 1994, NATURE, V371, P623, DOI 10.1038/371623a0; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WEINER AM, 1972, J BIOL CHEM, V247, P3242; WITHERELL GW, 1991, PROG NUCLEIC ACID RE, V40, P185; WITHERELL GW, 1989, BIOCHEMISTRY-US, V28, P71, DOI 10.1021/bi00427a011; WU HN, 1987, BIOCHEMISTRY-US, V26, P8221, DOI 10.1021/bi00399a030	19	32	41	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					31839	31845		10.1074/jbc.271.50.31839	http://dx.doi.org/10.1074/jbc.271.50.31839			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943226	Green Published, hybrid			2022-12-25	WOS:A1996VY34000017
J	Oliveira, HCF; Chouinard, RA; Agellon, LB; Bruce, C; Ma, LM; Walsh, A; Breslow, JL; Tall, AR				Oliveira, HCF; Chouinard, RA; Agellon, LB; Bruce, C; Ma, LM; Walsh, A; Breslow, JL; Tall, AR			Human Cholesteryl ester transfer protein gene proximal promoter contains dietary cholesterol positive responsive elements and mediates expression in small intestine and periphery while predominant liver and spleen expression is controlled by 5'-distal sequences - CIS-acting sequences mapped tn transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; STEROL REGULATORY ELEMENT; APOLIPOPROTEIN-A-I; LIPID TRANSFER PROTEIN; MESSENGER-RNA LEVELS; CELL-DERIVED CHOLESTEROL; LEUCINE ZIPPER PROTEIN; C-III GENE; TRANSCRIPTIONAL REGULATION; PLASMA-LIPOPROTEINS	The plasma cholesteryl ester transfer protein (CETP) facilitates the transfer of high density lipoprotein cholesteryl esters to other lipoproteins and appears to be a key regulated component of reverse cholesterol transport. Earlier studies showed that a CETP transgene containing natural Banking sequences (-3.4 kilobase pairs (kbp) upstream, +2.2 kbp downstream) was expressed in an authentic tissue distribution and induced in liver and other tissues in response to dietary or endogenous hypercholesterolemia. In order to localize the DNA elements responsible for these effects, we prepared transgenic mice expressing six new DNA constructs containing different amounts of natural flanking sequence of the CETP gene. Tissue-specific expression and dietary cholesterol response of CETP mRNA were determined, The native pattern of predominant expression in liver and spleen with cholesterol induction was shown by a -3.4 (5'), +0.2 (3') kbp transgene, indicating no major contribution of distal 3'-sequences. Serial 5'-deletions showed that a -570 base pairs (bp) transgene gave predominant expression in small intestine with cholesterol induction of CETP mRNA in that organ, and a -370 bp transgene gave highest expression in adrenal gland with partial dietary cholesterol induction of CETP mRNA and plasma activity. Further deletion to -138 bp 5'-flanking sequence resulted in a transgene that was not expressed in vivo. Both the -3.4 kbp and -138 bp transgenes were expressed when transfected into a cultured murine hepatocyte cell line, but only the former was induced by treating the cells with LDL. When linked to a human apoA-I transgene, the -570 to -138 segment of the CETP gene promoter gave rise to a relative positive response of hepatic apoA-I mRNA to the high cholesterol diet in two out of three transgenic lines, Thus, 5'-elements between -3,400 and -570 bp in the CETP promoter endow predominant expression in liver and spleen, Elements between -570 and -370 are required for expression in small intestine and some other tissues, and elements between -370 and -138 contribute to adrenal expression, The minimal CETP promoter element associated with a positive sterol response in vivo was found in the proximal CETP gene promoter between -370 and -138 bp. This region contains a tandem repeat of a sequence known to mediate sterol down-regulation of the HMG-CoA reductase gene, suggesting either the presence of separate positive and negative sterol response elements in this region or the use of a common DNA element for both positive and negative sterol responses.	COLUMBIA UNIV,DEPT MED,DIV MOL MED,NEW YORK,NY 10032; ROCKEFELLER UNIV,BIOCHEM GENET & METAB LAB,NEW YORK,NY 10021	Columbia University; Rockefeller University			Oliveira, Helena C. F./C-1343-2013; Breslow, Jan L/B-7544-2008; Tall, Alan/AAT-8528-2021	Oliveira, Helena C. F./0000-0003-0119-6992; Bruce, Can/0000-0002-3101-1250	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054591] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 54591] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGELLON LB, 1990, BIOCHEMISTRY-US, V29, P1372, DOI 10.1021/bi00458a004; AGELLON LB, 1991, J BIOL CHEM, V266, P10796; AZROLAN N, 1990, J LIPID RES, V31, P1141; BISAHA JG, 1995, J BIOL CHEM, V270, P19979, DOI 10.1074/jbc.270.34.19979; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; CASTRO GR, 1988, BIOCHEMISTRY-US, V27, P25, DOI 10.1021/bi00401a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V70, P75; DANG Q, 1995, J BIOL CHEM, V270, P22577, DOI 10.1074/jbc.270.38.22577; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; FRANCONE OL, 1989, J BIOL CHEM, V264, P7066; GAUDET F, 1995, J BIOL CHEM, V270, P29916; GINSBURG GS, 1995, J CLIN INVEST, V96, P528, DOI 10.1172/JCI118065; GLOMSET JA, 1968, J LIPID RES, V9, P155; GROENER JEM, 1989, BIOCHIM BIOPHYS ACTA, V1002, P93, DOI 10.1016/0005-2760(89)90070-2; HAGAN DL, 1994, J BIOL CHEM, V269, P28737; HESLER CB, 1988, J BIOL CHEM, V263, P5020; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; JIANG XC, 1995, J BIOL CHEM, V270, P17133, DOI 10.1074/jbc.270.29.17133; JIANG XC, 1992, J CLIN INVEST, V90, P1290, DOI 10.1172/JCI115993; JIANG XC, 1991, J BIOL CHEM, V266, P4631; KTISTAKI E, 1994, NUCLEIC ACIDS RES, V22, P4689, DOI 10.1093/nar/22.22.4689; KUNITAKE ST, 1992, J LIPID RES, V33, P1807; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; MARTIN LJ, 1993, J LIPID RES, V34, P437; MASUCCIMAGOULAS L, 1996, J CLIN INVEST, V97, P1; MCPHERSON R, 1991, ARTERIOSCLER THROMB, V11, P797, DOI 10.1161/01.ATV.11.4.797; OSBORNE TF, 1988, J BIOL CHEM, V263, P3380; OSBORNE TF, 1991, J BIOL CHEM, V266, P13947; OSBORNE TF, 1992, J BIOL CHEM, V267, P18973; PAPE ME, 1995, J LIPID RES, V36, P823; QUINET E, 1991, J CLIN INVEST, V87, P1559, DOI 10.1172/JCI115169; QUINET EM, 1990, J CLIN INVEST, V85, P357, DOI 10.1172/JCI114446; RAMIREZ MI, 1994, MOL CELL BIOL, V14, P2809, DOI 10.1128/MCB.14.4.2809; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SHIRAKATA M, 1988, MOL CELL BIOL, V8, P2581, DOI 10.1128/MCB.8.6.2581; SMITH JR, 1990, J BIOL CHEM, V265, P2306; SMITH JR, 1988, J BIOL CHEM, V263, P18480; SPEAR DH, 1994, J BIOL CHEM, V269, P25212; TALL A, 1995, ANNU REV BIOCHEM, V64, P235; TALL A, 1987, J CLIN INVEST, V79, P1217, DOI 10.1172/JCI112940; TALL AR, 1993, J LIPID RES, V34, P1255; TAYLOR JM, 1993, CURR OPIN LIPIDOL, V4, P84, DOI 10.1097/00041433-199304000-00002; Vallett SM, 1996, J BIOL CHEM, V271, P12247, DOI 10.1074/jbc.271.21.12247; WALSH A, 1993, J LIPID RES, V34, P617; WALSH A, 1989, J BIOL CHEM, V264, P6488; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WHITLOCK ME, 1989, J CLIN INVEST, V84, P129, DOI 10.1172/JCI114132; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9; ZARET KS, 1988, P NATL ACAD SCI USA, V85, P9076, DOI 10.1073/pnas.85.23.9076; ZECHNER R, 1991, J BIOL CHEM, V266, P10583; Zhong SB, 1996, J CLIN INVEST, V97, P2917, DOI 10.1172/JCI118751	51	57	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					31831	31838		10.1074/jbc.271.50.31831	http://dx.doi.org/10.1074/jbc.271.50.31831			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943225	hybrid			2022-12-25	WOS:A1996VY34000016
J	Wartmann, M; Cella, N; Hofer, P; Groner, B; Liu, XW; Hennighausen, L; Hynes, NE				Wartmann, M; Cella, N; Hofer, P; Groner, B; Liu, XW; Hennighausen, L; Hynes, NE			Lactogenic hormone activation of Stat5 and transcription of the beta-casein gene in mammary epithelial cells is independent of p42 ERK2 mitogen-activated protein kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; DNA-BINDING; MAP KINASE; SERINE PHOSPHORYLATION; DEPENDENT ACTIVATION; PROLACTIN RECEPTOR; NUCLEAR FACTOR; FACTOR APRF; EXPRESSION; TYROSINE	HC11 mammary epithelial cells have been used to characterize molecular events involved in the regulation of milk protein gene expression, Treatment of HC11 cells with the lactogenic hormones prolactin, insulin, and glucocorticoids results in transcription of the beta-casein gene, Prolactin induces a signaling event which involves tyrosine phosphorylation of the mammary gland factor, Stat5, a member of the family of signal transducers and activators of transcription (Stat). Here we show that HC11 cells express two Stat5 proteins, Stat5a and Stat5b. Phosphopeptide and phosphoamino acid analysis of Stat5a and Stat5b immunoprecipitated from phosphate-labeled HC11 cells revealed that both proteins were constitutively phosphorylated on serine, Lactogenic hormone treatment resulted in the appearance of a tyrosine-phosphorylated peptide in both Stat5 proteins, Consistent with this observation, a Western blot analysis of Stat5a and Stat5b showed that lactogenic hormones induced a rapid, transient increase in phosphotyrosine which paralleled the binding of Stat5 to its cognate recognition sequence in the beta-casein gene promoter, Lactogenic hormone treatment of the HC11 cells also led to a rapid activation of the mitogen activated protein (MAP) kinase pathway, We examined the role of this pathway in beta-casein transcription using a specific MAP kinase kinase inhibitor, PD98059, Concentrations of PD98059 which completely abrogated lactogen-induced MAP kinase activation did not affect the phosphorylation state of Stat5, its DNA binding activity, or transcriptional activation of a beta-casein reporter construct, This indicates that the MAP kinase pathway does not contribute to lactogenic hormone induction of the beta-casein gene.	FRIEDRICH MIESCHER INST, CH-4002 BASEL, SWITZERLAND; INST EXPT CANC RES, TUMOR BIOL CTR, D-79106 FREIBURG, GERMANY; NIDDK, BIOCHEM & METAB LAB, NIH, BETHESDA, MD 20892 USA	Friedrich Miescher Institute for Biomedical Research; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Cella, Nathalie/AAX-5494-2021; Cella, Nathalie/A-3542-2012	Cella, Nathalie/0000-0001-6060-1076; Cella, Nathalie/0000-0001-6060-1076; Hennighausen, Lothar/0000-0001-8319-9841				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ALTIOK S, 1993, MOL CELL BIOL, V13, P7303, DOI 10.1128/MCB.13.12.7303; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; Beadling C, 1996, EMBO J, V15, P1902, DOI 10.1002/j.1460-2075.1996.tb00541.x; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; BUCKLEY AR, 1993, MOL CELL ENDOCRINOL, V98, P17, DOI 10.1016/0303-7207(93)90231-8; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CAREY GB, 1995, ARCH BIOCHEM BIOPHYS, V316, P179, DOI 10.1006/abbi.1995.1026; CHAMMAS R, 1994, J CELL SCI, V107, P1031; CLEVENGER CV, 1994, J BIOL CHEM, V269, P5559; Dajee M, 1996, MOL ENDOCRINOL, V10, P171, DOI 10.1210/me.10.2.171; DANIELSON KG, 1984, P NATL ACAD SCI-BIOL, V81, P3756, DOI 10.1073/pnas.81.12.3756; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DUSANTERFOURT I, 1994, EMBO J, V13, P2583, DOI 10.1002/j.1460-2075.1994.tb06548.x; ERWIN RA, 1995, ENDOCRINOLOGY, V136, P3512, DOI 10.1210/en.136.8.3512; FLIER JS, 1989, NEW ENGL J MED, V321, P1383, DOI 10.1056/NEJM198911163212007; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; GOUT PW, 1980, CANCER RES, V40, P2433; GRONER B, 1995, CURR OPIN GENET DEV, V5, P587, DOI 10.1016/0959-437X(95)80027-1; HAPP B, 1993, CELL GROWTH DIFFER, V4, P9; HYNES NE, 1990, MOL CELL BIOL, V10, P4027, DOI 10.1128/MCB.10.8.4027; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; LUTTICKEN C, 1995, FEBS LETT, V360, P137, DOI 10.1016/0014-5793(95)00076-L; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MANSOUR SJ, 1994, J BIOCHEM-TOKYO, V116, P304, DOI 10.1093/oxfordjournals.jbchem.a124524; MARTE BM, 1994, CELL GROWTH DIFFER, V5, P239; MARTE BM, 1995, ONCOGENE, V10, P167; MARTI A, 1994, ONCOGENE, V9, P1213; MEIER VS, 1994, MOL CELL BIOL, V14, P128, DOI 10.1128/MCB.14.1.128; Merlo GR, 1996, EUR J CELL BIOL, V70, P97; Pelech SL, 1996, CURR BIOL, V6, P551, DOI 10.1016/S0960-9822(02)00540-7; Ram PA, 1996, J BIOL CHEM, V271, P5929, DOI 10.1074/jbc.271.10.5929; RAO YP, 1995, CELL GROWTH DIFFER, V6, P1235; RAUGHT B, 1995, MOL ENDOCRINOL, V9, P1223, DOI 10.1210/me.9.9.1223; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; ROSKELLEY CD, 1995, CURR OPIN CELL BIOL, V7, P736, DOI 10.1016/0955-0674(95)80117-0; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; RUI H, 1994, J BIOL CHEM, V269, P5364; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHMITT-NEY M, 1992, P NATL ACAD SCI USA, V89, P3130, DOI 10.1073/pnas.89.7.3130; SCHMITT-NEY M, 1991, MOL CELL BIOL, V11, P3745, DOI 10.1128/MCB.11.7.3745; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; Streuli C H, 1993, Semin Cell Biol, V4, P203, DOI 10.1006/scel.1993.1024; STREULI CH, 1995, J BIOL CHEM, V270, P21639, DOI 10.1074/jbc.270.37.21639; TAVERNA D, 1991, CELL GROWTH DIFFER, V2, P145; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; TOURKINE N, 1995, J BIOL CHEM, V270, P20952, DOI 10.1074/jbc.270.36.20952; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WELTE T, 1994, MOL ENDOCRINOL, V8, P1091, DOI 10.1210/me.8.8.1091; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Yang CH, 1996, J BIOL CHEM, V271, P8057, DOI 10.1074/jbc.271.14.8057; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	55	104	104	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					31863	31868		10.1074/jbc.271.50.31863	http://dx.doi.org/10.1074/jbc.271.50.31863			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943229	hybrid			2022-12-25	WOS:A1996VY34000020
J	Arn, EA; Abelson, JN				Arn, EA; Abelson, JN			The 2'-5' RNA ligase of Escherichia coli - Purification, cloning, and genomic disruption	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE; ENDONUCLEASE; BACTERIA; EXTRACT; TRANSCRIPTION; SYNTHETASE; EXPRESSION; SEQUENCES; INTRONS	An RNA ligase previously detected in extracts of Escherichia coli is capable of joining Saccharomyces cerevisiae tRNA splicing intermediates in the absence of ATP to form a 2'-5' phosphodiester linkage (Greer, C., Javor, B., and Abelson, J. (1983) Cell 33, 899-906), This enzyme specifically ligates tRNA half-molecules containing nucleoside base modifications and shows a preference among different tRNA species, In order to investigate the function of this enzyme in RNA metabolism, the ligase was purified to homogeneity from E. coli lysate utilizing chromatographic techniques and separation of proteins by SDS-polyacrylamide gel electrophoresis. A single polypeptide of approximately 20 kilodaltons exhibited RNA ligase activity, The amino terminus of this protein was sequenced, and the open reading frame (ORF) encoding it was identified by a data base search, This ORF, which encodes a novel protein with a pre dieted molecular mass of 19.9 kDa, was amplified from E. coli genomic DNA and cloned, ORFs coding for highly similar proteins were detected in Methanococcus jannaschii and Bacillus stearothermophilus. The chromosomal gene encoding RNA ligase in E. coli was disrupted, abolishing ligase activity in cell lysates, Cells lacking ligase activity grew normally under laboratory conditions, However, moderate overexpression of the ligase protein led to slower growth rates and a temperature-sensitive phenotype in both wild-type and RNA ligase knockout strains, The RNA ligase reaction was studied in vitro using purified enzyme and was found to be reversible, indicating that this enzyme may perform cleavage or ligation in vivo.	CALTECH,DIV BIOL 14775,PASADENA,CA 91125	California Institute of Technology								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMITSUR M, 1987, EMBO J, V6, P2499, DOI 10.1002/j.1460-2075.1987.tb02532.x; ANDACHI Y, 1989, J MOL BIOL, V209, P37, DOI 10.1016/0022-2836(89)90168-X; ARNEZ JG, 1994, BIOCHEMISTRY-US, V33, P7560, DOI 10.1021/bi00190a008; BINISZKIEWICZ D, 1994, EMBO J, V13, P4629, DOI 10.1002/j.1460-2075.1994.tb06785.x; BJORK GR, 1987, ESCHERICHIA COLI SAL, V1, P719; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CORNET F, 1994, J BACTERIOL, V176, P3188, DOI 10.1128/jb.176.11.3188-3195.1994; EVANS CF, 1990, METHOD ENZYMOL, V181, P439; FILIPOWICZ W, 1983, CELL, V32, P547, DOI 10.1016/0092-8674(83)90474-9; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FUJITA N, 1994, NUCLEIC ACIDS RES, V22, P1637, DOI 10.1093/nar/22.9.1637; GEGENHEIMER P, 1983, J BIOL CHEM, V258, P8365; GREER CL, 1983, CELL, V33, P899, DOI 10.1016/0092-8674(83)90032-6; GREER CL, 1983, CELL, V32, P537, DOI 10.1016/0092-8674(83)90473-7; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HERTEL KJ, 1995, BIOCHEMISTRY-US, V34, P1744, DOI 10.1021/bi00005a031; KAWAMUKAI M, 1991, J BACTERIOL, V173, P2644, DOI 10.1128/jb.173.8.2644-2648.1991; KJEMS J, 1989, CAN J MICROBIOL, V35, P210, DOI 10.1139/m89-033; KOHARA Y, 1990, BACTERIAL CHROMOSOME, P29; KOMINE Y, 1990, J MOL BIOL, V212, P579, DOI 10.1016/0022-2836(90)90224-A; LIONG EC, 1994, MOL GEN GENET, V243, P343, DOI 10.1007/BF00301070; LOEWEN PC, 1994, ANNU REV MICROBIOL, V48, P53, DOI 10.1146/annurev.mi.48.100194.000413; PEEBLES CL, 1983, CELL, V32, P525, DOI 10.1016/0092-8674(83)90472-5; PERRET V, 1990, NATURE, V344, P787, DOI 10.1038/344787a0; PRZYKORSKA A, 1995, BIOCHIMIE, V77, P109, DOI 10.1016/0300-9084(96)88113-2; RAUHUT R, 1990, J BIOL CHEM, V265, P18180; REINHOLDHUREK B, 1992, NATURE, V357, P173, DOI 10.1038/357173a0; REYES VM, 1987, ANAL BIOCHEM, V166, P90, DOI 10.1016/0003-2697(87)90551-3; RUSCHE LN, 1995, MOL CELL BIOL, V15, P2933; SAMPSON JR, 1993, NUCLEIC ACIDS RES, V21, P4467, DOI 10.1093/nar/21.19.4467; SCHAGGER H, 1986, METHOD ENZYMOL, V126, P224; TRUJILLO MA, 1987, EUR J BIOCHEM, V169, P167, DOI 10.1111/j.1432-1033.1987.tb13594.x; VICENTE M, 1991, MOL MICROBIOL, V5, P2085, DOI 10.1111/j.1365-2958.1991.tb02137.x; WALLACE RB, 1980, SCIENCE, V209, P1396, DOI 10.1126/science.6997991; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	36	52	57	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31145	31153		10.1074/jbc.271.49.31145	http://dx.doi.org/10.1074/jbc.271.49.31145			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940112	hybrid			2022-12-25	WOS:A1996VW68600023
J	Gatti, A; Robinson, PJ				Gatti, A; Robinson, PJ			Unique phosphorylation of protein kinase C-alpha in PC12 cells induces resistance to translocation and Down-regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTERS; ACTIVATION; CA-2+; AUTOPHOSPHORYLATION; PHOSPHATIDYLSERINE; STIMULATION; INCREASE; BINDING; DOMAIN	Cell exposure to phorbol ester stimulates translocation and activation of protein kinase C (PKC), ultimately followed by its down-regulation Upon activation, PKC-alpha, the best studied isotype of the PRC family, undergoes changes in its phosphorylation state. With a two-dimensional immunoblot procedure we have previously shown the existence in PC12 cells of several multiply phosphorylated forms of PRC-alpha, whose number increases in response to phorbol esters (Gatti, A., Wang, X., and Robinson, P. J. (1996) Biochim. Biophys. Acta 1313, 111-118), Using the same experimental system, here we report that besides the predominant pool of 80-kDa PKC-alpha forms that respond to phorbol ester by translocating to the cell membranes and down-regulating, there is a small pool of cytosolic 82-kDa PKC-alpha forms that are characterized by a more acidic pi and by an unique resistance to phorbol ester-mediated translocation and down-regulation, The appearance of similarly slower migrating and more acidic PKC-alpha forms is reproduced upon in vitro autophosphorylation in the presence of phosphatidylserine and phorbol ester, but not in the presence of calcium, These results suggest that site-specific transphosphorylation or autophosphorylation of this kinase may regulate its subcellular localization and susceptibility to down-regulation.			Gatti, A (corresponding author), IST EUROPEO ONCOL,DEPT EXPT ONCOL,VIA RIPAMONTI 435,I-20141 MILAN,ITALY.		Robinson, Phillip J/G-4008-2011	Robinson, Phillip J/0000-0002-7878-0313				BORNER C, 1989, J BIOL CHEM, V264, P13902; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CAZAUBON SM, 1993, J BIOL CHEM, V268, P17559; FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895; Gatti A, 1996, BBA-MOL CELL RES, V1313, P111, DOI 10.1016/0167-4889(96)00061-4; HOUSE C, 1989, FEBS LETT, V249, P243, DOI 10.1016/0014-5793(89)80632-5; HUANG KP, 1986, J BIOL CHEM, V261, P2134; INAGAKI M, 1986, FEBS LETT, V202, P277, DOI 10.1016/0014-5793(86)80701-3; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MITCHELL FE, 1989, BIOCHEM J, V261, P131, DOI 10.1042/bj2610131; MOCHLYROSEN D, 1987, J BIOL CHEM, V262, P2291; MOLINA CA, 1991, CANCER RES, V51, P4624; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OHNO S, 1994, J BIOL CHEM, V269, P17495; ORR JW, 1992, J BIOL CHEM, V267, P15263; PEARS C, 1992, BIOCHEM J, V283, P515, DOI 10.1042/bj2830515; ROBINSON PJ, 1992, J BIOL CHEM, V267, P21637; ROBINSON PJ, 1991, MOL NEUROBIOL, V5, P87, DOI 10.1007/BF02935541; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; TANAKA C, 1994, ANNU REV NEUROSCI, V17, P551, DOI 10.1146/annurev.ne.17.030194.003003; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRILIVAS I, 1989, J BIOL CHEM, V264, P3102; WOLF M, 1985, J BIOL CHEM, V260, P5718; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775	28	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31718	31722		10.1074/jbc.271.49.31718	http://dx.doi.org/10.1074/jbc.271.49.31718			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940195	hybrid			2022-12-25	WOS:A1996VW68600106
J	Ilaria, RL; VanEtten, RA				Ilaria, RL; VanEtten, RA			P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; HEMATOPOIETIC-CELL LINE; TRANSCRIPTION FACTOR; C-ABL; PHILADELPHIA-CHROMOSOME; KINASE-ACTIVITY; SH2 DOMAIN; ACTIVATION; PROTEIN; SIGNAL	The products of the Philadelphia chromosome translocation, P210 and p190(BCR/ABL), are cytoplasmic protein tyrosine kinases that share the ability to transform hematopoietic cytokine-dependent cell lines to cytokine independence but differ in the spectrum of leukemia induced in vivo. We have analyzed the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathways in hematopoietic cells transformed by Bcr/Abl, STAT5 and, to a lesser extent, STATs 1 and 3 were constitutively activated by tyrosine phosphorylation and induction of DNA binding activity in both P210 and p190(BCR/ABL)-transformed cells, but P190 differed in that it also prominently activated STAT6, There was low level tyrosine phosphorylation of JAKs 1, 2, and 3 in Bcr/Abl-transformed cells, but no detectable complex formation with Bcr/Abl, and activation of STAT5 by P210 was not blocked by two different dominant-negative JAK mutants, These results suggest that P210 and p190(BCR/ABL) directly activate specific STAT family members and may help explain their overlapping yet distinct roles in leukemogenesis.	HARVARD UNIV,SCH MED,DEPT GENET,CTR BLOOD RES,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,DIV HEMATOL ONCOL,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Brigham & Women's Hospital					NHLBI NIH HHS [K08HL03310-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003310] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BINARI R, 1994, GENE DEV, V8, P300, DOI 10.1101/gad.8.3.300; CARLESSO N, 1994, ONCOGENE, V9, P149; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1992, MOL CELL BIOL, V12, P1864, DOI 10.1128/MCB.12.4.1864; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; Hariharan I K, 1988, Oncogene Res, V3, P387; HARRISON DA, 1995, EMBO J, V14, P2857, DOI 10.1002/j.1460-2075.1995.tb07285.x; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; ILARIA RL, 1995, BLOOD, V86, P3897, DOI 10.1182/blood.V86.10.3897.bloodjournal86103897; JACKSON PK, 1993, ONCOGENE, V8, P1943; JACOBSON NG, 1995, J EXP MED, V181, P1755, DOI 10.1084/jem.181.5.1755; Kanwar VS, 1996, BLOOD, V87, P4911, DOI 10.1182/blood.V87.11.4911.bloodjournal87114911; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LANEUVILLE P, 1991, ONCOGENE, V6, P275; LEE JC, 1982, J IMMUNOL, V128, P2393; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; LUO H, 1995, EMBO J, V14, P1412, DOI 10.1002/j.1460-2075.1995.tb07127.x; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; OKUDA K, 1994, J BIOL CHEM, V269, P24602; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; ROTHMAN P, 1994, IMMUNITY, V1, P457, DOI 10.1016/1074-7613(94)90088-4; RUFFJAMISON S, 1994, J BIOL CHEM, V269, P12933; SCHIFFMAKER L, 1986, J VIROL, V57, P1182, DOI 10.1128/JVI.57.3.1182-1186.1986; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; Yan RQ, 1996, CELL, V84, P421, DOI 10.1016/S0092-8674(00)81287-8; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806; ZHUANG HM, 1994, J BIOL CHEM, V269, P21411	46	394	404	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31704	31710		10.1074/jbc.271.49.31704	http://dx.doi.org/10.1074/jbc.271.49.31704			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940193	hybrid			2022-12-25	WOS:A1996VW68600104
J	Salgia, R; Avraham, S; Pisick, E; Li, JL; Raja, S; Greenfield, EA; Sattler, M; Avraham, H; Griffin, JD				Salgia, R; Avraham, S; Pisick, E; Li, JL; Raja, S; Greenfield, EA; Sattler, M; Avraham, H; Griffin, JD			The related adhesion focal tyrosine kinase forms a complex with paxillin in hematopoietic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; PHOSPHORYLATION; BINDING; IDENTIFICATION; P210(BCR/ABL); PP125(FAK); ASSOCIATION; PROTEINS; PP125FAK; CLONING	Related adhesion focal tyrosine kinase (RAFTK), also known as proline-rich tyrosine kinase 2 and cellular adhesion kinase beta, has been recently cloned and characterized as a member of the focal adhesion kinase (FAR) subfamily. RAFTK has an overall 48% amino acid homology to p125(FAK) and contains a kinase domain but lacks a transmembrane region, myristylation sites, and Src homology region 2 and 3 domains. By Northern blot analysis, RAFTK is expressed in myeloid, lymphoid, and megakaryocytic hematopoietic cells. Like p125(FAK), we found that RAFTK interacts with the focal adhesion protein paxillin. In the lymphoid cell line BaF3 and the myeloid cell Line 32Dc13, RAFTK coprecipitates with paxillin. Using in vitro binding assays, RAFTK and paxillin were shown to bind directly, through a segment of paxillin that required amino acids 100-227 and a domain in the C terminus of RAFTK. In vitro, RAFTK could phosphorylate paxillin on tyrosine residues, These results suggest that RAFTK, as well as p125(FAK), may be important in phosphotyrosine-signaling events within the focal adhesion.	DANA FARBER CANC INST,DIV HEMATOL MALIGNANCIES,BOSTON,MA 02115; DEACONESS HOSP,DIV HEMATOL & ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School			Li, J L/E-6100-2018; Li, Jian-Liang/AAE-9315-2019	Li, J L/0000-0002-6487-081X; Li, Jian-Liang/0000-0002-6487-081X; Avraham, Hava/0000-0002-7545-3640	NCI NIH HHS [CA60821] Funding Source: Medline; NHLBI NIH HHS [HL55445, HL51456] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA060821] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051456, R01HL055445] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; BELLIS SL, 1995, J BIOL CHEM, V270, P17437, DOI 10.1074/jbc.270.29.17437; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; GEIGER B, 1990, CELL DIFFER DEV, V32, P343, DOI 10.1016/0922-3371(90)90049-3; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; ILLE D, 1995, NATURE, V377, P539; KANNER SB, 1994, P NATL ACAD SCI USA, V91, P10484, DOI 10.1073/pnas.91.22.10484; KHARBANDA S, 1995, P NATL ACAD SCI USA, V92, P6132, DOI 10.1073/pnas.92.13.6132; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LI S, 1996, BLOOD, V88, P417; LI SL, 1995, HYBRIDOMA, V14, P341, DOI 10.1089/hyb.1995.14.341; LO SH, 1994, CANCER METAST REV, V13, P9, DOI 10.1007/BF00690415; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MATULONIS U, 1993, EXP HEMATOL, V21, P1460; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; PARSONS JT, 1994, J CELL SCI, P109; SALGIA R, 1995, ONCOGENE, V11, P1149; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; Sambrook J., 2002, MOL CLONING LAB MANU; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SATTLER M, 1995, EXP HEMATOL, V23, P1040; SATTLER S, 1996, ONCOGENE, V12, P839; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLAEPFER DD, 1994, NATURE, V372, P786; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; TURNER CE, 1993, J CELL SCI, V105, P637; TURNER CE, 1994, J CELL SCI, V107, P1583	31	130	134	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31222	31226		10.1074/jbc.271.49.31222	http://dx.doi.org/10.1074/jbc.271.49.31222			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940124	hybrid			2022-12-25	WOS:A1996VW68600035
J	Williamson, TG; Mok, SS; Henry, A; Cappai, R; Lander, AD; Nurcombe, V; Beyreuther, K; Masters, CL; Small, DH				Williamson, TG; Mok, SS; Henry, A; Cappai, R; Lander, AD; Nurcombe, V; Beyreuther, K; Masters, CL; Small, DH			Secreted glypican binds to the amyloid precursor protein of Alzheimer's disease (APP) and inhibits APP-induced neurite outgrowth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; HUMAN-LUNG FIBROBLASTS; NERVE GROWTH-FACTOR; CELL-SURFACE; EXTRACELLULAR-MATRIX; NEUROBLASTOMA-CELLS; HIPPOCAMPAL-NEURONS; MONOCLONAL-ANTIBODY; CORE PROTEIN; PURIFICATION	The amyloid precursor protein (APP) of Alzheimer's disease has been shown to stimulate neurite outgrowth in vitro. The effect of APP on neurite outgrowth can be enhanced if APP is presented to neurons in substrate-bound form, in the presence of heparan sulfate proteog lycans. To identify specific heparan sulfate proteoglycans that bind to APP, conditioned medium from neonatal mouse brain cells was subjected to affinity chromatography with recombinant APP(695) as a ligand, Glypican bound strongly to the APP affinity column, Purified glypican bound to APP with an equilibrium dissociation constant of 2.8 nM and inhibited APP-induced neurite outgrowth from chick sympathetic neurons. The effect of glypican was specific for APP, as glypican did not inhibit laminin-induced neurite outgrowth, Furthermore, treatment of cultures with 4-methylumbelliferyl-beta-D-xyloside, a competitive inhibitor of proteoglycan glycanation, inhibited APP-induced neurite outgrowth but did not inhibit laminin-induced neurite outgrowth, This result suggests that endogenous proteoglycans are required for substrate-bound APP to stimulate neurite outgrowth, Secreted glypican may act to inhibit APP-induced neurite outgrowth in vivo by competing with endogenous proteoglycans for binding to APP.	UNIV MELBOURNE,DEPT PATHOL,PARKVILLE,VIC 3052,AUSTRALIA; UNIV MELBOURNE,DEPT ANAT & CELL BIOL,PARKVILLE,VIC 3052,AUSTRALIA; UNIV CALIF IRVINE,DEPT DEV & CELL BIOL,IRVINE,CA 92717; UNIV HEIDELBERG,CTR MOL BIOL,D-6900 HEIDELBERG,GERMANY; MENTAL HLTH RES INST,PARKVILLE,VIC 3052,AUSTRALIA	University of Melbourne; University of Melbourne; University of California System; University of California Irvine; Ruprecht Karls University Heidelberg; Florey Institute of Neuroscience & Mental Health			Lander, Arthur D/C-9008-2011; Lander, Arthur/L-2827-2019; Cappai, Roberto/B-3347-2010	Lander, Arthur D/0000-0002-4380-5525; Lander, Arthur/0000-0002-4380-5525; Cappai, Roberto/0000-0002-9505-8496	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026862] Funding Source: NIH RePORTER; NINDS NIH HHS [NS26862] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLINQUANT B, 1995, J CELL BIOL, V128, P919, DOI 10.1083/jcb.128.5.919; ARAKI W, 1991, BIOCHEM BIOPH RES CO, V181, P265, DOI 10.1016/S0006-291X(05)81412-3; BRONNERFRASER M, 1988, J CELL BIOL, V106, P1321, DOI 10.1083/jcb.106.4.1321; CAREY DJ, 1987, J CELL BIOL, V105, P1013, DOI 10.1083/jcb.105.2.1013; CHANDRASEKHAR S, 1987, ANAL BIOCHEM, V161, P103, DOI 10.1016/0003-2697(87)90658-0; CLARRIS HJ, 1995, DEV BRAIN RES, V88, P87, DOI 10.1016/0165-3806(95)00083-P; CLARRIS HJ, 1994, J NEUROSCI RES, V38, P248, DOI 10.1002/jnr.490380303; COLE GJ, 1986, NATURE, V320, P445, DOI 10.1038/320445a0; DAVID G, 1990, J CELL BIOL, V111, P3165, DOI 10.1083/jcb.111.6.3165; DEMORENO MR, 1985, ANAL BIOCHEM, V151, P466, DOI 10.1016/0003-2697(85)90206-4; DEWITT DA, 1993, EXP NEUROL, V121, P149, DOI 10.1006/exnr.1993.1081; EDGAR D, 1981, NATURE, V289, P294, DOI 10.1038/289294a0; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GURWITZ D, 1990, J CELL PHYSIOL, V142, P155, DOI 10.1002/jcp.1041420119; HANTAZAMBROISE D, 1987, J NEUROSCI, V7, P2293; HEREMANS A, 1988, J BIOL CHEM, V263, P4731; JALKANEN M, 1985, J CELL BIOL, V101, P976, DOI 10.1083/jcb.101.3.976; JIN LW, 1994, J NEUROSCI, V14, P5461; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KARTHIKEYAN L, 1992, BIOCHEM BIOPH RES CO, V188, P395, DOI 10.1016/0006-291X(92)92398-H; KARTHIKEYAN L, 1994, J CELL SCI, V107, P3213; KIM CW, 1994, MOL BIOL CELL, V5, P797, DOI 10.1091/mbc.5.7.797; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBLANC AC, 1992, J NEUROSCI RES, V31, P635, DOI 10.1002/jnr.490310407; LETOURNEAU PC, 1994, J NEUROSCI, V14, P915, DOI 10.1523/JNEUROSCI.14-03-00915.1994; LITWACK ED, 1994, J NEUROSCI, V14, P3713; LOFFLER J, 1992, J NEUROCHEM, V59, P1316, DOI 10.1111/j.1471-4159.1992.tb08443.x; LORIES V, 1986, EUR J BIOCHEM, V158, P351, DOI 10.1111/j.1432-1033.1986.tb09758.x; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MATTSON MP, 1994, J NEUROBIOL, V25, P439, DOI 10.1002/neu.480250409; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MILWARD EA, 1992, NEURON, V9, P129, DOI 10.1016/0896-6273(92)90228-6; MOIR RD, 1992, J NEUROCHEM, V59, P1490, DOI 10.1111/j.1471-4159.1992.tb08465.x; NARINDRASORASAK S, 1991, J BIOL CHEM, V266, P12878; NINOMIYA H, 1994, J NEUROCHEM, V63, P495; OHTA M, 1993, DEV BRAIN RES, V75, P151, DOI 10.1016/0165-3806(93)90019-7; QIU WQ, 1995, J NEUROSCI, V15, P2157, DOI 10.1523/JNEUROSCI.15-03-02157.1995; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; SCHUBERT D, 1993, BRAIN RES, V629, P275, DOI 10.1016/0006-8993(93)91331-L; SMALL DH, 1994, J NEUROSCI, V14, P2117; SMALL DH, 1992, J NEUROSCI, V12, P4143; SNOW AD, 1992, J HISTOCHEM CYTOCHEM, V40, P105, DOI 10.1177/40.1.1370306; SNOW AD, 1988, AM J PATHOL, V133, P455; STIPP CS, 1994, J CELL BIOL, V124, P149, DOI 10.1083/jcb.124.1.149; SU JH, 1992, NEUROSCIENCE, V51, P801, DOI 10.1016/0306-4522(92)90521-3; WALICKE PA, 1988, EXP NEUROL, V102, P144, DOI 10.1016/0014-4886(88)90087-8; WILLIAMSON TG, 1995, J NEUROCHEM, V65, P2201; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	50	89	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31215	31221		10.1074/jbc.271.49.31215	http://dx.doi.org/10.1074/jbc.271.49.31215			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940123	hybrid, Green Published			2022-12-25	WOS:A1996VW68600034
J	Pontow, SE; Blum, JS; Stahl, PD				Pontow, SE; Blum, JS; Stahl, PD			Delayed activation of the mannose receptor following synthesis - Requirement for exit from the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-RECOGNITION DOMAINS; SECRETORY PATHWAY; BREFELDIN-A; GOLGI MEMBRANES; LIGAND-BINDING; G PROTEINS; CELLS; MACROPHAGES; GLYCOSYLATION; TRANSPORT	The macrophage mannose receptor specifically recognizes proteins and particles bearing mannose terminal oligosaccharide chains. In the present study, we examined the ability of newly synthesized receptor to bind ligand. Human monocyte-derived macrophages were pulse-labeled with [S-35]Met and prepared for affinity chromatography on mannose-Sepharose. Mannose receptor in the flow-through and eluted fractions was detected by fluorography following immunoprecipitation and gel electrophoresis, Labeled mannose receptor was found exclusively in the nonbinding fraction until 10 min of chase. Following a 60-min chase, 67-86% of newly synthesized receptor was precipitated from the bound column fraction. The half-time for development of receptor binding activity was determined to be 35-40 min compared with a 45-min half-time for development of endoglycosidase H resistance. Mannose receptor synthesized by cells incubated in brefeldin A required more than 120 min to acquire endoglycosidase H resistance and maximal binding activity. Inhibitors of N-linked oligosaccharide processing or of O-glycosylation had no effect on the development of mannose receptor binding activity. Monensin prevented terminal sialylation of oligosaccharide side chains but did not inhibit receptor activation. Inclusion of aluminum fluoride in the chase media reversibly inhibited development of endoglycosidase H resistance and mannose-binding activity. We conclude that the mannose receptor undergoes delayed activation following synthesis and suggest that the activating event(s) occur following exit of the receptor from the endoplasmic reticulum and prior to its entry into the trans-Golgi.	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	Washington University (WUSTL)			Stahl, Philip/D-6315-2012					ARAR C, 1995, J BIOL CHEM, V270, P3551, DOI 10.1074/jbc.270.8.3551; BURGOYNE RD, 1992, TRENDS BIOCHEM SCI, V17, P87; CHUNG KN, 1984, J BIOL CHEM, V259, P4637; DIAZ R, 1989, BIOCHEM J, V260, P127, DOI 10.1042/bj2600127; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DRICKAMER K, 1993, BIOCHEM SOC T, V21, P468; ELBEIN AD, 1987, METHOD ENZYMOL, V138, P661; EZEKOWITZ RAB, 1990, J EXP MED, V172, P1785, DOI 10.1084/jem.172.6.1785; FIEDLER K, 1994, CELL, V77, P625, DOI 10.1016/0092-8674(94)90047-7; FINAZZI D, 1994, J BIOL CHEM, V269, P13325; FREEDMAN R, 1987, NATURE, V329, P196, DOI 10.1038/329196a0; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Hendriks R J, 1994, Subcell Biochem, V22, P101; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUAN SF, 1989, J BIOL CHEM, V264, P19271; LENNARTZ MR, 1989, J BIOL CHEM, V264, P2385; LENNARTZ MR, 1987, BIOCHEM J, V245, P705, DOI 10.1042/bj2450705; Lippincott-Schwartz J, 1993, Subcell Biochem, V21, P95; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MOLLENHAUER HH, 1990, BIOCHIM BIOPHYS ACTA, V1031, P225, DOI 10.1016/0304-4157(90)90008-Z; MULLIN NP, 1994, J BIOL CHEM, V269, P28405; POMMIER CG, 1984, BLOOD, V64, P858; PONTOW SE, 1992, INT REV CYTOL, V137B, P221; PONTOW SE, 1992, NATO ASI SERIES H, V91, P333; STAHL P, 1980, CELL, V19, P207, DOI 10.1016/0092-8674(80)90402-X; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; TAYLOR ME, 1992, J BIOL CHEM, V267, P1719; TAYLOR ME, 1993, J BIOL CHEM, V268, P399; TAYLOR ME, 1993, BIOCHEM SOC T, V21, P468, DOI 10.1042/bst0210468; TOOZE SA, 1988, J CELL BIOL, V106, P1475, DOI 10.1083/jcb.106.5.1475; Varki A, 1994, Subcell Biochem, V22, P71; YOSHIMORI T, 1990, J BIOL CHEM, V265, P15984	36	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30736	30740		10.1074/jbc.271.48.30736	http://dx.doi.org/10.1074/jbc.271.48.30736			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940052	hybrid			2022-12-25	WOS:A1996VV15800069
J	Stefanis, L; Park, DS; Yan, CYI; Farinelli, SE; Troy, CM; Shelanski, ML; Greene, LA				Stefanis, L; Park, DS; Yan, CYI; Farinelli, SE; Troy, CM; Shelanski, ML; Greene, LA			Induction of CPP32-like activity in PC12 cells by withdrawal of trophic support - Dissociation from apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; DEATH GENE CED-3; INTERLEUKIN-1-BETA CONVERTING-ENZYME; POLY(ADP-RIBOSE) POLYMERASE; C-ELEGANS; IL-1-BETA-CONVERTING ENZYME; NEURONAL DIFFERENTIATION; PHEOCHROMOCYTOMA CELLS; SYMPATHETIC NEURONS; CYSTEINE PROTEASES	Inhibitors of interleukin-1 beta converting enzyme (ICE) and a related group of cysteine aspartases of the ICE/ced-3 family inhibit cell death in a variety of settings, including in PC12 cells and sympathetic neurons following withdrawal of trophic support. To assess the particular member(s) of the ICE/ced-3 family that are relevant to cell death and to position their activation within the apoptotic pathway, we have used specific substrates to measure ICE-like and CPP32-like enzymatic activity in naive and neuronally differentiated PC12 cells that had been deprived of trophic support (nerve growth factor and/or serum). Rapid induction of CPP32-like, but not ICE-like, activity was observed. c-Jun kinase activation and the action of bcl-2 and other survival agents, such as cell cycle blockers, a NO generator, N-acetylcysteine, aurintricarboxylic acid, and actinomycin D occurred at a point further upstream in the apoptotic pathway compared with the aspartase activation. In living cells, zVAD-FRIR, a pseudosubstrate aspartase inhibitor, blocked the activity/activation of the aspartase at concentrations about one order of magnitude lower than those required to promote survival, raising the possibility that the CPP32-like aspartase is not the main death effector in this model.	COLUMBIA UNIV COLL PHYS & SURG, DEPT NEUROL, TAUB CTR ALZHEIMERS DIS RES, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, CTR NEUROBIOL & BEHAV, NEW YORK, NY 10032 USA	Columbia University; Columbia University	Stefanis, L (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, DEPT PATHOL, TAUB CTR ALZHEIMERS DIS RES, 630 W 168TH ST, NEW YORK, NY 10032 USA.		Stefanis, Leonidas/AAD-7192-2019; Yan, Chao Yun Irene/B-4700-2011; Troy, Carol/ABC-2771-2020	Yan, Chao Yun Irene/0000-0003-0527-5719; Park, David/0000-0002-4490-3784				BATISTATOU A, 1993, J CELL BIOL, V122, P523, DOI 10.1083/jcb.122.3.523; BATISTATOU A, 1991, J CELL BIOL, V115, P461, DOI 10.1083/jcb.115.2.461; BATISTATOU A, 1993, J NEUROSCI, V13, P4422; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604; DAVIES AM, 1995, TRENDS NEUROSCI, V18, P355, DOI 10.1016/0166-2236(95)93928-Q; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Farinelli SE, 1996, J NEUROSCI, V16, P2325; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FERRARI G, 1995, J NEUROSCI, V15, P2857; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GU Y, 1995, J BIOL CHEM, V270, P18715, DOI 10.1074/jbc.270.32.18715; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MESNER PW, 1992, J CELL BIOL, V119, P1669, DOI 10.1083/jcb.119.6.1669; MILLER DK, 1993, J BIOL CHEM, V268, P18062; MILLIGAN CE, 1995, NEURON, V15, P385, DOI 10.1016/0896-6273(95)90042-X; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OKADA N, 1995, J BIOL CHEM, V270, P16464, DOI 10.1074/jbc.270.27.16464; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; Park DS, 1996, J BIOL CHEM, V271, P8161, DOI 10.1074/jbc.271.14.8161; Park DS, 1996, J BIOL CHEM, V271, P21898, DOI 10.1074/jbc.271.36.21898; RUKENSTEIN A, 1991, J NEUROSCI, V11, P2552; RYDEL RE, 1988, P NATL ACAD SCI USA, V85, P1257, DOI 10.1073/pnas.85.4.1257; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; SHAW E, 1990, ADV ENZYMOL RAMB, V63, P271; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Troy CM, 1996, P NATL ACAD SCI USA, V93, P5635, DOI 10.1073/pnas.93.11.5635; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; YAN CYI, 1995, J BIOL CHEM, V270, P26827, DOI 10.1074/jbc.270.45.26827; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	53	148	148	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30663	30671		10.1074/jbc.271.48.30663	http://dx.doi.org/10.1074/jbc.271.48.30663			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940042	hybrid			2022-12-25	WOS:A1996VV15800059
J	Arakawa, T; Laneuville, O; Miller, CA; Lakkides, KM; Wingerd, BA; DeWitt, DL; Smith, WL				Arakawa, T; Laneuville, O; Miller, CA; Lakkides, KM; Wingerd, BA; DeWitt, DL; Smith, WL			Prostanoid receptors of murine NIH 3T3 and RAW 264.7 cells - Structure and expression of the murine prostaglandin EP4 receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATOR-ACTIVATED RECEPTORS; ENDOPEROXIDE SYNTHASE-2 GENE; NORTHERN BLOT ANALYSIS; EP(2) SUBTYPE; MOLECULAR CHARACTERIZATION; TRANSCRIPTION FACTOR; FUNCTIONAL EXPRESSION; PROSTACYCLIN RECEPTOR; SIGNAL-TRANSDUCTION; PROMOTER SEQUENCES	Prostaglandin endoperoxide H synthase-1 (PGHS-1) is expressed constitutively in murine NIH 3T3 cells and RAW 264.7 cells. PGHS-2 is inducibly expressed in these cells following stimulation with serum or bacterial lipopolysaccharide (LPS), respectively. Reverse transcription-polymerase chain reaction (RT-PCR) analysis established that a variety of G protein-linked and peroxisomal proliferator-activated prostanoid receptors are expressed in both of these cell types. The levels of the EP2 and EP4 prostaglandin E(2) (PGE(2)) receptors and the prostaglandin I-2 receptor were changed in these cells by serum or LPS stimulation, Quantitative RT-PCR indicated that the mRNA for the murine EP4 receptor, the butaprost-insensitive PGE(2) receptor that couples to G(s), increases 1.5-3-fold in response to serum (NIH 3T3) or LPS (RAW 264.7) with a time course approximating the induction of PGHS-2 expression. To study expression of the EP4 receptor we isolated the mouse EP4 receptor gene; the gene is 10 kilobase pairs (kb) in length and, like other known prostanoid receptor genes, contains three exons and two introns, The first intron is 0.5 kb and is located 16 base pairs (bp) downstream of the translational start site. This is a different location than that of the first introns of other prostanoid receptor genes. The second intron is located immediately following the sixth transmembrane domain at the same position as the second intron of the thromboxane A(2) receptor, prostaglandin D-2 receptor, prostaglandin I-2 receptor, and one of the PGE(2) (EP1) receptor genes. A major transcriptional start was detected at -142 bp upstream of the translational start. There are a variety of putative cis-acting elements within 1.5 kb upstream of the translational start site and within the first intron. Promoter analyses of the EP4 receptor gene promoter in RAW 264.7 cells indicated that there is a constitutive negative regulatory region between -992 and -928 bp, a constitutive positive region between -928 and -554 bp, and an LPS/serum-responsive region between -554 and -116 bp.	MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Michigan State University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK022042, R01DK022042] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK22042] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAM M, 1994, FEBS LETT, V338, P170, DOI 10.1016/0014-5793(94)80358-7; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AN SZ, 1993, BIOCHEM BIOPH RES CO, V197, P263, DOI 10.1006/bbrc.1993.2470; ANTHONYCAHILL SJ, 1992, SCIENCE, V255, P979, DOI 10.1126/science.1312255; BASTIEN L, 1994, J BIOL CHEM, V269, P11873; BATSHAKE B, 1995, EUR J BIOCHEM, V231, P809, DOI 10.1111/j.1432-1033.1995.tb20765.x; Breyer RM, 1996, AM J PHYSIOL-RENAL, V270, pF485, DOI 10.1152/ajprenal.1996.270.3.F485; BUCHER P, 1986, NUCLEIC ACIDS RES, V14, P10009, DOI 10.1093/nar/14.24.10009; COLEMAN RA, 1994, PROSTAGLANDINS, V47, P151, DOI 10.1016/0090-6980(94)90084-1; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; DEWITT DL, 1993, ARCH BIOCHEM BIOPHYS, V306, P94, DOI 10.1006/abbi.1993.1485; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; EVETT GE, 1993, ARCH BIOCHEM BIOPHYS, V306, P169, DOI 10.1006/abbi.1993.1496; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FUNK CD, 1993, J BIOL CHEM, V268, P26767; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; HERSCHMAN HR, 1994, CANCER METAST REV, V13, P241, DOI 10.1007/BF00666095; HIRATA M, 1994, P NATL ACAD SCI USA, V91, P11192, DOI 10.1073/pnas.91.23.11192; HONDA A, 1993, J BIOL CHEM, V268, P7759; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; JONES KA, 1985, NATURE, V317, P179, DOI 10.1038/317179a0; KANAI N, 1995, SCIENCE, V268, P866, DOI 10.1126/science.7754369; KATOH H, 1995, BBA-GEN SUBJECTS, V1244, P41, DOI 10.1016/0304-4165(94)00182-W; KATSUYAMA M, 1995, FEBS LETT, V372, P151, DOI 10.1016/0014-5793(95)00966-D; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KUJUBU DA, 1993, J BIOL CHEM, V268, P5425; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; Morris JK, 1996, J BIOL CHEM, V271, P16633, DOI 10.1074/jbc.271.28.16633; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; NAMBA T, 1992, BIOCHEM BIOPH RES CO, V184, P1197, DOI 10.1016/S0006-291X(05)80009-9; NAMBA T, 1994, J BIOL CHEM, V269, P9986; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; NISHIGAKI N, 1995, FEBS LETT, V364, P339, DOI 10.1016/0014-5793(95)00421-5; NUSING RM, 1993, J BIOL CHEM, V268, P25253; OGAWA Y, 1995, GENOMICS, V27, P142, DOI 10.1006/geno.1995.1016; REGAN JW, 1994, MOL PHARMACOL, V46, P213; RIESE J, 1994, J LEUKOCYTE BIOL, V55, P476, DOI 10.1002/jlb.55.4.476; Sambrook J., 2002, MOL CLONING LAB MANU; SANDO T, 1994, BIOCHEM BIOPH RES CO, V200, P1329, DOI 10.1006/bbrc.1994.1596; SIEBERT PD, 1993, BIOTECHNIQUES, V14, P244; SIROIS J, 1993, J BIOL CHEM, V268, P21931; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; SMITH WL, 1992, AM J PHYSIOL, V263, pF181; SUGIMOTO Y, 1992, J BIOL CHEM, V267, P6463; SUGIMOTO Y, 1994, J BIOL CHEM, V269, P1356; TAKETO M, 1994, GENOMICS, V19, P585, DOI 10.1006/geno.1994.1113; TOH H, 1995, FEBS LETT, V361, P17, DOI 10.1016/0014-5793(95)00129-W; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; URADE Y, 1995, J LIPID MEDIAT CELL, V12, P257, DOI 10.1016/0929-7855(95)00032-L; USHIKUBI F, 1995, J LIPID MEDIAT CELL, V12, P343, DOI 10.1016/0929-7855(95)00022-I; WATABE A, 1993, J BIOL CHEM, V268, P20175; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; XIE WL, 1994, MOL CELL BIOL, V14, P6531, DOI 10.1128/MCB.14.10.6531; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; YANG JH, 1994, BIOCHEM BIOPH RES CO, V198, P999, DOI 10.1006/bbrc.1994.1142; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975; ZHANG DE, 1994, J BIOL CHEM, V269, P11425; ZHU YJ, 1993, J BIOL CHEM, V268, P26817	65	95	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29569	29575		10.1074/jbc.271.47.29569	http://dx.doi.org/10.1074/jbc.271.47.29569			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939885	hybrid			2022-12-25	WOS:A1996VU52500013
J	SilvaNeto, MAC; Atella, GC; Fialho, E; Paes, MC; Zingali, RB; Petretski, JH; Alves, EW; Masuda, H				SilvaNeto, MAC; Atella, GC; Fialho, E; Paes, MC; Zingali, RB; Petretski, JH; Alves, EW; Masuda, H			Isolation of a calcium-binding phosphoprotein from the oocytes and hemolymph of the blood-sucking insect Rhodnius prolixus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YOLK PROTEINS; VITELLOGENIN GENE; ELECTROPHORETIC GELS; PHOSVITIN; LIPOVITELLIN; EMBRYOGENESIS; EVOLUTION; VITELLIN; SEQUENCE; PHOSPHORYLATION	A novel calcium-binding phosphoprotein was isolated from the oocytes of the blood-sucking bug Rhodnius prolixus. This protein exhibits an apparent molecular mass of 18 kDa on gel filtration, but migrates as an 8-kDa band on N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine/SDS-polyacrylamide gels. It has a high content of serine (24% of the total number of residues), and phosphoserine is the sole amino acid phosphorylated in vivo. A similar protein was partially purified from the hemolymph. It resembles the oocyte form of the protein in its NH2-terminal sequence and its ability to be taken up by growing ovaries. Ca-45 binding to the oocyte phosphoprotein was determined after SDS-polyacrylamide gel electrophoresis followed by blotting on nitrocellulose membranes. Titration of Ca2+-binding sites shows a high capacity (congruent to 50 mol/mol of protein), but a low affinity (K-0.5, congruent to 10(-3) M). Based on these characteristics, we have named this protein Rhodnius calcium-binding phosphoprotein, It resembles phosvitin, a phosphoprotein present in the oocytes of nonmammalian vertebrates.	ESCOLA TECN FED QUIM RIO DE JANEIRO,BR-20010000 RIO JANEIRO,BRAZIL; UNIV ESTADUAL NORTE FLUMINENSE,CTR BIOCIENCIAS & BIOTECNOL,LAB QUIM & FUNCAO PROT & PEPTIDEOS,BR-28015620 S JOSE CAMPOS,RJ,BRAZIL	Universidade Estadual do Norte Fluminense	SilvaNeto, MAC (corresponding author), FED UNIV RIO DE JANEIRO,INST CIENCIAS BIOMED,DEPT BIOQUIM MED,POB 68041,BR-21941590 RIO JANEIRO,BRAZIL.		Atella, Georgia/AAK-7897-2020; PAES, MARCIA CRISTINA/AAL-9530-2021; Zingali, Russolina/G-4862-2012; Fialho, Eliane/AAF-8856-2019	Zingali, Russolina/0000-0003-3156-6923				ALLERTON SE, 1965, J BIOL CHEM, V240, P3892; BANASZAK L, 1991, ANNU REV BIOPHYS BIO, V20, P221, DOI 10.1146/annurev.biophys.20.1.221; BERGINK EW, 1974, J BIOL CHEM, V249, P2897; BYRNE BM, 1984, BIOCHEMISTRY-US, V23, P4275, DOI 10.1021/bi00314a003; BYRNE BM, 1989, PROG BIOPHYS MOL BIO, V53, P33, DOI 10.1016/0079-6107(89)90005-9; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; CARDASIS CA, 1978, J CELL SCI, V77, P101; CHEN JS, 1994, J MOL BIOL, V237, P641, DOI 10.1006/jmbi.1994.1261; CHEN Y, 1992, J BIOL CHEM, V267, P24871; DANSAPETRETSKI M, 1995, J BIOL CHEM, V270, P10893, DOI 10.1074/jbc.270.18.10893; de Meis L, 1974, Biochemistry, V13, P2057, DOI 10.1021/bi00707a009; FLICKINGER RA, 1957, EXP CELL RES, V13, P312, DOI 10.1016/0014-4827(57)90010-1; Garcia ES, 1975, AN ACAD BRAS CIENC, V47, P539; GEORGE A, 1993, J BIOL CHEM, V268, P12624; GREENGARD O, 1964, BIOCHIM BIOPHYS ACTA, V90, P406, DOI 10.1016/0304-4165(64)90208-9; GRIZZUTI K, 1973, BIOCHEMISTRY-US, V12, P4399, DOI 10.1021/bi00746a016; HEGENAUER J, 1977, ANAL BIOCHEM, V78, P308, DOI 10.1016/0003-2697(77)90038-0; IZUMI S, 1994, J INSECT PHYSIOL, V40, P735, DOI 10.1016/0022-1910(94)90001-9; JAFFE LA, 1994, DEV BIOL, V164, P759; JOYAL JL, 1994, J BIOL CHEM, V269, P30039; KELLY GM, 1986, CAN J ZOOL, V64, P2425, DOI 10.1139/z86-362; KUNKEL JG, 1985, COMPREHENSIVE INSECT, V1, P83; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFLEUR GJ, 1995, J MOL EVOL, V41, P505, DOI 10.1007/BF00160323; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MADDRELL SH, 1969, J EXP BIOL, V51, P71; MARSH ME, 1989, BIOCHEMISTRY-US, V28, P339, DOI 10.1021/bi00427a046; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MASUDA H, 1985, INSECT BIOCHEM, V15, P543, DOI 10.1016/0020-1790(85)90068-X; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MECHAM DK, 1949, J AM CHEM SOC, V71, P3670, DOI 10.1021/ja01179a028; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; MONTORZI M, 1995, BIOCHEMISTRY-US, V34, P10851, DOI 10.1021/bi00034a018; MONTORZI M, 1994, BIOCHEM BIOPH RES CO, V200, P1407, DOI 10.1006/bbrc.1994.1607; NARDELLI D, 1987, BIOCHEMISTRY-US, V26, P6397, DOI 10.1021/bi00394a014; OLIVEIRA PL, 1986, J INSECT PHYSIOL, V32, P859, DOI 10.1016/0022-1910(86)90101-0; OLIVEIRA PL, 1995, J BIOL CHEM, V270, P10897, DOI 10.1074/jbc.270.18.10897; OLIVEIRA PL, 1989, INSECT BIOCHEM, V19, P489; RAIKHEL AS, 1992, ANNU REV ENTOMOL, V37, P217, DOI 10.1146/annurev.en.37.010192.001245; REINHARD E, 1995, DEV BIOL, V170, P50, DOI 10.1006/dbio.1995.1194; ROMANS P, 1995, INSECT BIOCHEM MOLEC, V25, P939, DOI 10.1016/0965-1748(95)00037-V; Sander K., 1985, P319; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHARROCK WJ, 1992, J MOL BIOL, V226, P903, DOI 10.1016/0022-2836(92)90642-W; SHIRAISHI K, 1995, DEV BIOL, V170, P594, DOI 10.1006/dbio.1995.1239; SORENSEN ES, 1995, PROTEIN SCI, V4, P2040, DOI 10.1002/pro.5560041009; STRICKER SA, 1995, DEV BIOL, V170, P496, DOI 10.1006/dbio.1995.1232; TABORSKY G, 1980, J BIOL CHEM, V255, P2976; Tata J R, 1979, Recent Prog Horm Res, V35, P47; TREWITT PM, 1992, J MOL EVOL, V34, P478, DOI 10.1007/BF00160462; WAHLI W, 1988, TRENDS GENET, V4, P227, DOI 10.1016/0168-9525(88)90155-2; WALLACE RA, 1986, ANAL BIOCHEM, V157, P256, DOI 10.1016/0003-2697(86)90623-8; WALLACE RA, 1986, BIOCHEM J, V240, P871, DOI 10.1042/bj2400871; WANDEL M, 1995, J BIOL CHEM, V270, P6125; YANO K, 1994, FEBS LETT, V356, P207, DOI 10.1016/0014-5793(94)01265-2; ZHANG YJ, 1992, INSECT BIOCHEM MOLEC, V22, P293, DOI 10.1016/0965-1748(92)90067-O	56	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30227	30232		10.1074/jbc.271.47.30227	http://dx.doi.org/10.1074/jbc.271.47.30227			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939975				2022-12-25	WOS:A1996VU52500103
J	Springer, C; Kunzler, M; Balmelli, T; Braus, GH				Springer, C; Kunzler, M; Balmelli, T; Braus, GH			Amino acid and adenine cross-pathway regulation act through the same 5'-TGACTC-3' motif in the yeast HIS7 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; GENERAL CONTROL; PROTEIN; GCN4; DNA; BIOSYNTHESIS; SEQUENCE; AMIDOTRANSFERASE; MUTAGENESIS	The HIS7 gene of Saccharomyces cerevisiae encodes a bifunctional glutamine amidotransferase:cyclase catalyzing two reactions that lead to the formation of biosynthetic intermediates of the amino acid histidine and the purine adenine. The HIS7 gene is activated by GCN4p under environmental conditions of amino acid starvation through two synergistic upstream sites GCRE1 and GCRE2. The BAS1p-BAS2p complex activates the HIS7 gene in response to adenine limitation. For this activation the proximal GCN4p-binding site GCRE2 is required. GCN4p and BAS1p bind to GCRE2 in vitro. Under conditions of simultaneous amino acid starvation and adenine limitation the effects of GCN4p and BAS1/2p are additive and both factors are necessary for maximal HIS7 transcription. These results suggest that GCN4p and BAS1/2p are able to act simultaneously through the same DNA sequence in vivo and use this site independently from each other in a non-exclusive manner.	UNIV ERLANGEN NURNBERG,INST MICROBIOL BIOCHEM & GENET,D-91058 ERLANGEN,GERMANY	University of Erlangen Nuremberg			Braus, Gerhard H/G-3999-2012	Braus, Gerhard H/0000-0002-3117-5626; Kunzler, Markus/0000-0003-1275-0629				ARNDT K, 1986, P NATL ACAD SCI USA, V83, P8516, DOI 10.1073/pnas.83.22.8516; ARNDT KT, 1987, SCIENCE, V237, P874, DOI 10.1126/science.3303332; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BRAUS G, 1989, EMBO J, V8, P939, DOI 10.1002/j.1460-2075.1989.tb03455.x; BRAZAS RM, 1993, MOL CELL BIOL, V13, P5524, DOI 10.1128/MCB.13.9.5524; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; DAIGNANFORNIER B, 1992, P NATL ACAD SCI USA, V89, P6746, DOI 10.1073/pnas.89.15.6746; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GIEBEL LB, 1990, NUCLEIC ACIDS RES, V18, P4947, DOI 10.1093/nar/18.16.4947; HILL DE, 1986, SCIENCE, V234, P451, DOI 10.1126/science.3532321; HINNEBUSCH AG, 1988, MICROBIOL REV, V52, P248, DOI 10.1128/MMBR.52.2.248-273.1988; HIRST K, 1994, EMBO J, V13, P5410, DOI 10.1002/j.1460-2075.1994.tb06876.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KUENZLER M, 1993, J BACTERIOL, V175, P5548, DOI 10.1128/JB.175.17.5548-5558.1993; MANTSALA P, 1984, J BIOL CHEM, V259, P8478; MIOZZARI G, 1978, J BACTERIOL, V134, P48, DOI 10.1128/JB.134.1.48-59.1978; MOSCH HU, 1991, J BIOL CHEM, V266, P20453; MOYEROWLEY WS, 1989, GENE DEV, V3, P283, DOI 10.1101/gad.3.3.283; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 2002, MOL CLONING LAB MANU; SENGSTAG C, 1987, NUCLEIC ACIDS RES, V15, P233, DOI 10.1093/nar/15.1.233; SIKORSKI RS, 1989, GENETICS, V122, P19; STOTZ A, 1993, CURR GENET, V24, P472, DOI 10.1007/BF00351708; STRUHL K, 1989, ANNU REV BIOCHEM, V58, P1051, DOI 10.1146/annurev.bi.58.070189.005155; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TICEBALDWIN K, 1989, SCIENCE, V246, P931, DOI 10.1126/science.2683089; VOGEL K, 1989, MOL CELL BIOL, V9, P2050, DOI 10.1128/MCB.9.5.2050; YOSHIDA K, 1989, MOL GEN GENET, V217, P40, DOI 10.1007/BF00330940; ZITOMER RS, 1976, J BIOL CHEM, V251, P6320	30	29	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29637	29643		10.1074/jbc.271.47.29637	http://dx.doi.org/10.1074/jbc.271.47.29637			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939895	hybrid			2022-12-25	WOS:A1996VU52500023
J	DiazGuerra, MJM; Bodelon, OG; Velasco, M; Whelan, R; Parker, PJ; Bosca, L				DiazGuerra, MJM; Bodelon, OG; Velasco, M; Whelan, R; Parker, PJ; Bosca, L			Up-regulation of protein kinase C-epsilon promotes the expression of cytokine-inducible nitric oxide synthase in RAW 264.7 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; MURINE PERITONEAL-MACROPHAGES; PHORBOL ESTER; INTERFERON-GAMMA; MAMMALIAN-CELLS; ACTIVATION; LIPOPOLYSACCHARIDE; INDUCTION; ALPHA; HEPATOCYTES	Stimulation of the murine macrophage RAW 264.7 cell line with phorbol esters fails to promote nitric oxide synthesis as occurs in rat hepatocytes or peritoneal macrophages. Transfection of RAW 264.7 cells with plasmids harboring protein kinase C (PKC) -epsilon isotype but not with PKC-alpha,-beta(1),-delta, or constitutively active -alpha and -beta(1) isotypes resulted in the expression of nitric oxide synthase type II (iNOS), as reflected by the synthesis of nitric oxide measured in the culture medium of transfected cells. cotransfection of RAW 264.7 cells with the -1592 to +121-base pair promoter region of the murine iNOS gene and PKC isotypes specifically induced the transactivation of this promoter in the case of the plasmids containing the PKC-epsilon isotype. The mechanism by which PKC-epsilon induced iNOS expression involved the activation of nuclear factor binding to kappa B sites (NF-kappa B) as deduced by the suppressive effect of pyrrolidine dithiocarbamate on nitric oxide synthesis, an inhibitor of NF-kappa B activation, and by the activation of kappa B sites in cells transfected with a vector containing a kappa B motif linked to a chloramphenicol acetyltransferase reporter gene, These results suggest that PKC-epsilon can regulate a pathway that promotes MOS expression in macrophages in response to phorbol ester activation.	UNIV COMPLUTENSE,INST BIOQUIM,CSIC,FAC FARM,E-28040 MADRID,SPAIN; IMPERIAL CANC RES FUND,PROT PHOSPHORYLAT LAB,LONDON WC2A 3PX,ENGLAND	Complutense University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Cancer Research UK			G. Bodelon, Oscar/C-8713-2012; Bosca, Lisardo/A-2059-2008; Parker, Peter j/D-5192-2013; Díaz-Guerra, María José M/M-2855-2014	G. Bodelon, Oscar/0000-0002-2854-8006; Bosca, Lisardo/0000-0002-0253-5469; Díaz-Guerra, María José M/0000-0003-3843-3912; parker, peter/0000-0002-6218-2933				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU SC, 1995, J BIOL CHEM, V270, P10625, DOI 10.1074/jbc.270.18.10625; DANIELSEN AG, 1995, J BIOL CHEM, V270, P21600, DOI 10.1074/jbc.270.37.21600; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DIAZGUERRA MJM, 1988, BIOCHIM BIOPHYS ACTA, V970, P157, DOI 10.1016/0167-4889(88)90174-7; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P522, DOI 10.1073/pnas.90.2.522; GENARO AM, 1995, J CLIN INVEST, V95, P1884, DOI 10.1172/JCI117869; GENG Y, 1995, J CELL PHYSIOL, V163, P545, DOI 10.1002/jcp.1041630315; GENOT EM, 1995, J BIOL CHEM, V270, P9833, DOI 10.1074/jbc.270.17.9833; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HIRANO M, 1995, BIOCHEM BIOPH RES CO, V206, P429, DOI 10.1006/bbrc.1995.1059; HORTELANO S, 1993, FEBS LETT, V320, P135, DOI 10.1016/0014-5793(93)80078-9; HORTELANO S, 1992, J BIOL CHEM, V267, P24937; JUN CD, 1995, J IMMUNOL, V154, P6541; JUN CD, 1994, J IMMUNOL, V153, P3684; KNOWLES RG, 1992, TRENDS BIOCHEM SCI, V17, P399, DOI 10.1016/0968-0004(92)90008-W; LEHEL C, 1995, P NATL ACAD SCI USA, V92, P1406, DOI 10.1073/pnas.92.5.1406; LIAO L, 1994, CELL GROWTH DIFFER, V5, P1185; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MARAIS RM, 1989, EUR J BIOCHEM, V182, P129, DOI 10.1111/j.1432-1033.1989.tb14809.x; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MCKENNA TM, 1994, SHOCK, V2, P84, DOI 10.1097/00024382-199408000-00002; MONCADA S, 1991, PHARMACOL REV, V43, P109; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OLIVIER AR, 1992, J CELL PHYSIOL, V152, P240, DOI 10.1002/jcp.1041520204; PAUL A, 1995, BRIT J PHARMACOL, V114, P482, DOI 10.1111/j.1476-5381.1995.tb13252.x; SANDS WA, 1994, EUR J IMMUNOL, V24, P2345, DOI 10.1002/eji.1830241013; SIMMONS ML, 1994, GLIA, V11, P227, DOI 10.1002/glia.440110303; SPINK J, 1995, J BIOL CHEM, V270, P29541, DOI 10.1074/jbc.270.49.29541; TERENZI F, 1995, J BIOL CHEM, V270, P6017, DOI 10.1074/jbc.270.11.6017; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; WEST MA, 1995, SURGERY, V118, P220, DOI 10.1016/S0039-6060(05)80327-7; XIE QW, 1994, J BIOL CHEM, V269, P4705; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; Yoon Hyun-Ju, 1994, Neuroimmunomodulation, V1, P377, DOI 10.1159/000097191	45	61	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32028	32033		10.1074/jbc.271.50.32028	http://dx.doi.org/10.1074/jbc.271.50.32028			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943252	hybrid			2022-12-25	WOS:A1996VY34000043
J	Toida, T; Hileman, RE; Smith, AE; Vlahova, PI; Linhardt, RJ				Toida, T; Hileman, RE; Smith, AE; Vlahova, PI; Linhardt, RJ			Enzymatic preparation of heparin oligosaccharides containing antithrombin III binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLAVOBACTERIUM-HEPARINUM; ANTICOAGULANT ACTIVITY; TITRATION CALORIMETRY; SEQUENCE; LYASES; AFFINITY; SPECIFICITY; SEPARATION; FRAGMENTS	Two new oligosaccharides were prepared from heparin by its partial depolymerization using heparin lyase I (EC 4.2.2.7) in an attempt to prepare oligosaccharides having intact-antithrombin III binding sites. The oligosaccharides were purified by chromatography on the basis of both size and charge and demonstrated a high level of purity by capillary electrophoresis. One- and two-dimensional H-1 NMR spectroscopy at 500 MHz revealed the structure of each oligosaccharide. The octasaccharide and decasaccharide are Delta UAp2S(1-->4)-alpha-D-GlcNpS 6S(1-->4)-alpha-L-IdoAp(1-->4)-alpha-D-GlcNpAc6S(1-->4)-beta-D-GlcAp (1-->4)-alpha-D-GlcNpS3S6S(1-->4)-alpha-L-IdoAp2S(1-->4)-alpha-D-GlcNpS6S (where Delta UAp is 4-deoxy-alpha-L-threo-hexenopyranosyluronic acid, GlcNp is 2-amino-2-deoxy-glucopyranose, GlcAp is glucopyranosyluronic acid, S is sulfate and Ac is acetate) and Delta UAp2S(1-->4)-alpha-D-Glc-NpS6S(1-->4)-alpha-L-IdoAp(1-->4)-alpha-D-GlcNpAc6S (1-->4)-beta-D-GlcAp( 1-->4)-alpha-D-GlcNp3S6S(1-->4)-alpha-L-IdoAp2S(1-->4)-alpha-D-GlcNpS6S(1-->4)-alpha-L-IdoAp2S(1-->4)-alpha-D-GlcNpS6S, respectively. A hexasaccharide containing a similar structural motif to that found in the antithrombin III binding site and having greatly reduced anticoagulant activity was also isolated, The structure of the hexasaccharide is Delta UAp2S(1-->4)-alpha-D-GlcNpAc6S(1-->4)-beta-D-GlcAp (1-->4)-alpha-D-GlcNpS3S6S(1-->4)-alpha-L-IdoAp (1-->4)-alpha-D-GlcNpS6S. The octasaccharide and decasaccharide correspond to the predominant structural moth found in porcine intestinal mucosal heparin, Sufficient quantities of the decasaccharide were obtained to examine its interaction with antithrombin III using microtitration calorimetry, This decasaccharide bound to antithrombin III with similar avidity as heparin and showed comparable anticoagulant activity, as determined using an antithrombin III dependent anti-factor Xa assay, Interestingly, while both decasaccharide and heparin bound to antithrombin with nanomolar affinity, very little heat of binding was observed.	UNIV IOWA, COLL ENGN, DEPT CHEM & BIOCHEM ENGN, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL PHARM, DIV MED & NAT PROD CHEM, IOWA CITY, IA 52242 USA	University of Iowa; University of Iowa					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052622] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038060] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 52622] Funding Source: Medline; NIGMS NIH HHS [GM38060] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATHA DH, 1984, P NATL ACAD SCI-BIOL, V81, P1030, DOI 10.1073/pnas.81.4.1030; BAE JH, 1994, BIOCHEM J, V301, P121, DOI 10.1042/bj3010121; BOURIN MC, 1993, BIOCHEM J, V289, P313, DOI 10.1042/bj2890313; CASU B, 1981, BIOCHEM J, V197, P599, DOI 10.1042/bj1970599; CASU B, 1985, ADV CARBOHYD CHEM BI, V43, P51, DOI 10.1016/S0065-2318(08)60067-0; CONNELLY PR, 1990, BIOCHEMISTRY-US, V29, P6108, DOI 10.1021/bi00477a031; DELAUDER S, 1992, BIOCHIM BIOPHYS ACTA, V1159, P141, DOI 10.1016/0167-4838(92)90018-9; DESAI UR, 1993, ARCH BIOCHEM BIOPHYS, V306, P461, DOI 10.1006/abbi.1993.1538; DESAI UR, 1993, BIOCHEMISTRY-US, V32, P8140, DOI 10.1021/bi00083a012; EDENS RE, 1995, BIOCHEMISTRY-US, V34, P2400, DOI 10.1021/bi00008a002; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; FREIRE E, 1990, ANAL CHEM, V62, pA950, DOI 10.1021/ac00217a002; FROMM JR, 1995, ARCH BIOCHEM BIOPHYS, V323, P279, DOI 10.1006/abbi.1995.9963; HOOK M, 1976, FEBS LETT, V66, P90, DOI 10.1016/0014-5793(76)80592-3; JAQUES LB, 1979, SCIENCE, V206, P528, DOI 10.1126/science.386509; KIM YS, 1988, THROMB RES, V51, P97, DOI 10.1016/0049-3848(88)90286-1; LANE DL, 1989, HEPARIN CHEM BIOL PR; LEDER IG, 1980, BIOCHEM BIOPH RES CO, V94, P1183, DOI 10.1016/0006-291X(80)90544-6; LINDAHL U, 1979, P NATL ACAD SCI USA, V76, P3198, DOI 10.1073/pnas.76.7.3198; LINDAHL U, 1983, J BIOL CHEM, V258, P9826; LINDAHL U, 1980, P NATL ACAD SCI-BIOL, V77, P6551, DOI 10.1073/pnas.77.11.6551; LINHARDT RJ, 1986, J BIOL CHEM, V261, P4448; LINHARDT RJ, 1992, J BIOL CHEM, V267, P2380; LINHARDT RJ, 1982, J BIOL CHEM, V257, P7310; LINHARDT RJ, 1994, CURRENT PROTOCOLS MO, V2; LINHARDT RJ, 1997, CARBOHYDRATES DRUGS; LOGANATHAN D, 1990, BIOCHEMISTRY-US, V29, P4362, DOI 10.1021/bi00470a015; LOHSE DL, 1992, J BIOL CHEM, V267, P24347; OTOTANI N, 1981, J BIOCHEM-TOKYO, V90, P241, DOI 10.1093/oxfordjournals.jbchem.a133456; OTOTANI N, 1982, BIOCHEM J, V205, P23, DOI 10.1042/bj2050023; OTOTANI N, 1981, J BIOCHEM-TOKYO, V90, P1553, DOI 10.1093/oxfordjournals.jbchem.a133625; PERVIN A, 1995, GLYCOBIOLOGY, V5, P83, DOI 10.1093/glycob/5.1.83; PERVIN A, 1994, ANAL BIOCHEM, V221, P182, DOI 10.1006/abio.1994.1395; RICE KG, 1989, CARBOHYD RES, V190, P219, DOI 10.1016/0008-6215(89)84127-8; ROSENBERG RD, 1979, P NATL ACAD SCI USA, V76, P1218, DOI 10.1073/pnas.76.3.1218; SINAY P, 1984, CARBOHYD RES, V132, pC5, DOI 10.1016/0008-6215(84)85236-2; THUNBERG L, 1982, CARBOHYD RES, V100, P393, DOI 10.1016/S0008-6215(00)81050-2; Tsuda H, 1996, J BIOL CHEM, V271, P10495, DOI 10.1074/jbc.271.18.10495; VANBOECKEL CAA, 1993, ANGEW CHEM INT EDIT, V32, P1671, DOI 10.1002/anie.199316713; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; YAMADA SH, 1993, J BIOL CHEM, V268, P4780	41	53	60	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32040	32047		10.1074/jbc.271.50.32040	http://dx.doi.org/10.1074/jbc.271.50.32040			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943254	hybrid			2022-12-25	WOS:A1996VY34000045
J	Farivar, RS; Brecher, P				Farivar, RS; Brecher, P			Salicylate is a transcriptional inhibitor of the inducible nitric oxide synthase in cultured cardiac fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; SMOOTH-MUSCLE CELLS; GROWTH-FACTOR-BETA; INTERFERON-GAMMA; SODIUM-SALICYLATE; ENDOTHELIAL-CELLS; MESSENGER-RNA; L-ARGININE; EXPRESSION; GENE	We have previously reported that salicylate inhibits the inducible NO synthase (NOS 2) in cytokine-induced cardiac fibroblasts (Farivar, R. S., Chobanian, A. V., and Brecher, P. (1996) Circ. Res. 78, 759-768). To define further the mechanism of inhibition of NOS 2 by salicylate, we investigated NOS 2 mRNA induction by cytokines and determined the kinetics of inhibition by salicylate as compared to dexamethasone. Interferon-gamma plus tumor necrosis factor-alpha induced NOS 2 mRNA synergistically in a time- and dose-dependent manner. Both dexamethasone and salicylate equally inhibited the induction of NOS 2 mRNA in a time and dose-dependent fashion, both before and after cytokine induction. Salicylate also inhibited interferon-gamma plus interleukin-1 beta-induced NOS 2 mRNA After 24 h of cytokine stimulation, salicylate stopped the induction of NOS 2 mRNG whereas dexamethasone delayed the accumulation of transcript. In half-life experiments of NOS 2 mRNA, we found that dexamethasone reduced the half-life of NOS 2 mRNA from 7 to 4 h, whereas salicylate had no effect on mRNA stability. Tumor necrosis factor-alpha and interferon-gamma induced NF-kappa B (p50/p65) and STAT-1, respectively, as assessed by gel shift assays. Salicylate did not inhibit the cytokine induction of NF-kappa B or STAT-1. This study suggests that the anti-inflammatory mechanism of salicylate involves inhibition of NOS 2 transcription and shows that the effect is independent of NF-kappa B activation.	BOSTON UNIV, SCH MED, WHITAKER CARDIOVASC INST, DEPT BIOCHEM, BOSTON, MA 02118 USA; BOSTON UNIV, SCH MED, WHITAKER CARDIOVASC INST, DEPT PATHOL, BOSTON, MA 02118 USA	Boston University; Boston University				Brecher, Peter/0000-0002-9347-6643	NHLBI NIH HHS [HL 53471, HL 55001] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053471] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AEBERHARD EE, 1995, BIOCHEM BIOPH RES CO, V208, P1053, DOI 10.1006/bbrc.1995.1441; AMIN AR, 1995, P NATL ACAD SCI USA, V92, P7926, DOI 10.1073/pnas.92.17.7926; BALLIGAND JL, 1994, J BIOL CHEM, V269, P27580; BOND JF, 1983, MOL CELL BIOL, V3, P1333, DOI 10.1128/MCB.3.8.1333; BRADY AJB, 1992, AM J PHYSIOL, V263, pH1963, DOI 10.1152/ajpheart.1992.263.6.H1963; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BROUET I, 1995, BIOCHEM BIOPH RES CO, V206, P533, DOI 10.1006/bbrc.1995.1076; CETKOVICCVRLJE M, 1993, ENDOCRINOLOGY, V133, P1739, DOI 10.1210/en.133.4.1739; CHANG CH, 1994, J EXP MED, V180, P1367, DOI 10.1084/jem.180.4.1367; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; EVANS T, 1994, FEBS LETT, P563; FARIVAR RS, 1995, HYPERTENSION, V25, P809, DOI 10.1161/01.HYP.25.4.809; Farivar RS, 1996, CIRC RES, V78, P759; FRANTZ B, 1995, SCIENCE, V270, P2017, DOI 10.1126/science.270.5244.2017; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P522, DOI 10.1073/pnas.90.2.522; GILBERT RS, 1993, J CELL PHYSIOL, V157, P128, DOI 10.1002/jcp.1041570117; HOU J, 1995, J CLIN INVEST, V96, P2469, DOI 10.1172/JCI118305; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; INSEL PA, 1990, PHARMACOL BASIS THER, P638; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; JORENS PG, 1992, EUR J PHARMACOL, V224, P7, DOI 10.1016/0014-2999(92)94811-9; JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KOIDE M, 1993, FEBS LETT, V318, P213, DOI 10.1016/0014-5793(93)80514-U; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Kunz D, 1996, P NATL ACAD SCI USA, V93, P255, DOI 10.1073/pnas.93.1.255; LAVNIKOVA N, 1995, J LEUKOCYTE BIOL, V58, P451, DOI 10.1002/jlb.58.4.451; LEE BS, 1995, P NATL ACAD SCI USA, V92, P7207, DOI 10.1073/pnas.92.16.7207; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIEW FY, 1990, J IMMUNOL, V144, P4794; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MIHM S, 1995, FASEB J, V9, P246, DOI 10.1096/fasebj.9.2.7781927; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; NATHAN C, 1994, J BIOL CHEM, V269, P13725; PERRELLA MA, 1994, J BIOL CHEM, V269, P14595; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P10043, DOI 10.1073/pnas.87.24.10043; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; ROBERTS AB, 1992, MOL ENDOCRINOL, V6, P1921, DOI 10.1210/me.6.11.1921; SAKURAI H, 1995, J CLIN INVEST, V96, P2357, DOI 10.1172/JCI118292; SIRSJO A, 1994, FEBS LETT, V338, P191, DOI 10.1016/0014-5793(94)80363-3; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; TAKASHIBA S, 1995, INFECT IMMUN, V63, P1529, DOI 10.1128/IAI.63.4.1529-1534.1995; UJIIE K, 1994, AM J PHYSIOL, V267, pF296, DOI 10.1152/ajprenal.1994.267.2.F296; VODOVOTZ Y, 1993, J EXP MED, V178, P605, DOI 10.1084/jem.178.2.605; WEBER C, 1995, CIRCULATION, V91, P1914, DOI 10.1161/01.CIR.91.7.1914; WEISS G, 1994, J EXP MED, V180, P969, DOI 10.1084/jem.180.3.969; WEISZ A, 1994, J BIOL CHEM, V269, P8324; WERNERFELMAYER G, 1990, J EXP MED, V172, P1599, DOI 10.1084/jem.172.6.1599; XIE QW, 1994, J BIOL CHEM, V269, P4705; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; YANG XC, 1994, J CLIN INVEST, V94, P714, DOI 10.1172/JCI117390	55	55	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31585	31592		10.1074/jbc.271.49.31585	http://dx.doi.org/10.1074/jbc.271.49.31585			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940176	hybrid			2022-12-25	WOS:A1996VW68600087
J	GarrettSinha, LA; Eberspaecher, H; Seldin, MF; deCrombrugghe, B				GarrettSinha, LA; Eberspaecher, H; Seldin, MF; deCrombrugghe, B			A gene for a novel zinc-finger protein expressed in differentiated epithelial cells and transiently in certain mesenchymal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KRUPPEL-LIKE FACTOR; TRANSCRIPTION FACTOR; WILMS-TUMOR; BETA-THALASSEMIA; NERVOUS-SYSTEM; FACTOR EKLF; MOUSE; IDENTIFICATION; MICE; CHROMOSOME-4	We have identified a novel zinc-finger protein whose mRNA is expressed at high levels in the epidermal layer of the skin and in epithelial cells in the tongue, palate, esophagus, stomach, and colon of newborn mice, Expression in epithelial cells is first detected at the time of their differentiation during embryonic development. In addition, during early embryonic development there is expression in mesenchymal cells of the skeletal primordia and the metanephric kidney which is later down-regulated, The expression pattern suggests that the protein could be involved in terminal differentiation of several epithelial cell types and could also be involved in early differentiation of the skeleton and kidney. The carboxyl terminus of the protein contains three zinc fingers with a high degree of homology to erythroid kruppel-like factor and binds to DNA fragments containing CACCC motifs, The amino-terminal portion of the protein is proline and serine-rich and can function as a transcriptional activator, The chromosomal location of the gene was mapped using mouse interspecific backcrosses and was shown to localize to mouse chromosome 4 and to cosegregate with the thioredoxin gene.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOL GENET,HOUSTON,TX 77030; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MICROBIOL,DURHAM,NC 27710	University of Texas System; UTMD Anderson Cancer Center; Duke University; Duke University			Garrett-Sinha, Lee Ann/K-5911-2019	Garrett-Sinha, Lee Ann/0000-0001-7806-4352	NCI NIH HHS [CA09299] Funding Source: Medline; NHGRI NIH HHS [HG00734] Funding Source: Medline; NHLBI NIH HHS [HL41264] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009299] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041264] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000734] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		AHSEE KW, 1994, CANCER RES, V54, P1617; ANDERSON KP, 1995, MOL CELL BIOL, V15, P5957; BISHOP D T, 1985, Genetic Epidemiology, V2, P349, DOI 10.1002/gepi.1370020404; BRESLOW NE, 1982, JNCI-J NATL CANCER I, V68, P429; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CECI J, 1990, GENOMICS, V5, P699; CUTTING GR, 1992, GENOMICS, V12, P801, DOI 10.1016/0888-7543(92)90312-G; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; FENG WC, 1994, J BIOL CHEM, V269, P1493; GAILANI MR, 1992, CELL, V69, P111, DOI 10.1016/0092-8674(92)90122-S; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GOUDIE DR, 1993, NAT GENET, V3, P165, DOI 10.1038/ng0293-165; Green EL, 1981, GENETICS PROBABILITY, P77; HAHN R, 1996, CELL, V85, P841; Hasegawa T, 1996, NUCLEIC ACIDS RES, V24, P3253, DOI 10.1093/nar/24.16.3253; HEPPELLPARTON A, 1995, GENOMICS, V26, P379, DOI 10.1016/0888-7543(95)80223-9; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; JOHNSON DR, 1979, J EMBRYOL EXP MORPH, V53, P327; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Levi G, 1996, DEVELOPMENT, V122, P113; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; Miura K, 1996, CANCER RES, V56, P1629; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; NARDELLI J, 1992, NUCLEIC ACIDS RES, V20, P4137, DOI 10.1093/nar/20.16.4137; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; PARROTT C, 1991, J VIROL, V65, P1414, DOI 10.1128/JVI.65.3.1414-1419.1991; PERKINS AC, 1995, NATURE, V375, P318; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; Sambrook J., 2002, MOL CLONING LAB MANU; SANKARAN L, 1992, ANAL BIOCHEM, V200, P180, DOI 10.1016/0003-2697(92)90296-J; SATO S, 1994, CANCER RES, V54, P5652; SCHNEIDERMAUNOURY S, 1993, CELL, V75, P1199, DOI 10.1016/0092-8674(93)90329-O; SELDIN MF, 1988, J EXP MED, V167, P688, DOI 10.1084/jem.167.2.688; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; TAKETO M, 1994, GENOMICS, V21, P251, DOI 10.1006/geno.1994.1252; TOPILKO P, 1994, NATURE, V371, P796, DOI 10.1038/371796a0; WATSON ML, 1994, METH MOL G, V5, P369; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0; ZHAO GQ, 1993, P NATL ACAD SCI USA, V90, P8633, DOI 10.1073/pnas.90.18.8633	46	266	279	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31384	31390		10.1074/jbc.271.49.31384	http://dx.doi.org/10.1074/jbc.271.49.31384			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940147	hybrid			2022-12-25	WOS:A1996VW68600058
J	Peterson, JE; Kulik, G; Jelinek, T; Reuter, CWM; Shannon, JA; Weber, MJ				Peterson, JE; Kulik, G; Jelinek, T; Reuter, CWM; Shannon, JA; Weber, MJ			Src phosphorylates the insulin-like growth factor type I receptor on the autophosphorylation sites - Requirement for transformation by src	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; DIMENSIONAL GEL-ELECTROPHORESIS; CARBOXYL-TERMINAL TYROSINES; PROTEIN-KINASE; HYBRID RECEPTORS; IGF-I; MONOCLONAL-ANTIBODIES; SIGNAL TRANSMISSION; PHOSPHOAMINO ACIDS; EMBRYO FIBROBLASTS	The insulin-like growth factor type I (IGF-I) receptor can become tyrosine phosphorylated and enzymatically activated either in response to ligand or because of the activity of the Src tyrosine kinase (Peterson, J. E., Jelinek, T., Kaleko, M., Siddle, K., and Weber, M. J. (1994) J. Biol. Chem. 269, 27315-27321). The goal of the present study was to analyze the mechanistic basis and functional significance of the Src-induced phosphorylation and activation of the IGF-I receptor, 1) We mapped the sites of IGF-I receptor autophosphorylation to peptides representing three different receptor domains: tyrosines 943 and 950 in the juxtamembrane region; tyrosines 1131, 1135, and 1136 within the kinase domain; and tyrosine 1316 in the carboxyl-terminal domain. The juxtamembrane and kinase-domain peptides were phosphorylated both in vivo and in vitro. The carboxyl-terminal site, although phosphorylated in vitro and in src-transformed cells, was not a major site of ligand-induced phosphorylation in vivo. 2) We determined that the sites of Src-induced phosphorylation of the IGF-I receptor are the same as the Ligand-induced autophosphorylation sites and that the Src kinase can catalyze these phosphorylations directly. 3) We showed that cells cultured from mice in which the IGF-I receptor has been knocked out by homologous recombination are defective for morphological transformation by src. Thus, the Src kinase can substitute for the receptor kinase in phosphorylating and activating the IGF-I receptor, and this receptor phosphorylation and activation are essential for transformation by src.	UNIV VIRGINIA, HLTH SCI CTR, DEPT MICROBIOL, CHARLOTTESVILLE, VA 22908 USA	University of Virginia					NCI NIH HHS [CA40042, CA39076] Funding Source: Medline; NIGMS NIH HHS [GM49772] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039076, R37CA039076] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMO M, 1992, BIOFACTORS, V3, P151; AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BASERGA R, 1995, CANCER RES, V55, P249; BEGUM N, 1993, J BIOL CHEM, V268, P7917; COBB MH, 1989, J BIOL CHEM, V264, P18701; CONTOR L, 1987, ANAL BIOCHEM, V160, P414, DOI 10.1016/0003-2697(87)90069-8; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; CZECH MP, 1982, FED PROC, V41, P2719; DEMEYTS P, 1994, HORM RES, V42, P152, DOI 10.1159/000184188; Drop S.L.S., 1991, MODERN CONCEPTS INSU, P311; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FARIA TN, 1994, J BIOL CHEM, V269, P13922; FRATTALI AL, 1993, J BIOL CHEM, V268, P7393; GIBSON W, 1974, VIROLOGY, V62, P319, DOI 10.1016/0042-6822(74)90395-X; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; JACOBS S, 1991, MODERN CONCEPTS INSU, P431; JANICOT M, 1991, J BIOL CHEM, V266, P9382; JELINEK T, 1993, BIOTECHNIQUES, V15, P628; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KATO H, 1994, MOL ENDOCRINOL, V8, P40, DOI 10.1210/me.8.1.40; KOZMA LM, 1990, MOL CELL BIOL, V10, P837, DOI 10.1128/MCB.10.2.837; KOZMA LM, 1990, MOL CELL BIOL, V10, P3626, DOI 10.1128/MCB.10.7.3626; LEE JS, 1993, J BIOL CHEM, V268, P4092; LEROITH D, 1994, HORM RES, V41, P74, DOI 10.1159/000183964; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LIU DL, 1992, J VIROL, V66, P374, DOI 10.1128/JVI.66.1.374-385.1992; LIU DL, 1993, J VIROL, V67, P6835, DOI 10.1128/JVI.67.11.6835-6840.1993; MCCLAIN DA, 1990, J BIOL CHEM, V265, P1678; MIURA M, 1995, CANCER RES, V55, P663; MOONEY RA, 1992, J BIOL CHEM, V267, P23443; MORGAN DO, 1991, METHOD ENZYMOL, V200, P645; PANG L, 1994, J BIOL CHEM, V269, P10604; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PESSIN JE, 1993, ADV EXP MED BIOL, V343, P133; PESSIN JE, 1993, MOL REPROD DEV, V35, P339, DOI 10.1002/mrd.1080350404; PETERSON JE, 1994, J BIOL CHEM, V269, P27315; PRAGER D, 1994, J BIOL CHEM, V269, P11984; RAO GN, 1995, J BIOL CHEM, V270, P27871, DOI 10.1074/jbc.270.46.27871; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; SELL C, 1995, CANCER RES, V55, P303; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SHANNON JD, 1995, TECH PROT CHEM, V6, P117, DOI 10.1016/S1080-8914(06)80017-7; SOOS MA, 1989, BIOCHEM J, V263, P553, DOI 10.1042/bj2630553; SOOS MA, 1993, ADV EXP MED BIOL, V343, P145; SOOS MA, 1991, MODERN CONCEPTS INSU, P461; SURMACZ E, 1995, EXP CELL RES, V218, P370, DOI 10.1006/excr.1995.1168; TAKATA Y, 1994, DIABETES METAB, V20, P31; TAKATA Y, 1992, J BIOL CHEM, V267, P9065; TAKATA Y, 1991, J BIOL CHEM, V266, P9135; TAVARE JM, 1988, BIOCHEM J, V252, P607, DOI 10.1042/bj2520607; TAVARE JM, 1988, BIOCHEM J, V253, P783, DOI 10.1042/bj2530783; THIES RS, 1989, J BIOL CHEM, V264, P12820; TORNQVIST HE, 1987, J BIOL CHEM, V262, P10212; TORNQVIST HE, 1988, J BIOL CHEM, V263, P4593; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; TREADWAY JL, 1991, P NATL ACAD SCI USA, V88, P214, DOI 10.1073/pnas.88.1.214; TREADWAY JL, 1991, MODERN CONCEPTS INSU, P449; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; VANOBBERGHEN E, 1994, DIABETOLOGIA, V37, pS125, DOI 10.1007/BF00400836; WEBER MJ, 1971, J BIOL CHEM, V246, P1828; WELHAM MJ, 1988, J VIROL, V62, P1898, DOI 10.1128/JVI.62.6.1898-1906.1988; WHITE MF, 1984, J CELL BIOCHEM, V26, P169, DOI 10.1002/jcb.240260305; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WHITE MF, 1985, BIOCHIM BIOPHYS ACTA, V822, P355, DOI 10.1016/0304-4157(85)90015-2; WHITE MF, 1988, J BIOL CHEM, V263, P2969; ZICK Y, 1986, P NATL ACAD SCI USA, V83, P9294, DOI 10.1073/pnas.83.24.9294	72	92	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31562	31571		10.1074/jbc.271.49.31562	http://dx.doi.org/10.1074/jbc.271.49.31562			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940173	hybrid			2022-12-25	WOS:A1996VW68600084
J	Price, A; Economou, A; Duong, F; Wickner, W				Price, A; Economou, A; Duong, F; Wickner, W			Separable ATPase and membrane insertion domains of the SecA subunit of preprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI PLASMA-MEMBRANE; ESCHERICHIA-COLI; PROTEIN TRANSLOCATION; ACIDIC PHOSPHOLIPIDS; PRECURSOR PROTEINS; TRIGGER FACTOR; COAT PROTEIN; BINDING; EXPORT; SECY/E	The SecA subunit of preprotein translocase drives ATP-dependent translocation of preproteins across the bacterial inner membrane concomitant with cycles of membrane insertion and de-insertion (Economou, A., and Wickner, W. (1994) Cell 78, 835-843). We have identified the membrane-inserting region of SecA as a 30-kDa domain in the C-terminal third of the protein beginning at aminoacyl residue 610, Limited proteolysis in the absence of translocation ligands indicates that the SecA monomer is composed of two primary structural domains, the 30-kDa membrane-inserting domain and an N-terminal 65-kDa ATPase domain This Limited protease treatment of SecA results in constitutive ATPase activity, indicating that intramolecular constraints between the two domains mag play a role in the regulation of ATP hydrolysis by SecA.	DARTMOUTH COLL, HITCHCOCK MED CTR, DARTMOUTH MED SCH, DEPT BIOCHEM, HANOVER, NH 03755 USA; UNIV CRETE, DEPT BIOL, GR-71110 IRAKLION, CRETE, GREECE	Dartmouth College; University of Crete			Economou, Anastassios/P-8292-2017	Economou, Anastassios/0000-0002-1770-507X				ARKOWITZ RA, 1994, BBA-REV BIOMEMBRANES, V1197, P311; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BREUKINK E, 1995, J BIOL CHEM, V270, P7902, DOI 10.1074/jbc.270.14.7902; BREUKINK E, 1992, BIOCHEMISTRY-US, V31, P1119, DOI 10.1021/bi00119a021; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CHANG CN, 1978, P NATL ACAD SCI USA, V75, P361, DOI 10.1073/pnas.75.1.361; CROOKE E, 1988, CELL, V54, P1003, DOI 10.1016/0092-8674(88)90115-8; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DOUVILLE K, 1994, J BIOL CHEM, V269, P18705; DOUVILLE K, 1995, J BIOL CHEM, V270, P20106, DOI 10.1074/jbc.270.34.20106; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; HANADA M, 1994, J BIOL CHEM, V269, P23625; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HENDRICK JP, 1991, J BIOL CHEM, V266, P24596; ITO K, 1980, J BIOL CHEM, V255, P2123; KIM YJ, 1994, CELL, V78, P845; KUMAMOTO CA, 1989, P NATL ACAD SCI USA, V86, P5320, DOI 10.1073/pnas.86.14.5320; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; MITCHELL C, 1993, MOL MICROBIOL, V10, P483, DOI 10.1111/j.1365-2958.1993.tb00921.x; RAJAPANDI T, 1994, BIOCHEM BIOPH RES CO, V200, P1477, DOI 10.1006/bbrc.1994.1617; Rajapandi T, 1996, MOL MICROBIOL, V20, P43, DOI 10.1111/j.1365-2958.1996.tb02487.x; SAMBROOK J, 1989, MOL CLONING LAB MANU, pA1; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SCHMIDT MG, 1988, J BACTERIOL, V170, P3404, DOI 10.1128/jb.170.8.3404-3414.1988; Uchida K, 1995, J BIOL CHEM, V270, P30862, DOI 10.1074/jbc.270.52.30862; ULBRANDT ND, 1992, J BIOL CHEM, V267, P15184; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533	32	61	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31580	31584		10.1074/jbc.271.49.31580	http://dx.doi.org/10.1074/jbc.271.49.31580			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940175	hybrid			2022-12-25	WOS:A1996VW68600086
J	Rice, WJ; MacLennan, DH				Rice, WJ; MacLennan, DH			Scanning mutagenesis reveals a similar pattern of mutation sensitivity in transmembrane sequences M4, M5, and M6, but not in M8, of the Ca2+-ATPase of sarcoplasmic reticulum (SERCA1a)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING DOMAIN; FUNCTIONAL CONSEQUENCES; AMINO-ACIDS; CA-2+-ATPASE; ATPASE; SITE; TRANSPORT; GLUTAMINE; BOUNDARY; GLU(771)	Scanning mutagenesis was performed on all amino acids in transmembrane sequences M5, M6, and M8, which, together with M4, make up the Ca2+ binding domain of the Ca2+-ATPase of sarcoplasmic reticulum (SERCA1a), When these transmembrane sequences were displayed on a helical net, examination of the effects of 101 novel point mutations and 95 prior mutations carried out on 92 transmembrane amino acids revealed ''patches'' of sensitivity to mutation in M4, M5, and M6 but not in M8. The patches of mutation-sensitive residues spanned 6 of the 7 tiers of the helical net and covered about 240 degrees at their widest point in tiers 3 or 4 and 140 degrees in tiers 2 and 5. A contiguous column of mutation-insensitive hydrophobic amino acids was found in M4 and M6 and in tiers 4 to 7 of M5. A six-residue motif, (E/D)GLPA(T/V) in tiers 3 and 4 of M4 and Mg with Ca2+-binding residues Glu(309) and Asp(800) as the first residue, was highlighted by mutation sensitivity, Elements of the motif could also be discerned in M5, but reading in the C-terminal to N-terminal direction Mutation sensitivity in tier 5 of M4 mirrored mutation sensitivity of tier 5 in M6, although the amino acid sequences were not similar, The motif or its counterpart was found in a region in M4, M5, and Mg that is made up of tiny or small amino acids but is bounded by tiers with a larger percentage of bulky amino acids, Tiers 3, 4, and 5 of M4, M5, and M6 contain Ca2+ binding and affinity mutations, E(1)P to E(2)P block mutations and E(2)P dephosphorylation mutations, indicating an important role for these central tiers in Ca2+ binding and in the conformational changes that accompany Ca2+ translocation. Analysis of M8 revealed only a single mutation-sensitive residue, the Ca2+-binding amino acid, Glu(908). This residue and a mutation-insensitive residue, Ala(912) ,were the only vestiges of the motif that was found in M4 and M6. Additional mutations to Glu(908) provided further evidence for its role in Ca2+ binding, Since mutation of M8 failed to identify residues involved in blocking conformational changes or altering Ca2+ affinity, it is apparent that M8 plays a peripheral role in Ca2+ binding and translocation in comparison with M4, M5, and M6.	UNIV TORONTO, CHARLES H BEST INST, BANTING & BEST DEPT MED RES, TORONTO, ON M5G 1L6, CANADA	University of Toronto				Rice, William/0000-0002-5187-255X	NIAMS NIH HHS [R01 AR 39280] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039280] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSEN JP, 1995, J BIOL CHEM, V270, P908, DOI 10.1074/jbc.270.2.908; ANDERSEN JP, 1994, J BIOL CHEM, V269, P15931; ANDERSEN JP, 1994, FEBS LETT, V354, P93, DOI 10.1016/0014-5793(94)01100-1; ANDERSEN JP, 1992, J BIOL CHEM, V267, P19383; ANDERSEN JP, 1992, J BIOL CHEM, V267, P2767; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen L, 1996, J BIOL CHEM, V271, P10745, DOI 10.1074/jbc.271.18.10745; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1993, J BIOL CHEM, V268, P18359; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; INESI G, 1987, J BIOL CHEM, V262, P16338; Kimura Y, 1996, J BIOL CHEM, V271, P21726, DOI 10.1074/jbc.271.36.21726; KINGSTON RE, 1992, CURRENT PROTOCOLS MO; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MACLENNAN DH, 1992, ACTA PHYSIOL SCAND, V146, P141; MACLENNAN DH, 1990, BIOPHYS J, V58, P1355, DOI 10.1016/S0006-3495(90)82482-6; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MARUYAMA K, 1989, J BIOL CHEM, V264, P13038; Rice WJ, 1996, BIOPHYS J, V70, pMAML6; SKERJANC IS, 1993, J BIOL CHEM, V268, P15944; TAYLOR WR, 1986, J THEOR BIOL, V119, P205, DOI 10.1016/S0022-5193(86)80075-3; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; VILSEN B, 1992, FEBS LETT, V306, P247, DOI 10.1016/0014-5793(92)81010-J; VILSEN B, 1991, J BIOL CHEM, V266, P18839; VILSEN B, 1989, J BIOL CHEM, V264, P21024; WEBER K, 1969, J BIOL CHEM, V244, P4406; ZHANG Y, 1995, J BIOL CHEM, V270, P87, DOI 10.1074/jbc.270.1.87; ZHANG Z, 1995, J BIOL CHEM, V270, P16283; ZUBRZYCKAGAARN E, 1984, J BIOENERG BIOMEMBR, V16, P441, DOI 10.1007/BF00743238	34	95	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31412	31419		10.1074/jbc.271.49.31412	http://dx.doi.org/10.1074/jbc.271.49.31412			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940151	hybrid			2022-12-25	WOS:A1996VW68600062
J	Wu, LJ; Ruffing, N; Shi, XJ; Newman, W; Soler, D; Mackay, CR; Qin, SX				Wu, LJ; Ruffing, N; Shi, XJ; Newman, W; Soler, D; Mackay, CR; Qin, SX			Discrete steps in binding and signaling of interleukin-8 with its receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOTACTIC CYTOKINES; NEUTROPHIL CHEMOTAXIS; MONOCLONAL-ANTIBODIES; AMINO TERMINUS; IL-8 RECEPTOR; A RECEPTOR; RESIDUES; LIGAND; TRANSDUCTION; MUTAGENESIS	The mechanisms by which chemokines bind and signal through their receptors are complex and poorly understood. in the present study, we sought to dissect these processes and to map important functional domains of the two CXC chemokine (interleukin-8) receptors, CXCR1 (formally IL-8RA) and CXCR2 (formally IL-8RB), using blocking monoclonal antibodies (mAbs) to the receptors and a series of chimeras between CXCR1 and CXCR2. A panel of specific mAbs against CXCR1 or CXCR2, generated by immunizing mice with transfectants expressing either receptor, were shown to effectively block IL-8- and/or growth-related oncogene a (GRO alpha) -mediated Ligand binding, chemotaxis, elastase release, and VCAM-1 binding in CXCR1 and CXCR2 transfectants and/or human neutrophils. Of particular interest was an anti-CXCR1 mAb, 7D9, that inhibited chemotaxis, elastase release, and VCAM-1 binding but had no detectable effects on Ligand binding. The epitopes of these blocking mAbs were mapped by using a series of CXCR1/2 chimera transfectants and synthetic peptides, Most of the anti-CXCR1 antibodies, except 7D9, mapped to the amino acid sequence WDFDDL (CXCR1 residues 10-15), and all the anti-CXCR2 antibodies mapped to the amino acid sequence FEDFW (CXCR1 residues 6-10). The epitope of mAb 7D9 mainly involved a region within the first 45 residues of CXCR1, and it appeared to be conformation-sensitive. These results support a model in which the binding and signaling of IL-8 with its receptor occur in at least two discrete steps involving distinct domains of the receptor, This model is consistent with the notion that discrete conformational changes of the receptor secondary to ligand binding are required to trigger various biological responses. Moreover, the ligand binding and chemotaxis properties of each CXCR1/2 chimeric receptor to IL-8 and GRO alpha were determined, It was found that each is distinct in its ability to confer Ligand binding and chemotactic response to IL-8 and GRO alpha, and two conclusions could be made. 1) The N-terminal segment of CXCR1 is a dominant determinant of receptor subtype selectivity, consistent with previous studies using rabbit/human CXCR1/2 chimeras; and 2) the specificity determinant for Oil-On binding in CXCR2 involves sequences in the N terminus, distal to the first 15 residues, as well as other parts of the receptor.			Wu, LJ (corresponding author), LEUKOSITE INC,215 1ST ST,CAMBRIDGE,MA 02142, USA.		Mackay, Charles R/A-9673-2008	Mackay, Charles R/0000-0002-6338-7340				Ahuja SK, 1996, J BIOL CHEM, V271, P225, DOI 10.1074/jbc.271.1.225; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BROADDUS VC, 1994, J IMMUNOL, V152, P2960; Campbell JJ, 1996, J CELL BIOL, V134, P255, DOI 10.1083/jcb.134.1.255; CHUNTHARAPAI A, 1994, J IMMUNOL, V153, P5682; CHUNTHARAPAI A, 1994, J IMMUNOL, V152, P1783; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; CLARKLEWIS I, 1994, J BIOL CHEM, V269, P16075; Damaj BB, 1996, J BIOL CHEM, V271, P12783, DOI 10.1074/jbc.271.22.12783; GAYLE RB, 1993, J BIOL CHEM, V268, P7283; GEISER T, 1993, J BIOL CHEM, V268, P15419; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HAMMOND MEW, 1995, J IMMUNOL, V155, P1428; Hammond MEW, 1996, J BIOL CHEM, V271, P8228, DOI 10.1074/jbc.271.14.8228; HEBERT CA, 1993, J BIOL CHEM, V268, P18549; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; Jones SA, 1996, P NATL ACAD SCI USA, V93, P6682, DOI 10.1073/pnas.93.13.6682; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; LEONG SR, 1994, J BIOL CHEM, V269, P19343; MOSER B, 1993, J BIOL CHEM, V268, P7125; MULLIGAN MS, 1993, J IMMUNOL, V150, P5585; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; PEVERI P, 1988, J EXP MED, V167, P1547, DOI 10.1084/jem.167.5.1547; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; Qin SX, 1996, EUR J IMMUNOL, V26, P640, DOI 10.1002/eji.1830260320; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SEKIDO N, 1993, NATURE, V365, P654, DOI 10.1038/365654a0; SICILIANO SJ, 1994, P NATL ACAD SCI USA, V91, P1214, DOI 10.1073/pnas.91.4.1214; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; Williams G, 1996, J BIOL CHEM, V271, P9579, DOI 10.1074/jbc.271.16.9579; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840	35	86	91	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31202	31209		10.1074/jbc.271.49.31202	http://dx.doi.org/10.1074/jbc.271.49.31202			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940121	hybrid			2022-12-25	WOS:A1996VW68600032
J	Hammes, A; OberdorfMaass, S; Jenatschke, S; Pelzer, T; Maass, AH; Gollnick, F; Meyer, R; Afflerbach, J; Neyses, L				Hammes, A; OberdorfMaass, S; Jenatschke, S; Pelzer, T; Maass, AH; Gollnick, F; Meyer, R; Afflerbach, J; Neyses, L			Expression of the plasma membrane Ca2+-ATPase in myogenic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING DOMAINS; CALCIUM-PUMP ISOFORMS; CA2+ PUMP; MOLECULAR-CLONING; CA-2+-TRANSPORTING ATPASE; FUNCTIONAL DOMAINS; SKELETAL-MUSCLE; MESSENGER-RNAS; GROWTH; DIFFERENTIATION	To study the physiological function of the plasma membrane calmodulin dependent calcium ATPase (PMCA) in intact cells, L6 myogenic cell lines stably overexpressing the human PMCA isoform 4CI (= human PMCA isoform 4b) were generated, Several independent L6 clones and controls stably transfected with the empty expression vector were analyzed in detail. The resting cytosolic calcium level in hPMCA4CI-overexpressing muscle cells (measured by the Fura-a method) was significantly reduced by 20-30% compared with controls. This was shown in a cytosolic window of 1322 single cells (p < 0.01). Furthermore, the differentiation process of these cells was remarkably accelerated compared with control myoblasts and parental nontransfected L6 cells as assessed by multinucleated myotube formation and creatine phosphokinase activity elevation. After 4 and 6 days of differentiation, PMCA-overexpressing L6 cells from four independent clones displayed a 3- and 4-fold higher creatine phosphokinase activity compared with controls (n = 5, p < 0.02). These results may extend the concept of the function of the PMCA from simple prevention of calcium overload to an active involvement in intracellular calcium regulation with potentially important consequences for cellular functions.	UNIV WURZBURG, DEPT MED, D-97080 WURZBURG, GERMANY; UNIV BONN, DEPT PHYSIOL, D-53111 BONN, GERMANY	University of Wurzburg; University of Bonn			Meyer, Rainer/H-5871-2013; Maass, Alexander/B-8534-2008; Neyses, Ludwig/AGY-7446-2022	Maass, Alexander/0000-0002-7936-360X; Hammes-Lewin, Annette/0000-0003-1663-8378				ADAMO HP, 1992, BIOCHEM J, V285, P791, DOI 10.1042/bj2850791; BORKE JL, 1989, AM J PHYSIOL, V257, pF842, DOI 10.1152/ajprenal.1989.257.5.F842; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDT P, 1992, J BIOL CHEM, V267, P4376; BROWN EM, 1995, CELL, V83, P679, DOI 10.1016/0092-8674(95)90180-9; CARAFOLI E, 1994, J NEUROBIOL, V25, P312, DOI 10.1002/neu.480250311; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; CARAFOLI E, 1991, PHYSIOL REV, V71, P129, DOI 10.1152/physrev.1991.71.1.129; CARAFOLI E, 1994, FASEB J, V8, P993, DOI 10.1096/fasebj.8.13.7926378; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; ENDO T, 1987, CELL, V49, P515, DOI 10.1016/0092-8674(87)90454-5; ENYEDI A, 1991, J BIOL CHEM, V266, P8952; ENYEDI A, 1994, J BIOL CHEM, V269, P41; FLORINI JR, 1991, J BIOL CHEM, V266, P15917; GOLLNICK F, 1991, EUR J CELL BIOL, V55, P262; GREEB J, 1989, J BIOL CHEM, V264, P18569; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUERINI D, 1995, J BIOL CHEM, V270, P14643, DOI 10.1074/jbc.270.24.14643; HAMMES A, 1994, FASEB J, V8, P428, DOI 10.1096/fasebj.8.6.8168693; HEIM R, 1992, J BIOL CHEM, V267, P24476; JAMES PH, 1989, BIOCHEMISTRY-US, V28, P4253, DOI 10.1021/bi00436a020; KEETON TP, 1995, BIOCHEM J, V306, P779, DOI 10.1042/bj3060779; KEETON TP, 1993, J BIOL CHEM, V268, P2740; KRAIN B, 1996, IN PRESS BASIC RES C; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU BF, 1995, MOL BIOL CELL, V78, pA14; LIUU BF, 1996, J BIOL CHEM, V271, P5536; MEANS AR, 1994, FEBS LETT, V347, P1, DOI 10.1016/0014-5793(94)00492-7; NEYSES L, 1985, J BIOL CHEM, V260, P283; NIGGLI V, 1979, J BIOL CHEM, V254, P9955; OLIVER IT, 1955, BIOCHEM J, V61, P116, DOI 10.1042/bj0610116; ROSALKI SB, 1963, J LAB CLIN MED, V62, P159; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHATZMANN HJ, 1966, EXPERIENTIA, V22, P364, DOI 10.1007/BF01901136; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; SHULL GE, 1988, J BIOL CHEM, V263, P8646; SIMONS M, 1995, AM J PHYSIOL-CELL PH, V268, pC856, DOI 10.1152/ajpcell.1995.268.4.C856; SIMONS M, 1993, J BIOL CHEM, V268, P627; STAUFFER TP, 1993, J BIOL CHEM, V268, P25993; STAUFFER TP, 1995, J BIOL CHEM, V270, P12114; Strehler E E, 1990, Semin Cell Biol, V1, P283; STREHLER EE, 1990, J BIOL CHEM, V265, P2835; STREHLER EE, 1989, P NATL ACAD SCI USA, V86, P6908, DOI 10.1073/pnas.86.18.6908; TOBWIN H, 1979, P NATL ACAD SCI USA, V76, P4350; WALDRON RT, 1994, J BIOL CHEM, V269, P11927; WOOD KV, 1991, BIOLUMINESCENCE AND CHEMILUMINESCENCE, P543; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477	50	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30816	30822		10.1074/jbc.271.48.30816	http://dx.doi.org/10.1074/jbc.271.48.30816			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940063	hybrid, Green Published			2022-12-25	WOS:A1996VV15800080
J	Kellenberger, S; Scheuer, T; Catterall, WA				Kellenberger, S; Scheuer, T; Catterall, WA			Movement of the Na+ channel inactivation gate during inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE SODIUM-CHANNELS; SOMATIC-CELL LINE; SHAKER K-CHANNELS; RAT-BRAIN; ALPHA-SUBUNIT; ACETYLCHOLINE-RECEPTOR; MEMBRANE PATCHES; SEGMENT IVS6; EXPRESSION; CURRENTS	Phenylalanine 1489 in the inactivation gate of the rat brain IIA sodium channel cu subunit is required for stable inactivation. It is proposed to move into the intracellular mouth of the pore and occlude it during inactivation, but direct evidence for movement of this residue during inactivation has not been presented. We used the substituted cysteine accessibility method to test the availability of a cysteine residue substituted at position 1489 to modification by methanethiosulfonate reagents applied from the cytoplasmic side. Mutation of Phe-1489 to Cys results in a small (8%) fraction of noninactivating current, Ag+ and methanethiosulfonate reagents irreversibly slowed the inactivation rate and increased the fraction of noninactivating current of F1489C but not wild-type channels. Single channel analysis showed that modification slowed inactivation from both closed and open states and destabilized the inactivated state. Depolarization prevented rapid modification of Cys-1489 by these reagents, and the voltage dependence of their reaction rate correlated closely with steady-state inactivation, Modification was not detectably voltage-dependent at voltages more negative than channel gating. Our results show that, upon inactivation, Phe-1489 in the inactivation gate moves from an exposed and modifiable position outside the membrane electric field to a buried and inaccessible position, perhaps in or near the intracellular mouth of the channel pore.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle				Kellenberger, Stephan/0000-0003-1755-6198	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015751] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 15751] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; ALDRICH RW, 1983, NATURE, V306, P436, DOI 10.1038/306436a0; ARMSTRONG CM, 1981, PHYSIOL REV, V61, P644, DOI 10.1152/physrev.1981.61.3.644; ARMSTRONG CM, 1973, J GEN PHYSIOL, V62, P375, DOI 10.1085/jgp.62.4.375; ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; AULD VJ, 1988, NEURON, V1, P449, DOI 10.1016/0896-6273(88)90176-6; BENNETT PB, 1995, CIRC RES, V77, P584, DOI 10.1161/01.RES.77.3.584; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; CHAHINE M, 1994, NEURON, V12, P281, DOI 10.1016/0896-6273(94)90271-2; Colquhoun David, 1995, P483; CUMMINS TR, 1996, BIOPHYS J, V51, P227; DANCE IG, 1986, POLYHEDRON, V5, P1037, DOI 10.1016/S0277-5387(00)84307-7; DEMO SD, 1991, NEURON, V7, P743, DOI 10.1016/0896-6273(91)90277-7; EAHOLTZ G, 1994, NEURON, V12, P1041, DOI 10.1016/0896-6273(94)90312-3; GOLDIN AL, 1986, P NATL ACAD SCI USA, V83, P7503, DOI 10.1073/pnas.83.19.7503; GONOI T, 1984, J NEUROSCI, V4, P2836; GONOI T, 1987, J GEN PHYSIOL, V89, P253, DOI 10.1085/jgp.89.2.253; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARTMANN HA, 1994, CIRC RES, V75, P114, DOI 10.1161/01.RES.75.1.114; Hille B., 1992, IONIC CHANNELS EXCIT; HORN R, 1991, BIOPHYS J, V60, P433, DOI 10.1016/S0006-3495(91)82069-0; HORN R, 1984, J GEN PHYSIOL, V84, P505, DOI 10.1085/jgp.84.4.505; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; ISOM LL, 1995, CELL, V83, P433, DOI 10.1016/0092-8674(95)90121-3; KUO CC, 1994, NEURON, V12, P819, DOI 10.1016/0896-6273(94)90335-2; MCPHEE JC, 1994, P NATL ACAD SCI USA, V91, P12346, DOI 10.1073/pnas.91.25.12346; MCPHEE JC, 1995, J BIOL CHEM, V270, P12025, DOI 10.1074/jbc.270.20.12025; METHFESSEL C, 1986, PFLUG ARCH EUR J PHY, V407, P577, DOI 10.1007/BF00582635; MURRELLLAGNADO RD, 1993, J GEN PHYSIOL, V102, P977, DOI 10.1085/jgp.102.6.977; MURRELLLAGNADO RD, 1993, J GEN PHYSIOL, V102, P949, DOI 10.1085/jgp.102.6.949; NODA M, 1986, NATURE, V322, P826, DOI 10.1038/322826a0; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; OLEARY ME, 1995, J GEN PHYSIOL, V106, P641, DOI 10.1085/jgp.106.4.641; PATLAK J, 1982, J GEN PHYSIOL, V79, P333, DOI 10.1085/jgp.79.3.333; ROBERTS DD, 1986, BIOCHEMISTRY-US, V25, P5595, DOI 10.1021/bi00367a038; Rogers JC, 1996, J BIOL CHEM, V271, P15950, DOI 10.1074/jbc.271.27.15950; SCANLEY BE, 1990, J GEN PHYSIOL, V95, P411, DOI 10.1085/jgp.95.3.411; SCHEUER T, 1990, SCIENCE, V247, P854, DOI 10.1126/science.2154850; SCHEUER T, 1993, BIOPHYS J, V64, pA88; SIGWORTH FJ, 1987, BIOPHYS J, V52, P1047, DOI 10.1016/S0006-3495(87)83298-8; STAUFFER DA, 1994, BIOCHEMISTRY-US, V33, P6840, DOI 10.1021/bi00188a013; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; VASSILEV P, 1989, P NATL ACAD SCI USA, V86, P8147, DOI 10.1073/pnas.86.20.8147; VASSILEV PM, 1988, SCIENCE, V241, P1658, DOI 10.1126/science.2458625; WEST JW, 1992, NEURON, V8, P59, DOI 10.1016/0896-6273(92)90108-P; WEST JW, 1992, P NATL ACAD SCI USA, V89, P10910, DOI 10.1073/pnas.89.22.10910; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	48	87	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30971	30979		10.1074/jbc.271.48.30971	http://dx.doi.org/10.1074/jbc.271.48.30971			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940085	hybrid			2022-12-25	WOS:A1996VV15800102
J	Nilius, B; Gerke, V; Prenen, J; Szucs, G; Heinke, S; Weber, K; Droogmans, G				Nilius, B; Gerke, V; Prenen, J; Szucs, G; Heinke, S; Weber, K; Droogmans, G			Annexin II modulates volume-activated chloride currents in vascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-SITE; LIGHT-CHAIN; CALPACTIN-I; MDCK CELLS; PROTEINS; P11; SUBSTRATE; CALCIUM; COMPLEX; CA2+	The membrane-associated, microfilament-binding protein annexin II is abundantly expressed in endothelial cells from calf pulmonary artery (CPAE cells). We have analyzed its role in the regulation of volume-activated chloride currents (I-Cl,I-vol) by loading the cells via the patch pipette with a peptide comprising the N-terminal 14 residues of annexin II. This sequence harbors the binding site for the intracellular annexin II ligand, p11, and the peptide interferes with the annexin II-p11 complex formation. Loading of a CPAE cell with this peptide caused a gradual decrease in the amplitude of I-Cl,I-vol during repetitive stimulations with a 28% hypotonic extracellular solution. This run down of the current was virtually absent in untreated cells and in cells that were loaded with a mutated li-amino acid peptide, which has a single amino acid replacement known to result in a more than 1000 times reduced affinity for binding to pll. We conclude that annexin II-p11 complex formation is either directly or indirectly involved in the activation of I-Cl,I-vol in endothelial cells.	UNIV MUNSTER,CELL RES GRP ENDOTHELIAL CELL BIOL,D-48149 MUNSTER,GERMANY; MAX PLANCK INST BIOPHYS CHEM,DEPT BIOCHEM,D-37077 GOTTINGEN,GERMANY	University of Munster; Max Planck Society	Nilius, B (corresponding author), KATHOLIEKE UNIV LEUVEN,FYSIOL LAB,CAMPUS GASTHUISBERG,HERESTR 49,B-3000 LOUVAIN,BELGIUM.		Szücs, Géza/A-2121-2008					BECKER T, 1990, EMBO J, V9, P4207, DOI 10.1002/j.1460-2075.1990.tb07868.x; CHAN HC, 1994, J BIOL CHEM, V269, P32464; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; GERKE V, 1992, ANNEXINS, P47; GLENNEY JR, 1987, BIOESSAYS, V7, P173, DOI 10.1002/bies.950070408; HARDER T, 1994, BBA-MOL CELL RES, V1223, P375, DOI 10.1016/0167-4889(94)90098-1; JOHNSSON N, 1988, EMBO J, V7, P2435, DOI 10.1002/j.1460-2075.1988.tb03089.x; KAETZEL MA, 1995, NEWS PHYSIOL SCI, V10, P171; KAISER E, 1970, ANAL BIOCHEM, V34, P595, DOI 10.1016/0003-2697(70)90146-6; KUBE E, 1992, J BIOL CHEM, V267, P14175; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOSS SE, 1995, NATURE, V378, P446, DOI 10.1038/378446a0; NEHER E, 1989, NEUROMUSCULAR JUNCTI, P65; NILIUS B, 1994, J GEN PHYSIOL, V103, P787, DOI 10.1085/jgp.103.5.787; NILIUS B, 1996, IN PRESS GEN PHARM, V27; OIKE M, 1994, P NATL ACAD SCI USA, V91, P2940, DOI 10.1073/pnas.91.8.2940; OIKE M, 1994, PFLUG ARCH EUR J PHY, V428, P569, DOI 10.1007/BF00374579; OSBORN M, 1988, EXP CELL RES, V175, P81, DOI 10.1016/0014-4827(88)90257-1; POWELL MA, 1987, BIOCHEM J, V247, P321, DOI 10.1042/bj2470321; PUSCH M, 1988, PFLUG ARCH EUR J PHY, V411, P204, DOI 10.1007/BF00582316; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; STRANGE K, 1995, KIDNEY INT, V48, P994, DOI 10.1038/ki.1995.381; Szucs G, 1996, PFLUG ARCH EUR J PHY, V431, P540, DOI 10.1007/s004240050033; Szucs G, 1996, PFLUG ARCH EUR J PHY, V431, P467, DOI 10.1007/s004240050023; Szucs G, 1996, J MEMBRANE BIOL, V149, P189, DOI 10.1007/s002329900019; THIEL C, 1992, J CELL SCI, V103, P733; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEBER K, 1992, ANNEXINS, P61; ZOKAS L, 1987, J CELL BIOL, V105, P2111, DOI 10.1083/jcb.105.5.2111	33	65	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30631	30636		10.1074/jbc.271.48.30631	http://dx.doi.org/10.1074/jbc.271.48.30631			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940038	hybrid			2022-12-25	WOS:A1996VV15800055
J	Proux, V; Provot, S; FelderSchmittbuhl, MPF; Laugier, D; Calothy, G; Marx, M				Proux, V; Provot, S; FelderSchmittbuhl, MPF; Laugier, D; Calothy, G; Marx, M			Characterization of a leucine zipper-containing protein identified by retroviral insertion in avian neuroretina cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; C-MIL; MOLECULAR-CLONING; TRANSFORMING RETROVIRUS; LYMPHOMATOSIS VIRUS; SARCOMA VIRUS; GENE ENCODES; V-MIL; ONCOGENE; EXPRESSION	We reported previously that post-mitotic chicken embryonic neuroretina (NR) cells are induced to proliferate following in vitro infection with RAV-1, a retrovirus that does not carry an oncogene, NR cell multiplication results from the frequent activation and subsequent retroviral transduction of two related serine/threonine protein kinases, the c-mil/c-raf or c-Rmil/B-raf genes. We also showed that a very early event in the activation of these proto-oncogenes is the synthesis of chimeric mRNAs containing viral and cellular sequences joined by a splicing mechanism, In the current study, we have examined the ability of RAV-1 to induce proliferation of quail NR cells, By using the reverse transcription polymerase chain reaction technique, we identified, in several proliferating quail NR cultures infected with RAV-1, a chimeric mRNA containing cellular sequences joined to the RAV-1 splice donor site, These cellular sequences are derived from a gene designated RIG, which is expressed through a 1.9-kilobase (kb) mRNA detected in several embryonic tissues, A second transcript of 2.3 kb is specifically expressed in the NR, where both transcripts are developmentally regulated, The R10 cDNA encodes a 251-amino acid polypeptide that contains a leucine zipper motif, It exhibits significant similarity with the putative D52/N8L protein, encoded by an mRNA reported previously to be overexpressed in human breast and lung carcinomas, By using polyclonal antibodies specific for its amino-terminal and leucine zipper-containing regions, we identified the R10 gene product as a cytoplasmic protein of 23 kDa in cultured avian fibroblasts, A second protein of 30 kDa is detected in post-mitotic NR cells that express the 2,3-kb transcript, We also show, by in vitro transcription/translation and immunoprecipitation, that the R10 protein can readily form homodimers, presumably through its leucine zipper motif.	INST CURIE,UNITE MIXTE RECH 146 CNRS,LAB 110,CTR UNIV,F-91405 ORSAY,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay				PROVOT, SYLVAIN/0000-0003-4087-4450				Alber T, 1992, CURR OPIN GENET DEV, V2, P205, DOI 10.1016/S0959-437X(05)80275-8; BARNIER JV, 1995, J BIOL CHEM, V270, P23381, DOI 10.1074/jbc.270.40.23381; BECHADE C, 1988, J VIROL, V62, P1211; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BYRNE JA, 1995, CANCER RES, V55, P2896; Chen SL, 1996, ONCOGENE, V12, P741; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLL J, 1983, EMBO J, V2, P2189, DOI 10.1002/j.1460-2075.1983.tb01722.x; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DOROW DS, 1993, EUR J BIOCHEM, V213, P701, DOI 10.1111/j.1432-1033.1993.tb17810.x; EZOE K, 1994, ONCOGENE, V9, P935; FELDER MP, 1991, J VIROL, V65, P3633, DOI 10.1128/JVI.65.7.3633-3640.1991; FELDER MP, 1994, J VIROL, V68, P4759, DOI 10.1128/JVI.68.8.4759-4767.1994; FELDER MP, 1993, J VIROL, V67, P6853, DOI 10.1128/JVI.67.11.6853-6856.1993; FELDER MP, 1994, FOLIA BIOL-PRAGUE, V40, P225; GALLO KA, 1994, J BIOL CHEM, V269, P15092; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; GUERMAH M, 1990, MOL CELL BIOL, V10, P3584, DOI 10.1128/MCB.10.7.3584; Harlow E., 1988, ANTIBODIES LAB MANUA; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; ING YL, 1994, ONCOGENE, V9, P1745; KAWAI S, 1992, VIROLOGY, V188, P778, DOI 10.1016/0042-6822(92)90532-T; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MARX M, 1988, J VIROL, V62, P4627, DOI 10.1128/JVI.62.12.4627-4633.1988; MARX M, 1988, EMBO J, V7, P3369, DOI 10.1002/j.1460-2075.1988.tb03209.x; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; PESSAC B, 1974, SCIENCE, V185, P709, DOI 10.1126/science.185.4152.709; Rehemtulla A, 1996, P NATL ACAD SCI USA, V93, P191, DOI 10.1073/pnas.93.1.191; REMAUT E, 1981, GENE, V15, P81, DOI 10.1016/0378-1119(81)90106-2; Sambrook J., 2002, MOL CLONING LAB MANU; SAMBUCETTI LC, 1986, SCIENCE, V234, P1417, DOI 10.1126/science.3491427; SANGER F, 1981, SCIENCE, V214, P1205, DOI 10.1126/science.7302589; SAVITT JW, 1995, NEURON, V14, P253, DOI 10.1016/0896-6273(95)90283-X; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STAVNEZER E, 1981, J VIROL, V39, P920, DOI 10.1128/JVI.39.3.920-934.1981; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; TREISMAN JE, 1995, DEVELOPMENT, V121, P2835; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VANLOHUIZEN M, 1990, BIOCHIM BIOPHYS ACTA, V1032, P213, DOI 10.1016/0304-419X(90)90005-L; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4	50	25	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30790	30797		10.1074/jbc.271.48.30790	http://dx.doi.org/10.1074/jbc.271.48.30790			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940059	hybrid			2022-12-25	WOS:A1996VV15800076
J	Zalcman, G; Closson, V; Camonis, J; Honore, N; RousseauMerck, MF; Tavitian, A; Olofsson, B				Zalcman, G; Closson, V; Camonis, J; Honore, N; RousseauMerck, MF; Tavitian, A; Olofsson, B			RhoGDI-3 is a new GDP dissociation inhibitor (GDI) - Identification of a non-cytosolic GDI protein interacting with the small GTP-binding proteins rhoB and rhoG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN STRESS FIBERS; MOLECULAR-CLONING; REGULATORY PROTEIN; GROWTH-FACTOR; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; EXCHANGE PROTEINS; FAMILY GTPASES; CDC42 GTPASES; NADPH OXIDASE	RhoB is a small GTP-binding protein highly homologous to the RhoA protein. While RhoA is known to regulate the assembly of focal adhesions and stress fibers in response to growth factors, the function of RhoB re mains unknown. We have reported that the transient expression of the endogenous RhoB protein is regulated during the cell cycle, contrasting with the permanent RhoA protein expression (1). Using the yeast two-hybrid system to characterize proteins interacting with RhoB, we identified a new mouse Rho GDP dissociation inhibitor, referenced as RhoGDI-3. The NH2-terminal alpha helix of RhoGDI-3 is strongly amphipatic and differs thus from that found in previously described bovine, human, and yeast RhoGDI proteins and mouse and human D4/Ly-GDIs. Contrary to the cytosolic localization of all known GDI proteins, acting on Rab or Rho, RhoGDI-3 is associated to a Triton X-100-insoluble membranous or cytoskeletal subcellular fraction. In the two-hybrid system, RhoGDI-3 interacts specifically with GDP- and GTP-bound forms of post-translationally processed RhoB and RhoG proteins, both of which show a growth-regulated expression in mammalian cells. No interaction is found with RhoA, RhoC, or Rac1 proteins. We show that GDI-3 is able to inhibit GDP/GTP exchange of RhoB and to release GDP-bound but not GTP-bound RhoB from cell membranes.	INST CURIE,SECT RECH,UNITE INSERM 248,F-75231 PARIS 05,FRANCE; HOP ST LOUIS,INST GENET MOL,INSERM U301,F-75010 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			ZALCMAN, Gerard/P-4150-2015; ZALCMAN, Gérard/L-7809-2015; ZALCMAN, Gerard/M-8113-2019	ZALCMAN, Gérard/0000-0002-0343-9575; 				ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; ARAKI S, 1990, J BIOL CHEM, V265, P13007; ARAKI S, 1995, J BIOL CHEM, V92, P2974; BERANGER F, 1994, MOL CELL BIOL, V14, P744, DOI 10.1128/MCB.14.1.744; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; BOURMEYSTER N, 1994, BIOCHEM BIOPH RES CO, V205, P174, DOI 10.1006/bbrc.1994.2646; CHARDIN P, 1988, NUCLEIC ACIDS RES, V16, P2717, DOI 10.1093/nar/16.6.2717; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; CHUANG TH, 1993, J BIOL CHEM, V268, P775; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; Dorseuil O, 1996, J BIOL CHEM, V271, P83, DOI 10.1074/jbc.271.1.83; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; HANCOCK JF, 1993, EMBO J, V12, P1915, DOI 10.1002/j.1460-2075.1993.tb05840.x; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; HERSKOWITZ I, 1988, MICROBIOL REV, V52, P536, DOI 10.1128/MMBR.52.4.536-553.1988; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HORI Y, 1991, ONCOGENE, V6, P515; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; ISOMURA M, 1991, ONCOGENE, V6, P119; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; JANOUEIXLEROSEY I, 1995, J BIOL CHEM, V270, P14801, DOI 10.1074/jbc.270.24.14801; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; JUST I, 1994, J BIOL CHEM, V269, P10706; KIKUCHI A, 1992, J BIOL CHEM, V267, P14611; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; LEFFERS H, 1993, EXP CELL RES, V209, P165, DOI 10.1006/excr.1993.1298; LELIAS JM, 1993, P NATL ACAD SCI USA, V90, P1479, DOI 10.1073/pnas.90.4.1479; LEONARD D, 1992, J BIOL CHEM, V267, P22860; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MASUDA T, 1994, J BIOL CHEM, V269, P19713; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MUNEMITSU S, 1990, MOL CELL BIOL, V10, P5977, DOI 10.1128/MCB.10.11.5977; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Nomanbhoy TK, 1996, J BIOL CHEM, V271, P10004, DOI 10.1074/jbc.271.17.10004; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; PLATKO JV, 1995, P NATL ACAD SCI USA, V92, P2974, DOI 10.1073/pnas.92.7.2974; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QUINN MT, 1993, J BIOL CHEM, V268, P20983; REINHARD J, 1995, EMBO J, V14, P697, DOI 10.1002/j.1460-2075.1995.tb07048.x; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rose M, 1990, LAB COURSE MANUAL ME; ROUSSEAUMERCK MF, 1991, HUM GENET, V86, P350; SASAKI T, 1993, J BIOL CHEM, V268, P23959; SCHERLE P, 1993, P NATL ACAD SCI USA, V90, P7568, DOI 10.1073/pnas.90.16.7568; SEALE JW, 1994, PROTEIN SCI, V3, P1741, DOI 10.1002/pro.5560031014; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TAKAISHI K, 1995, ONCOGENE, V11, P39; VINCENT S, 1992, MOL CELL BIOL, V12, P3138, DOI 10.1128/MCB.12.7.3138; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; ZALCMAN G, 1995, ONCOGENE, V10, P1935; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	64	96	97	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30366	30374		10.1074/jbc.271.48.30366	http://dx.doi.org/10.1074/jbc.271.48.30366			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8939998	hybrid			2022-12-25	WOS:A1996VV15800015
J	DeMott, MS; Shen, BH; Park, MS; Bambara, RA; Zigman, S				DeMott, MS; Shen, BH; Park, MS; Bambara, RA; Zigman, S			Human RAD2 homolog 1 5'- to 3'-exo/endonuclease can efficiently excise a displaced DNA fragment containing a 5'-terminal abasic lesion by endonuclease activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYRIBOSE-PHOSPHATE RESIDUES; APURINIC APYRIMIDINIC SITES; ESCHERICHIA-COLI; ELIMINATION REACTIONS; BETA-ELIMINATION; EXONUCLEASE-I; DAMAGED DNA; REPAIR; DEOXYRIBOPHOSPHODIESTERASE; POLYMERASE	Repair of abasic lesions, one of the most common types of damage found in DNA, is crucial to an organism's well-being, Studies in vitro indicate that after apurinic-apyrimidinic endonuclease cleaves immediately upstream of a baseless site, removal of the 8'-terminal sugar-phosphate residue is achieved by deoxyribophosphodiesterase activity, an enzyme-mediated beta-elimination reaction, or by endonucleolytic cleavage downstream of the baseless sugar, Synthesis and ligation complete repair. Eukaryotic RADS homolog 1 (RTH1) nuclease, by genetic and biochemical evidence, is involved in repair of modified DNA. Efficient endonucleolytic cleavage by RTH1 nuclease has been demonstrated for annealed primers that have unannealed 5'-tails, In vivo, such substrate structures could result from repair-related strand displacement synthesis, Using 5'-tailed substrates, we examined the ability of human RTH1 nuclease to efficiently remove 5'-terminal abasic residues, A series of upstream primers were used to increasingly displace an otherwise annealed downstream primer containing a 5'-terminal deoxyribose-5-phosphate. Until displacement of the first annealed nucleotide, substrates resisted cleavage, With further displacement, efficient cleavage occurred at the 3'-end of the tail, Therefore, in combination with strand displacement activity, RTH1 nucleases may serve as an important alternative to other pathways in repair of abasic sites in DNA.	UNIV ROCHESTER,MED CTR,DEPT OPHTHALMOL,SCH MED & DENT,ROCHESTER,NY 14642; UNIV ROCHESTER,MED CTR,DEPT BIOCHEM,SCH MED & DENT,ROCHESTER,NY 14642; LOS ALAMOS NATL LAB,DIV LIFE SCI,LOS ALAMOS,NM 87545	University of Rochester; University of Rochester; United States Department of Energy (DOE); Los Alamos National Laboratory			Park, Min Sung/HCH-2207-2022	Shen, Binghui/0000-0002-4408-407X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024441] Funding Source: NIH RePORTER; NEI NIH HHS [EY00459] Funding Source: Medline; NIGMS NIH HHS [GM24441] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILLY V, 1989, BIOCHEM J, V259, P761, DOI 10.1042/bj2590761; BAILLY V, 1988, BIOCHEM J, V253, P553, DOI 10.1042/bj2530553; BARNES CJ, 1996, IN PRESS J BIOL CHEM, V271; DIANOV G, 1994, NUCLEIC ACIDS RES, V22, P993, DOI 10.1093/nar/22.6.993; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; FRANKLIN WA, 1988, EMBO J, V7, P3617, DOI 10.1002/j.1460-2075.1988.tb03240.x; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P139; GRAVES RJ, 1992, J BIOL CHEM, V267, P14429; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; JACQUIER A, 1992, YEAST, V8, P122; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3610, DOI 10.1021/bi00769a018; LOVETT ST, 1989, P NATL ACAD SCI USA, V86, P2627, DOI 10.1073/pnas.86.8.2627; LYAMICHEV V, 1993, SCIENCE, V260, P778, DOI 10.1126/science.7683443; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MAZUMDER A, 1991, BIOCHEMISTRY-US, V30, P1119, DOI 10.1021/bi00218a033; MOSBAUGH DW, 1980, J BIOL CHEM, V255, P1743; MUN C, 1994, RADIAT RES, V138, P282, DOI 10.2307/3578599; MURANTE RS, 1994, J BIOL CHEM, V269, P1191; Murante RS, 1996, J BIOL CHEM, V271, P25888, DOI 10.1074/jbc.271.42.25888; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; OCONNOR TR, 1989, P NATL ACAD SCI USA, V86, P5222, DOI 10.1073/pnas.86.14.5222; PRICE A, 1991, BIOCHEMISTRY-US, V30, P8631, DOI 10.1021/bi00099a020; PRICE A, 1992, FEBS LETT, V300, P101, DOI 10.1016/0014-5793(92)80173-E; RANDERATH K, 1967, METHODS ENZYMOLOGY A, V12, P323; ROBINS P, 1994, J BIOL CHEM, V269, P28535; SANDIGURSKY M, 1992, NUCLEIC ACIDS RES, V20, P4699, DOI 10.1093/nar/20.18.4699; SANDIGURSKY M, 1994, NUCLEIC ACIDS RES, V22, P247, DOI 10.1093/nar/22.2.247; Shen BH, 1996, J BIOL CHEM, V271, P9173, DOI 10.1074/jbc.271.16.9173; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; WALLACE SS, 1994, INT J RADIAT BIOL, V66, P579, DOI 10.1080/09553009414551661	36	65	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30068	30076		10.1074/jbc.271.47.30068	http://dx.doi.org/10.1074/jbc.271.47.30068			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939954	hybrid			2022-12-25	WOS:A1996VU52500082
J	Dinbergs, ID; Brown, L; Edelman, ER				Dinbergs, ID; Brown, L; Edelman, ER			Cellular response to transforming growth factor-beta 1 and basic fibroblast growth factor depends on release kinetics and extracellular matrix interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPILLARY ENDOTHELIAL-CELLS; PLASMINOGEN-ACTIVATOR PRODUCTION; HEPARIN-LIKE MOLECULES; FACTOR-BETA; TGF-BETA; SUSTAINED-RELEASE; DNA-SYNTHESIS; PROTEOLYTIC DEGRADATION; ANGIOGENIC ACTIVITY; BASEMENT-MEMBRANE	The extracellular matrix plays an important role in growth factor biology, serving as a potential platform for rapid growth factor mobilization or a sink for concentrated sequestration, We now demonstrate that when a growth factor binds reversibly to the matrix, its effects are augmented by this interaction, and when the factor is absorbed irreversibly to the extracellular matrix, it becomes sequestered. These findings call into question the notion that all growth factors are best presented to cells and tissues in a sustained and controlled fashion, In our studies, we examined basic fibroblast growth factor (bFGF) and transforming growth factor-beta 1 (TGF-beta 1) release kinetics from synthetically fabricated microsphere devices and naturally synthesized extracellular matrix. While the sustained release of bFGF was up to 3.0-fold more potent at increasing vascular endothelial and smooth muscle cell proliferation than bolus administration, the reverse was true for TGF-beta 1 A bolus of TGF-beta 1 inhibited vascular cells up to 3.8-fold more efficiently than the same amount of TGF-beta 1 if control-released. Both growth factors bound to the extracellular matrix, but only bFGF was released in a controlled fashion (2.8%/day). Contact with the extracellular matrix and subsequent release enhanced bFGF activity such that it was 86% more effective at increasing smooth muscle cell numbers than equal amounts of growth factor diluted from frozen stock. TGF-beta 1 remained tightly adherent, The small amount of TGF-beta 1 released from the extracellular matrix was similar to 30% less effective than bolus administration at inhibiting vascular endothelial and smooth muscle cell growth, Sustained growth factor release may be the preferable mode of administration, but only when a similar mode of metabolism is utilized endogenously.	BRIGHAM & WOMENS HOSP, DEPT MED, DIV CARDIOVASC, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Dinbergs, ID (corresponding author), HARVARD UNIV, MIT, DIV HLTH SCI & TECHNOL, CAMBRIDGE, MA 02139 USA.			Brown, Larry/0000-0001-7954-9140	NHLBI NIH HHS [HL/GM 49039] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AEBISCHER P, 1989, J NEUROSCI RES, V23, P282, DOI 10.1002/jnr.490230306; AHARONOV A, 1978, J BIOL CHEM, V253, P3970; AUFDEMORTE TB, 1992, J BONE JOINT SURG AM, V74A, P1153, DOI 10.2106/00004623-199274080-00004; BAIRD A, 1986, BIOCHEM BIOPH RES CO, V138, P476, DOI 10.1016/0006-291X(86)90305-0; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; Beck LS, 1990, GROWTH FACTORS, V3, P267, DOI 10.3109/08977199009003669; BENTZ H, 1995, P 21 ANN M SOC BIOM, P291; BERSCHT PC, 1994, BIOMATERIALS, V15, P593, DOI 10.1016/0142-9612(94)90209-7; BROWN GL, 1988, ANN SURG, V208, P788, DOI 10.1097/00000658-198812000-00019; CAMARATA PJ, 1992, NEUROSURGERY, V30, P313, DOI 10.1227/00006123-199203000-00001; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; CHLEBOUN JO, 1992, BIOCHEM BIOPH RES CO, V185, P510, DOI 10.1016/0006-291X(92)91654-9; COFFEY RJ, 1990, ANN NY ACAD SCI, V593, P285, DOI 10.1111/j.1749-6632.1990.tb16120.x; DAVIDSON JM, 1993, J CELL PHYSIOL, V155, P149, DOI 10.1002/jcp.1041550119; EDELMAN ER, 1990, P NATL ACAD SCI USA, V87, P3773, DOI 10.1073/pnas.87.10.3773; EDELMAN ER, 1992, J CLIN INVEST, V89, P465, DOI 10.1172/JCI115607; EDELMAN ER, 1991, BIOMATERIALS, V12, P619, DOI 10.1016/0142-9612(91)90107-L; EDELMAN ER, 1993, P NATL ACAD SCI USA, V90, P1513, DOI 10.1073/pnas.90.4.1513; FAVA RA, 1987, J CELL PHYSIOL, V131, P184, DOI 10.1002/jcp.1041310207; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FLAUMENHAFT R, 1989, J CELL PHYSIOL, V140, P75, DOI 10.1002/jcp.1041400110; FLAUMENHAFT R, 1990, J CELL BIOL, V111, P1651, DOI 10.1083/jcb.111.4.1651; FOLKMAN J, 1988, AM J PATHOL, V130, P393; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; FRITZ IB, 1988, BIOL GROWTH FACTORS, P1; FUKUNAGA K, 1994, J PHARM PHARMACOL, V46, P168, DOI 10.1111/j.2042-7158.1994.tb03771.x; GAJDUSEK CM, 1993, J CELL PHYSIOL, V157, P133, DOI 10.1002/jcp.1041570118; GLOBUS RK, 1988, ENDOCRINOLOGY, V123, P98, DOI 10.1210/endo-123-1-98; GOLDSMITH KT, 1991, AM J PHYSIOL, V261, pL378, DOI 10.1152/ajplung.1991.261.6.L378; GOMBOTZ W, 1993, P INT S CONTROL REL, V20, P150; GOMBOTZ WR, 1993, J BIOMAT SCI-POLYM E, V5, P49; GONZALEZ AM, 1990, J CELL BIOL, V110, P753, DOI 10.1083/jcb.110.3.753; GOSPODAROWICZ D, 1979, EXP EYE RES, V28, P501, DOI 10.1016/0014-4835(79)90038-1; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; HEATH WF, 1991, BIOCHEMISTRY-US, V30, P5608, DOI 10.1021/bi00236a039; HICKEY MJ, 1994, BIOCHEM BIOPH RES CO, V201, P1066, DOI 10.1006/bbrc.1994.1813; HOFFMAN D, 1990, EXP NEUROL, V110, P39, DOI 10.1016/0014-4886(90)90049-X; HORTON WE, 1989, J CELL PHYSIOL, V141, P8, DOI 10.1002/jcp.1041410103; INOUE H, 1989, J CELL PHYSIOL, V138, P329, DOI 10.1002/jcp.1041380216; KHOURI RK, 1993, SURGERY, V114, P374; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KO C, 1995, ARTIF CELL BLOOD SUB, V23, P143, DOI 10.3109/10731199509117934; KOH GY, 1995, J CLIN INVEST, V95, P114, DOI 10.1172/JCI117627; KRESON CE, 1995, BRAIN RES, V680, P196; KSANDER GA, 1990, ANN SURG, V211, P288; LANGER R, 1991, J CELL BIOCHEM, V45, P340, DOI 10.1002/jcb.240450406; LIU SQ, 1992, BIOMATERIALS, V13, P50, DOI 10.1016/0142-9612(92)90095-6; LOGAN A, 1992, J ENDOCRINOL, V134, P157, DOI 10.1677/joe.0.1340157; MASSAGUE J, 1985, J BIOL CHEM, V260, P2636; MAYSINGER D, 1992, NEUROSCI LETT, V140, P71, DOI 10.1016/0304-3940(92)90684-Y; MCCAFFREY TA, 1992, J CELL PHYSIOL, V152, P430, DOI 10.1002/jcp.1041520226; MEIKLE MC, 1994, BIOMATERIALS, V15, P513, DOI 10.1016/0142-9612(94)90017-5; MEIKLE MC, 1993, BIOMATERIALS, V14, P177, DOI 10.1016/0142-9612(93)90020-3; MOSCATELLI D, 1988, J CELL BIOL, V107, P753, DOI 10.1083/jcb.107.2.753; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; MURRAY JB, 1983, IN VITRO CELL DEV B, V19, P743; MUSTOE TA, 1987, SCIENCE, V237, P1333, DOI 10.1126/science.2442813; NATHAN A, 1995, P NATL ACAD SCI USA, V92, P8130, DOI 10.1073/pnas.92.18.8130; NUGENT MA, 1992, J BIOL CHEM, V267, P21256; NUGENT MA, 1992, BIOCHEMISTRY-US, V31, P8876, DOI 10.1021/bi00152a026; NUGENT MA, 1992, MATER RES SOC SYMP P, V252, P273; PARALKAR VM, 1991, DEV BIOL, V143, P303, DOI 10.1016/0012-1606(91)90081-D; PARK CM, 1991, DEV BIOL, V148, P322, DOI 10.1016/0012-1606(91)90341-Y; PEPPER MS, 1993, EXP CELL RES, V204, P356, DOI 10.1006/excr.1993.1043; PERTOVAARA L, 1993, GROWTH FACTORS, V9, P81, DOI 10.3109/08977199308991584; PHILLIPS GD, 1990, P SOC EXP BIOL MED, V193, P197; PHILLIPS GD, 1993, J SUBMICR CYTOL PATH, V25, P149; POWELL EM, 1990, BRAIN RES, V515, P309, DOI 10.1016/0006-8993(90)90612-F; PRESTA M, 1991, CELL REGUL, V2, P719, DOI 10.1091/mbc.2.9.719; PRESTA M, 1989, J CELL PHYSIOL, V140, P68, DOI 10.1002/jcp.1041400109; PUOLAKKAINEN PA, 1995, J SURG RES, V58, P321, DOI 10.1006/jsre.1995.1050; PUOLAKKAINEN PA, 1994, GASTROENTEROLOGY, V107, P1319, DOI 10.1016/0016-5085(94)90533-9; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; REDDY CC, 1994, BIOTECHNOL PROGR, V10, P377, DOI 10.1021/bp00028a006; Reddy CC, 1996, J CELL PHYSIOL, V166, P512, DOI 10.1002/(SICI)1097-4652(199603)166:3<512::AID-JCP6>3.0.CO;2-S; ROGELJ S, 1989, J CELL BIOL, V109, P823, DOI 10.1083/jcb.109.2.823; ROHRER B, 1994, EXP EYE RES, V58, P553, DOI 10.1006/exer.1994.1049; SAKSELA O, 1987, J CELL BIOL, V105, P957, DOI 10.1083/jcb.105.2.957; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SANDERS KB, 1991, CRIT REV EUKAR GENE, V1, P157; SCHULTZ GS, 1987, SCIENCE, V235, P350, DOI 10.1126/science.3492044; SEFTON MV, 1984, J PHARM SCI-US, V73, P1859, DOI 10.1002/jps.2600731258; SILBERSTEIN GB, 1987, SCIENCE, V237, P291, DOI 10.1126/science.3474783; SOMMER A, 1989, J CELL PHYSIOL, V138, P215, DOI 10.1002/jcp.1041380129; SPARGO BJ, 1995, J MICROENCAPSUL, V12, P247, DOI 10.3109/02652049509010293; SPORN MB, 1991, PEPTIDE GROWTH FACTO, P6; TANIGUCHI E, 1991, Nippon Ganka Gakkai Zasshi, V95, P52; TELFFT JA, 1995, P 21 ANN M SOC BIOM, P299; VLODAVSKY I, 1991, J CELL BIOCHEM, V45, P167, DOI 10.1002/jcb.240450208; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; VLODAVSKY I, 1980, CELL, V19, P607, DOI 10.1016/S0092-8674(80)80037-7; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; YAMAMURA K, 1995, J BIOMED MATER RES, V29, P203, DOI 10.1002/jbm.820290210; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZHAN X, 1993, J BIOL CHEM, V268, P9611	95	90	118	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29822	29829		10.1074/jbc.271.47.29822	http://dx.doi.org/10.1074/jbc.271.47.29822			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939921	hybrid			2022-12-25	WOS:A1996VU52500049
J	Furukawa, M; Suzuki, Y; Ghoneim, MA; Tachibana, S; Hirose, S				Furukawa, M; Suzuki, Y; Ghoneim, MA; Tachibana, S; Hirose, S			Cryptic origin of SPAI, a plasma protein with a transglutaminase substrate domain and the WAP motif, revealed by in situ hybridization and immunohistochemistry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKING ENZYMES; ELASTASE INHIBITOR; K+-ATPASE; SEQUENCE; ELAFIN; PURIFICATION; DIFFERENTIATION; INTESTINE; PEPTIDE; TISSUES	SPAI, originally isolated as a sodium/potassium-ATPase inhibitor and now considered to be a proteinase inhibitor of unknown specificity based on its similarity to elafin (an elastase inhibitor), is a new type of plasma protein that has a transglutaminase substrate domain, which serves as an anchoring sequence to be covalently cross-linked at target sites. To determine the source of SPAI, we carried out in situ hybridization and immunohistochemistry using an antisense cRNA probe and an antiserum against recombinant SPAI, respectively. Since previous RNase protection analysis had indicated that SPAI mRNA is almost exclusively expressed in the porcine small intestine, we used its frozen sections for the staining. The lower crypt was decorated with both the cRNA probe and antiserum, indicating that SPAI is synthesized and secreted by the enteroendocrine cells located near the crypt base. The native form of SPAI was also characterized by Western blotting. This result together with the previous biochemical and molecular biological characterizations may set the stage for identifying the physiological roles of the conceptually very interesting protein SPAI.	EISAI & CO LTD,TSUKUBA RES LABS,TSUKUBA,IBARAKI 30026,JAPAN	Eisai Co Ltd	Furukawa, M (corresponding author), TOKYO INST TECHNOL,DEPT BIOL SCI,MIDORI KU,4259 NAGATSUTA CHO,YOKOHAMA,KANAGAWA 226,JAPAN.		Ghoneim, Magdy/I-7904-2012	ghoneim, magdy/0000-0003-0185-3024				AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; ARAKI K, 1989, BIOCHEM BIOPH RES CO, V164, P496, DOI 10.1016/0006-291X(89)91747-6; ARAKI K, 1990, BIOCHEM BIOPH RES CO, V172, P42, DOI 10.1016/S0006-291X(05)80170-6; Bairoch A, 1996, NUCLEIC ACIDS RES, V24, P189, DOI 10.1093/nar/24.1.189; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; Dayal Y, 1991, ENDOCR PATHOL, P1; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; GORDON JI, 1994, CURR OPIN CELL BIOL, V6, P795, DOI 10.1016/0955-0674(94)90047-7; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HAND D, 1993, INT J DEV NEUROSCI, V11, P709, DOI 10.1016/0736-5748(93)90060-Q; ICHINOSE A, 1990, J BIOL CHEM, V265, P13411; ISHIZUKA N, 1991, BIOCHIM BIOPHYS ACTA, V1069, P259, DOI 10.1016/0005-2736(91)90133-S; KUROKI J, 1995, J BIOL CHEM, V270, P22428, DOI 10.1074/jbc.270.38.22428; LOEFFLER M, 1993, J THEOR BIOL, V160, P471, DOI 10.1006/jtbi.1993.1031; MCKENZIE RM, 1978, J DAIRY SCI, V61, P723, DOI 10.3168/jds.S0022-0302(78)83639-X; MOLHUIZEN HOF, 1993, J BIOL CHEM, V268, P12028; NARA K, 1994, J BIOCHEM, V115, P441, DOI 10.1093/oxfordjournals.jbchem.a124357; PARDUE ML, 1985, NUCLEIC ACID HYBRIDI, P179; PONDER BAJ, 1985, NATURE, V313, P689, DOI 10.1038/313689a0; SAHEKI T, 1992, BIOCHEM BIOPH RES CO, V185, P240, DOI 10.1016/S0006-291X(05)80981-7; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; Tamechika I, 1996, J BIOL CHEM, V271, P7012, DOI 10.1074/jbc.271.12.7012; WIEDOW O, 1990, J BIOL CHEM, V265, P14791	23	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29517	29520		10.1074/jbc.271.47.29517	http://dx.doi.org/10.1074/jbc.271.47.29517			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939875	hybrid			2022-12-25	WOS:A1996VU52500003
J	Tunwell, REA; Lai, FA				Tunwell, REA; Lai, FA			Ryanodine receptor expression in the kidney and a non-excitable kidney epithelial cell	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-INDUCED CA2+ RELEASE; POLYMERASE CHAIN-REACTION; SKELETAL-MUSCLE; INOSITOL TRISPHOSPHATE; CHROMAFFIN CELLS; CHANNEL; BRAIN; STORE; OSCILLATIONS; SPECIFICITY	An oligonucleotide probe to a conserved 3' region within the three identified ryanodine receptor-calcium release channel isoforms hybridized to a single clone from a rabbit kidney cDNA library. The kidney clone encoded the carboxyl-terminal 338 amino acids within the putative transmembrane domain of the type 2 ryanodine receptor sequence. Reverse transcriptase-polymerase chain reaction with isoform-specific oligonucleotide primers demonstrated the presence of the type 2 ryanodine receptor transcript in rabbit kidney, as well as in a non-excitable cell line, LLC-RK1, derived from rabbit kidney epithelial cells. Amplification by rapid amplification of 51 cDNA ends indicated the kidney type 2 ryanodine receptor transcript extended >7000 base pairs from the stop codon and is therefore not homologous to the short RS R-1 transcript of similar to 2500 base pairs previously observed in rabbit brain, [H-3]Ryanodine binding and immunoblot analysis with a type 2 ryanodine receptor-specific antibody demonstrated that the native type 2 ryanodine receptor protein is expressed in the kidney. These observations suggest that the type 2 ryanodine receptor isoform may play a functional role in regulating intracellular calcium homeostasis in nonexcitable cells.	NATL INST MED RES,MRC,LONDON NW7 1AA,ENGLAND	MRC National Institute for Medical Research				Lai, Tony/0000-0003-2852-8547				BARMATZ VS, 1991, BIOCHEM J, V276, P41; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CHEEK TR, 1991, BIOCHEM J, V275, P697, DOI 10.1042/bj2750697; FASOLATO C, 1991, J BIOL CHEM, V266, P20159; FERRIS CD, 1992, ANNU REV PHYSIOL, V54, P469, DOI 10.1146/annurev.physiol.54.1.469; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; GIANNINI G, 1992, SCIENCE, V257, P91, DOI 10.1126/science.1320290; GUSE AH, 1993, BIOCHEM J, V291, P447, DOI 10.1042/bj2910447; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; ISLAM MS, 1992, FEBS LETT, V296, P287, DOI 10.1016/0014-5793(92)80306-2; KUWAJIMA G, 1992, NEURON, V9, P1133, DOI 10.1016/0896-6273(92)90071-K; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI FA, 1989, J BIOENERG BIOMEMBR, V21, P227, DOI 10.1007/BF00812070; LAI FA, 1992, BIOCHEM J, V288, P553, DOI 10.1042/bj2880553; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LEDBETTER MW, 1994, J BIOL CHEM, V269, P31544; LESH RE, 1993, CIRC RES, V72, P481, DOI 10.1161/01.RES.72.2.481; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; MACDONALD C, 1991, EXP CELL RES, V195, P458, DOI 10.1016/0014-4827(91)90396-C; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MALGAROLI A, 1990, J BIOL CHEM, V265, P3005; MCPHERSON PS, 1993, J BIOL CHEM, V268, P19785; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MIKOSHIBA K, 1993, TRENDS PHARMACOL SCI, V14, P86, DOI 10.1016/0165-6147(93)90069-V; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; OTSU K, 1990, J BIOL CHEM, V265, P13472; SANCHEZBUENO A, 1993, BIOCHEM J, V291, P169, DOI 10.1042/bj2910169; SORRENTINO V, 1993, TRENDS PHARMACOL SCI, V14, P98, DOI 10.1016/0165-6147(93)90072-R; SUZUKI M, 1991, AM J PHYSIOL, V260, pF757, DOI 10.1152/ajprenal.1991.260.5.F757; SWANN K, 1992, BIOCHEM J, V287, P79, DOI 10.1042/bj2870079; TAKESHIMA H, 1993, FEBS LETT, V322, P105, DOI 10.1016/0014-5793(93)81547-D; WAKUI M, 1990, CELL, V63, P1025, DOI 10.1016/0092-8674(90)90505-9	33	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29583	29588		10.1074/jbc.271.47.29583	http://dx.doi.org/10.1074/jbc.271.47.29583			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939887	hybrid			2022-12-25	WOS:A1996VU52500015
J	Yoshida, Y; Kurosawa, N; Kanematsu, T; Kojima, N; Tsuji, S				Yoshida, Y; Kurosawa, N; Kanematsu, T; Kojima, N; Tsuji, S			Genomic structure and promoter activity of the mouse polysialic acid synthase gene (mST8Sia II) - Brain-specific expression from a tata-less GC-rich sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPMENTALLY-REGULATED MEMBER; CELL-ADHESION MOLECULE; NEURON-SPECIFIC EXPRESSION; RECEPTOR GENE; SIALYLTRANSFERASE; CLONING; ALPHA-2,8-SIALYLTRANSFERASE; FAMILY; STX; MIGRATION	The mouse ST8Sia II (mST8Sia II/STX) gene encodes a neural cell adhesion molecule-specific polysialic acid synthase whose expression is regulated during the developmental stages of mouse brain, To elucidate the molecular mechanism by which the expression is tissue-specifically and developmentally regulated, we isolated the complete genomic DNA and characterized the promoter of the gene for mST8Sia II, The gene encoding mST8Sia II was found to span about 80 kilobases and to be composed of six exons. Primer extension and S1 nuclease protection analyses revealed that the transcription started from 167 nucleotides upstream of the translational initiation site, Promoter analyses of the 5'-flanking region of the mST8Sia II gene using a luciferase gene reporter system revealed strong promoter activity in retinoic acid-induced differentiated P19 cells, which highly express the mST8Sia II gene, Deletion analyses demonstrated that the minimal promoter activity detected for the proximal region 325 base pairs upstream from the translational initiation codon (-158 to +167) could be modulated by various sequences within the 9.5-kilobase 5'-flanking region, The minimal promoter was embedded in a GC-rich domain (74%, GC content), in which two Spl binding motifs as well as a long purine-rich region were found, but it lacked TATA and CAAT boxes, The positive regulatory region located between -159 and -659 contained two additional Sp1 binding motifs and a long pyrimidine-rich region, We also found that the minimal promoter region of the mST8Sia II gene was sufficient for expression of a reporter gene in mST8Sia II gene-expressing neural differentiated P19 cells but not in nonexpressing ones, Thus the TATA-less GC-rich minimal promoter region of mST8Sia II probably controls the cell type-specific expression of the mST8Sia II gene.	RIKEN,INST PHYS & CHEM RES,FRONTIER RES PROGRAM,WAKO,SAITAMA 35101,JAPAN	RIKEN			Yoshida, Yukiko/ABB-7218-2020	Yoshida, Yukiko/0000-0002-0629-0219; Kurosawa, Nobuyuki/0000-0002-1548-4541				BREEN KC, 1988, DEVELOPMENT, V104, P147; CHANG ML, 1995, GLYCOBIOLOGY, V5, P319, DOI 10.1093/glycob/5.3.319; CHIN LS, 1994, J BIOL CHEM, V269, P18507; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; DATTA AK, 1995, J BIOL CHEM, V270, P1497, DOI 10.1074/jbc.270.4.1497; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; FREDETTE B, 1993, J CELL BIOL, V123, P1867, DOI 10.1083/jcb.123.6.1867; FROTHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998; Kitagawa H, 1996, J BIOL CHEM, V271, P931, DOI 10.1074/jbc.271.2.931; KITAGAWA H, 1994, J BIOL CHEM, V269, P17872; KOJIMA N, 1995, FEBS LETT, V360, P1, DOI 10.1016/0014-5793(95)00059-I; Kojima N, 1996, J BIOL CHEM, V271, P22058, DOI 10.1074/jbc.271.36.22058; Kojima N, 1996, J BIOL CHEM, V271, P19457, DOI 10.1074/jbc.271.32.19457; KOJIMA N, 1995, FEBS LETT, V373, P119, DOI 10.1016/0014-5793(95)01024-9; Kurosawa N, 1996, J BIOL CHEM, V271, P15109, DOI 10.1074/jbc.271.25.15109; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; MASTRANGELO IA, 1991, P NATL ACAD SCI USA, V88, P5670, DOI 10.1073/pnas.88.13.5670; MAUE RA, 1990, NEURON, V4, P223, DOI 10.1016/0896-6273(90)90097-Y; MCCOY RD, 1985, J BIOL CHEM, V260, P2695; MINOWA MT, 1992, P NATL ACAD SCI USA, V89, P3045, DOI 10.1073/pnas.89.7.3045; NAKAYAMA J, 1995, P NATL ACAD SCI USA, V92, P7031, DOI 10.1073/pnas.92.15.7031; Nakayama J, 1996, J BIOL CHEM, V271, P1829, DOI 10.1074/jbc.271.4.1829; ONO K, 1994, NEURON, V13, P595, DOI 10.1016/0896-6273(94)90028-0; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SAUERWALD A, 1990, J BIOL CHEM, V265, P14932; SCHEIDEGGER EP, 1995, J BIOL CHEM, V270, P22685, DOI 10.1074/jbc.270.39.22685; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SVENSSON EC, 1990, J BIOL CHEM, V265, P20863; TAKAMATSU K, 1994, CANCER RES, V54, P2598; TANG JC, 1994, NEURON, V13, P405, DOI 10.1016/0896-6273(94)90356-5; TOMASIEWICZ H, 1993, NEURON, V11, P1163, DOI 10.1016/0896-6273(93)90228-J; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; TSUJI S, 1996, IN PRESS GLYCOBIOLOG, V6; VIBERT M, 1989, EUR J BIOCHEM, V181, P33, DOI 10.1111/j.1432-1033.1989.tb14690.x; WANG C, 1994, J NEUROSCI, V14, P4446; WANG MM, 1993, MOL CELL BIOL, V13, P5805, DOI 10.1128/MCB.13.9.5805; WANG X, 1990, Glycobiology, V1, P25, DOI 10.1093/glycob/1.1.25; YOSHIDA KY, 1996, IN PRESS GLYCOBIOLOG, V6; YOSHIDA Y, 1995, J BIOCHEM-TOKYO, V118, P658, DOI 10.1093/oxfordjournals.jbchem.a124960; YOSHIDA Y, 1995, J BIOL CHEM, V270, P14628, DOI 10.1074/jbc.270.24.14628	41	56	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30167	30173		10.1074/jbc.271.47.30167	http://dx.doi.org/10.1074/jbc.271.47.30167			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939967	hybrid			2022-12-25	WOS:A1996VU52500095
J	Balboa, MA; Balsinde, J; Winstead, MV; Tischfield, JA; Dennis, EA				Balboa, MA; Balsinde, J; Winstead, MV; Tischfield, JA; Dennis, EA			Novel group V phospholipase A(2) involved in arachidonic acid mobilization in murine P388D(1) macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-II PHOSPHOLIPASE-A(2); CELLS; EXPRESSION; CLONING; ENZYMES; RAT	Four related genes encode four different secretory phospholipase A(2) (sPLA(2)) enzymes in mammals, namely the well described Group I and IIA enzymes and the more recently described Groups IIC and V. A large body of research has putatively demonstrated that the Group IIA sPLA(2) is involved in diverse pathologic processes, such as rheumatoid arthritis, septic shock, intestinal neoplasia, and epidermal hyperplasia, as well as in cellular signaling by regulating the formation of arachidonate-derived lipid messengers, However, we demonstrate herein the involvement of another sPLA(2), i.e. the Group V sPLA(2), in arachidonic acid release and prostaglandin production in the mouse macrophage-like cell line P388D(I). Abundant message for Group V sPLA(2) was detected in both resting and activated cells, In contrast, Group IIA sPLA(2) message was undetectable as analyzed by Northern blot and reverse transcriptase-polymerase chain reaction, Moreover, blockage of Group V sPLA(2) gene expression by antisense RNA oligonucleotides resulted in inhibition of prostaglandin E(2) production as well as reduction of the amount of sPLA(2) protein at the cellular surface, Collectively, these results uncover Group V sPLA(2) as a novel effector involved in arachidonic acid-mediated signal transduction.	UNIV CALIF SAN DIEGO,DEPT CHEM & BIOCHEM,LA JOLLA,CA 92093; INDIANA UNIV,SCH MED,DEPT MED & MOL GENET,INDIANAPOLIS,IN 46202	University of California System; University of California San Diego; Indiana University System; Indiana University-Purdue University Indianapolis			Dennis, Edward A./M-5554-2019; Balboa, María A./V-9493-2018; Balsinde, Jesús/C-7833-2018	Dennis, Edward A./0000-0003-3738-3140; Balboa, María A./0000-0002-2130-5298; Balsinde, Jesús/0000-0002-4157-6714; Tischfield, Jay/0000-0003-3217-8287	NICHD NIH HHS [HD 26,171] Funding Source: Medline; NIDDK NIH HHS [DK 38,185] Funding Source: Medline; NIGMS NIH HHS [GM 20,501] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026171] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038185] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALSINDE J, 1994, P NATL ACAD SCI USA, V91, P11060, DOI 10.1073/pnas.91.23.11060; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; CHEN J, 1994, J BIOL CHEM, V269, P2365; CHEN J, 1994, J BIOL CHEM, V269, P23018; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Grass DS, 1996, J CLIN INVEST, V97, P2233, DOI 10.1172/JCI118664; HARWIG SSL, 1995, J CLIN INVEST, V95, P603, DOI 10.1172/JCI117704; KENNEDY BP, 1995, J BIOL CHEM, V271, P22375; KOREN HS, 1975, J IMMUNOL, V114, P894; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; MAYER RJ, 1993, FASEB J, V7, P339, DOI 10.1096/fasebj.7.2.8440410; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; PFEILSCHIFTER J, 1993, J CLIN INVEST, V92, P2516, DOI 10.1172/JCI116860; Reddy ST, 1996, J BIOL CHEM, V271, P186, DOI 10.1074/jbc.271.1.186; Tischfield JA, 1996, GENOMICS, V32, P328, DOI 10.1006/geno.1996.0126	18	189	191	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32381	32384		10.1074/jbc.271.50.32381	http://dx.doi.org/10.1074/jbc.271.50.32381			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943302	hybrid, Green Published			2022-12-25	WOS:A1996VY34000093
J	Busca, R; Bertolotto, C; Ortonne, JP; Ballotti, R				Busca, R; Bertolotto, C; Ortonne, JP; Ballotti, R			Inhibition of the phosphatidylinositol 3-kinase/p70(S6)-kinase pathway induces B16 melanoma cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; EPIDERMAL GROWTH-FACTOR; PHOSPHOINOSITIDE 3-KINASE; STIMULATING HORMONE; S6 KINASE; MAMMALIAN TYROSINASE; HUMAN MELANOCYTES; DNA-SYNTHESIS; MAP KINASE; CYCLIC-AMP	alpha-Melanocyte-stimulating hormone and cAMP-elevating agents are known to induce B16 cell differentiation, characterized by increased melanin synthesis and dendrite outgrowth. In order to elucidate intracellular signaling pathways involved in this differentiation process, we focused our interest on the phosphatidylinositol 3-kinase/p70(S6)-kinase pathway. The specific inhibition of phosphatidylinositol 3-kinase by LY294002 markedly stimulated dendrite outgrowth, thus mimicking the action of cAMP-elevating agents on B16 cell morphology, In addition, LY294002 and rapamycin, a specific p70(S6)-kinase inhibitor, were found to independently stimulate tyrosinase expression, thus increasing melanin synthesis, In an attempt to better dissect the molecular mechanisms triggered by cAMP to induce melanoma cell differentiation, we examined the effects of a cAMP-elevating agent forskolin, on both phosphatidylinositol 3-kinase and p70(S6)-kinase activities. Specific kinase assays revealed that forskolin partially inhibited phosphatidylinositol 3-kinase activity and completely blocked p70(S6)-kinase activity and phosphorylation. In conclusion, our results clearly demonstrate that the inhibition of phosphatidylinositol 3-kinase and p70(S6)-kinase is involved in the regulation of B16 cell differentiation, Furthermore, we provide evidence which suggests that cAMP-induced melanogenesis and dendricity are, at least partially, mediated by the cAMP inhibition of the phosphatidylinositol 3-kinase/p70(S6)-kinase signaling pathway.			Busca, R (corresponding author), FAC MED NICE,INSERM,U385,AVE VALOMBROSE,F-06107 NICE 02,FRANCE.		Bertolotto, Corine/AAF-6634-2021; Bertolotto-Ballotti, Corine/O-2155-2016; BALLOTTI, Robert/F-8825-2013	Bertolotto, Corine/0000-0001-6971-7753; BALLOTTI, Robert/0000-0002-7322-4908				AHMED MU, 1995, J BIOL CHEM, V270, P23816, DOI 10.1074/jbc.270.40.23816; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Bertolotto C, 1996, J CELL BIOL, V134, P747, DOI 10.1083/jcb.134.3.747; Boudewijn MT, 1995, NATURE, V376, P599; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; ENGLARO W, 1995, J BIOL CHEM, V270, P24315, DOI 10.1074/jbc.270.41.24315; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FULLER BB, 1987, J BIOL CHEM, V262, P4024; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; GROOT RP, 1994, CELL, V79, P81; HALABAN R, 1983, J CELL BIOL, V97, P480, DOI 10.1083/jcb.97.2.480; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HEARING VJ, 1991, FASEB J, V5, P2902, DOI 10.1096/fasebj.5.14.1752358; HEARING VJ, 1989, PIGM CELL RES, V2, P75, DOI 10.1111/j.1600-0749.1989.tb00166.x; HEARING VJ, 1987, INT J BIOCHEM, V19, P1141, DOI 10.1016/0020-711X(87)90095-4; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; HU P, 1994, MOL CELL BIOL, V14, P2577, DOI 10.1128/MCB.14.4.2577; HUNT G, 1994, J CELL SCI, V107, P205; JACKSON IJ, 1992, EMBO J, V11, P527, DOI 10.1002/j.1460-2075.1992.tb05083.x; Jackson TR, 1996, J CELL SCI, V109, P289; JIMENEZ M, 1989, J BIOL CHEM, V264, P3397; JIMENEZ M, 1991, J BIOL CHEM, V266, P1147; KAMEYAMA K, 1993, J INVEST DERMATOL, V100, P126, DOI 10.1111/1523-1747.ep12462778; KIMURA K, 1994, J BIOL CHEM, V269, P18961; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V208, P985, DOI 10.1006/bbrc.1995.1431; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; KOZMA SC, 1994, SEMIN CANCER BIOL, V5, P255; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LEVINE N, 1991, JAMA-J AM MED ASSOC, V266, P2730, DOI 10.1001/jama.266.19.2730; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PANAYOTOU G, 1992, TRENDS CELL BIOL, V2, P258; PARKER PJ, 1992, CELL GROWTH DIFFER, V3, P747; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; PETRITSCH C, 1995, J BIOL CHEM, V270, P26619, DOI 10.1074/jbc.270.44.26619; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; PROTA G, 1988, MED RES REV, V8, P525, DOI 10.1002/med.2610080405; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; SUSA M, 1992, J BIOL CHEM, V267, P6905; TAKAHASHI H, 1992, J INVEST DERMATOL, V98, P481, DOI 10.1111/1523-1747.ep12499862; TOKER A, 1994, J BIOL CHEM, V269, P32358; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; VOLINIA S, 1994, GENOMICS, V24, P472, DOI 10.1006/geno.1994.1655; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WONG G, 1975, NATURE, V255, P644, DOI 10.1038/255644a0; WYMANN M, 1994, BIOCHEM J, V298, P517, DOI 10.1042/bj2980517; YOKOYAMA K, 1994, J BIOL CHEM, V269, P27080	61	218	222	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					31824	31830		10.1074/jbc.271.50.31824	http://dx.doi.org/10.1074/jbc.271.50.31824			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943224	hybrid			2022-12-25	WOS:A1996VY34000015
J	Melcher, T; Maas, S; Herb, A; Sprengel, R; Higuchi, M; Seeburg, PH				Melcher, T; Maas, S; Herb, A; Sprengel, R; Higuchi, M; Seeburg, PH			RED2, a brain-specific member of the RNA-specific adenosine deaminase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; IN-VITRO; GLUR-B; CANDIDATE ENZYME; RECEPTOR; PURIFICATION; SITE; CONVERSION; EXPRESSION; INOSINE	The mammalian RNA specific adenosine deaminases DRADA/dsRAD (alias ADAR) and RED1 (alias ADARB1) have been implicated in the site selective editing of brain-expressed pre-mRNAs for glutamate receptor subunits and of antigenomic RNA of hepatitis delta virus, These enzymes are expressed in many if not all tissues, predicting an as yet unappreciated significance for adenosine deamination-mediated recoding of gene transcripts in the mammalian organism, We now report the molecular cloning of cDNA for RED2 (alias ADARB2), a third member of the RNA-specific adenosine deaminase family in the rodent, RED2 is closely sequence-related to RED1 but appears to be expressed only in the brain, where expression is widespread reaching highest levels in olfactory bulb and thalamus, RED2 further differs from RED1 in having a 54-residue amino-terminal extension which includes an arginine rich motif, Different from DRADA and RED1, recombinantly expressed RED2 did not deaminate adenosines in extended synthetic dsRNA or in GluR-B pre-mRNA, However, a chimera of RED1 and RED2 edited the GluR-B Q/R and R/G sites with moderate efficiency, Our data suggest that RED2 may edit brain specific transcripts with distinct structural features.	MAX PLANCK INST MED RES,NEUROBIOL LAB,D-69120 HEIDELBERG,GERMANY; UNIV HEIDELBERG,CTR MOL BIOL,D-69120 HEIDELBERG,GERMANY	Max Planck Society; Ruprecht Karls University Heidelberg								BASS BL, 1987, CELL, V48, P607, DOI 10.1016/0092-8674(87)90239-X; BHATTACHARYA S, 1994, TRENDS BIOCHEM SCI, V19, P105, DOI 10.1016/0968-0004(94)90200-3; BIANCHI F, 1994, BIOCHEM BIOPH RES CO, V201, P1197, DOI 10.1006/bbrc.1994.1832; BRIZZARD BL, 1994, BIOTECHNIQUES, V16, P730; BRUSA R, 1995, SCIENCE, V270, P1677, DOI 10.1126/science.270.5242.1677; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Davidson Nicholas O., 1995, Current Opinion in Lipidology, V6, P70, DOI 10.1097/00041433-199504000-00002; Herb A, 1996, P NATL ACAD SCI USA, V93, P1875, DOI 10.1073/pnas.93.5.1875; HERBERT A, 1995, P NATL ACAD SCI USA, V92, P7550, DOI 10.1073/pnas.92.16.7550; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; HOUGH RF, 1994, J BIOL CHEM, V269, P9933; KAO PN, 1994, J BIOL CHEM, V269, P20691; KIM U, 1994, J BIOL CHEM, V269, P13480; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAI F, 1995, J BIOL CHEM, V270, P17098, DOI 10.1074/jbc.270.29.17098; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; Maas S, 1996, J BIOL CHEM, V271, P12221, DOI 10.1074/jbc.271.21.12221; MELCHER T, 1995, J BIOL CHEM, V270, P8566, DOI 10.1074/jbc.270.15.8566; Melcher T, 1996, NATURE, V379, P460, DOI 10.1038/379460a0; OCONNELL MA, 1994, P NATL ACAD SCI USA, V91, P10596, DOI 10.1073/pnas.91.22.10596; OCONNELL MA, 1995, MOL CELL BIOL, V15, P1389; Polson AG, 1996, NATURE, V380, P454; RUETER SM, 1995, SCIENCE, V267, P1491, DOI 10.1126/science.7878468; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCOTT J, 1995, CELL, V81, P833, DOI 10.1016/0092-8674(95)90002-0; Seeburg PH, 1996, J NEUROCHEM, V66, P1; Simpson L, 1996, ANNU REV NEUROSCI, V19, P27, DOI 10.1146/annurev.ne.19.030196.000331; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; YANG JH, 1995, NATURE, V374, P77, DOI 10.1038/374077a0	31	232	241	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					31795	31798		10.1074/jbc.271.50.31795	http://dx.doi.org/10.1074/jbc.271.50.31795			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943218	hybrid			2022-12-25	WOS:A1996VY34000009
J	Wallace, A; Koblan, KS; Hamilton, K; MarquisOmer, DJ; Miller, PJ; Mosser, SD; Omer, CA; Schaber, MD; Cortese, R; Oliff, A; Gibbs, JB; Pessi, A				Wallace, A; Koblan, KS; Hamilton, K; MarquisOmer, DJ; Miller, PJ; Mosser, SD; Omer, CA; Schaber, MD; Cortese, R; Oliff, A; Gibbs, JB; Pessi, A			Selection of potent inhibitors of farnesyl-protein transferase from a synthetic tetrapeptide combinatorial library	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAS FARNESYLATION; PEPTIDE LIBRARY; FARNESYLTRANSFERASE; BINDING; PEPTIDOMIMETICS; IDENTIFICATION; CELLS	Inhibitors of farnesyl-protein transferase (FPTase) show promise as anticancer agents, Based on the sequence of the protein substrates of FPTase (the CAAX sequence), potent and selective peptidomimetic inhibitors have been developed; these compounds share with the peptide substrate a free thiol and a C-terminal carboxylate, We have used a synthetic tetrapeptide combinatorial library to screen for new leads devoid of these features: the peptides were C-terminally amidated, and no free thiol was included in the combinatorial building blocks, To compensate for this negative bias, an expanded set of 68 amino acids was used, including both L and D as web as many non-coded residues, Sixteen individual tetrapeptides derived from the consensus were synthesized and tested; all were active, showing IC50 values ranging from low micromolar to low nanomolar, The most active peptide, D-tryptophan-D-methionine-D-4-chlorophenylalanine-L-gamma-carboxyglutamic acid (K-i = 2 nM), is also very selective showing Little inhibitory activity against the related enzyme geranylgeranyl-protein transferase type I (IC50 > 50 mu M). In contrast to CAAX-based peptidomimetics, D-tryptophan-D-methionine-D-4-chlorophenylalanine-L-gamma-carboxyglutamic acid appeared to mimic the iso prenoid substrate farnesyl diphosphate as determined by kinetic and physical measurements, D-Tryptophan-D-methionine-D-4-chlorophenylalanine-L-gamma-carboxyglutamic acid was a competitive inhibitor of FPTase with respect to farnesyl diphosphate substrate and uncompetitive with respect to CAAX substrate, Furthermore, we demonstrated that FPTase undergoes ligand dependent conformational changes in its circular dichroism spectrum and that D-Typtophan-D-methionine-D-4-chlorophenylalanine-L-gamma-carboxyglutamic acid induced a conformational change identical to that observed with farnesyl diphosphate ligand.	IST RIC BIOL MOL P ANGELETTI,I-00040 POMEZIA,ROME,ITALY; MERCK RES LABS,DEPT CANC RES,W POINT,PA 19486; MERCK RES LABS,PHARMACEUT RES DEPT,W POINT,PA 19486	Merck & Company; Merck & Company; Merck & Company								BIANCHI E, 1995, J MOL BIOL, V247, P154, DOI 10.1006/jmbi.1994.0129; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; Dolence JM, 1995, BIOCHEMISTRY-US, V34, P16687, DOI 10.1021/bi00051a017; DOOLEY CT, 1993, P NATL ACAD SCI USA, V90, P10811, DOI 10.1073/pnas.90.22.10811; EICHLER J, 1993, BIOCHEMISTRY-US, V32, P11035, DOI 10.1021/bi00092a013; FURFINE ES, 1995, BIOCHEMISTRY-US, V34, P6857, DOI 10.1021/bi00020a032; FURKA A, 1991, INT J PEPT PROT RES, V37, P487, DOI 10.1111/j.1399-3011.1991.tb00765.x; GALLOP MA, 1994, J MED CHEM, V37, P1233, DOI 10.1021/jm00035a001; GARCIA AM, 1993, J BIOL CHEM, V268, P18415; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; Hamilton A., 1995, DRUG NEWS PERSPECT, V8, P138; HOUGHTEN RA, 1991, NATURE, V354, P82; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; NIGAM M, 1993, J BIOL CHEM, V268, P20695; OMER CA, 1995, METHOD ENZYMOL, V250, P3; PINILLA C, 1994, BIOCHEM J, V301, P847, DOI 10.1042/bj3010847; PINILLA C, 1992, BIOTECHNIQUES, V13, P901; POMPLIANO DL, 1993, BIOCHEMISTRY-US, V32, P8341, DOI 10.1021/bi00083a038; POMPLIANO DL, 1992, BIOCHEMISTRY-US, V31, P3800, DOI 10.1021/bi00130a010; SINGH SB, 1993, TETRAHEDRON, V49, P5917, DOI 10.1016/S0040-4020(01)87178-7; TAMANOI F, 1993, TRENDS BIOCHEM SCI, V18, P349, DOI 10.1016/0968-0004(93)90072-U; WALLACE A, 1994, PEPTIDE RES, V7, P27	26	49	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31306	31311		10.1074/jbc.271.49.31306	http://dx.doi.org/10.1074/jbc.271.49.31306			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940136	hybrid			2022-12-25	WOS:A1996VW68600047
J	Agius, L; Peak, M; Newgard, CB; GomezFoix, AM; Guinovart, JJ				Agius, L; Peak, M; Newgard, CB; GomezFoix, AM; Guinovart, JJ			Evidence for a role of glucose-induced translocation of glucokinase in the control of hepatic glycogen synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY PROTEIN; LIVER GLUCOKINASE; METABOLIC CONTROL; RAT HEPATOCYTES; INSULIN; EXPRESSION; FRUCTOSE; CELLS; GENE; PROMOTER	Glucokinase reversibly partitions between a bound and a free state in the hepatocyte in response to the metabolic status of the cell. Maximum binding occurs at low [glucose] (<5 mM) and minimum binding at high [glucose] or in the presence of sorbitol or fructose. In this study we determined the binding characteristics of glucokinase in the hepatocyte in situ, by adenovirus-mediated glucokinase overexpression combined with the digitonin-permeabilization technique. We also determined the sensitivity of glycogen synthesis to changes in either total glucokinase overexpression or in free glucokinase activity. Glucokinase overexpression is associated with an increase in both free and bound activity, with an overall decrease in the proportion of bound activity, In hepatocytes incubated at low [glucose] (0-5 mM), glucokinase binding involves a high-affinity binding site with a K-d of similar to 0.1 mu M and a binding capacity of similar to 3 pmol/mg total cell protein and low-affinity binding with a K-d of similar to 1.6 mu M. Increasing glucose concentration to 20 mM causes a dose-dependent increase in the K-d of the high-affinity site to similar to 0.6 mu M, and this effect was mimicked by 50 mu M sorbitol, a precursor of fructose 1-P, confirming that this site is the regulatory protein of glucokinase. Glycogen synthesis determined from the incorporation of [2-H-3,U-C-14]glucose into glycogen at 5 man or 10 mM glucose was very sensitive to small increases in total glucokinase activity and correlated more closely with the increase in free glucokinase activity. The relation between glycogenic flux and glucokinase activity is sigmoidal. Expression of the sensitivity of glycogen synthesis to glucokinase activity as the control coefficient reveals that the coefficient is greater for the incorporation of 2-tritium (which occurs exclusively by the direct pathway) than for incorporation of C-14 label (which involves direct and indirect pathways) and is greater at 5 mM glucose (when glucokinase is maximally sequestered at its high-affinity site) than at 10 mM glucose. The results support the hypothesis that compartmentation of glucokinase in the hepatocyte increases the sensitivity of glycogen synthesis to small changes in total glucokinase activity and that glucose-induced translocation of glucokinase has a major role in the acute control of glycogen synthesis.	UNIV TEXAS,SW MED CTR,GIFFORD LABS DIABET RES,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235; UNIV BARCELONA,DEPT BIOQUIM & BIOL MOL,E-08028 BARCELONA,SPAIN	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Barcelona	Agius, L (corresponding author), MED SCH NEWCASTLE UPON TYNE,DEPT MED,FRAMLINGTON PL,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND.			Peak, Matthew/0000-0003-1909-3211	PHS HHS [P5H2598801] Funding Source: Medline; Wellcome Trust Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); Wellcome Trust(Wellcome TrustEuropean Commission)		AGIUS L, 1990, BIOCHEM J, V271, P387, DOI 10.1042/bj2710387; AGIUS L, 1990, BIOCHEM J, V266, P91, DOI 10.1042/bj2660091; AGIUS L, 1995, BIOCHEM J, V309, P711, DOI 10.1042/bj3090711; AGIUS L, 1993, BIOCHEM J, V296, P785, DOI 10.1042/bj2960785; AGIUS L, 1994, BIOCHEM J, V298, P237, DOI 10.1042/bj2980237; AGIUS L, 1994, BIOCHEM J, V303, P841, DOI 10.1042/bj3030841; AGIUS L, 1993, BIOCHEM J, V289, P255, DOI 10.1042/bj2890255; ATKINSON DE, 1977, CELLULAR ENERGY META, P139; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Becker TC, 1996, J BIOL CHEM, V271, P390, DOI 10.1074/jbc.271.1.390; DAVIES DR, 1990, EUR J BIOCHEM, V192, P283, DOI 10.1111/j.1432-1033.1990.tb19225.x; DETHEUX M, 1991, EUR J BIOCHEM, V294, P551; FELL DA, 1985, EUR J BIOCHEM, V148, P555, DOI 10.1111/j.1432-1033.1985.tb08876.x; FELL DA, 1992, BIOCHEM J, V286, P313, DOI 10.1042/bj2860313; Hue L, 1981, Adv Enzymol Relat Areas Mol Biol, V52, P247; HUGHES SD, 1991, J BIOL CHEM, V266, P4521; IYNEDJIAN PB, 1993, BIOCHEM J, V293, P1; JETTON TL, 1994, J BIOL CHEM, V269, P3641; Kacser H, 1979, BIOCHEM SOC T, V7, P1149, DOI 10.1042/bst0071149; Katz J, 1976, Curr Top Cell Regul, V10, P237; MAGNUSON MA, 1989, J BIOL CHEM, V264, P15936; MAGNUSON MA, 1993, NUTRITION GENE EXPRE, P143; MASSAGUE J, 1977, FEBS LETT, V82, P317, DOI 10.1016/0014-5793(77)80610-8; NEWGARD CB, 1990, BIOCHEM SOC T, V18, P851, DOI 10.1042/bst0180851; Newsholme E A, 1976, Biochem Soc Symp, P61; NOUSPIKEL T, 1992, EUR J BIOCHEM, V210, P365, DOI 10.1111/j.1432-1033.1992.tb17430.x; ODoherty RM, 1996, J BIOL CHEM, V271, P20524, DOI 10.1074/jbc.271.34.20524; VANDERCAMMEN A, 1993, BIOCHEM J, V294, P551, DOI 10.1042/bj2940551; VANDERCAMMEN A, 1990, EUR J BIOCHEM, V191, P483, DOI 10.1111/j.1432-1033.1990.tb19147.x; VANDERCAMMEN A, 1991, EUR J BIOCHEM, V200, P545, DOI 10.1111/j.1432-1033.1991.tb16217.x; VANSCHAFTINGEN E, 1994, DIABETOLOGIA, V327, pS43; WALKER D. G., 1966, ESSAYS BIOCHEM, V2, P33; WALS PA, 1994, J BIOL CHEM, V269, P18343	33	134	135	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30479	30486		10.1074/jbc.271.48.30479	http://dx.doi.org/10.1074/jbc.271.48.30479			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940014	hybrid			2022-12-25	WOS:A1996VV15800031
J	McKay, BS; Annis, DS; Honda, S; Christie, D; Kunicki, TJ				McKay, BS; Annis, DS; Honda, S; Christie, D; Kunicki, TJ			Molecular requirements for assembly and function of a minimized human integrin alpha(IIIb)beta(3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET GLYCOPROTEIN-IIB; AMINO-ACID-SEQUENCE; BETA(3) SUBUNIT; I-DOMAIN; CRYSTAL-STRUCTURE; HUMAN FIBRONECTIN; LIGAND-BINDING; CELL-ADHESION; EXPRESSION; RECEPTOR	Integrin subunit compatibility within and between species plays a major role in heterodimer assembly and ligand specificity. As an example, human alpha(IIb) pairs only with human beta(3) and does not assemble a heterodimer with beta(3) from other species. We use interspecies subunit chimeras to identify molecular requirements for subunit compatibility and show that species-restricted heterodimer assembly depends on a unique hexapeptide VGSDNH in an extended loop of the hypothetical human beta(3) MIDAS domain. This allows us to express alpha(IIb)(1-233) and beta(3)(111-318) as a soluble, mini-integrin that retains RGD-dependent ligand recognition. Thus, in the case of one integrin, alpha(IIb)beta(3), the molecular requirements for integrin subunit compatibility and ligand recognition are intimately related.	Scripps Res Inst, DEPT MOL & EXPT MED, DIV EXPT HEMOSTASIS & THROMBOSIS, LA JOLLA, CA 92017 USA; Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92017 USA	Scripps Research Institute; Scripps Research Institute			McKay, Brian/E-5602-2012	McKay, Brian/0000-0002-2893-3959	NHLBI NIH HHS [HL-46979] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046979] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BAJT ML, 1994, J BIOL CHEM, V269, P20913; BASANI RB, 1995, BLOOD, V86, P201; BENNETT JS, 1993, J BIOL CHEM, V268, P3580; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CIEUTAT AM, 1993, BIOCHEM BIOPH RES CO, V193, P771, DOI 10.1006/bbrc.1993.1692; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; FAIRBANKS MB, 1995, FEBS LETT, V369, P197, DOI 10.1016/0014-5793(95)00747-W; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; FITZGERALD LA, 1987, BIOCHEMISTRY-US, V26, P8158, DOI 10.1021/bi00399a021; GULINO D, 1995, EUR J BIOCHEM, V227, P108, DOI 10.1111/j.1432-1033.1995.tb20365.x; HONDA S, 1995, J BIOL CHEM, V270, P11947, DOI 10.1074/jbc.270.20.11947; HONDA S, 1995, BLOOD, V86, P234, DOI 10.1182/blood.V86.1.234.bloodjournal861234; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KING SL, 1995, J VIROL, V69, P3237, DOI 10.1128/JVI.69.5.3237-3239.1995; KISHIMOTO TK, 1987, CELL, V48, P681, DOI 10.1016/0092-8674(87)90246-7; KODANDAPANI R, 1995, J BIOL CHEM, V270, P2268, DOI 10.1074/jbc.270.5.2268; KOUNS WC, 1994, BLOOD, V84, P1108; KUNICKI TJ, 1995, BLOOD CELL MOL DIS, V21, P131, DOI 10.1006/bcmd.1995.0015; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; LEE JO, 1995, CELL, V80, P931; Loftus JC, 1996, J BIOL CHEM, V271, P2033, DOI 10.1074/jbc.271.4.2033; LOFTUS JC, 1987, P NATL ACAD SCI USA, V840, P7114; MIMURA H, 1994, ENDOCRINOLOGY, V134, P1061, DOI 10.1210/en.134.3.1061; MOYLE M, 1991, J BIOL CHEM, V266, P19650; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; RAMASWAMY H, 1990, EMBO J, V9, P1561, DOI 10.1002/j.1460-2075.1990.tb08275.x; RANSOM DG, 1993, DEV BIOL, V160, P265, DOI 10.1006/dbio.1993.1304; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SHEPPARD D, 1990, J BIOL CHEM, V265, P11502; TAMURA RN, 1990, J CELL BIOL, V111, P1593, DOI 10.1083/jcb.111.4.1593; TOMIYAMA Y, 1992, J BIOL CHEM, V267, P18085; TUCKWELL D, 1995, J CELL SCI, V108, P1629; WIPPLER J, 1994, J BIOL CHEM, V269, P8754; YUAN Q, 1991, INT IMMUNOL, V3, P1373	36	47	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30544	30547		10.1074/jbc.271.48.30544	http://dx.doi.org/10.1074/jbc.271.48.30544			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940024	hybrid			2022-12-25	WOS:A1996VV15800041
J	Aulak, KS; Liu, J; Wu, JY; Hyatt, SL; Puppi, M; Henning, SJ; Hatzoglou, M				Aulak, KS; Liu, J; Wu, JY; Hyatt, SL; Puppi, M; Henning, SJ; Hatzoglou, M			Molecular sites of regulation of expression of the rat cationic amino acid transporter gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECOTROPIC RETROVIRAL RECEPTOR; CELL-SURFACE RECEPTOR; MESSENGER-RNA; MURINE RETROVIRUSES; PHOSPHOENOLPYRUVATE CARBOXYKINASE; LIVER-REGENERATION; POSTTRANSCRIPTIONAL REGULATION; INDUCTION-PATTERNS; MAMMALIAN-CELLS; SYSTEM Y(+)	Cat-1 is a protein with a dual function, a high affinity, low capacity cationic amino acid transporter of the y(+) system and the receptor for the ecotropic retrovirus. We have suggested that Cat-1 is required in the regenerating liver for the transport of cationic amino acids and polyamines in the late G(1) phase, a process that is essential for liver cells to enter mitosis, In our earlier studies we had shown that the cat-1 gene is silent in the quiescent liver but is induced in response to hormones, insulin, and glucocorticoids, and partial hepatectomy, Here we demonstrate that cat-1 is a classic delayed early growth response gene in the regenerating liver, since induction of its expression is sensitive to cycloheximide, indicating that protein synthesis is required. The peak of accumulation of the cat-1 mRNA (9-fold) by 3 h was not associated with increased transcriptional activity of the cat-1 gene in the regenerating liver, indicating posttranscriptional regulation of expression of this gene, Induction of the cat-1 gene results in the accumulation of two mRNA species (7.9 and 3.4 kilobase pairs (kb)). Both mRNAs hybridize with the previously described rat cat-1/2.9-kb cDNA clone, However, the 3' end of a longer rat cat-1 cDNA (rat cat-1/6.5-kb) hybridizes only to the 7.9-kb mRNA transcript, Sequence analysis of this clone indicated that the two mRNA species result from the use of alternative polyadenylation signals, The 6.5-kb clone contains a number of AT-rich mRNA destabilizing sequences which is reflected in the half-life of the cat-1 mRNAs (90 min for 7.9-kb mRNA and 250 min for 3.4-kb mRNA), Treatment of rats with cycloheximide superinduces the level of the 7.9-kb cat-1 mRNA in the kidney, spleen, and brain, but not in the liver, suggesting that cell type-specific labile factors are involved in its regulation, We conclude that the need for protein synthesis for induction of the cat-1 mRNA, the short lived nature of the mRNAs, and the multiple sites for regulation of gene expression indicate a tight control of expression of the caf-l gene within the regenerating liver and suggest that y(+) cationic amino acid transport in liver cells is regulated at the molecular level.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT NUTR,CLEVELAND,OH 44106; BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Case Western Reserve University; Baylor College of Medicine; Baylor College of Medicine			Henning, Susan/A-9356-2009		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK047431] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47431-0182] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBRITTON LM, 1993, J VIROL, V67, P2091, DOI 10.1128/JVI.67.4.2091-2096.1993; ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; BEALE EG, 1985, J BIOL CHEM, V260, P748; CHEESEMAN CI, 1991, PROG BIOPHYS MOL BIO, V55, P71, DOI 10.1016/0079-6107(91)90001-9; CHRISTENSEN HM, 1994, J EXP BIOL, V196, P151; CLOSS EI, 1993, J BIOL CHEM, V268, P20796; CLOSS EI, 1993, J VIROL, V67, P2097, DOI 10.1128/JVI.67.4.2097-2102.1993; CLOSS EI, 1993, J BIOL CHEM, V268, P7538; CORNFORD EM, 1980, AM J PHYSIOL, V238, pH553, DOI 10.1152/ajpheart.1980.238.4.H553; DEKLEIJN DPV, 1994, FEBS LETT, V353, P255, DOI 10.1016/0014-5793(94)01055-2; DESSERWIEST L, 1975, CELL TISSUE KINET, V8, P1, DOI 10.1111/j.1365-2184.1975.tb01201.x; Durante W, 1996, J BIOL CHEM, V271, P11838, DOI 10.1074/jbc.271.20.11838; EGLI CM, 1995, MOL CELL BIOL, V15, P2466; ESPAT NJ, 1994, ANN SURG ONCOL, V1, P147, DOI 10.1007/BF02303559; FINLEY KD, 1995, P NATL ACAD SCI USA, V92, P9378, DOI 10.1073/pnas.92.20.9378; GARREAU H, 1983, NUCLEIC ACIDS RES, V11, P8473, DOI 10.1093/nar/11.23.8473; GREAVES DR, 1985, J MOL BIOL, V185, P461, DOI 10.1016/0022-2836(85)90064-6; GROOT CJ, 1984, BIOCHEM BIOPH RES CO, V124, P882; HABER BA, 1993, J CLIN INVEST, V91, P1319, DOI 10.1172/JCI116332; HANDLOGTEN ME, 1984, J BIOL CHEM, V259, P3519; HATZOGLOU M, 1995, SOMAT CELL MOLEC GEN, V21, P265, DOI 10.1007/BF02255781; HUTSON RG, 1994, BIOCHEM J, V304, P745, DOI 10.1042/bj3040745; JACKSON RJ, 1993, CELL, V74, P9, DOI 10.1016/0092-8674(93)90290-7; KAKUDA DK, 1994, J EXP BIOL, V196, P93; Kakuda DK, 1993, TRANSGENE, V1, P91; KATZ RA, 1983, BIOCHIM BIOPHYS ACTA, V739, P258, DOI 10.1016/0167-4781(83)90099-4; KAVANAUGH MP, 1994, J BIOL CHEM, V269, P15445; KILBERG MS, 1986, TRENDS BIOCHEM SCI, V11, P183, DOI 10.1016/0968-0004(86)90138-6; KILBERG MS, 1993, ANNU REV NUTR, V13, P137, DOI 10.1146/annurev.nu.13.070193.001033; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; KRUBKE J, 1987, J GEN VIROL, V68, P3091, DOI 10.1099/0022-1317-68-12-3091; KRUYS V, 1994, BIOCHIMIE, V76, P862, DOI 10.1016/0300-9084(94)90188-0; LOW BC, 1995, J BIOL CHEM, V270, P27577, DOI 10.1074/jbc.270.46.27577; MACLEOD CL, 1990, MOL CELL BIOL, V10, P3663, DOI 10.1128/MCB.10.7.3663; MACLEOD CL, 1994, J EXP BIOL, V196, P109; Maniatis T., 1982, MOL CLONING; MARKOVICH D, 1993, J BIOL CHEM, V268, P1362; MOHN KL, 1991, MOL CELL BIOL, V11, P1393, DOI 10.1128/MCB.11.3.1393; MOHN KL, 1990, J BIOL CHEM, V265, P21914; MORELLO D, 1993, ONCOGENE, V8, P1921; MORRIS JG, 1978, SCIENCE, V199, P431, DOI 10.1126/science.619464; PETERSEN DD, 1989, P NATL ACAD SCI USA, V86, P7800, DOI 10.1073/pnas.86.20.7800; PUPPI M, 1995, P SOC EXP BIOL MED, V209, P38, DOI 10.3181/00379727-209-43875; REIZER J, 1993, PROTEIN SCI, V2, P20, DOI 10.1002/pro.5560020103; ROSA JL, 1992, BIOCHEM J, V287, P113, DOI 10.1042/bj2870113; ROSA JL, 1992, P NATL ACAD SCI USA, V89, P3746, DOI 10.1073/pnas.89.9.3746; SCHERER G, 1982, P NATL ACAD SCI-BIOL, V79, P7205, DOI 10.1073/pnas.79.23.7205; Simmons WW, 1996, J BIOL CHEM, V271, P11694, DOI 10.1074/jbc.271.20.11694; SOBCZAK J, 1989, ONCOGENE, V4, P1503; STEER CJ, 1995, FASEB J, V9, P1396, DOI 10.1096/fasebj.9.14.7589980; STOLL J, 1993, J NEUROCHEM, V60, P1956, DOI 10.1111/j.1471-4159.1993.tb13428.x; WANG H, 1992, J BIOL CHEM, V267, P23617; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WANG H, 1994, VIROLOGY, V202, P1058, DOI 10.1006/viro.1994.1439; WHITE MF, 1982, J BIOL CHEM, V257, P4450; WHITE MF, 1985, BIOCHIM BIOPHYS ACTA, V822, P355, DOI 10.1016/0304-4157(85)90015-2; WILKINSON MF, 1991, J EXP MED, V174, P269, DOI 10.1084/jem.174.1.269; WU JY, 1994, J VIROL, V68, P1615, DOI 10.1128/JVI.68.3.1615-1623.1994; YOSHIMOTO T, 1993, J VIROL, V67, P1310, DOI 10.1128/JVI.67.3.1310-1314.1993; YOSHIMOTO T, 1991, VIROLOGY, V185, P10, DOI 10.1016/0042-6822(91)90748-Z; YOSHIMOTO T, 1992, J VIROL, V66, P4377, DOI 10.1128/JVI.66.7.4377-4381.1992	61	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29799	29806		10.1074/jbc.271.47.29799	http://dx.doi.org/10.1074/jbc.271.47.29799			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939918	hybrid			2022-12-25	WOS:A1996VU52500046
J	Guilherme, A; Klarlund, JK; Krystal, G; Czech, MP				Guilherme, A; Klarlund, JK; Krystal, G; Czech, MP			Regulation of phosphatidylinositol 3,4,5-trisphosphate 5'-phosphatase activity by insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; ACTIVATED PROTEIN-KINASE; RAT ADIPOSE-CELLS; RECEPTOR SUBSTRATE-1; PHOSPHOINOSITIDE 3-KINASE; SIGNAL-TRANSDUCTION; GLUT4 TRANSLOCATION; WORTMANNIN; IRS-1; PHOSPHORYLATION	Polyphosphoinositides are thought to be mediators of cellular signaling pathways as well as regulators of cytoskeletal elements and membrane trafficking events. It has recently been demonstrated that a class of phos phatidylinositol (PI) 3,4,5-P-3 5'-phosphatases contains SH2 domains and proline-rich regions, which are present in many signaling proteins. We report here that insulin stimulation of Chinese hamster ovary cells (CHO-T) expressing human insulin receptors causes an 8-10-fold increase in PI 3,4,5-P-3 5'-phosphatase activity in anti-phosphotyrosine immunoprecipitates of the cell lysates, This insulin-sensitive polyphosphoinositide 5'-phosphatase did not catalyze dephosphorylation of PI 4,5-P-2. No change in 5'-phosphatase activity was detected in insulin receptor or IRS-1 immune complexes in response to insulin. However, insulin treatment of CHO-T cells markedly increased the PI 3,4,5-P-3 5'-phosphatase activity associated with She and Grb2. The insulin-regulated polyphosphoinositide 5'-phosphatase was not immunoreactive with antibody raised against the recently cloned SHIP 5'-phosphatase reported to associate with She and Grb2 in B lymphocytes. These data demonstrate that insulin causes formation of complexes containing a PI 3,4,5-P-3 5'-phosphatase, and Shc or Grb2, or both, suggesting an important role of this enzyme in insulin signaling.	UNIV MASSACHUSETTS,MED CTR,PROGRAM MOL MED,WORCESTER,MA 01605; UNIV MASSACHUSETTS,MED CTR,DEPT BIOCHEM & MOL BIOL,WORCESTER,MA 01605; UNIV BRITISH COLUMBIA,BRITISH COLUMBIA CANC AGCY,TERRY FOX LAB,VANCOUVER,BC V5Z 1L3,CANADA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; British Columbia Cancer Agency; University of British Columbia				Krystal, Gerald/0000-0002-1961-6281	NIDDK NIH HHS [DK30648, DK30898] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030898, R01DK030648, R01DK030898] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHOU CK, 1987, J BIOL CHEM, V262, P1842; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; HARUTA T, 1995, J BIOL CHEM, V270, P27991; HellerHarrison RA, 1996, J BIOL CHEM, V271, P10200, DOI 10.1074/jbc.271.17.10200; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; JACKSON SP, 1995, EMBO J, V14, P4490, DOI 10.1002/j.1460-2075.1995.tb00128.x; Kabuyama Y, 1996, EUR J BIOCHEM, V238, P350, DOI 10.1111/j.1432-1033.1996.0350z.x; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; KELLY KL, 1993, J BIOL CHEM, V268, P4291; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; LIPS DL, 1989, J BIOL CHEM, V264, P19911; Macdougall LK, 1995, CURR BIOL, V5, P1404, DOI 10.1016/S0960-9822(95)00278-8; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NORRIS FA, 1994, J BIOL CHEM, V269, P8716; OKADA T, 1994, J BIOL CHEM, V269, P3568; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; QUON MJ, 1994, J BIOL CHEM, V269, P27920; QUON MJ, 1995, MOL CELL BIOL, V15, P5403; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Virbasius JV, 1996, J BIOL CHEM, V271, P13304, DOI 10.1074/jbc.271.23.13304; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; Waters SB, 1996, J BIOL CHEM, V271, P18224, DOI 10.1074/jbc.271.30.18224; WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015; WHITE MF, 1994, J BIOL CHEM, V269, P1; Woscholski R, 1995, J BIOL CHEM, V270, P31001, DOI 10.1074/jbc.270.52.31001; YU KT, 1984, J BIOL CHEM, V259, P5277	44	30	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29533	29536		10.1074/jbc.271.47.29533	http://dx.doi.org/10.1074/jbc.271.47.29533			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939879	hybrid			2022-12-25	WOS:A1996VU52500007
J	Jenkins, BJ; Bagley, CJ; Woodcock, J; Lopez, AF; Gonda, TJ				Jenkins, BJ; Bagley, CJ; Woodcock, J; Lopez, AF; Gonda, TJ			Interacting residues in the extracellular region of the common beta subunit of the human granulocyte-macrophage colony-stimulating factor, interleukin (IL)-3, and IL-5 receptors involved in constitutive activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH SIGNAL-TRANSDUCTION; HUMAN GM-CSF; CYTOPLASMIC DOMAIN; ALPHA-CHAIN; ERYTHROPOIETIN RECEPTOR; EXPRESSION CLONING; POINT MUTATIONS; LIGAND-BINDING; TUMORIGENICITY; MOLECULES	A previous study using random mutagenesis identified an activating mutation in the common beta subunit (h beta c) of the human granulocyte-macrophage colony stimulating factor, interleukin-3, and interleukin-5 receptors in which an isoleucine residue (Ile(374)) in the extracellular region of h beta c is replaced by asparagine (Jenkins, B. J., D'Andrea, R., and Gonda, T. J. (1995) EMBO J 14, 4276-4287), To investigate the mechanism by which this mutation (I374N) acts, we employed site-directed mutagenesis to explore predictions based on a structural model of h beta c, We focused on possible interactions between Ile(374) and other hydrophobic residues in its vicinity and found that replacement of two such residues, Leu(356) and Trp(358), With asparagine resulted in constitutive activation of h beta c, Hydrophilic substitutions at both of these positions and at position 374 resulted in the greatest degree of activation, as measured by the growth rate of factor-independent cells, while hydrophobic substitutions had lesser or no effects, Moreover, these ''weak'' substitutions appeared to synergize, since factor-independent cells expressing the double mutants I374F/W358F and I374F/L356A showed substantially higher growth rates than the single mutants, Taken together, these results suggest that Ile(374) normally interacts with Leu(356) and Trp(358), and that disruption of these interactions results in a conformational change in h beta c that leads to constitutive activity, A model relating this notion to the predicted structure and to ligand- and alpha subunit-dependent activation of h beta c is proposed.	INST MED & VET SCI,DIV HUMAN IMMUNOL,ADELAIDE,SA 5000,AUSTRALIA	Institute Medical & Veterinary Science Australia	Jenkins, BJ (corresponding author), INST MED & VET SCI,HANSON CTR CANC RES,FROME RD,ADELAIDE,SA 5000,AUSTRALIA.		jenkins, brendan/J-7854-2012; jenkins, brendan/A-2401-2009; Lopez, Angel F/E-2260-2011	Jenkins, Brendan/0000-0002-7552-4656; Woodcock, Joanna/0000-0001-5127-9687; Lopez, Angel F/0000-0001-7430-0135				ALEXANDER WS, 1995, EMBO J, V14, P5569, DOI 10.1002/j.1460-2075.1995.tb00244.x; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARRY SC, 1994, J BIOL CHEM, V269, P8488; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CONTRERAS MA, 1983, METHOD ENZYMOL, V92, P277; DANDREA R, 1994, BLOOD, V83, P2802, DOI 10.1182/blood.V83.10.2802.2802; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; EDER M, 1994, J BIOL CHEM, V269, P30173; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GOODALL GJ, 1993, GROWTH FACTORS, V8, P87, DOI 10.3109/08977199309046929; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; JENKINS BJ, 1995, EMBO J, V14, P4276, DOI 10.1002/j.1460-2075.1995.tb00102.x; JOHNSON GR, 1980, J CELL PHYSIOL, V103, P371, DOI 10.1002/jcp.1041030302; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mui Alice L.-F., 1994, Progress in Growth Factor Research, V5, P15, DOI 10.1016/0955-2235(94)90015-9; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; MUTO A, 1995, BIOCHEM BIOPH RES CO, V208, P368, DOI 10.1006/bbrc.1995.1347; PAGLEY CJ, 1995, J LEUKOCYTE BIOL, V57, P739; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; PATTHY L, 1990, CELL, V61, P13, DOI 10.1016/0092-8674(90)90208-V; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; RAYNER JR, 1994, MOL CELL BIOL, V14, P880, DOI 10.1128/MCB.14.2.880; SAKAMAKI K, 1993, J BIOL CHEM, V268, P15833; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; STERNBERG MJE, 1989, NATURE, V339, P587, DOI 10.1038/339587a0; Stomski FC, 1996, MOL CELL BIOL, V16, P3035; Sun QY, 1996, BLOOD, V87, P83; TAKAKI S, 1994, MOL CELL BIOL, V14, P7404, DOI 10.1128/MCB.14.11.7404; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; WARD LD, 1994, J BIOL CHEM, V269, P23286; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WOODCOCK JM, 1994, EMBO J, V13, P5176, DOI 10.1002/j.1460-2075.1994.tb06848.x; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0; ZOLA H, 1990, J IMMUNOL METHODS, V135, P247, DOI 10.1016/0022-1759(90)90278-4	43	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29707	29714		10.1074/jbc.271.47.29707	http://dx.doi.org/10.1074/jbc.271.47.29707			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939904	hybrid			2022-12-25	WOS:A1996VU52500032
J	Murakami, M; Nakatani, Y; Kudo, I				Murakami, M; Nakatani, Y; Kudo, I			Type II secretory phospholipase A(2) associated with cell surfaces via C-terminal heparin-binding lysine residues augments stimulus-initiated delayed prostaglandin generation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; MESSENGER-RNA SYNTHESIS; RAT MESANGIAL CELLS; FORSKOLIN-INDUCED SYNTHESIS; TUMOR-NECROSIS-FACTOR; MOUSE MAST-CELLS; CYTOSOLIC PHOSPHOLIPASE-A2; GENE-EXPRESSION; EXTRACELLULAR PHOSPHOLIPASE-A2; PLATELET PHOSPHOLIPASE-A2	Type II secretory phospholipase A(2) (sPLA(2)) has been shown to be induced by a variety of proinflammatory stimuli and, therefore, has been implicated in the inflammatory process. In order to determine whether association of sPLA(2) with cell surfaces via heparan sulfate proteoglycan is important for its effects on cellular functions, we have identified the critical domain in sPLA(2) for heparin and cell surface binding and examined its role in cellular prostaglandin (PG) biosynthesis. Replacement of several conserved Lys residues in the C-terminal region of mouse and rat sPLA(2)s by Glu resulted in a marked reduction of their capacities to bind to heparin and mammalian cell surfaces without affecting their enzymatic activities toward dispersed phospholipid as a substrate. CHO cells stably transfected with wild-type sPLA(2) released about twice as much arachidonic acid (AA) during culture for 10 h with fetal calf serum and interleukin-1 beta than cells transfected with vector alone, whereas the ability to enhance AA release was impaired in sPLA(2) mutants incapable of binding to cell surfaces. AA released by wild-type sPLA(2)-transfected CHO cells was metabolized to prostaglandin E(2) via prostaglandin endoperoxide H synthase (PGHS)-2 after IL-1 beta stimulation, revealing a particular functional linkage of sPLA(2) to PGHS-(2). In contrast, A23187-initiated immediate AA release over 30 min was not affected by sPLA(2) overexpression, Taken together, these results suggest that sPLA(2) expressed endogenously and anchored on cell surfaces via its C-terminal heparin-binding domain is involved in the PGHS-2-dependent delayed PG biosynthesis initiated by growth factors and cytokines during long term culture.	SHOWA UNIV,SCH PHARMACEUT SCI,DEPT HLTH CHEM,SHINAGAWA KU,TOKYO 142,JAPAN	Showa University								ANGEL J, 1994, EUR J BIOCHEM, V226, P125, DOI 10.1111/j.1432-1033.1994.tb20033.x; BALSINDE J, 1994, P NATL ACAD SCI USA, V91, P11060, DOI 10.1073/pnas.91.23.11060; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; BARTOLI F, 1994, J BIOL CHEM, V269, P15625; CHANG HW, 1987, J BIOCHEM, V102, P147, DOI 10.1093/oxfordjournals.jbchem.a122026; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CHEPENIK KP, 1994, J BIOL CHEM, V269, P21786; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; deCarvalho MGS, 1996, J BIOL CHEM, V271, P6987, DOI 10.1074/jbc.271.12.6987; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DOLE VP, 1960, J BIOL CHEM, V235, P2595; DUA R, 1994, EUR J BIOCHEM, V221, P481, DOI 10.1111/j.1432-1033.1994.tb18761.x; FONTEH AN, 1994, J IMMUNOL, V152, P5438; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; FUJITA H, 1995, BIOCHEM BIOPH RES CO, V209, P293, DOI 10.1006/bbrc.1995.1502; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; HANASAKI K, 1992, BIOCHIM BIOPHYS ACTA, V1127, P233, DOI 10.1016/0005-2760(92)90226-L; HARA S, 1995, BBA-LIPID LIPID MET, V1257, P11, DOI 10.1016/0005-2760(95)00011-Z; HARA S, 1991, J BIOCHEM, V110, P163, DOI 10.1093/oxfordjournals.jbchem.a123550; HARA S, 1989, J BIOCHEM-TOKYO, V105, P395, DOI 10.1093/oxfordjournals.jbchem.a122675; HAYAKAWA M, 1993, J BIOL CHEM, V268, P11290; HIDI R, 1993, J IMMUNOL, V151, P5613; HOECK WG, 1993, P NATL ACAD SCI USA, V90, P4475, DOI 10.1073/pnas.90.10.4475; HORIGOME K, 1987, J BIOCHEM-TOKYO, V101, P625, DOI 10.1093/jb/101.3.625; INADA M, 1994, J BIOL CHEM, V269, P26338; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; KOMADA M, 1989, J BIOCHEM-TOKYO, V106, P545, DOI 10.1093/oxfordjournals.jbchem.a122890; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; LIN LL, 1992, J BIOL CHEM, V267, P23451; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Locati M, 1996, J BIOL CHEM, V271, P6010, DOI 10.1074/jbc.271.11.6010; LOMONTE B, 1994, J BIOL CHEM, V269, P29867; LYONSGIORDANO B, 1989, BIOCHEM BIOPH RES CO, V164, P488, DOI 10.1016/0006-291X(89)91746-4; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; MAYER RJ, 1993, FASEB J, V7, P339, DOI 10.1096/fasebj.7.2.8440410; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; MOUNIER C, 1993, EUR J BIOCHEM, V216, P169, DOI 10.1111/j.1432-1033.1993.tb18129.x; MURAKAMI M, 1995, J LIPID MEDIAT CELL, V12, P119, DOI 10.1016/0929-7855(95)00013-G; MURAKAMI M, 1991, FEBS LETT, V294, P247, DOI 10.1016/0014-5793(91)81440-J; MURAKAMI M, 1995, J BIOL CHEM, V270, P22653, DOI 10.1074/jbc.270.39.22653; MURAKAMI M, 1992, EUR J BIOCHEM, V209, P257, DOI 10.1111/j.1432-1033.1992.tb17284.x; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; MURAKAMI M, 1995, J EXP MED, V182, P197, DOI 10.1084/jem.182.1.197; MURAKAMI M, 1995, J BIOL CHEM, V270, P3239, DOI 10.1074/jbc.270.7.3239; MURAKAMI M, 1990, FEBS LETT, V268, P113, DOI 10.1016/0014-5793(90)80986-S; MURAKAMI M, 1988, J BIOCHEM-TOKYO, V104, P884, DOI 10.1093/oxfordjournals.jbchem.a122577; MURAKAMI M, 1990, BIOCHIM BIOPHYS ACTA, V1043, P34, DOI 10.1016/0005-2760(90)90107-9; NAKAMURA T, 1992, EMBO J, V11, P4917, DOI 10.1002/j.1460-2075.1992.tb05598.x; NAKANO T, 1990, FEBS LETT, V261, P171, DOI 10.1016/0014-5793(90)80663-4; NAKANO T, 1990, J BIOL CHEM, V265, P12745; NAKAZATO Y, 1991, J BIOL CHEM, V266, P14119; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; OKA S, 1991, J BIOL CHEM, V266, P9956; OWADA Y, 1994, MOL BRAIN RES, V25, P364, DOI 10.1016/0169-328X(94)90174-0; PERNAS P, 1991, BIOCHEM BIOPH RES CO, V178, P1298, DOI 10.1016/0006-291X(91)91035-B; PETERSGOLDEN M, 1993, BIOCHEM BIOPH RES CO, V196, P147, DOI 10.1006/bbrc.1993.2227; PFEILSCHIFTER J, 1993, J CLIN INVEST, V92, P2516, DOI 10.1172/JCI116860; PRUZANSKI W, 1990, J RHEUMATOL, V17, P1386; Reddy ST, 1996, J BIOL CHEM, V271, P186, DOI 10.1074/jbc.271.1.186; REDDY ST, 1994, J BIOL CHEM, V269, P15473; RIENDEAU D, 1994, J BIOL CHEM, V269, P15619; ROSHAK A, 1994, J BIOL CHEM, V269, P25999; Roshak A, 1996, J RHEUMATOL, V23, P420; SCHALKWIJK C, 1991, BIOCHEM BIOPH RES CO, V180, P46, DOI 10.1016/S0006-291X(05)81252-5; SCHALKWIJK C, 1992, J BIOL CHEM, V267, P8846; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SUGA H, 1993, EUR J BIOCHEM, V218, P807, DOI 10.1111/j.1432-1033.1993.tb18435.x; TAKAMURA H, 1987, J BIOL CHEM, V262, P2262; VIAL D, 1995, J BIOL CHEM, V270, P17327, DOI 10.1074/jbc.270.29.17327; WEISS J, 1994, J BIOL CHEM, V269, P26331; WIJKANDER J, 1995, J BIOL CHEM, V270, P26543, DOI 10.1074/jbc.270.44.26543; WINKLER JD, 1993, BIOCHEM J, V291, P825, DOI 10.1042/bj2910825; WU T, 1994, J CLIN INVEST, V93, P571, DOI 10.1172/JCI117009	82	120	120	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30041	30051		10.1074/jbc.271.47.30041	http://dx.doi.org/10.1074/jbc.271.47.30041			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939951	hybrid			2022-12-25	WOS:A1996VU52500079
J	Rajas, F; Gire, V; Rousset, B				Rajas, F; Gire, V; Rousset, B			Involvement of a membrane-bound form of glutamate dehydrogenase in the association of lysosomes to microtubules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFIED THYROID LYSOSOMES; ENDOCYTIC VESICLES; CYTOPLASMIC DYNEIN; BINDING PROTEIN; FUSION INVITRO; LATE ENDOSOMES; CELLS; IDENTIFICATION; KINESIN; TRANSPORT	A 50-kDa membrane protein corresponding to a membrane-bound isoform of glutamate dehydrogenase was proposed as a molecular species that could mediate lysosome-microtubule interactions. This protein, isolated from purified lysosome membranes, is a peripheral membrane protein with an ATP-dependent microtubule binding activity, We have produced antibodies against the purified 50-kDa protein to investigate its role in the association of lysosomes to microtubules using a cell-free reconstitution assay and cell microinjection, Pretreatment of purified lysosomes with the antibodies inhibited the association of these vesicles to microtubules. The blocking effect of antibodies was demonstrated by a differential sedimentation method and negative staining electron microscopy, allowing us to quantify the amount of microtubules interacting with lysosomes and the proportion of lysosomes bound to microtubules, respectively, Affinity-purified antibodies microinjected into intact cells altered the distribution of lysosomes that appeared less clustered in the vicinity of nuclei, The antibody-induced lysosome dispersion was assessed by quantitative videomicroscope analyses. These data show that the 50-kDa membrane protein could act, through its microtubule binding activity, as a molecule of attachment of lysosomes to microtubules. This membrane-bound isoform of glutamate dehydrogenase could be involved in the microtubule-dependent perinuclear localization of lysosomes.	RTH LAENNEC,FAC MED,INSERM U369,F-69372 LYON 08,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)			Gire, Véronique/AAC-2218-2020; Gire, Veronique/N-7553-2017; RAJAS, Fabienne/P-4091-2016	RAJAS, Fabienne/0000-0002-9233-7633; Gire, Veronique/0000-0002-9009-2185				ALQUIER C, 1985, BIOCHEM J, V232, P529, DOI 10.1042/bj2320529; AMIENTO F, 1993, J CELL BIOL, V123, P1373; BOMSEL M, 1990, CELL, V62, P719, DOI 10.1016/0092-8674(90)90117-W; CARLIER MF, 1980, BIOCHEM BIOPH RES CO, V96, P1761, DOI 10.1016/0006-291X(80)91378-9; COLLOT M, 1984, P NATL ACAD SCI-BIOL, V81, P788, DOI 10.1073/pnas.81.3.788; DEBRABANDER M, 1988, CELL MOTIL CYTOSKEL, V9, P30, DOI 10.1002/cm.970090105; GILL SR, 1991, J CELL BIOL, V115, P1639, DOI 10.1083/jcb.115.6.1639; GOLTZ JS, 1992, P NATL ACAD SCI USA, V89, P7026, DOI 10.1073/pnas.89.15.7026; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; Harlow E., 1988, ANTIBODIES LAB MANUA; HEUSER J, 1989, J CELL BIOL, V108, P855, DOI 10.1083/jcb.108.3.855; HOLLENBECK PJ, 1990, NATURE, V346, P864, DOI 10.1038/346864a0; HOLLENBECK PJ, 1989, J CELL BIOL, V108, P2335, DOI 10.1083/jcb.108.6.2335; JOHNSON LV, 1980, P NATL ACAD SCI-BIOL, V77, P990, DOI 10.1073/pnas.77.2.990; KELLY RB, 1990, CELL, V61, P5, DOI 10.1016/0092-8674(90)90206-T; KOSTROUCH Z, 1991, ENDOCRINOLOGY, V129, P2202, DOI 10.1210/endo-129-4-2202; KREIS TE, 1989, EUR J CELL BIOL, V49, P128; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN SXH, 1992, J CELL SCI, V101, P125; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; MATTEONI R, 1987, J CELL BIOL, V105, P1253, DOI 10.1083/jcb.105.3.1253; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; MITHIEUX G, 1988, BIOCHIM BIOPHYS ACTA, V971, P29; MITHIEUX G, 1988, BIOCHIM BIOPHYS ACTA, V969, P121, DOI 10.1016/0167-4889(88)90067-5; MITHIEUX G, 1989, J BIOL CHEM, V264, P4664; MUNARISILEM Y, 1990, J CELL PHYSIOL, V145, P414, DOI 10.1002/jcp.1041450305; NOIVA R, 1992, J BIOL CHEM, V267, P3553; PARTON RG, 1991, J CELL BIOL, V113, P261, DOI 10.1083/jcb.113.2.261; PIATIGORSKY J, 1989, CELL, V57, P197, DOI 10.1016/0092-8674(89)90956-2; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; PREISS T, 1993, J BIOL CHEM, V268, P25423; RAJAS F, 1993, BIOCHEM J, V295, P447, DOI 10.1042/bj2950447; RICKARD JE, 1991, J BIOL CHEM, V266, P17597; RICKARD JE, 1990, J CELL BIOL, V110, P1623, DOI 10.1083/jcb.110.5.1623; ROUSSET B, 1988, STRTUCTURE FUNCTIONS, P313; SCHEEL J, 1991, J BIOL CHEM, V266, P18141; SCHEEL J, 1990, J CELL SCI, V96, P711; SCHROER TA, 1988, J CELL BIOL, V107, P1785, DOI 10.1083/jcb.107.5.1785; SCHROER TA, 1989, CELL, V56, P937, DOI 10.1016/0092-8674(89)90627-2; SCHROER TA, 1991, J CELL BIOL, V115, P1309, DOI 10.1083/jcb.115.5.1309; SCHROER TA, 1991, ANNU REV PHYSIOL, V53, P629, DOI 10.1146/annurev.ph.53.030191.003213; SELMI S, 1989, ARCH BIOCHEM BIOPHYS, V273, P170, DOI 10.1016/0003-9861(89)90176-8; SELMI S, 1988, BIOCHEM J, V253, P523, DOI 10.1042/bj2530523; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; SWANSON J, 1987, P NATL ACAD SCI USA, V84, P1921, DOI 10.1073/pnas.84.7.1921; SWANSON JA, 1992, J CELL SCI, V103, P201; TONG PY, 1988, J BIOL CHEM, V263, P2585; TOYOSHIMA I, 1992, J CELL BIOL, V118, P1121, DOI 10.1083/jcb.118.5.1121; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247	49	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29882	29890		10.1074/jbc.271.47.29882	http://dx.doi.org/10.1074/jbc.271.47.29882			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939930	hybrid			2022-12-25	WOS:A1996VU52500058
J	Guojie; Breslow, E; Meister, A				Guojie; Breslow, E; Meister, A			The amino acid sequence of rat kidney 5-oxo-L-prolinase determined by cDNA cloning	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYVINYLIDENE DIFLUORIDE; 5-SUBSTITUTED HYDANTOINS; RNA-POLYMERASE; PROTEIN; GENES; EXPRESSION; 5-OXOPROLINASE; CONVERSION; QUANTITIES; MEMBRANES	5-Oxoprolinase (EC 3.5.2) catalyzes a reaction in which the endergonic cleavage of 5-oxo-L-proline to form L-glutamate is coupled to the exergonic hydrolysis of ATP to ADP and inorganic phosphate, Highly purified preparations of the enzyme have been obtained from rat kidney and Pseudomonas putida, The rat kidney enzyme is composed of two strongly interacting, apparently identical subunits (M(r) = 142,000), whereas that from P. putida is composed of two functionally different protein components that can readily be dissociated, Here we report the cloning of rat kidney 5-oxoprolinase with preliminary expression studies. cDNA clones encoding the enzyme were isolated by screening a lambda gt11 cDNA library beginning with a degenerate oligonucleotide probe based on peptide sequence data obtained from the purified enzyme, The whole cDNA clone was completed by amplifying its 5' end from a premade library of rat kidney Marathon-Ready(TM) cDNAs using polymerase chain reaction methodology, The composite cDNA (4,016 bases) revealed an uninterrupted open reading frame encoding 1,288 amino acid residues (M(r) = 137,759), The deduced amino acid sequence contains all four of the peptide sequences that were independently found in peptide fragments derived from the enzyme, Expression of the full-length clone in Escherichia coli yielded a product of the same size as the rat kidney enzyme and which reacted with antibodies directed against the rat kidney enzyme, The predicted amino acid sequence is almost 50% identical throughout its entire length to that of a hypothetical yeast protein YKL215C, It is also 26% identical in half its length to the bacterial hydantoinase HyuA and 26% identical in the other half to the bacterial hydantoinase HyuB, The results suggest unexpected evolutionary relationships among the hydantoinases and rat kidney 5-oxoprolinase which share the common property of hydrolyzing the imide bond of 5-membered rings but which do not all require ATP.	CORNELL UNIV,COLL MED,DEPT BIOCHEM,NEW YORK,NY 10021	Cornell University					NIDDK NIH HHS [DK-12034] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK012034, R37DK012034] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel FM., 1988, CURRENT PROTOCOLS MO; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHENCHIK A, 1995, CLONTECHNIQUES, V410, P5; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; KIM JM, 1987, BIOCHEM BIOPH RES CO, V142, P1006, DOI 10.1016/0006-291X(87)91514-2; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAPOINTE G, 1994, APPL ENVIRON MICROB, V60, P888, DOI 10.1128/AEM.60.3.888-895.1994; LI LY, 1988, J BIOL CHEM, V263, P6495; LI LY, 1989, J BIOL CHEM, V264, P3096; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MAZELIS M, 1978, PLANT PHYSIOL, V62, P798, DOI 10.1104/pp.62.5.798; MEISTER A, 1985, METHOD ENZYMOL, V133, P445; MOOZ ED, 1976, BIOCHEM BIOPH RES CO, V68, P1066, DOI 10.1016/0006-291X(76)90304-1; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEDDON AP, 1984, J BIOL CHEM, V259, P8091; SEDDON AP, 1986, J BIOL CHEM, V261, P1538; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TZERMIA M, 1994, YEAST, V10, P663, DOI 10.1002/yea.320100511; VANDERWERF P, 1975, J BIOL CHEM, V250, P6686; VANDERWERF P, 1971, P NATL ACAD SCI USA, V68, P2982; VANDERWERF P, 1974, BIOCHEM BIOPH RES CO, V56, P90, DOI 10.1016/S0006-291X(74)80319-0; WATABE K, 1992, J BACTERIOL, V174, P962, DOI 10.1128/jb.174.3.962-969.1992; WILLIAMSON JM, 1982, J BIOL CHEM, V257, P9161; YAMASHIRO A, 1988, AGR BIOL CHEM TOKYO, V52, P2857, DOI 10.1080/00021369.1988.10869160	27	13	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32293	32300		10.1074/jbc.271.50.32293	http://dx.doi.org/10.1074/jbc.271.50.32293			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943290	hybrid			2022-12-25	WOS:A1996VY34000081
J	Li, J; Cook, R; Chaiken, I				Li, J; Cook, R; Chaiken, I			Mutants of single chain interleukin 5 show asymmetric recruitment of receptor alpha and beta(c) subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; GM-CSF; BINDING; IDENTIFICATION; MOLECULES; IL-5; EOSINOPHILS; MUTAGENESIS; EXPRESSION; MUTATIONS	Dual asymmetric mutagenesis of single-chain interleukin 5 (scIL5) was used to obtain evidence that the normally homodimeric IL5 molecule, which contains two 4-helix bundle domains arranged symmetrically about a 2-fold axis, can recruit receptor alpha and beta(c) subunits asymmetrically, Functionally active scIL5 was constructed using recombinant DNA methods by linking two IL5 monomers with a Gly-Gly linker, Mutants were constructed at residues Arg(91), Glu(110), and Trp(111), previously shown to be involved in IL5 receptor alpha chain binding, and at residue Glu(13), known to be involved in signal transduction presumably through interaction with the receptor beta(c) chain, Mutants were examined for receptor alpha chain binding by an optical biosensor assay and for bioactivity using a cell proliferation assay, Substitution of the two binding site residues R91 and W111 in the same 4-helix bundle domain caused a 5-fold greater reduction in receptor binding affinity than when the two substitutions were distributed one in each domain. Substitution of E13 and R91 either in the same or in opposite domains gave comparable IL5R alpha chain binding kinetics, essentially unchanged from those of scIL5, However, in contrast to the binding affinity pattern observed with R91A/W111A dual mutants, distributing the E13A/R91A mutations between the two 4-helix bundle domains caused a 5-6-fold greater loss of bioactivity than when the two changes were in the same domain, leaving the other domain unaltered, Taken with previous mutagenesis data, these results are consistent with a single shared-site model of IL5-IL5R alpha chain recognition in which a single alpha chain can orientate in either of two modes, each one of which is stabilized preferentially by one of the two 4-helix bundles of IL5, Furthermore, the results suggest that a single beta(c) molecule is activated for each IL5, through the Glu(13) residue on the same helix bundle domain that dominates the IL5R alpha interaction.	UNIV PENN,SCH MED,DEPT MED,DIV RHEUMATOL,PHILADELPHIA,PA 19104; SMITHKLINE BEECHAM PHARMACEUT,DEPT MOL IMMUNOL,KING OF PRUSSIA,PA 19406	University of Pennsylvania; GlaxoSmithKline								ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; AMES RS, 1995, J IMMUNOL, V154, P6355; BENTLEY AM, 1992, AM REV RESPIR DIS, V146, P500, DOI 10.1164/ajrccm/146.2.500; DEVOS R, 1993, J BIOL CHEM, V268, P6581; Dickason RR, 1996, J MOL MED-JMM, V74, P535; Dickason RR, 1996, NATURE, V379, P652, DOI 10.1038/379652a0; DIEDERICHS K, 1991, SCIENCE, V254, P1779, DOI 10.1126/science.1837174; GRABER P, 1995, J BIOL CHEM, V270, P15762, DOI 10.1074/jbc.270.26.15762; JENKINS BJ, 1995, EMBO J, V14, P4276, DOI 10.1002/j.1460-2075.1995.tb00102.x; JOHANSON K, 1995, J BIOL CHEM, V270, P9459, DOI 10.1074/jbc.270.16.9459; Li J, 1996, J BIOL CHEM, V271, P1817, DOI 10.1074/jbc.271.4.1817; LOPEZ AF, 1991, J BIOL CHEM, V266, P24741; MCKENZIE ANJ, 1991, EMBO J, V10, P1193, DOI 10.1002/j.1460-2075.1991.tb08060.x; MILBURN MV, 1993, NATURE, V363, P172, DOI 10.1038/363172a0; MORTON T, 1995, P NATL ACAD SCI USA, V92, P10879, DOI 10.1073/pnas.92.24.10879; MURATA Y, 1992, J EXP MED, V175, P341, DOI 10.1084/jem.175.2.341; MUTO BA, 1996, J EXP MED, V183, P1911; Sanderson C J, 1992, Adv Pharmacol, V23, P163, DOI 10.1016/S1054-3589(08)60965-5; SUSSMAN DJ, 1984, MOL CELL BIOL, V4, P1641, DOI 10.1128/MCB.4.8.1641; TAKAKI S, 1994, INT ARCH ALLERGY IMM, V104, P36, DOI 10.1159/000236746; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TAVERNIER J, 1995, P NATL ACAD SCI USA, V92, P5194, DOI 10.1073/pnas.92.11.5194; WELLS JA, 1985, GENE, V34, P315, DOI 10.1016/0378-1119(85)90140-4	23	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31729	31734		10.1074/jbc.271.49.31729	http://dx.doi.org/10.1074/jbc.271.49.31729			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940197	hybrid			2022-12-25	WOS:A1996VW68600108
J	Sakatsume, O; Tsutsui, H; Wang, YF; Gao, H; Tang, XR; Yamauchi, T; Murata, T; Itakura, K; Yokoyama, KK				Sakatsume, O; Tsutsui, H; Wang, YF; Gao, H; Tang, XR; Yamauchi, T; Murata, T; Itakura, K; Yokoyama, KK			Binding of THZif-1, a MAZ-like zinc finger protein to the nuclease-hypersensitive element in the promoter region of the c-MYC protooncogene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIPLE-HELIX FORMATION; IN-VITRO; EMBRYONIC LETHALITY; BURKITT-LYMPHOMA; TRANSCRIPTIONAL INITIATION; FORMING OLIGONUCLEOTIDES; TARGETED DISRUPTION; MODULATE EXPRESSION; REGULATORY ELEMENTS; CHROMATIN STRUCTURE	A detailed analysis is reported of the binding of the zinc finger protein THZif-1 to the nuclease hypersensitive element (NHE) in the promoter region of the c-MYC gene using the electrophoretic mobility shift assay and a series of mutants of a fusion protein composed of glutathione S-transferase and THZif-1. The THZif-1 protein bound specifically to the single-stranded (ss) pyrimidine-rich DNA of the NHE (ss c-myc NHE-C) with an apparent dissociation constant (K-d(app)) of 0.077 mu M. By contrast, no binding to the single-stranded purine rich DNA of the NHE (ss c-myc NHE-me(5)C) was detected. Moreover, the binding affinity of THZif-1 protein was S-fold higher for the single-stranded 5-methyl-2'-deoxycytidine derivative of NHE (ss c-myc NHE-me(5)C) than for the unmethylated NHE, in the case of the binding of THZif-1 to methylated double-stranded (ds) NHE (ds c-myc NHE-me(5)CG), no significant binding to the DNA was observed. The decrease in binding: to DNA of THZif-1 was significant in the case of mutated ds c-myc NHE, in which more than two sites of deoxycytidine residues were methylated, However, the binding affinity of THZif-1 protein for methylated and for unmethylated triple-helical DNA of the NHE was almost identical, Moreover, the domain of the THZif-1 protein that made the major contribution to binding to ss c-myc NHE-C or ss c-myc NHE-me(5)C corresponded to the amino-terminal second zinc finger motif. Taken together, the results indicate that the THZif-1 protein exhibits preferential DNA-binding activity with ss c-myc NHE-C, ds c-myc NHE-CG, and ts c-myc NHE but not with ss c-myc NHE-G and ds c-myc NRE-me(5)CG in vitro.	INST PHYS & CHEM RES, TSUKUBA LIFE SCI CTR, TSUKUBA, IBARAKI 305, JAPAN; SHANGHAI UNIV SCI & TECHNOL, DEPT MATH, SHANGHAI, PEOPLES R CHINA; W CHINA UNIV MED SCI, DEPT MED GENET, SHENYANG, PEOPLES R CHINA; CITY HOPE NATL MED CTR, BECKMAN RES INST, DEPT MOL GENET, DUARTE, CA 91010 USA	RIKEN; University of Shanghai for Science & Technology; Sichuan University; City of Hope; Beckman Research Institute of City of Hope				Sakatsume, Osamu/0000-0003-1340-3661				ARCINAS M, 1994, ONCOGENE, V9, P2699; ASSELIN C, 1989, ONCOGENE, V4, P549; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BEAL PA, 1991, SCIENCE, V251, P1360, DOI 10.1126/science.2003222; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; BOLES TC, 1987, BIOCHEMISTRY-US, V26, P367, DOI 10.1021/bi00376a006; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; CHARRON J, 1992, GENE DEV, V6, P2248, DOI 10.1101/gad.6.12a.2248; CHRISTMAN JK, 1995, P NATL ACAD SCI USA, V92, P7347, DOI 10.1073/pnas.92.16.7347; CHUNG J, 1986, P NATL ACAD SCI USA, V83, P7918, DOI 10.1073/pnas.83.20.7918; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; CONREY AJ, 1988, CELL, V55, P887; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; DAVIS TL, 1989, P NATL ACAD SCI USA, V86, P9682, DOI 10.1073/pnas.86.24.9682; DESJARDINS E, 1993, MOL CELL BIOL, V13, P5710, DOI 10.1128/MCB.13.9.5710; DURLAND RH, 1991, BIOCHEMISTRY-US, V30, P9246, DOI 10.1021/bi00102a017; DYSON PJ, 1985, EMBO J, V4, P2885, DOI 10.1002/j.1460-2075.1985.tb04018.x; EBBINGHAUS SW, 1993, J CLIN INVEST, V92, P2433, DOI 10.1172/JCI116850; EHRLICH M, 1981, SCIENCE, V212, P1350, DOI 10.1126/science.6262918; EICK D, 1989, EMBO J, V8, P1965, DOI 10.1002/j.1460-2075.1989.tb03602.x; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANG GW, 1993, CELL, V74, P875, DOI 10.1016/0092-8674(93)90467-5; Filippova GN, 1996, MOL CELL BIOL, V16, P2802; FIRULLI AB, 1994, ARCH BIOCHEM BIOPHYS, V310, P236, DOI 10.1006/abbi.1994.1162; GLASER RL, 1990, J MOL BIOL, V211, P751, DOI 10.1016/0022-2836(90)90075-W; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRIGORIEV M, 1992, J BIOL CHEM, V267, P3389; HALL DJ, 1990, ONCOGENE, V5, P47; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; HELM CW, 1993, GYNECOL ONCOL, V49, P339, DOI 10.1006/gyno.1993.1136; Kawasaki H, 1996, ARTIF ORGANS, V20, P836, DOI 10.1111/j.1525-1594.1996.tb04556.x; KENNEDY GC, 1992, P NATL ACAD SCI USA, V89, P11498, DOI 10.1073/pnas.89.23.11498; KIMURA A, 1986, CELL, V44, P261, DOI 10.1016/0092-8674(86)90760-9; KINNIBURGH AJ, 1989, NUCLEIC ACIDS RES, V17, P7771, DOI 10.1093/nar/17.19.7771; KITABAYASHI I, 1995, EMBO J, V14, P3496, DOI 10.1002/j.1460-2075.1995.tb07356.x; KITABAYASHI I, 1992, EMBO J, V11, P167, DOI 10.1002/j.1460-2075.1992.tb05039.x; KLENOVA EM, 1993, MOL CELL BIOL, V13, P7612, DOI 10.1128/MCB.13.12.7612; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; KOLLURI R, 1992, NUCLEIC ACIDS RES, V20, P111, DOI 10.1093/nar/20.1.111; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MAYFIELD C, 1994, J BIOL CHEM, V269, P18232; MAYFIELD C, 1994, BIOCHEMISTRY-US, V33, P3358, DOI 10.1021/bi00177a029; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; MICHELOTTI EF, 1995, J BIOL CHEM, V270, P9494, DOI 10.1074/jbc.270.16.9494; Michelotti GA, 1996, MOL CELL BIOL, V16, P2656, DOI 10.1128/mcb.16.6.2656; MOBERG KH, 1992, ONCOGENE, V7, P411; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; ORSON FM, 1991, NUCLEIC ACIDS RES, V19, P3435, DOI 10.1093/nar/19.12.3435; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; POSTEL EH, 1991, P NATL ACAD SCI USA, V88, P8227, DOI 10.1073/pnas.88.18.8227; POVSIC TJ, 1989, J AM CHEM SOC, V111, P3059, DOI 10.1021/ja00190a047; PYRC JJ, 1992, BIOCHEMISTRY-US, V31, P4102, DOI 10.1021/bi00131a029; RAJAGOPAL P, 1989, NATURE, V339, P637, DOI 10.1038/339637a0; SAWAI S, 1993, DEVELOPMENT, V117, P1445; SCHMID P, 1989, SCIENCE, V243, P226, DOI 10.1126/science.2911736; SIEBENLIST U, 1988, MOL CELL BIOL, V8, P867, DOI 10.1128/MCB.8.2.867; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STANTON BR, 1992, GENE DEV, V6, P2235, DOI 10.1101/gad.6.12a.2235; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; TOMONAGA T, 1995, J BIOL CHEM, V270, P4875, DOI 10.1074/jbc.270.9.4875; Tomonaga T, 1996, P NATL ACAD SCI USA, V93, P5830, DOI 10.1073/pnas.93.12.5830; TOTH M, 1990, J MOL BIOL, V214, P673, DOI 10.1016/0022-2836(90)90285-T; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; XODO LE, 1991, NUCLEIC ACIDS RES, V19, P5625, DOI 10.1093/nar/19.20.5625; YOKOYAMA K, 1987, P NATL ACAD SCI USA, V84, P7363, DOI 10.1073/pnas.84.21.7363; YOKOYAMA K, 1990, PROSPECT ANTISENSE N, P35; YOKOYAMA K, 1991, ANTISENSE RNA DNA, P335	76	38	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31322	31333		10.1074/jbc.271.49.31322	http://dx.doi.org/10.1074/jbc.271.49.31322			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940139	hybrid			2022-12-25	WOS:A1996VW68600050
J	Sarkissian, M; Winne, A; Lafyatis, R				Sarkissian, M; Winne, A; Lafyatis, R			The mammalian homolog of suppressor-of-white-apricot regulates alternative mRNA splicing of CD45 exon 4 and fibronectin IIICS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; SMALL NUCLEAR RIBONUCLEOPROTEIN; IMMUNODEFICIENCY-VIRUS TYPE-1; PROTEIN-PROTEIN INTERACTIONS; SR-PROTEINS; PREMESSENGER RNA; SITE SELECTION; BINDING SPECIFICITIES; TYROSINE-PHOSPHATASE; FUNCTIONAL DOMAINS	We have previously described human (HsSWAP) and mouse (MmSWAP) homologs to the Drosophila alternative splicing regulator suppressor-of-white-apricot (su(w(a)) or DmSWAP), DmSWAP was formally defined as an alternative splicing regulator by studies showing that it autoregulates splicing of its own pre-mRNA. We report here that mammalian SWAP regulates its own splicing, and also the splicing of fibronectin and CD45. Using an in vivo system of cell transfection, mammalian SWAP regulated 5' splice site selection in splicing of its own second intron, SWAP enhanced splicing to the distal 5' splice site, whereas the SR protein ASF/SF2 enhanced splicing to the proximal site, SWAP also regulated alternative splicing of the fibronectin IIICS region by promoting exclusion of the entire IIICS region, In contrast, ASF/SF2 stimulated inclusion of the entire IIICS region. Finally, SWAP regulated splicing of CD45 exon 4, promoting exclusion of this exon, an effect also seen with ASF/SF2, Experiments using SWAP deletion mutants showed that splicing regulation of the fibronectin IIICS region and CD45 exon 4 requires a region including a carboxyl-terminal arginine/serine (WS)-rich motif, Since WS motifs of various splicing proteins have been shown to interact with each other, these results suggest that the WS motif in SWAP may regulate splicing, at least in part, through interactions with other R/S containing splicing factors.	BOSTON UNIV, SCH MED, CTR ARTHRITIS, BOSTON, MA 02118 USA	Boston University				Lafyatis, Robert/0000-0002-9398-5034	NIAMS NIH HHS [P60AR20613] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020613] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AKBAR AN, 1988, J IMMUNOL, V140, P2171; AMENDT BA, 1995, MOL CELL BIOL, V15, P4606; AMREIN H, 1994, CELL, V76, P735, DOI 10.1016/0092-8674(94)90512-6; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BIRKELAND ML, 1989, P NATL ACAD SCI USA, V86, P6734, DOI 10.1073/pnas.86.17.6734; BROSI R, 1993, SCIENCE, V262, P102, DOI 10.1126/science.8211112; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; CACERES JF, 1993, EMBO J, V12, P4715, DOI 10.1002/j.1460-2075.1993.tb06160.x; CAPUTI M, 1994, NUCLEIC ACIDS RES, V22, P1018, DOI 10.1093/nar/22.6.1018; CHOU TB, 1987, EMBO J, V6, P4095, DOI 10.1002/j.1460-2075.1987.tb02755.x; DENHEZ F, 1994, J BIOL CHEM, V269, P16170; FU XD, 1993, NATURE, V365, P82, DOI 10.1038/365082a0; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; HERSHBERGER RP, 1990, MOL CELL BIOL, V10, P662, DOI 10.1128/MCB.10.2.662; HUH GS, 1994, GENE DEV, V8, P1561, DOI 10.1101/gad.8.13.1561; HUMPHREY MB, 1995, MOL CELL BIOL, V15, P3979; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; LAFYATIS R, 1994, NATO ADV SCI INST SE, V80, P59; LAVIGUEUR A, 1993, GENE DEV, V7, P2405, DOI 10.1101/gad.7.12a.2405; LI H, 1991, CELL, V67, P335, DOI 10.1016/0092-8674(91)90185-2; LYNCH KW, 1995, GENE DEV, V9, P284, DOI 10.1101/gad.9.3.284; MARDON HJ, 1992, J CELL SCI, V103, P423; MAYEDA A, 1992, P NATL ACAD SCI USA, V89, P1301, DOI 10.1073/pnas.89.4.1301; MAYEDA A, 1993, MOL CELL BIOL, V13, P2993, DOI 10.1128/MCB.13.5.2993; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PIRROTTA V, 1984, EMBO J, V3, P563, DOI 10.1002/j.1460-2075.1984.tb01847.x; RAMCHATESINGH J, 1995, MOL CELL BIOL, V15, P4898; ROGERS PR, 1992, J IMMUNOL, V148, P4054; ROTHSTEIN DM, 1992, J BIOL CHEM, V267, P7139; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; SPIKES DA, 1994, NUCLEIC ACIDS RES, V22, P4510, DOI 10.1093/nar/22.21.4510; STAFFA A, 1995, MOL CELL BIOL, V15, P4597; STAKNIS D, 1994, MOL CELL BIOL, V14, P7670, DOI 10.1128/MCB.14.11.7670; STREULI M, 1989, EMBO J, V8, P787, DOI 10.1002/j.1460-2075.1989.tb03439.x; SUN Q, 1993, GENE DEV, V7, P2598, DOI 10.1101/gad.7.12b.2598; TACKE R, 1995, EMBO J, V14, P3540, DOI 10.1002/j.1460-2075.1995.tb07360.x; TANAKA K, 1994, MOL CELL BIOL, V14, P1347, DOI 10.1128/MCB.14.2.1347; TIAN M, 1992, SCIENCE, V256, P237, DOI 10.1126/science.1566072; TIAN M, 1993, CELL, V74, P105, DOI 10.1016/0092-8674(93)90298-5; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; VALCARCEL J, 1993, NATURE, V362, P171, DOI 10.1038/362171a0; WATAKABE A, 1993, GENE DEV, V7, P407, DOI 10.1101/gad.7.3.407; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; YANG XM, 1994, P NATL ACAD SCI USA, V91, P6924, DOI 10.1073/pnas.91.15.6924; ZACHAR ZZ, 1987, EMBO J, V6, P4105, DOI 10.1002/j.1460-2075.1987.tb02756.x; ZAHLER AM, 1993, MOL CELL BIOL, V13, P4023, DOI 10.1128/MCB.13.7.4023; ZAHLER AM, 1995, P NATL ACAD SCI USA, V92, P2642, DOI 10.1073/pnas.92.7.2642; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZUO P, 1993, EMBO J, V12, P4727, DOI 10.1002/j.1460-2075.1993.tb06161.x	54	48	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31106	31114		10.1074/jbc.271.49.31106	http://dx.doi.org/10.1074/jbc.271.49.31106			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940107	hybrid			2022-12-25	WOS:A1996VW68600018
J	Slotboom, DJ; Lolkema, JS; Konings, WN				Slotboom, DJ; Lolkema, JS; Konings, WN			Membrane topology of the C-terminal half of the neuronal, glial, and bacterial glutamate transporter family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; HIGH-AFFINITY; RAT-BRAIN; FUNCTIONAL EXPRESSION; SEQUENCE; PROTEINS; DOMAINS; GLT-1	Secondary glutamate transporters in neuronal and glial cells in the mammalian central nervous system remove the excitatory neurotransmitter glutamate from the synaptic cleft and prevent the extracellular glutamate concentration to rise above neurotoxic levels. Secondary structure prediction algorithms predict 6 trans membrane helices in the first half of the transporters but fail in the C-terminal half where no clear helix-loop-helix motif is resolved in the hydropathy profile of the primary sequences. A number of previous studies have emphasized the importance of the C-terminal half of the molecules for the function. Here we determine the membrane topology of the C-terminal half of the glutamate transporters by applying the phoA gene fusion technique to the homologous bacterial glutamate transporter of Bacillus stearothermophilus. High sequence conservation and very similar hydropathy profiles in the C-terminal half warrant a similar folding as in the glutamate transporters of the mammalian central nervous system, The C-terminal half contains four putative transmembrane helices. The strong hydrophobic moment and substitution moment of the most C-terminal helix X that point to opposite faces of the helix suggest that the helix faces the lipid environment with its least conserved, hydrophobic face and the interior of the protein with its well conserved, hydrophilic face, Residues that were shown before to be critical for function cluster in helix X and VII.	UNIV GRONINGEN,DEPT MICROBIOL,GRONINGEN BIOMOL SCI & BIOTECHNOL INST,NL-9751 NN HAREN,NETHERLANDS	University of Groningen			Konings, Wilhelmus N./C-7063-2013					CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; CONRADT M, 1995, J BIOL CHEM, V270, P25207, DOI 10.1074/jbc.270.42.25207; DONNELLY D, 1993, PROTEIN SCI, V2, P55; EISENBERG D, 1984, ANNU REV BIOCHEM, V53, P595, DOI 10.1146/annurev.bi.53.070184.003115; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; Gaillard I, 1996, BIOCHEMISTRY-US, V35, P6150, DOI 10.1021/bi953005v; GRUNEWALD M, 1995, J BIOL CHEM, V270, P17017, DOI 10.1074/jbc.270.28.17017; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; KANAI Y, 1995, J BIOL CHEM, V270, P16561, DOI 10.1074/jbc.270.28.16561; KANAI Y, 1993, FASEB J, V7, P1450, DOI 10.1096/fasebj.7.15.7903261; KANAI Y, 1992, NATURE, V360, P367; KANNER BI, 1993, FEBS LETT, V325, P95, DOI 10.1016/0014-5793(93)81421-U; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MICHAELIS S, 1986, J BACTERIOL, V167, P160, DOI 10.1128/jb.167.1.160-167.1986; PINES G, 1995, J BIOL CHEM, V270, P17093, DOI 10.1074/jbc.270.29.17093; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; Pourcher T, 1996, BIOCHEMISTRY-US, V35, P4161, DOI 10.1021/bi9527496; REES DC, 1989, SCIENCE, V245, P510, DOI 10.1126/science.2667138; ROTHSTEIN JD, 1993, P NATL ACAD SCI USA, V90, P6591, DOI 10.1073/pnas.90.14.6591; Sambrook J., 2002, MOL CLONING LAB MANU; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; TOLNER B, 1992, MOL MICROBIOL, V6, P2845, DOI 10.1111/j.1365-2958.1992.tb01464.x; TOLNER B, 1992, J BACTERIOL, V174, P2391, DOI 10.1128/JB.174.7.2391-2393.1992; TOLNER B, 1995, J BACTERIOL, V177, P2863, DOI 10.1128/jb.177.10.2863-2869.1995; VANDENBERG RJ, 1995, J BIOL CHEM, V270, P17668, DOI 10.1074/jbc.270.30.17668; vanGeest M, 1996, J BIOL CHEM, V271, P25582, DOI 10.1074/jbc.271.41.25582	26	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31317	31321		10.1074/jbc.271.49.31317	http://dx.doi.org/10.1074/jbc.271.49.31317			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940138	hybrid, Green Published			2022-12-25	WOS:A1996VW68600049
J	Wan, JX; Blakeley, SD; Dennis, DT; Ko, K				Wan, JX; Blakeley, SD; Dennis, DT; Ko, K			Transit peptides play a major role in the preferential import of proteins into leucoplasts and chloroplasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE 1,5-BISPHOSPHATE CARBOXYLASE; CHLOROPHYLL-A/B PROTEIN; OUTER ENVELOPE MEMBRANE; THYLAKOID MEMBRANE; BINDING PROTEIN; SMALL SUBUNIT; TRANSPORT; PRECURSORS; PLANTS; LOCALIZATION	The in vitro import characteristics of six different precursors of plastid proteins were assessed to determine differences in the protein import pathways of leucoplasts and chloroplasts. Five of these precursor proteins are destined to different subchloroplast sites, and one is a leucoplast stromal precursor protein. The results indicate that some of these precursors can be imported equally into both plastid types and others preferentially into one type of plastid versus the other. The ability of plastids to import different proteins correlates with the in vivo steady state levels of these proteins. Additional differences were also observed in the intraorganellar portion of the translocation pathway for two thylakoidal proteins. The differences in import characteristics were found to be predominantly governed by information in the transit peptides, since attachment of the various transit peptides to different plastid and foreign proteins demonstrated that the import behavior of the proteins is transferable with the transit sequence. These results indicate that the import mechanisms of leucoplasts and chloroplasts are sufficiently different such that the plastids respond differently to the information present in the transit peptides.	QUEENS UNIV, DEPT BIOL, KINGSTON, ON K7L 3N6, CANADA	Queens University - Canada								BARTLETT SG, 1982, METHODS CHLOROPLAST, P1081; BOYLE SA, 1986, PLANT PHYSIOL, V81, P817, DOI 10.1104/pp.81.3.817; CLINE K, 1988, PLANT PHYSIOL, V86, P1120, DOI 10.1104/pp.86.4.1120; CLINE K, 1985, J BIOL CHEM, V260, P3691; CLINE K, 1984, PLANT PHYSIOL, V75, P675, DOI 10.1104/pp.75.3.675; DEBOER D, 1988, EMBO J, V7, P2631, DOI 10.1002/j.1460-2075.1988.tb03115.x; FISCHER K, 1994, J BIOL CHEM, V269, P25754; GREENWOOD JS, 1982, CAN J BOT, V60, P1751, DOI 10.1139/b82-222; HALPIN C, 1989, FEBS LETT, V258, P32, DOI 10.1016/0014-5793(89)81608-4; HAND JM, 1989, EMBO J, V8, P3195, DOI 10.1002/j.1460-2075.1989.tb08478.x; HOFFMAN NE, 1987, P NATL ACAD SCI USA, V84, P8844, DOI 10.1073/pnas.84.24.8844; JOYARD J, 1983, J BIOL CHEM, V258, P1; KEEGSTRA K, 1989, CELL, V56, P247, DOI 10.1016/0092-8674(89)90898-2; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; KLOSGEN RB, 1991, MOL GEN GENET, V225, P297, DOI 10.1007/BF00269862; KLOSGEN RB, 1989, MOL GEN GENET, V217, P155, DOI 10.1007/BF00330955; KO K, 1989, EMBO J, V8, P3187, DOI 10.1002/j.1460-2075.1989.tb08477.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPPA GK, 1988, J BIOL CHEM, V263, P14996; OLSEN LJ, 1989, J BIOL CHEM, V264, P6724; SCHINDLER C, 1986, ARCH BIOCHEM BIOPHYS, V247, P211, DOI 10.1016/0003-9861(86)90550-3; SCHMIDT GW, 1986, ANNU REV BIOCHEM, V55, P879; Scott SV, 1996, J CELL BIOL, V132, P63, DOI 10.1083/jcb.132.1.63; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; SMEEKENS S, 1987, PLANT MOL BIOL, V9, P377, DOI 10.1007/BF00014912; STRZALKA K, 1987, BIOCHEM BIOPH RES CO, V149, P799, DOI 10.1016/0006-291X(87)90438-4; Theg Steven M., 1993, Trends in Cell Biology, V3, P186, DOI 10.1016/0962-8924(93)90212-J; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDENBROECK G, 1985, NATURE, V313, P358, DOI 10.1038/313358a0; VANDENBROECK G, 1988, PLANT SCI, V58, P171, DOI 10.1016/0168-9452(88)90006-4; VIITANEN PV, 1988, J BIOL CHEM, V263, P15000; WAN JX, 1995, J BIOL CHEM, V270, P16731, DOI 10.1074/jbc.270.28.16731; WEISBEEK P, 1987, PROGR PHOTOSYNTHESIS, V4, P569; WU CB, 1994, J BIOL CHEM, V269, P32264	34	52	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31227	31233		10.1074/jbc.271.49.31227	http://dx.doi.org/10.1074/jbc.271.49.31227			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940125	hybrid			2022-12-25	WOS:A1996VW68600036
J	Wang, JJ; Breslow, E; Sykes, BD				Wang, JJ; Breslow, E; Sykes, BD			Differential binding of desmopressin and vasopressin to neurophysin-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE NEUROPHYSINS; PEPTIDE; OXYTOCIN; IDENTIFICATION; CONFORMATION	Desmopressin is a synthetic analog of the peptide hormone vasopressin in which the N-terminal alpha-amino group has been removed and L-arginine in position 8 has been replaced by D-arginine, Using H-1-NMR spectroscopy, we show that desmopressin binds to neurophysin-II, whereas deamino-vasopressin does not bind, Thus, the change in configuration at Arg(8) causes a significant difference in the binding of these hormones to neurophysin-II, We have determined the structure of desmopressin bound to neurophysin-II: using two-dimensional H-1 nuclear magnetic resonance-transferred nuclear Overhauser effect techniques, A common binding motif for vasopressin and desmopressin is proposed that includes a positive charge group along with the hydrophobic surface formed by the side chains of Tyr(2) and a beta-methylene provided by Phe-3, In vasopressin, the positive charge is provided by the N-terminal NEI, whereas in desmopressin, the side chain of Arg-8 contributes the positive charge. The type II beta-turn found in residues Cys(6)-Pro(7)-D-Arg(8)-Gly(9) of the bound structure of desmopressin folds the Arg(8) side chain back toward the disulfide-bond loop, which allows the positive charged side chain of Arg(8) to participate in binding, Such a type II beta-turn is not found in deamino-vasopressin in the presence of neurophysin-II.	UNIV ALBERTA, DEPT BIOCHEM, PROT ENGN NETWORK CTR EXCELLENCE, EDMONTON, AB T6G 2S2, CANADA; CORNELL UNIV, COLL MED, DEPT BIOCHEM, NEW YORK, NY 10021 USA	University of Alberta; Cornell University								BRESLOW E, 1990, ADV ENZYMOL RAMB, V63, P1; BRESLOW E, 1973, BIOCHEMISTRY-US, V12, P4644, DOI 10.1021/bi00747a016; BRESLOW E, 1966, P NATL ACAD SCI USA, V56, P640, DOI 10.1073/pnas.56.2.640; CAMPBELL AP, 1991, J MOL BIOL, V222, P405, DOI 10.1016/0022-2836(91)90219-V; CARLSON J, 1981, BIOCHEM BIOPH RES CO, V100, P455, DOI 10.1016/S0006-291X(81)80118-0; CHEN LQ, 1991, P NATL ACAD SCI USA, V88, P4240, DOI 10.1073/pnas.88.10.4240; FASSINA G, 1988, J BIOL CHEM, V263, P13539; JOST K, 1987, CRC HDB NEUROHYPOPHY, V2, P97; LIAN LY, 1994, METHOD ENZYMOL, V239, P657; LIPPENS G, 1993, BIOCHEMISTRY-US, V32, P9423, DOI 10.1021/bi00087a022; LIVE DH, 1987, BIOCHEMISTRY-US, V26, P6415, DOI 10.1021/bi00394a018; LORD ST, 1979, INT J PEPT PROT RES, V13, P71; Rose JP, 1996, NAT STRUCT BIOL, V3, P163, DOI 10.1038/nsb0296-163; WAGNER G, 1986, J MOL BIOL, V187, P131, DOI 10.1016/0022-2836(86)90413-4; WANG J, 1993, TECHNIQUES PROTEIN C, V4, P569; WANG JJ, 1995, INT J PEPT PROT RES, V45, P471; WANG JJ, 1995, J AM CHEM SOC, V117, P8627, DOI 10.1021/ja00138a019; WHITTAKER BA, 1985, BIOCHEMISTRY-US, V24, P2782, DOI 10.1021/bi00332a028; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; Wuthrich K., 1986, NMR PROTEINS NUCL AC	20	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31354	31359		10.1074/jbc.271.49.31354	http://dx.doi.org/10.1074/jbc.271.49.31354			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940142	hybrid			2022-12-25	WOS:A1996VW68600053
J	Kornilova, E; Sorkina, T; Beguinot, L; Sorkin, A				Kornilova, E; Sorkina, T; Beguinot, L; Sorkin, A			Lysosomal targeting of epidermal growth factor receptors via a kinase-dependent pathway is mediated by the receptor carboxyl-terminal residues 1022-1123	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A431 CELLS; DOWN-REGULATION; EGF RECEPTOR; POSTENDOCYTIC TRAFFICKING; DIRECT VISUALIZATION; HUMAN-FIBROBLASTS; ENDOCYTIC SYSTEM; KB CELLS; INTERNALIZATION; DEGRADATION	Binding of epidermal growth factor (EGF) to its receptor induces rapid internalization and degradation of both ligand and receptor via the lysosomal pathway, To study the mechanism of intracellular sorting of EGF-EGF receptor complexes to lysosomes, NIH 3T3 cells transfected with wild-type and mutant EGF receptors were employed, The kinetics of I-125-EGF trafficking was analyzed using low concentrations of the ligand to avoid saturation of the specific sorting system. The relative size of the pool of internalized I-125-EGF-receptor complexes that were capable of recycling decreased as receptors traversed the endosomal system, The rate of I-125-EGF sequestration from the recycling pathway correlated with the rate of I-125-EGF transition from early to late endosomes as measured by Percoll gradient fractionation. Deletion of the last 63 amino acids of the EGF receptor cytoplasmic tail did not inhibit the process of sequestration and targeting to the late endosomes and lysosomes. Truncation of the 123 residues, however, resulted in impaired lysosomal targeting and increased recycling of EGF, Receptor mutant in which 165 residues were deleted displayed maximal ability to recycle and a minimal extent of sorting to the late endosomes. The data suggest that two regions of the EGF receptor molecule, residues 1022-1063 and to a lesser extent residues 1063-1123, contribute in the regulation of routing of EGF receptors to the degradation pathway, The kinase-negative receptor mutant recycled EGF more intensively compared with the wild-type receptor, and the transport of this mutant to late endosomes was inhibited. These results support the view that the receptor kinase activity is important for ligand-induced sorting of EGF receptors to the pathway of lysosomal degradation.	UNIV COLORADO, HLTH SCI CTR, DEPT PHARMACOL, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, CTR CANC, DENVER, CO 80262 USA; RUSSIAN ACAD SCI, INST CYTOL, ST PETERSBURG 194064, RUSSIA; DIBIT, ONCOL MOL LAB, I-20132 MILAN, ITALY; CNR, INST NEUROSCI & BIOMMAGINI, I-20132 MILAN, ITALY	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Institute of Cytology RAS; Consiglio Nazionale delle Ricerche (CNR)			Kornilova, Elena Sergeevna/AAB-5559-2021	Sorkin, Alexander/0000-0002-4446-1920; Kornilova, Elena/0000-0002-2951-6292				BEGUINOT L, 1984, P NATL ACAD SCI-BIOL, V81, P2384, DOI 10.1073/pnas.81.8.2384; CARLBERG K, 1991, EMBO J, V10, P877, DOI 10.1002/j.1460-2075.1991.tb08020.x; CARPENTER G, 1976, J CELL BIOL, V71, P159, DOI 10.1083/jcb.71.1.159; CARPENTIER JL, 1987, J CELL BIOL, V105, P2751, DOI 10.1083/jcb.105.6.2751; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; COKER KJ, 1994, P NATL ACAD SCI USA, V91, P6967, DOI 10.1073/pnas.91.15.6967; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FELDER S, 1992, J CELL BIOL, V117, P203, DOI 10.1083/jcb.117.1.203; FRENCH AR, 1994, J BIOL CHEM, V269, P15749; Futter CE, 1996, J CELL BIOL, V132, P1011, DOI 10.1083/jcb.132.6.1011; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; Griffiths G, 1991, Trends Cell Biol, V1, P5, DOI 10.1016/0962-8924(91)90047-D; HAIGLER HT, 1979, J CELL BIOL, V81, P382, DOI 10.1083/jcb.81.2.382; HELIN K, 1991, ONCOGENE, V6, P825; HERBST JJ, 1994, J BIOL CHEM, V269, P12865; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HUECKSTEADT T, 1986, J BIOL CHEM, V261, P8655; KORNILOVA ES, 1992, ONCOGENE, V7, P511; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; LAI WH, 1989, J CELL BIOL, V109, P2751, DOI 10.1083/jcb.109.6.2751; LUND KA, 1990, J BIOL CHEM, V265, P15713; LYALL RM, 1985, J CELL PHYSIOL, V122, P166, DOI 10.1002/jcp.1041220125; MARSH EW, 1995, J CELL BIOL, V129, P1509, DOI 10.1083/jcb.129.6.1509; MCKANNA JA, 1979, P NATL ACAD SCI USA, V76, P5689, DOI 10.1073/pnas.76.11.5689; MILLER K, 1986, J CELL BIOL, V102, P500, DOI 10.1083/jcb.102.2.500; MILOSO M, 1995, J BIOL CHEM, V270, P19557, DOI 10.1074/jbc.270.33.19557; OPRESKO LK, 1995, J BIOL CHEM, V270, P4325, DOI 10.1074/jbc.270.9.4325; SCHWARTZ AL, 1984, J CELL BIOL, V98, P732, DOI 10.1083/jcb.98.2.732; SELVA E, 1993, J BIOL CHEM, V268, P2250; SORKIN A, 1992, J BIOL CHEM, V267, P8672; SORKIN A, 1991, J BIOL CHEM, V266, P8355; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; SORKIN A, 1989, BIOCHIM BIOPHYS ACTA, V1011, P88, DOI 10.1016/0167-4889(89)90083-9; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; SORKIN A, 1991, J CELL BIOL, V112, P55, DOI 10.1083/jcb.112.1.55; SORKIN A, 1992, ENDOCYTOSIS, P181; SORKIN AD, 1988, EXP CELL RES, V175, P192, DOI 10.1016/0014-4827(88)90266-2; STARBUCK C, 1992, BIOTECHNOL PROGR, V8, P132, DOI 10.1021/bp00014a007; STOORVOGEL W, 1987, J CELL BIOL, V104, P1261, DOI 10.1083/jcb.104.5.1261; STOSCHECK CM, 1984, J CELL BIOL, V98, P1048, DOI 10.1083/jcb.98.3.1048; VELU TJ, 1989, MOL CELL BIOL, V9, P1772, DOI 10.1128/MCB.9.4.1772; WILEY HS, 1988, J CELL BIOL, V107, P801, DOI 10.1083/jcb.107.2.801; WILEY HS, 1991, J BIOL CHEM, V266, P11083	44	97	104	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30340	30346		10.1074/jbc.271.48.30340	http://dx.doi.org/10.1074/jbc.271.48.30340			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8939994	hybrid			2022-12-25	WOS:A1996VV15800011
J	Lowe, M; Kreis, TE				Lowe, M; Kreis, TE			In vivo assembly of coatomer, the COP-I coat precursor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; GOLGI MEMBRANES REQUIRES; GTP-BINDING PROTEIN; ENDOPLASMIC-RETICULUM; BREFELDIN-A; BETA-COP; ORGANELLE STRUCTURE; GUANINE-NUCLEOTIDE; VESICLES; SUBUNIT	Coatomer, a seven-subunit hetero-oligomeric complex, is the major component of the COP-I membrane coat of transport vesicles of the early secretory pathway, We have followed the assembly of this complex in vivo by pulse-chase experiments and immunoprecipitation of native coatomer subunits and found that it is an ordered process that takes 1-2 h to complete. During assembly, direct interactions between alpha-, beta'- and delta-COP, beta- and delta-COP, and gamma-, zeta-, and delta-COP occur. Coatomer, once it has assembled, is stable with a half-life of similar to 28 h. No significant amounts of partial coatomer complexes have been detected, The only subunit to exist at steady state out of the complex is zeta-COP, which has a similar half-life to coatomer subunits within the complex. Assembly is inhibited by brefeldin A, suggesting that it may be a regulated process. These results describe for the first time in vivo assembly of a coat protein complex involved in membrane traffic and extend our knowledge of how coatomer is structured.	UNIV GENEVA,DEPT BIOL CELLULAIRE,CH-1211 GENEVA,SWITZERLAND	University of Geneva								Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; BACHURSKI CJ, 1994, MOL CELL BIOL, V14, P4076, DOI 10.1128/MCB.14.6.4076; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; Cosson P, 1996, EMBO J, V15, P1792, DOI 10.1002/j.1460-2075.1996.tb00528.x; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; ELAZAR Z, 1994, J CELL BIOL, V124, P415, DOI 10.1083/jcb.124.4.415; GERICH B, 1995, P NATL ACAD SCI USA, V92, P3229, DOI 10.1073/pnas.92.8.3229; HARAKUGE S, 1994, J CELL BIOL, V124, P883, DOI 10.1083/jcb.124.6.883; HARRISONLAVOIE KJ, 1993, EMBO J, V12, P2847, DOI 10.1002/j.1460-2075.1993.tb05946.x; HARTER C, 1995, FEBS LETT, V369, P89, DOI 10.1016/0014-5793(95)00621-F; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Kreis TE, 1995, ANNU REV CELL DEV BI, V11, P677, DOI 10.1146/annurev.cb.11.110195.003333; KREIS TE, 1986, CELL, V46, P929, DOI 10.1016/0092-8674(86)90075-9; KUGE O, 1993, J CELL BIOL, V123, P1727, DOI 10.1083/jcb.123.6.1727; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Lowe M, 1995, J BIOL CHEM, V270, P31364, DOI 10.1074/jbc.270.52.31364; ORCI L, 1993, NATURE, V362, P648, DOI 10.1038/362648a0; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; Sheff D, 1996, J BIOL CHEM, V271, P7230, DOI 10.1074/jbc.271.12.7230; STENBECK G, 1992, FEBS LETT, V314, P195, DOI 10.1016/0014-5793(92)80973-K; STENBECK G, 1993, EMBO J, V12, P2841, DOI 10.1002/j.1460-2075.1993.tb05945.x; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WHITNEY JA, 1995, CELL, V83, P703	31	42	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30725	30730		10.1074/jbc.271.48.30725	http://dx.doi.org/10.1074/jbc.271.48.30725			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940050	hybrid			2022-12-25	WOS:A1996VV15800067
J	Osborn, MT; Chambers, TC				Osborn, MT; Chambers, TC			Role of the stress-activated/c-Jun NH2-terminal protein kinase pathway in the cellular response to adriamycin and other chemotherapeutic drugs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; RESISTANCE MDR1 GENE; DNA-DAMAGING AGENTS; MULTIDRUG RESISTANCE; DEATH APOPTOSIS; MAMMALIAN-CELLS; CARCINOMA-CELLS; HEAT-SHOCK; PHOSPHORYLATION; P53	c-Jun NH2-terminal protein kinase (JNK), a member of the mitogen activated protein kinase family, is activated in response to many stressful stimuli including heat shock, UV irradiation, protein synthesis inhibitors, and inflammatory cytokines, In this study, we investigated whether JNK plays a role in the cellular response to different drugs commonly used in cancer chemotherapy. Treatment of human KB-3 carcinoma cells with Adriamycin resulted in a time and dose dependent activation of JNK of up to 40-fold. Treatment with vinblastine or etoposide (VP-16) also activated JNK, with maximum increases of 6.5- and 4.3 fold, respectively, Consistent with these findings, increased c-Jun phosphorylation was observed after drug treatment of cells, In contrast, none of the drugs significantly activated the extracellular response kinase/mitogen activated protein kinase pathway, Since these drugs are transport substrates for the MDR1 gene product, P-glycoprotein, JNK was assayed in two multidrug-resistant (MDR) KB cell lines, KB-A1 and KB-V1, selected for resistance to Adriamycin and vinblastine, respectively. Relative to KB-3 cells, basal JNK activity was increased 7-fold in KB-A1 cells and 4-fold in KB-V1 cells, with no change in JNK protein expression, indicating that JNK is present in a more highly activated form in the MDR cell lines. Under conditions optimal for JNK activation, Adriamycin, vinblastine, and VP 16 all induced MDR1 mRNA expression in KB-3 cells. Our findings suggest that JNK activation is an important component of the cellular response to several structurally and functionally distinct anticancer drugs and may also play a role in the MDR phenotype.	UNIV ARKANSAS MED SCI HOSP,DEPT BIOCHEM & MOL BIOL,LITTLE ROCK,AR 72205	University of Arkansas System; University of Arkansas Medical Sciences								ANAND S, 1995, CANCER LETT, V88, P101, DOI 10.1016/0304-3835(94)03617-R; CHAUDHARY PM, 1993, J NATL CANCER I, V85, P632, DOI 10.1093/jnci/85.8.632; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CHIN KV, 1990, J BIOL CHEM, V265, P221; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KASTAN MB, 1991, CANCER RES, V51, P6304; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEE JM, 1995, CANCER METAST REV, V14, P149, DOI 10.1007/BF00665797; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Mertens S, 1996, FEBS LETT, V383, P273, DOI 10.1016/0014-5793(96)00255-4; MIZUMOTO K, 1994, MOL PHARMACOL, V46, P890; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; REED JC, 1995, HEMATOL ONCOL CLIN N, V9, P451, DOI 10.1016/S0889-8588(18)30104-7; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SHEN DW, 1986, J BIOL CHEM, V261, P7762; SKLADANOWSKI A, 1993, BIOCHEM PHARMACOL, V46, P375, DOI 10.1016/0006-2952(93)90512-U; TISHLER RB, 1993, CANCER RES, V53, P2212; TISHLER RB, 1995, CANCER RES, V55, P6021; TSUKIDATE K, 1993, AM J PATHOL, V143, P918; UCHIUMI T, 1993, FEBS LETT, V326, P11, DOI 10.1016/0014-5793(93)81750-T; UEDA K, 1987, J BIOL CHEM, V262, P505; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; YAN MH, 1994, NATURE, V372, P798; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	37	209	215	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30950	30955		10.1074/jbc.271.48.30950	http://dx.doi.org/10.1074/jbc.271.48.30950			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940082	hybrid			2022-12-25	WOS:A1996VV15800099
J	Casimir, DA; Ntambi, JM				Casimir, DA; Ntambi, JM			cAMP activates the expression of stearoyl-CoA desaturase gene 1 during early preadipocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3T3-L1 ADIPOCYTE DIFFERENTIATION; TRANSCRIPTION FACTOR; DIETARY-REGULATION; INDUCTION; BINDING; ENHANCER; ACID; CARBOXYLASE; PROMOTER; AP-2	Stearoyl-CoA desaturase gene 1 (scd1) mRNA levels were induced during the Ist day of 3T3-L1 differentiation. scd1 expression had previously been observed only in late-stage differentiation, during the period of triacylglycerol accumulation. The induction of 3T3-L1 differentiation requires treatment with insulin, dexamethasone, and an agent that increases intracellular cAMP levels, Treatment of preadipocytes with cAMP-elevating agents caused an increase in scd1 mRNA concentrations, Insulin and dexamethasone had no effect on scd1 mRNA expression in preadipocytes, The increase in mRNA resulted from transcriptional activation of the scd1 gene. 8-Bromo-cAMP treatment of differentiated adipocytes had no effect on scd1 mRNA levels, suggesting a preadipocyte-specific effect. The increase in scd1 mRNA occurred maximally after 6 h of cAMP treatment and was shown to require protein synthesis. Deletion and mutagenesis analyses have localized the cAMP response to sequence within the first 250 base pairs of the 5'-flanking region of the scd1 gene. Treatment with phorbol ester enhanced the induction of scd1 mRNA by cAMP, suggesting the involvement of AP-2 as a mediator of the cAMP response. The induction of scd1 expression by cAMP during early differentiation was distinct from that observed during late adipocyte development. This early expression presents a novel regulated function of scd1 during the differentiation process, independent of its lipogenic role in late adipocyte development, The induction of scd1 also introduces a role for cAMP in 3T3-L1 differentiation.	UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706; UNIV WISCONSIN,DEPT NUTR SCI,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042825] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007215] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42825] Funding Source: Medline; NIGMS NIH HHS [T32 GM07215] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKER PB, 1987, CELL, V51, P435, DOI 10.1016/0092-8674(87)90639-8; BERNLOHR DA, 1985, J BIOL CHEM, V260, P5563; Casimir DA, 1996, DIFFERENTIATION, V60, P203, DOI 10.1046/j.1432-0436.1996.6040203.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KADESCH T, 1986, MOL CELL BIOL, V6, P2593, DOI 10.1128/MCB.6.7.2593; KAESTNER KH, 1989, J BIOL CHEM, V264, P14755; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; LOVE JD, 1985, ANAL BIOCHEM, V150, P429, DOI 10.1016/0003-2697(85)90532-9; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MILLER CW, 1996, IN PRESS ENDOCRINOLO; NAGAE Y, 1988, NUCLEIC ACIDS RES, V16, P10363, DOI 10.1093/nar/16.21.10363; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NTAMBI JM, 1995, PROSTAG LEUKOTR ESS, V52, P117, DOI 10.1016/0952-3278(95)90009-8; NTAMBI JM, 1995, PROG LIPID RES, V34, P139, DOI 10.1016/0163-7827(94)00010-J; NTAMBI JM, 1992, J BIOL CHEM, V267, P10925; PARK K, 1993, J BIOL CHEM, V268, P17811; PHILLIPS M, 1995, J CELL SCI, V108, P395; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SADOWSKI HB, 1992, J BIOL CHEM, V266, P4722; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; TAE HJ, 1995, J BIOL CHEM, V270, P21487, DOI 10.1074/jbc.270.37.21487; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X	30	44	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29847	29853		10.1074/jbc.271.47.29847	http://dx.doi.org/10.1074/jbc.271.47.29847			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939924	hybrid			2022-12-25	WOS:A1996VU52500052
J	Coletta, M; Ascenzi, P; DAvino, R; diPrisco, G				Coletta, M; Ascenzi, P; DAvino, R; diPrisco, G			Proton-linked subunit kinetic heterogeneity for carbon monoxide binding to hemoglobin from Chelidonichthys kumu	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LASER PHOTOLYSIS; LIGAND-BINDING; T-STATE; OXYGEN; PH; DEOXYHEMOGLOBIN; REACTIVITY; MYOGLOBIN; MECHANISM; BOND	The pH dependence of CO binding kinetics to Chelidonichthys kumu hemoglobin (Hb) and human adult Hb has been investigated between pH 2.0 and 9.0 at 20 degrees C. For both Hbs, CO binding kinetics is characterized by two proton linked transitions, with different pK(a) values for alpha- and beta-chains in C. kumu Hb, leading to a relevant functional kinetic heterogeneity at most pH values, On the other hand, in human adult Hb the CO binding does not display a functional heterogeneity, Lowering the pH from 9 to 6 brings about a decrease of the CO binding rate constants, to a different extent for human adult Hb and the two chains of C. kumu Hb, Further lowering the pH from 6 to 2 induces an enhancement of CO binding rate constants, probably related to the protonation of proximal His(F8) N-epsilon atom and the cleavage (or severe weakening) of the His(F8)-Fe bond, The presence of physiological concentrations of ATP (approximate to 3 mM) affects the pH dependence of CO binding kinetics to C. kumu, Moreover, the effect of temperature (between 8 degrees C and 38 degrees C) on CO binding kinetics has been investigated in the absence of ATP at different pH values. These results allow to interpret the functional kinetic heterogeneity of C. kumu Hb on the basis of different regulatory aspects in the alpha and beta subunits, as suggested by structural considerations.	THIRD UNIV ROME,DEPT BIOL,I-00154 ROME,ITALY; INST PROT BIOCHEM & ENZYMOL,CONSIGLIO NAZL RICH,I-80125 NAPLES,ITALY	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica delle Proteine (IBP-CNR)	Coletta, M (corresponding author), UNIV CAMERINO,DEPT MOL CELLULAR & ANIM BIOL,VIA FILIPPO CAMERINI 2,I-62032 CAMERINO,ITALY.		Coletta, Massimo/N-9049-2015; Coletta, Massimiliano/GSN-5927-2022	COLETTA, Massimiliano/0000-0002-5489-9467				ANTONINI E, 1971, HEMOGLOBIN MYOGLOBIN, P2; BALDWIN J, 1979, J MOL BIOL, V129, P175, DOI 10.1016/0022-2836(79)90277-8; Brunori M, 1975, Curr Top Cell Regul, V9, P1; CAMARDELLA L, 1992, J MOL BIOL, V224, P449, DOI 10.1016/0022-2836(92)91007-C; COLETTA M, 1992, FEBS LETT, V296, P184, DOI 10.1016/0014-5793(92)80375-Q; COLETTA M, 1985, J BIOL CHEM, V260, P4151; COLETTA M, 1988, J BIOL CHEM, V263, P18286; COLETTA M, 1993, BIOCHIM BIOPHYS ACTA, V1162, P309, DOI 10.1016/0167-4838(93)90295-3; COLETTA M, 1990, J BIOL CHEM, V265, P4828; Eyring H, 1935, J CHEM PHYS, V3, P107, DOI 10.1063/1.1749604; FAGO A, 1993, EUR J BIOCHEM, V218, P829, DOI 10.1111/j.1432-1033.1993.tb18438.x; GIARDINA B, 1978, BIOCHEM J, V175, P407, DOI 10.1042/bj1750407; HO C, 1987, BIOCHEMISTRY-US, V26, P6299, DOI 10.1021/bi00394a001; HO C, 1992, ADV PROTEIN CHEM, V43, P153, DOI 10.1016/S0065-3233(08)60555-0; IKEDASAITO M, 1980, J MOL BIOL, V138, P845, DOI 10.1016/0022-2836(80)90068-6; ITO N, 1995, J MOL BIOL, V250, P648, DOI 10.1006/jmbi.1995.0405; KNUTH A, 1979, ACTA HAEMATOL-BASEL, V61, P121, DOI 10.1159/000207643; MARDEN MC, 1988, BIOCHEMISTRY-US, V27, P1659, DOI 10.1021/bi00405a041; MATHEWS AJ, 1989, J BIOL CHEM, V264, P16573; MATTHEW JB, 1979, BIOCHEMISTRY-US, V18, P1919, DOI 10.1021/bi00577a011; MIYAJI R, 1966, CLIN CHIM ACTA, V14, P624; NOBLE RW, 1970, J BIOL CHEM, V245, P6628; OLSON JS, 1971, J BIOL CHEM, V246, P5919; PERUTZ MF, 1990, ANNU REV PHYSIOL, V52, P1; PERUTZ MF, 1979, ANNU REV BIOCHEM, V48, P327, DOI 10.1146/annurev.bi.48.070179.001551; PHILO JS, 1990, J BIOL CHEM, V265, P139; Riggs A., 1981, Methods in Enzymology, V76, P5; SAFFRAN WA, 1978, J BIOL CHEM, V253, P3171; SAWICKI CA, 1977, J BIOL CHEM, V252, P7538; SAWICKI CA, 1976, J BIOL CHEM, V251, P1533; SMERDON SJ, 1993, BIOCHEMISTRY-US, V32, P5132, DOI 10.1021/bi00070a023	31	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29859	29864		10.1074/jbc.271.47.29859	http://dx.doi.org/10.1074/jbc.271.47.29859			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939926	hybrid			2022-12-25	WOS:A1996VU52500054
J	Fuentes, GM; Palaniappan, C; Fay, PJ; Bambara, RA				Fuentes, GM; Palaniappan, C; Fay, PJ; Bambara, RA			Strand displacement synthesis in the central polypurine tract region of HIV-1 promotes DNA to DNA strand transfer recombination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REVERSE-TRANSCRIPTASE; VIRUS; GENOMES; RNA	Two distinct plus strand initiation sites have been identified in human immunodeficiency virus (HN), the central polypurine tract (cPPT) and the polypurine tract located just upstream of the U3 region (US-PPT), When synthesis from the U3-PPT reaches the cPPT, the elongating primer causes limited strand displacement of the product created from the cPPT, We examined whether reverse transcriptase (RT) catalyzed strand transfer recombination is promoted by this process. Using a substrate having the viral sequence of the displaced region, we measured transfer of an elongating DNA primer from a donor DNA to an acceptor DNA, Strand transfer synthesis was only efficient when RT was performing strand displacement synthesis, Transfer efficiency was directly related to acceptor concentration but independent of the reaction time. Transfer could occur to accepters containing 80, 40, or 20 nucle otides of homology with the template DNA. Using different accepters, we found that DNA to DNA transfer occurred at positions throughout the donor template, except near the 5' end. This shows that a number of the sequences downstream of the cPPT region can promote transfer, but once synthesis has progressed to the point where the downstream segment is completely displaced transfer is not allowed, When the DNA to DNA transfer reactions were performed using a template containing nonviral sequences, the transfer efficiency dropped significantly. This indicates that transfer efficiency is determined by the sequences of the templates used, HIV-RT RNase H-dependent strand transfer between RNA templates is well documented. We propose a quite different mechanism for DNA to DNA transfer, consistent with the ability of RNase H minus RT to perform this reaction, If these DNA to DNA transfer events occur in vivo, they will result in plus strand recombination.	UNIV ROCHESTER,SCH MED & DENT,DEPT MICROBIOL & IMMUNOL,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT BIOCHEM,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT MED,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,CTR CANC,ROCHESTER,NY 14642	University of Rochester; University of Rochester; University of Rochester; University of Rochester					NCI NIH HHS [CA11198] Funding Source: Medline; NIGMS NIH HHS [GM 49573, 1F 31 GM 17200-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA011198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049573, F31GM017200] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHARNEAU P, 1991, J VIROL, V65, P2415, DOI 10.1128/JVI.65.5.2415-2421.1991; CHARNEAU P, 1994, J MOL BIOL, V241, P651, DOI 10.1006/jmbi.1994.1542; COFFIN JM, 1979, J GEN VIROL, V42, P1, DOI 10.1099/0022-1317-42-1-1; DESTEFANO JJ, 1992, J VIROL, V66, P6370, DOI 10.1128/JVI.66.11.6370-6378.1992; Fuentes GM, 1996, J BIOL CHEM, V271, P1966, DOI 10.1074/jbc.271.4.2063; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; HU WS, 1990, P NATL ACAD SCI USA, V87, P1556, DOI 10.1073/pnas.87.4.1556; JUNGHANS RP, 1982, J VIROL, V43, P544, DOI 10.1128/JVI.43.2.544-554.1982; KLARMANN GJ, 1993, J BIOL CHEM, V268, P9793; LeGrice SFJ, 1995, METHOD ENZYMOL, V262, P130, DOI 10.1016/0076-6879(95)62015-X; LUO G, 1990, J VIROL, V64, P4321, DOI 10.1128/JVI.64.9.4321-4328.1990; PATEL PH, 1994, P NATL ACAD SCI USA, V91, P549, DOI 10.1073/pnas.91.2.549; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; Sambrook J., 2002, MOL CLONING LAB MANU; SCHATZ O, 1989, FEBS LETT, V257, P311, DOI 10.1016/0014-5793(89)81559-5; SKALKA AM, 1983, J CELL BIOL, V294, P75; WHITCOMB JM, 1992, ANNU REV CELL BIOL, V8, P275, DOI 10.1146/annurev.cb.08.110192.001423	18	26	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29605	29611		10.1074/jbc.271.47.29605	http://dx.doi.org/10.1074/jbc.271.47.29605			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939890	hybrid			2022-12-25	WOS:A1996VU52500018
J	Liu, J; Barry, CE; Besra, GS; Nikaido, H				Liu, J; Barry, CE; Besra, GS; Nikaido, H			Mycolic acid structure determines the fluidity of the mycobacterial cell wall	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUBERCULOSIS; IDENTIFICATION; PERMEABILITY; BIOSYNTHESIS; RESISTANT; SMEGMATIS; CHELONAE	The low permeability of the mycobacterial cell wall is thought to contribute to the well known resistance of mycobacteria to antibiotics and chemotherapeutic agents, We have used differential scanning calorimetry to demonstrate that the high temperature phase transition observed in purified cell walls, usually in the 60-70 degrees C range, suggestive of a lipid environment of extremely low fluidity, can also be observed in whole organisms and in cell walls from which much of the free lipids was removed by extraction with Triton X-114, A survey of seven mycobacterial species demonstrated that this high temperature transition was a general property of these organisms, Cell walls isolated from two Corynebacterium species, which contain much shorter corynemycolic acids, displayed a much lower temperature transition, suggesting that the transition temperature was directly correlated to the length of mycolic acid. Methyl esters of mycolic acids were found to have a phase transition temperature that was linearly related to the amount of fl ans-mycolate. Both Mycobacterium avium and M. smegmatis responded to increasing growth temperature by increasing the proportion of trans-mycolate and displaying a correspondingly higher melting temperature, Whole cells of M. smegmatis grown at higher temperature allowed a less rapid influx of two lipophilic agents, norfloxacin and chenodeoxycholate. These results provide strong evidence that the nature of mycolic acid plays a crucial role in determining the fluidity and permeability of mycobacterial cell wall.	UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,BERKELEY,CA 94720; NIAID,ROCKY MT LABS,TB RES UNIT,HAMILTON,MT 59840; COLORADO STATE UNIV,DEPT MICROBIOL,FT COLLINS,CO 80523	University of California System; University of California Berkeley; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Colorado State University			Barry, III, Clifton/H-3839-2012; Liu, Jun/AAC-9209-2019; Barry, Clifton E/ABE-7992-2020	Barry, III, Clifton/0000-0002-2927-270X; Liu, Jun/0000-0002-0522-6733; Barry, Clifton E/0000-0002-2927-270X; Besra, Gurdyal/0000-0002-5605-0395	Intramural NIH HHS [Z01 AI000783-11] Funding Source: Medline; NIAID NIH HHS [AI-18357, AI-09644, AI-33702] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033702, R37AI009644, R22AI018357, R37AI018357, R01AI009644, R01AI018357] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BABA T, 1989, J BIOCHEM-TOKYO, V106, P81, DOI 10.1093/oxfordjournals.jbchem.a122825; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; BRENNAN PJ, 1989, REV INFECT DIS, V11, pS420; Dewa T, 1996, J AM CHEM SOC, V118, P3435, DOI 10.1021/ja953905z; Dobson G., 1985, CHEM METHODS BACTERI, P237; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; GALEY WR, 1973, J GEN PHYSIOL, V61, P727, DOI 10.1085/jgp.61.6.727; GEORGE KM, 1995, J BIOL CHEM, V270, P27292, DOI 10.1074/jbc.270.45.27292; GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802; HAMID ME, 1993, J GEN MICROBIOL, V139, P2203, DOI 10.1099/00221287-139-9-2203; JARLIER V, 1990, J BACTERIOL, V172, P1418, DOI 10.1128/jb.172.3.1418-1423.1990; JARLIER V, 1994, FEMS MICROBIOL LETT, V123, P1; KANEDA K, 1995, MICROBIOL IMMUNOL, V39, P563, DOI 10.1111/j.1348-0421.1995.tb02243.x; KANEDA K, 1988, J GEN MICROBIOL, V134, P2213; Lewis R.N.A.H., 1991, STRUCTURE BIOL MEMBR, P73; Liu J, 1996, J BACTERIOL, V178, P3791, DOI 10.1128/jb.178.13.3791-3795.1996; LIU J, 1995, P NATL ACAD SCI USA, V92, P11254, DOI 10.1073/pnas.92.24.11254; LUTTON ES, 1967, FATTY ACIDS THEIR 4, P2588; Minnikin D. E., 1980, MICROBIOLOGICAL CLAS, P189; Minnikin D. E., 1988, BACTERIAL CELL SURFA, P125; MINNIKIN DE, 1982, BIOL MYCOBACTERIA, V1, P95; NIKAIDO H, 1993, MOL MICROBIOL, V8, P1025, DOI 10.1111/j.1365-2958.1993.tb01647.x; Nikaido H., 1990, MEMBRANE TRANSPORT I, P165; SNYDER F, 1959, BIOCHIM BIOPHYS ACTA, V34, P244; TAKAYAMA K, 1978, AM REV RESPIR DIS, V118, P113; TORIYAMA S, 1978, FEBS LETT, V95, P111, DOI 10.1016/0014-5793(78)80063-5; TRIAS J, 1994, MOL MICROBIOL, V14, P283, DOI 10.1111/j.1365-2958.1994.tb01289.x; TRIAS J, 1992, SCIENCE, V258, P1479, DOI 10.1126/science.1279810; YUAN Y, 1995, P NATL ACAD SCI USA, V92, P6630, DOI 10.1073/pnas.92.14.6630	30	220	232	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29545	29551		10.1074/jbc.271.47.29545	http://dx.doi.org/10.1074/jbc.271.47.29545			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939881	hybrid			2022-12-25	WOS:A1996VU52500009
J	Powers, C; Krutzsch, H; Gardner, K				Powers, C; Krutzsch, H; Gardner, K			Modulation of JunD center dot AP-1 DNA binding activity by AP-1-associated factor 1 (AF-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TRANSACTIVATOR TAX; TRANSCRIPTION FACTORS; SIGNALING PATHWAY; GENE FAMILY; FOS GENE; T-CELLS; JUN; AP-1; PROTEIN; PHOSPHORYLATION	AP-1-associated factor 1 (AF-1), is a novel protein complex that dramatically enhances the assembly of JunD-containing dimers onto AP-1 consensus sites. We describe the partial purification of AF-1 from nuclear extracts of the T-cell line MLA 144 by ionic, hydrophobic and gel filtration chromatography. AF-1 is a DNA-binding protein composed of low molecular mass polypeptides of 7-17 kDa that exists in solution as a 34-kDa complex. JunD interactions with DNA are accelerated in the presence of AF-1 through the formation of a true tri-molecular complex with JunD dimers and DNA that assembles much more rapidly on DNA than JunD alone. DNA binding analysis of AF-1 interaction with JunD . AP-1 and DNA shows that AF-1 increases the DNA binding affinity of JunD for AP-1 sites over 100-fold. DNA cleavage footprint analysis of isolated AF-1 . JunD DNA complexes shows that the ternary complex makes nearly twice as many contacts with DNA than JunD dimers alone. AF-1 interacts readily, but differentially with Jun homodimers and Jun . Fos heterodimers. These findings distinguish AF-1 as a significant protein-specific modulator of AP-1 . JunD in T-cells.	NCI,PATHOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Powers, Ciaran/E-3890-2011					ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P7298; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; AVOTS A, 1995, IMMUNOBIOLOGY, V193, P254, DOI 10.1016/S0171-2985(11)80551-6; BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BUSCH SJ, 1990, ONCOGENE, V5, P1549; CLIPSTONE NA, 1994, J BIOL CHEM, V269, P26431; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; GARDNER K, 1994, J BIOL CHEM, V269, P32963; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; KUWABARA MD, 1987, BIOCHEMISTRY-US, V26, P7234, DOI 10.1021/bi00397a006; LIN A, 1993, ADV SEC MESS PHOSPH, V28, P255; LOEWENSTEIN YL, 1995, J VIROL, V69, P3017; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MCKNIGHT SL, 1991, SCI AM, V264, P54, DOI 10.1038/scientificamerican0491-54; MONTECLARO FS, 1993, P NATL ACAD SCI USA, V90, P6726, DOI 10.1073/pnas.90.14.6726; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; QUINN JP, 1989, MOL CELL BIOL, V9, P4713, DOI 10.1128/MCB.9.11.4713; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SIGMAN DS, 1991, METHOD ENZYMOL, V208, P414; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; ULLMAN KS, 1993, GENE DEV, V7, P188, DOI 10.1101/gad.7.2.188; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	34	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30089	30095		10.1074/jbc.271.47.30089	http://dx.doi.org/10.1074/jbc.271.47.30089			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939957	hybrid			2022-12-25	WOS:A1996VU52500085
J	Kosugi, S; Mori, T; Shenker, A				Kosugi, S; Mori, T; Shenker, A			The role of Asp(578) in maintaining the inactive conformation of the human lutropin/choriogonadotropin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUTEINIZING-HORMONE RECEPTOR; LIMITED PRECOCIOUS PUBERTY; PROTEIN-COUPLED RECEPTOR; ACTIVATING POINT MUTATION; 2ND TRANSMEMBRANE DOMAIN; CHORIOGONADOTROPIN RECEPTOR; CONSTITUTIVE ACTIVATION; SIGNAL-TRANSDUCTION; BINDING; GENE	A constitutively activating mutation encoding Asp(578)-->Gly in transmembrane helix 6 of the lutropin/choriogonadotropin receptor (LHR) is the most common cause of gonadotropin-independent, male-limited precocious puberty. This mutant LHR produces a 4.5-fold increase in basal cAMP when expressed in COS-7 cells. To better understand the normal role of Asp(578) in the LHR we studied the effect of seven other amino acid substitutions at this position. No agonist binding or response was detected with the Asp(578)-->Pro mutant. Agonist binding affinity was unaffected by the other substitutions and estimated receptor concentrations ranged from 11 to 184% of wild type. Substitution of Asp(578) with Asn, a similarly sized, uncharged residue, did not produce agonist-independent activation. In contrast, replacement with Glu, Ser, or Leu caused 4.9-5.6-fold stimulation of basal cAMP. Substitution with Tyr (8.5-fold) or Phe (7.5-fold) had a greater activating effect. Only the Tyr, Phe, and Leu mutants showed constitutive activation of the inositol phosphate pathway. Our data suggest that it is the ability of the Asp(578) side chain to serve as a properly positioned hydrogen bond acceptor, rather than its negative charge, that is important for stabilizing the inactive state of the LHR. A bulky aromatic side chain at position 578 may further destabilize the inactive receptor conformation.	KYOTO UNIV HOSP,SCH MED,DEPT LAB MED,SAKYO KU,KYOTO 60601,JAPAN; NIDDK,METAB DIS BRANCH,NIH,BETHESDA,MD 20892; CHILDRENS MEM HOSP,CHICAGO,IL 60614; NORTHWESTERN UNIV,SCH MED,DEPT PEDIAT,DIV ENDOCRINOL,CHICAGO,IL 60614	Kyoto University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University			KOSUGI, Shinji/GYR-2946-2022					ARNIS S, 1994, J BIOL CHEM, V269, P23879; BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; CETANI F, 1994, FEBS LETT, V356, P291; COHEN GB, 1993, BIOCHEMISTRY-US, V32, P6111, DOI 10.1021/bi00074a024; Gilchrist RL, 1996, J BIOL CHEM, V271, P19283, DOI 10.1074/jbc.271.32.19283; GUDERMANN T, 1992, J BIOL CHEM, V267, P4479; Hoflack J, 1993, Drug Des Discov, V10, P157; JI IH, 1991, J BIOL CHEM, V266, P14953; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KOSUGI S, 1994, FEBS LETT, V356, P291, DOI 10.1016/0014-5793(94)01286-5; KOSUGI S, 1995, HUM MOL GENET, V4, P183, DOI 10.1093/hmg/4.2.183; KRAAIJ R, 1995, J CLIN ENDOCR METAB, V80, P3168, DOI 10.1210/jc.80.11.3168; KREMER H, 1993, HUM MOL GENET, V2, P1779, DOI 10.1093/hmg/2.11.1779; LATRONICO AC, 1995, J CLIN ENDOCR METAB, V80, P2490, DOI 10.1210/jc.80.8.2490; LAUE L, 1995, P NATL ACAD SCI USA, V92, P1906, DOI 10.1073/pnas.92.6.1906; LNAYI JK, 1995, NATURE, V375, P461; MINEGISH T, 1990, BIOCHEM BIOPH RES CO, V172, P1049, DOI 10.1016/0006-291X(90)91552-4; MULLER J, 1995, HORM RES S, V41, P113; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NOTHACKER HP, 1993, BIOCHEM BIOPH RES CO, V197, P1062, DOI 10.1006/bbrc.1993.2586; OLSON KD, 1995, P NATL ACAD SCI USA, V92, P3185, DOI 10.1073/pnas.92.8.3185; PORCELLINI A, 1994, J CLIN ENDOCR METAB, V79, P657, DOI 10.1210/jc.79.2.657; QUINTANA J, 1993, MOL ENDOCRINOL, V7, P767, DOI 10.1210/me.7.6.767; RAO VR, 1994, NATURE, V367, P639, DOI 10.1038/367639a0; RATH P, 1993, J BIOL CHEM, V268, P17742; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; SHENKER A, 1995, BAILLIERE CLIN ENDOC, V9, P427, DOI 10.1016/S0950-351X(95)80519-2; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; TENSEN CP, 1994, P NATL ACAD SCI USA, V91, P4816, DOI 10.1073/pnas.91.11.4816; Tonacchera M, 1996, J CLIN ENDOCR METAB, V81, P547, DOI 10.1210/jc.81.2.547; WANG Z, 1993, MOL ENDOCRINOL, V7, P85, DOI 10.1210/me.7.1.85; YANO K, 1995, J CLIN ENDOCR METAB, V80, P1162, DOI 10.1210/jc.80.4.1162; YANO K, 1994, J CLIN ENDOCR METAB, V79, P1818, DOI 10.1210/jc.79.6.1818	34	77	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					31813	31817		10.1074/jbc.271.50.31813	http://dx.doi.org/10.1074/jbc.271.50.31813			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943222	hybrid			2022-12-25	WOS:A1996VY34000013
J	Orntoft, TF; Vestergaard, EM; Holmes, E; Jakobsen, JS; Grunnet, N; Mortensen, M; Johnson, P; Bross, P; Gregersen, N; Skorstengaard, K; Jensen, UB; Bolund, L; Wolf, H				Orntoft, TF; Vestergaard, EM; Holmes, E; Jakobsen, JS; Grunnet, N; Mortensen, M; Johnson, P; Bross, P; Gregersen, N; Skorstengaard, K; Jensen, UB; Bolund, L; Wolf, H			Influence of Lewis alpha 1-3/4-L-fucosyltransferase (FUT3) gene mutations on enzyme activity, erythrocyte phenotyping, and circulating tumor marker sialyl-Lewis a levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP ALPHA(1,2)FUCOSYLTRANSFERASE GENE; HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; FUCT-III GENE; MOLECULAR-CLONING; ANTIGEN EXPRESSION; CANCER-PATIENTS; DETERMINES EXPRESSION; NEGATIVE INDIVIDUALS; CELL-ADHESION; DEFICIENCY	Fucosylated glycoproteins carrying alpha 1-4 fucose residues are of importance for cell adhesion and as tumor markers. The Lewis gene, FUT3, encodes the only known alpha 1-4-fucosyltransferase (FucT), and individuals who are deficient in this enzyme type as Lewis-negative on erythrocytes. We examined the mutational spectrum of the Lewis gene in Denmark and found 6 different mutations, Five, T59G, T202C, C314T, G508A, and T1067A, were frequent, and one, C445A, was only detected in one out of 40 individuals. Allele-specific polymerase chain reaction as web as cloning of FUT3 alleles showed that the 202 and 314 mutations mere co-located on the same allele. COS7 cells transfected with an allele having the 202/314 mutations lacked enzyme activity. Polymerase chain reaction-cleavage assays were established for the genotyping of healthy individuals as well as 20 genuine Lewis-negative cancer patients and 10 non-genuine. The latter have Lewis-negative erythrocytes but saliva alpha 1-4FucT activity. The genuine Lewis-negative individuals had mutations on both FUT3 alleles. In 66 healthy individuals, a gene dosage effect was detected as FUT3 heterozygous individuals had a lower alpha 1-4FucT activity in saliva than did homozygous wild-type individuals. The lower enzyme level in heterozygous individuals resulted in a significantly (p < 0.04) lower level of circulating sialyl-Lewis a structure in serum. This has the clinical impact that cut-off levels in tumor marker assays should be defined on the basis of genotyping. In the group of non-genuine Lewis-negative cancer patients, whose erythrocytes convert from Lewis-positive to Lewis-negative during the disease, FUT3 heterozygosity was significantly (p < 0.05) more common.	SKEJBY UNIV HOSP, DEPT UROL, DK-8200 AARHUS N, DENMARK; SKEJBY UNIV HOSP, DEPT CLIN IMMUNOL, DK-8200 AARHUS N, DENMARK; SKEJBY UNIV HOSP, CTR MED MOL BIOL, DK-8200 AARHUS N, DENMARK; AARHUS UNIV, INST HUMAN GENET, DK-8000 AARHUS C, DENMARK; HAREFIELD HOSP, DEPT CARDIOTHORAC SURG, NHLI, HAREFIELD UB9 6JH, MIDDX, ENGLAND; NW MEM HOSP, DEPT CELL SURFACE BIOCHEM, SEATTLE, WA 98125 USA	Aarhus University; Aarhus University; Aarhus University; Aarhus University; Imperial College London; Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital	Orntoft, TF (corresponding author), SKEJBY UNIV HOSP, DEPT CLIN BIOCHEM, DK-8200 AARHUS N, DENMARK.		Jensen, Uffe Birk/E-6066-2017; Bross, Peter/B-7219-2013; Vestergaard, else marie/AAA-1646-2020; Jensen, Uffe Birk/ABA-8306-2021	Jensen, Uffe Birk/0000-0002-6205-6355; Bross, Peter/0000-0001-9526-8525; Jensen, Uffe Birk/0000-0002-6205-6355				CLAUSEN H, 1985, P NATL ACAD SCI USA, V82, P1199, DOI 10.1073/pnas.82.4.1199; CUMMINGS RD, 1992, BIOESSAYS, V14, P849, DOI 10.1002/bies.950141210; ELMGREN A, 1993, BIOCHEM BIOPH RES CO, V196, P515, DOI 10.1006/bbrc.1993.2280; Elmgren A, 1996, VOX SANG, V70, P97, DOI 10.1111/j.1423-0410.1996.tb01300.x; GOELZ S, 1994, J BIOL CHEM, V269, P1033; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAKOMORI S, 1983, JNCI-J NATL CANCER I, V71, P231; HAMMAR L, 1981, VOX SANG, V40, P27, DOI 10.1111/j.1423-0410.1981.tb00665.x; HERLYN M, 1982, J CLIN IMMUNOL, V2, P135, DOI 10.1007/BF00916897; HIRANO K, 1987, J NATL CANCER I, V79, P1261; HOLMES EH, 1987, J BIOL CHEM, V262, P15649; JOHNSON PH, 1992, GLYCOCONJUGATE J, V9, P251, DOI 10.1007/BF00731137; KELLY RJ, 1995, J BIOL CHEM, V270, P4640, DOI 10.1074/jbc.270.9.4640; KELLY RJ, 1994, P NATL ACAD SCI USA, V91, P5843, DOI 10.1073/pnas.91.13.5843; KOPROWSKI H, 1979, SOMAT CELL GENET, V5, P957, DOI 10.1007/BF01542654; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LANGKILDE NC, 1991, BRIT J CANCER, V63, P583, DOI 10.1038/bjc.1991.135; LANGKILDE NC, 1991, BRIT J HAEMATOL, V79, P493, DOI 10.1111/j.1365-2141.1991.tb08061.x; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; LEGAULT DJ, 1995, J BIOL CHEM, V270, P20987, DOI 10.1074/jbc.270.36.20987; LOWE JB, 1991, J BIOL CHEM, V266, P17467; MAGNANI JL, 1982, J BIOL CHEM, V257, P4365; MOLLICONE R, 1994, J BIOL CHEM, V269, P20987; MOLLICONE R, 1994, J BIOL CHEM, V269, P12662; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; NISHIHARA S, 1993, BIOCHEM BIOPH RES CO, V190, P42, DOI 10.1006/bbrc.1993.1008; NISHIHARA S, 1994, J BIOL CHEM, V269, P29271; NISHIHARA S, 1993, BIOCHEM BIOPH RES CO, V196, P624, DOI 10.1006/bbrc.1993.2295; ORNTOFT TF, 1991, BLOOD, V77, P1389; ORNTOFT TF, 1995, GLYCOCONJUGATE J, V12, P200, DOI 10.1007/BF00731320; ROUQUIER S, 1995, J BIOL CHEM, V270, P4632, DOI 10.1074/jbc.270.9.4632; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SKYLER M, 1995, GENOMICS, V26, P142; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; YAZAWA S, 1995, CANCER RES, V55, P1473	37	78	81	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32260	32268		10.1074/jbc.271.50.32260	http://dx.doi.org/10.1074/jbc.271.50.32260			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943285	hybrid			2022-12-25	WOS:A1996VY34000076
J	Aiyar, J; Rizzi, JP; Gutman, GA; Chandy, KG				Aiyar, J; Rizzi, JP; Gutman, GA; Chandy, KG			The signature sequence of voltage-gated potassium channels projects into the external vestibule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+ CHANNEL; CHARYBDOTOXIN BLOCK; MUTANT CYCLES; PORE; MECHANISM; TETRAETHYLAMMONIUM; CONTRIBUTE; MUTATIONS; INTERFACE; PROTEIN	A highly conserved motif, GYGD, contributes to the formation of the ion selectivity filter in voltage-gated K+ channels and is thought to interact with the scorpion toxin residue, Lys(27). By probing the pore of the Kv1.3 channel with synthetic kaliotoxin-Lys(27) mutants, each containing a non-natural lysine analog of a different length, and using mutant cycle analysis, we determined the spatial locations of Tyr(400) and Asp(402) in the GYGD moth, relative to His(404) located at the base of the outer vestibule. Our data indicate that the terminal amines of the shorter Lys(27) analogs lie close to His(404) and to Asp(402) while Lys(27) itself interacts with Tyr(400). Based on these data, we developed a molecular model of this region of the channel. The junction between the outer vestibule and the pore is defined by a ring (similar to 8-9-Angstrom diameter) formed from alternating Asp(402) and His(404) residues. Tyr(400) lies 4-6 Angstrom deeper into the pore, and its interaction with kaliotoxin-Lys(27) is in competition with K+ ions, Studies with dimeric Kv1.3 constructs suggest that two Tyr(400) residues in the tetramer are sufficient to bind K+ ions. Thus, at least part of the K+ channel signature sequence extends into a shallow trough at the center of a wide external vestibule.	UNIV CALIF IRVINE, COLL MED, DEPT MICROBIOL & MOL GENET, IRVINE, CA 92697 USA; UNIV CALIF IRVINE, COLL MED, DEPT MICROBIOL & MOL GENET, IRVINE, CA 92697 USA; AMGEN INC, BOULDER, CO 80301 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; Amgen					NIAID NIH HHS [AI24783] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024783] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AIYAR J, 1994, BIOPHYS J, V67, P2261, DOI 10.1016/S0006-3495(94)80710-6; AIYAR J, 1995, NEURON, V15, P1169, DOI 10.1016/0896-6273(95)90104-3; CHANDY KG, 1995, HDB RECEPTORS CHANNE, P1; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CROSS A, 1996, NEURON, V16, P399; DECOURSEY TE, 1984, NATURE, V307, P465, DOI 10.1038/307465a0; Goldstein SAN, 1996, NEURON, V16, P717, DOI 10.1016/S0896-6273(00)80092-6; GOLDSTEIN SAN, 1993, BIOPHYS J, V65, P1613, DOI 10.1016/S0006-3495(93)81200-1; GRISSMER S, 1990, P NATL ACAD SCI USA, V87, P9411, DOI 10.1073/pnas.87.23.9411; GUY HR, 1994, SOC GEN PHY, V49, P197; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; JAN LY, 1992, ANNU REV PHYSIOL, V54, P535, DOI 10.1146/annurev.physiol.54.1.535; KAVANAUGH MP, 1992, NEURON, V8, P493, DOI 10.1016/0896-6273(92)90277-K; KAVANAUGH MP, 1991, J BIOL CHEM, V266, P7583; KIRSCH GE, 1995, BIOPHYS J, V68, P1804, DOI 10.1016/S0006-3495(95)80357-7; KUMPF RA, 1993, SCIENCE, V261, P1708, DOI 10.1126/science.8378771; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; LOPEZ GA, 1994, NATURE, V367, P179, DOI 10.1038/367179a0; MACKINNON R, 1988, J GEN PHYSIOL, V91, P335, DOI 10.1085/jgp.91.3.335; MACKINNON R, 1995, NEURON, V14, P889, DOI 10.1016/0896-6273(95)90327-5; Naranjo D, 1996, NEURON, V16, P123, DOI 10.1016/S0896-6273(00)80029-X; PARK CS, 1992, NEURON, V9, P307, DOI 10.1016/0896-6273(92)90169-E; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; SCHREIBER G, 1995, J MOL BIOL, V248, P478, DOI 10.1006/jmbi.1995.0235; SOREQ H, 1992, METHOD ENZYMOL, V207, P225	27	106	110	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31013	31016		10.1074/jbc.271.49.31013	http://dx.doi.org/10.1074/jbc.271.49.31013			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940091	hybrid			2022-12-25	WOS:A1996VW68600002
J	Farizo, KM; Cafarella, TG; Burns, DL				Farizo, KM; Cafarella, TG; Burns, DL			Evidence for a ninth gene, ptlI in the locus encoding the pertussis toxin secretion system of Bordetella pertussis and formation of a PtlI-PtlF complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISLET-ACTIVATING PROTEIN; ADENYLATE-CYCLASE; SUBCELLULAR-LOCALIZATION; NUCLEOTIDE-SEQUENCE; VIRB OPERON; PLASMID; MODEL	The pertussis toxin secretion system of Bordetella pertussi initially was thought to comprise eight proteins, Pt1A-Pt1H. We have investigated the existence of another protein, PtlI, encoded by a putative gene located between ptlD and ptlE. A B. pertussis strain expressing a ptlI::phoA translational fusion possessed alkaline phosphatase activity, suggesting that ptlI encodes a protein. In B. pertussis, a protein with an apparent molecular weight of similar to 5,200 (similar to that predicted by the ptlI sequence) was immunoreactive with an antibody raised to a PtlI-maltose-binding protein fusion protein, PtlE expression in a mutant sustaining an in-frame deletion in ptlI indicated that ptlE starts further downstream than initially predicted. Pt1F, not detected in the ptlI deletion mutant, was restored partially by expressing ptlI in trans, A 36-kDa species, consistent with a Pt1I-Pt1F complex, was immunoreactive with antibodies to Pt1I and Pt1F in nonreduced cell extracts of a Bordetella bronchiseptica strain which overexpresses the Pt1 proteins. Upon dithiothreitol treatment, the 36-kDa species was diminished greatly or undetectable. In B. pertussis, Pt1I and Pt1F co-precipitated with antibody to Pt1F. These findings demonstrate the existence of Pt1I and a Pt1I-Pt1F complex, providing the first description of an interaction between Pt1 proteins.			Farizo, KM (corresponding author), US FDA,CTR BIOL EVALUAT & RES,DIV BACTERIAL PROD,HFM-434,BLDG 29,RM 418,8800 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							ARICO B, 1987, J BACTERIOL, V169, P2847, DOI 10.1128/jb.169.6.2847-2853.1987; BARRY EM, 1991, J BACTERIOL, V173, P720, DOI 10.1128/jb.173.2.720-726.1991; BERGER BR, 1994, J BACTERIOL, V176, P3646, DOI 10.1128/JB.176.12.3646-3660.1994; BRIGGS MS, 1986, ADV PROTEIN CHEM, V38, P109, DOI 10.1016/S0065-3233(08)60527-6; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; COVACCI A, 1993, MOL MICROBIOL, V8, P429, DOI 10.1111/j.1365-2958.1993.tb01587.x; DEFEYTER R, 1993, MOL PLANT MICROBE IN, V6, P225, DOI 10.1094/MPMI-6-225; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Harlow E., 1988, ANTIBODIES LAB MANUA; Hausman SZ, 1996, INFECT IMMUN, V64, P4020, DOI 10.1128/IAI.64.10.4020-4026.1996; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; IDIGBE EO, 1981, J MED MICROBIOL, V14, P409, DOI 10.1099/00222615-14-4-409; JOHNSON FD, 1994, J BACTERIOL, V176, P5350, DOI 10.1128/JB.176.17.5350-5356.1994; KATADA T, 1982, P NATL ACAD SCI-BIOL, V79, P3129, DOI 10.1073/pnas.79.10.3129; KULDAU GA, 1990, MOL GEN GENET, V221, P256, DOI 10.1007/BF00261729; LACEY B. W., 1960, JOUR HYG, V58, P57; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOCHT C, 1986, SCIENCE, V232, P1258, DOI 10.1126/science.3704651; NICOSIA A, 1986, P NATL ACAD SCI USA, V83, P4631, DOI 10.1073/pnas.83.13.4631; OKA A, 1981, J MOL BIOL, V147, P217, DOI 10.1016/0022-2836(81)90438-1; POHLMAN RF, 1994, MOL MICROBIOL, V14, P655, DOI 10.1111/j.1365-2958.1994.tb01304.x; SCHNEIDER DR, 1982, INFECT IMMUN, V38, P548, DOI 10.1128/IAI.38.2.548-553.1982; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; STIBITZ S, 1991, J BACTERIOL, V173, P4288, DOI 10.1128/JB.173.14.4288-4296.1991; STIBITZ S, 1994, METHOD ENZYMOL, V235, P458; Sweden Ad Hoc Group for the Study of Pertussis Vaccines, 1988, Lancet, Vi, P955; TAMURA M, 1982, BIOCHEMISTRY-US, V21, P5516, DOI 10.1021/bi00265a021; TROLLFORS B, 1995, NEW ENGL J MED, V333, P1045, DOI 10.1056/NEJM199510193331604; WARD JE, 1988, J BIOL CHEM, V263, P5804; WARD JE, 1990, J BIOL CHEM, V265, P4768; WEISS AA, 1989, INFECT IMMUN, V57, P3757, DOI 10.1128/IAI.57.12.3757-3764.1989; WEISS AA, 1984, J INFECT DIS, V150, P219, DOI 10.1093/infdis/150.2.219; WEISS AA, 1993, P NATL ACAD SCI USA, V90, P2970, DOI 10.1073/pnas.90.7.2970; WEISS AA, 1989, INFECT IMMUN, V57, P2674, DOI 10.1128/IAI.57.9.2674-2682.1989; Winans SC, 1996, TRENDS MICROBIOL, V4, P64, DOI 10.1016/0966-842X(96)81513-7; ZAMBRYSKI PC, 1992, ANNU REV PLANT PHYS, V43, P465, DOI 10.1146/annurev.pp.43.060192.002341	37	41	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31643	31649		10.1074/jbc.271.49.31643	http://dx.doi.org/10.1074/jbc.271.49.31643			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940184	hybrid			2022-12-25	WOS:A1996VW68600095
J	Freiberg, RA; Spencer, DM; Choate, KA; Peng, PD; Schreiber, SL; Crabtree, GR; Khavari, PA				Freiberg, RA; Spencer, DM; Choate, KA; Peng, PD; Schreiber, SL; Crabtree, GR; Khavari, PA			Specific triggering of the Fas signal transduction pathway in normal human keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; DEATH DOMAIN; CELL-DEATH; APOPTOSIS; RECEPTOR; ANTIGEN; PROTEIN; EXPRESSION; INTERACTS; FAMILY	The epidermis is continually exposed to genotoxic injury and requires an efficient mechanism to eliminate genetically altered cells. The membrane receptor, Fas, initiates apoptosis in many cell types, including keratinocytes, Receptor cross-linking is the vital post-ligand binding step in Fas signal transduction, and we have utilized FK1012, capable of oligomerizing proteins engineered to contain the FK506 binding protein (FKBP), to trigger Fas via FKBP-linked receptor cytoplasmic domains in human heratinocytes, An FKBP chimera containing the Fas cytoplasmic domain targeted to the plasma membrane induced an up to 89% decrease in viability of keratinocytes, as reflected by the activity of constitutive promoters, in response to FK1012. Oligomerization of Fas, either with engineered Fas-FKBP by FK1012 or via antibody cross-linking of full-length Fas induced cellular changes consistent with apoptosis, The lpr Fas point mutation abolished this effect A Fas-FKBP construct unlinked to the membrane was fully active in this assay, Early developmental age or pre-treatment of cells with GM-CSF, TGF-beta, EGF, KGF, IFN-gamma, or phorbol ester failed to protect against Fas effects, These findings reveal that the Fas signal transduction pathway is active in keratinocytes, requires no induction, and dominantly overrides growth stimuli.	PALO ALTO HLTH CARE SYST, VET ADM, PALO ALTO, CA 94304 USA; STANFORD UNIV, DEPT DERMATOL, STANFORD, CA 94305 USA; STANFORD UNIV, CTR MOL & GENET MED, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA; HARVARD UNIV, DEPT CHEM, CAMBRIDGE, MA 02138 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University; Howard Hughes Medical Institute; Stanford University; Harvard University					NIAMS NIH HHS [AR43799, AR/OD4337101] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR043799, R01AR043799] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AGGARWAL BB, 1995, FEBS LETT, V364, P5, DOI 10.1016/0014-5793(95)00339-B; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; HAAKE AR, 1993, J INVEST DERMATOL, V101, P107, DOI 10.1111/1523-1747.ep12363594; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; JIANG CK, 1991, J INVEST DERMATOL, V97, P969, DOI 10.1111/1523-1747.ep12491889; KAZLAUSKAS A, 1994, CURR OPIN GENET DEV, V4, P5, DOI 10.1016/0959-437X(94)90085-X; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; MERINO R, 1995, J IMMUNOL, V155, P3830; Nagata S, 1994, Semin Immunol, V6, P3, DOI 10.1006/smim.1994.1002; NICKOLOFF BJ, 1994, J AM ACAD DERMATOL, V30, P535, DOI 10.1016/S0190-9622(94)70059-1; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; SAYAMA K, 1994, J INVEST DERMATOL, V103, P330, DOI 10.1111/1523-1747.ep12394858; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SPENCER DM, 1996, CURR BIOL, V6, P7; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	21	29	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31666	31669		10.1074/jbc.271.49.31666	http://dx.doi.org/10.1074/jbc.271.49.31666			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940187	Green Submitted, hybrid			2022-12-25	WOS:A1996VW68600098
J	Lagriffoul, A; Charpentier, N; Carrette, J; Tougard, C; Bockaert, J; Homburger, V				Lagriffoul, A; Charpentier, N; Carrette, J; Tougard, C; Bockaert, J; Homburger, V			Secretion of protease nexin-1 by C6 glioma cells is under the control of a heterotrimeric G protein, G(o1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN-G(O); ANTERIOR-PITUITARY-CELLS; NEURITE-PROMOTING FACTOR; ALPHA-SUBUNIT; INHIBITORY ACTIVITY; NEURONAL CELLS; EXOCYTOSIS; BRAIN; EXPRESSION; MASTOPARAN	Heterotrimeric G(o) proteins have recently been described as regulators of vesicular traffic. The G(o) alpha gene encodes, by alternative splicing, two G(o) alpha polypeptides, G(o1)alpha and G(o2)alpha. By immunofluorescence and electron microscopy, we detected G(o1)alpha on the membrane of small intracellular vesicles in C6 glioma cells. After stable transfection of these cells, overexpression of G(o1)alpha but not G(o2)alpha was followed by a rise in the secretion of a serine protease inhibitor, protease nexin-1 (PN-1). This secretion was enhanced as a function of the amount of expressed G(o1)alpha. Metabolic cell labeling indicated that this increase in PN-1 secretion was not the result of an enhancement in PN-1 biosynthesis or a decrease in its uptake, but revealed a potential role of G(o1)alpha in the regulation of vesicular PN-1 trafficking. Furthermore,regulation of vesicular PN-1 trafficking. Furthermore, activators of G(o) proteins, mastoparan and a peptide derived from the amino terminus of the growth cone-associated protein GAP43, increased PN-1 secretion in parental and G(o1)alpha-overexpressing cells. Brefeldin A, an inhibitor of vesicular traffic, inhibited both basal and mastoparan-stimulated PN-1 secretions. These results indicate, that in C6 glioma cells, PN-1 secretion could be regulated by both G(o1)alpha expression and activation.	INSERM,CNRS UPR 9023,INSERM,CTR PHARMACOL & ENDOCRINOL,F-34095 MONTPELLIER 05,FRANCE; COLL FRANCE,CNRS URA 1115,F-75231 PARIS 5,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; UDICE-French Research Universities; PSL Research University Paris; College de France								AHNERTHILGER G, 1994, EUR J CELL BIOL, V65, P26; ARIDOR M, 1993, SCIENCE, V262, P1569, DOI 10.1126/science.7504324; Barr F A, 1992, Trends Cell Biol, V2, P91, DOI 10.1016/0962-8924(92)90001-4; BIRNBAUMER L, 1995, J RECEPT SIGNAL TR R, V15, P213; BLEUEL A, 1995, J NEUROSCI RES, V42, P562, DOI 10.1002/jnr.490420414; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRABET P, 1988, J NEUROSCI, V8, P701; BRABET P, 1993, HDB EXPT PHARM, P429; BRINKLEY BR, 1967, J CELL BIOL, V35, P279, DOI 10.1083/jcb.35.1.279; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CHARPENTIER N, 1993, J BIOL CHEM, V268, P8980; COON HG, 1989, P NATL ACAD SCI USA, V86, P1703, DOI 10.1073/pnas.86.5.1703; CUNNINGHAM DD, 1992, ANN NY ACAD SCI, V674, P228, DOI 10.1111/j.1749-6632.1992.tb27491.x; GARIBAY JLR, 1991, BIOCHIM BIOPHYS ACTA, V1094, P193, DOI 10.1016/0167-4889(91)90008-L; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GLENN KC, 1980, J BIOL CHEM, V255, P6609; GLOOR S, 1986, CELL, V47, P687; GUENTHER J, 1985, EMBO J, V4, P1963, DOI 10.1002/j.1460-2075.1985.tb03878.x; HARRISWARRICK RM, 1988, NEURON, V1, P27, DOI 10.1016/0896-6273(88)90206-1; HELMS JB, 1995, FEBS LETT, V369, P84, DOI 10.1016/0014-5793(95)00620-O; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HOFFMANN MC, 1992, NEUROSCIENCE, V49, P397, DOI 10.1016/0306-4522(92)90105-B; HOWARD EW, 1986, J BIOL CHEM, V261, P14184; HSU WH, 1990, J BIOL CHEM, V265, P11220; JOYCEBRADY M, 1991, J BIOL CHEM, V266, P6859; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KOMATSU M, 1993, J BIOL CHEM, V268, P23297; LANG J, 1995, EMBO J, V14, P3635, DOI 10.1002/j.1460-2075.1995.tb00033.x; LEYTE A, 1992, EMBO J, V11, P4795, DOI 10.1002/j.1460-2075.1992.tb05585.x; LLEDO PM, 1992, NEURON, V8, P455, DOI 10.1016/0896-6273(92)90273-G; Luini Alberto, 1993, Trends in Cell Biology, V3, P290, DOI 10.1016/0962-8924(93)90002-I; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MONARD D, 1973, P NATL ACAD SCI USA, V70, P1894, DOI 10.1073/pnas.70.6.1894; MONARD D, 1988, TRENDS NEUROSCI, V11, P541, DOI 10.1016/0166-2236(88)90182-8; MORIARTY TM, 1990, NATURE, V343, P79, DOI 10.1038/343079a0; MULLER L, 1994, MOL CELL NEUROSCI, V5, P556, DOI 10.1006/mcne.1994.1068; NEER EJ, 1984, J BIOL CHEM, V259, P4222; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; REFOLO LM, 1991, J NEUROSCI, V11, P3888; REINHARD E, 1994, J NEUROSCI RES, V37, P256, DOI 10.1002/jnr.490370211; ROUOT B, 1992, MOL PHARMACOL, V41, P273; SCHMID SL, 1995, FASEB J, V9, P1445, DOI 10.1096/fasebj.9.14.7589986; SCOTTI AL, 1994, J NEUROSCI RES, V37, P156; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P6477, DOI 10.1073/pnas.87.17.6477; STRITTMATTER SM, 1994, J NEUROSCI, V14, P5503; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; TOUGARD C, 1986, AM J ANAT, V175, P161, DOI 10.1002/aja.1001750206; TSUKAMOTO T, 1991, P NATL ACAD SCI USA, V88, P2974, DOI 10.1073/pnas.88.8.2974; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; VANDONGEN AMJ, 1988, SCIENCE, V242, P1433, DOI 10.1126/science.3144040; VAUGHAN PJ, 1993, J BIOL CHEM, V268, P3720; VITALE N, 1994, J BIOL CHEM, V269, P30293; VITALE N, 1993, J BIOL CHEM, V268, P14715; WAGNER SL, 1989, P NATL ACAD SCI USA, V86, P8284, DOI 10.1073/pnas.86.21.8284	60	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31508	31516		10.1074/jbc.271.49.31508	http://dx.doi.org/10.1074/jbc.271.49.31508			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940166	hybrid			2022-12-25	WOS:A1996VW68600077
J	Vito, P; Wolozin, B; Ganjei, JK; Iwasaki, K; Lacana, E; DAdamio, L				Vito, P; Wolozin, B; Ganjei, JK; Iwasaki, K; Lacana, E; DAdamio, L			Requirement of the familial Alzheimer's disease gene PS2 for apoptosis - Opposing effect of ALG-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL HYBRIDOMAS; DNA FRAGMENTATION; CLONAL ELIMINATION; MISSENSE MUTATIONS; SELF-TOLERANCE; ENTEROTOXIN-B; IN-SITU; DEATH; ACTIVATION; ANTIGEN	ALG-3, a truncated mouse homologue of the chromosome I familial Alzheimer's disease gene PS2, rescues T hybridoma 3DO cells from T-cell receptor-induced apoptosis by inhibiting Fas ligand induction and Fas signaling, Here we show that ALG-3 transfected 3DO cells express a COOH-terminal PS2 polypeptide, Overexpression of PS2 in ALG-3 transfected 3DO cells reconstitutes sensitivity to receptor-induced cell death, suggesting that the artificial PS2 polypeptide functions as a dominant negative mutant of PS2, ALG-3 and antisense PS2 protect PC12 cells from glutamate-induced apoptosis but not from death induced by hydrogen peroxide or the free radical MPP(+). Thus, the PS2 gene is required for some forms of cell death in diverse cell types, and its function is opposed by ALG-3.	NIAID,T CELL MOL BIOL UNIT,CELLULAR & MOL IMMUNOL LAB,NIH,BETHESDA,MD 20892; NIMH,UNIV ALZHEIMER BIOL,CLIN SCI LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)			vito, pasquale/ABF-5505-2020	vito, pasquale/0000-0002-5721-7716; D'Adamio, Luciano/0000-0002-9820-4882; D'Adamio, Luciano/0000-0002-2204-9441				ASHWELL JD, 1987, J EXP MED, V165, P173, DOI 10.1084/jem.165.1.173; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; COTMAN CW, 1995, MOL NEUROBIOL, V10, P19, DOI 10.1007/BF02740836; CURRAN J, 1988, EMBO J, V7, P245, DOI 10.1002/j.1460-2075.1988.tb02806.x; DADAMIO L, 1993, EUR J IMMUNOL, V23, P747, DOI 10.1002/eji.1830230327; DADAMIO L, 1992, J IMMUNOL, V149, P3550; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; GSCHWIND M, 1995, J NEUROCHEM, V65, P292; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KAWABE Y, 1990, J EXP MED, V172, P1065, DOI 10.1084/jem.172.4.1065; KAWABE Y, 1991, NATURE, V349, P245, DOI 10.1038/349245a0; KISELOW P, 1988, NATURE, V335, P730; LAFERLA FM, 1995, NAT GENET, V9, P21, DOI 10.1038/ng0195-21; LASSMANN H, 1995, ACTA NEUROPATHOL, V89, P35, DOI 10.1007/BF00294257; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SHI YF, 1990, J IMMUNOL, V144, P3326; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SU JH, 1994, NEUROREPORT, V5, P2529, DOI 10.1097/00001756-199412000-00031; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; WOLOZIN B, 1996, IN PRESS SCIENCE; WOOD KA, 1993, NEURON, V11, P621, DOI 10.1016/0896-6273(93)90074-2	32	127	130	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31025	31028		10.1074/jbc.271.49.31025	http://dx.doi.org/10.1074/jbc.271.49.31025			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940094	hybrid			2022-12-25	WOS:A1996VW68600005
J	Yerushalmi, H; Lebendiker, M; Schuldiner, S				Yerushalmi, H; Lebendiker, M; Schuldiner, S			Negative dominance studies demonstrate the oligomeric structure of EmrE, a multidrug antiporter from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTOSE PERMEASE; MEMBRANE-PROTEIN; RESISTANCE; GENE; COMPLEMENTATION; BACTERIA; CARRIER; HUMANS	EmrE, the smallest known ion-coupled transporter, is an Escherichia coli 12-kDa protein 80% helical and soluble in organic solvents, EmrE is a polyspecific antiporter that exchanges hydrogen ions with aromatic toxic cations such as methyl viologen. Since it is many times smaller than the classical consensus 12 transmembrane segments transporters, it was particularly interesting to determine its oligomeric state, For this purpose, a series of nonfunctional mutants has been generated and characterized to test their effect on the activity of the wild-type protein upon mixing, As opposed to the wild type, these mutants do not confer resistance to methyl viologen, ethidium bromide, or a series of other toxicants, Co expression of each of the nonfunctional mutants with the wild-type protein results in a reduction in the ability of the functional transporter to confer resistance to several toxicants. To perform mixing experiments in vitro, all the mutants have been purified by extraction with organic solvents, reconstituted in proteoliposomes, and found to be inactive, When co-reconstituted with wild-type protein, they inhibit the activity of the latter in a dose-dependent form up to full inhibition. We assume that this inhibition is due to the formation of mixed oligomers in which the presence of one nonfunctional subunit causes full inactivation, A binomial analysis of the results based on the latter assumptions do not provide statistically significant answers but suggests that the oligomer is composed of three subunits, The results described provide the first in vitro demonstration of the functional oligomeric structure of an ion-coupled transporter.	HEBREW UNIV JERUSALEM, ALEXANDER SILBERMAN INST LIFE SCI, IL-91904 JERUSALEM, ISRAEL	Hebrew University of Jerusalem			Schuldiner, Shimon/F-7628-2012	Schuldiner, Shimon/0000-0002-4874-6237				Arkin IT, 1996, BIOCHEMISTRY-US, V35, P7233, DOI 10.1021/bi960094i; BIBI E, 1992, P NATL ACAD SCI USA, V89, P1524, DOI 10.1073/pnas.89.5.1524; CURIALE MS, 1984, J BACTERIOL, V157, P211, DOI 10.1128/JB.157.1.211-217.1984; DOIGE CA, 1993, ANNU REV MICROBIOL, V47, P291, DOI 10.1146/annurev.micro.47.1.291; GOLDBERG EB, 1987, P NATL ACAD SCI USA, V84, P2615, DOI 10.1073/pnas.84.9.2615; GRIFFITH J K, 1992, Current Opinion in Cell Biology, V4, P684, DOI 10.1016/0955-0674(92)90090-Y; GRINIUS L, 1992, PLASMID, V27, P119, DOI 10.1016/0147-619X(92)90012-Y; GRINIUS LL, 1994, J BIOL CHEM, V269, P29998; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; KABACK HR, 1992, BIOCHIM BIOPHYS ACTA, V1101, P210, DOI 10.1016/0005-2728(92)90227-S; KLINGENBERG M, 1993, J BIOENERG BIOMEMBR, V25, P447, DOI 10.1007/BF01108402; Lebendiker M, 1996, J BIOL CHEM, V271, P21193, DOI 10.1074/jbc.271.35.21193; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; MIESCHENDAHL M, 1981, P NATL ACAD SCI-BIOL, V78, P7652, DOI 10.1073/pnas.78.12.7652; PAULSEN IT, 1995, J BACTERIOL, V177, P2827, DOI 10.1128/jb.177.10.2827-2833.1995; Paulsen IT, 1996, MOL MICROBIOL, V19, P1167, DOI 10.1111/j.1365-2958.1996.tb02462.x; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHULDINER S, 1995, PHYSIOL REV, V75, P369, DOI 10.1152/physrev.1995.75.2.369; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; WANG KW, 1995, NEURON, V14, P1303, DOI 10.1016/0896-6273(95)90277-5; WRIGHT JK, 1983, FEBS LETT, V162, P11; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YERUSHALMI H, 1995, J BIOL CHEM, V270, P6856, DOI 10.1074/jbc.270.12.6856	27	100	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31044	31048		10.1074/jbc.271.49.31044	http://dx.doi.org/10.1074/jbc.271.49.31044			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940098	hybrid			2022-12-25	WOS:A1996VW68600009
J	Jans, DA; Jans, P; Briggs, LJ; Sutton, V; Trapani, JA				Jans, DA; Jans, P; Briggs, LJ; Sutton, V; Trapani, JA			Nuclear transport of granzyme B (fragmentin-2) - Dependence on perforin in vivo and cytosolic factors in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTO-TOXIC LYMPHOCYTES; SV40 T-ANTIGEN; PORE-FORMING PROTEIN; NATURAL-KILLER-CELLS; II SITE FLANKING; TYROSINE PHOSPHORYLATION; TRANSCRIPTION FACTOR; DNA FRAGMENTATION; POLY(ADP-RIBOSE) POLYMERASE; NUCLEOCYTOPLASMIC TRANSPORT	Cytotoxic T and natural killer cells are able to kill their target cells through synergistic action of the pore-forming protein perforin and the serine protease granzyme B, resulting in very distinctive nuclear changes typical of apoptosis. Whereas perforin acts at the membrane, granzyme B appears to be both capable of entering the cytoplasm of target cells and accumulating in isolated nuclei, In this study we examine nuclear transport of fluoresceinated granzyme B both in vivo in intact cells in the presence of perforin and in vitro in semipermeabilized cells using confocal laser scanning microscopy. Granzyme B alone was observed to enter the cytoplasm of intact cells but did not accumulate in nuclei, In the presence of sublytic concentrations of perforin, however, it accumulated strongly in intact cell nuclei to levels maximally about 1.5 times those in the cytoplasm after about 2.5 h, In vitro nuclear transport assays showed maximal levels of nuclear and nucleolar accumulation of granzyme B of about 2.5- and 3-fold those in the cytoplasm, In contrast to signal-dependent nuclear accumulation of SV40 large tumor antigen (T-Ag) fusion proteins in vitro, nuclear/nucleolar import of granzyme B was independent of ATP and not inhibitable by the non-hydrolyzable GTP analog GTP gamma S (guanosine 5'-O-(3-thiotriphosphate)). Similar to T-Ag fusion proteins, however, granzyme B nuclear and nucleolar accumulation was dependent on exogenously added cytosol, Specific inhibitors of granzyme B protease activity had no effect on nuclear/nucleolar accumulation, implying that proteolytic activity was not essential for nuclear targeting, The results imply that granzyme B (32 kDa) may be transported from the cytoplasm to the nucleus through passive diffusion and accumulate by binding to nuclear/nucleolar factors in a cytosolic factor-mediated process, Active and passive nuclear transport properties were normal in the presence of unlabeled granzyme B, implying that the nuclear envelope and pore complex are not granzyme B substrates.	AUSTIN RES INST, CELLULAR CYTOTOX LAB, HEIDELBERG, VIC 3084, AUSTRALIA	Austin Research Institute	Jans, DA (corresponding author), AUSTRALIAN NATL UNIV, JOHN CURTIN SCH MED RES, DIV BIOCHEM & MOL BIOL, NUCL SIGNALLING LAB, POB 334, CANBERRA, ACT 2601, AUSTRALIA.		Briggs, Lyndall J/A-7549-2011	Trapani, Joseph/0000-0003-0983-1532				BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG TW, 1980, J IMMUNOL, V124, P1028; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CLEVER J, 1991, P NATL ACAD SCI USA, V88, P7333, DOI 10.1073/pnas.88.16.7333; CROUCH MF, 1991, FASEB J, V5, P200, DOI 10.1096/fasebj.5.2.1900794; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; DUKE RC, 1989, J EXP MED, V170, P1451, DOI 10.1084/jem.170.4.1451; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; ELDAR H, 1992, EXP CELL RES, V202, P259, DOI 10.1016/0014-4827(92)90073-H; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; GOVIND S, 1991, TRENDS GENET, V7, P119, DOI 10.1016/0168-9525(91)90456-Z; GRONOWSKI AM, 1994, J BIOL CHEM, V269, P7874; HENKART PA, 1985, ANNU REV IMMUNOL, V3, P31, DOI 10.1146/annurev.iy.03.040185.000335; HEPLER PK, 1994, P NATL ACAD SCI USA, V91, P2176, DOI 10.1073/pnas.91.6.2176; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; HUDIG D, 1991, J IMMUNOL, V147, P1360; JANS DA, 1995, J BIOL CHEM, V270, P17064, DOI 10.1074/jbc.270.29.17064; JANS DA, 1995, BIOCHEM J, V311, P705, DOI 10.1042/bj3110705; JANS DA, 1994, ONCOGENE, V9, P2961; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; JANS DA, 1994, FASEB J, V8, P841, DOI 10.1096/fasebj.8.11.8070633; KAUFMANN SH, 1993, CANCER RES, V53, P3976; LAMY F, 1993, J BIOL CHEM, V268, P8398; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LEACH KL, 1989, J CELL BIOL, V109, P685, DOI 10.1083/jcb.109.2.685; LEACH KL, 1992, J BIOL CHEM, V267, P21816; LIU CC, 1986, J EXP MED, V164, P2061, DOI 10.1084/jem.164.6.2061; LOBE CG, 1986, P NATL ACAD SCI USA, V83, P1448, DOI 10.1073/pnas.83.5.1448; MAEDA Y, 1992, EMBO J, V11, P3695, DOI 10.1002/j.1460-2075.1992.tb05454.x; MARTIN K, 1991, CELL, V67, P117, DOI 10.1016/0092-8674(91)90576-K; MARTIN K, 1991, J VIROL, V65, P232, DOI 10.1128/JVI.65.1.232-244.1991; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MEINKOTH JL, 1990, P NATL ACAD SCI USA, V87, P9595, DOI 10.1073/pnas.87.24.9595; MOORE MS, 1994, TRENDS BIOCHEM SCI, V19, P211, DOI 10.1016/0968-0004(94)90024-8; MORELAND RB, 1987, MOL CELL BIOL, V7, P4048, DOI 10.1128/MCB.7.11.4048; NAKAJIMA H, 1994, J IMMUNOL, V152, P1057; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; ORTALDO JR, 1992, J LEUKOCYTE BIOL, V52, P483, DOI 10.1002/jlb.52.5.483; PASTERNACK MS, 1991, J BIOL CHEM, V266, P14703; PEARSON D, 1991, EXP CELL RES, V192, P315, DOI 10.1016/0014-4827(91)90193-X; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; Pinkoski MJ, 1996, J BIOL CHEM, V271, P10225, DOI 10.1074/jbc.271.17.10225; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SCHMID J, 1987, J IMMUNOL, V139, P250; SCHMIDTZACHMANN MS, 1993, J CELL SCI, V105, P799; Schmitz M L, 1991, Trends Cell Biol, V1, P130, DOI 10.1016/0962-8924(91)90118-S; SHI LF, 1992, J EXP MED, V175, P553, DOI 10.1084/jem.175.2.553; SHIVER JW, 1992, CELL, V71, P315, DOI 10.1016/0092-8674(92)90359-K; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SMYTH MJ, 1995, IMMUNOL TODAY, V16, P202, DOI 10.1016/0167-5699(95)80122-7; TRAPANI JA, 1994, J BIOL CHEM, V269, P18359; TRAPANI JA, 1993, BIOCHEM BIOPH RES CO, V195, P910, DOI 10.1006/bbrc.1993.2131; TRAPANI JA, 1988, P NATL ACAD SCI USA, V85, P6924, DOI 10.1073/pnas.85.18.6924; Trapani JA, 1996, J BIOL CHEM, V271, P4127; WALASCHEWSKI U, 1995, METHOD MOL CELL BIOL, V5, P87; Xiao CY, 1996, J BIOL CHEM, V271, P6451, DOI 10.1074/jbc.271.11.6451; XUE ZX, 1993, EUR J CELL BIOL, V62, P13; YAN C, 1993, J CELL BIOL, V123, P1081, DOI 10.1083/jcb.123.5.1081; Ymer S, 1996, BIOTECHNIQUES, V20, P834; YOUNG JD, 1986, CELL, V46, P641, DOI 10.1016/0092-8674(86)90336-3	69	94	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30781	30789		10.1074/jbc.271.48.30781	http://dx.doi.org/10.1074/jbc.271.48.30781			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940058	hybrid			2022-12-25	WOS:A1996VV15800075
J	Szapary, D; Xu, M; Simons, SS				Szapary, D; Xu, M; Simons, SS			Induction properties of a transiently transfected glucocorticoid-responsive gene vary with glucocorticoid receptor concentration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE AMINOTRANSFERASE GENE; PROTEIN-PROTEIN INTERACTIONS; HUMAN PROGESTERONE-RECEPTOR; THYROID-HORMONE RECEPTOR; HUMAN ESTROGEN-RECEPTOR; TRANSCRIPTIONAL ACTIVATION FUNCTIONS; DNA-BINDING; DEXAMETHASONE 21-MESYLATE; NUCLEAR-LOCALIZATION; STEROID-RECEPTORS	Transient transfections of steroid receptors have yielded much of the data used to construct the current models of steroid hormone action, These experiments invariably examine the ability of receptors to regulate transcription when occupied by saturating concentrations of steroid, We now report that other induction properties of a transiently transfected gene are not constant but vary with the concentration of transiently transfected glucocorticoid receptors, Thus, the percentage of maximal induction seen with subsaturating concentrations of glucocorticoid could be dramatically increased, and an antiglucocorticoid could be converted into a partial glucocorticoid, simply by increasing the concentration of glucocorticoid receptors. This behavior was observed in HeLa cells, containing endogenous receptors, or in CV-1 cells, containing almost no endogenous receptor, with either homologous or heterologous receptors, These increases were relatively insensitive to the concentration of reporter gene, suggesting the titration of some transcription factor(s) involved in regulating the position of the glucocorticoid dose-response curve and the agonist activity of an antiglucocorticoid. This property of transfected glucocorticoid receptors required a full-length, functionally active receptor but was retained, albeit reduced in magnitude, in the absence of binding to a glucocorticoid response element, Furthermore, this phenomenon was specific in that the A form of the human progesterone receptor had no effect under the same conditions, These variations in induction properties of antiglucocorticoids and of subsaturating concentrations of glucocorticoid, in a manner that was proportional to the amount of transfected receptor, reveal processes that are not operative with saturating concentrations of glucocorticoid. These variations also demonstrate that caution should be exercised in making mechanistic conclusions based solely on experiments conducted with saturating concentrations of glucocorticoid.	NIDDK, STEROID HORMONES SECT, MOL & CELLULAR BIOL LAB, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								ALROY I, 1992, NUCLEIC ACIDS RES, V20, P1045, DOI 10.1093/nar/20.5.1045; ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743; BANIAHMAD C, 1995, MOL ENDOCRINOL, V9, P34, DOI 10.1210/me.9.1.34; BAUMANN H, 1993, BIOCHEMISTRY-US, V32, P13463, DOI 10.1021/bi00212a011; BECK CA, 1993, P NATL ACAD SCI USA, V90, P4441, DOI 10.1073/pnas.90.10.4441; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; CHALBOS D, 1994, J BIOL CHEM, V269, P23007; CHALEPAKIS G, 1990, DNA CELL BIOL, V9, P355, DOI 10.1089/dna.1990.9.355; DANIELSEN M, 1987, MOL ENDOCRINOL, V1, P816, DOI 10.1210/mend-1-11-816; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINKEL T, 1993, J BIOL CHEM, V268, P5; GAGNE D, 1988, J STEROID BIOCHEM, V31, P917, DOI 10.1016/0022-4731(88)90333-0; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; HOECK W, 1992, J STEROID BIOCHEM, V41, P283, DOI 10.1016/0960-0760(92)90353-K; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; HORI R, 1994, CURR OPIN GENET DEV, V4, P236, DOI 10.1016/S0959-437X(05)80050-4; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; ING NH, 1992, J BIOL CHEM, V267, P17617; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; KASTNER P, 1990, J BIOL CHEM, V265, P12163; KAZMI SMI, 1993, ENDOCRINOLOGY, V133, P1230, DOI 10.1210/en.133.3.1230; KRALLI A, 1995, P NATL ACAD SCI USA, V92, P4701, DOI 10.1073/pnas.92.10.4701; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; LANZ RB, 1994, ENDOCRINOLOGY, V135, P2183, DOI 10.1210/en.135.5.2183; LEDOUARIN B, 1995, NUCLEIC ACIDS RES, V23, P876, DOI 10.1093/nar/23.5.876; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MCDONNELL DP, 1992, P NATL ACAD SCI USA, V89, P10563, DOI 10.1073/pnas.89.22.10563; MCDONNELL DP, 1994, J STEROID BIOCHEM, V48, P425, DOI 10.1016/0960-0760(94)90190-2; MCEWAN IJ, 1993, MOL CELL BIOL, V13, P399, DOI 10.1128/MCB.13.1.399; MIESFELD R, 1987, SCIENCE, V236, P423, DOI 10.1126/science.3563519; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; NITSCH D, 1993, P NATL ACAD SCI USA, V90, P5479, DOI 10.1073/pnas.90.12.5479; NORDEEN SK, 1990, MOL ENDOCRINOL, V4, P1866, DOI 10.1210/mend-4-12-1866; NORDEEN SK, 1993, MOL ENDOCRINOL, V7, P731, DOI 10.1210/me.7.6.731; OSHIMA H, 1993, J BIOL CHEM, V268, P26858; OSHIMA H, 1992, MOL ENDOCRINOL, V6, P416, DOI 10.1210/me.6.3.416; OSHIMA H, 1992, ENDOCRINOLOGY, V130, P2106, DOI 10.1210/en.130.4.2106; PICARD D, 1990, CELL REGUL, V1, P291, DOI 10.1091/mbc.1.3.291; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; SARTORIUS CA, 1993, J BIOL CHEM, V268, P9262; SIMONS SS, 1987, J BIOL CHEM, V262, P9676; SIMONS SS, 1994, VITAM HORM, V49, P49; SIMONS SS, 1992, MOL ENDOCRINOL, V6, P995, DOI 10.1210/me.6.7.995; SIMONS SS, 1981, P NATL ACAD SCI-BIOL, V78, P3541, DOI 10.1073/pnas.78.6.3541; SMITH CL, 1993, P NATL ACAD SCI USA, V90, P11202, DOI 10.1073/pnas.90.23.11202; SPANJAARD RA, 1993, MOL ENDOCRINOL, V7, P12, DOI 10.1210/me.7.1.12; STRICKLAND S, 1981, P NATL ACAD SCI-BIOL, V78, P1366, DOI 10.1073/pnas.78.3.1366; SZAPARY D, 1992, ENDOCRINOLOGY, V130, P3492, DOI 10.1210/en.130.6.3492; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7; VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WEHLE H, 1995, STEROIDS, V60, P368, DOI 10.1016/0039-128X(94)00067-M; WRIGHT APH, 1992, J BIOL CHEM, V267, P11191; Xu M, 1996, J BIOL CHEM, V271, P21430, DOI 10.1074/jbc.271.35.21430; ZILLIACUS J, 1991, J BIOL CHEM, V266, P3101	61	71	71	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30576	30582		10.1074/jbc.271.48.30576	http://dx.doi.org/10.1074/jbc.271.48.30576			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940029	hybrid			2022-12-25	WOS:A1996VV15800046
J	vanVlijmen, BJM; vanDijk, KW; vantHof, HB; vanGorp, PJJ; vanderZee, A; vanderBoom, H; Breuer, ML; Hofker, MH; Havekes, LM				vanVlijmen, BJM; vanDijk, KW; vantHof, HB; vanGorp, PJJ; vanderZee, A; vanderBoom, H; Breuer, ML; Hofker, MH; Havekes, LM			In the absence of endogenous mouse apolipoprotein E, apolipoprotein E*2(Arg-158->Cys) transgenic mice develop more severe hyperlipoproteinemia than apolipoprotein E*3-Leiden transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; E-DEFICIENT MICE; III HYPERLIPOPROTEINEMIA; MESSENGER-RNA; ATHEROSCLEROSIS; HYPERCHOLESTEROLEMIA; METABOLISM; BINDING; EXPRESSION; INHIBITION	Apolipoprotein E*2(Arg-158 --> Cys) (APOE*2) transgenic mice were generated and compared to the previously generated apolipoprotein E*3-Leiden (APOE*3-Leiden) transgenic mice to study the variable expression of hyperlipoproteinemia associated with these two APOE variants. In the presence of the endogenous mouse Apoe gene, the expression of the APOE*3-Leiden gene resulted in slightly elevated levels of serum cholesterol as compared with control mice (2.7 +/- 0.5 versus 2.1 +/- 0.2 mmol/liter, respectively), whereas the expression of the APOE*2 (Arg-158 --> Cys) gene did not affect serum cholesterol levels, even after high/fat cholesterol-feeding, The extreme cholesterol level usually found in apoE-deficient mice (Apoe(-/-) mice; 23.6 +/- 5.0 mmol/liter) could be rescued by introducing the APOE*3-Leiden gene (APOE*3-Leiden . Apoe(-/-); 3.6 +/- 1.5 mmol/liter), whereas the expression of the APOE*2(Arg-158 --> Cys) gene in Apoe(-/-) mice minimally reduced serum cholesterol levels (APOE*2 . Apoe(-/-); 16.6 +/- 2.9 mmol/liter), In vivo very low density lipoprotein (VLDL) turnover studies revealed that APOE*2 . Apoe(-/-) VLDL and APOE*3-Leiden . Apoe(-/-) VLDL display strongly reduced fractional catabolic rates as compared with control mouse VLDL (4.0 and 6.1 versus 22.1 pools/h), In vitro low density lipoprotein (LDL) receptor binding studies using HepG2 and J774 cells showed that APOE*2 . Apoe(-/-) VLDL is completely defective in binding to the LDL receptor, whereas APOE*3-Leiden . Apoe(-/-) VLDL still displayed a considerable binding activity to the LDL receptor, After transfection of APOE*(2) . Apoe(-/-) and APOE*3-Leiden . Apoe(-/-) mice with adenovirus carrying the gene for the receptor-associated protein (AdCMV-RAP), serum lipid levels strongly increased (15.3 to 42.8 and 1.4 to 15.3 mmol/liter for cholesterol and 5.0 to 35.7 and 0.3 to 20.7 mmol/liter for triglycerides, respectively), This indicates that RAP-sensitive receptors, possibly the LDL receptor-related protein (LRP), mediate the plasma clearance of both APOE*2 . Apoe(-/-) and APOE*3-Leiden . Apoe(-/-) VLDL. We conclude that in vivo the APOE*2 variant is completely defective in LDL receptor binding but not in binding to LRP, whereas for the APOE*3-Leiden mutant both LRP and LDL receptor binding activity are only mildly affected. As a consequence of this difference, APOE*2 . Apoe(-/-) develop more severe hypercholesterolemia than APOE*3-Leiden . Apoe(-/-) mice.	TNO, PG, GAUBIUS LAB, NL-2301 CE LEIDEN, NETHERLANDS; LEIDEN UNIV, DEPT HUMAN GENET, NL-2300 RC LEIDEN, NETHERLANDS; LEIDEN UNIV, DEPT MOL CARCINOGENESIS, NL-2300 RC LEIDEN, NETHERLANDS; ACAD HOSP LEIDEN, DEPT CARDIOL, NL-2300 RA LEIDEN, NETHERLANDS; ACAD HOSP LEIDEN, DEPT INTERNAL MED, NL-2300 RA LEIDEN, NETHERLANDS	Netherlands Organization Applied Science Research; Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC)			van Gorp, Patrick/S-3892-2019; van Dijk, Ko Willems/AAT-4681-2021; van Dijk, Ko Willems/A-1798-2008; van Gorp, Patrick/L-9580-2018	van Gorp, Patrick/0000-0002-0355-5349; van Dijk, Ko Willems/0000-0002-2172-7394; van Dijk, Ko Willems/0000-0002-2172-7394; van Gorp, Patrick/0000-0002-0355-5349				BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BREWER HB, 1983, ANN INTERN MED, V98, P623, DOI 10.7326/0003-4819-98-5-623; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; DEKNIJFF P, 1991, J CLIN INVEST, V88, P643, DOI 10.1172/JCI115349; DEMANT T, 1991, J CLIN INVEST, V88, P1490, DOI 10.1172/JCI115459; EHNHOLM C, 1984, P NATL ACAD SCI-BIOL, V81, P5566, DOI 10.1073/pnas.81.17.5566; Fallaux FJ, 1996, HUM GENE THER, V7, P215, DOI 10.1089/hum.1996.7.2-215; GHISELLI G, 1981, SCIENCE, V214, P1239, DOI 10.1126/science.6795720; Groot PHE, 1996, ARTERIOSCL THROM VAS, V16, P926, DOI 10.1161/01.ATV.16.8.926; Hendriks WL, 1996, BIOCHEM J, V314, P563, DOI 10.1042/bj3140563; HIGUCHI K, 1992, J LIPID RES, V33, P1753; HOGAN B, 1986, MANIPULATING MOUSE E; HOLMQUIST L, 1978, ANAL BIOCHEM, V88, P457, DOI 10.1016/0003-2697(78)90444-X; JI ZS, 1994, J BIOL CHEM, V269, P13421; JI ZS, 1994, J BIOL CHEM, V269, P2764; Jong MC, 1996, ARTERIOSCL THROM VAS, V16, P934, DOI 10.1161/01.ATV.16.8.934; KITA T, 1982, P NATL ACAD SCI-BIOL, V79, P5693, DOI 10.1073/pnas.79.18.5693; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUSIS AJ, 1987, J BIOL CHEM, V262, P7594; Mahley Jr RWRS, 1989, METABOLIC BASIS INHE, P1195; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1990, CURRENT OPINION LIPI, V1, P87; MCCONATHY WJ, 1989, FEBS LETT, V251, P250, DOI 10.1016/0014-5793(89)81464-4; MULDER M, 1991, BIOCHIM BIOPHYS ACTA, V1081, P308, DOI 10.1016/0005-2760(91)90287-R; MULDER M, 1994, ATHEROSCLEROSIS, V108, P183, DOI 10.1016/0021-9150(94)90113-9; NISHINA PM, 1990, J LIPID RES, V31, P859; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; RALL SC, 1992, J INTERN MED, V231, P653, DOI 10.1111/j.1365-2796.1992.tb01254.x; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; Rensen PCN, 1996, J BIOL CHEM, V271, P14791, DOI 10.1074/jbc.271.25.14791; SCHAEFER EJ, 1986, J CLIN INVEST, V78, P1206, DOI 10.1172/JCI112704; SHACHTER NS, 1993, J LIPID RES, V34, P1699; VANDENMAAGDENBERG AMJM, 1993, J BIOL CHEM, V268, P10540; VANREE JH, 1994, ATHEROSCLEROSIS, V111, P25, DOI 10.1016/0021-9150(94)90188-0; vanVlijmen BJM, 1996, J CLIN INVEST, V97, P1184, DOI 10.1172/JCI118532; VANVLIJMEN BJM, 1994, J CLIN INVEST, V93, P1403, DOI 10.1172/JCI117117; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; ZANNIS VI, 1984, J BIOL CHEM, V259, P5495; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	40	46	46	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30595	30602		10.1074/jbc.271.48.30595	http://dx.doi.org/10.1074/jbc.271.48.30595			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940032	hybrid, Green Published			2022-12-25	WOS:A1996VV15800049
J	Cassano, S; Gallo, A; Buccigrossi, V; Porcellini, A; Cerillo, R; Gottesman, ME; Avvedimento, EV				Cassano, S; Gallo, A; Buccigrossi, V; Porcellini, A; Cerillo, R; Gottesman, ME; Avvedimento, EV			Membrane localization of cAMP-dependent protein kinase amplifies cAMP signaling to the nucleus in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; REGULATORY SUBUNIT; TRANSCRIPTION; EXPRESSION; CREB	The A126 cell line, in contrast to its PC12 parent, does not differentiate, accumulate nuclear cAMP-dependent protein kinase A (PKA) catalytic subunit, or transcribe cAMP-dependent promoters in response to cAMP. Total PKA is reduced by 50% and is partly resistant to cAMP-induced dissociation in vivo. Unlike PC12, where PKAII is membrane-associated, PKAII is exclusively cytosolic in A126, Cotransfection with the RII anchor protein (AKAP75) and the PKA catalytic subunit (C-PKA) restored cAMP-induced transcription to levels found in PC12. These data indicate that membrane-bound PKAII amplifies cAMP signaling to the nucleus and suggest that cAMP-mediated responses are specified by the type and cellular localization of the PKA isoform.	UNIV NAPLES,FAC MED,DIPARTIMENTO BIOL & PATOL MOL & CELL,I-80131 NAPLES,ITALY; COLUMBIA UNIV,INST CANC RES,NEW YORK,NY 10032; UNIV REGGIO CALABRIA,FAC MED CATANZARO,DIPARTIMENTO MED SPERIMENTALE,I-88100 CATANZARO,ITALY	University of Naples Federico II; Columbia University; Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria			Porcellini, Antonio/AAC-6097-2019; Porcellini, Antonio/E-1900-2011	Porcellini, Antonio/0000-0001-6882-9518; CASSANO, SILVANA/0000-0001-9868-7936				BEEBE SJ, 1986, ENZYMES, V17, P43; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; CARR DW, 1992, TRENDS BIOCHEM SCI, V17, P246, DOI 10.1016/0968-0004(92)90402-U; CARR DW, 1993, J BIOL CHEM, V268, P20729; DAMON DH, 1990, J CELL BIOL, V110, P1333, DOI 10.1083/jcb.110.4.1333; DECAMILLI P, 1986, J CELL BIOL, V103, P189, DOI 10.1083/jcb.103.1.189; Feliciello A, 1996, J BIOL CHEM, V271, P25350, DOI 10.1074/jbc.271.41.25350; GALLO A, 1992, GENE DEV, V6, P1621, DOI 10.1101/gad.6.9.1621; GINTY DD, 1991, J BIOL CHEM, V266, P15325; GLANTZ SB, 1992, MOL BIOL CELL, V3, P1215, DOI 10.1091/mbc.3.11.1215; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HOFMANN F, 1975, J BIOL CHEM, V250, P7795; HUFFAKER T, 1984, J CELL PHYSIOL, V120, P188, DOI 10.1002/jcp.1041200212; Maniatis T., 1982, MOL CLONING; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; NDUBUKA C, 1993, J BIOL CHEM, V268, P7621; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; TORTORA G, 1990, J BIOL CHEM, V265, P18067; VANBUSKIRK R, 1985, MOL CELL BIOL, V5, P1984, DOI 10.1128/MCB.5.8.1984; Ventra C, 1996, J NEUROCHEM, V66, P1752; WEBER W, 1986, BIOCHEMISTRY-US, V25, P5661, DOI 10.1021/bi00367a047	28	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29870	29875		10.1074/jbc.271.47.29870	http://dx.doi.org/10.1074/jbc.271.47.29870			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939928	hybrid			2022-12-25	WOS:A1996VU52500056
J	Garnier, G; Circolo, A; Colten, HR				Garnier, G; Circolo, A; Colten, HR			Constitutive expression of murine complement factor B gene is regulated by the interaction of its upstream promoter with hepatocyte nuclear factor 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE RECEPTOR SUPERFAMILY; CELL GROWTH-FACTOR; MOLECULAR MAP; OVERLAP EXTENSION; ACTING ELEMENTS; MAMMALIAN-CELLS; LYMPHOCYTES-B; BINDING-SITE; TRANSCRIPTION; REGION	Factor B (Bf) is a constituent of the alternative pathway of complement activation encoded within the major histocompatibility complex, Transcription of the murine gene from two initiation sites generates two Bf mRNA species differing in size and tissue distribution, Striking genetic, tissue-specific differences in Bf mRNA levels at extrahepatic sites (kidney and intestine) among mouse strains correlate with a DNA sequence polymorphism in the 5'-flanking region of the gene and differential nuclear protein binding at the Bf upstream transcriptional initiation site (UIS), To ascertain the functional consequences of this polymorphism in the Bf promoter, we analyzed the effects of strain-specific sequences in the Bf 5' region on the expression of a chloramphenicol acetyltransferase (CAT) reporter gene transfected in human and mouse hepatoma cells, The CAT activity and mRNA level produced when transcription was driven by the sequence of strains with high extrahepatic expression were reduced to background levels when the sequence specific to the low expressor strains was used, Eighty percent of this difference was accounted for by a point substitution that affects DNA-protein interaction at the UIS, the sequence of higher affinity conferring higher expression, Hepatocyte nuclear factor 4 (HNF-4), derived from HepG2, mouse liver and kidney or cell-free translation of HNF-4 RNA, is the nuclear protein that preferentially binds to the high expressor UIS, Bf-CAT is not expressed in cells that lack HNF-4 (CV-1), However, co-transfection of HNF-4 into CV-I cells drives Bf-CAT expression and reproduces the differences derived from the substitution that affect HNF-4 binding in vitro. These data show that interaction of HNF-4 with polymorphic variants of the upstream Bf promoter is the major determinant of strain-specific extrahepatic factor B expression.	WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110	Washington University (WUSTL)					NIAID NIH HHS [AI24836, AI24739] Funding Source: Medline; NICHD NIH HHS [HD17461] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD017461] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024739, R01AI024836, R37AI024739] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALPER CA, 1980, CLIN IMMUNOL IMMUNOP, V16, P84, DOI 10.1016/0090-1229(80)90169-5; AMBRUS JL, 1991, J BIOL CHEM, V266, P3702; ASHFIELD R, 1994, EMBO J, V13, P5656, DOI 10.1002/j.1460-2075.1994.tb06904.x; ASHFIELD R, 1991, EMBO J, V10, P4197, DOI 10.1002/j.1460-2075.1991.tb04998.x; CARROLL MC, 1984, NATURE, V307, P237, DOI 10.1038/307237a0; CHAPLIN DD, 1983, P NATL ACAD SCI-BIOL, V80, P6947, DOI 10.1073/pnas.80.22.6947; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Colten HR, 1993, COMPLEMENT HLTH DIS, V20, P127; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FALUS A, 1987, J IMMUNOL, V138, P856; GARNIER G, 1995, J IMMUNOL, V154, P3275; GARNIER G, 1992, J EXP MED, V175, P471, DOI 10.1084/jem.175.2.471; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GOTZE O, 1979, J EXP MED, V149, P372, DOI 10.1084/jem.149.2.372; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HALL RE, 1982, J EXP MED, V156, P834, DOI 10.1084/jem.156.3.834; HIRANI S, 1985, CELL IMMUNOL, V92, P235, DOI 10.1016/0008-8749(85)90005-X; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; ING NH, 1992, J BIOL CHEM, V267, P17617; ISHIKAWA N, 1990, J BIOL CHEM, V265, P19040; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KATZ Y, 1989, J IMMUNOL, V142, P3862; KATZ Y, 1989, EUR J IMMUNOL, V19, P983, DOI 10.1002/eji.1830190605; KAWAMURA N, 1992, BIOCHEM J, V283, P705, DOI 10.1042/bj2830705; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LEIJH PCJ, 1982, J IMMUNOL, V129, P332; MALIK S, 1995, NUCLEIC ACIDS RES, V23, P1536, DOI 10.1093/nar/23.9.1536; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; MISKIMINS WK, 1985, P NATL ACAD SCI USA, V82, P6741, DOI 10.1073/pnas.82.20.6741; MORRIS KM, 1982, J CLIN INVEST, V70, P906, DOI 10.1172/JCI110687; MULLER U, 1987, EMBO J, V6, P369, DOI 10.1002/j.1460-2075.1987.tb04764.x; Naughton MA, 1996, J IMMUNOL, V156, P3051; NONAKA M, 1989, MOL CELL BIOCHEM, V89, P1; NONAKA M, 1990, MOL CELL BIOL, V10, P6283, DOI 10.1128/MCB.10.12.6283; NONAKA M, 1989, J IMMUNOL, V142, P1377; OGAMI K, 1990, J BIOL CHEM, V265, P9808; PASSWELL J, 1988, J CLIN INVEST, V82, P1676, DOI 10.1172/JCI113780; PETERS MG, 1988, J EXP MED, V168, P1225, DOI 10.1084/jem.168.4.1225; PRAZ F, 1986, J EXP MED, V163, P1349, DOI 10.1084/jem.163.5.1349; PURNELL BA, 1994, GENE DEV, V8, P830, DOI 10.1101/gad.8.7.830; RAMADORI G, 1985, J EXP MED, V162, P930, DOI 10.1084/jem.162.3.930; RAMADORI G, 1985, J IMMUNOL, V135, P3645; REIJNEN MJ, 1992, P NATL ACAD SCI USA, V89, P6300, DOI 10.1073/pnas.89.14.6300; REIJNEN MJ, 1993, BLOOD, V82, P151, DOI 10.1182/blood.V82.1.151.bloodjournal821151; REUE K, 1988, J BIOL CHEM, V263, P6857; ROTHER K, 1988, COMPLEMENT SYSTEM; ROTTMAN JN, 1993, J BIOL CHEM, V268, P11994; Sambrook J., 2002, MOL CLONING LAB MANU; SEGAL S, 1986, BASIC METHODS MOL BI, P286; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; STRUNK RC, 1985, J CLIN INVEST, V76, P985, DOI 10.1172/JCI112099; STRUNK RC, 1985, J BIOL CHEM, V260, P5280; WILEY SR, 1992, P NATL ACAD SCI USA, V89, P5814, DOI 10.1073/pnas.89.13.5814; WU LC, 1987, CELL, V48, P331, DOI 10.1016/0092-8674(87)90436-3	57	10	10	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30205	30211		10.1074/jbc.271.47.30205	http://dx.doi.org/10.1074/jbc.271.47.30205			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939972	hybrid			2022-12-25	WOS:A1996VU52500100
J	Muthalif, MM; Benter, IF; Uddin, MR; Malik, KU				Muthalif, MM; Benter, IF; Uddin, MR; Malik, KU			Calcium/calmodulin-dependent protein kinase II alpha mediates activation of mitogen-activated protein kinase and cytosolic phospholipase A(2) in norepinephrine-induced arachidonic acid release in rabbit aortic smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; ANTISENSE OLIGONUCLEOTIDES; PROSTAGLANDIN SYNTHESIS; TYROSINE KINASE; STIMULI; MEMBRANE; PHOSPHORYLATION; EXPRESSION; MECHANISM; INHIBITOR	We have investigated the contribution of Ca2+/calmodulin dependent protein kinase II (CaM kinase II) and mitogen-activated protein kinase (MAP kinase) in norepinephrine (NE)-induced arachidonic acid (AA) release in rabbit aortic vascular smooth muscle cells (VSMC), NE enhanced release of AA via activation of cytosolic phospholipase A(2) (cPLA(2)) but not secretory PLA(2) in VSMC prelabeled with [H-3]AA. NE (10 mu M) enhanced CaM kinase II and MAP kinase activity, In cells transiently transfected with antisense oligonucleotides complementary to the translation initiation sites of CaM kinase II and MAP kinase, NE-induced AA release was inhibited by 100 and 35% respectively. Treatment of cells with PD-098059, a MAP kinase kinase inhibitor, or with MAP kinase antisense oligonucleotide reduced NE-induced activation of MAP kinase and cPLA(2). NE-induced MAP kinase and cPLA(2) activation was also inhibited in cells treated with a CaM kinase II inhibitor, KN-93, or with CaM kinase II antisense oligonucleotide. On the other hand, inhibition of MAP kinase kinase with PD-098059 or of MAP kinase with antisense oligonucleotides did not alter the NE-induced increase in CaM kinase II activity, Phosphorylation of MAP kinase and CaM kinase II by NE, studied by P-32 incorporation and immune complex kinase assays, was inhibited by KN-93. Collectively, these data suggest that CaM kinase II can activate MAP kinase, which in turn activates cPLA(2) to release AA for prostacyclin synthesis in the rabbit VSMC. This novel pathway for activation of MAP kinase by CaM kinase II appears to be mediated through stimulation of MAP kinase kinase, Activation of adrenergic receptors with NE in VSMC caused translocation of CaM kinase II, MAP kinase, and cPLA(2) to the nuclear envelope only in the presence of extracellular Ca2+. Okadaic acid, which increased phosphorylation and activity, did not translocate these enzymes, Therefore, it appears that in rabbit VSMC, NE, by promoting extracellular Ca2+ influx, increases CaM kinase II activity, leading to activation of MAP kinase and cPLA(2) and translocation to the nuclear envelope, resulting in release of AA from the nuclear envelope for prostacyclin synthesis.	UNIV TENNESSEE, CTR HLTH SCI, DEPT PHARMACOL, COLL MED, MEMPHIS, TN 38163 USA; SO COLL OPTOMETRY, MEMPHIS, TN 38104 USA; LE MOYNE COLL, MEMPHIS, TN 38126 USA	University of Tennessee System; University of Tennessee Health Science Center			Benter, Ibrahim Fadil/AAY-2527-2020		PHS HHS [19134] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; BURGESS TL, 1995, P NATL ACAD SCI USA, V92, P4051, DOI 10.1073/pnas.92.9.4051; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CAPRIOTTI AM, 1988, J BIOL CHEM, V263, P10029; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DURSTIN M, 1994, P NATL ACAD SCI USA, V91, P3142, DOI 10.1073/pnas.91.8.3142; Eguchi S, 1996, J BIOL CHEM, V271, P14169, DOI 10.1074/jbc.271.24.14169; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; LESLIE CC, 1990, METHOD ENZYMOL, V187, P216; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MALIK KU, 1988, AM J MED SCI, V295, P280, DOI 10.1097/00000441-198804000-00011; NEBIGIL C, 1990, J PHARMACOL EXP THER, V254, P633; NEBIGIL C, 1993, J PHARMACOL EXP THER, V266, P1113; NEUFELD EJ, 1985, J CELL BIOL, V101, P573, DOI 10.1083/jcb.101.2.573; QIU ZH, 1994, J BIOL CHEM, V269, P19480; ROSHAK A, 1994, J BIOL CHEM, V269, P25999; SA G, 1995, J BIOL CHEM, V270, P2360, DOI 10.1074/jbc.270.5.2360; SADOSHIMA J, 1995, CIRC RES, V76, P1; SCHALKWIJK CG, 1990, BIOCHIM BIOPHYS ACTA, V1044, P139, DOI 10.1016/0005-2760(90)90229-Q; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SRINIVASAN M, 1994, J CELL BIOL, V126, P839, DOI 10.1083/jcb.126.4.839; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006-291X(91)92031-E; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; WATERMAN WH, 1995, BIOCHEM BIOPH RES CO, V209, P271, DOI 10.1006/bbrc.1995.1499; WINITZ S, 1994, J BIOL CHEM, V269, P1889; Xing MB, 1996, J CLIN INVEST, V97, P1302, DOI 10.1172/JCI118546	33	144	146	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30149	30157		10.1074/jbc.271.47.30149	http://dx.doi.org/10.1074/jbc.271.47.30149			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939965	hybrid			2022-12-25	WOS:A1996VU52500093
J	Tai, TAC; Jennermann, C; Brown, KK; Oliver, BB; MacGinnitie, MA; Wilkison, WO; Brown, HR; Lehmann, JM; Kliewer, SA; Morris, DC; Graves, RA				Tai, TAC; Jennermann, C; Brown, KK; Oliver, BB; MacGinnitie, MA; Wilkison, WO; Brown, HR; Lehmann, JM; Kliewer, SA; Morris, DC; Graves, RA			Activation of the nuclear receptor peroxisome proliferator-activated gamma promotes brown adipocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNCOUPLING PROTEIN GENE; RETINOID-X-RECEPTOR; ADIPOSE-TISSUE THERMOGENESIS; OB OB MICE; INSULIN-RESISTANCE; TRANSGENIC MICE; LIPID-METABOLISM; BINDING-PROTEIN; MESSENGER-RNA; FATTY-ACIDS	Brown adipose tissue (BAT) functions in non-shivering and diet-induced thermogenesis via its capacity for uncoupled mitochondrial respiration. BAT dysfunction in rodents is associated with severe defects in energy homeostasis, resulting in obesity and hyperglycemia. Here, we report that the nuclear receptor peroxisome proliferator-activated receptor gamma (PPAR gamma), a prostaglandin-activated transcription factor recently implicated as a central regulator of white adipose tissue differentiation, also regulates brown adipocyte function. PPAR gamma is abundantly expressed in both embryonic and adult BAT. Treatment of CD-1 rats with the PPAR gamma-selective ligand BRL49653, an anti-diabetic drug of the thiazolidinedione class, results in marked increases in the mass of interscapular BAT. In vitro, BRL49653 induces the terminal differentiation of the brown preadipocyte cell line HIB-1B as judged by both changes in cell morphology and expression of uncoupling protein and other adipocyte-specific mRNAs. These data demonstrate that PPAR gamma is a key regulatory factor in brown adipocytes and suggest that PPAR gamma functions not only in the storage of excess energy in white adipose tissue but also in its dissipation in BAT.	UNIV CHICAGO, DEPT MED, GASTROENTEROL SECT, CHICAGO, IL 60637 USA; GLAXO WELLCOME INC, RES & DEV, DEPT MOL PHARMACOL, RES TRIANGLE PK, NC 27709 USA; GLAXO WELLCOME INC, RES & DEV, DEPT PHARMACOL, RES TRIANGLE PK, NC 27709 USA; GLAXO WELLCOME INC, RES & DEV, DEPT CELL BIOL, RES TRIANGLE PK, NC 27709 USA; GLAXO WELLCOME INC, RES & DEV, DEPT MOL BIOCHEM, RES TRIANGLE PK, NC 27709 USA; GLAXO WELLCOME INC, RES & DEV, DEPT PATHOL, RES TRIANGLE PK, NC 27709 USA	University of Chicago; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026678] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK26678] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALVAREZ R, 1995, J BIOL CHEM, V270, P5666, DOI 10.1074/jbc.270.10.5666; CASSARDDOULCIER AM, 1994, J BIOL CHEM, V269, P24335; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; COLCA JR, 1990, NEW ANTIDIABETIC DRU, P255; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GEARING KL, 1993, P NATL ACAD SCI USA, V90, P1440, DOI 10.1073/pnas.90.4.1440; GLICK Z, 1987, Journal of Obesity and Weight Regulation, V6, P170; GRAVES RA, 1991, GENE DEV, V5, P428, DOI 10.1101/gad.5.3.428; HAMANN A, 1995, DIABETES, V44, P1266, DOI 10.2337/diabetes.44.11.1266; Hamann A, 1996, ENDOCRINOLOGY, V137, P21, DOI 10.1210/en.137.1.21; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; HIMMSHAGEN J, 1985, INT J OBESITY, V9, P17; HIMMSHAGEN J, 1990, FASEB J, V4, P2890, DOI 10.1096/fasebj.4.11.2199286; HIMMSHAGEN J, 1989, PROG LIPID RES, V28, P67, DOI 10.1016/0163-7827(89)90009-X; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; IBRAHIMI A, 1994, MOL PHARMACOL, V46, P1070; KELLER H, 1993, ANN NY ACAD SCI, V684, P157, DOI 10.1111/j.1749-6632.1993.tb32279.x; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KEMNITZ JW, 1994, DIABETES, V43, P204, DOI 10.2337/diabetes.43.2.204; KLAUS S, 1994, J CELL SCI, V107, P313; KLAUS S, 1991, INT J BIOCHEM, V23, P791, DOI 10.1016/0020-711X(91)90062-R; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KOZAK UC, 1994, MOL CELL BIOL, V14, P59, DOI 10.1128/MCB.14.1.59; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; MERCER SW, 1986, FEBS LETT, V195, P12, DOI 10.1016/0014-5793(86)80120-X; MERCER SW, 1987, J NUTR, V117, P2147; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803; RABELO R, 1995, ENDOCRINOLOGY, V136, P1003, DOI 10.1210/en.136.3.1003; ROSS SR, 1992, P NATL ACAD SCI USA, V89, P7561, DOI 10.1073/pnas.89.16.7561; ROTHWELL NJ, 1987, MOL CELL ENDOCRINOL, V51, P253, DOI 10.1016/0303-7207(87)90035-9; ROTHWELL NJ, 1979, NATURE, V281, P31, DOI 10.1038/281031a0; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Sears IB, 1996, MOL CELL BIOL, V16, P3410; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; THURLBY PL, 1987, BIOSCIENCE REP, V7, P573, DOI 10.1007/BF01119774; TONTONOZ P, 1994, NUCLEIC ACIDS RES, V22, P5628, DOI 10.1093/nar/22.25.5628; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Trayhurn P, 1988, Prog Clin Biol Res, V265, P69; TRAYHURN P, 1990, INT J OBESITY, V1, P17; Willson TM, 1996, J MED CHEM, V39, P665, DOI 10.1021/jm950395a; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975; ZHU YJ, 1993, J BIOL CHEM, V268, P26817	49	140	149	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29909	29914		10.1074/jbc.271.47.29909	http://dx.doi.org/10.1074/jbc.271.47.29909			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939934	hybrid			2022-12-25	WOS:A1996VU52500062
J	Morris, HR; Dell, A; Easton, RL; Panico, M; Koistinen, H; Koistinen, R; Oehninger, S; Patankar, MS; Seppala, M; Clark, GF				Morris, HR; Dell, A; Easton, RL; Panico, M; Koistinen, H; Koistinen, R; Oehninger, S; Patankar, MS; Seppala, M; Clark, GF			Gender-specific glycosylation of human glycodelin affects its contraceptive activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PLACENTAL PROTEIN-14; HUMAN SEMINAL PLASMA; ENDOMETRIAL PROTEIN; HUMAN-SPERMATOZOA; HEMIZONA ASSAY; MUCUS GLYCOPROTEINS; ZONA-PELLUCIDA; FERTILIZATION; EXPRESSION; CELLS	We have recently demonstrated that a human amniotic fluid-derived glycoprotein, glycodelin-A (GdA; previously known as PP14 or PAEP), potently inhibits gamete binding in an established sperm-egg binding system and expresses immunosuppressive activities directed against a variety of different immune cell types, GdA has high mannose-, hybrid-, and complex-type bi-antennary oligosaccharides including structures with fucosylated or sialylated N,N'-diacetyllactose diamine (GalNAc beta 1-4GlcNAc) sequences, which are rare in other human glycoproteins. We now report the characterization of glycodelin-S (GdS), This is a human seminal plasma glycoprotein that is immunologically indistinguishable from GdA, but unlike the latter, does not inhibit human sperm-zona pellucida binding under hemizona assay conditions. Analysis of the N-glycans of GdS by mass spectrometry revealed that all glycoforms of GdS are different from those of GdA. GdS glycans are unusually fucose-rich, and the major complex-type structures are biantennary glycans with Lewis(x) (Gal beta 1-4(Fuc alpha 1-3)GlcNAc) and Lewis(y) (Fuc alpha 1-2Gal beta 1-4 (Fuc alpha 1-3)GlcNAc) antennae, It is probable that these highly fucosylated epitopes contribute to the immunosuppressive activity of human seminal plasma and to the low immunogenicity of sperm, This study provides the first evidence for gender-specific glycosylation that may serve to regulate key processes involved in human reproduction.	UNIV CENT HOSP,DEPT OBSTET & GYNAECOL,FIN-00290 HELSINKI,FINLAND; EASTERN VIRGINIA MED SCH,JONES INST REPROD MED,DEPT OBSTET & GYNECOL,NORFOLK,VA 23507; EASTERN VIRGINIA MED SCH,DEPT BIOCHEM,NORFOLK,VA 23501	Eastern Virginia Medical School; Eastern Virginia Medical School	Morris, HR (corresponding author), UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,DEPT BIOCHEM,LONDON SW7 2AY,ENGLAND.		Seppala, Markku/AAT-6618-2021; Koistinen, Hannu/AGU-1279-2022; Oehninger, Sergio/AAZ-8443-2020	Koistinen, Hannu/0000-0003-0926-3109; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALBERSHEIM PETER, 1967, CARBOHYD RES, V5, P340, DOI 10.1016/S0008-6215(00)80510-8; Bohn H, 1982, Placenta Suppl, V4, P67; BOLTON AE, 1987, LANCET, V1, P593; BURKMAN LJ, 1988, FERTIL STERIL, V49, P688; CLARK GF, 1995, HUM REPROD, V10, P31, DOI 10.1093/humrep/10.suppl_1.31; DELL A, 1995, J BIOL CHEM, V270, P24116, DOI 10.1074/jbc.270.41.24116; DELL A, 1993, GLYCOBIOLOGY PRACTIC, P187; GRINNELL BW, 1994, GLYCOBIOLOGY, V4, P221, DOI 10.1093/glycob/4.2.221; HANISCH FG, 1986, EUR J BIOCHEM, V155, P239, DOI 10.1111/j.1432-1033.1986.tb09482.x; HANISCH FG, 1985, EUR J BIOCHEM, V152, P343, DOI 10.1111/j.1432-1033.1985.tb09204.x; HIRAISHI K, 1993, GLYCOBIOLOGY, V3, P381, DOI 10.1093/glycob/3.4.381; HUNT E, 1973, BIOCHEM J, V135, P833, DOI 10.1042/bj1350833; JULKUNEN M, 1986, ENDOCRINOLOGY, V118, P1782, DOI 10.1210/endo-118-5-1782; Julkunen M, 1984, Arch Androl, V12 Suppl, P59; JULKUNEN M, 1988, P NATL ACAD SCI USA, V85, P8845, DOI 10.1073/pnas.85.23.8845; JULKUNEN M, 1985, BRIT J OBSTET GYNAEC, V92, P1145, DOI 10.1111/j.1471-0528.1985.tb03027.x; JULKUNEN M, 1986, HUM REPROD, V1, P7, DOI 10.1093/oxfordjournals.humrep.a136349; KAMARAINEN M, 1994, BLOOD, V84, P467; KASHIWAGI N, 1994, TOHOKU J EXP MED, V173, P115, DOI 10.1620/tjem.173.115; KOISTINEN H, 1996, IN PRESS MOL HUM REP; LASKY LA, 1995, ANNU REV BIOCHEM, V64, P113, DOI 10.1146/annurev.bi.64.070195.000553; LLOYD KO, 1966, BIOCHEMISTRY-US, V5, P1489, DOI 10.1021/bi00869a007; MACEK MB, 1988, GAMETE RES, V20, P93, DOI 10.1002/mrd.1120200109; MILLER DJ, 1990, MOL REPROD DEV, V26, P184, DOI 10.1002/mrd.1080260213; MINAMIDE S, 1995, HISTOCHEM CELL BIOL, V103, P339, DOI 10.1007/BF01457808; OEHNINGER S, 1995, FERTIL STERIL, V63, P377; OEHNINGER S, 1993, MOL REPROD DEV, V35, P57, DOI 10.1002/mrd.1080350110; OEHNINGER S, 1991, AM J OBSTET GYNECOL, V164, P1210, DOI 10.1016/0002-9378(91)90684-J; OKAMOTO N, 1991, AM J REPROD IMMUNOL, V26, P137, DOI 10.1111/j.1600-0897.1991.tb00713.x; PATANKAR MS, 1993, J BIOL CHEM, V268, P21770; POCKLEY AG, 1988, J REPROD IMMUNOL, V13, P31, DOI 10.1016/0165-0378(88)90046-0; POCKLEY AG, 1989, CLIN EXP IMMUNOL, V77, P252; POCKLEY AG, 1990, IMMUNOLOGY, V69, P277; POWELL LD, 1995, J BIOL CHEM, V270, P7523, DOI 10.1074/jbc.270.13.7523; REASON AJ, 1994, GLYCOBIOLOGY, V4, P593, DOI 10.1093/glycob/4.5.593; RIITTINEN L, 1991, J IMMUNOL METHODS, V136, P85, DOI 10.1016/0022-1759(91)90253-C; Saitoh F, 1995, ANTICANCER RES, V15, P2137; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; VANHALBEEK H, 1985, BIOCHEM BIOPH RES CO, V131, P507, DOI 10.1016/0006-291X(85)91831-5; VELUPILLAI P, 1994, P NATL ACAD SCI USA, V91, P18, DOI 10.1073/pnas.91.1.18; WASSARMAN PM, 1990, DEVELOPMENT, V108, P1	41	132	140	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32159	32167		10.1074/jbc.271.50.32159	http://dx.doi.org/10.1074/jbc.271.50.32159			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943270	hybrid			2022-12-25	WOS:A1996VY34000061
J	Chen, Y; Takeshita, A; Ozaki, K; Kitano, S; Hanazawa, S				Chen, Y; Takeshita, A; Ozaki, K; Kitano, S; Hanazawa, S			Transcriptional regulation by transforming growth factor beta of the expression of retinoic acid and retinoid X receptor genes in osteoblastic cells is mediated through AP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOCLAST-LIKE CELLS; MONOCYTE CHEMOATTRACTANT JE; HUMAN MARROW CULTURES; FETAL-RAT BONE; THYROID-HORMONE; INHIBITS FORMATION; ADENYLATE-CYCLASE; RESPONSE ELEMENTS; MC3T3-E1 CELLS; BINDING	We now report that transforming growth factor pi (TGF-PI), a potent regulatory cytokine of bone remodeling, is a powerful stimulator for gene expression of retinoic acid receptors (RARs) and retinoid X receptors (RXRs) in osteoblastic MC3T3-E1 cells. TGF-beta 1 transcriptionally stimulated the expression of RAR alpha, RAR gamma, and RXR alpha genes, but did not do so for RAR beta, RXR beta, and RXR gamma genes. We also observed that AP-1, a transcriptional factor, plays an important role in the signal pathway for expression of RAR alpha, RAR gamma, and RXR alpha genes stimulated by TGF-beta 1 because stimulation of the expression of these genes in the cytokine-treated cells was markedly inhibited by a mixture of antisense c-fos and c-jun. A gel mobility shift assay demonstrated that TGF-beta 1 is able to increase, in a dose-dependent manner, the binding of nuclear proteins to direct repeat 5, a consensus sequence with high affinity for RAR-RXR heterodimers. The mobility shift assay, using specific antibody for each receptor, showed that direct repeat B-binding proteins may be RAR and RXR isoforms. The stimulated binding to direct repeat 5 was inhibited strongly by H-7, an inhibitor of serine/threonine kinase, and by curcumin, an inhibitor of AP-1, The present study suggests a novel pathway for TGF-beta 1 action in osteoblastic cells via stimulation of RAR-RXR transcriptional activity in a ligand-dependent fashion.	MEIKAI UNIV, SCH DENT, DEPT ORAL MICROBIOL, SAKADO, SAITAMA 35002, JAPAN	Meikai University								BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CENTRELLA M, 1987, J BIOL CHEM, V262, P2869; CENTRELLA M, 1992, ENDOCRINOLOGY, V131, P2863, DOI 10.1210/en.131.6.2863; CHENU C, 1988, P NATL ACAD SCI USA, V85, P5683, DOI 10.1073/pnas.85.15.5683; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; GUTIERREZ GE, 1990, J CELL PHYSIOL, V144, P438, DOI 10.1002/jcp.1041440311; HANAZAWA S, 1994, J BIOL CHEM, V269, P21379; HANAZAWA S, 1993, J BIOL CHEM, V268, P9526; HASHIMOTO M, 1992, J BIOL CHEM, V267, P4999; HAUSCHKA PV, 1988, CIBA F SYMP, V136, P207; HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KOTOYORI J, 1993, CELL SIGNAL, V5, P411, DOI 10.1016/0898-6568(93)90080-6; KUKITA A, 1990, P NATL ACAD SCI USA, V87, P3023, DOI 10.1073/pnas.87.8.3023; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; Maniatis T., 1982, MOL CLONING; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; PFEILSCHIFTER J, 1988, J CLIN INVEST, V82, P680, DOI 10.1172/JCI113647; ROBERTS AB, 1984, RETINOIDS, V2, P28; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; SCHNEIDER HG, 1992, ENDOCRINOLOGY, V131, P1383, DOI 10.1210/en.131.3.1383; SCHULZ WA, 1989, BIOCHIM BIOPHYS ACTA, V1013, P125, DOI 10.1016/0167-4889(89)90040-2; SHIBANUMA M, 1992, BIOCHEM BIOPH RES CO, V187, P1418, DOI 10.1016/0006-291X(92)90460-3; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; SUVA LJ, 1991, MOL CELL BIOL, V11, P2503, DOI 10.1128/MCB.11.5.2503; TAKAHASHI N, 1986, J CLIN INVEST, V78, P894, DOI 10.1172/JCI112677; TAKESHITA A, 1995, J IMMUNOL, V155, P419; Ten Dijke Peter, 1994, Progress in Growth Factor Research, V5, P55, DOI 10.1016/0955-2235(94)90017-5; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; WRANA JL, 1988, J CELL BIOL, V106, P915, DOI 10.1083/jcb.106.3.915; XIE T, 1994, SCIENCE, V263, P1756, DOI 10.1126/science.8134837; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0; ZHOU H, 1993, J CELL PHYSIOL, V155, P112, DOI 10.1002/jcp.1041550115	43	50	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31602	31606		10.1074/jbc.271.49.31602	http://dx.doi.org/10.1074/jbc.271.49.31602			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940178	hybrid			2022-12-25	WOS:A1996VW68600089
J	Kusk, P; John, S; Fragoso, G; Michelotti, J; Hager, GL				Kusk, P; John, S; Fragoso, G; Michelotti, J; Hager, GL			Characterization of an NF-1/CTF family member as a functional activator of the mouse mammary tumor virus long terminal repeat 5' enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR FACTOR-I; TGGCA-BINDING PROTEIN; TRANSGENIC MICE; DNA-REPLICATION; GLUCOCORTICOID REGULATION; TRANSCRIPTION FACTOR; PROVIRAL ACTIVATION; RESPONSIVE ELEMENT; ONCOGENE INT-1; ADENOVIRUS DNA	The long terminal repeat of the mouse mammary tumor virus restricts virus expression primarily to the mammary epithelium. The extreme 5' end of the long terminal repeat contains an enhancer that has been associated with tissue-specific expression of the virus. A total of six functional cis-acting elements have been identified in the enhancer. Although proteins binding to these elements have been reported, only one has been identified; this factor, mp5, is identical or closely related to the transcription factor AP-2 (Mellentin-Michelotti, J., John, S., Pennie, W. D., Williams, T., and Hager, G. L. (1994) J. Biol. Chem. 269, 31983-31990). The other factors are hitherto unidentified and poorly described. We report here the characterization of another of the six elements, previously referred to as the F3 site (Mink, S., Hartig, E., Jennewein, P., Doppler, W., and Cato, A. C. (1992) Mol. Cell Biol, 12, 4906-4918), We show that the F3 binding activity and AP-2 act synergistically to enhance mouse mammary tumor virus-directed transcription, but only in the presence of glucocorticoid hormone, The F3 element has an NF-l-like half-site, but the activity recognizing this element has binding characteristics distinct from the NF-1/CTF family as well as the rest of the CCAAT-binding proteins. We conclude that the F3 activity represents a new member of the NF-1/CTF family.	NCI,LAB RECEPTOR BIOL & GENE EXPRESS,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ALAM T, 1993, J BIOL CHEM, V268, P15681; BENOR S, 1993, MOL CELL BIOL, V13, P331, DOI 10.1128/MCB.13.1.331; BORGMEYER U, 1984, NUCLEIC ACIDS RES, V12, P4295, DOI 10.1093/nar/12.10.4295; BUETTI E, 1989, NUCLEIC ACIDS RES, V17, P3065, DOI 10.1093/nar/17.8.3065; BUETTI E, 1986, J MOL BIOL, V190, P379, DOI 10.1016/0022-2836(86)90009-4; CATO ACB, 1987, EMBO J, V6, P363, DOI 10.1002/j.1460-2075.1987.tb04763.x; CATO ACB, 1988, EMBO J, V7, P1403, DOI 10.1002/j.1460-2075.1988.tb02957.x; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; GIL G, 1988, P NATL ACAD SCI USA, V85, P8963, DOI 10.1073/pnas.85.23.8963; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; GUNZBURG WH, 1992, BIOCHEM J, V283, P625; HENRARD D, 1988, J VIROL, V62, P3046, DOI 10.1128/JVI.62.8.3046-3049.1988; HUANG AL, 1981, CELL, V27, P245, DOI 10.1016/0092-8674(81)90408-6; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KENNEDY GC, 1990, J BIOL CHEM, V265, P6279; KRUSE U, 1994, FEBS LETT, V348, P46, DOI 10.1016/0014-5793(94)00585-0; KUSK P, 1995, MOL ENDOCRINOL, V9, P1180, DOI 10.1210/me.9.9.1180; LEEGWATER PAJ, 1985, EMBO J, V4, P1515, DOI 10.1002/j.1460-2075.1985.tb03811.x; LEFEBVRE P, 1991, MOL CELL BIOL, V11, P2529, DOI 10.1128/MCB.11.5.2529; MELLENTINMICHELOTTI J, 1994, J BIOL CHEM, V269, P31983; MIKSICEK R, 1987, EMBO J, V6, P1355, DOI 10.1002/j.1460-2075.1987.tb02375.x; MINK S, 1992, MOL CELL BIOL, V12, P4906, DOI 10.1128/MCB.12.11.4906; MIWA K, 1987, P NATL ACAD SCI USA, V84, P4939, DOI 10.1073/pnas.84.14.4939; MOK E, 1992, J VIROL, V66, P7529, DOI 10.1128/JVI.66.12.7529-7532.1992; NAGATA K, 1983, P NATL ACAD SCI-BIOL, V80, P6177, DOI 10.1073/pnas.80.20.6177; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; OSTROWSKI MC, 1983, MOL CELL BIOL, V3, P2045, DOI 10.1128/MCB.3.11.2045; PARKS WP, 1976, CELL, V8, P87, DOI 10.1016/0092-8674(76)90189-6; PAYVAR F, 1983, CELL, V35, P381, DOI 10.1016/0092-8674(83)90171-X; PETERS G, 1986, NATURE, V320, P628, DOI 10.1038/320628a0; ROSS SR, 1990, MOL CELL BIOL, V10, P5822, DOI 10.1128/MCB.10.11.5822; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SONNENBERG A, 1987, EMBO J, V6, P121, DOI 10.1002/j.1460-2075.1987.tb04728.x; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; STEWART TA, 1988, MOL CELL BIOL, V8, P473, DOI 10.1128/MCB.8.1.473; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; VANLEEUWEN F, 1995, SEMIN CANCER BIOL, V6, P127, DOI 10.1006/scbi.1995.0018; VANOOYEN A, 1984, CELL, V39, P233, DOI 10.1016/0092-8674(84)90209-5; WORKMAN JL, 1985, BIOCHEMISTRY-US, V24, P4731, DOI 10.1021/bi00339a004; YANAGAWA S, 1991, J VIROL, V65, P526, DOI 10.1128/JVI.65.1.526-531.1991	47	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31269	31276		10.1074/jbc.271.49.31269	http://dx.doi.org/10.1074/jbc.271.49.31269			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940131	hybrid			2022-12-25	WOS:A1996VW68600042
J	Magnifico, A; Tagliabue, E; Buto, S; Ardini, E; Castronovo, V; Colnaghi, MI; Menard, S				Magnifico, A; Tagliabue, E; Buto, S; Ardini, E; Castronovo, V; Colnaghi, MI; Menard, S			Peptide G, containing the binding site of the 67-kDa laminin receptor, increases and stabilizes laminin binding to cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BREAST CARCINOMAS; MELANOMA-CELLS; PROGNOSTIC-SIGNIFICANCE; SURFACE LAMININ; TUMOR INVASION; EXPRESSION; INTEGRIN; AFFINITY; METASTASIS; PROTEIN	We investigated the effect of peptide G, a synthetic peptide derived from the sequence of the 37-kDa laminin receptor precursor, on the interaction of laminin in two tumor cell lines one of which produces laminin and one of which does not, Addition of peptide G to the culture medium induced a significant increase in the amount of endogenous laminin detectable on the cell membrane of both cell lines, Moreover, pretreatment of exogenous laminin with peptide G dramatically increased laminin binding on both cell lines, Kinetics analysis of membrane-bound labeled laminin revealed a 3-fold decrease in the k(d) of peptide G-treated laminin compared with untreated or unrelated or scrambled peptide-treated laminin, Moreover, the affinity constant of peptide cr-treated laminin increased S-fold, with a doubling of the number of laminin binding sites, as de termined by Scatchard analysis, Expression of the VLA6 integrin receptor on the cell membrane increased after incubation with peptide G-treated laminin, However, the lower binding inhibition of peptide G-treated laminin after anti-VLA6 antibody or cation chelation treatment indicates that membrane molecules in addition to integrin receptors are involved in the recognition of peptide G-modified laminin, These ''new'' laminin-binding proteins also mediated cell adhesion to laminin, the first step in tumor invasion, Together, the data suggest that peptide G increases and stabilizes laminin binding on tumor cells, involving surface receptors that normally do not take part in this interaction, This might explain the abundant clinical and experimental data suggesting a key role for the 67-kDa laminin receptor in the interaction between cancer cells and the basement membrane glycoprotein laminin during tumor invasion and metastasis.	IST NAZL TUMORI, DIV EXPT ONCOL E, I-20133 MILAN, ITALY; UNIV LIEGE, METASTASIS RES LAB, B-4000 LIEGE 1, BELGIUM	Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Liege			Tagliabue, Elda/B-9377-2017	Tagliabue, Elda/0000-0001-9877-2903				ALBELDA SM, 1993, LAB INVEST, V68, P4; BOTTINI C, 1993, INT J CANCER, V54, P261, DOI 10.1002/ijc.2910540217; CANEVARI S, 1985, J NATL CANCER I, V75, P831, DOI 10.1093/jnci/75.5.831; CASALINI P, 1991, INT J CANCER, V48, P284, DOI 10.1002/ijc.2910480222; CASTRONOVO V, 1991, CANCER RES, V51, P5672; CASTRONOVO V, 1991, J BIOL CHEM, V266, P20440; CASTRONOVO V, 1993, INVAS METAST, V13, P1; CASTRONOVO V, 1991, BIOCHEM BIOPH RES CO, V177, P177, DOI 10.1016/0006-291X(91)91965-F; CASTRONOVO V, 1990, AM J PATHOL, V137, P1373; CIOCE V, 1991, J NATL CANCER I, V83, P29, DOI 10.1093/jnci/83.1.29; DAVIS CM, 1991, EXP CELL RES, V193, P262, DOI 10.1016/0014-4827(91)90095-C; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; FELDMAN LE, 1991, CANCER RES, V51, P1065; GRAF J, 1987, CELL, V48, P989, DOI 10.1016/0092-8674(87)90707-0; GROSSO LE, 1991, BIOCHEMISTRY-US, V30, P3346, DOI 10.1021/bi00227a026; GUO NH, 1992, J BIOL CHEM, V267, P17743; HAND PH, 1985, CANCER RES, V45, P2713; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; Karpatova M, 1996, J CELL BIOCHEM, V60, P226; KLEINMAN HK, 1991, ARCH BIOCHEM BIOPHYS, V290, P320, DOI 10.1016/0003-9861(91)90547-V; KLEINMAN HK, 1988, P NATL ACAD SCI USA, V85, P1282, DOI 10.1073/pnas.85.4.1282; LIOTTA LA, 1986, ANNU REV BIOCHEM, V55, P1037, DOI 10.1146/annurev.biochem.55.1.1037; LIOTTA LA, 1983, LAB INVEST, V49, P636; LIOTTA LA, 1986, CANCER RES, V46, P1; MALINOFF HL, 1984, INT J CANCER, V33, P651, DOI 10.1002/ijc.2910330516; MARTIGNONE S, 1992, CLIN EXP METASTAS, V10, P379, DOI 10.1007/BF00133466; MARTIGNONE S, 1993, J NATL CANCER I, V85, P398, DOI 10.1093/jnci/85.5.398; MECHAM RP, 1991, J CELL BIOL, V113, P187, DOI 10.1083/jcb.113.1.187; MERCURIO AM, 1995, TRENDS CELL BIOL, V5, P419, DOI 10.1016/S0962-8924(00)89100-X; PELLEGRINI R, 1994, INT J CANCER, P116; PELLEGRINI R, 1995, BREAST CANCER RES TR, V35, P195, DOI 10.1007/BF00668209; RAMOS DM, 1990, CANCER RES, V50, P728; RAO CN, 1989, BIOCHEMISTRY-US, V28, P7476, DOI 10.1021/bi00444a047; ROMANOV V, 1994, CELL ADHES COMMUN, V2, P201, DOI 10.3109/15419069409004438; SONNENBERG A, 1988, NATURE, V336, P487, DOI 10.1038/336487a0; TARABOLETTI G, 1993, J NATL CANCER I, V85, P235, DOI 10.1093/jnci/85.3.235; VARANI J, 1983, AM J PATHOL, V111, P27; WANG KS, 1992, J VIROL, V66, P4992, DOI 10.1128/JVI.66.8.4992-5001.1992; WEWER UM, 1987, CANCER RES, V47, P5691; YOW HK, 1988, P NATL ACAD SCI USA, V85, P6394, DOI 10.1073/pnas.85.17.6394	40	43	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31179	31184		10.1074/jbc.271.49.31179	http://dx.doi.org/10.1074/jbc.271.49.31179			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940117	hybrid			2022-12-25	WOS:A1996VW68600028
J	Moss, JB; Olson, EN; Schwartz, RJ				Moss, JB; Olson, EN; Schwartz, RJ			The myogenic regulatory factor MRF4 represses the cardiac alpha-actin promoter through a negative-acting N-terminal protein domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; SKELETAL-MUSCLE; DNA-BINDING; TRANSGENIC MICE; BASIC REGION; GENE; EXPRESSION; MYOD; COMPLEX; CELLS	Cardiac alpha-actin is activated early during the development of embryonic skeletal muscle and cardiac myocytes. The gene product remains highly expressed in adult striated cardiac muscle yet is dramatically reduced in skeletal muscle, Activation and repression of cardiac alpha-actin gene activity in developing skeletal muscle correlates with changes in the relative content of the four myogenic regulatory factors, Cardiac alpha-actin promoter activity, assessed in primary chick myogenic cultures, was activated by endogenous myogenic regulatory factors but was inhibited in the presence of coexpressed MRF4. By exchanging N- and C-terminal domains of MRF4 and MyoD, the N terminus of MRF4 was identified as the mediator of repressive activity, revealing a novel negative regulatory role for MRFC. The relative ratios of myogenic regulatory factors may have fundamental roles in selecting specific muscle genes for activation and/or repression.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; UNIV TEXAS,SW MED CTR,HAMON CTR BASIC CANC RES,DALLAS,TX 75235	Baylor College of Medicine; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038401, P01HL049953] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL38401, P01 HL49953] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANERJEEBASU S, 1993, MOL CELL BIOL, V13, P7019, DOI 10.1128/MCB.13.11.7019; Biben C, 1996, DEV BIOL, V173, P200, DOI 10.1006/dbio.1996.0017; BRAUN T, 1990, NATURE, V346, P663, DOI 10.1038/346663a0; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P5675, DOI 10.1073/pnas.88.13.5675; CHAKRABORTY T, 1991, MOL CELL BIOL, V11, P6103, DOI 10.1128/MCB.11.12.6103; COX RD, 1992, DEV BIOL, V149, P228, DOI 10.1016/0012-1606(92)90279-P; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; FRENCH BA, 1991, MOL CELL BIOL, V11, P2439, DOI 10.1128/MCB.11.5.2439; GUNDERSEN K, 1995, MOL CELL BIOL, V15, P7127; HAYWARD LJ, 1986, J CELL BIOL, V102, P1485, DOI 10.1083/jcb.102.4.1485; HIGUCHI R, 1990, RECOMBINANT PCR PCR; HINTERBERGER TJ, 1991, DEV BIOL, V147, P144, DOI 10.1016/S0012-1606(05)80014-4; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LI H, 1993, NUCLEIC ACIDS RES, V21, P335, DOI 10.1093/nar/21.2.335; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; MAK KL, 1992, MOL CELL BIOL, V12, P4334, DOI 10.1128/MCB.12.10.4334; MOSS JB, 1994, J BIOL CHEM, V269, P12731; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; Olson EN, 1996, CELL, V85, P1, DOI 10.1016/S0092-8674(00)81073-9; OTT MO, 1991, DEVELOPMENT, V111, P1097; PESCE S, 1993, MOL CELL BIOL, V13, P7874, DOI 10.1128/MCB.13.12.7874; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; SAITOH O, 1993, NUCLEIC ACIDS RES, V21, P2503, DOI 10.1093/nar/21.10.2503; Sambrook J., 2002, MOL CLONING LAB MANU; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; SCHWARZ JJ, 1992, MOL CELL BIOL, V12, P266, DOI 10.1128/MCB.12.1.266; SKERJANC IS, 1994, DEV BIOL, V163, P125, DOI 10.1006/dbio.1994.1128; SMITH TH, 1994, J CELL BIOL, V127, P95, DOI 10.1083/jcb.127.1.95; VANDEKERCKHOVE J, 1986, J BIOL CHEM, V261, P1838; VANDOREN M, 1991, DEVELOPMENT, V113, P245; VENUTI JM, 1995, J CELL BIOL, V128, P563, DOI 10.1083/jcb.128.4.563; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; ZHANG W, 1995, GENE DEV, V9, P1388, DOI 10.1101/gad.9.11.1388	37	12	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31688	31694		10.1074/jbc.271.49.31688	http://dx.doi.org/10.1074/jbc.271.49.31688			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940190	hybrid			2022-12-25	WOS:A1996VW68600101
J	Chook, YM; Gish, GD; Kay, CM; Pai, EF; Pawson, T				Chook, YM; Gish, GD; Kay, CM; Pai, EF; Pawson, T			The Grb2-mSos1 complex binds phosphopeptides with higher affinity than Grb2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; EXCHANGE FACTOR SON; MAP KINASE PHOSPHORYLATION; TERMINAL SH3 DOMAIN; SIGNAL-TRANSDUCTION; PHOSPHOTYROSINE MOTIFS; TYROSINE KINASES; RAS; ACTIVATION; RECEPTOR	Epidermal growth factor (EGF) stimulation leads to autophosphorylation of the epidermal growth factor receptor (EGFR) and tyrosine phosphorylation of Shc. The Grb2 SH2 domain binds to Tyr(1068) of EGFR and Tyr(317) of Shc while its SH3 domains bind to mSos1. Therefore, EGF treatment potentially results in the formation of several multimeric signaling complexes, including EGFR-Grb2-mSos1, EGFR-Shc-Grb2-mSos1, and Shc-Grb2-mSos1, linking the receptor to activation of the Ras GTPase. We have purified Grb2, mSos1, and the Grb2-mSos1 complex to high homogeneity, and used these isolated proteins to obtain binding affinities of mSos1 for Grb2 and of either Grb2 or Grb2-mSos1 for phosphotyrosine-containing peptides. mSos1 bound Grb2 with a K-D of 0.4 mu M; the stoichiometry of the Grb2-mSos1 complex was 1:1. An EGFR-derived phosphopeptide bound Grb2 with a K-D of 0.7 mu M, whereas the Shc-derived phosphopeptide bound Grb2 with a K-D of 0.2 mu M. Since Grb2 exists in a stable complex with mSos1, and both proteins can exist in a constitutive complex in unstimulated cells, we performed phosphopeptide binding studies on the Grb2-mSos1 complex to gain a better understanding of binding events in the intact cell. Grb2-mSos1 bound to both EGFR- and Shc-derived phosphopeptides with higher affinities (K-D of 0.3 mu M and 31 nM, respectively) than Grb2 alone. These findings suggest that the proximity of mSos1 to Grb2 in the complex can influence the interactions of the Grb2 SH2 domain with phosphopeptides and raise the possibility that in the Grb2-mSos1 complex the SH2 and SH3 domains of Grb2 are not independent of each other but may be indirectly linked by mSos1.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, PROGRAM MOL BIOL & CANC, TORONTO, ON M5G 1X5, CANADA; UNIV TORONTO, DEPT BIOCHEM, TORONTO, ON M5S 1A8, CANADA; UNIV ALBERTA, DEPT BIOCHEM, MRC, GRP PROT STRUCT & FUNCT, EDMONTON, AB T6G 2H7, CANADA; PROT ENGN NETWORK CTR EXCELLENCE, EDMONTON, AB T6G 2H7, CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Alberta			Chook, Yuh Min/AAA-9549-2019; Pai, Emil/R-8908-2019; Pai, Emil F/D-2526-2013; Gish, Gerald D/C-7228-2017; Pawson, Tony J/E-4578-2013	Pai, Emil/0000-0002-1162-7242; 				BABUL J, 1969, ANAL BIOCHEM, V28, P216, DOI 10.1016/0003-2697(69)90172-9; BASU T, 1994, ONCOGENE, V9, P3483; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUDAY L, 1995, ONCOGENE, V11, P1327; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; GELIN BR, 1983, J MOL BIOL, V171, P489, DOI 10.1016/0022-2836(83)90042-6; GOUDREAU N, 1994, NAT STRUCT BIOL, V1, P898, DOI 10.1038/nsb1294-898; Grzesiek S, 1996, NAT STRUCT BIOL, V3, P340, DOI 10.1038/nsb0496-340; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; Lee CH, 1996, CELL, V85, P931, DOI 10.1016/S0092-8674(00)81276-3; LEMMON MA, 1994, J BIOL CHEM, V269, P31653; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MAIGNAN S, 1995, SCIENCE, V268, P291, DOI 10.1126/science.7716522; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; Porfiri E, 1996, J BIOL CHEM, V271, P5871, DOI 10.1074/jbc.271.10.5871; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; ROZAKISADCOCK M, 1995, ONCOGENE, V11, P1417; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SASAOKA T, 1994, J BIOL CHEM, V269, P32621; SATOH T, 1992, J BIOL CHEM, V267, P24149; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; TERASAWA H, 1994, NAT STRUCT BIOL, V1, P891, DOI 10.1038/nsb1294-891; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; WANG W, 1995, NAT GENET, V10, P294, DOI 10.1038/ng0795-294; Waters SB, 1996, J BIOL CHEM, V271, P18224, DOI 10.1074/jbc.271.30.18224; WITTEKIND M, 1994, BIOCHEMISTRY-US, V33, P13531, DOI 10.1021/bi00250a004; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	38	63	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30472	30478		10.1074/jbc.271.48.30472	http://dx.doi.org/10.1074/jbc.271.48.30472			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940013	hybrid			2022-12-25	WOS:A1996VV15800030
J	Fenton, SE; Groce, NS; Lee, DC				Fenton, SE; Groce, NS; Lee, DC			Characterization of the mouse epidermal growth factor promoter and 5'-flanking region - Role for an atypical TATA sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOPE FIBROMA VIRUS; FACTOR-ALPHA; MESSENGER-RNA; SUBMANDIBULAR-GLAND; FACTOR GENE; BINDING-SITE; EXPRESSION; TRANSCRIPTION; CELLS; LOCALIZATION	As a step toward delineating mechanisms that regulate its activity, we have characterized the mouse epidermal growth factor (EGF) promoter, Primer extension and S1 nuclease analyses identified prominent (+1/+2) and minor (+28) transcription start sites, with the dominant +1/+2 site located 33 bases downstream from a TTTAAA sequence, A restriction fragment that spanned these start sites and contained 390 base pairs of 6'-flanking sequence directed transcription from the +1/+2 site in vitro in the presence of HeLa cell nuclear extracts. Additionally, it promoted expression of a coupled luciferase reporter gene in transfected cell lines, The inclusion of additional 5'-flanking sequence either stimulated or inhibited luciferase expression depending on the cell line. Approximately 2 kilobases of EGF 5'-flanking sequence was determined and found to contain several motifs with partial homology to steroid hormone response elements. Despite this fact and evidence that EGF expression might be regulated by androgens in vitro, EGF promoter-luciferase constructs were not steroid-responsive in cells cotransfected with steroid receptor expression vectors. An oligonucleotide containing the aforementioned TTTAAA sequence specifically bound TATA-binding protein and TFILA in gel shift assays, and an EGF promoter-luciferase construct in which the core TA dinucleotide was mutated to CG was not active in transfected cells. These data suggest that the TTTAAA sequence functions as an atypical TATA box.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT MICROBIOL & IMMUNOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill			Chesters, Heather/C-6089-2009		NCI NIH HHS [CA63775, CA43793, CA09156] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009156, F32CA063775, R01CA043793] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER AJ, 1993, MOL CELL BIOL, V13, P6326, DOI 10.1128/MCB.13.10.6326; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BARTHE PL, 1974, ENDOCRINOLOGY, V95, P1019, DOI 10.1210/endo-95-4-1019; BARTON CM, 1991, J PATHOL, V163, P111, DOI 10.1002/path.1711630206; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BLASBAND AJ, 1990, MOL CELL BIOL, V10, P2111, DOI 10.1128/MCB.10.5.2111; BULLOCK LP, 1975, ENDOCRINOLOGY, V97, P189, DOI 10.1210/endo-97-1-189; CARPENTER G, 1990, PEPTIDE GROWTH FACTO, V1; CHANG W, 1987, MOL CELL BIOL, V7, P535, DOI 10.1128/MCB.7.1.535; CHANG W, 1990, VIROLOGY, V179, P926, DOI 10.1016/0042-6822(90)90170-V; CHAPDELAINE P, 1991, DNA CELL BIOL, V10, P49, DOI 10.1089/dna.1991.10.49; COHEN S, 1962, J BIOL CHEM, V237, P1555; DIAUGUSTINE RP, 1988, ENDOCRINOLOGY, V122, P2355, DOI 10.1210/endo-122-6-2355; ELDER JB, 1978, NATURE, V271, P466, DOI 10.1038/271466a0; FENTON SE, 1991, BIOCHEM BIOPH RES CO, V181, P1063, DOI 10.1016/0006-291X(91)92045-L; FOWLER JE, 1988, J UROLOGY, V139, P857, DOI 10.1016/S0022-5347(17)42662-0; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; GRAY A, 1983, NATURE, V303, P722, DOI 10.1038/303722a0; GREGORY H, 1975, NATURE, V257, P325, DOI 10.1038/257325a0; GUBITS RM, 1986, ENDOCRINOLOGY, V119, P1382, DOI 10.1210/endo-119-3-1382; GUZOWSKI JF, 1993, J VIROL, V67, P5098, DOI 10.1128/JVI.67.9.5098-5108.1993; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HOSOI K, 1992, ENDOCRINOLOGY, V130, P1044, DOI 10.1210/en.130.2.1044; ISAACS JT, 1991, S GROWTH FACT REPROD; KIM Y, 1995, BIOL CHEM H-S, V376, P431; KOHLER M, 1989, ANTICANCER RES, V9, P1537; LEE DC, 1995, PHARMACOL REV, V47, P51; LUND SD, 1991, MOL CELL BIOL, V11, P5426, DOI 10.1128/MCB.11.11.5426; MORRELL JI, 1987, J HISTOCHEM CYTOCHEM, V35, P1053, DOI 10.1177/35.10.3624850; MULLICK J, 1995, BIOCHEMISTRY-US, V34, P13729, DOI 10.1021/bi00042a003; PASCALL JC, 1988, J MOL ENDOCRINOL, V1, P5, DOI 10.1677/jme.0.0010005; PASCALL JC, 1989, J ENDOCRINOL, V121, P501, DOI 10.1677/joe.0.1210501; PIERCE AJ, 1992, NUCLEIC ACIDS RES, V20, P6583, DOI 10.1093/nar/20.24.6583; PRIGENT S A, 1992, Progress in Growth Factor Research, V4, P1, DOI 10.1016/0955-2235(92)90002-Y; RALL LB, 1985, NATURE, V313, P228, DOI 10.1038/313228a0; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; ROCHE PJ, 1992, MOL ENDOCRINOL, V6, P2229, DOI 10.1210/me.6.12.2229; SALIDO EC, 1990, DIFFERENTIATION, V45, P38, DOI 10.1111/j.1432-0436.1990.tb00454.x; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASADA R, 1993, BIOCHEM BIOPH RES CO, V190, P1173, DOI 10.1006/bbrc.1993.1173; SCOTT J, 1983, SCIENCE, V221, P236, DOI 10.1126/science.6602382; SHIN TH, 1995, MOL CELL BIOL, V15, P4694; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SNEDEKER SM, 1991, P NATL ACAD SCI USA, V88, P276, DOI 10.1073/pnas.88.1.276; SUGIYAMA K, 1990, CANCER, V63, P1557; TAVIANINI MA, 1984, J BIOL CHEM, V259, P1798; TODARO GJ, 1976, NATURE, V264, P26, DOI 10.1038/264026a0; TODARO GJ, 1978, CANCER RES, V38, P4147; TOYODA H, 1995, J BIOL CHEM, V270, P7495, DOI 10.1074/jbc.270.13.7495; YAMAHARA M, 1988, VIRCHOWS ARCH A, V412, P301, DOI 10.1007/BF00750255	53	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30870	30878		10.1074/jbc.271.48.30870	http://dx.doi.org/10.1074/jbc.271.48.30870			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940071	hybrid			2022-12-25	WOS:A1996VV15800088
J	Gessner, JE; Grussenmeyer, T; Dumbsky, M; Schmidt, RE				Gessner, JE; Grussenmeyer, T; Dumbsky, M; Schmidt, RE			Separate promoters from proximal and medial control regions contribute to the natural killer cell-specific transcription of the human Fc gamma RIII-A (CD16-A) receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOMERULAR MESANGIAL CELLS; BINDING-SITE; EXPRESSION; ACTIVATION; IGG; NEUTROPHILS; IDENTIFICATION; CHAIN; ACID; LINE	The molecular events governing the differentiation pathway of natural killer (Mt) cells are not well understood. The phenotype of mature NK cells is specified by the expression of the low affinity Fc receptor for IgG (human Fc gamma RIII, CD16) encoded by the Fc gamma RIII-A gene. Here we report that the Pprox promoter (-198/-10) of Fc gamma RIII-A stimulated by its own intron enhancer (+10/+712) was only one of the cis-elements that target the expression of a reporter gene in the immature NK cell line, YT. The transcription start sites of the Fc gamma RIII-A a2/3 and a5/6 splice alternatives in NK cells were mapped to the medial -1817/-850 Fc gamma RIII-A control region. Two promoters, Pmedl (-942/-850) and Pmed2 (-1376/-1123) resided in this region and controlled for the initiation of these transcript classes encoding the known Fc gamma RIII-A receptor protein. Deletion mapping studies demonstrated that the 93 base pairs -942/-850 Pmedl sequence was sufficient to confer cell type specific expression in YT cells. The 5' end of Pmedl (-942 to -921) was required for full promoter function indicating the presence of an important sequence motif recognized by a YT-specific factor. Our data suggest that this motif might be a useful tool for subsequent identification of putative transcription factors uniquely active in YT and Nh cells.			Gessner, JE (corresponding author), HANNOVER MED SCH,DEPT CLIN IMMUNOL,KONSTANTY GUTSCHOW STR 8,D-30625 HANNOVER,GERMANY.		Grussenmeyer, Thomas/B-9859-2009	Grussenmeyer, Thomas/0000-0002-6236-9976				ANDERSON P, 1990, P NATL ACAD SCI USA, V87, P2274, DOI 10.1073/pnas.87.6.2274; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEVERS HC, 1993, IMMUNOL TODAY, V14, P591, DOI 10.1016/0167-5699(93)90198-T; COLLINS SJ, 1987, BLOOD, V70, P1233; GESSNER JE, 1995, IMMUN INFEKT, V23, P67; GESSNER JE, 1995, IMMUNOBIOLOGY, V193, P341, DOI 10.1016/S0171-2985(11)80564-4; GESSNER JE, 1995, J BIOL CHEM, V270, P1350, DOI 10.1074/jbc.270.3.1350; GUMPERZ JE, 1995, NATURE, V378, P245, DOI 10.1038/378245a0; HOFFMEYER F, 1995, J IMMUNOL, V155, P4016; HUNDT M, 1992, EUR J IMMUNOL, V22, P811, DOI 10.1002/eji.1830220327; KOIZUMI H, 1993, MOL CELL BIOL, V13, P6690, DOI 10.1128/MCB.13.11.6690; KUROSAKI T, 1989, NATURE, V342, P805, DOI 10.1038/342805a0; LEIDEN JM, 1992, IMMUNOL TODAY, V13, P22, DOI 10.1016/0167-5699(92)90200-Q; Li M, 1996, J EXP MED, V183, P1259, DOI 10.1084/jem.183.3.1259; PELTZ GA, 1989, P NATL ACAD SCI USA, V86, P1013, DOI 10.1073/pnas.86.3.1013; PHILLIPS JH, 1991, EUR J IMMUNOL, V21, P895, DOI 10.1002/eji.1830210406; RADEKE HH, 1994, J IMMUNOL, V153, P1281; RAVETCH JV, 1989, J EXP MED, V170, P481, DOI 10.1084/jem.170.2.481; ROBERTSON MJ, 1990, BLOOD, V76, P2421; STOCKL J, 1995, J IMMUNOL, V154, P5452; Tamm A, 1996, J BIOL CHEM, V271, P3659; UCIECHOWSKI P, 1992, EUR J IMMUNOL, V22, P1635, DOI 10.1002/eji.1830220643; UCIECHOWSKI P, 1992, IMMUNOBIOLOGY, V165, P28; VANDEWINKEL JGJ, 1993, IMMUNOL TODAY, V14, P215, DOI 10.1016/0167-5699(93)90166-I; WERFEL T, 1989, J IMMUNOL, V142, P1102; YODOI J, 1985, J IMMUNOL, V134, P1623; ZHOU MJ, 1994, J CELL BIOL, V125, P1407, DOI 10.1083/jcb.125.6.1407	27	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30755	30764		10.1074/jbc.271.48.30755	http://dx.doi.org/10.1074/jbc.271.48.30755			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940055	hybrid			2022-12-25	WOS:A1996VV15800072
J	Furlong, EEM; Keon, NK; Thornton, FD; Rein, T; Martin, F				Furlong, EEM; Keon, NK; Thornton, FD; Rein, T; Martin, F			Expression of a 74-kDa nuclear factor 1 (NF1) protein is induced in mouse mammary gland involution - Involution-enhanced occupation of a twin NF1 binding element in the testosterone-repressed prostate message-2/clustertin promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER-SPECIFIC TRANSCRIPTION; ADENOVIRUS DNA-REPLICATION; HORMONE PROXIMAL SILENCER; FACTOR-I FAMILY; GENE-EXPRESSION; EXTRACELLULAR-MATRIX; CELL-DEATH; EPITHELIAL-CELLS; SULFATED GLYCOPROTEIN-2; BASEMENT-MEMBRANE	Testosterone repressed prostate message-2 (TRPM-2)/clusterin gene expression is rapidly induced in early involution of the mouse mammary gland, after weaning, and in the rat ventral prostate, after castration, A search for involution-enhanced DNaseI footprints in the proximal mouse TRPM-2/clusterin gene promoter led to the identification and characterization (by DNase I footprinting and EMSA) of a twin nuclear factor 1 (NF1) binding element at -356/-309, relative to the proposed transcription start site; nuclear extracts from 2-day involuting mouse mammary gland showed an enhanced footprint over the proximal NF1 element; extracts from involuting prostate showed enhanced occupancy of both NF1 binding elements. Subsequent EMSA and Western analysis led to the detection of a 74-kDa NF1 protein whose expression is triggered in early involution in the mouse mammary gland; such an induced protein is not found in the involuting rat ventral prostate, This protein was not found in lactation where three other NF1 proteins of 114, 68, and 46 kDa were detected. Reiteration of the epithelial cell apoptosis associated with early mammary gland involution, in vitro, in a primary cell culture system, triggered the appearance of the 74-kDa NF1, Overlaying the cells with laminin-rich extracellular matrix suppressed the apoptosis and the expression of the 74-kDa NF1 and, in the presence of lactogenic hormones, initiated milk protein gene expression and the expression of two of the lactation-associated NF1 proteins (68 and 46 kDa), This study, thus, identifies for the first time the occurrence of a switch in expression of different members of the family of NF1 transcription factors as mammary epithelial cells move from the differentiated to the involution/apoptotic state, and it is likely that the involution-specific 74-kDa NF1 accounts for the enhanced NF1 footprint detected on the TRPM-2/clusterin promoter with extracts of mouse mammary gland.	NATL UNIV IRELAND UNIV COLL DUBLIN,DEPT PHARMACOL,DUBLIN 4,IRELAND; NATL UNIV IRELAND UNIV COLL DUBLIN,CTR BIOTECHNOL,DUBLIN 4,IRELAND; UNIV MUNICH,INST BIOCHEM,D-8000 MUNICH 2,GERMANY	University College Dublin; University College Dublin; University of Munich				Furlong, Eileen/0000-0002-9544-8339; Rein, Theo/0000-0003-2850-4289				ADAMS AD, 1995, J BIOL CHEM, V270, P6975, DOI 10.1074/jbc.270.12.6975; AMEMIYA K, 1992, J BIOL CHEM, V267, P14204; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; APT D, 1994, NUCLEIC ACIDS RES, V22, P3825, DOI 10.1093/nar/22.19.3825; APT D, 1993, J VIROL, V67, P4455, DOI 10.1128/JVI.67.8.4455-4463.1993; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; ARENDS MJ, 1990, AM J PATHOL, V136, P593; AUSUBEL FM, 1987, CURRENT PROTOCOLS MO, V2; Ausubel FM, 1987, CURRENT PROTOCOLS MO, V1-5; BARCELLOSHOFF MH, 1989, DEVELOPMENT, V105, P223; BETTUZZI S, 1991, BIOCHEM BIOPH RES CO, V175, P810, DOI 10.1016/0006-291X(91)91637-R; BLUM JL, 1988, J CELL PHYSIOL, V135, P13, DOI 10.1002/jcp.1041350103; BORGMEYER U, 1984, NUCLEIC ACIDS RES, V12, P4295, DOI 10.1093/nar/12.10.4295; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BUTTYAN R, 1988, MOL ENDOCRINOL, V2, P650, DOI 10.1210/mend-2-7-650; EARNSHAW WC, 1995, TRENDS CELL BIOL, V5, P217, DOI 10.1016/S0962-8924(00)89006-6; ENGLISH HF, 1987, PROSTATE, V11, P229, DOI 10.1002/pros.2990110304; EUL J, 1989, EMBO J, V8, P83, DOI 10.1002/j.1460-2075.1989.tb03351.x; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GOUNARI F, 1990, EMBO J, V9, P559, DOI 10.1002/j.1460-2075.1990.tb08143.x; GOYAL N, 1990, MOL CELL BIOL, V10, P1041, DOI 10.1128/MCB.10.3.1041; GRAVES RA, 1991, GENE DEV, V5, P428, DOI 10.1101/gad.5.3.428; GRISWOLD MD, 1986, BIOCHEMISTRY-US, V25, P7265, DOI 10.1021/bi00371a003; GURLEY LR, 1973, BIOCHEMISTRY-US, V12, P237, DOI 10.1021/bi00726a010; HAY RT, 1985, EMBO J, V1, P421; HENNIGHAUSEN LG, 1982, EUR J BIOCHEM, V125, P131, DOI 10.1111/j.1432-1033.1982.tb06660.x; INOUE T, 1990, J BIOL CHEM, V265, P19065; IVANOV V I, 1990, Molekulyarnaya Biologiya (Moscow), V24, P1605; JACKSON DA, 1993, MOL CELL BIOL, V13, P2401, DOI 10.1128/MCB.13.4.2401; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; KAWAMURA H, 1993, BIOCHEM BIOPH RES CO, V192, P1424, DOI 10.1006/bbrc.1993.1575; KIRSZBAUM L, 1989, EMBO J, V8, P711, DOI 10.1002/j.1460-2075.1989.tb03430.x; LEE EYH, 1984, J CELL BIOL, V98, P8831; LI S, 1995, MOL CELL BIOL, V15, P2063; LI S, 1994, J BIOL CHEM, V269, P14235; LUBON H, 1987, NUCLEIC ACIDS RES, V15, P2103, DOI 10.1093/nar/15.5.2103; LUBON H, 1988, BIOCHEM J, V256, P391, DOI 10.1042/bj2560391; LUND RL, 1996, DEVELOPMENT CAMB, V122, P181; MARTI A, 1994, ONCOGENE, V9, P1213; MINK S, 1992, MOL CELL BIOL, V12, P4906, DOI 10.1128/MCB.12.11.4906; MUL YM, 1992, EMBO J, V11, P751, DOI 10.1002/j.1460-2075.1992.tb05108.x; NEBL G, 1994, J BIOL CHEM, V269, P7371; NOVAK A, 1992, J BIOL CHEM, V267, P12986; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; Rajput B, 1996, J BIOL CHEM, V271, P5131, DOI 10.1074/jbc.271.9.5131; REIFELMILLER AE, 1994, J BIOL CHEM, V269, P23861; REIN T, 1995, J BIOL CHEM, V270, P19643, DOI 10.1074/jbc.270.33.19643; ROBIDOUX S, 1992, MOL CELL BIOL, V12, P3796, DOI 10.1128/MCB.12.9.3796; ROSKELLEY CD, 1995, CURR OPIN CELL BIOL, V7, P736, DOI 10.1016/0955-0674(95)80117-0; ROY RJ, 1994, EUR J BIOCHEM, V225, P419, DOI 10.1111/j.1432-1033.1994.00419.x; ROY RJ, 1994, EUR J BIOCHEM, V219, P799, DOI 10.1111/j.1432-1033.1994.tb18560.x; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SAWCZUK IS, 1989, KIDNEY INT, V35, P1315, DOI 10.1038/ki.1989.128; SENSIBAR JA, 1991, ENDOCRINOLOGY, V128, P2091, DOI 10.1210/endo-128-4-2091; STRANGE R, 1992, DEVELOPMENT, V115, P49; STREULI CH, 1995, J CELL BIOL, V129, P591, DOI 10.1083/jcb.129.3.591; STREULI CH, 1990, J CELL BIOL, V110, P1405; STREULI CH, 1995, J BIOL CHEM, V270, P21639, DOI 10.1074/jbc.270.37.21639; STREULI CH, 1991, J CELL BIOL, V115, P1383, DOI 10.1083/jcb.115.5.1383; STUDZINSKI GP, 1995, CELL GROWTH APOPTOSI, P132; SZABO P, 1995, J BIOL CHEM, V270, P10212, DOI 10.1074/jbc.270.17.10212; TALHOUK RS, 1992, J CELL BIOL, V118, P1271, DOI 10.1083/jcb.118.5.1271; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WALKER NI, 1989, AM J ANAT, V185, P19, DOI 10.1002/aja.1001850104; WASTON CJ, 1991, NUCLEIC ACIDS RES, V19, P6603; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WONG P, 1994, EUR J BIOCHEM, V221, P917, DOI 10.1111/j.1432-1033.1994.tb18807.x; WONG P, 1993, J BIOL CHEM, V268, P5021; YULEE LY, 1986, NUCLEIC ACIDS RES, V14, P1883, DOI 10.1093/nar/14.4.1883	70	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29688	29697		10.1074/jbc.271.47.29688	http://dx.doi.org/10.1074/jbc.271.47.29688			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939902	hybrid			2022-12-25	WOS:A1996VU52500030
J	Nicolini, G; Miloso, M; Moroni, MC; Beguinot, L; Scotto, L				Nicolini, G; Miloso, M; Moroni, MC; Beguinot, L; Scotto, L			Post-transcriptional control regulates transforming growth factor alpha in the human carcinoma KB cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIH 3T3 CELLS; MESSENGER-RNA; EGF-RECEPTOR; AUTOCRINE GROWTH; GENE-EXPRESSION; PHORBOL ESTER; INTERLEUKIN-3; PHENOTYPE; CANCER	Expression of epidermal growth factor receptor (EGF-R) antisense RNA results in a drastic reduction of EGF-R levels in the human carcinoma KB cell line and induces a reversion of their transformed phenotype (Moroni, M. C., Willingham, M. C., and Beguinot, L. (1992) J. Biol. Chem. 267, 2714-2722), We used parental and EGF-R antisense KB clones as a genetic system to study, in the same cell line, the role of transforming growth factor alpha (TGF-alpha) in the establishment and maintenance of the transformed phenotype, KB cells produce TGF-alpha mRNA, and their conditioned medium is able to sustain growth of antisense cells, mimicking the effect of exogenous EGF or TGF-alpha. In antisense cells there is a marked reduction of TGF-alpha mRNA steady-state levels. In addition, the decrease in TGF-alpha parallels the levels of residual EGF-R in the various antisense clones, indicating a direct correlation between receptors and growth factor levels, The addition of exogenous TGF-alpha (10 ng/ml) to antisense clones induces TGF-alpha levels. The half-life of TGF-alpha mRNA is 40-60 min in antisense cells and more than 8 h in parental KB cells, as determined by actinomycin D decay curves. This result indicates a predominant regulation of TGF-alpha mRNA at the post-transcriptional level. Nuclear Min-on experiments show that there is only a marginal effect at the transcriptional level, We conclude that the autocrine loop responsible for the transformed phenotype of the human carcinoma KB cell line is dependent on both elevated levels of EGF-R and the presence of TGF-alpha, In addition, TGF-alpha is able to induce its own mRNA via a signal due to activation of the EGF-R acting predominantly at the post-transcriptional level.	HOSP SAN RAFFAELE,DIBIT,ONCOL MOL LAB,I-20132 MILAN,ITALY; HOSP SAN RAFFAELE,CNR,IST NEUROSCI & BIOIMMAGINI,I-20132 MILAN,ITALY	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Consiglio Nazionale delle Ricerche (CNR); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele			Miloso, Mariarosaria/AAC-7373-2021; Moroni, Maria Cristina/H-7044-2018; NIcolini, Gabriella/AAK-9155-2020	Moroni, Maria Cristina/0000-0003-2409-5764; NICOLINI, GABRIELLA/0000-0002-6241-4538				AUSBEL FM, 1994, CURRENT PROTOCOLS MO, V4; AUSBEL FM, 1994, CURRENT PROTOCOLS MO, V1; BEGUINOT L, 1986, J BIOL CHEM, V261, P1801; BJORGE JD, 1989, J BIOL CHEM, V264, P4021; BROWDER TM, 1989, MOL CELL BIOL, V9, P204, DOI 10.1128/MCB.9.1.204; CARE A, 1986, EMBO J, V5, P905, DOI 10.1002/j.1460-2075.1986.tb04302.x; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; COFFEY RJ, 1992, CELL GROWTH DIFFER, V3, P347; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; CUTITTA F, 1985, NATURE, V316, P823; DERYNCK R, 1992, ADV CANCER RES, V58, P27, DOI 10.1016/S0065-230X(08)60289-4; DERYNCK R, 1987, CANCER RES, V47, P702; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DUNBAR CE, 1989, SCIENCE, V245, P1493, DOI 10.1126/science.2789432; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; IMANISHI K, 1989, BRIT J CANCER, V59, P761, DOI 10.1038/bjc.1989.159; JINNO Y, 1988, NUCLEIC ACIDS RES, V16, P4957, DOI 10.1093/nar/16.11.4957; JU WD, 1991, NEW BIOL, V3, P380; MALDEN LT, 1989, INT J CANCER, V43, P380, DOI 10.1002/ijc.2910430305; Maniatis T, 1989, DECONTAMINATION DILU; MILOSO M, 1995, J BIOL CHEM, V270, P19557, DOI 10.1074/jbc.270.33.19557; MORONI MC, 1992, J BIOL CHEM, V267, P2714; MUELLER SG, 1989, MOL ENDOCRINOL, V3, P976, DOI 10.1210/mend-3-6-976; NISTER M, 1988, CANCER RES, V48, P3910; PAULSSON Y, 1987, NATURE, V328, P715, DOI 10.1038/328715a0; QIAN JF, 1993, GENE, V132, P291; SIDDIQI I, 1995, BIOCHEM BIOPH RES CO, V215, P309, DOI 10.1006/bbrc.1995.2467; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; TAKEKURA N, 1991, INT J CANCER, V47, P938, DOI 10.1002/ijc.2910470626; TODD R, 1989, CARCINOGENESIS, V10, P1553, DOI 10.1093/carcin/10.8.1553; VANDEVIJVER MJ, 1991, J BIOL CHEM, V266, P7503; VANOBBERGHENSCHILLING E, 1988, J BIOL CHEM, V263, P7741; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; WARNER SJC, 1987, J EXP MED, V165, P1316, DOI 10.1084/jem.165.5.1316; WATANABE T, 1994, J BIOL CHEM, V269, P9966; YOSHIDA K, 1990, JPN J CANCER RES, V81, P43, DOI 10.1111/j.1349-7006.1990.tb02505.x	37	16	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30290	30296		10.1074/jbc.271.47.30290	http://dx.doi.org/10.1074/jbc.271.47.30290			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939983	hybrid			2022-12-25	WOS:A1996VU52500111
J	Zhou, JQ; Tan, CK; So, AG; Downey, KM				Zhou, JQ; Tan, CK; So, AG; Downey, KM			Purification and characterization of the catalytic subunit of human DNA polymerase delta expressed in baculovirus-infected insect cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; NUCLEAR ANTIGEN; AUXILIARY PROTEIN; CALF THYMUS; REPLICATION; GENE; EPSILON	The catalytic subunit of human DNA polymerase delta has been overexpressed in insect cells by a recombinant baculovirus. The recombinant protein has a M(r) = similar to 125,000 and is recognized by polyclonal antisera against N-terminal and C-terminal peptides of the catalytic subunit of human DNA polymerase delta, The recombinant protein was purified to near homogeneity (approximately 1200-fold) from insect cells by chromatography on DEAE-cellulose, phosphocellulose, heparin-agarose, and single-stranded DNA-cellulose, The purified protein had both DNA polymerase and 3'-5' exonuclease activities. The properties of the recombinant catalytic subunit were compared with those of the native heterodimeric DNA polymerase delta isolated from fetal calf thymus, and the enzymes were found to differ in several respects. Although the native heterodimer is equally active with either Mn2+ or Mg2+ as divalent cation activator, the recombinant catalytic subunit is approximately 5-fold more active in Mn2+ than in Mg2+. The most striking difference between the two proteins is the response to the proliferating cell nuclear antigen (PCNA). The activity and processivity of native DNA polymerase delta are markedly stimulated by PCNA whereas it has no effect on the recombinant catalytic subunit. These results suggest that the small subunit of DNA polymerase delta is essential for functional interaction with PCNA.	UNIV MIAMI,SCH MED,DEPT MED,MIAMI,FL 33101; UNIV MIAMI,SCH MED,DEPT BIOCHEM & MOL BIOL,MIAMI,FL 33101	University of Miami; University of Miami					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026206] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK26206] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; Arroyo MP, 1996, J BIOL CHEM, V271, P15971, DOI 10.1074/jbc.271.27.15971; BAUER GA, 1988, P NATL ACAD SCI USA, V85, P7506, DOI 10.1073/pnas.85.20.7506; BOULET A, 1989, EMBO J, V8, P1849, DOI 10.1002/j.1460-2075.1989.tb03580.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN WC, 1993, J BIOL CHEM, V268, P21706; BROWN WC, 1993, J BIOL CHEM, V268, P982; BUDD ME, 1993, MOL CELL BIOL, V13, P496, DOI 10.1128/MCB.13.1.496; CHANG LS, 1995, GENOMICS, V28, P411, DOI 10.1006/geno.1995.1169; Chiang CS, 1995, GENE, V166, P237, DOI 10.1016/0378-1119(95)00567-6; CHIANG CS, 1993, P NATL ACAD SCI USA, V90, P9105, DOI 10.1073/pnas.90.19.9105; CHUNG DW, 1991, P NATL ACAD SCI USA, V88, P11197, DOI 10.1073/pnas.88.24.11197; Downey KM, 1995, METHOD ENZYMOL, V262, P84; GOULIAN M, 1990, J BIOL CHEM, V265, P16402; HINDGES R, 1995, GENE, V158, P241, DOI 10.1016/0378-1119(95)00065-E; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MYWT, 1991, J BIOL CHEM, V266, P2423; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; McConnell M, 1996, BIOCHEMISTRY-US, V35, P8268, DOI 10.1021/bi9530649; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; Sambrook J., 2002, MOL CLONING LAB MANU; SIMON M, 1991, EMBO J, V10, P2165, DOI 10.1002/j.1460-2075.1991.tb07751.x; TAN CK, 1986, J BIOL CHEM, V261, P2310; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; YANG CL, 1992, NUCLEIC ACIDS RES, V20, P735, DOI 10.1093/nar/20.4.735; ZENG XR, 1994, J BIOL CHEM, V269, P24027; ZHANG P, 1995, J BIOL CHEM, V270, P7993, DOI 10.1074/jbc.270.14.7993; Zlotkin T, 1996, EMBO J, V15, P2298, DOI 10.1002/j.1460-2075.1996.tb00583.x	29	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29740	29745		10.1074/jbc.271.47.29740	http://dx.doi.org/10.1074/jbc.271.47.29740			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939909	hybrid			2022-12-25	WOS:A1996VU52500037
J	Zhu, H; Ownby, DW; Riggs, CK; Nolasco, NJ; Stoops, JK; Riggs, AF				Zhu, H; Ownby, DW; Riggs, CK; Nolasco, NJ; Stoops, JK; Riggs, AF			Assembly of the gigantic hemoglobin of the earthworm Lumbricus terrestris - Roles of subunit equilibria, non-globin linker chains, and valence of the heme iron	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORSE SPLEEN APOFERRITIN; POTATO BETA-AMYLASE; BRILLIANT BLUE-R; EXTRACELLULAR HEMOGLOBIN; LIGHT-SCATTERING; ORNITHINE DECARBOXYLASE; OXYGENATION PROPERTIES; BOVINE THYROGLOBULIN; TETRAMERIC COMPONENT; CONFORMATIONAL DRIFT	The extracellular hemoglobin of the earthworm Lumbricus terrestris has four major kinds of O-2-binding chains: a, b, and c (forming a disulfide-linked trimer), and chain d. Non-heme, non-globin structural chains, ''linkers,'' are also present, Light-scattering techniques have been used to show that the ferrous CO saturated abe trimer and chain d form an (abcd)(4) complex of 285 kDa at neutral pH. Formation of the full-sized 4-MDa molecule requires the addition of linker chains in the proportion of two linkers per (abcd)(4) and occurs much more rapidly in the presence of 10 mM calcium. This stoichiometry is supported not only by direct quantitative analysis of the intact hemoglobin but also by the fact that the addition of 50% of the proposed stoichiometric quantity of linkers results in the conversion of 50% of the (abcd)(4) to full-sized molecules, Isolated CO-saturated abe trimers self-associate to (abc)(2) and higher aggregates up to an apparent limit of (abc)(10) similar to 550 kDa, The CO-saturated chain d forms dimers, (d)(2), and tetramers, (d)(4). Oxidation of the (abcd)(4) complex with ferricyanide causes complete dissociation of chain d from the abe trimer, but addition of CN- maintains the (abcd)(4) complex, Valence hybrids have also been studied, The ferrous CO-saturated abe trimer and met (ferric) chain d also associate to form (abcd)(4), but the met abe trimer and ferrous CO-saturated chain d do not, Oxidation of the abc trimer and chain d to the ferric form causes the formation of a characteristic hemichrome spectrum with a maximum at 565 nm and a shoulder near 530 nm, These results show that interactions between the abe trimer and chain d are strongly dependent on the ligand and valence state of the heme iron, Light-scattering measurements reveal that oxidation of the intact Hb produces a significant drop In molecular mass from 4.1 to 3.6 MDa. Inclusion of CN- prevents this drop, These experiments indicate that oxidation causes the Hb to shed subunits, The observations provide an explanation for the wide variations in the molecular mass of L. terrestris Hb that have been observed previously.	UNIV TEXAS,DEPT ZOOL,AUSTIN,TX 78712; UNIV TEXAS,HLTH SCI CTR,DEPT PATHOL & LAB MED,HOUSTON,TX 77030	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Health Science Center Houston					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046278, R01GM035847] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 35847, GM 46278] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ackers G K, 1970, Adv Protein Chem, V24, P343, DOI 10.1016/S0065-3233(08)60245-4; AROSIO P, 1978, J BIOL CHEM, V253, P4451; ASCOLI F, 1978, J MOL BIOL, V119, P191, DOI 10.1016/0022-2836(78)90433-3; BALL EH, 1986, ANAL BIOCHEM, V155, P23, DOI 10.1016/0003-2697(86)90218-6; BENESCH R, 1964, SCIENCE, V144, P68, DOI 10.1126/science.144.3614.68; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3018; BICKAR D, 1984, J BIOL CHEM, V259, P777; BOFFI A, 1991, J BIOL CHEM, V266, P17898; CANN JR, 1970, INTERACTING MACROMOL, P249; COBB JA, 1992, J BIOL CHEM, V267, P1183; COHN EJ, 1943, PROTEINS AMINO ACIDS, P340; CRICHTON RR, 1973, BIOCHEM J, V131, P855, DOI 10.1042/bj1310855; DAVID MM, 1974, J MOL BIOL, V87, P89, DOI 10.1016/0022-2836(74)90561-0; EDELHOCH H, 1960, J BIOL CHEM, V235, P1326; ELBAUM D, 1974, BIOCHEMISTRY-US, V13, P1268, DOI 10.1021/bi00703a033; FARMER TB, 1991, BIOL MASS SPECTROM, V20, P796, DOI 10.1002/bms.1200201209; FUSHITANI K, 1986, J BIOL CHEM, V261, P8414; FUSHITANI K, 1991, J BIOL CHEM, V266, P10275; GARLICK RL, 1979, ARCH BIOCHEM BIOPHYS, V194, P13, DOI 10.1016/0003-9861(79)90590-3; GIBSON QH, 1969, J BIOL CHEM, V244, P4668; GOSS DJ, 1975, BIOCHEMISTRY-US, V14, P5461, DOI 10.1021/bi00696a012; GROS G, 1978, BIOPHYS J, V22, P453, DOI 10.1016/S0006-3495(78)85499-X; GUIRARD BM, 1980, J BIOL CHEM, V255, P5960; HACKERT ML, 1994, J BACTERIOL, V176, P7391, DOI 10.1128/JB.176.23.7391-7394.1994; HARRINGT.JP, 1973, BIOCHIM BIOPHYS ACTA, V328, P61, DOI 10.1016/0005-2795(73)90330-9; HERSKOVITS TT, 1986, BIOCHEMISTRY-US, V25, P931, DOI 10.1021/bi00352a029; HERSKOVITS TT, 1975, BIOCHEMISTRY-US, V14, P4964, DOI 10.1021/bi00693a027; HEUSTERSPREUTE M, 1981, FEBS LETT, V129, P322, DOI 10.1016/0014-5793(81)80193-7; HOARE RJ, 1975, NATURE, V255, P653, DOI 10.1038/255653a0; KAPP OH, 1984, J BIOL CHEM, V259, P628; KEILIN D, 1961, NATURE, V190, P717, DOI 10.1038/190717a0; KING L, 1986, BIOCHEMISTRY-US, V25, P3632, DOI 10.1021/bi00360a023; Kruis A, 1936, Z PHYS CHEM B-CHEM E, V34, P13; Martin PD, 1996, J MOL BIOL, V255, P170, DOI 10.1006/jmbi.1996.0014; Martin PD, 1996, J MOL BIOL, V255, P154, DOI 10.1006/jmbi.1996.0013; MCMEEKIN TL, 1962, BIOCHEM BIOPH RES CO, V7, P151, DOI 10.1016/0006-291X(62)90165-1; MERCKEN L, 1985, NATURE, V316, P647, DOI 10.1038/316647a0; MILLER KI, 1988, BIOCHEMISTRY-US, V27, P7282, DOI 10.1021/bi00419a016; MITCHELL DT, 1995, J MOL BIOL, V251, P421, DOI 10.1006/jmbi.1995.0445; MOMANY C, 1995, J MOL BIOL, V252, P643, DOI 10.1006/jmbi.1995.0526; OWNBY DW, 1993, J BIOL CHEM, V268, P13539; PILZ I, 1980, INT J BIOL MACROMOL, V2, P279, DOI 10.1016/0141-8130(80)90045-8; RACHMILEWITZ EA, 1971, J BIOL CHEM, V246, P3356; RAWITCH AB, 1993, ARCH BIOCHEM BIOPHYS, V300, P271, DOI 10.1006/abbi.1993.1038; RICHTER GW, 1967, BIOCHEMISTRY-US, V6, P2871, DOI 10.1021/bi00861a031; ROCHE J, 1965, STUDIES COMPARATIVE, V23, P62; ROSSIFANELLI MR, 1970, ARCH BIOCHEM BIOPHYS, V141, P278; RUSSELL DW, 1983, J BIOL CHEM, V258, P2674; SCHATZ M, 1995, J STRUCT BIOL, V114, P28, DOI 10.1006/jsbi.1995.1003; SCHROETER JP, 1992, J STRUCT BIOL, V109, P235, DOI 10.1016/1047-8477(92)90036-A; Schroeter JP, 1996, J STRUCT BIOL, V116, P131, DOI 10.1006/jsbi.1996.0021; Sharma PK, 1996, J BIOL CHEM, V271, P8754, DOI 10.1074/jbc.271.15.8754; SILVA JL, 1989, J BIOL CHEM, V264, P15863; SILVA JL, 1993, ANNU REV PHYS CHEM, V44, P89, DOI 10.1146/annurev.pc.44.100193.000513; STOOPS JK, 1991, J ELECTRON MICR TECH, V18, P157, DOI 10.1002/jemt.1060180210; Svedberg T, 1932, NATURE, V130, P434; TAL M, 1985, J BIOL CHEM, V260, P9976; TAM LT, 1993, J BIOL CHEM, V268, P26972; Tanford C., 1961, PHYSICAL CHEM MACROM, P275; TODA H, 1993, EUR J BIOCHEM, V216, P25, DOI 10.1111/j.1432-1033.1993.tb18112.x; UNSER M, 1987, ULTRAMICROSCOPY, V23, P39, DOI 10.1016/0304-3991(87)90225-7; VANASSENDELFT OW, 1965, CLIN CHIM ACTA, V11, P571, DOI 10.1016/0009-8981(65)90015-X; VANASSENDELFT OW, 1970, SPECTROPHOTOMETRY HA, P57; VANDERWALT B, 1978, J BIOL CHEM, V253, P1853; VINOGRADOV SN, 1986, P NATL ACAD SCI USA, V83, P8034, DOI 10.1073/pnas.83.21.8034; VINOGRADOV SN, 1991, J BIOL CHEM, V266, P13091; WEBER G, 1986, BIOCHEMISTRY-US, V25, P3626, DOI 10.1021/bi00360a022; WOLF HU, 1984, CLIN CHIM ACTA, V136, P95, DOI 10.1016/0009-8981(84)90251-1; WOOD EJ, 1976, BIOCHEM J, V153, P589, DOI 10.1042/bj1530589; WYATT PJ, 1993, J CHROMATOGR, V648, P27, DOI 10.1016/0021-9673(93)83285-Z; WYATT PJ, 1993, ANAL CHIM ACTA, V272, P1, DOI 10.1016/0003-2670(93)80373-S; WYATT PJ, 1993, LC GC-MAG SEP SCI, V11, P862; XIE Q, 1996, IN PRESS BIOCH ACTA; YOSHIDA N, 1991, J BIOCHEM-TOKYO, V110, P196, DOI 10.1093/oxfordjournals.jbchem.a123556; Zhu H, 1996, J BIOL CHEM, V271, P29999, DOI 10.1074/jbc.271.47.29999; ZIMM BH, 1948, J CHEM PHYS, V16, P1099, DOI 10.1063/1.1746740; 1930, INT CRIT TABLES, V7, P64	77	75	77	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30007	30021		10.1074/jbc.271.47.30007	http://dx.doi.org/10.1074/jbc.271.47.30007			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939947	hybrid			2022-12-25	WOS:A1996VU52500075
J	Chen, YR; Wang, XP; Templeton, D; Davis, RJ; Tan, TH				Chen, YR; Wang, XP; Templeton, D; Davis, RJ; Tan, TH			The role of c-Jun N-terminal kinase (JNK) in apoptosis induced by ultraviolet C and gamma radiation - Duration of JNK activation may determine cell death and proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; PC12 CELLS; TYROSINE KINASE; IN-VIVO; STRESS; PHOSPHORYLATION; COSTIMULATION; INTEGRATION	c-Jun N-terminal kinases (JNKs) participate in cellular responses to mitogenic stimuli, environmental stresses, and apoptotic agents. The mechanisms by which JNK integrates with other signaling pathways and regulates the diverse cellular events are unclear. We found JNK, but not p38-mitogen-activated protein kinase (MAPK) or extracellular signal-regulated kinase 2, to be persistently activated in apoptosis induced by gamma radiation, UV-C, and anti-Fas treatment. Direct correlation was found between JNK activation and apoptosis induced by UV-C and gamma radiation; however, JNK induction and apoptosis induced by Fas signaling were not well correlated. Overexpression of activated JNK1 caused cell death in transfected cells, and the expression of a dominant-negative mutant of MAPK kinase 1 or JNK1 (but not a dominant-negative mutant of p38-MAPK or c-Raf) prevented the UV-C- and gamma radiation-induced cell death. The inductions of JNK in T-cell activation and apoptosis were distinguished by the different activation patterns, transient versus persistent, respectively. Co-treatment with a tyrosine phosphatase inhibitor (sodium orthovanadate) and T-cell activation signals (phorbol 12-myristate 13-acetate plus ionomycin) prolonged JNK induction, followed by T-cell apoptosis. Our data revealed the requirement of the JNK pathway in radiation-induced apoptosis and implicated the importance of the duration of JNK activation in determining the cell fates.	CASE WESTERN RESERVE UNIV,INST PATHOL,CLEVELAND,OH 44106; UNIV MASSACHUSETTS,SCH MED,HOWARD HUGHES MED INST,WORCESTER,MA 01605; UNIV MASSACHUSETTS,SCH MED,PROGRAM MOL MED,DEPT BIOCHEM & MOL BIOL,WORCESTER,MA 01605	Case Western Reserve University; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Chen, YR (corresponding author), BAYLOR COLL MED,DEPT MICROBIOL & IMMUNOL,M929,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.		Tan, Tse-Hua/ABD-7080-2021; Chen, Yi-Rong/CAH-7991-2022; Chen, Yi-Rong/CAF-2186-2022; Tan, Tse-Hua/E-3983-2010; Chen, Yi-Rong/E-3991-2010; Templeton, Dennis J/F-7695-2011	Tan, Tse-Hua/0000-0003-4969-3170; Chen, Yi-Rong/0000-0002-4307-3002; Chen, Yi-Rong/0000-0002-4307-3002; Tan, Tse-Hua/0000-0003-4969-3170; Chen, Yi-Rong/0000-0002-4307-3002; 	NIAID NIH HHS [R01-AI38649] Funding Source: Medline; NIGMS NIH HHS [R01-GM49875] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038649] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049875] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berberich I, 1996, EMBO J, V15, P92, DOI 10.1002/j.1460-2075.1996.tb00337.x; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HEARSLEY LE, 1992, MOL BIOL CELL, V3, P545; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MEMON SA, 1995, J IMMUNOL METHODS, V180, P15, DOI 10.1016/0022-1759(94)00294-7; Meyer CF, 1996, J BIOL CHEM, V271, P8971, DOI 10.1074/jbc.271.15.8971; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; NUNEZ G, 1994, IMMUNOL TODAY, V15, P582, DOI 10.1016/0167-5699(94)90221-6; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROZENGURT E, 1992, Current Opinion in Cell Biology, V4, P161, DOI 10.1016/0955-0674(92)90027-A; Sakata N, 1995, J BIOL CHEM, V270, P30823, DOI 10.1074/jbc.270.51.30823; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu X, 1996, ONCOGENE, V13, P135; Yu R, 1996, CANCER RES, V56, P2954; Yu R, 1996, CANCER LETT, V107, P73, DOI 10.1016/0304-3835(96)04345-5	44	451	476	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					31929	31936		10.1074/jbc.271.50.31929	http://dx.doi.org/10.1074/jbc.271.50.31929			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943238	hybrid			2022-12-25	WOS:A1996VY34000029
J	DiNoia, JM; Pollevick, GD; Xavier, MT; Previato, JO; MendocaPreviato, L; Sanchez, DO; Frasch, ACC				DiNoia, JM; Pollevick, GD; Xavier, MT; Previato, JO; MendocaPreviato, L; Sanchez, DO; Frasch, ACC			High diversity in mucin genes and mucin molecules in Trypanosoma cruzi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-SIALIDASE; MAMMALIAN-CELLS; GLYCOPROTEINS; ACID; EPIMASTIGOTES; MEMBRANE; FORMS; OLIGOSACCHARIDES; 35-KILODALTON; INFECTIVITY	Mucins are highly O-glycosylated molecules which in mammalian cells accomplish essential functions, like cytoprotection and cell-cell interactions. In the protozoan parasite Trypanosoma cruzi, mucin-related glycoproteins have been shown to play a relevant role in the interaction with and invasion of host cells, We have previously reported a family of mucin-like genes in T. cruzi whose overall structure resembled that of mammalian mucin genes, We have now analyzed the relationship between these genes and mucin proteins, a monoclonal antibody specific for a mucin sugar epitope and a polyclonal serum directed to peptide epitopes in a MUC gene-encoded recombinant protein, detected identical bands in three out of seven strains of T, cruzi. Immunoprecipitation experiments confirmed these results, When expressed in eukaryotic cells, the MUC gene product is post-translationally modified, most likely, through extensive O-glycosylation, Gene sequencing showed that the central domains encoding the repeated sequences with the consensus T8KP2, varies in number from 1 to 10, and the number of Thr residues in each repeat could be 7, 8, or 10. A run of 16 to 18 Thr residues was present in some, but not all, MUC gene-derived sequences, Direct compositional analysis of mucin core proteins showed that Thr residues are much more frequent than Ser residues, The same fact occurs in MUC gene-derived protein sequences. Molecular mass determinations of the 35-kDa glycoproteins further extend the heterogeneity of the family to the natural mucin molecules. Difficulties in assigning each of the several MUC genes identified to a mucin product arise from the high diversity and partial sequence conservation of the members of this family.	UNIV BUENOS AIRES,FAC CIENCIAS EXACTAS & NAT,RA-1405 BUENOS AIRES,DF,ARGENTINA; FED UNIV RIO DE JANEIRO,DEPT MICROBIOL GERAL,BR-21944 RIO JANEIRO,BRAZIL	University of Buenos Aires			Di Noia, Javier Marcelo/D-2285-2012	Di Noia, Javier Marcelo/0000-0003-2896-0321; sanchez, daniel/0000-0002-5427-7764; Previato, Jose Osvaldo/0000-0002-9233-9954; Frasch, Alberto Carlos/0000-0001-7532-653X				ALMEIDA IC, 1994, BIOCHEM J, V304, P793, DOI 10.1042/bj3040793; ALVES MJM, 1975, FEBS LETT, V52, P188, DOI 10.1016/0014-5793(75)80803-9; BRENER Z, 1963, Rev Inst Med Trop Sao Paulo, V5, P220; CAPPA SMG, 1981, MEDICINA-BUENOS AIRE, V41, P549; CARREIRA JO, 1996, IN PRESS GLYCOCONJ J, V13; CAZZULO JJ, 1985, MOL BIOCHEM PARASIT, V16, P329, DOI 10.1016/0166-6851(85)90074-X; CAZZULO JJ, 1992, FASEB J, V6, P3259, DOI 10.1096/fasebj.6.14.1426764; DESOUSA MA, 1983, MEM I O CRUZ, V83, P123; DEVINE PL, 1992, BIOESSAYS, V14, P619, DOI 10.1002/bies.950140909; DINOIA JM, 1995, J BIOL CHEM, V270, P24146, DOI 10.1074/jbc.270.41.24146; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FAUCONNET M, 1978, ANAL BIOCHEM, V91, P403, DOI 10.1016/0003-2697(78)90525-0; FERGUSON MAJ, 1985, BIOCHIM BIOPHYS ACTA, V842, P39, DOI 10.1016/0304-4165(85)90290-9; GONZALEZCAPPA SM, 1980, MEDICINA-BUENOS AIRE, V40, P63; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUM JR, 1992, AM J RESP CELL MOL, V7, P557, DOI 10.1165/ajrcmb/7.6.557; Gum JR, 1995, BIOCHEM SOC T, V23, P795, DOI 10.1042/bst0230795; HANSEN JE, 1995, BIOCHEM J, V308, P801, DOI 10.1042/bj3080801; Harlow E., 1988, ANTIBODIES LAB MANUA; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; MORTARA RA, 1992, INFECT IMMUN, V60, P4673, DOI 10.1128/IAI.60.11.4673-4678.1992; POLLEVICK GD, 1991, MOL BIOCHEM PARASIT, V47, P247, DOI 10.1016/0166-6851(91)90185-9; PREVIATO JO, 1985, MOL BIOCHEM PARASIT, V16, P85, DOI 10.1016/0166-6851(85)90051-9; PREVIATO JO, 1995, J BIOL CHEM, V270, P7241, DOI 10.1074/jbc.270.13.7241; PREVIATO JO, 1994, BIOCHEM J, V301, P151, DOI 10.1042/bj3010151; PROCHOWNIK EV, 1983, J BIOL CHEM, V258, P8389; RAVDIN JI, 1993, VACCINE, V11, P241, DOI 10.1016/0264-410X(93)90024-R; REYES MB, 1994, GENE, V140, P139, DOI 10.1016/0378-1119(94)90745-5; RUIZ RD, 1993, PARASITE IMMUNOL, V15, P121, DOI 10.1111/j.1365-3024.1993.tb00591.x; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHENKMAN S, 1991, CELL, V65, P1117, DOI 10.1016/0092-8674(91)90008-M; SCHENKMAN S, 1993, MOL BIOCHEM PARASIT, V59, P293, DOI 10.1016/0166-6851(93)90227-O; SCHENKMAN S, 1994, ANNU REV MICROBIOL, V48, P499, DOI 10.1146/annurev.mi.48.100194.002435; SCHENKMAN S, 1993, PARASITOL TODAY, V9, P218, DOI 10.1016/0169-4758(93)90017-A; SERRANO AA, 1995, J BIOL CHEM, V270, P27244, DOI 10.1074/jbc.270.45.27244; Silva LHP, 1953, FOLIA CLIN BIOL, V20, P191; SINGH BN, 1994, J BIOL CHEM, V269, P21972; TIBAYRENC M, 1987, PARASITOL TODAY, V3, P189, DOI 10.1016/0169-4758(87)90179-7; VANKLINKEN BJ, 1995, AM J PHYSIOL, V269, P913; YOSHIDA N, 1989, INFECT IMMUN, V57, P1663, DOI 10.1128/IAI.57.6.1663-1667.1989; ZINGALES B, 1985, MOL BIOCHEM PARASIT, V16, P21, DOI 10.1016/0166-6851(85)90046-5	44	41	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32078	32083		10.1074/jbc.271.50.32078	http://dx.doi.org/10.1074/jbc.271.50.32078			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943259	hybrid, Green Published			2022-12-25	WOS:A1996VY34000050
J	LopezBoado, YS; Klaus, M; Dawson, MI; LopezOtin, C				LopezBoado, YS; Klaus, M; Dawson, MI; LopezOtin, C			Retinoic acid-induced expression of apolipoprotein D and concomitant growth arrest in human breast cancer cells are mediated through a retinoic acid receptor RAR alpha-dependent signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROSS CYSTIC-DISEASE; CO-REPRESSOR; HUMAN-PLASMA; PERIPHERAL-NERVE; GENE-EXPRESSION; DOUBLE MUTANTS; A-I; PROTEIN; INHIBITION; RXR	Apolipoprotein D (apoD) is a human plasma protein, belonging to the lipocalin superfamily, that is produced by a specific subtype of highly differentiated breast carcinomas and that is strongly up-regulated by retinoic acid (RA) in breast cancer cells. Ln this work, we have examined the molecular mechanisms mediating the induction of apoD gene expression by retinoids in T-47D human breast cancer cells, Northern blot analysis revealed that Ro40-6055, a synthetic retinoid that selectively binds and activates the retinoic acid receptor RAR alpha induced the accumulation of apoD mRNA in breast cancer cells in a time- and dose dependent manner. The time course analysis demonstrated that apoD mRNA was induced 14-fold over control cells after 48 h of incubation with 10(-8) M Ro40-6055. As little as 10(-11) M of this retinoid induced apoD mRNA 8-fold over the control, whereas incubation with 10(-7) RI Ro40-6055 induced maximally 15-fold over control cells, RAR alpha-selective antagonists counteracted the inductive effects of all-trans-RA, 9-cis-RA, and Ro40-6055 on the expression of apoD, when present at the same concentration as the retinoid agonists. By contrast, RAP beta-, RAR gamma-, and RXR-selective retinoids did not affect apoD gene expression. The retinoid agonist Ro40-6055 had an antiproliferative effect on T-47D cells, with maximal growth inhibition of approximately 60% obtained after 7 days of incubation with 10(-7) RI, This antiproliferative effect could be counteracted by a 100-fold excess of the antagonist Ro41-5253. Treatment of the cells with retinoids that do not bind the nuclear retinoic acid receptors did not affect apoD expression, despite the fact that they did have a strong antiproliferative effect on T-47D cells. On the basis of these results, a role for RAR alpha on apoD gene expression induction by retinoids in breast cancer cells is proposed.	UNIV OVIEDO, DEPT BIOQUIM & BIOL MOL, FAC MED, E-33006 OVIEDO, SPAIN; F HOFFMANN LA ROCHE & CO LTD, DIV PHARMA, CH-4002 BASEL, SWITZERLAND; SRI INT, DIV LIFE SCI, MENLO PK, CA 94025 USA	University of Oviedo; Roche Holding; SRI International			López-Otín, Carlos/AAB-2106-2020	López-Otín, Carlos/0000-0001-6964-1904				APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129; BALBIN M, 1990, BIOCHEM J, V271, P803, DOI 10.1042/bj2710803; BLANCOVACA F, 1992, J LIPID RES, V33, P1785; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; BOYLES JK, 1990, J BIOL CHEM, V265, P17805; CABRAL JHM, 1995, FEBS LETT, V366, P53, DOI 10.1016/0014-5793(95)00484-Q; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRETTAZ M, 1990, BIOCHEM J, V272, P391, DOI 10.1042/bj2720391; DAWSON MI, 1995, CANCER RES, V55, P4446; DIEZITZA I, 1994, AM J PATHOL, V144, P310; DILLEY WG, 1990, BREAST CANCER RES TR, V16, P253, DOI 10.1007/BF01806333; DRAYNA D, 1986, J BIOL CHEM, V261, P6535; ELIASON JF, 1993, BRIT J CANCER, V67, P1293, DOI 10.1038/bjc.1993.240; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; FIELDING PE, 1980, P NATL ACAD SCI-BIOL, V77, P3327, DOI 10.1073/pnas.77.6.3327; FRANCONE OL, 1989, J BIOL CHEM, V264, P7066; GIANNI M, 1993, BIOCHEM BIOPH RES CO, V196, P252, DOI 10.1006/bbrc.1993.2242; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; HUSMANN M, 1991, MOL CELL BIOL, V11, P4097, DOI 10.1128/MCB.11.8.4097; KEIDEL S, 1994, MOL CELL BIOL, V14, P287, DOI 10.1128/MCB.14.1.287; KOOISTRA T, 1995, EUR J BIOCHEM, V232, P425, DOI 10.1111/j.1432-1033.1995.425zz.x; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LEA OA, 1987, CANCER RES, V47, P6189; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; Liu Y, 1996, MOL CELL BIOL, V16, P1138; LOHNES D, 1994, DEVELOPMENT, V120, P2723; LOPEZBOADO YS, 1994, J BIOL CHEM, V269, P26871; LOTAN R, 1995, CANCER RES, V55, P232; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MAZOUJIAN G, 1990, ANN NY ACAD SCI, V586, P188, DOI 10.1111/j.1749-6632.1990.tb17806.x; MCCONATH.WJ, 1973, FEBS LETT, V37, P178, DOI 10.1016/0014-5793(73)80453-3; MENDELSOHN C, 1994, DEVELOPMENT, V120, P2749; MILNE RW, 1993, CURR OPIN LIPIDOL, V4, P100, DOI 10.1097/00041433-199304000-00005; Peitsch M C, 1990, New Biol, V2, P197; ROMAN SD, 1992, CANCER RES, V52, P2236; ROMAN SD, 1993, CANCER RES, V53, P5940; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANCHEZ LM, 1992, CANCER RES, V52, P95; SANCHEZ LM, 1992, CLIN CHEM, V38, P695; SHAO ZM, 1994, INT J ONCOL, V4, P859; SHEIKH MS, 1993, J CELL BIOCHEM, V53, P394, DOI 10.1002/jcb.240530417; SHEIKH MS, 1994, J BIOL CHEM, V269, P21440; SILVA JS, 1982, SURGERY, V92, P443; SIMARD J, 1992, ENDOCRINOLOGY, V130, P1115, DOI 10.1210/en.130.3.1115; SIMARD J, 1990, ENDOCRINOLOGY, V126, P3223, DOI 10.1210/endo-126-6-3223; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; SPREYER P, 1990, EMBO J, V9, P2479, DOI 10.1002/j.1460-2075.1990.tb07426.x; VANDERBURG B, 1993, MOL CELL ENDOCRINOL, V91, P149, DOI 10.1016/0303-7207(93)90267-N; VANDERLEEDE BJM, 1995, MOL CELL ENDOCRINOL, V109, P77, DOI 10.1016/0303-7207(95)03487-R; WEECH PK, 1991, PROG LIPID RES, V30, P259, DOI 10.1016/0163-7827(91)90023-X; ZHANG LX, 1995, J BIOL CHEM, V270, P6022, DOI 10.1074/jbc.270.11.6022; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHAO ZR, 1995, EXP CELL RES, V219, P555, DOI 10.1006/excr.1995.1264	57	35	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32105	32111		10.1074/jbc.271.50.32105	http://dx.doi.org/10.1074/jbc.271.50.32105			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943263	hybrid			2022-12-25	WOS:A1996VY34000054
J	Sundstrom, M; Lundqvist, T; Rodin, J; Giebel, LB; Milligan, D; Norstedt, G				Sundstrom, M; Lundqvist, T; Rodin, J; Giebel, LB; Milligan, D; Norstedt, G			Crystal structure of an antagonist mutant of human growth hormone, G120R, in complex with its receptor at 2.9 angstrom resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR DOMAIN; PROLACTIN RECEPTORS; ESCHERICHIA-COLI; BINDING-PROTEIN; DIMERIZATION; ACTIVATION; EXPRESSION; PATTERN; DESIGN; CELLS	Human growth hormone binds two receptor molecules and thereby induces signal transduction through receptor dimerization. At high concentrations, growth hormone acts as an antagonist because of a large difference in affinities at the respective binding sites, This antagonist action can be enhanced further by reducing binding in the low affinity binding site, A growth hormone antagonist mutant Gly-120 --> Arg, has been crystallized with its receptor as a 1:1 complex and the crystal structure determined at 2.9 Angstrom resolution. The 1:1 complex is remarkably similar to the native growth hormone-receptor 1:2 complex, A comparison between the two structures reveals only minimal differences in the conformations of the hormone or its receptor in the two complexes, including the angle between the two immunoglobulin-like domains of the receptor, Further, two symmetry-related 1:1 complexes in the crystal form a 2:2 complex with a large solvent inaccessible area between two receptor molecules, In addition, we present here a native human growth hormon-human growth hormone-binding protein 1:2 complex structure at 2.5 Angstrom resolution, One important difference between our structure and the previously published crystal structure at 2.8 Angstrom is revealed. Trp-104 in the receptor, a key residue in the hormone-receptor interaction, has an altered conformation in the low affinity site enabling a favorable hydrogen bond to be formed with Asp-116 of the hormone.	PHARMACIA & UPJOHN INC,PRECLIN RES & DEV,DEPT BIOCHEM,S-11287 STOCKHOLM,SWEDEN; PHARMACIA & UPJOHN INC,PRECLIN RES & DEV,DEPT CELL BIOL,S-11287 STOCKHOLM,SWEDEN; ARRIS PHARMACEUT CORP,S SAN FRANCISCO,CA 94080	Pfizer; Pharmacia Corporation; Pfizer; Pharmacia Corporation	Sundstrom, M (corresponding author), PHARMACIA & UPJOHN INC,PRECLIN RES & DEV,DEPT STRUCT BIOCHEM,NORDENFLYCHTSVAGEN 62-6,S-11287 STOCKHOLM,SWEDEN.							ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BAUMANN G, 1994, J CLIN ENDOCR METAB, V78, P1113, DOI 10.1210/jc.78.5.1113; BAUMGARTNER JW, 1994, J BIOL CHEM, V269, P29094; BRUNGER AT, 1989, ACTA CRYSTALLOGR A, V45, P50, DOI 10.1107/S0108767388009195; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, XPLOR MANUAL; CHEN WY, 1994, J BIOL CHEM, V269, P15892; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DATTANI MT, 1995, J BIOL CHEM, V270, P9222, DOI 10.1074/jbc.270.16.9222; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FRANK SJ, 1994, ENDOCRINOLOGY, V135, P148, DOI 10.1210/en.135.1.148; FUH G, 1993, J BIOL CHEM, V268, P5376; FUH G, 1990, J BIOL CHEM, V265, P3111; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GOEDDEL DV, 1979, NATURE, V281, P544, DOI 10.1038/281544a0; Gourdou I, 1996, MOL ENDOCRINOL, V10, P45, DOI 10.1210/me.10.1.45; Harding PA, 1996, J BIOL CHEM, V271, P6708, DOI 10.1074/jbc.271.12.6708; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KOSSIAKOFF AA, 1994, PROTEIN SCI, V3, P1697, DOI 10.1002/pro.5560031008; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; SHANAFELT AB, 1992, J BIOL CHEM, V267, P25466; ULTSCH M, 1991, J MOL BIOL, V222, P865, DOI 10.1016/0022-2836(91)90578-T; ULTSCH M, 1993, J MOL BIOL, V231, P1133, DOI 10.1006/jmbi.1993.1359; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; WELLS JA, 1993, ANNU REV BIOPH BIOM, V22, P329, DOI 10.1146/annurev.bb.22.060193.001553; WELLS JA, 1994, CURR OPIN CELL BIOL, V6, P163, DOI 10.1016/0955-0674(94)90132-5; WOOD TJJ, 1995, J BIOL CHEM, V270, P9448, DOI 10.1074/jbc.270.16.9448; [No title captured]	37	77	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32197	32203		10.1074/jbc.271.50.32197	http://dx.doi.org/10.1074/jbc.271.50.32197			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943276	hybrid			2022-12-25	WOS:A1996VY34000067
J	Alessandrini, A; Greulich, H; Huang, WD; Erikson, RL				Alessandrini, A; Greulich, H; Huang, WD; Erikson, RL			Mek1 phosphorylation site mutants activate Raf-1 in NIH 3T3 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE KINASE; NERVE GROWTH-FACTOR; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; GENE-PRODUCT; TRANSFORMATION; THREONINE; FIBROBLASTS; PHOSPHATASE; SERINE	MAP (mitogen-activated protein) kinases are activated by a family of dual specificity kinases called Meks (MAP kinase/Erk kinase). Mek1 can be activated by Raf by phosphorylation on serine 218 and serine 222. Mutation of these sites to acidic residues leads to constitutively active Mek1 in some cases, When fibroblast Lines were infected with high titer retroviral stocks carrying these Mek1 genes, the resultant transformation and morphological changes correlated with the kinase activity of the respective Mek1 enzymes. Although [Asp(218)]and [Asp(218),Asp(222)]Mek immunoprecipitated from clonal cell lines could phosphorylate kinase-inactive Erk1 equally well in vitro, the endogenous MAP kinase activity was 5-7-fold greater in [Asp(218)]Mek1-infected clonal Lines, and did not correlate with the degree of transformation. Analysis of the Erk1 pathway revealed Raf-l activation, which correlated qualitatively with the MAP kinase activity seen in the [Asp(218)]. and [Asp(218),Asp(222)]Mek1-infected clonal cell lines. Expression of dominant negative Ras did not affect the elevated Raf-1 activity observed in these cells, however. These data suggest that Mek1 phosphorylation site mutants activate Raf-1 and MAP kinase by a Ras-independent pathway and that the mechanism by which transformation occurs may utilize pathways that are MAP kinase-independent.			Alessandrini, A (corresponding author), HARVARD UNIV,DEPT MOL & CELLULAR BIOL,16 DIVIN AVE,CAMBRIDGE,MA 02138, USA.				NATIONAL CANCER INSTITUTE [R35CA042580] Funding Source: NIH RePORTER; NCI NIH HHS [CA42580] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHN NG, 1993, P NATL ACAD SCI USA, V90, P5143, DOI 10.1073/pnas.90.11.5143; ALESSANDRINI A, 1992, P NATL ACAD SCI USA, V89, P8200, DOI 10.1073/pnas.89.17.8200; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Bokemeyer D, 1996, J BIOL CHEM, V271, P639, DOI 10.1074/jbc.271.2.639; BRUNET A, 1994, ONCOGENE, V9, P3379; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7953; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HUANG WD, 1995, MOL BIOL CELL, V6, P237, DOI 10.1091/mbc.6.3.237; HUANG WD, 1994, P NATL ACAD SCI USA, V91, P8960, DOI 10.1073/pnas.91.19.8960; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SARCEVIC B, 1993, J BIOL CHEM, V268, P25075; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; WARD Y, 1994, SCIENCE, V367, P651; XU SC, 1995, P NATL ACAD SCI USA, V92, P6808, DOI 10.1073/pnas.92.15.6808; ZHENG CF, 1993, J BIOL CHEM, V268, P16116; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	34	49	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31612	31618		10.1074/jbc.271.49.31612	http://dx.doi.org/10.1074/jbc.271.49.31612			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940180	hybrid, Green Published			2022-12-25	WOS:A1996VW68600091
J	Filtz, TM; Paterson, A; Harden, TK				Filtz, TM; Paterson, A; Harden, TK			Purification and gr protein subunit regulation of a phospholipase C-beta from Xenopus laevis oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SUBUNITS; PHOSPHATIDYLINOSITOL PATHWAY; SEQUENCE DETERMINATION; TURKEY ERYTHROCYTES; MOLECULAR-CLONING; RECEPTOR; ACTIVATION; ACETYLCHOLINE; METABOLISM; COUPLES	Xenopus oocytes exhibit both pertussis toxin-sensitive and -insensitive inositol lipid signaling responses to G protein-coupled receptor activation. The G protein subunits G alpha(i), G alpha(o), G alpha(q), G alpha(s), and G(beta gamma) all have been proposed to function as activators of phospholipase C in oocytes. Ma et al. (Ma, H.-W., Blitzer, R, D., Healy, E. C., Premont, R. T., Landau, E. M., and Iyengar, R. J. Biol. Chem. 268, 19915-19918) cloned a Xenopus phospholipase C (PLC-beta X) that exhibits homology to the PLC-beta class of isoenzymes. Although this enzyme was proposed to function as a signaling protein in the pertussis toxin sensitive inositol Lipid signaling pathway of oocytes, its regulation by G protein subunits has not been directly assessed. As such we have utilized baculovirus-promoted overexpression of PLC-beta X in Sf9 insect cells and have purified a recombinant 150-kDa isoenzyme. PLC-beta X catalyzes hydrolysis of phosphatidylinositol(4,5)bisphosphate and phosphatidylinositol(4)monophosphate, and reaction velocity is de pendent on Ca2+. Recombinant PLC-beta X was activated by both G alpha(q), and G(beta gamma). PLC-beta X exhibited a higher apparent affinity for G alpha(q) than G(beta gamma), and G alpha(q) was more efficacious than G(beta gamma) at lower concentrations of PLC-beta X Relative to other PLC-beta isoenzymes, PLC-beta X was less sensitive to stimulation by Ga-q than PLC-beta 1 but similar to PLC-beta 2 and PLC-beta T, PLC beta X was more sensitive to stimulation by G(beta gamma) than PLC-beta 1 but less sensitive than PLC-beta 2 and PLC-beta T. in contrast PLC-beta X was not activated by the pertussis toxin substrate G proteins G alpha(i1), G alpha(i2), G alpha(i3), or G alpha(o). These results are consistent with the idea that PLC-PX is regulated by alpha-subunits of the G(q) family and by G(beta gamma) and do not support the idea that alpha-subunits of pertussis toxin-sensitive G proteins are directly involved in regulation of this protein.	UNIV N CAROLINA, SCH MED, DEPT PHARMACOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine				Filtz, Theresa/0000-0002-5348-1114	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057391, R37GM029536, F32GM016918, R01GM029536] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM16918, GM29536] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; BLITZER RD, 1993, J BIOL CHEM, V268, P7532; BOYER JL, 1992, J BIOL CHEM, V267, P25451; DELAPENA P, 1995, J BIOL CHEM, V270, P3554, DOI 10.1074/jbc.270.8.3554; GILLO B, 1987, J PHYSIOL-LONDON, V392, P349, DOI 10.1113/jphysiol.1987.sp016784; GUTTRIDGE KL, 1995, P NATL ACAD SCI USA, V92, P1297, DOI 10.1073/pnas.92.5.1297; Hepler JR, 1996, J BIOL CHEM, V271, P496, DOI 10.1074/jbc.271.1.496; KANEKO S, 1992, FEBS LETT, V299, P179, DOI 10.1016/0014-5793(92)80242-9; KASAHARA J, 1994, FEBS LETT, V355, P41, DOI 10.1016/0014-5793(94)01170-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MA HW, 1993, J BIOL CHEM, V268, P19915; MIYAMAE T, 1993, FEBS LETT, V333, P311, DOI 10.1016/0014-5793(93)80677-M; MORIARTY TM, 1988, P NATL ACAD SCI USA, V85, P8865, DOI 10.1073/pnas.85.23.8865; MORIARTY TM, 1990, NATURE, V343, P79, DOI 10.1038/343079a0; MORIARTY TM, 1989, J BIOL CHEM, V264, P13524; MORRIS AJ, 1990, J BIOL CHEM, V265, P13501; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NAKAMURA K, 1994, J PHYSIOL-LONDON, V474, P35, DOI 10.1113/jphysiol.1994.sp020000; OLATE J, 1989, FEBS LETT, V244, P188, DOI 10.1016/0014-5793(89)81190-1; OLATE J, 1990, FEBS LETT, V268, P27, DOI 10.1016/0014-5793(90)80964-K; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PADRELL E, 1991, J BIOL CHEM, V266, P9771; PARK DG, 1993, J BIOL CHEM, V268, P4573; PATERSON A, 1995, CELL SIGNAL, V7, P709, DOI 10.1016/0898-6568(95)00039-R; PATERSON A, IN PRESS PRACTICAL A; SHAPIRA H, 1994, FEBS LETT, V348, P89, DOI 10.1016/0014-5793(94)00570-2; STEHNOBITTEL L, 1995, J BIOL CHEM, V270, P30068; UEDA H, 1995, MOL BRAIN RES, V32, P166, DOI 10.1016/0169-328X(95)00077-6; Waldo GL, 1996, BIOCHEM J, V316, P559, DOI 10.1042/bj3160559; WALDO GL, 1994, METHOD ENZYMOL, V237, P182	31	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31121	31126		10.1074/jbc.271.49.31121	http://dx.doi.org/10.1074/jbc.271.49.31121			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940109	hybrid, Green Published			2022-12-25	WOS:A1996VW68600020
J	Liu, F; Hill, DE; Chernoff, J				Liu, F; Hill, DE; Chernoff, J			Direct binding of the proline-rich region of protein tyrosine phosphatase 1B to the src homology 3 domain of p130(Cas)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED CELL-ADHESION; ENDOPLASMIC-RETICULUM; TERMINAL SEQUENCE; HUMAN-PLACENTA; SH3 DOMAINS; KINASE; PHOSPHORYLATION; P130; CRK; TRANSFORMATION	Protein tyrosine phosphatase 1B (PTP1B) is an abundant intracellular enzyme that is thought to act as a negative regulator of certain signaling pathways. The C terminus of PTP1B contains two proline-rich regions which conform to the canonical class II Src homology 3 domain binding motif, Pro-X-X-Pro-X-Arg. In this study, we establish that PTP1B interacts with Crk, Grb2, and p130(Cas) in vitro and with at least one of these, p130(Cas), in intact cells. The interaction of PTP1B and p130(Cas) is independent of tyrosine phosphorylation but can be disrupted by replacing two critical proline residues in the proline rich domain of PTP1B between amino acids 301 and 315. When wild-type PTP1B is expressed in 3Y1-v-crk cells, p130(Cas) shows substantial dephosphorylation, whereas the PTP1B proline mutant does not have this effect. In 3Y1 and 3Y1 v-crk-transformed fibroblasts, almost all of the total PTP1B and about 40% of total p130(Cas) co-sediment with membranes composed primarily of endoplasmic reticulum. These results suggest that the proline-rich domain between amino acids 301 and 315 in PTP1B binds Src homology 3-containing proteins and that p130(Cas) may be a physiological target of this phosphatase in cells.	FOX CHASE CANC CTR, PHILADELPHIA, PA 19111 USA; TEMPLE UNIV, DEPT CHEM, PHILADELPHIA, PA 19122 USA; ONCOGENE RES PROD, CAMBRIDGE, MA 02142 USA	Fox Chase Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			Hill, David E/B-6617-2011; Chernoff, Jonathan/I-7631-2014	Chernoff, Jonathan/0000-0002-4803-7836	NCI NIH HHS [R01 CA58836, CA-06927] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058836, P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; AVRUCH J, 1971, BIOCHIM BIOPHYS ACTA, V233, P334, DOI 10.1016/0005-2736(71)90331-2; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; Charest A, 1996, J BIOL CHEM, V271, P8424, DOI 10.1074/jbc.271.14.8424; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; CHIDA K, 1994, MOL CELL BIOL, V14, P3782, DOI 10.1128/MCB.14.6.3782; COOL DE, 1992, P NATL ACAD SCI USA, V89, P5422, DOI 10.1073/pnas.89.12.5422; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DEUTSCHER MP, 1990, METHOD ENZYMOL, V182, P220; DEUTSCHER MP, 1990, METHOD ENZYMOL, V182, P62; Falet H, 1996, FEBS LETT, V383, P165, DOI 10.1016/0014-5793(96)00232-3; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FLINT AJ, 1993, EMBO J, V12, P1937, DOI 10.1002/j.1460-2075.1993.tb05843.x; FRANGIENI JV, 1996, EMBO J, V12, P4843; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Law SF, 1996, MOL CELL BIOL, V16, P3327; LORENZEN JA, 1995, J CELL BIOL, V131, P631, DOI 10.1083/jcb.131.3.631; Lotti LV, 1996, MOL CELL BIOL, V16, P1946; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; McMillan D. Randy, 1994, Current Opinion in Biotechnology, V5, P540, DOI 10.1016/0958-1669(94)90071-X; MERCHENTHALER I, 1993, J COMP NEUROL, V336, P378, DOI 10.1002/cne.903360306; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; Neel B G, 1993, Semin Cell Biol, V4, P419, DOI 10.1006/scel.1993.1050; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; PATCH LA, 1995, J CELL SCI, V108, P1371; PENG ZY, 1995, ONCOGENE, V11, P1955; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHIEVELLA AR, 1993, CELL GROWTH DIFFER, V4, P239; SELLS MA, 1995, GENE, V152, P187, DOI 10.1016/0378-1119(94)00685-L; SHIFRIN VI, 1993, J BIOL CHEM, V268, P25376; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; Streuli M, 1996, CURR OPIN CELL BIOL, V8, P182, DOI 10.1016/S0955-0674(96)80064-0; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZANDER NF, 1993, ONCOGENE, V8, P1175	50	208	217	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31290	31295		10.1074/jbc.271.49.31290	http://dx.doi.org/10.1074/jbc.271.49.31290			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940134	hybrid			2022-12-25	WOS:A1996VW68600045
J	Saeki, K; Tokuda, K; Fukuyama, K; Matsubara, H; Nadanami, K; Go, M; Itoh, S				Saeki, K; Tokuda, K; Fukuyama, K; Matsubara, H; Nadanami, K; Go, M; Itoh, S			Site-specific mutagenesis of Rhodobacter capsulatus ferredoxin I, FdxN, that functions in nitrogen fixation - Role of extra residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CLUSTERS; RHODOPSEUDOMONAS-CAPSULATA; AZOTOBACTER-VINELANDII; RHIZOBIUM-MELILOTI; GENETIC-ANALYSIS; PROTEIN REARRANGEMENT; DIRECTED MUTAGENESIS; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; REDOX POTENTIALS	One of the two [4Fe-4S] type clusters of the Rhodobacter capsulatus ferredoxin I, FdxN, was modified through site-specific mutagenesis of the distinctive features of the second cluster-binding motif, Cys(38)-X(2)-Cys(41)-X(8)-Cys(50)-X(8)-Cys(50)-X(3)-Cys(59). First, various mutagenized products were tested to learn whether they could rescue the decreased capacity of an fdxN-null strain MSA1 to fix nitrogen: the phenotype of MSA1 was reassessed to Nif(s) (slow growth by nitrogen fixation) from our previous description of Nif(-) (Saeki, K., Suetsugu, Y., Tokuda, H., Miyatake, P., Young, D. A., Marrs, B. L. and Matsubara, H. (1991) J. Biol. Chem. 266, 12889-12895). Substitution of Cys(59) to Ser yielded an almost fully active product, while that of Cys(54) did not. Gradual deletions and deletion-substitution of the 8 residues between Cys(41) and Cys(50) also yielded active products. Second, three of the modified FdxN proteins were subjected to purification. Only the GA protein, whose 8 residues between positions 42 and 49 were replaced by the Gly-Ala sequence, was purified. The GA protein and the authentic FdxN showed similar optical properties. The two clusters in the former had E(m) values of -490 and -430 mV, while those in the latter had an identical value of -490 mV, when determined by EPR analysis. It was concluded that: 1) Cys(59) is not a ligand to [4Fe-4S] clusters but is important for structural integrity, 2) the residues between positions 42 and 49 may form a ''loop-out'' from a structure analogous to the Peptococcus aerogenes ferredoxin, and 3) the loop-out region does not have functional significance in nitrogen fixation but may be responsible for maintaining the highly negative redox potential of one of the two clusters.	NAGOYA UNIV,GRAD SCH SCI,DIV BIOL SCI,CHIKUSA KU,NAGOYA,AICHI 46401,JAPAN; NATL INST BASIC BIOL,OKAZAKI,AICHI 444,JAPAN	Nagoya University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)	Saeki, K (corresponding author), OSAKA UNIV,GRAD SCH SCI,DEPT BIOL,TOYONAKA,OSAKA 560,JAPAN.		Saeki, Kazuhiko/F-9904-2013; Saeki, Kazuhiko/ABC-8447-2020	Saeki, Kazuhiko/0000-0002-4198-9754; Saeki, Kazuhiko/0000-0002-4198-9754				ADMAN ET, 1973, J BIOL CHEM, V248, P3987; BACKES G, 1991, J AM CHEM SOC, V113, P2055, DOI 10.1021/ja00006a027; CAMMACK R, 1992, ADV INORG CHEM, V38, P281, DOI 10.1016/S0898-8838(08)60066-5; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P622; Dutton P L, 1978, Methods Enzymol, V54, P411; EBELING S, 1988, J BACTERIOL, V170, P1999, DOI 10.1128/jb.170.4.1999-2001.1988; FLEISCHMANN RD, 1995, SCIENCE, V269, P498; FUKUYAMA K, 1988, J MOL BIOL, V199, P183, DOI 10.1016/0022-2836(88)90388-9; HALLENBECK PC, 1982, BIOCHIM BIOPHYS ACTA, V681, P168, DOI 10.1016/0005-2728(82)90020-2; HALLENBECK PC, 1991, BIOCHIM BIOPHYS ACTA, V1057, P97, DOI 10.1016/S0005-2728(05)80088-X; HASE T, 1977, J BIOCHEM, V81, P1745, DOI 10.1093/oxfordjournals.jbchem.a131635; HASE T, 1978, J BIOCHEM, V83, P1321, DOI 10.1093/oxfordjournals.jbchem.a132039; HOWARD JB, 1991, ADV PROTEIN CHEM, V42, P199; HUBER JG, 1995, BIOCHEMISTRY-US, V34, P194, DOI 10.1021/bi00001a024; JENSEN GM, 1994, BIOCHEMISTRY-US, V33, P10911, DOI 10.1021/bi00202a010; JOERGER RD, 1990, J BACTERIOL, V172, P3400, DOI 10.1128/jb.172.6.3400-3408.1990; JOERGER RD, 1988, J BACTERIOL, V170, P1475, DOI 10.1128/jb.170.4.1475-1487.1988; JOUANNEAU Y, 1995, BBA-BIOENERGETICS, V1232, P33, DOI 10.1016/0005-2728(95)00106-X; KLIPP W, 1989, MOL GEN GENET, V216, P293, DOI 10.1007/BF00334368; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANGEN R, 1992, J BIOL CHEM, V267, P25625; MARTIN AE, 1990, P NATL ACAD SCI USA, V87, P598, DOI 10.1073/pnas.87.2.598; MASEPOHL B, 1992, MOL GEN GENET, V233, P33, DOI 10.1007/BF00587558; MATHEWS R, 1974, J BIOL CHEM, V249, P4326; MATSUBARA H, 1992, ADV INORG CHEM, V38, P223, DOI 10.1016/S0898-8838(08)60065-3; MAYO SL, 1990, J PHYS CHEM-US, V94, P8897, DOI 10.1021/j100389a010; MINAMI Y, 1984, J BIOCHEM-TOKYO, V96, P585, DOI 10.1093/oxfordjournals.jbchem.a134873; MORENOVIVIAN C, 1989, J BACTERIOL, V171, P2591, DOI 10.1128/jb.171.5.2591-2598.1989; MULLIGAN ME, 1988, J BACTERIOL, V170, P4406, DOI 10.1128/jb.170.9.4406-4410.1988; Naud I, 1996, EUR J BIOCHEM, V237, P399, DOI 10.1111/j.1432-1033.1996.0399k.x; NAUD I, 1994, EUR J BIOCHEM, V222, P933, DOI 10.1111/j.1432-1033.1994.tb18942.x; PRINCE RC, 1987, J BIOL CHEM, V262, P5125; ROBSON R, 1986, EMBO J, V5, P1159, DOI 10.1002/j.1460-2075.1986.tb04341.x; SAEKI K, 1990, NUCLEIC ACIDS RES, V18, P1060, DOI 10.1093/nar/18.4.1060; SAEKI K, 1991, J BIOL CHEM, V266, P12889; SAEKI K, 1993, PLANT CELL PHYSIOL, V34, P185; SAEKI K, 1990, J BIOCHEM-TOKYO, V108, P476; SAEKI K, 1992, RES PHOTOSYNTHESIS, V4, P43; Sambrook J., 2002, MOL CLONING LAB MANU; SCHATT E, 1989, J BACTERIOL, V171, P6218, DOI 10.1128/jb.171.11.6218-6226.1989; SCHMEHL M, 1993, MOL GEN GENET, V241, P602, DOI 10.1007/BF00279903; SHEN B, 1995, P NATL ACAD SCI USA, V92, P10064, DOI 10.1073/pnas.92.22.10064; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; SUETSUGU Y, 1991, FEBS LETT, V292, P13, DOI 10.1016/0014-5793(91)80822-K; TANAKA M, 1974, BIOCHEMISTRY-US, V13, P2953, DOI 10.1021/bi00711a026; TANAKA M, 1974, BIOCHEMISTRY-US, V14, P1938; TAYLOR DP, 1983, J BACTERIOL, V154, P580, DOI 10.1128/JB.154.2.580-590.1983; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VONSTERNBERG R, 1993, BIOCHIM BIOPHYS ACTA, V1144, P435, DOI 10.1016/0005-2728(93)90131-X; WEAVER PF, 1975, ARCH MICROBIOL, V105, P207, DOI 10.1007/BF00447139; WILLISON JC, 1993, GENE, V133, P39, DOI 10.1016/0378-1119(93)90222-O; YAKUNIN A F, 1987, Biokhimiya, V52, P1977; YAKUNIN AF, 1983, BIOCHIM BIOPHYS ACTA, V725, P298, DOI 10.1016/0005-2728(83)90203-7; YAKUNIN AF, 1993, J BACTERIOL, V175, P6775, DOI 10.1128/jb.175.21.6775-6780.1993; YEN HC, 1976, J BACTERIOL, V126, P619, DOI 10.1128/JB.126.2.619-629.1976; YOUNG DA, 1989, MOL GEN GENET, V218, P1, DOI 10.1007/BF00330558	56	14	15	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31399	31406		10.1074/jbc.271.49.31399	http://dx.doi.org/10.1074/jbc.271.49.31399			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940149	hybrid			2022-12-25	WOS:A1996VW68600060
J	Vanags, DM; PornAres, MI; Coppola, S; Burgess, DH; Orrenius, S				Vanags, DM; PornAres, MI; Coppola, S; Burgess, DH; Orrenius, S			Protease involvement in fodrin cleavage and phosphatidylserine exposure in apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PHOSPHOLIPID ASYMMETRY; HUMAN ERYTHROCYTE-MEMBRANE; PLATELET PLASMA-MEMBRANE; PROGRAMMED CELL-DEATH; INTERLEUKIN-1-BETA CONVERTING-ENZYME; SPIN-LABELED PHOSPHOLIPIDS; FAS-MEDIATED APOPTOSIS; GENE CED-3; IL-1-BETA-CONVERTING ENZYME; PHAGOCYTE RECOGNITION	A detailed kinetic analysis of three extranuclear end points of apoptosis, phosphatidylserine exposure, alpha-fodrin degradation, and plasma membrane blebbing, was performed and compared with nuclear fragmentation and the activation of the intertleukin-1 beta-converting enzyme (ICE)-like proteases in Jurkat T lymphocytes stimulated by anti-Fas monoclonal antibody (anti-Fas mAb) and in monocytic U937 cells stimulated by tumor necrosis factor (TNF) and cycloheximide. Phosphatidylserine exposure was quantitated by plasma clotting time, as well as annexin V-fluorescein isothiocyanate binding, and the ICE-like protease activity was examined by the cleavage of a specific fluorogenic peptide substrate Ac-Asp-Glu-Val-Asp-amino-4-methylcoumarin. VAD-chloromethylketone (VAD-cmk), an inhibitor of ICE-like proteases, effectively inhibited ICE-like activity in both cell types studied, whereas the calpain inhibitor calpeptin was ineffective. VAD-cmk also effectively inhibited all three extranuclear events, as well as nuclear fragmentation, in Jurkat cells stimulated by anti-Fas monoclonal antibody, indicating that ICE-like proteases play an important role in the regulation of this apoptotic system, Calpain inhibitors were ineffective in this system. TNF-induced extranuclear and nuclear changes in U937 cells were inhibited by calpeptin but were not as effectively inhibited by VAD-cmk as in Jurkat cells. This suggests that ICE-like enzymes predominate in anti-Fas monoclonal antibody-stimulated Jurkat cells, whereas proteases affected by calpain inhibitors as well as the ICE-like enzymes are involved in the signaling of apoptotic events in TNF-induced U937 cells, Importantly, the two apoptotic systems seem to be regulated by different proteases.			Vanags, DM (corresponding author), KAROLINSKA INST,INST ENVIRONM MED,DIV TOXICOL,BOX 210,S-17177 STOCKHOLM,SWEDEN.		Coppola, Simona/A-6638-2015	Coppola, Simona/0000-0001-7851-9409				ATSMA DE, 1995, CIRC RES, V76, P1071, DOI 10.1161/01.RES.76.6.1071; BASSE F, 1993, BIOCHEMISTRY-US, V32, P2337, DOI 10.1021/bi00060a027; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BLACK RA, 1989, J BIOL CHEM, V264, P5323; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BROWN DG, 1993, J BIOL CHEM, V268, P3037; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; CHARD PS, 1995, NEUROSCIENCE, V65, P1099, DOI 10.1016/0306-4522(94)00548-J; CHIU D, 1981, BLOOD, V58, P398; CHOW SC, 1995, FEBS LETT, V364, P134, DOI 10.1016/0014-5793(95)00370-O; COMFURIUS P, 1990, BIOCHIM BIOPHYS ACTA, V1026, P153, DOI 10.1016/0005-2736(90)90058-V; CONNOR J, 1994, J BIOL CHEM, V269, P2399; COTTER TG, 1992, CANCER RES, V52, P997; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; EDELSTEIN CL, 1995, P NATL ACAD SCI USA, V92, P7662, DOI 10.1073/pnas.92.17.7662; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FADOK VA, 1992, J IMMUNOL, V148, P2207; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FOX JEB, 1987, BLOOD, V69, P537; FOX JEB, 1990, J CELL BIOL, V111, P483, DOI 10.1083/jcb.111.2.483; GAFFET P, 1995, EUR J CELL BIOL, V67, P336; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GOODMAN SR, 1988, CRIT REV BIOCHEM MOL, V23, P171, DOI 10.3109/10409238809088319; HAEST CWM, 1978, BIOCHIM BIOPHYS ACTA, V509, P21, DOI 10.1016/0005-2736(78)90004-4; HAEST CWM, 1976, BIOCHIM BIOPHYS ACTA, V436, P353, DOI 10.1016/0005-2736(76)90199-1; HARRIS AS, 1988, J BIOL CHEM, V263, P15754; HARRIS AS, 1990, P NATL ACAD SCI USA, V87, P3009, DOI 10.1073/pnas.87.8.3009; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; KUYPERS FA, 1993, BLOOD, V81, P1051; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARTIN OC, 1987, J BIOL CHEM, V262, P5890; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; MEHDI S, 1991, TRENDS BIOCHEM SCI, V16, P150, DOI 10.1016/0968-0004(91)90058-4; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1996, NAT BIOTECHNOL, V14, P297, DOI 10.1038/nbt0396-297; OPDENKAMP JAF, 1979, ANNU REV BIOCHEM, V48, P47, DOI 10.1146/annurev.bi.48.070179.000403; SARIN A, 1993, J EXP MED, V178, P1693, DOI 10.1084/jem.178.5.1693; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; SEIGNEURET M, 1984, P NATL ACAD SCI-BIOL, V81, P3751, DOI 10.1073/pnas.81.12.3751; SIMS PJ, 1989, J BIOL CHEM, V264, P17049; SMEETS EF, 1994, BBA-BIOMEMBRANES, V1195, P281, DOI 10.1016/0005-2736(94)90268-2; SQUIER MKT, 1994, J CELL PHYSIOL, V159, P229, DOI 10.1002/jcp.1041590206; SULPICE JC, 1994, J BIOL CHEM, V269, P6347; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THIAGARAJAN P, 1991, J BIOL CHEM, V266, P24302; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TSUJINAKA T, 1988, BIOCHEM BIOPH RES CO, V153, P1201, DOI 10.1016/S0006-291X(88)81355-X; VERHOVEN B, 1995, J EXP MED, V182, P1597, DOI 10.1084/jem.182.5.1597; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WILLIAMS MS, 1994, J IMMUNOL, V153, P4247; WILLIAMSON P, 1992, BIOCHEMISTRY-US, V31, P6355, DOI 10.1021/bi00142a027; WILLIAMSON P, 1987, FEBS LETT, V219, P316, DOI 10.1016/0014-5793(87)80243-0; WILLIAMSON P, 1994, MOL MEMBR BIOL, V11, P199, DOI 10.3109/09687689409160430; WILLIAMSON P, 1982, CELL, V30, P725, DOI 10.1016/0092-8674(82)90277-X; WYLLIE AH, 1980, INT REV CYTOL, V68, P2251; YOKOTA M, 1995, STROKE, V26, P1901, DOI 10.1161/01.STR.26.10.1901; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZACHOWSKI A, 1990, EXPERIENTIA, V46, P644, DOI 10.1007/BF01939703; ZACHOWSKI A, 1987, BIOCHIM BIOPHYS ACTA, V897, P197, DOI 10.1016/0005-2736(87)90328-2; ZHIVOTOVSKY B, 1995, EXP CELL RES, V221, P204; ZWAAL RFA, 1993, BIOCHEM SOC T, V21, P248, DOI 10.1042/bst0210248	75	349	356	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31075	31085		10.1074/jbc.271.49.31075	http://dx.doi.org/10.1074/jbc.271.49.31075			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940103	hybrid			2022-12-25	WOS:A1996VW68600014
J	Fukuda, M; Kojima, T; Kabayama, H; Mikoshiba, K				Fukuda, M; Kojima, T; Kabayama, H; Mikoshiba, K			Mutation of the pleckstrin homology domain of Bruton's tyrosine kinase in immunodeficiency impaired inositol 1,3,4,5-tetrakisphosphate binding capacity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED AGAMMAGLOBULINEMIA; GTPASE-ACTIVATING PROTEIN; BETA-GAMMA-SUBUNITS; PH DOMAIN; FAMILY; MEMBER	Bruton's tyrosine kinase (Btk), a cytoplasmic protein-tyrosine kinase, plays a pivotal role in B cell activation and development. Mutations in the pleckstrin homology (PH) domain of the Btk gene cause human X-linked agammaglobulinemia (XLA) and murine X-linked immunodeficiency (Xid). In this paper, we report that the PH domain of Btk functions as an inositol 1,3,4,5-tetrakisphosphate (IP4), inositol 1,3,4,5,6-pentakisphosphate, and inositol 1,2,3,4,5,6-hexakisphosphate (IP6) binding domain (K-d of approximately 40 nM for IP4), and that all of the XLA (Phe replaced by Ser at position 25 (F25S), R28H, T33P, V64F, and V113D) and Xid mutations (R28C) found in the PH domain result in a dramatic reduction of IP4 binding activity. Furthermore, the rare alternative splicing variant, with 33 amino acids deleted in the PH domain, corresponding to exon 3 of the Btk gene, also impaired IP4 binding capacity. In contrast, a gain-of-function mutant called Btk*, which carries a E41K mutation in the PH domain, binds IP6 with two times higher affinity than the wild type. Our data suggest that B cell differentiation is closely correlated with the IP4 binding capacity of the PH domain of Btk.	UNIV TOKYO,INST MED SCI,DEPT MOL NEUROBIOL,MINATO KU,TOKYO 108,JAPAN; ERATO,CALCIOSIGNAL NET PROJECT,TOKYO 153,JAPAN	University of Tokyo; Japan Science & Technology Agency (JST)	Fukuda, M (corresponding author), INST PHYS & CHEM RES,RIKEN,TSUKUBA LIFE SCI CTR,MOL NEUROBIOL LAB,3-1-1 KOYADAI,TSUKUBA,IBARAKI 305,JAPAN.		Fukuda, MItsunori/I-1511-2015; Kabayama, Hiroyuki/AAC-2070-2021; Mikoshiba, Katsuhiko/N-7943-2015	Fukuda, MItsunori/0000-0002-8620-5853; Kabayama, Hiroyuki/0000-0002-5482-1950; 				CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Fukuda M, 1996, J BIOL CHEM, V271, P18838, DOI 10.1074/jbc.271.31.18838; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; LI TJ, 1995, IMMUNITY, V2, P451, DOI 10.1016/1074-7613(95)90026-8; MAEKAWA M, 1994, MOL CELL BIOL, V14, P6879, DOI 10.1128/MCB.14.10.6879; MANO H, 1995, BLOOD, V85, P343; MOUNTFORD JC, 1994, BBA-MOL CELL RES, V1222, P101, DOI 10.1016/0167-4889(94)90030-2; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; VIHINEN M, 1994, FEBS LETT, V350, P263, DOI 10.1016/0014-5793(94)00783-7; Vihinen M, 1996, NUCLEIC ACIDS RES, V24, P160, DOI 10.1093/nar/24.1.160; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175	24	180	184	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30303	30306		10.1074/jbc.271.48.30303	http://dx.doi.org/10.1074/jbc.271.48.30303			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8939985	hybrid			2022-12-25	WOS:A1996VV15800002
J	Xie, XS				Xie, XS			Reconstitution of ATPase activity from individual subunits of the clathrin-coated vesicle proton pump - The requirement and effect of three small subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; SACCHAROMYCES-CEREVISIAE; TRANSLOCATING ATPASE; 14-KDA SUBUNIT; YEAST; GENE; ACIDIFICATION; POLYPEPTIDE; ENCODES; PROTEIN	The vacuolar-type proton pump of clathrin coated vesicles is composed of two general domains, a peripheral, catalytic sector (V-C) and a transmembranous proton channel (V-B). In its native form, the enzyme can hydrolyze both MgATP and CaATP, whereas V-C, when separated from V-B, loses its MgATPase activity and switches to a state that can hydrolyze only CaATP. Further dissociation of V-C results in subcomplexes that are depleted of one or more subunits and lack ATPase activity altogether. Reconstitution of recombinant sub units to these biochemically prepared subcomplexes has demonstrated the necessity of polypeptides of 70, 58, 40, and 33 kDa (subunits A, B, C, and E, respectively) for CaATPase activity of the V-C complex. The current studies demonstrate that mixtures of these four recombinant subunits cannot support CaATPase activity in the absence of a biochemically prepared subcomplex. Investigation of the other components required for ATPase activity has led to the identification of three additional polypeptides present in preparations of V-C, with apparent molecular masses of 15, 14, and 10 kDa. Each of these proteins was found to activate ATPase activity of mixtures of subunits A, B, C, and E. In addition, ATPase reconstituted from these individual subunits hydrolyses ATP, not only in the presence of Ca2+ but also in the presence of Mg2+. Investigation of the individual properties of these three subunits revealed that the 10-kDa polypeptide is subunit F, as determined by immunoblot analysis. This subunit had no effect on MgATPase activity of V-C but stimulated CaATPase activity B-fold in the presence of subunit D. Under optimal conditions the 14-kDa component resulted in a 10-fold stimulation and the 15-kDa component a 20-fold stimulation of MgATPase activity; based on this observation, the 14- and 15-kDa polypeptides were named subunits G and H, respectively. In addition, proton pumping activity was reconstituted through the reassembly of subunits A-H with V-B and SFD, a previously described pump component composed of polypeptides of 50 and 57 kDa (Xie, X. S, Crider, B.P., Ma, Y. M., and Stone, D. K. (1994) J. Biol. Chem. 269, 25809-25815). Together, these experiments completely define the catalytic center of the vacuolar proton pump of clathrin-coated vesicles.			Xie, XS (corresponding author), UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DIV MOL TRANSPORT,DALLAS,TX 75235, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033627] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-33627] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALPERN RJ, 1990, KIDNEY; ANRAKU Y, 1992, J BIOENERG BIOMEMBR, V24, P395, DOI 10.1007/BF00762532; ARAI H, 1987, J BIOL CHEM, V262, P8796; BOWMAN BJ, 1992, J BIOENERG BIOMEMBR, V24, P361, DOI 10.1007/BF00762529; FOURY F, 1990, J BIOL CHEM, V265, P18554; GRAF R, 1994, J BIOL CHEM, V269, P3767; GRAF R, 1995, P GER ZOOL SOC, P103; GRAHAM LA, 1994, J BIOL CHEM, V269, P25974; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; KANE PM, 1992, J BIOENERG BIOMEMBR, V24, P383, DOI 10.1007/BF00762531; KIBAK H, 1992, J BIOENERG BIOMEMBR, V24, P415, DOI 10.1007/BF00762534; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATTSSON JP, 1994, J BIOL CHEM, V269, P24979; NELSON H, 1994, J BIOL CHEM, V269, P24150; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; Peng SB, 1996, J BIOL CHEM, V271, P3324, DOI 10.1074/jbc.271.6.3324; PENG SB, 1994, J BIOL CHEM, V269, P27778; PENG SB, 1994, J BIOL CHEM, V269, P11356; PENG SB, 1993, J BIOL CHEM, V268, P23519; PENG SB, 1995, J BIOL CHEM, V270, P16926; PRESTON RA, 1989, P NATL ACAD SCI USA, V86, P7027, DOI 10.1073/pnas.86.18.7027; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SHIH CK, 1988, MOL CELL BIOL, V8, P3094, DOI 10.1128/MCB.8.8.3094; STONE DK, 1984, J BIOL CHEM, V259, P2701; STONE DK, 1988, KIDNEY INT, V33, P403; SZE H, 1992, J BIOENERG BIOMEMBR, V24, P371, DOI 10.1007/BF00762530; XIE XS, 1994, J BIOL CHEM, V269, P25809; XIE XS, 1988, J BIOL CHEM, V263, P9859	29	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30980	30985						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940086				2022-12-25	WOS:A1996VV15800103
J	Yao, M; Kow, YW				Yao, M; Kow, YW			Cleavage of insertion/deletion mismatches, flap and pseudo-Y DNA structures by deoxyinosine 3'-endonuclease from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURE-SPECIFIC ENDONUCLEASE; SIMPLE REPETITIVE DNA; HUMAN MSH2 PROTEIN; MICROSATELLITE INSTABILITY; HETERODUPLEX DNA; 3' EXONUCLEASE; REPAIR; SEQUENCES; EXTRACTS; YEAST	Deoxyinosine 3'-endonuclease, an Escherichia coli repair enzyme that recognizes and cleaves DNA containing deoxyinosine and base mismatches, can cleave heteroduplexes containing a hairpin or unpaired loop. These DNA structures, referred to as insertion/deletion mismatches (IDM), are abnormal intermediate structures generated during replication of repetitive DNA sequences. In addition, the enzyme also cleaved the 5'-single-stranded tails of flap and pseudo-Y DNA structures, suggesting that deoxyinosine 3'-endonuclease is a bacterial functional homologue of human FEN1 and yeast RTH1 nucleases, These biochemical properties suggest that deoxyinosine S'-endonuclease might be important in the repair of IDM structures generated in lagging strand during DNA replication.	EMORY UNIV,SCH MED,DEPT RADIAT ONCOL,DIV CANC BIOL,ATLANTA,GA 30335	Emory University					NIGMS NIH HHS [GM 37216] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037216] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLATTNER FR, 1993, NUCLEIC ACIDS RES, V21, P5408; CARRAWAY M, 1993, J BACTERIOL, V175, P3972, DOI 10.1128/JB.175.13.3972-3980.1993; FISHEL R, 1994, CANCER RES, V54, P5539; FISHEL R, 1994, SCIENCE, V266, P1403, DOI 10.1126/science.7973733; FISHEL R, 1989, J BACTERIOL, V171, P3046, DOI 10.1128/jb.171.6.3046-3052.1989; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; HIRAOKA LR, 1995, GENOMICS, V25, P220, DOI 10.1016/0888-7543(95)80129-A; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; KUNKEL TA, 1993, NATURE, V365, P207, DOI 10.1038/365207a0; LAHUE RS, 1987, P NATL ACAD SCI USA, V84, P1482, DOI 10.1073/pnas.84.6.1482; LEACH DRF, 1994, BIOESSAYS, V16, P893, DOI 10.1002/bies.950161207; LEVINSON G, 1987, NUCLEIC ACIDS RES, V15, P5323, DOI 10.1093/nar/15.13.5323; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LYAMICHEV V, 1993, SCIENCE, V260, P778, DOI 10.1126/science.7683443; Miret JJ, 1996, NUCLEIC ACIDS RES, V24, P721, DOI 10.1093/nar/24.4.721; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; MURANTE RS, 1994, J BIOL CHEM, V269, P1191; PARKER BO, 1992, P NATL ACAD SCI USA, V89, P1730, DOI 10.1073/pnas.89.5.1730; ROBINS P, 1994, J BIOL CHEM, V269, P28535; SIEGAL G, 1992, P NATL ACAD SCI USA, V89, P9377, DOI 10.1073/pnas.89.20.9377; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; SPEICHER MR, 1995, ONCOL RES, V7, P267; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; SZANKASI P, 1995, SCIENCE, V267, P1166, DOI 10.1126/science.7855597; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; UMAR A, 1994, SCIENCE, V266, P814, DOI 10.1126/science.7973637; WAGA S, 1994, J BIOL CHEM, V269, P10923; YAO M, 1995, J BIOL CHEM, V270, P28609, DOI 10.1074/jbc.270.48.28609; YAO M, 1994, J BIOL CHEM, V269, P31390; YAO M, 1994, J BIOL CHEM, V269, P16260	33	60	66	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30672	30676		10.1074/jbc.271.48.30672	http://dx.doi.org/10.1074/jbc.271.48.30672			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940043	hybrid			2022-12-25	WOS:A1996VV15800060
J	Ishida, R; Iwai, M; Marsh, KL; Austin, CA; Yano, T; Shibata, M; Nozaki, N; Hara, A				Ishida, R; Iwai, M; Marsh, KL; Austin, CA; Yano, T; Shibata, M; Nozaki, N; Hara, A			Threonine 1342 in human topoisomerase II alpha is phosphorylated throughout the cell cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; C-TERMINAL DOMAIN; DNA TOPOISOMERASE; SACCHAROMYCES-CEREVISIAE; MITOTIC CHROMOSOMES; IN-VIVO; DEPENDENT PHOSPHORYLATION; ANTITUMOR DRUGS; PHORBOL ESTER; PROTEIN	To investigate the relationship between the modulation of topoisomerase II activity and its phosphorylation state during the cell cycle, a monoclonal antibody against C-terminal peptide (residues 1335-1350) of topoisomerase II alpha containing a consensus sequence of casein kinase II, TDDE and its phosphorylated threonine were prepared, In an enzyme-linked immunosorbent assay, the antibody, named PT1342, recognized the immunogenic phosphopeptide but not the non-phosphorylated form of the peptide. The PT1342 antibody reacted only with a 170-kDa protein from HeLa cells and recognized anti-topoisomerase II alpha immunoprecipitants. Furthermore, the antibody did not react with the human topoisomerase II alpha mutated at codon 1342 from threonine to alanine, showing that PT1342 was directed against the phosphorylated threonine 1342. To examine the level of phosphorylation of threonine 1342 of topoisomerase II alpha through the cell cycle, HeLa cells were stained simultaneously for phosphorylated topoisomerase II alpha and DNA and analyzed by flow cytometry, Cells in the G(2)-M phase contained about double the PT1341-reacted topoisomerase II alpha than did cells in G(1) or S phases, The antibody stained the nuclei in interphase and mitotic chromosomes and its periphery, as seen with anti-topoisomerase II alpha antibody, Thus, threonine 1342 in topoisomerase II alpha is phosphorylated throughout the cell cycle.	AICHI CANC CTR,RES INST,BIOCHEM LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; GIFU PHARMACEUT UNIV,DEPT BIOCHEM,GIFU 502,JAPAN; UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT BIOCHEM & GENET,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND; MED & BIOL LABS,NAGANO 396,JAPAN; KANAGAWA DENT COLL,DEPT ORAL BIOCHEM,YOKOSUKA,KANAGAWA 238,JAPAN	Aichi Cancer Center; Gifu Pharmaceutical University; Newcastle University - UK; Kanagawa Dental College	Ishida, R (corresponding author), AICHI CANC CTR,RES INST,LAB CHEMOTHERAPY,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN.			Austin, Caroline/0000-0002-1921-5947; West, Katherine/0000-0002-5994-8969				ACKERMAN P, 1985, P NATL ACAD SCI USA, V82, P3164, DOI 10.1073/pnas.82.10.3164; ACKERMAN P, 1988, J BIOL CHEM, V263, P12653; ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; AUSTIN CA, 1995, J BIOL CHEM, V270, P15739, DOI 10.1074/jbc.270.26.15739; BOJANOWSKI K, 1993, J BIOL CHEM, V268, P22920; BURDEN DA, 1993, BIOCHEM J, V293, P297, DOI 10.1042/bj2930297; BURDEN DA, 1994, BIOCHEMISTRY-US, V33, P14651, DOI 10.1021/bi00253a001; CARDENAS ME, 1993, J CELL SCI, V104, P219; CARDENAS ME, 1992, EMBO J, V11, P1785, DOI 10.1002/j.1460-2075.1992.tb05230.x; CARDENAS ME, 1993, J CELL SCI, V104, P533; CARON PR, 1994, MOL CELL BIOL, V14, P3197, DOI 10.1128/MCB.14.5.3197; CARON PR, 1993, MOL BIOL DNA TOPOISO, P207; CORBETT AH, 1992, J BIOL CHEM, V267, P20513; CRENSHAW DG, 1993, J BIOL CHEM, V268, P21328; DANG Q, 1994, J MOL BIOL, V243, P10, DOI 10.1006/jmbi.1994.1626; DARKINRATTRAY SJ, 1991, BIOCHIM BIOPHYS ACTA, V1088, P285, DOI 10.1016/0167-4781(91)90065-T; DARPA P, 1989, BIOCHIM BIOPHYS ACTA, V989, P163, DOI 10.1016/0304-419X(89)90041-3; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DRAKE FH, 1989, BIOCHEMISTRY-US, V28, P8154, DOI 10.1021/bi00446a029; DUGUET M, 1983, NUCLEIC ACIDS RES, V11, P1059, DOI 10.1093/nar/11.4.1059; EARNSHAW WC, 1988, BIOESSAYS, V9, P147, DOI 10.1002/bies.950090502; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; EARNSHAW WC, 1985, J CELL BIOL, V100, P1716, DOI 10.1083/jcb.100.5.1716; ESTEY E, 1987, BIOCHEMISTRY-US, V26, P4338, DOI 10.1021/bi00388a023; FISHER D, 1993, EXP CELL RES, V209, P255; GASSER SM, 1987, TRENDS GENET, V3, P16, DOI 10.1016/0168-9525(87)90156-9; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; GASSER SM, 1986, EMBO J, V5, P511, DOI 10.1002/j.1460-2075.1986.tb04240.x; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; HECK MMS, 1986, J CELL BIOL, V103, P2569, DOI 10.1083/jcb.103.6.2569; HECK MMS, 1989, J BIOL CHEM, V264, P15161; HIRANO T, 1993, J CELL BIOL, V120, P601, DOI 10.1083/jcb.120.3.601; HSIANG YH, 1988, CANCER RES, V48, P3230; ISHIDA R, 1995, CANCER RES, V55, P2299; ISHIDA R, 1994, J CELL BIOL, V126, P1341, DOI 10.1083/jcb.126.6.1341; ISHIDA R, 1991, CANCER RES, V51, P4909; ISHIMI Y, 1995, J MOL BIOL, V247, P835, DOI 10.1006/jmbi.1995.0183; KIM RA, 1989, J MOL BIOL, V208, P257, DOI 10.1016/0022-2836(89)90387-2; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; Meisner H, 1991, CURR OPIN CELL BIOL, V3, P474, DOI 10.1016/0955-0674(91)90076-B; MULNERLORILLON O, 1990, EUR J BIOCHEM, V193, P529, DOI 10.1111/j.1432-1033.1990.tb19368.x; NISHIZAWA K, 1991, J BIOL CHEM, V266, P3074; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROCA J, 1994, P NATL ACAD SCI USA, V91, P1781, DOI 10.1073/pnas.91.5.1781; ROTTMANN M, 1987, EMBO J, V6, P3939, DOI 10.1002/j.1460-2075.1987.tb02735.x; SAHYOUN N, 1986, P NATL ACAD SCI USA, V83, P1603, DOI 10.1073/pnas.83.6.1603; SAIJO M, 1992, BIOCHEMISTRY-US, V31, P359, DOI 10.1021/bi00117a007; SANDER M, 1984, P NATL ACAD SCI-BIOL, V81, P6938, DOI 10.1073/pnas.81.22.6938; SHIOZAKI K, 1992, J CELL BIOL, V119, P1023, DOI 10.1083/jcb.119.5.1023; STEVEN WS, 1994, EXP CELL RES, V211, P275; TAAGEPERA S, 1993, P NATL ACAD SCI USA, V90, P8407, DOI 10.1073/pnas.90.18.8407; TAKANO H, 1991, CANCER RES, V51, P3951; TAN KB, 1992, CANCER RES, V52, P231; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; WAKAMIYA T, 1993, CHEM LETT, P1401, DOI 10.1246/cl.1993.1401; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WASSERMAN RA, 1993, CANCER RES, V53, P3591; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; WELLS NJ, 1994, J BIOL CHEM, V269, P29746; YANO T, 1991, BIOCHEM BIOPH RES CO, V175, P1144, DOI 10.1016/0006-291X(91)91685-6; ZWELLING LA, 1989, J BIOL CHEM, V264, P16411	63	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30077	30082		10.1074/jbc.271.47.30077	http://dx.doi.org/10.1074/jbc.271.47.30077			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939955	hybrid			2022-12-25	WOS:A1996VU52500083
J	Yu, H; Li, X; Marchetto, GS; Dy, R; Hunter, D; Calvo, B; Dawson, TL; Wilm, M; Anderegg, RJ; Graves, LM; Earp, HS				Yu, H; Li, X; Marchetto, GS; Dy, R; Hunter, D; Calvo, B; Dawson, TL; Wilm, M; Anderegg, RJ; Graves, LM; Earp, HS			Activation of a novel calcium-dependent protein-tyrosine kinase - Correlation with c-jun N-terminal kinase but not mitogen-activated protein kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOMERULAR MESANGIAL CELLS; SMOOTH-MUSCLE CELLS; ANGIOTENSIN-II; SIGNALING PATHWAY; PHOSPHORYLATION; IDENTIFICATION; CDC42	Many G protein-coupled receptors (e.g. that of angiotensin II) activate phospholipase C beta, initially increasing intracellular calcium and activating protein kinase C. In the WB and GN4 rat liver epithelial cell lines, agonist-induced calcium signals also stimulate tyrosine phosphorylation and subsequently increase the activity of c-Jun N-terminal kinase (JNK), We have now purified the major calcium-dependent tyrosine kinase (CADTK), and by peptide and nucleic acid sequencing identified it as a rat homologue of human PYK2. CADTK/PYK2 is most closely related to p125(FAK) and both enzymes are expressed in WE and GN4 cells, Angiotensin II, which only slightly increases p125(FAK) tyrosine phosphorylation in GN4 cells, substantially increased CADTK tyrosine autophosphorylation and kinase activity, Agonists for other G protein-coupled receptors (e.g. LPA), or those increasing intracellular calcium (thapsigargin), also stimulated CADTK. In comparing the two rat liver cell lines, GN4 cells exhibited similar to 5-fold greater angiotensin II- and thapsigargin-dependent CADTK activation than WB cells, Although maximal JNK activation by stress-dependent pathways (e.g. UV and anisomycin) was equivalent in the two cell lines, calcium-dependent JNK activation was B-fold greater in GN4, correlating with CADTK activation. In contrast to JNK, the thapsigargin-dependent calcium signal did not activate mitogen-activated protein kinase and Ang II-dependent mitogen-activated protein kinase activation was not correlated with CADTK activation. Finally, while some stress-dependent activators of the JNK pathway (NaCl and sorbitol) stimulated CADTK, others (anisomycin, UV, and TNF alpha) did not, In summary, cells expressing CADTK/PYK2 appear to have two alternative JNK activation pathways: one stress-activated and the other calcium-dependent.	UNIV N CAROLINA,SCH MED,LINEBERGER COMPREHENS CANC CTR,DEPT MED,CHAPEL HILL,NC 27599; UNIV N CAROLINA,SCH MED,DEPT PHARMACOL,CHAPEL HILL,NC 27599; EUROPEAN MOL BIOL LAB,PROT & PEPTIDE GRP,D-69012 HEIDELBERG,GERMANY; GLAXO WELLCOME INC,RES & DEV,RES TRIANGLE PK,NC 27709	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; European Molecular Biology Laboratory (EMBL); GlaxoSmithKline			Graves, Lee/AAG-5470-2021	Dawson, Thomas/0000-0003-3878-1722; Wilm, Matthias/0000-0002-5461-6834	NIDDK NIH HHS [DK 31683] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031683] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1995, BIOESSAYS, V17, P491, DOI 10.1002/bies.950170605; BRAUN HP, 1995, ANN REV PHYSL, V57, P417; BUTCHER RD, 1993, BIOCHEM BIOPH RES CO, V196, P1280, DOI 10.1006/bbrc.1993.2391; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; COX AD, 1995, METHOD ENZYMOL, V255, P195; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; EARP HS, J BIOL CHEM, V270, P28440; FORCE T, 1991, J BIOL CHEM, V266, P6650; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HUCKLE WR, 1992, P NATL ACAD SCI USA, V89, P8837, DOI 10.1073/pnas.89.18.8837; HUCKLE WR, 1990, MOL CELL BIOL, V10, P6290, DOI 10.1128/MCB.10.12.6290; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; MARRERO MB, 1994, J BIOL CHEM, V269, P10935; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MOLLOY CJ, 1993, J BIOL CHEM, V268, P7338; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; SALLES JP, 1993, J BIOL CHEM, V268, P12805; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHORB W, 1994, J BIOL CHEM, V269, P19626; SHEVCHENKO A, 1996, IN PRESS ANAL CHEM; STABEL S, 1994, SEMIN CANCER BIOL, V5, P277; TSAO MS, 1985, CANCER RES, V45, P5134; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; YAN MH, 1994, NATURE, V372, P798; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	36	242	246	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29993	29998		10.1074/jbc.271.47.29993	http://dx.doi.org/10.1074/jbc.271.47.29993			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939945	hybrid			2022-12-25	WOS:A1996VU52500073
J	Zhang, L; Plow, EF				Zhang, L; Plow, EF			A discrete site modulates activation of I domains - Application to integrin alpha(M)beta(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL INHIBITORY FACTOR; PLATELET GLYCOPROTEIN-IB; MONOCLONAL-ANTIBODIES; COMPLEMENT RECEPTOR; CRYSTAL-STRUCTURE; CR3 CD11B/CD18; FACTOR BINDING; A-DOMAIN; IDENTIFICATION; MAC-1	A central characteristic of integrin adhesion receptors is their capacity to become activated, thereby enhancing their affinity for ligands. Here, we report the identification of a discrete site within the I domain of integrin alpha(M) beta(2), which modulates the adhesive activity of this receptor. Based upon the crystal structure, this region is composed of two short and spatially proximal loops, E(162)QLKKSKTL and Q(190)NNPNPRS. Mutations in these loops yield receptors which support spontaneous cell adhesion to fibrinogen, whereas mutation of an adjacent region and wild-type receptors require activation to adhere to this substrate. An activating monoclonal antibody enhanced the adhesive activity of one but not the other loop mutants, suggesting that the activation states of these two mutant receptors were not identical. Given that similar I domains exist in several other integrin alpha subunits and non-integrin proteins, and possibly in all integrin beta subunits, these two loop segments may represent a universal target for controlling integrin activation and the function of other I domain-containing proteins. In support of this hypothesis, several naturally occurring mutations that activate von Willebrand factor map to the same loops of its I(A) domain.			Zhang, L (corresponding author), CLEVELAND CLIN FDN,DEPT MOL CARDIOL,JOSEPH J JACOBS CTR THROMBOSIS & VASC BIOL,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043721, R01HL038292, R29HL043721] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43721, HL38292] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1988, J CELL BIOL, V107, P1893, DOI 10.1083/jcb.107.5.1893; ANDERSON DC, 1986, J IMMUNOL, V137, P15; BAJT ML, 1992, J BIOL CHEM, V267, P22211; BARNARD JW, 1995, J IMMUNOL, V155, P4876; BILSLAND CAG, 1994, J IMMUNOL, V152, P4582; DAVIS GE, 1992, EXP CELL RES, V200, P242, DOI 10.1016/0014-4827(92)90170-D; DIAMOND MS, 1993, J CELL BIOL, V120, P10311; DOOLITTLE RF, 1967, ARCH BIOCHEM BIOPHYS, V118, P456, DOI 10.1016/0003-9861(67)90374-8; GAMBLE JR, 1985, P NATL ACAD SCI USA, V82, P8667, DOI 10.1073/pnas.82.24.8667; GINSBURG D, 1993, THROMB HAEMOSTASIS, V69, P177; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; MATSUSHITA T, 1995, J BIOL CHEM, V270, P13406, DOI 10.1074/jbc.270.22.13406; MUCHOWSKI PJ, 1994, J BIOL CHEM, V269, P26419; ORLTEPP S, 1995, EUR J IMMUNOL, V25, P637; PHILLIPS DR, 1977, J BIOL CHEM, V252, P2121; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; RABB H, 1993, J IMMUNOL, V151, P990; ROSS GD, 1982, J EXP MED, V155, P96, DOI 10.1084/jem.155.1.96; SHAPPELL SB, 1990, J IMMUNOL, V144, P2702; SUGIMOTO M, 1991, J BIOL CHEM, V266, P18172; UEDA T, 1994, P NATL ACAD SCI USA, V91, P10680, DOI 10.1073/pnas.91.22.10680; VIOLETTE SM, 1995, J IMMUNOL, V155, P3092; Weiss EJ, 1996, NEW ENGL J MED, V334, P1090, DOI 10.1056/NEJM199604253341703; ZHANG L, 1990, BIOCHEMISTRY-US, V29, P10828, DOI 10.1021/bi00500a016; Zhang L, 1996, J BIOL CHEM, V271, P18211, DOI 10.1074/jbc.271.30.18211; ZHOU LB, 1994, J BIOL CHEM, V269, P17075	27	50	58	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29953	29957		10.1074/jbc.271.47.29953	http://dx.doi.org/10.1074/jbc.271.47.29953			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939940	hybrid			2022-12-25	WOS:A1996VU52500068
J	Okada, K; Urano, T; Baba, H; Furukawa, K; Furukawa, K; Shiku, H				Okada, K; Urano, T; Baba, H; Furukawa, K; Furukawa, K; Shiku, H			Independent and differential expression of two isotypes of human Nm23: Analysis of the promoter regions of the nm23-H1 and H2 genes	ONCOGENE			English	Article						nm23; NDP kinase; promoter; transcription; metastasis	NUCLEOSIDE DIPHOSPHATE KINASE; TUMOR-METASTASIS; RNA; DNA; AMPLIFICATION; CARCINOMAS; SUPPRESSOR; CELLS; LINE; RAT	We isolated genomic clones of two isotypes of human NDP kinase, nm23-H1 and H2, The nm23-H1 and H2 genes located in a tandem array contained 5 exons and most of the splicing sites in the exon-intron junctions of two isotypes were essentially identical, The regulatory elements of nm23-H1 and H2 genes were also analysed, One major and several minor transcriptional initiation sites were detected in the two isotypes by 5' RACE analysis in HeLa cell, We also identified them by means of an RNase protection assay and primer extension Promoter activities were found in the 5' sequences of the two genes when placed upstream of the chloramphenicol acetyltransferase gene, Transcriptional activities of nm23-H1 and H2 regulatory regions were measured in a series of human cancer lines, The nm23-H1/nm23-H2 gene transcriptional activity ratio varied depending on the cell line, DNA sequencing of these two genes showed that their promoter regions contain distinct binding sites for known transcriptional factors, These studies suggest that the two isotypes of the nm23 genes might be regulated dissimilarly, and in cell type specific manner.	NAGASAKI UNIV,SCH MED,DEPT ONCOL,NAGASAKI 852,JAPAN; NAGASAKI UNIV,SCH MED,DEPT ORTHOPAED SURG,NAGASAKI 852,JAPAN; MIE UNIV,SCH MED,DEPT INTERNAL MED 2,TSU,MIE 514,JAPAN; TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111	Nagasaki University; Nagasaki University; Mie University; Tufts University				Urano, Takeshi/0000-0003-3383-3554				BABA H, 1995, CANCER RES, V55, P1977; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; CHEN HC, 1994, ONCOGENE, V9, P2905; FISHMAN JR, 1994, J UROLOGY, V152, P202, DOI 10.1016/S0022-5347(17)32862-8; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HAMA H, 1991, GENE, V105, P31, DOI 10.1016/0378-1119(91)90510-I; HIGASHIYAMA M, 1992, BRIT J CANCER, V66, P533, DOI 10.1038/bjc.1992.308; KIMURA N, 1990, J BIOL CHEM, V265, P15744; LEONE A, 1993, ONCOGENE, V8, P2325; LEONE A, 1993, ONCOGENE, V8, P855; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; OKABEKADO J, 1992, BIOCHEM BIOPH RES CO, V182, P987, DOI 10.1016/0006-291X(92)91829-F; OKADA K, 1994, CANCER RES, V54, P3979; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEIFERT M, 1995, BIOCHEM BIOPH RES CO, V215, P910, DOI 10.1006/bbrc.1995.2550; SHIMADA N, 1993, J BIOL CHEM, V268, P2583; STAHL JA, 1991, CANCER RES, V51, P445; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; TOKUNAGA Y, 1993, INT J CANCER, V55, P66, DOI 10.1002/ijc.2910550113; URANO T, 1992, FEBS LETT, V309, P358, DOI 10.1016/0014-5793(92)80807-S; URANO T, 1992, INT J ONCOL, V1, P425; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; YAMASHIRO S, 1994, ONCOGENE, V9, P2461	26	19	21	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 7	1996	13	9					1937	1943						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934540				2022-12-25	WOS:A1996VR79500013
J	Ikin, AF; Annaert, WG; Takei, K; DeCamilli, P; Jahn, R; Greengard, P; Buxbaum, JD				Ikin, AF; Annaert, WG; Takei, K; DeCamilli, P; Jahn, R; Greengard, P; Buxbaum, JD			Alzheimer amyloid protein precursor is localized in nerve terminal preparations to Rab5-containing vesicular organelles distinct from those implicated in the synaptic vesicle pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERIC IMMUNOGLOBULIN RECEPTOR; POLARIZED EPITHELIAL-CELLS; HIPPOCAMPAL-NEURONS; ENDOCYTIC PATHWAY; PLASMA-MEMBRANE; PC12 CELLS; SYNAPSIN-I; TRANSPORT; SYNAPTOPHYSIN; TRAFFICKING	In order to localize amyloid protein precursor (APP) in nerve terminals, we have immunoisolated vesicular organelles from nerve terminal preparations using antibodies to Rab5 and synaptophysin, These immunoisolates were then analyzed by electron microscopy and by immunoblotting. The synaptophysin immunoisolates represented a nearly homogeneous population of small synaptic vesicles, with less than 10% contamination by other organelles, and very little APP. In contrast, Rab5 immunoisolates contained, in addition to small synaptic vesicles, substantial numbers of large uni- and bilamellar vesicles and high levels of APP. Thus, it appears that nerve terminal APP is contained predominantly in large vesicular organelles, distinct from synaptic vesicles and from the synaptic vesicle recycling pathway.	ROCKEFELLER UNIV, MOL & CELLULAR NEUROSCI LAB, NEW YORK, NY 10021 USA; ROCKEFELLER UNIV, ZACHARY & ELIZABETH M FISHER CTR, NEW YORK, NY 10021 USA; YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06536 USA; YALE UNIV, SCH MED, HOWARD HUGHES MED INST, NEW HAVEN, CT 06536 USA	Rockefeller University; Rockefeller University; Yale University; Howard Hughes Medical Institute; Yale University			Buxbaum, Joseph D/G-6001-2010	Buxbaum, Joseph/0000-0001-8898-8313; Jahn, Reinhard/0000-0003-1542-3498; Takei, Kohji/0000-0002-6555-9425	NATIONAL INSTITUTE ON AGING [P01AG009464] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BONZELIUS F, 1994, J CELL BIOL, V127, P1603, DOI 10.1083/jcb.127.6.1603; BOOTH RFG, 1978, BIOCHEM J, V176, P365, DOI 10.1042/bj1760365; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; BUCCI C, 1994, P NATL ACAD SCI USA, V91, P5061, DOI 10.1073/pnas.91.11.5061; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; CAPORASO GL, 1994, J NEUROSCI, V14, P3122; CHILCOTE TJ, 1995, J CELL BIOL, V129, P219, DOI 10.1083/jcb.129.1.219; DEHOOP M, 1995, J CELL BIOL, V130, P1447, DOI 10.1083/jcb.130.6.1447; DEHOOP MJ, 1994, NEURON, V13, P11, DOI 10.1016/0896-6273(94)90456-1; FLETCHER TL, 1991, J NEUROSCI, V11, P1617; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; JAHN R, 1994, ANNU REV NEUROSCI, V17, P219, DOI 10.1146/annurev.ne.17.030194.001251; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; KELLY RB, 1993, ANNU REV NEUROSCI, V16, P95, DOI 10.1146/annurev.ne.16.030193.000523; Koo EH, 1996, J CELL SCI, V109, P991; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; KOO EH, 1994, J BIOL CHEM, V269, P17386; MAYCOX PR, 1992, J CELL BIOL, V118, P1379, DOI 10.1083/jcb.118.6.1379; MORIN PJ, 1993, J NEUROCHEM, V61, P464; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; MOSTOV KE, 1994, ANNU REV IMMUNOL, V12, P63, DOI 10.1146/annurev.immunol.12.1.63; MUNDIGL O, 1994, CURR OPIN CELL BIOL, V6, P561, DOI 10.1016/0955-0674(94)90077-9; NICHOLLS DG, 1978, BIOCHEM J, V170, P511, DOI 10.1042/bj1700511; SIMONS M, 1995, J NEUROSCI RES, V41, P121, DOI 10.1002/jnr.490410114; SISODIA SS, 1995, FASEB J, V9, P366, DOI 10.1096/fasebj.9.5.7896005; SISODIA SS, 1993, J NEUROSCI, V13, P3136; SUDHOF TC, 1993, PROG BRAIN RES, V98, P235; TOMIMOTO H, 1995, BRAIN RES, V672, P187, DOI 10.1016/0006-8993(94)01160-J; VONMOLLARD GF, 1994, EUR J CELL BIOL, V65, P319; YAMAZAKI T, 1995, J CELL BIOL, V129, P431, DOI 10.1083/jcb.129.2.431; Yamazaki T, 1996, J CELL SCI, V109, P999; Zerial M., 1993, Cytotechnology, V11, pS47, DOI 10.1007/BF00746052	34	73	75	1	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					31783	31786		10.1074/jbc.271.50.31783	http://dx.doi.org/10.1074/jbc.271.50.31783			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943215	hybrid			2022-12-25	WOS:A1996VY34000006
J	Penix, LA; Sweetser, MT; Weaver, WM; Hoeffler, JP; Kerppola, TK; Wilson, CB				Penix, LA; Sweetser, MT; Weaver, WM; Hoeffler, JP; Kerppola, TK; Wilson, CB			The proximal regulatory element of the interferon-gamma promoter mediates selective expression in T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; CYTOKINE GENE-EXPRESSION; NF-AT; NUCLEAR FACTOR; CYCLIC-AMP; C-JUN; TRANSCRIPTIONAL REGULATION; PROSTAGLANDIN E(2); ANTIGEN RECEPTOR; CYCLOSPORINE-A	Interferon-gamma (IFN-gamma) is produced by natural killer cells and certain subsets of T cells, but the basis for its selective expression is unknown. Within the region between -108 and -40 base pairs of the IFN-gamma promoter are two conserved and essential regulatory elements, which confer activation-specific expression in T cells. This report describes studies indicating that the most proximal of these two regulatory elements is an important determinant of its restricted expression. The proximal element is a composite site that binds members of the CREB/ATF, AP-1, and octamer families of transcription factors. Jun is essential for activation-induced transcription and binds preferably as a heterodimer with ATF-2. In contrast, CREB appears to dampen transcription from this element. The CpG dinucleotide in this element is selectively methylated in Th2 T cells and other cells that do not express IFN-gamma, and methylation markedly reduces transcription factor binding, As a target for DNA methylation and for binding of transcription factors that mediate or impede transcription, this element appears to play a central role in controlling IFN-gamma expression.	UNIV WASHINGTON,DEPT PEDIAT,SCH MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT IMMUNOL,SCH MED,SEATTLE,WA 98195; YALE UNIV,SCH MED,DEPT PEDIAT,NEW HAVEN,CT 06520; INVITROGEN CORP,SAN DIEGO,CA 92121; UNIV MICHIGAN,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Yale University; Thermo Fisher Scientific; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan				Kerppola, Tom/0000-0002-0611-9446	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007411] Funding Source: NIH RePORTER; NIAID NIH HHS [AI01117, AI07411] Funding Source: Medline; NICHD NIH HHS [HD94002] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ABATE C, 1990, P NATL ACAD SCI USA, V87, P1031; ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; BENBROOK DM, 1994, NUCLEIC ACIDS RES, V22, P1463, DOI 10.1093/nar/22.8.1463; BETZ M, 1991, J IMMUNOL, V146, P108; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BURCHETT SK, 1988, J IMMUNOL, V140, P3473; CHUVPILO S, 1993, NUCLEIC ACIDS RES, V21, P5694, DOI 10.1093/nar/21.24.5694; CIPPITELLI M, 1995, J BIOL CHEM, V270, P12548, DOI 10.1074/jbc.270.21.12548; DAYTON MA, 1992, CYTOKINE, V4, P454, DOI 10.1016/1043-4666(92)90005-C; DEGRAZIA U, 1994, J EXP MED, V180, P1485, DOI 10.1084/jem.180.4.1485; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; FEUERSTEIN N, 1995, J IMMUNOL, V154, P68; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GEORGOPOULOS K, 1992, MOL CELL BIOL, V12, P747, DOI 10.1128/MCB.12.2.747; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HILKENS CMU, 1995, EUR J IMMUNOL, V25, P59, DOI 10.1002/eji.1830250112; HO LC, 1991, EMBO J, V10, P1187; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; KATAMURA K, 1995, J IMMUNOL, V155, P4604; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P5479, DOI 10.1128/MCB.13.9.5479; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEDERER JA, 1994, J IMMUNOL, V152, P77; LEE MR, 1992, J IMMUNOL, V148, P1906; LEWIS DB, 1988, P NATL ACAD SCI USA, V85, P9743, DOI 10.1073/pnas.85.24.9743; LOCKSLEY RM, 1995, PRINCIPLES PRACTICE, V1, P102; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; MELVIN AJ, 1995, EUR J IMMUNOL, V25, P426, DOI 10.1002/eji.1830250218; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; NOVAK TJ, 1990, P NATL ACAD SCI USA, V87, P9353, DOI 10.1073/pnas.87.23.9353; PANG YB, 1992, BLOOD, V80, P724; PENIX L, 1993, J EXP MED, V178, P1483, DOI 10.1084/jem.178.5.1483; PFEUFFER I, 1994, J IMMUNOL, V153, P5572; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; ROONEY JW, 1994, EMBO J, V13, P625, DOI 10.1002/j.1460-2075.1994.tb06300.x; ROONEY JW, 1995, MOL CELL BIOL, V15, P6299; ROONEY JW, 1995, IMMUNITY, V2, P473, DOI 10.1016/1074-7613(95)90028-4; SASSONECORSI P, 1994, EMBO J, V13, P4717, DOI 10.1002/j.1460-2075.1994.tb06797.x; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; STIMAC E, 1988, MOL CELL BIOL, V8, P3734, DOI 10.1128/MCB.8.9.3734; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; SWAIN SL, 1991, IMMUNOL REV, V123, P115, DOI 10.1111/j.1600-065X.1991.tb00608.x; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; TSURUTA L, 1995, J IMMUNOL, V154, P5255; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; ULLMAN KS, 1993, GENE DEV, V7, P188, DOI 10.1101/gad.7.2.188; ULLMAN KS, 1991, SCIENCE, V254, P558, DOI 10.1126/science.1683003; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; WEIH F, 1991, EMBO J, V10, P2559, DOI 10.1002/j.1460-2075.1991.tb07796.x; YOUNG HA, 1994, J IMMUNOL, V153, P3603	63	163	165	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					31964	31972		10.1074/jbc.271.50.31964	http://dx.doi.org/10.1074/jbc.271.50.31964			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943243	hybrid			2022-12-25	WOS:A1996VY34000034
J	Fotedar, A; Cannella, D; Fitzgerald, P; Rousselle, T; Gupta, S; Doree, M; Fotedar, R				Fotedar, A; Cannella, D; Fitzgerald, P; Rousselle, T; Gupta, S; Doree, M; Fotedar, R			Role for cyclin A-dependent kinase in DNA replication in human S phase cell extracts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN VIRUS-40 DNA; XENOPUS EGG EXTRACTS; LARGE-TUMOR-ANTIGEN; PROTEIN-KINASE; NUCLEAR ANTIGEN; T-ANTIGEN; POLYMERASE-DELTA; SV40 ORIGIN; STARFISH OOCYTES; BINDING-PROTEIN	Cell cycle progression is regulated by cyclin dependent kinases, Using in vitro replication of SV40 origin containing DNA as a model system, we have performed a detailed analysis of the dependence on cyclin-associated kinases of mammalian DNA replication, Complete immunodepletion of cyclin A from human S phase cell extracts decreases replication, and replication activity of cyclin A-depleted S phase extracts can subsequently be restored by the addition of purified CDK2-cyclin A kinase, Addition of cyclin A alone reconstitutes both kinase activity and DNA replication, whereas addition of cyclin E or cyclin B reconstitutes neither, We therefore conclude that reconstitution of DNA replication specifically correlates with an increase in kinase activity, By comparison, depletion of cyclin E from S phase cell extracts does not have any significant inhibitory effect on DNA replication, Moreover, specific p21(Waf1) mutants that bind to CDK2-cyclin and inhibit both cyclin A and cyclin E kinase activities, but do not bind to proliferating cell nuclear antigen, inhibit DNA replication to the same extent as cyclin A depletion. Together, these results show that the kinase activity associated with cyclin A, but not with cyclin E, is primarily responsible for activating SV40 plasmid replication in mammalian S phase cell extracts, Finally, we present evidence that the cyclin-dependent kinase does not influence the assembly of initiation complexes but acts at a stage prior to elongation.	LA JOLLA INST ALLERGY & IMMUNOL, DIV MOL BIOL, LA JOLLA, CA 92037 USA; INST BIOL STRUCT, F-38027 GRENOBLE 1, FRANCE; CNRS, CRBM, UPR 9008, F-34033 MONTPELLIER, FRANCE	La Jolla Institute for Immunology; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier			Cannella, Dominique/F-4879-2019	Cannella, Dominique/0000-0002-1665-9833	NIAID NIH HHS [AI3145301] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031453] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI Y, 1994, EMBO J, V13, P4153, DOI 10.1002/j.1460-2075.1994.tb06733.x; ATHERTONFESSLER S, 1993, MOL CELL BIOL, V13, P1675, DOI 10.1128/MCB.13.3.1675; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BRENOTBOSC F, 1995, CHROMOSOMA, V103, P517, DOI 10.1007/BF00355316; BRUSH GS, 1994, P NATL ACAD SCI USA, V91, P12520, DOI 10.1073/pnas.91.26.12520; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CHEVALIER S, 1995, J CELL SCI, V108, P1831; DODSON M, 1987, SCIENCE, V238, P964, DOI 10.1126/science.2823389; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; EKI T, 1992, J BIOL CHEM, V267, P7284; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FOTEDAR R, 1991, COLD SH Q B, V56, P325; Fotedar R, 1996, ONCOGENE, V12, P2155; FOTEDAR R, 1992, EMBO J, V11, P2177, DOI 10.1002/j.1460-2075.1992.tb05277.x; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOUBIN F, 1995, ONCOGENE, V10, P2281; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P24203; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; HOSS A, 1990, J VIROL, V64, P4799; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; KOBAYASHI H, 1991, COLD SH Q B, V56, P437; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LABBE JC, 1991, METHOD ENZYMOL, V200, P291; LORCA T, 1992, J CELL SCI, V102, P55; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MCVEY D, 1993, J VIROL, V67, P5206, DOI 10.1128/JVI.67.9.5206-5215.1993; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; NASHEUER HP, 1991, J BIOL CHEM, V266, P7893; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; NURSE P, 1991, NATURE, V354, P356, DOI 10.1038/354356a0; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAN ZQ, 1994, P NATL ACAD SCI USA, V91, P8343, DOI 10.1073/pnas.91.18.8343; PINES J, 1993, BIOCHEM SOC T, V21, P921, DOI 10.1042/bst0210921; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PONDAVEN P, 1990, GENE DEV, V4, P9, DOI 10.1101/gad.4.1.9; PROSPERI E, 1994, EXP CELL RES, V215, P257, DOI 10.1006/excr.1994.1341; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; ROBERTS JM, 1988, SCIENCE, V241, P1486, DOI 10.1126/science.2843984; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STILLMAN B, 1985, EMBO J, V4, P2933, DOI 10.1002/j.1460-2075.1985.tb04026.x; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P3839, DOI 10.1128/MCB.9.9.3839; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; WOBBE CR, 1986, P NATL ACAD SCI USA, V83, P4612, DOI 10.1073/pnas.83.13.4612; WOLD MS, 1987, P NATL ACAD SCI USA, V84, P3643, DOI 10.1073/pnas.84.11.3643; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YAN H, 1995, J CELL BIOL, V129, P1, DOI 10.1083/jcb.129.1.1; ZENG XR, 1994, J BIOL CHEM, V269, P24027; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	73	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31627	31637		10.1074/jbc.271.49.31627	http://dx.doi.org/10.1074/jbc.271.49.31627			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940182	hybrid			2022-12-25	WOS:A1996VW68600093
J	Liebmann, C; Graness, A; Boehmer, A; Kovalenko, M; Adomeit, A; Steinmetzer, T; Nurnberg, B; Wetzker, R; Boehmer, FD				Liebmann, C; Graness, A; Boehmer, A; Kovalenko, M; Adomeit, A; Steinmetzer, T; Nurnberg, B; Wetzker, R; Boehmer, FD			Tyrosine phosphorylation of G(s alpha) and inhibition of bradykinin-induced activation of the cyclic AMP pathway in A431 cells by epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ALPHA-SUBUNITS; REGULATORY PROTEIN; ADENYLATE-CYCLASE; CARCINOMA-CELLS; BINDING; IDENTIFICATION; STIMULATION; MEMBRANES	An increasing amount of experimental data suggest that cross-talk exists between pathways involving tyrosine kinases and heterotrimeric G proteins. In a previous study, we demonstrated that bradykinin (BK) increases the intracellular accumulation of cAMP in the human epidermoid carcinoma cell line A431 by stimulating adenylate cyclase activity via a stimulatory G protein (G(s alpha)) (Liebmann, C., Graness, A., Ludwig, B., Adomeit, A., Boehmer, A., Boehmer, F.-D., Nurnberg, B., and Wetzker, R. (1996) Biochem. J. 318, 109-118). Here, we present several lines of evidence indicating the ability of epidermal growth factor (EGF) to suppress BK-induced activation of the cAMP pathway in A431 cells via tyrosine phosphorylation of G(s alpha). G(s alpha) was specifically immunoprecipitated from A431 cells using the anti-alpha(s) antiserum AS 348. Tyrosine phosphorylation of G(s alpha) was detectable in EGF-pretreated cells with monoclonal anti-phosphotyrosine antibodies. Additionally, A431 cells were labeled with [P-32]orthophosphate in vivo and treated with EGF, and the resolved immunoprecipitates were subjected to amino acid analysis. The results clearly indicate that EGF induces tyrosine phosphorylation of G(s alpha) in A431 cells. Treatment of A431 cells with EGF decreased BK-induced cAMP accumulation in intact cells as well as the stimulation of adenylate cyclase by Bg, NaF, and guanyl nucleotides, but not by forskolin. Also, EGF treatment abolished both the BK- and isoprenaline-induced stimulation of guanosine 5'-O-(3-[S-35]thiotriphosphate) binding to G(s alpha). In contrast, the BK-evoked, G(q)-mediated stimulation of inositol phosphate formation in A431 cells was not affected by EGF pretreatment. Thus, EGF-induced tyrosine phosphorylation of G(s alpha) is accompanied by a loss of its susceptibility to G protein-coupled receptors and its ability to stimulate adenylate cyclase via guanyl nucleotide exchange. me propose that G(s alpha) may represent a key regulatory protein in the cross talk between the signal transduction pathways of BK and EGF in A431 cells.	UNIV JENA, MAX PLANCK GESELL, ARBEITSGRP MOL ZELLBIOL, FAK MED, D-07747 JENA, GERMANY; UNIV JENA, FAK MED, DEPT BIOCHEM 2, D-07743 JENA, GERMANY; FREE UNIV BERLIN, INST PHARMAKOL, D-14195 BERLIN, GERMANY	Friedrich Schiller University of Jena; Max Planck Society; Friedrich Schiller University of Jena; Free University of Berlin	Liebmann, C (corresponding author), UNIV JENA, INST BIOCHEM & BIOPHYS, BIOL PHARMAZEUT FAK, PHILOSOPHENWEG 12, D-07743 JENA, GERMANY.		Wetzker, Reinhard/AAD-8713-2019	Nurnberg, Bernd/0000-0002-5995-6555				ALLGEIER A, 1994, J BIOL CHEM, V269, P13733; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; GUDERMANN T, 1992, J BIOL CHEM, V267, P4479; HAUSDORFF WP, 1992, P NATL ACAD SCI USA, V89, P5720, DOI 10.1073/pnas.89.13.5720; HOSOI K, 1993, J CELL PHYSIOL, V157, P1, DOI 10.1002/jcp.1041570102; KOICH W, 1993, NATURE, V364, P249; KRUPINSKI J, 1988, J BIOL CHEM, V263, P12333; LAUGWITZ KL, 1994, METHOD ENZYMOL, V237, P283; LIANG M, 1991, J BIOL CHEM, V266, P13342; LIEBMANN C, 1991, EUR J PHARM-MOLEC PH, V207, P67, DOI 10.1016/S0922-4106(05)80039-2; LIEBMANN C, 1994, EUR J PHARM-MOLEC PH, V288, P35, DOI 10.1016/0922-4106(94)90007-8; Liebmann C, 1996, BIOCHEM J, V313, P109, DOI 10.1042/bj3130109; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOYERS JS, 1995, BIOCHEM J, V305, P411, DOI 10.1042/bj3050411; NAIR BG, 1990, J BIOL CHEM, V265, P21317; NAIR BG, 1993, BIOCHEM PHARMACOL, V46, P1239, DOI 10.1016/0006-2952(93)90473-A; NAKAJIMA Y, 1992, J BIOL CHEM, V267, P2437; NURNBERG B, 1994, BIOCHEM J, V300, P387; Poppleton H, 1996, J BIOL CHEM, V271, P6947, DOI 10.1074/jbc.271.12.6947; REUSDOMIANO S, 1995, FASEB J, V9, P1059; SCHULTZ G, 1983, METHOD ENZYMAT AN, V4, P369; SPICHER K, 1994, BIOCHEM BIOPH RES CO, V198, P906, DOI 10.1006/bbrc.1994.1129; TEITELBAUM I, 1990, J BIOL CHEM, V265, P4218; TILLY BC, 1987, BIOCHEM J, V244, P129, DOI 10.1042/bj2440129	29	37	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31098	31105		10.1074/jbc.271.49.31098	http://dx.doi.org/10.1074/jbc.271.49.31098			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940106	hybrid			2022-12-25	WOS:A1996VW68600017
J	Hill, RE; Himmeldirk, K; Kennedy, IA; Pauloski, RM; Sayer, BG; Wolf, E; Spenser, ID				Hill, RE; Himmeldirk, K; Kennedy, IA; Pauloski, RM; Sayer, BG; Wolf, E; Spenser, ID			The biogenetic anatomy of vitamin B-6 - A C-13 NMR investigation of the biosynthesis of pyridoxol in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							4-HYDROXY-L-THREONINE; 1-DEOXY-D-XYLULOSE; PRECURSOR; ORIGIN	It is shown by incorporation experiments with C-13 bond-labeled substrates, followed by analysis by means of C-13 NMR spectroscopy, that two compounds, 1-deoxy-D-xylulose (12) and 4-hydroxy-L-threonine (13), serve as precursors of pyridoxol (vitamin B-6) (1) in Escherichia coli. Together, these two compounds account for the entire C8N skeleton of the vitamin. 1-Deoxy-D-xylulose supplies the intact C-5 unit, C-2',2,3,4,4' of pyridoxol. 4-Hydroxy-L-threonine undergoes decarboxylation in supplying the intact C3N unit, N-1,C-6,5,5'. Both precursors are ultimately derived from glucose. The C-5 unit of pyridoxol that is derived from l-deoxy-D-xylulose originates by union of a triose phosphate (yielding C-3,4,4') with pyruvic acid (which decarboxylates to yield C-2',2). D-Erythroate (11) enters the C-3 unit, C-6,5,5', and is therefore an intermediate on the route from glucose into 4-hydroxy-L-threonine.	MCMASTER UNIV,DEPT CHEM,HAMILTON,ON L8S 4M1,CANADA; MCMASTER UNIV,DEPT PATHOL,HAMILTON,ON L8S 4M1,CANADA	McMaster University; McMaster University					NIGMS NIH HHS [GM 50778] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050778] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BADDILEY J, 1952, J CHEM SOC, P2583, DOI 10.1039/jr9520002583; Bain AD, 1996, CROAT CHEM ACTA, V69, P681; BROOKS HG, 1966, J HETEROCYCLIC CHEM, V3, P126, DOI 10.1002/jhet.5570030203; DEMPSEY WB, 1971, J BACTERIOL, V108, P1001, DOI 10.1128/JB.108.3.1001-1007.1971; DREWKE C, 1993, FEBS LETT, V318, P125, DOI 10.1016/0014-5793(93)80005-F; HILL RE, 1970, SCIENCE, V169, P773, DOI 10.1126/science.169.3947.773; HILL RE, 1971, J AM CHEM SOC, V93, P518; HILL RE, 1972, J BIOL CHEM, V247, P1869; HILL RE, 1977, J AM CHEM SOC, V99, P4179, DOI 10.1021/ja00454a058; HILL RE, 1989, J AM CHEM SOC, V111, P1916, DOI 10.1021/ja00187a076; HILL RE, 1987, J BIOL CHEM, V262, P7463; HILL RE, 1974, CAN J BIOCHEM CELL B, V52, P271, DOI 10.1139/o74-042; HILL RE, 1986, J CHEM SOC CHEM COMM, P612, DOI 10.1039/c39860000612; HILL RE, 1975, J CHEM SOC PERK T 1, P1622, DOI 10.1039/p19750001622; HILL RE, 1973, CAN J BIOCHEM CELL B, V51, P1412, DOI 10.1139/o73-185; HILL RE, 1986, VITAMIN B6 PYRIDOX A, P417; HIMMELDIRK K, 1996, J CHEM SOC CHEM COMM, P1187; IWANOW A, 1984, J AM CHEM SOC, V106, P1840, DOI 10.1021/ja00318a051; KENNEDY IA, 1995, CAN J CHEM, V73, P1329, DOI 10.1139/v95-164; KENNEDY IA, 1995, J AM CHEM SOC, V117, P1661, DOI 10.1021/ja00110a032; KOMIOTIS D, 1995, EUR J MED CHEM, V30, P321, DOI 10.1016/0223-5234(96)88240-7; LAM HM, 1990, J BACTERIOL, V172, P6518, DOI 10.1128/jb.172.11.6518-6528.1990; MAU TK, 1996, J BACTERIOL, V178, P2445; NOTHEIS C, 1995, BBA-PROTEIN STRUCT M, V1247, P265, DOI 10.1016/0167-4838(94)00235-9; Postma P. W., 1996, ESCHERICHIA COLI SAL, V1, P1149; POTTIE M, 1994, B SOC CHIM BELG, V103, P285; SPENSER ID, 1995, NAT PROD REP, V12, P555, DOI 10.1039/np9951200555; VELLA GJ, 1981, J BIOL CHEM, V256, P469; VELLA GJ, 1982, J BIOL CHEM, V257, P4008; VELLA GJ, 1980, J BIOL CHEM, V255, P3042; WOLF E, 1995, J ORG CHEM, V60, P6937, DOI 10.1021/jo00126a052; WOLF E, 1995, J CHEM SOC CHEM COMM, P1339, DOI 10.1039/c39950001339; YOKOTA A, 1986, AGR BIOL CHEM TOKYO, V50, P2517, DOI 10.1080/00021369.1986.10867789; YOKOTA A, 1984, AGR BIOL CHEM TOKYO, V48, P149, DOI 10.1080/00021369.1984.10866109; ZHAO GS, 1995, J BACTERIOL, V177, P883, DOI 10.1128/jb.177.4.883-891.1995; ZHAO GS, 1995, J BACTERIOL, V177, P2804, DOI 10.1128/jb.177.10.2804-2812.1995; Zhao GS, 1996, FEMS MICROBIOL LETT, V135, P275, DOI 10.1016/0378-1097(95)00466-1	37	103	108	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30426	30435		10.1074/jbc.271.48.30426	http://dx.doi.org/10.1074/jbc.271.48.30426			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940007	hybrid			2022-12-25	WOS:A1996VV15800024
J	Salamero, J; LeBorgne, R; Saudrais, C; Goud, B; Hoflack, B				Salamero, J; LeBorgne, R; Saudrais, C; Goud, B; Hoflack, B			Expression of major histocompatibility complex class II molecules in HeLa cells promotes the recruitment of AP-1 Golgi-specific assembly proteins on Golgi membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; INVARIANT CHAIN CONTAINS; ENDOSOMAL COMPARTMENTS; ANTIGEN PRESENTATION; CYTOPLASMIC TAIL; POPULATIONS; CLATHRIN; ADAPTERS; RECEPTOR; BINDING	The newly synthesized major histocompatibility complex (MHC) class II molecules, an alpha beta dimer associated with the Ii invariant chain, must be targeted to endosomal, lysosomal enzyme-rich compartments in order to bind and present immunogenic peptides, The precise route followed by this complex at the exit of the trans Golgi network, the last sorting station of the biosynthetic pathway, is poorly understood, We show here that overexpression of alpha beta Ii complexes in HeLa cells promotes the first step of clathrin-coat assembly in vitro, that is the ARF-dependent translocation of AP-1 Golgi-specific assembly proteins on membranes, In contrast, alpha beta dimers alone or associated with Ii lacking most of its cytoplasmic domain fail to recruit AP-1, This study strongly suggests that the invariant chain (Ii) is responsible for the AP-l-dependent sorting of the alpha beta dimers in the trans-Golgi network of HeLa cells and that the MHC class II molecules are, like the mannose 6-phosphate receptors, transported directly from this compartment to endosomes via clathrin-coated vesicles.	EUROPEAN MOL BIOL LAB,D-69012 HEIDELBERG,GERMANY; INST CURIE,LAB MECANISMES MOL TRANSPORT INTRACELLULAIRE,UMR 144 CNRS,F-75005 PARIS,FRANCE	European Molecular Biology Laboratory (EMBL); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite			Goud, Bruno/GWC-4807-2022; HOFLACK, Bernard/AAZ-6668-2020	LE BORGNE, Roland/0000-0001-6892-278X; salamero, jean/0000-0002-2610-5826				BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BHAKDI S, 1993, MED MICROBIOL IMMUN, V182, P167; BONNEROT C, 1995, IMMUNITY, V3, P335, DOI 10.1016/1074-7613(95)90118-3; BREMNES B, 1994, J CELL SCI, V107, P2021; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P999; GLICKMAN JN, 1993, J CELL BIOL, V123, P99, DOI 10.1083/jcb.123.1.99; Glickman JN, 1996, J CELL BIOL, V132, P769, DOI 10.1083/jcb.132.5.769; GUY K, 1982, EUR J IMMUNOL, V12, P942, DOI 10.1002/eji.1830121109; Harding CV, 1993, CURR OPIN CELL BIOL, V5, P596, DOI 10.1016/0955-0674(93)90128-D; HUMBERT M, 1993, EUR J IMMUNOL, V23, P3158, DOI 10.1002/eji.1830231218; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LAMPSON LA, 1980, J IMMUNOL, V125, P293; LeBorgne R, 1996, J BIOL CHEM, V271, P2162; LEBORGNE R, 1993, J BIOL CHEM, V268, P22552; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; MELLMAN I, 1995, CURR OPIN CELL BIOL, V7, P564, DOI 10.1016/0955-0674(95)80014-X; NEEFJES J J, 1991, Current Opinion in Cell Biology, V3, P601, DOI 10.1016/0955-0674(91)90029-X; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; NIJENHUIS M, 1994, EUR J IMMUNOL, V24, P873, DOI 10.1002/eji.1830240415; PIETERS J, 1993, J CELL SCI, V106, P831; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561	25	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30318	30321		10.1074/jbc.271.48.30318	http://dx.doi.org/10.1074/jbc.271.48.30318			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8939989	hybrid			2022-12-25	WOS:A1996VV15800006
J	Cao, JA; Rehemtulla, A; Bahou, W; Zucker, S				Cao, JA; Rehemtulla, A; Bahou, W; Zucker, S			Membrane type matrix metalloproteinase 1 activates pro-gelatinase A without furin cleavage of the N-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-SPECIFICITY; VONWILLEBRAND-FACTOR; 72-KDA GELATINASE; TISSUE INHIBITOR; CELLS; PRECURSOR; IDENTIFICATION; ANGIOGENESIS; COLLAGENASE; EXPRESSION	Membrane type matrix metalloproteinase 1 (MT-MMP1), a novel 63-kDa member of the matrix metalloproteinase family, is a membrane-anchored enzyme and an activator for gelatinase A. In addition to its C-terminal hydrophobic transmembrane domain, MT-MMP1 has an insertion of 11 amino acids between its propeptide and catalytic domain encrypted with a RRKR recognition motif for the paired basic amino acid cleaving enzyme, furin. In this report, we investigated whether the cleavage of the RRKR motif of MT-MMP1 by Golgi-associated furin is analogous to a similar enzyme activation mechanism observed with stromelysin-3. Mutant forms of MT-MMP1 were cotransfected into COS-1 cells with cDNAs for pro-gelatinase A and/or furin. Immunoprecipitation and immunoblotting using specific antibodies were employed to characterize cell proteins, Whereas furin readily cleaved soluble MT-MMP1 lacking the transmembrane domain (Delta MT-MMP1), a soluble stromelysin-1/Delta MT-MMP1 chimera without the RRKR basic motif was resistant to furin-induced cleavage. COS-1 cells cotransfected with wild type MT-MMP1 cDNA and furin cDNA demonstrated a 63-kDa protein (latent enzyme) on SDS-polyacrylamide gel electrophoresis rather than the anticipated lower molecular weight activated enzyme. Inhibition of furin activity with alpha 1-protease inhibitor(Pittsburgh) (a furin inhibitor) did not affect the pro-gelatinase A activation mechanism in COS-1 cells cotransfected with MT-MMP1 and pro-gelatinase A cDNAs. Furthermore, substitution of the RRKR motif of MT-MMP1 with alanine residues by site-directed mutagenesis resulted in the same 63-kDa protein without loss of pro-gelatinase A activation function. These data indicate that furin-induced activation of MT-MMP1 is not a prerequisite for pro-gelatinase A activation, The mechanism of activation of cell-bound MT-MMP1 remains to be elucidated.	VET ADM MED CTR,DEPT VET AFFAIRS MED CTR,DEPT MED,NORTHPORT,NY 11768; VET ADM MED CTR,DEPT VET AFFAIRS MED CTR,RES DEPT,NORTHPORT,NY 11768; SUNY STONY BROOK,DEPT MED,STONY BROOK,NY 11794; UNIV MICHIGAN,DEPT RADIOTHERAPY,ANN ARBOR,MI 48109	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Michigan System; University of Michigan					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002431] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-49149, HL-02431] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; BENJANNET S, 1992, J BIOL CHEM, V267, P11417; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; CAO J, 1995, J BIOL CHEM, V270, P801, DOI 10.1074/jbc.270.2.801; CRABBE T, 1994, BIOCHEMISTRY-US, V33, P6684, DOI 10.1021/bi00187a039; Foda HD, 1996, LAB INVEST, V74, P538; Imai K, 1996, CANCER RES, V56, P2707; KLUXEN FW, 1993, ANAL BIOCHEM, V208, P352, DOI 10.1006/abio.1993.1060; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MILHIET PE, 1995, BIOCHEM J, V309, P683, DOI 10.1042/bj3090683; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; OGATA Y, 1992, J BIOL CHEM, V267, P3581; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; Puente XS, 1996, CANCER RES, V56, P944; REHEMTULLA A, 1993, BIOCHEMISTRY-US, V32, P11586, DOI 10.1021/bi00094a015; REHEMTULLA A, 1992, BLOOD, V79, P2349; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; STRICKLAND DK, 1988, BIOCHEMISTRY-US, V27, P1458, DOI 10.1021/bi00405a010; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; WASLEY LC, 1993, J BIOL CHEM, V268, P8458; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378; ZUCKER S, 1995, J BIOL CHEM, V270, P23730, DOI 10.1074/jbc.270.40.23730; ZUCKER S, 1987, CANCER RES, V47, P1608	28	98	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30174	30180		10.1074/jbc.271.47.30174	http://dx.doi.org/10.1074/jbc.271.47.30174			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939968	hybrid			2022-12-25	WOS:A1996VU52500096
J	Chen, XC; Xu, HD; Tai, PC				Chen, XC; Xu, HD; Tai, PC			A significant fraction of functional SecA is permanently embedded in the membrane - SecA cycling on and off the membrane is not essential during protein translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI PLASMA-MEMBRANE; PROTON MOTIVE FORCE; ESCHERICHIA-COLI; PREPROTEIN TRANSLOCASE; SECRETORY PROTEIN; PRECURSOR PROTEIN; INNER MEMBRANE; ACIDIC PHOSPHOLIPIDS; ALKALINE-PHOSPHATASE; ESSENTIAL COMPONENT	SecA has been suggested to cycle on and off the cytoplasmic membrane of Escherichia coli during protein translocation, We have reconstituted S-35-SecA onto SecA-depleted membrane vesicles and followed the fate of the membrane-associated S-35-SecA during protein translocation. Some S-35-SecA was released from the membranes in a translocation-independent manner. However, a significant fraction of S-35-SecA remained on the membranes even after incubation with excess SecA. This fraction of S-35-SecA was shown to be integrated into the membrane and was active in protein translocation, indicating that SecA cycling on and off membrane is not required for protein translocation. Proteolysis experiments did not support the model of SecA insertion and deinsertion during protein translocation; instead, a major 48-kDa domain was found persistently embedded in the membrane regardless of translocation status, Thus, in addition to catalyzing ATP hydrolysis, certain domains of SecA probably play an important structural role in the translocation machinery, perhaps forming part of the protein-conducting channels.	GEORGIA STATE UNIV, DEPT BIOL, ATLANTA, GA 30303 USA	University System of Georgia; Georgia State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034766] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34766] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKITA M, 1990, J BIOL CHEM, V265, P8164; AKITA M, 1991, BIOCHEM BIOPH RES CO, V174, P211, DOI 10.1016/0006-291X(91)90507-4; ARKOWITZ RA, 1993, EMBO J, V12, P243, DOI 10.1002/j.1460-2075.1993.tb05650.x; BIEKER KL, 1990, J BIOENERG BIOMEMBR, V22, P291, DOI 10.1007/BF00763169; BIEKERBRADY K, 1992, EMBO J, V11, P3165, DOI 10.1002/j.1460-2075.1992.tb05393.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREUKINK E, 1995, J BIOL CHEM, V270, P7902, DOI 10.1074/jbc.270.14.7902; BREUKINK E, 1992, BIOCHEMISTRY-US, V31, P1119, DOI 10.1021/bi00119a021; BRUNDAGE L, 1992, J BIOL CHEM, V267, P4166; BRUSILOW WSA, 1993, MOL MICROBIOL, V9, P419, DOI 10.1111/j.1365-2958.1993.tb01703.x; CABELLI RJ, 1991, J BIOL CHEM, V266, P24420; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; CHEN L, 1985, J BACTERIOL, V161, P973, DOI 10.1128/JB.161.3.973-980.1985; CHEN L, 1986, J BACTERIOL, V167, P389, DOI 10.1128/jb.167.1.389-392.1986; CHEN LL, 1987, NATURE, V328, P164, DOI 10.1038/328164a0; CHEN LL, 1985, P NATL ACAD SCI USA, V82, P4384, DOI 10.1073/pnas.82.13.4384; CHUN SY, 1994, J BACTERIOL, V176, P4197, DOI 10.1128/jb.176.14.4197-4203.1994; CROOKE E, 1987, P NATL ACAD SCI USA, V84, P5216, DOI 10.1073/pnas.84.15.5216; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DOLAN KM, 1991, J BIOL CHEM, V266, P23329; DOUVILLE K, 1995, J BIOL CHEM, V270, P20106, DOI 10.1074/jbc.270.34.20106; DRIESSEN AJM, 1993, BIOCHEMISTRY-US, V32, P13190, DOI 10.1021/bi00211a030; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; ERNST F, 1994, J BIOL CHEM, V269, P12840; FANDL J, 1990, J BIOENERG BIOMEMBR, V22, P369, DOI 10.1007/BF00763173; FANDL JP, 1988, P NATL ACAD SCI USA, V85, P8953, DOI 10.1073/pnas.85.23.8953; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HASAN SM, 1978, J BACTERIOL, V133, P108, DOI 10.1128/JB.133.1.108-113.1978; HENDRICK JP, 1991, J BIOL CHEM, V266, P24596; HOFFSCHUTE HK, 1994, J BIOL CHEM, V269, P12833; JOLY JC, 1993, EMBO J, V12, P255, DOI 10.1002/j.1460-2075.1993.tb05651.x; KAWASAKI H, 1989, FEBS LETT, V242, P431, DOI 10.1016/0014-5793(89)80516-2; KIM YJ, 1994, CELL, V78, P845; KIMURA E, 1991, J BIOL CHEM, V266, P6600; KOONIN EV, 1992, FEBS LETT, V298, P6, DOI 10.1016/0014-5793(92)80009-6; LIEBKE HH, 1987, J BACTERIOL, V169, P1174, DOI 10.1128/jb.169.3.1174-1181.1987; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; MITCHELL C, 1993, MOL MICROBIOL, V10, P483, DOI 10.1111/j.1365-2958.1993.tb00921.x; NISHIYAMA K, 1991, BIOCHIM BIOPHYS ACTA, V1065, P89, DOI 10.1016/0005-2736(91)90015-Z; NISHIYAMA K, 1993, EMBO J, V12, P3409, DOI 10.1002/j.1460-2075.1993.tb06015.x; OLIVER DB, 1982, CELL, V30, P311, DOI 10.1016/0092-8674(82)90037-X; OLIVER DB, 1993, MOL MICROBIOL, V7, P159, DOI 10.1111/j.1365-2958.1993.tb01107.x; OLIVER DB, 1981, CELL, V25, P765, DOI 10.1016/0092-8674(81)90184-7; OLIVER DB, 1990, J BIOENERG BIOMEMBR, V22, P311, DOI 10.1007/BF00763170; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; Rajapandi T, 1996, MOL MICROBIOL, V20, P43, DOI 10.1111/j.1365-2958.1996.tb02487.x; RHOADS DB, 1984, J BACTERIOL, V159, P63, DOI 10.1128/JB.159.1.63-70.1984; ROLLO EE, 1988, J BACTERIOL, V170, P3281, DOI 10.1128/jb.170.7.3281-3282.1988; SALAVATI R, 1995, RNA, V1, P745; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SCHMIDT MG, 1988, J BACTERIOL, V170, P3404, DOI 10.1128/jb.170.8.3404-3414.1988; SHIOZUKA K, 1990, J BIOL CHEM, V265, P18843; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; TAI PC, 1991, METHOD CELL BIOL, V34, P167; TAI PC, 1992, ANTON LEEUW INT J G, V61, P105, DOI 10.1007/BF00580615; THOM JR, 1988, J BACTERIOL, V170, P5654, DOI 10.1128/jb.170.12.5654-5661.1988; ULBRANDT ND, 1992, J BIOL CHEM, V267, P15184; WATANABE M, 1990, P NATL ACAD SCI USA, V87, P1960, DOI 10.1073/pnas.87.5.1960; WATANABE M, 1993, P NATL ACAD SCI USA, V90, P9011, DOI 10.1073/pnas.90.19.9011; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; YAMADA H, 1989, J BIOL CHEM, V264, P18577	65	76	78	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29698	29706		10.1074/jbc.271.47.29698	http://dx.doi.org/10.1074/jbc.271.47.29698			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939903	hybrid			2022-12-25	WOS:A1996VU52500031
J	Cahill, CM; Waterman, WR; Xie, Y; Auron, PE; Calderwood, SK				Cahill, CM; Waterman, WR; Xie, Y; Auron, PE; Calderwood, SK			Transcriptional repression of the prointerleukin 1 beta gene by heat shock factor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; EXPRESSION; INTERLEUKIN-1; CELLS; BINDING; LIPOPOLYSACCHARIDE; TRANSDUCTION; TEMPERATURE; ACTIVATION; SEQUENCE	Heat shock factor 1 activates the promoters of heat shock genes at elevated temperatures through its interaction with heat shock elements. We have examined a new role for heat shock factor 1 in the repression of the prointerluekin 1 beta gene in human monocytes responding to stimulation with lipopolysaccharide. Both exposure to elevated temperatures and heat-independent heat shock factor 1 expression repressed the transcription of the prointerleukin 1 beta gene, and repression was strictly dependent on an intact consensus heat shock element in the prointerleukin 1 beta promoter to which heat shock factor 1 bound. This is the first demonstration of heat shock factor 1 as a transcriptional repressor and suggests a role for the factor in the counter-regulation of cytokine gene transcription.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,JOINT CTR RADIAT THERAPY,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School					NCI NIH HHS [CA47407, CA50642] Funding Source: Medline; NIAID NIH HHS [AI27850] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047407, R01CA050642] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027850] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; AURON PE, 1994, EUR CYTOKINE NETW, V5, P573; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BRUCE JL, 1993, CANCER RES, V53, P12; DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745; DINARELLO CA, 1986, CANCER RES, V46, P6236; FENTON MJ, 1988, J IMMUNOL, V140, P2267; FENTON MJ, 1987, J IMMUNOL, V138, P3972; HAHN GM, 1982, HYPERTHERMIA CANCER, P7; HENSOLD JO, 1990, MOL CELL BIOL, V10, P1600, DOI 10.1128/MCB.10.4.1600; HUNT C, 1990, GENE, V87, P199, DOI 10.1016/0378-1119(90)90302-8; JAKOBSEN BK, 1988, MOL CELL BIOL, V8, P5040, DOI 10.1128/MCB.8.11.5040; KAPPEL M, 1991, IMMUNOLOGY, V73, P304; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KNUDSEN PJ, 1987, J IMMUNOL, V139, P4129; KOMINATO Y, 1995, MOL CELL BIOL, V15, P59; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; PRICE BD, 1991, MOL CELL BIOL, V11, P3365, DOI 10.1128/MCB.11.6.3365; SCHILLER P, 1985, J MOL BIOL, V203, P97; SCHMIDT JA, 1988, J IMMUNOL, V141, P2027; SORGER PK, 1987, EMBO J, V6, P3035, DOI 10.1002/j.1460-2075.1987.tb02609.x; VELASCO S, 1991, J CLIN INVEST, V87, P1674, DOI 10.1172/JCI115184; Voellmy Richard, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P357; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; ZHANG Y, 1993, MOL CELL BIOL, V13, P3831, DOI 10.1128/MCB.13.6.3831; [No title captured]	28	164	175	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24874	24879						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8926278				2022-12-25	WOS:A1996VM67400086
J	Chiang, YC; Komarnitsky, P; Chase, D; Denis, CL				Chiang, YC; Komarnitsky, P; Chase, D; Denis, CL			ADR1 activation domains contact the histone acetyltransferase GCN5 and the core transcriptional factor TFIIB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY PROTEIN ADR1; REPRESSIBLE ALCOHOL-DEHYDROGENASE; HYDROPHOBIC AMINO-ACIDS; TATA-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; YEAST; IDENTIFICATION; ADA2; GAL4	The yeast transcriptional activator ADR1, which is required for ADH2 and peroxisomal gene expression, contains four separable and partially redundant activation domains (TADs), Mutations in ADA2 or GCN5, encoding components of the ADA coactivator complex involved in histone acetylation, severely reduced LexA-ADR1-TAD activation of a LexA-lacZ reporter gene, Similarly, the ability of the wild-type ADR1 gene to activate an ADH2-driven promoter was compromised in strains deleted for ADA2 or GCN5, In contrast, defects in other general transcription cofactors such as CCR4, CAF1/POP2, and SNF/SWI displayed much less or no effect on LexA-ADR1-TAD activation, Using an in vitro protein binding assay, ADA2 and GCN5 were found to specifically contact individual ADR1 TADs, ADA2 could bind TAD II, and GCN5 physically interacted with all four TADs, Both TADs I and IV were also shown to make specific contacts to the C-terminal segment of TFIIB, In contrast, no significant binding to TBP was observed, TAD IV deletion analysis indicated that its ability to bind GCN5 and TFIIB was directly correlated with its ability to activate transcription in vivo, ADR1 TADs appear to make several contacts, which may help explain both their partial redundancy and their varying requirements at different promoters, The contact to and dependence on GCN5, a histone acetyltransferase, suggests that rearrangement of nucleosomes may be one important means by which ADR1 activates transcription.	UNIV NEW HAMPSHIRE,DEPT BIOCHEM & MOL BIOL,DURHAM,NH 03824	University System Of New Hampshire; University of New Hampshire					NIGMS NIH HHS [GM41215] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041215] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; BARLEV NA, 1995, J BIOL CHEM, V270, P19337, DOI 10.1074/jbc.270.33.19337; BEMIS LT, 1988, MOL CELL BIOL, V8, P2125, DOI 10.1128/MCB.8.5.2125; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; CHENG C, 1994, MOL CELL BIOL, V14, P3842, DOI 10.1128/MCB.14.6.3842; CHERRY JR, 1989, CELL, V56, P409, DOI 10.1016/0092-8674(89)90244-4; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; CIRIACY M, 1981, MOL GEN GENET, V182, P159, DOI 10.1007/BF00422784; COOK WJ, 1994, J BIOL CHEM, V269, P9374; COOK WJ, 1994, MOL CELL BIOL, V14, P629, DOI 10.1128/MCB.14.1.629; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DENIS CL, 1983, MOL CELL BIOL, V3, P360, DOI 10.1128/MCB.3.3.360; DENIS CL, 1987, MOL GEN GENET, V208, P101, DOI 10.1007/BF00330429; DENIS CL, 1981, J MOL BIOL, V148, P355, DOI 10.1016/0022-2836(81)90181-9; DENIS CL, 1984, GENETICS, V108, P833; DONOVIEL MS, 1995, MOL CELL BIOL, V15, P3442; DRAPER MP, 1994, MOL CELL BIOL, V14, P4522, DOI 10.1128/MCB.14.7.4522; DRAPER MP, 1995, MOL CELL BIOL, V15, P3487; DRYSDALE CM, 1995, MOL CELL BIOL, V15, P1220, DOI 10.1128/MCB.15.3.1220; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HARTSHORNE TA, 1986, NATURE, V320, P283, DOI 10.1038/320283a0; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; LAURENT BC, 1992, GENE DEV, V6, P1707, DOI 10.1101/gad.6.9.1707; LEUTHER KK, 1993, CELL, V72, P575, DOI 10.1016/0092-8674(93)90076-3; LOHNING C, 1993, CURR GENET, V24, P193, DOI 10.1007/BF00351791; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; MELCHER K, 1995, MOL CELL BIOL, V15, P2839; PAVLIK P, 1993, CURR GENET, V24, P21, DOI 10.1007/BF00324660; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PINA B, 1993, MOL CELL BIOL, V13, P5981, DOI 10.1128/MCB.13.10.5981; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; SAKAI A, 1992, NUCLEIC ACIDS RES, V20, P6227, DOI 10.1093/nar/20.23.6227; SCHILD D, 1995, GENETICS, V140, P115; SILVERMAN N, 1994, P NATL ACAD SCI USA, V91, P11665, DOI 10.1073/pnas.91.24.11665; SIMON M, 1991, MOL CELL BIOL, V11, P669; SIMON MM, 1995, MOL GEN GENET, V249, P289, DOI 10.1007/BF00290529; TAGUCHI AKW, 1987, GENETICS, V116, P523; THUKRAL SK, 1989, MOL CELL BIOL, V9, P2360, DOI 10.1128/MCB.9.6.2360; Verdone L, 1996, MOL CELL BIOL, V16, P1978; YU J, 1989, MOL CELL BIOL, V9, P34, DOI 10.1128/MCB.9.1.34	44	69	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32359	32365		10.1074/jbc.271.50.32359	http://dx.doi.org/10.1074/jbc.271.50.32359			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943299	hybrid			2022-12-25	WOS:A1996VY34000090
J	Ingham, RJ; Krebs, DL; Barbazuk, SM; Turck, CW; Hirai, H; Matsuda, M; Gold, MR				Ingham, RJ; Krebs, DL; Barbazuk, SM; Turck, CW; Hirai, H; Matsuda, M; Gold, MR			B cell antigen receptor signaling induces the formation of complexes containing the Crk adapter proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; NUCLEOTIDE DISSOCIATION STIMULATOR; RAS-DEPENDENT ACTIVATION; BRUTONS TYROSINE KINASE; CROSS-LINKING; SH3 DOMAIN; RAS-P21 GTPASE; PC12 CELLS; IN-VIVO; INHIBITION	Crk proteins are Src homology (SH) 2/SH3-containing adapter proteins that can mediate the formation of signaling complexes, We show that engaging the B cell antigen receptor (BCR) on the RAMOS B cell Line caused both Crk-L and Crk II to associate with several tyrosine-phosphorylated proteins, me identified two of these phosphoproteins as Cas and Cbr and showed that both bound to the Crk SH2 domain after BCR engagement, ECR ligation also increased the amount of Crk proteins in the particulate fraction of the cells and induced the formation of Crk . Cas and Crk . Cbl complexes in the particulate fraction. We propose that tyrosine phosphorylation of membrane-associated Cas and Cbl creates binding sites for the Crk SH2 domain and recruits Crk complexes to cellular membranes, Thus, Crk proteins may participate in BCR signaling by using their SH2 domains to direct the interactions and subcellular localization of proteins that bind to their SH3 domains, In RAMOS cells, we found that the SH3 domains of Crk-L and Crk II bound C3G. Since C3G activates Rap, a negative regulator of the Ras pathway, Crk proteins may participate in regulation of Ras signaling by the BCR.	UNIV BRITISH COLUMBIA, DEPT MICROBIOL & IMMUNOL, VANCOUVER, BC V6T 1Z3, CANADA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA; UNIV TOKYO, FAC MED, DEPT INTERNAL MED 3, BUNKYO KU, TOKYO 113, JAPAN; NATL INST HLTH, DEPT PATHOL, SHINJUKU KU, TOKYO 162, JAPAN	University of British Columbia; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of Tokyo			Gold, Michael/AAF-2081-2021	Gold, Michael/0000-0003-1222-3191; Krebs, Danielle/0000-0002-6522-7308; Matsuda, Michiyuki/0000-0002-5876-9969				BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BAUMANN G, 1994, EUR J IMMUNOL, V24, P1799, DOI 10.1002/eji.1830240812; BLAKE TJ, 1991, ONCOGENE, V6, P653; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMPA MJ, 1991, BIOCHEM BIOPH RES CO, V174, P1, DOI 10.1016/0006-291X(91)90475-M; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEFRANCO AL, 1993, ANNU REV CELL BIOL, V9, P377, DOI 10.1146/annurev.cellbio.9.1.377; DEWEERS M, 1994, J BIOL CHEM, V269, P23857; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FARRELL FX, 1993, BIOCHEM J, V289, P349, DOI 10.1042/bj2890349; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GOLD MR, 1991, P NATL ACAD SCI USA, V88, P3436, DOI 10.1073/pnas.88.8.3436; GOLD MR, 1995, INT REV CYTOL, V157, P181, DOI 10.1016/S0074-7696(08)62159-2; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; HARIHARAN IK, 1991, CELL, V67, P717, DOI 10.1016/0092-8674(91)90066-8; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; HATA Y, 1990, J BIOL CHEM, V265, P7104; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; Kehry MR, 1996, J IMMUNOL, V156, P2345; KIM TJ, 1995, J BIOL CHEM, V270, P27504, DOI 10.1074/jbc.270.46.27504; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KLINZ FJ, 1992, EUR J BIOCHEM, V207, P207, DOI 10.1111/j.1432-1033.1992.tb17039.x; KNUDSEN BS, 1995, EMBO J, V14, P2191, DOI 10.1002/j.1460-2075.1995.tb07213.x; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MATSUDA M, 1993, J BIOL CHEM, V268, P4441; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MOTTO DG, 1994, J BIOL CHEM, V269, P21608; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SANUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524; SAXTON TM, 1994, J IMMUNOL, V153, P623; SCHUMACHER C, 1995, J BIOL CHEM, V270, P15341, DOI 10.1074/jbc.270.25.15341; Smit L, 1996, J BIOL CHEM, V271, P8564, DOI 10.1074/jbc.271.15.8564; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TENHOEVE J, 1993, ONCOGENE, V8, P2469; TORDAI A, 1994, J BIOL CHEM, V269, P7538; WITTINGHOFER A, 1995, FEBS LETT, V369, P52, DOI 10.1016/0014-5793(95)00667-X	51	68	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32306	32314		10.1074/jbc.271.50.32306	http://dx.doi.org/10.1074/jbc.271.50.32306			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943292	hybrid			2022-12-25	WOS:A1996VY34000083
J	Mitton, KP; Kamiya, T; Tumminia, SJ; Russell, P				Mitton, KP; Kamiya, T; Tumminia, SJ; Russell, P			Cysteine protease activated by expression of HIV-1 protease in transgenic mice - MIP26 (aquaporin-0) cleavage and cataract formation in vivo and ex vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL CHANNEL PROTEIN; LENS MEMBRANE; CALMODULIN; SEQUENCE; PERMEABILITY; LIPOSOMES; COMPLEX; FAMILY; AIDS	Transgenic mice, homozygous for HIV-1 protease expression in the eye lens, display degradation of some lens crystallins and cytoskeletal proteins prior to cataract formation on postnatal days 23-25, Alterations to the internal lens hydration state also occur; therefore, the status of the aquaporin protein MIP26 was examined over postnatal days 16-25 to determine if it was altered during cataractogenesis. The MTP was identical in transgenic and control lenses until day 21. By postnatal day 25 (frank cataract), in the lenses obtained from transgenic animals, the 26-kDa band was absent and there was a concurrent increase in the proportion of MIP23, Immunoblotting demonstrated cleavage at the C terminus, Lenses were also maintained in an organ culture system to demonstrate that the cataractogenic process is inherent to the isolated lens and to determine the contribution of cysteine protease action, Organ culture experiments revealed a similar progression to nuclear cataract formation as seen in vivo. Two-dimensional gel analysis of the soluble lens crystallin fraction of organ cultured lenses revealed the same cleavage pattern as occurs in vivo, Organ culture of transgenic lenses with E64, a cysteine protease inhibitor, dramatically delayed cataractogenesis and prevented proteolytic cleavage of both MIP26 and crystallins, HIV-1 protease, while the trigger of cataract formation, does not appear to be the protease responsible for cleavage of MIP or lens crystallins. These results suggest that activation of endogenous cysteine protease activity is involved in the cleavage of these proteins and occurs downstream of HIV-1 protease action.	KYOWA HAKKO KOGYO CO LTD,TOKYO 194,JAPAN	Kyowa Kirin Ltd	Mitton, KP (corresponding author), NEI,LAB MECHANISM OCULAR DIS,NIH,BLDG 6,RM 228,BETHESDA,MD 20892, USA.		mitton, kenneth/Y-1974-2019	mitton, kenneth/0000-0002-4751-7440				AGRE P, 1995, CURR OPIN CELL BIOL, V7, P472, DOI 10.1016/0955-0674(95)80003-4; ALCALA J, 1980, EXP EYE RES, V30, P695; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; Bettelheim FA, 1995, ARCH BIOCHEM BIOPHYS, V324, P223, DOI 10.1006/abbi.1995.0034; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CENEDELLA RJ, 1992, CURR EYE RES, V11, P801, DOI 10.3109/02713689209000753; CHEPELINSKY AB, 1994, HDB MEMBRANE CHANNEL, P413; DAVID LL, 1988, CURR EYE RES, V7, P411, DOI 10.3109/02713688809031791; EHRING GR, 1991, J MEMBRANE BIOL, V126, P75; ETO A, 1995, J BIOL CHEM, V270, P25115, DOI 10.1074/jbc.270.42.25115; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; GIRSCH SJ, 1985, J MEMBRANE BIOL, V83, P217, DOI 10.1007/BF01868696; GIRSCH SJ, 1985, J MEMBRANE BIOL, V83, P227, DOI 10.1007/BF01868697; GIRSCH SJ, 1991, CURR EYE RES, V10, P839, DOI 10.3109/02713689109013880; IWAKURA Y, 1992, AIDS, V6, P1069, DOI 10.1097/00002030-199210000-00002; LAMPE PD, 1990, EUR J BIOCHEM, V194, P541, DOI 10.1111/j.1432-1033.1990.tb15650.x; MICHEA LF, 1995, EXP EYE RES, V61, P293, DOI 10.1016/S0014-4835(05)80124-1; NAKAMURA M, 1989, BIOCHEMISTRY-US, V28, P449, DOI 10.1021/bi00428a007; PALMISANO DV, 1993, INVEST OPHTHALMOL  S, V34, P3158; PEARSON RB, 1985, J BIOL CHEM, V260, P4471; PERACCHIA C, 1985, CURR EYE RES, V4, P431, DOI 10.3109/02713688509025157; PERACCHIA C, 1985, BIOCHEM BIOPH RES CO, V133, P688, DOI 10.1016/0006-291X(85)90959-3; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; REDDY MC, 1992, BIOCHEM BIOPH RES CO, V189, P1578, DOI 10.1016/0006-291X(92)90256-K; REIZER J, 1993, CRIT REV BIOCHEM MOL, V28, P235, DOI 10.3109/10409239309086796; ROY D, 1979, BIOCHEM BIOPH RES CO, V88, P30, DOI 10.1016/0006-291X(79)91692-9; RUSSELL P, 1980, INVEST OPHTHALMOL  S, V19, P150; Schnaudigel O.-E., 1994, Ophthalmologe, V91, P668; Shiels A, 1996, NAT GENET, V12, P212, DOI 10.1038/ng0296-212; SONIGO P, 1985, CELL, V42, P369, DOI 10.1016/S0092-8674(85)80132-X; TAKEMOTO L, 1986, BIOCHEM BIOPH RES CO, V135, P965, DOI 10.1016/0006-291X(86)91022-3; TUMMINIA SJ, 1994, EXP EYE RES, V58, P367, DOI 10.1006/exer.1994.1027; Tumminia SJ, 1996, J BIOL CHEM, V271, P425, DOI 10.1074/jbc.271.1.425; WISTOW GJ, 1991, TRENDS BIOCHEM SCI, V16, P170, DOI 10.1016/0968-0004(91)90065-4; YOSHIDA H, 1985, INVEST OPHTH VIS SCI, V26, P953	35	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					31803	31806		10.1074/jbc.271.50.31803	http://dx.doi.org/10.1074/jbc.271.50.31803			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943220	hybrid			2022-12-25	WOS:A1996VY34000011
J	Rothman, A; Padan, E; Schuldiner, S				Rothman, A; Padan, E; Schuldiner, S			Topological analysis of NhaA, a Na+/H+ antiporter from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEINS; EXPRESSION; GENE; ANT	Analysis of the hydropathic profile of the amino acid sequence of NhaA, a Na+/H+ antiporter form Escherichia coli has previously suggested the existence of 11 putative transmembrane segments (Taglicht, D., Padan, E., and Schuldiner, S. (1991) J. Biol. Chem. 266, 11289-11294). In the present work to test the location of the C terminus, right-side-out and inside-out membrane vesicles were digested with carboxypeptidase B and probed with an antibody raised against a synthetic peptide whose sequence was based on the C terminus sequence, The results demonstrate that the C terminus is facing the cell interior because it is available for digestion only hom the inside, Previous evidence from an NhaA-beta-galactosidase fusion to loop 5 of NhaA indicated that this loop is also facing the cytoplasm (Karpel, R., Alon, T., Glaser, G., Schuldiner, S., and Padan, E. (1991) J. Biol. Chem. 266, 21753-21759) and therefore was not consistent with the position of the C terminus in an 11-transmembrane segment model, Therefore, the model was re-evaluated. For this purpose, 10 nhaA'-'phoA gene fusions were constructed and assayed for alkaline phosphatase activity, The results support a 12-transmembrane segment model with the N and C termini located in the cytoplasm, The evidence indicates that two very short segments, 14 and 16 amino acids long, must cross the membrane in an unknown conformation.	HEBREW UNIV JERUSALEM,ALEXANDER SILBERMAN INST LIFE SCI,IL-91904 JERUSALEM,ISRAEL	Hebrew University of Jerusalem			Schuldiner, Shimon/F-7628-2012	Schuldiner, Shimon/0000-0002-4874-6237				BIBI E, 1994, J BIOL CHEM, V269, P19910; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRICKMAN E, 1975, J MOL BIOL, V96, P307, DOI 10.1016/0022-2836(75)90350-2; DAVIS BD, 1950, J BACTERIOL, V60, P17, DOI 10.1128/JB.60.1.17-28.1950; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; GERCHMAN Y, 1993, P NATL ACAD SCI USA, V90, P1212, DOI 10.1073/pnas.90.4.1212; Gold L., 1987, ESCHERICHIA COLI SAL, V2, P1302; GOLDBERG EB, 1987, P NATL ACAD SCI USA, V84, P2615, DOI 10.1073/pnas.84.9.2615; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; KARPEL R, 1988, J BIOL CHEM, V263, P10408; KARPEL R, 1991, J BIOL CHEM, V266, P21753; KING SM, 1985, P NATL ACAD SCI USA, V82, P4717, DOI 10.1073/pnas.82.14.4717; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; OLAMI Y, 1996, IN PRESS J BIOL CHEM; PADAN E, 1994, BBA-BIOENERGETICS, V1185, P129, DOI 10.1016/0005-2728(94)90204-6; Padan E., 1996, HDB BIOL PHYS, V2, P501; ROSEN BP, 1986, METHOD ENZYMOL, V125, P328; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAGLICHT D, 1991, J BIOL CHEM, V266, P11289; TAGLICHT D, 1993, J BIOL CHEM, V268, P5382; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x	25	60	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32288	32292		10.1074/jbc.271.50.32288	http://dx.doi.org/10.1074/jbc.271.50.32288			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943289	hybrid			2022-12-25	WOS:A1996VY34000080
J	Lawn, RM; Pearle, AD; Kunz, LL; Rubin, EM; Reckless, J; Metcalfe, JC; Grainger, DJ				Lawn, RM; Pearle, AD; Kunz, LL; Rubin, EM; Reckless, J; Metcalfe, JC; Grainger, DJ			Feedback mechanism of focal vascular lesion formation in transgenic apolipoprotein(a) mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; GROWTH-FACTOR-BETA; EXPRESSING HUMAN APOLIPOPROTEIN(A); LOW-DENSITY-LIPOPROTEIN; TRANSFORMING GROWTH-FACTOR-BETA-1; FACTOR-BETA-1; DISEASE; ATHEROGENESIS; ACTIVATION; TAMOXIFEN	Apolipoprotein(a) (apo(a)), the distinguishing protein of atherogenic lipoprotein(a), directs accumulation of the lipoprotein(a) particle to sites in the arterial wall where atherosclerotic lipid lesions develop in man and in transgenic mice expressing human apo(a). It has been proposed that focal apo(a) accumulation in the transgenic mouse vessel wall causes the observed severe local inhibition of transforming growth factor-beta (TGF-beta) activity and the consequent activation of the smooth muscle cells, which subsequently accumulate lipid to form lesions if the mice are fed a high fat diet, We show that blocking formation of these vascular lesions by two independent mechanisms, tamoxifen treatment and increasing high density lipoprotein, also abolishes apo(a) accumulation, inhibition of TGF-beta activity, and activation of smooth muscle cells. The data are consistent with a feedback mechanism in which an initial accumulation of apo(a) inhibits local TGF-beta activity, leading to further accumulation of apo(a). Breaking the feedback loop prevents smooth muscle cell activation and therefore lipid lesion development.	NEORX CORP,SEATTLE,WA 98119; UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,BERKELEY,CA 94720; UNIV CAMBRIDGE,DEPT BIOCHEM,CAMBRIDGE CB2 1QW,ENGLAND	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of Cambridge	Lawn, RM (corresponding author), STANFORD UNIV,SCH MED,FALK CARDIOVASC RES CTR,300 PASTEUR DR,STANFORD,CA 94305, USA.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Assmann G, 1996, AM J CARDIOL, V77, P1179, DOI 10.1016/S0002-9149(96)00159-2; BJORKERUD S, 1991, ARTERIOSCLER THROMB, V63, P515; Bostom AG, 1996, JAMA-J AM MED ASSOC, V276, P544, DOI 10.1001/jama.276.7.544; BOTTALICO LA, 1991, J BIOL CHEM, V266, P22866; CAMPBELL JH, 1985, ARTERIOSCLEROSIS, V5, P318, DOI 10.1161/01.ATV.5.4.318; CHIESA G, 1992, J BIOL CHEM, V267, P24369; COLLETTA AA, 1991, J CLIN INVEST, V87, P277, DOI 10.1172/JCI114983; CUSHING GL, 1989, ARTERIOSCLEROSIS, V9, P593, DOI 10.1161/01.ATV.9.5.593; GALLUCCI BB, 1982, AM J SURG PATHOL, V6, P293, DOI 10.1097/00000478-198206000-00002; GAMBLE JR, 1988, SCIENCE, V242, P97; GIACHELLI C, 1991, BIOCHEM BIOPH RES CO, V177, P867, DOI 10.1016/0006-291X(91)91870-I; GRAINGER DJ, 1993, BIOCHEM J, V294, P109, DOI 10.1042/bj2940109; GRAINGER DJ, 1995, NAT MED, V1, P74, DOI 10.1038/nm0195-74; GRAINGER DJ, 1994, NATURE, V370, P460, DOI 10.1038/370460a0; GRAINGER DJ, 1995, NAT MED, V1, P1067, DOI 10.1038/nm1095-1067; GRAINGER DJ, 1995, BIOL REV, V70, P571, DOI 10.1111/j.1469-185X.1995.tb01652.x; GRAINGER DJ, 1993, SCIENCE, V260, P1655, DOI 10.1126/science.8503012; HEARN JA, 1992, AM J CARDIOL, V69, P736, DOI 10.1016/0002-9149(92)90497-M; JURGENS G, 1995, STROKE, V26, P1841, DOI 10.1161/01.STR.26.10.1841; KOJIMA S, 1991, J CELL BIOL, V113, P1439, DOI 10.1083/jcb.113.6.1439; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; LAWN RM, 1992, NATURE, V360, P670, DOI 10.1038/360670a0; LEFER AM, 1993, P NATL ACAD SCI USA, V90, P1018, DOI 10.1073/pnas.90.3.1018; LI HM, 1995, J CLIN INVEST, V95, P122, DOI 10.1172/JCI117628; LIU AC, 1994, J LIPID RES, V35, P2263; LYONS RM, 1988, J CELL BIOL, V106, P1659, DOI 10.1083/jcb.106.5.1659; MAJESKY MW, 1991, J CLIN INVEST, V88, P904, DOI 10.1172/JCI115393; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; Mosedale DE, 1996, J HISTOCHEM CYTOCHEM, V44, P1043, DOI 10.1177/44.9.8773570; NABEL EG, 1993, P NATL ACAD SCI USA, V90, P10759, DOI 10.1073/pnas.90.22.10759; NACHMAN RL, 1992, BLOOD, V79, P1897, DOI 10.1182/blood.V79.8.1897.bloodjournal7981897; Nielsen LB, 1996, CIRC RES, V78, P615, DOI 10.1161/01.RES.78.4.615; OWENS GK, 1988, J CELL BIOL, V107, P771, DOI 10.1083/jcb.107.2.771; PALABRICA TM, 1995, NAT MED, V1, P256, DOI 10.1038/nm0395-256; PITAS RE, 1990, J BIOL CHEM, V265, P12722; RATH M, 1989, ARTERIOSCLEROSIS, V9, P579, DOI 10.1161/01.ATV.9.5.579; RHOADS GG, 1986, JAMA-J AM MED ASSOC, V256, P2540, DOI 10.1001/jama.256.18.2540; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SANDERSON N, 1995, P NATL ACAD SCI USA, V92, P2572, DOI 10.1073/pnas.92.7.2572; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; SCHAEFER EJ, 1994, JAMA-J AM MED ASSOC, V271, P999, DOI 10.1001/jama.271.13.999; SHANAHAN CM, 1993, CIRC RES, V73, P193, DOI 10.1161/01.RES.73.1.193; SHEWMON DA, 1994, ARTERIOSCLER THROMB, V14, P1586, DOI 10.1161/01.ATV.14.10.1586; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; SORENSEN KE, 1994, J CLIN INVEST, V93, P50, DOI 10.1172/JCI116983; TERRES W, 1995, CIRCULATION, V91, P948, DOI 10.1161/01.CIR.91.4.948; TSURUMI Y, 1995, J AM COLL CARDIOL, V26, P1242, DOI 10.1016/0735-1097(95)00321-5; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; WILLIAMS JK, 1993, ARTERIOSCLER THROMB, V13, P548, DOI 10.1161/01.ATV.13.4.548; WOLF YG, 1994, J CLIN INVEST, V93, P1172, DOI 10.1172/JCI117070; ZYSOW BR, 1997, IN PRESS ARTERIOSCLE	51	49	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31367	31371		10.1074/jbc.271.49.31367	http://dx.doi.org/10.1074/jbc.271.49.31367			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940144	hybrid			2022-12-25	WOS:A1996VW68600055
J	Gao, P; Malbon, CC				Gao, P; Malbon, CC			Differentiation of F9 teratocarcinoma stem cells to primitive endoderm is regulated by the G(i alpha 2)/G(s alpha) axis via phospholipase C and not adenylylcyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; RETINOIC ACID; GS-ALPHA; MESSENGER-RNA; EXPRESSION; ACTIVATION; SUBUNIT; GAMMA; PLASMINOGEN; INDUCTION	Morphogen-induced decline in G(i alpha) triggers F9 teratocarcinoma stem cells to progress to primitive endoderm via activation of protein kinase C and mitogen-activated protein kinase (Gao, P., and Malbon, C. C, (1996) J. Biol. Chem. 271, 9002-9008). Constitutive expression of G(i alpha 2) blocks, whereas expression of G(s alpha) provokes, progression to primitive endoderm, permitting identification of the effectors of the response-utilizing chimera created between G(i alpha 2) and G(s alpha). N-terminal substitution of G(s alpha) with G(i alpha 2) sequence to create chimera G(i alpha 2 (1-54))/G(s alpha) produced a chimera that activated adenylylcyclase but abolished progression to primitive endoderm and activation of phospholipase C, C-terminal substitution of G(s alpha) with G(i alpha 2) sequence to G(s alpha)/G(i alpha 2 (320-355)) enhanced the ability of G(i alpha 2) to promote progression, The Q205L-activated mutant of G(i alpha 2) suppresses, whereas the G225T-activated mutant of G(s alpha) strongly activates phospholipase C and progression in these cells, The N-terminal region of G(s alpha) (residues 62-86) appears to act as a dominant switch for the G(s alpha)- (activation) versus G(i alpha 2)- (suppression) mediated control of phospholipase C and progression to primitive endoderm.	SUNY STONY BROOK,MED CTR,DEPT MOL PHARMACOL,SCH MED,HSC,DIABET & METAB DIS RES CTR,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			malbon, craig/ABF-3604-2020					ANDRADEGORDON P, 1986, BIOCHEMISTRY-US, V25, P4033, DOI 10.1021/bi00362a007; Bell R M, 1986, Methods Enzymol, V124, P353; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BROWN BL, 1971, BIOCHEM J, V121, P561, DOI 10.1042/bj1210561; CHAN SDH, 1990, J BIOL CHEM, V265, P20081; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DARROW AL, 1990, METHOD ENZYMOL, V190, P110; GALVINPARTON PA, 1990, J BIOL CHEM, V265, P1771; Gao P, 1996, J BIOL CHEM, V271, P9002, DOI 10.1074/jbc.271.15.9002; GAO P, 1995, AM J PHYSIOL-CELL PH, V268, pC1460, DOI 10.1152/ajpcell.1995.268.6.C1460; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; GUPTA SK, 1991, J CELL BIOCHEM, V47, P359, DOI 10.1002/jcb.240470410; HU L, 1990, MOL CELL BIOL, V10, P391, DOI 10.1128/MCB.10.1.391; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LAROSA GJ, 1988, P NATL ACAD SCI USA, V85, P329, DOI 10.1073/pnas.85.2.329; OSAWA S, 1990, CELL, V63, P697, DOI 10.1016/0092-8674(90)90136-3; PREISS JE, 1987, METHOD ENZYMOL, V141, P294; RICKLES RJ, 1988, J BIOL CHEM, V263, P1563; ROBISHAW JD, 1986, J BIOL CHEM, V261, P9587; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; Venkatakrishnan G, 1996, J BIOL CHEM, V271, P5066; WATKINS DC, 1994, BIOCHEM J, V299, P593, DOI 10.1042/bj2990593; WATKINS DC, 1992, SCIENCE, V258, P1373, DOI 10.1126/science.1455234; WORLEY PF, 1987, NATURE, V325, P159, DOI 10.1038/325159a0; WU TCJ, 1992, DIFFERENTIATION, V51, P219, DOI 10.1111/j.1432-0436.1992.tb00699.x; YASUDA I, 1990, BIOCHEM BIOPH RES CO, V166, P1220, DOI 10.1016/0006-291X(90)90996-Z	26	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30692	30698		10.1074/jbc.271.48.30692	http://dx.doi.org/10.1074/jbc.271.48.30692			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940046	hybrid			2022-12-25	WOS:A1996VV15800063
J	Menhart, N; Mitchell, T; Lusitani, D; Topouzian, N; Fung, LWM				Menhart, N; Mitchell, T; Lusitani, D; Topouzian, N; Fung, LWM			Peptides with more than one 106-amino acid sequence motif are needed to mimic the structural stability of spectrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE SPECTRIN; SECONDARY STRUCTURE; HEREDITARY ELLIPTOCYTOSIS; CONFORMATIONAL UNIT; LIMITED PROTEOLYSIS; MOLECULAR-STRUCTURE; CIRCULAR-DICHROISM; SEGMENTAL MOBILITY; ALPHA-SPECTRIN; SITE	The primary sequence of human erythrocyte spectrin contains repetitive homologous sequence motifs of approximately 106 amino acids with 22 such motifs in the alpha-subunit and 17 in the beta-subunit. These homologous sequence motifs have been proposed to form domains with a triple-helical bundle type structure (Speicher, D. W., and Marchesi, V, T, (1984) Nature 311, 177-180; Parry, D. A. D., Dixon, T. W,, and Cohen, C. (1992) Biophys. J. 61, 858-867). In this study, we show that these sequence motifs, while they do form compact proteolytically resistant units, are not completely independent, Peptides composed of two or three such motifs in tandem are substantially more stable than peptides composed of a single motif, as measured by proteolysis or by fluorescence or circular dichroism studies of urea or thermal denaturation, Circular dichroism and infrared spectroscopy measurements also indicate that these larger, more stable peptides exhibit greater secondary structure. In these respects, the peptides with tandem sequence motifs are more similar to intact spectrin than the peptide with a single sequence motif, Thus, we conclude that peptides with more than one sequence motif model spec trin more adequately than the peptides with one sequence motif, and that these sequence motifs are not completely independent domains.	LOYOLA UNIV, DEPT CHEM, CHICAGO, IL 60626 USA	Loyola University Chicago								BAKLOUTI F, 1992, BLOOD, V79, P2464; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BOIVIN P, 1990, UCLA SYM BI, V118, P235; BUDZYNSKI DM, 1992, BIOCHEMISTRY-US, V31, P3653, DOI 10.1021/bi00129a014; CALVERT R, 1980, EUR J BIOCHEM, V107, P355; COETZER T, 1990, UCLA SYM BI, V118, P211; DELAUNAY J, 1993, SEMIN HEMATOL, V30, P21; EFTINK MR, 1994, BIOPHYS J, V66, P482, DOI 10.1016/S0006-3495(94)80799-4; FONTANA A, 1986, BIOCHEMISTRY-US, V25, P1847, DOI 10.1021/bi00356a001; FREIFELDER D, 1982, PHYSICAL BIOCH, P691; GALLAGHER PG, 1993, BLOOD, V82, P2210; GILMORE AP, 1994, EUR J BIOCHEM, V225, P235, DOI 10.1111/j.1432-1033.1994.00235.x; HARTWIG JH, 1994, PROTEIN PROFILE, V1, P711; KAHANA E, 1994, J MOL BIOL, V235, P1271, DOI 10.1006/jmbi.1994.1080; LABRAKE CC, 1993, BIOCHEMISTRY-US, V32, P10296, DOI 10.1021/bi00090a004; LUSITANI DM, 1994, J BIOL CHEM, V269, P25955; MACDONALD RI, 1994, P NATL ACAD SCI USA, V91, P1299, DOI 10.1073/pnas.91.4.1299; Mach H, 1995, Methods Mol Biol, V40, P91; MANNING MC, 1989, J PHARMACEUT BIOMED, V7, P1103, DOI 10.1016/0731-7085(89)80049-4; MARCHESI SL, 1989, RED BLOOD CELL MEMBR, P77; MOHANDAS N, 1994, ANNU REV BIOPH BIOM, V23, P787, DOI 10.1146/annurev.bb.23.060194.004035; NOVOTNY J, 1987, FEBS LETT, V211, P185, DOI 10.1016/0014-5793(87)81433-3; PARKER JC, 1986, PHYSL MEMBRANE DISOR, P785; PARRY DAD, 1992, BIOPHYS J, V61, P858, DOI 10.1016/S0006-3495(92)81893-3; Ralston G, 1996, BIOCHEMISTRY-US, V35, P5257, DOI 10.1021/bi952224d; RALSTON GB, 1978, J SUPRAMOL STR CELL, V8, P361, DOI 10.1002/jss.400080313; RALSTON GB, 1979, BIOCHIM BIOPHYS ACTA, V579, P20, DOI 10.1016/0005-2795(79)90083-7; Royer C A, 1995, Methods Mol Biol, V40, P65; ROYER CA, 1993, PROTEIN SCI, V2, P1844, DOI 10.1002/pro.5560021106; SAHR KE, 1990, J BIOL CHEM, V265, P4434; SHOTTON DM, 1979, J MOL BIOL, V131, P303, DOI 10.1016/0022-2836(79)90078-0; SPEICHER DW, 1992, J BIOL CHEM, V267, P14775; SPEICHER DW, 1984, NATURE, V311, P177, DOI 10.1038/311177a0; SPEICHER DW, 1993, J BIOL CHEM, V268, P4227; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; STEER BA, 1995, BIOCHEMISTRY-US, V34, P7225, DOI 10.1021/bi00021a038; TSE WT, 1990, J CLIN INVEST, V86, P909, DOI 10.1172/JCI114792; WINKELMANN JC, 1993, BLOOD, V81, P3173; WINOGRAD E, 1991, P NATL ACAD SCI USA, V88, P10788, DOI 10.1073/pnas.88.23.10788; YAN Y, 1993, SCIENCE, V262, P2027, DOI 10.1126/science.8266097	41	32	33	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30410	30416		10.1074/jbc.271.48.30410	http://dx.doi.org/10.1074/jbc.271.48.30410			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940005	hybrid			2022-12-25	WOS:A1996VV15800022
J	Hara, N; Tsuchiya, M; Shimoyama, M				Hara, N; Tsuchiya, M; Shimoyama, M			Glutamic acid 207 in rodent T-cell RT6 antigens is essential for arginine-specific ADP-ribosylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATION MARKER RT6; ALLOANTIGEN RT6.1; SKELETAL-MUSCLE; RAT LYMPHOCYTES; RIBOSYLTRANSFERASE; SEQUENCE; NAD; NUCLEOTIDE; AUTOMODIFICATION; CONSERVATION	A rat T-cell antigen RT6.1 catalyzes NAD glycohydrolysis but not ADP-ribose transfer, even though the antigen has significant amino acid identity with eucaryotic arginine-specific ADP-ribosyltransferases. Since a highly conserved Glu in the catalytic region of these transferases is substituted with Gin at position 207 in RT6.1, we replaced the Gin with Glu, Asp, or Ale, by site-directed mutagenesis. The Glu-207 mutant produced ADP-ribosylarginine during incubation with NAD and L-arginine, The Asp-207 mutant but not the Ala 207 mutant produced ADP-ribosylarginine, but at a lower rate. In contrast, these mutations affected NAD glycohydrolase activity of RT6.1 to a much lesser extent. Kinetic studies of transferase reaction revealed that k(cat) of the Glu-207 mutant increased compared to findings with the Asp-207 mutant. Moreover, the mouse homologue of rat RT6 last arginine-specific ADP ribosyltransferase activity when Glu-207 was replaced with Grin. Thus, Glu-207 in rodent T cell RT6 antigens is essential for transfer reaction of ADP-ribose to arginine.	SHIMANE MED UNIV,DEPT BIOCHEM,IZUMO,SHIMANE 693,JAPAN	Shimane University								DAVIS T, 1995, GENE, V164, P371, DOI 10.1016/0378-1119(95)00504-Y; GREINER DL, 1987, J EXP MED, V166, P461, DOI 10.1084/jem.166.2.461; HAAG F, 1995, EUR J IMMUNOL, V25, P2355, DOI 10.1002/eji.1830250835; HAAG F, 1990, NUCLEIC ACIDS RES, V18, P1047, DOI 10.1093/nar/18.4.1047; HSIA JA, 1985, J BIOL CHEM, V260, P6187; KOCH F, 1990, P NATL ACAD SCI USA, V87, P964, DOI 10.1073/pnas.87.3.964; KOCH F, 1990, NUCLEIC ACIDS RES, V18, P3636, DOI 10.1093/nar/18.12.3636; KOCH F, 1988, IMMUNOLOGY, V65, P259; KOCH F, 1986, J EXP MED, V164, P1338, DOI 10.1084/jem.164.4.1338; KOCH T, 1994, VIROLOGY, V203, P294, DOI 10.1006/viro.1994.1487; KochNolte F, 1996, J BIOL CHEM, V271, P7686, DOI 10.1074/jbc.271.13.7686; MACHAMA T, 1996, FEBS LETT, V388, P189; MAEHAMA T, 1995, J BIOL CHEM, V270, P22747, DOI 10.1074/jbc.270.39.22747; MEKALANOS JJ, 1983, NATURE, V306, P551, DOI 10.1038/306551a0; MOSS J, 1992, J BIOL CHEM, V267, P10481; OHNO T, 1995, ANAL BIOCHEM, V231, P115, DOI 10.1006/abio.1995.1510; OKAZAKI IJ, 1994, BIOCHEMISTRY-US, V33, P12828, DOI 10.1021/bi00209a014; PERELLE S, 1995, INFECT IMMUN, V63, P4967, DOI 10.1128/IAI.63.12.4967-4967.1995; SHIMOYAMA M, 1992, POSTTRANSLATIONAL MO, P183; SOMAN G, 1991, BIOCHEM BIOPH RES CO, V176, P301, DOI 10.1016/0006-291X(91)90924-V; TAKADA T, 1994, J BIOL CHEM, V269, P9420; TAKADA T, 1995, J BIOL CHEM, V270, P541, DOI 10.1074/jbc.270.2.541; TSUCHIYA M, 1986, ANAL BIOCHEM, V157, P381, DOI 10.1016/0003-2697(86)90641-X; TSUCHIYA M, 1994, J BIOL CHEM, V269, P27451; vanDamme J, 1996, FEBS LETT, V380, P291, DOI 10.1016/0014-5793(96)00052-X; WANG J, 1994, J IMMUNOL, V153, P4048; Williamson KC, 1990, ADP RIBOSYLATING TOX, P493; WONIGEIT K, 1987, TRANSPLANT P, V19, P296; YAMADA K, 1994, ARCH BIOCHEM BIOPHYS, V308, P31, DOI 10.1006/abbi.1994.1004; YAMAMOTO T, 1987, J BACTERIOL, V169, P1852; ZOLKIEWSKA A, 1992, P NATL ACAD SCI USA, V89, P11352, DOI 10.1073/pnas.89.23.11352	31	37	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29552	29555		10.1074/jbc.271.47.29552	http://dx.doi.org/10.1074/jbc.271.47.29552			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939882	hybrid			2022-12-25	WOS:A1996VU52500010
J	Lin, TA; Lawrence, JC				Lin, TA; Lawrence, JC			Control of the translational regulators PHAS-I and PHAS-II by insulin and AMP in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; HEAT-STABLE PROTEIN; RAT ADIPOSE-TISSUE; P70 S6 KINASE; INITIATION-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; FAT-CELLS; PHOSPHORYLATION; RAPAMYCIN; WORTMANNIN	The eukaryotic initiation factor 4E (eIF-4E)-binding proteins PHAS-I and PHAS-II were found to have overlapping but different patterns of expression in tissues, Both PHAS proteins were expressed in 3T3-L1 adipocytes, in which insulin stimulated their phosphorylation, promoted dissociation of PHAS eIF-4E complexes, and decreased the ability of both to bind exogenous eIF-4E. The effects of insulin were attenuated by rapamycin and wortmannin, two agents that block activation of p70(S6K). Unlike PHAS-I, PHAS-II was readily phosphorylated by cAMP-dependent protein kinase in vitro; however, the effects of insulin on both PHAS proteins were attenuated by agents that increase intracellular cAMP, by cAMP derivatives, and by phosphodiesterase inhibitors. These agents also markedly inhibited the activation of p70(S6K). In summary, our results indicate that PHAS-I and -II are controlled by the mammalian target of rapamycin and p70(S6K) Signaling pathway and that in 3T3-L1 adipocytes this pathway is inhibited by increased cAMP.	UNIV VIRGINIA, HLTH SCI CTR, SCH MED, DEPT PHARMACOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, SCH MED, DEPT MED, CHARLOTTESVILLE, VA 22908 USA; ST LOUIS UNIV, SCH MED, DEPT MOL BIOL & PHARMACOL, ST LOUIS, MO 63110 USA	University of Virginia; University of Virginia; Saint Louis University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028312] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR41180] Funding Source: Medline; NIDDK NIH HHS [DK28312] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; Azpiazu I, 1996, J BIOL CHEM, V271, P5033; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; BLACKSHEAR PJ, 1982, BIOCHEM J, V204, P817, DOI 10.1042/bj2040817; BLACKSHEAR PJ, 1983, BIOCHEM J, V214, P11, DOI 10.1042/bj2140011; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; BRUNN GJ, 1996, IN PRESS EMBO J; Chasin M, 1976, Adv Cyclic Nucleotide Res, V7, P225; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DIGGLE TA, 1995, BIOCHEM J, V306, P135, DOI 10.1042/bj3060135; DIGGLE TA, 1992, BIOCHEM J, V282, P729, DOI 10.1042/bj2820729; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FREDERICKSON RM, 1992, CELL BIOL, V3, P107; FROST V, 1995, J BIOL CHEM, V270, P26698, DOI 10.1074/jbc.270.44.26698; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KIMBALL SR, 1994, ANNU REV PHYSIOL, V56, P321, DOI 10.1146/annurev.ph.56.030194.001541; Kimball SR, 1996, AM J PHYSIOL-CELL PH, V270, pC705, DOI 10.1152/ajpcell.1996.270.2.C705; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lawrence JC, 1995, INT CONGR SER, V1100, P622; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; LIN TA, 1996, IN PRESS DIABETOLOGI; Lin Tai-An, 1994, Journal of Biological Chemistry, V269, P21255; MADER S, 1995, BIOCHIMIE, V77, P40, DOI 10.1016/0300-9084(96)88102-8; MADER S, 1995, MOL CELL BIOL, V15, P4990; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PETRITSCH C, 1995, J BIOL CHEM, V270, P26619, DOI 10.1074/jbc.270.44.26619; PROUD CG, 1992, CURR TOP CELL REGUL, V32, P243; Proud CG, 1996, TRENDS BIOCHEM SCI, V21, P181, DOI 10.1016/0968-0004(96)10016-5; RAMAKRISHNA S, 1983, BIOCHEM BIOPH RES CO, V117, P758, DOI 10.1016/0006-291X(83)91662-5; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; Scott PH, 1996, BIOCHEM J, V318, P965, DOI 10.1042/bj3180965; STERN BD, 1993, PROTEIN EXPRES PURIF, V4, P320, DOI 10.1006/prep.1993.1041; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; WANG HCR, 1992, MOL BIOL CELL, V3, P1329, DOI 10.1091/mbc.3.12.1329	43	84	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30199	30204		10.1074/jbc.271.47.30199	http://dx.doi.org/10.1074/jbc.271.47.30199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939971	hybrid			2022-12-25	WOS:A1996VU52500099
J	Cho, MR; Thatte, HS; Lee, RC; Golan, DE				Cho, MR; Thatte, HS; Lee, RC; Golan, DE			Reorganization of microfilament structure induced by ac electric fields	FASEB JOURNAL			English	Article						microfilaments; integral membrane proteins; signal transduction	EMBRYONIC MUSCLE-CELL; INDUCED REDISTRIBUTION; HUMAN-FIBROBLASTS; DNA-SYNTHESIS; SHAPE CHANGES; RECEPTORS; ELECTROPHORESIS; SURFACE; STIMULATION; MEMBRANE	AC electric fields induce redistribution of integral membrane proteins, Cell-surface receptor redistribution does not consistently follow electric field lines and depends critically on the frequency of the applied ac electric fields, suggesting that mechanisms other than electroosmosis are involved, We hypothesized that cytoskeletal reorganization is responsible for electric field-induced cell-surface receptor redistribution, and used fluorescence video microscopy to study the reorganization of microfilaments in human hepatoma (Hep3B) cells exposed to low-frequency electric fields ranging in strength from 25 mV/cm to 20 V/cm (peak to peak), The frequency of the applied electric field was varied from 1 to 120 Hz and the field exposure duration from 1 to 60 min, In control cells, cytoplasmic microfilaments were aligned in the form of continuous parallel cables along the longitudinal axis of the cell, Exposure of cells to ac electric fields induced alterations in microfilament structure in a manner that depended on the frequency of the applied field, A 1 or 10 Hz ac field caused microfilament reorganization from continuous, aligned cable structures to discontinuous globular patches, In contrast, the structure of microfilaments in cells exposed to 20-120 Hz electric fields did not differ from that in control cells, The extent of microfilament reorganization increased nonlinearly with the electric field strength, The characteristic time for microfilament reorganization in cells exposed to a 1 Hz, 20 V/cm electric field was similar to 5 min, Applied ac electric fields could initiate signal transduction cascades, which in turn cause reorganization of cytoskeletal structures.	HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOL PHARMACOL, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DIV HEMATOL ONCOL, BOSTON, MA 02115 USA; UNIV CHICAGO, DEPT SURG, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT ANAT, CHICAGO, IL 60637 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; University of Chicago; University of Chicago				Lee, Raphael C./0000-0002-6628-1867; Cho, Myoung Rae/0000-0002-8191-8045	NHLBI NIH HHS [HL-32854, HL-15157] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032854, R37HL032854, P60HL015157] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADEY WR, 1981, PHYSIOL REV, V61, P435, DOI 10.1152/physrev.1981.61.2.435; ADEY WR, 1983, NONLINEAR ELECTRODYN, P2; BASCH RM, 1988, THESIS MIT BOSTON; BEAR CE, 1991, AM J PHYSIOL, V261, pC1018, DOI 10.1152/ajpcell.1991.261.6.C1018; BOURGUIGNON GJ, 1987, FASEB J, V1, P398, DOI 10.1096/fasebj.1.5.3678699; BRETSCHER A, 1994, J CELL BIOL, V126, P821, DOI 10.1083/jcb.126.4.821; Bretscher A, 1993, CURR OPIN CELL BIOL, V5, P653, DOI 10.1016/0955-0674(93)90136-E; CARPEN O, 1992, J CELL BIOL, V118, P1223, DOI 10.1083/jcb.118.5.1223; CHO MR, 1994, FASEB J, V8, P771, DOI 10.1096/fasebj.8.10.8050677; DENHARTIGH JC, 1992, J CELL BIOL, V119, P349, DOI 10.1083/jcb.119.2.349; HAHN WC, 1993, J IMMUNOL, V150, P2607; HINKLE L, 1981, J PHYSIOL-LONDON, V314, P121, DOI 10.1113/jphysiol.1981.sp013695; JAFFE LF, 1977, NATURE, V265, P600, DOI 10.1038/265600a0; LAUB F, 1984, BIOCHIM BIOPHYS ACTA, V803, P308, DOI 10.1016/0167-4889(84)90122-8; LEE RC, 1993, BIOPHYS J, V64, P44, DOI 10.1016/S0006-3495(93)81339-0; LIN JC, 1996, BIOL EFFECTS ELECTRO, P337; LUTHER PW, 1983, NATURE, V303, P61, DOI 10.1038/303061a0; MCLEOD KJ, 1987, SCIENCE, V236, P1465, DOI 10.1126/science.3589667; MCLEOD KJ, 1992, BIOELECTROMAGNETICS, P161, DOI 10.1002/bem.2250130716; MELAMED I, 1991, J IMMUNOL, V147, P1139; ONUMA EK, 1985, CELL CALCIUM, V6, P281, DOI 10.1016/0143-4160(85)90012-0; ONUMA EK, 1988, J CELL BIOL, V106, P2067, DOI 10.1083/jcb.106.6.2067; POO MM, 1977, NATURE, V265, P602, DOI 10.1038/265602a0; POO MM, 1978, J CELL BIOL, V76, P483, DOI 10.1083/jcb.76.2.483; POO MM, 1981, ANNU REV BIOPHYS BIO, V10, P245, DOI 10.1146/annurev.bb.10.060181.001333; RAO KMK, 1991, MUTAT RES, V256, P139, DOI 10.1016/0921-8734(91)90007-X; RODAN GA, 1978, SCIENCE, V199, P690, DOI 10.1126/science.625660; RUBIN CT, 1993, J BONE MINER RES, V8, pS573; RYAN TA, 1988, SCIENCE, V239, P61, DOI 10.1126/science.2962287; SAWANOBORI T, 1989, J CELL PHYSIOL, V139, P580, DOI 10.1002/jcp.1041390318; SISKEN BF, 1975, J EMBRYOL EXP MORPH, V33, P29; SMITH BA, 1979, P NATL ACAD SCI USA, V76, P5641, DOI 10.1073/pnas.76.11.5641; STOLPEN AH, 1988, P NATL ACAD SCI USA, V85, P1844, DOI 10.1073/pnas.85.6.1844; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; TANK DW, 1985, J CELL BIOL, V101, P148, DOI 10.1083/jcb.101.1.148; THATTE HS, 1994, J CELL PHYSIOL, V160, P345, DOI 10.1002/jcp.1041600216; WALLECZEK J, 1992, FASEB J, V6, P3177, DOI 10.1096/fasebj.6.13.1397839; WEEDS A, 1982, NATURE, V296, P811, DOI 10.1038/296811a0; YANG WP, 1984, EXP CELL RES, V155, P92, DOI 10.1016/0014-4827(84)90770-5	39	59	60	2	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1996	10	13					1552	1558		10.1096/fasebj.10.13.8940302	http://dx.doi.org/10.1096/fasebj.10.13.8940302			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VU982	8940302				2022-12-25	WOS:A1996VU98200013
J	Liu, JK; Wang, XY; Shigenaga, MK; Yeo, HC; Mori, A; Ames, BN				Liu, JK; Wang, XY; Shigenaga, MK; Yeo, HC; Mori, A; Ames, BN			Immobilization stress causes oxidative damage to lipid, protein, and DNA in the brain of rats	FASEB JOURNAL			English	Article						mitochondria; lipid peroxidation; protein oxidation; DNA damage	INDUCED EXTRACELLULAR ACCUMULATION; ANTIOXIDANT DEFENSE CHANGES; EXCITATORY AMINO-ACIDS; REDUCED GLUTATHIONE; BIOLOGICAL-FLUIDS; OXIDIZED PROTEINS; NUCLEAR-DNA; CELL-DEATH; GLUCOCORTICOIDS; HIPPOCAMPUS	Immobilization stress of male Sprague-Dawley rats induces oxidative damage to lipid, protein, and DNA in the brain, Significant increases in lipid peroxidation were found in the cerebral cortex, cerebellum, hippocampus, and midbrain compared to the unstressed controls, Significant increases in levels of protein oxidation were also found in the cortex, hypothalamus, striatum, and medulla oblongata, Oxidative nuclear DNA damage increased after stress in all brain regions, although only the cerebral cortex showed a significant increase, Depletion of glutathione showed some stimulation to oxidative damage in the unstressed control and stressed animals, Further studies of the mitochondrial and cytosol fractions of cerebral cortex demonstrated that mitochondria showed a significantly greater increase in lipid peroxidation and protein oxidation than cytosol, Data from plasma and liver showed oxidative damage similar to that of the brain, These findings provide evidence to support the idea that stress produces oxidants, and that the oxidative damage in stress could contribute to the degenerative diseases of aging, including brain dysfunction.	UNIV CALIF BERKELEY, DIV BIOCHEM & MOL BIOL, BERKELEY, CA 94720 USA; OKAYAMA UNIV, SCH MED, INST MOL & CELLULAR MED, DEPT NEUROSCI, OKAYAMA 700, JAPAN	University of California System; University of California Berkeley; Okayama University			Liu, Jiankang/A-1610-2011		NCI NIH HHS [CA39910] Funding Source: Medline; NIEHS NIH HHS [ESO1896] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039910] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001896] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADACHI S, 1993, CANCER RES, V53, P4153; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; ANDINE P, 1991, J NEUROCHEM, V57, P222, DOI 10.1111/j.1471-4159.1991.tb02119.x; ARMARIO A, 1990, FREE RADICAL RES COM, V9, P113, DOI 10.3109/10715769009148578; BEAL MF, 1992, ANN NEUROL, V31, P119, DOI 10.1002/ana.410310202; BEAL MF, 1993, TRENDS NEUROSCI, V16, P125, DOI 10.1016/0166-2236(93)90117-5; BONDY SC, 1991, TOXICOL LETT, V58, P13, DOI 10.1016/0378-4274(91)90185-9; BONDY SC, 1994, ALCOHOL ALCOHOLISM, V29, P375; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BULON VV, 1990, B EXP BIOL MED+, V110, P1524, DOI 10.1007/BF00841310; CEREMUZYNSKI L, 1991, EXP PATHOL-JENA, V43, P213, DOI 10.1016/S0232-1513(11)80120-9; CHOI DW, 1992, SCIENCE, V258, P241, DOI 10.1126/science.1357748; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; CHOU YC, 1994, BRAIN RES, V654, P8, DOI 10.1016/0006-8993(94)91565-2; CLARK JB, 1970, J BIOL CHEM, V245, P4724; CLIMENT I, 1989, ANAL BIOCHEM, V182, P226, DOI 10.1016/0003-2697(89)90584-8; FLOYD RA, 1991, ARCH GERONTOL GERIAT, V12, P155, DOI 10.1016/0167-4943(91)90025-L; GLOWINSKI J, 1966, J NEUROCHEM, V13, P655, DOI 10.1111/j.1471-4159.1966.tb09873.x; GUTTERIDGE JMC, 1990, TRENDS BIOCHEM SCI, V15, P129, DOI 10.1016/0968-0004(90)90206-Q; HAGEN TM, 1987, AM J PHYSIOL, V252, pG607, DOI 10.1152/ajpgi.1987.252.5.G607; HALLIWELL B, 1992, J LAB CLIN MED, V119, P598; HASEGAWA T, 1993, ANN NY ACAD SCI, V691, P281, DOI 10.1111/j.1749-6632.1993.tb26196.x; HERBACZYNSKACEDRO K, 1990, CLIN EXP PHARMACOL P, V17, P1, DOI 10.1111/j.1440-1681.1990.tb01258.x; HIDALGO J, 1991, HORM METAB RES, V23, P104, DOI 10.1055/s-2007-1003626; ITOH T, 1993, BRAIN RES, V618, P318, DOI 10.1016/0006-8993(93)91283-X; KOVACHEVAIVANOVA S, 1992, B EXP BIOL MED+, V113, P164; LANDFIELD PW, 1994, NEUROBIOL AGING, V15, P579, DOI 10.1016/0197-4580(94)90101-5; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; LIU J, 1996, IN PRESS FREE RADICA; LIU J, 1996, IN PRESS MOL ASPECTS; LIU JK, 1994, INT J STRESS MANAGE, V1, P249, DOI 10.1007/BF01857992; LIU JK, 1994, INT J BIOCHEM, V26, P511, DOI 10.1016/0020-711X(94)90008-6; LOWY MT, 1995, J NEUROCHEM, V65, P268; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; MOGHADDAM B, 1994, BRAIN RES, V655, P251, DOI 10.1016/0006-8993(94)91622-5; MOGHADDAM B, 1993, J NEUROCHEM, V60, P1650, DOI 10.1111/j.1471-4159.1993.tb13387.x; MORONI F, 1991, EUR J PHARMACOL, V199, P227, DOI 10.1016/0014-2999(91)90461-X; OLANOW CW, 1992, ANN NEUROL, V32, pS2, DOI 10.1002/ana.410320703; OLIVER CN, 1987, J BIOL CHEM, V262, P5488; PARE WP, 1965, J GERONTOL, V20, P78, DOI 10.1093/geronj/20.1.78; RICHTER C, 1991, CHEM-BIOL INTERACT, V77, P1, DOI 10.1016/0009-2797(91)90002-O; SAPOLSKY RM, 1993, BEHAV BRAIN RES, V57, P175, DOI 10.1016/0166-4328(93)90133-B; SEREDENIN SB, 1992, B EXP BIOL MED, V108, P46; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; SHIGENAGA MK, 1994, METHOD ENZYMOL, V234, P16; Shvets V. N., 1993, Ukrainskii Biokhimicheskii Zhurnal, V65, P91; SMITH CD, 1991, P NATL ACAD SCI USA, V88, P10540, DOI 10.1073/pnas.88.23.10540; Sosnovskii A. S., 1992, Byulleten' Eksperimental'noi Biologii i Meditsiny, V113, P486; SOSNOVSKII AS, 1992, B EXP BIOL MED+, V113, P25, DOI 10.1007/BF00787736; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; STARKEREED PE, 1989, ARCH BIOCHEM BIOPHYS, V275, P559, DOI 10.1016/0003-9861(89)90402-5; STEINBEHRENS BA, 1994, J NEUROCHEM, V63, P596; STEINBEHRENS BA, 1992, J NEUROCHEM, V58, P1730, DOI 10.1111/j.1471-4159.1992.tb10047.x; STEINBEHRENS BA, 1992, AGING-CLIN EXP RES, V4, P197; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; WIECHELMAN KJ, 1988, ANAL BIOCHEM, V175, P231, DOI 10.1016/0003-2697(88)90383-1; YEGEN BC, 1992, AGENTS ACTIONS, V35, P130, DOI 10.1007/BF01990962; YEO HC, 1994, ANAL BIOCHEM, V220, P391, DOI 10.1006/abio.1994.1355	59	308	318	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1996	10	13					1532	1538		10.1096/fasebj.10.13.8940299	http://dx.doi.org/10.1096/fasebj.10.13.8940299			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VU982	8940299				2022-12-25	WOS:A1996VU98200010
J	Higaki, J; Catalano, R; Guzzetta, AW; Quon, D; Nave, JF; Tarnus, C; DOrchymont, H; Cordell, B				Higaki, J; Catalano, R; Guzzetta, AW; Quon, D; Nave, JF; Tarnus, C; DOrchymont, H; Cordell, B			Processing of beta-amyloid precursor protein by cathepsin D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; RAT-BRAIN; PEPTIDE; FRAGMENTS; IDENTIFICATION; GENERATION; CELLS; SECRETION; CLEAVAGE; PATHWAY	The events leading to the formation of beta-amyloid (beta A4) from its precursor (beta APP) involve proteolytic cleavages that produce the amino and carboxyl termini of beta A4. The enzyme activities responsible for these cleavages have been termed beta- and gamma-secretase, respectively, although these protease(s) have not been identified, Since beta A4 is known to possess heterogeneity at both the amino and carboxyl termini, beta- and gamma-secretases may actually be a collection of proteolytic activities or perhaps a single proteolytic enzyme with broad amino acid specificity. We investigated the role of cathepsin D in the processing of beta APP since this enzyme has been widely proposed as a gamma-secretase candidate. Treatment of a synthetic peptide that spans the gamma-secretase site of beta APP with human cathepsin D resulted in the cleavage of this substrate at Ala(42)-Thr(43). A sensitive liquid chromatography/mass spectrometry technique was also developed to further investigate the ability of cathepsin D to process longer recombinant beta APP substrates (156 and 100 amino acids of beta APP carboxyl terminus) in vitro, The precise cathepsin D cleavage sites within these recombinant beta APP substrates were identified using this technique, Both recombinant substrates were cleaved at the following sites: Leu(49)-Val(50), Asp(68)-Ala(69), Phe(93)-Phe(94), No cleavages were observed at putative gamma-secretase sites: Val(40)-Ile(41) or Ala(42)-Thr(43), suggesting that cathepsin D is not gamma-secretase as defined by these beta A4 termini, Under conditions where the beta APP156 substrate was first denatured prior to cathepsin D digestion, two additional cleavage sites near the amino terminus of beta A4, Glu(-3)-Val(-2) and Glu(3)-Phe(4), were observed, indicating that cathepsin D cleavage of beta APP is influenced by the structural integrity of the substrate, Taken together, these results indicate that in vitro, cathepsin D is unlikely to function as gamma-secretase; however, the ability of this enzyme to efficiently cleave beta APP substrates at nonamyloidogenic sites within the molecule may reflect a role in beta APP catabolism.	MARION MERRELL RES CTR,F-67084 STRASBOURG,FRANCE		Higaki, J (corresponding author), SCIOS NOVA INC,2450 BAYSHORE PKWY,MOUNTAIN VIEW,CA 94043, USA.							AZARYAN A, 1983, BIOMED BIOCHIM ACTA, V10, P1237; Brown AM, 1996, J NEUROCHEM, V66, P2436; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P2252, DOI 10.1073/pnas.89.6.2252; CATALDO AM, 1991, P NATL ACAD SCI USA, V88, P10998, DOI 10.1073/pnas.88.24.10998; CATALDO AM, 1990, P NATL ACAD SCI USA, V87, P3861, DOI 10.1073/pnas.87.10.3861; CATALDO AM, 1995, NEURON, V14, P671, DOI 10.1016/0896-6273(95)90324-0; CITRON M, 1995, NEURON, V14, P661, DOI 10.1016/0896-6273(95)90323-2; COWBURN RF, 1995, TRENDS NEUROSCI, V18, P483, DOI 10.1016/0166-2236(95)92769-M; DIMENT S, 1988, J BIOL CHEM, V263, P6901; DREYER RN, 1994, EUR J BIOCHEM, V224, P265, DOI 10.1111/j.1432-1033.1994.00265.x; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; EVIN G, 1995, BIOCHEMISTRY-US, V34, P14185, DOI 10.1021/bi00043a024; EVIN G, 1994, AMYLOID, V1, P263, DOI 10.3109/13506129409146118; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GULNIK S, 1992, J MOL BIOL, V227, P265, DOI 10.1016/0022-2836(92)90696-H; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1993, J BIOL CHEM, V268, P3021; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HARDY J, 1994, CLIN GERIATR MED, V10, P239, DOI 10.1016/S0749-0690(18)30343-4; HAYASHI Y, 1992, BIOCHEM BIOPH RES CO, V187, P1249, DOI 10.1016/0006-291X(92)90437-P; HIGAKI J, 1995, NEURON, V14, P651, DOI 10.1016/0896-6273(95)90322-4; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; KENESSEY A, 1989, J NEUROSCI RES, V23, P454, DOI 10.1002/jnr.490230412; KOO EH, 1994, J BIOL CHEM, V269, P17386; LADROR US, 1994, J BIOL CHEM, V269, P18422; LANSBURY PT, 1995, ARZNEIMITTEL-FORSCH, V45-1, P432; MANTLE D, 1995, J NEUROL SCI, V131, P65, DOI 10.1016/0022-510X(95)00035-Z; MARKS N, 1995, INT J PEPT PROT RES, V46, P306; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MILLER DL, 1993, ARCH BIOCHEM BIOPHYS, V301, P41, DOI 10.1006/abbi.1993.1112; MUNGER JS, 1995, BIOCHEM J, V311, P299, DOI 10.1042/bj3110299; NAKANISHI H, 1994, EXP NEUROL, V126, P119, DOI 10.1006/exnr.1994.1048; NORDSTEDT C, 1993, J BIOL CHEM, V268, P608; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; RUNQUIST EA, 1991, J BIOL CHEM, V266, P22557; SCHENK DB, 1995, J MED CHEM, V38, P4141, DOI 10.1021/jm00021a001; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SIMAN R, 1993, J BIOL CHEM, V268, P16602; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; Tischer E, 1996, J BIOL CHEM, V271, P21914, DOI 10.1074/jbc.271.36.21914; VANNOORT JM, 1989, J BIOL CHEM, V264, P14159; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WILLIAMS KP, 1993, ARCH BIOCHEM BIOPHYS, V305, P298, DOI 10.1006/abbi.1993.1426; WISNIEWSKI T, 1994, ANN NEUROL, V35, P245, DOI 10.1002/ana.410350223; WOLF D, 1990, EMBO J, V9, P2079, DOI 10.1002/j.1460-2075.1990.tb07375.x; ZHONG ZY, 1994, J BIOL CHEM, V269, P627; ZHONG ZY, 1994, J BIOL CHEM, V269, P12179	52	28	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					31885	31893		10.1074/jbc.271.50.31885	http://dx.doi.org/10.1074/jbc.271.50.31885			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943232	hybrid			2022-12-25	WOS:A1996VY34000023
J	Kato, M; Sasaki, T; Ohya, T; Nakanishi, H; Nishioka, H; Imamura, M; Takai, Y				Kato, M; Sasaki, T; Ohya, T; Nakanishi, H; Nishioka, H; Imamura, M; Takai, Y			Physical and functional interaction of rabphilin-3A with alpha-actinin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; SYNAPTIC VESICLE; CHROMAFFIN CELLS; TARGET PROTEIN; SMOOTH-MUSCLE; PC12 CELLS; SMG P25A; PURIFICATION; RAB3A; SYNAPTOTAGMIN	Rabphilin-3A is a downstream target molecule of Rab3A small GTP-binding protein and implicated in Ca2+-dependent neurotransmitter release. Here we have isolated a rabphilin-3A-interacting molecule from a human brain cDNA library by the yeast two-hybrid method and identified it to be alpha-actinin, known to cross-link actin filaments into a bundle. alpha-Actinin interacts with the N-terminal region of rabphilin-3A, with which GTP-Rab3A interacts, and this interaction stimulates the activity of alpha-actinin to cross-link actin filaments into a bundle. The interaction of rabphilin-3A with alpha-actinin is inhibited by guanosine 5'-(3-O-thio)triphosphate-Rab3A. These results suggest that the Rab3A-rabphilin-3A system regulates the alpha-actinin-regulated reorganization of actin filaments. It has been shown that reorganization of actin filaments is also involved in Ca2+-dependent exocytosis. Therefore, rabphilin-3A may serve as a linker for Rab3A and cytoskeleton.	OSAKA UNIV,SCH MED,DEPT MOL BIOL & BIOCHEM,SUITA,OSAKA 565,JAPAN; ERATO,JAPAN SCI & TECHNOL COOPERAT,TAKAI BIOTIMER PROJECT,KOBE 65122,JAPAN; NCNP,NATL INST NEUROSCI,DEPT CELL BIOL,KODAIRA,TOKYO 187,JAPAN	Osaka University; Japan Science & Technology Agency (JST); National Center for Neurology & Psychiatry - Japan				Nakanishi, Hiroyuki/0000-0002-9765-0266				BAJJALIEH SM, 1995, J BIOL CHEM, V270, P1971, DOI 10.1074/jbc.270.5.1971; BENNETT V, 1989, BIOCHIM BIOPHYS ACTA, V988, P107, DOI 10.1016/0304-4157(89)90006-3; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHUNG SH, 1995, J BIOL CHEM, V270, P16714, DOI 10.1074/jbc.270.28.16714; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; DARCHEN F, 1995, J CELL SCI, V108, P1639; ENDO T, 1982, J BIOCHEM, V92, P1457, DOI 10.1093/oxfordjournals.jbchem.a134070; FERAMISCO JR, 1980, J BIOL CHEM, V255, P1194; FISCHER V, 1990, P NATL ACAD SCI USA, V87, P1988; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; IMAMURA M, 1992, J BIOL CHEM, V267, P25927; IMAZUMI K, 1994, BIOCHEM BIOPH RES CO, V205, P1409, DOI 10.1006/bbrc.1994.2822; JOCKUSH BM, 1977, NATURE, V270, P628, DOI 10.1038/270628a0; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KIKUCHI A, 1995, METHOD ENZYMOL, V257, P57; Komuro R, 1996, BIOCHEM BIOPH RES CO, V219, P435, DOI 10.1006/bbrc.1996.0251; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; LLINAS R, 1994, P NATL ACAD SCI USA, V91, P12990, DOI 10.1073/pnas.91.26.12990; MACLEANFLETCHER SD, 1980, J CELL BIOL, V85, P414, DOI 10.1083/jcb.85.2.414; MATSUDAIRA P, 1991, TRENDS BIOCHEM SCI, V16, P87, DOI 10.1016/0968-0004(91)90039-X; MIYAZAKI M, 1994, BIOCHEM BIOPH RES CO, V205, P460, DOI 10.1006/bbrc.1994.2688; MIYAZAKI M, 1995, MOL BRAIN RES, V28, P29, DOI 10.1016/0169-328X(94)00180-M; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; MIZOGUCHI A, 1994, BIOCHEM BIOPH RES CO, V202, P1235, DOI 10.1006/bbrc.1994.2063; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; OTTO JJ, 1994, CURR OPIN CELL BIOL, V6, P105, DOI 10.1016/0955-0674(94)90123-6; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; PODLUBNAYA ZA, 1975, J MOL BIOL, V92, P357, DOI 10.1016/0022-2836(75)90234-X; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHIAVO G, 1995, NATURE, V378, P733, DOI 10.1038/378733a0; Sherman F., 1986, METHODS YEAST GENETI; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SHIRATAKI H, 1994, J BIOL CHEM, V269, P32717; SHIRATAKI H, 1992, J BIOL CHEM, V267, P10946; SHIRATAKI H, 1995, METHOD ENZYMOL, V257, P291; SIMONS K, 1993, NEURON, V11, P789, DOI 10.1016/0896-6273(93)90109-5; Stahl B, 1996, EMBO J, V15, P1799, DOI 10.1002/j.1460-2075.1996.tb00529.x; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Takai Y, 1996, GENES CELLS, V1, P615, DOI 10.1046/j.1365-2443.1996.00257.x; TRIFARO JM, 1993, TRENDS NEUROSCI, V2, P27; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; YAMAGUCHI T, 1993, J BIOL CHEM, V268, P27164	46	96	98	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					31775	31778		10.1074/jbc.271.50.31775	http://dx.doi.org/10.1074/jbc.271.50.31775			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943213	hybrid			2022-12-25	WOS:A1996VY34000004
J	Matthews, RP; McKnight, GS				Matthews, RP; McKnight, GS			Characterization of the cAMP response element of the cystic fibrosis transmembrane conductance regulator gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; TRANSCRIPTION FACTOR-II; CYCLIC ADENOSINE-3',5'-MONOPHOSPHATE; PHORBOL ESTER; CATALYTIC SUBUNIT; BASAL EXPRESSION; BINDING PROTEIN; CELL-LINE; PHOSPHORYLATION; ACTIVATION	A dominant negative inhibitor of the cAMP-dependent protein kinase has been shown to inhibit the basal expression of the cystic fibrosis transmembrane conductance regulator (CFTR) gene in the human colon carcinoma cell line, T84. A functional cAMP response element (CRE) was localized at -48 in the CFTR promoter, and we have analyzed the interactions of this regulatory region with transcription factors. An adjacent inverted CCAAT element (Y box) at position -60 was also investigated. Mutation of the CRE or the Y box decreases the activity of the promoter in transient transfections of T84 or JEG-3 cells. Electrophoretic mobility shift assays demonstrate that CRE-binding protein (CREB) binds to the CFTR CRE with high affinity and independently of the adjacent Y box and that the CFTR CRE binds CREB and activating transcription factor-1 in nuclear extracts of T84 and CaLu-3 cells. In transient transfections of JEG-3 cells, activation of the CFTR promoter is blocked by a dominant negative CREB mutant. The CFTR CRE will also drive cAMP-mediated expression when placed upstream of a heterologous basal promoter. These results demonstrate that CFTR is a bona fide CRE-dependent gene, and we suggest that CFTR expression levels in vivo may be responsive to hormones or drugs that activate the cAMP-dependent protein kinase system.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NIGMS NIH HHS [GM32875] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032875] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743; BREUER W, 1992, J BIOL CHEM, V267, P10465; CHENG SH, 1995, AM J PHYSIOL-LUNG C, V268, pL615, DOI 10.1152/ajplung.1995.268.4.L615; CHOU JL, 1991, J BIOL CHEM, V266, P24471; DEGROOT RP, 1992, ONCOGENE, V7, P2281; DRUST DS, 1991, MOL ENDOCRINOL, V5, P1541, DOI 10.1210/mend-5-10-1541; DUAN CM, 1995, J BIOL CHEM, V270, P24844, DOI 10.1074/jbc.270.42.24844; ELLIS MJC, 1995, MOL ENDOCRINOL, V9, P255, DOI 10.1210/me.9.2.255; ENGLARO W, 1995, J BIOL CHEM, V270, P24315, DOI 10.1074/jbc.270.41.24315; EVERS BM, 1995, MOL CELL BIOL, V15, P3870; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HOEFFLER JP, 1991, MOL ENDOCRINOL, V5, P256, DOI 10.1210/mend-5-2-256; HORDVIK NL, 1985, AM REV RESPIR DIS, V131, P889; HYMAN SE, 1989, MOL CELL BIOL, V9, P321, DOI 10.1128/MCB.9.1.321; KIM J, 1995, J BIOL CHEM, V270, P1282, DOI 10.1074/jbc.270.3.1282; KOH J, 1993, J BIOL CHEM, V268, P15912; KRUYT FAE, 1992, NUCLEIC ACIDS RES, V20, P6393, DOI 10.1093/nar/20.23.6393; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; LORIAUX MM, 1993, P NATL ACAD SCI USA, V90, P9046, DOI 10.1073/pnas.90.19.9046; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MCDONALD RA, 1995, P NATL ACAD SCI USA, V92, P7560, DOI 10.1073/pnas.92.16.7560; MEDCALF RL, 1990, J BIOL CHEM, V265, P14618; OKIMURA Y, 1994, MOL ENDOCRINOL, V8, P1559, DOI 10.1210/me.8.11.1559; ORELLANA SA, 1992, P NATL ACAD SCI USA, V89, P4726, DOI 10.1073/pnas.89.10.4726; ORELLANA SA, 1990, J BIOL CHEM, V265, P3048; PARK K, 1993, J BIOL CHEM, V268, P17811; PEI L, 1991, MOL ENDOCRINOL, V5, P521, DOI 10.1210/mend-5-4-521; PITTMAN N, 1995, J BIOL CHEM, V270, P28848, DOI 10.1074/jbc.270.48.28848; Rangan VS, 1996, J BIOL CHEM, V271, P2307, DOI 10.1074/jbc.271.4.2307; ROGERS KV, 1990, P NATL ACAD SCI USA, V87, P8975, DOI 10.1073/pnas.87.22.8975; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; TRAPNELL BC, 1991, P NATL ACAD SCI USA, V88, P6565, DOI 10.1073/pnas.88.15.6565; TRAPNELL BC, 1991, J BIOL CHEM, V266, P10319; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; VENEPALLY P, 1995, J BIOL CHEM, V270, P25402, DOI 10.1074/jbc.270.43.25402; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; YOSHIMURA K, 1991, J BIOL CHEM, V266, P9140; ZHANG PL, 1995, MOL ENDOCRINOL, V9, P1571, DOI 10.1210/me.9.11.1571	39	54	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					31869	31877		10.1074/jbc.271.50.31869	http://dx.doi.org/10.1074/jbc.271.50.31869			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943230	hybrid			2022-12-25	WOS:A1996VY34000021
J	Szeltner, Z; Polgar, L				Szeltner, Z; Polgar, L			Rate-determining steps in HIV-1 protease catalysis - The hydrolysis of the most specific substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS PROTEASE; TYPE-1 PROTEASE; CLEAVAGE SITES; ACTIVE-SITE; REQUIREMENTS; PROTEINASES; MECHANISMS; INHIBITOR; ELUCIDATE; COMPLEX	The human immunodeficiency virus type-1 (HIV-1) encodes a protease which is essential for the production of infectious virus, The protease prefers substrates that contain glutamic acid or glutamine at the P2' position. The catalytic role of these residues has been studied by using a highly specific fluorogen substrate, 2-aminobenzoyl-Thr-Ile-Nle-Phe(NO2)-Gln-Arg (substrate QR), and its counterpart (substrate ER) containing Glu in place of Gln. The newly designed substrate ER that contains a pair of charged residues at P2' and P3' sites is the most specific substrate described so far for HIV-1 protease. The specificity rate constant (k(cat)/K-m = 2.1 x 10(7) M(-1) s(-1)) approaches, but does not reach, the diffusion limit, This follows from the appreciable solvent kinetic deuterium isotope effects on the rate constants, indicating that, independent of the salt concentration, the rate-limiting step of the catalysis is a chemical process rather than a physical one, The reaction also has positive entropy of activation, On the other hand, the rate-limiting step for substrate QR changes with increasing salt concentration from a physical to chemical step, while the negative activation entropy becomes positive, The rate increase with substrate ER is 50-fold with respect to substrate QR in the presence of 0.1 M NaCl and diminishes to 3.5-fold at 2.0 M NaCl concentration, as a consequence of a considerable rate increase at high salt concentration with substrate QR but not with substrate ER. The K-m value is much lower for the substrate ER (0.8 pH) than for substrate QR (15 mu M), indicating a more effective binding for substrate ER at 0.1 M NaCl. Unexpectedly, the strong binding appears to be achieved by the unionized form of Glu in P2', as follows from the remarkably different pH-rate profiles for substrates QR and ER, The effective binding elicited by the glutamic acid may be utilized in designing inhibitors for therapeutic purposes.	HUNGARIAN ACAD SCI,BIOL RES CTR,INST ENZYMOL,H-1518 BUDAPEST,HUNGARY	Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences								BAUM EZ, 1990, P NATL ACAD SCI USA, V87, P5573, DOI 10.1073/pnas.87.14.5573; BENDER ML, 1965, ANNU REV BIOCHEM, V34, P49, DOI 10.1146/annurev.bi.34.070165.000405; DUGGLEBY RG, 1995, METHOD ENZYMOL, V249, P61; DUNN BM, 1994, METHOD ENZYMOL, V241, P254; GLASOE PK, 1960, J PHYS CHEM-US, V64, P188, DOI 10.1021/j100830a521; GRIFFITHS JT, 1992, BIOCHEMISTRY-US, V31, P5193, DOI 10.1021/bi00137a015; HYLAND LJ, 1991, BIOCHEMISTRY-US, V30, P8454, DOI 10.1021/bi00098a024; HYLAND LJ, 1992, BIOCHEMISTRY-US, V31, P9491; LEATHERBARROW RG, 1990, GRAFIT VERSION 2 0; LIN YZ, 1995, BIOCHEMISTRY-US, V34, P1143, DOI 10.1021/bi00004a007; MANCHESTER M, 1994, J BIOL CHEM, V269, P7689; MEEK TD, 1994, METHOD ENZYMOL, V241, P127; MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029; POLGAR L, 1994, BIOCHEMISTRY-US, V33, P9351, DOI 10.1021/bi00197a040; POLGAR L, 1989, MECHANISMS PROTEASE, P157; Szeltner Z, 1996, J BIOL CHEM, V271, P5458, DOI 10.1074/jbc.271.10.5458; TOMASZEK TA, 1992, BIOCHEMISTRY-US, V31, P10153, DOI 10.1021/bi00157a003; TONG L, 1993, P NATL ACAD SCI USA, V90, P8387, DOI 10.1073/pnas.90.18.8387; TOTH MV, 1990, INT J PEPT PROT RES, V36, P544; TOZSER J, 1991, FEBS LETT, V281, P77, DOI 10.1016/0014-5793(91)80362-7; WLODAWER A, 1993, ANNU REV BIOCHEM, V62, P543, DOI 10.1146/annurev.bi.62.070193.002551; WONDRAK EM, 1991, FEBS LETT, V280, P344, DOI 10.1016/0014-5793(91)80327-Y	22	37	37	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32180	32184		10.1074/jbc.271.50.32180	http://dx.doi.org/10.1074/jbc.271.50.32180			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943273	hybrid			2022-12-25	WOS:A1996VY34000064
J	Akiyama, Y; Kihara, A; Tokuda, H; Ito, K				Akiyama, Y; Kihara, A; Tokuda, H; Ito, K			FtsH (HflB) is an ATP-dependent protease selectively acting on SecY and some other membrane proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI FTSH; PREPROTEIN TRANSLOCASE; GENE; MUTATIONS; INVOLVEMENT; DEGRADATION; COMPLEX; CELL; RECONSTITUTION; MITOCHONDRIA	The FtsH protein is a membrane-bound ATPase of Escherichia coli that was proposed to be involved in membrane protein assembly as well as degradation of some unstable proteins, SecY, a subunit of protein translocase, is FtsH dependently degraded in vivo when it fails to associate with its partner (the SecE protein), We constructed a series of mutants in which mutations were introduced into conserved residues in the two ATP binding consensus sequences or the zinc binding sequence of FtsH, We purified wild-type and mutant FtsH proteins by making use of a polyhistidine tag attached to their carboxyl termini, Complementation analysis and ATPase activity assays in vitro indicated that, of the two sets of ATP binding sequence motifs, the one located C-terminally (Al) is essential for ATPase activity and in two functioning of FtsH, Wild-type FtsH protein degraded purified SecY in an ATP hydrolysis-dependent manner in vitro. Mutant proteins without ATPase activity were inactive in proteolysis. A zinc binding motif mutant showed a decreased proteolytic activity. SecY and FtsH were cross linkable with each other in the membrane, provided that FtsH had an ATPase-inactivating mutation, These results demonstrate that FtsH binds to and degrades SecY, its Al motif and the zinc binding motif being important for the proteolytic activity. FtsH-dependent proteolysis was also demonstrated for SecY in crude membrane extracts, whereas a majority of other membrane proteins were not degraded, indicating that FtsH has high selectivity in protein degradation.	UNIV TOKYO, INST MOL & CELLULAR BIOSCI, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo	Akiyama, Y (corresponding author), KYOTO UNIV, DEPT CELL BIOL, INST VIRUS RES, KYOTO 60601, JAPAN.		KIHARA, AKIO/A-3802-2012	KIHARA, AKIO/0000-0001-5889-0788				AKIMARU J, 1991, P NATL ACAD SCI USA, V88, P6545, DOI 10.1073/pnas.88.15.6545; AKIYAMA Y, 1990, BIOCHEM BIOPH RES CO, V167, P711, DOI 10.1016/0006-291X(90)92083-C; AKIYAMA Y, 1994, J BIOL CHEM, V269, P5218; AKIYAMA Y, 1994, J BIOL CHEM, V269, P5225; AKIYAMA Y, 1995, J BIOL CHEM, V270, P23485, DOI 10.1074/jbc.270.40.23485; AKIYAMA Y, 1985, EMBO J, V4, P3351, DOI 10.1002/j.1460-2075.1985.tb04088.x; AKIYAMA Y, 1995, MOL GEN GENET, V249, P202, DOI 10.1007/BF00290367; Arlt H, 1996, CELL, V85, P875, DOI 10.1016/S0092-8674(00)81271-4; BABA T, 1994, P NATL ACAD SCI USA, V91, P4539, DOI 10.1073/pnas.91.10.4539; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; BRUNDAGE L, 1992, J BIOL CHEM, V267, P4166; CHAN KM, 1986, ANAL BIOCHEM, V157, P375, DOI 10.1016/0003-2697(86)90640-8; DOUVILLE K, 1995, J BIOL CHEM, V270, P20106, DOI 10.1074/jbc.270.34.20106; FLOWER AM, 1995, EMBO J, V14, P884, DOI 10.1002/j.1460-2075.1995.tb07070.x; Guelin E, 1996, FEBS LETT, V381, P42, DOI 10.1016/0014-5793(96)00074-9; HERMAN C, 1993, P NATL ACAD SCI USA, V90, P10861, DOI 10.1073/pnas.90.22.10861; HERMAN C, 1995, P NATL ACAD SCI USA, V92, P3516, DOI 10.1073/pnas.92.8.3516; HOOPER NM, 1994, FEBS LETT, V354, P1, DOI 10.1016/0014-5793(94)01079-X; IOST I, 1995, EMBO J, V14, P3252, DOI 10.1002/j.1460-2075.1995.tb07328.x; KIHARA A, 1995, P NATL ACAD SCI USA, V92, P4532, DOI 10.1073/pnas.92.10.4532; KIHARA A, 1996, IN PRESS EMBO J, V15; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MATSUYAMA S, 1990, FEBS LETT, V269, P96, DOI 10.1016/0014-5793(90)81128-B; MURPHY CK, 1994, P NATL ACAD SCI USA, V91, P2557, DOI 10.1073/pnas.91.7.2557; NAKAI T, 1995, MOL CELL BIOL, V15, P4441; NISHIYAMA K, 1994, EMBO J, V13, P3272, DOI 10.1002/j.1460-2075.1994.tb06628.x; PAJIC A, 1994, FEBS LETT, V353, P201, DOI 10.1016/0014-5793(94)01046-3; SHIBA K, 1984, EMBO J, V3, P631, DOI 10.1002/j.1460-2075.1984.tb01859.x; SHIMOIKE T, 1995, J BIOL CHEM, V270, P5519, DOI 10.1074/jbc.270.10.5519; Silhavy T.J., 1984, EXPT GENE FUSIONS; TAKESHITA S, 1987, GENE, V61, P63, DOI 10.1016/0378-1119(87)90365-9; TAURA T, 1993, J BACTERIOL, V175, P7771, DOI 10.1128/JB.175.24.7771-7775.1993; TAURA T, 1994, MOL GEN GENET, V243, P261, DOI 10.1007/BF00301061; TOMOYASU T, 1993, J BACTERIOL, V175, P1352, DOI 10.1128/JB.175.5.1352-1357.1993; TOMOYASU T, 1995, EMBO J, V14, P2551, DOI 10.1002/j.1460-2075.1995.tb07253.x; TOMOYASU T, 1993, J BACTERIOL, V175, P1344, DOI 10.1128/JB.175.5.1344-1351.1993; Weber ER, 1996, MOL BIOL CELL, V7, P307, DOI 10.1091/mbc.7.2.307	37	136	138	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31196	31201		10.1074/jbc.271.49.31196	http://dx.doi.org/10.1074/jbc.271.49.31196			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940120	hybrid			2022-12-25	WOS:A1996VW68600031
J	Contreras, JA; Karlsson, M; Osterlund, T; Laurell, H; Svensson, A; Holm, C				Contreras, JA; Karlsson, M; Osterlund, T; Laurell, H; Svensson, A; Holm, C			Hormone-sensitive lipase is structurally related to acetylcholinesterase, bile salt-stimulated lipase, and several fungal lipases - Building of a three-dimensional model for the catalytic domain of hormone-sensitive lipase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CANDIDA-RUGOSA LIPASE; GEOTRICHUM-CANDIDUM; LIPOPROTEIN-LIPASE; PANCREATIC LIPASE; ADIPOSE-TISSUE; ACTIVE-SITE; SEQUENCE; PROTEIN; IDENTIFICATION	Hormone-sensitive Lipase is the key enzyme in the mobilization of fatty acids from adipose tissue, thereby playing a crucial role in the overall energy homeostasis in mammals, Its activity is stimulated by catecholamines through cAMP-dependent phosphorylation of a single serine, a process that is prevented by insulin, This regulatory property is unique to this enzyme among all known Lipases and has been acquired during evolution through insertion of a regulatory module into an ancestral Lipase, Sequence alignments have failed to detect significant homology between hormone-sensitive lipase and the rest of the mammalian lipases and esterases, to which this enzyme is only very distantly related, In the present work, Fee report the finding of a remarkable secondary structure homology between hormone-sensitive Lipase and the enzymes from a superfamily of esterases and lipases that includes acetylcholinesterase, bile salt-stimulated lipase, and several fungal lipases. This finding, based on the identification of the secondary structure elements in the hormone-sensitive lipase sequence, has allowed us to construct a three-dimensional model for the catalytic domain of hormone-sensitive Lipase, The model reveals the topological organization, predicts the components of the catalytic triad, suggests a three-dimensional localization of the regulatory module, and provides a valuable tool for the future study of structural and functional aspects of this metabolically important enzyme.	LUND UNIV,DEPT MOL BIOPHYS,S-22100 LUND,SWEDEN	Lund University	Contreras, JA (corresponding author), LUND UNIV,DEPT CELL & MOL BIOL,POB 94,S-22100 LUND,SWEDEN.			Laurell, Henrik/0000-0001-7328-935X; Osterlund, Torben/0000-0002-2047-767X				AUYOUNG J, 1992, P NATL ACAD SCI USA, V89, P4094, DOI 10.1073/pnas.89.9.4094; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CYGLER M, 1993, PROTEIN SCI, V2, P366; DEREWENDA ZS, 1993, ADV PROTEIN CHEM, V45, P1; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FREDRIKSON G, 1981, J BIOL CHEM, V256, P6311; GARTON AJ, 1990, EUR J BIOCHEM, V191, P245, DOI 10.1111/j.1432-1033.1990.tb19116.x; GARTON AJ, 1989, EUR J BIOCHEM, V179, P249, DOI 10.1111/j.1432-1033.1989.tb14548.x; GJELLESVIK DR, 1994, EUR J BIOCHEM, V226, P603, DOI 10.1111/j.1432-1033.1994.tb20086.x; GROCHULSKI P, 1994, PROTEIN SCI, V3, P82; GROCHULSKI P, 1993, J BIOL CHEM, V268, P12843; Guex N., 1996, Experientia (Basel), V52, pA26; HEMILA H, 1994, BBA-LIPID LIPID MET, V1210, P249, DOI 10.1016/0005-2760(94)90129-5; HOLM C, 1987, BIOCHEM BIOPH RES CO, V148, P99, DOI 10.1016/0006-291X(87)91081-3; HOLM C, 1988, SCIENCE, V241, P1503, DOI 10.1126/science.3420405; HOLM C, 1994, FEBS LETT, V344, P234, DOI 10.1016/0014-5793(94)00403-X; LANGIN D, 1993, P NATL ACAD SCI USA, V90, P4897, DOI 10.1073/pnas.90.11.4897; LANGIN D, 1993, TRENDS BIOCHEM SCI, V18, P466, DOI 10.1016/0968-0004(93)90007-A; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LI ZG, 1994, GENOMICS, V24, P259, DOI 10.1006/geno.1994.1614; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Osterlund T, 1996, BIOCHEM J, V319, P411, DOI 10.1042/bj3190411; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; SCHRAG JD, 1993, J MOL BIOL, V230, P575, DOI 10.1006/jmbi.1993.1171; STRALFORS P, 1984, P NATL ACAD SCI-BIOL, V81, P3317, DOI 10.1073/pnas.81.11.3317; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TILBEURGH H, 1992, NATURE, V359, P159; UPPENBERG J, 1994, STRUCTURE, V2, P293, DOI 10.1016/S0969-2126(00)00031-9; VANTILBEURGH H, 1994, J BIOL CHEM, V269, P4626; VERNET T, 1993, J BIOL CHEM, V268, P26212; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; YEAMAN SJ, 1990, BIOCHIM BIOPHYS ACTA, V1052, P128, DOI 10.1016/0167-4889(90)90067-N	35	84	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31426	31430		10.1074/jbc.271.49.31426	http://dx.doi.org/10.1074/jbc.271.49.31426			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940153	hybrid			2022-12-25	WOS:A1996VW68600064
J	Finegold, AA; Shatwell, KP; Segal, AW; Klausner, RD; Dancis, A				Finegold, AA; Shatwell, KP; Segal, AW; Klausner, RD; Dancis, A			Intramembrane bis-heme motif for transmembrane electron transport conserved in a yeast iron reductase and the human NADPH oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; SACCHAROMYCES-CEREVISIAE; CYTOCHROME-B; FERRIC REDUCTASE; GENE; PHAGOCYTES; LOCATION; PROTEIN; SYSTEM	A plasma membrane iron reductase, required for cellular iron acquisition by Saccharomyces cerevisiae, and the human phagocytic NADPH oxidase, implicated in cellular defense, contain low potential plasma membrane b cytochromes that share elements of structure and function, Four critical histidine residues in the FRE1 protein of the iron reductase were identified by site-directed mutagenesis, Individual mutation of each histidine to alanine eliminated the entire heme spectrum without affecting expression of the apoprotein, documenting the specificity of the requirement for the histidine residues, These critical residues are predicted to coordinate a bis-heme structure between transmembrane domains of the FRE1 protein. The histidine residues are conserved in the related gp91(phox) protein of the NADPH oxidase of human granulocytes, predicting the sites of heme coordination in that protein complex, Similarly spaced histidine residues have also been implicated in heme binding by organelle b cytochromes with little overall sequence similarity to the plasma membrane b cytochromes. This bis-heme motif may play a role in transmembrane electron transport by distinct families of polytopic b cytochromes.	NICHHD,CELL BIOL & METAB BRANCH,NIH,BETHESDA,MD 20892; UNIV LONDON UNIV COLL,SCH MED,DEPT MED,LONDON WC1E 6JJ,ENGLAND	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of London; University College London; UCL Medical School				Segal, Anthony/0000-0001-7602-9043	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; CLAROS MG, 1995, EUR J BIOCHEM, V228, P762, DOI 10.1111/j.1432-1033.1995.0762m.x; CRAMER WA, 1990, ENERGY TRANSDUCTION, P330; CROSS AR, 1995, J BIOL CHEM, V270, P17075, DOI 10.1074/jbc.270.29.17075; DANCIS A, 1992, P NATL ACAD SCI USA, V89, P3869, DOI 10.1073/pnas.89.9.3869; GEORGATSOU E, 1994, MOL CELL BIOL, V14, P3065, DOI 10.1128/MCB.14.5.3065; Groom QJ, 1996, PLANT J, V10, P515, DOI 10.1046/j.1365-313X.1996.10030515.x; HURST JK, 1991, J BIOL CHEM, V266, P1627; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lesuisse E, 1996, J BIOL CHEM, V271, P13578, DOI 10.1074/jbc.271.23.13578; LESUISSE E, 1989, J GEN MICROBIOL, V135, P257; LI F, 1994, BLOOD, V84, P53, DOI 10.1182/blood.V84.1.53.bloodjournal84153; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; QUINN MT, 1992, J BIOL CHEM, V267, P7303; ROMAN DG, 1993, MOL CELL BIOL, V13, P4342, DOI 10.1128/MCB.13.7.4342; Roos D, 1996, BLOOD, V87, P1663; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; SARASTE M, 1984, FEBS LETT, V166, P367, DOI 10.1016/0014-5793(84)80114-3; Segal A W, 1993, Immunodeficiency, V4, P167; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; Shatwell KP, 1996, J BIOL CHEM, V271, P14240, DOI 10.1074/jbc.271.24.14240; SIKORSKI RS, 1989, GENETICS, V122, P19; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; THRASHER AJ, 1994, BBA-MOL BASIS DIS, V1227, P1, DOI 10.1016/0925-4439(94)90100-7; THRASHER AJ, 1995, BLOOD, V86, P761, DOI 10.1182/blood.V86.2.761.bloodjournal862761; WIDGER WR, 1984, P NATL ACAD SCI-BIOL, V81, P674, DOI 10.1073/pnas.81.3.674	27	154	161	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31021	31024		10.1074/jbc.271.49.31021	http://dx.doi.org/10.1074/jbc.271.49.31021			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940093	hybrid			2022-12-25	WOS:A1996VW68600004
J	Carel, K; Kummer, JL; Schubert, C; Leitner, W; Heidenreich, KA; Draznin, B				Carel, K; Kummer, JL; Schubert, C; Leitner, W; Heidenreich, KA; Draznin, B			Insulin stimulates mitogen-activated protein kinase by a Ras-independent pathway in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; MEK KINASE; NETWORK; CELLS; REQUIREMENT; COMPONENTS; CASCADE; P21RAS	To characterize tissue-specific differences in insulin signaling, we compared the mechanisms of mitogen-activated protein (MAP) kinase activation by insulin in the mitogenically active 3T3-L1 fibroblasts with the metabolically active 3T3-L1 adipocytes. In both cell lines, insulin significantly increased p21(ras). GTP loading (1.5-2-fold) and MAP kinase activity (5-8-fold). Inhibition of Ras farnesylation with lovastatin blocked activation of p21(ras) and Raf-1 kinase in both 3T3-L1 fibroblasts and 3T3-L1 adipocytes. In 3T3-L1 fibroblasts, this was accompanied by an inhibition of the stimulatory effect of insulin on MAP kinase. In contrast, in 3T3-L1 adipocytes, despite an inhibition of activation of p21(ras) and Raf-1 by lovastatin, insulin continued to stimulate MAP kinase activity. Fractionation of the cell lysates on the FPLC Mono-Q column revealed that lovastatin inhibited insulin stimulation of ERK2 (and, to a lesser extent, ERK1) in 3T3-L1 fibroblasts and had no effect on the insulin-stimulated ERK2 in 3T3-L1 adipocytes. These results demonstrate an important distinction between the mechanism of insulin signaling in the metabolically and mitogenically active cells. Insulin activates MAP kinase by the Pas-dependent pathway in the 3T3-L1 fibroblasts and by the Pas-independent pathway in the 3T3-L1 adipocytes.	VET AFFAIRS MED CTR,SECT ENDOCRINOL 111H,MED RES SERV,DENVER,CO 80220; VET AFFAIRS MED CTR,DEPT MED,DENVER,CO 80220; VET AFFAIRS MED CTR,DEPT PHARMACOL,DENVER,CO 80220; UNIV COLORADO,HLTH SCI CTR,DENVER,CO 80220	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								AHN NG, 1991, J BIOL CHEM, V266, P4220; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BUSCHER D, 1995, MOL CELL BIOL, V15, P466; CHAO TSO, 1994, J BIOL CHEM, V269, P7337; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DePaolo D, 1996, MOL CELL BIOL, V16, P1450; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DRAZNIN B, 1993, J BIOL CHEM, V268, P19998; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HAYSTEAD CMM, 1994, J BIOL CHEM, V269, P12804; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; REUSCH JEB, 1995, J BIOL CHEM, V270, P2036, DOI 10.1074/jbc.270.5.2036; Schubert C, 1996, J BIOL CHEM, V271, P15311, DOI 10.1074/jbc.271.26.15311; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; WHITE MF, 1994, J BIOL CHEM, V269, P1; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442; ZHENG CF, 1993, J BIOL CHEM, V268, P23933; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	29	37	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30625	30630		10.1074/jbc.271.48.30625	http://dx.doi.org/10.1074/jbc.271.48.30625			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940037	hybrid			2022-12-25	WOS:A1996VV15800054
J	Hamilton, TG; Flynn, GC				Hamilton, TG; Flynn, GC			Cer1p, a novel hsp70-related protein required for posttranslational endoplasmic reticulum translocation in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; SACCHAROMYCES-CEREVISIAE; CARBOXYPEPTIDASE-Y; SEC PROTEINS; MEMBRANES; TRANSPORT; HOMOLOG; GENE; BIP; INVERTASE	Proteins enter the secretory pathway by translocation across the endoplasmic reticulum (ER) membrane, In Saccharomyces cerevisiae, import of proteins into the ER occurs both cotranslationally and posttranslationally, Presumably, the cotranslational targeting to the ER membrane is directed by the signal recognition particle, as demonstrated in other eukaryotic systems, The deletion of a gene, called CER1, inhibits the translocation of proteins that enter the ER posttranslationally, but not those that enter cotranslationally. This translocation defect is more pronounced at lower temperatures. A strain possessing a null mutation of CER1 in combination with a kar2 temperature-sensitive mutation displays synthetic growth defects, whereas overexpression of the ER DnaJ homolog Scj1p suppresses the translocation defect in cer1 Delta strains, CER1 is predicted to encode a 100-kDa polypeptide, residing in the ER lumen that is related to the hsp70 family of molecular chaperones.	UNIV OREGON,INST MOL BIOL,EUGENE,OR 97403	University of Oregon								BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BLUMBERG H, 1991, NATURE, V349, P627, DOI 10.1038/349627a0; BRODSKY JL, 1995, P NATL ACAD SCI USA, V92, P9643, DOI 10.1073/pnas.92.21.9643; CHIRICO WJ, 1988, NATURE, V332, P800; Craven RA, 1996, EMBO J, V15, P2640, DOI 10.1002/j.1460-2075.1996.tb00624.x; DAVIS NG, 1993, J CELL BIOL, V122, P53, DOI 10.1083/jcb.122.1.53; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; Finke K, 1996, EMBO J, V15, P1482, DOI 10.1002/j.1460-2075.1996.tb00492.x; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HANSEN W, 1986, CELL, V45, P397, DOI 10.1016/0092-8674(86)90325-9; HANSEN W, 1988, J CELL BIOL, V106, P1075, DOI 10.1083/jcb.106.4.1075; JOHNSSON N, 1994, EMBO J, V13, P2686, DOI 10.1002/j.1460-2075.1994.tb06559.x; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; NGSEE JK, 1989, MOL CELL BIOL, V9, P3400, DOI 10.1128/MCB.9.8.3400; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; RASMUSSEN SW, 1994, YEAST, V10, pS69, DOI 10.1002/yea.320100009; RASSOW J, 1995, TRENDS CELL BIOL, V5, P207, DOI 10.1016/S0962-8924(00)89001-7; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SCHLENSTEDT G, 1995, J CELL BIOL, V129, P979, DOI 10.1083/jcb.129.4.979; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WALTER P, 1982, NATURE, V299, P691, DOI 10.1038/299691a0; WANG TF, 1993, J BIOL CHEM, V268, P26049; WAY JC, 1993, CELL, V74, P5	30	39	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30610	30613		10.1074/jbc.271.48.30610	http://dx.doi.org/10.1074/jbc.271.48.30610			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940034	hybrid			2022-12-25	WOS:A1996VV15800051
J	Herrero, I; SanchezPrieto, J				Herrero, I; SanchezPrieto, J			cAMP-dependent facilitation of glutamate release by beta-adrenergic receptors in cerebrocortical nerve terminals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; PROTEIN-KINASE; CYCLIC-AMP; SYNAPTIC TRANSMISSION; HIPPOCAMPAL-NEURONS; ARACHIDONIC-ACID; CALCIUM CHANNELS; RAT HIPPOCAMPUS; DENTATE GYRUS; PHOSPHORYLATION	We have investigated the presence of a cAMP-protein kinase A-dependent pathway in cerebrocortical nerve terminals and its role in the modulation of glutamate release. The activation of adenylyl cyclase with forskolin enhances intrasynaptosomal cAMP and induces Ca2+-dependent glutamate release. The membrane permeant analogue dibutyryl cAMP mimics this facilitatory effect, whereas the inactive compound 1,9-dideoxyforskolin is without effect. This cAMP-induced facilitation is consistent with the induction of spontaneous action potentials that are abolished by the Nat channel blocker tetrodotoxin and by reducing nerve terminal excitability with arachidonic acid. We have also demonstrated that a beta-adrenergic receptor is linked to this pathway because isoproterenol increases cAMP levels and glutamate release, and both actions are antagonized by the receptor antagonist propanolol and the protein kinase A inhibitors H89 and 8-chloroadenosine 3',5'-monophosphorothioate ((R(p))-isomer). The finding that the increase in cytoplasmic free Ca2+ concentration induced by synaptic activity reduces the concentration of agonist required to maximally activate adenylyl cyclase suggests that this enzyme may act as a coincidence detector, integrating glutamatergic neurotransmission and noradrenaline release.	UNIV COMPLUTENSE MADRID, FAC VET, DEPT BIOQUIM, E-28040 MADRID, SPAIN	Complutense University of Madrid				Sanchez-Prieto, Jose/0000-0002-8513-3501				BARRIE AP, 1991, J NEUROCHEM, V57, P1398, DOI 10.1111/j.1471-4159.1991.tb08306.x; BOLSHAKOV VY, 1995, NEUROPHARMACOLOGY, V34, P1581, DOI 10.1016/0028-3908(95)00127-R; CHAVEZNORIEGA LE, 1994, J NEUROSCI, V14, P310; CHAVEZNORIEGA LE, 1992, BRAIN RES, V574, P85, DOI 10.1016/0006-8993(92)90803-H; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; COLWELL CS, 1995, J NEUROSCI, V15, P1704, DOI 10.1523/JNEUROSCI.15-03-01704.1995; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; DALY JW, 1982, J NEUROCHEM, V38, P532, DOI 10.1111/j.1471-4159.1982.tb08660.x; DUNWIDDIE TV, 1980, BRIT J PHARMACOL, V69, P59, DOI 10.1111/j.1476-5381.1980.tb10883.x; FOEHRING RC, 1989, J NEUROPHYSIOL, V61, P245, DOI 10.1152/jn.1989.61.2.245; FRASER DD, 1993, NEURON, V11, P633, DOI 10.1016/0896-6273(93)90075-3; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; FYKSE EM, 1995, J NEUROSCI, V15, P2385, DOI 10.1523/JNEUROSCI.15-03-02385.1995; GRAY R, 1987, NATURE, V327, P620, DOI 10.1038/327620a0; GREENGARD P, 1991, SCIENCE, V253, P1135, DOI 10.1126/science.1716001; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAAS HL, 1983, NATURE, V302, P432, DOI 10.1038/302432a0; HELL JW, 1995, EMBO J, V14, P3036, DOI 10.1002/j.1460-2075.1995.tb07306.x; HERRERO I, 1991, J NEUROCHEM, V57, P718, DOI 10.1111/j.1471-4159.1991.tb03805.x; HERRERO I, 1991, NEUROSCI LETT, V126, P41, DOI 10.1016/0304-3940(91)90366-2; HERRERO I, 1992, NATURE, V360, P163, DOI 10.1038/360163a0; HOPKINS WF, 1988, J NEUROPHYSIOL, V59, P667, DOI 10.1152/jn.1988.59.2.667; Huang CC, 1996, J NEUROSCI, V16, P1026; Huang YY, 1996, NEURON, V16, P611, DOI 10.1016/S0896-6273(00)80080-X; HUANG YY, 1994, CELL, V79, P69, DOI 10.1016/0092-8674(94)90401-4; LLINAS R, 1985, P NATL ACAD SCI USA, V82, P3035, DOI 10.1073/pnas.82.9.3035; MADISON DV, 1982, NATURE, V299, P636, DOI 10.1038/299636a0; MAGISTRETTI PJ, 1984, NATURE, V308, P280, DOI 10.1038/308280a0; MCMAHON HT, 1991, J NEUROCHEM, V56, P86, DOI 10.1111/j.1471-4159.1991.tb02566.x; MCMAHON HT, 1992, J BIOL CHEM, V267, P21338; MONS N, 1995, P NATL ACAD SCI USA, V92, P8473, DOI 10.1073/pnas.92.18.8473; MOORE RY, 1979, ANNU REV NEUROSCI, V2, P113, DOI 10.1146/annurev.ne.02.030179.000553; NICHOLLS DG, 1987, J NEUROCHEM, V49, P50, DOI 10.1111/j.1471-4159.1987.tb03393.x; PARFITT KD, 1992, HIPPOCAMPUS, V2, P59, DOI 10.1002/hipo.450020108; Raman IM, 1996, NEURON, V16, P415, DOI 10.1016/S0896-6273(00)80059-8; RAYMOND LA, 1993, NATURE, V361, P637, DOI 10.1038/361637a0; SIMS PJ, 1974, BIOCHEMISTRY-US, V13, P3315, DOI 10.1021/bi00713a022; SMELLIE FW, 1979, LIFE SCI, V24, P2475, DOI 10.1016/0024-3205(79)90458-2; STANTON PK, 1985, BRAIN RES, V361, P276, DOI 10.1016/0006-8993(85)91299-5; TIBBS GR, 1989, J NEUROCHEM, V53, P1693, DOI 10.1111/j.1471-4159.1989.tb09232.x; VERHAGE M, 1991, NEURON, V6, P517, DOI 10.1016/0896-6273(91)90054-4; WANG LY, 1991, SCIENCE, V253, P1132, DOI 10.1126/science.1653455; WEISSKOPF MG, 1994, SCIENCE, V265, P1878, DOI 10.1126/science.7916482	43	59	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30554	30560		10.1074/jbc.271.48.30554	http://dx.doi.org/10.1074/jbc.271.48.30554			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940026	hybrid			2022-12-25	WOS:A1996VV15800043
J	RodriguezTarduchy, G; Sahuquillo, AG; Alarcon, B; Bragado, R				RodriguezTarduchy, G; Sahuquillo, AG; Alarcon, B; Bragado, R			Apoptosis but not other activation events is inhibited by a mutation in the transmembrane domain of T cell receptor beta that impairs CD3 xi association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUREUS ENTEROTOXIN-B; TANDEM SH2 DOMAINS; ANTIGEN RECEPTOR; SIGNAL-TRANSDUCTION; ZETA-CHAIN; FAS-LIGAND; GENETIC RECONSTITUTION; ENDOPLASMIC-RETICULUM; TCR/CD3 COMPLEX; ZAP-70 BIND	The transmembrane domain of T cell receptor (TCR) beta contains a conserved immunoreceptor tyrosine-based activation-like motif consisting of a duplicated YXXL sequence. The motif is also present in TCR gamma, the equivalent chain to TCR beta in gamma delta T lymphocytes but is absent in TCR alpha and TCR delta. To determine the putative role of this sequence in TCR-CD3 complex assembly and signal transduction, a TCR beta chain cDNA was mutated in the C-terminal tyrosine of the moth, cloned in an expression vector, and transfected into TCR beta-negative Jurkat cells. Transfectants of the mutated chain (MUT) expressed, on average, much less TCR-CD3 complex on the membrane than wild type TCR beta transfectants. Radiolabeling experiments suggested that the mutation caused a loose association of the CD36 chain resulting in a defective assembly. However, stimulation of high TCR-CD3 expressing wild type and MUT clones with monoclonal antibodies and Staphylococcus aureus enterotoxin B resulted in similar levels of CD25 and CD69 expression, interleukin-2 secretion, and TCR CD3 complex downregulation. By contrast, MUT cells were clearly resistant to activation-induced cell death, and they did not express CD95-ligand upon activation. These results suggest a differentiated intracellular signaling pathway leading to apoptosis in which Tyr-TM11 of the immunoreceptor tyrosine-based activation motif-like motif and CD3 zeta appear to be involved.	UNIV AUTONOMA MADRID,CSIC,CTR BIOL MOL SEVERO OCHOA,MADRID 28049,SPAIN; FDN JIMENEZ DIAZ,DEPT IMMUNOL,MADRID 28040,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)			Alarcon, Balbino/N-9648-2016	Alarcon, Balbino/0000-0001-7820-1070				ALARCON B, 1988, J BIOL CHEM, V263, P2953; ALCOVER A, 1988, EMBO J, V7, P1973, DOI 10.1002/j.1460-2075.1988.tb03035.x; AOE T, 1995, J EXP MED, V181, P1881, DOI 10.1084/jem.181.5.1881; BLUMBERG RS, 1991, EUR J IMMUNOL, V21, P473, DOI 10.1002/eji.1830210233; BRUCKER T, 1995, J EXP MED, V181, P1653; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CAMBIER JC, 1992, CURR OPIN IMMUNOL, V4, P257, DOI 10.1016/0952-7915(92)90074-O; Campbell K S, 1994, Semin Immunol, V6, P393, DOI 10.1006/smim.1994.1049; CHAN AC, 1992, CURR OPIN IMMUNOL, V4, P246, DOI 10.1016/0952-7915(92)90072-M; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; ETTINGER R, 1995, J IMMUNOL, V154, P4302; FINKE JH, 1993, CANCER RES, V53, P5613; GRUPP SA, 1995, J EXP MED, V181, P161, DOI 10.1084/jem.181.1.161; HALL C, 1991, INT IMMUNOL, V3, P359, DOI 10.1093/intimm/3.4.359; HEWITT CRA, 1992, J EXP MED, V175, P1493, DOI 10.1084/jem.175.6.1493; ISAKOV N, 1995, J EXP MED, V181, P375, DOI 10.1084/jem.181.1.375; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KAPPLER J, 1989, SCIENCE, V244, P811, DOI 10.1126/science.2524876; MALISSEN B, 1993, CURR OPIN IMMUNOL, V5, P324, DOI 10.1016/0952-7915(93)90049-X; MANOLIOS N, 1991, EMBO J, V10, P1643, DOI 10.1002/j.1460-2075.1991.tb07687.x; MANOLIOS N, 1994, EUR J IMMUNOL, V24, P84, DOI 10.1002/eji.1830240114; NAKAGOMI H, 1993, CANCER RES, V53, P5610; NIEDERGANG F, 1995, J BIOL CHEM, V270, P12839, DOI 10.1074/jbc.270.21.12839; NOCENTINI G, 1995, EUR J IMMUNOL, V25, P1405, DOI 10.1002/eji.1830250540; PLEIMAN CM, 1994, J IMMUNOL, V152, P2837; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; SALMERON A, 1995, J IMMUNOL, V154, P1675; SANCHO J, 1989, J BIOL CHEM, V264, P20760; SHINKAI Y, 1995, IMMUNITY, V2, P401; SHORES EW, 1994, SCIENCE, V266, P1047, DOI 10.1126/science.7526464; STEVENS TL, 1994, J IMMUNOL, V152, P4397; STRAUS DB, 1993, J EXP MED, V178, P1523, DOI 10.1084/jem.178.5.1523; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; VIGNAUX F, 1995, J EXP MED, V181, P781, DOI 10.1084/jem.181.2.781; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WEISSMAN AM, 1989, EMBO J, V8, P3651, DOI 10.1002/j.1460-2075.1989.tb08539.x; YAO XR, 1995, J IMMUNOL, V155, P652	41	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30417	30425		10.1074/jbc.271.48.30417	http://dx.doi.org/10.1074/jbc.271.48.30417			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940006	hybrid			2022-12-25	WOS:A1996VV15800023
J	Ryden, M; Imamura, T; Jornvall, H; Belluardo, N; Neveu, I; Trupp, M; Okadome, T; tenDijke, P; Ibanez, CF				Ryden, M; Imamura, T; Jornvall, H; Belluardo, N; Neveu, I; Trupp, M; Okadome, T; tenDijke, P; Ibanez, CF			A novel type I receptor serine-threonine kinase predominantly expressed in the adult central nervous system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING GROWTH-FACTOR; TGF-BETA RECEPTOR; MEMBRANE PROTEOGLYCAN; HETEROMERIC COMPLEX; SIGNALING RECEPTORS; ACTIVIN; CLONING; CELLS; BETAGLYCAN; NEURONS	Receptor serine-threonine kinases (RSTK) mediate inhibitory as well as stimulatory signals for growth and differentiation by binding to members of the transforming growth factor-beta (TGF-beta) superfamily. Over 12 different RSTKs have been isolated so far, displaying wide expression in peripheral tissues and in the nervous system. Here we report the isolation and characterization of a novel type I RSTK termed activin receptor-like kinase-7 (ALK-7) that, unlike other members of this receptor family, is predominantly expressed in the adult central nervous system. The ALK-7 gene encodes a 55-kDa cell-surface protein that exhibits up to 78% amino acid sequence identity in the kinase domain to previously isolated type I receptors for TGF-beta and activin. In the extracellular domain, however, ALK-7 is more divergent, displaying comparable similarities with all members of the ALK subfamily. RNase protection and in situ hybridization studies demonstrated a highly specific mRNA distribution restricted to neurons in several regions of the adult rat central nervous system, including cerebellum, hippocampus, and nuclei of the brainstem. Receptor reconstitution and cross-linking experiments indicated that ALK-7 can form complexes with type II RSTKs for TGF-beta and activin in a ligand-dependent manner, although direct binding of ALK-7 to ligand in these complexes could not be demonstrated. The specific expression pattern of ALK-7, restricted to the postnatal central nervous system, indicates that this receptor may play an important role in the maturation and maintenance of several neuronal subpopulations.	KAROLINSKA INST,MOL NEUROBIOL LAB,DEPT NEUROSCI,S-17177 STOCKHOLM,SWEDEN; LUDWIG INST CANC RES,CTR BIOMED,S-75124 UPPSALA,SWEDEN; UNIV CATANIA,IST FISIOL UMANA,I-95125 CATANIA,ITALY	Karolinska Institutet; Ludwig Institute for Cancer Research; University of Catania			Neveu, Isabelle/K-2387-2015; Dijke, Peter ten/AAG-4660-2021	Dijke, Peter ten/0000-0002-7234-342X; Neveu, Isabelle/0000-0003-4665-7844				Arenas E, 1995, NEURON, V15, P1465, DOI 10.1016/0896-6273(95)90024-1; Arenas E, 1996, MOL PSYCHIATR, V1, P179; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BAARENDS WM, 1994, DEVELOPMENT, V120, P189; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CHEIFETZ S, 1988, J BIOL CHEM, V263, P16984; CONSTAM DB, 1994, EUR J NEUROSCI, V6, P766, DOI 10.1111/j.1460-9568.1994.tb00988.x; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; FLANDERS KC, 1991, DEVELOPMENT, V113, P183; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; HE WW, 1993, DEV DYNAM, V196, P133, DOI 10.1002/aja.1001960207; ICHIJO H, 1993, BIOCHEM BIOPH RES CO, V194, P1508, DOI 10.1006/bbrc.1993.1995; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRIEGLSTEIN K, 1995, INT J DEV NEUROSCI, V13, P301, DOI 10.1016/0736-5748(94)00062-8; LEE SJ, 1991, P NATL ACAD SCI USA, V88, P4250, DOI 10.1073/pnas.88.10.4250; LEGRAND J, 1979, TRENDS NEUROSCI, V2, P234, DOI 10.1016/0166-2236(79)90091-2; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LIU F, 1995, MOL CELL BIOL, V15, P3479; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1994, J CELL BIOL, V124, P557, DOI 10.1083/jcb.124.4.557; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; Mehler M. F., 1993, Society for Neuroscience Abstracts, V19, P416; Neveu I, 1996, J CELL BIOL, V133, P631, DOI 10.1083/jcb.133.3.631; PELTON RW, 1991, J CELL BIOL, V115, P1091, DOI 10.1083/jcb.115.4.1091; PELTON RW, 1990, DEVELOPMENT, V110, P609; POULSEN KT, 1994, NEURON, V13, P1245, DOI 10.1016/0896-6273(94)90062-0; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; SALAZARGRUESO EF, 1991, NEUROREPORT, V2, P505, DOI 10.1097/00001756-199109000-00002; SAWCHENKO PE, 1988, NATURE, V334, P615, DOI 10.1038/334615a0; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TENDIJKE P, 1993, ONCOGENE, V8, P2879; TOMIZAWA K, 1995, MOL BRAIN RES, V28, P122, DOI 10.1016/0169-328X(94)00199-O; TRUPP M, 1995, J CELL BIOL, V130, P137, DOI 10.1083/jcb.130.1.137; VIVIEN D, 1995, EXP CELL RES, V221, P60, DOI 10.1006/excr.1995.1352; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WHITTEMORE SR, 1993, BRAIN RES, V615, P27, DOI 10.1016/0006-8993(93)91111-5; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMASHITA H, 1994, J BIOL CHEM, V269, P1995; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172	46	66	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30603	30609		10.1074/jbc.271.48.30603	http://dx.doi.org/10.1074/jbc.271.48.30603			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940033	hybrid			2022-12-25	WOS:A1996VV15800050
J	Liu, L; Jefferson, AB; Zhang, XL; Norris, FA; Majerus, PW; Krystal, G				Liu, L; Jefferson, AB; Zhang, XL; Norris, FA; Majerus, PW; Krystal, G			A novel phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase associates with the interleukin-3 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; GROWTH-FACTOR RECEPTORS; INOSITOL POLYPHOSPHATE 5-PHOSPHATASE; TYROSINE-PHOSPHORYLATED PROTEINS; SIGNAL-TRANSDUCTION; ERYTHROPOIETIN RECEPTOR; PHOSPHOINOSITIDE 3-KINASE; HEMATOPOIETIC-CELLS; GENE FAMILY; KINASE	To gain insight into the intracellular signaling cascades that are activated by the binding of interleukin-3 (IL-3) to its target cells, we have embarked on the identification of proteins that are associated with the IL-3 receptor (IL-3R). In a previous study we reported that a 110-kDa serine/threonine protein kinase is constitutively associated with the IL-3R and activated following IL-3 stimulation, We now report that a phosphatidylinositol-3,4,5-trisphosphate (PtdIns-3,4,5-P-3) 5-phosphatase (5-ptase) is also constitutively associated with the IL-3R. This 5-ptase is magnesium-dependent and removes the B-position phosphate from PtdIns-3,4,5-P-3 but does not metabolize PtdIns-4,5-P-2, inositol (Ins)-1,3,4,5-P-4, or Ins-1,4,5-P-3. This substrate specificity distinguishes it from any previously characterized 5-ptase. Interestingly, it may be bound indirectly via phosphatidylinositol 3-kinase (PI 3-kinase), another enzyme that is constitutively bound to the IL-3R. However, unlike PI 3-kinase which becomes activated following IL-3 stimulation, this receptor-associated 5-ptase activity does not increase following IL-3 stimulation, and its primary function may be to keep the principal in vivo product of PI 3-kinase, PtdIns-3,4,5-P-3, at low levels in unstimulated cells, to terminate the PI 3-kinase signal following IL-3 stimulation or to metabolize PtdIns-3,4,5-P-3 to a metabolically active second messenger, i.e. PtdIns-3,4-P-2.	UNIV BRITISH COLUMBIA, BRITISH COLUMBIA CANC AGCY, TERRY FOX LAB, VANCOUVER, BC V5Z 1L3, CANADA; UNIV WASHINGTON, SCH MED, ST LOUIS, MO 63110 USA	British Columbia Cancer Agency; University of British Columbia; Washington University (WUSTL)				Krystal, Gerald/0000-0002-1961-6281	NHLBI NIH HHS [HL16634, HL55672] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016634, R37HL016634, R01HL055672] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUGUSTINE JA, 1991, MOL CELL BIOL, V11, P4431, DOI 10.1128/MCB.11.9.4431; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DAMEN JE, 1993, BLOOD, V81, P3204; DAMEN JE, 1993, BLOOD, V82, P2296; DAMEN JE, 1995, J BIOL CHEM, V270, P23402, DOI 10.1074/jbc.270.40.23402; DURONIO V, 1992, J BIOL CHEM, V267, P21856; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; GOLD MR, 1994, J BIOL CHEM, V269, P5403; GORMAN DM, 1990, P NATL ACAD SCI USA, V87, P5459, DOI 10.1073/pnas.87.14.5459; HARA T, 1992, EMBO J, V11, P1875, DOI 10.1002/j.1460-2075.1992.tb05239.x; HARPUR AG, 1992, ONCOGENE, V7, P1347; HAWKINS PT, 1992, NATURE, V358, P157, DOI 10.1038/358157a0; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; ISFORT R, 1988, J BIOL CHEM, V263, P19203; ISFORT RJ, 1988, P NATL ACAD SCI USA, V85, P7982, DOI 10.1073/pnas.85.21.7982; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; JACKSON SP, 1995, EMBO J, V14, P4490, DOI 10.1002/j.1460-2075.1995.tb00128.x; JEFFERSON AB, 1995, J BIOL CHEM, V270, P9370, DOI 10.1074/jbc.270.16.9370; KANAKURA Y, 1990, BLOOD, V76, P706; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KRYSTAL G, 1991, HEMATOL PATHOL, V5, P141; LINNEKIN D, 1990, BIOCHEM J, V271, P317, DOI 10.1042/bj2710317; LIOUBIN MN, 1994, MOL CELL BIOL, V14, P5682, DOI 10.1128/MCB.14.9.5682; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; LIU L, 1994, J BIOL CHEM, V269, P16774; LIU L, 1995, J BIOL CHEM, V270, P22422, DOI 10.1074/jbc.270.38.22422; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; MITCHELL CA, 1989, J BIOL CHEM, V264, P8873; MIYAJIMA A, 1993, BLOOD, V82, P1960; MUI ALF, 1992, J BIOL CHEM, V267, P16523; NORRIS FA, 1994, J BIOL CHEM, V269, P8716; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OKUDA K, 1992, BLOOD, V79, P2880; PALMER RH, 1995, J BIOL CHEM, V270, P22412, DOI 10.1074/jbc.270.38.22412; PANAYOTOU G, 1993, BIOESSAYS, V15, P171, DOI 10.1002/bies.950150305; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; RAO P, 1995, J BIOL CHEM, V270, P6886, DOI 10.1074/jbc.270.12.6886; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SORENSEN P, 1989, J BIOL CHEM, V264, P19253; SORENSEN PHB, 1989, BLOOD, V73, P406; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; TOKER A, 1994, J BIOL CHEM, V269, P32358; TOKER A, 1995, J BIOL CHEM, V270, P29525, DOI 10.1074/jbc.270.49.29525; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; Woscholski R, 1995, J BIOL CHEM, V270, P31001, DOI 10.1074/jbc.270.52.31001; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; ZHANG XL, 1995, P NATL ACAD SCI USA, V92, P4853, DOI 10.1073/pnas.92.11.4853; ZHU XY, 1994, J BIOL CHEM, V269, P5518; ZUCKER M, 1995, J BIOL CHEM, V270, P27817	56	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29729	29733		10.1074/jbc.271.47.29729	http://dx.doi.org/10.1074/jbc.271.47.29729			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939907	hybrid			2022-12-25	WOS:A1996VU52500035
J	Sessler, AM; Kaur, N; Palta, JP; Ntambi, JM				Sessler, AM; Kaur, N; Palta, JP; Ntambi, JM			Regulation of stearoyl-CoA desaturase 1 mRNA stability by polyunsaturated fatty acids in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED GENE-EXPRESSION; MESSENGER-RNA DEGRADATION; ADIPOSE CELL LINE; RAT-LIVER; 3'-UNTRANSLATED REGION; RECEPTOR SYNTHESIS; MOUSE-LIVER; DIFFERENTIATION; PREADIPOCYTES; TRANSCRIPTION	The effects of arachidonic acid (20:4, n-6) and other fatty acids on the expression of stearoyl-CoA desaturase gene 1 were investigated in fully differentiated 3T3-L1 adipocytes. Treatment of 3T3-L1 adipocytes with arachidonic acid resulted in a decrease in stearoyl-CoA desaturase (Scd) enzyme activity and scd1 mRNA, Arachidonic acid did not alter the transcription of the scd1 gene, whereas the half-life of the scd1 mRNA was reduced from 25.1 to 8.5 h, Blocking the conversion of arachidonic acid to eicosanoids by pretreatment of the cells with cyclooxygenase, lipoxygenase, or cytochrome P-450 epoxygenase inhibitors did not reverse the inhibition caused by arachidonic acid, indicating that eicosanoid synthesis is not necessary for the repression of scd1 mRNA expression. Treatment of adipocytes with linoleic (18:2, n-6) and linolenic (18:3, n-3) acids also resulted in inhibition of scd1 mRNA accumulation. By contrast, oleic acid (18:1, n-9) and stearic acid (18:0) had no effect on scd1 mRNA levels. Taken together, these results suggest that polyunsaturated fatty acids repress the expression of the scd1 gene in mature adipocytes by reducing the stability of scd1 mRNA.	UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706; UNIV WISCONSIN,DEPT HORT,MADISON,WI 53706; UNIV WISCONSIN,DEPT NUTR SCI,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042825] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42825] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERTA JA, 1994, J BIOL CHEM, V269, P4532; BERNLOHR DA, 1984, P NATL ACAD SCI-BIOL, V81, P5468, DOI 10.1073/pnas.81.17.5468; BERNLOHR DA, 1985, J BIOL CHEM, V260, P5563; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CLANDININ MT, 1991, FASEB J, V5, P2761, DOI 10.1096/fasebj.5.13.1916101; CLARKE SD, 1990, J NUTR, V120, P225, DOI 10.1093/jn/120.2.225; CLARKE SD, 1993, PROG LIPID RES, V32, P139, DOI 10.1016/0163-7827(93)90013-M; CLARKE SD, 1994, ANNU REV NUTR, V14, P83, DOI 10.1146/annurev.nu.14.070194.000503; COLEMAN RA, 1978, J BIOL CHEM, V253, P7256; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; ENOCH HG, 1976, J BIOL CHEM, V251, P5095; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1979, J CELL PHYSIOL, V101, P169, DOI 10.1002/jcp.1041010119; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; Jeffcoat R, 1979, Essays Biochem, V15, P1; JUMP DB, 1993, P NATL ACAD SCI USA, V90, P8454, DOI 10.1073/pnas.90.18.8454; JUMP DB, 1994, J LIPID RES, V35, P1076; KAESTNER KH, 1989, J BIOL CHEM, V264, P14755; KASTURI I, 1982, J BIOL CHEM, V257, P12224; LANDSCHULZ KT, 1994, BIOCHEM BIOPH RES CO, V200, P763, DOI 10.1006/bbrc.1994.1516; LIIMATTA M, 1994, MOL ENDOCRINOL, V8, P1147, DOI 10.1210/me.8.9.1147; Long SD, 1996, BIOCHEM BIOPH RES CO, V220, P949, DOI 10.1006/bbrc.1996.0512; MACKALL JC, 1976, J BIOL CHEM, V251, P6462; Marzluff William F., 1992, Gene Expression, V2, P93; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MONTGOMERY MR, 1977, MOL PHARMACOL, V13, P60; NAGAE Y, 1988, NUCLEIC ACIDS RES, V16, P10363, DOI 10.1093/nar/16.21.10363; NTAMBI JM, 1988, J BIOL CHEM, V263, P17291; NTAMBI JM, 1992, J BIOL CHEM, V267, P10925; PALTA JP, 1993, PLANT PHYSIOL, V103, P793, DOI 10.1104/pp.103.3.793; REED BC, 1980, P NATL ACAD SCI-BIOL, V77, P285, DOI 10.1073/pnas.77.1.285; REED BC, 1981, J BIOL CHEM, V256, P3917; Rosen O M, 1979, Recent Prog Horm Res, V35, P477; SALATI LM, 1986, ARCH BIOCHEM BIOPHYS, V246, P82, DOI 10.1016/0003-9861(86)90451-0; Sambrook J., 2002, MOL CLONING LAB MANU; SCHWARTZ RS, 1982, BIOCHIM BIOPHYS ACTA, V711, P316, DOI 10.1016/0005-2760(82)90041-8; SEMENKOVICH CF, 1989, J BIOL CHEM, V264, P9030; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SPECTOR AA, 1985, J LIPID RES, V26, P1015; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; TEBBEY PW, 1994, J BIOL CHEM, V269, P639; THEIDE MA, 1986, J BIOL CHEM, V261, P13230; WEINER FR, 1991, J BIOL CHEM, V266, P23525; WOLFORD JK, 1995, BIOCHEM BIOPH RES CO, V211, P819, DOI 10.1006/bbrc.1995.1885	48	117	127	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29854	29858		10.1074/jbc.271.47.29854	http://dx.doi.org/10.1074/jbc.271.47.29854			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939925	hybrid			2022-12-25	WOS:A1996VU52500053
J	Drees, BL; Rye, HS; Glazer, AN; Nelson, HCM				Drees, BL; Rye, HS; Glazer, AN; Nelson, HCM			Environment-sensitive labels in multiplex fluorescence analyses of protein-DNA complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK TRANSCRIPTION FACTOR; DOUBLE-STRANDED DNA; GEL SCANNER; ENERGY-TRANSFER; LAC PROMOTER; DYES; YEAST; ELECTROPHORESIS; STOICHIOMETRY; ACTIVATOR	Fluorescein is widely used for protein labeling because of its high extinction coefficient and fluorescence emission quantum yield. However, its emission is readily quenched by various pathways, We exploit these properties of fluorescein to examine the self-association of a DNA binding protein and determine the amount of the protein in gel-shifted complexes with specific DNA. A construct (HSFDT385SH) of the heat shock transcription factor (HSF) was expressed that contains the DNA-binding and trimerization domains, residues 192-385 of HSF, with four additional COOH-terminal residues, GMLC, and then labeled at the COOH-terminal cysteine with fluorescein 5-maleimide to form HSFDT385-F1). The fluorescence increase accompanying the formation of heterotrimers on titration of HSFDT385-F1 with HSFDT385SH) led to an estimate of 3 x 10(-16) M(2) for the equilibrium constant for trimerization of HSFDT385SH. HSFDT385-F1 fluorescence also increased 1.7-fold on binding to specific DNA, but not to nonspecific DNA. The protein and DNA content of the several gel-shifted complexes of HSFDT385-F1 (lambda(max)(em) 532 nm) with specific DNA labeled noncovalently with the energy transfer heterodimer TOTAB (lambda(max)(em) 658 nm) were accurately determined by a two-color fluorescence emission assay with 488 nm excitation.	UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley				Rye, Hays/0000-0002-9420-3137	NIGMS NIH HHS [GM-44086] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044086] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMIN J, 1988, MOL CELL BIOL, V8, P3761, DOI 10.1128/MCB.8.9.3761; BENSON SC, 1993, NUCLEIC ACIDS RES, V21, P5720, DOI 10.1093/nar/21.24.5720; BENSON SC, 1993, NUCLEIC ACIDS RES, V21, P5727, DOI 10.1093/nar/21.24.5727; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FRIED MG, 1983, NUCLEIC ACIDS RES, V11, P141, DOI 10.1093/nar/11.1.141; GARNER MM, 1982, BIOCHEMISTRY-US, V21, P6032, DOI 10.1021/bi00267a001; GRANGERSCHNARR M, 1988, ANAL BIOCHEM, V174, P235, DOI 10.1016/0003-2697(88)90540-4; HENDRICKSON W, 1985, P NATL ACAD SCI USA, V82, P3129, DOI 10.1073/pnas.82.10.3129; HUANG XHC, 1992, ANAL CHEM, V64, P2149, DOI 10.1021/ac00042a021; JAKOBSEN BK, 1991, EMBO J, V10, P369, DOI 10.1002/j.1460-2075.1991.tb07958.x; KOLB A, 1983, NUCLEIC ACIDS RES, V11, P7833, DOI 10.1093/nar/11.22.7833; PARK CW, 1992, J BIOL CHEM, V267, P15642; QUESADA MA, 1991, BIOTECHNIQUES, V10, P616; RYE HS, 1991, NUCLEIC ACIDS RES, V19, P327, DOI 10.1093/nar/19.2.327; RYE HS, 1993, J BIOL CHEM, V268, P25229; RYE HS, 1993, ANAL BIOCHEM, V208, P144, DOI 10.1006/abio.1993.1020; RYE HS, 1992, NUCLEIC ACIDS RES, V20, P2803, DOI 10.1093/nar/20.11.2803; RYE HS, 1993, METHOD ENZYMOL, V217, P414; Sambrook J, 1989, MOL CLONING LAB MANU, VII; SORGER PK, 1987, EMBO J, V6, P3035, DOI 10.1002/j.1460-2075.1987.tb02609.x; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; XIAO H, 1988, SCIENCE, V239, P1139, DOI 10.1126/science.3125608; [No title captured]	24	14	14	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32168	32173		10.1074/jbc.271.50.32168	http://dx.doi.org/10.1074/jbc.271.50.32168			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943271	hybrid			2022-12-25	WOS:A1996VY34000062
J	Estrada, E; Agostinis, P; Vandenheede, JR; Goris, J; Merlevede, W; Francois, J; Goffeau, A; Ghislain, M				Estrada, E; Agostinis, P; Vandenheede, JR; Goris, J; Merlevede, W; Francois, J; Goffeau, A; Ghislain, M			Phosphorylation of yeast plasma membrane H+-ATPase by casein kinase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOTHIOCYANATE-BINDING-SITE; SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; SCHIZOSACCHAROMYCES-POMBE; BETA-SUBUNIT; GLUCOSE; TUMOR; GENE; IDENTIFICATION; INACTIVATION	The plasma membrane H+-ATPase of Saccharomyces cerevisiae is subject to phosphorylation by a casein kinase I activity in vitro. We show this casein kinase I activity to result from the combined function of YCK1 and YCK2, two highly similar and plasma membrane-associated casein kinase I homologues. First, H+-ATPase phosphorylation is severely impaired in the plasma membrane of YCK-deficient yeast strains. Furthermore, the wild-type level of the phosphoprotein is restored by the addition of purified mammalian casein kinase I to the mutant membranes. We used the H+-ATPase as web as a synthetic peptide substrate that contains a phosphorylation site for casein kinase I to compare kinase activity in membranes prepared from yeast cells grown in the presence or absence of glucose, The addition of glucose results in increased H+-ATPase activity which is associated with a decline in the phosphorylation level of the enzyme. Mutations in both YCK1 and YCK2 affect this regulation, suggesting that H+; ATPase activity is modulated by glucose via a combination of a ''down-regulating'' casein kinase I activity and another, yet uncharacterize, ''up-regulating'' kinase activity. Biochemical mapping of phosphorylated H+- ATPase identifies a major phosphopeptide that contains a consensus phosphorylation site (Ser-507) for casein kinase I. Site-directed mutagenesis of this consensus sequence indicates that Glu-504 is important for glucose-induced decrease in the apparent K-m for ATP.	UNIV CATHOLIQUE LOUVAIN, UNITE BIOCHIM PHYSIOL, B-1348 LOUVAIN, BELGIUM; CATHOLIC UNIV LEUVEN, BIOCHEM LAB, FAC MED, B-3001 HEVERLEE, BELGIUM; INST NATL SCI APPL, DEPT GENIE BIOCHIM & ALIMENTAIRE, F-31077 TOULOUSE, FRANCE	Universite Catholique Louvain; KU Leuven; Universite Federale Toulouse Midi-Pyrenees (ComUE); Universite de Toulouse; Institut National des Sciences Appliquees de Toulouse			Agostinis, Patrizia/ABI-1177-2020; Estrada, Enrique/C-7774-2009; Agostinis, Patrizia/AAO-2468-2020	Agostinis, Patrizia/0000-0003-1314-2115; Francois, Jean marie/0000-0001-9884-5535				AGOSTINIS P, 1992, FEBS LETT, V305, P121, DOI 10.1016/0014-5793(92)80877-J; AGOSTINIS P, 1987, FEBS LETT, V224, P385, DOI 10.1016/0014-5793(87)80489-1; AGOSTINIS P, 1989, FEBS LETT, V259, P75, DOI 10.1016/0014-5793(89)81498-X; BEYAERT R, 1995, J BIOL CHEM, V270, P23293, DOI 10.1074/jbc.270.40.23293; BIDWAI AP, 1995, J BIOL CHEM, V270, P10395, DOI 10.1074/jbc.270.18.10395; BLANPAIN JP, 1992, J BIOL CHEM, V267, P3735; BROCKMAN JL, 1991, J BIOL CHEM, V266, P2508; BUSTAMANTE E, 1981, J BIOL CHEM, V256, P8699; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; CARMEL G, 1994, J BIOL CHEM, V269, P7304; CELENZA JL, 1989, MOL CELL BIOL, V9, P5034, DOI 10.1128/MCB.9.11.5034; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; CHANG A, 1991, J CELL BIOL, V115, P289, DOI 10.1083/jcb.115.2.289; CHAUHAN VPS, 1993, BIOCHIM BIOPHYS ACTA, V1177, P318, DOI 10.1016/0167-4889(93)90128-C; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; DEXAERDE AD, 1995, J BIOL CHEM, V270, P23828, DOI 10.1074/jbc.270.40.23828; DOSPASSOS JB, 1992, BIOCHIM BIOPHYS ACTA, V1136, P57; ERASO P, 1994, J BIOL CHEM, V269, P10393; FOURY F, 1975, J BIOL CHEM, V250, P2354; GOFFEAU A, 1988, METHOD ENZYMOL, V157, P528; GRASSER FA, 1988, VIROLOGY, V165, P13, DOI 10.1016/0042-6822(88)90653-8; GRAVES PR, 1995, J BIOL CHEM, V270, P21689, DOI 10.1074/jbc.270.37.21689; KOLAROV J, 1988, J BIOL CHEM, V263, P10613; LOPES R, 1994, BIOCHIM BIOPHYS ACTA, V1223, P117; MALDONADO AM, 1995, J BIOL CHEM, V270, P8655, DOI 10.1074/jbc.270.15.8655; MARIN O, 1994, EUR J BIOCHEM, V223, P647, DOI 10.1111/j.1432-1033.1994.tb19037.x; MARIN O, 1994, BIOCHEM BIOPH RES CO, V198, P898, DOI 10.1006/bbrc.1994.1128; MAZON MJ, 1982, EUR J BIOCHEM, V127, P605; MCCUSKER JH, 1987, MOL CELL BIOL, V7, P4082, DOI 10.1128/MCB.7.11.4082; MCDONOUGH JP, 1982, J BIOL CHEM, V257, P4579; MILNE DM, 1992, ONCOGENE, V7, P1361; PARDO JP, 1988, J BIOL CHEM, V263, P18664; PERLIN DS, 1988, J BIOL CHEM, V263, P18118; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PORTILLO F, 1989, EUR J BIOCHEM, V186, P501, DOI 10.1111/j.1432-1033.1989.tb15235.x; RAPUANO M, 1991, J BIOL CHEM, V266, P12902; ROBINSON LC, 1992, P NATL ACAD SCI USA, V89, P28, DOI 10.1073/pnas.89.1.28; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SERRANO R, 1983, FEBS LETT, V156, P11, DOI 10.1016/0014-5793(83)80237-3; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SPECTOR M, 1980, J BIOL CHEM, V255, P8370; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; ULASZEWSKI S, 1989, FEBS LETT, V245, P131, DOI 10.1016/0014-5793(89)80206-6; VANCURA A, 1994, J BIOL CHEM, V269, P19271; VANCURA A, 1993, ARCH BIOCHEM BIOPHYS, V305, P1; VANLINT J, 1993, ADV ENZYME REGUL, V33, P143; WACH A, 1991, EUR J BIOCHEM, V201, P91, DOI 10.1111/j.1432-1033.1991.tb16260.x; WACH A, 1992, J BIOENERG BIOMEMBR, V24, P309; Wach A, 1996, BIOCHEMISTRY-US, V35, P883, DOI 10.1021/bi951998r; WANG P, MOL BIOL CELL, V3, P275; YANAGITA Y, 1987, P NATL ACAD SCI USA, V84, P925, DOI 10.1073/pnas.84.4.925	52	67	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32064	32072		10.1074/jbc.271.50.32064	http://dx.doi.org/10.1074/jbc.271.50.32064			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943257	Green Published, hybrid			2022-12-25	WOS:A1996VY34000048
J	Kadrmas, JL; Brozek, KA; Raetz, CRH				Kadrmas, JL; Brozek, KA; Raetz, CRH			Lipopolysaccharide core glycosylation in Rhizobium leguminosarum - An unusual mannosyl transferase resembling the heptosyl transferase I of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-A BIOSYNTHESIS; SALMONELLA-TYPHIMURIUM; OUTER MEMBRANE; 3-DEOXY-D-MANNO-OCTULOSONIC ACID; O-ANTIGEN; MUTANTS; PURIFICATION; ENDOTOXINS; PROTEIN; GENE	The lipopolysaccharide structure of the nitrogen-fixing bacterium Rhizobium leguminosarum differs from that of Escherichia coli in several ways, one of which is the sugar composition of the core. The E. coli inner core consists of 3-deoxy-D-manno-octulosonic acid (Kdo) and L-glycero-D-manno-heptose (heptose), while the inner core of R. leguminosarum contains 2-keto-3-deoxy-D-manno-octulosonic acid (Hdo), mannose, galactose, and galacturonic acid. The two Kdo residues and their Linkages appear to be identical in both species. The Linkages of heptose in E. coli and of mannose in R. leguminosarum to Kdo are both alpha 1-5. We now characterize a membrane-associated glycosyl transferase in R. leguminosarum extracts that incorporates mannose into nascent lipopolysaccharide, using Kdo(2)-lipid IVA as the acceptor and GDP-mannose (or synthetic ADP-mannose) as the donor. The mannosyl transferase is associated with the inner membrane. The apparent K-m values for GDP-mannose and Kdo(2)-lipid IVA are 4.3 mu M and 7.1 mu M, respectively, in the presence of excess co-substrate. Extracts of E. coli do not catalyze GDP-mannose-dependent glycosylation of Kdo(2)-lipid IVA, but they are active when ADP-mannose is substituted for GDP-mannose. Given the structural similarity of ADP-mannose to ADP-heptose, we examined the possibility that heptosyl transferase I of E. coli (the product of the rfaC gene) catalyzes mannose transfer from ADP-mannose to Kdo(2)-lipid IVA. Extracts of E. coli mutants defective in the rfaC gene are unable carry out ADP-mannose-dependent glycosylation of Kdo(2)-lipid IVA. Plasmids bearing rfaC(+) not only restore the missing activity but also direct its overexpression. Our assay using ADP-mannose as a substitute for ADP-heptose (which is not readily available) should facilitate the purification and characterization of heptosyl transferase I of E. coli. The GDP-mannose-dependent enzyme of R. leguminosarum may represent a functional equivalent of E. coli RfaC.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007105, R37GM051796, R01GM051310, R01GM051796] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-51310, GM-51796, 5T32GM07105] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES GF, 1974, J BACTERIOL, V117, P406, DOI 10.1128/JB.117.2.406-416.1974; BELUNIS CJ, 1992, J BIOL CHEM, V267, P9988; BHAT UR, 1991, CARBOHYD RES, V220, P219, DOI 10.1016/0008-6215(91)80020-N; BOWMAN HG, 1968, GENET RES, V12, P169; BROZEK K, 1995, FASEB J, V9, pA1376; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; BROZEK KA, 1995, J BIOL CHEM, V9, pA137; CARLSON RW, 1995, J BIOL CHEM, V270, P11783, DOI 10.1074/jbc.270.20.11783; CAVA JR, 1989, J BACTERIOL, V171, P8, DOI 10.1128/jb.171.1.8-15.1989; Clementz T, 1996, J BIOL CHEM, V271, P12095, DOI 10.1074/jbc.271.20.12095; CLEMENTZ T, 1995, FASEB J, V9, pA1311; COLEMAN WG, 1983, J BIOL CHEM, V258, P1985; DING L, 1994, J BIOL CHEM, V269, P24384; GALLOWAY SM, 1990, J BIOL CHEM, V265, P6394; GOLDMAN R, 1987, NATURE, V329, P162, DOI 10.1038/329162a0; GRUNDSTROM T, 1980, J BACTERIOL, V143, P1127; GUYCAFFEY JK, 1992, J BACTERIOL, V174, P2460, DOI 10.1128/jb.174.8.2460-2465.1992; HAMMOND SM, 1987, NATURE, V327, P730, DOI 10.1038/327730a0; HAMPTON RY, 1992, METHOD ENZYMOL, V209, P466; HAVEKES L, 1977, J BACTERIOL, V129, P1; KONTROHR T, 1981, J BIOL CHEM, V256, P7715; KOPLOW J, 1974, J BACTERIOL, V117, P527, DOI 10.1128/JB.117.2.527-543.1974; LAIRD MW, 1994, J BACTERIOL, V176, P2259, DOI 10.1128/JB.176.8.2259-2264.1994; Makela P. H., 1984, HDB ENDOTOXIN, P59; Miller J.H., 1972, EXPT MOL GENETICS; NIKAIDO H, 1987, ESCHERICHIA COLI SAL, V1, P7; NISHIJIMA M, 1977, EUR J BIOCHEM, V73, P115, DOI 10.1111/j.1432-1033.1977.tb11297.x; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; PRICE NPJ, 1995, P NATL ACAD SCI USA, V92, P7352, DOI 10.1073/pnas.92.16.7352; PRICE NPJ, 1994, J BACTERIOL, V176, P4646, DOI 10.1128/JB.176.15.4646-4655.1994; Raetz C. R. H., 1996, ESCHERICHIA COLI SAL, V1, P1035; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RICK PD, 1977, J BIOL CHEM, V252, P4895; RICK PD, 1987, ESCHERICHIA COLI SAL, V1, P648; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; RUSSA R, 1985, ARCH MICROBIOL, V141, P284, DOI 10.1007/BF00428838; SANDERSON KE, 1974, CAN J MICROBIOL, V20, P1127, DOI 10.1139/m74-175; SCHNAITMAN CA, 1993, MICROBIOL REV, V57, P655, DOI 10.1128/MMBR.57.3.655-682.1993; SIRISENA DM, 1992, J BIOL CHEM, V267, P18874; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEVENSON G, 1994, J BACTERIOL, V176, P4144, DOI 10.1128/JB.176.13.4144-4156.1994; VAARA M, 1993, ANTIMICROB AGENTS CH, V37, P2255, DOI 10.1128/AAC.37.11.2255; WHITE KA, 1995, FASEB J, V9, pA1376	44	33	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32119	32125		10.1074/jbc.271.50.32119	http://dx.doi.org/10.1074/jbc.271.50.32119			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943265	hybrid			2022-12-25	WOS:A1996VY34000056
J	Mezna, M; Michelangeli, F				Mezna, M; Michelangeli, F			The effects of inositol 1,4,5-trisphosphate (InsP(3)) analogues on the transient kinetics of Ca2+ release from cerebellar microsomes - InsP(3) analogues act as partial agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE; MOBILIZATION; TRISPHOSPHATE; HEPATOCYTES; PHOSPHATES; RECEPTOR; CAFFEINE; CHANNEL; BINDING; STORES	An investigation of the effects of a number of inositol trisphosphate analogues on the transient kinetics of Ca2+ release from cerebellar microsomes was undertaken. All the analogues investigated could release the total Ca2+ content of the inositol 1,4,5-trisphosphate (Ins(1,4,5)P-3) mobilizable Ca2+ store; however, their potencies were substantially reduced compared to Ins(1,4,5)P-3. The concentration required to induce half-maximal Ca2+ mobilization was 0.14 mu M for Ins(1,4,5)P-3, 1.8 mu M for 3-deoxyinositol 1,4,5-trisphosphate (3-deoxy-InsP(3)), 1.0 mu M for 2,3-dideoxyinositol 1,4,5-trisphosphate (2,3-dideoxyInsP(3)), 24 mu M for 2,3,6-trideoxyinositol 1,4,5-trisphopshate (2,3,6-trideoxyInsP(3)), and 2.9 mu M for inositol 2,4,5-trisphosphate (Ins(2,4,5)P-3). In all cases and for all concentrations tested, the inositol trisphosphate analogues induced biphasic transient release of Ca2+, which could fit to a biexponential equation assuming two independent processes, The rate constants calculated for the release process were much larger for Ins(1,4,5)P-3 than the other inositol trisphosphates (the fast phase rate constant varying from 0.3 to 1.6 s(-1) and the slow phase from 0.01-0.5 s(-1), at concentrations between 0.03 and 20 mu M Ins(1,4,5)P-3). The rate constants for all other inositol trisphosphates did not appear to exceed 0.4 s(-1) for the fast phase and 0.1 s(-1) for the slow phase at their highest concentrations tested. The maximum amplitudes for Ca2+ release by the two phases appeared to be similar for all inositol trisphosphates (approximately 45% for the fast phase and approximately 55% for the slow phase). On comparing the rate constants for Ca2+ release at inositol trisphosphate concentrations for the analogues which all induced the same extent of Ca2+ release, it was apparent that the rates of release were independent of the extent of Ca2+ release. As the extent of Ca2+ release can be related to degree of occupancy of the binding sites, it is evident that different analogues which occupy the binding site of the receptor to the same extent can induce Ca2+ to be released at different rates. We explain this conclusion in terms of partial agonism where inositol phosphates can induce two (or more) occupied states of the channel.	UNIV BIRMINGHAM,SCH BIOCHEM,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Birmingham								BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BROWN GR, 1992, BIOCHEM J, V282, P309, DOI 10.1042/bj2820309; BROWN GR, 1994, BBA-BIOMEMBRANES, V1195, P252, DOI 10.1016/0005-2736(94)90264-X; CHAMPEIL P, 1989, J BIOL CHEM, V264, P17665; CHEEK TR, 1993, J BIOL CHEM, V268, P27076; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; GAWLER DJ, 1991, BIOCHEM J, V276, P163, DOI 10.1042/bj2760163; HAJNOCZKY G, 1994, NATURE, V370, P474, DOI 10.1038/370474a0; HIROTA J, 1995, FEBS LETT, V368, P248, DOI 10.1016/0014-5793(95)00659-W; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; KOZIKOWSKI AP, 1993, J AM CHEM SOC, V115, P4429, DOI 10.1021/ja00064a002; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MEZNA M, 1995, NATURE, V376, P300, DOI 10.1038/376300a0; MEZNA M, 1995, J BIOL CHEM, V270, P28097; Mezna M, 1996, BIOCHEM J, V314, P175, DOI 10.1042/bj3140175; MICHELANGELI F, 1995, NEUROPHARMACOLOGY, V34, P1111, DOI 10.1016/0028-3908(95)00053-9; MUALLEM S, 1989, J BIOL CHEM, V264, P205; NAHORSKI SR, 1989, TRENDS PHARMACOL SCI, V10, P139, DOI 10.1016/0165-6147(89)90165-X; OLDERSHAW KA, 1991, BIOCHEM J, V278, P705, DOI 10.1042/bj2780705; RANG HP, 1991, PHARMACOLOGY, P3; SAFRANY ST, 1993, MOL PHARMACOL, V43, P499; STAUDERMAN KA, 1988, BIOCHEM J, V255, P677; SWILLENS S, 1994, P NATL ACAD SCI USA, V91, P10074, DOI 10.1073/pnas.91.21.10074; WATRAS J, 1991, J NEUROSCI, V11, P3239	24	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					31818	31823		10.1074/jbc.271.50.31818	http://dx.doi.org/10.1074/jbc.271.50.31818			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943223	hybrid			2022-12-25	WOS:A1996VY34000014
J	Peng, B; Morrice, NA; Groenen, LC; Wettenhall, REH				Peng, B; Morrice, NA; Groenen, LC; Wettenhall, REH			Phosphorylation events associated with different states of activation of a hepatic cardiolipin protease-activated protein kinase - Structural identity to the protein kinase N-type protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZIPPER-LIKE SEQUENCES; RIBOSOMAL PROTEIN-S6; RAT-LIVER; CRYSTAL-STRUCTURE; CATALYTIC DOMAIN; FATTY-ACID; FAMILY; S6; IDENTIFICATION; PRODUCTS	Cardiolipin- or protease activated protein kinase, isolated from rat liver cytosol and originally named liver PAK-1, was found to be the natural form of protein kinase N (PKN) by comparing the sequences of 43 tryptic peptides of the purified liver enzyme and determining the corresponding liver cDNA sequence. These analyses also identified (i) Arg-546 as the major site of proteolytic activation, (ii) the protease resistance of the C-terminal extension beyond the catalytic domain, and (iii) in vivo stoichiometric phosphorylation of Thr-778 in the mature enzyme. Homology modeling of the catalytic domain indicated that phosphothreonine 778 functions as an anchoring site similar to Thr-197 in cAMP-dependent protein kinase, which stabilizes an active site compatible with preferred substrate sequences of PAK-1/PKN. Sigmoidal autophosphorylation kinetics and increased S6-(229-239) peptide kinase activity following preincubation with ATP suggested phosphorylation-dependent activation of PAK-1/PKN. The onset of activation corresponded with phosphorylation of the regulatory domain site Ser-377 (located within a spectrin homology region), followed by Thr-504 (within a limited protein kinase C homology region), and, to a lesser extent, Thr-64 (in the RhoA-binding region). Several additional sites in the hinge region adjacent to a PEST protein degradation signal were selectively autophosphorylated following cardiolipin activation. Overall, these observations suggest that the regulation of this class of protein kinase involves complex interactions among phosphorylation-, lipid-, and other ligand-dependent activation events.	UNIV MELBOURNE, RUSSELL GRIMWADE SCH BIOCHEM & MOL BIOL, PARKVILLE, VIC 3052, AUSTRALIA; ROYAL MELBOURNE HOSP, LUDWIG INST CANC RES, MELBOURNE, VIC 3050, AUSTRALIA; ROYAL MELBOURNE HOSP, COOPERAT RES CTR CELLULAR GROWTH FACTORS, MELBOURNE, VIC 3050, AUSTRALIA	University of Melbourne; Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Royal Melbourne Hospital								Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; AZZI A, 1992, EUR J BIOCHEM, V208, P547, DOI 10.1111/j.1432-1033.1992.tb17219.x; BEAVIS RC, 1992, ORG MASS SPECTROM, V27, P156, DOI 10.1002/oms.1210270217; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRUNGER AT, 1992, XPLOR VERSION 3 1; CAZAUBON S, 1994, BIOCHEM J, V301, P443, DOI 10.1042/bj3010443; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; GABRIELLI B, 1984, FEBS LETT, V175, P219, DOI 10.1016/0014-5793(84)80740-1; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HOUSE C, 1987, J BIOL CHEM, V262, P772; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; KITAGAWA M, 1995, BIOCHEM J, V310, P657, DOI 10.1042/bj3100657; Kitagawa M, 1996, BIOCHEM BIOPH RES CO, V220, P963, DOI 10.1006/bbrc.1996.0515; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEENHOUTS JM, 1993, FEBS LETT, V327, P172, DOI 10.1016/0014-5793(93)80164-P; MACKERELL AD, 1995, J AM CHEM SOC, V117, P11946, DOI 10.1021/ja00153a017; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MORRICE NA, 1994, FEBS LETT, V351, P171, DOI 10.1016/0014-5793(94)00854-X; MORRICE NA, 1994, J BIOL CHEM, V269, P20040; MUKAI H, 1995, BBA-GENE STRUCT EXPR, V1261, P296, DOI 10.1016/0167-4781(95)00030-K; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V199, P897, DOI 10.1006/bbrc.1994.1313; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V204, P348, DOI 10.1006/bbrc.1994.2466; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PALMER RH, 1995, EUR J BIOCHEM, V227, P344, DOI 10.1111/j.1432-1033.1995.tb20395.x; PALMER RH, 1994, FEBS LETT, V356, P5, DOI 10.1016/0014-5793(94)01202-4; PALMER RH, 1995, J BIOL CHEM, V270, P22412, DOI 10.1074/jbc.270.38.22412; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; POLYA GM, 1989, FEBS LETT, V253, P137, DOI 10.1016/0014-5793(89)80946-9; Ponting CP, 1996, PROTEIN SCI, V5, P162; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; WETTENHALL R E H, 1991, Peptide Research, V4, P158; WETTENHALL REH, 1992, J BIOL CHEM, V267, P9021; WETTENHALL REH, 1991, METHOD ENZYMOL, V201, P186; WETTENHALL REH, 1984, J BIOL CHEM, V259, P2084; ZHENG JH, 1993, ACTA CRYSTALLOGR D, V49, P362, DOI 10.1107/S0907444993000423; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	48	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32233	32240		10.1074/jbc.271.50.32233	http://dx.doi.org/10.1074/jbc.271.50.32233			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943281	hybrid			2022-12-25	WOS:A1996VY34000072
J	Fu, DX; Sine, SM				Fu, DX; Sine, SM			Asymmetric contribution of the conserved disulfide loop to subunit oligomerization and assembly of the nicotinic acetylcholine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR DISSECTION; LIGAND-BINDING; DELTA-SUBUNIT; GAMMA-SUBUNIT; IDENTIFICATION; SELECTIVITY; INTERFACES; RESIDUES; SITE	The acetylcholine receptor (AChR) at the motor synapse is a pentamer of homologous subunits with the composition alpha(2) beta gamma delta. Owing to the circular arrangement of subunits that forms a central ion channel, each subunit interface contains contributions from opposite faces of each subunit, designated + and -. Common to all subunits of the AChR and members of its superfamily is a disulfide loop formed between cysteines 128 and 142 of the major extracellular domain, To gain insight into the structural contribution of the disulfide loop and its possible location, we mutated the invariant proline at position 136 to glycine (P136G) and examined subunit assembly. When introduced into any AChR subunit, P136G disrupted assembly by affecting the - face of the subunit, suggesting equivalent positioning of the loop in each subunit and localization to the - face, Also, the contribution of the loop in the overall assembly process differed for each subunit. In the beta and gamma subunits, P136G prevented assembly of higher order heteroligomers, whereas in the alpha and delta subunits, P136G prevented transport of assembled pentamers to the cell surface, The results demonstrate asymmetry in the contribution of the disulfide loop to formation of subunit interfaces, and that the loop in each subunit contributes at different stages of assembly.	MAYO CLIN & MAYO FDN,DEPT PHYSIOL & BIOPHYS,ROCHESTER,MN 55905	Mayo Clinic				Fu, Dax/0000-0002-2663-1316	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031744, R37NS031744] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 31744] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLOUNT P, 1990, J CELL BIOL, V111, P2613, DOI 10.1083/jcb.111.6.2613; BLOUNT P, 1990, J CELL BIOL, V111, P2601, DOI 10.1083/jcb.111.6.2601; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; COCKCROFT VB, 1990, PROTEINS, V8, P386, DOI 10.1002/prot.340080412; CRIADO M, 1986, BIOCHEMISTRY-US, V25, P2839, DOI 10.1021/bi00358a015; CZAJKOWSKI C, 1993, P NATL ACAD SCI USA, V90, P6285, DOI 10.1073/pnas.90.13.6285; FU DX, 1994, J BIOL CHEM, V269, P26152; GREEN WN, 1993, CELL, V74, P57, DOI 10.1016/0092-8674(93)90294-Z; GULLICK WJ, 1983, BIOCHEMISTRY-US, V22, P3312, DOI 10.1021/bi00283a003; KREIENKAMP HJ, 1995, NEURON, V14, P635, DOI 10.1016/0896-6273(95)90320-8; LEE BS, 1991, J BIOL CHEM, V266, P11448; MISHINA M, 1985, NATURE, V313, P364, DOI 10.1038/313364a0; NUMA S, 1989, COLD SPRING HARB SYM, V48, P57; ROSE GD, 1985, ADV PROTEIN CHEM, V37, P1, DOI 10.1016/S0065-3233(08)60063-7; SINE S, 1979, J BIOL CHEM, V254, P3315; SINE SM, 1991, J BIOL CHEM, V266, P19369; SINE SM, 1993, P NATL ACAD SCI USA, V90, P9436, DOI 10.1073/pnas.90.20.9436; SINE SM, 1995, NEURON, V15, P205, DOI 10.1016/0896-6273(95)90077-2; SUMIKAWA K, 1992, J BIOL CHEM, V267, P6286	19	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31479	31484		10.1074/jbc.271.49.31479	http://dx.doi.org/10.1074/jbc.271.49.31479			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940161	hybrid			2022-12-25	WOS:A1996VW68600072
J	Nawratil, P; Lenzen, S; Kellermann, J; Haupt, H; Schinke, T; MullerEster, W; JahnenDechent, W				Nawratil, P; Lenzen, S; Kellermann, J; Haupt, H; Schinke, T; MullerEster, W; JahnenDechent, W			Limited proteolysis of human alpha(2)-HS glycoprotein fetuin - Evidence that a chymotryptic activity can release the connecting peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-2-HS GLYCOPROTEIN; AMINO-ACID-SEQUENCE; INSULIN-RECEPTOR; TYROSINE KINASE; HUMAN ALPHA-2-HS-GLYCOPROTEIN; HS-GLYCOPROTEIN; A-CHAIN; B-CHAIN; BONE; INHIBITOR	alpha(2)-HS glycoprotein is a major protein of human plasma whose function is still obscure, A proteolytically processed form of alpha(2)-HS glycoprotein lacking a segment of 40 amino acid residues bridging its heavy and light chain portions (''connecting peptide'') has been described suggesting that this peptide is released by posttranslational processing to fulfill biological role(s) of alpha(2)-HS glycoprotein. To test this hypothesis we investigated how the connecting peptide is released from the parental molecule by limited proteolysis. We developed monoclonal antibodies to various portions of the connecting peptide and its NH2-terminal flanking region which cross-react with the native alpha(2)-HS glycoprotein, Purified alpha(2)-HS glycoprotein from human plasma was subjected to limited proteolysis by proteinases including trypsin, chymotrypsin, elastase plasmin, kallikrein, thrombin, and renin. Immunoprint analysis of the proteolytic digests indicated that alpha(2)-HS glycoprotein is readily cleaved in its connecting peptide region, NH2-terminal amino sequence analysis of the generated fragments demonstrated that a single proteinase, chymotrypsin, cleaves the critical Leu-Leu bond flanking the NH2-terminal portion of the connecting peptide region. Most but not all of the other proteinase cleavage sites map to a short stretch of 9 residues located in the center portion of the connecting peptide region, Immunoprint analysis of plasma samples from patients with sepsis demonstrate that the connecting peptide region is cleaved under pathological conditions, Our results indicate that the connecting peptide and/or fragments thereof are readily releasable from alpha(2)-HS glycoprotein in vitro and in vivo.	UNIV MAINZ,INST PHYSIOL CHEM & PATHOBIOCHEM,D-55099 MAINZ,GERMANY; UNIV MUNICH,DEPT CLIN CHEM & CLIN BIOCHEM,D-80336 MUNICH,GERMANY; MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY; BEHRINGWERKE AG,D-35007 MARBURG,GERMANY; UNIV MAINZ,INST PHYSIOL CHEM & PATHOBIOCHEM,D-55099 MAINZ,GERMANY	Johannes Gutenberg University of Mainz; University of Munich; Max Planck Society; Johannes Gutenberg University of Mainz			Jahnen-Dechent, Willi/A-7608-2011	Jahnen-Dechent, Willi/0000-0003-1315-4407				ANDERSEN JK, 1984, J BIOCHEM BIOPH METH, V10, P203; AUBERGER P, 1989, CELL, V58, P631, DOI 10.1016/0092-8674(89)90098-6; BROWN WM, 1992, EUR J BIOCHEM, V205, P321, DOI 10.1111/j.1432-1033.1992.tb16783.x; CAMPBELL AD, 1987, NATURE, V329, P744, DOI 10.1038/329744a0; CARLSSON J, 1978, BIOCHEM J, V173, P723, DOI 10.1042/bj1730723; CHANG JY, 1978, FEBS LETT, V93, P205, DOI 10.1016/0014-5793(78)81105-3; COLCLASURE GC, 1988, J CLIN ENDOCR METAB, V66, P187, DOI 10.1210/jcem-66-1-187; Demetriou M, 1996, J BIOL CHEM, V271, P12755, DOI 10.1074/jbc.271.22.12755; Dziegielewska K., 1995, MOL BIOL INTELLIGENC; DZIEGIELEWSKA KM, 1987, CELL TISSUE RES, V248, P33, DOI 10.1007/BF01239959; EDGE ASB, 1987, J BIOL CHEM, V262, P16135; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; ELZANOWSKI A, 1988, FEBS LETT, V227, P167, DOI 10.1016/0014-5793(88)80890-1; ENGVALL E, 1972, J IMMUNOL, V109, P129; GEJYO F, 1983, J BIOL CHEM, V258, P4966; HAYASE T, 1992, BIOCHEMISTRY-US, V31, P4915, DOI 10.1021/bi00135a024; Hayashi R, 1977, Methods Enzymol, V47, P84; HOCK J, 1990, J BIOL CHEM, V265, P12005; JAHNENDECHENT W, 1994, EUR J BIOCHEM, V226, P59, DOI 10.1111/j.1432-1033.1994.tb20026.x; KELLERMANN J, 1989, J BIOL CHEM, V264, P14121; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CC, 1987, P NATL ACAD SCI USA, V84, P4403, DOI 10.1073/pnas.84.13.4403; MIZUNO M, 1991, BONE MINER, V13, P1, DOI 10.1016/0169-6009(91)90046-3; MODROW S, 1986, P NATL ACAD SCI USA, V83, P5703, DOI 10.1073/pnas.83.15.5703; OHNISHI T, 1993, J BONE MINER RES, V8, P367; Pedersen KO, 1944, NATURE, V154, P575, DOI 10.1038/154575a0; PUCK TT, 1968, P NATL ACAD SCI USA, V59, P192, DOI 10.1073/pnas.59.1.192; RAO PVS, 1983, J IMMUNOL METHODS, V57, P71, DOI 10.1016/0022-1759(83)90066-2; RAUTH G, 1992, EUR J BIOCHEM, V204, P523, DOI 10.1111/j.1432-1033.1992.tb16663.x; Schinke T, 1996, J BIOL CHEM, V271, P20789, DOI 10.1074/jbc.271.34.20789; SCHMID K, 1961, BIOCHIM BIOPHYS ACTA, V47, P440, DOI 10.1016/0006-3002(61)90539-X; SRINIVAS PR, 1993, MOL ENDOCRINOL, V7, P1445, DOI 10.1210/me.7.11.1445; SUMMERS MD, 1996, MANUAL METHODS BACUL; TRIFFITT JT, 1976, NATURE, V262, P226, DOI 10.1038/262226a0; VOGEL R, 1988, J BIOL CHEM, V263, P12661; WHITE H, 1993, EUR J BIOCHEM, V213, P523, DOI 10.1111/j.1432-1033.1993.tb17790.x; YAMAGUCHI K, 1988, ANAL BIOCHEM, V172, P104, DOI 10.1016/0003-2697(88)90417-4; YOSHIOKA Y, 1986, J BIOL CHEM, V261, P1665	39	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31735	31741		10.1074/jbc.271.49.31735	http://dx.doi.org/10.1074/jbc.271.49.31735			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940198	hybrid			2022-12-25	WOS:A1996VW68600109
J	Shyu, JF; Inoue, D; Baron, R; Horne, WC				Shyu, JF; Inoue, D; Baron, R; Horne, WC			The deletion of 14 amino acids in the seventh transmembrane domain of a naturally occurring calcitonin receptor isoform alters ligand binding and selectively abolishes coupling to phospholipase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3',5'-CYCLIC ADENOSINE-MONOPHOSPHATE; VASOACTIVE-INTESTINAL-PEPTIDE; HORMONE-RELATED PEPTIDE; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; RAT OSTEOCLASTS; CHROMOSOMAL LOCALIZATION; NEUROKININ-1 RECEPTOR; PARATHYROID-HORMONE; SALMON-CALCITONIN	The cDNA that encodes the rabbit calcitonin receptor was cloned by screening a rabbit osteoclast library. Reverse transcription-polymerase chain reaction amplification of calcitonin receptor sequences from rabbit osteoclast RNA yielded cDNAs that encode two isoforms of the calcitonin receptor. One isoform is homologous to the Cia isoform previously identified in multiple cell types and species, while the second, designated CTR Delta e13, is a previously unidentified isoform that is apparently generated by alternative splicing during mRNA processing that deletes exon 13, resulting in the absence of 14 amino acids in the predicted seventh transmembrane domain. Expression of mRNA transcripts encoding the two isoforms varies in a tissue-specific manner, with CTR Delta e13 accounting for less than 15% of the total calcitonin receptor mRNA in osteoclasts, kidney, and brain, but comprising at least 50% of the transcripts in skeletal muscle and lung. The two isoforms were expressed, and the ligand binding and signal transduction properties were characterized. Deletion of the residues in the seventh transmembrane domain in CTR Delta e13 reduced the binding affinity for salmon and human calcitonin by more than 10-fold and approximately a-fold, respectively, resulting in a receptor that failed to discriminate between the two forms of calcitonin. Both isoforms activated adenylyl cyclase, with EC(50) values consistent with the difference in ligand affinities. In contrast, only the Cia isoform, but not the CTR Delta 13 isoform, activated phospholipase C. Thus, while the CTR Delta e13 remains active despite the deletion of a significant portion of its seventh transmembrane domain, it has significantly altered ligand recognition and signal transduction properties.	YALE UNIV,SCH MED,DEPT ORTHOPAED,NEW HAVEN,CT 06520; YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06520	Yale University; Yale University					NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE004724, R37DE004724] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE-04724] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AINO H, 1995, GENE, V164, P301, DOI 10.1016/0378-1119(95)00391-I; Aiyar N, 1996, J BIOL CHEM, V271, P11325, DOI 10.1074/jbc.271.19.11325; ALBRANDT K, 1995, ENDOCRINOLOGY, V136, P5377, DOI 10.1210/en.136.12.5377; ALBRANDT K, 1993, FEBS LETT, V325, P225, DOI 10.1016/0014-5793(93)81078-E; ARVINTE T, 1993, J BIOL CHEM, V268, P4608; Ausubel FM., 2006, ENZYMATIC MANIPULATI; Azria M., 1989, CALCITONINS PHYSL PH; BEAUMONT K, 1993, MOL PHARMACOL, V44, P493; BURCELIN R, 1995, GENE, V164, P305, DOI 10.1016/0378-1119(95)00472-I; CANFIELD VA, 1993, BIOCHEMISTRY-US, V32, P13782, DOI 10.1021/bi00213a005; CHABRE O, 1992, MOL ENDOCRINOL, V6, P551, DOI 10.1210/me.6.4.551; CHAKRABORTY M, 1994, P NATL ACAD SCI USA, V91, P2115, DOI 10.1073/pnas.91.6.2115; CHAKRABORTY M, 1991, SCIENCE, V251, P1078, DOI 10.1126/science.1847755; DELTOSO R, 1989, EMBO J, V8, P4025; DING C, 1995, J BONE MINER RES, V10, pS484; EGERTON M, 1995, J MOL ENDOCRINOL, V14, P179, DOI 10.1677/jme.0.0140179; EPAND RM, 1985, INT J PEPT PROT RES, V25, P105; FEGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413; FINDLAY DM, 1994, MOL ENDOCRINOL, V8, P1691, DOI 10.1210/me.8.12.1691; FONG TM, 1992, J BIOL CHEM, V267, P25664; FORCE T, 1992, AM J PHYSIOL, V262, pF1110, DOI 10.1152/ajprenal.1992.262.6.F1110; FRENDO JL, 1994, FEBS LETT, V342, P214, DOI 10.1016/0014-5793(94)80503-2; GORN AH, 1992, J CLIN INVEST, V90, P1726, DOI 10.1172/JCI116046; GORN AH, 1995, J CLIN INVEST, V95, P2680, DOI 10.1172/JCI117970; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; HUANG RRC, 1994, BIOCHEMISTRY-US, V33, P3007, DOI 10.1021/bi00176a033; IKEGAME M, 1995, J BONE MINER RES, V10, P59; KENNEY MA, 1993, BIOCHEM BIOPH RES CO, V197, P8, DOI 10.1006/bbrc.1993.2433; KONG XF, 1994, BIOCHEM BIOPH RES CO, V200, P1290, DOI 10.1006/bbrc.1994.1591; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KUESTNER RE, 1994, MOL PHARMACOL, V46, P246; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; LIN SC, 1993, NATURE, V364, P208, DOI 10.1038/364208a0; LOVENBERG TW, 1995, P NATL ACAD SCI USA, V92, P836, DOI 10.1073/pnas.92.3.836; MCCUAIG KA, 1994, P NATL ACAD SCI USA, V91, P5051, DOI 10.1073/pnas.91.11.5051; MOORE EE, 1995, MOL ENDOCRINOL, V9, P959, DOI 10.1210/me.9.8.959; NUSSENZVEIG DR, 1995, ENDOCRINOLOGY, V136, P2047, DOI 10.1210/en.136.5.2047; NUSSENZVEIG DR, 1994, J BIOL CHEM, V269, P28123; Offermanns S, 1996, MOL ENDOCRINOL, V10, P566, DOI 10.1210/me.10.5.566; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; SEGRE GV, 1993, TRENDS ENDOCRIN MET, V4, P309, DOI 10.1016/1043-2760(93)90071-L; SEXTON PM, 1993, MOL ENDOCRINOL, V7, P815, DOI 10.1210/me.7.6.815; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; SREEDHARAN SP, 1995, P NATL ACAD SCI USA, V92, P2939, DOI 10.1073/pnas.92.7.2939; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; SU YJ, 1992, ENDOCRINOLOGY, V131, P1497, DOI 10.1210/en.131.3.1497; TEZUKA K, 1992, BIOCHEM BIOPH RES CO, V186, P911, DOI 10.1016/0006-291X(92)90832-6; TsaiMorris CH, 1996, J BIOL CHEM, V271, P14519, DOI 10.1074/jbc.271.24.14519; YAMIN M, 1994, ENDOCRINOLOGY, V135, P2635, DOI 10.1210/en.135.6.2635; ZAIDI M, 1990, J ENDOCRINOL, V126, P473, DOI 10.1677/joe.0.1260473; ZOLNIEROWICZ S, 1994, J BIOL CHEM, V269, P19530	51	66	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31127	31134		10.1074/jbc.271.49.31127	http://dx.doi.org/10.1074/jbc.271.49.31127			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940110	hybrid			2022-12-25	WOS:A1996VW68600021
J	Swanson, HI; Yang, JH				Swanson, HI; Yang, JH			Mapping the protein/DNA contact sites of the Ah receptor and Ah receptor nuclear translocator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIOXIN-RESPONSIVE ENHANCER; ARYL-HYDROCARBON RECEPTOR; TRANSCRIPTION FACTOR; FUNCTIONAL DOMAINS; CRYSTAL-STRUCTURE; DNA INTERACTIONS; B/HLH/Z DOMAIN; BINDING; RECOGNITION; ARNT	The Ah receptor (AHR) and its DNA binding partner, the Ah receptor nuclear translocator (ARNT), are basic helix-loop-helix proteins distinguished by their PER, AHR, ARNT, and SLM (PAS) homology regions. To identify the amino acids of the AHR ARNT heterodimer that contact the TNGCGTG recognition sequence, we have performed deletion mapping and amino acid substitutions within the N termini of both the AHR and ARNT. The ability of the variant AHR and ARNT proteins to bind DNA and activate gene transcription was determined by the gel shift analysis and transient transfection assays. We have found that the amino acids of ARNT that contact DNA are similar to those of other basic/helix-loop-helix proteins and include glutamic acid residue 83 and arginine residues 86 and 87. Although our initial experiments indicated that DNA binding of the AHR may involve two regions that are bordered by amino acids 9-17 and amino acids 34-42, further analysis demonstrated that only amino acids 34-39 are critical for the AHR-TNGC interaction. These experiments indicate that while the structural features of the ARNT-GTG complex may closely resemble that deduced for proteins such as Max, E47, and USF, the AHR-TNGC complex may represent a unique DNA binding form of basic/helix-loop-helix proteins.			Swanson, HI (corresponding author), UNIV KENTUCKY,MED CTR,DEPT PHARMACOL,LEXINGTON,KY 40536, USA.			Swanson, Hollie/0000-0002-3725-5504	NIEHS NIH HHS [R29 ES008088] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES008088] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANTONSSON C, 1995, J BIOL CHEM, V270, P13968, DOI 10.1074/jbc.270.23.13968; Bacsi SG, 1996, J BIOL CHEM, V271, P8843, DOI 10.1074/jbc.271.15.8843; BASCI SG, 1995, MOL PHARM, V47, P432; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CHAN WK, 1994, J BIOL CHEM, V269, P26464; CREWS ST, 1988, CELL, V52, P143, DOI 10.1016/0092-8674(88)90538-7; DANG CV, 1992, P NATL ACAD SCI USA, V89, P599, DOI 10.1073/pnas.89.2.599; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DENISON MS, 1989, J BIOL CHEM, V264, P16478; DOCHERTY K, 1993, GENE TRANSCRIPTION P, P71; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; Dong LQ, 1996, J BIOL CHEM, V271, P7942, DOI 10.1074/jbc.271.14.7942; ELLENBERGER T, 1994, CURR OPIN STRUC BIOL, V4, P12, DOI 10.1016/S0959-440X(94)90054-X; ELLENBERGER T, 1994, GENE DEV, V8, P970, DOI 10.1101/gad.8.8.970; ELLINGTON A, 1987, CURRENT PROTOCOLS MO; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; FUKUNAGA BN, 1995, J BIOL CHEM, V270, P29270, DOI 10.1074/jbc.270.49.29270; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; JACKSON FR, 1986, NATURE, V320, P185, DOI 10.1038/320185a0; JEIN S, 1994, J BIOL CHEM, V269, P31518; JONES PBC, 1985, SCIENCE, V227, P1499, DOI 10.1126/science.3856321; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LINDEBRO MC, 1995, EMBO J, V14, P3528, DOI 10.1002/j.1460-2075.1995.tb07359.x; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; MA Q, 1995, J BIOL CHEM, V270, P12697, DOI 10.1074/jbc.270.21.12697; MARINI F, 1993, NUCLEIC ACIDS RES, V9, P2277; OKEY AB, 1994, TOXICOL LETT, V70, P1, DOI 10.1016/0378-4274(94)90139-2; REISZPORSZASZ S, 1994, MOL CELL BIOL, V14, P6075, DOI 10.1128/MCB.14.9.6075; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEN ES, 1992, J BIOL CHEM, V267, P6815; SOGAWA K, 1995, P NATL ACAD SCI USA, V92, P1936, DOI 10.1073/pnas.92.6.1936; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; WANG GL, 1993, J BIOL CHEM, V268, P21513; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WHITELAW ML, 1994, J BIOL CHEM, V269, P8343; YAO EF, 1992, BIOCHEMISTRY-US, V31, P5060, DOI 10.1021/bi00136a019	44	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31657	31665		10.1074/jbc.271.49.31657	http://dx.doi.org/10.1074/jbc.271.49.31657			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940186	hybrid			2022-12-25	WOS:A1996VW68600097
J	Yoder, JA; Yen, RWC; Vertino, PM; Bestor, TH; Baylin, SB				Yoder, JA; Yen, RWC; Vertino, PM; Bestor, TH; Baylin, SB			New 5' regions of the murine and human genes for DNA (cytosine-5)-methyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALING PATHWAY; METHYLTRANSFERASE; METHYLATION; EXPRESSION; CELLS; EMBRYOS; CANCER; DOMAIN; CDNA	DNA (cytosine-5)-methyltransferases (EC 2.1.1.37) maintain patterns of methylated cytosine residues in the mammalian genome; faithful maintenance of methylation patterns is required for normal development of mice, and aberrant methylation patterns are associated with certain human tumors and developmental abnormalities. The organization of coding sequences at the 5'-end of the murine and human DNA methyltransferase genes was investigated, and the DNA methyltransferase open reading frame was found to be longer than previously suspected, Expression of the complete open read ing frame by in vitro transcription-translation and by transfection of expression constructs into COS7 cells resulted in the production of an active DNA methyltransferase of the same apparent mass as the endogenous protein, while translation from the second in-frame ATG codon produced a slightly smaller but fully active protein, Characterization of mRNA 5' sequences and the intron-exon structure of the 5' region of the murine and human genes indicated that a previously described promoter element (Rouleau, J., Tanigawa, G., and Szyf, M. (1992) J. Biol, Chen, 267, 7368-7377) actually Lies in an intron that is more than 5 kilobases downstream of the transcription start sites.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT GENET & DEV,NEW YORK,NY 10032; JOHNS HOPKINS UNIV,SCH MED,JOHNS HOPKINS ONCOL CTR,BALTIMORE,MD 21231	Columbia University; Johns Hopkins University; Johns Hopkins Medicine			Yoder, Jeffrey A./I-5329-2019	Yoder, Jeffrey A./0000-0002-6083-1311	NATIONAL CANCER INSTITUTE [R01CA043318, R01CA060610] Funding Source: NIH RePORTER; NCI NIH HHS [CA60610, CA43318] Funding Source: Medline; NIGMS NIH HHS [GM00616] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEARD C, 1995, GENE DEV, V9, P2325, DOI 10.1101/gad.9.19.2325; Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045; BELL MV, 1991, CELL, V64, P861, DOI 10.1016/0092-8674(91)90514-Y; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x; BESTOR TH, 1993, CURR BIOL, V3, P384, DOI 10.1016/0960-9822(93)90209-7; BESTOR TH, 1990, PHILOS T ROY SOC B, V326, P179, DOI 10.1098/rstb.1990.0002; BESTOR TH, 1994, CURR OPIN CELL BIOL, V6, P380, DOI 10.1016/0955-0674(94)90030-2; Bestor TH, 1996, NAT GENET, V12, P363, DOI 10.1038/ng0496-363; CARLSON LL, 1992, GENE DEV, V6, P2536, DOI 10.1101/gad.6.12b.2536; CZANK A, 1991, GENE, V109, P259, DOI 10.1016/0378-1119(91)90618-L; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; HAKE LE, 1993, J BIOL CHEM, V268, P4788; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235; Jones PA, 1996, CANCER RES, V56, P2463; KOZAK M, 1995, P NATL ACAD SCI USA, V92, P2662, DOI 10.1073/pnas.92.7.2662; LAIRD PW, 1994, HUM MOL GENET, V3, P1487, DOI 10.1093/hmg/3.suppl_1.1487; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LI E, 1993, COLD SPRING HARB SYM, V58, P297, DOI 10.1101/SQB.1993.058.01.035; MACLEOD AR, 1995, J BIOL CHEM, V270, P11327, DOI 10.1074/jbc.270.19.11327; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MONK M, 1987, DEVELOPMENT, V99, P371; Rost B, 1996, METHOD ENZYMOL, V266, P525; ROULEAU J, 1995, J BIOL CHEM, V270, P1595, DOI 10.1074/jbc.270.4.1595; ROULEAU J, 1992, J BIOL CHEM, V267, P7368; Sambrook J., 2002, MOL CLONING LAB MANU; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; TAJIMA S, 1995, J BIOCHEM-TOKYO, V117, P1050, DOI 10.1093/oxfordjournals.jbchem.a124805; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vertino PM, 1996, MOL CELL BIOL, V16, P4555, DOI 10.1128/mcb.16.8.4555; YEN RWC, 1992, NUCLEIC ACIDS RES, V20, P2287, DOI 10.1093/nar/20.9.2287	34	83	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31092	31097		10.1074/jbc.271.49.31092	http://dx.doi.org/10.1074/jbc.271.49.31092			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940105	hybrid			2022-12-25	WOS:A1996VW68600016
J	Blaschke, UK; Hedbom, E; Bruckner, P				Blaschke, UK; Hedbom, E; Bruckner, P			Distinct isoforms of chicken decorin contain either one or two dermatan sulfate chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH REPEATS; BOVINE ARTICULAR-CARTILAGE; KERATAN SULFATE; CORE PROTEIN; MONOCLONAL-ANTIBODIES; SMALL PROTEOGLYCAN; COLLAGEN FIBRILS; II DECORIN; BINDING; CORNEAL	Decorin, a member of a family of proteins with leucine-rich repeat motifs, is a widely distributed extracellular matrix proteoglycan that is thought to be responsible for the structure, tissue organization, and surface properties of fibrils. In mammals, decorin carries one chondroitin/dermatan sulfate chain as a distinction from its homologue, biglycan, which contains two glycosaminoglycan chains. With the aim to study decorin-collagen interactions in chicken, where the fibrillar organization of cartilage collagens is best understood, we have isolated decorin-related proteoglycans from sternal cartilage of 10-day-old broiler chickens. Small chondroitin/dermatan sulfate proteoglycans were resolved by hydrophobic interaction chromatography into two fractions, DCN I and DCN II. Both forms contained dermatan sulfate and, in addition, keratan sulfate chains. Tryptic fingerprinting revealed that the core proteins of DCN I and DCN II were identical. The protein was identified as decorin by amino-terminal sequencing. DCN II was found to contain two dermatan sulfate chains, whereas DCN I had a single dermatan sulfate chain. The dermatan sulfate attachment sites are located near the NH2 terminus of the core protein, i.e. at Ser-4 and Ser-16 in DCN II and at Ser-4 in DCN I. The keratan sulfate attachment sites are located in the central portion of the core protein, at Asn-179 and Asn-230. The presence of two dermatan sulfate chains renders the chicken proteoglycan DCN II structurally similar to mammalian biglycan. Interestingly, biglycan has not been detected in chicken. Therefore, in birds, DCN II may function as a biglycan substitute.	UNIV MUNSTER, INST PHYSIOL CHEM & PATHOBIOCHEM, D-48149 MUNSTER, GERMANY	University of Munster			Bruckner, Peter/F-4817-2019	Bruckner, Peter/0000-0002-5566-5611				ANTONSSON P, 1991, J BIOL CHEM, V266, P16859; BENGTSSON E, 1995, J BIOL CHEM, V270, P25639, DOI 10.1074/jbc.270.43.25639; BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P20613; BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P347; BOURDON MA, 1987, P NATL ACAD SCI USA, V84, P3194, DOI 10.1073/pnas.84.10.3194; BROWN DC, 1990, MATRIX, V9, P468, DOI 10.1016/S0934-8832(11)80016-8; BRUCKNER P, 1994, MICROSC RES TECHNIQ, V28, P378, DOI 10.1002/jemt.1070280504; CATERSON B, 1983, J BIOL CHEM, V258, P8848; CHOI HU, 1989, J BIOL CHEM, V264, P2876; CHOPRA RK, 1985, BIOCHEM J, V232, P277, DOI 10.1042/bj2320277; Corpuz LM, 1996, J BIOL CHEM, V271, P9759, DOI 10.1074/jbc.271.16.9759; EIKENBERRY EF, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P133; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; FISHER LW, 1989, J BIOL CHEM, V264, P4571; FLEISCHMAJER R, 1991, J STRUCT BIOL, V106, P82, DOI 10.1016/1047-8477(91)90065-5; FONT B, 1993, J BIOL CHEM, V268, P25015; FORMATO M, 1994, CARBOHYD RES, V255, P27, DOI 10.1016/S0008-6215(00)90969-8; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HEDBOM E, 1993, J BIOL CHEM, V268, P27307; HUBER S, 1988, J BIOL CHEM, V263, P752; INGROSSO D, 1989, BIOCHEM BIOPH RES CO, V162, P1528, DOI 10.1016/0006-291X(89)90848-6; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; KAJAVA AV, 1995, STRUCTURE, V3, P867, DOI 10.1016/S0969-2126(01)00222-2; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KRESSE H, 1993, EXPERIENTIA, V49, P403, DOI 10.1007/BF01923585; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landon, 1977, Methods Enzymol, V47, P145; LENNON DP, 1991, MATRIX, V11, P412, DOI 10.1016/S0934-8832(11)80196-4; LI W, 1992, ARCH BIOCHEM BIOPHYS, V296, P190, DOI 10.1016/0003-9861(92)90562-B; MANN DM, 1990, J BIOL CHEM, V265, P5317; MCBAIN JA, 1992, BIOCHEM J, V287, P131, DOI 10.1042/bj2870131; MIDURA RJ, 1989, J BIOL CHEM, V264, P1423; NEAME PJ, 1989, J BIOL CHEM, V264, P8653; NEAME PJ, 1994, J BIOL CHEM, V269, P21547; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; POGANY G, 1994, ARCH BIOCHEM BIOPHYS, V313, P102, DOI 10.1006/abbi.1994.1365; PRINGLE GA, 1990, J HISTOCHEM CYTOCHEM, V38, P1405, DOI 10.1177/38.10.1698203; SCHONHERR E, 1995, J BIOL CHEM, V270, P2776, DOI 10.1074/jbc.270.6.2776; SCOTT JE, 1992, FASEB J, V6, P2639, DOI 10.1096/fasebj.6.9.1612287; SHINOMURA T, 1992, J BIOL CHEM, V267, P1265; SVENSSON L, 1995, J BIOL CHEM, V270, P20712, DOI 10.1074/jbc.270.35.20712; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VOGEL KG, 1985, J BIOL CHEM, V260, P9298; VOGEL KG, 1987, COLLAGEN REL RES, V7, P105; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; ZEBROWER ME, 1986, ANAL BIOCHEM, V157, P93, DOI 10.1016/0003-2697(86)90201-0	47	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30347	30353		10.1074/jbc.271.48.30347	http://dx.doi.org/10.1074/jbc.271.48.30347			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8939995	hybrid			2022-12-25	WOS:A1996VV15800012
J	Fricker, LD; Berman, YL; Leiter, EH; Devi, LA				Fricker, LD; Berman, YL; Leiter, EH; Devi, LA			Carboxypeptidase E activity is deficient in mice with the fat mutation - Effect on peptide processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENKEPHALIN-SYNTHESIZING CARBOXYPEPTIDASE; IDENTIFICATION; PURIFICATION; EXPRESSION; PITUITARY; ENZYME; FURIN; CDNA; CONVERTASE; SEQUENCE	Carboxypeptidase E (CPE) is involved in the biosynthesis of many peptide hormones and neurotransmitters. Mice with the fat mutation have previously been found to have a point mutation in the cpe gene, and to have greatly reduced levels of CPE-like enzyme activity in the pituitary and pancreatic islets (Naggert, J. It., Fricker, L. D., Varlamov, O., Nishina, P. M., Rouille, Y., Steiner, D. F., Carroll, R. J., Paigen, B. J., and Leiter, E. H. (1995) Nat. Genet. 10, 135-142). In the present report, we examined CPE-like activity and peptide processing in several tissues of C57BLKS/LtJ-Cpe(fat)/Cpe(fat) mutant (Cpe(fat)/Cpe(fat) mice. whereas CPE-like activity is detected in homogenates of Cpe(fat)/Cpe(fat) mouse tissues, the majority of this activity is not due to CPE based on the sensitivity to p-chloromercuriphenyl sulfonate. In addition, the Cpe(fat)/Cpe(fat) activity does not bind to a substrate affinity column under conditions that bind CPE. Furthermore, the enzyme activity and immunoreactive properties' of the activity purified from Cpe(fat)/Cpe(fat) brain are distinct from those of CPE. Taken together, these data suggest that CPE is completely inactive in the Cpe(fat)/Cpe(fat) mice, and that all of the CPE-like activity is due to other carboxypeptidases such as carboxypeptidase D. Levels of Leu-enkephalin in Cpe(fat)/Cpe(fat) mouse brain are approximately 5-fold lower than those in control brain. Treatment of the Cpe(fat)/Cpe(fat) brain extract with carboxypeptidase B restores the level of Leu-enkephalin to the level in control brain. Interestingly, the large molecular weight enkephalin-containing peptides are elevated 2-3-fold in Cpe(fat)/Cpe(fat) mouse brain. These data indicate that CPE plays an important role in the processing of peptide hormones in various tissues, but that other carboxypeptidases also contribute to peptide processing. Furthermore, the increase in levels of high molecular weight enkephalin peptides in the Cpe(fat)/Cpe(fat) mouse suggests that CPE is required for efficient peptide processing by the endopeptidases.	NYU, MED CTR, DEPT PHARMACOL, NEW YORK, NY 10016 USA; JACKSON LAB, BAR HARBOR, ME 04609 USA	New York University; Jackson Laboratory	Fricker, LD (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MOL PHARMACOL, 1300 MORRIS PK AVE, BRONX, NY 10461 USA.		Devi P, Lakshmi/GXM-5982-2022	Devi P, Lakshmi/0000-0001-9274-4776	NIDA NIH HHS [DA-04494, T32 DA-07254, DA-00194] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [T32DA007254, R01DA004494, K02DA000194] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		[Anonymous], 1995, METH NEUROSCI; BERMAN YL, 1995, J BIOL CHEM, V270, P23845, DOI 10.1074/jbc.270.40.23845; CHESNEAU V, 1994, J BIOL CHEM, V269, P2056; CONE RI, 1982, NEUROPEPTIDES, V3, P97, DOI 10.1016/0143-4179(82)90005-1; DEVI L, 1989, MOL ENDOCRINOL, V3, P1852, DOI 10.1210/mend-3-11-1852; DOCHERTY K, 1982, ANNU REV PHYSIOL, V44, P625, DOI 10.1146/annurev.ph.44.030182.003205; EIPPER BA, 1986, TRENDS NEUROSCI, V9, P463, DOI 10.1016/0166-2236(86)90149-9; FRICKER LD, 1990, J BIOL CHEM, V265, P2476; FRICKER LD, 1983, J BIOL CHEM, V258, P950; FRICKER LD, 1988, ANNU REV PHYSIOL, V50, P309, DOI 10.1146/annurev.ph.50.030188.001521; FRICKER LD, 1989, MOL ENDOCRINOL, V3, P666, DOI 10.1210/mend-3-4-666; FRICKER LD, 1982, P NATL ACAD SCI-BIOL, V79, P3886, DOI 10.1073/pnas.79.12.3886; FRICKER LD, 1991, PEPTIDE BIOSYNTHESIS, P199; HE GP, 1995, NATURE, V378, P92, DOI 10.1038/378092a0; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; JEAN F, 1993, BIOCHEM J, V292, P891, DOI 10.1042/bj2920891; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; KUROKI K, 1994, J VIROL, V68, P2091, DOI 10.1128/JVI.68.4.2091-2096.1994; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; NAKAGAWA T, 1993, J BIOCHEM-TOKYO, V113, P132, DOI 10.1093/oxfordjournals.jbchem.a124015; PARKINSON D, 1990, J BIOL CHEM, V265, P17101; Rovere C, 1996, ENDOCRINOLOGY, V137, P2954, DOI 10.1210/en.137.7.2954; SCHAFER MKH, 1993, J NEUROSCI, V13, P1258; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SKIDGEL RA, 1988, TRENDS PHARMACOL SCI, V9, P299, DOI 10.1016/0165-6147(88)90015-6; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SONG LX, 1995, J BIOL CHEM, V270, P25007, DOI 10.1074/jbc.270.42.25007; Steiner D. F., 1991, PEPTIDE BIOSYNTHESIS, P1; Varlamov O, 1996, J BIOL CHEM, V271, P13981, DOI 10.1074/jbc.271.24.13981; WEBB E C, 1986, European Journal of Biochemistry, V157, P1; WEBER E, 1982, BIOCHEM BIOPH RES CO, V108, P81, DOI 10.1016/0006-291X(82)91834-4; YI Z, 1993, J BIOL CHEM, V268, P5615; ZHENG M, 1994, J NEUROSCI, V14, P4656; Zhu X, 1996, P NATL ACAD SCI USA, V93, P4919, DOI 10.1073/pnas.93.10.4919	34	127	129	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30619	30624		10.1074/jbc.271.48.30619	http://dx.doi.org/10.1074/jbc.271.48.30619			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940036	hybrid			2022-12-25	WOS:A1996VV15800053
J	Fukasawa, KM; Fukasawa, K; Kanari, M; Fujii, S; Harada, M				Fukasawa, KM; Fukasawa, K; Kanari, M; Fujii, S; Harada, M			Molecular cloning and expression of rat liver aminopeptidase B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; LEUKOTRIENE-A4 HYDROLASE; ARGININE AMINOPEPTIDASE; SKELETAL-MUSCLE; PURIFICATION; PROTEIN; ENZYME; CDNA; INHIBITION; BESTATIN	We isolated, by immunological screening of a Uni-ZAP XR cDNA Library constructed from rat liver mRNAs, a cDNA clone with 2212 base pairs encoding aminopeptidase B (EC 3.4.11.6). The open reading frame encodes a 649-amino acid protein with a theoretical molecular mass of 72,545 Da and bears the consensus sequence of the zinc metalloexopeptidases, indicating that the enzyme belongs to this family, which includes aminopeptidase A, aminopeptidase N, and leukotriene-A(4) hydrolase. Escherichia coli SOLR cells infected with the pBluescript phagemid excised from the Uni-ZAP XR vector containing the aminopeptidase B cDNA had a high L-arginyl-beta-naphthylamidase activity. The recombinant protein was purified to homogeneity from the recombinant E. coli extracts. The enzyme had Cl--dependent aminopeptidase activity specifically restricted to the Arg and Lye derivatives and contained 1 mol of zinc per mol of the enzyme.	SHINSHU UNIV,SCH MED,DEPT OBSTET & GYNECOL,MATSUMOTO,NAGANO 390,JAPAN	Shinshu University	Fukasawa, KM (corresponding author), MATSUMOTO DENT COLL,DEPT ORAL BIOCHEM,SHIOJIRI,NAGANO 39907,JAPAN.							BARELLI H, 1992, BIOCHEM J, V287, P621, DOI 10.1042/bj2870621; BELHACENE N, 1993, EUR J IMMUNOL, V23, P1848; CADEL S, 1995, MOL CELL ENDOCRINOL, V110, P149, DOI 10.1016/0303-7207(95)03529-G; CAPRIOGLIO DR, 1993, J BIOL CHEM, V268, P14310; FLORES M, 1993, BIOCHIMIE, V75, P861, DOI 10.1016/0300-9084(93)90040-Y; GOLDBARG JA, 1958, CANCER, V11, P283, DOI 10.1002/1097-0142(195803/04)11:2<283::AID-CNCR2820110209>3.0.CO;2-8; HARBESON SL, 1988, BIOCHEMISTRY-US, V27, P7301, DOI 10.1021/bi00419a019; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; HOPSU VK, 1964, LIFE SCI, V3, P1449, DOI 10.1016/0024-3205(64)90087-6; HOPSU VK, 1966, ARCH BIOCHEM BIOPHYS, V114, P567, DOI 10.1016/0003-9861(66)90381-X; HOPSU VK, 1966, ARCH BIOCHEM BIOPHYS, V114, P557, DOI 10.1016/0003-9861(66)90380-8; ISHIURA S, 1987, J BIOCHEM-TOKYO, V102, P1023, DOI 10.1093/oxfordjournals.jbchem.a122140; JONGENEEL CV, 1989, FEBS LETT, V242, P211, DOI 10.1016/0014-5793(89)80471-5; KAWATA S, 1980, J BIOCHEM, V88, P1025, DOI 10.1093/oxfordjournals.jbchem.a133053; KIRSCHKE H, 1976, ACTA BIOL MED GER, V35, P285; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAKINEN KK, 1978, BIOCHEM J, V175, P1051; MAKINEN KK, 1971, INT J PROT RES, V3, P41; MAKITA N, 1992, FEBS LETT, V299, P273, DOI 10.1016/0014-5793(92)80130-9; MANTLE D, 1985, EUR J BIOCHEM, V147, P307, DOI 10.1111/j.1432-1033.1985.tb08751.x; MCDERMOTT JR, 1988, J NEUROCHEM, V50, P176, DOI 10.1111/j.1471-4159.1988.tb13246.x; McDonald J.K., 1986, EXOPEPTIDASES, VVolume 2, P48; MEDINA JF, 1991, BIOCHEM BIOPH RES CO, V176, P1516, DOI 10.1016/0006-291X(91)90459-K; MEDINA JF, 1991, P NATL ACAD SCI USA, V88, P7620, DOI 10.1073/pnas.88.17.7620; MINAMI M, 1987, J BIOL CHEM, V262, P13873; MINAMI M, 1995, GENE, V161, P249, DOI 10.1016/0378-1119(95)00179-A; NAGATA Y, 1991, ENZYME, V45, P165, DOI 10.1159/000468885; NANUS DM, 1993, P NATL ACAD SCI USA, V90, P7069, DOI 10.1073/pnas.90.15.7069; NISHIMURA T, 1983, EUR J BIOCHEM, V137, P23, DOI 10.1111/j.1432-1033.1983.tb07790.x; OCAIN TD, 1987, BIOCHEM BIOPH RES CO, V145, P1038, DOI 10.1016/0006-291X(87)91540-3; OLSEN J, 1988, FEBS LETT, V238, P307, DOI 10.1016/0014-5793(88)80502-7; ORLOWSKI M, 1983, EUR J BIOCHEM, V135, P81, DOI 10.1111/j.1432-1033.1983.tb07620.x; PARSONS ME, 1979, INT J BIOCHEM, V10, P217, DOI 10.1016/0020-711X(79)90037-5; PIEROTTI A, 1990, BIOCHEMISTRY-US, V29, P10323, DOI 10.1021/bi00497a006; PONTREMOLI S, 1980, EUR J BIOCHEM, V110, P421, DOI 10.1111/j.1432-1033.1980.tb04883.x; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; ROSS E, 1973, ANAL BIOCHEM, V54, P304, DOI 10.1016/0003-2697(73)90280-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARGENT MG, 1987, ANAL BIOCHEM, V163, P476, DOI 10.1016/0003-2697(87)90251-X; SINGH H, 1978, J BIOL CHEM, V253, P4319; SODERLING E, 1983, ARCH BIOCHEM BIOPHYS, V220, P1, DOI 10.1016/0003-9861(83)90380-6; SODERLING E, 1983, ARCH BIOCHEM BIOPHYS, V220, P11, DOI 10.1016/0003-9861(83)90381-8; SUDA H, 1976, ARCH BIOCHEM BIOPHYS, V177, P196, DOI 10.1016/0003-9861(76)90429-X; TAYLOR A, 1993, TRENDS BIOCHEM SCI, V18, P167; UMEZAWA H, 1983, J ANTIBIOT, V36, P1572, DOI 10.7164/antibiotics.36.1572; UMEZAWA H, 1976, J ANTIBIOT, V29, P97, DOI 10.7164/antibiotics.29.97; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WATT VM, 1989, J BIOL CHEM, V264, P5480; WU Q, 1990, P NATL ACAD SCI USA, V87, P993, DOI 10.1073/pnas.87.3.993; YAMADA M, 1994, FEBS LETT, V342, P53, DOI 10.1016/0014-5793(94)80583-0	51	39	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30731	30735		10.1074/jbc.271.48.30731	http://dx.doi.org/10.1074/jbc.271.48.30731			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940051	hybrid			2022-12-25	WOS:A1996VV15800068
J	Tanimura, A; Turner, RJ				Tanimura, A; Turner, RJ			Inositol 1,4,5-trisphosphate-dependent oscillations of luminal [Ca2+] in permeabilized HSY cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM OSCILLATIONS; FLUORESCENT INDICATOR; INTRACELLULAR STORES; RELEASE; TRISPHOSPHATE; STIMULATION; HEPATOCYTES; CHANNELS; KINASE; WAVES	Oscillations in intracellular Ca2+ concentration ([Ca2+](i)) are thought to play an important role in phosphoinositide-linked Ca2+ signaling events, We demonstrate corresponding inositol 1,4,5-trisphosphate (IP3) dependent oscillations of Ca2+ concentration within the lumen of the IP3-sensitive stores ([Ca2+](L)) of saponin-permeabilized HSY cells by monitoring [Ca2+](L) with the fluorescent Ca2+ indicator Mag-fura-a, The associated openings and closings of the IP3-sensitive Ca2+ release channel were detected via quenching of Mag-fura-a fluorescence due to the entry of Mn2+, a Ca2+ surrogate, into the stores, Evidence for complimentary Ca2+ oscillations at the external surface of the stores was provided by the membrane-bound Ca2+ probe Calcium Green C-18. The permeabilization of saponin-treated HSY cells to macromolecules was confirmed by demonstrating that permeabilized cells readily took up and lost (t(1/2) approximate to 46 s) a fluorescently tagged 70-kDa dextran. Our results impose a number of constraints on possible mechanisms for [Ca2+](i) oscillations. In addition, they support recent proposals that [Ca2+](i) oscillations arise directly from the (biphasic) effects of Ca2+ itself on IP3-sensitive Ca2+ channel activity.	NIDR,CLIN INVEST & PATIENT CARE BRANCH,NIH,BETHESDA,MD 20892; HLTH SCI UNIV HOKKAIDO,DEPT DENT PHARMACOL,ISHIKARI,HOKKAIDO 06102,JAPAN	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Health Sciences University of Hokkaido								ATRI A, 1993, BIOPHYS J, V65, P1727, DOI 10.1016/S0006-3495(93)81191-3; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; CHATTON JY, 1995, FEBS LETT, V368, P165, DOI 10.1016/0014-5793(95)00632-J; DEYOUNG GW, 1992, P NATL ACAD SCI USA, V89, P9895, DOI 10.1073/pnas.89.20.9895; FEWTRELL C, 1993, ANNU REV PHYSIOL, V55, P427, DOI 10.1146/annurev.physiol.55.1.427; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; HAJNOCZKY G, 1994, NATURE, V370, P474, DOI 10.1038/370474a0; HOFER AM, 1993, P NATL ACAD SCI USA, V90, P2598, DOI 10.1073/pnas.90.7.2598; LI YX, 1995, AM J PHYSIOL-CELL PH, V269, pC1079, DOI 10.1152/ajpcell.1995.269.5.C1079; LI YX, 1994, P NATL ACAD SCI USA, V91, P58, DOI 10.1073/pnas.91.1.58; LLOYD QP, 1995, J BIOL CHEM, V270, P22445, DOI 10.1074/jbc.270.38.22445; MORAN A, 1993, AM J PHYSIOL, V265, pC1405, DOI 10.1152/ajpcell.1993.265.5.C1405; PATTON LL, 1991, IN VITRO CELL DEV B, V27, P779; PETERSEN OH, 1994, ANNU REV PHYSIOL, V56, P297, DOI 10.1146/annurev.ph.56.030194.001501; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; RAJU B, 1989, AM J PHYSIOL, V256, pC540, DOI 10.1152/ajpcell.1989.256.3.C540; RENARDROONEY DC, 1993, J BIOL CHEM, V268, P23601; SHORT AD, 1993, J BIOL CHEM, V268, P25887; SNEYD J, 1995, FASEB J, V9, P1463, DOI 10.1096/fasebj.9.14.7589988; Tanimura A, 1996, J CELL BIOL, V132, P607, DOI 10.1083/jcb.132.4.607; TSE FW, 1994, P NATL ACAD SCI USA, V91, P9750, DOI 10.1073/pnas.91.21.9750; YANAGAWA T, 1986, VIRCHOWS ARCH B, V51, P187, DOI 10.1007/BF02899028; ZHANG BX, 1993, J BIOL CHEM, V268, P10997	24	32	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30904	30908		10.1074/jbc.271.48.30904	http://dx.doi.org/10.1074/jbc.271.48.30904			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940075	hybrid			2022-12-25	WOS:A1996VV15800092
J	Yang, RJ; Gerstenfeld, LC				Yang, RJ; Gerstenfeld, LC			Signal transduction pathways mediating parathyroid hormone stimulation of bone sialoprotein gene expression in osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-FOS EXPRESSION; DEPENDENT PROTEIN-KINASE; TYROSINE-HYDROXYLASE GENE; TRANSCRIPTIONAL REGULATION; TRANSGENIC MICE; BINDING-PROTEINS; CELL-LINE; CAMP; HYBRIDIZATION; RECEPTOR	Bone sialoprotein is a major noncollagenous protein of bone, Parathyroid hormone (PTH) was shown to cause a 2-4-fold increase in the steady-state levels of bone sialoprotein mRNAs within primary cultures of embryonic osteoblasts. The induction could be mimicked by both forskolin and phorbol 12-myristate 13-acetate and was not inhibited by cycloheximide. Transient expression of a similar to 1200-base pair avian 5' bsp promoter/reporter construct demonstrated similar inductions as mRNA levels, Co-transfection of an expression plasmid encoding heat-stable inhibitor of cAMP-dependent protein kinase, a peptide inhibitor of PKA, decreased both the basal and PTH-induced bsp transcription, while co-expression of the catalytic subunit of PKA-induced bsp expression 3-fold, Protein kinase C activation, on the other hand, did not appear to work through its activation of c-fos, since co-transfection of an expression clone for c-fos had no effect. Interestingly, heat-stable inhibitor of cAMP-dependent protein kinase also inhibited the phorbol 12-myristate 13-acetate induction, suggesting that the protein kinase C acts through some form of interaction with the cAMP/PKA pathway, A half-cAMP response element site in the bsp promoter was identified as the cis-acting element that mediated the PTH response by the transient transfections with reporter constructs containing nested deletions of the promoter or a heterologous promoter containing the cAMP response element, In conclusion, these data indicate that PTH stimulation of bsp gene expression is specific to osteoblasts and mediated by changing cellular cAMP/PKA levels, They further suggest that although protein kinase C is capable of stimulating the gene by itself, it plays a minimal role in mediating the PTH induction of bone sialoprotein.	CHILDRENS HOSP,LAB STUDY SKELETAL DIS & REHABIL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School				/0000-0002-0477-1211	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022400] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007112, P01AR034078] Funding Source: NIH RePORTER; NIAMS NIH HHS [P01 AR 34078, AR07112] Funding Source: Medline; NICHD NIH HHS [R01 HD22400] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BASUDEV H, 1995, ACTA DIABETOL, V32, P32, DOI 10.1007/BF00581042; BIANCO P, 1991, CALCIFIED TISSUE INT, V49, P421, DOI 10.1007/BF02555854; BOHMANN D, 1988, COLD SPRING HARB SYM, V53, P695, DOI 10.1101/SQB.1988.053.01.079; CANDELIERE GA, 1995, NEW ENGL J MED, V332, P1546, DOI 10.1056/NEJM199506083322304; CHATTON B, 1994, ONCOGENE, V9, P375; CHEN JK, 1991, MATRIX, V11, P133, DOI 10.1016/S0934-8832(11)80217-9; CIVITELLI R, 1988, AM J PHYSIOL, V255, pE660, DOI 10.1152/ajpendo.1988.255.5.E660; CLAUSS IM, 1993, DEV DYNAM, V197, P146, DOI 10.1002/aja.1001970207; CLOHISY JC, 1992, MOL ENDOCRINOL, V6, P1834, DOI 10.1210/me.6.11.1834; CLOSS EI, 1990, J CELL BIOL, V111, P1313, DOI 10.1083/jcb.111.3.1313; COSMAN F, 1989, J BONE MINER RES, V4, P413; DAY RN, 1989, J BIOL CHEM, V264, P431; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Fitzpatrick L. A., 1992, DISORDERS BONE MINER, P123; Gerstenfeld LC, 1996, ENDOCRINOLOGY, V137, P3957, DOI 10.1210/en.137.9.3957; GERSTENFELD LC, 1988, J CELL BIOL, V106, P979, DOI 10.1083/jcb.106.3.979; GERSTENFELD LC, 1987, DEV BIOL, V122, P49, DOI 10.1016/0012-1606(87)90331-9; GERSTENFELD LC, 1995, ANN NY ACAD SCI, V760, P67, DOI 10.1111/j.1749-6632.1995.tb44621.x; GROVE JR, 1989, J BIOL CHEM, V264, P19506; GUNNESSHEY M, 1989, BONE, V10, P447, DOI 10.1016/8756-3282(89)90077-X; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HOWARD GA, 1981, P NATL ACAD SCI-BIOL, V78, P3204, DOI 10.1073/pnas.78.5.3204; HUNTER GK, 1993, P NATL ACAD SCI USA, V90, P8562, DOI 10.1073/pnas.90.18.8562; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; KIM KS, 1994, J NEUROCHEM, V63, P834; KIM KS, 1993, P NATL ACAD SCI USA, V90, P3471, DOI 10.1073/pnas.90.8.3471; KREAM BE, 1993, MOL ENDOCRINOL, V7, P399, DOI 10.1210/me.7.3.399; KRONENBERG HM, 1994, PRRIMER METABOLIC BO, P58; LEE K, 1994, ENDOCRINOLOGY, V134, P441, DOI 10.1210/en.134.1.441; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; MCKNIGHT SL, 1980, NUCLEIC ACIDS RES, V8, P5949, DOI 10.1093/nar/8.24.5949; MCKNIGHT SL, 1981, CELL, V25, P385, DOI 10.1016/0092-8674(81)90057-X; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; MIDURA RJ, 1994, J BIOL CHEM, V269, P13200; MUFF R, 1994, MOL CELL ENDOCRINOL, V100, P35, DOI 10.1016/0303-7207(94)90275-5; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; NODA M, 1989, J CELL BIOL, V108, P713, DOI 10.1083/jcb.108.2.713; PARTRIDGE NC, 1994, J CELL BIOCHEM, V55, P321, DOI 10.1002/jcb.240550308; RAFIDI K, 1994, GENE, V140, P163, DOI 10.1016/0378-1119(94)90540-1; Reimold AM, 1996, NATURE, V379, P262, DOI 10.1038/379262a0; RUTHER U, 1989, ONCOGENE, V4, P861; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; Sambrook J., 2002, MOL CLONING LAB MANU; SCOTT DK, 1992, MOL ENDOCRINOL, V6, P2153, DOI 10.1210/me.6.12.2153; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; TAM CS, 1982, ENDOCRINOLOGY, V110, P506, DOI 10.1210/endo-110-2-506; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; YANG R, 1996, IN PRESS J CELL BIOC; YANG RJ, 1995, J BONE MINER RES, V10, P632; ZU YL, 1993, ONCOGENE, V8, P2749	57	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29839	29846		10.1074/jbc.271.47.29839	http://dx.doi.org/10.1074/jbc.271.47.29839			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939923	hybrid			2022-12-25	WOS:A1996VU52500051
J	Biener, Y; Feinstein, R; Mayak, M; Kaburagi, Y; Kadowaki, T; Zick, Y				Biener, Y; Feinstein, R; Mayak, M; Kaburagi, Y; Kadowaki, T; Zick, Y			Annexin II is a novel player in insulin signal transduction - Possible association between annexin II phosphorylation and insulin receptor internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; PROTEIN-TYROSINE KINASE; INSULINOMIMETIC AGENTS H2O2; CALPACTIN-I; PHOSPHOLIPID-BINDING; JUXTAMEMBRANE REGION; MEDIATED ENDOCYTOSIS; MULTIVESICULAR BODY; DOWN-REGULATION; INTACT-CELLS	Annexin II is a Ca2+-, phospholipid-, and actin- binding protein that was implicated in the regulation of vesicular traffic and endosome fusion. It is a known substrate for protein kinases including the platelet-derived growth factor receptor, src protein-tyrosine kinase, and protein kinase C. In the present study we investigated the possible involvement of annexin II in insulin signal transduction. Phosphorylation of annexin II in response to insulin treatment of intact Chinese hamster ovary (CHO)-T cells was detected by 5 min and reached maximal levels after a 2-3-h incubation with the hormone, However, unlike other receptor substrates, annexin II failed to undergo insulin induced Tyr phosphorylation under conditions where receptor internalization was inhibited. This was evident in CHO cells, overexpressing the insulin receptor, in which internalization was inhibited either by tyrosine kinase inhibitors or by lowering the temperature to 4 degrees C, and in CHO cells overexpressing various insulin receptor mutants in which normal internalization was impaired. Hence, Tyr phosphorylation of annexin II could be part of the internalization and sorting mechanism of the insulin receptor.	WEIZMANN INST SCI, DEPT MOL CELL BIOL, IL-76100 REHOVOT, ISRAEL; UNIV TOKYO, FAC MED, DEPT INTERNAL MED 3, BUNKYO KU, TOKYO 113, JAPAN	Weizmann Institute of Science; University of Tokyo			Zick, Yehiel/K-1479-2012					ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BACKER JM, 1991, J CELL BIOL, V115, P1535, DOI 10.1083/jcb.115.6.1535; BACKER JM, 1990, J BIOL CHEM, V265, P16450; BENLEVY R, 1992, J BIOL CHEM, V267, P17304; BERNIER M, 1987, P NATL ACAD SCI USA, V84, P1844, DOI 10.1073/pnas.84.7.1844; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; BRAMBILLA R, 1991, BIOCHEM J, V278, P447, DOI 10.1042/bj2780447; BURGOYNE RD, 1994, TRENDS BIOCHEM SCI, V19, P231, DOI 10.1016/0968-0004(94)90143-0; CAMA A, 1992, J BIOL CHEM, V267, P8383; CARPENTIER JL, 1984, J BIOL CHEM, V259, P4190; CARPENTIER JL, 1994, ANN NY ACAD SCI, V733, P266, DOI 10.1111/j.1749-6632.1994.tb17276.x; CARPENTIER JL, 1981, J CELL BIOL, V91, P17, DOI 10.1083/jcb.91.1.17; CARPENTIER JL, 1995, J BIOL CHEM, V270, P5001, DOI 10.1074/jbc.270.10.5001; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; DEBANT A, 1988, P NATL ACAD SCI USA, V85, P8032, DOI 10.1073/pnas.85.21.8032; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; EMANS N, 1993, J CELL BIOL, V120, P1357, DOI 10.1083/jcb.120.6.1357; FAVA RA, 1984, J BIOL CHEM, V259, P2636; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FUTTER CE, 1993, J CELL BIOL, V120, P77, DOI 10.1083/jcb.120.1.77; GLENNEY J, 1986, P NATL ACAD SCI USA, V83, P4258, DOI 10.1073/pnas.83.12.4258; GLENNEY JR, 1991, METHOD ENZYMOL, V196, P65; GOULD KL, 1986, MOL CELL BIOL, V6, P2738, DOI 10.1128/MCB.6.7.2738; GREENBERG ME, 1983, CELL, V33, P767, DOI 10.1016/0092-8674(83)90019-3; Gruenberg Jean, 1993, Trends in Cell Biology, V3, P224, DOI 10.1016/0962-8924(93)90116-I; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HADARI YR, 1992, J BIOL CHEM, V267, P17483; HAFT CR, 1994, J BIOL CHEM, V269, P26286; HARDER T, 1993, J CELL BIOL, V123, P1119, DOI 10.1083/jcb.123.5.1119; HARI J, 1987, J BIOL CHEM, V262, P15341; HEFFETZ D, 1992, BIOCHEM J, V288, P631, DOI 10.1042/bj2880631; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HELLERHARRISON RA, 1995, J BIOL CHEM, V270, P24442, DOI 10.1074/jbc.270.41.24442; JOHNSSON N, 1988, EMBO J, V7, P2435, DOI 10.1002/j.1460-2075.1988.tb03089.x; JOHNSTONE SA, 1992, J BIOL CHEM, V267, P25976; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; KABURAGI Y, 1993, J BIOL CHEM, V268, P16610; KARASIK A, 1988, J BIOL CHEM, V263, P18558; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KLEE CB, 1988, BIOCHEMISTRY-US, V27, P6645, DOI 10.1021/bi00418a001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; LARKIN JM, 1986, J CELL BIOL, V103, P2619, DOI 10.1083/jcb.103.6.2619; LEVITZKI A, 1992, FASEB J, V6, P3275, DOI 10.1096/fasebj.6.14.1426765; MARSHALL S, 1981, DIABETES, V30, P746, DOI 10.2337/diab.30.9.746; Moss S. E, 1992, ANNEXINS; NAKATA T, 1990, J CELL BIOL, V110, P13, DOI 10.1083/jcb.110.1.13; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OGAWA W, 1994, J BIOL CHEM, V269, P29602; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PERROTTI N, 1987, P NATL ACAD SCI USA, V84, P3137, DOI 10.1073/pnas.84.10.3137; PILCH PF, 1983, J CELL BIOL, V96, P133, DOI 10.1083/jcb.96.1.133; POWELL MA, 1987, BIOCHEM J, V247, P321, DOI 10.1042/bj2470321; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; SARIS CJM, 1986, CELL, V46, P201, DOI 10.1016/0092-8674(86)90737-3; SAWYER ST, 1985, J BIOL CHEM, V260, P8233; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SEGER R, 1995, J BIOL CHEM, V270, P28325; SENDA T, 1994, CELL TISSUE RES, V277, P51; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUNG CK, 1994, J BIOL CHEM, V269, P12503; WILDEN PA, 1992, J BIOL CHEM, V267, P16660; YAMADA K, 1995, J BIOL CHEM, V270, P3115, DOI 10.1074/jbc.270.7.3115; ZOKAS L, 1987, J CELL BIOL, V105, P2111, DOI 10.1083/jcb.105.5.2111	69	67	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29489	29496		10.1074/jbc.271.46.29489	http://dx.doi.org/10.1074/jbc.271.46.29489			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910617				2022-12-25	WOS:A1996VT05200109
J	Erny, KM; Peli, J; Lambert, JF; Muller, V; Diggelmann, H				Erny, KM; Peli, J; Lambert, JF; Muller, V; Diggelmann, H			Involvement of the Tp1-2/cot oncogene in MMTV tumorigenesis	ONCOGENE			English	Article						MMTV; Tp1-2/cot; mammary tumor	MAMMARY-TUMOR VIRUS; T-CELL LYMPHOMAS; PROTEIN-KINASE; COT PROTOONCOGENE; TRANSFORMING GENE; SERINE KINASE; EXPRESSION; TPL-2; IDENTIFICATION; ACTIVATION	We report for the first time a relationship between the Tpl-2/cot oncogene and Mouse Mammary Tumor Virus (MMTV) associated transformation of mammary gland cells, A sub-genomic library generated from a primary mammary gland tumor yielded a novel MMTV integration site which disrupted the Tpl-2/cot proto-oncogene between exons 7 and 8, Comparison of a cell line derived from normal mammary gland (comma-D) and a cell line established from an MMTV induced mammary tumor (GR) demonstrated similar rearrangements within Tpl-2/cot for the GR cells but not in the comma-D cells, These rearrangements in the cell line were accompanied by an increase in the level of Tpl-2/cot specific mRNA, This data suggests that Tpl-2/cot expression may be important in epithelial cell transformation or tumor progression.	CHU VAUDOIS, INST MICROBIOL, CH-1011 LAUSANNE, SWITZERLAND; SWISS INST CANC RES, ISREC, EPALINGES, SWITZERLAND	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Swiss Institute Experimental Cancer Research				Erny-Albrecht, Katrina/0000-0003-3538-1475				AOKI M, 1993, J BIOL CHEM, V268, P22723; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BONNER TI, 1985, MOL CELL BIOL, V5, P1400, DOI 10.1128/MCB.5.6.1400; CHAN AML, 1993, ONCOGENE, V8, P1329; DANIELSON KG, 1984, P NATL ACAD SCI-BIOL, V81, P3756, DOI 10.1073/pnas.81.12.3756; HELD W, 1993, CELL, V74, P529, DOI 10.1016/0092-8674(93)80054-I; HIGASHI T, 1990, P NATL ACAD SCI USA, V87, P2409, DOI 10.1073/pnas.87.7.2409; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KOZAK C, 1987, J VIROL, V61, P1651, DOI 10.1128/JVI.61.5.1651-1654.1987; LAMBERT JF, 1993, MOL IMMUNOL, V30, P1399, DOI 10.1016/0161-5890(93)90101-G; MAKRIS A, 1993, J VIROL, V67, P4283, DOI 10.1128/JVI.67.7.4283-4289.1993; MIYOSHI J, 1991, MOL CELL BIOL, V11, P4088, DOI 10.1128/MCB.11.8.4088; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Nusse R, 1991, Curr Top Microbiol Immunol, V171, P43; OHARA R, 1995, J CELL SCI, V108, P97; OHARA R, 1993, JPN J CANCER RES, V84, P518, DOI 10.1111/j.1349-7006.1993.tb00170.x; PADMA R, 1991, CANCER RES, V51, P2486; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; PATRIOTIS C, 1993, P NATL ACAD SCI USA, V90, P2251, DOI 10.1073/pnas.90.6.2251; PETERS G, 1983, CELL, V33, P369, DOI 10.1016/0092-8674(83)90418-X; RINGOLD G, 1975, VIROLOGY, V65, P135, DOI 10.1016/0042-6822(75)90014-8; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SELTEN G, 1986, CELL, V46, P603, DOI 10.1016/0092-8674(86)90886-X; Varmus H E, 1983, Prog Clin Biol Res, V119, P23; WATSON R, 1982, P NATL ACAD SCI-BIOL, V79, P4078, DOI 10.1073/pnas.79.13.4078	25	59	62	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	1996	13	9					2015	2020						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934549				2022-12-25	WOS:A1996VR79500022
J	Portella, G; Salvatore, D; Botti, G; Cerrato, A; Zhang, L; Mineo, A; Chiappetta, G; Santelli, G; Pozzi, L; Vecchio, G; Fusco, A; Santoro, M				Portella, G; Salvatore, D; Botti, G; Cerrato, A; Zhang, L; Mineo, A; Chiappetta, G; Santelli, G; Pozzi, L; Vecchio, G; Fusco, A; Santoro, M			Development of mammary and cutaneous gland tumors in transgenic mice carrying the RET/PTC1 oncogene	ONCOGENE			English	Article						transgenic; oncogene; RET; mammary; thyroid	RET PROTO-ONCOGENE; TYROSINE KINASE; THYROID CARCINOMAS; METASTATIC DISEASE; NEU PROTOONCOGENE; RECEPTOR RET; HUMAN-BREAST; H4 D10S170; GENE; EXPRESSION	RET/PTC1 is a chimeric oncogene created by the fusion of the tyrosine kinase domain of RET to the 5'-terminal region of another gene named H4, So far, this oncogene has been found activated only in human papillary thyroid carcinomas, In order to investigate its transforming properties in vivo, we have produced transgenic mice carrying RET/PTC1 under the control of the H4 promoter, The transgene was expressed in several tissues, consistently with the ubiquitous expression of the wild type H4 gene, Mammary adenocarcinomas and, less frequently, hyperplasia of sebaceous glands and rare benign skin tumors, named pilomatrixomas, developed in these mice, The tumors were shown to express the transgene both at the RNA and protein level, These results demonstrate that the transforming ability of the RET/PTC1 oncogene is not restricted to the thyroid epithelium in vivo, Despite its ubiquitous expression, however, RET/PTC1 was able to induce only a limited number of tumor types; specifically mammary epithelium was affected by transgene expression, thus suggesting that RET/PTC1 is able to couple with transforming pathways specific for these glandular cells.	UNIV NAPLES,FAC MED & CHIRURG,DIPARTIMENTO BIOL & PATOL CELLULARE & MOL,CNR,I-80131 NAPLES,ITALY; FDN PASCALE,IST NAZL TUMORI NAPOLI,I-80131 NAPLES,ITALY; IST REGINA ELENA,I-00161 ROME,ITALY; UNIV REGGIO CALABRIA,FAC MED & CHIRURG CATANZARO,DIPARTIMENTO MED SPERIMENTALE & CLIN,I-88100 CATANZARO,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; IRCCS Fondazione Pascale; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria			Cerrato, Aniello/AAY-1484-2020; Salvatore, Domenico/D-4881-2013; Portella, Giuseppe/AFU-6826-2022	SALVATORE, DOMENICO/0000-0002-4556-7620; Fusco, Alfredo/0000-0003-3332-5197; PORTELLA, Giuseppe/0000-0001-8276-9769; Botti, Gerardo/0000-0002-6287-733X				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; CHALSTRE.LJ, 1966, BRIT J CANCER, V20, P670, DOI 10.1038/bjc.1966.78; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FUGAZZOLA L, 1995, CANCER RES, V55, P5617; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; GRIECO M, 1994, ONCOGENE, V9, P2531; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; HEADINGTON JT, 1976, AM J PATHOL, V85, P480; HOGAN B, 1986, MANIPULATING MOUSE E, P79; ITO T, 1993, CANCER RES, V53, P2940; ITO T, 1994, LANCET, V344, P250; IWAMOTO T, 1991, EUR J IMMUNOL, V21, P1809, DOI 10.1002/eji.1830210805; IWAMOTO T, 1991, EMBO J, V10, P3167, DOI 10.1002/j.1460-2075.1991.tb04878.x; IWAMOTO T, 1990, ONCOGENE, V5, P533; Jhiang SM, 1996, ENDOCRINOLOGY, V137, P375, DOI 10.1210/en.137.1.375; Klugbauer S, 1995, ONCOGENE, V11, P2459; LANZI C, 1992, ONCOGENE, V7, P2189; Mak YF, 1996, CURR OPIN GENET DEV, V6, P82, DOI 10.1016/S0959-437X(96)90015-5; MALLORY SB, 1995, DERMATOL CLIN, V13, P27, DOI 10.1016/S0733-8635(18)30103-7; MICHAELS RD, 1993, J ENDOCRINOL INVEST, V11, P909; MOROY T, 1990, EMBO J, V9, P3659, DOI 10.1002/j.1460-2075.1990.tb07577.x; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; RASSOULZADEGAN M, 1990, ONCOGENE, V5, P1507; ROMANO A, 1995, ONCOGENE, V9, P2923; RON E, 1984, BRIT J CANCER, V49, P87, DOI 10.1038/bjc.1984.13; SANTORO M, 1993, BRIT J CANCER, V68, P460, DOI 10.1038/bjc.1993.370; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; Santoro M, 1996, ONCOGENE, V12, P1821; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SUDA Y, 1987, EMBO J, V6, P4055, DOI 10.1002/j.1460-2075.1987.tb02751.x; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TONG Q, 1995, ONCOGENE, V10, P1781	37	26	26	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 7	1996	13	9					2021	2026						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934550				2022-12-25	WOS:A1996VR79500023
J	Willumsen, BM; Cox, AD; Solski, PA; Der, CJ; Buss, JE				Willumsen, BM; Cox, AD; Solski, PA; Der, CJ; Buss, JE			Novel determinants of H-Ras plasma membrane localization and transformation	ONCOGENE			English	Article						palmitoylation; lipid modification; Ras transformation	POLYBASIC DOMAIN; CAAX MOTIF; PROTEINS; P21RAS; PALMITOYLATION; PALMITATE; ONCOGENE; PRODUCT; CYCLASE; SIGNAL	Although it is well-established that modification of Ras by farnesol is a critical step for its membrane association and transforming activity, the contribution of other C-terminal sequences and palmitate modification to Ras localization and function remains unclear, We have characterized H-Ras mutant proteins with alterations in the palmitoylated cysteines or in sequences flanking these residues, We found that non-palmitoylated proteins were impaired not only in membrane association but also in transforming activity, Mutations which drastically altered residues adjacent to the palmitoylated cysteine did not abolish palmitoylation, However, despite continued lipid modification the mutant proteins failed to bind to plasma membranes and instead accumulated on internal membranes and, importantly, were not transforming, Addition of an N-terminal myristoylation signal to these defective mutants, or to proteins entirely lacking the C-terminal 25 residues restored both plasma membrane association and transforming activity, Thus, H-Ras does not absolutely require prenylation or palmitoylation nor indeed its hypervariable domain in order to interact with effecters that ultimately cause transformation, However, in this native state, the C-terminus appears to provide a combination of lipids and a previously unrecognized signal for specific plasma membrane targeting that are essential for the correct localization and biological function of H-Ras.	UNIV N CAROLINA,DEPT RADIAT ONCOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PHARMACOL,CHAPEL HILL,NC 27599; IOWA STATE UNIV SCI & TECHNOL,DEPT BIOCHEM & BIOPHYS,AMES,IA 50011	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Iowa State University	Willumsen, BM (corresponding author), UNIV COPENHAGEN,DEPT MOL CELL BIOL,OSTER FARIMAGSGADE 2A,DK-1353 COPENHAGEN,DENMARK.		Willumsen, Berthe M/H-1903-2012	Willumsen, Berthe M/0000-0002-2277-6999; Cox, Adrienne D./0000-0002-4901-2454; Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [R01CA052072, R29CA061951, R01CA042978] Funding Source: NIH RePORTER; NCI NIH HHS [CA52072, CA61951, CA42978] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; CADWALLADER KA, 1994, MOL CELL BIOL, V14, P4722, DOI 10.1128/MCB.14.7.4722; CAMP LA, 1993, J BIOL CHEM, V268, P22566; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; Dudler T, 1996, J BIOL CHEM, V271, P11541, DOI 10.1074/jbc.271.19.11541; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; GUTIERREZ L, 1991, BIOCHIM BIOPHYS ACTA, V1078, P147, DOI 10.1016/0167-4838(91)99003-B; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HORIUCHI H, 1992, MOL CELL BIOL, V12, P4515, DOI 10.1128/MCB.12.10.4515; JHAPPAN C, 1986, J VIROL, V60, P750, DOI 10.1128/JVI.60.2.750-753.1986; Kato K, 1992, Semin Cancer Biol, V3, P179; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; LACAL PM, 1988, ONCOGENE, V2, P533; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; LOWY DR, 1988, CELLULAR MOL BIOL TU, P203; LU JY, 1995, J BIOL CHEM, V270, P7251, DOI 10.1074/jbc.270.13.7251; NEWMAN CMH, 1992, J BIOL CHEM, V267, P12329; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WILLUMSEN BM, 1991, MOL CELL BIOL, V11, P6026, DOI 10.1128/MCB.11.12.6026; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; WILLUMSEN BM, 1985, EMBO J, V4, P2893, DOI 10.1002/j.1460-2075.1985.tb04019.x; WILLUMSEN BM, 1995, METHODS ENZYMOL LIPI, V220, P269; WILSON PT, 1995, J BIOL CHEM, V270, P9967	27	84	85	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 7	1996	13	9					1901	1909						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934536				2022-12-25	WOS:A1996VR79500009
J	Probst, JC; Zetzsche, T; Weber, M; Theilemann, P; Skutella, T; Landgraf, R; Jirikowski, GF				Probst, JC; Zetzsche, T; Weber, M; Theilemann, P; Skutella, T; Landgraf, R; Jirikowski, GF			Human intestinal trefoil factor is expressed in human hypothalamus and pituitary: Evidence for a novel neuropeptide	FASEB JOURNAL			English	Article						cloning; immunohistochemistry; peptides; epithelial cell migration	PANCREATIC SPASMOLYTIC POLYPEPTIDE; PS2 GENE; MOUSE ASTROCYTES; RAT; PEPTIDE; PROTEIN; IDENTIFICATION; SECRETION; MIGRATION; STOMACH	Human intestinal trefoil factor, hITF, a secretory polypeptide found mainly in the human gastrointestinal tract, is a member of the newly characterized trefoil factor or P-domain peptide family representing putative growth factors. Here we describe the identification of this gut peptide in the human brain and pituitary. With reverse transcriptase polymerase chain reaction, we were able to isolate and clone the transcript from human hypothalamus. An antibody generated against a synthetic peptide derived from the carboxyl terminus of hITF was used for immunohistochemical studies of appropriate tissue sections. Neurons expressing hITF were identified in two magnocellular hypothalamic nuclei, the paraventricular and periventricular nuclei. hITF polypeptide was also observed in Herring bodies of the neurohypophysis and in secretory cells of the adenohypophysis. Double immunostaining with antigrowth hormone antibody showed partial coexistence in a selected subpopulation of adenohypophysial cells. Localization of hITF in the hypothalamo-neurohypophysial system may suggest a modulatory action on the classic al magnocellular nonapeptides vasopressin and oxytocin, and further indicates an adenohypophysial importance of this peptide. It is likely that hITF represents a novel neuropeptide of yet unknown function.	MAX PLANCK INST PSYCHIAT, INST CLIN, DEPT NEUROENDOCRINOL, D-80804 MUNICH, GERMANY; UNIV JENA, INST ANAT 2, D-6900 JENA, GERMANY	Max Planck Society; Friedrich Schiller University of Jena								ALISON MR, 1994, CELL BIOL INT, V18, P1, DOI 10.1006/cbir.1994.1001; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; CHINERY R, 1995, PEPTIDES, V16, P749, DOI 10.1016/0196-9781(95)00045-L; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIGNASS A, 1994, J CLIN INVEST, V94, P376, DOI 10.1172/JCI117332; ENGLERBLUM G, 1993, ANAL BIOCHEM, V210, P235, DOI 10.1006/abio.1993.1189; FALLON JH, 1984, SCIENCE, V224, P1107, DOI 10.1126/science.6144184; FRANDSEN EK, 1988, REGUL PEPTIDES, V20, P45, DOI 10.1016/0167-0115(88)90056-0; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GAJHEDE M, 1993, DIGESTION, V55, P353; HAUSER F, 1993, P NATL ACAD SCI USA, V90, P6961, DOI 10.1073/pnas.90.15.6961; HENRY JA, 1991, BRIT J CANCER, V64, P677, DOI 10.1038/bjc.1991.380; HIROTA M, 1994, BIOCHEM MOL BIOL INT, V33, P515; HIROTA M, 1994, NEUROSCI LETT, V171, P49, DOI 10.1016/0304-3940(94)90601-7; HIROTA M, 1995, BIOCHEM MOL BIOL INT, V35, P1079; HOOSEIN NM, 1989, FEBS LETT, V247, P303, DOI 10.1016/0014-5793(89)81357-2; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; JIRIKOWSKI GF, 1989, CELL TISSUE RES, V256, P411; JORGENSEN KD, 1982, REGUL PEPTIDES, V3, P231, DOI 10.1016/0167-0115(82)90128-8; LUQMANI Y, 1989, INT J CANCER, V44, P806, DOI 10.1002/ijc.2910440510; MASHIMO H, 1995, BIOCHEM BIOPH RES CO, V210, P31, DOI 10.1006/bbrc.1995.1623; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MORRISON RS, 1989, ENZYCLOPEDIA NEURO S, V1; PLAYFORD RJ, 1995, GASTROENTEROLOGY, V108, P108, DOI 10.1016/0016-5085(95)90014-4; PODOLSKY DK, 1993, J BIOL CHEM, V268, P6694; POULSOM R, 1993, J CLIN GASTROENTEROL, V17, pS78, DOI 10.1097/00004836-199312001-00016; PROBST JC, 1995, MOL BRAIN RES, V33, P269, DOI 10.1016/0169-328X(95)00137-H; SANDS BE, 1995, J BIOL CHEM, V270, P9353, DOI 10.1074/jbc.270.16.9353; SKUTELLA T, 1994, MOL BRAIN RES, V23, P179, DOI 10.1016/0169-328X(94)90224-0; SUEMORI S, 1991, P NATL ACAD SCI USA, V88, P11017, DOI 10.1073/pnas.88.24.11017; THIM L, 1989, FEBS LETT, V250, P85, DOI 10.1016/0014-5793(89)80690-8; TOMASETTO C, 1990, EMBO J, V9, P407, DOI 10.1002/j.1460-2075.1990.tb08125.x; Vigh-Teichmann I., 1974, Advances Anat Embryol Cell Biol, V50, P1; von Euler US, 1931, J PHYSIOL-LONDON, V72, P74, DOI 10.1113/jphysiol.1931.sp002763; WRIGHT NA, 1993, GUT, V34, P577, DOI 10.1136/gut.34.5.577; WRIGHT NA, 1992, SCAND J GASTROENTERO, V27, P76, DOI 10.3109/00365529209096010	36	40	48	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1996	10	13					1518	1523		10.1096/fasebj.10.13.8940297	http://dx.doi.org/10.1096/fasebj.10.13.8940297			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VU982	8940297				2022-12-25	WOS:A1996VU98200008
J	Han, M; Lin, SW; Smith, SO; Sakmar, TP				Han, M; Lin, SW; Smith, SO; Sakmar, TP			The effects of amino acid replacements of glycine 121 on transmembrane helix 3 of rhodopsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIFF-BASE COUNTERION; DOMINANT RETINITIS-PIGMENTOSA; TRANSFORM INFRARED-SPECTROSCOPY; BINDING-SITE CREVICE; BOVINE RHODOPSIN; METARHODOPSIN-II; SPECIES SELECTIVITY; TRANSDUCIN INTERACTION; MEMBRANE ENVIRONMENTS; PROJECTION STRUCTURE	Rhodopsin is a member of a family of G protein-coupled receptors with seven transmembrane (TM) helices. In rhodopsin, Gly(121) is a highly conserved amino acid residue near the middle of TM helix 3. TM helix 3 is known to be involved in chromophore-protein interactions and contains the chromophore Schiff base counterion at position 113, We prepared a set of seven single amino acid replacement mutants of rhodopsin at position 121 (G121A, Ser, Thr, Val, Ile, Leu, and Trp) and control mutants with replacements of Gly(114) or Ala(117). The mutant opsins were expressed in COS cells and reconstituted with either 11-cis-retinal, the groundstate chromophore of rhodopsin, or all-trans-retinal, the isomer formed upon receptor photoactivation. The replacement of Gly(121) resulted in a relative reversal in the selectivity of the opsin apoprotein for reconstitution with 11-cis-retinal over all-trans-retinal in COS cell membranes, The mutant pigments also were found to be thermally unstable to varying degrees and reactive to hydroxylamine in the dark, In addition, the size of the residue substituted at position 121 correlated directly to the degree of blue-shift in the lambda(max) value of the pigment, These results suggest that Gly(121) is an important and specific component of the 11-cis-retinal binding pocket in rhodopsin.	ROCKEFELLER UNIV,HOWARD HUGHES MED INST,BIOCHEM & MOL BIOL LAB,NEW YORK,NY 10021; YALE UNIV,DEPT MOL BIOPHYS & BIOCHEM,NEW HAVEN,CT 06520	Howard Hughes Medical Institute; Rockefeller University; Yale University			Sakmar, Thomas P/D-1833-2015	Sakmar, Thomas P/0000-0002-2836-8953	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041412] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 41412] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALKORTA I, 1994, PROTEIN ENG, V7, P1231, DOI 10.1093/protein/7.10.1231; Almaula N, 1996, J BIOL CHEM, V271, P14672, DOI 10.1074/jbc.271.25.14672; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BIRGE RR, 1985, P NATL ACAD SCI USA, V82, P4117, DOI 10.1073/pnas.82.12.4117; BIRGE RR, 1990, BIOCHIM BIOPHYS ACTA, V1016, P293, DOI 10.1016/0005-2728(90)90163-X; CARRUTHERS CJL, 1994, J BIOL CHEM, V269, P29321; CHAN T, 1992, J BIOL CHEM, V267, P9478; CHOTHIA C, 1975, NATURE, V254, P304, DOI 10.1038/254304a0; COSSON P, 1992, SCIENCE, V258, P659, DOI 10.1126/science.1329208; FAHMY K, 1995, BIOPHYS CHEM, V56, P171, DOI 10.1016/0301-4622(95)00030-2; FAHMY K, 1993, P NATL ACAD SCI USA, V90, P10206, DOI 10.1073/pnas.90.21.10206; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P7229, DOI 10.1021/bi00079a020; FAHMY K, 1994, BIOCHEMISTRY-US, V33, P13700, DOI 10.1021/bi00250a021; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P8812, DOI 10.1021/bi00027a033; FERRETTI L, 1986, P NATL ACAD SCI USA, V83, P599, DOI 10.1073/pnas.83.3.599; FONG TM, 1992, J BIOL CHEM, V267, P25668; FRANKE RR, 1988, J BIOL CHEM, V263, P2119; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; GARCIA PD, 1995, EMBO J, V14, P4460, DOI 10.1002/j.1460-2075.1995.tb00125.x; GAT Y, 1993, J AM CHEM SOC, V115, P3772, DOI 10.1021/ja00062a052; HAN M, 1993, BIOPHYS J, V65, P899, DOI 10.1016/S0006-3495(93)81117-2; HAN M, 1995, BIOCHEMISTRY-US, V34, P1425, DOI 10.1021/bi00004a037; Han M, 1996, J BIOL CHEM, V271, P32337, DOI 10.1074/jbc.271.50.32337; HAN M, 1995, BIOPHYS CHEM, V56, P23, DOI 10.1016/0301-4622(95)00011-L; JAGER F, 1994, BIOCHEMISTRY-US, V33, P10878; Jager S, 1996, BIOCHEMISTRY-US, V35, P2901, DOI 10.1021/bi9524068; JAVITCH JA, 1995, NEURON, V14, P825, DOI 10.1016/0896-6273(95)90226-0; JAVITCH JA, 1994, P NATL ACAD SCI USA, V91, P10355, DOI 10.1073/pnas.91.22.10355; JENSEN CJ, 1994, MOL PHARMACOL, V45, P294; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KAUSHAL S, 1994, BIOCHEMISTRY-US, V33, P10878; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; LI SC, 1992, INT J PEPT PROT RES, V40, P243; LI SC, 1992, FEBS LETT, V311, P217, DOI 10.1016/0014-5793(92)81106-V; Lin SW, 1996, BIOCHEMISTRY-US, V35, P11149, DOI 10.1021/bi960858u; LIN SW, 1994, BIOCHEMISTRY-US, V33, P2151, DOI 10.1021/bi00174a023; LO KM, 1984, P NATL ACAD SCI-BIOL, V81, P2285, DOI 10.1073/pnas.81.8.2285; LONGSTAFF C, 1986, P NATL ACAD SCI USA, V83, P4209, DOI 10.1073/pnas.83.12.4209; LUGTENBURG J, 1988, TRENDS BIOCHEM SCI, V13, P388, DOI 10.1016/0968-0004(88)90181-8; MILLAN JM, 1995, MOL CELL PROBE, V9, P67, DOI 10.1016/S0890-8508(95)91052-2; MIN KC, 1993, J BIOL CHEM, V268, P9400; NAKANISHI K, 1979, PHOTOCHEM PHOTOBIOL, V29, P657, DOI 10.1111/j.1751-1097.1979.tb07745.x; NATHANS J, 1990, BIOCHEMISTRY-US, V29, P9746, DOI 10.1021/bi00493a034; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; Rao VR, 1996, ANNU REV BIOPH BIOM, V25, P287; RIDGE KD, 1995, BIOCHEMISTRY-US, V34, P8804, DOI 10.1021/bi00027a032; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; SACHAIS BS, 1993, J BIOL CHEM, V268, P2319; SAKMAR TP, 1991, P NATL ACAD SCI USA, V88, P3079, DOI 10.1073/pnas.88.8.3079; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SCHERTLER GFX, 1995, P NATL ACAD SCI USA, V92, P11578, DOI 10.1073/pnas.92.25.11578; SMITH SO, 1992, PHOTOCHEM PHOTOBIOL, V56, P1035, DOI 10.1111/j.1751-1097.1992.tb09726.x; SMITH SO, 1995, P NATL ACAD SCI USA, V92, P488, DOI 10.1073/pnas.92.2.488; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840; ZHANG HZ, 1994, J AM CHEM SOC, V116, P10165, DOI 10.1021/ja00101a040; ZHUKOVSKY EA, 1989, SCIENCE, V246, P928, DOI 10.1126/science.2573154; ZHUKOVSKY EA, 1992, BIOCHEMISTRY-US, V31, P10400, DOI 10.1021/bi00157a030; ZVYAGA TA, 1994, BIOCHEMISTRY-US, V33, P9753, DOI 10.1021/bi00198a046; ZVYAGA TA, 1994, J BIOL CHEM, V269, P13056; ZVYAGA TA, 1993, J BIOL CHEM, V268, P4661; Zvyaga TA, 1996, BIOCHEMISTRY-US, V35, P7536, DOI 10.1021/bi960391n	65	70	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32330	32336		10.1074/jbc.271.50.32330	http://dx.doi.org/10.1074/jbc.271.50.32330			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943295	hybrid			2022-12-25	WOS:A1996VY34000086
J	Levit, M; Liu, Y; Surette, M; Stock, J				Levit, M; Liu, Y; Surette, M; Stock, J			Active site interference and asymmetric activation in the chemotaxis protein histidine kinase CheA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL SIGNALING PROTEINS; ESCHERICHIA-COLI; AUTOPHOSPHORYLATION; TRANSDUCTION; BINDING; PHOSPHOTRANSFER; EXPRESSION; RESONANCE; REGULATOR; FRAGMENTS	The histidine protein kinase CheA is a multidomain protein that mediates stimulus-response coupling in bacterial chemotaxis, We have previously shown that the purified protein exhibits an equilibrium between inactive monomer and active dimer (Surette, M., Levit, M., Liu, Y., Lukat, G., Ninfa, E., Ninfa, A., and Stock, J. (1996) J, Biol, Chem. 271, 939-945). We report here a study of the kinetics of phosphorylation of the isolated phosphoacceptor domain of CheA catalyzed by the isolated catalytic domain of the protein, The reaction fits Michaelis-Menten kinetics (K-m = 0.26 mM for ATP and 0.10 mM for phosphoacceptor domain; k(obs) = 17 min(-1)), The catalytic domain exhibits the same equilibrium between inactive monomers and active dimers as the full-length CheA protein, Thus, CheA dimerization is an intrinsic property of this domain, independent of any other portion of the molecule and is required for its catalytic activity, In equimolar mixtures of full-length CheA and catalytic domain, homodimers and heterodimers are formed in equal concentration, indicating that all of the determinants for the dimerization are localized entirely on the catalytic domain, An analysis of the kinetics of phosphorylation catalyzed by CheA catalytic domain heterodimers indicates half of the sites reactivity, The rate of CheA phosphorylation within this heterodimer is over 5-fold greater than that observed in CheA homodimers, The dramatic increase in activity within this asymmetric dimer raises the possibility that CheA activation by receptors involves a mechanism that directs catalysis to one active site while preventing interference from the other.	PRINCETON UNIV,DEPT MOL BIOL,PRINCETON,NJ 08544	Princeton University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020980] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20980] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMES P, 1994, J BACTERIOL, V176, P6340, DOI 10.1128/jb.176.20.6340-6348.1994; BORKOVICH KA, 1989, P NATL ACAD SCI USA, V86, P1208, DOI 10.1073/pnas.86.4.1208; BOURRET RB, 1993, J BACTERIOL, V175, P2097, DOI 10.1128/JB.175.7.2097-2101.1993; DIXON M, 1979, ENZYMES, P61; GEGNER JA, 1991, P NATL ACAD SCI USA, V88, P750, DOI 10.1073/pnas.88.3.750; KOFOID EC, 1988, P NATL ACAD SCI USA, V85, P4981, DOI 10.1073/pnas.85.14.4981; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI JY, 1995, BIOCHEMISTRY-US, V34, P14626, DOI 10.1021/bi00045a003; MATSUMURA P, 1990, BIOL CHEMOTACTIC RES, P135; MCEVOY MM, 1995, BIOCHEMISTRY-US, V34, P13871, DOI 10.1021/bi00042a019; McEvoy MM, 1996, BIOCHEMISTRY-US, V35, P5633, DOI 10.1021/bi952707h; MORRISON TB, 1994, P NATL ACAD SCI USA, V91, P5485, DOI 10.1073/pnas.91.12.5485; NINFA EG, 1993, J BACTERIOL, V175, P7024, DOI 10.1128/jb.175.21.7024-7032.1993; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; STOCK A, 1988, P NATL ACAD SCI USA, V85, P1403, DOI 10.1073/pnas.85.5.1403; Stock J.B., 1995, 2 COMPONENT SIGNAL T, P25; Stock JB, 1996, ESCHERICHIA COLI SAL, P1103; Surette MG, 1996, J BIOL CHEM, V271, P939, DOI 10.1074/jbc.271.2.939; Surette MG, 1996, J BIOL CHEM, V271, P17966, DOI 10.1074/jbc.271.30.17966; SWANSON RV, 1993, MOL MICROBIOL, V8, P435, DOI 10.1111/j.1365-2958.1993.tb01588.x; SWANSON RV, 1993, BIOCHEMISTRY-US, V32, P7623, DOI 10.1021/bi00081a004; TAWA P, 1994, BIOCHEMISTRY-US, V33, P7917, DOI 10.1021/bi00191a019; TAWA P, 1994, J BACTERIOL, V176, P4210, DOI 10.1128/jb.176.14.4210-4218.1994; WOLFE AJ, 1993, P NATL ACAD SCI USA, V90, P1513; YANG Y, 1991, P NATL ACAD SCI USA, V88, P11057, DOI 10.1073/pnas.88.24.11057; Zhou HJ, 1996, BIOCHEMISTRY-US, V35, P433, DOI 10.1021/bi951960e; ZHOU HJ, 1995, BIOCHEMISTRY-US, V34, P13858, DOI 10.1021/bi00042a018	28	52	53	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32057	32063		10.1074/jbc.271.50.32057	http://dx.doi.org/10.1074/jbc.271.50.32057			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943256	hybrid			2022-12-25	WOS:A1996VY34000047
J	Li, SC; Lai, KMV; Gish, GD; Parris, WE; vanderGeer, P; FormanKay, J; Pawson, T				Li, SC; Lai, KMV; Gish, GD; Parris, WE; vanderGeer, P; FormanKay, J; Pawson, T			Characterization of the phosphotyrosine-binding domain of the drosophila she protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTORS; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; NUCLEOTIDE EXCHANGE; ADAPTER PROTEIN; GRB2; RAS; INSULIN; TRANSFORMATION; ASSOCIATION	The phosphotyrosine-binding (PTB) domain of Drosophila Shc (dShc) binds in vitro to phosphopeptides containing the sequence motif NPXpY, and physically associates with the activated Drosophila epidermal growth factor receptor homologue (DER) in vivo. The structural elements, specificity and binding kinetics of the dShc PTB domain have now been characterized. The dShc PTB domain appeared similar to the insulin-like receptor substrate-1 PTB domain in secondary structure as suggested by Fourier transform infrared spectroscopy. Surface plasmon resonance measurements indicated that the dShc PTB domain bound with high affinity to phosphopeptides (Der) derived from the Tyr(1228) site of the DER receptor. The kinetics of the dShc PTB domain-Der phosphopeptide interaction differed from those of a typical SH2 domain-ligand interaction, in that the PTB domain displayed slower on/off rates. Competition binding assays using truncated versions of the Der peptides revealed that high affinity binding to the dShc PTB domain requires, in addition to the NPXpY motif, the presence of hydrophobic residues at both positions -5 and -7 relative to phosphotyrosine. The dShc PTB domain showed a similar binding specificity to the human Shc (hShc) PTB domain, but subtle differences were noted; such that the hShc PTB domain bound preferentially to a phosphopeptide from the mammalian nerve growth factor receptor, whereas the dShc PTB domain bound preferentially to phosphopeptides from the Drosophila DER receptor. The invertebrate dShc PTB domain therefore possesses a binding specificity for tyrosine-phosphorylated peptides that is optimally suited for recognition of the activated DER receptor.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, PROGRAM MOL BIOL & CANC, TORONTO, ON M5G 1X5, CANADA; UNIV TORONTO, DEPT MOL & MED GENET, TORONTO, ON M5S 1A8, CANADA; HOSP SICK CHILDREN, RES INST, DIV BIOCHEM RES, TORONTO, ON M5G 1X8, CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Gish, Gerald D/C-7228-2017; Pawson, Tony J/E-4578-2013	Forman-Kay, Julie/0000-0001-8265-972X				BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BLESEN TV, 1995, NATURE, V376, P781; BOURNE HR, 1995, NATURE, V376, P727, DOI 10.1038/376727a0; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURNS LA, 1993, J BIOL CHEM, V268, P17659; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; HE WM, 1995, J BIOL CHEM, V270, P23258, DOI 10.1074/jbc.270.40.23258; Isakoff SJ, 1996, J BIOL CHEM, V271, P3959; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAI KMV, 1995, MOL CELL BIOL, V15, P4810; Laminet AA, 1996, J BIOL CHEM, V271, P264, DOI 10.1074/jbc.271.1.264; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MARENGERE LEM, 1994, J CELL SCI, P97; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; OBryan JP, 1996, P NATL ACAD SCI USA, V93, P2729, DOI 10.1073/pnas.93.7.2729; Okabayashi Y, 1996, J BIOL CHEM, V271, P5265; OKADA S, 1995, J BIOL CHEM, V270, P20737, DOI 10.1074/jbc.270.35.20737; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRIGENT SA, 1995, J BIOL CHEM, V270, P22097, DOI 10.1074/jbc.270.38.22097; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SAVITZKY A, 1964, ANAL CHEM, V36, P1627, DOI 10.1021/ac60214a047; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUREWICZ WK, 1988, BIOCHIM BIOPHYS ACTA, V952, P115, DOI 10.1016/0167-4838(88)90107-0; TARTAREDECKERT S, 1995, J BIOL CHEM, V270, P23456, DOI 10.1074/jbc.270.40.23456; TOUHARA K, 1995, P NATL ACAD SCI USA, V92, P9284, DOI 10.1073/pnas.92.20.9284; TRUB T, 1995, J BIOL CHEM, V270, P18205; vanderGeer P, 1996, P NATL ACAD SCI USA, V93, P963, DOI 10.1073/pnas.93.3.963; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; Zhou MM, 1995, J BIOL CHEM, V270, P31119, DOI 10.1074/jbc.270.52.31119; Zhou MM, 1996, NAT STRUCT BIOL, V3, P388, DOI 10.1038/nsb0496-388; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	48	16	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					31855	31862		10.1074/jbc.271.50.31855	http://dx.doi.org/10.1074/jbc.271.50.31855			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943228	hybrid			2022-12-25	WOS:A1996VY34000019
J	Meng, F; Taylor, LP; Hoversten, MT; Ueda, Y; Ardati, A; Reinscheid, RK; Monsma, FJ; Watson, SJ; Civelli, O; Akil, H				Meng, F; Taylor, LP; Hoversten, MT; Ueda, Y; Ardati, A; Reinscheid, RK; Monsma, FJ; Watson, SJ; Civelli, O; Akil, H			Moving from the Orphanin FQ receptor to an opioid receptor using four point mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPIATE-RECEPTOR; EXTRACELLULAR LOOP; AGONIST; SELECTIVITY; AFFINITY; LIGAND	It is unclear how receptor/ligand families that are evolutionarily closely related achieve functional separation. To address this question, we focus here on the newly discovered Orphanin FQ, a peptide homologous to the opioid peptide Dynorphin, and its receptor, the Orphanin FQ receptor, which is highly homologous to the opioid receptors. In spite of this high degree of homology in terms of both ligands and receptors, there is little direct cross-talk between the Orphanin FQ system and the endogenous opioid system. Thus, the opioid peptides show either relatively low affinity or no affinity toward the Orphanin FQ receptor; conversely, Orphanin FQ has no affinity toward any of the opioid receptors. We sought to investigate the molecular basis of such discrimination by attempting to reverse it and endowing the Orphanin FQ receptor with the ability to bind opioids. We report that by mutating as few as four amino acids, we can produce a receptor that recognizes pro Dynorphin products with very high affinity and yet still binds Orphanin F-Q as well as the wild-type receptor. This suggests that the Orphanin FQ receptor has developed features that specifically exclude the opioids and that these features are distinct from those required for the high affinity binding of its own endogenous ligand.	HOFFMANN LA ROCHE AG,CNS RES,DIV PHARMA,CH-4070 BASEL,SWITZERLAND	Roche Holding	Meng, F (corresponding author), UNIV MICHIGAN,MENTAL HLTH RES INST,205 WASHTENAW PL,ANN ARBOR,MI 48109, USA.		Civelli, Olivier/A-8392-2012		NIADDK NIH HHS [P30-AM34933] Funding Source: Medline; NIDA NIH HHS [R01 DA02265] Funding Source: Medline; NIDDK NIH HHS [5 P30 DK34933] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [P30AM034933] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034933] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA002265] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		CHAVKIN C, 1981, P NATL ACAD SCI-BIOL, V78, P6543, DOI 10.1073/pnas.78.10.6543; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Devine DP, 1996, BRAIN RES, V727, P225; DEVINE DP, 1996, IN PRESS NEUROCHEM R; GOLDSTEIN A, 1989, MOL PHARMACOL, V36, P265; HJORTH SA, 1995, MOL PHARMACOL, V47, P1089; HUGGENVIK JI, 1991, MOL ENDOCRINOL, V5, P921, DOI 10.1210/mend-5-7-921; MENG F, 1995, J BIOL CHEM, V270, P12730, DOI 10.1074/jbc.270.21.12730; Meng F, 1996, EUR J PHARMACOL, V311, P285, DOI 10.1016/0014-2999(96)00431-1; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; ONOGI T, 1995, FEBS LETT, V357, P93, DOI 10.1016/0014-5793(94)01341-W; OSTROWSKI J, 1992, ANNU REV PHARMACOL, V32, P167, DOI 10.1146/annurev.pharmtox.32.1.167; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; Reinscheid RK, 1996, J BIOL CHEM, V271, P14163, DOI 10.1074/jbc.271.24.14163; REISINE T, 1993, TRENDS NEUROSCI, V16, P506, DOI 10.1016/0166-2236(93)90194-Q; Schwyzer R, 1977, Ann N Y Acad Sci, V297, P3, DOI 10.1111/j.1749-6632.1977.tb41843.x; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; SURRATT CK, 1994, J BIOL CHEM, V269, P20548; UHL GR, 1994, TRENDS NEUROSCI, V17, P89, DOI 10.1016/0166-2236(94)90110-4; WANG JB, 1994, J BIOL CHEM, V269, P25966; Wang WW, 1995, P NATL ACAD SCI USA, V92, P12436, DOI 10.1073/pnas.92.26.12436; XUE JC, 1995, J BIOL CHEM, V270, P12977	24	79	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32016	32020		10.1074/jbc.271.50.32016	http://dx.doi.org/10.1074/jbc.271.50.32016			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943250	hybrid			2022-12-25	WOS:A1996VY34000041
J	Heckert, LL; Schultz, K; Nilson, JH				Heckert, LL; Schultz, K; Nilson, JH			The cAMP response elements of the alpha subunit gene bind similar proteins in trophoblasts and gonadotropes but have distinct functional sequence requirements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PITUITARY-SPECIFIC EXPRESSION; CELL-SPECIFIC EXPRESSION; CYCLIC-AMP; TRANSCRIPTION FACTORS; REGULATORY ELEMENTS; DIFFERENT COMBINATIONS; GLYCOPROTEIN HORMONES; NUCLEAR-PROTEIN; PLACENTA; ENHANCER	The alpha subunit gene encodes a common subunit shared by all glycoprotein hormones, This single copy gene is expressed in pituitary gonadotropes and thyrotropes of all mammals and in placental trophoblasts of primates and horses. Tandem cAMP response elements (CREs) in the promoter of the human gene are key mediators of this pattern of cell-specific expression. Replacing the palindromic CREs with non-primate variant CREs significantly attenuated activity in trophoblasts but not in gonadotropes, Furthermore, proteins binding the palin-dromic CRE cross-reacted with antibodies for CREB, CREM, ATF1, ATF2, and c-Jun, while proteins binding the variant CRE cross-reacted only with ATF2 and c-Jun antibodies, The data suggest that ATF2 and c-Jun can activate transcription through the CREs in gonadotropes but not in trophoblasts. Additional analyses indicated that while promoters with either palindromic or variant CREs have similar overall activity in gonadotropes, the variant CREs make a much smaller contribution to promoter activity than their palindromic counterparts, The weaker contribution of the variant CREs is compensated by the activity of two upstream elements present in the promoter, This compensation probably occurs through an indirect mechanism, as the binding affinity of proteins to the CRE is not influenced by the presence of these upstream elements.	CASE WESTERN RESERVE UNIV,DEPT PHARMACOL,SCH MED,CLEVELAND,OH 44106	Case Western Reserve University					NIDDK NIH HHS [DK 28559, DK08975-02] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028559, F32DK008975] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABMAYR SM, 1994, CURRENT PROTOCOLS MO; ANDERSEN B, 1990, MOL ENDOCRINOL, V4, P573, DOI 10.1210/mend-4-4-573; ANDERSEN B, 1990, J BIOL CHEM, V265, P21874; BOKAR JA, 1988, J BIOL CHEM, V263, P19740; BOKAR JA, 1989, MOL CELL BIOL, V9, P5113, DOI 10.1128/MCB.9.11.5113; CHIN WW, 1984, PITUITARY GLAND, P103; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DRUST DS, 1991, MOL ENDOCRINOL, V5, P1541, DOI 10.1210/mend-5-10-1541; FENSTERMAKER RA, 1990, MOL ENDOCRINOL, V4, P1480, DOI 10.1210/mend-4-10-1480; FIDDES J C, 1981, Journal of Molecular and Applied Genetics, V1, P3; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HECKERT LL, 1995, J BIOL CHEM, V270, P26497, DOI 10.1074/jbc.270.44.26497; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HORN F, 1992, MOL CELL BIOL, V12, P2143, DOI 10.1128/MCB.12.5.2143; JAMESON JL, 1989, J BIOL CHEM, V264, P16190; JAMESON JL, 1988, J BIOL CHEM, V263, P9879; JAMESON JL, 1987, MOL CELL BIOL, V7, P3032, DOI 10.1128/MCB.7.9.3032; JAMESON JL, 1989, MOL ENDOCRINOL, V3, P763, DOI 10.1210/mend-3-5-763; KENNEDY GC, 1990, J BIOL CHEM, V265, P6279; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MOORE WT, 1980, CHORIONIC GONADOTROP, P89; NILSON JH, 1991, BIOL REPROD, V44, P231, DOI 10.1095/biolreprod44.2.231; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; SCHODERBEK WE, 1992, MOL ENDOCRINOL, V6, P893, DOI 10.1210/me.6.6.893; SILVER BJ, 1987, P NATL ACAD SCI USA, V84, P2198, DOI 10.1073/pnas.84.8.2198; STEGER DJ, 1991, MOL ENDOCRINOL, V5, P243, DOI 10.1210/mend-5-2-243; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; WINDLE JJ, 1990, MOL ENDOCRINOL, V4, P597, DOI 10.1210/mend-4-4-597; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	31	52	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31650	31656		10.1074/jbc.271.49.31650	http://dx.doi.org/10.1074/jbc.271.49.31650			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940185	hybrid			2022-12-25	WOS:A1996VW68600096
J	Jin, RZ; Zhou, XM; Novick, RP				Jin, RZ; Zhou, XM; Novick, RP			The inactive pT181 initiator heterodimer, RepC/C*, binds but fails to induce melting of the plasmid replication origin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAPHYLOCOCCUS-AUREUS; PROTEIN; SPECIFICITY; DNA	Staphylococcus aureus plasmid pT181 replicates via a rolling circle mechanism, The synthesis of the pT181 initiator protein (RepC) is regulated by antisense RNAs, and RepC is inactivated after usage by the attachment of an oligonucleotide to one of its subunits. The inactivated heterodimeric RepC/C* has been shown be unable to initiate replication in vitro (Rasooly, A and Novick, R. P. (1993) Science 262, 1048-1050). The inactive RepC/C* has been found to be very stable and constitute about 90-95% of the total RepC antigen inside the cell. We studied the specific interaction of the RepC/C and RepC/C* complex with the pT181 double strand origin. The results indicated that RepC/C and RepC/C* footprint supercoiled DNA differently although their footprints on Linear DNA are similar; we also find that RepC/C is able to enhance cruciform extrusion while RepC/C* cannot. RepC/C* binds and bends the double strand origin much more weakly than does RepC/C. These results suggest that the attached oligonucleotide induces a conformational change in the RepC/C* molecule that is responsible for its lack of activity.	NYU,MED CTR,DEPT MOL PATHOGENESIS,SKIRBALL INST BIOMOL MED,NEW YORK,NY 10016	New York University				Novick, richard/0000-0003-4418-7893	NIGMS NIH HHS [R01-GM14372] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM014372] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DIAZ R, 1981, NATURE, V289, P326, DOI 10.1038/289326a0; GENNARO ML, 1989, J MOL BIOL, V205, P355, DOI 10.1016/0022-2836(89)90346-X; GRALLA JD, 1993, FOOTPRINTING TECHNIQ, P107; IORDANESCU S, 1989, MOL GEN GENET, V217, P481, DOI 10.1007/BF02464921; KOEPSEL RR, 1986, SCIENCE, V233, P1316, DOI 10.1126/science.3749879; KOEPSEL RR, 1985, P NATL ACAD SCI USA, V82, P6845, DOI 10.1073/pnas.82.20.6845; KOEPSEL RR, 1986, P NATL ACAD SCI USA, V83, P5484, DOI 10.1073/pnas.83.15.5484; NOIROT P, 1990, P NATL ACAD SCI USA, V87, P8560, DOI 10.1073/pnas.87.21.8560; NOVICK RP, 1972, J MOL BIOL, V68, P285, DOI 10.1016/0022-2836(72)90214-8; NOVICK RP, 1993, EMBO J, V12, P3967, DOI 10.1002/j.1460-2075.1993.tb06074.x; RASOOLY A, 1993, SCIENCE, V262, P1048, DOI 10.1126/science.8235621; WANG PZ, 1993, EMBO J, V12, P45, DOI 10.1002/j.1460-2075.1993.tb05630.x	12	14	14	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31086	31091		10.1074/jbc.271.49.31086	http://dx.doi.org/10.1074/jbc.271.49.31086			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940104	hybrid			2022-12-25	WOS:A1996VW68600015
J	Yun, CH; Song, M; Ahn, T; Kim, H				Yun, CH; Song, M; Ahn, T; Kim, H			Conformational change of cytochrome p450 1A2 induced by sodium chloride	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER MICROSOMAL CYTOCHROME-P-450; BETA-NAPHTHOFLAVONE; CIRCULAR-DICHROISM; RAPID METHOD; REDUCTASE; PURIFICATION; FORMS; NOMENCLATURE; REPLACEMENT; EXPRESSION	Recently, it was reported that the activity of rabbit P450 1A2 is markedly increased at elevated sodium phosphate concentration. Here, the possible structural change of rabbit P450 1A2 accompanying the NaCl-induced increase in its enzyme activity is investigated by fluorescence spectroscopy, circular dichroism, and absorption spectroscopy, It was found that NaCl increased alpha-helix content and lowered beta-sheet content of P450 1A2 in the presence as well as in the absence of a phospholipid. Intrinsic fluorescence emissions also increased with increasing NaCl concentration. The low spin iron configuration of P450 1A2 shifted toward the high spin configuration in response to the increased salt concentration, The effect of increased potassium phosphate and NaCl on the P450 1A2 activity was also studied. It was found that the activity increase of rabbit P450 1A2 occurs concomitantly with the conformational change including raised alpha-helix content.	KOREA ADV INST SCI & TECHNOL,DEPT BIOL SCI,TAEJON 305701,SOUTH KOREA	Korea Advanced Institute of Science & Technology (KAIST)	Yun, CH (corresponding author), PAI CHAI UNIV,DEPT BIOCHEM,SEO KU,439-6, DOMA DONG,TAEJON 302735,SOUTH KOREA.			Yun, Chul-Ho/0000-0003-2685-2968				ALTERMAN MA, 1990, BIOMED CHROMATOGR, V4, P221, DOI 10.1002/bmc.1130040510; CHIANG YL, 1979, ARCH BIOCHEM BIOPHYS, V195, P178, DOI 10.1016/0003-9861(79)90339-4; COON MJ, 1973, DRUG METAB DISPOS, V1, P92; GrahamLorence S, 1996, FASEB J, V10, P206, DOI 10.1096/fasebj.10.2.8641554; Guengerich F. Peter, 1994, P1259; GUENGERICH FP, 1983, BIOCHEMISTRY-US, V22, P2811, DOI 10.1021/bi00281a007; GUENGERICH FP, 1982, BIOCHEMISTRY-US, V21, P6019, DOI 10.1021/bi00266a045; GUENGERICH FP, 1979, BIOCHEMISTRY-US, V18, P5442, DOI 10.1021/bi00591a029; GUENGERICH FP, 1978, J BIOL CHEM, V253, P7931; HAUGEN DA, 1976, J BIOL CHEM, V251, P7929; IMAOKA S, 1992, BIOCHEMISTRY-US, V31, P6063, DOI 10.1021/bi00141a015; Jansson I, 1996, ARCH BIOCHEM BIOPHYS, V325, P265, DOI 10.1006/abbi.1996.0033; LANGE R, 1980, EUR J BIOCHEM, V107, P441; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; OMURA T, 1964, J BIOL CHEM, V239, P2370; PALMER G, 1992, J BIOL CHEM, V267, P665; POHL RJ, 1980, ANAL BIOCHEM, V107, P150, DOI 10.1016/0003-2697(80)90505-9; POMPON D, 1988, EUR J BIOCHEM, V177, P285, DOI 10.1111/j.1432-1033.1988.tb14375.x; PORTER TD, 1991, J BIOL CHEM, V266, P13469; SANDHU P, 1994, ARCH BIOCHEM BIOPHYS, V309, P168, DOI 10.1006/abbi.1994.1099; SCHENKMAN JB, 1994, ARCH BIOCHEM BIOPHYS, V314, P234, DOI 10.1006/abbi.1994.1435; TAMBURINI PP, 1984, BIOCHEMISTRY-US, V23, P4526, DOI 10.1021/bi00315a004; Timasheff S.N., 1989, PROTEIN STRUCTURE PR, P331; TRETIAKOV VE, 1989, ARCH BIOCHEM BIOPHYS, V275, P429, DOI 10.1016/0003-9861(89)90389-5; VOZNESENSKY AI, 1994, J BIOL CHEM, V269, P15724; VOZNESENSKY AI, 1992, J BIOL CHEM, V267, P14669; WAGNER SL, 1987, BIOCHEMISTRY-US, V26, P2343, DOI 10.1021/bi00382a040; WHITE RE, 1982, J BIOL CHEM, V257, P3073; YAMAZAKI H, 1995, BIOCHEMISTRY-US, V34, P8380, DOI 10.1021/bi00026a020; YANG JT, 1986, METHOD ENZYMOL, V130, P208	30	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31312	31316		10.1074/jbc.271.49.31312	http://dx.doi.org/10.1074/jbc.271.49.31312			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940137	hybrid			2022-12-25	WOS:A1996VW68600048
J	Jia, YP; Kumar, A; Patel, SS				Jia, YP; Kumar, A; Patel, SS			Equilibrium and stopped-flow kinetic studies of interaction between T7 RNA polymerase and its promoters measured by protein and 2-aminopurine fluorescence changes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; T7-RNA POLYMERASE; RRNB P1; RATE CONSTANTS; TRANSCRIPTION; COMPLEXES; DNA; BACTERIOPHAGE-T7; GENE; EXPRESSION	The mechanism of bacteriophage T7 RNA polymerase binding to its promoter DNA was investigated using stopped-flow and equilibrium methods, To measure the kinetics of protein-DNA interactions in real time, changes in tryptophan fluorescence in the polymerase and 2-aminopurine (2-AP) fluorescence in the promoter DNA upon binary complex formation were used as probes, The protein fluorescence changes measured conformational changes in the polymerase whereas the fluorescence changes of 2-AP base, substituted in place of dA in the initiation region (-4 to +4), measured structural changes in the promoter DNA, such as DNA melting, The kinetic studies, carried out in the absence of the initiating nucleotide, are consistent with a two-step DNA binding mechanism, E + D reversible arrow(K)1 ED(a) (k)-2 reversible arrow(k)2 ED(b) where the RNA polymerase forms an initial weak ED, complex rapidly with an equilibrium association constant K-1, The ED(a) complex then undergoes a conformational change to ED(1), wherein RNA polymerase is specifically and tightly bound to the promoter DNA. Both the polymerase and the promoter DNA may undergo structural changes during this isomerization step, The isomerization of ED(a) to ED(b) is a fast step relative to the rate of transcription initiation and its rate does not limit transcription initiation, To understand how T7 RNA polymerase modulates its transcriptional efficiency at various promoters at the level of DNA binding, comparative studies with two natural T7 promoters, Phi 10 and Phi 3.8, were conducted, The results indicate that kinetics, the bimolecular rate constant of DNA binding, k(on) (K1K2), and the dissociation rate constant, k(off) (h(-2)), and thermodynamics, the equilibrium constants of the two steps (K-1 and k(2)/k(-2)) both play a role in modulating the transcriptional efficiency at the level of DNA binding, Thus, the 2-fold lower k(on), the 4-fold higher k(off), and the 2-5-fold weaker equilibrium interactions together make Phi 3.8 a weaker promoter relative to Phi 10.	OHIO STATE UNIV,DEPT BIOCHEM,COLUMBUS,OH 43210	University System of Ohio; Ohio State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM051966, R01GM051966] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51966] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHAMBERL.M, 1970, NATURE, V228, P227, DOI 10.1038/228227a0; Chamberlin M., 1982, ENZYMES, V15, P87; DAVANLOO P, 1984, P NATL ACAD SCI-BIOL, V81, P2035, DOI 10.1073/pnas.81.7.2035; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; FERSHT AR, 1971, J MOL BIOL, V60, P279, DOI 10.1016/0022-2836(71)90294-4; FOX JJ, 1958, J AM CHEM SOC, V80, P1669, DOI 10.1021/ja01540a041; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; HAYATSU H, 1967, BIOCHEM BIOPH RES CO, V29, P556, DOI 10.1016/0006-291X(67)90521-9; IKEDA RA, 1992, J BIOL CHEM, V267, P2640; Johnson K. A., 1992, ENZYMES, V20, P1, DOI DOI 10.1016/S1874-6047(08)60019-0; KAINZ M, 1992, SCIENCE, V255, P838, DOI 10.1126/science.1536008; KING GC, 1986, BIOCHEMISTRY-US, V25, P36, DOI 10.1021/bi00349a006; KOTANI H, 1987, NUCLEIC ACIDS RES, V15, P2653, DOI 10.1093/nar/15.6.2653; MARTIN CT, 1987, BIOCHEMISTRY-US, V26, P2690, DOI 10.1021/bi00384a006; Millar DP, 1996, CURR OPIN STRUC BIOL, V6, P322, DOI 10.1016/S0959-440X(96)80050-9; MOFFATT BA, 1984, J MOL BIOL, V173, P265, DOI 10.1016/0022-2836(84)90194-3; MULLER DK, 1989, BIOCHEMISTRY-US, V28, P3306, DOI 10.1021/bi00434a028; NEWLANDS JT, 1991, J MOL BIOL, V220, P569, DOI 10.1016/0022-2836(91)90101-B; OAKLEY JL, 1979, BIOCHEMISTRY-US, V18, P528, DOI 10.1021/bi00570a023; OHLSEN KL, 1992, J BIOL CHEM, V267, P19813; OSTERMAN HL, 1981, BIOCHEMISTRY-US, V20, P4884, DOI 10.1021/bi00520a013; Record Jr MT, 1996, ESCHERICHIA COLI SAL, P792; ROE JH, 1985, J MOL BIOL, V184, P441, DOI 10.1016/0022-2836(85)90293-1; SOUSA R, 1994, J MOL BIOL, V244, P6, DOI 10.1006/jmbi.1994.1699; SUH WC, 1993, SCIENCE, V259, P358, DOI 10.1126/science.8420002; TRAVERS AA, 1987, CRIT REV BIOCHEM MOL, V22, P181, DOI 10.3109/10409238709101483; WARD DC, 1969, J BIOL CHEM, V244, P1228; WELLINGTON SR, 1993, J BIOL CHEM, V268, P7205; Zhang X, 1996, J MOL BIOL, V258, P14, DOI 10.1006/jmbi.1996.0230	29	99	101	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30451	30458		10.1074/jbc.271.48.30451	http://dx.doi.org/10.1074/jbc.271.48.30451			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940010	hybrid			2022-12-25	WOS:A1996VV15800027
J	Sarmay, G; Koncz, G; Gergely, J				Sarmay, G; Koncz, G; Gergely, J			Human type II Fc gamma receptors inhibit B cell activation by interacting with the p21(ras)-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CROSS-LINKING; TYROSINE PHOSPHORYLATION; LYMPHOCYTES; SHC; IMMUNOGLOBULIN; P21(RAS); COMPLEX; FC-GAMMA-RIIB1; STIMULATION	Co-ligation of antigen receptors and type II Fc gamma receptors (Fc gamma RIIb) on B cells interrupts signal transduction and ultimately inhibits antibody production. We have identified p52 She in the Fc gamma RIIb1-specific immunoprecipitates isolated from the membrane fraction of BL41 Burkitt lymphoma cells following B cell receptor-Fc gamma RIIb1 co-ligation. The insolubilized synthetic peptide representing the phosphorylated form of the tyrosine-based inhibitory moth of Fc gamma RIIb also binds She from the lysates of activated but not from resting BL41 cells. This suggests that the binding does not depend on the interaction of Fc gamma RIIb1-phosphotyrosine with the SH2 domain of She. Tyr phosphorylation of Fc gamma RIIb1-associated She is low, indicating an impaired function. She is implicated in regulating p21(ras) activation; thus, we have compared p21(ras) activities in BL41 cells treated in different ways. p21(ras) activity is reduced when B cell receptor and Fc gamma RIIb1 are co-ligated. p21(ras) couples protein-tyrosine kinase-dependent events to the Ser/Thr kinase-mediated signaling pathway leading to the activation of mitogen-activated protein kinases (MAPK). Our results show that B cell receptor-Fc gamma RIIb1 co-crosslinking partially inhibits mitogen-activated protein kinase activity. We conclude that Fc gamma RIIb1-dependent inhibition of human B cell activation may be based on interrupting signal transduction between protein-tyrosine kinases and the p21(ras)/mitogen-activated protein kinase-dependent activation pathway.	VIENNA INT RES COOPERAT CTR, SFI, VIENNA, AUSTRIA		Sarmay, G (corresponding author), EOTVOS LORAND UNIV, DEPT IMMUNOL, IMMUNOREGULAT LAB, JAVORKA SANDOR U 14, H-2131 GOD, HUNGARY.		Sarmay, Gabriella/AAF-3460-2020; Koncz, Gabor/AAL-4415-2021	Koncz, Gabor/0000-0002-4888-6838				Bewarder N, 1996, MOL CELL BIOL, V16, P4735; BUDDE P, 1994, J BIOL CHEM, V269, P30636; CANTRELL DA, 1985, P NATL ACAD SCI USA, V82, P8158, DOI 10.1073/pnas.82.23.8158; CHAN PL, 1971, IMMUNOLOGY, V21, P967; CHOQUET D, 1993, J CELL BIOL, V121, P355, DOI 10.1083/jcb.121.2.355; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DIEGEL ML, 1994, J BIOL CHEM, V269, P11409; DISATNIK MH, 1994, P NATL ACAD SCI USA, V91, P559, DOI 10.1073/pnas.91.2.559; GOTTSCHALK AR, 1994, J IMMUNOL, V152, P2115; GRAZIADEI L, 1990, NATURE, V347, P396, DOI 10.1038/347396a0; HENRY C, 1968, J EXP MED, V128, P133, DOI 10.1084/jem.128.1.133; KLAUS GGB, 1985, IMMUNOLOGY, V56, P321; KUMAR G, 1995, BIOCHEM J, V307, P215, DOI 10.1042/bj3070215; LAZARUS AH, 1993, J EXP MED, V178, P1765, DOI 10.1084/jem.178.5.1765; MCMAHON SB, 1995, J EXP MED, V181, P417, DOI 10.1084/jem.181.1.417; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; NAGAI K, 1995, J BIOL CHEM, V270, P6824, DOI 10.1074/jbc.270.12.6824; Okabayashi Y, 1996, J BIOL CHEM, V271, P5265; PANI G, 1995, J EXP MED, V181, P2077, DOI 10.1084/jem.181.6.2077; PRONK GJ, 1994, BBA-REV CANCER, V1198, P131, DOI 10.1016/0304-419X(94)90010-8; Rapp W., 1990, INNOVATION PERSPECTI, P205; SARMAY G, 1995, IMMUNOL LETT, V44, P125, DOI 10.1016/0165-2478(95)00203-H; SARMAY G, 1994, P NATL ACAD SCI USA, V91, P4140, DOI 10.1073/pnas.91.10.4140; SARMAY G, 1995, EUR J IMMUNOL, V25, P262, DOI 10.1002/eji.1830250143; SAXTON TM, 1994, J IMMUNOL, V153, P623; SHEN ZH, 1994, J IMMUNOL, V152, P3017; SMIT L, 1994, J BIOL CHEM, V269, P20209; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TORDAI A, 1994, J BIOL CHEM, V269, P7538; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	30	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30499	30504						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940017				2022-12-25	WOS:A1996VV15800034
J	Asano, Y; Ito, H; Dairi, T; Kato, Y				Asano, Y; Ito, H; Dairi, T; Kato, Y			An alkaline D-stereospecific endopeptidase with beta-lactamase activity from Bacillus cereus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; GENE; CLONING; AMINOPEPTIDASE; HYDROLYSIS; PEPTIDASE; PROTEIN	We purified a novel extracellular D-stereospecific endopeptidase, alkaline D-peptidase (D-stereospecific peptide hydrolase, EC 3.4.11.-), to homogeneity from the culture broth of the soil bacterium Bacillus cereus strain DF4-B. The M(r) of the enzyme was 37,952, and it was composed of a single polypeptide chain. The optimal pH for activity was similar to 10.3, The enzyme was strictly D-stereospecific toward oligopeptides composed of D-phenylalanine such as (D-Phe)(3) and (D-Phe)(4). The enzyme also acted to a lesser extent on (D-Phe)(6), Boc-(D-Phe)(4) (where Boc is tert-butoxycarbonyl), Boc-(D-Phe)(4) methyl ester, Boc-(D-Phe)(3) methyl ester, Boc (D-Phe)(2), (D-Phe)(2), and others, but not upon their corresponding peptides composed of L-Phe, (D-Ala)(n) (n = 2-5), (D-Val)(3), and (D-Leu)(2), The mode of action of the enzyme was clarified with synthetic substrates ((D-Phe)(2)-D-Tyr and D-Tyr-(D-Phe)(2)) and eight stereoisomers of (Phe)(3). The enzyme had beta-lactamase activity toward ampicillin and penicillin G, although carboxypeptidase DD and D-aminopeptidase activities were undetectable. The gene coding for alkaline D-peptidase (adp) was cloned into plasmid pUC118, and a 1164-base pair open reading frame consisting of 388 codons was identified as the adp gene, The predicted polypeptide was similar to carboxypeptidase DD from Streptomyces R61, penicillin-binding proteins from Streptomyces lactamdurans and Bacillus subtilis, and class C beta-lactamases, Thus, the enzyme was categorized as a new ''penicillin-recognizing enzyme.''			Asano, Y (corresponding author), TOYAMA PREFECTURAL UNIV,BIOTECHNOL RES CTR,5180 KUROKAWA,TOYAMA 93903,JAPAN.		Asano, Yasuhisa/K-5898-2016; Dairi, Tohru/A-5448-2012	Asano, Yasuhisa/0000-0003-3645-3952; Dairi, Tohru/0000-0002-3406-7970				ADAM M, 1990, BIOCHEM J, V270, P525, DOI 10.1042/bj2700525; AKINO T, 1989, APPL ENVIRON MICROB, V55, P3178, DOI 10.1128/AEM.55.12.3178-3183.1989; ASANO Y, 1992, FRONTIERS AND NEW HORIZONS IN AMINO ACID RESEARCH, P333; ASANO Y, 1989, J BIOL CHEM, V264, P14233; ASANO Y, 1992, BIOCHEMISTRY-US, V31, P2316, DOI 10.1021/bi00123a016; COQUE JJR, 1993, EMBO J, V12, P631, DOI 10.1002/j.1460-2075.1993.tb05696.x; DUEZ C, 1987, EUR J BIOCHEM, V162, P509, DOI 10.1111/j.1432-1033.1987.tb10669.x; FRERE JM, 1985, CRC CR REV MICROBIOL, V11, P299; GALLENI M, 1988, BIOCHEM J, V250, P753, DOI 10.1042/bj2500753; HOBBS M, 1991, MOL MICROBIOL, V5, P543, DOI 10.1111/j.1365-2958.1991.tb00726.x; JORIS B, 1985, BIOCHEM J, V228, P241, DOI 10.1042/bj2280241; JORIS B, 1986, BIOCHEM J, V239, P581, DOI 10.1042/bj2390581; LINDBERG F, 1986, EUR J BIOCHEM, V156, P441, DOI 10.1111/j.1432-1033.1986.tb09601.x; Maniatis T., 1982, MOL CLONING; MCKAY DB, 1992, J GEN MICROBIOL, V138, P701, DOI 10.1099/00221287-138-4-701; MEZES PSF, 1983, FEBS LETT, V161, P195, DOI 10.1016/0014-5793(83)81006-0; Milton S. C. F., 1992, SCIENCE, V256, P1445; POPHAM DL, 1993, J BACTERIOL, V175, P2917, DOI 10.1128/JB.175.10.2917-2925.1993; PRATT RF, 1984, P NATL ACAD SCI-BIOL, V81, P1302, DOI 10.1073/pnas.81.5.1302; REYNOLDS PE, 1994, MOL MICROBIOL, V13, P1065, DOI 10.1111/j.1365-2958.1994.tb00497.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEEHAN JC, 1965, J AM CHEM SOC, V87, P2492, DOI 10.1021/ja01089a034; SIMONEN M, 1993, MICROBIOL REV, V57, P109, DOI 10.1128/MMBR.57.1.109-137.1993; Sneath P. H., 1986, BERGEYS MANUAL SYSTE, V2, P1104; SUGIE M, 1986, AGR BIOL CHEM TOKYO, V50, P1397, DOI 10.1080/00021369.1986.10867589; TAKASE K, 1988, J BIOL CHEM, V263, P11548; TARBELL DS, 1972, P NATL ACAD SCI USA, V69, P730, DOI 10.1073/pnas.69.3.730; VAUGHAN JR, 1952, J AM CHEM SOC, V74, P676, DOI 10.1021/ja01123a028	28	59	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30256	30262		10.1074/jbc.271.47.30256	http://dx.doi.org/10.1074/jbc.271.47.30256			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939979	hybrid			2022-12-25	WOS:A1996VU52500107
J	Codina, J; Kone, BC; DelmasMata, JT; Dubose, TD				Codina, J; Kone, BC; DelmasMata, JT; Dubose, TD			Functional expression of the colonic H+,K+-ATPase alpha-subunit - Pharmacologic properties and assembly with X(+),K+-ATPase beta-subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT DISTAL COLON; K+-ATPASE; GASTRIC H+,K+-ATPASE; GENE FAMILY; OUABAIN; H,K-ATPASE; CLONING; KIDNEY; NA+; NA+,K+-ATPASE	The functional and pharmacological properties of the a-subunit of the colonic H+,K+-ATPase (alpha(C)) were studied in Xenopus laevis oocytes. alpha(C) was injected with different rat beta-subunits, the beta-subunit of the gastric H+,K+-ATPase (beta(G), the only H+,K+-ATPase beta-subunit identified in rat), or the beta(1)-subunit of the Na+,K+-ATPase (beta(1)) (associated with the basolateral Na+,K+-ATPase, but also expressed in the epithelial apical membranes of rat distal colon) (Marxer, A., Stieger, B., Quarini, A., Kashgarian, M., and Hauri, H. P. (1989) J. Cell Biol. 109, 1057-1069). The effect of the different beta-subunits was studied by measuring Rb-86(+) uptake (a K+ congener) in the presence or absence of Sch-28080 and ouabain. Significant Na+-independent Rb-86(+) uptake was observed only when alpha(C) was coexpressed with one of the beta-subunits. The expressed alpha(C) beta(1) and alpha(C) beta(G) complexes were not inhibited by Sch-28080, were only partially sensitive to ouabain (IC50 = 400-600 mu M, in the presence of external 1 mm KCl), and exhibited comparable K+ activation kinetics. Coexpression of alpha(C) with epitope-tagged beta(G) or beta(1), followed by immunopurification of the alpha beta complexes, confirmed stable assembly of alpha(C) beta(G) and alpha(C) beta(1) complexes. Since the beta(1)-subunit, but not the alpha(1)-subunit, of Na+,K+-ATPase is expressed in the apical membrane of rat colonocytes, our data support the view that, in rat distal colon, the beta(1)-subunit may play a surrogate role as the beta-subunit for the colonic H+,K+-ATPase.	UNIV TEXAS,SCH MED,DEPT INTERNAL MED,DIV RENAL DIS & HYPERTENS,HOUSTON,TX 77030; UNIV TEXAS,SCH MED,DEPT INTEGRAT BIOL,HOUSTON,TX 77030	University of Texas System; University of Texas System					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047981, R29DK047981, R01DK030603] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-30603, DK-47981] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAMSE SI, 1995, BIOCHEM BIOPH RES CO, V207, P1003, DOI 10.1006/bbrc.1995.1284; Ahn KY, 1996, AM J PHYSIOL-RENAL, V271, pF314, DOI 10.1152/ajprenal.1996.271.2.F314; Ahn KY, 1996, AM J PHYSIOL-RENAL, V270, pF557, DOI 10.1152/ajprenal.1996.270.4.F557; CANESSA CM, 1992, EMBO J, V11, P1681, DOI 10.1002/j.1460-2075.1992.tb05218.x; CHEVAL L, 1991, AM J PHYSIOL, V260, pF800, DOI 10.1152/ajprenal.1991.260.6.F800; Cougnon M, 1996, J BIOL CHEM, V271, P7277, DOI 10.1074/jbc.271.13.7277; CROWSON MS, 1992, J BIOL CHEM, V267, P13740; DELCASTILLO JR, 1994, AM J PHYSIOL, V266, pG1083, DOI 10.1152/ajpgi.1994.266.6.G1083; DELCASTILLO JR, 1991, AM J PHYSIOL, V261, pG1005, DOI 10.1152/ajpgi.1991.261.6.G1005; DUBOSE TD, 1995, AM J PHYSIOL-RENAL, V269, pF500, DOI 10.1152/ajprenal.1995.269.4.F500; EAKLE KA, 1995, J BIOL CHEM, V270, P13937, DOI 10.1074/jbc.270.23.13937; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FOSTER ES, 1985, GASTROENTEROLOGY, V88, P41, DOI 10.1016/S0016-5085(85)80130-X; GALLAGHAN JM, 1995, AM J PHYSIOL, V268, pF363; GRISHIN AV, 1994, FEBS LETT, V349, P144, DOI 10.1016/0014-5793(94)00655-5; HORISBERGER JD, 1991, J BIOL CHEM, V266, P19131; JAISSER F, 1994, J GEN PHYSIOL, V103, P605, DOI 10.1085/jgp.103.4.605; JAISSER F, 1993, PFLUG ARCH EUR J PHY, V425, P446, DOI 10.1007/BF00374871; JAISSER F, 1993, J CELL BIOL, V123, P1421, DOI 10.1083/jcb.123.6.1421; JAISSER F, 1995, AM J PHYSIOL, V39, pC679; Kone BC, 1996, MINER ELECTROL METAB, V22, P349; LEE JS, 1995, J CLIN INVEST, V96, P2002, DOI 10.1172/JCI118247; LEMAS MV, 1994, J BIOL CHEM, V269, P18651; MARXER A, 1989, J CELL BIOL, V109, P1057, DOI 10.1083/jcb.109.3.1057; MCDONOUGH AA, 1994, AM J PHYSIOL-CELL PH, V267, pC901, DOI 10.1152/ajpcell.1994.267.4.C901; MODYANOV NN, 1995, AM J PHYSIOL-CELL PH, V269, pC992, DOI 10.1152/ajpcell.1995.269.4.C992; Palasis M, 1996, J BIOL CHEM, V271, P14176, DOI 10.1074/jbc.271.24.14176; PANDIYAN V, 1992, GASTROENTEROLOGY, V102, P1846, DOI 10.1016/0016-5085(92)90304-H; Parent L, 1995, BIOPHYS J, V69, P1801, DOI 10.1016/S0006-3495(95)80050-0; RABON E, 1985, J BIOL CHEM, V260, P200; SANFORD J, 1991, J BIOL CHEM, V266, P9570; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHULL GE, 1990, J BIOL CHEM, V265, P12123; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SUSUKI Y, 1993, JPN J PHYSL, V43, P291; SVERDLOV ED, 1991, GENETICA, V85, P91, DOI 10.1007/BF00056110; VACHON V, 1995, BIOCHEMISTRY-US, V34, P15157, DOI 10.1021/bi00046a023; WALLMARK B, 1987, J BIOL CHEM, V262, P2077; WATANABE T, 1990, AM J PHYSIOL, V258, pG506, DOI 10.1152/ajpgi.1990.258.4.G506; WATANABE T, D21854 GEN; WINGO CS, 1995, AM J PHYSIOL-RENAL, V269, pF1, DOI 10.1152/ajprenal.1995.269.1.F1; YOUNESIBRAHIM M, 1995, AM J PHYSIOL-RENAL, V268, pF1141, DOI 10.1152/ajprenal.1995.268.6.F1141; YOUNG RM, 1987, J BIOL CHEM, V262, P4905	43	79	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29759	29763		10.1074/jbc.271.47.29759	http://dx.doi.org/10.1074/jbc.271.47.29759			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939912	hybrid			2022-12-25	WOS:A1996VU52500040
J	Ghanta, J; Shen, CL; Kiessling, LL; Murphy, RM				Ghanta, J; Shen, CL; Kiessling, LL; Murphy, RM			A strategy for designing inhibitors of beta-amyloid toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; CELL-DEATH; PEPTIDE; PROTEIN; AMYLOIDOGENICITY; PATHOGENESIS; FRAGMENTS	beta-Amyloid peptide is the major protein component of Alzheimer's plaques. When aggregated into amyloid fibrils, the peptide is toxic to neuronal cells. Here, an approach to the design of inhibitors of beta-amyloid toxicity is described; in this strategy, a recognition element, which interacts specifically with beta-amyloid, is combined with a disrupting element, which alters beta-amyloid aggregation pathways. The synthesis, biophysical characterization, and biological activity of such an inhibitor is reported, This prototype inhibitor is composed of residues 15-25 of beta-amyloid peptide, designed to function as the recognition element, linked to an oligolysine disrupting element. The inhibitor does not alter the apparent secondary structure of beta-amyloid nor prevent its aggregation; rather, it causes changes in aggregation kinetics and higher order structural characteristics of the aggregate. Evidence for these effects includes changes in fibril morphology and a reduction in thioflavin T fluorescence, In addition to its influence on the physical properties of beta-amyloid aggregates, the inhibitor completely blocks beta-amyloid toxicity to PC-12 cells. Together, these data suggest that this general strategy for design of beta-amyloid toxicity inhibitors is effective, Significantly, these results demonstrate that complete disruption of amyloid fibril formation is not necessary for abrogation of toxicity.	UNIV WISCONSIN,DEPT CHEM,MADISON,WI 53706; UNIV WISCONSIN,DEPT CHEM ENGN,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison			Kiessling, Laura L/A-4074-2008	Kiessling, Laura/0000-0001-6829-1500				CAMILLERI P, 1994, FEBS LETT, V341, P256, DOI 10.1016/0014-5793(94)80467-2; Esler WP, 1996, BIOCHEMISTRY-US, V35, P749, DOI 10.1021/bi951685w; FRASER PE, 1994, J MOL BIOL, V244, P64, DOI 10.1006/jmbi.1994.1704; FRASER PE, 1991, BIOPHYS J, V60, P1190, DOI 10.1016/S0006-3495(91)82154-3; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; HALVERSON K, 1990, BIOCHEMISTRY-US, V29, P2639, DOI 10.1021/bi00463a003; HILBICH C, 1992, J MOL BIOL, V228, P460, DOI 10.1016/0022-2836(92)90835-8; Hughes SR, 1996, P NATL ACAD SCI USA, V93, P2065, DOI 10.1073/pnas.93.5.2065; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; JOACHIM CL, 1992, ALZ DIS ASSOC DIS, V6, P7, DOI 10.1097/00002093-199205000-00003; KISILEVSKY R, 1995, NAT MED, V1, P143, DOI 10.1038/nm0295-143; LEE JP, 1995, BIOCHEMISTRY-US, V34, P5191, DOI 10.1021/bi00015a033; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; Lomakin A, 1996, P NATL ACAD SCI USA, V93, P1125, DOI 10.1073/pnas.93.3.1125; PIKE CJ, 1993, J NEUROSCI, V13, P1676; POLLACK SJ, 1995, NEUROSCI LETT, V197, P211, DOI 10.1016/0304-3940(95)11939-T; SHEARMAN MS, 1994, P NATL ACAD SCI USA, V91, P1470, DOI 10.1073/pnas.91.4.1470; SHEN CL, 1995, BIOPHYS J, V69, P640, DOI 10.1016/S0006-3495(95)79940-4; SHEN CL, 1993, BIOPHYS J, V65, P2383, DOI 10.1016/S0006-3495(93)81312-2; SIMMONS LK, 1994, MOL PHARMACOL, V45, P373; TERZI E, 1995, J MOL BIOL, V252, P633, DOI 10.1006/jmbi.1995.0525; Tjernberg LO, 1996, J BIOL CHEM, V271, P8545, DOI 10.1074/jbc.271.15.8545; UEDA K, 1994, BRAIN RES, V639, P240, DOI 10.1016/0006-8993(94)91736-1; WONG CW, 1985, P NATL ACAD SCI USA, V82, P8729, DOI 10.1073/pnas.82.24.8729; WOOD SJ, 1995, BIOCHEMISTRY-US, V34, P724, DOI 10.1021/bi00003a003; Wood SJ, 1996, J BIOL CHEM, V271, P4086	26	208	226	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29525	29528		10.1074/jbc.271.47.29525	http://dx.doi.org/10.1074/jbc.271.47.29525			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939877	hybrid			2022-12-25	WOS:A1996VU52500005
J	Koller, E; Ranscht, B				Koller, E; Ranscht, B			Differential targeting of T- and N-cadherin in polarized epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESION MOLECULE UVOMORULIN; PROTEIN TYROSINE KINASES; GLYCOSYL-PHOSPHATIDYLINOSITOL; CYTOPLASMIC DOMAIN; MEMBRANE-PROTEINS; ANCHORED PROTEINS; SURFACE POLARITY; MDCK CELLS; EXPRESSION; SIGNAL	To test whether glycosyl phosphatidylinositol-linked T-cadherin is a component of cell junctions like classical cadherins, we have examined its distribution and targeting in polarized epithelial cells. In vivo, T-cadherin was detected on the apical cell surface of the chick intestinal epithelium. In cultures of transfected Madin-Darby canine kidney cells, T-cadherin was also expressed apically, whereas classical N-cadherin resided basolaterally, Both cadherins were directly targeted to their respective membrane domains, Mutant proteins were expressed in Madin-Darby canine kidney cells to identify the regions responsible for differential cadherin localization. N Delta cyt, an N-cadherin cytoplasmic domain deletion mutant, was stably distributed basolaterally, This mutant was transported to both the apical and basolateral membrane compartments, followed by preferential removal from the apical surface, T-N Delta cyt, a T-cadherin mutant with the N-cadherin cytoplasmic domain deletion, was localized basolaterally, whereas N-T-GPI, a GPI-anchored N-cadherin mutant, resided at the apical domain, The T-cadherin carboxyl-terminal 76 amino acids contain the apical targeting signal and include the signal for GPI anchor attachment. Basolateral localization of N-cadherin is achieved through targeting signals in the cytoplasmic domain, Thus, GPI-linked T-cadherin is not a component of cell junctions, consistent with a function as a recognition rather than a cell adhesion molecule.	BURNHAM INST, LA JOLLA CANC RES CTR, LA JOLLA, CA 92307 USA	Sanford Burnham Prebys Medical Discovery Institute					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048077] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 48077] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMERONGEN HM, 1989, J CELL BIOL, V109, P2129, DOI 10.1083/jcb.109.5.2129; BEHRENS J, 1985, J CELL BIOL, V101, P1307, DOI 10.1083/jcb.101.4.1307; BERNDORFF D, 1994, J CELL BIOL, V125, P1353, DOI 10.1083/jcb.125.6.1353; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; CHEN YT, 1995, COLD SPRING HARBO S, V60, P34; CIFUENTESDIAZ C, 1994, DEVELOPMENT, V120, P1; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; Doyle D. D., 1995, Molecular Biology of the Cell, V6, p403A; FREDETTE BJ, 1994, J NEUROSCI, V14, P7331; FREDETTE BJ, 1996, IN PRESS DEV CAMB; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GONZAQLESMARISC.L, 1985, J MEMBRANE BIOL, V96, P113; GORODINSKY A, 1995, J CELL BIOL, V129, P619, DOI 10.1083/jcb.129.3.619; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; GUMBINER B, 1986, J CELL BIOL, V102, P457, DOI 10.1083/jcb.102.2.457; GUMBINER BM, 1993, NEURON, V11, P551, DOI 10.1016/0896-6273(93)90068-3; HATTA K, 1988, J CELL BIOL, V106, P873, DOI 10.1083/jcb.106.3.873; HOESSLI D, 1985, EXP CELL RES, V156, P239, DOI 10.1016/0014-4827(85)90278-2; HOPKINS CR, 1991, CELL, V66, P827, DOI 10.1016/0092-8674(91)90427-Z; IMHOF BA, 1983, CELL, V35, P667, DOI 10.1016/0092-8674(83)90099-5; KIRKPATRICK C, 1995, CURR OPIN GENET DEV, V5, P56, DOI 10.1016/S0959-437X(95)90054-3; KODUKULA K, 1993, J CELL BIOL, V120, P657, DOI 10.1083/jcb.120.3.657; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MCNEILL H, 1990, CELL, V62, P309, DOI 10.1016/0092-8674(90)90368-O; Nagafuchi A, 1993, Semin Cell Biol, V4, P175, DOI 10.1006/scel.1993.1021; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NELSON WJ, 1986, J CELL BIOL, V103, P1751, DOI 10.1083/jcb.103.5.1751; OJAKIAN GK, 1994, J CELL SCI, V107, P561; OZAWA M, 1990, CELL, V63, P1033, DOI 10.1016/0092-8674(90)90506-A; PRILL V, 1993, EMBO J, V12, P2181, DOI 10.1002/j.1460-2075.1993.tb05866.x; RANSCHT B, 1991, NEURON, V7, P391, DOI 10.1016/0896-6273(91)90291-7; RANSCHT B, 1991, DEVELOPMENT, V111, P15; RODRIGUEZBOULAN E, 1989, METHOD CELL BIOL, V32, P37; SACRISTAN MP, 1993, J NEUROSCI RES, V34, P664, DOI 10.1002/jnr.490340610; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SHENOYSCARIA AM, 1992, J IMMUNOL, V149, P3535; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; THOMAS PM, 1992, J BIOL CHEM, V267, P12317; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VEGASALAS DE, 1987, J CELL BIOL, V104, P1249, DOI 10.1083/jcb.104.5.1249; VESTAL DJ, 1992, J CELL BIOL, V119, P451, DOI 10.1083/jcb.119.2.451; VOLK T, 1984, EMBO J, V3, P2249, DOI 10.1002/j.1460-2075.1984.tb02123.x; WOLLNER DA, 1992, J CELL BIOL, V116, P889, DOI 10.1083/jcb.116.4.889; ZISCH AH, 1995, MOL CELL NEUROSCI, V6, P263, DOI 10.1006/mcne.1995.1021; [No title captured]	50	41	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30061	30067		10.1074/jbc.271.47.30061	http://dx.doi.org/10.1074/jbc.271.47.30061			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939953	hybrid			2022-12-25	WOS:A1996VU52500081
J	Linder, B; Jin, ZJ; Freedman, JH; Rubin, CS				Linder, B; Jin, ZJ; Freedman, JH; Rubin, CS			Molecular characterization of a novel, developmentally regulated small embryonic chaperone from Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; HEAT-SHOCK PROTEINS; ALPHA-CRYSTALLIN; ACTIN POLYMERIZATION; BINDING-PROTEIN; C-ELEGANS; II-BETA; GENE; EXPRESSION; CLONING	Low molecular weight chaperones inhibit protein aggregation and facilitate refolding of partially denatured polypeptides in cells subjected to physical and chemical stresses. The nematode Caenorhabditis elegans provides a system amenable for investigations on roles for chaperone proteins in normal homeostasis and development, We characterized a C. elegans gene and cDNAs that encode a novel, small embryonic chaperone-like protein (SEC-1) that is composed of 159 amino acids, The central core of SEC-1 (residues 45-126) is similar to 40% identical with a corresponding segment of mammalian Hsp27 and alpha B crystallin, Expression of SEC-1 in Escherichia coli confers thermotolerance on the bacterium. SEC-1 mRNA is evident only in C. elegans oocytes and developing embryos. Translation and accumulation of SEC-1 protein is temporally coupled with a prolonged burst of intense protein synthesis and rapid mitogenesis during early embryogenesis. As the rate of protein synthesis decreases during late embryogenesis, levels of SEC-1 and its cognate mRNA decline precipitously. Induction/deinduction of SEC-1 is precisely regulated by intrinsic developmental factors rather than extrinsic stresses, In vivo injection of C. elegans oocytes with antisense oligonucleotides that complement the 5'-end of SEC-1 mRNA arrests nematode development at an early stage after fertilization, Thus, SEC-1 appears to be adapted to perform essential functions in early embryogenesis.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOL PHARMACOL,ATRAN LABS,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT PEDIAT,ATRAN LABS,BRONX,NY 10461; DUKE UNIV,SCH ENVIRONM,DURHAM,NC 27708	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Duke University					NATIONAL CANCER INSTITUTE [R01CA061337] Funding Source: NIH RePORTER; NCI NIH HHS [CA 61337] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; CHRETIEN P, 1989, J CELL BIOL, V137, P7; CIOCCA DR, 1993, JNCI-J NATL CANCER I, V85, P1558, DOI 10.1093/jnci/85.19.1558; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FREEDMAN JH, 1993, J BIOL CHEM, V268, P2554; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HESCHL MFP, 1989, DNA-J MOLEC CELL BIO, V8, P233, DOI 10.1089/dna.1.1989.8.233; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; HU E, 1991, J BIOL CHEM, V266, P19796; HU ED, 1990, J BIOL CHEM, V265, P5072; IWAKI A, 1990, J BIOL CHEM, V265, P22197; JAKOB U, 1993, J BIOL CHEM, V268, P1517; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; JONES D, 1986, J BIOL CHEM, V261, P2006; KENYON C, 1988, SCIENCE, V240, P1448, DOI 10.1126/science.3287621; LAND M, 1994, J BIOL CHEM, V269, P9234; LANDRY J, 1992, J BIOL CHEM, V267, P794; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; LI Y, 1995, J BIOL CHEM, V270, P1935, DOI 10.1074/jbc.270.4.1935; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LU XY, 1990, J BIOL CHEM, V265, P3293; MERCK KB, 1993, J BIOL CHEM, V268, P1046; MIRON T, 1988, EUR J BIOCHEM, V178, P543, DOI 10.1111/j.1432-1033.1988.tb14481.x; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; NOVER L, HEAT SHOCK RESPONSE, P41; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; QUAXJEUKEN Y, 1985, P NATL ACAD SCI USA, V82, P5819, DOI 10.1073/pnas.82.17.5819; REEDER RH, 1983, CELL, V35, P449, DOI 10.1016/0092-8674(83)90178-2; ROSS LH, 1995, J BIOL CHEM, V270, P22066, DOI 10.1074/jbc.270.37.22066; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; RUSSNAK RH, 1985, MOL CELL BIOL, V5, P1268, DOI 10.1128/MCB.5.6.1268; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sax C M, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P155; SLICE LW, 1990, J BIOL CHEM, V265, P256; SMITH PJ, 1988, J BIOL CHEM, V263, P9402; SNUTCH TP, 1988, GENE, V64, P241, DOI 10.1016/0378-1119(88)90339-3; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; SULSTON J, 1988, NEMATODE CAENORHABDI, P123; Sulston J., 1988, NEMATODE CAENORHABDI, P603; WADSWORTH WG, 1988, P NATL ACAD SCI USA, V85, P8435, DOI 10.1073/pnas.85.22.8435; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Wood W. B., 1988, NEMATODE C ELEGANS, P215; WOOD WB, 1980, DEV BIOL, V74, P446, DOI 10.1016/0012-1606(80)90445-5; [No title captured]	54	36	39	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30158	30166		10.1074/jbc.271.47.30158	http://dx.doi.org/10.1074/jbc.271.47.30158			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939966	hybrid			2022-12-25	WOS:A1996VU52500094
J	Arbeit, JM; Olson, DC; Hanahan, D				Arbeit, JM; Olson, DC; Hanahan, D			Upregulation of fibroblast growth factors and their receptors during multi-stage epidermal carcinogenesis in K14-HPV16 transgenic mice	ONCOGENE			English	Article						fibroblast growth factors; growth factor receptors; human papillomavirus; epidermal carcinogenesis	HUMAN PANCREATIC-CANCER; SQUAMOUS-CELL CARCINOMAS; HUMAN BREAST-CANCER; FACTOR EXPRESSION; FGF FAMILY; FACTOR-I; DIFFERENTIAL EXPRESSION; HUMAN PAPILLOMAVIRUS; SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS	Upregulation of acidic and factors (FGF-1 and -2), and FGFR-1 and -2, has been demonstrated in a variety of epithelial malignancies, However, the patterns of FGF/FGFR expression at specific stages of epithelial carcinogenesis have not been extensively characterized. In this report, the levels of FGF-1, FGF-2, FGF-7 mRNA and their receptors FGFR-1 and FGFR-2, were investigated during epidermal carcinogenesis in transgenic mice expressing the early region of the 'high risk' papillomavirus type 16 (HPV16) under control of the human keratin-14 enhancer/promoter (K14-HPV16 transgenic mice). FGF-1 was first upregulated in dysplasias, while FGF-2 was constitutively expressed in non-transgenic, neoplastic, and malignant keratinocytes throughout carcinogenesis. Expression of FGF-7 was undetectable in non-transgenic epidermis, and remained at threshold levels at all stages of progression. In well differentiated squamous cancers, FGFR-1 was upregulated and co-localized with angiogenic capillaries in the dermis underlying dysplastic lesions and within papillary fronds of invasive cancers. Tn contrast, FGFR-1 was upregulated specifically within the malignant squamous cells of moderate-poorly differentiated squamous cancers. The expression of FGFR-2 was essentially constitutive in both non-transgenic and neoplastic epidermis. Collectively the data suggest that the FGF/FGFR signaling pathways may potentially contribute to several facets of multi-stage epithelial carcinogenesis, including auto- or paracrine growth stimulation, upregulation of angiogenesis, and stromal remodeling.	UNIV CALIF SAN FRANCISCO,DEPT SURG,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Arbeit, JM (corresponding author), UNIV CALIF SAN FRANCISCO,HORMONE RES INST,503 PARNASSAS AVE,RM HSW 1090,SAN FRANCISCO,CA 94143, USA.		Arbeit, Jeffrey/K-6920-2019					ADNANE J, 1991, ONCOGENE, V6, P659; ARBEIT JM, 1994, J VIROL, V68, P4358, DOI 10.1128/JVI.68.7.4358-4368.1994; ARBEIT JM, 1996, CANC SURVEYS, V26, P1; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRICKARD K, 1994, GYNECOL ONCOL, V55, P277, DOI 10.1006/gyno.1994.1290; DIBLASIO AM, 1995, J STEROID BIOCHEM, V53, P375, DOI 10.1016/0960-0760(95)00082-B; FLORKIEWICZ RZ, 1995, J CELL PHYSIOL, V162, P388, DOI 10.1002/jcp.1041620311; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; HASEGAWA Y, 1994, BIOCHEM BIOPH RES CO, V200, P1435, DOI 10.1006/bbrc.1994.1611; HEBERT JM, 1990, DEV BIOL, V138, P454, DOI 10.1016/0012-1606(90)90211-Z; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HOGAN B, 1994, MANIPULATING MOUSE E, P153; HUGHES CJ, 1994, AM J SURG, V168, P381, DOI 10.1016/S0002-9610(05)80080-7; Hurlin PJ, 1995, ONCOGENE, V11, P2487; JACKSON A, 1995, J BIOL CHEM, V270, P33, DOI 10.1074/jbc.270.1.33; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; JACQUEMIER J, 1994, INT J CANCER, V59, P373, DOI 10.1002/ijc.2910590314; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JAYSON GC, 1994, CANCER RES, V54, P5718; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KOBRIN MS, 1993, CANCER RES, V53, P4741; KULESZMARTIN M, 1985, CARCINOGENESIS, V6, P1245, DOI 10.1093/carcin/6.9.1245; LEUNG HY, 1994, INT J CANCER, V59, P667, DOI 10.1002/ijc.2910590515; LOWY DR, 1994, P NATL ACAD SCI USA, V91, P2436, DOI 10.1073/pnas.91.7.2436; LUQMANI YA, 1992, BRIT J CANCER, V66, P273, DOI 10.1038/bjc.1992.256; MACIAG T, 1994, RECENT PROG HORM RES, V49, P105; MASON IJ, 1994, MECH DEVELOP, V45, P15, DOI 10.1016/0925-4773(94)90050-7; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MORE JAW, 1991, DEVELOPMENT, V111, P741; MYOKEN Y, 1994, J ORAL PATHOL MED, V23, P451, DOI 10.1111/j.1600-0714.1994.tb00443.x; NAKAMOTO T, 1992, CANCER RES, V52, P571; PENAULTLLORCA F, 1995, INT J CANCER, V61, P170, DOI 10.1002/ijc.2910610205; PETERS KG, 1992, DEVELOPMENT, V114, P233; PEYRAT JP, 1992, J STEROID BIOCHEM, V43, P87, DOI 10.1016/0960-0760(92)90191-K; REED JA, 1994, AM J PATHOL, V144, P329; ROBINSON ML, 1995, DEVELOPMENT, V121, P505; Sambrook J., 2002, MOL CLONING LAB MANU; SCHULTZHECTOR S, 1993, CANCER RES, V53, P1444; SINGH RK, 1994, AM J PATHOL, V145, P365; SLACK J, 1994, MOL REPROD DEV, V39, P118, DOI 10.1002/mrd.1080390118; SOUTTOU B, 1994, CELL GROWTH DIFFER, V5, P615; STOLER AB, 1993, J CELL BIOL, V122, P1103, DOI 10.1083/jcb.122.5.1103; TAKAHASHI JA, 1992, J NEUROSURG, V76, P792, DOI 10.3171/jns.1992.76.5.0792; TAKAHASHI JA, 1990, P NATL ACAD SCI USA, V87, P5710, DOI 10.1073/pnas.87.15.5710; TAYLOR WR, 1993, EXP CELL RES, V204, P295, DOI 10.1006/excr.1993.1036; THEILLET C, 1993, GENE CHROMOSOME CANC, V7, P219, DOI 10.1002/gcc.2870070407; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484; YAMAGUCHI TP, 1992, DEV BIOL, V152, P75, DOI 10.1016/0012-1606(92)90157-C; YAMANAKA Y, 1993, CANCER RES, V53, P5289; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513	62	57	61	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 7	1996	13	9					1847	1857						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934530				2022-12-25	WOS:A1996VR79500003
J	Chatterjee, TK; Sharma, RV; Fisher, RA				Chatterjee, TK; Sharma, RV; Fisher, RA			Molecular cloning of a novel variant of the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor that stimulates calcium influx by activation of L-type calcium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE INTESTINAL POLYPEPTIDE; FUNCTIONAL EXPRESSION; TISSUE DISTRIBUTION; SIGNAL-TRANSDUCTION; CALCITONIN RECEPTOR; PARATHYROID-HORMONE; G-PROTEINS; CELL-LINE; PEPTIDE; PATHWAYS	Pituitary adenylate cyclase-activating polypeptide (PACAP) is a novel neuropeptide that produces its biological effects by interacting with G protein-coupled receptors. Molecular cloning of the PACAP receptor revealed the existence of five splice variant receptor forms differing in the third intracellular loop region, with four variants activating both adenylyl cyclase and phospho inositide phospholipase C and one variant activating only adenylyl cyclase (Spengler, D., Waeber, C., Pantaloni, C., Holsboer, F., Bockaert, J., Seeburg, P. H., and Journot, L. (1993) Nature 365, 170-175). Here, we report cloning of a novel PACAP receptor variant, designated PACAPR TM4 (transmembrane domain IV), that differs from the previously cloned short form of the PACAP receptor (PACAPR) primarily by discrete sequences located in transmembrane domains II and IV. Reverse transcriptase-polymerase chain reaction and primer extension analyses demonstrated tissue-specific differential expression of mRNAs encoding PACAPR TM4 and splice variant forms of the PACAP receptor. PACAPR TM4 and PACAPR possess identical intracellular domains, implicated as primary determinants of G protein recognition by rhodopsin-like receptors. However, unlike the PACAPR, PACAPR TM4 does not activate either adenylyl cyclase or phosphoinositide phospholipase C in response to PACAP in either transient or stable expression systems. However, PACAP stimulates increases in [Ca2+](i) in cells expressing PACAPR TM4 by activating L-type Ca2+ channels, a response not elicited by stimulation with vasoactive intestinal poly-peptide. The signaling phenotype of PACAPR TM4 is characteristic of the PACAP receptor involved in regulation of insulin secretion from pancreatic beta islets, a tissue expressing transcripts for PACAPR TM4 but not for PACAPR or its longer splice variant forms. These findings are consistent with a role of PACAPR TM4 in the physiological control of insulin release by PACAP in beta-islet cells. The finding that PACAPR TM4 has a unique signaling phenotype, although it possesses intracellular domains identical to those of the PACAPR, suggests that receptor-G protein recognition by rhodopsin-like receptors can be determined by sequences other than those located in intracellular receptor domains.	UNIV IOWA,COLL MED,DEPT PHARMACOL,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT ANAT,IOWA CITY,IA 52242	University of Iowa; University of Iowa			Chatterjee, Rima/J-8066-2017	Fisher, Rory/0000-0003-3108-4836	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041071, R29HL041071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41071] Funding Source: Medline; NIDDK NIH HHS [DK25295] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARIMURA A, 1991, ENDOCRINOLOGY, V129, P2787, DOI 10.1210/endo-129-5-2787; ARIMURA A, 1992, REGUL PEPTIDES, V37, P287; BRINGHURST FR, 1993, ENDOCRINOLOGY, V132, P2090, DOI 10.1210/en.132.5.2090; BROWN E, 1984, J NEUROCHEM, V42, P1379, DOI 10.1111/j.1471-4159.1984.tb02798.x; BUSCAIL L, 1990, FEBS LETT, V262, P77, DOI 10.1016/0014-5793(90)80158-F; CHABRE O, 1992, MOL ENDOCRINOL, V6, P551, DOI 10.1210/me.6.4.551; CHATTERJEE TK, 1995, METH NEUROSCI, V26, P29; CHRISTOPHE J, 1993, BIOCHIM BIOPHYS ACTA, V1154, P183, DOI 10.1016/0304-4157(93)90011-C; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; DELPORTE C, 1995, MOL CELL ENDOCRINOL, V107, P71, DOI 10.1016/0303-7207(94)03424-R; DEUTSCH PJ, 1992, J BIOL CHEM, V267, P5108; HASHIMOTO H, 1993, NEURON, V11, P333, DOI 10.1016/0896-6273(93)90188-W; HAWES BE, 1994, J BIOL CHEM, V269, P15776; INAGAKI N, 1994, P NATL ACAD SCI USA, V91, P2679, DOI 10.1073/pnas.91.7.2679; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KOVES K, 1991, NEUROENDOCRINOLOGY, V54, P159, DOI 10.1159/000125864; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; MAYO KE, 1992, MOL ENDOCRINOL, V6, P1734, DOI 10.1210/me.6.10.1734; MIYAMOTO Y, 1994, BBA-GENE STRUCT EXPR, V1218, P297, DOI 10.1016/0167-4781(94)90181-3; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; MIYATA A, 1990, BIOCHEM BIOPH RES CO, V170, P643, DOI 10.1016/0006-291X(90)92140-U; MORROW JA, 1993, FEBS LETT, V329, P99, DOI 10.1016/0014-5793(93)80202-6; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; OGI K, 1993, BIOCHEM BIOPH RES CO, V196, P1511, DOI 10.1006/bbrc.1993.2423; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; OSTROWSKI J, 1992, ANNU REV PHARMACOL, V32, P167, DOI 10.1146/annurev.pharmtox.32.1.167; PISEGNA JR, 1993, P NATL ACAD SCI USA, V90, P6345, DOI 10.1073/pnas.90.13.6345; RAWLINGS SR, 1994, J BIOL CHEM, V269, P5680; SCHOMERUS E, 1994, ENDOCRINOLOGY, V134, P315, DOI 10.1210/en.134.1.315; SCHREIBER RE, 1994, J BIOL CHEM, V269, P326; SHARMA RV, 1993, AM J PHYSIOL, V264, pC71, DOI 10.1152/ajpcell.1993.264.1.C71; SHIVERS BD, 1991, ENDOCRINOLOGY, V128, P3055, DOI 10.1210/endo-128-6-3055; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WONG SKF, 1990, J BIOL CHEM, V265, P6219; YADA T, 1994, J BIOL CHEM, V269, P1290	42	137	139	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32226	32232		10.1074/jbc.271.50.32226	http://dx.doi.org/10.1074/jbc.271.50.32226			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943280	hybrid			2022-12-25	WOS:A1996VY34000071
J	Deans, Z; Dawson, SJ; Xie, JL; Young, AP; Wallace, D; Latchman, DS				Deans, Z; Dawson, SJ; Xie, JL; Young, AP; Wallace, D; Latchman, DS			Differential regulation of the two neuronal nitric-oxide synthase gene promoters by the Oct-2 transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENES; SENSORY NEURONS; IMMUNOGLOBULIN GENES; OCTAMER MOTIF; PROTEIN; EXPRESSION; BINDING; RAT; ACTIVATION; DOMAINS	The Oct-2 transcription factor has been shown previ ously to repress both the cellular tyrosine hydroxylase and the herpes simplex virus immediate-early genes in neuronal cells, Here we identify the gene encoding the neuronal nitric oxide synthase (nNOS) as the first example of a gene activated in neuronal cells by Oct-2, The levels of the nNOS mRNA and protein are greatly reduced in neuronal cell lines in which Oct-2 levels have been reduced by an antisense method, although these cells have enhanced levels of tyrosine hydroxylase, Moreover, the nNOS gene regulatory region is activated by Oct-2 expression vectors upon cotransfection into both neuronal and non-neuronal cells, and this response is dependent upon a 20-amino acid region within the COOH-terminal activation domain of Oct-2. Of the two closely linked promoters that drive nNOS gene expression, only the downstream 5.1 promoter is activated by Oct-2, whereas the 5.2 promoter is unaffected. These effects are discussed in terms of the potential role of Oct-2 in regulating nNOS expression in the nervous system.	UCL, SCH MED, DEPT MOL PATHOL, LONDON W1P 6DB, ENGLAND; OHIO STATE UNIV, COLL PHARM, NEUROBIOTECHNOL CTR, OHIO STATE BIOCHEM PROGRAM, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, COLL PHARM, DIV PHARMACOL, COLUMBUS, OH 43210 USA; GLAXO WELLCOME RES & DEV LTD, MED RES CTR, STEVENAGE SG1 2NY, HERTS, ENGLAND	University of London; University College London; UCL Medical School; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; GlaxoSmithKline				Dawson, Sally/0000-0002-4421-2043				ABKEN H, 1992, NUCLEIC ACIDS RES, V20, P3527, DOI 10.1093/nar/20.13.3527; AIMI Y, 1991, J COMP NEUROL, V306, P382, DOI 10.1002/cne.903060303; Begbie JL, 1996, NEUROSCI LETT, V207, P183, DOI 10.1016/0304-3940(96)12514-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOI DW, 1993, P NATL ACAD SCI USA, V90, P9741, DOI 10.1073/pnas.90.21.9741; CORCORAN LM, 1993, GENE DEV, V7, P570, DOI 10.1101/gad.7.4.570; DAWSON SJ, 1994, NUCLEIC ACIDS RES, V22, P1023, DOI 10.1093/nar/22.6.1023; Deans L, 1995, J MOL NEUROSCI, V6, P159, DOI 10.1007/BF02736762; DHILLON V, 1993, BRIT J RHEUMATOL, V32, P883; EDELMAN GM, 1992, P NATL ACAD SCI USA, V89, P11651, DOI 10.1073/pnas.89.24.11651; FALKNER FG, 1986, NUCLEIC ACIDS RES, V13, P7847; GERSTER T, 1990, EMBO J, V9, P1635, DOI 10.1002/j.1460-2075.1990.tb08283.x; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HALL AV, 1994, J BIOL CHEM, V269, P33082; KEMP LM, 1990, NEURON, V4, P215, DOI 10.1016/0896-6273(90)90096-X; KENDALL G, 1995, J NEUROSCI RES, V40, P169, DOI 10.1002/jnr.490400205; KENDALL G, 1994, MOL BRAIN RES, V25, P73, DOI 10.1016/0169-328X(94)90280-1; KONIG H, 1995, GENE DEV, V9, P1598, DOI 10.1101/gad.9.13.1598; LILLYCROP KA, 1995, BIOCHEM J, V307, P581, DOI 10.1042/bj3070581; LILLYCROP KA, 1994, MOL CELL BIOL, V14, P7633, DOI 10.1128/MCB.14.11.7633; LILLYCROP KA, 1992, J BIOL CHEM, V267, P24960; LILLYCROP KA, 1991, NEURON, V7, P381, DOI 10.1016/0896-6273(91)90290-G; Liu YZ, 1996, J BIOL CHEM, V271, P20853, DOI 10.1074/jbc.271.34.20853; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MULLERIMMERGLUCK MM, 1990, EMBO J, V9, P1625, DOI 10.1002/j.1460-2075.1990.tb08282.x; PFISTERER P, 1994, EMBO J, V13, P1654, DOI 10.1002/j.1460-2075.1994.tb06429.x; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; STOYKOVA AS, 1992, NEURON, V8, P541, DOI 10.1016/0896-6273(92)90282-I; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; VERGE VMK, 1992, P NATL ACAD SCI USA, V89, P11617, DOI 10.1073/pnas.89.23.11617; VERRIJZER CP, 1990, EMBO J, V9, P1883, DOI 10.1002/j.1460-2075.1990.tb08314.x; Wegner M, 1993, CURR OPIN CELL BIOL, V5, P488, DOI 10.1016/0955-0674(93)90015-I; WIRTH T, 1991, NUCLEIC ACIDS RES, V19, P43, DOI 10.1093/nar/19.1.43; WOOD JN, 1990, P ROY SOC B-BIOL SCI, V241, P187, DOI 10.1098/rspb.1990.0084; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; XIE JL, 1995, P NATL ACAD SCI USA, V92, P1242, DOI 10.1073/pnas.92.4.1242; YOON SO, 1992, NEURON, V9, P55, DOI 10.1016/0896-6273(92)90220-8; [No title captured]	42	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32153	32158		10.1074/jbc.271.50.32153	http://dx.doi.org/10.1074/jbc.271.50.32153			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943269	hybrid			2022-12-25	WOS:A1996VY34000060
J	King, SM; Dillman, JF; Benashski, SE; Lye, RJ; PatelKing, RS; Pfister, KK				King, SM; Dillman, JF; Benashski, SE; Lye, RJ; PatelKing, RS; Pfister, KK			The blouse t-complex-encoded protein Tctex-1 is a light chain of brain cytoplasmic dynein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER ARM DYNEIN; INTERMEDIATE CHAIN; CHLAMYDOMONAS FLAGELLA; IDENTIFICATION; LOCALIZATION; MICROTUBULES; POLYPEPTIDE; FAMILY; ATPASE; CELL	Mammalian brain cytoplasmic dynein contains three light chains of M(r) = 8,000, 14,000, add 22,000 (King, S. M., Barbarese, E., Dillman, J. F., III, Patel-King, R. S., Carson, J. H., and Pfister, K. Kr (1996) J. Biol. Chem. 271, 19358-19366). Peptide sequence data (16/16 residues correct) implicate the M(r) = 14,000 polypeptide as Tctex-1, a protein encoded within the mouse t-complex. Tctex-1 cosediments with microtubules and is eluted with ATP or salt but not with GTP as expected for a dynein subunit, The ATP-eluted protein precisely cosediments with known cytoplasmic dynein proteins in sucrose density gradients, Tctex-1 also is immunoprecipitated from brain and other tissue homogenates by a monoclonal antibody raised against the 74-kDa cytoplasmic dynein intermediate chain, Quantitative densitometry indicates that Tctex-1 is a stoichiometric component of the dynein complex, As Tctex-1 is a candidate for involvement in the transmission ratio distortion (meiotic drive) of mouse t-haplotypes, these results suggest that cytoplasmic dynein dysfunction may play an important role in non-mendelian chromosome segregation.	UNIV VIRGINIA, HLTH SCI CTR, DEPT CELL BIOL, CHARLOTTESVILLE, VA 22908 USA	University of Virginia	King, SM (corresponding author), UNIV CONNECTICUT, CTR HLTH, DEPT BIOCHEM, 263 FARMINGTON AVE, FARMINGTON, CT 06032 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051293] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029996] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 51293] Funding Source: Medline; NINDS NIH HHS [NS 29996] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BARKALOW K, 1994, J CELL BIOL, V126, P727, DOI 10.1083/jcb.126.3.727; BECKWITH SM, 1995, MOL BIOL CELL, V6, P24; CORTHESYTHEULAZ I, 1992, J CELL BIOL, V118, P1333, DOI 10.1083/jcb.118.6.1333; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Dick T, 1996, MOL CELL BIOL, V16, P1966; DILLMAN JF, 1994, J CELL BIOL, V127, P1671, DOI 10.1083/jcb.127.6.1671; Egan SE, 1996, NATURE, V381, P194, DOI 10.1038/381194a0; ESPINDOLA FS, 1996, IN PRESS MOL BIOL CE, V7; GILL SR, 1994, MOL BIOL CELL, V5, P645, DOI 10.1091/mbc.5.6.645; HILLIER L, 1995, WASHU MERCK EST PROJ; Holzbaur Erika L. F., 1994, V13, P251; HUGHES SM, 1995, J CELL SCI, V108, P17; HUW LY, 1995, DEV BIOL, V170, P183, DOI 10.1006/dbio.1995.1206; KARKI S, 1995, J BIOL CHEM, V270, P28806, DOI 10.1074/jbc.270.48.28806; KING SM, 1995, J CELL SCI, V108, P3757; KING SM, 1990, J BIOL CHEM, V265, P19807; King SM, 1996, J BIOL CHEM, V271, P19358, DOI 10.1074/jbc.271.32.19358; KING SM, 1995, J BIOL CHEM, V270, P11445, DOI 10.1074/jbc.270.19.11445; KING SM, 1991, J BIOL CHEM, V266, P8401; KING SM, 1995, J CELL BIOL, V131, P399, DOI 10.1083/jcb.131.2.399; LADER E, 1989, CELL, V58, P969, DOI 10.1016/0092-8674(89)90948-3; LI YY, 1993, P NATL ACAD SCI USA, V90, P10096, DOI 10.1073/pnas.90.21.10096; LYON MF, 1986, CELL, V44, P357, DOI 10.1016/0092-8674(86)90770-1; Meindl A, 1996, NAT GENET, V13, P35, DOI 10.1038/ng0596-35; MITCHELL DR, 1986, CELL MOTIL CYTOSKEL, V6, P510, DOI 10.1002/cm.970060510; MITCHELL DR, 1994, INT REV CYTOL, V155, P141, DOI 10.1016/S0074-7696(08)62098-7; MUSARELLA MA, 1991, GENOMICS, V11, P263, DOI 10.1016/0888-7543(91)90132-X; NEELY MD, 1988, J CELL BIOL, V107, P1767, DOI 10.1083/jcb.107.5.1767; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; OLMSTED JB, 1986, METHOD ENZYMOL, V134, P467; ONEILL MJ, 1995, DEVELOPMENT, V121, P561; PASCHAL BM, 1993, J BIOL CHEM, V268, P15318; PASCHAL BM, 1987, J CELL BIOL, V105, P1273, DOI 10.1083/jcb.105.3.1273; PASCHAL BM, 1987, NATURE, V330, P181, DOI 10.1038/330181a0; PASCHAL BM, 1992, J CELL BIOL, V118, P1133, DOI 10.1083/jcb.118.5.1133; PASCHAL BM, 1991, METHOD ENZYMOL, V196, P181; PatelKing RS, 1996, J BIOL CHEM, V271, P6283, DOI 10.1074/jbc.271.11.6283; PATELKING RS, 1996, IN PRESS MOL BIOL CE, V7; PFARR CM, 1990, NATURE, V345, P263, DOI 10.1038/345263a0; PFISTER KK, 1982, CELL MOTIL CYTOSKEL, V2, P525, DOI 10.1002/cm.970020604; Pfister KK, 1996, MOL BIOL CELL, V7, P331, DOI 10.1091/mbc.7.2.331; Pfister KK, 1996, J BIOL CHEM, V271, P1687, DOI 10.1074/jbc.271.3.1687; PFISTER KK, 1989, J CELL BIOL, V108, P1453, DOI 10.1083/jcb.108.4.1453; PFISTER KK, 1984, J BIOL CHEM, V259, P2072; ROUX AF, 1994, HUM MOL GENET, V3, P257, DOI 10.1093/hmg/3.2.257; SAKAKIBARA H, 1993, J CELL BIOL, V122, P653, DOI 10.1083/jcb.122.3.653; SALE WS, 1985, J CELL BIOL, V101, P1400, DOI 10.1083/jcb.101.4.1400; SAUNDERS WS, 1995, J CELL BIOL, V128, P617, DOI 10.1083/jcb.128.4.617; SCHROER TA, 1989, CELL, V56, P937, DOI 10.1016/0092-8674(89)90627-2; SILVER LM, 1993, TRENDS GENET, V9, P250, DOI 10.1016/0168-9525(93)90090-5; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vaisberg EA, 1996, J CELL BIOL, V133, P831, DOI 10.1083/jcb.133.4.831; VALLEE RB, 1988, NATURE, V332, P561, DOI 10.1038/332561a0; VAUGHAN KT, 1995, J CELL BIOL, V131, P1507, DOI 10.1083/jcb.131.6.1507; Warner F.D., 1989, CELL MOVEMENT, V1; WILKERSON CG, 1995, J CELL BIOL, V129, P169, DOI 10.1083/jcb.129.1.169; Witman George B., 1994, V13, P229; XIANG X, 1994, P NATL ACAD SCI USA, V91, P2100, DOI 10.1073/pnas.91.6.2100; YOSHIDA T, 1994, J CELL SCI, V107, P625	62	118	119	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32281	32287		10.1074/jbc.271.50.32281	http://dx.doi.org/10.1074/jbc.271.50.32281			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943288	hybrid			2022-12-25	WOS:A1996VY34000079
J	Paucek, P; YarovYarovoy, V; Sun, XC; Garlid, KD				Paucek, P; YarovYarovoy, V; Sun, XC; Garlid, KD			Inhibition of the mitochondrial K-ATP channel by long-chain Acyl-CoA esters and activation by guanine nucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H EXCHANGER; RAT-LIVER; PURIFICATION; UNMASKING; VOLUME	The mitochondrial K-ATP channel (mitoK(ATP)) is highly sensitive to ATP, which inhibits K+ flux with K-1/2 values of 20-40 mu M. This raises the question, how can mitoK(ATP) be opened in the presence of physiological concentrations of ATP? We measured K+ flux in liposomes reconstituted with purified mitoK(ATP) and found that guanine nucleotides are potent activators of this channel, ATP-inhibited K+ flux was completely reactivated by both GTP (K-1/2 = 7 mu M) and GDP (K-1/2 = 140 mu M). These ligands had no effect in the absence of ATP, The K-1/2 for ATP inhibition exhibited quadratic dependence on [GTP] and [GDP], consistent with two binding sites for guanine nucleotides. We also found that palmitoyl-CoA and oleoyl-CoA inhibited K+ flux through reconstituted mitoK(ATP) with K-1/2 values of 260 nM and 80 nM, respectively. This inhibition was reversed by GTP (K-1/2 = 232 mu M) as well as by the K+ channel openers cromakalim (20 mu M) and diazoxide (10 mu M). Inhibition of mitoK(ATP) by long-chain acyl-CoA esters, like that of ATP, exhibited an absolute requirement for Mg2+ ions. We propose that the open-closed state of the mitochondrial K-ATP channel is determined by the relative cytosolic concentrations of GTP and long-chain acyl-CoA esters.	OREGON GRAD INST SCI & TECHNOL, DEPT CHEM BIOCHEM & MOL BIOL, PORTLAND, OR 97291 USA				Yarov-Yarovoy, Vladimir/ABE-5454-2020	Yarov-Yarovoy, Vladimir/0000-0002-2325-4834; Garlid, Keith/0000-0002-6777-1235	NHLBI NIH HHS [HL 36573] Funding Source: Medline; NIGMS NIH HHS [GM 31086] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031086] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEAVIS AD, 1993, J BIOL CHEM, V268, P997; BRIERLEY GP, 1978, MOL BIOL MEMBRANES, P295; Garlid KD, 1995, METHOD ENZYMOL, V260, P331, DOI 10.1016/0076-6879(95)60149-X; GARLID KD, 1979, BIOCHEM BIOPH RES CO, V87, P842, DOI 10.1016/0006-291X(79)92034-5; Garlid KD, 1996, BBA-BIOENERGETICS, V1275, P123, DOI 10.1016/0005-2728(96)00061-8; Garlid KD, 1996, J BIOL CHEM, V271, P8796, DOI 10.1074/jbc.271.15.8796; GARLID KD, 1978, BIOCHEM BIOPH RES CO, V83, P1450, DOI 10.1016/0006-291X(78)91383-9; GARLID KD, 1988, INTEGRATION MITOCHON, P257; Garlid Keith D., 1996, Biophysical Journal, V70, pA311; GUI G, 1991, J MOL CELL CARDIOL, V23, pS78; HALESTRAP AP, 1989, BIOCHIM BIOPHYS ACTA, V973, P355, DOI 10.1016/S0005-2728(89)80378-0; HALESTRAP AP, 1994, BIOCHEM SOC T, V22, P552; HEGAZY M G, 1991, Biophysical Journal, V59, p136A; INOUE I, 1991, NATURE, V352, P244, DOI 10.1038/352244a0; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; Larsson O, 1996, J BIOL CHEM, V271, P10623, DOI 10.1074/jbc.271.18.10623; MCENERY MW, 1989, J BIOL CHEM, V264, P12029; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; NICHOLLS DG, 1972, EUR J BIOCHEM, V31, P526, DOI 10.1111/j.1432-1033.1972.tb02561.x; Paucek P., 1995, Biophysical Journal, V68, pA145; PAUCEK P, 1992, J BIOL CHEM, V267, P26062; Szewczyk Adam, 1993, Acta Biochimica Polonica, V40, P329; VALLIN I, 1970, ACTA ZOOLOGICA, V51, P129; WOLDEGIORGIS G, 1995, FEBS LETT, V364, P143, DOI 10.1016/0014-5793(95)00375-J	25	83	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32084	32088		10.1074/jbc.271.50.32084	http://dx.doi.org/10.1074/jbc.271.50.32084			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943260	hybrid			2022-12-25	WOS:A1996VY34000051
J	Christodoulidou, A; Bouriotis, V; Thireos, G				Christodoulidou, A; Bouriotis, V; Thireos, G			Two sporulation-specific chitin deacetylase-encoding genes are required for the ascospore wall rigidity of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUCOR-ROUXII; COLLETOTRICHUM-LINDEMUTHIANUM; CELL-CYCLE; YEAST; CHITOSAN; PURIFICATION; DITYROSINE; MATURATION; SYNTHASE-3; CSD2	The formation of the ascospore wall of Saccharomyces cerevisiae requires the coordinate activity of enzymes involved in the biosynthesis of its components such as chitosan, the deacetylated form of chitin, We have cloned the CDA1 and CDA2 genes which together account for the total chitin deacetylase activity of the organism. We hare shown that expression of these genes is restricted to a distinct time period during sporulation. The two genes are functionally redundant, each contributing equally to the total chitin deacetylase activity. Diploids disrupted for both genes sporulate as efficiently as wild type cells, and the resulting mutant spores are viable under standard laboratory conditions. However, they fail to emit the natural fluorescence of yeast spores imparted by the dityrosine residues of the outermost ascospore wall layer. Moreover, mutant spores are relatively sensitive to hydrolytic enzymes, ether, and heat shock, a fact that underscores the importance of the CDA genes for the proper formation of the ascospore wall.	FDN RES & TECHNOL HELLAS, INST MOL BIOL & BIOTECHNOL, GR-71110 IRAKLION, GREECE; UNIV CRETE, DEPT BIOL, IRAKLION, CRETE, GREECE	Foundation for Research & Technology - Hellas (FORTH); University of Crete								ALFONSO C, 1995, CURR MICROBIOL, V30, P49, DOI 10.1007/BF00294524; ARAKI Y, 1975, EUR J BIOCHEM, V55, P71, DOI 10.1111/j.1432-1033.1975.tb02139.x; ARAKI Y, 1988, METHOD ENZYMOL, V161, P510; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BALLOU CE, 1977, P NATL ACAD SCI USA, V74, P4351, DOI 10.1073/pnas.74.10.4351; Bartnicki-Garcia S., 1989, CHITIN CHITOSAN, P23; BARTNICKIGARCIA S, 1962, BIOCHIM BIOPHYS ACTA, V58, P102, DOI 10.1016/0006-3002(62)90822-3; BRIZA P, 1986, J BIOL CHEM, V261, P4288; BRIZA P, 1990, J BIOL CHEM, V265, P15118; BRIZA P, 1988, J BIOL CHEM, V263, P11569; BRIZA P, 1990, GENE DEV, V4, P1775, DOI 10.1101/gad.4.10.1775; BULAWA CE, 1992, MOL CELL BIOL, V12, P1764, DOI 10.1128/MCB.12.4.1764; BULAWA CE, 1993, ANNU REV MICROBIOL, V47, P505, DOI 10.1146/annurev.micro.47.1.505; CHOI WJ, 1994, MOL CELL BIOL, V14, P7685, DOI 10.1128/MCB.14.12.7685; CID VJ, 1995, MICROBIOL REV, V59, P345, DOI 10.1128/MMBR.59.3.345-386.1995; DAVIS LL, 1984, BIOCHEMISTRY-US, V23, P1065, DOI 10.1021/bi00301a005; DAVIS LL, 1984, J GEN MICROBIOL, V130, P2095; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P9509; DRISCOLLPENN M, 1984, MOL CELL BIOL, V4, P520; GAO XD, 1995, J BIOCHEM, V117, P257, DOI 10.1093/jb/117.2.257; HEPWORTH SR, 1995, MOL CELL BIOL, V15, P3934; JOHN M, 1993, P NATL ACAD SCI USA, V90, P2564; KAFETZOPOULOS D, 1993, P NATL ACAD SCI USA, V90, P8005, DOI 10.1073/pnas.90.17.8005; KAFETZOPOULOS D, 1993, P NATL ACAD SCI USA, V90, P2564, DOI 10.1073/pnas.90.7.2564; KATHODA S, 1984, AGR BIOL CHEM TOKYO, V48, P895; KAUSS H, 1983, PLANT SCI LETT, V28, P231, DOI 10.1016/S0304-4211(83)80014-5; KLIS FM, 1994, YEAST, V10, P851, DOI 10.1002/yea.320100702; KREGERVANRIJ NJW, 1978, ARCH MICROBIOL, V117, P73, DOI 10.1007/BF00689354; LAW DTS, 1988, MOL CELL BIOL, V8, P912, DOI 10.1128/MCB.8.2.912; MILLER JJ, 1989, YEASTS; MITCHELL AP, 1994, MICROBIOL REV, V58, P56, DOI 10.1128/MMBR.58.1.56-70.1994; PAMMER M, 1992, YEAST, V8, P1089, DOI 10.1002/yea.320081211; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; SHAW JA, 1991, J CELL BIOL, V114, P111, DOI 10.1083/jcb.114.1.111; STRATFORD M, 1994, YEAST, V10, P1741, DOI 10.1002/yea.320101307; TSIGOS I, 1995, J BIOL CHEM, V270, P26286, DOI 10.1074/jbc.270.44.26286; VALDIVIESO MH, 1991, J CELL BIOL, V114, P101, DOI 10.1083/jcb.114.1.101	37	90	94	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31420	31425		10.1074/jbc.271.49.31420	http://dx.doi.org/10.1074/jbc.271.49.31420			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940152	hybrid			2022-12-25	WOS:A1996VW68600063
J	Pullner, A; Mautner, J; Albert, T; Eick, D				Pullner, A; Mautner, J; Albert, T; Eick, D			Nucleosomal structure of active and inactive c-myc genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; BURKITTS-LYMPHOMA CELLS; FAR UPSTREAM ELEMENT; CHROMATIN STRUCTURE; TRANSCRIPTIONAL ELONGATION; PROMOTER SHIFT; REPRESSES TRANSCRIPTION; TRANS-ACTIVATION; PROTEIN-BINDING; DOWN-REGULATION	The nucleosomal structure of active and inactive c-myc genes has been analyzed in detail in undifferentiated and differentiated cells of the promyelocytic leukemia cell Line HL60. The c-myc P2 promoter was never found in nucleosomal configuration, no matter whether c-myc was expressed or not. Differences in the nucleosomal structure, however, were found in the promoter upstream region proximal to a previously described DNase I-hypersensitive site I, at the P0 promoter, and at the P1 promoter and upstream thereof. In these regions nucleosomes were detected in differentiated but not undifferentiated HL60 cells. Similar patterns of nucleosomes as found for active and inactive c-myc genes in HL60 cells were found for active and inactive episomal c-myc genes in stably transfected B cell Lines. In these cell lines three activation stages could be described for episomal c-myc constructs: (i) uninducible, (ii) inducible, and (iii) induced. Significant differences in the nucleosomal structure of c-myc were observed for the uninducible and inducible stages, but not for the inducible and induced stages.	GSF MUNICH, FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT, INST KLIN MOL BIOL & TUMOR GENET, D-81377 MUNICH, GERMANY	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health				Albert, Thomas Karl/0000-0002-2488-0706				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ARCINAS M, 1994, ONCOGENE, V9, P2699; AVIGAN MI, 1990, J BIOL CHEM, V265, P18538; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BAZAR L, 1995, ONCOGENE, V10, P2229; BENTLEY DL, 1995, CURR OPIN GENET DEV, V5, P210, DOI 10.1016/0959-437X(95)80010-7; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; BRYS A, 1994, P NATL ACAD SCI USA, V91, P4915, DOI 10.1073/pnas.91.11.4915; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DALLAFAVERA R, 1982, NATURE, V299, P61; DESJARDINS E, 1993, MOL CELL BIOL, V13, P5710, DOI 10.1128/MCB.13.9.5710; DUFORT D, 1994, MOL CELL BIOL, V14, P4251, DOI 10.1128/MCB.14.6.4251; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; DYSON PJ, 1985, EMBO J, V4, P2885, DOI 10.1002/j.1460-2075.1985.tb04018.x; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; FAHRLANDER PD, 1985, EMBO J, V4, P3195, DOI 10.1002/j.1460-2075.1985.tb04065.x; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; Filippova GN, 1996, MOL CELL BIOL, V16, P2802; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HORTNAGEL K, 1995, ONCOGENE, V10, P1393; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; KOHLHUBER F, 1993, ONCOGENE, V8, P1099; KRUMM A, 1995, GENE DEV, V9, P559, DOI 10.1101/gad.9.5.559; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; KUMAR S, 1991, J MOL BIOL, V222, P45, DOI 10.1016/0022-2836(91)90736-P; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LANG JC, 1991, ONCOGENE, V6, P2067; LAVENU A, 1994, ONCOGENE, V9, P527; MADISEN L, 1994, GENE DEV, V8, P2212, DOI 10.1101/gad.8.18.2212; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Mautner J, 1996, ONCOGENE, V12, P1299; MAUTNER J, 1995, NUCLEIC ACIDS RES, V23, P72, DOI 10.1093/nar/23.1.72; MEYER KB, 1989, EMBO J, V8, P1959, DOI 10.1002/j.1460-2075.1989.tb03601.x; MICHELOTTI EF, 1995, J BIOL CHEM, V270, P9494, DOI 10.1074/jbc.270.16.9494; Michelotti GA, 1996, MOL CELL BIOL, V16, P2656, DOI 10.1128/mcb.16.6.2656; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; POLACK A, 1991, ONCOGENE, V6, P2033; POLACK A, 1993, EMBO J, V12, P3913, DOI 10.1002/j.1460-2075.1993.tb06069.x; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SIEBENLIST U, 1988, MOL CELL BIOL, V8, P867, DOI 10.1128/MCB.8.2.867; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STROBL LJ, 1993, ONCOGENE, V8, P1437; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; TAKIMOTO M, 1989, J BIOL CHEM, V264, P8992; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; Wilson CJ, 1996, CELL, V84, P235, DOI 10.1016/S0092-8674(00)80978-2; WITTIG B, 1992, EMBO J, V11, P4653, DOI 10.1002/j.1460-2075.1992.tb05567.x; WOLF DA, 1995, NUCLEIC ACIDS RES, V23, P3373, DOI 10.1093/nar/23.17.3373; WOLFFE AP, 1994, CELL, V77, P13, DOI 10.1016/0092-8674(94)90229-1; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2	63	26	26	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31452	31457		10.1074/jbc.271.49.31452	http://dx.doi.org/10.1074/jbc.271.49.31452			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940157	hybrid			2022-12-25	WOS:A1996VW68600068
J	Richieri, GV; Ogata, RT; Kleinfeld, AM				Richieri, GV; Ogata, RT; Kleinfeld, AM			Thermodynamic and kinetic properties of fatty acid interactions with rat liver fatty acid-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENT-PROBE ADIFAB; ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE; LIGAND-BINDING; RESOLUTION; ADIPOCYTE; APOPROTEIN; CYTOSOL; FAMILY	Fatty acid-binding protein from rat liver (L-FABP) binds 2 fatty acids (FA) per protein, in contrast to FABPs from adipocyte, heart, and intestine, for which binding and structural studies are consistent with a single FA binding site, To understand better the unique characteristics of L-FABP, we have carried out equilibrium binding and kinetic measurements of long- chain FA us ing the fluorescent probes of free fatty acids (FFA), ADIFAB and ADIFAB2, to monitor the concentration of FFA in the reaction of FA with L-FABP, We found that the dissociation constants (K-d) ranged from about 1 nM to 4 mu M, being largest for myristate at 45 degrees C and smallest for oleate at 10 degrees C, and that 2 FA were bound per L-FABP for all temperatures and Fk The binding measurements also revealed that at temperatures below 37 degrees C, affinities for the two binding sites differ by between 5- and 20-fold but as the temperature was increased, the affinities converge toward equal values, Off-rate constants (K-off were similar for all FA and for temperatures between 10 and 45 degrees C, ranged from about 0.1 s(-1) to 50 s(-1). Moreover, for all FA, k(off) values for dissociation from both the high and low affinity sites were similar, indicating that binding affinity differences at the lower temperatures reflect lower on-rates for binding to the ion: affinity site, The temperature at which the affinities of the two sites become equivalent depends upon the FA; higher temperatures (45-50 degrees C) are required for the unsaturated FA and myristate than for the longer chain saturated FA (<37 degrees C. This transition from different to equivalent affinity binding sites at specific tempera tures reflects a nonlinear van't Hoff behavior of the high affinity site, which in turn is a reflection of large heat capacity changes (between -0.6 and -1.2 kcal K-1 mol(-1)) that accompany FA binding to the high affinity site, These heat capacity changes, which are unique to L-FABP, do not appear to be correlated with a significant conformational change upon ligand binding, The differences between long chain saturated and unsaturated FA suggest that the conformation of FA bound to L-FABP may differ with both FA type and temperature, and that, in comparison to other FABPs, L-FABP may have distinctly different effects on saturated and unsaturated FA metabolism.	INST MED BIOL,LA JOLLA,CA 92037						NIGMS NIH HHS [GM46931] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046931] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANASZAK L, 1994, ADV PROTEIN CHEM, V45, P89; BASS NM, 1988, INT REV CYTOL, V111, P143, DOI 10.1016/S0074-7696(08)61733-7; BRECHER P, 1984, J BIOL CHEM, V259, P3395; BRUNAUER LS, 1994, BIOCHEMISTRY-US, V33, P4527, DOI 10.1021/bi00181a013; Cantor C.R., 1980, BIOPHYS CHEM; CISTOLA DP, 1989, J BIOL CHEM, V264, P2700; Guinto ER, 1996, BIOCHEMISTRY-US, V35, P8800, DOI 10.1021/bi9608828; HAUNERLAND NH, 1994, BIOCHEMISTRY-US, V33, P12378, DOI 10.1021/bi00207a004; JAKOBY MG, 1993, BIOCHEMISTRY-US, V32, P872, DOI 10.1021/bi00054a019; KIM HK, 1992, J BIOL CHEM, V267, P77; Kleinfeld Alan M., 1996, Biophysical Journal, V70, pA236; Kurian E, 1996, BIOCHEMISTRY-US, V35, P3865, DOI 10.1021/bi952589y; LALONDE JM, 1994, J BIOL CHEM, V269, P25339; LEVI AJ, 1969, J CLIN INVEST, V48, P2156, DOI 10.1172/JCI106182; LOWE JB, 1987, J BIOL CHEM, V262, P5931; MISHKIN S, 1975, AM J PHYSIOL, V228, P1634, DOI 10.1152/ajplegacy.1975.228.6.1634; NAGHIBI H, 1995, P NATL ACAD SCI USA, V92, P5597, DOI 10.1073/pnas.92.12.5597; NEMECZ G, 1991, ARCH BIOCHEM BIOPHYS, V286, P300, DOI 10.1016/0003-9861(91)90044-J; OCKNER RK, 1972, SCIENCE, V177, P56, DOI 10.1126/science.177.4043.56; Oliveberg M, 1996, BIOCHEMISTRY-US, V35, P2738, DOI 10.1021/bi950967t; RICHIERI GV, 1992, J BIOL CHEM, V267, P23495; RICHIERI GV, 1995, J BIOL CHEM, V270, P15076, DOI 10.1074/jbc.270.25.15076; RICHIERI GV, 1995, J LIPID RES, V36, P229; RICHIERI GV, 1993, BIOCHEMISTRY-US, V32, P7574, DOI 10.1021/bi00080a032; Richieri GV, 1996, J BIOL CHEM, V271, P11291, DOI 10.1074/jbc.271.19.11291; RICHIERI GV, 1994, J BIOL CHEM, V269, P23918; Rolf B, 1995, BBA-LIPID LIPID MET, V1259, P245, DOI 10.1016/0005-2760(95)00170-0; SACCHETTINI JC, 1992, J BIOL CHEM, V267, P23534; SACCHETTINI JC, 1993, J BIOL CHEM, V268, P18399; STORCH J, 1989, J BIOL CHEM, V264, P8708; SWEETSER DA, 1986, J BIOL CHEM, V261, P5553; TAKAHASHI K, 1983, EUR J BIOCHEM, V136, P589, DOI 10.1111/j.1432-1033.1983.tb07781.x; THUMSER AEA, 1994, BIOCHEM J, V297, P103, DOI 10.1042/bj2970103; VEERKAMP JH, 1992, BIOCHEM SOC T, V20, P801, DOI 10.1042/bst0200801; VEERKAMP JH, 1991, BIOCHIM BIOPHYS ACTA, V1081, P1, DOI 10.1016/0005-2760(91)90244-C; XU ZH, 1993, J BIOL CHEM, V268, P7874; YOUNG ACM, 1994, STRUCTURE, V2, P523, DOI 10.1016/S0969-2126(00)00052-6; ZANOTTI G, 1992, J BIOL CHEM, V267, P18541	38	49	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31068	31074		10.1074/jbc.271.49.31068	http://dx.doi.org/10.1074/jbc.271.49.31068			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940102	hybrid			2022-12-25	WOS:A1996VW68600013
J	Zhao, J; Paganini, L; Mucke, L; Gordon, M; Refolo, L; Carman, M; Sinha, S; Oltersdorf, T; Lieberburg, I; McConlogue, L				Zhao, J; Paganini, L; Mucke, L; Gordon, M; Refolo, L; Carman, M; Sinha, S; Oltersdorf, T; Lieberburg, I; McConlogue, L			beta-secretase processing of the beta-amyloid precursor protein in transgenic mice is efficient in neurons but inefficient in astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; MESSENGER-RNA; REACTIVE ASTROCYTES; A-BETA; EXPRESSION; PEPTIDE; DAMAGE; BRAINS; CELLS; GENE	Alzheimer's disease is characterized by the extracellular deposition of beta-amyloid peptide (A beta) in cerebral plaques and evidence is accumulating that amyloid is neurotoxic, A beta is derived from the beta-amyloid precursor protein (APP). Proteolytic processing of APP by the enzyme, beta-secretase, produces the N terminus of A beta, and releases a secreted ectodomain of APP (beta-s-APP), To develop animal models for measuring beta-secretase activity in specific brain cells in vivo, we have targeted the expression of the full-length human APP to either neurons or astrocytes in transgenic mice using the neuron-specific enolase (NSE) promoter or a modified glial. fibrillary acidic protein (GFAP) gene, respectively, The APP cDNAs expressed were mutated (KM to NL at 670/671) to encode amino acid substitutions that enhance amyloidogenic processing in vitro, Western analyses revealed abundant production of beta-s-APP in the brains of NSE-APP mice and enzyme-linked immunosorbent assay analyses showed production of A beta in fetal primary mixed brain cultures and brain homogenates from these transgenic animals, Because the NSE promoter drives expression primarily in neurons, this provides in vivo evidence that the beta-secretase cleavage necessary for generation of beta-s-APP and A beta is efficiently performed in neurons, In contrast, only little beta-s-APP was detected in brain homogenates of GFAP-APP mice, indicating that astrocytes show very little beta-secretase activity in vivo. This provides strong in vivo evidence that the major source of A beta in brain is from neurons and not from astrocytes.	ATHENA NEUROSCI INC, S SAN FRANCISCO, CA 94080 USA; UNIV CALIF SAN FRANCISCO, GLADSTONE MOL NEUROBIOL PROGRAM, SAN FRANCISCO, CA 94141 USA; UNIV CALIF SAN FRANCISCO, DEPT NEUROL, SAN FRANCISCO, CA 94141 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco				Mucke, Lennart/0000-0001-6256-9559	NATIONAL INSTITUTE ON AGING [R37AG011385, R01AG011385] Funding Source: NIH RePORTER; NIA NIH HHS [AG11385] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABE K, 1991, NEUROSCI LETT, V125, P172, DOI 10.1016/0304-3940(91)90020-T; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CHOI T, 1991, MOL CELL BIOL, V11, P3070, DOI 10.1128/MCB.11.6.3070; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; DELACOURTE A, 1990, NEUROLOGY, V40, P33, DOI 10.1212/WNL.40.1.33; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; FORSSPETTER S, 1990, NEURON, V5, P187, DOI 10.1016/0896-6273(90)90308-3; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HUANG MTF, 1990, MOL CELL BIOL, V10, P1805, DOI 10.1128/MCB.10.4.1805; JOHNSON WB, 1995, GLIA, V13, P174, DOI 10.1002/glia.440130304; JOHNSONWOOD K, 1996, P NATL ACAD SCI US; KAWARABAYASHI T, 1991, BRAIN RES, V563, P334, DOI 10.1016/0006-8993(91)91558-I; KNOPS J, 1995, J BIOL CHEM, V270, P2419, DOI 10.1074/jbc.270.6.2419; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; MUCKE L, 1991, NEW BIOL, V3, P465; MUCKE L, 1994, BRAIN RES, V666, P151, DOI 10.1016/0006-8993(94)90767-6; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; PALMITER RD, 1991, P NATL ACAD SCI USA, V88, P478, DOI 10.1073/pnas.88.2.478; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; QUON D, 1991, NATURE, V352, P239, DOI 10.1038/352239a0; ROCKENSTEIN EM, 1995, J BIOL CHEM, V270, P28257; SELKOE DJ, 1994, J NEUROPATH EXP NEUR, V53, P438, DOI 10.1097/00005072-199409000-00003; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; SELKOE DJ, 1993, TRENDS NEUROSCI, V16, P403, DOI 10.1016/0166-2236(93)90008-A; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SIMAN R, 1989, NEURON, V3, P275, DOI 10.1016/0896-6273(89)90252-3; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TINAKARAN G, 1996, J BIOL CHEM, V271, P9390; TOGGAS SM, 1994, NATURE, V367, P188, DOI 10.1038/367188a0; WALLACE WC, 1995, J NEUROSCI, V15, P4896; WISNIEWSKI HM, 1992, ANN NY ACAD SCI, V673, P270	39	78	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31407	31411		10.1074/jbc.271.49.31407	http://dx.doi.org/10.1074/jbc.271.49.31407			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940150	hybrid			2022-12-25	WOS:A1996VW68600061
J	Akeson, AL; Woods, CW; Hsieh, LC; Bohnke, RA; Ackermann, BL; Chan, KY; Robinson, JL; Yanofsky, SD; Jacobs, JW; Barrett, RW; Bowlin, TL				Akeson, AL; Woods, CW; Hsieh, LC; Bohnke, RA; Ackermann, BL; Chan, KY; Robinson, JL; Yanofsky, SD; Jacobs, JW; Barrett, RW; Bowlin, TL			AF12198, a novel low molecular weight antagonist, selectively binds the human type I interleukin (IL)-1 receptor and blocks in vivo responses to IL-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IDENTIFICATION; RESOLUTION; IL-1-BETA; SITES	Interleukin-1 (IL-1) -alpha and -beta are potent regulators of inflammatory responses, The naturally occurring interleukin-1 receptor antagonist (IL-1ra) is effective in vitro and in vivo in modulating biological responses to IL-1, We have previously reported the discovery of IL-1 antagonist peptides from the search of phage display libraries, Further characterization of this group of peptides has led to a 15-mer, AF12198, Ac-FEWTPGWYQJYALPL-NH2 (J represents the unnatural amino acid, 2-azetidine-1-carboxylic acid), with both in vitro and in vivo IL-1 antagonist activity, AF12198 selectively binds the human type I IL-1 receptor but not the human type II receptor or the murine type I receptor, In vitro, AF12198 inhibits IL-1-induced IL-8 production by human dermal fibroblasts with a half-maximal inhibition concentration or IC50 of 25 nM and IL-1-induced intercellular adhesion molecule-1 (ICAM-1) expression by endothelial cells with an IC50 of 9 nM. When given as an intravenous infusion to cynomolgus monkeys, AF12198 blocks ex vitro IL-1 induction of IL-6 and down modulates in vivo induction of IL-6. This is the first small molecule to show IL-1 receptor antagonist activity in vivo.	AFFYMAX,PALO ALTO,CA 94304		Akeson, AL (corresponding author), HOECHST MARION ROUSSEL,2110 E GALBRAITH RD,CINCINNATI,OH 45215, USA.							AKESON A, 1996, IN PRESS J PHARM TOX; AREND WP, 1995, ARTHRITIS RHEUM, V38, P151, DOI 10.1002/art.1780380202; CASINIRAGGI V, 1995, J IMMUNOL, V154, P2434; DINARELLO CA, 1991, BLOOD, V77, P1627; DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745; EVANS RJ, 1995, J BIOL CHEM, V270, P11477, DOI 10.1074/jbc.270.19.11477; FISCHER E, 1991, AM J PHYSIOL, V261, pR442, DOI 10.1152/ajpregu.1991.261.2.R442; GIELDS GB, 1990, INT J PEPT PROT RES, V35, P161; GRAVES BJ, 1990, BIOCHEMISTRY-US, V29, P2679, DOI 10.1021/bi00463a009; GRUTTER MG, 1994, PROTEIN ENG, V7, P663, DOI 10.1093/protein/7.5.663; LABRIOLATOMPKINS E, 1991, P NATL ACAD SCI USA, V88, P11182, DOI 10.1073/pnas.88.24.11182; LEWTHWAITE J, 1995, ANN RHEUM DIS, V54, P591, DOI 10.1136/ard.54.7.591; Makarov SS, 1996, P NATL ACAD SCI USA, V93, P402, DOI 10.1073/pnas.93.1.402; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; PIQUET PF, 1993, CYTOKINE, V5, P57; PRIESTLE JP, 1989, P NATL ACAD SCI USA, V86, P9667, DOI 10.1073/pnas.86.24.9667; SCHREUDER H, 1995, FEBS LETT, V373, P39, DOI 10.1016/0014-5793(95)01009-4; SCHREUDER HA, 1995, EUR J BIOCHEM, V227, P838, DOI 10.1111/j.1432-1033.1995.tb20209.x; SIMS JE, 1993, P NATL ACAD SCI USA, V90, P6155, DOI 10.1073/pnas.90.13.6155; SYMONS JA, 1995, P NATL ACAD SCI USA, V92, P1714, DOI 10.1073/pnas.92.5.1714; VIGERS GPA, 1994, J BIOL CHEM, V269, P14284; Yanofsky SD, 1996, P NATL ACAD SCI USA, V93, P7381, DOI 10.1073/pnas.93.14.7381	22	38	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30517	30523		10.1074/jbc.271.48.30517	http://dx.doi.org/10.1074/jbc.271.48.30517			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940020	hybrid			2022-12-25	WOS:A1996VV15800037
J	Muniz, M; Alonso, M; Hidalgo, J; Velasco, A				Muniz, M; Alonso, M; Hidalgo, J; Velasco, A			A regulatory role for cAMP-dependent protein kinase in protein traffic along the exocytic route	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR STOMATITIS-VIRUS; TRANS-GOLGI NETWORK; SECRETORY VESICLE FORMATION; CANINE KIDNEY-CELLS; ENDOPLASMIC-RETICULUM; INTERMEDIATE COMPARTMENT; MEMBRANE-PROTEIN; MDCK CELLS; COMPLEX; PHOSPHORYLATION	The influence of protein kinase A activity on transport of newly synthesized vesicular stomatitis virus G glycoprotein along the exocytic pathway was examined. Transport of vesicular stomatitis virus G glycoprotein to the cell surface was inhibited by N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), a selective inhibitor of protein kinase A. This block occurred at the exit of the Golgi complex, whereas transport through the Golgi compartments or from the endoplasmic reticulum to the Golgi was decreased in the presence of H-89. As judged by immunofluorescence endoplasmic reticulum to Golgi transport was accelerated in cells incubated with activators of protein kinase A such as isobutylmethylxanthine (IBMX) or forskolin (FK). Treatment with IBMX and FR also increased transport from the trans-Golgi network to the cell surface. During incubation with IBMX and Fh, the organization of the Golgi complex was altered showing intercisternae fusion and miscompartmentalization of resident proteins. These structural changes affected both the kinetics of acquisition of endoglycosidase H resistance and transport activities. These data support a differential regulatory role for protein kinase A in different transport steps along the exocytic pathway. In particular, transport from the trans-Golgi network to the cell surface was dependent on protein kinase A activity. In addition, the results suggest the involvement of this enzyme on the maintenance of the Golgi complex organization.	UNIV SEVILLE, FAC BIOL, DEPT CELL BIOL, E-41012 SEVILLE, SPAIN	University of Sevilla			IBIS, EUCARIONTES/H-7494-2016; muñiz, manuel/Q-2890-2019	muñiz, manuel/0000-0001-8011-6991				AKITA Y, 1994, J BIOL CHEM, V269, P4653; BALCH WE, 1986, J BIOL CHEM, V261, P4681; BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; BERGMANN JE, 1989, METHOD CELL BIOL, V32, P85; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781; Buccione R, 1996, J BIOL CHEM, V271, P3523; CARDONE MH, 1994, J CELL BIOL, V124, P717, DOI 10.1083/jcb.124.5.717; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; COLOMBO MI, 1994, J BIOL CHEM, V269, P14919; DAVIDSON HW, 1992, J CELL BIOL, V116, P1343, DOI 10.1083/jcb.116.6.1343; DAVIDSON HW, 1993, J BIOL CHEM, V268, P4216; DEMATTEIS MA, 1993, NATURE, V364, P818, DOI 10.1038/364818a0; EKER P, 1994, J BIOL CHEM, V269, P18607; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; GRIFFITHS G, 1985, J CELL BIOL, V101, P949, DOI 10.1083/jcb.101.3.949; HANSEN SH, 1994, J CELL BIOL, V126, P677, DOI 10.1083/jcb.126.3.677; Jilling T, 1996, J BIOL CHEM, V271, P4381; KEHLENBACH RH, 1994, NATURE, V372, P804; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG J, 1995, EMBO J, V14, P3635, DOI 10.1002/j.1460-2075.1995.tb00033.x; LEFRANCOIS L, 1982, VIROLOGY, V121, P157, DOI 10.1016/0042-6822(82)90125-8; LEHEL C, 1995, P NATL ACAD SCI USA, V92, P1406, DOI 10.1073/pnas.92.5.1406; LEYTE A, 1992, EMBO J, V11, P4795, DOI 10.1002/j.1460-2075.1992.tb05585.x; LOTTI LV, 1992, J CELL BIOL, V118, P43, DOI 10.1083/jcb.118.1.43; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; MONTMAYEUR JP, 1994, SCIENCE, V263, P95, DOI 10.1126/science.8272874; NIGG EA, 1985, CELL, V41, P1039, DOI 10.1016/S0092-8674(85)80084-2; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; OHASHI M, 1994, J BIOL CHEM, V269, P24897; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PEREZVILAR J, 1991, J BIOL CHEM, V266, P23967; PIMPLIKAR SW, 1994, J BIOL CHEM, V269, P19054; RIOS RM, 1992, EMBO J, V11, P1723, DOI 10.1002/j.1460-2075.1992.tb05224.x; SCHWEIZER A, 1990, EUR J CELL BIOL, V53, P185; SEKSEK O, 1995, J BIOL CHEM, V270, P4967, DOI 10.1074/jbc.270.10.4967; STACK JH, 1993, EMBO J, V12, P2195, DOI 10.1002/j.1460-2075.1993.tb05867.x; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; STREHLER BL, 1965, METHOD ENZYMAT AN, P559; TAKUMA T, 1994, J BIOL CHEM, V269, P22124; TOKUYASU KT, 1989, HISTOCHEM J, V21, P163, DOI 10.1007/BF01007491; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; WOODMAN PG, 1992, J CELL BIOL, V116, P331, DOI 10.1083/jcb.116.2.331	44	59	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30935	30941		10.1074/jbc.271.48.30935	http://dx.doi.org/10.1074/jbc.271.48.30935			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940080	Green Published, hybrid			2022-12-25	WOS:A1996VV15800097
J	Smith, JD; Miyata, M; Ginsberg, M; Grigaux, C; Shmookler, E; Plump, AS				Smith, JD; Miyata, M; Ginsberg, M; Grigaux, C; Shmookler, E; Plump, AS			Cyclic AMP induces apolipoprotein E binding activity and promotes cholesterol efflux from a macrophage cell line to apolipoprotein acceptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; PROTEIN-KINASE-C; A-I; INTRACELLULAR CHOLESTEROL; MOUSE MACROPHAGES; HUMAN FIBROBLASTS; E GENE; EXPRESSION; RECEPTOR; SURFACE	RAW 264 mouse macrophage cells were stably transfected with human apolipoprotein E (apoE) expression vectors. Clonal derivatives were characterized for expression of the human apoE2, apoE3, and apoE4 isoforms. An apoE4-expressing clonal cell line and a non-expressing clonal control cell line were loaded overnight with either [H-3]cholesterol or [H-3]choline, The cells were washed and incubated for 24 h in serum-free medium with or without the addition of 8-bromo-cyclic AMP (8-Br-cAMP), Only the apoE-secreting cells and only in the presence of 8-Br-cAMP released large amounts of labeled cholesterol or phosphatidylcholine into the medium, Mass analyses of cellular free and esterified cholesterol confirmed the results of the labeling studies; a decrease in cellular cholesterol content was observed in the 8-Br-cAMP-treated apoE-secreting cells, concurrent with an increase in cholesterol found in the medium. FPLC analysis of the medium demonstrated that 8-Br-cAMP treatment of the apoE-secreting cells led to an increased size fraction and amount of a peak of secreted cholesterol which comigrated with apoE, The 8-Br-cAMP-mediated increase in cholesterol efflux was also observed in non-apoE-secreting cells incubated with exogenous apoE or apoAI, and the effect of apoE was saturable, The apoE2, apoE3, and apoE4 isoforms were equally efficient in promoting 8-Br-cAMP-dependent cholesterol efflux, Reductive methylation of apoE abolished its ability to promote 8-Br-cAMP-dependent cholesterol efflux, Brefeldin A and monensin, inhibitors of protein processing through the Golgi, both blocked the 8-Br-cAMP stimulation of cholesterol efflux to exogenous apoE, 8-Br-cAMP induced specific apoE and apoAI binding, but not apoE degradation, by the RAW cells. We present a model wherein cAMP induces a membrane apolipoprotein receptor that does not lead to endocytosis and degradation, but instead promotes the transfer of lipids to apolipoproteins, which can then be released from the cell.			Smith, JD (corresponding author), ROCKEFELLER UNIV,BIOCHEM GENET & METAB LAB,1230 YORK AVE,NEW YORK,NY 10021, USA.		Smith, Jonathan D./H-9723-2013	Smith, Jonathan D./0000-0002-0415-386X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054591] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL54591] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; BASU SK, 1981, P NATL ACAD SCI-BIOL, V78, P7545, DOI 10.1073/pnas.78.12.7545; BASU SK, 1983, SCIENCE, V219, P871, DOI 10.1126/science.6823554; BELLOSTA S, 1995, J CLIN INVEST, V96, P2170, DOI 10.1172/JCI118271; BERG KA, 1988, MOL CELL BIOCHEM, V84, P29; BRINTON EA, 1989, J CLIN INVEST, V84, P262, DOI 10.1172/JCI114149; BROWN MS, 1979, J CELL BIOL, V82, P597, DOI 10.1083/jcb.82.3.597; BURCH RM, 1988, J PHARMACOL EXP THER, V244, P765; BUTLER JD, 1992, J BIOL CHEM, V267, P23797; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; DAS HK, 1985, J BIOL CHEM, V260, P6240; DELAMATRE J, 1986, BIOCHIM BIOPHYS ACTA, V875, P419, DOI 10.1016/0005-2760(86)90061-5; EMI M, 1988, GENOMICS, V3, P373, DOI 10.1016/0888-7543(88)90130-9; FOLCH J, 1957, J BIOL CHEM, V226, P497; FRAENKELCONRAT H, 1957, METHOD ENZYMOL, V4, P247, DOI 10.1016/0076-6879(57)04059-8; FREEMAN DA, 1987, J BIOL CHEM, V262, P13061; GOLDSTEIN JL, 1974, J BIOL CHEM, V249, P5153; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GRANOT E, 1990, J LIPID RES, V31, P2133; HARA H, 1991, J BIOL CHEM, V266, P3080; HERSCOVITZ H, 1992, J LIPID RES, V33, P791; HUANG YD, 1994, P NATL ACAD SCI USA, V91, P1834, DOI 10.1073/pnas.91.5.1834; INNERARITY TL, 1986, ARTERIOSCLEROSIS, V6, P114, DOI 10.1161/01.ATV.6.1.114; JOHNSON WJ, 1986, J BIOL CHEM, V261, P5766; KARLIN JB, 1987, J BIOL CHEM, V262, P12557; KRUTH HS, 1994, J BIOL CHEM, V269, P24511; MADDEN EA, 1986, CANCER RES, V46, P617; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MAZZONE T, 1987, J BIOL CHEM, V262, P11657; MAZZONE T, 1994, J LIPID RES, V35, P1345; MCKNIGHT GL, 1992, J BIOL CHEM, V267, P12131; MENDEZ AJ, 1994, J CLIN INVEST, V94, P1698, DOI 10.1172/JCI117515; MENDEZ AJ, 1995, J BIOL CHEM, V270, P5891, DOI 10.1074/jbc.270.11.5891; MENDEZ AJ, 1991, J BIOL CHEM, V266, P10104; ORAM JF, 1987, J BIOL CHEM, V262, P2405; PETTY HR, 1989, BIOCHIM BIOPHYS ACTA, V1012, P284, DOI 10.1016/0167-4889(89)90110-9; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; PRACK MM, 1994, BIOCHEMISTRY-US, V33, P5049, DOI 10.1021/bi00183a007; RALL SC, 1986, METHOD ENZYMOL, V128, P273; ROTHBLAT GH, 1992, J LIPID RES, V33, P1091; ROTHBLAT GH, 1991, CURR OPIN LIPIDOL, V2, P288; SCHMITZ G, 1985, EMBO J, V4, P613, DOI 10.1002/j.1460-2075.1985.tb03674.x; SMITH JD, 1988, J BIOL CHEM, V263, P8300; SMITH JD, 1990, J BIOL CHEM, V265, P14709; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; VIA DP, 1985, BIOCHIM BIOPHYS ACTA, V833, P417, DOI 10.1016/0005-2760(85)90099-2; WEISGRABER KH, 1978, J BIOL CHEM, V253, P9053; WERB Z, 1983, J CELL BIOL, V97, P1113, DOI 10.1083/jcb.97.4.1113; WILLNOW TE, 1992, J BIOL CHEM, V267, P26171; WISSLER RW, 1994, ATHEROSCLEROSIS, V108, pS3, DOI 10.1016/0021-9150(94)90149-X; ZANNIS VI, 1985, BIOCHEMISTRY-US, V24, P4450, DOI 10.1021/bi00337a028	51	150	158	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30647	30655		10.1074/jbc.271.48.30647	http://dx.doi.org/10.1074/jbc.271.48.30647			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940040	hybrid			2022-12-25	WOS:A1996VV15800057
J	Aucoin, JM; Pishko, EJ; Baker, DP; Kantrowitz, ER				Aucoin, JM; Pishko, EJ; Baker, DP; Kantrowitz, ER			Engineered complementation in Escherichia coli aspartate transcarbamoylase - Heterotropic regulation by quaternary structure stabilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONCERTED ALLOSTERIC TRANSITION; CATALYTIC CHAIN; DOMAIN CLOSURE; MODEL; N-(PHOSPHONACETYL)-L-ASPARTATE; CARBAMOYLTRANSFERASE; ACTIVATION; BEHAVIOR; CTP; ATP	Escherichia coli aspartate transcarbamoylase regulates pyrimidine biosynthesis by altering its activity homotropically in response to one of its substrates and heterotropically in response to nucleotide effecters, The mechanism of this regulation involves two structurally and functionally different forms of the enzyme, one with low activity and low affinity for substrates (T state) and the other with high activity and high affinity for substrates (R state), Heterotropic regulation may be due to the direct transmission of a regulatory ''signal'' between the regulatory site and the active site some 60 Angstrom away and/or may involve altering the relative stability of the two forms of the enzyme, By combining a T state-stabilized mutant version of the enzyme, previously thought to have a defect in a heterotropic transmission pathway, with a known R state-stabilized mutant enzyme, we were able to restore some properties of the wild-type enzyme, These data imply that the relative stabilization of the T and R states of the enzyme is in part responsible for the homotropic and heterotropic properties of aspartate transcarbamoylase and that direct pathways for transmission of the heterotropic signals are unlikely.	BOSTON COLL,DEPT CHEM,MERKERT CHEM CTR,CHESTNUT HILL,MA 02167	Boston College				Aucoin, Jennifer/0000-0001-9595-3020	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026237] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26237] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLLINS KD, 1971, J BIOL CHEM, V246, P6599; FETLER L, 1995, BIOCHEMISTRY-US, V34, P15654, DOI 10.1021/bi00048a008; GERHART JC, 1967, J BIOL CHEM, V242, P2886; GERHART JC, 1962, J BIOL CHEM, V237, P891; HOWLETT GJ, 1977, BIOCHEMISTRY-US, V16, P5091, DOI 10.1021/bi00642a023; JONES ME, 1955, J AM CHEM SOC, V77, P819, DOI 10.1021/ja01608a101; KANTROWITZ ER, 1988, SCIENCE, V241, P669, DOI 10.1126/science.3041592; KANTROWITZ ER, 1990, TRENDS BIOCHEM SCI, V15, P53, DOI 10.1016/0968-0004(90)90176-C; KIM KH, 1987, J MOL BIOL, V196, P853, DOI 10.1016/0022-2836(87)90410-4; KRAUSE KL, 1985, P NATL ACAD SCI USA, V82, P1643, DOI 10.1073/pnas.82.6.1643; LADJIMI MM, 1988, BIOCHEMISTRY-US, V27, P276, DOI 10.1021/bi00401a042; LEE BH, 1995, J BIOL CHEM, V270, P15620, DOI 10.1074/jbc.270.26.15620; LIPSCOMB WN, 1994, ADV ENZYMOL RAMB, V68, P67; NEWTON CJ, 1990, BIOCHEMISTRY-US, V29, P1444, DOI 10.1021/bi00458a015; NOWLAN SF, 1985, J BIOL CHEM, V260, P4712; PASTRALANDIS SC, 1981, ANAL BIOCHEM, V118, P358, DOI 10.1016/0003-2697(81)90594-7; PASTRALANDIS SC, 1978, J BIOL CHEM, V253, P4624; REICHARD P, 1956, ACTA CHEM SCAND, V10, P548, DOI 10.3891/acta.chem.scand.10-0548; SILVER RS, 1983, J MOL BIOL, V168, P729, DOI 10.1016/S0022-2836(83)80072-2; STEVENS RC, 1990, BIOCHEM BIOPH RES CO, V171, P1312, DOI 10.1016/0006-291X(90)90829-C; TAUC P, 1990, J MOL BIOL, V214, P327, DOI 10.1016/0022-2836(90)90164-H; TAUC P, 1994, PROTEIN SCI, V3, P1998, DOI 10.1002/pro.5560031112; THIRY L, 1978, J MOL BIOL, V125, P515, DOI 10.1016/0022-2836(78)90314-5; VANVLIET F, 1991, P NATL ACAD SCI USA, V88, P9180, DOI 10.1073/pnas.88.20.9180; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WILD JR, 1989, P NATL ACAD SCI USA, V86, P46, DOI 10.1073/pnas.86.1.46; XI XG, 1994, J MOL BIOL, V242, P139, DOI 10.1006/jmbi.1994.1565	28	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29865	29869		10.1074/jbc.271.47.29865	http://dx.doi.org/10.1074/jbc.271.47.29865			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939927	hybrid			2022-12-25	WOS:A1996VU52500055
J	Barnes, CJ; Wahl, AF; Shen, BH; Park, MS; Bambara, RA				Barnes, CJ; Wahl, AF; Shen, BH; Park, MS; Bambara, RA			Mechanism of tracking and cleavage of adduct-damaged DNA substrates by the mammalian 5'- to 3'-exonuclease endonuclease RAD2 homologue 1 or flap endonuclease 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; POLYMERASE-EPSILON; 3' EXONUCLEASE; CALF THYMUS; DRUG CIS-DIAMMINEDICHLOROPLATINUM(II); REPLICATION; YEAST; CISPLATIN; RESISTANCE; ENCODES	The mammalian 5'- to 3'-exonuclease/endonuclease, called RAD2 homologue 1 or flap endonuclease 1, has a unique cleavage activity, dependent on specific substrate structure. On a primer-template, in which the primer has an unannealed 5'-tail, endonucleolytic cleavage near the annealing point releases the tail intact. Entering at the 5'-end, the nuclease tracks along the entire tail to the point of cleavage, Genetic analyses suggest that this nuclease removes DNA adducts in vivo (Sommers, C. H., Miller, E. J., Dujon, B., Prakash, S., and Prakash, L. (1995) J. Biol. Chem. 270, 4193-4196). Micrococcal nuclease footprinting shows that after tracking the nuclease protects a region of the tail 25 nucleotides long, adjacent to the cleavage site. Substrates with adducts at specific locations were used to assess the mechanism of RAD2 homologue 1 nuclease tracking and its ability to cleave modified DNA. Either a conventional cis-diamminedichloroplatinum (II) (CDDP) or a bulky CDDP derivative was placed within or beyond the region protected by the nuclease. The nuclease cleaved the tail of both substrates. In contrast, a CDDP adduct just adjacent to the expected cleavage point was inhibitory. A CDDP adduct at the very 5'-end of the tail was also cleaved. The nuclease could remove tails containing adducts on the sugar-phosphate backbone. Apparently, the nuclease is designed to slide over various types of damage on single stranded DNA and then cut past the damaged site.	UNIV ROCHESTER, MED CTR, DEPT BIOCHEM, SCH MED & DENT, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, SCH MED & DENT, CTR CANC, ROCHESTER, NY 14642 USA; BRISTOL MYERS SQUIBB PHARMACEUT RES INST, GROWTH REGULAT DEPT, SEATTLE, WA 98121 USA; LOS ALAMOS NATL LAB, DIV LIFE SCI, LOS ALAMOS, NM 87545 USA	University of Rochester; University of Rochester; Bristol-Myers Squibb; United States Department of Energy (DOE); Los Alamos National Laboratory			Park, Min Sung/HCH-2207-2022	Shen, Binghui/0000-0002-4408-407X	NIGMS NIH HHS [GM24441] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024441] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAMBARA RA, 1991, BIOCHIM BIOPHYS ACTA, V1088, P11, DOI 10.1016/0167-4781(91)90147-E; BAMBARA RA, 1995, PROG NUCLEIC ACID RE, V51, P93, DOI 10.1016/S0079-6603(08)60877-6; BELLON SF, 1990, BIOPHYS CHEM, V35, P179, DOI 10.1016/0301-4622(90)80007-T; BELLON SF, 1991, BIOCHEMISTRY-US, V30, P8026, DOI 10.1021/bi00246a021; BUDD ME, 1995, J BIOL CHEM, V270, P26766, DOI 10.1074/jbc.270.45.26766; BUDD ME, 1996, IN PRESS MOL CELL BI; BURGERS PMJ, 1993, J BIOL CHEM, V268, P19923; CANON JL, 1990, EUR J CANCER, V26, P1, DOI 10.1016/0277-5379(90)90247-Q; Ceska TA, 1996, NATURE, V382, P90, DOI 10.1038/382090a0; COHEN GL, 1979, SCIENCE, V203, P1014, DOI 10.1126/science.370979; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; HABRAKEN Y, 1995, J BIOL CHEM, V270, P30194; HABRAKEN Y, 1993, NATURE, V366, P365, DOI 10.1038/366365a0; HABRAKEN Y, 1994, J BIOL CHEM, V269, P31342; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARRINGTON JJ, 1995, J BIOL CHEM, V270, P4503, DOI 10.1074/jbc.270.9.4503; HUANG L, 1993, BIOCHEMISTRY-US, V32, P841, DOI 10.1021/bi00054a015; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; LEE SH, 1991, J BIOL CHEM, V266, P22707; LYAMICHEV V, 1993, SCIENCE, V193, P963; MARROT L, 1989, BIOCHEMISTRY-US, V28, P1454, DOI 10.1021/bi00430a005; MELLISH KJ, 1994, INT J CANCER, V59, P65, DOI 10.1002/ijc.2910590114; MEUSER TC, 1996, CELL, V85, P1101; Moggs JG, 1996, J BIOL CHEM, V271, P7177, DOI 10.1074/jbc.271.12.7177; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; MURANTE RS, 1994, J BIOL CHEM, V269, P1191; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; MURANTE RS, 1996, IN PRESS J BIOL CHEM, V271; MURRAY JM, 1994, MOL CELL BIOL, V14, P4878, DOI 10.1128/MCB.14.7.4878; NATHANEL T, 1990, J VIROL, V64, P5912; OBERLISCHRAMMLI AE, 1994, INT J CANCER, V59, P629, DOI 10.1002/ijc.2910590509; ROBINS P, 1994, J BIOL CHEM, V269, P28535; SCANLON KJ, 1989, CANCER INVEST, V7, P581, DOI 10.3109/07357908909017533; SCOVELL WM, 1982, BIOCHEM BIOPH RES CO, V107, P1138, DOI 10.1016/0006-291X(82)90640-4; Shen BH, 1996, J BIOL CHEM, V271, P9173, DOI 10.1074/jbc.271.16.9173; SIBGHATULLAH, 1989, NUCLEIC ACIDS RES, V17, P4471, DOI 10.1093/nar/17.12.4471; SIEGAL G, 1992, P NATL ACAD SCI USA, V89, P9377, DOI 10.1073/pnas.89.20.9377; SIEGAL G, 1992, J BIOL CHEM, V267, P13629; SIEGAL G, 1992, J BIOL CHEM, V267, P3991; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; SORRENSEN CM, 1988, CANCER RES, V48, P6703; SORRENSON CM, 1990, J NATL CANCER I, V82, P749; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; TURCHI JJ, 1993, J BIOL CHEM, V268, P1536; USHAY HM, 1982, J BIOCH, V20, P3744; WAGA S, 1994, J BIOL CHEM, V269, P10923; ZAMBLE DB, 1995, TRENDS BIOCHEM SCI, V20, P435, DOI 10.1016/S0968-0004(00)89095-7	51	45	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29624	29631		10.1074/jbc.271.47.29624	http://dx.doi.org/10.1074/jbc.271.47.29624			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939893	hybrid			2022-12-25	WOS:A1996VU52500021
J	Fagan, AM; Bu, GJ; Sun, YL; Daugherty, A; Holtzman, DM				Fagan, AM; Bu, GJ; Sun, YL; Daugherty, A; Holtzman, DM			Apolipoprotein E-containing high density lipoprotein promotes neurite outgrowth and is a ligand for the low density lipoprotein receptor-related protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL NERVOUS-SYSTEM; SPORADIC ALZHEIMERS-DISEASE; CEREBROSPINAL-FLUID; TYPE-4 ALLELE; CELL-LINE; EXPRESSION; NEURONS; GROWTH; IDENTIFICATION; CHOLESTEROL	Presence of the epsilon 4 allele of apolipoprotein E (apoE) is a risk factor for Alzheimer's disease (AD), although the mechanism(s) by which it confers this risk is unknown. ApoE may play a direct role in AD neuropathology by modulating neuronal structure, We previously showed that apoE3-containing beta-very low density lipoprotein (beta-VLDL) can stimulate neurite outgrowth to a significantly greater extent than apoE4-enriched beta-VLDL in a central nervous system-derived neuronal cell line and that this effect is mediated by interaction with the low density lipoprotein receptor-related protein (LRP). To determine whether similar differences exist when apoE is associated with other lipoprotein particles, the effects of high density lipoprotein (HDL) derived from plasma and cerebrospinal fluid were defined. ApoE3-enriched HDL significantly enhanced neurite outgrowth as com pared with apoE4-enriched HDL, and the majority of this stimulation was blocked in the presence of the receptor-associated protein or a neutralizing antibody to LRP. We also found that cholesterol esterification in the presence of apoE-containing plasma HDL was attenuated in fibroblasts lacking LRP. Therefore, apoE-containing HDL dan serve as an LRP ligand, and apoE isoform-specific effects on neurite outgrowth are observed when HDL is the carrier particle.	WASHINGTON UNIV,SCH MED,DEPT BIOL MOL,CTR STUDY NERVOUS SYST INJURY,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PHARMACOL,CTR STUDY NERVOUS SYST INJURY,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,EDWARD MALLINCKRODT DEPT PEDIAT & MOL BIOL & PHAR,DIV CARDIOVASC,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Fagan, AM (corresponding author), WASHINGTON UNIV,SCH MED,DEPT NEUROL,CTR STUDY NERVOUS SYST INJURY,ST LOUIS,MO 63110, USA.		Daugherty, Alan/C-8282-2009	Daugherty, Alan/0000-0003-2093-3775				BELLOSTA S, 1995, J BIOL CHEM, V270, P27063, DOI 10.1074/jbc.270.45.27063; BOYLES JK, 1985, J CLIN INVEST, V76, P1501, DOI 10.1172/JCI112130; BU GJ, 1994, J BIOL CHEM, V269, P18521; BU GJ, 1993, J BIOL CHEM, V268, P13002; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DAUGHERTY A, 1988, ARTERIOSCLEROSIS, V8, P768, DOI 10.1161/01.ATV.8.6.768; DAVIES CA, 1987, J NEUROL SCI, V78, P151, DOI 10.1016/0022-510X(87)90057-8; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P203, DOI 10.1073/pnas.82.1.203; FLOOD DG, 1986, CAN J NEUROL SCI, V13, P475; HANDELMANN GE, 1992, J LIPID RES, V33, P1677; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HOLTZMAN DM, 1995, P NATL ACAD SCI USA, V92, P9480, DOI 10.1073/pnas.92.21.9480; IGNATIUS MJ, 1986, P NATL ACAD SCI USA, V83, P1125, DOI 10.1073/pnas.83.4.1125; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1984, J LIPID RES, V25, P1277; MAYEUX R, 1993, ANN NEUROL, V34, P752, DOI 10.1002/ana.410340527; MELLON PL, 1990, NEURON, V5, P1, DOI 10.1016/0896-6273(90)90028-E; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; NATHAN BP, 1995, J BIOL CHEM, V270, P19791, DOI 10.1074/jbc.270.34.19791; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; OKUIZUMI K, 1994, NAT GENET, V7, P10, DOI 10.1038/ng0594-10b; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; PITAS RE, 1987, J BIOL CHEM, V262, P14352; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; REBECK GW, 1993, NEURON, V11, P575; ROHEIM PS, 1979, P NATL ACAD SCI USA, V76, P4646, DOI 10.1073/pnas.76.9.4646; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCHEFF SW, 1990, NEUROBIOL AGING, V11, P29, DOI 10.1016/0197-4580(90)90059-9; SNIPES JG, 1986, P NATL ACAD SCI USA, V83, P1130; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; WARSHAWSKY I, 1993, J BIOL CHEM, V268, P22046; WILLNOW TE, 1994, J CELL SCI, V107, P719; ZHOU J, 1994, P NATL ACAD SCI USA, V91, P3824, DOI 10.1073/pnas.91.9.3824	36	185	187	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30121	30125		10.1074/jbc.271.47.30121	http://dx.doi.org/10.1074/jbc.271.47.30121			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939961	hybrid			2022-12-25	WOS:A1996VU52500089
J	Vezza, R; Habib, A; Li, HW; Lawson, JA; FitzGerald, GA				Vezza, R; Habib, A; Li, HW; Lawson, JA; FitzGerald, GA			Regulation of cyclooxygenases by protein kinase C - Evidence against the importance of direct enzyme phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE-2; COUPLED RECEPTOR KINASES; HUMAN ENDOTHELIAL-CELLS; PHORBOL ESTER; SUBSTRATE-SPECIFICITY; SELECTIVE-INHIBITION; G/H SYNTHASE-1; EXPRESSION; ASPIRIN; PHOSPHATASES	Cyclooxygenases (COXs) are key prostaglandin biosynthetic enzymes. While COX-1 expression is largely constitutive, COX-2 is highly regulated by cytokines, growth factors, and tumor promoters, such as the protein kinase C (PKC) activator, phorbol la-myristate 13-acetate (PMA). While phosphorylation of transcription factors may regulate COX transcription, the existence of PKC consensus sequences suggests that direct enzyme phosphorylation might also regulate differential expression of the enzymes, Nevertheless, phosphorylation of both human recombinant COX-1 and COX-2 by rat brain PKC in vitro was minimal, as was phosphorylation of peptides based on PKC consensus sequences in COX-1 (less than 4% of the phosphorylation of the PKC-alpha pseudosubstrate peptide), Similarly, phosphorylation of the corresponding COX-2 peptides was not observed using either the phosphocellulose paper absorption method or electrospray mass spectrometry, MEG-01 and NTH 3T3 cells were labeled with [P-32]orthophosphate to investigate COX phosphorylation in vivo. COX-2 synthesis was induced by PMA (100 nM) or serum stimulation in NIH 3T3 cells, COX-1 was expressed constitutively in MEG-01 cells. Specific poly clonal antibodies raised against sequences of human COX-1 (Ala(24)-Cys(35)) and COX-2 (Asn(588)-Lys(598)) were used for immunoprecipitation, Neither COX-1 nor COX-2 was phosphorylated in vice, irrespective of the presence of a phosphatase inhibitor (1 mu M okadaic acid), Although COX-1 and COX-2 are differentially regulated, no differences were observed in terms of susceptibility to phosphorylation by PKC either in vitro or in vivo. Despite regulated expression of COX-2 by PMA and the existence of consensus sequences for PKC phosphorylation, it appears that it is an unfavorable substrate for this enzyme.	UNIV PENN,CTR EXPT THERAPEUT,STELLAR CHANCE LABS 905,PHILADELPHIA,PA 19104	University of Pennsylvania			Habib, Aida/H-8647-2019; FitzGerald, Garret A/A-4222-2010	Habib, Aida/0000-0001-6027-0043; 	NHLBI NIH HHS [HL54500] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054500] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson GD, 1996, J CLIN INVEST, V97, P2672, DOI 10.1172/JCI118717; BARNETT J, 1994, BBA-PROTEIN STRUCT M, V1209, P130, DOI 10.1016/0167-4838(94)90148-1; BLANCO A, 1995, BIOCHEM J, V312, P419, DOI 10.1042/bj3120419; BLUE ML, 1987, J IMMUNOL, V139, P3949; BLUMBERG PM, 1988, CANCER RES, V48, P1; BOTT CM, 1994, J IMMUNOL, V153, P1; BROWNER M, 1996, W HARV FDN S NEW TAR, P19; CROFFORD LJ, 1994, J CLIN INVEST, V93, P1095, DOI 10.1172/JCI117060; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; HABIB A, 1993, J BIOL CHEM, V268, P23448; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HIRASAWA N, 1995, J IMMUNOL, V154, P5391; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; IWAMI G, 1995, J BIOL CHEM, V270, P12481, DOI 10.1074/jbc.270.21.12481; JACOBOWITZ O, 1994, P NATL ACAD SCI USA, V91, P10630, DOI 10.1073/pnas.91.22.10630; JONES DA, 1993, J BIOL CHEM, V268, P9049; KARGMAN SL, 1995, CANCER RES, V55, P2556; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KINSELLA BT, 1994, J BIOL CHEM, V269, P29914; KOSAKA T, 1994, EUR J BIOCHEM, V221, P889, DOI 10.1111/j.1432-1033.1994.tb18804.x; KWON YG, 1994, J BIOL CHEM, V269, P4839; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECOMTE M, 1994, J BIOL CHEM, V269, P13207; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MANCINI JA, 1994, FEBS LETT, V342, P33, DOI 10.1016/0014-5793(94)80579-2; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; NAKADATE T, 1987, J BIOL CHEM, V262, P11507; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; PRATICO D, 1995, J BIOL CHEM, V270, P9800, DOI 10.1074/jbc.270.17.9800; RAZ A, 1988, J BIOL CHEM, V263, P3022; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; TRACY S, 1995, J BIOL CHEM, V270, P10587, DOI 10.1074/jbc.270.18.10587; VALMU L, 1995, J IMMUNOL, V155, P1175	40	24	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30028	30033		10.1074/jbc.271.47.30028	http://dx.doi.org/10.1074/jbc.271.47.30028			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939949	hybrid			2022-12-25	WOS:A1996VU52500077
J	Wiedemann, P; Giehl, K; Almo, SC; Fedorov, AA; Girvin, M; Steinberger, P; Rudiger, M; Ortner, M; Sippl, M; Dolecek, C; Kraft, D; Jockusch, B; Valenta, R				Wiedemann, P; Giehl, K; Almo, SC; Fedorov, AA; Girvin, M; Steinberger, P; Rudiger, M; Ortner, M; Sippl, M; Dolecek, C; Kraft, D; Jockusch, B; Valenta, R			Molecular and structural analysis of a continuous birch profilin epitope defined by a monoclonal antibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BINDING PROTEIN; ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE; PEPTIDE-SYNTHESIS; POLLEN ALLERGEN; ANTIGEN COMPLEX; CDNA CLONING; AMINO-ACID; EXPRESSION; IDENTIFICATION	The interaction of a mouse monoclonal antibody (4A6) and birch profilin, a structurally well conserved actin and phosphoinositide-binding protein and cross-reactive allergen, was characterized, In contrast to serum IgE from allergic patients, which shows cross-reactivity with most plants, monoclonal antibody 4A6 selectively reacted with tree pollen profilins. Using synthetic overlapping peptides, a continuous hexapeptide epitope was identified. The exchange of a single amino acid (Gln-47 --> Glu) within the epitope was found to abolish the bind ing of monoclonal antibody 4A6 to other plant profilins. The MMR analyses of the birch and the nonreactive timothy grass profilin peptides showed that the loss of binding was not due to major structural differences. Both peptides adopted extended conformations similar to that observed for the epitope in the x-ray crystal structure of the native birch profilin. Binding studies with peptides and birch profilin mutants generated by in vitro mutagenesis demonstrated that the change of Gln-47 to acidic amino acids (e.g. Glu or Asp) led to electrostatic repulsion of monoclonal antibody 4A6. In conclusion the molecular and structural analyses of the interaction of a monoclonal antibody with a continuous peptide epitope, recognized in a conformation similar to that displayed on the native protein, are presented.	UNIV VIENNA,AKH,INST GEN & EXPT PATHOL,A-1090 VIENNA,AUSTRIA; TECH UNIV CAROLO WILHELMINA BRAUNSCHWEIG,INST ZOOL,DEPT CELL BIOL,D-38106 BRAUNSCHWEIG,GERMANY; ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461; SALZBURG UNIV,CTR APPL MOL ENGN,A-5020 SALZBURG,AUSTRIA	University of Vienna; Braunschweig University of Technology; Yeshiva University; Albert Einstein College of Medicine; Salzburg University				Valenta, Rudolf/0000-0001-5944-3365; Steinberger, Peter/0000-0001-6848-4097	NIGMS NIH HHS [GM 53807] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053807] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMO SC, 1994, J MOL BIOL, V236, P950, DOI 10.1006/jmbi.1994.1200; AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; ARCHER SJ, 1994, FEBS LETT, V337, P145, DOI 10.1016/0014-5793(94)80262-9; BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; Battey, 1986, BASIC METHODS MOL BI; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BERZOFSKY JA, 1985, SCIENCE, V229, P932, DOI 10.1126/science.2410982; BJORKEGREN C, 1993, FEBS LETT, V333, P123, DOI 10.1016/0014-5793(93)80388-B; BRADEN BC, 1995, FASEB J, V9, P9, DOI 10.1096/fasebj.9.1.7821765; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DROBAK BK, 1994, PLANT J, V6, P389, DOI 10.1046/j.1365-313X.1994.06030389.x; ENGVALL E, 1972, J IMMUNOL, V109, P129; FEDOROV AA, 1994, J MOL BIOL, V241, P480, DOI 10.1006/jmbi.1994.1522; FERNANDEZ JA, 1994, BIOCHEMISTRY-US, V33, P11073, DOI 10.1021/bi00203a003; GEFTER ML, 1977, SOMAT CELL GENET, V3, P231, DOI 10.1007/BF01551818; GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8; GEYSEN HM, 1985, P NATL ACAD SCI USA, V82, P178, DOI 10.1073/pnas.82.1.178; GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998; GIEHL K, 1994, EUR J BIOCHEM, V226, P681, DOI 10.1111/j.1432-1033.1994.tb20096.x; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; GRIESINGER C, 1987, J MAGN RESON, V75, P261, DOI 10.1016/0022-2364(87)90035-7; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; HWANG TL, 1995, J MAGN RESON SER A, V112, P275, DOI 10.1006/jmra.1995.1047; JEMMERSON R, 1989, MOL IMMUNOL, V26, P301, DOI 10.1016/0161-5890(89)90084-9; KAISER DA, 1989, CELL MOTIL CYTOSKEL, V14, P251, DOI 10.1002/cm.970140211; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVER WG, 1990, CELL, V61, P553, DOI 10.1016/0092-8674(90)90464-P; Machesky Laura M., 1993, Trends in Cell Biology, V3, P381, DOI 10.1016/0962-8924(93)90087-H; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MERTENS N, 1995, BIO-TECHNOL, V13, P175, DOI 10.1038/nbt0295-175; METZLER WJ, 1994, J BIOL CHEM, V269, P4620; MITTERMANN I, 1995, PLANT MOL BIOL, V27, P137, DOI 10.1007/BF00019185; NAVON A, 1995, J BIOL CHEM, V270, P4255, DOI 10.1074/jbc.270.9.4255; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; RIHS HP, 1994, INT ARCH ALLERGY IMM, V105, P190, DOI 10.1159/000236824; Rothkegel M, 1996, J CELL SCI, V109, P83; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; SEIBERLER S, 1994, EMBO J, V13, P3481, DOI 10.1002/j.1460-2075.1994.tb06654.x; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; SIPPL MJ, 1992, PROTEIN SCI, V1, P625, DOI 10.1002/pro.5560010509; SIPPL MJ, 1990, J MOL BIOL, V213, P859, DOI 10.1016/S0022-2836(05)80269-4; SOHN RH, 1994, BIOESSAYS, V7, P165; STAIGER CJ, 1994, CURR BIOL, V4, P215, DOI 10.1016/S0960-9822(00)00050-6; STAIGER CJ, 1993, PLANT J, V4, P631, DOI 10.1046/j.1365-313X.1993.04040631.x; STRAUS DB, 1988, GENE DEV, V2, P1851, DOI 10.1101/gad.2.12b.1851; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUSANI M, 1995, BIOCHEM BIOPH RES CO, V215, P250, DOI 10.1006/bbrc.1995.2460; TANAKA M, 1985, EUR J BIOCHEM, V151, P291, DOI 10.1111/j.1432-1033.1985.tb09099.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TULIP WR, 1990, COLD SPRING HARB SYM, V54, P257; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; VALENTA R, 1993, J BIOL CHEM, V268, P22777; VALENTA R, 1994, BIOCHEM BIOPH RES CO, V199, P106, DOI 10.1006/bbrc.1994.1201; VALLIER P, 1992, CLIN EXP ALLERGY, V22, P774, DOI 10.1111/j.1365-2222.1992.tb02818.x; VANZIJL PCM, 1995, J MAGN RESON SER A, V113, P265, DOI 10.1006/jmra.1995.1092; VRTALA S, 1996, IN PRESS BIOCH BIOPH; WEHLAND J, 1984, EMBO J, V3, P1295, DOI 10.1002/j.1460-2075.1984.tb01965.x; Wuthrich K, 1986, NMR PROTEINS NUCL AC	64	35	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29915	29921		10.1074/jbc.271.47.29915	http://dx.doi.org/10.1074/jbc.271.47.29915			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939935	hybrid			2022-12-25	WOS:A1996VU52500063
J	Zhu, H; Hargrove, M; Xie, Q; Nozaki, Y; Linse, K; Smith, SS; Olson, JS; Riggs, AF				Zhu, H; Hargrove, M; Xie, Q; Nozaki, Y; Linse, K; Smith, SS; Olson, JS; Riggs, AF			Stoichiometry of subunits and heme content of hemoglobin from the earthworm Lumbricus terrestris	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRILLIANT BLUE-R; EXTRACELLULAR HEMOGLOBIN; QUATERNARY STRUCTURE; DISSOCIATION; PROTEIN; GLOBIN; CHAINS; REASSOCIATION; TRIMER; MODEL	The extracellular hemoglobin (Hb) of the earthworm, Lumbricus terrestris, has four major O-2-binding chains, a, b, c (forming a disulfide-linked trimer), and d (''monomer''), Additional structural chains, ''linkers,'' are required for the assembly of the similar to 200-polypeptide molecule, The proportion of linker chains had been reported to be one-third of the total mass on the basis of densitometry of Coomassie Blue-stained SDS-gels, Reverse-phase high performance liquid chromatography (HPLC), however, gave 16.3% linkers on the basis of both 220-nm absorbance and amino acid analysis (Ownby, D. W., Zhu, H., Schneider, K., Beavis, R. C., Chait, B. C., and Riggs, A. F. (1993) J. Biol. Chem. 268, 13539-13547). The subunit proportions have now been redetermined by SDS capillary electrophoresis as a test of the HPLC results, The electrophoresis, monitored at 214 nm, avoided the use of Coomassie Blue and provided results identical with those obtained by HPLC, Capillary electrophoresis monitored at both 214 and 415 nm was used to show that linker chains do not bind heme, Heme content has been found to be 2.9% by determination of hemin, amino acid analysis and dry weight, Measurement of the rate of hemin loss from oxidized L. ferrestris Hb shows that high rates of loss can account for values of heme content significantly below 2.9% (or 0.26% iron).	UNIV TEXAS,DEPT ZOOL,AUSTIN,TX 78712; UNIV TEXAS,PROT MICROANAL FACIL,AUSTIN,TX 78712; RICE UNIV,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77005; RICE UNIV,KECK CTR COMPUTAT BIOL,HOUSTON,TX 77005; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; Rice University; Rice University; Duke University				Olson, John/0000-0002-0760-5403	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035847, R01GM035649] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 47020] Funding Source: Medline; NIGMS NIH HHS [GM 35649, GM 35847] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALL EH, 1986, ANAL BIOCHEM, V155, P23, DOI 10.1016/0003-2697(86)90218-6; BENESCH RE, 1995, J BIOL CHEM, V270, P13785, DOI 10.1074/jbc.270.23.13785; BRANTLEY RE, 1993, J BIOL CHEM, V268, P6995; CAMERON BF, 1965, ANAL BIOCHEM, V11, P164, DOI 10.1016/0003-2697(65)90002-3; DEDUVE C, 1948, ACTA CHEM SCAND, V2, P264, DOI 10.3891/acta.chem.scand.02-0264; FROSSARD P, 1982, BIOCHIM BIOPHYS ACTA, V704, P524, DOI 10.1016/0167-4838(82)90076-0; FUSHITANI K, 1988, J BIOL CHEM, V263, P6502; FUSHITANI K, 1991, J BIOL CHEM, V266, P10275; Fushitani K, 1996, BBA-PROTEIN STRUCT M, V1292, P273, DOI 10.1016/0167-4838(95)00214-6; GIBSON QH, 1991, J BIOL CHEM, V266, P13097; HARGROVE MS, 1994, J BIOL CHEM, V269, P4207; HARGROVE MS, 1995, THESIS W MARSH RICE; KAPP OH, 1984, J BIOL CHEM, V259, P628; LEVIN O, 1963, J MOL BIOL, V6, P95, DOI 10.1016/S0022-2836(63)80084-4; MAINWARING MG, 1986, J BIOL CHEM, V261, P899; MATSUBARA H, 1969, BIOCHEM BIOPH RES CO, V35, P175, DOI 10.1016/0006-291X(69)90263-0; NOZAKI Y, 1986, ARCH BIOCHEM BIOPHYS, V249, P437, DOI 10.1016/0003-9861(86)90020-2; OWNBY DW, 1993, J BIOL CHEM, V268, P13539; ROCHE J, 1960, BIOCHIM BIOPHYS ACTA, V41, P182, DOI 10.1016/0006-3002(60)90397-8; ROYER WE, 1988, J BIOL CHEM, V263, P13762; SCHATZ M, 1995, J STRUCT BIOL, V114, P28, DOI 10.1006/jsbi.1995.1003; SHISHIKURA F, 1987, J BIOL CHEM, V262, P3123; SHLOM JM, 1973, J BIOL CHEM, V248, P7904; SUZUKI T, 1993, J BIOL CHEM, V268, P13548; SUZUKI T, 1990, J BIOL CHEM, V265, P12168; TAL M, 1985, J BIOL CHEM, V260, P9976; VANASSENDELFT OW, 1970, SPECTROPHOTOMETRY HA, P100; VINOGRADOV SN, 1982, ANAL BIOCHEM, V120, P111, DOI 10.1016/0003-2697(82)90325-6; VINOGRADOV SN, 1977, BIOCHIM BIOPHYS ACTA, V492, P136, DOI 10.1016/0005-2795(77)90221-5; VINOGRADOV SN, 1986, P NATL ACAD SCI USA, V83, P8034, DOI 10.1073/pnas.83.21.8034; VINOGRADOV SN, 1991, J BIOL CHEM, V266, P13091; VINOGRADOV SN, 1991, COMP BIOCHEM PHYS B, V98, P187, DOI 10.1016/0305-0491(91)90165-A; Weber K, 1972, Methods Enzymol, V26, P3; WOLF HU, 1984, CLIN CHIM ACTA, V136, P95, DOI 10.1016/0009-8981(84)90251-1; XIE Q, 1996, IN PRESS BIOCH BIOPH; ZHANG L, 1991, J BIOL CHEM, V266, P24698; Zhu H, 1996, J BIOL CHEM, V271, P30007, DOI 10.1074/jbc.271.47.30007	37	30	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29999	30006		10.1074/jbc.271.47.29999	http://dx.doi.org/10.1074/jbc.271.47.29999			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939946	hybrid			2022-12-25	WOS:A1996VU52500074
J	Furuhata, T; Tokino, T; Urano, T; Nakamura, Y				Furuhata, T; Tokino, T; Urano, T; Nakamura, Y			Isolation of a novel GPI-anchored gene specifically regulated by p53; Correlation between its expression and anti-cancer drug sensitivity	ONCOGENE			English	Article						p53; GPI-anchored protein; anti-cancer drug; esophageal cancer	CELL-GROWTH; PROTEIN; SUPPRESSION; INHIBITOR; KINASES; THB; P21; DNA	We have identified a novel gene inducible by wild-type p53. A significant correlation between expression of this gene and p53 status in cells derived from esophageal cancers indicated that this gene is likely to be specifically regulated in a p53-dependent manner. As the predicted amino acid sequence showed a high degree of homology to the family of glycosyl-phosphatidylinositol (GPI)-anchored membrane proteins, we termed this gene GML (GPI-anchored molecule-like protein). Introduction of GML cDNA suppressed the growth of esophageal cancer cells in culture. A correlation between the presence of GML expression and the sensitivity of esophageal cancer cells to anti-cancer drugs implied that the gene product plays a significant role in the apoptotic pathway or cell-cycle regulation induced by p53 after DNA damage.	UNIV TOKYO, INST MED SCI, MOL MED LAB, TOKYO, JAPAN	University of Tokyo			Tokino, Takashi/AAI-9887-2021; Urano, Tomohiko/AFS-9574-2022					BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BRAKENHOFF RH, 1995, J CELL BIOL, V129, P1677, DOI 10.1083/jcb.129.6.1677; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GUMLEY TP, 1992, J IMMUNOL, V149, P2615; HARPER JW, 1993, CELL, V75, P805; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MIYASHITA T, 1995, CELL, V80, P293; NAN HJ, 1995, HUM MOL GENET, V4, P237, DOI 10.1093/hmg/4.2.237; NISHIHIRA T, 1993, J CANCER RES CLIN, V119, P441, DOI 10.1007/BF01215923; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; ROCK KL, 1989, IMMUNOL REV, V111, P195, DOI 10.1111/j.1600-065X.1989.tb00547.x; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; TOKINO T, 1991, AM J HUM GENET, V48, P258; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126	21	52	53	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	1996	13	9					1965	1970						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934543				2022-12-25	WOS:A1996VR79500016
J	Manev, H; Uz, T; Kharlamov, A; Joo, JY				Manev, H; Uz, T; Kharlamov, A; Joo, JY			Increased brain damage after stroke or excitotoxic seizures in melatonin-deficient rats	FASEB JOURNAL			English	Article						kainate; pinealectomy; carotid artery; cerebral artery	PINEAL-GLAND; NUCLEAR RECEPTOR; EXPRESSION; INDUCTION; SECRETION; SUBTYPES; P53	The pineal hormone melatonin is neuroprotective in vitro, and in vivo it is neuroprotective when given in pharmacological doses. Consequently, it has been hypothesized that with aging, as circulating levels of melatonin in mammals normally decrease, the brain might be at increased risk of neurodegeneration. However, direct evidence that melatonin deficiency leads to increased brain vulnerability is still lacking, We created melatonin deficiency in rats by pinealectomy and induced neurodegeneration by two models of focal brain ischemia/stroke and by glutamate receptor-mediated, epilepsy-like seizures, We observed greater neurodegeneration in melatonin-deficient animals than in controls, Our results suggest that endogenous melatonin may play a neuroprotective role, and that melatonin deficiency might be a pathophysiological mechanism in neurodegenerative diseases.	ALLEGHENY SINGER RES INST,PITTSBURGH,PA 15212; MED COLL PENN & HAHNEMANN UNIV,DEPT NEUROSURG,PITTSBURGH,PA 15212	Drexel University	Manev, H (corresponding author), UNIV ILLINOIS,INST PSYCHIAT,1601 W TAYLOR ST,M-C 912,CHICAGO,IL 60612, USA.				NATIONAL INSTITUTE ON AGING [K07AG000532] Funding Source: NIH RePORTER; NIA NIH HHS [KO7AG00532] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ACUNACASTROVIEJO D, 1995, J PINEAL RES, V19, P57; Antolin I, 1996, FASEB J, V10, P882, DOI 10.1096/fasebj.10.8.8666165; BARLOWWALDEN LR, 1995, NEUROCHEM INT, V26, P497, DOI 10.1016/0197-0186(94)00154-M; BECKERANDRE M, 1994, J BIOL CHEM, V269, P28531; BRUGGER P, 1995, LANCET, V345, P1408, DOI 10.1016/S0140-6736(95)92600-3; CAGNOLI CM, 1995, J PINEAL RES, V18, P222, DOI 10.1111/j.1600-079X.1995.tb00163.x; CharriautMarlangue C, 1995, NEUROREPORT, V7, P61, DOI 10.1097/00001756-199512290-00014; DAVIS M, 1995, STROKE, V26, P1072, DOI 10.1161/01.STR.26.6.1072; DUBOCOVICH ML, 1995, TRENDS PHARMACOL SCI, V16, P50, DOI 10.1016/S0165-6147(00)88978-6; GIUSTI P, 1995, EXP NEUROL, V131, P39, DOI 10.1016/0014-4886(95)90005-5; Giusti P, 1996, FASEB J, V10, P891, DOI 10.1096/fasebj.10.8.8666166; GIUSTI P, 1996, IN PRESS J PINEAL RE; HIRAMATSU K, 1993, ACTA NEUROCHIR, V120, P66, DOI 10.1007/BF02001472; MANEV H, 1994, NEUROREPORT, V5, P2661, DOI 10.1097/00001756-199412000-00064; MANEV H, 1996, NEUROL NEUROSCI, V9, P251; MELCHIORRI D, 1995, FASEB J, V9, P1205, DOI 10.1096/fasebj.9.12.7672513; MENENDEZPELAEZ A, 1993, J CELL BIOCHEM, V53, P373, DOI 10.1002/jcb.240530415; Osborne NN, 1996, J NEUROCHEM, V66, pS57; PANG SF, 1990, J PINEAL RES, V9, P193, DOI 10.1111/j.1600-079X.1990.tb00708.x; Paxinos G, 1988, RAT BRAIN STEREOTAXI; REITER RJ, 1995, FRONT NEUROENDOCRIN, V16, P383, DOI 10.1006/frne.1995.1014; REITER RJ, 1973, EXP NEUROL, V38, P386, DOI 10.1016/0014-4886(73)90161-1; REITER RJ, 1972, PHYSIOL BEHAV, V9, P203, DOI 10.1016/0031-9384(72)90236-3; REITER RJ, 1995, FASEB J, V9, P526, DOI 10.1096/fasebj.9.7.7737461; REITER RJ, 1991, MOL CELL ENDOCRINOL, V79, pC153, DOI 10.1016/0303-7207(91)90087-9; Reiter Russel J., 1994, Acta Neurobiologiae Experimentalis (Warsaw), V54, P31; REPPERT SM, 1995, NEURON, V15, P1003, DOI 10.1016/0896-6273(95)90090-X; Reppert SM, 1995, CELL, V83, P1059, DOI 10.1016/0092-8674(95)90131-0; ROJDMARK S, 1993, METABOLISM, V42, P1047, DOI 10.1016/0026-0495(93)90021-F; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; SAKHI S, 1994, P NATL ACAD SCI USA, V91, P7525, DOI 10.1073/pnas.91.16.7525; Sakhi S, 1996, NEUROREPORT, V7, P493, DOI 10.1097/00001756-199601310-00028; SANDYK R, 1992, INT J NEUROSCI, V62, P243; STEINHILBER D, 1995, J BIOL CHEM, V270, P7037, DOI 10.1074/jbc.270.13.7037; STOKKAN KA, 1991, BRAIN RES, V545, P66, DOI 10.1016/0006-8993(91)91270-B; Tan DX, 1993, ENDOCR J, V1, P57; UNLAP T, 1995, MOL BRAIN RES, V28, P193, DOI 10.1016/0169-328X(94)00202-P; Uz T, 1996, NEUROSCIENCE, V73, P631, DOI 10.1016/0306-4522(96)00155-8; WATSON BD, 1985, ANN NEUROL, V17, P497, DOI 10.1002/ana.410170513	39	196	203	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1996	10	13					1546	1551		10.1096/fasebj.10.13.8940301	http://dx.doi.org/10.1096/fasebj.10.13.8940301			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VU982	8940301				2022-12-25	WOS:A1996VU98200012
J	Sulica, A; Herberman, RB				Sulica, A; Herberman, RB			Cytophilic immunoglobulins revisited via natural killer cells	FASEB JOURNAL			English	Article						Fc receptors; immunoregulation; cytotosic cells; antibodies	LARGE GRANULAR LYMPHOCYTES; HUMAN-IGG; MONOMERIC IGG; CYTO-TOXICITY; BINDING-SITE; FC-RECEPTORS; INHIBITION; EXPRESSION; ANTIBODIES; AFFINITY	Cytophilia is one of the biologic properties of the Fe region of immunoglobulins operationally defined as the ability of an antibody molecule to attach to certain cell types before combination with antigen, By attachment of cytophilic antibody to membrane Fc receptors, cells become ''armed'' with antibodies and able to interact specifically with soluble or particulate antigens, In contrast to this cytophilia, the so-called opsonic antibody binds to FcR of various cell types only after it has complexed with antigen, In spite of knowledge of cytophilic properties of immunoglobulins for more than 30 years and an impressive accumulation of facts regarding the structure and function of cell-surface FcR binding IgG, IgE, or IgA molecules, less progress has been made in understanding the molecular basis of cytophilia. Our extensive studies of the structural and functional aspects of the interaction of IgG in monomeric form with human natural killer cells, via the type IIIA IgG Fc receptor (Fc gamma RIIIA), provide a focal point for revisiting this major pathway of direct and continuous communication between the humoral and cellular compartments of the immune system.	UNIV PITTSBURGH, INST CANC, PITTSBURGH, PA 15213 USA; SOS MIHAI BRAVU, CTR IMMUNOL, BUCHAREST 79650, ROMANIA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Romanian Academy of Sciences; Stefan S. Nicolau Institute of Virology			Institute of Virology, Stefan S Nicolau/HGE-9069-2022					AREND WP, 1973, J IMMUNOL, V110, P1455; BANCU AC, 1988, CELL IMMUNOL, V114, P246, DOI 10.1016/0008-8749(88)90319-X; BERKEN A, 1966, J EXP MED, V123, P119, DOI 10.1084/jem.123.1.119; BOYDEN SV, 1963, CELL BOUND ANTIBODIE, P7; BRODT P, 1981, J RETICULOENDOTH SOC, V30, P283; BURTON DR, 1985, MOL IMMUNOL, V22, P161, DOI 10.1016/0161-5890(85)90151-8; CAPRON M, 1984, CELL IMMUNOL, V83, P60, DOI 10.1016/0008-8749(84)90225-9; CHAPPEL MS, 1991, P NATL ACAD SCI USA, V88, P9036, DOI 10.1073/pnas.88.20.9036; deHaas M, 1996, J IMMUNOL, V156, P2948; DUNCAN AR, 1988, NATURE, V332, P563, DOI 10.1038/332563a0; ENGELHARD D, 1986, J PEDIATR-US, V108, P77, DOI 10.1016/S0022-3476(86)80772-7; FLORES M, 1977, CANCER, V39, P494, DOI 10.1002/1097-0142(197702)39:2<494::AID-CNCR2820390218>3.0.CO;2-8; FORTUNE F, 1990, CLIN EXP IMMUNOL, V82, P326; GALATIUC C, 1995, CELL IMMUNOL, V163, P167, DOI 10.1006/cimm.1995.1113; GHERMAN M, 1987, MOL IMMUNOL, V24, P743, DOI 10.1016/0161-5890(87)90057-5; Herberman RB, 1985, UCLA S MOL CELLULAR, V27, P193; HERMAN R, 1980, INFECT IMMUN, V28, P585; HULETT MD, 1994, ADV IMMUNOL, V57, P1, DOI 10.1016/S0065-2776(08)60671-9; IMIR T, 1976, J IMMUNOL, V117, P1938; JAIN S, 1986, Journal of Hygiene Epidemiology Microbiology and Immunology (Prague), V30, P207; JEFFERIS R, 1995, IMMUNOL LETT, V44, P111, DOI 10.1016/0165-2478(94)00201-2; KOREN HS, 1978, J IMMUNOL, V120, P796; KULCZYCK.A, 1974, J EXP MED, V140, P1676, DOI 10.1084/jem.140.6.1676; LANIER LL, 1983, J IMMUNOL, V131, P1789; Leibson PJ, 1995, NAT IMMUN, V14, P117; Leslie R G, 1979, Curr Top Microbiol Immunol, V88, P25; LOBO PI, 1976, J IMMUNOL, V117, P939; LYNCH RG, 1990, FC RECEPTORS ACTION, P305; MANCIULEA M, 1989, MOL IMMUNOL, V26, P1087, DOI 10.1016/0161-5890(89)90052-7; Manciulea M, 1996, CELL IMMUNOL, V167, P63, DOI 10.1006/cimm.1996.0008; METES D, 1994, NAT IMMUN, V13, P289; MITSUNAGA M, 1987, ACTA MED OKAYAMA, V41, P205; MURAYAMA T, 1990, CLIN IMMUNOL IMMUNOP, V55, P297, DOI 10.1016/0090-1229(90)90105-Y; ONICA D, 1988, APMIS, V96, P525, DOI 10.1111/j.1699-0463.1988.tb05339.x; PARISH WE, 1965, NATURE, V208, P594, DOI 10.1038/208594a0; PARRILLO JE, 1977, IMMUNOLOGY, V33, P839; Perlmann P, 1970, Cell Immunol, V1, P300, DOI 10.1016/0008-8749(70)90051-1; PETERSON PK, 1983, J INFECT DIS, V148, P1040, DOI 10.1093/infdis/148.6.1040; PRICOP L, 1993, J IMMUNOL, V151, P3018; RABINOWICH H, 1996, IN PRESS J IMMUNOL; ROSENBLATT J, 1977, J IMMUNOL, V118, P981; SEGAL DM, 1977, J IMMUNOL, V118, P1338; SORKIN E, 1963, IMMUNOLOGICALLY COMP, P38; SULICA A, 1982, J IMMUNOL, V128, P1031; SULICA A, 1976, SCAND J IMMUNOL, V5, P1191; SULICA A, 1979, IMMUNOLOGY, V38, P173; SULICA A, 1993, CELL IMMUNOL, V147, P397, DOI 10.1006/cimm.1993.1079; SULICA A, 1979, EUR J IMMUNOL, V9, P979, DOI 10.1002/eji.1830091212; TAO MH, 1989, J IMMUNOL, V143, P2595; TIZARD IR, 1971, BACTERIOL REV, V35, P365, DOI 10.1128/MMBR.35.4.365-378.1971; TIZARD IR, 1969, INT ARCH ALLER A IMM, V36, P332, DOI 10.1159/000230755; TRINCHIERI G, 1993, NAT IMMUN, V12, P218; TROYE M, 1977, J IMMUNOL, V119, P1061; TRUCCO M, 1981, IMMUNOLOGICAL METHOD, V2, P1; TYLER DS, 1989, AIDS RES HUM RETROV, V5, P557, DOI 10.1089/aid.1989.5.557; VANCE BA, 1993, J IMMUNOL, V151, P6429; WHELEN AC, 1993, J PARASITOL, V79, P908, DOI 10.2307/3283729; WHITESIDE TL, 1989, CLIN IMMUNOL IMMUNOP, V53, P1, DOI 10.1016/0090-1229(89)90096-2; WILSON AB, 1985, CELL IMMUNOL, V90, P196, DOI 10.1016/0008-8749(85)90181-9; WRIGHT JF, 1990, J BIOL CHEM, V265, P10506	60	7	7	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1996	10	13					1495	1504		10.1096/fasebj.10.13.8940295	http://dx.doi.org/10.1096/fasebj.10.13.8940295			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VU982	8940295				2022-12-25	WOS:A1996VU98200006
J	Brozek, KA; Kadrmas, JL; Raetz, CRH				Brozek, KA; Kadrmas, JL; Raetz, CRH			Lipopolysaccharide biosynthesis in Rhizobium leguminosarum - Novel enzymes that process precursors containing 3-deoxy-D-manno-octulosonic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC SIGNAL-TRANSDUCTION; LIPID-A; ESCHERICHIA-COLI; BACTERIAL-ENDOTOXINS; BIOVAR PHASEOLI; PURIFICATION	The lipopolysaccharide of Rhizobium leguminosarum differs from that of other Gram-negative organisms. R. leguminosarum lipid A lacks phosphate groups, but it contains a galacturonic acid residue at the 4'-position and an aminogluconate moiety in place of the usual glucosamine 1-phosphate unit. R. leguminosarum lipid A is esterified with a peculiar long chain fatty acid, 27-hydroxyoctacosanoate, not found in enteric Gramnegative bacteria, and the inner core of R. leguminosarum contains mannose and galactose in place of heptose. Despite these differences, the biosynthesis of R. leguminosarum lipid A is initiated by the same seven enzyme pathway as in Escherichia coli (Raetz, C. R. H. (1993) J. Bacteriol. 175, 5745-5753) to form the phosphorylated precursor, (Kdo)(2)-lipid IVA which is then processed differently. We now describe several novel Rhizobium-specific enzymes that recognize and modify (Kdo)(2)-lipid IVA. The 1- and 4'-phosphatases were detected using (Kdo)(2)-[1-P-32]-lipid IVA and (Kdo)(2)-[4'-P-32]-lipid IVA, respectively, as shown by release of P-32(i). In the presence of GDP-mannose and/or UDP-galactose, membranes of R. leguminosarum first transferred mannose and then galactose to (Kdo)(2)-[4'-P-32]-lipid IVA. In addition, at least two hydrophobic metabolites were generated from (Kdo)(2)-[4'-P-32]-lipid IVA in a manner that was dependent upon both membranes and a cytosolic factor from R. leguminosarum. These compounds are attributed to novel acylations of (Kdo)(2)-[4'-P-32]-lipid IVA. E. coli membranes and cytosol did not catalyze any of the unique reactions detected in R. leguminosarum extracts. Our findings establish the conservation and versatility of (Hdo)(2)-lipid IVA as a lipid A precursor in bacteria.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University					NIGMS NIH HHS [5T32GM07105, GM-51796] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051796, T32GM007105, R37GM051796] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAO WJ, 1993, ARCH BIOCHEM BIOPHYS, V300, P705, DOI 10.1006/abbi.1993.1098; BELUNIS CJ, 1992, J BIOL CHEM, V267, P9988; BHAT UR, 1991, J BACTERIOL, V173, P2155, DOI 10.1128/JB.173.7.2155-2159.1991; BHAT UR, 1994, J BIOL CHEM, V269, P14402; BHAT UR, 1991, CARBOHYD RES, V220, P219, DOI 10.1016/0008-6215(91)80020-N; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; BROZEK KA, 1990, J BIOL CHEM, V265, P15410; CAVA JR, 1989, J BACTERIOL, V171, P8, DOI 10.1128/jb.171.1.8-15.1989; Clementz T, 1996, J BIOL CHEM, V271, P12095, DOI 10.1074/jbc.271.20.12095; GALLOWAY SM, 1990, J BIOL CHEM, V265, P6394; HAMPTON RY, 1992, METHOD ENZYMOL, V209, P466; LEVIN J, 1993, ENDOTOXIN RES SERIES, V2; MORISON DC, 1992, BACTERIAL ENDOTOXIC, V1; PRICE NPJ, 1995, P NATL ACAD SCI USA, V92, P7352, DOI 10.1073/pnas.92.16.7352; PRICE NPJ, 1994, J BACTERIOL, V176, P4646, DOI 10.1128/JB.176.15.4646-4655.1994; Raetz C. R. H., 1996, ESCHERICHIA COLI SAL, V1, P1035; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RAETZ CRH, 1991, FASEB J, V5, P2652, DOI 10.1096/fasebj.5.12.1916089; REEVES PR, 1994, BACTERIAL CELL WALL, V27, P281; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; RIETSCHEL ET, 1992, SCI AM, V267, P54, DOI 10.1038/scientificamerican0892-54; SCHNAITMAN CA, 1993, MICROBIOL REV, V57, P655, DOI 10.1128/MMBR.57.3.655-682.1993; SEGOVIA L, 1993, INT J SYST BACTERIOL, V43, P374, DOI 10.1099/00207713-43-2-374; SIRISENA DM, 1992, J BIOL CHEM, V267, P18874; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stacey G., 1992, BIOL NITROGEN FIXATI; ULEVITCH RJ, 1994, CURR OPIN IMMUNOL, V6, P125, DOI 10.1016/0952-7915(94)90043-4; URBANIKSYPNIEWSKA T, 1989, ARCH MICROBIOL, V152, P527, DOI 10.1007/BF00425481; Young K, 1995, J BIOL CHEM, V270, P30384, DOI 10.1074/jbc.270.51.30384; ZEVENHUIZEN LPTM, 1980, ARCH MICROBIOL, V125, P1, DOI 10.1007/BF00403191	31	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32112	32118		10.1074/jbc.271.50.32112	http://dx.doi.org/10.1074/jbc.271.50.32112			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943264	hybrid			2022-12-25	WOS:A1996VY34000055
J	Newrzella, D; Stoffel, W				Newrzella, D; Stoffel, W			Functional analysis of the glycosylation of murine acid sphingomyelinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIEMANN-PICK DISEASE; N-LINKED OLIGOSACCHARIDE; VIRUS-G PROTEIN; INTRACELLULAR-TRANSPORT; LYSOSOMAL SPHINGOMYELINASE; ENDOPLASMIC-RETICULUM; NUCLEOTIDE-SEQUENCE; TARGETING SIGNAL; INFLUENZA-VIRUS; DEFICIENT MICE	Glycosylation plays a crucial role in glycoprotein stability and its correct folding. Murine acid sphingomyelinase (ASM) is a lysosomal glycoprotein. We studied the functional role of its individual N-linked oligosaccharides needed to maintain enzymatic activity and protein stability. Mutagenized cDNA constructs were heterologously expressed, All six potential N-glycosylation sites were modified, Incomplete glycosylation of the most distant C-terminal site resulted in two isoforms, Oligosaccharides at N-84, N-173, and N-611 were found to be of minor importance for enzymatic activity, The glycosylation defect at N-333 or N-393 reduced the enzymatic activity to 40% and at N-518 to less than 20%. These mutations did not effect the K-m value. Glycosylation at N-333 and N-393 mainly contributed to the enzyme stability and prevented degradation at lysosomal acidic pH, whereas the low residual enzymatic activity of mutant ASM deficient in glycosylation at N-518 was caused by protein misfolding. The mutant protein was also prone to proteolysis when trapped in the endoplasmic reticulum/cis-Golgi after brefeldin A application, Insufficiently glycosylated ASM formed a stable complex with BiP, an immunoglobulin heavy chain-binding protein, and thus remained in the endoplasmic reticulum, (32)pO(4) labeling revealed that the glycosylation mutants of ASM were phosphorylated predominantly at mannose residues of oligosaccharides linked to N-84, N-333, and N-393.	UNIV COLOGNE, INST BIOCHEM 1, FAC MED, D-50931 COLOGNE, GERMANY	University of Cologne								ANDRIEU N, 1994, BIOCHEM J, V303, P341, DOI 10.1042/bj3030341; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; DUBE S, 1988, J BIOL CHEM, V263, P17516; DUCH M, 1990, GENE, V95, P285, DOI 10.1016/0378-1119(90)90373-Y; GALLAGHER PJ, 1992, J VIROL, V66, P7136, DOI 10.1128/JVI.66.12.7136-7145.1992; GRABER D, 1994, J NEUROCHEM, V63, P1060; HAAS IG, 1991, CURR TOP MICROBIOL, V167, P71; HAAS IG, 1994, EXPERIENTIA, V50, P1012, DOI 10.1007/BF01923455; HALABAN R, 1988, P NATL ACAD SCI USA, V85, P7241, DOI 10.1073/pnas.85.19.7241; HORINOUCHI K, 1995, NAT GENET, V10, P288, DOI 10.1038/ng0795-288; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; HURWITZ R, 1994, J BIOL CHEM, V269, P5440; KRETZ KA, 1990, P NATL ACAD SCI USA, V87, P2541, DOI 10.1073/pnas.87.7.2541; KUNO K, 1994, INT IMMUNOL, V6, P1269, DOI 10.1093/intimm/6.8.1269; MACHAMER CE, 1990, J BIOL CHEM, V265, P6879; MACHAMER CE, 1988, J BIOL CHEM, V263, P5955; MACHAMER CE, 1985, MOL CELL BIOL, V5, P3074, DOI 10.1128/MCB.5.11.3074; MARQUARDT T, 1992, J CELL BIOL, V117, P505, DOI 10.1083/jcb.117.3.505; MATZUK MM, 1988, J CELL BIOL, V106, P1049, DOI 10.1083/jcb.106.4.1049; METCALF P, 1993, EMBO J, V12, P1293, DOI 10.1002/j.1460-2075.1993.tb05774.x; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; NEWRZELLA D, 1992, BIOL CHEM H-S, V373, P1233, DOI 10.1515/bchm3.1992.373.2.1233; NG DTW, 1990, MOL CELL BIOL, V10, P1989, DOI 10.1128/MCB.10.5.1989; OTTERBACH B, 1995, CELL, V81, P1053, DOI 10.1016/S0092-8674(05)80010-8; PAREKH RB, 1989, BIOCHEMISTRY-US, V28, P7644, DOI 10.1021/bi00445a021; PIQUE C, 1992, J VIROL, V66, P906, DOI 10.1128/JVI.66.2.906-913.1992; PLATT SG, 1987, ANAL BIOCHEM, V162, P529, DOI 10.1016/0003-2697(87)90429-5; QUINTERN LE, 1987, BIOCHIM BIOPHYS ACTA, V922, P323, DOI 10.1016/0005-2760(87)90055-5; SCHUCHMAN EH, 1991, J BIOL CHEM, V266, P8531; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; SHIPLEY JM, 1993, J BIOL CHEM, V268, P12193; STOFFEL W, 1971, H-S Z PHYSIOL CHEM, V352, P1058, DOI 10.1515/bchm2.1971.352.2.1058; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TIFFT CJ, 1992, J BIOL CHEM, V267, P3268; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WALSH MT, 1990, BIOCHEMISTRY-US, V29, P6250, DOI 10.1021/bi00478a020; WEITZ G, 1992, J BIOL CHEM, V267, P10039; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WILLIAMS AM, 1993, J BIOL CHEM, V268, P12780	41	37	50	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32089	32095		10.1074/jbc.271.50.32089	http://dx.doi.org/10.1074/jbc.271.50.32089			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943261	hybrid			2022-12-25	WOS:A1996VY34000052
J	Begum, N; Ragolia, L				Begum, N; Ragolia, L			cAMP counter-regulates insulin-mediated protein phosphatase-2A inactivation in rat skeletal muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; DEPENDENT ACTIVATION; KINASE; GROWTH; 2A; INHIBITION; SUBUNIT	In this study, we examined the mechanism of recently reported inactivation of protein phosphatase-2A (PP-2A) by insulin (Srinivasan, IM., and Begum, N, (1994) J. Biol. Chem, 269, 12514-12520) and its counter-regulation by cAMP agonists, Exposure of L6 myotubes to insulin resulted in a rapid inhibition of PP-W that was accompanied by a 3-fold increase in the phosphotyrosine content of the immunoprecipitated PP-2A catalytic subunit, Pretreatment with (S-p) cAMP, a cAMP agonist, completely blocked insulin-mediated inhibition of PP-2A activity and decreased the tyrosine phosphorylation of PP-2A catalytic subunit to control levels. To understand the mechanism of counter regulation of PP-2A by (S-p)-cAMP, cells were pretreated with sodium orthovanadate, an inhibitor of phosphotyrosine phosphatases. Vanadate prevented the effect of (S-p)-cAMP on PP-2A activity and increased the phosphorylation status of PP-2A catalytic subunit to the level observed with insulin, Wortmannin, a phosphatidylinositol 8-kinase inhibitor, and rapamycin, an inhibitor of 70-kDa S6 kinase activation, prevented insulin-mediated inactivation of PP-2A, suggesting that these pathways may participate in insulin mediated phosphorylation and inactivation of PP-2A These results show that insulin signaling results in a rapid inactivation of PP-PA by increased tyrosine phosphorylation and cAMP agonists counter-regulate insulin's effect on PP-2A by decreasing phosphorylation, presumably via an activated phosphatase.	SUNY STONY BROOK, SCH MED, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Begum, N (corresponding author), WINTHROP UNIV HOSP, DIABET RES LABS, 259 1ST ST, MINEOLA, NY 11501 USA.		Ragolia, Louis/AAW-2383-2021	Ragolia, Louis/0000-0002-8292-5159				AHMAD F, 1995, AM J PHYSIOL-ENDOC M, V268, pE932, DOI 10.1152/ajpendo.1995.268.5.E932; BARNES GN, 1995, J NEUROCHEM, V64, P340; Begum N, 1996, EUR J BIOCHEM, V238, P214, DOI 10.1111/j.1432-1033.1996.0214q.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brautigan David L., 1993, Molecular and Cellular Biochemistry, V127-128, P121, DOI 10.1007/BF01076763; BRAUTIGAN DL, 1993, ADV PROT PHOSPHATASE, V7, P49; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; Chajry N, 1996, EUR J BIOCHEM, V235, P97, DOI 10.1111/j.1432-1033.1996.00097.x; CHEN J, 1994, J BIOL CHEM, V269, P7957; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; ERHARDT P, 1995, MOL CELL BIOL, V15, P5524; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GUO H, 1993, J BIOL CHEM, V268, P11193; GUO H, 1993, P NATL ACAD SCI USA, V90, P2500, DOI 10.1073/pnas.90.6.2500; KAMIBAYASHI C, 1991, J BIOL CHEM, V266, P13251; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mayer-Jaekel Regina E., 1994, Trends in Cell Biology, V4, P287, DOI 10.1016/0962-8924(94)90219-4; MAYERJAEKEL RE, 1993, CELL, V72, P621, DOI 10.1016/0092-8674(93)90080-A; MAYEROWITCH J, 1992, BIOCHEMISTRY-US, V31, P10338; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; OKADA T, 1994, J BIOL CHEM, V269, P3568; PETRITSCH C, 1995, J BIOL CHEM, V270, P22619; REUDIGER R, 1991, MOL CELL BIOL, V11, P4282; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SRINIVASAN M, 1994, J BIOL CHEM, V269, P12514; STEVENSON BR, 1993, P NATL ACAD SCI USA, V90, P10305; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; XIE HY, 1994, J BIOL CHEM, V269, P1981; Zhang WR, 1996, MOL ENDOCRINOL, V10, P575, DOI 10.1210/me.10.5.575	33	73	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31166	31171		10.1074/jbc.271.49.31166	http://dx.doi.org/10.1074/jbc.271.49.31166			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940115	hybrid			2022-12-25	WOS:A1996VW68600026
J	Friedman, WJ; Thakur, S; Seidman, L; Rabson, AB				Friedman, WJ; Thakur, S; Seidman, L; Rabson, AB			Regulation of nerve growth factor mRNA by interleukin-1 in rat hippocampal astrocytes is mediated by NF kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR MESSENGER-RNA; TUMOR-NECROSIS-FACTOR; GENE-EXPRESSION; TRANSCRIPTION FACTOR; INTERFERON-GAMMA; VIRUS TYPE-1; FACTOR-ALPHA; FACTOR NGF; AGED RATS; CELLS	Cytokines such as interleukin-1 beta (IL-1) are produced in the brain during development and during inflammatory processes that result from lesions or disease. One function of IL-1 in the brain appears to be the stimulation of astrocytes to proliferate and produce a variety of cytokines and trophic factors, including nerve growth factor. The mechanisms by which IL-1 exerts its actions on astrocytes remain poorly defined. We present evidence that this cytokine elicits activation of the NF kappa B transcription factor and that this transcription factor mediates effects of Il-1 on nerve growth factor mRNA expression. Elucidation of the processes by which cytokines activate astrocytes and influence trophic factor expression may provide insight into mechanisms governing inflammatory processes within the central nervous system.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT NEUROSCI & CELL BIOL,PISCATAWAY,NJ 08854; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT MOL GENET & MICROBIOL,PISCATAWAY,NJ 08854; CTR ADV BIOTECHNOL & MED,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center					NINDS NIH HHS [NS 31357] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS031357] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AYERLELIEVRE C, 1988, SCIENCE, V240, P1339, DOI 10.1126/science.2897715; BANDTLOW CE, 1987, EMBO J, V6, P891, DOI 10.1002/j.1460-2075.1987.tb04835.x; BAUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BENVENISTE EN, 1992, NEUROIMMUNOENDOCRINO, V52, P106; BIELINSKA A, 1990, SCIENCE, V250, P997, DOI 10.1126/science.2237444; CARMANKRZAN M, 1991, J NEUROCHEM, V56, P636, DOI 10.1111/j.1471-4159.1991.tb08197.x; CAULEY K, 1994, P NATL ACAD SCI USA, V91, P390, DOI 10.1073/pnas.91.1.390; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; D'MELLO S R, 1991, Molecular and Cellular Neuroscience, V2, P157, DOI 10.1016/1044-7431(91)90008-C; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; ECK SL, 1993, MOL CELL BIOL, V13, P6530, DOI 10.1128/MCB.13.10.6530; ERNFORS P, 1990, NEURON, V5, P511, DOI 10.1016/0896-6273(90)90090-3; FAGARASAN MO, 1990, P NATL ACAD SCI USA, V87, P7871, DOI 10.1073/pnas.87.20.7871; FISCHER W, 1987, NATURE, V329, P65, DOI 10.1038/329065a0; FISCHER W, 1989, EUR J NEUROSCI, V1, P34, DOI 10.1111/j.1460-9568.1989.tb00772.x; FRIEDMAN WJ, 1990, J NEUROSCI RES, V27, P374, DOI 10.1002/jnr.490270316; FRIEDMAN WJ, 1992, J NEUROSCI RES, V33, P37, DOI 10.1002/jnr.490330106; GIMBLE JM, 1988, J VIROL, V62, P4104, DOI 10.1128/JVI.62.11.4104-4112.1988; HEFTI F, 1986, ANN NEUROL, V20, P275, DOI 10.1002/ana.410200302; HEFTI F, 1984, BRAIN RES, V293, P305, DOI 10.1016/0006-8993(84)91237-X; HENGERER B, 1990, P NATL ACAD SCI USA, V87, P3899, DOI 10.1073/pnas.87.10.3899; HERTZ L, 1990, IMMUNOL TODAY, V11, P265, DOI 10.1016/0167-5699(90)90106-J; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; KALTSCHMIDT B, 1993, MOL ASPECTS MED, V14, P171, DOI 10.1016/0098-2997(93)90004-W; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; KOOP EB, 1995, ADV IMMUNOL, V58, P1; LARGE TH, 1986, SCIENCE, V234, P352, DOI 10.1126/science.3764415; LARKFORS L, 1987, MOL BRAIN RES, V3, P55, DOI 10.1016/0169-328X(87)90044-1; LARKFORS L, 1987, J NEUROSCI RES, V18, P525, DOI 10.1002/jnr.490180404; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIEBERMAN AP, 1989, P NATL ACAD SCI USA, V86, P6348, DOI 10.1073/pnas.86.16.6348; LINDHOLM D, 1987, NATURE, V330, P658, DOI 10.1038/330658a0; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LIPTAY S, 1994, MOL CELL BIOL, V14, P7695, DOI 10.1128/MCB.14.12.7695; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; LU B, 1991, J NEUROSCI, V11, P318; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; MONTERO CN, 1988, J NEUROSCI, V8, P2986; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; OLSON L, 1992, J NEURAL TRANSM-PARK, V4, P79, DOI 10.1007/BF02257624; OMALLEY EK, 1994, BRAIN RES, V647, P83, DOI 10.1016/0006-8993(94)91401-X; RATTNER A, 1993, EMBO J, V12, P4261, DOI 10.1002/j.1460-2075.1993.tb06110.x; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J VIROL, V66, P6288, DOI 10.1128/JVI.66.11.6288-6293.1992; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SPARACIO SM, 1992, J NEUROIMMUNOL, V39, P231, DOI 10.1016/0165-5728(92)90257-L; SPRANGER M, 1990, EUR J NEUROSCI, V2, P69, DOI 10.1111/j.1460-9568.1990.tb00382.x; SWINGLER S, 1994, BIOCHEM BIOPH RES CO, V203, P623, DOI 10.1006/bbrc.1994.2228; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; THAKUR S, 1994, ONCOGENE, V9, P2335; Troy CM, 1996, J NEUROSCI, V16, P253; VIDOVIC M, 1990, J NEUROIMMUNOL, V30, P189, DOI 10.1016/0165-5728(90)90103-T; WHITTEMORE SR, 1987, J NEUROSCI, V7, P244; WHITTEMORE SR, 1986, P NATL ACAD SCI USA, V83, P817, DOI 10.1073/pnas.83.3.817; WHITTEMORE SR, 1988, J NEUROSCI RES, V20, P403, DOI 10.1002/jnr.490200402; WILLIAMS LR, 1986, P NATL ACAD SCI USA, V83, P9231, DOI 10.1073/pnas.83.23.9231	59	89	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31115	31120		10.1074/jbc.271.49.31115	http://dx.doi.org/10.1074/jbc.271.49.31115			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940108	hybrid			2022-12-25	WOS:A1996VW68600019
J	Kudlicki, W; Odom, OW; Kramer, G; Hardesty, B				Kudlicki, W; Odom, OW; Kramer, G; Hardesty, B			Binding of an N-terminal rhodanese peptide to DnaJ and to ribosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA; CONFORMATIONAL-CHANGES; BOVINE LIVER; SYSTEM; ACTIVATION; PROTEINS; ATPASE; CYCLE; TRANSLATION; GROEL	A peptide corresponding to the N-terminal 17 amino acids of bovine rhodanese was fluorescently labeled with a coumarin derivative at its primary amino group(s) and then purified by high performance liquid chromatography. This peptide interacted with the molecular chaperone DnaJ in the absence of other chaperones and ATP, In the presence of ATP, the molecular chaperone DnaK bound to the DnaJ-peptide complex, but not to the peptide alone, The chaperone GrpE appeared to cause the release of the peptide bound to the ternary complex in the presence of ATP but not in the presence of ADP, This nucleotide apparently stabilized the complex, The peptide also bound to salt-washed Escherichia coli 70 S ribosomes, specifically to 50 S ribosomal subunits, not to 30 S subunits, DnaJ plus DnaK interacted with the peptide on the ribosome, GrpE caused dissociation of the peptide from the ribosome; ATP was required for this reaction, It was inhibited by ADP, A comparable series of chaperone-mediated reactions is assumed to occur with the N-terminal segment of the nascent polypeptide to facilitate its folding on ribosomes.	UNIV TEXAS,DEPT CHEM & BIOCHEM,AUSTIN,TX 78712	University of Texas System; University of Texas Austin								BUCHBERGER A, 1995, J BIOL CHEM, V270, P16903, DOI 10.1074/jbc.270.28.16903; EISENSTEIN M, 1994, SUPRAMOLECULAR STRUC, P213; FARR CD, 1995, BIOCHEMISTRY-US, V34, P15574, DOI 10.1021/bi00047a024; FEDOROV AN, 1995, P NATL ACAD SCI USA, V92, P1227, DOI 10.1073/pnas.92.4.1227; GRAGEROV A, 1994, J MOL BIOL, V235, P848, DOI 10.1006/jmbi.1994.1043; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; JORDAN R, 1995, J BIOL CHEM, V270, P4563, DOI 10.1074/jbc.270.9.4563; KAMATHLOEB AS, 1995, J BIOL CHEM, V270, P30051; KOLB VA, 1994, EMBO J, V13, P3631, DOI 10.1002/j.1460-2075.1994.tb06670.x; KUDLICKI W, 1995, BIOCHEMISTRY-US, V34, P14284, DOI 10.1021/bi00044a003; KUDLICKI W, 1994, J BIOL CHEM, V269, P16549; KUDLICKI W, 1994, J MOL BIOL, V244, P319, DOI 10.1006/jmbi.1994.1732; KUDLICKI W, 1995, J MOL BIOL, V252, P203, DOI 10.1006/jmbi.1995.0488; KUDLICKI W, 1995, J BIOL CHEM, V270, P10650, DOI 10.1074/jbc.270.18.10650; KUDLICKI W, 1992, ANAL BIOCHEM, V206, P389, DOI 10.1016/0003-2697(92)90383-I; KUDLICKI W, 1996, IN PRESS PROTEIN FOL; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; MERRILL GA, 1992, J PROTEIN CHEM, V11, P193, DOI 10.1007/BF01025225; MILLER DM, 1991, J BIOL CHEM, V266, P4686; ODOM OW, 1980, BIOCHEMISTRY-US, V19, P5947, DOI 10.1021/bi00567a001; PALLEROS DR, 1994, J BIOL CHEM, V269, P13107; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345	25	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31160	31165		10.1074/jbc.271.49.31160	http://dx.doi.org/10.1074/jbc.271.49.31160			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940114	hybrid			2022-12-25	WOS:A1996VW68600025
J	Leprini, A; Gherzi, R; Siri, A; Querze, G; Viti, F; Zardi, L				Leprini, A; Gherzi, R; Siri, A; Querze, G; Viti, F; Zardi, L			The human tenascin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURITE GROWTH; MESSENGER-RNA; ADULT-MOUSE; IN-VITRO; JANUSIN; RESTRICTIN; MOLECULE; FAMILY; LOCALIZATION; FIBRONECTIN	The human tenascin-R gene encodes a multidomain protein belonging to the tenascin family, until now detected only in the central nervous system, During embryo development, tenascin-R is presumed to play a pivotal role in axonal path finding through its adhesive and repulsive properties, Recently, the primary structure of human tenascin-R has been elucidated (Carnemolla, B., Leprini, A., Borsi, L., Querze, G., Urbini, S., and Zardi, L. (1996) J. Biol. Chem. 271, 8157-8160). As a further step to investigate the role of human tenascin-R we defined the structure of its gene, The gene, which spans a region of chromosome 1 approximately 85 kilobases in length, consists of 21 exons, ranging in size from 90 to >670 base pairs, The sequence analysis of intron splice donor and acceptor sites revealed that the position of introns in human tenascin-R are precisely conserved in the other two tenascin family members, tenascin-C and tenascin-X, The determination of intronic sequences flanking the exon boundaries will allow investigation of whether mutations may be responsible for altered function of the gene product(s) leading to central nervous system development defects.	IST NAZL RIC CANC, CELL BIOL LAB, I-16132 GENOA, ITALY	University of Genoa; IRCCS AOU San Martino IST			Gherzi, Roberto/AAA-7256-2020	Gherzi, Roberto/0000-0001-8654-0611				BARTSCH U, 1993, GLIA, V9, P57, DOI 10.1002/glia.440090108; BRISTOW J, 1993, J CELL BIOL, V122, P265, DOI 10.1083/jcb.122.1.265; Carnemolla B, 1996, J BIOL CHEM, V271, P8157, DOI 10.1074/jbc.271.14.8157; CHIQUETEHRISMANN R, 1994, PERSPECT DEV NEUROBI, V2, P3; Erickson HP, 1993, CURR OPIN CELL BIOL, V5, P869, DOI 10.1016/0955-0674(93)90037-Q; ERICKSON HP, 1994, PERSPECT DEV NEUROBI, V2, P9; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; FUSS B, 1993, J CELL BIOL, V120, P1237, DOI 10.1083/jcb.120.5.1237; GEFFROTIN C, 1995, EUR J BIOCHEM, V231, P83, DOI 10.1111/j.1432-1033.1995.0083f.x; GHERZI R, 1995, J BIOL CHEM, V270, P3429, DOI 10.1074/jbc.270.7.3429; GULCHER JR, 1991, P NATL ACAD SCI USA, V88, P9438, DOI 10.1073/pnas.88.21.9438; LOCHTER A, 1993, J NEUROSCI, V13, P3986; MATSUMOTO K, 1994, J CELL BIOL, V125, P483, DOI 10.1083/jcb.125.2.483; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NORENBERG U, 1992, NEURON, V8, P849, DOI 10.1016/0896-6273(92)90199-N; NORENBERG U, 1995, J CELL BIOL, V130, P473, DOI 10.1083/jcb.130.2.473; PATTHY L, 1990, CELL, V61, P13, DOI 10.1016/0092-8674(90)90208-V; PESHEVA P, 1989, J CELL BIOL, V109, P1765, DOI 10.1083/jcb.109.4.1765; RATHJEN FG, 1991, DEVELOPMENT, V113, P151; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHACHNER M, 1994, PERSPECT DEV NEUROBI, V2, P33; SCHWAB ME, 1993, ANNU REV NEUROSCI, V16, P565, DOI 10.1146/annurev.ne.16.030193.003025; TAYLOR J, 1993, J NEUROSCI RES, V35, P347, DOI 10.1002/jnr.490350402; WINTERGERST ES, 1993, EUR J NEUROSCI, V5, P299, DOI 10.1111/j.1460-9568.1993.tb00497.x	24	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31251	31254		10.1074/jbc.271.49.31251	http://dx.doi.org/10.1074/jbc.271.49.31251			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940128	hybrid			2022-12-25	WOS:A1996VW68600039
J	Davies, SA; Goodwin, SF; Kelly, DC; Wang, ZS; Sozen, MA; Kaiser, K; Dow, JAT				Davies, SA; Goodwin, SF; Kelly, DC; Wang, ZS; Sozen, MA; Kaiser, K; Dow, JAT			Analysis and inactivation of vha55, the gene encoding the vacuolar ATPase B-subunit in Drosophila melanogaster reveals a larval lethal phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY ACTIVE-TRANSPORT; TOBACCO HORNWORM MIDGUT; INSECT V-ATPASE; H+-ATPASE; PLASMA-MEMBRANE; MALPIGHIAN TUBULES; FINE-STRUCTURE; MANDUCA-SEXTA; PUMP; CELLS	Vacuolar ATPases play major roles in endomembrane and plasma membrane proton transport in eukaryotes. A Drosophila melanogaster cDNA encoding vha55, the 55-kDa vacuolar ATPase (V-ATPase) regulatory B-subunit, was characterized and mapped to 87C2-4 on chromosome 3R. A fly line was identified that carried a single lethal P-element insertion within the coding portion of gene, and its LacZ reporter gene revealed elevated expression in Malpighian tubules, rectum, antennal palps, and oviduct, regions where V-ATPases are believed to play a plasma membrane, rather than an endomembrane, role. The P-element vha55 insertion was shown to be allelic to a known lethal complementation group 1(3)SzA (=l(3)87Ca) at 87C, for which many alleles have been described previously. Deletions of the locus have been shown to be larval lethal, whereas point mutations show a range of phenotypes hom subvital to embryonic lethal, implying that severe alleles confer a partial dominant negative phenotype. The P-element null allele of vha55 was shown also to suppress ectopic sex combs in Polycomb males, suggesting that transcriptional silencing may be modulated by genes other than those with known homeotic or DNA binding functions.	UNIV GLASGOW,DIV MOL GENET,INST BIOMED & LIFE SCI,GLASGOW G11 6NU,LANARK,SCOTLAND	University of Glasgow			Dow, Julian/M-2371-2019	Dow, Julian/0000-0002-9595-5146; Goodwin, Stephen/0000-0002-0552-4140				ANDERSON E, 1966, J CELL BIOL, V31, P107, DOI 10.1083/jcb.31.1.107; ANRAKU Y, 1992, J EXP BIOL, V172, P67; AOTA S, 1988, NUCLEIC ACIDS RES, V16, pR315, DOI 10.1093/nar/16.suppl.r315; Ashburner M., 2004, DROSOPHILA LAB MANUA, V2nd; BERNASCONI P, 1989, FEBS LETT, V251, P132, DOI 10.1016/0014-5793(89)81442-5; BERTRAM G, 1991, J INSECT PHYSIOL, V37, P201, DOI 10.1016/0022-1910(91)90070-G; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; BROWN D, 1992, J EXP BIOL, V172, P231; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIOFFI M, 1983, TISSUE CELL, V15, P781, DOI 10.1016/0040-8166(83)90050-2; CIOFFI M, 1979, TISSUE CELL, V11, P467, DOI 10.1016/0040-8166(79)90057-0; DEFRANCO PE, 1995, J AM SOC NEPHROL, V6, P295; DIMITRIADIS VK, 1991, J INSECT PHYSIOL, V37, P167, DOI 10.1016/0022-1910(91)90067-A; DOW JAT, 1992, J EXP BIOL, V172, P355; DOW JAT, 1984, AM J PHYSIOL, V246, pR633, DOI 10.1152/ajpregu.1984.246.4.R633; DOW JAT, 1994, J EXP BIOL, V197, P421; DOW JAT, 1994, ORGANELLAR PROTON AT, P75; GAUSZ J, 1979, GENETICS, V93, P917; GHISLAIN M, 1992, YEAST, V8, P791, DOI 10.1002/yea.320080913; GILL SS, 1991, ARCH BIOCHEM BIOPHYS, V291, P92, DOI 10.1016/0003-9861(91)90109-V; Gloor G. B., 1992, DROSOPHILA INFORMATI, V71, P148; GLUCK S, 1992, J EXP BIOL, V172, P29; GU HH, 1990, NUCLEIC ACIDS RES, V18, P7446, DOI 10.1093/nar/18.24.7446; Guo YQ, 1996, BBA-BIOMEMBRANES, V1283, P4, DOI 10.1016/0005-2736(96)00103-4; Guo YQ, 1996, GENE, V172, P239, DOI 10.1016/0378-1119(96)00057-1; HARVEY WR, 1983, AM J PHYSIOL, V244, pR163, DOI 10.1152/ajpregu.1983.244.2.R163; HARVEY WR, 1983, J EXP BIOL, V106, P91; KAISER K, 1990, P NATL ACAD SCI USA, V87, P1686, DOI 10.1073/pnas.87.5.1686; KENNISON JA, 1988, P NATL ACAD SCI USA, V85, P8136, DOI 10.1073/pnas.85.21.8136; KLEIN U, 1992, J EXP BIOL, V172, P345; LEWIS EB, 1954, AM NAT, V88, P225, DOI 10.1086/281833; Liu Q, 1996, J BIOL CHEM, V271, P2018, DOI 10.1074/jbc.271.4.2018; MANOLSON MF, 1988, J BIOL CHEM, V263, P17987; MOEHRLE A, 1994, DEV GENET, V15, P478, DOI 10.1002/dvg.1020150606; MYERS M, 1993, J BIOL CHEM, V268, P9184; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; NELSON H, 1989, J BIOL CHEM, V264, P1775; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NELSON N, 1991, TRENDS PHARMACOL SCI, V12, P71, DOI 10.1016/0165-6147(91)90501-I; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; NELSON RD, 1992, P NATL ACAD SCI USA, V89, P3541, DOI 10.1073/pnas.89.8.3541; NOVAK FJS, 1992, BIOCHIM BIOPHYS ACTA, V1132, P67, DOI 10.1016/0167-4781(92)90053-3; ODonnell MJ, 1996, J EXP BIOL, V199, P1163; PUOPOLO K, 1992, J BIOL CHEM, V267, P3696; RUBIN GM, 1988, SCIENCE, V240, P1453, DOI 10.1126/science.3131880; SCHWEIKL H, 1989, J BIOL CHEM, V264, P11136; STONE DK, 1990, KIDNEY INT, V38, P649, DOI 10.1038/ki.1990.255; WIECZOREK H, 1991, J BIOL CHEM, V266, P15340; WIECZOREK H, 1992, J EXP BIOL, V172, P335	49	100	114	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30677	30684		10.1074/jbc.271.48.30677	http://dx.doi.org/10.1074/jbc.271.48.30677			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940044	hybrid			2022-12-25	WOS:A1996VV15800061
J	Duyvis, MG; Wassink, H; Haaker, H				Duyvis, MG; Wassink, H; Haaker, H			Pre-steady-state kinetics of nitrogenase from Azotobacter vinelandii - Evidence for an ATP-induced conformational change of the nitrogenase complex as part of the reaction mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KLEBSIELLA-PNEUMONIAE NITROGENASE; MOLYBDENUM-IRON PROTEIN; MOFE-PROTEIN; ELECTRON-TRANSFER; SODIUM DITHIONITE; FE-PROTEIN; P-CLUSTERS; REDUCTION; SIMULATION; DISSOCIATION	The pre-steady-state electron transfer reactions of nitrogenase from Azotobact With reduced nitrogenase proteins after the initial absorbance increase at 430 nm (which is associated with electron transfer from the Fe protein to the MoFe protein and is complete in 50 ms) the absorbance decreases, which, dependent on the ratio [Av2]/[Av1], is followed by an increase of the absorbance. The mixing of reductant-free nitrogenase proteins with MgATP leads after 20 ms to a decrease of the absorbance, which could be fitted (from 0.05 to 1 s) with a single exponential decay with a rate constant k(obs)=6.6+/-0.8 s(-1). This reaction of nitrogenase was measured at different wavelengths. The data indicate the formation of a species with a blue shift of the absorbance of metal-sulfur clusters of nitrogenase from 430 to 360 nm. The absorbance decrease at 430 nm observed (after 50 ms) in the case of the reduced nitrogenase proteins could only be simulated well if, after the initial electron transfer from the Fe protein to the MoFe protein and before dissociation of the nitrogenase complex, an additional reaction was assumed. The rate constant of this reaction was of the same order as the rate constant of the MgATP-dependent pre-steady-state proton production by nitrogenase from A. vinelandii: k(obs)=14+/-4 s(-1) with reduced nitrogenase proteins and k(obs)=6+/-2 s(-1) with dithionite-free nitrogenase proteins (Duyvis, M. G., Wassink, H., and Haaker, H. (1994) Eur. J. Biochem, 225, 881-890). It is proposed that in the presence and absence of reductant, the observed absorbance decrease at 430 nm of nitrogenase is caused by a change of the conformation of the nitrogenase complex, as a consequence of hydrolysis of MgATP.	AGR UNIV WAGENINGEN, DEPT BIOCHEM, NL-6703 HA WAGENINGEN, NETHERLANDS	Wageningen University & Research								ASHBY GA, 1987, BIOCHEM J, V246, P455, DOI 10.1042/bj2460455; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BOLIN JT, 1993, ACS SYM SER, V535, P186; CHABRE M, 1990, TRENDS BIOCHEM SCI, V15, P6, DOI 10.1016/0968-0004(90)90117-T; CHAN MK, 1993, SCIENCE, V260, P792, DOI 10.1126/science.8484118; DUYVIS MG, 1994, EUR J BIOCHEM, V225, P881, DOI 10.1111/j.1432-1033.1994.0881b.x; Duyvis MG, 1996, FEBS LETT, V380, P233, DOI 10.1016/0014-5793(96)00019-1; FISHER K, 1991, BIOCHEM J, V279, P81, DOI 10.1042/bj2790081; FOGUEL D, 1995, J BIOL CHEM, V270, P28759, DOI 10.1074/jbc.270.48.28759; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; HADFIELD KL, 1969, BIOCHEMISTRY-US, V8, P5103, DOI 10.1021/bi00840a064; HOWARD JB, 1994, ANNU REV BIOCHEM, V63, P235, DOI 10.1146/annurev.bi.63.070194.001315; KIM JS, 1992, SCIENCE, V257, P1677, DOI 10.1126/science.1529354; Lowe D. J., 1995, Nitrogen fixation: fundamentals and applications. Proceedings of the 10th International Congress on Nitrogen Fixation, St. Petersburg, Russia, May 28-June 3 1995., P103; LOWE DJ, 1984, BIOCHEM J, V224, P877, DOI 10.1042/bj2240877; LOWE DJ, 1990, BIOCHEM J, V272, P621, DOI 10.1042/bj2720621; LOWE DJ, 1984, BIOCHEM J, V224, P895, DOI 10.1042/bj2240895; LOWE DJ, 1993, BIOCHEM J, V292, P93, DOI 10.1042/bj2920093; MENSINK RE, 1992, EUR J BIOCHEM, V208, P295, DOI 10.1111/j.1432-1033.1992.tb17186.x; MENSINK RE, 1992, EUR J BIOCHEM, V208, P289, DOI 10.1111/j.1432-1033.1992.tb17185.x; MULLER F, 1973, BIOCHEMISTRY-US, V12, P4654; PETERS JW, 1995, J BIOL CHEM, V270, P27007, DOI 10.1074/jbc.270.45.27007; PIERIK AJ, 1993, EUR J BIOCHEM, V212, P51, DOI 10.1111/j.1432-1033.1993.tb17632.x; Renner KA, 1996, BIOCHEMISTRY-US, V35, P5353, DOI 10.1021/bi960441o; THORNELEY RNF, 1984, BIOCHEM J, V224, P903, DOI 10.1042/bj2240903; THORNELEY RNF, 1983, BIOCHEM J, V215, P393, DOI 10.1042/bj2150393; TITTSWORTH RC, 1993, J AM CHEM SOC, V115, P9763, DOI 10.1021/ja00074a050	27	15	15	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29632	29636		10.1074/jbc.271.47.29632	http://dx.doi.org/10.1074/jbc.271.47.29632			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939894	hybrid			2022-12-25	WOS:A1996VU52500022
J	Hausner, W; Wettach, J; Hethke, C; Thomm, M				Hausner, W; Wettach, J; Hethke, C; Thomm, M			Two transcription factors related with the eucaryal transcription factors TATA-binding protein and transcription factor IIB direct promoter recognition by an archaeal RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE TRANSCRIPTION; METHANOCOCCUS-THERMOLITHOTROPHICUS; FACTOR-TFIIB; ARCHAEBACTERIAL PROMOTER; SULFOLOBUS-SHIBATAE; GENES; EUKARYOTES; ELEMENT; BOX; EXPRESSION	We reported previously that cell-free transcription in the Archaea Methanococcus and Pyrococcus depends upon two archaeal transcription factors, archaeal transcription factor A (aTFA) and archaeal transcription factor B (aTFB), In the genome of Pyrococcus genes encoding putative homologues of eucaryal transcription factors TATA-binding protein (TBP) and TFIIB have been detected, Here, we report that Escherichia coli synthesized Pyrococcus homologues of TBP and TFIIB are able to replace endogenous aTFB and aTFA in cell-free transcription reactions, Antibodies raised against archaeal TBP and TFIIB bind to polypeptides of identical molecular mass in the aTFB and aTFA fraction. These data identify aTFB as archaeal TBP and aTFA as the archaeal homologue of TFIIB, At the Pyrococcus glutamate dehydrogenase (gdh) promoter these two bacterially produced transcription factors and endogenous RNA polymerase are sufficient to direct accurate and active initiation of transcription, DNase I protection experiments revealed Pyrococcus-TBP producing a characteristic footprint between position -20 and -34 centered around the TATA box of gdh promoter, Pyrococcus-TFIIB did not bind to the TATA box but bound cooperatively with Pyrococcus-TBP generating an extended DNase I footprinting pattern ranging from position -19 to -42, These data suggest that the Pyrococcus homologue of TFIIB associates with the TBP-promoter binary complex as its eucaryal counterpart, but in contrast to eucaryal TFIIB, it causes an extension of the protection to the region upstream of the TATA box.	CHRISTIAN ALBRECHTS UNIV KIEL,INST ALLGEMEINE MIKROBIOL,D-24118 KIEL,GERMANY	University of Kiel								CRETI R, 1993, NUCLEIC ACIDS RES, V21, P2942, DOI 10.1093/nar/21.12.2942; FREY G, 1990, NUCLEIC ACIDS RES, V18, P1361, DOI 10.1093/nar/18.6.1361; GOHL HP, 1995, NUCLEIC ACIDS RES, V23, P3837, DOI 10.1093/nar/23.19.3837; GOHL HP, 1992, MOL GEN GENET, V231, P286, DOI 10.1007/BF00279802; GROPP F, 1986, SYST APPL MICROBIOL, V7, P95, DOI 10.1016/S0723-2020(86)80130-8; HAUSNER W, 1991, J MOL BIOL, V222, P495, DOI 10.1016/0022-2836(91)90492-O; HAUSNER W, 1993, J BIOL CHEM, V268, P24047; HAUSNER W, 1995, J BIOL CHEM, V270, P17649, DOI 10.1074/jbc.270.30.17649; HETHKE C, 1996, NUCLEIC ACIDS RES, V12, P2369; HUDEPOHL U, 1990, P NATL ACAD SCI USA, V87, P5851, DOI 10.1073/pnas.87.15.5851; LEE S, 1995, NATURE, V376, P609, DOI 10.1038/376609a0; MALIK S, 1993, MOL CELL BIOL, V13, P6253, DOI 10.1128/MCB.13.10.6253; MARSH TL, 1994, P NATL ACAD SCI USA, V91, P4180, DOI 10.1073/pnas.91.10.4180; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; OUZOUNIS C, 1992, CELL, V71, P189, DOI 10.1016/0092-8674(92)90347-F; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; QURESHI SA, 1995, NUCLEIC ACIDS RES, V23, P1775, DOI 10.1093/nar/23.10.1775; QURESHI SA, 1995, P NATL ACAD SCI USA, V92, P6077, DOI 10.1073/pnas.92.13.6077; RASHID N, 1995, GENE, V166, P139, DOI 10.1016/0378-1119(95)00603-2; REITER WD, 1990, P NATL ACAD SCI USA, V87, P9509, DOI 10.1073/pnas.87.24.9509; ROWLANDS T, 1994, SCIENCE, V264, P1326, DOI 10.1126/science.8191287; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THOMM M, 1988, NUCLEIC ACIDS RES, V16, P151, DOI 10.1093/nar/16.1.151; WETTACH J, 1995, P NATL ACAD SCI USA, V92, P472, DOI 10.1073/pnas.92.2.472; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	27	96	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30144	30148		10.1074/jbc.271.47.30144	http://dx.doi.org/10.1074/jbc.271.47.30144			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939964	hybrid			2022-12-25	WOS:A1996VU52500092
J	Joh, T; Kagami, Y; Yamamoto, K; Segawa, T; Takizawa, J; Takahashi, T; Ueda, R; Seto, M				Joh, T; Kagami, Y; Yamamoto, K; Segawa, T; Takizawa, J; Takahashi, T; Ueda, R; Seto, M			Identification of MLL and chimeric MLL gene products involved in 11q23 translocation and possible mechanisms of leukemogenesis by MLL truncation	ONCOGENE			English	Article						translocation; 11q23; MLL; AF9/LTG9; ENL/LTG19; leukemogenesis	ACUTE MYELOID LEUKEMIAS; PROLINE-RICH PROTEIN; CHROMOSOMAL TRANSLOCATIONS; DROSOPHILA-TRITHORAX; ALL-1 GENE; EXPRESSION; CLONING; ABNORMALITIES; CELLS; HRX	11q23 chromosome aberrations are frequently observed in infantile as web as therapy-related leukemias, The target gene at 11q23, MLL, is disrupted by the translocation and becomes fused to various translocation partner genes such as AF4/FEL, LTG9/AF9 and LTG19/ENL, The resulting chimeric mRNAs are fused in frame and have been predicted to encode leukemia-specific chimeric proteins, In the present study, we raised antibodies against MLL, LTG9 and LTG19 and demonstrated that MLL and chimeric MLL-LTG9 and MLL-LTG19 products are synthesized in vivo and are localized in the nuclei, using immunofluorescence and cell fractionation studies, The truncated N-terminal portion of the MLL product common to the various types of 11q23 translocation was also localized in the nuclei in a similar fashion, Murine 32Dc13 cells stably expressing the truncated N-terminal MLL protein exhibited an inhibition of differentiation and a growth advantage following stimulation by granulocyte-colony stimulating factor, although the IL-3 dependency was not significantly changed in comparison to the parental cells, These results suggest that the N-terminal portion common to various MLL-chimeric products plays an important role in leukemogenesis.	AICHI CANC CTR, RES INST, LAB CHEMOTHERAPY, CHIKUSA KU, NAGOYA, AICHI 464, JAPAN; AICHI CANC CTR, RES INST, IMMUNOL LAB, CHIKUSA KU, NAGOYA, AICHI 464, JAPAN; AICHI CANC CTR HOSP, DEPT HEMATOL & CHEMOTHERAPY, CHIKUSA KU, NAGOYA, AICHI 464, JAPAN	Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center								ABE R, 1984, CANCER GENET CYTOGEN, V13, P121, DOI 10.1016/0165-4608(84)90053-0; BATISTATOU A, 1993, J CELL BIOL, V122, P523, DOI 10.1083/jcb.122.3.523; BERNARD OA, 1994, ONCOGENE, V9, P1039; CHAPLIN T, 1995, BLOOD, V85, P1435, DOI 10.1182/blood.V85.6.1435.bloodjournal8561435; CORRAL J, 1993, P NATL ACAD SCI USA, V90, P8538, DOI 10.1073/pnas.90.18.8538; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DANIEL MT, 1993, BLOOD, V82, P1858; DENDEREN VJ, 1989, J EXP MED, V169, P87; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; IIDA S, 1993, ONCOGENE, V8, P3085; KANEKO Y, 1986, BLOOD, V67, P484; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; MAVILIO F, 1989, ONCOGENE, V4, P301; MITANI K, 1995, BLOOD, V85, P2017, DOI 10.1182/blood.V85.8.2017.bloodjournal8582017; MORRISSEY J, 1993, BLOOD, V81, P1124; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PRASAD R, 1993, CANCER RES, V53, P5624; PRASAD R, 1994, P NATL ACAD SCI USA, V90, P4631; PUI CH, 1989, NEW ENGL J MED, V321, P136, DOI 10.1056/NEJM198907203210302; PUI CH, 1991, BLOOD, V77, P440; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; ROVERA G, 1989, ANN NY ACAD SCI, V567, P154, DOI 10.1111/j.1749-6632.1989.tb16467.x; ROWLEY JD, 1990, P NATL ACAD SCI USA, V87, P9358, DOI 10.1073/pnas.87.23.9358; RUBNITZ JE, 1994, BLOOD, V84, P1747; THIRMAN MJ, 1993, NEW ENGL J MED, V329, P909, DOI 10.1056/NEJM199309233291302; THIRMAN MJ, 1994, P NATL ACAD SCI USA, V91, P12110, DOI 10.1073/pnas.91.25.12110; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; TRENT JM, 1989, CYTOGENET CELL GENET, V51, P533, DOI 10.1159/000132807; TSE W, 1995, BLOOD, V85, P650, DOI 10.1182/blood.V85.3.650.bloodjournal853650; WETZLER M, 1993, J CLIN INVEST, V92, P1925, DOI 10.1172/JCI116786; YAMAMOTO K, 1994, BLOOD, V83, P2912, DOI 10.1182/blood.V83.10.2912.2912; YAMAMOTO K, 1993, ONCOGENE, V8, P479; YAMAMOTO K, 1993, ONCOGENE, V8, P2617; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0	37	35	36	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	1996	13	9					1945	1953						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934541				2022-12-25	WOS:A1996VR79500014
